DDPD00006
Bivalirudin
2180.2853
C98H138N24O33
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O
DB00006
16129704
59173
http://www.drugs.com/cdi/bivalirudin.html
10482069
-2.0
-
-2.0
-
DRUGBANK
0.204
L/h/kg
3.4
ml/min/kg
normal,healthy;
DRUGBANK
0.204
L/h/kg
3.4
ml/min/kg
mild renal function;
DRUGBANK
0.162
L/h/kg
2.7
ml/min/kg
moderate renal function;
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
severe renal function;
DRUGBANK
0.06
L/h/kg
1.0
ml/min/kg
DRUGBANK
0.486
L/h/kg
8.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
L/kg
0.2
L/kg
DRUGBANK
0.27
L/kg
0.27
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.416666666666667
h
25
min
normal,healthy;
DRUGBANK
0.95
h
57.0
min
severe renal function;
DRUGBANK
3.5
h
3.5
h
DRUGBANK
0.42
h
0.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
42.0
mg/kg/day
1.75
mg/kg/h
intravenous infusion, iv in drop
Angiomax
bivalirudin
PDR
42.0
mg/kg/day
1.75
mg/kg/hour
intravenous infusion, iv in drop
Angiomax
bivalirudin
PDR
DDPD00007
Leuprolide
1209.3983
C59H84N16O12
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
DB00007
6427
http://www.drugs.com/cdi/leuprolide.html
571356
-2.0
-
-2.0
-
DRUGBANK
108.3
ng/ml
4.6-212
ng/ml
intravenous injection, IV;
DRUGBANK
4.5
h
4-5
h
intravenous injection, IV;
DRUGBANK
672.0
h
4
week
intravenous injection, IV;
DRUGBANK
7.95
L/h
7.6-8.3
L/h
Average clearance; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
27.0
L
27.0
L
Steady state volume of distribution; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
0.38
L/kg
0.38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
elimination half-life;
DRUGBANK
2.9
h
2.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
<5
%
Urinary excretion;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
46.0
%
43-49
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
DDPD00014
Goserelin
1269.4105
C59H84N18O14
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
DB00014
5311128
5523
http://www.drugs.com/cdi/goserelin.html
4470656
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
7.26
L/h
121±42.4
ml/min
DRUGBANK
44.1
L
44.1±13.6
L
subcutaneous injection, SC;
DRUGBANK
4.5
h
4-5
h
DRUGBANK
90.0
%
>90
%
Urinary excretion; subcutaneous injection, SC;
DRUGBANK
27.3
%
27.3
%
DRUGBANK
3.6
mg
3.6
mg
subcutaneous injection, SC
q4w
Zoladex Implant 3.6 mg
goserelin acetate
PDR
10.8
mg
10.8
mg
subcutaneous injection, SC; every 3 months
Zoladex Implant 3.6 mg
goserelin acetate
PDR
3.6
mg
3.6
mg
subcutaneous injection, SC
q4w
Zoladex Implant 3.6 mg
goserelin acetate
PDR
3.6
mg
3.6
mg
subcutaneous injection, SC
q4w
Zoladex Implant 3.6 mg
goserelin acetate
PDR
10.8
mg
10.8
mg
subcutaneous injection, SC; every 3 months
Zoladex Implant 3.6 mg
goserelin acetate
PDR
3.6
mg
3.6
mg
subcutaneous injection, SC
q4w
Zoladex Implant 3.6 mg
goserelin acetate
PDR
DDPD00027
Gramicidin D
1811.253
C96H135N19O16
CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO
DB00027
45267103
24623445
-2.0
-
-2.0
-
DRUGBANK
DDPD00035
Desmopressin
1069.22
C46H64N14O12S2
NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O
DB00035
4450
http://www.drugs.com/cdi/desmopressin.html
4470602
-2.0
-
-2.0
-
DRUGBANK
3.7
%
3.3-4.1
%
inhalation, IH;
DRUGBANK
0.12
%
0.08-0.16
%
PO, oral;
DRUGBANK
0.004
ng/ml
4.00±3.85
pg/ml
inhalation, IH;
DRUGBANK
0.00911
ng/ml
9.11±6.90
pg/ml
inhalation, IH;
DRUGBANK
0.25
h
0.25
h
inhalation, IH;
DRUGBANK
0.75
h
0.75
h
inhalation, IH;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
0.0
%
0.0
%
Liver metabolism;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.26
L/kg
0.2–0.32
L/kg
PO, oral;
DRUGBANK
0.3
L/kg
0.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
h
2.8
h
terminal half-life; inhalation, IH;
DRUGBANK
3.0
h
3.0
h
normal,healthy;
DRUGBANK
9.0
h
9.0
h
severe renal function;
DRUGBANK
2.555
h
2-3.11
h
PO, oral;
DRUGBANK
3.0
h
3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1e-06
mg/kg/dayay
0.3
ug/kg/10M
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95.0
%
~95
%
Urinary excretion; PO, oral;
DRUGBANK
17.3
%
17.3±1.5
%
plasma proteins; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD00050
Cetrorelix
1431.038
C70H92ClN17O14
CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
DB00050
25074887
59224
http://www.drugs.com/cdi/cetrorelix-acetate.html
10482082
-2.0
-
-2.0
-
DRUGBANK
85.0
%
85.0
%
subcutaneous injection, SC; Female, women;
DRUGBANK
0.0768
L/h/kg
1.28
ml/min/kg
subcutaneous injection, SC; normal,healthy; Female, women;
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.16
L/kg
1.16
L/kg
DRUGBANK
0.39
L/kg
0.39
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.8
h
~62.8
h
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.0
%
86
%
DRUGBANK
10.0
mg/day
10
mg/day
subcutaneous injection, SC
Cetrotide
cetrorelix acetate
PDR
10.0
mg/day
10
mg/day
subcutaneous injection, SC
Cetrotide
cetrorelix acetate
PDR
DDPD00067
Vasopressin
2140.46
C92H130N28O24S4
NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O.NC1CSSCC(NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O
DB00067
http://www.drugs.com/mtm/vasopressin.html
10152658
-2.0
-
-2.0
-
DRUGBANK
0.25
h
10-20
min
DRUGBANK
1.0
%
1
%
DRUGBANK
DDPD00080
Daptomycin
1620.693
C72H101N17O26
CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
DB00080
16134395
600103
http://www.drugs.com/cdi/daptomycin.html
10200644
-2.0
-
-2.0
-
DRUGBANK
99000.0
ng/ml
99±12
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
48.0
h
48
h
DRUGBANK
0.0084
L/h/kg
0.14±0.01
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.0096
L/h/kg
0.16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
L/kg
0.1
L/kg
normal,healthy; adults;
DRUGBANK
0.096
L/kg
0.096±0.009
L/kg
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.088
L/kg
0.088
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.5
h
8-9
h
elimination half-life;
DRUGBANK
28.0
h
28
h
elimination half-life; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
7.8
h
7.8±1.0
h
severe renal function ↑ ;
DRUGBANK
8.1
h
8.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
78.0
%
~78
%
Urinary excretion; normal,healthy;
renal insufficiency → ;
DRUGBANK
5.7
%
5.7
%
Faeces excretion; normal,healthy;
DRUGBANK
47.0
%
47±12
%
Urinary excretion; Unchanged drug;
DRUGBANK
91.5
%
90-93
%
plasma proteins; human, homo sapiens;
DRUGBANK
92.0
%
92
%
DRUGBANK
DDPD00091
Cyclosporine
1202.635
C62H111N11O12
CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
DB00091
T3D3498
5284373
4031
http://www.drugs.com/cdi/cyclosporine-drops.html
4447449
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30.0
%
PO, oral;
DRUGBANK
38.7
%
38.7
%
Capsule, PO, Oral;
DRUGBANK
38.7
%
38.7
%
Liquid;
DRUGBANK
28.0
%
28±18
%
PO, oral; Drug form; renal transplant;
DRUGBANK
1101.0
ng/ml
1101±570
ng/ml
PO, oral; Drug form; renal transplant;
DRUGBANK
1333.0
ng/ml
1333±469
ng/ml
PO, oral; Drug form; renal transplant;
DRUGBANK
3.5
h
3.5
h
PO, oral;
DRUGBANK
2.9
h
1.8-4.0
h
PO, oral; Drug form; renal transplant;
DRUGBANK
1.75
h
1.5-2
h
PO, oral; Drug form; renal transplant;
DRUGBANK
1.69
L/h/kg
0.38-3
L/h/kg
DRUGBANK
22.5
L/h
~22.5
L/h
Capsule, PO, Oral;
DRUGBANK
0.342
L/h/kg
5.7(0.6-24)
ml/min/kg
renal transplant; patients; hydrolysis;
Children ↑ ;Elderly ↓ ;Hepatitis, Hep ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.45
L/h/kg
7.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
L/kg
4.0-8
L/kg
DRUGBANK
4.5
L/kg
4.5(0.12-15.5)
L/kg
renal transplant; patients;
Children ↑ ;Elderly ↓ ;
DRUGBANK
3.3
L/kg
3.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
19.0
h
~19(10-27)
h
terminal half-life;
DRUGBANK
10.7
h
10.7(4.3-53)
h
renal transplant; patients;
Children ↓ ;Age → ;
DRUGBANK
7.3
h
7.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1480.0
mg/kg
1480.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2329.0
mg/kg
2329.0
mg/kg
PO, oral; mouse;
DRUGBANK
1480.0
mg/kg
1480.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; rabbit;
DRUGBANK
148.0
mg/kg
148.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
104.0
mg/kg
104.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
46.0
mg/kg
46.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
12.0
mg/kg
12.0
mg/kg
human, homo sapiens;
DRUGBANK
4.5
%
3-6
%
Urinary excretion;
DRUGBANK
90.0
%
90
%
Bile excretion;
DRUGBANK
1.0
%
<1
%
Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
~50
%
serum albumin;
DRUGBANK
34.0
%
~34
%
DRUGBANK
93.0
%
93±2
%
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Gengraf Capsules
cyclosporine
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Gengraf Capsules
cyclosporine
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Gengraf Capsules
cyclosporine
PDR
DDPD00104
Octreotide
1019.25
C49H66N10O10S2
[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O
DB00104
448601
http://www.drugs.com/cdi/octreotide.html
395352
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
subcutaneous injection, SC;
DRUGBANK
2.5
ng/ml
2.5
ng/ml
Capsule, PO, Oral; acromegaly;
DRUGBANK
5.3
ng/ml
5.3
ng/ml
Capsule, PO, Oral; acromegaly;
DRUGBANK
0.5
h
0.5
h
subcutaneous injection, SC;
DRUGBANK
2.085
h
1.67-2.5
h
Capsule, PO, Oral;
DRUGBANK
8.5
L/h
7.0-10
L/h
DRUGBANK
0.1428
L/h/kg
2.38
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.6
L
13.6
L
normal,healthy;
DRUGBANK
24.25
L
18.1-30.4
L
intravenous injection, IV;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
h
0.2
h
elimination half-life; subcutaneous injection, SC;
DRUGBANK
2.5
h
2.3-2.7
h
elimination half-life; PO, oral; subcutaneous injection, SC;
DRUGBANK
1.54166666666667
h
72-113
min
elimination half-life; PO, oral;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.0
%
32
%
Urinary excretion;
DRUGBANK
32.0
%
~32
%
Urinary excretion; Unchanged drug;
DRUGBANK
65.0
%
~65
%
DRUGBANK
0.24
mg/kg/day
10
mcg/kg/hour
intravenous infusion, iv in drop
Sandostatin
octreotide acetate
PDR
0.04
mg/kg/day
40
mcg/kg/day
subcutaneous injection, SC;intravenous injection, IV;
Sandostatin
octreotide acetate
PDR
0.015
mg/kg/day
15
mcg/kg/day
subcutaneous injection, SC
Sandostatin
octreotide acetate
PDR
0.015
mg/kg/day
15
mcg/kg/day
subcutaneous injection, SC
Sandostatin
octreotide acetate
PDR
0.24
mg/kg/day
10
mcg/kg/h
intravenous infusion, iv in drop
Sandostatin
octreotide acetate
PDR
0.04
mg/kg/day
40
mcg/kg/day
subcutaneous injection, SC;intravenous injection, IV;
Sandostatin
octreotide acetate
PDR
0.24
mg/kg/day
10
mcg/kg/hour
intravenous infusion, iv in drop
Sandostatin
octreotide acetate
PDR
0.04
mg/kg/day
40
mcg/kg/day
subcutaneous injection, SC;intravenous injection, IV;
Sandostatin
octreotide acetate
PDR
DDPD00106
Abarelix
1416.09
C72H95ClN14O14
CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
DB00106
16131215
337298
http://www.drugs.com/cdi/abarelix.html
10482301
-2.0
-
-2.0
-
DRUGBANK
43.4
ng/ml
43.4
ng/ml
IM,intramuscular injection;
DRUGBANK
72.0
h
72
h
IM,intramuscular injection;
DRUGBANK
316.8
h
13.2±3.2
day
DRUGBANK
97.5
%
96-99
%
DRUGBANK
DDPD00114
Pyridoxal phosphate
247.1419
C8H10NO6P
CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O
DB00114
1051
18405
1022
-2.0
-
-2.0
-
DRUGBANK
DDPD00115
Cyanocobalamin
1355.3652
C63H88CoN14O14P
C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP([O-])(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)N1C=NC2=C1C=C(C)C(C)=C2
DB00115
T3D0673
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
70678590
17439
http://www.drugs.com/cdi/cyanocobalamin-b12.html
21864832
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
IM,intramuscular injection;
DRUGBANK
144.0
h
~6
day
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; mouse;
DRUGBANK
8000.0
mg/kg
>8000
mg/kg
PO, oral; mouse;
DRUGBANK
1e-07
mg/L
0.0001
mg/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
DDPD00118
Ademetionine
398.44
C15H22N6O5S
C[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2N
DB00118
T3D4456
34755
67040
http://www.drugs.com/cdi/s-adenosylmethionine.html
31982
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50.0
%
Liver metabolism;
DRUGBANK
DDPD00119
Pyruvic acid
88.0621
C3H4O3
CC(=O)C(O)=O
DB00119
T3D4325
1060
32816
1031
-2.0
-
-2.0
-
DRUGBANK
DDPD00120
Phenylalanine
165.1891
C9H11NO2
N[C@@H](CC1=CC=CC=C1)C(O)=O
DB00120
T3D4366
6140
17295
5910
-2.0
-
-2.0
-
DRUGBANK
DDPD00121
Biotin
244.311
C10H16N2O3S
[H][C@]12CS[C@@H](CCCCC(O)=O)[C@@]1([H])NC(=O)N2
DB00121
T3D2690
171548
15956
http://www.drugs.com/cons/biotin.html
149962
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50.0
%
DRUGBANK
DDPD00122
Choline
104.1708
C5H14NO
C[N+](C)(C)CCO
DB00122
305
15354
299
-2.0
-
-2.0
-
DRUGBANK
3400.0
mg/kg
3400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00123
L-Lysine
146.1876
C6H14N2O2
NCCCC[C@H](N)C(O)=O
DB00123
5962
18019
5747
-2.0
-
-2.0
-
DRUGBANK
DDPD00126
Ascorbic acid
176.1241
C6H8O6
[H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO
DB00126
54670067
29073
http://www.drugs.com/cdi/ascorbic-acid.html
10189562
-2.0
-
-2.0
-
DRUGBANK
80.0
%
70-90
%
DRUGBANK
0.063
L/h/kg
1.05
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.35
L/kg
0.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
384.0
h
16
day
DRUGBANK
3.4
h
3.4
h
DRUGBANK
11.4
h
11.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
%
25
%
DRUGBANK
DDPD00128
Aspartic acid
133.1027
C4H7NO4
N[C@@H](CC(O)=O)C(O)=O
DB00128
5960
17053
5745
-2.0
-
-2.0
-
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
Rattus, Rat;
DRUGBANK
DDPD00129
Ornithine
132.161
C5H12N2O2
NCCC[C@H](N)C(O)=O
DB00129
6262
15729
6026
-2.0
-
-2.0
-
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00130
L-Glutamine
146.1445
C5H10N2O3
N[C@@H](CCC(N)=O)C(O)=O
DB00130
T3D4319
5961
58359
5746
-2.0
-
-2.0
-
DRUGBANK
0.5
h
0.5
h
Oral single dose;
DRUGBANK
0.2
L/kg
200.0
ml/kg
intravenous injection, IV;
DRUGBANK
1.0
h
1
h
elimination half-life;
DRUGBANK
DDPD00131
Adenosine phosphate
347.2212
C10H14N5O7P
NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1
DB00131
6083
16027
5858
-2.0
-
-2.0
-
DRUGBANK
DDPD00132
alpha-Linolenic acid
278.4296
C18H30O2
CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O
DB00132
T3D4812
5280934
27432
4444437
-2.0
-
-2.0
-
DRUGBANK
DDPD00134
Methionine
149.211
C5H11NO2S
CSCC[C@H](N)C(O)=O
DB00134
T3D4328
6137
16643
5907
-2.0
-
-2.0
-
DRUGBANK
DDPD00135
Tyrosine
181.1885
C9H11NO3
N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
DB00135
T3D4371
6057
58315
5833
-2.0
-
-2.0
-
DRUGBANK
5510.0
mg/kg
5510.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5110.0
mg/kg
5110.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00136
Calcitriol
416.6365
C27H44O3
C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
DB00136
T3D2692
5280453
17823
http://www.drugs.com/cdi/calcitriol.html
4444108
-2.0
-
-2.0
-
DRUGBANK
70.6
%
70.6±5.8
%
PO, oral; normal,healthy; Male, men;
DRUGBANK
72.2
%
72.2±4.8
%
PO, oral; RD, renal impairment, Renal disease，including uremia; Male, men;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
61.0
%
~61
%
PO, oral;
DRUGBANK
67.0
%
~67
%
Intraperitoneal, IP;
DRUGBANK
0.06
ng/ml
60.0±4.4
pg/ml
Oral single dose;
DRUGBANK
0.09
ng/ml
~90
pg/ml
PO, oral;
DRUGBANK
0.105
ng/ml
~105
pg/ml
Intraperitoneal, IP;
DRUGBANK
0.46
ng/ml
~460
pg/ml
intravenous injection, IV;
DRUGBANK
2.0
h
2
h
Oral single dose;
DRUGBANK
4.5
h
3-6
h
Oral single dose;
DRUGBANK
4.5
h
3-6
h
PO, oral;
DRUGBANK
2.5
h
2-3
h
Intraperitoneal, IP;
DRUGBANK
1.41
L/h
23.5±4.34
ml/min
Total clearance; normal,healthy; Male, men;
DRUGBANK
0.606
L/h
10.1±1.35
ml/min
Total clearance; RD, renal impairment, Renal disease，including uremia; Male, men;
DRUGBANK
0.0153
L/h/kg
15.3
ml/h/kg
pediatric patients;
DRUGBANK
0.0258
L/h/kg
0.43±0.04
ml/min/kg
young; patients;
DRUGBANK
0.0186
L/h/kg
0.31
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.49
L/kg
0.49±0.14
L/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
0.27
L/kg
0.27±0.06
L/kg
intravenous injection, IV; RD, renal impairment, Renal disease，including uremia; Male, men;
DRUGBANK
0.25
L/kg
0.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
5-8
h
elimination half-life; Oral single dose;
DRUGBANK
16.5
h
16.5±3.1
h
young; peritoneal dialysis;
Children ↑ ;
DRUGBANK
6.5
h
5-8
h
normal,healthy; adults;
DRUGBANK
27.0
h
27±12
h
PO, oral;
DRUGBANK
77760.0
h
2-16
year
Children;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
620.0
mg/kg
620.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.0
mg/kg
>5
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
0.62
mg/kg
620.0
ug/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.0
mg/kg
>5
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
27.0
%
~27
%
Faeces excretion; normal,healthy;
DRUGBANK
7.0
%
~7
%
Urinary excretion; normal,healthy;
DRUGBANK
16.0
%
16
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
49.0
%
49
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
10.0
%
<10
%
Urinary excretion; young; peritoneal dialysis; human, homo sapiens; Unchanged drug;
DRUGBANK
99.9
%
~99.9
%
DRUGBANK
99.9
%
99.9
%
young; peritoneal dialysis; human, homo sapiens;
DRUGBANK
28571.4285714286
mg/day
200
g/week
skin/dermal
Vectical
calcitriol
PDR
28571.4285714286
mg/day
200
g/week
skin/dermal
Vectical
calcitriol
PDR
0.00025
mg/day
0.25
mcg/day
PO, oral
Vectical
calcitriol
PDR
DDPD00137
Lutein
568.886
C40H56O2
C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C
DB00137
5281243
28838
4444655
-2.0
-
-2.0
-
DRUGBANK
DDPD00138
Cystine
240.3
C6H12N2O4S2
N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O
DB00138
67678
16283
60997
-2.0
-
-2.0
-
DRUGBANK
DDPD00139
Succinic acid
118.088
C4H6O4
OC(=O)CCC(O)=O
DB00139
T3D4453
1110
15741
1078
-2.0
-
-2.0
-
DRUGBANK
2260.0
mg/kg
2260.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2260.0
mg/kg
2260.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00140
Riboflavin
376.3639
C17H20N4O6
CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)C3=NC(=O)NC(=O)C3=NC2=C1
DB00140
T3D4817
493570
17015
http://www.drugs.com/mtm/riboflavin.html
431981
-2.0
-
-2.0
-
DRUGBANK
1.25
h
66-84
min
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD00141
N-Acetylglucosamine
221.2078
C8H15NO6
[H]C(=O)[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@H](O)CO
DB00141
1738118
17411
1376695
-2.0
-
-2.0
-
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
4170.0
mg/kg
4170.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
DDPD00142
Glutamic acid
147.1293
C5H9NO4
N[C@@H](CCC(O)=O)C(O)=O
DB00142
T3D4296
33032
16015
30572
-2.0
-
-2.0
-
DRUGBANK
DDPD00143
Glutathione
307.323
C10H17N3O6S
N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O
DB00143
T3D4352
124886
16856
111188
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
4020.0
mg/kg
4020.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
IM,intramuscular injection; mouse;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; mouse;
DRUGBANK
4020.0
mg/kg
4020.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
IM,intramuscular injection; mouse;
DRUGBANK
DDPD00144
Phosphatidyl serine
385.3041
C13H24NO10P
CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O
DB00144
6323481
84519
7826046
-2.0
-
-2.0
-
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2
g/kg
rabbit;
DRUGBANK
DDPD00145
Glycine
75.0666
C2H5NO2
NCC(O)=O
DB00145
T3D4318
750
15428
730
-2.0
-
-2.0
-
DRUGBANK
7930.0
mg/kg
7930.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5200.0
mg/kg
5200.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
4920.0
mg/kg
4920.0
mg/kg
PO, oral; mouse;
DRUGBANK
7930.0
mg/kg
7930.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5200.0
mg/kg
5200.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
4920.0
mg/kg
4920.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00146
Calcifediol
400.6371
C27H44O2
C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
DB00146
T3D2694
5283731
17933
4446820
-2.0
-
-2.0
-
DRUGBANK
288.0
h
288
h
DRUGBANK
0.06
mg/day
60
mcg/day
PO, oral
Rayaldee
calcifediol
PDR
0.06
mg/day
60
mcg/day
PO, oral
Rayaldee
calcifediol
PDR
DDPD00148
Creatine
131.1332
C4H9N3O2
CN(CC(O)=O)C(N)=N
DB00148
T3D4290
586
16919
http://www.drugs.com/creatine.html
566
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3
h
DRUGBANK
DDPD00150
Tryptophan
204.2252
C11H12N2O2
N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
DB00150
T3D4369
6305
16828
6066
-2.0
-
-2.0
-
DRUGBANK
16000.0
mg/kg
>16
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00151
Cysteine
121.158
C3H7NO2S
N[C@@H](CS)C(O)=O
DB00151
T3D4156
5862
17561
5653
-2.0
-
-2.0
-
DRUGBANK
DDPD00152
Thiamine
265.355
C12H17N4OS
CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N
DB00152
T3D2696
1130
18385
http://www.drugs.com/cdi/thiamine.html
1098
-2.0
-
-2.0
-
DRUGBANK
8224.0
mg/kg
8224.0
mg/kg
PO, oral; mouse;
DRUGBANK
3710.0
mg/kg
3710.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8224.0
mg/kg
8224.0
mg/kg
PO, oral; mouse;
DRUGBANK
3710.0
mg/kg
3710.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
92.0
%
90-94
%
DRUGBANK
DDPD00153
Ergocalciferol
396.6484
C28H44O
CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
DB00153
T3D2697
5280793
28934
http://www.drugs.com/cdi/ergocalciferol.html
4444351
-2.0
-
-2.0
-
DRUGBANK
36.0
h
1-2
day
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
23.7
mg/kg
23.7
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.1
mg/day
100
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
4000.0
International Units/day
4000
International Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.1
mg/day
100
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
4000.0
units/day
4000
International Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.1
mg/day
100
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
4000.0
International Units/day
4000
International Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.1
mg/day
100
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
4000.0
InternationaL Units/day
4000
InternationaL Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.075
mg/day
75
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
3000.0
InternationaL Units/day
3000
InternationaL Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.0625
mg/day
62.5
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
2500.0
InternationaL Units/day
2500
InternationaL Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.0375
mg/day
37.5
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
1500.0
International Units/day
1500
International Units/day
PO, oral
Drisdol
ergocalciferol
PDR
0.025
mg/day
25
mcg/day
PO, oral
Drisdol
ergocalciferol
PDR
1000.0
International Units/day
1000
International Units/day
PO, oral
Drisdol
ergocalciferol
PDR
DDPD00155
Citrulline
175.1857
C6H13N3O3
N[C@@H](CCCNC(N)=O)C(O)=O
DB00155
T3D4295
9750
16349
9367
-2.0
-
-2.0
-
DRUGBANK
DDPD00156
Threonine
119.1192
C4H9NO3
C[C@@H](O)[C@H](N)C(O)=O
DB00156
T3D4368
6288
16857
6051
-2.0
-
-2.0
-
DRUGBANK
DDPD00157
NADH
665.441
C21H29N7O14P2
NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=NC3=C(N)N=CN=C23)[C@@H](O)[C@H]1O
DB00157
439153
16908
388299
-2.0
-
-2.0
-
DRUGBANK
DDPD00158
Folic acid
441.3975
C19H19N7O6
NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1
DB00158
T3D2698
6037
27470
http://www.drugs.com/folic_acid.html
5815
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
3.12
L/h/kg
52
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.7
L/kg
9.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
mg/kg
85.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
120.0
mg/kg
120.0
mg/kg
intravenous injection, IV; guinea pigs;
DRUGBANK
239.0
mg/kg
239.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
410.0
mg/kg
410.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
85.0
mg/kg
85.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
120.0
mg/kg
120.0
mg/kg
intravenous injection, IV; guinea pigs;
DRUGBANK
239.0
mg/kg
239.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
410.0
mg/kg
410.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
50.0
%
~50
%
Urinary excretion; PO, oral;
DRUGBANK
50.0
%
~50
%
Urinary excretion; PO, oral;
DRUGBANK
90.0
%
≤90
%
Urinary excretion; Oral single dose;
DRUGBANK
0.8
mg/day
0.8
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
1.0
mg/day
1
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
5.0
mg/day
5
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
15.0
mg/day
15
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
0.6
mg/day
0.6
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
0.4
mg/day
0.4
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
0.3
mg/day
0.3
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
1.0
mg/day
1
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
5.0
mg/day
5
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
15.0
mg/day
15
mg/day
PO, oral
Folic Acid Tablets
folic acid
PDR
DDPD00159
Icosapent
302.451
C20H30O2
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
DB00159
446284
28364
http://www.drugs.com/mtm/epa-fish-oil.html
393682
-2.0
-
-2.0
-
DRUGBANK
DDPD00161
Valine
117.1463
C5H11NO2
CC(C)[C@H](N)C(O)=O
DB00161
T3D4370
6287
16414
6050
-2.0
-
-2.0
-
DRUGBANK
DDPD00162
Vitamin A
286.4516
C20H30O
C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C
DB00162
T3D2699
445354
17336
http://www.drugs.com/mtm/vitamin-a.html
393012
-2.0
-
-2.0
-
DRUGBANK
1.9
h
1.9
h
DRUGBANK
5.0
%
<5
%
DRUGBANK
2.8
mg/day
2800
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
9333.0
International Units/day
9333
International Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
1.7
mg/day
1700
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
5667.0
International Units/day
5667
International Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
3.0
mg/day
3000
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
10000.0
units/day
10000
International Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
3.0
mg/day
3000
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
10000.0
International Units/day
10000
International Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
2.8
mg/day
2800
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
9333.0
International Units/day
9333
International Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
1.7
mg/day
1700
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
5667.0
InternationaL Units/day
5667
InternationaL Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
0.9
mg/day
900
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
3000.0
InternationaL Units/day
3000
InternationaL Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
0.6
mg/day
600
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
2000.0
InternationaL Units/day
2000
InternationaL Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
0.6
mg/day
600
mcg/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
2000.0
International Units/day
2000
International Units/day
PO, oral
Aquasol A
vitamin A palmitate
PDR
DDPD00163
Vitamin E
430.7061
C29H50O2
CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C
DB00163
T3D2700
14985
18145
http://www.drugs.com/vitamin_e.html
14265
-2.0
-
-2.0
-
DRUGBANK
21.5
%
10-33
%
PO, oral;
DRUGBANK
36.0
%
36.0
%
PO, oral; Derivative;
DRUGBANK
9.0
%
9.0
%
PO, oral; Derivative;
DRUGBANK
9.7
h
9.7
h
PO, oral; Derivative;
DRUGBANK
2.4
h
2.4
h
PO, oral; Derivative;
DRUGBANK
0.0065
L/h/kg
6.5
ml/h/kg
IM,intramuscular injection; Prem, premature;
DRUGBANK
0.41
L/kg
0.41
L/kg
IM,intramuscular injection; Prem, premature;
DRUGBANK
44.0
h
44
h
IM,intramuscular injection; Prem, premature;
DRUGBANK
0.2
h
12
min
intravenous injection, IV;
DRUGBANK
DDPD00165
Pyridoxine
169.1778
C8H11NO3
CC1=C(O)C(CO)=C(CO)C=N1
DB00165
T3D2701
1054
16709
http://www.drugs.com/cdi/pyridoxine-vitamin-b6-extended-release-tablets.html
1025
-2.0
-
-2.0
-
DRUGBANK
5.5
h
5.5
h
PO, oral;
DRUGBANK
420.0
h
15-20
day
adults;
DRUGBANK
4000.0
mg/kg
4.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
4000.0
mg/kg
4.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
70.0
mg/kg/dose
70
mg/kg/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
5000.0
mg/dose
5
g/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
20000.0
mg
20
g
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
70.0
mg/kg/dose
70
mg/kg/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
5000.0
mg/dose
5
g/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
20000.0
mg
20
g
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
70.0
mg/kg/dose
70
mg/kg/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
5.0
g/dose
5
g/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
20.0
g
20
g
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
70.0
mg/kg/dose
70
mg/kg/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
5.0
g/dose
5
g/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
20.0
g
20
g
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
500.0
mg
500
mg
IM,intramuscular injection
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
70.0
mg/kg/dose
70
mg/kg/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
5.0
g/dose
5
g/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
20.0
g
20
g
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
500.0
mg
500
mg
intravenous injection, IV
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
70.0
mg/kg/dose
70
mg/kg/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
5.0
g/dose
5
g/dose
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
20000.0
mg
20
g
Pyridoxine Hydrochloride
pyridoxine hydrochloride
PDR
DDPD00166
Lipoic acid
206.326
C8H14O2S2
OC(=O)CCCC[C@@H]1CCSS1
DB00166
T3D2702
6112
30314
5886
-2.0
-
-2.0
-
DRUGBANK
0.69
L/h/kg
11.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.804
L/h/kg
13.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
L/kg
0.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.21
h
0.21
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.21
h
0.21
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00169
Cholecalciferol
384.6377
C27H44O
CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
DB00169
T3D2703
5280795
28940
http://www.drugs.com/mtm/cholecalciferol.html
4444353
-2.0
-
-2.0
-
DRUGBANK
0.104166666666667
L/h
~2.5
L/day
Average clearance; organ transplants; patients;
DRUGBANK
237.0
L
~237
L
Average volume of distribution; renal transplant; patients;
DRUGBANK
1200.0
h
~50
day
DRUGBANK
65.0
%
50-80
%
DRUGBANK
DDPD00170
Menadione
172.18
C11H8O2
CC1=CC(=O)C2=CC=CC=C2C1=O
DB00170
T3D2704
4055
28869
3915
-2.0
-
-2.0
-
DRUGBANK
45.0
%
10-80
%
DRUGBANK
DDPD00173
Adenine
135.1267
C5H5N5
NC1=C2NC=NC2=NC=N1
DB00173
T3D4279
190
16708
185
-2.0
-
-2.0
-
DRUGBANK
DDPD00174
Asparagine
132.1179
C4H8N2O3
N[C@@H](CC(N)=O)C(O)=O
DB00174
T3D4362
6267
58048
6031
-2.0
-
-2.0
-
DRUGBANK
DDPD00175
Pravastatin
424.5277
C23H36O7
[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
DB00175
54687
63618
http://www.drugs.com/cdi/pravastatin.html
49398
-2.0
-
-2.0
-
DRUGBANK
75.0
ng.h/ml
60-90
mcg.h/L
PO, oral;
DRUGBANK
17.0
%
17.0
%
PO, oral;
DRUGBANK
18.0
%
18±8
%
Oral single dose;
DRUGBANK
42.5
ng/ml
30-55
mcg/L
PO, oral;
DRUGBANK
33.0
ng/ml
28-38
ng/ml
Oral single dose;
DRUGBANK
1.25
h
1-1.5
h
PO, oral;
DRUGBANK
1.2
h
1-1.4
h
Oral single dose;
DRUGBANK
0.594
L/h/kg
6.3-13.5
ml/min/kg
adults;
DRUGBANK
450.0
L/h
4.0-11
L/min
Children;
DRUGBANK
0.81
L/h/kg
13.5±2.4
ml/min/kg
Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.5
L/kg
0.5
L/kg
DRUGBANK
0.034
L/kg
31-37
mL/kg
Steady state volume of distribution; Children;
DRUGBANK
0.46
L/kg
0.46±0.04
L/kg
DRUGBANK
1.8
h
1.8
h
elimination half-life;
DRUGBANK
0.8
h
0.8±0.2
h
DRUGBANK
1.8
h
1.8±0.8
h
PO, oral;
RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
8939.0
mg/kg
8939.0
mg/kg
PO, oral; mouse;
DRUGBANK
70.0
%
~70
%
Faeces excretion;
DRUGBANK
20.0
%
~20
%
Urinary excretion;
DRUGBANK
47.0
%
~47
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
53.0
%
53
%
Bile excretion; intravenous injection, IV;
DRUGBANK
47.0
%
47±7
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
~43-48
%
plasma proteins;
DRUGBANK
45.5
%
43-48
%
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
60.0
mg/day
60
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
60.0
mg/day
60
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
60.0
mg/day
60
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
60.0
mg/day
60
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Pravastatin Sodium
pravastatin sodium
PDR
DDPD00176
Fluvoxamine
318.34
C15H21F3N2O2
COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F
DB00176
T3D2705
3404
5138
http://www.drugs.com/cdi/fluvoxamine.html
4481878
-2.0
-
-2.0
-
DRUGBANK
53.0
%
53.0
%
DRUGBANK
1.917
L/h/kg
31.95
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
L/kg
25.0
L/kg
DRUGBANK
23.5
L/kg
23.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.6
h
15.6
h
DRUGBANK
12.5
h
12.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.0
%
94
%
Urinary excretion; PO, oral;
DRUGBANK
2.0
%
~2
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
~77-80
%
plasma proteins;
DRUGBANK
DDPD00177
Valsartan
435.5188
C24H29N5O3
CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
DB00177
60846
9927
http://www.drugs.com/cdi/valsartan.html
54833
-2.0
-
-2.0
-
DRUGBANK
23.0
%
23±7
%
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
1600.0
ng/ml
1.6±0.6
mcg/ml
Male, men; adults; normal,healthy;
DRUGBANK
5.0
h
4-6
h
Oral single dose; patients;
DRUGBANK
2.0
h
2(1.5-3)
h
Male, men; adults; normal,healthy;
DRUGBANK
9.0
%
9
%
Liver metabolism; Drug form;
DRUGBANK
2.0
L/h
~2
L/h
Plasma clearance;
DRUGBANK
0.62
L/h
0.62
L/h
Renal clearance;
DRUGBANK
0.0294
L/h/kg
0.49±0.09
ml/min/kg
normal,healthy; adults; Male, men;
Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.0294
L/h/kg
0.49
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
L
17.0
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
0.23
L/kg
0.23±0.09
L/kg
normal,healthy; adults; Male, men;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
~6
h
intravenous injection, IV; elimination half-life;
DRUGBANK
9.4
h
9.4±3.8
h
normal,healthy; adults; Male, men;
Age ↑ ;
DRUGBANK
9.5
h
9.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
~>2000
mg/kg
intragastric;
DRUGBANK
83.0
%
~83
%
Faeces excretion; Liquid;
DRUGBANK
13.0
%
~13
%
Urinary excretion; Liquid;
DRUGBANK
29.0
%
29±5.8
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
95.0
%
95
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
2.7
mg/kg/day
2.7
mg/kg/day
PO, oral
Valsartan
valsartan
PDR
160.0
mg/day
160
mg/day
PO, oral
Valsartan
valsartan
PDR
320.0
mg/day
320
mg/day
PO, oral
Valsartan
valsartan
PDR
320.0
mg/day
320
mg/day
PO, oral
Valsartan
valsartan
PDR
2.7
mg/kg/day
2.7
mg/kg/day
PO, oral
Valsartan
valsartan
PDR
160.0
mg/day
160
mg/day
PO, oral
Valsartan
valsartan
PDR
320.0
mg/day
320
mg/day
PO, oral
Valsartan
valsartan
PDR
DDPD00178
Ramipril
416.5106
C23H32N2O5
[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
DB00178
5362129
8774
http://www.drugs.com/ramipril.html
4514937
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
PO, oral;
DRUGBANK
28.0
%
28.0
%
PO, oral;
DRUGBANK
44.0
%
44.0
%
PO, oral;
DRUGBANK
28.0
%
28.0
%
PO, oral;
DRUGBANK
48.0
%
48.0
%
PO, oral; Active metabolite;
DRUGBANK
43.3
ng/ml
43.3±10.2
ng/ml
PO, oral;
DRUGBANK
24.1
ng/ml
24.1±5.6
ng/ml
PO, oral; Active metabolite;
DRUGBANK
1.2
h
1.2±0.3
h
PO, oral;
DRUGBANK
3.0
h
3.0±0.7
h
PO, oral; Active metabolite;
DRUGBANK
75.0
%
75.0
%
Liver metabolism; Active metabolite;
DRUGBANK
1.46705202312139
L/h/m2
7.2-77.4
ml/min/1.73m2
DRUGBANK
4.125
L/h
10.7-126.8
ml/min
Renal clearance; normal,healthy; Geriatric;
DRUGBANK
1.38
L/h/kg
23.0
ml/min/kg
PO, oral; intravenous injection, IV;
DRUGBANK
3.0
h
2-4
h
distribution half-life;
DRUGBANK
13.5
h
9-18
h
elimination half-life;
DRUGBANK
50.0
h
>50
h
terminal half-life;
DRUGBANK
15.0
h
13-17
h
DRUGBANK
31.5
h
27-36
h
DRUGBANK
5.0
h
5±2
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
13.5
h
9-18
h
elimination half-life; Active metabolite;
DRUGBANK
120.0
h
~120
h
terminal half-life;
DRUGBANK
10000.0
mg/kg
10.0
g/kg
Rattus, Rat;
DRUGBANK
10500.0
mg/kg
10.5
g/kg
mouse;
DRUGBANK
1000.0
mg/kg
1.0
g/kg
dog;
DRUGBANK
60.0
%
60
%
Urinary excretion;
DRUGBANK
40.0
%
40
%
Faeces excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
<2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
13.0
%
13±6
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
73.0
%
73
%
DRUGBANK
73.0
%
73±2
%
PO, oral; intravenous injection, IV;
DRUGBANK
56.0
%
56±2
%
PO, oral; intravenous injection, IV; Active metabolite;
DRUGBANK
6.0
mg/m2/day
6
mg/m2/day
PO, oral
Altace
ramipril
PDR
20.0
mg/day
20
mg/day
PO, oral
Altace
ramipril
PDR
10.0
mg/day
10
mg/day
PO, oral
Altace
ramipril
PDR
6.0
mg/m2/day
6
mg/m2/day
PO, oral
Altace
ramipril
PDR
20.0
mg/day
20
mg/day
PO, oral
Altace
ramipril
PDR
10.0
mg/day
10
mg/day
PO, oral
Altace
ramipril
PDR
DDPD00179
Masoprocol
302.3649
C18H22O4
C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
DB00179
T3D4813
71398
73468
64490
-2.0
-
-2.0
-
DRUGBANK
1.5
%
<1-2
%
DRUGBANK
DDPD00180
Flunisolide
434.4977
C24H31FO6
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
DB00180
82153
5106
http://www.drugs.com/cdi/flunisolide-spray.html
74144
-2.0
-
-2.0
-
DRUGBANK
0.57
L/h/kg
9.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.08
L/kg
1.08
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
1.8
h
DRUGBANK
1.68
h
1.68
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
%
~40
%
PO, oral;
DRUGBANK
0.64
mg/day
640
mcg/day
inhalation, IH
Aerospan
flunisolide
PDR
100.0
mcg/nostril/day
100
mcg/nostril/day
nasal spray
Aerospan
flunisolide
PDR
0.32
mg/day
320
mcg/day
inhalation, IH
Aerospan
flunisolide
PDR
100.0
mcg/nostril/day
100
mcg/nostril/day
nasal spray
Aerospan
flunisolide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Aerospan
flunisolide
PDR
200.0
mcg/nostriL/day
200
mcg/nostriL/day
nasal spray
Aerospan
flunisolide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Aerospan
flunisolide
PDR
200.0
mcg/nostril/day
200
mcg/nostril/day
nasal spray
Aerospan
flunisolide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Aerospan
flunisolide
PDR
100.0
mcg/nostril/day
100
mcg/nostril/day
nasal spray
Aerospan
flunisolide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Aerospan
flunisolide
PDR
0.2
mg/day
200
mcg/nostril/day
nasal spray
Aerospan
flunisolide
PDR
DDPD00181
Baclofen
213.661
C10H12ClNO2
NCC(CC(O)=O)C1=CC=C(Cl)C=C1
DB00181
T3D2554
2284
2972
http://www.drugs.com/baclofen.html
2197
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; increasing doses;
increasing doses ↓ ;
DRUGBANK
70.0
%
>70
%
PO, oral;
DRUGBANK
160.0
ng/ml
160±49
ng/ml
Oral single dose;
DRUGBANK
1.0
h
1.0(0.5-4)
h
Oral single dose;
DRUGBANK
15.0
%
15
%
Liver metabolism;
DRUGBANK
85.0
%
85
%
Renal metabolism; Urinary excretion; Faeces excretion;
DRUGBANK
10.8
L/h
180.0
ml/min
Total clearance;
DRUGBANK
6.18
L/h
103.0
ml/min
Renal clearance;
DRUGBANK
0.1632
L/h/kg
2.72±0.93
ml/min/kg
apparent clearance; Rectal Administration; normal,healthy; Male, men; adults;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
59.0
L
59.0
L
Apparent volume of distribution;
DRUGBANK
0.813
L/kg
0.81±0.12
L/kg
Apparent volume of distribution; Rectal Administration; normal,healthy; Male, men; adults;
DRUGBANK
0.65
L/kg
0.65
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
~5.5
h
elimination half-life;
DRUGBANK
3.75
h
3.75±0.96
h
normal,healthy; adults; Male, men;
DRUGBANK
5.24
h
5.24
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
145.0
mg/kg
145.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
45.0
mg/kg
45.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
78.0
mg/kg
78.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
75.0
%
70-80
%
Urinary excretion; Unchanged drug;
DRUGBANK
69.0
%
69±14
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
30.0
%
30
%
DRUGBANK
31.0
%
31±11
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Baclofen
baclofen
PDR
40.0
mg/day
40
mg/day
PO, oral
Baclofen
baclofen
PDR
80.0
mg/day
80
mg/day
PO, oral
Baclofen
baclofen
PDR
150.0
mg/day
150
mg/day
PO, oral
Baclofen
baclofen
PDR
80.0
mg/day
80
mg/day
PO, oral
Baclofen
baclofen
PDR
150.0
mg/day
150
mg/day
PO, oral
Baclofen
baclofen
PDR
80.0
mg/day
80
mg/day
PO, oral
Baclofen
baclofen
PDR
150.0
mg/day
150
mg/day
PO, oral
Baclofen
baclofen
PDR
DDPD00182
Amphetamine
135.2062
C9H13N
CC(N)CC1=CC=CC=C1
DB00182
T3D2706
3007
132233
http://www.drugs.com/amphetamine.html
13852819
-2.0
-
-2.0
-
DRUGBANK
75.0
%
>75
%
PO, oral; intravenous injection, IV;
DRUGBANK
0.7
L/h/kg
0.7
L/h/kg
DRUGBANK
0.4
L/h/kg
0.4
L/h/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
4.0
L/kg
4.0
L/kg
DRUGBANK
10.0
h
9-11
h
Raceme D;
DRUGBANK
12.5
h
11-14
h
Raceme L;
DRUGBANK
7.0
h
7
h
acidity;
DRUGBANK
34.0
h
34
h
alkalinity;
DRUGBANK
180.0
mg/kg
180.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
90.0
%
~90
%
Urinary excretion; PO, oral;
Urine alkaline ↓ ;
DRUGBANK
40.0
%
~40
%
Urinary excretion; Unchanged drug;
Urine alkaline ↓ ;
DRUGBANK
20.0
%
20
%
DRUGBANK
18.8
mg/day
18.8
mg/day
Tablet,PO，oral
Evekeo
amphetamine sulfate
PDR
20.0
mg/day
20
mg/day
Liquid
Evekeo
amphetamine sulfate
PDR
40.0
mg/day
40
mg/day
PO, oral
Evekeo
amphetamine sulfate
PDR
40.0
mg/day
40
mg/day
PO, oral
Evekeo
amphetamine sulfate
PDR
12.5
mg/day
12.5
mg/day
Tablet,PO，oral
Evekeo
amphetamine sulfate
PDR
60.0
mg/day
60
mg/day
PO, oral
Evekeo
amphetamine sulfate
PDR
12.5
mg/day
12.5
mg/day
Tablet,PO，oral
Evekeo
amphetamine sulfate
PDR
20.0
mg/day
20
mg/day
Liquid
Evekeo
amphetamine sulfate
PDR
40.0
mg/day
40
mg/day
PO, oral
Evekeo
amphetamine sulfate
PDR
12.5
mg/day
12.5
mg/day
Tablet,PO，oral
Evekeo
amphetamine sulfate
PDR
60.0
mg/day
60
mg/day
PO, oral
Evekeo
amphetamine sulfate
PDR
DDPD00183
Pentagastrin
767.9
C37H49N7O9S
CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
DB00183
9853654
31974
8029364
-2.0
-
-2.0
-
DRUGBANK
0.166666666666667
h
<=10
min
DRUGBANK
DDPD00184
Nicotine
162.2316
C10H14N2
CN1CCC[C@H]1C1=CN=CC=C1
DB00184
T3D0799
89594
17688
http://www.drugs.com/nicotine.html
80863
-2.0
-
-2.0
-
DRUGBANK
72.0
L/h
1.2
L/min
adults; normal,healthy; Somking;
DRUGBANK
1.08
L/h/kg
18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
L/kg
2.0-3
L/kg
DRUGBANK
2.6
L/kg
2.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
1-3
h
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
mg/kg
24.0
mg/kg
PO, oral; mouse;
DRUGBANK
140.0
mg/kg
140.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
25.0
mg/kg
25.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
5.9
mg/kg
5900.0
ug/kg
Intraperitoneal, IP; mouse;
DRUGBANK
2.8
mg/kg
2.8
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
24.0
mg/kg
24.0
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
%
~10
%
Urinary excretion; Unchanged drug;
DRUGBANK
5.0
%
<5
%
DRUGBANK
24.0
pieces/day
24
pieces/day
PO, oral
Nicotrol NS
nicotine
PDR
21.0
mg/day
21
mg/day
skin/dermal
Nicotrol NS
nicotine
PDR
20.0
Lozenges/day
20
Lozenges/day
PO, oral
Nicotrol NS
nicotine
PDR
40.0
sprays/day
40
sprays/day
nasal spray
Nicotrol NS
nicotine
PDR
64.0
mg/day
64
mg/day
inhalation, IH
Nicotrol NS
nicotine
PDR
24.0
pieces/day
24
pieces/day
PO, oral
Nicotrol NS
nicotine
PDR
21.0
mg/day
21
mg/day
skin/dermal
Nicotrol NS
nicotine
PDR
14.0
mg/day
14
mg/day
skin/dermal
Nicotrol NS
nicotine
PDR
24.0
pieces/day
24
pieces/day
PO, oral
Nicotrol NS
nicotine
PDR
21.0
mg/day
21
mg/day
skin/dermal
Nicotrol NS
nicotine
PDR
20.0
lozenges/day
20
lozenges/day
PO, oral
Nicotrol NS
nicotine
PDR
40.0
sprays/day
40
sprays/day
nasal spray
Nicotrol NS
nicotine
PDR
64.0
mg/day
64
mg/day
inhalation, IH
Nicotrol NS
nicotine
PDR
DDPD00185
Cevimeline
199.313
C10H17NOS
CC1O[C@@]2(CS1)CN1CCC2CC1
DB00185
25137844
3568
http://www.drugs.com/cdi/cevimeline.html
21864737
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1.5-2
h
DRUGBANK
44.5
%
44.5
%
Liver metabolism;
DRUGBANK
22.3
%
22.3
%
Liver metabolism;
DRUGBANK
4.0
%
4
%
Liver metabolism;
DRUGBANK
6.0
L/kg
6.0
L/kg
DRUGBANK
5.0
h
5±1
h
DRUGBANK
84.0
%
84
%
Urinary excretion;
DRUGBANK
20.0
%
<20
%
DRUGBANK
90.0
mg/day
90
mg/day
PO, oral
Evoxac
cevimeline hydrochloride
PDR
90.0
mg/day
90
mg/day
PO, oral
Evoxac
cevimeline hydrochloride
PDR
DDPD00186
Lorazepam
321.158
C15H10Cl2N2O2
OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
DB00186
T3D4585
3958
6539
http://www.drugs.com/lorazepam.html
3821
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
90.0
%
90.0
%
PO, oral;
DRUGBANK
93.0
%
93±10
%
PO, oral;
DRUGBANK
48.0
ng/ml
48.0
ng/ml
IM,intramuscular injection;
DRUGBANK
28.0
ng/ml
~28
ng/ml
PO, oral; adults; normal,healthy;
DRUGBANK
30.0
ng/ml
~30
ng/ml
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
75.0
ng/ml
~75
ng/ml
intravenous injection, IV; adults; normal,healthy;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
0.375
h
0.25-0.5
h
IM,intramuscular injection;
DRUGBANK
1.9
h
1.2-2.6
h
PO, oral; adults; normal,healthy;
DRUGBANK
1.2
h
1.2
h
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
0.348
L/h/kg
5.8
ml/min/kg
DRUGBANK
0.066
L/h/kg
1.1±0.4
ml/min/kg
metabolism of ugt;
Elderly → ;metastatic prostate cancer → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis ↑ ;Burn ↑ ;Somking → ;
DRUGBANK
0.06
L/h/kg
1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
L/kg
1.3
L/kg
DRUGBANK
1.3
L/kg
1.3±0.2
L/kg
Apparent volume of distribution;
Elderly → ;metastatic prostate cancer → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↑ ;Burn ↑ ;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.0
h
14
h
parenteral administration;
DRUGBANK
14.0
h
14±5
h
Neonates ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;CPBS → ;acute viral hepatitis AVH → ;Burn ↓ ;Age → ;
DRUGBANK
17.0
h
17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1850.0
mg/kg
1850.0
mg/kg
PO, oral; mouse;
DRUGBANK
1850.0
mg/kg
1850.0
mg/kg
PO, oral; mouse;
DRUGBANK
3178.0
mg/kg
3178.0
mg/kg
PO, oral; mouse;
DRUGBANK
88.0
%
88
%
Urinary excretion; Oral single dose; normal,healthy;
DRUGBANK
7.0
%
7
%
Faeces excretion; Oral single dose; normal,healthy;
DRUGBANK
0.3
%
0.3
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
85.0
%
85
%
DRUGBANK
91.0
%
91±2
%
Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Burn → ;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Ativan Tablets
lorazepam
PDR
4.0
mg/day
4
mg/day
PO, oral
Ativan Tablets
lorazepam
PDR
10.0
mg/day
10
mg/day
PO, oral
Ativan Tablets
lorazepam
PDR
10.0
mg/day
10
mg/day
PO, oral
Ativan Tablets
lorazepam
PDR
4.0
mg/day
4
mg/day
PO, oral
Ativan Tablets
lorazepam
PDR
10.0
mg/day
10
mg/day
PO, oral
Ativan Tablets
lorazepam
PDR
DDPD00187
Esmolol
295.374
C16H25NO4
COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1
DB00187
59768
88206
http://www.drugs.com/cdi/esmolol.html
53916
-2.0
-
-2.0
-
DRUGBANK
0.0833333333333333
h
5.0
min
DRUGBANK
20.0
L/h/kg
20.0
L/kg/h
Male, men;
DRUGBANK
17.4
L/h/kg
290
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0333333333333333
h
~2
min
rapid distribution half-life;
DRUGBANK
0.15
h
~9
min
elimination half-life;
DRUGBANK
3.7
h
~3.7
h
elimination half-life; Metabolite;
DRUGBANK
0.15
h
0.15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
55.0
%
55
%
plasma proteins; human, homo sapiens;
DRUGBANK
1.0
mg/kg/dose
1000
mcg/kg/dose
intravenous injection, IV
Brevibloc
esmolol hydrochloride
PDR
1440.0
mg/kg/day
1000
mcg/kg/minute
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
500.0
mcg/kg/dose
500
mcg/kg/dose
intravenous injection, IV
Brevibloc
esmolol hydrochloride
PDR
288.0
mg/kg/day
200
mcg/kg/min
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
432.0
mg/kg/day
300
mcg/kg/min
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
1.0
mg/kg/dose
1000
mcg/kg/dose
intravenous injection, IV
Brevibloc
esmolol hydrochloride
PDR
1440.0
mg/kg/day
1000
mcg/kg/minute
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
500.0
mcg/kg/dose
500
mcg/kg/dose
intravenous injection, IV
Brevibloc
esmolol hydrochloride
PDR
288.0
mg/kg/day
200
mcg/kg/minute
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
432.0
mg/kg/day
300
mcg/kg/minute
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
1.0
mg/kg/dose
1000
mcg/kg/dose
intravenous injection, IV
Brevibloc
esmolol hydrochloride
PDR
1440.0
mg/kg/day
1000
mcg/kg/min
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
500.0
mcg/kg/dose
500
mcg/kg/dose
intravenous injection, IV
Brevibloc
esmolol hydrochloride
PDR
720.0
mg/kg/day
500
mcg/kg/minute
intravenous infusion, iv in drop
Brevibloc
esmolol hydrochloride
PDR
DDPD00188
Bortezomib
384.237
C19H25BN4O4
CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
DB00188
387447
52717
http://www.drugs.com/cdi/bortezomib.html
343402
-2.0
-
-2.0
-
DRUGBANK
57.0
ng/ml
57.0
ng/ml
intravenous injection, IV;
DRUGBANK
112.0
ng/ml
112.0
ng/ml
intravenous injection, IV;
DRUGBANK
86.5
ng/ml
67-106
ng/ml
intravenous injection, IV;
DRUGBANK
104.5
ng/ml
89-120
ng/ml
intravenous injection, IV;
DRUGBANK
102.0
L/h
102.0
L/h
Average clearance;
DRUGBANK
112.0
L/h
112.0
L/h
Average clearance;
DRUGBANK
15.0
L/h
15.0
L/h
Average clearance;
DRUGBANK
32.0
L/h
32.0
L/h
Average clearance;
DRUGBANK
1.14
L/h/kg
19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1191.0
L/m2
498-1884
L/m2
Average volume of distribution; multiple myeloma; patients;
DRUGBANK
10.0
L/kg
10
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
116.5
h
40-193
h
elimination half-life; Multiple dose;
DRUGBANK
92.0
h
76-108
h
Multiple dose;
DRUGBANK
18.0
h
18
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.357142857142857
mg/kg/day
5.0
mg/kg/14D
mouse;
DRUGBANK
0.133333333333333
mg/kg/day
1.6
mg/kg/12D
mouse;
DRUGBANK
83.0
%
~83
%
plasma proteins; human, homo sapiens;
DRUGBANK
1.3
mg/m2/dose
1.3
mg/m2/dose
intravenous injection, IV;subcutaneous injection, SC;
Velcade
bortezomib
PDR
1.6
mg/m2/dose
1.6
mg/m2/dose
intravenous injection, IV
Velcade
bortezomib
PDR
1.3
mg/m2/dose
1.3
mg/m2/dose
intravenous injection, IV;subcutaneous injection, SC;
Velcade
bortezomib
PDR
1.6
mg/m2/dose
1.6
mg/m2/dose
intravenous injection, IV
Velcade
bortezomib
PDR
DDPD00189
Ethchlorvynol
144.6
C7H9ClO
CCC(O)(\C=C\Cl)C#C
DB00189
T3D2708
5281077
4882
http://www.drugs.com/cons/ethchlorvynol.html
4444534
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
Liver metabolism;
DRUGBANK
15.0
h
~10-20
h
elimination half-life;
DRUGBANK
60.5
h
21-100
h
terminal half-life;
DRUGBANK
42.5
%
35-50
%
DRUGBANK
DDPD00190
Carbidopa
226.2292
C10H14N2O4
C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
DB00190
34359
39585
http://www.drugs.com/cdi/carbidopa.html
31640
-2.0
-
-2.0
-
DRUGBANK
55.0
%
40-70
%
PO, oral;
DRUGBANK
321.333333333333
ng.h/ml
19.28
mcg.min/ml
PO, oral;
DRUGBANK
58.0
%
58.0
%
PO, oral;
DRUGBANK
85.0
ng/ml
0.085
mcg/ml
PO, oral;
DRUGBANK
165.0
ng/ml
165±77
ng/ml
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
81.0
ng/ml
81±28
ng/ml
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
2.38333333333333
h
143
min
PO, oral;
DRUGBANK
2.1
h
2.1±1.0
h
PO, oral; adults; normal,healthy;
DRUGBANK
51.7
L/h
51.7
L/h
DRUGBANK
1.08
L/h/kg
18±7
ml/min/kg
normal,healthy; adults;
DRUGBANK
3.6
L/kg
3.6
L/kg
DRUGBANK
1.78333333333333
h
~107
min
DRUGBANK
2.0
h
~2
h
normal,healthy; adults;
DRUGBANK
4810.0
mg/kg
4810.0
mg/kg
Rattus, Rat;
DRUGBANK
50.0
%
50
%
Urinary excretion; human, homo sapiens;
DRUGBANK
5.3
%
5.3±2.1
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
76.0
%
76
%
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Lodosyn
carbidopa
PDR
200.0
mg/day
200
mg/day
PO, oral
Lodosyn
carbidopa
PDR
DDPD00191
Phentermine
149.2328
C10H15N
CC(C)(N)CC1=CC=CC=C1
DB00191
T3D2709
4771
8080
http://www.drugs.com/phentermine.html
4607
-2.0
-
-2.0
-
DRUGBANK
6.0
h
6
h
PO, oral;
DRUGBANK
6.0
%
6.0
%
DRUGBANK
8.79
L/h
8.79
L/h
PO, oral;
DRUGBANK
59.0
L/kg
5.0
L/kg
DRUGBANK
20.0
h
~20
h
elimination half-life;
DRUGBANK
7.5
h
7-8
h
elimination half-life; Uric acid;
DRUGBANK
151.0
mg/kg
151.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
17.5
mg/kg
15-20
mg/kg
monkey;
DRUGBANK
75.0
%
~70-80
%
Urinary excretion; Unchanged drug;
DRUGBANK
17.5
%
17.5
%
DRUGBANK
37.5
mg/day
37.5
mg/day
PO, oral
Lomaira
phentermine hydrochloride
PDR
37.5
mg/day
37.5
mg/day
PO, oral
Lomaira
phentermine hydrochloride
PDR
37.5
mg/day
37.5
mg/day
PO, oral
Lomaira
phentermine hydrochloride
PDR
DDPD00192
Indecainide
308.4174
C20H24N2O
CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=CC=CC=C12
DB00192
52195
135314
47194
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; Rattus, Rat; young; adults; mouse; Rattus, Rat;
DRUGBANK
DDPD00193
Tramadol
263.3752
C16H25NO2
COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
DB00193
T3D2575
33741
75725
http://www.drugs.com/tramadol.html
31105
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
75.0
%
75.0
%
PO, oral;
DRUGBANK
77.0
%
77.0
%
Rectal Administration;
DRUGBANK
72.5
%
70-75
%
PO, oral;
DRUGBANK
300.0
ng/ml
300.0
ug/L
Oral single dose;
DRUGBANK
348.0
ng/ml
348.0
ug/L
Oral multiple dose;
DRUGBANK
166.0
ng/ml
166.0
ug/L
IM,intramuscular injection;
DRUGBANK
294.0
ng/ml
294.0
ug/L
Rectal Administration;
DRUGBANK
592.0
ng/ml
592±178
ng/ml
Tablet, PO, oral; immediate release formulation;
DRUGBANK
110.0
ng/ml
110±32
ng/ml
Tablet, PO, oral; Active metabolite; immediate release formulation;
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
1.75
h
1.6-1.9
h
Oral single dose;
DRUGBANK
0.75
h
0.75
h
IM,intramuscular injection;
DRUGBANK
3.3
h
3.3
h
Rectal Administration;
DRUGBANK
2.3
h
2.3±1.4
h
Tablet, PO, oral; immediate release formulation;
DRUGBANK
2.4
h
2.4±1.1
h
Tablet, PO, oral; Active metabolite; immediate release formulation;
DRUGBANK
48.0
h
2.0
day
Oral single dose;
DRUGBANK
92.5
%
90-95
%
Liver metabolism; Caucasian;
DRUGBANK
7.5
%
5-10
%
Liver metabolism; poor metabolizers, PM;
DRUGBANK
0.2238
L/h/kg
3.73
ml/min/kg
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
0.51
L/h/kg
8.5
ml/min/kg
normal,healthy; adults;
DRUGBANK
0.48
L/h/kg
8(6-12)
ml/min/kg
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.39
L/h/kg
6.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.75
L/kg
2.6-2.9
L/kg
DRUGBANK
306.0
L
306.0
L
Total volume of distribution; PO, oral;
DRUGBANK
203.0
L
203.0
L
Total volume of distribution; parenteral administration;
DRUGBANK
2.7
L/kg
2.7(2.3-3.9)
L/kg
DRUGBANK
2.8
L/kg
2.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
5-6
h
DRUGBANK
8.0
h
8
h
Metabolite;
DRUGBANK
5.5
h
5.5(4.5-7.5)
h
RD, renal impairment, Renal disease，including uremia ↑ ;chronic liver disease ↑ ;
DRUGBANK
5.8
h
5.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
PO, oral; mouse;
DRUGBANK
325.0
mg/kg
300-350
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
30.0
%
~30
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
10-30
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
20.0
%
~20
%
plasma proteins;
DRUGBANK
20.0
%
20
%
DRUGBANK
0.0
0
Ultram ER
tramadol hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Ultram ER
tramadol hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Ultram ER
tramadol hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Ultram ER
tramadol hydrochloride
PDR
300.0
mg/day
300
mg/day
Tablet,PO，oral
Ultram ER
tramadol hydrochloride
PDR
300.0
mg/day
300
mg/day
Tablet,PO，oral
Ultram ER
tramadol hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Ultram ER
tramadol hydrochloride
PDR
300.0
mg
300
mg
PO, oral
Ultram ER
tramadol hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Ultram ER
tramadol hydrochloride
PDR
0.0
0
Ultram ER
tramadol hydrochloride
PDR
DDPD00194
Vidarabine
267.2413
C10H13N5O4
NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
DB00194
21704
45327
http://www.drugs.com/mtm/vidarabine-ophthalmic.html
20400
-2.0
-
-2.0
-
DRUGBANK
5020.0
mg/kg
>5020
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
31.0
%
24-38
%
DRUGBANK
DDPD00195
Betaxolol
307.4278
C18H29NO3
CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
DB00195
2369
3082
http://www.drugs.com/cdi/betaxolol-drops.html
2279
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
89.0
%
>89
%
PO, oral;
DRUGBANK
85.0
%
85
%
Liver metabolism;
DRUGBANK
0.204
L/h/kg
3.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.8
L/kg
4.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
14-22
h
DRUGBANK
17.0
h
17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
375.0
mg/kg
350-400
mg/kg
PO, oral; mouse;
DRUGBANK
920.0
mg/kg
860-980
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
%
50
%
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Betoptic S
betaxolol hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Betoptic S
betaxolol hydrochloride
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Betoptic S
betaxolol hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Betoptic S
betaxolol hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Betoptic S
betaxolol hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Betoptic S
betaxolol hydrochloride
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Betoptic S
betaxolol hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Betoptic S
betaxolol hydrochloride
PDR
DDPD00196
Fluconazole
306.2708
C13H12F2N6O
OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
DB00196
T3D2711
3365
46081
http://www.drugs.com/cdi/fluconazole.html
3248
-2.0
-
-2.0
-
DRUGBANK
20.3
null
20.3
null
PO, oral; normal,healthy;
DRUGBANK
90.0
%
>90
%
PO, oral; food;
food → ;
DRUGBANK
90.0
%
>90
%
intravenous injection, IV;
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
10600.0
ng/ml
10.6±0.4
mcg/ml
PO, oral; adults; normal,healthy;
DRUGBANK
3.0
h
3
h
PO, oral; patients;
DRUGBANK
1.5
h
1-2
h
PO, oral; normal,healthy;
DRUGBANK
3.0
h
1.7-4.3
h
PO, oral; adults; normal,healthy;
DRUGBANK
180.0
h
5-10
day
Oral multiple dose;
DRUGBANK
6.5
%
6.5
%
Urinary excretion;
DRUGBANK
2.0
%
2
%
Urinary excretion;
DRUGBANK
0.0138
L/h/kg
0.23
ml/min/kg
Average clearance; adults;
DRUGBANK
1.17
L/h
19.5±4.7
ml/min
Total clearance; normal,healthy;
DRUGBANK
0.882
L/h
14.7±3.7
ml/min
Renal clearance; normal,healthy;
DRUGBANK
0.0162
L/h/kg
0.27±0.07
ml/min/kg
Neonates → ;Prem, premature ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;AIDS,HIV → ;
DRUGBANK
0.0186
L/h/kg
0.31
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39.0
L
39.0
L
Apparent volume of distribution;
DRUGBANK
0.6
L/kg
0.60±0.11
L/kg
Neonates ↑ ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.75
L/kg
0.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
h
~30(20-50)
h
elimination half-life; PO, oral;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
32.0
h
32±5
h
Prem, premature ↑ ;Children ↓ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
30.0
h
30
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1271.0
mg/kg
1271.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
93.3
%
93.3
%
Urinary excretion;
DRUGBANK
80.0
%
~80
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
75.0
%
75±9
%
Urinary excretion; Unchanged drug;
DRUGBANK
11.5
%
11-12
%
DRUGBANK
11.0
%
11±1
%
DRUGBANK
12.0
mg/kg/day
12
mg/kg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
600.0
mg/day
600
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
800.0
mg/day
800
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
800.0
mg/day
800
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
800.0
mg/day
800
mg/day
PO, oral;intravenous injection, IV;
Diflucan
fluconazole
PDR
DDPD00197
Troglitazone
441.54
C24H27NO5S
CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O
DB00197
T3D4789
5591
9753
http://www.drugs.com/mtm/troglitazone.html
5389
-2.0
-
-2.0
-
DRUGBANK
23.0
h
16-30
h
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD00198
Oseltamivir
312.4045
C16H28N2O4
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
DB00198
65028
7798
http://www.drugs.com/oseltamivir.html
58540
-2.0
-
-2.0
-
DRUGBANK
112.0
ng.h/ml
112.0
ng.h/ml
Capsule, PO, Oral; food;
food → ;
DRUGBANK
2719.0
ng.h/ml
2719.0
ng.h/ml
Capsule, PO, Oral; food; Active metabolite;
food → ;
DRUGBANK
75.0
%
>75
%
PO, oral;
DRUGBANK
65.0
ng/ml
65.0
ng/ml
Capsule, PO, Oral; food;
food → ;
DRUGBANK
348.0
ng/ml
348.0
ng/ml
Capsule, PO, Oral; food; Active metabolite;
food → ;
DRUGBANK
18.8
L/h
18.8
L/h
Renal clearance;
DRUGBANK
24.5
L
~23-26
L
Average volume of distribution; human, homo sapiens;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
8.0
h
6-10
h
PO, oral;
DRUGBANK
20.0
%
<20
%
Faeces excretion; PO, oral;
DRUGBANK
42.0
%
42
%
plasma proteins; human, homo sapiens;
DRUGBANK
75.0
mg
75
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
60.0
mg
60
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
45.0
mg
45
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
30.0
mg
30
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
75.0
mg
75
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
300.0
mg/day
300
mg/day
PO, oral
Tamiflu
oseltamivir phosphate
PDR
75.0
mg
75
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
75.0
mg
75
mg
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
6.0
mg/kg/day
3
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
7.0
mg/kg/day
3.5
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
6.0
mg/kg/day
3
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
6.0
mg/kg/day
3
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
6.0
mg/kg/day
3
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
6.0
mg/kg/day
3
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
3.0
mg/kg/day
1.5
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
2.0
mg/kg/day
1
mg/kg/dose
PO, oral
bid
Tamiflu
oseltamivir phosphate
PDR
DDPD00199
Erythromycin
733.9268
C37H67NO13
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
DB00199
T3D4764
12560
42355
http://www.drugs.com/cdi/erythromycin-ointment.html
12041
-2.0
-
-2.0
-
DRUGBANK
7300.0
ng.h/ml
7.3±3.9
mg.h/l
PO, oral;
DRUGBANK
31.5
%
18-45
%
PO, oral;
DRUGBANK
35.0
%
35±25
%
DRUGBANK
1.8
ng/ml
1.8
mcg/L
PO, oral;
DRUGBANK
2200.0
ng/ml
0.9-3.5
mcg/ml
PO, oral; extended release formulation;
DRUGBANK
950.0
ng/ml
0.5-1.4
mcg/ml
Tablet, PO, oral;
DRUGBANK
1.2
h
1.2
h
PO, oral;
DRUGBANK
3.0
h
2.1-3.9
h
PO, oral; extended release formulation;
DRUGBANK
2.5
h
2-3
h
Tablet, PO, oral;
DRUGBANK
0.53
L/h/kg
0.53±0.13
l/h/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
42.2
L/h
42.2±10.1
L/h
Hepatitis, Hep; patients;
Hepatitis, Hep ↓ ;
DRUGBANK
113.2
L/h
113.2±44.2
L/h
normal,healthy; patients;
DRUGBANK
0.546
L/h/kg
9.1±4.1
ml/min/kg
hydrolysis;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.336
L/h/kg
5.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.78
L/kg
0.78±0.44
L/kg
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.95
L/kg
0.95
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3.5
h
elimination half-life; PO, oral; different study;
DRUGBANK
2.75
h
2.4-3.1
h
elimination half-life; PO, oral; different study;
DRUGBANK
1.6
h
1.6±0.7
h
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9272.0
mg/kg
9272.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.0
%
<5
%
Urinary excretion; PO, oral;
DRUGBANK
12.0
%
12±7
%
Urinary excretion; Unchanged drug;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
84.0
%
84±3
%
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
2000.0
mg/day
2
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
2000.0
mg/day
2
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Erythrocin Stearate
erythromycin stearate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Erythrocin Stearate
erythromycin stearate
PDR
DDPD00200
Hydroxocobalamin
1346.3551
C62H89CoN13O15P
[N+]1=2[Co-3]345([N+]6=C7[C@H]([C@@](CC(=O)N)(C)[C@@]6([C@@]6(N3C(=C(C)C3=[N+]4C(C(C)(C)[C@@H]3CCC(=O)N)=CC3=[N+]5C(=C7C)[C@@](CC(=O)N)([C@@H]3CCC(=O)N)C)[C@@](C)([C@H]6CC(=O)N)CCC(NC[C@@H](C)OP(=O)(O[C@@H]3[C@H](O[C@H](N(C4=CC(=C(C=C14)C)C)C=2)[C@@H]3O)CO)[O-])=O)[H])C)CCC(=O)N)O[H]
DB00200
T3D0677
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
70678542
27786
http://www.drugs.com/cdi/hydroxocobalamin.html
21403074
-2.0
-
-2.0
-
DRUGBANK
144.0
h
~6
day
DRUGBANK
50.0
ml/kg
>50
mL/kg
intravenous injection, IV; mouse;
DRUGBANK
1e-07
mg/L
0.0001
mg/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
90.0
%
90
%
high protein binding;
DRUGBANK
DDPD00201
Caffeine
194.1906
C8H10N4O2
CN1C=NC2=C1C(=O)N(C)C(=O)N2C
DB00201
T3D2712
2519
27732
http://www.drugs.com/caffeine.html
2424
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; adults;
adults ↑ ;
DRUGBANK
8000.0
ng/ml
6-10
mg/L
PO, oral;
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
Average clearance;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.85
L/kg
0.8-0.9
L/kg
Average volume of distribution; Infants;
DRUGBANK
0.6
L/kg
0.6
L/kg
Average volume of distribution; adults;
DRUGBANK
0.63
L/kg
0.63
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~5
h
Children; Adolescents;
DRUGBANK
2.5
h
~2.5
h
Somking;
DRUGBANK
20.0
h
>20
h
Preg, pregnant;
DRUGBANK
8.0
h
~8
h
Neonates;
DRUGBANK
100.0
h
100
h
Prem, premature;
hepatopathy，LD ↑ ;
DRUGBANK
4.9
h
4.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
192.0
mg/kg
192.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
127.0
mg/kg
127.0
mg/kg
PO, oral; mouse;
DRUGBANK
1.25
%
0.5-2
%
Urinary excretion;
DRUGBANK
23.0
%
10-36
%
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Caffeine Citrate
caffeine citrate
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caffeine Citrate
caffeine citrate
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caffeine Citrate
caffeine citrate
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caffeine Citrate
caffeine citrate
PDR
3.75
mg/kg/day
3.75
mg/kg/day
PO, oral;intravenous injection, IV;
Caffeine Citrate
caffeine citrate
PDR
3.75
mg/kg/day
3.75
mg/kg/day
PO, oral;intravenous injection, IV;
Caffeine Citrate
caffeine citrate
PDR
DDPD00202
Succinylcholine
290.399
C14H30N2O4
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
DB00202
5314
45652
http://www.drugs.com/cdi/succinylcholine.html
5123
-2.0
-
-2.0
-
DRUGBANK
10.0
%
~10
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.5
mg/kg/dose
1.5
mg/kg/dose
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
4.0
mg/kg/dose
4
mg/kg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
150.0
mg/dose
150
mg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
2.0
mg/kg/dose
2
mg/kg/dose
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
4.0
mg/kg/dose
4
mg/kg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
1.5
mg/kg
1.5
mg/kg
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
150.0
mg
150
mg
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
1.5
mg/kg/dose
1.5
mg/kg/dose
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
4.0
mg/kg/dose
4
mg/kg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
150.0
mg/dose
150
mg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
1.5
mg/kg
1.5
mg/kg
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
150.0
mg
150
mg
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
2.0
mg/kg/dose
2
mg/kg/dose
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
4.0
mg/kg/dose
4
mg/kg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
4.0
mg/kg/dose
4
mg/kg/dose
intravenous injection, IV
Quelicin
succinylcholine chloride
PDR
5.0
mg/kg/dose
5
mg/kg/dose
IM,intramuscular injection
Quelicin
succinylcholine chloride
PDR
4.0
mg/kg/dose
4
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
Quelicin
succinylcholine chloride
PDR
DDPD00203
Sildenafil
474.576
C22H30N6O4S
CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1
DB00203
5212
9139
http://www.drugs.com/cdi/sildenafil.html
5023
-2.0
-
-2.0
-
DRUGBANK
41.0
%
~41
%
PO, oral;
DRUGBANK
44.0
%
25-63
%
PO, oral;
DRUGBANK
58.63
%
58.63
%
Oral multiple dose; hypertension; increasing doses;
hypertension ↑ ;increasing doses ↑ ;
DRUGBANK
38.0
%
38.0
%
DRUGBANK
212.0
ng/ml
212±59
ng/ml
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
1.2
h
1.2±0.3
h
DRUGBANK
41.0
L/h
41.0
L/h
Total clearance;
DRUGBANK
0.36
L/h/kg
6.0±1.1
ml/min/kg
hydrolysis; hydrolysis; normal,healthy; Male, men;
Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.54
L/h/kg
9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
105.0
L
~105
L
Steady state volume of distribution;
DRUGBANK
1.2
L/kg
1.2±0.3
L/kg
hydrolysis; hydrolysis; normal,healthy; Male, men;
DRUGBANK
1.36
L/kg
1.36
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
~3-5
h
terminal half-life;
DRUGBANK
2.4
h
2.4±1.0
h
Male, men;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
~80
%
Faeces excretion; PO, oral;
DRUGBANK
13.0
%
~13
%
Urinary excretion; PO, oral;
DRUGBANK
0.0
%
0
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
96.0
%
96
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
20.0
mg
20
mg
PO, oral
tid
Revatio
sildenafil
PDR
10.0
mg
10
mg
PO, oral
tid
Revatio
sildenafil
PDR
100.0
mg/day
100
mg/day
PO, oral
Revatio
sildenafil
PDR
60.0
mg/day
60
mg/day
PO, oral
Revatio
sildenafil
PDR
30.0
mg/day
30
mg/day
intravenous injection, IV
Revatio
sildenafil
PDR
240.0
mg/day
240
mg/day
PO, oral
Revatio
sildenafil
PDR
20.0
mg
20
mg
PO, oral
tid
Revatio
sildenafil
PDR
100.0
mg/day
100
mg/day
PO, oral
Revatio
sildenafil
PDR
60.0
mg/day
60
mg/day
PO, oral
Revatio
sildenafil
PDR
30.0
mg/day
30
mg/day
intravenous injection, IV
Revatio
sildenafil
PDR
240.0
mg/day
240
mg/day
PO, oral
Revatio
sildenafil
PDR
3.0
mg/kg/day
1
mg/kg/dose
PO, oral
q8h
Revatio
sildenafil
PDR
3.0
mg/kg/day
1
mg/kg/dose
PO, oral
q8h
Revatio
sildenafil
PDR
0.4
mg/kg/dose
0.4
mg/kg/dose
intravenous injection, IV
Revatio
sildenafil
PDR
0.00279166666666667
mg/kg/day
0.067
mg/kg/hour
intravenous infusion, iv in drop
Revatio
sildenafil
PDR
DDPD00204
Dofetilide
441.565
C19H27N3O5S2
CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
DB00204
71329
4681
http://www.drugs.com/cdi/dofetilide.html
64435
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
food ↓ ;
DRUGBANK
96.0
%
96(83-108)
%
PO, oral;
DRUGBANK
2.3
ng/ml
2.3±1.1
ng/ml
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
1.75
h
1-2.5
h
PO, oral;
DRUGBANK
0.3138
L/h/kg
5.23±0.30
ml/min/kg
hydrolysis; normal,healthy; adults;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.312
L/h/kg
5.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
L/kg
3.0
L/kg
DRUGBANK
3.44
L/kg
3.44±0.25
L/kg
hydrolysis; normal,healthy; adults;
DRUGBANK
3.3
L/kg
3.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
10
h
DRUGBANK
7.5
h
7.5±0.4
h
normal,healthy; Male, men; Female, women;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
8.1
h
8.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
52.0
%
52±2
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
65.0
%
60-70
%
DRUGBANK
60.0
%
64
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
1.0
mg/day
1000
mcg/day
PO, oral
Tikosyn
dofetilide
PDR
1.0
mg/day
1000
mcg/day
PO, oral
Tikosyn
dofetilide
PDR
DDPD00205
Pyrimethamine
248.711
C12H13ClN4
CCC1=C(C(N)=NC(N)=N1)C1=CC=C(Cl)C=C1
DB00205
T3D4779
4993
8673
http://www.drugs.com/cdi/pyrimethamine.html
4819
-2.0
-
-2.0
-
DRUGBANK
4.0
h
2-6
h
DRUGBANK
0.00312
L/h/kg
0.052
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
96.0
h
96
h
DRUGBANK
140.0
h
140
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.0
%
87
%
DRUGBANK
1.0
mg/kg/day
1
mg/kg/day
Daraprim
pyrimethamine
PDR
2.0
mg/kg/day
2
mg/kg/day
Daraprim
pyrimethamine
PDR
50.0
mg/day
50
mg/day
Daraprim
pyrimethamine
PDR
75.0
mg/day
75
mg/day
PO, oral
Daraprim
pyrimethamine
PDR
75.0
mg/day
75
mg/day
PO, oral
Daraprim
pyrimethamine
PDR
75.0
mg/day
75
mg/day
PO, oral
Daraprim
pyrimethamine
PDR
1.0
mg/kg/day
1
mg/kg/day
Daraprim
pyrimethamine
PDR
2.0
mg/kg/day
2
mg/kg/day
Daraprim
pyrimethamine
PDR
1.0
mg/kg/day
1
mg/kg/day
Daraprim
pyrimethamine
PDR
2.0
mg/kg/day
2
mg/kg/day
Daraprim
pyrimethamine
PDR
DDPD00206
Reserpine
608.6787
C33H40N2O9
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2
DB00206
T3D2713
5770
28487
http://www.drugs.com/cdi/reserpine.html
5566
-2.0
-
-2.0
-
DRUGBANK
420.0
mg/kg
420.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
44.0
mg/kg
44.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
15.0
mg/kg
15.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
200.0
mg/kg
200.0
mg/kg
PO, oral; mouse;
DRUGBANK
52.0
mg/kg
52.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
7.0
mg/kg
7.0
mg/kg
Intraperitoneal, IP; rabbit;
DRUGBANK
420.0
mg/kg
420.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
44.0
mg/kg
44.0
mg/kg
Intraperitoneal, IP; parenteral administration; Rattus, Rat;
DRUGBANK
15.0
mg/kg
15.0
mg/kg
intravenous injection, IV; parenteral administration; Rattus, Rat;
DRUGBANK
200.0
mg/kg
200.0
mg/kg
PO, oral; mouse;
DRUGBANK
52.0
mg/kg
52.0
mg/kg
subcutaneous injection, SC; parenteral administration; mouse;
DRUGBANK
7.0
mg/kg
7.0
mg/kg
Intraperitoneal, IP; parenteral administration; rabbit;
DRUGBANK
62.0
%
62
%
DRUGBANK
0.5
mg/day
0.5
mg/day
PO, oral
Reserpine
reserpine
PDR
1.0
mg/day
1
mg/day
PO, oral
Reserpine
reserpine
PDR
0.25
mg/day
0.25
mg/day
PO, oral
Reserpine
reserpine
PDR
DDPD00207
Azithromycin
748.9845
C38H72N2O12
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
DB00207
447043
2955
http://www.drugs.com/cdi/azithromycin-drops.html
10482163
-2.0
-
-2.0
-
DRUGBANK
37.0
%
37.0
%
PO, oral; food;
food → ;
DRUGBANK
34.0
%
34±19
%
PO, oral;
DRUGBANK
400.0
ng/ml
0.4
mcg/ml
PO, oral; adults; patients;
DRUGBANK
2.5
h
2-3
h
PO, oral; adults; patients;
DRUGBANK
37.8
L/h
630.0
ml/min
Plasma clearance; PO, oral; intravenous injection, IV;
DRUGBANK
0.54
L/h/kg
9.0
ml/min/kg
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
31.1
L/kg
31.1
L/kg
Steady state volume of distribution; PO, oral;
DRUGBANK
31.0
L/kg
31.0
L/kg
DRUGBANK
33.0
L/kg
33
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
68.0
h
68
h
elimination half-life;
DRUGBANK
40.0
h
40.0
h
Hepatic cirrhosis, cirr → ;
DRUGBANK
68.0
h
68±8
h
terminal half-life;
DRUGBANK
69.0
h
69
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
6.0
%
~6
%
Urinary excretion; Unchanged drug;
DRUGBANK
12.0
%
12
%
Urinary excretion; Unchanged drug;
DRUGBANK
51.0
%
51
%
human, homo sapiens;
DRUGBANK
7.0
%
7
%
human, homo sapiens;
DRUGBANK
28.5
%
7-50
%
DRUGBANK
50.0
%
50
%
DRUGBANK
12.0
%
12
%
DRUGBANK
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
30.0
mg/kg
30
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
30.0
mg/kg
30
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/dose
500
mg/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1500.0
mg/dose
1.5
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
2000.0
mg/dose
2
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/dose
500
mg/dose
intravenous injection, IV
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/day
500
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
2000.0
mg/dose
2
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/day
500
mg/day
intravenous infusion, iv in drop
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/day
500
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
2000.0
mg/dose
2
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/day
500
mg/day
intravenous infusion, iv in drop
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
30.0
mg/kg/dose
30
mg/kg/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1200.0
mg/kg
1200
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/dose
500
mg/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1500.0
mg/dose
1.5
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
2000.0
mg/dose
2
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/dose
500
mg/dose
intravenous injection, IV
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/day
500
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
2.0
g/dose
2
g/dose
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
500.0
mg/day
500
mg/day
intravenous infusion, iv in drop
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
30.0
mg/kg
30
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Zithromax 250 mg and 500 mg Tablets and Oral Suspension
azithromycin
PDR
DDPD00208
Ticlopidine
263.786
C14H14ClNS
ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2
DB00208
5472
9588
http://www.drugs.com/cdi/ticlopidine.html
5273
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
PO, oral; food;
food ↑ ;
DRUGBANK
7.9
h
~7.9
h
Single dose; adults;
DRUGBANK
12.6
h
12.6
h
Single dose; Elderly;
DRUGBANK
96.0
h
~4
day
adults;
DRUGBANK
120.0
h
~5
day
Elderly;
DRUGBANK
60.0
%
60
%
Urinary excretion;
DRUGBANK
23.0
%
23
%
Faeces excretion;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
15.0
%
≤15
%
DRUGBANK
500.0
mg/day
500
mg/day
PO, oral
Ticlopidine Hydrochloride
ticlopidine hydrochloride
PDR
500.0
mg/day
500
mg/day
PO, oral
Ticlopidine Hydrochloride
ticlopidine hydrochloride
PDR
DDPD00209
Trospium
392.518
C25H30NO3
[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1
DB00209
5284632
145791
http://www.drugs.com/cdi/trospium.html
10482307
-2.0
-
-2.0
-
DRUGBANK
9.6
%
9.6
%
DRUGBANK
29.07
L/h
29.07
L/h
Renal clearance;
DRUGBANK
0.834
L/h/kg
13.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
395.0
L
395±140
L
DRUGBANK
5.1
L/kg
5.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
h
20
h
DRUGBANK
5.0
h
5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.2
%
85.2
%
Faeces excretion; PO, oral;
DRUGBANK
5.8
%
5.8
%
Urinary excretion; PO, oral;
DRUGBANK
60.0
%
60
%
Urinary excretion; Unchanged drug;
DRUGBANK
67.5
%
50-85
%
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Trospium Chloride Tablets
trospium chloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Trospium Chloride Tablets
trospium chloride
PDR
DDPD00210
Adapalene
412.5201
C28H28O3
COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2
DB00210
T3D4673
60164
31174
http://www.drugs.com/cdi/adapalene-cream.html
54244
-2.0
-
-2.0
-
DRUGBANK
8.37
ng.h/ml
8.37±8.46
ng.h/ml
skin/dermal;
DRUGBANK
0.553
ng/ml
0.553±0.466
ng/ml
skin/dermal;
DRUGBANK
25.0
%
25
%
Liver metabolism;
DRUGBANK
17.2
h
17.2±10.2(7-51)
h
elimination half-life; ointment; gel; Oral multiple dose;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
10.0
ml/kg
>10
mL/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
75.0
%
~75
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD00211
Midodrine
254.2823
C12H18N2O4
COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1
DB00211
4195
6933
http://www.drugs.com/cdi/midodrine.html
4050
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93.0
%
PO, oral; food;
food → ;
DRUGBANK
0.5
h
0.5
h
PO, oral;
DRUGBANK
23.1
L/h
385.0
ml/min
Renal clearance;
DRUGBANK
1.674
L/h/kg
27.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
~3-4
h
Metabolite;
DRUGBANK
0.6
h
0.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
mg/kg
~30-50
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
675.0
mg/kg
~675
mg/kg
PO, oral; mouse;
DRUGBANK
142.5
mg/kg
~125-160
mg/kg
PO, oral; dog;
DRUGBANK
DDPD00213
Pantoprazole
383.37
C16H15F2N3O4S
COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
DB00213
4679
7915
http://www.drugs.com/cdi/pantoprazole.html
4517
-2.0
-
-2.0
-
DRUGBANK
5000.0
ng.h/ml
5.0
ug.h/ml
Oral single dose; food;
food → ;
DRUGBANK
77.0
%
77.0
%
PO, oral; increasing dosing frequency;
increasing dosing frequency → ;
DRUGBANK
2.5
ng/ml
~2.5
ug/L
Oral single dose; food;
food → ;
DRUGBANK
2.5
h
2-3
h
PO, oral; increasing dosing frequency;
increasing dosing frequency → ;
DRUGBANK
2.5
h
2-3
h
Oral single dose; food;
food → ;
DRUGBANK
80.0
%
80
%
Urinary excretion; PO, oral; intravenous injection, IV;
DRUGBANK
20.0
%
20
%
Faeces excretion; PO, oral; intravenous injection, IV;
DRUGBANK
10.8
L/h
7.6-14.0
L/h
Total clearance; intravenous injection, IV; extensive metabolizers, EM; adults;
gaining weight ↑ ;
DRUGBANK
2.4
L/h
2.4
L/h
gastroesophageal reflux disease; Children;
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.3
L
11-23.6
L
Apparent volume of distribution;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
747.0
mg/kg
747.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
71.0
%
~71
%
Urinary excretion; Oral single dose; intravenous injection, IV; normal,healthy;
DRUGBANK
18.0
%
18
%
Faeces excretion; Oral single dose; intravenous injection, IV; normal,healthy;
DRUGBANK
98.0
%
~98
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral;intravenous injection, IV;
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
160.0
mg/day
160
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
240.0
mg/day
240
mg/day
PO, oral;intravenous injection, IV;
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral;intravenous injection, IV;
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
160.0
mg/day
160
mg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
240.0
mg/day
240
mg/day
PO, oral;intravenous injection, IV;
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
1.2
mg/kg/day
1.2
mg/kg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
1.2
mg/kg/day
1.2
mg/kg/day
PO, oral
Protonix Delayed Release Oral Suspension and Tablets
pantoprazole sodium
PDR
DDPD00214
Torasemide
348.42
C16H20N4O3S
CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1
DB00214
41781
9637
38123
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
DRUGBANK
1.0
h
1
h
PO, oral; food;
food → ;
DRUGBANK
80.0
%
80
%
Liver metabolism; Inactive metabolite;
DRUGBANK
9.0
%
9
%
DRUGBANK
11.0
%
11
%
DRUGBANK
0.2
L/kg
0.2
L/kg
DRUGBANK
3.5
h
3.5
h
DRUGBANK
5000.0
mg/kg
5.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
75.0
%
70-80
%
Faeces excretion;
DRUGBANK
25.0
%
20-30
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral;intravenous injection, IV;
Demadex
torsemide
PDR
200.0
mg
200
mg
PO, oral;intravenous injection, IV;
Demadex
torsemide
PDR
40.0
mg
40
mg
PO, oral;intravenous injection, IV;
Demadex
torsemide
PDR
10.0
mg/day
10
mg/day
PO, oral;intravenous injection, IV;
Demadex
torsemide
PDR
200.0
mg
200
mg
PO, oral;intravenous injection, IV;
Demadex
torsemide
PDR
40.0
mg
40
mg
PO, oral;intravenous injection, IV;
Demadex
torsemide
PDR
DDPD00215
Citalopram
324.3919
C20H21FN2O
CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
DB00215
T3D2715
2771
77397
http://www.drugs.com/citalopram.html
2669
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80.0
%
Oral single dose; food;
food → ;
DRUGBANK
80.0
%
80±13
%
PO, oral; Drug form;
DRUGBANK
50.0
ng/ml
50±9
ng/ml
Oral single dose; Drug form;
DRUGBANK
21.0
ng/ml
21±4
ng/ml
Oral single dose; Drug form;
DRUGBANK
4.0
h
4
h
Oral single dose; food;
food → ;
DRUGBANK
4.5
h
4-5
h
Oral single dose; Drug form;
DRUGBANK
4.5
h
4-5
h
Oral single dose; Drug form;
DRUGBANK
19.8
L/h
330.0
ml/min
Total clearance;
DRUGBANK
0.258
L/h/kg
4.3±1.2
ml/min/kg
hydrolysis;
Elderly ↓ ;Hepatitis, Hep ↓ ;
DRUGBANK
0.528
L/h/kg
8.8±3.2
ml/min/kg
apparent clearance; hydrolysis;
Elderly ↓ ;Hepatitis, Hep ↓ ;
DRUGBANK
0.258
L/h/kg
4.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
L/kg
12.0
L/kg
DRUGBANK
12.3
L/kg
12.3±2.3
L/kg
DRUGBANK
15.4
L/kg
15.4±2.4
L/kg
Apparent volume of distribution;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
h
~35
h
DRUGBANK
33.0
h
33±4
h
Raceme D/L; CYP2C19;
chronic liver disease ↑ ;moderate renal function ↑ ;Age ↑ ;
DRUGBANK
22.0
h
22±6
h
CYP2C19;
chronic liver disease ↑ ;moderate renal function ↑ ;Age ↑ ;
DRUGBANK
33.0
h
33
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
56.0
mg/kg
56.0
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
179.0
mg/kg
179.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
17.5
%
12-23
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
10.0
%
10
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
10.5
%
10.5±1.4
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
8.0
%
8
%
Urinary excretion; Raceme D; Unchanged drug;
DRUGBANK
80.0
%
80
%
plasma proteins;
DRUGBANK
80.0
%
80
%
Raceme D/L;
DRUGBANK
56.0
%
56
%
Raceme D;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
20.0
mg/day
20
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
40.0
mg/day
40
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
20.0
mg/day
20
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
20.0
mg/day
20
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
40.0
mg/day
40
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
20.0
mg/day
20
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
20.0
mg/day
20
mg/day
PO, oral
Celexa
citalopram hydrobromide
PDR
DDPD00216
Eletriptan
382.519
C22H26N2O2S
CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
DB00216
77993
50922
http://www.drugs.com/cdi/eletriptan.html
70379
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50.0
%
PO, oral;
DRUGBANK
3.9
L/h
3.9
L/h
Renal clearance;
DRUGBANK
0.318
L/h/kg
5.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
138.0
L
138.0
L
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
~4
h
elimination half-life;
DRUGBANK
4.2
h
4.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
%
~85
%
plasma proteins;
DRUGBANK
DDPD00217
Bethanidine
177.2462
C10H15N3
CN\C(NCC1=CC=CC=C1)=N/C
DB00217
2368
37937
2278
-2.0
-
-2.0
-
DRUGBANK
9.0
h
9(7-11)
h
DRUGBANK
DDPD00218
Moxifloxacin
401.4314
C21H24FN3O4
[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O
DB00218
152946
63611
http://www.drugs.com/cdi/moxifloxacin-drops.html
134802
-2.0
-
-2.0
-
DRUGBANK
90.0
%
~90
%
PO, oral; food;
food → ;
DRUGBANK
86.0
%
86±1
%
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
2500.0
ng/ml
2.5±1.3
mcg/ml
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
2.0
h
2.0(0.5-6.0)
h
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
52.0
%
52
%
PO, oral; intravenous injection, IV;
DRUGBANK
38.0
%
38
%
PO, oral; intravenous injection, IV;
DRUGBANK
14.0
%
14
%
PO, oral; intravenous injection, IV;
DRUGBANK
12.0
L/h
12±2
L/h
DRUGBANK
0.1362
L/h/kg
2.27±0.24
ml/min/kg
normal,healthy; adults; Male, men; metabolism of ugt; hydrolysis;
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.2
L/kg
1.7-2.7
L/kg
DRUGBANK
2.05
L/kg
2.05±1.15
L/kg
DRUGBANK
1.4
L/kg
1.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.55
h
11.5-15.6
h
Oral single dose;
DRUGBANK
15.4
h
15.4±1.2
h
normal,healthy; adults; Male, men;
DRUGBANK
8.2
h
8.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
Urinary excretion; PO, oral; intravenous injection, IV; Unchanged drug;
DRUGBANK
25.0
%
~25
%
Faeces excretion; PO, oral; intravenous injection, IV; Unchanged drug;
DRUGBANK
21.9
%
21.9±3.6
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
50.0
%
50
%
Plasma Concentration → ;
DRUGBANK
39.4
%
39.4±2.4
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Vigamox
moxifloxacin hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Vigamox
moxifloxacin hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Vigamox
moxifloxacin hydrochloride
PDR
DDPD00219
Oxyphenonium
348.4996
C21H34NO3
CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
DB00219
5749
94329
5547
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93
%
DRUGBANK
DDPD00220
Nelfinavir
567.782
C32H45N3O4S
[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
DB00220
64143
7496
http://www.drugs.com/cdi/nelfinavir.html
57718
-2.0
-
-2.0
-
DRUGBANK
50.0
%
20-80
%
PO, oral; food; AIDS,HIV;
DRUGBANK
3200.0
ng/ml
3.2±1.2
mcg/ml
adults; AIDS,HIV;
DRUGBANK
3.0
h
3.0±1.1
h
adults; AIDS,HIV;
DRUGBANK
0.72
L/h/kg
12.0±7.2
ml/min/kg
apparent clearance; normal,healthy; patients;
Children ↑ ;
DRUGBANK
4.5
L/kg
2.0-7
L/kg
DRUGBANK
4.5
L/kg
2-7
L/kg
Apparent volume of distribution; normal,healthy; patients;
DRUGBANK
4.25
h
3.5-5
h
DRUGBANK
4.0
h
3-5
h
PO, oral;
DRUGBANK
5000.0
mg/kg
>5
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
87.0
%
87
%
Faeces excretion; PO, oral;
DRUGBANK
1.5
%
1-2
%
Urinary excretion; PO, oral;
DRUGBANK
22.0
%
22
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
1.5
%
1-2
%
Urinary excretion; normal,healthy; AIDS,HIV; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
98
%
DRUGBANK
98.5
%
98-99
%
normal,healthy; AIDS,HIV; human, homo sapiens;
DRUGBANK
110.0
mg/kg/day
110
mg/kg/day
PO, oral
Viracept
nelfinavir mesylate
PDR
2500.0
mg/day
2500
mg/day
PO, oral
Viracept
nelfinavir mesylate
PDR
2500.0
mg/day
2500
mg/day
PO, oral
Viracept
nelfinavir mesylate
PDR
2500.0
mg/day
2500
mg/day
PO, oral
Viracept
nelfinavir mesylate
PDR
2500.0
mg/day
2500
mg/day
PO, oral
Viracept
nelfinavir mesylate
PDR
DDPD00221
Isoetharine
239.3107
C13H21NO3
CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1
DB00221
3762
6005
http://www.drugs.com/mtm/isoetharine-inhalation.html
3630
-2.0
-
-2.0
-
DRUGBANK
DDPD00222
Glimepiride
490.62
C24H34N4O5S
CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O
DB00222
3476
5383
http://www.drugs.com/cdi/glimepiride.html
16740595
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
359.0
ng/ml
359±98
ng/ml
Oral single dose;
DRUGBANK
2.5
h
2-3
h
Oral single dose; normal,healthy;
DRUGBANK
2.5
h
2-3
h
Oral multiple dose; diabetes;
DRUGBANK
2.5
h
2-3
h
Oral single dose;
DRUGBANK
3.126
L/h
52.1±16.0
ml/min
Total clearance;
DRUGBANK
2.91
L/h
48.5±29.3
ml/min
Total clearance; Oral single dose; diabetes; patients;
DRUGBANK
3.162
L/h
52.7±40.3
ml/min
Total clearance; Oral multiple dose; diabetes; patients;
DRUGBANK
2.868
L/h
47.8
ml/min
Total clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
0.0372
L/h/kg
0.62±0.26
ml/min/kg
severe renal function ↑ ;
DRUGBANK
0.03
L/h/kg
0.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.8
L
8.8
L
intravenous injection, IV; normal,healthy;
DRUGBANK
0.18
L/kg
0.18
L/kg
severe renal function ↑ ;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
~5-8
h
elimination half-life;
DRUGBANK
3.4
h
3.4±2.0
h
normal,healthy; Male, men;
moderate renal function → ;severe renal function → ;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10000.0
mg/kg
>10000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3950.0
mg/kg
3950.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
60.0
%
~60
%
Urinary excretion; PO, oral; Male, men; normal,healthy;
DRUGBANK
40.0
%
~40
%
Faeces excretion; PO, oral; Male, men; normal,healthy;
DRUGBANK
0.5
%
<0.5
%
Urinary excretion; Male, men; normal,healthy; Unchanged drug;
DRUGBANK
99.5
%
>99.5
%
plasma proteins;
DRUGBANK
99.5
%
>99.5
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
8.0
mg/day
8
mg/day
PO, oral
Amaryl
glimepiride
PDR
8.0
mg/day
8
mg/day
PO, oral
Amaryl
glimepiride
PDR
8.0
mg/day
8
mg/day
PO, oral
Amaryl
glimepiride
PDR
8.0
mg/day
8
mg/day
PO, oral
Amaryl
glimepiride
PDR
DDPD00223
Diflorasone
410.4515
C22H28F2O5
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB00223
71415
59750
http://www.drugs.com/cdi/diflorasone-diacetate-cream.html
64505
-2.0
-
-2.0
-
DRUGBANK
1428.57142857
mg/day
10
g/week
skin/dermal
ApexiCon E
diflorasone diacetate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
ApexiCon E
diflorasone diacetate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
ApexiCon E
diflorasone diacetate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
ApexiCon E
diflorasone diacetate
PDR
DDPD00224
Indinavir
613.7895
C36H47N5O4
CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
DB00224
5362440
44032
http://www.drugs.com/cdi/indinavir.html
4515036
-2.0
-
-2.0
-
DRUGBANK
1.08
L/h/kg
18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.82
L/kg
0.82
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
1.8±0.4
h
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
<20
%
Urinary excretion; Unchanged drug;
DRUGBANK
60.0
%
60
%
DRUGBANK
2400.0
mg/day
2400
mg/day
PO, oral
Crixivan
indinavir sulfate
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Crixivan
indinavir sulfate
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Crixivan
indinavir sulfate
PDR
DDPD00225
Gadodiamide
573.66
C16H26GdN5O8
O=C1[O-][Gd+3]234567[O]=C(C[N]2(CC[N]3(CC([O-]4)=O)CC[N]5(CC(=[O]6)NC)CC(=O)[O-]7)C1)NC
DB00225
24847884
37333
135661
-2.0
-
-2.0
-
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
Renal clearance;
DRUGBANK
0.108
L/h/kg
1.8
ml/min/kg
Plasma clearance;
DRUGBANK
0.1074
L/h/kg
1.79
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
L/kg
200±61
mL/kg
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0616666666666667
h
3.7±2.7
min
distribution half-life;
DRUGBANK
1.29666666666667
h
77.8±16
min
elimination half-life;
DRUGBANK
1.46
h
1.46
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00226
Guanadrel
213.2768
C10H19N3O2
NC(N)=NCC1COC2(CCCCC2)O1
DB00226
38521
5555
http://www.drugs.com/mtm/guanadrel.html
35305
-2.0
-
-2.0
-
DRUGBANK
10.0
h
10
h
DRUGBANK
20.0
%
~20
%
DRUGBANK
DDPD00227
Lovastatin
404.5396
C24H36O5
[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
DB00227
T3D4787
53232
40303
http://www.drugs.com/cdi/lovastatin.html
48085
-2.0
-
-2.0
-
DRUGBANK
33.5
ng.h/ml
14-53
ng.h/ml
PO, oral;
DRUGBANK
5.0
%
≤5
%
PO, oral;
DRUGBANK
3.013
ng/ml
3.013
ng/ml
DRUGBANK
2.535
ng/ml
1.04-4.03
ng/ml
PO, oral;
DRUGBANK
41.0
ngEq/ml
41±6
ngEq/ml
PO, oral; Active metabolite;
DRUGBANK
50.0
ngEq/ml
50±8
ngEq/ml
PO, oral; Active metabolite;
DRUGBANK
3.36
h
3.36
h
DRUGBANK
2.0
h
2.0±0.9
h
PO, oral; Active metabolite;
DRUGBANK
3.1
h
3.1±2.9
h
PO, oral; Active metabolite;
DRUGBANK
0.678
L/h/kg
4.3-18.3
ml/min/kg
hydrolysis;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
13.37
h
13.37
h
DRUGBANK
1.85
h
0.7-3
h
elimination half-life;
DRUGBANK
2.5
h
1-4
h
DRUGBANK
15000.0
mg/m2
>15
g/m2
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
%
10
%
Urinary excretion; PO, oral; Male, men;
DRUGBANK
83.0
%
83
%
Faeces excretion; PO, oral; Male, men;
DRUGBANK
10.0
%
10
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
>95
%
plasma proteins; human, homo sapiens;
DRUGBANK
95.0
%
>95
%
DRUGBANK
40.0
mg/day
40
mg/day
Tablet,PO，oral
Altoprev
lovastatin
PDR
80.0
mg/day
80
mg/day
Tablet,PO，oral
Altoprev
lovastatin
PDR
60.0
mg/day
60
mg/day
Tablet,PO，oral
Altoprev
lovastatin
PDR
20.0
mg/day
20
mg/day
PO, oral
Altoprev
lovastatin
PDR
40.0
mg/day
40
mg/day
PO, oral
Altoprev
lovastatin
PDR
20.0
mg/day
20
mg/day
PO, oral
Altoprev
lovastatin
PDR
40.0
mg/day
40
mg/day
Tablet,PO，oral
Altoprev
lovastatin
PDR
80.0
mg/day
80
mg/day
PO, oral
Altoprev
lovastatin
PDR
60.0
mg/day
60
mg/day
PO, oral
Altoprev
lovastatin
PDR
20.0
mg/day
20
mg/day
PO, oral
Altoprev
lovastatin
PDR
40.0
mg/day
40
mg/day
PO, oral
Altoprev
lovastatin
PDR
20.0
mg/day
20
mg/day
PO, oral
Altoprev
lovastatin
PDR
DDPD00228
Enflurane
184.492
C3H2ClF5O
FC(F)OC(F)(F)C(F)Cl
DB00228
T3D2717
3226
4792
3113
-2.0
-
-2.0
-
DRUGBANK
3.5
%
2-5
%
Liver metabolism;
DRUGBANK
9.0
%
9
%
Liver metabolism; different study;
DRUGBANK
4666.66666666667
mg/kg/h
14000.0
ppm/3h
DRUGBANK
5.4
ml/kg
5.4
ml/kg
PO, oral; Rattus, Rat;
DRUGBANK
97.0
%
97
%
plasma proteins;
DRUGBANK
DDPD00229
Cefotiam
525.628
C18H23N9O4S3
[H][C@]12SCC(CSC3=NN=NN3CCN(C)C)=C(N1C(=O)[C@H]2NC(=O)CC1=CSC(N)=N1)C(O)=O
DB00229
43708
355510
39831
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60.0
%
IM,intramuscular injection;
DRUGBANK
0.348
L/h/kg
5.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.26
L/kg
0.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
DRUGBANK
0.84
h
0.84
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
%
40
%
DRUGBANK
DDPD00230
Pregabalin
159.2261
C8H17NO2
CC(C)C[C@H](CN)CC(O)=O
DB00230
5486971
64356
http://www.drugs.com/cdi/pregabalin.html
4589156
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral; increasing doses;
increasing doses → ;
DRUGBANK
1.5
h
1.5
h
PO, oral; increasing dosing frequency;
increasing dosing frequency → ;
DRUGBANK
3.0
h
3
h
PO, oral; food;
food ↑ ;
DRUGBANK
36.0
h
24-48
h
Oral multiple dose;
DRUGBANK
2.0
%
<2
%
DRUGBANK
0.0
%
0
%
Urinary excretion;
DRUGBANK
4.437
L/h
67-80.9
ml/min
Renal clearance; normal,healthy; young;
DRUGBANK
0.5
L/kg
~0.5
L/kg
Apparent volume of distribution; PO, oral;
DRUGBANK
6.3
h
6.3
h
elimination half-life;
DRUGBANK
100.0
%
~100
%
Urinary excretion;
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Lyrica CR
pregabalin
PDR
600.0
mg/day
600
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
14.0
mg/kg/day
14
mg/kg/day
PO, oral
Lyrica CR
pregabalin
PDR
300.0
mg/day
300
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
600.0
mg/day
600
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
450.0
mg/day
450
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
330.0
mg/day
330
mg/day
Tablet,PO，oral
Lyrica CR
pregabalin
PDR
660.0
mg/day
660
mg/day
Tablet,PO，oral
Lyrica CR
pregabalin
PDR
600.0
mg/day
600
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Lyrica CR
pregabalin
PDR
600.0
mg/day
600
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
14.0
mg/kg/day
14
mg/kg/day
PO, oral
Lyrica CR
pregabalin
PDR
300.0
mg/day
300
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
600.0
mg/day
600
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
450.0
mg/day
450
mg/day
PO, oral
Lyrica CR
pregabalin
PDR
330.0
mg/day
330
mg/day
Tablet,PO，oral
Lyrica CR
pregabalin
PDR
660.0
mg/day
660
mg/day
Tablet,PO，oral
Lyrica CR
pregabalin
PDR
14.0
mg/kg/day
14
mg/kg/day
PO, oral
Lyrica CR
pregabalin
PDR
DDPD00231
Temazepam
300.74
C16H13ClN2O2
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1
DB00231
T3D2719
5391
9435
http://www.drugs.com/temazepam.html
5198
-2.0
-
-2.0
-
DRUGBANK
95.0
%
90-100
%
PO, oral;
DRUGBANK
824.0
ng/ml
666-982
ng/ml
DRUGBANK
865.0
ng/ml
865.0
ng/ml
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
1.4
h
1.2-1.6
h
DRUGBANK
1.5
h
1.5
h
DRUGBANK
6.5
%
5-8
%
Liver metabolism;
DRUGBANK
0.0618
L/h/kg
1.03
ml/min/kg
Total clearance;
DRUGBANK
1.86
L/h/kg
31.0
ml/min/kg
Plasma clearance;
DRUGBANK
1.4
L/kg
1.3-1.5
L/kg
DRUGBANK
55.5
L/kg
43-68
L/kg
Total volume of distribution;
DRUGBANK
9.0
h
9(3.5-18)
h
terminal half-life;
DRUGBANK
1963.0
mg/kg
1963.0
mg/kg
PO, oral; mouse;
DRUGBANK
1833.0
mg/kg
1833.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2400.0
mg/kg
>2400
mg/kg
PO, oral; rabbit;
DRUGBANK
85.0
%
80-90
%
Urinary excretion; Single dose;
DRUGBANK
8.0
%
3-13
%
Faeces excretion; Single dose;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Single dose; Unchanged drug;
DRUGBANK
96.0
%
~96
%
plasma proteins;
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Restoril
temazepam
PDR
30.0
mg/day
30
mg/day
PO, oral
Restoril
temazepam
PDR
DDPD00233
Aminosalicylic acid
153.1354
C7H7NO3
NC1=CC(O)=C(C=C1)C(O)=O
DB00233
4649
27565
http://www.drugs.com/cdi/aminosalicylic-acid-controlled-release-granules-packet.html
4488
-2.0
-
-2.0
-
DRUGBANK
0.558
L/h/kg
9.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.33
L/kg
0.33
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.61
h
0.61
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4000.0
mg/kg
4.0
g/kg
PO, oral; mouse;
DRUGBANK
3650.0
mg/kg
3650.0
mg/kg
PO, oral; rabbit;
DRUGBANK
55.0
%
50-60
%
DRUGBANK
300.0
mg/kg/day
300
mg/kg/day
PO, oral
Paser
aminosalicylic acid
PDR
12000.0
mg/day
12
g/day
PO, oral
Paser
aminosalicylic acid
PDR
12000.0
mg/day
12
g/day
PO, oral
Paser
aminosalicylic acid
PDR
300.0
mg/kg/day
300
mg/kg/day
PO, oral
Paser
aminosalicylic acid
PDR
12000.0
mg/day
12
g/day
PO, oral
Paser
aminosalicylic acid
PDR
12000.0
mg/day
12
g/day
PO, oral
Paser
aminosalicylic acid
PDR
300.0
mg/kg/day
300
mg/kg/day
PO, oral
Paser
aminosalicylic acid
PDR
DDPD00234
Reboxetine
313.397
C19H23NO3
[H][C@@](OC1=CC=CC=C1OCC)(C1=CC=CC=C1)[C@@]1([H])CNCCO1
DB00234
T3D2720
127151
135342
112870
-2.0
-
-2.0
-
DRUGBANK
0.0492
L/h/kg
0.82
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.65
L/kg
0.65
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.5
h
12.5
h
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD00235
Milrinone
211.2194
C12H9N3O
CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1
DB00235
4197
50693
http://www.drugs.com/cdi/milrinone.html
4052
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; normal,healthy;
DRUGBANK
92.0
%
92.0
%
PO, oral; normal,healthy;
DRUGBANK
0.13
L/h/kg
0.13
L/kg/h
intravenous injection, IV; heart disease; patients;
DRUGBANK
0.14
L/h/kg
0.14
L/kg/h
intravenous injection, IV; heart disease; patients;
DRUGBANK
0.372
L/h/kg
6.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.38
L
0.38
L
intravenous injection, IV; heart disease;
DRUGBANK
0.45
L
0.45
L
intravenous injection, IV; heart disease;
DRUGBANK
0.25
L/kg
0.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.3
h
2.3
h
DRUGBANK
0.8
h
0.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
mg/L
0.3
mg/L
Rattus, Rat;
DRUGBANK
75.0
%
70-80
%
DRUGBANK
1.08
mg/kg/day
0.75
mcg/kg/minute
intravenous infusion, iv in drop
Milrinone Lactate
milrinone lactate
PDR
1.08
mg/kg/day
0.75
mcg/kg/min
intravenous infusion, iv in drop
Milrinone Lactate
milrinone lactate
PDR
1.08
mg/kg/day
0.75
mcg/kg/minute
intravenous infusion, iv in drop
Milrinone Lactate
milrinone lactate
PDR
1.08
mg/kg/day
0.75
mcg/kg/minute
intravenous infusion, iv in drop
Milrinone Lactate
milrinone lactate
PDR
1.08
mg/kg/day
0.75
mcg/kg/min
intravenous infusion, iv in drop
Milrinone Lactate
milrinone lactate
PDR
1.08
mg/kg/day
0.75
mcg/kg/minute
intravenous infusion, iv in drop
Milrinone Lactate
milrinone lactate
PDR
DDPD00236
Pipobroman
356.054
C10H16Br2N2O2
BrCCC(=O)N1CCN(CC1)C(=O)CCBr
DB00236
4842
8242
4676
-2.0
-
-2.0
-
DRUGBANK
DDPD00237
Butabarbital
212.2456
C10H16N2O3
CCC(C)C1(CC)C(=O)NC(=O)NC1=O
DB00237
T3D2721
2479
3228
http://www.drugs.com/cdi/butabarbital.html
2385
-2.0
-
-2.0
-
DRUGBANK
100.0
h
100
h
terminal half-life;
DRUGBANK
4.0
%
3-5
%
Urinary excretion; dog; Unchanged drug;
DRUGBANK
6.0
mg/kg/dose
6
mg/kg/dose
PO, oral
Butisol Sodium
butabarbital sodium
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Butisol Sodium
butabarbital sodium
PDR
120.0
mg/day
120
mg/day
PO, oral
Butisol Sodium
butabarbital sodium
PDR
6.0
mg/kg/dose
6
mg/kg/dose
PO, oral
Butisol Sodium
butabarbital sodium
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Butisol Sodium
butabarbital sodium
PDR
120.0
mg/day
120
mg/day
PO, oral
Butisol Sodium
butabarbital sodium
PDR
6.0
mg/kg/dose
6
mg/kg/dose
PO, oral
Butisol Sodium
butabarbital sodium
PDR
DDPD00238
Nevirapine
266.2979
C15H14N4O
CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
DB00238
4463
63613
http://www.drugs.com/cdi/nevirapine.html
4308
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral; normal,healthy; AIDS,HIV;
DRUGBANK
93.0
%
93±9
%
normal,healthy; adults;
DRUGBANK
91.0
%
91±8
%
normal,healthy; adults;
DRUGBANK
93.0
%
93±9
%
PO, oral;
DRUGBANK
2000.0
ng/ml
2±0.4
mcg/ml
PO, oral;
DRUGBANK
2000.0
ng/ml
2±0.4
mcg/ml
Oral single dose; adults; AIDS,HIV;
DRUGBANK
4500.0
ng/ml
4.5±1.9
mcg/ml
Oral multiple dose; adults; AIDS,HIV;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
3.0
h
2-4
h
DRUGBANK
0.03
L/h/kg
0.23-0.77
ml/min/kg
apparent clearance; Single dose;
DRUGBANK
0.0534
L/h/kg
0.89
ml/min/kg
apparent clearance; Multiple dose;
Children ↑ ;
DRUGBANK
0.018
L/h/kg
0.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.21
L/kg
1.21±0.09
L/kg
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
1.2
L/kg
1.2±0.09
L/kg
DRUGBANK
1.2
L/kg
1.2
L/kg
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
h
45
h
DRUGBANK
45.0
h
45.0
h
Single dose;
DRUGBANK
30.0
h
25-35
h
Multiple dose;
DRUGBANK
53.0
h
53
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
%
<3
%
Urinary excretion; adults; normal,healthy; AIDS,HIV; human, homo sapiens; Unchanged drug;
DRUGBANK
60.0
%
60
%
plasma proteins;
DRUGBANK
60.0
%
60
%
adults; normal,healthy; AIDS,HIV; human, homo sapiens;
DRUGBANK
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/m2/day
400
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Viramune XR
nevirapine
PDR
400.0
mg/m2/day
400
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/m2/day
400
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/day
400
mg/day
PO, oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
400.0
mg/day
400
mg/day
PO, oral
Viramune XR
nevirapine
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Viramune XR
nevirapine
PDR
300.0
mg/m2/day
300
mg/m2/day
PO, oral
Viramune XR
nevirapine
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Viramune XR
nevirapine
PDR
8.0
mg/day
8
mg/day
PO, oral
Viramune XR
nevirapine
PDR
12.0
mg/day
12
mg/day
PO, oral
Viramune XR
nevirapine
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Viramune XR
nevirapine
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Viramune XR
nevirapine
PDR
DDPD00239
Oxiconazole
429.12
C18H13Cl4N3O
ClC1=CC(Cl)=C(CO\N=C(/CN2C=CN=C2)C2=CC=C(Cl)C=C2Cl)C=C1
DB00239
T3D2722
5353853
7825
http://www.drugs.com/cdi/oxiconazole-cream.html
4510239
-2.0
-
-2.0
-
DRUGBANK
2.0
application/day
2
application/day
Oxistat
oxiconazole nitrate
PDR
2.0
application/day
2
application/day
Oxistat
oxiconazole nitrate
PDR
2.0
application/day
2
application/day
Oxistat
oxiconazole nitrate
PDR
2.0
application/day
2
application/day
Oxistat
oxiconazole nitrate
PDR
DDPD00240
Alclometasone
408.916
C22H29ClO5
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C
DB00240
5311000
53776
http://www.drugs.com/cdi/alclometasone-cream.html
4470541
-2.0
-
-2.0
-
DRUGBANK
DDPD00241
Butalbital
224.2563
C11H16N2O3
CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O
DB00241
2481
102524
2387
-2.0
-
-2.0
-
DRUGBANK
2100.0
ng/ml
2.1
mg/L
PO, oral;
DRUGBANK
2.0
h
~2
h
PO, oral;
DRUGBANK
100.0
%
~100
%
Liver metabolism;
DRUGBANK
0.8
L/kg
~0.8
L/kg
DRUGBANK
35.0
h
~35
h
elimination half-life;
DRUGBANK
61.0
h
61(35-88)
h
elimination half-life; normal,healthy; Drug combination;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; Female, women;
DRUGBANK
160.0
mg/kg
160.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
73.5
%
59-88
%
Urinary excretion;
DRUGBANK
3.6
%
~3.6
%
Urinary excretion; Unchanged drug;
DRUGBANK
45.0
%
45
%
plasma proteins; high protein binding;
DRUGBANK
DDPD00242
Cladribine
285.687
C10H12ClN5O3
NC1=C2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2=NC(Cl)=N1
DB00242
T3D4774
20279
567361
http://www.drugs.com/cdi/cladribine.html
19105
-2.0
-
-2.0
-
DRUGBANK
41.0
%
34-48
%
PO, oral;
DRUGBANK
0.978
L/h/kg
978±422
ml/h/kg
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
L/kg
4.5±2.8
L/kg
hematologic malignancies; patients;
DRUGBANK
9.0
L/kg
9.0
L/kg
DRUGBANK
7.7
L/kg
7.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.4
h
5.4
h
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
20
%
DRUGBANK
0.09
mg/kg/day
0.09
mg/kg/day
intravenous injection, IV
Cladribine
cladribine
PDR
3.5
mg/kg
3.5
mg/kg
PO, oral; in 2 years
Cladribine
cladribine
PDR
0.09
mg/kg/day
0.09
mg/kg/day
intravenous injection, IV
Cladribine
cladribine
PDR
3.5
mg/kg
3.5
mg/kg
PO, oral; in 2 years
Cladribine
cladribine
PDR
DDPD00243
Ranolazine
427.5365
C24H33N3O4
COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1
DB00243
56959
87690
http://www.drugs.com/cdi/ranolazine.html
51354
-2.0
-
-2.0
-
DRUGBANK
76.0
%
76.0
%
Tablet, PO, oral;
DRUGBANK
4.0
h
3-5
h
DRUGBANK
72.0
h
<3
day
DRUGBANK
45.0
L/h
45.0
L/h
Oral multiple dose;
DRUGBANK
0.57
L/h/kg
9.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
53.2
L
53.2
L
Apparent volume of distribution;
DRUGBANK
132.5
L
85-180
L
Steady state volume of distribution;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
7
h
terminal half-life;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
75.0
%
~75
%
Urinary excretion;
DRUGBANK
25.0
%
~25
%
Faeces excretion;
DRUGBANK
5.0
%
~5
%
Unchanged drug;
DRUGBANK
62.0
%
~62
%
plasma proteins;
DRUGBANK
2000.0
mg/day
2000
mg/day
PO, oral
Ranexa
ranolazine
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Ranexa
ranolazine
PDR
DDPD00244
Mesalazine
153.1354
C7H7NO3
NC1=CC(C(O)=O)=C(O)C=C1
DB00244
4075
6775
3933
-2.0
-
-2.0
-
DRUGBANK
25.0
%
20-30
%
Capsule, PO, Oral;
DRUGBANK
80.0
%
~80
%
Liquid;
DRUGBANK
2.05
L/h
2.05
L/h
Renal clearance; fasting; young;
DRUGBANK
2.085
L/h
2.04-2.13
L/h
Renal clearance; fasting; Elderly;
DRUGBANK
0.2
L/kg
~0.2
L/kg
Steady state volume of distribution; adults;
DRUGBANK
9.5
h
7-12
h
elimination half-life; PO, oral; extended release formulation;
DRUGBANK
17.5
h
12-23
h
elimination half-life; PO, oral; extended release formulation; Active metabolite; Metabolite;
DRUGBANK
3370.0
mg/kg
3370.0
mg/kg
PO, oral; mouse;
DRUGBANK
2800.0
mg/kg
2800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
skin/dermal; rabbit;
DRUGBANK
8.0
%
<8
%
Urinary excretion; PO, oral; extended release formulation; Unchanged drug;
DRUGBANK
43.0
%
~43
%
plasma proteins;
DRUGBANK
44.0
mg/kg/day
44
mg/kg/day
PO, oral
Canasa
mesalamine
PDR
2400.0
mg/day
2.4
g/day
PO, oral
Canasa
mesalamine
PDR
61.0
mg/kg/day
61
mg/kg/day
PO, oral
Canasa
mesalamine
PDR
2000.0
mg/day
2
g/day
PO, oral
Canasa
mesalamine
PDR
71.0
mg/kg/day
71
mg/kg/day
PO, oral
Canasa
mesalamine
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Canasa
mesalamine
PDR
4000.0
mg/day
4
g/day
Rectal Administration
Canasa
mesalamine
PDR
1500.0
mg/day
1.5
g/day
Rectal Administration
Canasa
mesalamine
PDR
1500.0
mg/day
1.5
g/day
Capsule, PO, Oral
Canasa
mesalamine
PDR
2400.0
mg/day
2.4
g/day
Tablet,PO，oral;Capsule, PO, Oral;
Canasa
mesalamine
PDR
4000.0
mg/day
4
g/day
Capsule, PO, Oral
Canasa
mesalamine
PDR
4800.0
mg/day
4.8
g/day
Tablet,PO，oral
Canasa
mesalamine
PDR
44.0
mg/kg/day
44
mg/kg/day
PO, oral
Canasa
mesalamine
PDR
2400.0
mg/day
2.4
g/day
PO, oral
Canasa
mesalamine
PDR
61.0
mg/kg/day
61
mg/kg/day
PO, oral
Canasa
mesalamine
PDR
2000.0
mg/day
2
g/day
PO, oral
Canasa
mesalamine
PDR
71.0
mg/kg/day
71
mg/kg/day
PO, oral
Canasa
mesalamine
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Canasa
mesalamine
PDR
4000.0
mg/day
4
g/day
Rectal Administration
Canasa
mesalamine
PDR
1500.0
mg/day
1.5
g/day
Rectal Administration
Canasa
mesalamine
PDR
1500.0
mg/day
1.5
g/day
Capsule, PO, Oral
Canasa
mesalamine
PDR
2400.0
mg/day
2.4
g/day
Tablet,PO，oral;Capsule, PO, Oral;
Canasa
mesalamine
PDR
4000.0
mg/day
4
g/day
Capsule, PO, Oral
Canasa
mesalamine
PDR
4800.0
mg/day
4.8
g/day
Tablet,PO，oral
Canasa
mesalamine
PDR
DDPD00245
Benzatropine
307.4293
C21H25NO
[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C
DB00245
T3D2724
1201549
3048
http://www.drugs.com/cdi/benztropine.html
16736541
-2.0
-
-2.0
-
DRUGBANK
29.0
%
29.0
%
PO, oral;
DRUGBANK
2.5
ng/ml
2.5
ng/ml
PO, oral;
DRUGBANK
7.0
h
7
h
PO, oral;
DRUGBANK
21.0
L/kg
12.0-30
L/kg
DRUGBANK
36.0
h
~36
h
elimination half-life;
DRUGBANK
940.0
mg/kg
940.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
95
%
plasma proteins;
DRUGBANK
0.05
mg/kg/dose
0.05
mg/kg/dose
PO, oral;IM,intramuscular injection;intravenous injection, IV;
Benztropine Mesylate
benztropine mesylate
PDR
1.0
mg/dose
1
mg/dose
PO, oral;IM,intramuscular injection;intravenous injection, IV;
Benztropine Mesylate
benztropine mesylate
PDR
8.0
mg/day
8
mg/day
PO, oral;IM,intramuscular injection;intravenous injection, IV;
Benztropine Mesylate
benztropine mesylate
PDR
0.05
mg/kg/dose
0.05
mg/kg/dose
PO, oral;IM,intramuscular injection;intravenous injection, IV;
Benztropine Mesylate
benztropine mesylate
PDR
8.0
mg/day
8
mg/day
PO, oral;IM,intramuscular injection;intravenous injection, IV;
Benztropine Mesylate
benztropine mesylate
PDR
8.0
mg/day
8
mg/day
PO, oral;IM,intramuscular injection;intravenous injection, IV;
Benztropine Mesylate
benztropine mesylate
PDR
0.0
0
Benztropine Mesylate
benztropine mesylate
PDR
DDPD00246
Ziprasidone
412.936
C21H21ClN4OS
ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
DB00246
60854
10119
http://www.drugs.com/cdi/ziprasidone.html
54841
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
DRUGBANK
60.0
%
60.0
%
DRUGBANK
100.0
%
100.0
%
PO, oral; food;
food ↑ ;
DRUGBANK
59.0
%
59.0
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
IM,intramuscular injection;
DRUGBANK
68.0
ng/ml
68±20
ng/ml
PO, oral;
DRUGBANK
156.0
ng/ml
156.0
ng/ml
DRUGBANK
4.0
h
4±1
h
PO, oral;
DRUGBANK
0.7
h
0.7
h
DRUGBANK
0.45
L/h/kg
7.5
ml/min/kg
Average clearance;
DRUGBANK
0.702
L/h/kg
11.7
ml/min/kg
DRUGBANK
0.306
L/h/kg
5.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.5
L/kg
Apparent volume of distribution;
DRUGBANK
2.3
L/kg
2.3
L/kg
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
6-7
h
DRUGBANK
2.9
h
2.9
h
Elderly ↑ ;food ↓ ;
DRUGBANK
3.1
h
3.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
4.0
%
<4
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
99.9
%
99.9±0.08
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
10.0
mg/dose
10
mg/dose
IM,intramuscular injection
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
40.0
mg/day
40
mg/day
PO, oral
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
160.0
mg/day
160
mg/day
PO, oral
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
40.0
mg/day
40
mg/day
PO, oral
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
20.0
mg/dose
20
mg/dose
IM,intramuscular injection
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
40.0
mg/day
40
mg/day
PO, oral
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
10.0
mg/dose
10
mg/dose
IM,intramuscular injection
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
160.0
mg/day
160
mg/day
PO, oral
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Geodon
(ziprasidone hydrochloride); (ziprasidone mesylate)
PDR
DDPD00247
Methysergide
353.458
C21H27N3O2
[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
DB00247
T3D2726
6540428
584020
5022813
-2.0
-
-2.0
-
DRUGBANK
DDPD00248
Cabergoline
451.6043
C26H37N5O2
[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC
DB00248
T3D2727
54746
3286
http://www.drugs.com/cdi/cabergoline.html
49452
-2.0
-
-2.0
-
DRUGBANK
5.0
%
4-6
%
Liver metabolism;
DRUGBANK
0.48
L/h
0.008
L/min
Renal clearance;
DRUGBANK
192.0
L/h
3.2
L/min
Plasma clearance;
DRUGBANK
66.0
h
63-69
h
elimination half-life; normal,healthy;
DRUGBANK
20.0
%
~20
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
60.0
%
~60
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
4.0
%
<4
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
41.0
%
40-42
%
plasma proteins; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
1.0
mg
1
mg
PO, oral
biw
Cabergoline
cabergoline
PDR
1.0
mg
1
mg
PO, oral
biw
Cabergoline
cabergoline
PDR
DDPD00249
Idoxuridine
354.0985
C9H11IN2O5
OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O
DB00249
5905
147675
http://www.drugs.com/mtm/idoxuridine-ophthalmic.html
5694
-2.0
-
-2.0
-
DRUGBANK
3080.0
mg/kg
3080.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00250
Dapsone
248.301
C12H12N2O2S
NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
DB00250
T3D2482
2955
4325
http://www.drugs.com/cdi/dapsone.html
2849
-2.0
-
-2.0
-
DRUGBANK
75.0
%
70-80
%
PO, oral;
DRUGBANK
93.0
%
93±8
%
PO, oral;
DRUGBANK
75.0
%
70-80
%
PO, oral; leprosy;
leprosy ↓ ;
DRUGBANK
1600.0
ng/ml
1.6±0.4
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
3300.0
ng/ml
3.3
mcg/ml
Oral multiple dose; adults; normal,healthy;
DRUGBANK
2.1
h
2.1±0.8
h
Oral single dose; adults; normal,healthy;
DRUGBANK
0.036
L/h/kg
0.60±0.17
ml/min/kg
Neonates ↑ ;Children → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
0.0288
L/h/kg
0.48
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1.0±0.1
L/kg
DRUGBANK
0.83
L/kg
0.83
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.0
h
28(10-50)
h
DRUGBANK
22.4
h
22.4±5.6
h
Children → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
22.0
h
22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
496.0
mg/kg
496.0
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
%
5-15
%
Urinary excretion; Unchanged drug;
DRUGBANK
80.0
%
70-90
%
DRUGBANK
73.0
%
73±1
%
RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
2.0
application/day
2
application/day
gel
Dapsone
dapsone
PDR
1.0
application/day
1
application/day
gel
Dapsone
dapsone
PDR
1.0
application/day
1
application/day
gel
Dapsone
dapsone
PDR
100.0
mg/day
100
mg/day
PO, oral
Dapsone
dapsone
PDR
300.0
mg/day
300
mg/day
PO, oral
Dapsone
dapsone
PDR
200.0
mg/day
200
mg/day
PO, oral
Dapsone
dapsone
PDR
2.0
appLication/day
2
appLication/day
gel
Dapsone
dapsone
PDR
1.0
appLication/day
1
appLication/day
gel
Dapsone
dapsone
PDR
100.0
mg/day
100
mg/day
PO, oral
Dapsone
dapsone
PDR
300.0
mg/day
300
mg/day
PO, oral
Dapsone
dapsone
PDR
200.0
mg/day
200
mg/day
PO, oral
Dapsone
dapsone
PDR
2.0
application/day
2
application/day
gel
Dapsone
dapsone
PDR
1.0
application/day
1
application/day
gel
Dapsone
dapsone
PDR
100.0
mg/day
100
mg/day
PO, oral
Dapsone
dapsone
PDR
300.0
mg/day
300
mg/day
PO, oral
Dapsone
dapsone
PDR
200.0
mg/day
200
mg/day
PO, oral
Dapsone
dapsone
PDR
2.0
application/day
2
application/day
gel
Dapsone
dapsone
PDR
1.0
application/day
1
application/day
gel
Dapsone
dapsone
PDR
DDPD00251
Terconazole
532.462
C26H31Cl2N5O3
CC(C)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1
DB00251
441383
82980
http://www.drugs.com/cdi/terconazole-cream.html
390122
-2.0
-
-2.0
-
DRUGBANK
6.5
%
5-8
%
Vaginal Administration; hysterectomized;
DRUGBANK
14.0
%
12-16
%
Vaginal Administration; tubal ligations;
DRUGBANK
6.9
h
6.9(4.0-11.3)
h
DRUGBANK
1741.0
mg/kg
1741.0
mg/kg
PO, oral; male rat;
DRUGBANK
849.0
mg/kg
849.0
mg/kg
PO, oral; female rat;
DRUGBANK
44.0
%
32-56
%
Urinary excretion; PO, oral;
DRUGBANK
49.5
%
47-52
%
Faeces excretion; PO, oral;
DRUGBANK
94.9
%
94.9
%
DRUGBANK
DDPD00252
Phenytoin
252.268
C15H12N2O2
O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
DB00252
T3D2728
1775
8107
http://www.drugs.com/cdi/phenytoin.html
1710
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
90.0
%
90±3
%
PO, oral;
DRUGBANK
675.0
ng/ml
0-5(27%)
mcg/ml
Capsule, PO, Oral;
DRUGBANK
2250.0
ng/ml
5-10(30%)
mcg/ml
Capsule, PO, Oral;
DRUGBANK
4350.0
ng/ml
10-20(29%)
mcg/ml
Capsule, PO, Oral;
DRUGBANK
2500.0
ng/ml
20-30(10%)
mcg/ml
Capsule, PO, Oral;
DRUGBANK
2.25
h
1.5-3
h
PO, oral; immediate release formulation;
DRUGBANK
8.0
h
4-12
h
PO, oral; extended release formulation;
DRUGBANK
7.5
h
3-12
h
Capsule, PO, Oral;
DRUGBANK
0.245833333333333
mg/h/kg
5.9±1.2
mg/kg/day
Children ↑ ;Elderly ↓ ;
DRUGBANK
5.7
mg/L
5.7±2.9
mg/L
Children ↓ ;Elderly → ;Prem, premature ↓ ;Asian ↓ ;acute viral hepatitis AVH → ;RD, renal impairment, Renal disease，including uremia ↑ ;nephritic syndrome ↑ ;hyperthyroid, HTh → ;LTh hypothyroid → ;Somking → ;
DRUGBANK
0.0222
L/h/kg
0.37
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
L/kg
0.75
L/kg
DRUGBANK
0.64
L/kg
0.64±0.04
L/kg
Apparent volume of distribution;
Neonates ↑ ;acute viral hepatitis AVH → ;RD, renal impairment, Renal disease，including uremia ↑ ;hyperthyroid, HTh → ;LTh hypothyroid → ;nephritic syndrome ↑ ;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
22(7-42)
h
PO, oral;
DRUGBANK
12.5
h
10-15
h
intravenous injection, IV;
DRUGBANK
15.0
h
6-24
h
Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;acute viral hepatitis AVH → ;LTh hypothyroid → ;Somking → ;
DRUGBANK
16.8
h
16.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
150.0
mg/kg
150.0
mg/kg
PO, oral; mouse;
DRUGBANK
1635.0
mg/kg
1635.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.0
%
~1-5
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
2±8
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
~90
%
DRUGBANK
89.0
%
89±23
%
Neonates ↓ ;Preg, pregnant ↓ ;Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;hypoalbuminemia Alb ↓ ;acute viral hepatitis AVH ↓ ;Hepatitis, Hep ↓ ;nephritic syndrome ↓ ;Burn ↓ ;Obesity → ;Somking → ;
DRUGBANK
DDPD00253
Medrysone
344.4877
C22H32O3
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
DB00253
247839
34829
http://www.drugs.com/mtm/medrysone-ophthalmic.html
216968
-2.0
-
-2.0
-
DRUGBANK
DDPD00254
Doxycycline
444.4346
C22H24N2O8
[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
DB00254
T3D3950
54671203
50845
http://www.drugs.com/doxycycline.html
10469369
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; food;
food → ;
DRUGBANK
93.0
%
93.0
%
PO, oral;
DRUGBANK
2600.0
ng/ml
2.6
mcg/ml
Oral single dose;
DRUGBANK
1850.0
ng/ml
1.7-2
mcg/ml
PO, oral; adults;
DRUGBANK
2800.0
ng/ml
2.8
mcg/ml
adults;
DRUGBANK
2.0
h
2
h
Oral single dose;
DRUGBANK
1.5
h
1-2
h
PO, oral; adults;
DRUGBANK
4.5
L/h
~75
ml/min
normal,healthy;
DRUGBANK
0.0318
L/h/kg
0.53±0.18
ml/min/kg
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia → ;HL,hyperlipoproteinemia ↓ ;
DRUGBANK
0.0276
L/h/kg
0.46
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
L/kg
0.7
L/kg
DRUGBANK
0.75
L/kg
0.75±0.32
L/kg
Elderly ↓ ;HL,hyperlipoproteinemia ↓ ;
DRUGBANK
0.69
L/kg
0.69
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.33
h
16.33±4.53
h
DRUGBANK
16.0
h
16±6
h
RD, renal impairment, Renal disease，including uremia → ;HL,hyperlipoproteinemia → ;Age → ;
DRUGBANK
14.0
h
14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
262.0
mg/kg
262.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
50.0
%
40-60
%
Urinary excretion;
DRUGBANK
30.0
%
30
%
Faeces excretion;
DRUGBANK
41.0
%
41±19
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
>90
%
DRUGBANK
88.0
%
88±5
%
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Oracea
doxycycline
PDR
600.0
mg
600
mg
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Oracea
doxycycline
PDR
240.0
mg/day
240
mg/day
PO, oral
Oracea
doxycycline
PDR
720.0
mg
720
mg
PO, oral
Oracea
doxycycline
PDR
40.0
mg/day
40
mg/day
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
intravenous injection, IV
Oracea
doxycycline
PDR
5.3
mg/kg/day
5.3
mg/kg/day
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
intravenous injection, IV
Oracea
doxycycline
PDR
5.3
mg/kg/day
5.3
mg/kg/day
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
PO, oral
Oracea
doxycycline
PDR
600.0
mg
600
mg
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Oracea
doxycycline
PDR
240.0
mg/day
240
mg/day
PO, oral
Oracea
doxycycline
PDR
720.0
mg
720
mg
PO, oral
Oracea
doxycycline
PDR
40.0
mg/day
40
mg/day
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
PO, oral
Oracea
doxycycline
PDR
600.0
mg
600
mg
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Oracea
doxycycline
PDR
240.0
mg/day
240
mg/day
PO, oral
Oracea
doxycycline
PDR
720.0
mg
720
mg
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
intravenous injection, IV
Oracea
doxycycline
PDR
5.3
mg/kg/day
5.3
mg/kg/day
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
PO, oral
Oracea
doxycycline
PDR
600.0
mg
600
mg
PO, oral
Oracea
doxycycline
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Oracea
doxycycline
PDR
240.0
mg/day
240
mg/day
PO, oral
Oracea
doxycycline
PDR
720.0
mg
720
mg
PO, oral
Oracea
doxycycline
PDR
40.0
mg/day
40
mg/day
PO, oral
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
PO, oral;intravenous injection, IV;
Oracea
doxycycline
PDR
4.4
mg/kg/day
4.4
mg/kg/day
PO, oral;intravenous injection, IV;
Oracea
doxycycline
PDR
DDPD00255
Diethylstilbestrol
268.356
C18H20O2
CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
DB00255
T3D4744
3054
41922
395306
-2.0
-
-2.0
-
DRUGBANK
DDPD00256
Lymecycline
602.6328
C29H38N4O10
[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C
DB00256
T3D3952
54707177
59040
20121315
-2.0
-
-2.0
-
DRUGBANK
77.5
%
77-78
%
PO, oral;
DRUGBANK
21900.0
ng.h/ml
21.9±4.3
mg.h/l
PO, oral;
DRUGBANK
70.0
%
70.0
%
PO, oral;
DRUGBANK
2100.0
ng/ml
2.1
mg/L
PO, oral;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
1.5
L/kg
1.3-1.7
L/kg
DRUGBANK
8.0
h
~8
h
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
25.0
%
25
%
Urinary excretion;
DRUGBANK
DDPD00257
Clotrimazole
344.837
C22H17ClN2
ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
DB00257
T3D2729
2812
3764
http://www.drugs.com/mtm/clotrimazole.html
2710
-2.0
-
-2.0
-
DRUGBANK
708.0
mg/kg
708.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
445.0
mg/kg
445.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
761.0
mg/kg
761.0
mg/kg
PO, oral; mouse;
DRUGBANK
108.0
mg/kg
108.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD00258
Calcium acetate
158.166
C4H6CaO4
[Ca++].CC([O-])=O.CC([O-])=O
DB00258
6116
3310
http://www.drugs.com/cdi/calcium-acetate.html
5890
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40.0
%
PO, oral; food;
food ↓ ;
DRUGBANK
4280.0
mg/kg
4280.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
200.0
mg/kg/dose
200
mg/kg/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
3000.0
mg/dose
3
g/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
PhosLo
calcium acetate
PDR
3000.0
mg/dose
3
g/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
200.0
mg/kg/dose
200
mg/kg/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
3000.0
mg/dose
3
g/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
PhosLo
calcium acetate
PDR
3.0
g/dose
3
g/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
200.0
mg/kg/dose
200
mg/kg/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
PhosLo
calcium acetate
PDR
200.0
mg/kg/dose
200
mg/kg/dose
intravenous injection, IV
PhosLo
calcium acetate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
PhosLo
calcium acetate
PDR
2000.0
mg
2000
mg
Calcium Acetate
calcium acetate
PDR
12.0
dose
12
dose
Tablet,PO，oral;Capsule, PO, Oral;
Calcium Acetate
calcium acetate
PDR
60.0
ml/day
60
ml/day
PO, oral
Calcium Acetate
calcium acetate
PDR
2000.0
mg
2000
mg
Calcium Acetate
calcium acetate
PDR
12.0
dose
12
dose
Tablet,PO，oral;Capsule, PO, Oral;
Calcium Acetate
calcium acetate
PDR
60.0
ml/day
60
ml/day
PO, oral
Calcium Acetate
calcium acetate
PDR
2000.0
mg
2000
mg
Calcium Acetate
calcium acetate
PDR
12.0
dose
12
dose
Tablet,PO，oral;Capsule, PO, Oral;
Calcium Acetate
calcium acetate
PDR
60.0
ml/day
60
ml/day
PO, oral
Calcium Acetate
calcium acetate
PDR
2000.0
mg
2000
mg
Calcium Acetate
calcium acetate
PDR
12.0
dose
12
dose
Tablet,PO，oral;Capsule, PO, Oral;
Calcium Acetate
calcium acetate
PDR
60.0
ml/day
60
ml/day
PO, oral
Calcium Acetate
calcium acetate
PDR
2000.0
mg
2000
mg
Calcium Acetate
calcium acetate
PDR
60.0
ml/day
60
ml/day
PO, oral
Calcium Acetate
calcium acetate
PDR
DDPD00259
Sulfanilamide
172.205
C6H8N2O2S
NC1=CC=C(C=C1)S(N)(=O)=O
DB00259
5333
45373
http://www.drugs.com/cdi/sulfanilamide.html
5142
-2.0
-
-2.0
-
DRUGBANK
3700.0
mg/kg
3700.0
mg/kg
PO, oral; mouse;
DRUGBANK
621.0
mg/kg
621.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
PO, oral; rabbit;
DRUGBANK
2.0
appLicatorfuL/day
2
appLicatorfuL/day
Vaginal Administration
AVC
sulfanilamide
PDR
2.0
suppositories/day
2
suppositories/day
Vaginal Administration
AVC
sulfanilamide
PDR
2.0
applicatorful/day
2
applicatorful/day
Vaginal Administration
AVC
sulfanilamide
PDR
2.0
suppositories/day
2
suppositories/day
Vaginal Administration
AVC
sulfanilamide
PDR
DDPD00260
Cycloserine
102.0919
C3H6N2O2
N[C@@H]1CONC1=O
DB00260
6234
40009
http://www.drugs.com/cdi/cycloserine.html
5998
-2.0
-
-2.0
-
DRUGBANK
80.0
%
70-90
%
PO, oral;
DRUGBANK
10.0
h
10
h
patients; normal renal function;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
5290.0
mg/kg
5290.0
mg/kg
PO, oral; mouse;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00261
Anagrelide
256.088
C10H7Cl2N3O
ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl
DB00261
2182
142290
http://www.drugs.com/cdi/anagrelide.html
2097
-2.0
-
-2.0
-
DRUGBANK
70.0
%
~70
%
PO, oral; food;
food ↑ ;
DRUGBANK
1.0
h
1
h
PO, oral; food;
food ↑ ;
DRUGBANK
1.5
h
~1.5
h
DRUGBANK
2.5
h
~2.5
h
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2500.0
mg/kg
>2500
mg/kg
PO, oral; mouse;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.5
mg/dose
2.5
mg/dose
PO, oral
Agrylin
anagrelide hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral
Agrylin
anagrelide hydrochloride
PDR
2.5
mg/dose
2.5
mg/dose
PO, oral
Agrylin
anagrelide hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral
Agrylin
anagrelide hydrochloride
PDR
2.5
mg/dose
2.5
mg/dose
PO, oral
Agrylin
anagrelide hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral
Agrylin
anagrelide hydrochloride
PDR
2.5
mg/dose
2.5
mg/dose
PO, oral
Agrylin
anagrelide hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral
Agrylin
anagrelide hydrochloride
PDR
DDPD00262
Carmustine
214.05
C5H9Cl2N3O2
ClCCNC(=O)N(CCCl)N=O
DB00262
T3D4681
2578
3423
http://www.drugs.com/cdi/carmustine.html
2480
-2.0
-
-2.0
-
DRUGBANK
16.5
%
5-28
%
DRUGBANK
0.375
h
15-30
min
DRUGBANK
20.0
mg/kg
20.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
45.0
mg/kg
45.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
20.0
mg/kg
20.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
45.0
mg/kg
45.0
mg/kg
PO, oral; mouse;
DRUGBANK
65.0
%
~60-70
%
Urinary excretion;
DRUGBANK
10.0
%
~10
%
lung excretion;
DRUGBANK
80.0
%
80
%
DRUGBANK
200.0
mg/m2
200
mg/m2
intravenous injection, IV; nan
q6w
Gliadel
carmustine
PDR
300.0
mg/m2
300
mg/m2
intravenous injection, IV
Gliadel
carmustine
PDR
61.6
mg
61.6
mg
implanted intracranially
Gliadel
carmustine
PDR
200.0
mg/m2
200
mg/m2
intravenous injection, IV; nan
q6w
Gliadel
carmustine
PDR
300.0
mg/m2
300
mg/m2
intravenous injection, IV
Gliadel
carmustine
PDR
61.6
mg
61.6
mg
implanted intracranially
Gliadel
carmustine
PDR
DDPD00263
Sulfisoxazole
267.304
C11H13N3O3S
CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
DB00263
5344
102484
http://www.drugs.com/mtm/sulfisoxazole-ophthalmic.html
5151
-2.0
-
-2.0
-
DRUGBANK
0.018
L/h/kg
0.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.4
h
7.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6800.0
mg/kg
6800.0
mg/kg
PO, oral; mouse;
DRUGBANK
97.0
%
97
%
Urinary excretion; PO, oral;
DRUGBANK
DDPD00264
Metoprolol
267.3639
C15H25NO3
COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
DB00264
4171
6904
http://www.drugs.com/metoprolol.html
4027
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
intravenous injection, IV;
DRUGBANK
38.0
%
38±14
%
PO, oral;
DRUGBANK
99.0
ng/ml
99±53
ng/ml
PO, oral; extensive metabolizers, EM;
DRUGBANK
262.0
ng/ml
262±29
ng/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
0.42
h
0.42
h
intravenous injection, IV;
DRUGBANK
2.0
h
~2
h
PO, oral; extensive metabolizers, EM;
DRUGBANK
3.0
h
~3
h
PO, oral; poor metabolizers, PM;
DRUGBANK
50.0
%
50
%
Liver metabolism;
DRUGBANK
48.0
L/h
0.8
L/min
normal,healthy; patients;
DRUGBANK
36.6
L/h
0.61
L/min
Hepatitis, Hep; patients;
DRUGBANK
0.9
L/h/kg
15±3
ml/min/kg
hydrolysis;
Female, women ↓ ;Elderly → ;Preg, pregnant ↑ ;hyperthyroid, HTh ↑ ;Somking → ;
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.2
L/kg
4.2
L/kg
DRUGBANK
4.2
L/kg
4.2±0.7
L/kg
Female, women ↓ ;Preg, pregnant ↑ ;
DRUGBANK
3.1
L/kg
3.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~3-7
h
immediate release formulation;
DRUGBANK
3.2
h
3.2±0.2
h
Preg, pregnant → ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;hyperthyroid, HTh → ;Age → ;Somking → ;
DRUGBANK
3.6
h
3.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3880.0
mg/kg
3090-4670
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.0
%
<5
%
Unchanged drug;
DRUGBANK
10.0
%
10±3
%
Urinary excretion; Unchanged drug;
DRUGBANK
11.0
%
~11
%
plasma proteins;
DRUGBANK
11.0
%
11±1
%
Preg, pregnant → ;
DRUGBANK
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
6.0
mg/kg/day
6
mg/kg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
2.4
mg/kg/day
2.4
mg/kg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
6.0
mg/kg/day
6
mg/kg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
2.4
mg/kg/day
2.4
mg/kg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
200.0
mg/day
200
mg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
450.0
mg/day
450
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
6.0
mg/kg/day
6
mg/kg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
2.4
mg/kg/day
2.4
mg/kg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
200.0
mg/day
200
mg/day
PO, oral
Lopressor Tablets
metoprolol tartrate
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
450.0
mg/day
450
mg/day
Tablet,PO，oral
Lopressor Tablets
metoprolol tartrate
PDR
DDPD00265
Crotamiton
203.2802
C13H17NO
CCN(C(=O)C=CC)C1=CC=CC=C1C
DB00265
2883
http://www.drugs.com/cdi/crotamiton-cream.html
599515
-2.0
-
-2.0
-
DRUGBANK
10.0
%
10.0
%
DRUGBANK
1.0
application/day
1
application/day
Eurax
crotamiton
PDR
1.0
appLication/day
1
appLication/day
Eurax
crotamiton
PDR
1.0
appLication/day
1
appLication/day
Eurax
crotamiton
PDR
1.0
application/day
1
application/day
Eurax
crotamiton
PDR
1.0
application/day
1
application/day
Eurax
crotamiton
PDR
1.0
application/day
1
application/day
Eurax
crotamiton
PDR
1.0
appLication/day
1
appLication/day
Eurax
crotamiton
PDR
DDPD00266
Dicoumarol
336.295
C19H12O6
OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2
DB00266
T3D3735
54676038
4513
10183330
-2.0
-
-2.0
-
DRUGBANK
233.0
mg/kg
233.0
mg/kg
PO, oral; mouse;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
233.0
mg/kg
233.0
mg/kg
PO, oral; mouse;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00267
Cefmenoxime
511.558
C16H17N9O5S3
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
DB00267
9570757
55490
7845223
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
IM,intramuscular injection;
DRUGBANK
0.0
%
~0
%
DRUGBANK
0.219
L/h/kg
3.65
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
DRUGBANK
0.89
h
0.89
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
50-70
%
DRUGBANK
DDPD00268
Ropinirole
260.3746
C16H24N2O
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
DB00268
T3D2731
5095
8888
http://www.drugs.com/cdi/ropinirole.html
4916
-2.0
-
-2.0
-
DRUGBANK
50.0
%
45-55
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
PO, oral; extended release formulation;
extended release formulation ↑ ;
DRUGBANK
55.0
%
55.0
%
PO, oral; Parkinson;
DRUGBANK
7.4
ng/ml
7.4(2.4-13)
ng/ml
PO, oral; Parkinson;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
4.0
h
3.5-4.5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
1.0
h
1.0(0.5-6.0)
h
PO, oral; Parkinson;
DRUGBANK
47.0
L/h
47.0
L/h
PO, oral;
DRUGBANK
0.672
L/h/kg
11.2±5.0
ml/min/kg
apparent clearance; PO, oral; Parkinson; Male, men; Female, women; patients; hydrolysis;
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
1.8
L/h/kg
30
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
L/kg
7.5
L/kg
Apparent volume of distribution;
DRUGBANK
7.5
L/kg
7.5±2.4
L/kg
Apparent volume of distribution; PO, oral; Parkinson; Male, men; Female, women; patients; hydrolysis;
DRUGBANK
7.7
L/kg
7.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
~6
h
DRUGBANK
6.0
h
6.0
h
PO, oral;
DRUGBANK
6.0
h
6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
88.0
%
>88
%
Urinary excretion;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Parkinson; human, homo sapiens; Unchanged drug;
DRUGBANK
40.0
%
40
%
plasma proteins;
DRUGBANK
40.0
%
~40
%
Parkinson; human, homo sapiens;
DRUGBANK
24.0
mg/day
24
mg/day
PO, oral
Requip
ropinirole
PDR
24.0
mg/day
24
mg/day
PO, oral
Requip
ropinirole
PDR
DDPD00270
Isradipine
371.3871
C19H21N3O5
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
DB00270
3784
6073
http://www.drugs.com/cdi/isradipine.html
3652
-2.0
-
-2.0
-
DRUGBANK
92.5
%
90-95
%
DRUGBANK
19.5
%
15-24
%
DRUGBANK
1.56
L/h/kg
26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8
h
DRUGBANK
3.3
h
3.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.5
%
~60-65
%
Urinary excretion;
DRUGBANK
27.5
%
25-30
%
Faeces excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Isradipine
isradipine
PDR
20.0
mg/day
20
mg/day
PO, oral
Isradipine
isradipine
PDR
20.0
mg/day
20
mg/day
PO, oral
Isradipine
isradipine
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Isradipine
isradipine
PDR
20.0
mg/day
20
mg/day
PO, oral
Isradipine
isradipine
PDR
20.0
mg/day
20
mg/day
PO, oral
Isradipine
isradipine
PDR
0.27
mg/kg/day
0.27
mg/kg/day
Isradipine
isradipine
PDR
0.27
mg/kg/day
0.27
mg/kg/day
Isradipine
isradipine
PDR
DDPD00271
Diatrizoate
613.9136
C11H9I3N2O4
CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
DB00271
2140
53691
2055
-2.0
-
-2.0
-
DRUGBANK
DDPD00272
Betazole
111.1451
C5H9N3
NCCC1=CC=NN1
DB00272
7741
59170
7455
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD00273
Topiramate
339.362
C12H21NO8S
[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
DB00273
T3D2733
5284627
63631
http://www.drugs.com/cdi/topiramate.html
4447672
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80.0
%
Tablet, PO, oral;
DRUGBANK
70.0
%
≥70
%
PO, oral; adults; normal,healthy; epilepsy;
DRUGBANK
15215.0
ng/ml
1.73-28.7
ug/ml
PO, oral;
DRUGBANK
5500.0
ng/ml
5.5±0.6
mcg/ml
PO, oral; adults; normal,healthy; epilepsy;
DRUGBANK
3.05
h
1.8-4.3
h
PO, oral;
DRUGBANK
1.7
h
1.7±0.6
h
PO, oral; adults; normal,healthy; epilepsy;
DRUGBANK
96.0
h
4.0
day
PO, oral; normal,healthy;
DRUGBANK
1.74
L/h
22-36
ml/min
Plasma clearance; PO, oral;
DRUGBANK
1.05
L/h
17-18
ml/min
Renal clearance; PO, oral;
DRUGBANK
1.5
L/h
~20-30
ml/min
Plasma clearance; PO, oral; adults;
DRUGBANK
0.0246
L/h/kg
0.31-0.51
ml/min/kg
apparent clearance; PO, oral; normal,healthy; Male, men; patients;
Children ↑ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.0162
L/h/kg
0.27
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
L/kg
0.6-0.8
L/kg
Apparent volume of distribution;
DRUGBANK
0.7
L/kg
0.6-0.8
L/kg
Apparent volume of distribution; PO, oral; normal,healthy; Male, men; patients;
DRUGBANK
0.8
L/kg
0.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.0
h
19-23
h
elimination half-life;
DRUGBANK
13.5
h
12-15
h
enzyme-inducers;
DRUGBANK
21.0
h
19-23
h
moderate renal function; severe renal function;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
34.8
h
34.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
75.0
%
~70-80
%
Urinary excretion; Unchanged drug;
DRUGBANK
83.5
%
70-97
%
Urinary excretion; adults; normal,healthy; epilepsy; human, homo sapiens; human, homo sapiens; Unchanged drug;
DRUGBANK
13.0
%
9-17
%
plasma proteins;
DRUGBANK
28.0
%
15-41
%
DRUGBANK
15.0
%
13-17
%
adults; normal,healthy; epilepsy; human, homo sapiens;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
100.0
mg/day
100
mg/day
PO, oral
Trokendi XR
topiramate
PDR
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
350.0
mg/day
350
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
300.0
mg/day
300
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
250.0
mg/day
250
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
100.0
mg/day
100
mg/day
PO, oral
Trokendi XR
topiramate
PDR
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
100.0
mg/day
100
mg/day
PO, oral
Trokendi XR
topiramate
PDR
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Trokendi XR
topiramate
PDR
100.0
mg/day
100
mg/day
PO, oral
Trokendi XR
topiramate
PDR
400.0
mg/day
400
mg/day
PO, oral
Trokendi XR
topiramate
PDR
100.0
mg/day
100
mg/day
PO, oral
Trokendi XR
topiramate
PDR
DDPD00274
Cefmetazole
471.534
C15H17N7O5S3
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O
DB00274
42008
3489
38311
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
0.0
%
~0
%
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.50±0.14
h
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3204.0
mg/kg
3204.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00275
Olmesartan
446.5016
C24H26N6O3
CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
DB00275
158781
48416
http://www.drugs.com/cdi/olmesartan.html
139674
-2.0
-
-2.0
-
DRUGBANK
10750.0
ng.h/ml
1.6-19.9
mg.h/L
PO, oral;
DRUGBANK
4.5
%
4.5
%
PO, oral;
DRUGBANK
1160.0
ng/ml
0.22-2.1
mg/L
PO, oral;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
1.3
L/h
1.3
L/h
Plasma clearance;
DRUGBANK
0.6
L/h
0.6
L/h
Renal clearance;
DRUGBANK
0.0174
L/h/kg
0.29
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
L
17.0
L
DRUGBANK
12.5
h
10-15
h
elimination half-life; Oral multiple dose;
DRUGBANK
10.8
h
10.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
dog;
DRUGBANK
13.0
%
~10-16
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
20.0
mg/day
20
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
40.0
mg/day
40
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
40.0
mg/day
40
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
40.0
mg/day
40
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
20.0
mg/day
20
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
40.0
mg/day
40
mg/day
PO, oral
Benicar
olmesartan medoxomil
PDR
DDPD00276
Amsacrine
393.459
C21H19N3O3S
COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1
DB00276
T3D4674
2179
2687
2094
-2.0
-
-2.0
-
DRUGBANK
0.258
L/h/kg
4.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.5
h
8-9
h
DRUGBANK
4.7
h
4.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
97.0
%
96-98
%
DRUGBANK
DDPD00277
Theophylline
180.164
C7H8N4O2
CN1C2=C(NC=N2)C(=O)N(C)C1=O
DB00277
T3D4780
2153
28177
http://www.drugs.com/cdi/theophylline.html
2068
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
96.0
%
96±8
%
PO, oral;
DRUGBANK
7900.0
ng/ml
7.9±0.6
mcg/ml
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
15000.0
ng/ml
15±2.8
mcg/ml
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
14000.0
ng/ml
14±3.7
mcg/ml
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
1.5
h
~1.5
h
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
11.5
h
11.5±7.5
h
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
11.3
h
11.3±4.8
h
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
6.0
%
6
%
DRUGBANK
0.0279
L/h/kg
0.29-0.64
ml/kg/min
Prem, premature; Neonates;
DRUGBANK
0.078
L/h/kg
0.9-1.7
ml/kg/min
Children;
DRUGBANK
0.039
L/h/kg
0.65
ml/kg/min
adults;
DRUGBANK
0.0246
L/h/kg
0.41
ml/kg/min
Elderly; normal,healthy;
DRUGBANK
0.0198
L/h/kg
0.33
ml/kg/min
lung disease;
DRUGBANK
0.0324
L/h/kg
0.54
ml/kg/min
Geriatric; COPD, Chronic obstructive pulmonary disease;
DRUGBANK
0.0288
L/h/kg
0.48
ml/kg/min
COPD, Chronic obstructive pulmonary disease; CP,cor pulmonale;
DRUGBANK
0.075
L/h/kg
1.25
ml/kg/min
Cystic fibrosis;
DRUGBANK
0.0198
L/h/kg
0.31-0.35
ml/kg/min
Hepatitis, Hep;
DRUGBANK
0.039
L/h/kg
0.65
ml/kg/min
cholestasis;
DRUGBANK
0.0282
L/h/kg
0.47
ml/kg/min
Sepsis; multi-organ failure;
DRUGBANK
0.0228
L/h/kg
0.38
ml/kg/min
LTh hypothyroid;
DRUGBANK
0.048
L/h/kg
0.8
ml/kg/min
hyperthyroid, HTh;
DRUGBANK
0.039
L/h/kg
0.65±0.20
ml/min/kg
Neonates ↓ ;Prem, premature ↓ ;Children ↑ ;Elderly → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;CP,cor pulmonale ↓ ;congestive heart disease ↓ ;Hepatitis, Hep ↓ ;LTh hypothyroid ↓ ;Obesity ↓ ;Cystic fibrosis ↑ ;hyperthyroid, HTh ↑ ;RD, renal impairment, Renal disease，including uremia → ;COPD, Chronic obstructive pulmonary disease → ;Somking ↑ ;
DRUGBANK
0.0516
L/h/kg
0.86
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
L/kg
0.3-0.7
L/kg
DRUGBANK
0.5
L/kg
0.50±0.16
L/kg
Elderly → ;Preg, pregnant → ;Prem, premature ↑ ;Obesity ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;hyperthyroid, HTh → ;LTh hypothyroid → ;Cystic fibrosis ↑ ;
DRUGBANK
0.51
L/kg
0.51
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8
h
DRUGBANK
9.0
h
9.0±2.1
h
Prem, premature ↑ ;Neonates ↑ ;Cystic fibrosis ↓ ;hyperthyroid, HTh ↓ ;Hepatic cirrhosis, cirr ↑ ;congestive heart disease ↑ ;Hepatitis, Hep ↑ ;CP,cor pulmonale ↑ ;LTh hypothyroid ↑ ;RD, renal impairment, Renal disease，including uremia → ;Somking ↓ ;Age → ;normal BMI ↓ ;
DRUGBANK
7.2
h
7.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
~50
%
Urinary excretion; Neonates; Unchanged drug;
DRUGBANK
10.0
%
~10
%
Urinary excretion; Infants; Unchanged drug;
DRUGBANK
10.0
%
~10
%
Urinary excretion; adults; Unchanged drug;
DRUGBANK
18.0
%
18±3
%
Urinary excretion; Unchanged drug;
Neonates ↑ ;Prem, premature ↑ ;Elderly → ;Cystic fibrosis → ;
DRUGBANK
40.0
%
40
%
DRUGBANK
56.0
%
56±4
%
Elderly ↓ ;Neonates ↓ ;Preg, pregnant ↓ ;Hepatic cirrhosis, cirr ↓ ;Obesity ↓ ;Cystic fibrosis → ;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
400.0
mg/day
400
mg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
400.0
mg/day
400
mg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
400.0
mg/day
400
mg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
400.0
mg/day
400
mg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
400.0
mg/day
400
mg/day
PO, oral
Elixophyllin
theophylline anhydrous
PDR
DDPD00278
Argatroban
508.64
C23H36N6O5S
C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2
DB00278
152951
94385
http://www.drugs.com/cdi/argatroban.html
83702
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
intravenous injection, IV;
DRUGBANK
5.1
L/h/kg
5.1
L/kg/h
intravenous infusion, IV in drop;
DRUGBANK
0.3
L/h/kg
5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.174
L/kg
174.0
ml/kg
DRUGBANK
12.18
L
12.18
L
adults;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
h
39-51
min
DRUGBANK
0.4
h
0.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
65.0
%
65
%
Faeces excretion;
DRUGBANK
22.0
%
22
%
Urinary excretion;
DRUGBANK
54.0
%
54
%
DRUGBANK
DDPD00279
Liothyronine
650.9735
C15H12I3NO4
N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O
DB00279
T3D4759
5920
18258
http://www.drugs.com/cdi/liothyronine.html
5707
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral; food;
food → ;
DRUGBANK
47.42
ng.h/ml
4742.0
ng.h/dl
Oral multiple dose;
DRUGBANK
34600.0
ng/ml
346.0
ng/dl
Oral multiple dose;
DRUGBANK
2.5
h
2.5
h
Oral multiple dose;
DRUGBANK
0.15
L/kg
0.1-0.2
L/kg
DRUGBANK
36.0
h
1-2
day
DRUGBANK
4540.0
mg/kg
>4540
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
99.7
%
~99.7
%
plasma proteins;
DRUGBANK
0.1
mg/day
100
mcg/day
PO, oral;intravenous injection, IV;
Cytomel
liothyronine sodium
PDR
0.1
mg/day
100
mcg/day
PO, oral;intravenous injection, IV;
Cytomel
liothyronine sodium
PDR
0.1
mg/day
100
mcg/day
PO, oral;intravenous injection, IV;
Cytomel
liothyronine sodium
PDR
0.1
mg/day
100
mcg/day
PO, oral
Cytomel
liothyronine sodium
PDR
DDPD00280
Disopyramide
339.4745
C21H29N3O
CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C
DB00280
3114
4657
http://www.drugs.com/cdi/disopyramide.html
3002
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
0.054
L/h/kg
0.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.52
L/kg
0.52
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.7
h
6.7(4-10)
h
DRUGBANK
7.0
h
7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
580.0
mg/kg
580.0
mg/kg
Rattus, Rat;
DRUGBANK
50.0
%
~50
%
Urinary excretion; Male, men; normal,healthy; Unchanged drug;
DRUGBANK
57.5
%
50-65
%
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
800.0
mg/day
800
mg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
800.0
mg/day
800
mg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Norpace/Norpace CR
disopyramide phosphate
PDR
DDPD00281
Lidocaine
234.3373
C14H22N2O
CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
DB00281
T3D2735
3676
6456
http://www.drugs.com/cdi/lidocaine-gel.html
3548
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
parenteral administration;
DRUGBANK
35.0
%
35.0
%
PO, oral;
DRUGBANK
35.0
%
35±11
%
parenteral administration;
DRUGBANK
3500.0
ng/ml
2-5
mcg/ml
DRUGBANK
38.4
L/h
0.64±0.18
L/min
Average clearance; intravenous injection, IV; adults;
DRUGBANK
0.552
L/h/kg
9.2±2.4
ml/min/kg
hydrolysis;
Neonates → ;Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;acute viral hepatitis AVH → ;Obesity ↓ ;congestive heart disease ↓ ;CPBS ↓ ;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
0.7-1.5
L/kg
the more highly perfused ↑ ;
DRUGBANK
1.1
L/kg
1.1±0.4
L/kg
Neonates ↑ ;Elderly → ;congestive heart disease ↓ ;CPBS ↓ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.75
h
1.5-2
h
elimination half-life; intravenous injection, IV;
hepatopathy，LD ↑ ;
DRUGBANK
3.0
h
>3
h
hepatopathy，LD;
DRUGBANK
1.8
h
1.8±0.4
h
Neonates ↑ ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;RD, renal impairment, Renal disease，including uremia → ;CPBS → ;congestive heart disease → ;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
459.0
mg/kg
459(346-773)
mg/kg
food; female rat;
DRUGBANK
214.0
mg/kg
214(159-324)
mg/kg
fasting; female rat;
DRUGBANK
459.0
mg/kg
459(346-773)
mg/kg
PO, oral; food; female rat;
DRUGBANK
214.0
mg/kg
214(159-324)
mg/kg
PO, oral; fasting; female rat;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
2±1
%
Urinary excretion; Unchanged drug;
Neonates ↑ ;
DRUGBANK
70.0
%
~60-80
%
DRUGBANK
70.0
%
70±5
%
Neonates ↓ ;Elderly ↑ ;Children → ;myocardial infarction ↑ ;CPBS ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;nephritic syndrome → ;Somking → ;
DRUGBANK
1.0
mg/kg
1
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
100.0
mg
100
mg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
72.0
mg/kg/day
50
mcg/kg/minute
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
2.0
mg/kg
2
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
144.0
mg/kg/day
6
mg/kg/hour
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
100.0
mg/dose
100
mg/dose
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
300.0
mg
300
mg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
1.5
mg/kg/dose
1.5
mg/kg/dose
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
5760.0
mg/day
4
mg/minute
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
72.0
mg/kg/day
50
mcg/kg/minute
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
100.0
mg/dose
100
mg/dose
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
300.0
mg
300
mg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
1.5
mg/kg/dose
1.5
mg/kg/dose
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
0.00277777777777778
mg/day
4
mg/minute
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
72.0
mg/kg/day
50
mcg/kg/minute
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
1.0
mg/kg
1
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
100.0
mg
100
mg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
72.0
mg/kg/day
50
mcg/kg/min
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
2.0
mg/kg
2
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
144.0
mg/kg/day
6
mg/kg/h
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
1.0
mg/kg
1
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
72.0
mg/kg/day
50
mcg/kg/minute
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
2.0
mg/kg
2
mg/kg
intravenous injection, IV
Lidocaine Cream
lidocaine
PDR
0.25
mg/kg/day
6
mg/kg/hour
intravenous infusion, iv in drop
Lidocaine Cream
lidocaine
PDR
DDPD00282
Pamidronic acid
235.0695
C3H11NO7P2
NCCC(O)(P(O)(O)=O)P(O)(O)=O
DB00282
T3D2665
4674
7903
http://www.drugs.com/cdi/pamidronate.html
4512
-2.0
-
-2.0
-
DRUGBANK
10200.0
ng.h/ml
10.2±6.95
ug.h/ml
normal,healthy;
DRUGBANK
7305.0
ng.h/ml
10.7-3.91
ug.h/ml
mild renal function;
DRUGBANK
10100.0
ng.h/ml
10.1±3.38
ug.h/ml
moderate renal function;
DRUGBANK
34000.0
ng.h/ml
34.0±8.37
ug.h/ml
severe renal function;
DRUGBANK
1920.0
ng/ml
1.92±1.08
ug/ml
normal,healthy;
DRUGBANK
1860.0
ng/ml
1.86±0.50
ug/ml
mild renal function;
DRUGBANK
1840.0
ng/ml
1.84±0.58
ug/ml
moderate renal function;
DRUGBANK
1930.0
ng/ml
1.93±0.53
ug/ml
severe renal function;
DRUGBANK
4.0
h
4
h
normal,healthy;
DRUGBANK
4.0
h
4
h
mild renal function;
DRUGBANK
4.0
h
4
h
moderate renal function;
DRUGBANK
4.0
h
4
h
severe renal function;
DRUGBANK
0.0
%
0
%
DRUGBANK
6.42
L/h
107±50
ml/min
Average clearance;
DRUGBANK
2.94
L/h
49±28
ml/min
Renal clearance;
DRUGBANK
28.0
h
28±7
h
elimination half-life;
DRUGBANK
46.0
%
46±16
%
Urinary excretion;
DRUGBANK
54.0
%
~54
%
DRUGBANK
90.0
mg/dose
90
mg/dose
intravenous injection, IV
Pamidronate Disodium
pamidronate disodium
PDR
90.0
mg/dose
90
mg/dose
intravenous injection, IV
Pamidronate Disodium
pamidronate disodium
PDR
DDPD00283
Clemastine
343.89
C21H26ClNO
CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
DB00283
26987
3738
http://www.drugs.com/cdi/clemastine.html
25129
-2.0
-
-2.0
-
DRUGBANK
3550.0
mg/kg
3550.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
730.0
mg/kg
730.0
mg/kg
PO, oral; mouse;
DRUGBANK
8.04
mg/day
8.04
mg/day
PO, oral
Tavist Allergy
clemastine fumarate
PDR
6.0
mg/day
6
mg/day
PO, oral
Tavist Allergy
clemastine fumarate
PDR
8.04
mg/day
8.04
mg/day
PO, oral
Tavist Allergy
clemastine fumarate
PDR
6.0
mg/day
6
mg/day
PO, oral
Tavist Allergy
clemastine fumarate
PDR
8.04
mg/day
8.04
mg/day
PO, oral
Tavist Allergy
clemastine fumarate
PDR
6.0
mg/day
6
mg/day
PO, oral
Tavist Allergy
clemastine fumarate
PDR
0.0
0
Tavist Allergy
clemastine fumarate
PDR
DDPD00284
Acarbose
645.608
C25H43NO18
[H]C(=O)[C@H](O)[C@@H](O)[C@]([H])(O[C@@]1([H])O[C@H](CO)[C@@]([H])(O[C@H]2O[C@H](C)[C@@H](N[C@@]3([H])C=C(CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)CO
DB00284
9811704
2376
http://www.drugs.com/cdi/acarbose.html
23264314
-2.0
-
-2.0
-
DRUGBANK
2.0
%
<2
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.32
L/kg
0.32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
normal,healthy;
DRUGBANK
2.7
h
2.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Precose
acarbose
PDR
300.0
mg/day
300
mg/day
PO, oral
Precose
acarbose
PDR
150.0
mg/day
150
mg/day
PO, oral
Precose
acarbose
PDR
300.0
mg/day
300
mg/day
PO, oral
Precose
acarbose
PDR
DDPD00285
Venlafaxine
277.4018
C17H27NO2
COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
DB00285
T3D2736
5656
9943
http://www.drugs.com/venlafaxine.html
5454
-2.0
-
-2.0
-
DRUGBANK
92.0
%
92.0
%
Oral single dose; food;
food → ;
DRUGBANK
45.0
%
45.0
%
Oral single dose; food;
food → ;
DRUGBANK
27.5
%
10-45
%
PO, oral;
DRUGBANK
167.0
ng/ml
167±55
ng/ml
PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
397.0
ng/ml
397±81
ng/ml
PO, oral; Active metabolite; immediate release formulation; adults; normal,healthy;
DRUGBANK
2.0
h
2.0±0.4
h
PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
2.8
h
2.8±0.8
h
PO, oral; Active metabolite; immediate release formulation; adults; normal,healthy;
DRUGBANK
5.5
h
5.5
h
PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
9.0
h
9
h
PO, oral; Active metabolite; extended release formulation; adults; normal,healthy;
DRUGBANK
72.0
h
3.0
day
DRUGBANK
1.3
L/h/kg
1.3±0.6
L/h/kg
Plasma clearance;
DRUGBANK
0.4
L/h/kg
0.4±0.2
L/h/kg
Plasma clearance;
DRUGBANK
1.32
L/h/kg
22±10
ml/min/kg
apparent clearance;
Female, women → ;Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
L/kg
7.5±3.7
L/kg
DRUGBANK
5.7
L/kg
5.7±1.8
L/kg
DRUGBANK
7.5
L/kg
7.5±3.7
L/kg
Apparent volume of distribution;
Female, women → ;Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
4.4
L/kg
4.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5
h
DRUGBANK
4.9
h
4.9±2.4
h
Female, women → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Age → ;
DRUGBANK
10.3
h
10.3±54.3
h
Female, women → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Age → ;
DRUGBANK
5.0
h
5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
48.0
%
~48
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion; Unchanged drug;
DRUGBANK
4.6
%
4.6±3
%
Urinary excretion; Unchanged drug;
DRUGBANK
29.0
%
29±7
%
Urinary excretion; Unchanged drug;
DRUGBANK
27.0
%
27±2
%
plasma proteins; human, homo sapiens;
DRUGBANK
27.0
%
27±2
%
DRUGBANK
30.0
%
30±12
%
Metabolite;
DRUGBANK
112.5
mg/day
112.5
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
375.0
mg/day
375
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
225.0
mg/day
225
mg/day
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
112.5
mg/day
112.5
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
375.0
mg/day
375
mg/day
PO, oral
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
225.0
mg/day
225
mg/day
Venlafaxine Tablets
venlafaxine hydrochloride
PDR
DDPD00286
Conjugated estrogens
N.A.
N.A.
CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+]
DB00286
45357473
8389
https://www.drugs.com/cdi/conjugated-estrogens.html
9532
-2.0
-
-2.0
-
DRUGBANK
35.0
ng.h/ml
35.0
ng.h/ml
Oral multiple dose;
DRUGBANK
2.6
ng/ml
2.6
ng/ml
Oral multiple dose;
DRUGBANK
7.0
h
7
h
PO, oral;
DRUGBANK
615.0
L/m2
~615
L/m2
DRUGBANK
17.0
h
17
h
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
65.0
%
~50-80
%
plasma proteins;
DRUGBANK
DDPD00287
Travoprost
500.5477
C26H35F3O6
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F
DB00287
5282226
746859
http://www.drugs.com/cdi/travoprost-drops.html
4445407
-2.0
-
-2.0
-
DRUGBANK
0.025
ng/ml
<25
pg/ml
ophthalmic administration;
DRUGBANK
0.5
h
0.5
h
ophthalmic administration;
DRUGBANK
2.6
L/kg
2.6
L/kg
Rattus, Rat;
DRUGBANK
0.75
h
~45(17-86)
min
elimination half-life;
DRUGBANK
61.0
%
61
%
Bile excretion; subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
34.0
%
34
%
Urinary excretion; subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
80.0
%
80
%
plasma proteins;
DRUGBANK
DDPD00288
Amcinonide
502.5717
C28H35FO7
[H][C@@]12C[C@H]3OC4(CCCC4)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00288
443958
31199
http://www.drugs.com/cdi/amcinonide-cream.html
392009
-2.0
-
-2.0
-
DRUGBANK
3.0
application/day
3
application/day
skin/dermal
Amcinonide Lotion
amcinonide
PDR
3.0
appLication/day
3
appLication/day
skin/dermal
Amcinonide Lotion
amcinonide
PDR
3.0
application/day
3
application/day
skin/dermal
Amcinonide Lotion
amcinonide
PDR
3.0
application/day
3
application/day
skin/dermal
Amcinonide Lotion
amcinonide
PDR
DDPD00289
Atomoxetine
255.3547
C17H21NO
CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
DB00289
T3D2737
54841
127342
http://www.drugs.com/cdi/atomoxetine.html
49516
-2.0
-
-2.0
-
DRUGBANK
2000.0
ng.h/ml
2.0
mcg.h/ml
PO, oral;
DRUGBANK
63.0
%
63.0
%
PO, oral;
DRUGBANK
94.0
%
94.0
%
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
63.0
%
63.0
%
PO, oral; extensive metabolizers, EM;
DRUGBANK
94.0
%
94.0
%
PO, oral; poor metabolizers, PM;
DRUGBANK
350.0
ng/ml
350.0
ng/ml
PO, oral;
DRUGBANK
160.0
ng/ml
160.0
ng/ml
PO, oral; extensive metabolizers, EM;
DRUGBANK
915.0
ng/ml
915.0
ng/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
2.0
h
2.0
h
PO, oral; poor metabolizers, PM; extensive metabolizers, EM;
DRUGBANK
0.47
L/h/kg
0.27-0.67
L/h/kg
DRUGBANK
0.372
L/h/kg
6.2
ml/min/kg
apparent clearance; at steady state; hydrolysis; extensive metabolizers, EM;
hepatopathy，LD ↓ ;
DRUGBANK
0.036
L/h/kg
0.6
ml/min/kg
apparent clearance; at steady state; hydrolysis; poor metabolizers, PM;
DRUGBANK
0.558
L/h/kg
9.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
L/kg
1.6-2.6
L/kg
PO, oral;
DRUGBANK
0.85
L/kg
~0.85
L/kg
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
2.3
L/kg
2.3
L/kg
Apparent volume of distribution; at steady state; hydrolysis; extensive metabolizers, EM;
DRUGBANK
1.1
L/kg
1.1
L/kg
Apparent volume of distribution; at steady state; hydrolysis; poor metabolizers, PM;
DRUGBANK
0.85
L/kg
0.85
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.3
h
3-5.6
h
CYP2D6 genetic polymorphisms;
DRUGBANK
5.3
h
5.3
h
extensive metabolizers, EM; at steady state;
DRUGBANK
20.0
h
20.0
h
poor metabolizers, PM; at steady state;
DRUGBANK
5.2
h
5.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
>80
%
Urinary excretion;
DRUGBANK
17.0
%
<17
%
Faeces excretion;
DRUGBANK
3.0
%
<3
%
Unchanged drug;
DRUGBANK
1.5
%
1-2
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.7
%
98.7
%
plasma proteins;
DRUGBANK
96.2
%
~96.2
%
DRUGBANK
98.7
%
98.7±0.3
%
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Strattera
atomoxetine
PDR
1.4
mg/kg/day
1.4
mg/kg/day
PO, oral
Strattera
atomoxetine
PDR
100.0
mg/day
100
mg/day
PO, oral
Strattera
atomoxetine
PDR
1.4
mg/kg/day
1.4
mg/day/kg
PO, oral
Strattera
atomoxetine
PDR
100.0
mg/day
100
mg/day
PO, oral
Strattera
atomoxetine
PDR
DDPD00290
Bleomycin
1415.552
C55H84N17O21S3
[H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O
DB00290
T3D2738
5360373
22907
http://www.drugs.com/cdi/bleomycin.html
4514492
-2.0
-
-2.0
-
DRUGBANK
45.0
%
45.0
%
DRUGBANK
0.0756
L/h/kg
1.26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.91666666666667
h
115
min
DRUGBANK
3.9
h
3.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
1
%
DRUGBANK
400.0
units
400
units
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Bleomycin
bleomycin sulfate
PDR
400.0
units
400
units
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Bleomycin
bleomycin sulfate
PDR
400.0
units
400
units
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Bleomycin
bleomycin sulfate
PDR
DDPD00291
Chlorambucil
304.212
C14H19Cl2NO2
OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
DB00291
T3D4684
2708
28830
http://www.drugs.com/cdi/chlorambucil.html
2607
-2.0
-
-2.0
-
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.26
L/kg
0.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5
h
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
DDPD00292
Etomidate
244.289
C14H16N2O2
CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
DB00292
667484
4910
http://www.drugs.com/cdi/etomidate.html
580864
-2.0
-
-2.0
-
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.7
L/kg
2.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.25
h
75
min
DRUGBANK
3.5
h
3.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
%
~75
%
Urinary excretion;
DRUGBANK
76.0
%
76
%
DRUGBANK
DDPD00293
Raltitrexed
458.488
C21H22N4O6S
CN(CC1=CC2=C(NC(C)=NC2=O)C=C1)C1=CC=C(S1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
DB00293
104758
5847
94568
-2.0
-
-2.0
-
DRUGBANK
0.054
L/h/kg
0.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.57
L/kg
6.57
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
198.0
h
198
h
DRUGBANK
140.0
h
140
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
93.0
%
>93
%
DRUGBANK
DDPD00294
Etonogestrel
324.4565
C22H28O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
DB00294
6917715
50777
http://www.drugs.com/mtm/etonogestrel-implant.html
5292944
-2.0
-
-2.0
-
DRUGBANK
82.0
%
82.0
%
subcutaneous injection, SC;
DRUGBANK
7.5
L/h
7.5
L/h
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
201.0
L
201.0
L
Apparent volume of distribution;
DRUGBANK
2.87
L/kg
2.87
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
h
25
h
elimination half-life;
DRUGBANK
25.0
h
25
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
97.5
%
96-99
%
DRUGBANK
68.0
mg/dose
68
mg/dose
subdermal implant; every 3 years
Nexplanon
etonogestrel
PDR
68.0
mg/dose
68
mg/dose
subdermal implant; every 3 years
Nexplanon
etonogestrel
PDR
DDPD00295
Morphine
285.3377
C17H19NO3
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
DB00295
T3D2740
5288826
17303
http://www.drugs.com/morphine.html
4450907
-2.0
-
-2.0
-
DRUGBANK
73.4742775
ng.h/ml
225-290
nmol.h/L
PO, oral;
DRUGBANK
90.0
%
80-100
%
PO, oral;
DRUGBANK
24.0
%
24±12
%
PO, oral;
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
80.7505691
ng/ml
283.0
nmol/L
PO, oral;
DRUGBANK
70.0
ng/ml
~70
ng/ml
IM,intramuscular injection;
DRUGBANK
10.0
ng/ml
10.0
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
7.4
ng/ml
7.4
ng/ml
PO, oral; Sustained Release formulation;
DRUGBANK
300.0
ng/ml
200-400
ng/ml
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
0.25
h
0.2-0.3
h
IM,intramuscular injection;
DRUGBANK
1.0
h
0.5-1.5
h
PO, oral; immediate release formulation;
DRUGBANK
5.5
h
3-8
h
PO, oral; Sustained Release formulation;
DRUGBANK
36.0
h
24-48
h
PO, oral;
DRUGBANK
90.0
%
90
%
DRUGBANK
96.0
L/h
1600.0
ml/min
intravenous injection, IV; subcutaneous injection, SC;
DRUGBANK
1.44
L/h/kg
24±10
ml/min/kg
Elderly → ;Children → ;Neonates ↓ ;Prem, premature ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;Burn ↓ ;
DRUGBANK
1.56
L/h/kg
26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.31
L/kg
5.31
L/kg
DRUGBANK
3.61
L/kg
3.61
L/kg
DRUGBANK
3.3
L/kg
3.3±0.9
L/kg
Neonates → ;Hepatic cirrhosis, cirr → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
2.3
L/kg
2.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
1.9
h
1.9±0.5
h
Children → ;Neonates ↑ ;Prem, premature ↑ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
4.0
h
4.0±1.5
h
Active metabolite;
DRUGBANK
50.0
h
50±37
h
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.78
mg/L
0.78
ug/ml
Male, men;
DRUGBANK
0.98
mg/L
0.98
ug/ml
Female, women;
DRUGBANK
461.0
mg/kg
461.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; mouse;
DRUGBANK
8.5
%
7-10
%
Faeces excretion;
DRUGBANK
6.0
%
2-10
%
Urinary excretion; Unchanged drug;
DRUGBANK
4.0
%
4±5
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
14.0
%
14±7
%
Urinary excretion; IM,intramuscular injection; Unchanged drug;
DRUGBANK
35.0
%
35
%
DRUGBANK
35.0
%
35±2
%
acute viral hepatitis AVH ↓ ;Hepatic cirrhosis, cirr ↓ ;hypoalbuminemia Alb ↓ ;
DRUGBANK
0.2
mg/kg/dose
0.2
mg/kg/dose
PO, oral
Duramorph
morphine sulfate
PDR
4.0
mg/dose
4
mg/dose
PO, oral
Duramorph
morphine sulfate
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Duramorph
morphine sulfate
PDR
16.0
mg/day
16
mg/day
PO, oral
Duramorph
morphine sulfate
PDR
1600.0
mg/day
1600
mg/day
Capsule, PO, Oral
Duramorph
morphine sulfate
PDR
15.0
mg/dose
15
mg/dose
epidural administration
Duramorph
morphine sulfate
PDR
6.0
mg/dose
6
mg/dose
PO, oral
Duramorph
morphine sulfate
PDR
24.0
mg/day
24
mg/day
PO, oral
Duramorph
morphine sulfate
PDR
4.0
mg/dose
4
mg/dose
PO, oral
Duramorph
morphine sulfate
PDR
16.0
mg/day
16
mg/day
PO, oral
Duramorph
morphine sulfate
PDR
0.2
mg/kg/dose
0.2
mg/kg/dose
PO, oral
Duramorph
morphine sulfate
PDR
4.0
mg/dose
4
mg/dose
PO, oral
Duramorph
morphine sulfate
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Duramorph
morphine sulfate
PDR
16.0
mg/day
16
mg/day
PO, oral
Duramorph
morphine sulfate
PDR
1600.0
mg/day
1600
mg/day
Capsule, PO, Oral
Duramorph
morphine sulfate
PDR
15.0
mg/dose
15
mg/dose
epidural administration
Duramorph
morphine sulfate
PDR
6.0
mg/dose
6
mg/dose
PO, oral
Duramorph
morphine sulfate
PDR
24.0
mg/day
24
mg/day
PO, oral
Duramorph
morphine sulfate
PDR
4.0
mg/dose
4
mg/dose
PO, oral
Duramorph
morphine sulfate
PDR
16.0
mg/day
16
mg/day
PO, oral
Duramorph
morphine sulfate
PDR
DDPD00296
Ropivacaine
274.4011
C17H26N2O
CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
DB00296
T3D2741
175805
8890
http://www.drugs.com/cdi/ropivacaine.html
153165
-2.0
-
-2.0
-
DRUGBANK
92.5
%
87-98
%
epidural administration;
DRUGBANK
1100.0
ng/ml
1.1±0.2
mcg/ml
DRUGBANK
2300.0
ng/ml
2.3±0.8
mcg/ml
skin/dermal;
DRUGBANK
0.7
h
0.7±0.2
h
DRUGBANK
0.9
h
0.9±0.4
h
skin/dermal;
DRUGBANK
23.22
L/h
387±107
ml/min
DRUGBANK
432.0
L/h
7.2±1.6
L/min
Plasma clearance;
DRUGBANK
0.378
L/h/kg
5.5-7.1
ml/min/kg
Average clearance;
DRUGBANK
0.33
L/h/kg
5.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
L/kg
0.54-0.86
L/kg
Average volume of distribution;
DRUGBANK
0.75
L/kg
0.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.2
h
~4.2
h
DRUGBANK
1.8
h
1.6-2.0
h
different study;
DRUGBANK
5.5
h
4-7
h
epidural administration; IM,intramuscular injection;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.0
%
86
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
94.0
%
94
%
DRUGBANK
92.0
%
90-94
%
DRUGBANK
DDPD00297
Bupivacaine
288.4277
C18H28N2O
CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
DB00297
T3D2742
2474
77431
http://www.drugs.com/cdi/bupivacaine-solution.html
2380
-2.0
-
-2.0
-
DRUGBANK
800.0
ng/ml
0.8
mcg/ml
epidural administration; adults; patients;
DRUGBANK
0.335
h
0.17-0.5
h
epidural administration; adults; patients;
DRUGBANK
0.426
L/h/kg
7.1±2.8
ml/min/kg
Total clearance; normal,healthy; Male, men;
Children ↑ ;Elderly ↓ ;
DRUGBANK
0.258
L/h/kg
4.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
L/kg
0.9±0.4
L/kg
Steady state volume of distribution; normal,healthy; Male, men;
Children ↑ ;
DRUGBANK
0.84
L/kg
0.84
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.7
h
2.7
h
adults;
DRUGBANK
8.1
h
8.1
h
Neonates;
DRUGBANK
2.4
h
2.4±1.2
h
Children → ;Age → ;
DRUGBANK
3.1
h
3.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
mg/kg
6-8
mg/kg
intravenous injection, IV; monkey;
DRUGBANK
41.5
mg/kg
38-45
mg/kg
subcutaneous injection, SC; monkey;
DRUGBANK
7.0
mg/kg
6-8
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
46.0
mg/kg
38-54
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
6.0
%
6
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
2±2
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
95.0
%
95±1
%
Neonates ↓ ;
DRUGBANK
266.0
mg
266
mg
Transdermal preparations
Exparel
bupivacaine liposome
PDR
133.0
mg
133
mg
epidural administration
Exparel
bupivacaine liposome
PDR
266.0
mg
266
mg
Transdermal preparations
Exparel
bupivacaine liposome
PDR
133.0
mg
133
mg
epidural administration
Exparel
bupivacaine liposome
PDR
175.0
mg/dose
175
mg/dose
Marcaine Spinal
bupivacaine hydrochloride
PDR
400.0
mg/day
400
mg/day
Marcaine Spinal
bupivacaine hydrochloride
PDR
90.0
mg/procedure
90
mg/procedure
Marcaine Spinal
bupivacaine hydrochloride
PDR
75.0
mg
75
mg
Marcaine Spinal
bupivacaine hydrochloride
PDR
DDPD00298
Dapiprazole
325.4512
C19H27N5
CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1
DB00298
3033538
51066
http://www.drugs.com/cdi/dapiprazole.html
2298190
-2.0
-
-2.0
-
DRUGBANK
1644.5
mg/kg
1189-2100
mg/kg
PO, oral; mouse; Rattus, Rat; rabbit;
DRUGBANK
DDPD00299
Penciclovir
253.2578
C10H15N5O3
NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2
DB00299
4725
7956
http://www.drugs.com/cdi/penciclovir.html
4563
-2.0
-
-2.0
-
DRUGBANK
0.504
L/h/kg
8.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
<20
%
DRUGBANK
DDPD00300
Tenofovir disoproxil
519.448
C19H30N5O10P
[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
DB00300
5481350
63717
http://www.drugs.com/cdi/tenofovir.html
4587262
-2.0
-
-2.0
-
DRUGBANK
3320.0
ng.h/ml
3.32±1.37
ug.h/ml
PO, oral;
DRUGBANK
330.0
ng/ml
0.33±0.12
ug/ml
PO, oral;
DRUGBANK
18.0
L/h
~300
ml/min
Total clearance;
DRUGBANK
12.6
L/h
210.0
ml/min
Renal clearance;
DRUGBANK
1.3
L/kg
1.3±0.6
L/kg
at steady state; intravenous injection, IV;
DRUGBANK
1.2
L/kg
1.2±0.4
L/kg
at steady state; intravenous injection, IV;
DRUGBANK
17.0
h
~17
h
terminal half-life; Oral single dose;
DRUGBANK
76.0
%
~72-80
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
0.7
%
<0.7
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
7.2
%
<7.2
%
high protein binding; human, homo sapiens;
DRUGBANK
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
300.0
mg/day
300
mg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
300.0
mg/day
300
mg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
300.0
mg/day
300
mg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
300.0
mg/day
300
mg/day
PO, oral
Viread
tenofovir disoproxil fumarate
PDR
DDPD00301
Flucloxacillin
453.872
C19H17ClFN3O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1F)C(O)=O
DB00301
21319
5098
20037
-2.0
-
-2.0
-
DRUGBANK
60.0
%
50-70
%
PO, oral;
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.875
h
0.75-1
h
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00302
Tranexamic acid
157.2102
C8H15NO2
NC[C@H]1CC[C@@H](CC1)C(O)=O
DB00302
5526
48669
http://www.drugs.com/cdi/tranexamic-acid.html
10482000
-2.0
-
-2.0
-
DRUGBANK
40.0
%
30-50
%
PO, oral;
DRUGBANK
5.0
%
<5
%
DRUGBANK
6.78
L/h
110-116
ml/min
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.5
L
9-12.0
L
DRUGBANK
0.38
L/kg
0.38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3
h
elimination half-life;
DRUGBANK
2.3
h
2.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10000.0
mg/kg
10.0
g/kg
PO, oral; mouse;
DRUGBANK
3.0
%
~3
%
plasma proteins;
DRUGBANK
3900.0
mg/day
3900
mg/day
PO, oral
Lysteda
tranexamic acid
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Lysteda
tranexamic acid
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Lysteda
tranexamic acid
PDR
3900.0
mg/day
3900
mg/day
PO, oral
Lysteda
tranexamic acid
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Lysteda
tranexamic acid
PDR
3900.0
mg/day
3900
mg/day
PO, oral
Lysteda
tranexamic acid
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Lysteda
tranexamic acid
PDR
3900.0
mg/day
3900
mg/day
PO, oral
Lysteda
tranexamic acid
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Lysteda
tranexamic acid
PDR
DDPD00303
Ertapenem
475.515
C22H25N3O7S
[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
DB00303
150610
404903
http://www.drugs.com/cdi/ertapenem.html
132758
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
92.0
%
92.0
%
IM,intramuscular injection;
DRUGBANK
77.0
%
77.0
%
IM,intramuscular injection; Male, men;
DRUGBANK
1.8
L/h
1.8
L/h
DRUGBANK
0.027
L/h/kg
0.45
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.12
L/kg
0.12
L/kg
adults;
DRUGBANK
0.18
L/kg
0.16-0.2
L/kg
pediatric patients;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
~4
h
elimination half-life;
DRUGBANK
3.8
h
3.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
38.0
%
~38
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
~95
%
DRUGBANK
85.0
%
~85
%
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
1.0
g/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Invanz
ertapenem
PDR
DDPD00304
Desogestrel
310.473
C22H30O
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]
DB00304
40973
4453
37400
-2.0
-
-2.0
-
DRUGBANK
3000.0
ng.h/ml
3000.0
ng.h/ml
PO, oral;
DRUGBANK
70.0
%
60-80
%
PO, oral;
DRUGBANK
2.0
ng/ml
2.0
ng/ml
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
0.12
L/h/kg
2.0
ml/min/kg
Total clearance;
DRUGBANK
1.5
L/kg
1.5
L/kg
Apparent volume of distribution;
DRUGBANK
30.0
h
30
h
terminal half-life; Oral single dose;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
85.0
%
~85
%
DRUGBANK
97.0
%
~96-98
%
plasma proteins;
DRUGBANK
DDPD00305
Mitomycin
334.3272
C15H18N4O5
[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O
DB00305
T3D2743
5746
27504
http://www.drugs.com/cdi/mitomycin.html
5544
-2.0
-
-2.0
-
DRUGBANK
0.466666666666667
h
8-48
min
DRUGBANK
23.0
mg/kg
23.0
mg/kg
PO, oral; mouse;
DRUGBANK
30.0
mg/kg
30.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
23.0
mg/kg
23.0
mg/kg
PO, oral; mouse;
DRUGBANK
30.0
mg/kg
30.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
%
~10
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
mg/m2
20
mg/m2
intravenous injection, IV
Mitomycin
mitomycin
PDR
60.0
mg
60
mg
Mitomycin
mitomycin
PDR
15.0
ml
15
mL
Mitomycin
mitomycin
PDR
20.0
mg/m2
20
mg/m2
intravenous injection, IV
Mitomycin
mitomycin
PDR
60.0
mg
60
mg
Mitomycin
mitomycin
PDR
15.0
ml
15
ml
Mitomycin
mitomycin
PDR
DDPD00306
Talbutal
224.2563
C11H16N2O3
CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
DB00306
8275
134923
7976
-2.0
-
-2.0
-
DRUGBANK
DDPD00307
Bexarotene
348.4779
C24H28O2
CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C
DB00307
82146
50859
http://www.drugs.com/cdi/bexarotene.html
74139
-2.0
-
-2.0
-
DRUGBANK
7.0
h
7
h
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
400.0
mg/m2/day
400
mg/m2/day
PO, oral
Targretin Capsules
bexarotene
PDR
1.0
appLication
1
appLication
gel
qid
Targretin Capsules
bexarotene
PDR
400.0
mg/m2/day
400
mg/m2/day
Capsule, PO, Oral
Targretin Capsules
bexarotene
PDR
1.0
application
1
application
gel
qid
Targretin Capsules
bexarotene
PDR
DDPD00308
Ibutilide
384.576
C20H36N2O3S
CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
DB00308
60753
5856
http://www.drugs.com/cdi/ibutilide.html
54755
-2.0
-
-2.0
-
DRUGBANK
1.74
L/h/kg
29.0
ml/min/kg
DRUGBANK
1.56
L/h/kg
26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
L/kg
11.0
L/kg
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
6(2-12)
h
DRUGBANK
7.0
h
7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
mg/kg
>50
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
82.0
%
~82
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
19.0
%
~19
%
Faeces excretion; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
7.0
%
~7
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
40.0
%
40
%
DRUGBANK
2.0
mg
2
mg
intravenous injection, IV
Corvert
ibutilide fumarate
PDR
2.0
mg
2
mg
intravenous injection, IV
Corvert
ibutilide fumarate
PDR
DDPD00309
Vindesine
753.941
C43H55N5O7
[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC
DB00309
T3D2479
40839
36373
9818189
-2.0
-
-2.0
-
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
L/kg
5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
24
h
DRUGBANK
35.0
h
35
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
mg/kg
4.0
mg/kg
mouse;
DRUGBANK
70.0
%
65-75
%
DRUGBANK
DDPD00310
Chlorthalidone
338.766
C14H11ClN2O4S
NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12
DB00310
2732
3654
http://www.drugs.com/cdi/chlorthalidone.html
2631
-2.0
-
-2.0
-
DRUGBANK
64.0
%
64±10
%
PO, oral;
DRUGBANK
3700.0
ng/ml
3.7±0.9
mcg/ml
Male, men; adults; normal,healthy;
DRUGBANK
13.8
h
13.8±6.3
h
Male, men; adults; normal,healthy;
DRUGBANK
0.0024
L/h/kg
0.04±0.01
ml/min/kg
Elderly ↓ ;
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14±0.07
L/kg
DRUGBANK
3.9
L/kg
3.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
h
40-50
h
DRUGBANK
47.0
h
47±22
h
Age ↑ ;
DRUGBANK
36.0
h
36
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
65.0
%
65±9
%
Urinary excretion; Unchanged drug;
DRUGBANK
75.0
%
~75
%
plasma proteins;
DRUGBANK
58.0
%
58
%
DRUGBANK
75.0
%
75±1
%
DRUGBANK
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
50.0
mg/day
50
mg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
100.0
mg/day
100
mg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
200.0
mg/day
200
mg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
50.0
mg/day
50
mg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
100.0
mg/day
100
mg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
200.0
mg/day
200
mg/day
PO, oral
Chlorthalidone
chlorthalidone
PDR
DDPD00312
Pentobarbital
226.2722
C11H18N2O3
CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
DB00312
T3D2745
4737
7983
http://www.drugs.com/mtm/pentobarbital.html
4575
-2.0
-
-2.0
-
DRUGBANK
0.0282
L/h/kg
0.47
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.91
L/kg
0.91
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
27.5
h
5-50
h
DRUGBANK
22.0
h
22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.5
%
~25-50
%
Urinary excretion;
DRUGBANK
6.0
mg/kg/dose
6
mg/kg/dose
IM,intramuscular injection;intravenous injection, IV;PO, oral;
Nembutal
pentobarbital sodium
PDR
100.0
mg/dose
100
mg/dose
IM,intramuscular injection;intravenous injection, IV;PO, oral;
Nembutal
pentobarbital sodium
PDR
6.0
mg/kg/dose
6
mg/kg/dose
IM,intramuscular injection;intravenous injection, IV;PO, oral;
Nembutal
pentobarbital sodium
PDR
100.0
mg/dose
100
mg/dose
IM,intramuscular injection;intravenous injection, IV;PO, oral;
Nembutal
pentobarbital sodium
PDR
6.0
mg/kg/dose
6
mg/kg/dose
IM,intramuscular injection;intravenous injection, IV;
Nembutal
pentobarbital sodium
PDR
8.0
mg/kg/dose
8
mg/kg/dose
PO, oral
Nembutal
pentobarbital sodium
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Nembutal
pentobarbital sodium
PDR
6.0
mg/kg/dose
6
mg/kg/dose
intravenous injection, IV
Nembutal
pentobarbital sodium
PDR
DDPD00313
Valproic acid
144.2114
C8H16O2
CCCC(CCC)C(O)=O
DB00313
T3D2558
3121
39867
http://www.drugs.com/cdi/valproate.html
3009
-2.0
-
-2.0
-
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
100.0
%
~100
%
PO, oral; extended release formulation;
extended release formulation ↑ ;
DRUGBANK
100.0
%
100±10
%
PO, oral;
DRUGBANK
34000.0
ng/ml
34±8
mcg/ml
Capsule, PO, Oral; Drug form; Male, men; adults; normal,healthy;
DRUGBANK
4.0
h
4
h
Tablet, PO, oral; extended release formulation;
DRUGBANK
8.0
h
8
h
Tablet, PO, oral; extended release formulation; food;
food ↑ ;
DRUGBANK
4.05
h
3.3-4.8
h
Capsule, PO, Oral;
DRUGBANK
2.5
h
1-4
h
Capsule, PO, Oral; Drug form; Male, men; adults; normal,healthy;
DRUGBANK
10.5
h
7-14
h
Capsule, PO, Oral; Drug form; extended release formulation;
DRUGBANK
0.56
L/h/m2
0.56
L/h/m2
DRUGBANK
0.0066
L/h/kg
0.11±0.02
ml/min/kg
Multiple dose;
Children ↑ ;Elderly → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
0.0096
L/h/kg
0.16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.35838150289017
L/m2
11.0
l/1.73m2
DRUGBANK
0.22
L/kg
0.22±0.07
L/kg
Neonates ↑ ;Children → ;Elderly → ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
h
13-19
h
DRUGBANK
14.0
h
14±3
h
Multiple dose;
Neonates ↑ ;Children ↓ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ;normal BMI ↓ ;
DRUGBANK
9.8
h
9.8±2.6
h
Single dose;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1098.0
mg/kg
1098.0
mg/kg
PO, oral; mouse;
DRUGBANK
670.0
mg/kg
670.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1098.0
mg/kg
1098.0
mg/kg
PO, oral; mouse;
DRUGBANK
670.0
mg/kg
670.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.0
%
<3
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.8
%
1.8±2.4
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
10
%
DRUGBANK
18.5
%
18.5
%
DRUGBANK
93.0
%
93±1
%
Preg, pregnant ↓ ;Elderly ↓ ;Neonates ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;Burn ↓ ;hypoalbuminemia Alb ↓ ;
DRUGBANK
60.0
mg/kg/day
60
mg/kg/day
PO, oral;intravenous injection, IV;
Depakote Tablets
divalproex sodium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral;intravenous injection, IV;
Depakote Tablets
divalproex sodium
PDR
1000.0
mg/kg/day
1000
mg/kg/day
PO, oral
Depakote Tablets
divalproex sodium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Depakote Tablets
divalproex sodium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral;intravenous injection, IV;
Depakote Tablets
divalproex sodium
PDR
1000.0
mg/kg/day
1000
mg/kg/day
PO, oral
Depakote Tablets
divalproex sodium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral;intravenous injection, IV;
Depakote Tablets
divalproex sodium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral;intravenous injection, IV;
Depakote Tablets
divalproex sodium
PDR
1000.0
mg/kg/day
1000
mg/kg/day
PO, oral
Depakote Tablets
divalproex sodium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Depakote Tablets
divalproex sodium
PDR
DDPD00314
Capreomycin
1321.4123
C50H88N28O15
[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O
DB00314
3000502
3371
http://www.drugs.com/cdi/capreomycin.html
2272094
-2.0
-
-2.0
-
DRUGBANK
514.0
mg/kg
514.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
52.0
%
52
%
Urinary excretion; IM,intramuscular injection; normal,healthy; human, homo sapiens;
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Capastat Sulfate
capreomycin sulfate
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Capastat Sulfate
capreomycin sulfate
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
qd
Capastat Sulfate
capreomycin sulfate
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
qd
Capastat Sulfate
capreomycin sulfate
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Capastat Sulfate
capreomycin sulfate
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
Capastat Sulfate
capreomycin sulfate
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
qd
Capastat Sulfate
capreomycin sulfate
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV;IM,intramuscular injection;
qd
Capastat Sulfate
capreomycin sulfate
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Capastat Sulfate
capreomycin sulfate
PDR
DDPD00315
Zolmitriptan
287.3568
C16H21N3O2
CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12
DB00315
T3D2748
60857
10124
http://www.drugs.com/cdi/zolmitriptan.html
54844
-2.0
-
-2.0
-
DRUGBANK
129100.0
ng.h/ml
84.4-173.8
ug.h/ml
Tablet, PO, oral;
DRUGBANK
40.0
%
~40
%
PO, oral; food;
food → ;
DRUGBANK
40.8
%
40.8
%
inhalation, IH;
DRUGBANK
20.6
ng/ml
16-25.2
ng/ml
Tablet, PO, oral;
DRUGBANK
1.5
h
1.5
h
Tablet, PO, oral;
DRUGBANK
3.0
h
3
h
Tablet, PO, oral; immediate release formulation;
DRUGBANK
1.89
L/h/kg
31.5
ml/min/kg
Tablet, PO, oral;
DRUGBANK
1.554
L/h/kg
25.9
ml/min/kg
inhalation, IH;
DRUGBANK
0.402
L/h/kg
6.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.7
L/kg
7-8.4
L/kg
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
elimination half-life;
DRUGBANK
3.5
h
~3.5
h
Active metabolite;
DRUGBANK
3.6
h
3.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
65.0
%
~65
%
Urinary excretion;
DRUGBANK
30.0
%
~30
%
Faeces excretion;
DRUGBANK
25.0
%
~25
%
plasma proteins;
DRUGBANK
5.0
mg/dose
5
mg/dose
intranasal
Zomig Nasal Spray
zolmitriptan
PDR
10.0
mg/day
10
mg/day
intranasal
Zomig Nasal Spray
zolmitriptan
PDR
5.0
mg/dose
5
mg/dose
PO, oral;intranasal;
Zomig Nasal Spray
zolmitriptan
PDR
10.0
mg/day
10
mg/day
PO, oral;intranasal;
Zomig Nasal Spray
zolmitriptan
PDR
5.0
mg/dose
5
mg/dose
intranasal
Zomig Nasal Spray
zolmitriptan
PDR
10.0
mg/day
10
mg/day
intranasal
Zomig Nasal Spray
zolmitriptan
PDR
5.0
mg/dose
5
mg/dose
PO, oral;intranasal;
Zomig Nasal Spray
zolmitriptan
PDR
10.0
mg/day
10
mg/day
PO, oral;intranasal;
Zomig Nasal Spray
zolmitriptan
PDR
DDPD00316
Acetaminophen
151.1626
C8H9NO2
CC(=O)NC1=CC=C(O)C=C1
DB00316
T3D2571
1983
46195
http://www.drugs.com/acetaminophen.html
1906
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88.0
%
PO, oral;
DRUGBANK
88.0
%
88±15
%
PO, oral;
DRUGBANK
20000.0
ng/ml
20
ug/ml
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
3.0
h
3
h
Rectal Administration;
DRUGBANK
0.865
h
0.33-1.4
h
PO, oral;
DRUGBANK
0.27
L/h/kg
0.27
L/h/kg
intravenous injection, IV; adults;
DRUGBANK
0.34
L/h/kg
0.34
L/h/kg
intravenous injection, IV; Children;
DRUGBANK
0.3
L/h/kg
5.0±1.4
ml/min/kg
normal,healthy; adults;
Children → ;Elderly → ;Preg, pregnant ↑ ;Hepatitis, Hep ↓ ;Obesity ↑ ;hyperthyroid, HTh ↑ ;
DRUGBANK
0.3
L/h/kg
5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
L/kg
0.9
L/kg
DRUGBANK
0.95
L/kg
0.95±0.12
L/kg
normal,healthy; adults;
Children → ;Elderly → ;Hepatitis, Hep → ;hyperthyroid, HTh → ;LTh hypothyroid → ;
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; adults;
DRUGBANK
6.0
h
4-8
h
hepatopathy，LD; overdose;
DRUGBANK
2.0
h
2.0±0.4
h
Children → ;Neonates ↑ ;Preg, pregnant ↓ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;Hepatitis, Hep ↑ ;hyperthyroid, HTh ↓ ;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
338.0
mg/kg
338.0
mg/kg
PO, oral; mouse;
DRUGBANK
1944.0
mg/kg
1944.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
338.0
mg/kg
338.0
mg/kg
PO, oral; mouse;
DRUGBANK
1944.0
mg/kg
1944.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
>90
%
DRUGBANK
3.0
%
3±1
%
Urinary excretion; Unchanged drug;
Neonates → ;Children → ;
DRUGBANK
17.5
%
10-25
%
plasma proteins;
DRUGBANK
20.0
%
<20
%
DRUGBANK
4000.0
mg/day
4000
mg/day
PO, oral;Rectal Administration;
Ofirmev
acetaminophen
PDR
750.0
mg/dose
750
mg/dose
intravenous injection, IV
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
3750.0
mg/day
3750
mg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral
Ofirmev
acetaminophen
PDR
1000.0
mg/dose
1000
mg/dose
Rectal Administration
Ofirmev
acetaminophen
PDR
100.0
mg/kg/day
100
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
750.0
mg/dose
750
mg/dose
intravenous injection, IV
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
3750.0
mg/day
3750
mg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral;intravenous injection, IV;
Ofirmev
acetaminophen
PDR
3750.0
mg/day
3750
mg/day
PO, oral;intravenous injection, IV;
Ofirmev
acetaminophen
PDR
100.0
mg/kg/day
100
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Ofirmev
acetaminophen
PDR
100.0
mg/kg/day
100
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral;intravenous injection, IV;Rectal Administration;
Ofirmev
acetaminophen
PDR
1300.0
mg/dose
1300
mg/dose
PO, oral
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral
qd
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral;Rectal Administration;intravenous injection, IV;
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral
Ofirmev
acetaminophen
PDR
1000.0
mg/dose
1000
mg/dose
Rectal Administration
Ofirmev
acetaminophen
PDR
100.0
mg/kg/day
100
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral;intravenous injection, IV;
Ofirmev
acetaminophen
PDR
3750.0
mg/day
3750
mg/day
PO, oral;intravenous injection, IV;
Ofirmev
acetaminophen
PDR
100.0
mg/kg/day
100
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral;intravenous injection, IV;Rectal Administration;
Ofirmev
acetaminophen
PDR
1300.0
mg/dose
1300
mg/dose
PO, oral
Ofirmev
acetaminophen
PDR
4000.0
mg/day
4000
mg/day
PO, oral
qd
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
qd
Ofirmev
acetaminophen
PDR
75.0
mg/kg/day
75
mg/kg/day
Rectal Administration
qd
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
qd
Ofirmev
acetaminophen
PDR
90.0
mg/kg/day
90
mg/kg/day
PO, oral
Ofirmev
acetaminophen
PDR
90.0
mg/kg/day
90
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
50.0
mg/kg/day
50
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
50.0
mg/kg/day
50
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Ofirmev
acetaminophen
PDR
60.0
mg/kg/day
60
mg/kg/day
Rectal Administration
Ofirmev
acetaminophen
PDR
50.0
mg/kg/day
50
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral;Rectal Administration;
Ofirmev
acetaminophen
PDR
22.5
mg/kg/day
22.5
mg/kg/day
intravenous injection, IV
Ofirmev
acetaminophen
PDR
DDPD00317
Gefitinib
446.902
C22H24ClFN4O3
COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
DB00317
123631
49668
http://www.drugs.com/cdi/gefitinib.html
110217
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60.0
%
PO, oral;
DRUGBANK
60.0
%
60.0
%
PO, oral;
DRUGBANK
341.0
ng/ml
341±208
ng/ml
PO, oral; tumor;
DRUGBANK
5.0
h
3-7
h
PO, oral;
DRUGBANK
5.0
h
5(3-7)
h
PO, oral; tumor;
DRUGBANK
35.7
L/h
595.0
ml/min
intravenous injection, IV;
DRUGBANK
0.438
L/h/kg
7.3(2.8-21)
ml/min/kg
hydrolysis; tumor; patients;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1400.0
L
1400.0
L
intravenous injection, IV;
DRUGBANK
20.0
L/kg
20(12-39)
L/kg
hydrolysis; tumor; patients;
DRUGBANK
23.0
L/kg
23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
48.0
h
48
h
intravenous injection, IV;
DRUGBANK
48.0
h
48(10-136)
h
DRUGBANK
34.0
h
34
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.0
%
86
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; tumor; Unchanged drug;
DRUGBANK
90.0
%
90
%
Plasma Concentration → ;
DRUGBANK
90.0
%
90
%
tumor;
DRUGBANK
250.0
mg/day
250
mg/day
PO, oral
Iressa
gefitinib
PDR
250.0
mg/day
250
mg/day
PO, oral
Iressa
gefitinib
PDR
DDPD00318
Codeine
299.3642
C18H21NO3
[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC
DB00318
T3D2749
5284371
16714
http://www.drugs.com/cdi/codeine-phosphate-soluble-tablets.html
4447447
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50±7
%
PO, oral; intravenous injection, IV;
DRUGBANK
149.0
ng/ml
149±60
ng/ml
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
3.8
ng/ml
3.8±2.4
ng/ml
PO, oral; Active metabolite; Male, men; adults; normal,healthy;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
1.0
h
1.0±0.5
h
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
1.0
h
1.0±0.4
h
PO, oral; Active metabolite; Male, men; adults; normal,healthy;
DRUGBANK
120.0
h
5.0
day
DRUGBANK
75.0
%
70-80
%
Liver metabolism;
DRUGBANK
10.98
L/h
183±59
ml/min
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.66
L/h/kg
11±2
ml/min/kg
apparent clearance; hydrolysis;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
L/kg
~3-6.0
L/kg
Apparent volume of distribution;
DRUGBANK
2.6
L/kg
2.6±0.3
L/kg
Apparent volume of distribution; hydrolysis;
DRUGBANK
3.5
L/kg
3.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
elimination half-life;
DRUGBANK
3.0
h
~3
h
elimination half-life; Metabolite;
DRUGBANK
2.9
h
2.9±0.7
h
DRUGBANK
4.0
h
4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
427.0
mg/kg
427.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
~90
%
Urinary excretion;
DRUGBANK
10.0
%
~10
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
16.0
%
7-25
%
plasma proteins;
DRUGBANK
7.0
%
7
%
DRUGBANK
1.0
mg/kg/dose
1
mg/kg/dose
Codeine Sulfate Tablets
codeine sulfate
PDR
60.0
mg/dose
60
mg/dose
Codeine Sulfate Tablets
codeine sulfate
PDR
0.0
0
Codeine Sulfate Tablets
codeine sulfate
PDR
60.0
mg/dose
60
mg/dose
PO, oral
Codeine Sulfate Tablets
codeine sulfate
PDR
360.0
mg/day
360
mg/day
PO, oral
Codeine Sulfate Tablets
codeine sulfate
PDR
1.0
mg/kg/dose
1
mg/kg/dose
Codeine Sulfate Tablets
codeine sulfate
PDR
60.0
mg/dose
60
mg/dose
Codeine Sulfate Tablets
codeine sulfate
PDR
60.0
mg/dose
60
mg/dose
PO, oral
Codeine Sulfate Tablets
codeine sulfate
PDR
360.0
mg/day
360
mg/day
PO, oral
Codeine Sulfate Tablets
codeine sulfate
PDR
0.0
0
Codeine Sulfate Tablets
codeine sulfate
PDR
DDPD00319
Piperacillin
517.555
C23H27N5O7S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=CC=C1)C(O)=O
DB00319
43672
8232
http://www.drugs.com/cdi/piperacillin.html
39798
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0.0
%
PO, oral;
DRUGBANK
1.2485549132948
L/h/m2
31-41
ml/min/1.73m2
DRUGBANK
4.92485549132948
L/h/m2
124-160
ml/min/1.73m2
pediatric patients;
DRUGBANK
0.24
L/h/kg
4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.101
L/kg
101.0
mL/kg
intravenous injection, IV; Neonates;
DRUGBANK
0.27
L/kg
0.27
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
h
36-72
min
DRUGBANK
0.96
h
0.96
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00320
Dihydroergotamine
583.6774
C33H37N5O5
[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
DB00320
T3D2750
10531
4562
http://www.drugs.com/cdi/dihydroergotamine.html
10091
-2.0
-
-2.0
-
DRUGBANK
90.0
L/h
1.5
L/min
DRUGBANK
0.9042
L/h/kg
15.07
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
800.0
L
800.0
L
DRUGBANK
0.33
L/kg
0.33
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
9
h
DRUGBANK
0.55
h
0.55
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
%
6-7
%
Urinary excretion; IM,intramuscular injection; Unchanged drug;
DRUGBANK
93.0
%
93
%
plasma proteins;
DRUGBANK
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection
bid
D.H.E 45
dihydroergotamine mesylate
PDR
0.25
mg/dose
0.25
mg/dose
intravenous injection, IV
bid
D.H.E 45
dihydroergotamine mesylate
PDR
0.14285714
mg/day
1
mg/week
D.H.E 45
dihydroergotamine mesylate
PDR
0.0
0
D.H.E 45
dihydroergotamine mesylate
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV;IM,intramuscular injection;
D.H.E 45
dihydroergotamine mesylate
PDR
3.0
mg/day
3
mg/day
IM,intramuscular injection
D.H.E 45
dihydroergotamine mesylate
PDR
2.0
mg/day
2
mg/day
intravenous injection, IV
D.H.E 45
dihydroergotamine mesylate
PDR
0.857142857142857
mg/day
6
mg/week
D.H.E 45
dihydroergotamine mesylate
PDR
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection
bid
D.H.E 45
dihydroergotamine mesylate
PDR
0.25
mg/dose
0.25
mg/dose
intravenous injection, IV
bid
D.H.E 45
dihydroergotamine mesylate
PDR
0.142857142857143
mg/day
1
mg/week
D.H.E 45
dihydroergotamine mesylate
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV;IM,intramuscular injection;
D.H.E 45
dihydroergotamine mesylate
PDR
3.0
mg/day
3
mg/day
IM,intramuscular injection
D.H.E 45
dihydroergotamine mesylate
PDR
2.0
mg/day
2
mg/day
intravenous injection, IV
D.H.E 45
dihydroergotamine mesylate
PDR
0.857142857142857
mg/day
6
mg/week
D.H.E 45
dihydroergotamine mesylate
PDR
DDPD00321
Amitriptyline
277.4033
C20H23N
CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
DB00321
T3D2480
2160
2666
http://www.drugs.com/amitriptyline.html
2075
-2.0
-
-2.0
-
DRUGBANK
48.0
%
48±11
%
PO, oral;
Elderly → ;
DRUGBANK
64.0
ng/ml
64±35
ng/ml
adults;
DRUGBANK
3.6
h
3.6±1.4
h
adults;
DRUGBANK
39.24
L/h
39.24±10.18
L/h
Average clearance;
DRUGBANK
0.69
L/h/kg
11.5±3.4
ml/min/kg
Total clearance;
Elderly → ;Somking → ;
DRUGBANK
0.366
L/h/kg
6.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1221.0
L
1221±280
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
15.0
L/kg
15±3
L/kg
Steady state volume of distribution;
Elderly ↑ ;
DRUGBANK
8.7
L/kg
8.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.65
h
24.65±6.31(16.49-40.36)
h
PO, oral;
DRUGBANK
504.0
h
21±5
day
Age ↑ ;
DRUGBANK
17.0
h
17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
PO, oral; mouse;
DRUGBANK
4.167
mg/kg
4167.0
ug/kg
PO, oral; Children;
DRUGBANK
0.714
mg/kg/day
714.0
ug/kg/1D
PO, oral; Male, men;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Female, women;
DRUGBANK
2.0
%
~2
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
94.8
%
94.8±0.8
%
Elderly → ;HL,hyperlipoproteinemia ↑ ;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Amitriptyline Hydrochloride
amitriptyline hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Amitriptyline Hydrochloride
amitriptyline hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Amitriptyline Hydrochloride
amitriptyline hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Amitriptyline Hydrochloride
amitriptyline hydrochloride
PDR
DDPD00322
Floxuridine
246.1924
C9H11FN2O5
OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O
DB00322
5790
60761
http://www.drugs.com/cdi/floxuridine.html
5586
-2.0
-
-2.0
-
DRUGBANK
215.0
mg/kg
215.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.6
mg/kg/day
0.6
mg/kg/day
intra-arterial infusion
Floxuridine
floxuridine
PDR
0.6
mg/kg/day
0.6
mg/kg/day
intra-arterial infusion
Floxuridine
floxuridine
PDR
DDPD00323
Tolcapone
273.2408
C14H11NO5
CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O
DB00323
T3D2751
4659569
63630
http://www.drugs.com/cdi/tolcapone.html
3848682
-2.0
-
-2.0
-
DRUGBANK
65.0
%
65.0
%
DRUGBANK
7.0
L/h
7.0
L/h
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
L
9.0
L
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.75
h
2-3.5
h
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.5
%
0.5
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.9
%
>99.9
%
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Tasmar
tolcapone
PDR
600.0
mg/day
600
mg/day
PO, oral
Tasmar
tolcapone
PDR
DDPD00324
Fluorometholone
376.4617
C22H29FO4
[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
DB00324
9878
31625
http://www.drugs.com/cdi/fluorometholone.html
9494
-2.0
-
-2.0
-
DRUGBANK
234.0
mg/kg
234.0
mg/kg
Rattus, Rat;
DRUGBANK
DDPD00325
Nitroprusside
215.938
C5FeN6O
O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N
DB00325
T3D0768
11963622
7596
http://www.drugs.com/mtm/nitroprusside.html
21607452
-2.0
-
-2.0
-
DRUGBANK
0.0333333333333333
h
~2
min
DRUGBANK
2.8
mg/kg
2.8
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
5.0
mg/kg
5.0
mg/kg
intravenous injection, IV; dog;
DRUGBANK
8.4
mg/kg
8.4
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
11.2
mg/kg
11.2
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
14.4
mg/kg/day
10
mcg/kg/minute
intravenous injection, IV
Nipride RTU
sodium nitroprusside
PDR
14.4
mg/kg/day
10
mcg/kg/min
intravenous injection, IV
Nipride RTU
sodium nitroprusside
PDR
14.4
mg/kg/day
10
mcg/kg/minute
intravenous injection, IV
Nipride RTU
sodium nitroprusside
PDR
14.4
mg/kg/day
10
mcg/kg/minute
intravenous injection, IV
Nipride RTU
sodium nitroprusside
PDR
14.4
mg/kg/day
10
mcg/kg/min
intravenous injection, IV
Nipride RTU
sodium nitroprusside
PDR
14.4
mg/kg/day
10
mcg/kg/minute
intravenous injection, IV
Nipride RTU
sodium nitroprusside
PDR
DDPD00327
Hydromorphone
285.3377
C17H19NO3
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
DB00327
T3D2752
5284570
5790
http://www.drugs.com/cdi/hydromorphone.html
4447624
-2.0
-
-2.0
-
DRUGBANK
34.0
ng.h/ml
34.0
ng.h/ml
PO, oral;
DRUGBANK
60.0
%
60.0
%
PO, oral;
DRUGBANK
78.0
%
78.0
%
parenteral administration;
DRUGBANK
42.0
%
42±23
%
PO, oral; Male, men; normal,healthy;
DRUGBANK
80.0
%
~80
%
subcutaneous injection, SC; Male, men; normal,healthy;
DRUGBANK
0.0
null
~0
null
parenteral administration;
DRUGBANK
11.8
ng/ml
11.8±2.6
ng/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
242.0
ng/ml
242.0
ng/ml
intravenous injection, IV; Male, men; normal,healthy;
DRUGBANK
0.75
h
0.5-1
h
PO, oral; immediate release formulation;
DRUGBANK
9.0
h
>9
h
PO, oral; extended release formulation;
extended release formulation ↑ ;
DRUGBANK
1.1
h
1.1±0.2
h
PO, oral; Male, men; normal,healthy;
DRUGBANK
62.0
%
62
%
Liver metabolism;
DRUGBANK
6.342
L/h
105.7
ml/min
Plasma clearance;
DRUGBANK
117.6
L/h
1.96
L/min
Total clearance;
DRUGBANK
0.876
L/h/kg
14.6±7.6
ml/min/kg
DRUGBANK
1.68
L/h/kg
28
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
L/kg
4.0
L/kg
DRUGBANK
2.9
L/kg
2.90±1.31
L/kg
Apparent volume of distribution;
DRUGBANK
4.3
L/kg
4.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
immediate release formulation;
DRUGBANK
11.5
h
8-15
h
extended release formulation;
DRUGBANK
2.4
h
2.4±0.6
h
normal,healthy; Male, men;
DRUGBANK
2.3
h
2.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
104.0
mg/kg
104.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
84.0
mg/kg
84.0
mg/kg
PO, oral; mouse;
DRUGBANK
6.0
%
6
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
13.5
%
~8-19
%
DRUGBANK
7.1
%
7.1
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD00328
Indomethacin
357.788
C19H16ClNO4
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
DB00328
T3D2753
3715
49662
http://www.drugs.com/cdi/indomethacin.html
3584
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
85.0
%
80-90
%
Rectal Administration;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
1540.0
ng/ml
1.54±0.76
ug/ml
DRUGBANK
2650.0
ng/ml
2.65±1.03
ug/ml
DRUGBANK
4920.0
ng/ml
4.92±1.88
ug/ml
DRUGBANK
2400.0
ng/ml
~2.4
mcg/ml
Oral single dose; food;
DRUGBANK
1.4
h
0.9±0.4-1.5±0.8
h
PO, oral; fasting;
DRUGBANK
1.3
h
~1.3
h
Oral single dose; food;
DRUGBANK
0.105
L/h/kg
1-2.5
ml/kg/min
Plasma clearance; PO, oral;
DRUGBANK
0.084
L/h/kg
1.4±0.2
ml/min/kg
Neonates ↓ ;Elderly ↓ ;Prem, premature ↓ ;
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.955
L/kg
0.34-1.57
L/kg
PO, oral; intravenous injection, IV; Rectal Administration; normal,healthy;
DRUGBANK
0.29
L/kg
0.29±0.04
L/kg
Elderly → ;
DRUGBANK
0.096
L/kg
0.096
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
distribution half-life;
DRUGBANK
6.9
h
2.6-11.2
h
elimination half-life;
DRUGBANK
4.5
h
~4.5
h
PO, oral;
DRUGBANK
20.0
h
~20
h
elimination half-life; intravenous injection, IV; Neonates;
DRUGBANK
15.0
h
15
h
Infants; weighing more than 1000g;
DRUGBANK
21.0
h
21
h
Infants; weighing less than 1000g;
DRUGBANK
2.4
h
2.4±0.2
h
Neonates ↑ ;Prem, premature ↑ ;rheumatoid arthritis → ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ;
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.42
mg/kg
2.42
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
13.0
mg/kg
13.0
mg/kg
PO, oral; mouse;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
PO, oral; mouse;
DRUGBANK
12.0
mg/kg
12.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
PO, oral; mouse;
DRUGBANK
12.0
mg/kg
12.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
60.0
%
~60
%
Urinary excretion; PO, oral;
DRUGBANK
33.0
%
33
%
Faeces excretion; PO, oral;
DRUGBANK
15.0
%
15±8
%
Urinary excretion; Unchanged drug;
DRUGBANK
94.5
%
90-99
%
plasma proteins;
DRUGBANK
90.0
%
90
%
Neonates → ;hypoalbuminemia Alb → ;AIDS,HIV → ;
DRUGBANK
4.0
mg/kg/day
4
mg/kg/day
Capsule, PO, Oral;Liquid;
Indocin Oral Suspension
indomethacin
PDR
0.0
0
Indocin Oral Suspension
indomethacin
PDR
175.0
mg/day
175
mg/day
Capsule, PO, Oral;Liquid;
Indocin Oral Suspension
indomethacin
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral;Liquid;
Indocin Oral Suspension
indomethacin
PDR
120.0
mg
120
mg
Capsule, PO, Oral
Indocin Oral Suspension
indomethacin
PDR
150.0
mg/day
150
mg/day
Capsule, PO, Oral
Indocin Oral Suspension
indomethacin
PDR
100.0
mg/day
100
mg/day
PO, oral
Indocin Oral Suspension
indomethacin
PDR
4.0
mg/kg/day
4
mg/kg/day
Capsule, PO, Oral;Liquid;
Indocin Oral Suspension
indomethacin
PDR
175.0
mg/day
175
mg/day
Capsule, PO, Oral;Liquid;
Indocin Oral Suspension
indomethacin
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral;Liquid;
Indocin Oral Suspension
indomethacin
PDR
120.0
mg
120
mg
Capsule, PO, Oral
Indocin Oral Suspension
indomethacin
PDR
150.0
mg/day
150
mg/day
Capsule, PO, Oral
Indocin Oral Suspension
indomethacin
PDR
0.25
mg/kg
0.25
mg/kg
intravenous injection, IV
Indocin Oral Suspension
indomethacin
PDR
0.2
mg/kg
0.2
mg/kg
intravenous injection, IV
Indocin Oral Suspension
indomethacin
PDR
DDPD00330
Ethambutol
204.3098
C10H24N2O2
CC[C@@H](CO)NCCN[C@@H](CC)CO
DB00330
14052
4877
http://www.drugs.com/cdi/ethambutol.html
13433
-2.0
-
-2.0
-
DRUGBANK
77.5
%
75-80
%
PO, oral;
DRUGBANK
77.0
%
77±8
%
DRUGBANK
3500.0
ng/ml
2-5
mcg/ml
DRUGBANK
3.0
h
2-4
h
Oral single dose; normal,healthy;
DRUGBANK
15.0
%
15
%
Liver metabolism; Inactive metabolite;
DRUGBANK
0.516
L/h/kg
8.6±0.8
ml/min/kg
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6±0.2
L/kg
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
gastroesophageal reflux disease; normal renal function;
DRUGBANK
8.0
h
8
h
gastroesophageal reflux disease; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
3.1
h
3.1±0.4
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
3.1
h
3.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
~50
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
21.0
%
20-22
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
79.0
%
79±3
%
Urinary excretion; Unchanged drug;
DRUGBANK
25.0
%
20-30
%
DRUGBANK
18.0
%
6-30
%
DRUGBANK
25.0
mg/kg/day
25
mg/kg/dose
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
2500.0
mg
2.5
g
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
14.2857142857143
mg/kg/day
50
mg/kg/dose
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
4000.0
mg
4
g
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
25.0
mg/kg/day
25
mg/kg/dose
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
2500.0
mg
2.5
g
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
50.0
mg/kg/dose
50
mg/kg/dose
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
4000.0
mg
4
g
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
30.0
mg/kg/dose
30
mg/kg/dose
PO, oral
tiw
Myambutol
ethambutol hydrochloride
PDR
2400.0
mg
2.4
g
PO, oral
tiw
Myambutol
ethambutol hydrochloride
PDR
25.0
mg/kg/dose
25
mg/kg/dose
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
2500.0
mg
2.5
g
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
50.0
mg/kg/dose
50
mg/kg/dose
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
1142.85714285714
mg
4
g
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
30.0
mg/kg/dose
30
mg/kg/dose
PO, oral
tiw
Myambutol
ethambutol hydrochloride
PDR
2400.0
mg
2.4
g
PO, oral
tiw
Myambutol
ethambutol hydrochloride
PDR
25.0
mg/kg
25
mg/kg
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
2.5
g
2.5
g
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
25.0
mg/kg/day
25
mg/kg/dose
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
2500.0
mg
2.5
g
PO, oral
qd
Myambutol
ethambutol hydrochloride
PDR
14.2857142857143
mg/kg/day
50
mg/kg/dose
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
4000.0
mg
4
g
PO, oral
biw
Myambutol
ethambutol hydrochloride
PDR
12.8571428571429
mg/kg/day
30
mg/kg/dose
PO, oral
tiw
Myambutol
ethambutol hydrochloride
PDR
2400.0
mg
2.4
g
PO, oral
tiw
Myambutol
ethambutol hydrochloride
PDR
DDPD00331
Metformin
129.1636
C4H11N5
CN(C)C(=N)NC(N)=N
DB00331
T3D3522
4091
6801
http://www.drugs.com/metformin.html
3949
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
Tablet, PO, oral; fasting;
DRUGBANK
52.0
%
52±5(40-55)
%
PO, oral;
DRUGBANK
1600.0
ng/ml
1.6±0.2
mcg/ml
Tablet, PO, oral;
DRUGBANK
2050.0
ng/ml
1.0-3.1
mcg/ml
PO, oral;
DRUGBANK
7.0
h
7(4-8)
h
PO, oral; extended release formulation;
DRUGBANK
1.9
h
1.9±0.4
h
Tablet, PO, oral;
DRUGBANK
2.5
h
1.5-3.5
h
PO, oral;
DRUGBANK
36.0
h
24-48
h
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.492
L/h/kg
6.3-10.1
ml/min/kg
Elderly ↓ ;mild renal function ↓ ;moderate renal function ↓ ;severe renal function ↓ ;
DRUGBANK
0.444
L/h/kg
7.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
654.0
L
654±358
L
Apparent volume of distribution; PO, oral;
DRUGBANK
2.25
L/kg
0.9-3.94
L/kg
DRUGBANK
0.64
L/kg
0.64
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.2
h
6.2
h
DRUGBANK
17.6
h
17.6
h
elimination half-life;
DRUGBANK
1.74
h
1.74±0.20(1.5-4.5)
h
mild renal function ↑ ;moderate renal function ↑ ;severe renal function ↑ ;Age ↑ ;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
mg/kg
1.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
1450.0
mg/kg
1450.0
mg/kg
PO, oral; mouse;
DRUGBANK
420.0
mg/kg
420.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
225.0
mg/kg
225.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
PO, oral; rabbit;
DRUGBANK
90.0
%
~90
%
Urinary excretion; PO, oral;
DRUGBANK
99.9
%
99.9±0.5
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
89.5
%
79-100
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
0.0
%
~0
%
human, homo sapiens;
DRUGBANK
2000.0
mg/day
2000
mg/day
Tablet,PO，oral;Liquid;
Riomet
metformin hydrochloride
PDR
2000.0
mg/day
2000
mg/day
Liquid
Riomet
metformin hydrochloride
PDR
2550.0
mg/day
2550
mg/day
Tablet,PO，oral;Liquid;
Riomet
metformin hydrochloride
PDR
2000.0
mg/day
2000
mg/day
Liquid
Riomet
metformin hydrochloride
PDR
2250.0
mg/day
2250
mg/day
Tablet,PO，oral
Riomet
metformin hydrochloride
PDR
2000.0
mg/day
2000
mg/day
Tablet,PO，oral;Liquid;
Riomet
metformin hydrochloride
PDR
2000.0
mg/day
2000
mg/day
Liquid
Riomet
metformin hydrochloride
PDR
2550.0
mg/day
2550
mg/day
Tablet,PO，oral;Liquid;
Riomet
metformin hydrochloride
PDR
2000.0
mg/day
2000
mg/day
Liquid
Riomet
metformin hydrochloride
PDR
2250.0
mg/day
2250
mg/day
Tablet,PO，oral
Riomet
metformin hydrochloride
PDR
DDPD00332
Ipratropium
332.463
C20H30NO3
[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C
DB00332
657308
46659
http://www.drugs.com/mtm/ipratropium-nasal.html
19962157
-2.0
-
-2.0
-
DRUGBANK
2.0
%
2.0
%
PO, oral; inhalation, IH;
DRUGBANK
1.5
h
1-2
h
PO, oral; inhalation, IH;
DRUGBANK
10.0
%
~10
%
gastrointestinal tract;
DRUGBANK
138.0
L/h
2.3
L/min
Average clearance;
DRUGBANK
54.0
L/h
0.9
L/min
Renal clearance;
DRUGBANK
1.884
L/h/kg
31.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.6
L/kg
4.6
L/kg
DRUGBANK
5.1
L/kg
5.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
h
~1.6
h
DRUGBANK
1.64
h
1.64
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
~80-100
%
Urinary excretion;
DRUGBANK
20.0
%
<20
%
Faeces excretion;
DRUGBANK
4.5
%
0-9
%
DRUGBANK
0.672
mg/day
672
mcg/day
intranasal
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
0.504
mg/day
504
mcg/day
intranasal
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
0.672
mg/day
672
mcg/day
intranasal
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
0.204
mg/day
204
mcg/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
0.672
mg/day
672
mcg/day
intranasal
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
0.672
mg/day
672
mcg/day
intranasal
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
0.204
mg/day
204
mcg/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Atrovent Nasal Spray 0.03%
ipratropium bromide
PDR
DDPD00333
Methadone
309.4452
C21H27NO
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
DB00333
T3D2676
4095
6807
http://www.drugs.com/methadone.html
3953
-2.0
-
-2.0
-
DRUGBANK
68.0
%
36-100
%
PO, oral;
DRUGBANK
92.0
%
92±21
%
PO, oral;
DRUGBANK
689.5
ng/ml
124-1255
ng/ml
PO, oral;
DRUGBANK
524.5
ng/ml
69-980
ng/ml
PO, oral; patients;
DRUGBANK
500.0
ng/ml
450-550
ng/ml
intravenous injection, IV; patients;
DRUGBANK
4.25
h
1-7.5
h
PO, oral;
DRUGBANK
3.0
h
~3
h
PO, oral; patients;
DRUGBANK
3.0
h
~3
h
intravenous injection, IV; patients;
DRUGBANK
63.7
L/h
1.4-126
L/h
DRUGBANK
0.102
L/h/kg
1.7±0.9
ml/min/kg
Children ↑ ;Burn ↑ ;
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
329.5
L
189-470
L
DRUGBANK
3.6
L/kg
3.6±1.2
L/kg
Apparent volume of distribution;
DRUGBANK
4.4
L/kg
4.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
33.0
h
7-59
h
DRUGBANK
27.0
h
27±12
h
Children ↓ ;Burn ↓ ;
DRUGBANK
31.0
h
31
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
%
24±10
%
Urinary excretion; Unchanged drug;
DRUGBANK
87.5
%
85-90
%
DRUGBANK
89.0
%
89±2.9
%
DRUGBANK
DDPD00334
Olanzapine
312.432
C17H20N4S
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
DB00334
T3D2754
4585
7735
http://www.drugs.com/cdi/olanzapine.html
10442212
-2.0
-
-2.0
-
DRUGBANK
333.0
ng.h/ml
333.0
ng.h/ml
DRUGBANK
60.0
%
~60
%
PO, oral;
DRUGBANK
156.9
ng/ml
156.9
ng/ml
PO, oral; food;
food → ;
DRUGBANK
12.9
ng/ml
12.9±7.5
ng/ml
Oral single dose; Male, men; normal,healthy;
DRUGBANK
6.0
h
6
h
PO, oral; food;
food → ;
DRUGBANK
6.1
h
6.1±1.9
h
Oral single dose; Male, men; normal,healthy;
DRUGBANK
40.0
%
40
%
Liver metabolism; Inactive metabolite;
DRUGBANK
27.2
L/h
25-29.4
L/h
DRUGBANK
0.372
L/h/kg
6.2±2.9
ml/min/kg
apparent clearance; Male, men; Female, women; schizophrenia;
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
1000.0
L
1000.0
L
DRUGBANK
16.4
L/kg
16.4±5.1
L/kg
Apparent volume of distribution; Male, men; Female, women; schizophrenia;
DRUGBANK
30.0
h
30(21-54)
h
DRUGBANK
33.1
h
33.1±10.3
h
Male, men; Female, women; schizophrenia; patients;
Age ↑ ;
DRUGBANK
53.0
%
~53
%
Urinary excretion;
DRUGBANK
30.0
%
~30
%
Faeces excretion;
DRUGBANK
7.0
%
7
%
Unchanged drug;
DRUGBANK
7.3
%
7.3
%
Urinary excretion; schizophrenia; human, homo sapiens; Unchanged drug;
DRUGBANK
93.0
%
~93
%
plasma proteins;
DRUGBANK
93.0
%
93
%
schizophrenia; human, homo sapiens;
DRUGBANK
12.0
mg/day
12
mg/day
PO, oral
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral
Zyprexa
olanzapine
PDR
1.0
mg/day
20
mg/day
PO, oral
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral;IM,intramuscular injection;
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral;IM,intramuscular injection;
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral
Zyprexa
olanzapine
PDR
30.0
mg/day
30
mg/day
IM,intramuscular injection
Zyprexa
olanzapine
PDR
21.4285714285714
mg/day
300
mg/dose
IM,intramuscular injection
q2w
Zyprexa
olanzapine
PDR
14.4642857142857
mg/day
405
mg/dose
IM,intramuscular injection
q4w
Zyprexa
olanzapine
PDR
12.0
mg/day
12
mg/day
PO, oral
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral;IM,intramuscular injection;
Zyprexa
olanzapine
PDR
20.0
mg/day
20
mg/day
PO, oral
Zyprexa
olanzapine
PDR
30.0
mg/day
30
mg/day
IM,intramuscular injection
Zyprexa
olanzapine
PDR
21.4285714285714
mg/dose
300
mg/dose
IM,intramuscular injection
q2w
Zyprexa
olanzapine
PDR
14.4642857142857
mg/dose
405
mg/dose
IM,intramuscular injection
q4w
Zyprexa
olanzapine
PDR
DDPD00335
Atenolol
266.3361
C14H22N2O3
CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
DB00335
T3D3480
2249
2904
http://www.drugs.com/atenolol.html
2162
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50.0
%
PO, oral;
DRUGBANK
58.0
%
58±16
%
PO, oral;
DRUGBANK
280.0
ng/ml
0.28±0.09
mcg/ml
Oral single dose;
DRUGBANK
3.3
h
3.3±1.3
h
Oral single dose;
DRUGBANK
11.5
%
10-13
%
Liver metabolism;
DRUGBANK
8.208
L/h
97.3-176.3
ml/min
Total clearance;
DRUGBANK
7.89
L/h
95-168
ml/min
Renal clearance;
DRUGBANK
0.144
L/h/kg
2.4±0.3
ml/min/kg
Elderly ↓ ;
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
88.15
L
63.8-112.5
L
Total volume of distribution;
DRUGBANK
1.3
L/kg
1.3±0.5
L/kg
DRUGBANK
0.95
L/kg
0.95
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
6-7
h
DRUGBANK
6.1
h
6.1±2.0
h
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
6.1
h
6.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
2.0
g/kg
PO, oral; mouse;
DRUGBANK
57.0
mg/kg
57.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
134.0
mg/kg
134.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
2000.0
mg/kg
2.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
77.0
mg/kg
77.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
2500.0
mg/kg
2000-3000
mg/kg
PO, oral; mouse;
DRUGBANK
85.0
%
85
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
10.0
%
10
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
94.0
%
94±8
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
11.0
%
6-16
%
DRUGBANK
5.0
%
<5
%
DRUGBANK
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Tenormin
atenolol
PDR
100.0
mg/day
100
mg/day
PO, oral
Tenormin
atenolol
PDR
100.0
mg/day
100
mg/day
PO, oral
Tenormin
atenolol
PDR
200.0
mg/day
200
mg/day
PO, oral
Tenormin
atenolol
PDR
100.0
mg/day
100
mg/day
PO, oral
Tenormin
atenolol
PDR
100.0
mg/day
100
mg/day
PO, oral
Tenormin
atenolol
PDR
100.0
mg/day
100
mg/day
PO, oral
Tenormin
atenolol
PDR
200.0
mg/day
200
mg/day
PO, oral
Tenormin
atenolol
PDR
DDPD00336
Nitrofural
198.1362
C6H6N4O4
NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O
DB00336
T3D4752
5447130
http://www.drugs.com/cons/nitrofurazone-topical.html
4566720
-2.0
-
-2.0
-
DRUGBANK
5.0
h
5
h
DRUGBANK
590.0
mg/kg
590.0
mg/kg
Rattus, Rat;
DRUGBANK
590.0
mg/kg
590.0
mg/kg
Rattus, Rat;
DRUGBANK
DDPD00337
Pimecrolimus
810.46
C43H68ClNO11
[H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC
DB00337
6509979
135888
http://www.drugs.com/cdi/pimecrolimus.html
21111755
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
skin/dermal;
DRUGBANK
80.0
%
80
%
Faeces excretion;
DRUGBANK
80.5
%
74-87
%
plasma proteins; high protein binding;
DRUGBANK
2.0
application/day
2
application/day
skin/dermal
Elidel
pimecrolimus
PDR
2.0
appLication/day
2
appLication/day
skin/dermal
Elidel
pimecrolimus
PDR
2.0
application/day
2
application/day
skin/dermal
Elidel
pimecrolimus
PDR
2.0
application/day
2
application/day
skin/dermal
Elidel
pimecrolimus
PDR
DDPD00338
Omeprazole
345.416
C17H19N3O3S
COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
DB00338
T3D3524
4594
77260
http://www.drugs.com/omeprazole.html
4433
-2.0
-
-2.0
-
DRUGBANK
35.0
%
30-40
%
DRUGBANK
2.0
h
0.5-3.5
h
DRUGBANK
33.0
L/h
500-600
ml/min
normal,healthy;
DRUGBANK
15.0
L/h
250.0
ml/min
Plasma clearance; Geriatric;
DRUGBANK
4.2
L/h
70.0
ml/min
Plasma clearance; hepatopathy，LD;
DRUGBANK
0.504
L/h/kg
8.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
L/kg
~0.3
L/kg
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
h
0.5-1
h
normal,healthy; extended release formulation; Capsule, PO, Oral;
DRUGBANK
3.0
h
~3
h
hepatopathy，LD;
DRUGBANK
0.58
h
0.58
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
PO, oral; mouse;
DRUGBANK
2210.0
mg/kg
2210.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
~95
%
plasma proteins; human, homo sapiens;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
80.0
mg/day
80
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
10.0
mg/day
10
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
40.0
mg/day
40
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
5.0
mg/day
5
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
40.0
mg/day
40
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
160.0
mg/day
160
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
360.0
mg/day
360
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
40.0
mg/day
40
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
80.0
mg/day
80
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
40.0
mg/day
40
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
160.0
mg/day
160
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
360.0
mg/day
360
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
10.0
mg/day
10
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
40.0
mg/day
40
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
5.0
mg/day
5
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
1.5
mg/day
1.5
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
1.5
mg/day
1.5
mg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
0.7
mg/kg/day
0.7
mg/kg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
1.5
mg/kg/day
1.5
mg/kg/day
PO, oral
Prilosec Delayed Release Capsules and Oral Suspension
(omeprazole); (omeprazole magnesium)
PDR
DDPD00339
Pyrazinamide
123.1127
C5H5N3O
NC(=O)C1=NC=CN=C1
DB00339
1046
45285
http://www.drugs.com/cdi/pyrazinamide.html
1017
-2.0
-
-2.0
-
DRUGBANK
35000.0
ng/ml
35(19-103)
mcg/ml
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
0.066
L/h/kg
1.1(0.2-2.3）
ml/min/kg
apparent clearance; tuberculosis; Male, men; Female, women; adults;
Children ↑ ;
DRUGBANK
0.57
L/kg
0.57（0.13-1.04）
L/kg
Apparent volume of distribution; tuberculosis; Male, men; Female, women; adults;
DRUGBANK
9.5
h
9-10
h
normal,healthy;
DRUGBANK
6.0
h
6(2-23)
h
Children ↓ ;
DRUGBANK
70.0
%
~70
%
Urinary excretion; PO, oral;
DRUGBANK
9.0
%
4-14
%
Urinary excretion; PO, oral; adults; tuberculosis; human, homo sapiens; Unchanged drug;
DRUGBANK
10.0
%
~10
%
plasma proteins;
DRUGBANK
10.0
%
10
%
DRUGBANK
40.0
mg/kg/day
40
mg/kg/dose
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
2000.0
mg/dose
2
g/dose
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
21.4285714285714
mg/kg/day
50
mg/kg/dose
PO, oral; 3 days/week
biw
Pyrazinamide
pyrazinamide
PDR
3000.0
mg/dose
3
g/dose
PO, oral; 3 days/week
Pyrazinamide
pyrazinamide
PDR
4000.0
mg/dose
4
g/dose
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
30.0
mg/kg/day
30
mg/kg/dose
PO, oral
qd
Pyrazinamide
pyrazinamide
PDR
3000.0
mg/dose
3
g/dose
PO, oral
qd
Pyrazinamide
pyrazinamide
PDR
75.0
mg/kg/dose
75
mg/kg/dose
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
2000.0
mg
2
g
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
3000.0
mg
3
g
PO, oral; 3 days/week
Pyrazinamide
pyrazinamide
PDR
4000.0
mg
4
g
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
1500.0
mg
1.5
g
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
2500.0
mg
2.5
g
PO, oral; 3 days/week
Pyrazinamide
pyrazinamide
PDR
3000.0
mg
3
g
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
1000.0
mg
1
g
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
1500.0
mg
1.5
g
PO, oral; 3 days/week
Pyrazinamide
pyrazinamide
PDR
2000.0
mg
2
g
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
40.0
mg/kg/dose
40
mg/kg/dose
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
2000.0
mg/dose
2
g/dose
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
50.0
mg/kg/dose
50
mg/kg/dose
PO, oral; 3 days/week
biw
Pyrazinamide
pyrazinamide
PDR
1285.71428571429
mg/dose
3
g/dose
PO, oral; 3 days/week
Pyrazinamide
pyrazinamide
PDR
1142.85714285714
mg/dose
4
g/dose
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
30.0
mg/kg/dose
30
mg/kg/dose
PO, oral
qd
Pyrazinamide
pyrazinamide
PDR
3000.0
mg/day
3
g/dose
PO, oral
qd
Pyrazinamide
pyrazinamide
PDR
75.0
mg/kg/dose
75
mg/kg/dose
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
2000.0
mg
2
g
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
3000.0
mg
3
g
PO, oral
Pyrazinamide
pyrazinamide
PDR
4000.0
mg
4
g
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
1500.0
mg
1.5
g
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
2500.0
mg
2.5
g
PO, oral
Pyrazinamide
pyrazinamide
PDR
3000.0
mg
3
g
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
1000.0
mg
1
g
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
1500.0
mg
1.5
g
PO, oral
Pyrazinamide
pyrazinamide
PDR
2000.0
mg
2
g
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
40.0
mg/kg/day
40
mg/kg/dose
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
2.0
g/dose
2
g/dose
PO, oral; 5 days/week
qd
Pyrazinamide
pyrazinamide
PDR
50.0
mg/kg/dose
50
mg/kg/dose
PO, oral; 3 days/week
biw
Pyrazinamide
pyrazinamide
PDR
3.0
g/dose
3
g/dose
PO, oral; 3 days/week
Pyrazinamide
pyrazinamide
PDR
4.0
g/dose
4
g/dose
PO, oral
biw
Pyrazinamide
pyrazinamide
PDR
DDPD00340
Metixene
309.468
C20H23NS
CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1
DB00340
T3D2755
4167
51024
4023
-2.0
-
-2.0
-
DRUGBANK
DDPD00341
Cetirizine
388.888
C21H25ClN2O3
OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
DB00341
T3D2756
2678
3561
http://www.drugs.com/cetirizine-hcl.html
2577
-2.0
-
-2.0
-
DRUGBANK
70.0
%
>70
%
DRUGBANK
311.0
ng/ml
311.0
ng/ml
Tablet, PO, oral; Capsule, PO, Oral; normal,healthy;
DRUGBANK
313.0
ng/ml
313±45
ng/ml
Oral single dose; normal,healthy;
DRUGBANK
0.9
h
0.9±0.2
h
Oral single dose; normal,healthy;
DRUGBANK
70.0
%
70
%
Urinary excretion;
DRUGBANK
10.0
%
10
%
Faeces excretion;
DRUGBANK
3.18
L/h
~53
ml/min
Total clearance; Renal metabolism;
DRUGBANK
0.0444
L/h/kg
0.74±0.19
ml/min/kg
apparent clearance; normal,healthy; Male, men; Female, women;
Children ↑ ;Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.44
L/kg
0.44±0.19
L/kg
Apparent volume of distribution;
DRUGBANK
0.58
L/kg
0.58±0.16
L/kg
Apparent volume of distribution; normal,healthy; Male, men; Female, women;
DRUGBANK
8.3
h
8.3
h
elimination half-life;
DRUGBANK
9.42
h
9.42±2.4
h
normal,healthy; Male, men; Female, women;
Children ↓ ;chronic liver disease ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
365.0
mg/kg
365.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.1
mg/kg
0.1
mg/kg
PO, oral; mouse;
DRUGBANK
77.5
%
70-85
%
Urinary excretion; PO, oral;
DRUGBANK
11.5
%
10-13
%
Faeces excretion; PO, oral;
DRUGBANK
70.9
%
70.9±7.8
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
93.0
%
93
%
plasma proteins;
DRUGBANK
98.8
%
98.8±0.8
%
normal,healthy; human, homo sapiens;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral;intravenous injection, IV;
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
5.0
mg/day
5
mg/day
PO, oral
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.5
mg/day
2.5
mg/day
intravenous injection, IV
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
5.0
mg/day
5
mg/day
PO, oral
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
0.25
mg/kg
0.25
mg/kg
PO, oral
bid
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.5
mg/day
2.5
mg/day
intravenous injection, IV
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
5.0
mg/day
5
mg/day
PO, oral
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
0.25
mg/kg
0.25
mg/kg
PO, oral
bid
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.5
mg/day
2.5
mg/day
intravenous injection, IV
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral;intravenous injection, IV;
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral;intravenous injection, IV;
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral;intravenous injection, IV;
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
5.0
mg/day
5
mg/day
PO, oral
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
2.5
mg/day
2.5
mg/day
PO, oral;intravenous injection, IV;
Cetirizine Hydrochloride Tablets
cetirizine hydrochloride
PDR
DDPD00342
Terfenadine
471.6734
C32H41NO2
CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
DB00342
T3D2757
5405
9453
http://www.drugs.com/mtm/terfenadine.html
5212
-2.0
-
-2.0
-
DRUGBANK
70.0
%
>70
%
PO, oral;
DRUGBANK
3.5
h
3.5
h
DRUGBANK
5000.0
mg/kg
5.0
g/kg
PO, oral; mouse;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; mouse;
DRUGBANK
70.0
%
70
%
DRUGBANK
DDPD00343
Diltiazem
414.518
C22H26N2O4S
COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O
DB00343
T3D2758
39186
101278
http://www.drugs.com/diltiazem.html
35850
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40(24-74)
%
PO, oral;
DRUGBANK
38.0
%
38±11
%
PO, oral;
DRUGBANK
151.0
ng/ml
151±46
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
14.5
h
11-18
h
PO, oral;
DRUGBANK
4.0
h
4.0±0.4
h
Oral single dose; adults; normal,healthy;
DRUGBANK
65.0
L/h
~65
L/h
Total clearance; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
48.0
L/h
48.0
L/h
Total clearance; intravenous infusion, IV in drop; normal,healthy; Male, men;
DRUGBANK
0.708
L/h/kg
11.8±2.2
ml/min/kg
Multiple dose;
Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
305.0
L
~305
L
Apparent volume of distribution; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
3.3
L/kg
3.3±1.2
L/kg
Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
4.1
L/kg
4.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.75
h
~3.0-4.5
h
elimination half-life; Oral single dose; Oral multiple dose;
hepatopathy，LD ↑ ;increasing doses ↑ ;
DRUGBANK
7.5
h
6-9
h
elimination half-life; Single dose; Multiple dose; extended release formulation;
DRUGBANK
3.4
h
3.4
h
elimination half-life;
DRUGBANK
4.4
h
4.4±1.3
h
PO, oral;
RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
9.0
h
9±2
h
Active metabolite;
DRUGBANK
7.5
h
7.5±1
h
Active metabolite;
DRUGBANK
5.6
h
5.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
577.5
mg/kg
415-740
mg/kg
PO, oral; mouse;
DRUGBANK
685.0
mg/kg
560-810
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
mg/kg
>50
mg/kg
PO, oral; dog;
DRUGBANK
60.0
mg/kg
60.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
38.0
mg/kg
38.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
740.0
mg/kg
740.0
mg/kg
PO, oral; mouse;
DRUGBANK
3.0
%
2-4
%
Urinary excretion; Unchanged drug;
DRUGBANK
4.0
%
<4
%
Urinary excretion; Unchanged drug;
DRUGBANK
75.0
%
~70-80
%
plasma proteins;
DRUGBANK
40.0
%
~40
%
DRUGBANK
30.0
%
~30
%
DRUGBANK
78.0
%
78±3
%
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Cardizem CD
diltiazem hydrochloride
PDR
360.0
mg/day
360
mg/day
PO, oral
Cardizem CD
diltiazem hydrochloride
PDR
480.0
mg/day
480
mg/day
PO, oral
Cardizem CD
diltiazem hydrochloride
PDR
540.0
mg/day
540
mg/day
PO, oral
qd
Cardizem CD
diltiazem hydrochloride
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Cardizem CD
diltiazem hydrochloride
PDR
360.0
mg/day
360
mg/day
PO, oral
Cardizem CD
diltiazem hydrochloride
PDR
480.0
mg/day
480
mg/day
PO, oral
Cardizem CD
diltiazem hydrochloride
PDR
540.0
mg/day
540
mg/day
PO, oral
qd
Cardizem CD
diltiazem hydrochloride
PDR
DDPD00344
Protriptyline
263.3767
C19H21N
CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12
DB00344
T3D2759
4976
8597
http://www.drugs.com/cdi/protriptyline.html
4805
-2.0
-
-2.0
-
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
DDPD00345
Aminohippuric acid
194.1873
C9H10N2O3
NC1=CC=C(C=C1)C(=O)NCC(O)=O
DB00345
2148
104011
2063
-2.0
-
-2.0
-
DRUGBANK
7220.0
mg/kg
7.22
g/kg
intravenous injection, IV; female mouse;
DRUGBANK
DDPD00346
Alfuzosin
389.4488
C19H27N5O4
COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1
DB00346
2092
51141
http://www.drugs.com/cdi/alfuzosin.html
2008
-2.0
-
-2.0
-
DRUGBANK
50.0
%
<50
%
PO, oral; fasting;
DRUGBANK
0.354
L/h/kg
5.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.2
L/kg
3.2
L/kg
normal,healthy; Male, men;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
10
h
DRUGBANK
4.8
h
4.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
69.0
%
69
%
Faeces excretion; PO, oral;
DRUGBANK
24.0
%
24
%
Urinary excretion; PO, oral;
DRUGBANK
86.0
%
82-90
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Uroxatral
alfuzosin hydrochloride
PDR
10.0
mg/day
10
mg/day
PO, oral
Uroxatral
alfuzosin hydrochloride
PDR
DDPD00347
Trimethadione
143.1406
C6H9NO3
CN1C(=O)OC(C)(C)C1=O
DB00347
T3D2760
5576
9727
http://www.drugs.com/mtm/trimethadione.html
5374
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD00348
Nitisinone
329.2281
C14H10F3NO5
[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O
DB00348
115355
50378
http://www.drugs.com/cdi/nitisinone.html
103195
-2.0
-
-2.0
-
DRUGBANK
54.0
h
~54
h
DRUGBANK
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Orfadin
nitisinone
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Orfadin
nitisinone
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Orfadin
nitisinone
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Orfadin
nitisinone
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Orfadin
nitisinone
PDR
DDPD00349
Clobazam
300.74
C16H13ClN2O2
CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O
DB00349
T3D4564
2789
31413
http://www.drugs.com/cdi/clobazam.html
2687
-2.0
-
-2.0
-
DRUGBANK
87.0
%
87.0
%
PO, oral; food;
food → ;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
2.49
L/h
~2.49
L/h
DRUGBANK
100.0
L
100.0
L
DRUGBANK
32.0
h
32
h
elimination half-life; PO, oral;
DRUGBANK
57.0
h
57
h
epilepsy ↑ ;
DRUGBANK
94.0
%
~94
%
Urinary excretion;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Sympazan
clobazam
PDR
20.0
mg/day
20
mg/day
PO, oral
Sympazan
clobazam
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Sympazan
clobazam
PDR
40.0
mg/day
40
mg/day
PO, oral
Sympazan
clobazam
PDR
40.0
mg/day
40
mg/day
PO, oral
Sympazan
clobazam
PDR
20.0
mg/day
20
mg/day
PO, oral
Sympazan
clobazam
PDR
40.0
mg/day
40
mg/day
PO, oral
Sympazan
clobazam
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Sympazan
clobazam
PDR
DDPD00350
Minoxidil
209.2483
C9H15N5O
NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1
DB00350
4201
6942
http://www.drugs.com/cdi/minoxidil.html
10438564
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90.0
%
PO, oral; Male, men;
DRUGBANK
90.0
%
90
%
DRUGBANK
0.69
L/h/kg
11.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
L/kg
0.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.2
h
4.2
h
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2406.5
mg/kg
1321-3492
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2552.0
mg/kg
2456-2648
mg/kg
PO, oral; mouse;
DRUGBANK
0.0
%
0
%
plasma proteins;
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Minoxidil
minoxidil
PDR
100.0
mg/day
100
mg/day
PO, oral
Minoxidil
minoxidil
PDR
2.0
ml/day
2
ml/day
skin/dermal
Minoxidil
minoxidil
PDR
1.0
capfuL/day
1
capfuL/day
skin/dermal
Minoxidil
minoxidil
PDR
100.0
mg/day
100
mg/day
PO, oral
Minoxidil
minoxidil
PDR
100.0
mg/day
100
mg/day
PO, oral
Minoxidil
minoxidil
PDR
2.0
ml/day
2
ml/day
skin/dermal
Minoxidil
minoxidil
PDR
1.0
capful/day
1
capful/day
skin/dermal
Minoxidil
minoxidil
PDR
DDPD00351
Megestrol acetate
384.516
C24H32O4
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C
DB00351
11683
6723
http://www.drugs.com/cdi/megestrol.html
11192
-2.0
-
-2.0
-
DRUGBANK
6.5
%
5-8
%
Urinary excretion;
DRUGBANK
34.0
h
34
h
DRUGBANK
800.0
mg/day
800
mg/day
Liquid
Megestrol Acetate
megestrol acetate
PDR
625.0
mg/day
625
mg/day
Liquid
Megestrol Acetate
megestrol acetate
PDR
800.0
mg/day
800
mg/day
Liquid
Megestrol Acetate
megestrol acetate
PDR
625.0
mg/day
625
mg/day
Liquid
Megestrol Acetate
megestrol acetate
PDR
800.0
mg/day
800
mg/day
Liquid
Megestrol Acetate
megestrol acetate
PDR
625.0
mg/day
625
mg/day
Liquid
Megestrol Acetate
megestrol acetate
PDR
DDPD00352
Tioguanine
167.192
C5H5N5S
NC1=NC(=S)C2=C(N1)N=CN2
DB00352
T3D4770
2723601
9555
http://www.drugs.com/cdi/thioguanine.html
2005804
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30(14-46)
%
PO, oral;
DRUGBANK
0.133333333333333
h
80(25-240)
min
elimination half-life; Single dose;
DRUGBANK
160.0
mg/kg
160.0
mg/kg
PO, oral; mouse;
DRUGBANK
160.0
mg/kg
160.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00353
Methylergometrine
339.4314
C20H25N3O2
[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
DB00353
T3D3686
8226
92607
http://www.drugs.com/cdi/methylergonovine.html
7933
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60.0
%
PO, oral;
DRUGBANK
78.0
%
78.0
%
IM,intramuscular injection;
DRUGBANK
0.4308
L/h/kg
7.18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
56.1
L
56.1
L
DRUGBANK
0.96
L/kg
0.96
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.39
h
3.39
h
DRUGBANK
1.85
h
1.85
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.8
mg/day
0.8
mg/day
PO, oral; up to 7 days
Methylergonovine Maleate Injection
methylergonovine maleate
PDR
0.8
mg/day
0.8
mg/day
PO, oral; up to 7 days
Methylergonovine Maleate Injection
methylergonovine maleate
PDR
DDPD00354
Buclizine
433.028
C28H33ClN2
CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1
DB00354
6729
3205
6473
-2.0
-
-2.0
-
DRUGBANK
DDPD00355
Aztreonam
435.433
C13H17N5O8S2
C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O
DB00355
9568617
161680
http://www.drugs.com/cdi/aztreonam.html
4674940
-2.0
-
-2.0
-
DRUGBANK
1.0
%
<1
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
IM,intramuscular injection;
DRUGBANK
16.0
%
16
%
Liver metabolism; Inactive metabolite;
DRUGBANK
5460.0
L/h
91.0
L/min
normal,healthy;
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.6
L
12.6
L
DRUGBANK
0.18
L/kg
0.18
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
h
1.7(1.5-2.0）
h
elimination half-life; normal renal function;
dose → ;
DRUGBANK
5.35
h
4.7-6
h
Elderly; patients;
DRUGBANK
2.1
h
2.1
h
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
56.0
%
56
%
dose → ;
DRUGBANK
39.5
%
36-43
%
renal insufficiency;
DRUGBANK
120.0
mg/kg/day
120
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
8000.0
mg/day
8
g/day
intravenous injection, IV
Cayston
aztreonam
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Cayston
aztreonam
PDR
120.0
mg/kg/day
120
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
225.0
mg/day
225
mg/day
skin/dermal
Cayston
aztreonam
PDR
225.0
mg/day
225
mg/day
skin/dermal
Cayston
aztreonam
PDR
8000.0
mg/day
8
g/day
intravenous injection, IV;IM,intramuscular injection;
Cayston
aztreonam
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Cayston
aztreonam
PDR
225.0
mg/day
225
mg/day
skin/dermal
Cayston
aztreonam
PDR
120.0
mg/kg/day
120
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
8000.0
mg/day
8
g/day
intravenous injection, IV
Cayston
aztreonam
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Cayston
aztreonam
PDR
225.0
mg/day
225
mg/day
skin/dermal
Cayston
aztreonam
PDR
8000.0
mg/day
8
g/day
intravenous injection, IV;IM,intramuscular injection;
Cayston
aztreonam
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Cayston
aztreonam
PDR
120.0
mg/kg/day
120
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
120.0
mg/kg/day
120
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
120.0
mg/kg/day
120
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
90.0
mg/kg/day
90
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
90.0
mg/kg/day
90
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Cayston
aztreonam
PDR
DDPD00356
Chlorzoxazone
169.565
C7H4ClNO2
ClC1=CC2=C(OC(=O)N2)C=C1
DB00356
2733
3655
http://www.drugs.com/cdi/chlorzoxazone.html
2632
-2.0
-
-2.0
-
DRUGBANK
440.0
mg/kg
440.0
mg/kg
PO, oral; mouse;
DRUGBANK
763.0
mg/kg
763.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.5
%
13-18
%
DRUGBANK
3000.0
mg/day
3000
mg/day
PO, oral
Lorzone
chlorzoxazone
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Lorzone
chlorzoxazone
PDR
DDPD00357
Aminoglutethimide
232.2783
C13H16N2O2
CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1
DB00357
T3D4806
2145
2654
http://www.drugs.com/cdi/aminoglutethimide.html
2060
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
44.0
%
34-54
%
Urinary excretion;
DRUGBANK
12.5
h
12.5±1.6
h
DRUGBANK
1800.0
mg/kg
1800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
mg/kg
>100
mg/kg
PO, oral; dog;
DRUGBANK
156.0
mg/kg
156.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
100.0
mg/kg
>100
mg/kg
intravenous injection, IV; dog;
DRUGBANK
1800.0
mg/kg
1800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
mg/kg
>100
mg/kg
PO, oral; dog;
DRUGBANK
156.0
mg/kg
156.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
100.0
mg/kg
>100
mg/kg
intravenous injection, IV; dog;
DRUGBANK
44.0
%
34-54
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
23.0
%
21-25
%
DRUGBANK
DDPD00358
Mefloquine
378.3122
C17H16F6N2O
OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F
DB00358
4046
63681
http://www.drugs.com/cdi/mefloquine.html
3906
-2.0
-
-2.0
-
DRUGBANK
910.0
ng/ml
800-1020
ng/ml
Oral single dose;
DRUGBANK
420.0
ng/ml
420±141
ng/ml
Oral multiple dose;
DRUGBANK
13.3
h
7-19.6
h
Oral single dose;
DRUGBANK
12.0
h
12±8
h
Oral multiple dose;
DRUGBANK
1.8
L/h
30.0
ml/min
DRUGBANK
0.0258
L/h/kg
0.43±0.14
ml/min/kg
apparent clearance;
Children → ;Preg, pregnant ↑ ;
DRUGBANK
20.0
L/kg
20.0
L/kg
normal,healthy; adults;
DRUGBANK
19.0
L/kg
19±6
L/kg
Apparent volume of distribution;
DRUGBANK
504.0
h
2-4
week
DRUGBANK
480.0
h
20±4
day
Preg, pregnant ↓ ;Children → ;
DRUGBANK
880.0
mg/kg
880.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
9.0
%
~9
%
Urinary excretion; at steady state; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.0
%
98
%
DRUGBANK
98.2
%
98.2
%
DRUGBANK
1250.0
mg
1250
mg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
250.0
mg
250
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
187.5
mg
187.5
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
125.0
mg
125
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
62.5
mg
62.5
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
1250.0
mg
1250
mg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
250.0
mg
250
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
1250.0
mg
1250
mg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
250.0
mg
250
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
187.5
mg
187.5
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
1250.0
mg
1250
mg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
250.0
mg
250
mg
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
5.0
mg/kg/dose
5
mg/kg/dose
PO, oral
qw
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
22.5
mg/kg
22.5
mg/kg
PO, oral
Mefloquine Hydrochloride
mefloquine hydrochloride
PDR
DDPD00359
Sulfadiazine
250.277
C10H10N4O2S
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
DB00359
5215
9328
http://www.drugs.com/cdi/sulfadiazine.html
5026
-2.0
-
-2.0
-
DRUGBANK
0.033
L/h/kg
0.55
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.29
L/kg
0.29
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00360
Sapropterin
241.2471
C9H15N5O3
[H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O
DB00360
44257
59560
40270
-2.0
-
-2.0
-
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
Kuvan
sapropterin dihydrochloride
PDR
20.0
mg/kg/day
20
mg/kg/day
Kuvan
sapropterin dihydrochloride
PDR
20.0
mg/kg/day
20
mg/kg/day
Kuvan
sapropterin dihydrochloride
PDR
20.0
mg/kg/day
20
mg/kg/day
Kuvan
sapropterin dihydrochloride
PDR
DDPD00361
Vinorelbine
778.947
C45H54N4O8
[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
DB00361
44424639
480999
http://www.drugs.com/cdi/vinorelbine.html
4470974
-2.0
-
-2.0
-
DRUGBANK
27.0
%
27±12
%
Liquid;
DRUGBANK
114.0
ng/ml
114±43
ng/ml
DRUGBANK
1130.0
ng/ml
1130±636
ng/ml
DRUGBANK
2.0
h
2
h
DRUGBANK
1.5
h
1.5±1.0
h
DRUGBANK
0.775
L/kg
0.29-1.26
L/kg
Plasma clearance; patients;
DRUGBANK
1.26
L/h/kg
21±7
ml/min/kg
hepatopathy，LD ↓ ;
DRUGBANK
1.2
L/h/kg
20
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.75
L/kg
25.4-40.1
L/kg
Steady state volume of distribution;
DRUGBANK
76.0
L/kg
76±41
L/kg
DRUGBANK
23.0
L/kg
23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.65
h
27.7-43.6
h
terminal half-life;
DRUGBANK
42.0
h
42±21
h
elimination half-life;
DRUGBANK
26.0
h
26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
%
~18
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
46.0
%
~46
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
20.0
%
<20
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
45.0
%
30-60
%
Faeces excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
11.0
%
11
%
Urinary excretion; Unchanged drug;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
87.0
%
87(80-91)
%
DRUGBANK
30.0
mg/m2
30
mg/m2
intravenous injection, IV
Navelbine
vinorelbine tartrate
PDR
30.0
mg/m2
30
mg/m2
intravenous injection, IV
Navelbine
vinorelbine tartrate
PDR
DDPD00362
Anidulafungin
1140.2369
C58H73N7O17
[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O
DB00362
T3D2763
166548
55346
http://www.drugs.com/cdi/anidulafungin.html
145752
-2.0
-
-2.0
-
DRUGBANK
1.0
L/h
1.0
L/h
DRUGBANK
0.0126
L/h/kg
0.21
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
L
30-50
L
DRUGBANK
0.57
L/kg
0.57
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
h
40-50
h
DRUGBANK
40.0
h
40
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
84.0
%
84
%
DRUGBANK
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Eraxis
anidulafungin
PDR
200.0
mg/dose
200
mg/dose
intravenous injection, IV
Eraxis
anidulafungin
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Eraxis
anidulafungin
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Eraxis
anidulafungin
PDR
3.0
mg/kg
3
mg/kg
intravenous injection, IV
Eraxis
anidulafungin
PDR
200.0
mg/dose
200
mg/dose
intravenous injection, IV
Eraxis
anidulafungin
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Eraxis
anidulafungin
PDR
DDPD00363
Clozapine
326.823
C18H19ClN4
CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
DB00363
T3D2764
2818
3766
http://www.drugs.com/clozapine.html
10442628
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
55.0
%
55±12
%
PO, oral;
DRUGBANK
546.0
ng/ml
546±307
ng/ml
Tablet, PO, oral; adults;
DRUGBANK
1.9
h
1.9±0.8
h
Tablet, PO, oral; adults;
DRUGBANK
0.366
L/h/kg
6.1±1.6
ml/min/kg
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.4
L/kg
5.4±3.5
L/kg
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8(4-12)
h
DRUGBANK
12.0
h
12±4
h
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
30.0
%
~30
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
95.0
%
>95
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Clozaril
clozapine
PDR
900.0
mg/day
900
mg/day
PO, oral
Clozaril
clozapine
PDR
300.0
mg/day
300
mg/day
PO, oral
Clozaril
clozapine
PDR
900.0
mg/day
900
mg/day
PO, oral
Clozaril
clozapine
PDR
DDPD00364
Sucralfate
1558.67
C12H35Al9O55S8
O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
DB00364
70789197
http://www.drugs.com/cdi/sucralfate.html
32701653
-2.0
-
-2.0
-
DRUGBANK
0.009
%
0.001-0.017
%
PO, oral; normal,healthy;
DRUGBANK
13.0
h
6-20
h
elimination half-life; animals;
DRUGBANK
80.0
mg/kg/day
80
mg/kg/day
PO, oral
Carafate Tablets
sucralfate
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Carafate Tablets
sucralfate
PDR
4000.0
mg/day
4
g/day
PO, oral
Carafate Tablets
sucralfate
PDR
4000.0
mg/day
4
g/day
PO, oral
Carafate Tablets
sucralfate
PDR
4000.0
mg/day
4
g/day
PO, oral
Carafate Tablets
sucralfate
PDR
DDPD00365
Grepafloxacin
359.3947
C19H22FN3O3
CC1CN(CCN1)C1=C(F)C(C)=C2C(=O)C(=CN(C3CC3)C2=C1)C(O)=O
DB00365
72474
5543
http://www.drugs.com/mtm/grepafloxacin.html
65391
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70.0
%
PO, oral;
DRUGBANK
0.354
L/h/kg
5.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
h
15±3
h
DRUGBANK
9.2
h
9.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
50
%
DRUGBANK
DDPD00366
Doxylamine
270.3694
C17H22N2O
CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1
DB00366
3162
51380
http://www.drugs.com/cdi/doxylamine.html
3050
-2.0
-
-2.0
-
DRUGBANK
10.0
h
10
h
DRUGBANK
DDPD00367
Levonorgestrel
312.4458
C21H28O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
DB00367
T3D4749
13109
6443
http://www.drugs.com/cdi/levonorgestrel.html
12560
-2.0
-
-2.0
-
DRUGBANK
360.1
ng.h/ml
360.1
ng.h/ml
PO, oral;
DRUGBANK
202.69
ng.h/ml
197.28-208.1
ng.h/ml
PO, oral; Obesity;
Obesity ↓ ;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
16.2
ng/ml
16.2
ng/ml
PO, oral;
DRUGBANK
10.5
ng/ml
10.5
ng/ml
PO, oral; Obesity;
Obesity ↓ ;
DRUGBANK
60.0
h
2-3
day
subdermal implant;
DRUGBANK
1.0
h
1
h
Oral single dose;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral; Obesity;
Obesity ↓ ;
DRUGBANK
4.8
L/h
4.8
L/h
normal,healthy; Female, women;
DRUGBANK
8.105
L/h
7.70-8.51
L/h
Obesity; patients;
DRUGBANK
7.06
L/h
7.06
L/h
Average clearance;
DRUGBANK
0.108
L/h/kg
1.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
162.2
L
162.2
L
Steady state volume of distribution; normal,healthy;
DRUGBANK
435.55
L
404.7-466.4
L
Steady state volume of distribution; Obesity;
DRUGBANK
260.0
L
260.0
L
Average volume of distribution;
DRUGBANK
1.8
L/kg
1.8
L/kg
Apparent volume of distribution;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
h
20-60
h
elimination half-life;
DRUGBANK
29.7
h
29.7
h
elimination half-life; Female, women;
DRUGBANK
43.7
h
41.0-46.4
h
elimination half-life; BMI over; Female, women;
DRUGBANK
24.4
h
24.4
h
elimination half-life; patients;
DRUGBANK
9.4
h
9.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
45.0
%
~45
%
Urinary excretion; PO, oral;
DRUGBANK
32.0
%
~32
%
Faeces excretion; PO, oral;
DRUGBANK
98.25
%
97.5-99
%
DRUGBANK
DDPD00368
Norepinephrine
169.1778
C8H11NO3
NC[C@H](O)C1=CC(O)=C(O)C=C1
DB00368
T3D4154
439260
18357
http://www.drugs.com/mtm/norepinephrine.html
388394
-2.0
-
-2.0
-
DRUGBANK
2.88
mg/kg/day
2
mcg/kg/minute
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
43.2
mg/day
30
mcg/min
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
4.752
mg/kg/day
3.3
mcg/kg/min
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
2.88
mg/kg/day
2
mcg/kg/minute
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
43.2
mg/day
30
mcg/minute
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
4.752
mg/kg/day
3.3
mcg/kg/minute
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
2.88
mg/kg/day
2
mcg/kg/min
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
2.88
mg/kg/day
2
mcg/kg/minute
intravenous infusion, iv in drop
Levophed
norepinephrine bitartrate
PDR
DDPD00369
Cidofovir
279.187
C8H14N3O6P
NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1
DB00369
60613
3696
http://www.drugs.com/cdi/cidofovir.html
54636
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
DRUGBANK
98.0
%
98±10
%
subcutaneous injection, SC;
DRUGBANK
5.0
%
<5
%
PO, oral;
DRUGBANK
19600.0
ng/ml
19.6±7.2
mcg/ml
DRUGBANK
6.20809248554913
L/h/m2
179±23.1
ml/min/1.73m2
DRUGBANK
0.126
L/h/kg
2.1±0.6
ml/min/kg
AIDS,HIV; positive for CMV;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.537
L/kg
537±126
mL/kg
DRUGBANK
0.41
L/kg
410±102
mL/kg
DRUGBANK
0.36
L/kg
0.36±0.13
L/kg
AIDS,HIV; positive for CMV;
DRUGBANK
0.49
L/kg
0.49
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
h
2.4-3.2
h
DRUGBANK
2.3
h
2.3±0.5
h
AIDS,HIV; positive for CMV; patients;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.1
%
70.1±21.4
%
Urinary excretion; AIDS,HIV; positive for CMV; human, homo sapiens; Unchanged drug;
DRUGBANK
6.0
%
6
%
DRUGBANK
6.0
%
<6
%
AIDS,HIV; positive for CMV; human, homo sapiens;
DRUGBANK
0.714285714285714
mg/kg/day
5
mg/kg/week
intravenous injection, IV
Vistide
cidofovir
PDR
0.714285714285714
mg/kg/day
5
mg/kg/week
intravenous injection, IV
Vistide
cidofovir
PDR
DDPD00370
Mirtazapine
265.3529
C17H19N3
CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
DB00370
T3D2767
4205
6950
http://www.drugs.com/cdi/mirtazapine.html
4060
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral; food;
food → ;
DRUGBANK
50.0
%
50.0
%
PO, oral; food;
food → ;
DRUGBANK
50.0
%
50±10
%
PO, oral;
DRUGBANK
41.8
ng/ml
41.8±7.7
ng/ml
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral; food;
food → ;
DRUGBANK
1.5
h
1.5±0.7
h
PO, oral;
DRUGBANK
120.0
h
5.0
day
PO, oral;
DRUGBANK
31.0
L/h
31.0
L/h
Total clearance; intravenous injection, IV; Male, men;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Age ↓ ;
DRUGBANK
0.5472
L/h/kg
9.12±1.14
ml/min/kg
normal,healthy; adults; hydrolysis; hydrolysis; hydrolysis;
hepatopathy，LD ↓ ;moderate renal function ↓ ;severe renal function ↓ ;
DRUGBANK
0.48
L/h/kg
8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
107.0
L
107±42
L
PO, oral;
DRUGBANK
4.5
L/kg
4.5±1.7
L/kg
normal,healthy; adults; hydrolysis; hydrolysis; hydrolysis;
DRUGBANK
4.2
L/kg
4.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
h
20-40
h
DRUGBANK
16.3
h
16.3±4.6
h
chronic liver disease ↑ ;moderate renal function ↑ ;severe renal function ↑ ;
DRUGBANK
15.0
h
15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
830.0
mg/kg
830.0
mg/kg
PO, oral; Male, men; mouse;
DRUGBANK
660.0
mg/kg
600-720
mg/kg
PO, oral; mouse;
DRUGBANK
405.0
mg/kg
320-490
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
75.0
%
75
%
Urinary excretion;
DRUGBANK
15.0
%
15
%
Faeces excretion;
DRUGBANK
85.0
%
~85
%
plasma proteins;
DRUGBANK
85.0
%
85
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
45.0
mg/day
45
mg/day
PO, oral
Mirtazapine
mirtazapine
PDR
45.0
mg/day
45
mg/day
PO, oral
Mirtazapine
mirtazapine
PDR
DDPD00371
Meprobamate
218.2502
C9H18N2O4
CCCC(C)(COC(N)=O)COC(N)=O
DB00371
4064
6761
http://www.drugs.com/cdi/meprobamate.html
3924
-2.0
-
-2.0
-
DRUGBANK
0.036
L/h/kg
0.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
L/kg
0.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
~10
h
elimination half-life;
DRUGBANK
14.0
h
14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00372
Thiethylperazine
399.616
C22H29N3S2
CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1
DB00372
5440
9544
http://www.drugs.com/mtm/thiethylperazine.html
5245
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD00373
Timolol
316.42
C13H24N4O3S
[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
DB00373
33624
9599
http://www.drugs.com/cdi/timolol-drops.html
31013
-2.0
-
-2.0
-
DRUGBANK
4.78
ng.h/ml
4.78
ng.h/ml
ophthalmic administration;
DRUGBANK
6.46
ng.h/ml
6.46
ng.h/ml
intravenous injection, IV;
DRUGBANK
78.0
%
78.0±24.5
%
ophthalmic administration; different study;
DRUGBANK
60.0
%
60.0
%
ophthalmic administration; different study;
DRUGBANK
61.0
%
61±6
%
PO, oral;
DRUGBANK
1.14
ng/ml
1.14
ng/ml
ophthalmic administration;
DRUGBANK
61.0
ng/ml
61±39
ng/ml
PO, oral; extensive metabolizers, EM;
DRUGBANK
114.0
ng/ml
114±21
ng/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
0.25
h
0.25
h
ophthalmic administration;
DRUGBANK
1.2
h
1.2±0.4
h
PO, oral; extensive metabolizers, EM;
DRUGBANK
1.8
h
1.8±0.8
h
PO, oral; poor metabolizers, PM;
DRUGBANK
90.0
%
90
%
Liver metabolism;
DRUGBANK
33.42
L/h
557±61
ml/min
Plasma clearance; normal,healthy;
DRUGBANK
45.09
L/h
751.5±90.6
ml/min
Total clearance; normal,healthy;
DRUGBANK
5.832
L/h
97.2±10.1
ml/min
Renal clearance; normal,healthy;
DRUGBANK
0.462
L/h/kg
7.7±1.2
ml/min/kg
hydrolysis;
DRUGBANK
0.51
L/h/kg
8.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.3-1.7
L/kg
DRUGBANK
1.7
L/kg
1.7±0.2
L/kg
hydrolysis;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.9
h
2.9±0.3
h
normal,healthy;
DRUGBANK
2.7
h
2.7±0.5
h
CYP2D6 genetic polymorphisms;
DRUGBANK
7.5
h
7.5±3.0
h
poor metabolizers, PM; hydrolysis; PO, oral;
DRUGBANK
3.7
h
3.7±1.7
h
extensive metabolizers, EM; PO, oral;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1028.0
mg/kg
1028.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1137.0
mg/kg
1137.0
mg/kg
PO, oral; mouse;
DRUGBANK
8.0
%
8±4
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
10.0
%
~10
%
plasma proteins;
DRUGBANK
10.0
%
<10
%
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
bid
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Betimol
timolol
PDR
60.0
mg/day
60
mg/day
PO, oral
Betimol
timolol
PDR
30.0
mg/day
30
mg/day
PO, oral
Betimol
timolol
PDR
20.0
mg/day
20
mg/day
PO, oral
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
bid
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
bid
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Betimol
timolol
PDR
60.0
mg/day
60
mg/day
PO, oral
Betimol
timolol
PDR
30.0
mg/day
30
mg/day
PO, oral
Betimol
timolol
PDR
20.0
mg/day
20
mg/day
PO, oral
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
bid
Betimol
timolol
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Betimol
timolol
PDR
DDPD00374
Treprostinil
390.5131
C23H34O5
[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=C(C2)C(OCC(O)=O)=CC=C1
DB00374
6918140
50861
http://www.drugs.com/cdi/treprostinil-inhalation-solution.html
5293353
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
subcutaneous injection, SC;
DRUGBANK
100.0
%
100.0
%
subcutaneous injection, SC;
DRUGBANK
0.642
L/h/kg
10.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
L/kg
0.2
L/kg
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~2-4
h
elimination half-life;
DRUGBANK
0.566666666666667
h
34
min
elimination half-life; intravenous infusion, IV in drop;
DRUGBANK
1.41666666666667
h
85
min
elimination half-life; subcutaneous infusion;
DRUGBANK
0.82
h
0.82
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
91.0
%
~91
%
plasma proteins; human, homo sapiens;
DRUGBANK
0.4176
mg/kg/day
290
ng/kg/min
parenteral administration
Remodulin
treprostinil
PDR
9.0
breaths
9
breaths
inhalation, IH
qid
Remodulin
treprostinil
PDR
21.0
mg
21
mg
Tablet,PO，oral
bid
Remodulin
treprostinil
PDR
0.00029
mg/kg/day
290
ng/kg/min
parenteral administration
Remodulin
treprostinil
PDR
8.6e-05
mg/kg/day
86
ng/kg/min
intravenous injection, IV
Remodulin
treprostinil
PDR
0.004176
mg/kg/day
290
ng/kg/min
parenteral administration
Remodulin
treprostinil
PDR
9.0
breaths
9
breaths
inhalation, IH
qid
Remodulin
treprostinil
PDR
21.0
mg
21
mg
Tablet,PO，oral
bid
Remodulin
treprostinil
PDR
DDPD00375
Colestipol
N.A.
N.A.
C1C(O1)CCl.C(CNCCNCCNCCN)N
DB00375
62816
http://www.drugs.com/cdi/colestipol.html
56550
-2.0
-
-2.0
-
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15000.0
mg/day
15
g/day
PO, oral
Colestid Granules
colestipol hydrochloride
PDR
30000.0
mg/day
30
g/day
PO, oral
Colestid Granules
colestipol hydrochloride
PDR
16000.0
mg/day
16
g/day
Tablet,PO，oral
Colestid Granules
colestipol hydrochloride
PDR
15000.0
mg/day
15
g/day
PO, oral
Colestid Granules
colestipol hydrochloride
PDR
30000.0
mg/day
30
g/day
PO, oral
Colestid Granules
colestipol hydrochloride
PDR
16000.0
mg/day
16
g/day
Tablet,PO，oral
Colestid Granules
colestipol hydrochloride
PDR
DDPD00376
Trihexyphenidyl
301.4662
C20H31NO
OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1
DB00376
T3D2770
5572
9720
http://www.drugs.com/cdi/trihexyphenidyl.html
5371
-2.0
-
-2.0
-
DRUGBANK
3.7
h
3.3-4.1
h
DRUGBANK
DDPD00377
Palonosetron
296.414
C19H24N2O
[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2
DB00377
6337614
85161
http://www.drugs.com/cdi/palonosetron.html
4892289
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
Liver metabolism;
DRUGBANK
0.16
L/h/kg
160±35
ml/h/kg
DRUGBANK
0.156
L/h/kg
2.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.3
L/kg
8.3 ± 2.5
L/kg
DRUGBANK
6.3
L/kg
6.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
h
~40
h
DRUGBANK
39.0
h
39
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
%
~8
%
Urinary excretion;
DRUGBANK
62.0
%
62
%
DRUGBANK
1.5
mg/dose
1.5
mg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
0.02
mg/kg/dose
20
mcg/kg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
0.25
mg/dose
0.25
mg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
0.5
mg/dose
0.5
mg/dose
PO, oral
Aloxi
palonosetron hydrochloride
PDR
1.5
mg/dose
1.5
mg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
0.02
mg/kg/dose
20
mcg/kg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
0.25
mg/dose
0.25
mg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
0.5
mg/dose
0.5
mg/dose
PO, oral
Aloxi
palonosetron hydrochloride
PDR
0.02
mg/kg/dose
20
mcg/kg/dose
intravenous injection, IV
Aloxi
palonosetron hydrochloride
PDR
DDPD00378
Dydrogesterone
312.4458
C21H28O2
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C
DB00378
9051
31527
8699
-2.0
-
-2.0
-
DRUGBANK
28.0
%
28.0
%
PO, oral;
DRUGBANK
6.0
h
5-7
h
DRUGBANK
15.5
h
14-17
h
DRUGBANK
4640.0
mg/kg
4640.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00379
Mexiletine
179.2588
C11H17NO
CC(N)COC1=C(C)C=CC=C1C
DB00379
4178
6916
http://www.drugs.com/cdi/mexiletine.html
4034
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90.0
%
PO, oral;
DRUGBANK
85.0
%
85
%
Liver metabolism;
DRUGBANK
0.498
L/h/kg
8.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
L/lg
5-7.0
L/lg
DRUGBANK
5.9
L/kg
5.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
10-12
h
DRUGBANK
9.9
h
9.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
~10
%
Urinary excretion; Unchanged drug;
DRUGBANK
55.0
%
50-60
%
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Mexiletine Hydrochloride
mexiletine hydrochloride
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Mexiletine Hydrochloride
mexiletine hydrochloride
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Mexiletine Hydrochloride
mexiletine hydrochloride
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Mexiletine Hydrochloride
mexiletine hydrochloride
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Mexiletine Hydrochloride
mexiletine hydrochloride
PDR
DDPD00380
Dexrazoxane
268.2691
C11H16N4O4
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
DB00380
T3D2771
71384
50223
http://www.drugs.com/cdi/dexrazoxane.html
64479
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
intravenous injection, IV;
DRUGBANK
7.88
L/h/m2
7.88
L/h/m2
DRUGBANK
6.25
L/h/m2
6.25
L/h/m2
DRUGBANK
0.186
L/h/kg
3.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.8
L/m2
9-22.6
L/m2
DRUGBANK
0.55
L/kg
0.55
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
2000.0
mg/kg
2.0
g/kg
intravenous injection, IV; dog;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
2000.0
mg/kg
2.0
g/kg
intravenous injection, IV; dog;
DRUGBANK
42.0
%
42
%
Urinary excretion;
DRUGBANK
2.0
%
<2
%
DRUGBANK
1000.0
mg/m2
1000
mg/m2
Zinecard
dexrazoxane
PDR
2000.0
mg
2000
mg
Zinecard
dexrazoxane
PDR
1000.0
mg/m2
1000
mg/m2
Zinecard
dexrazoxane
PDR
2000.0
mg
2000
mg
Zinecard
dexrazoxane
PDR
DDPD00381
Amlodipine
408.876
C20H25ClN2O5
CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
DB00381
2162
2668
http://www.drugs.com/amlodipine.html
2077
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral; food;
food → ;
DRUGBANK
77.0
%
64-90
%
PO, oral; food;
food → ;
DRUGBANK
74.0
%
74±17
%
PO, oral;
Elderly → ;
DRUGBANK
18.1
ng/ml
18.1±7.1
ng/ml
PO, oral; Male, men; adults;
Elderly ↑ ;
DRUGBANK
9.0
h
6-12
h
PO, oral; food;
food → ;
DRUGBANK
6.7
h
5.4-8.0
h
PO, oral; Male, men; adults;
DRUGBANK
180.0
h
7-8
day
PO, oral; Oral multiple dose;
DRUGBANK
90.0
%
90
%
Liver metabolism; Inactive metabolite;
DRUGBANK
55.0
%
55
%
Urinary excretion;
DRUGBANK
0.42
L/h/kg
7±1.3
ml/min/kg
Total clearance; normal,healthy;
Geriatric ↓ ;Age ↓ ;
DRUGBANK
0.354
L/h/kg
5.9±1.5
ml/min/kg
Elderly → ;Hepatitis, Hep ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.42
L/h/kg
7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.0
L/kg
21.0
L/kg
DRUGBANK
16.0
L/kg
16±4
L/kg
Elderly → ;
DRUGBANK
17.0
L/kg
17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
h
30-50
h
elimination half-life;
DRUGBANK
39.0
h
39±8
h
RD, renal impairment, Renal disease，including uremia → ;Hepatitis, Hep ↑ ;Age ↑ ;
DRUGBANK
34.0
h
34
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.0
mg/kg
37.0
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
%
10
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
10
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.0
%
~98
%
DRUGBANK
93.0
%
93±1
%
Elderly → ;
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Norvasc
amlodipine besylate
PDR
20.0
mg/day
20
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Norvasc
amlodipine besylate
PDR
20.0
mg/day
20
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
10.0
mg/day
10
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
5.0
mg/day
5
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Norvasc
amlodipine besylate
PDR
20.0
mg/day
20
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
10.0
mg/day
10
mg/day
PO, oral
Norvasc
amlodipine besylate
PDR
DDPD00382
Tacrine
198.2637
C13H14N2
NC1=C2CCCCC2=NC2=CC=CC=C12
DB00382
T3D2772
1935
45980
http://www.drugs.com/cdi/tacrine.html
1859
-2.0
-
-2.0
-
DRUGBANK
17.0
%
17.0
%
DRUGBANK
3.36
L/h/kg
56
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
349.0
L
349±193
L
DRUGBANK
11.0
L/kg
11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
2-4
h
DRUGBANK
3.3
h
3.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
mg/kg
40.0
mg/kg
Oral single dose; Rattus, Rat;
DRUGBANK
55.0
%
55
%
DRUGBANK
DDPD00383
Oxyphencyclimine
344.4479
C20H28N2O3
CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
DB00383
4642
7868
4481
-2.0
-
-2.0
-
DRUGBANK
DDPD00384
Triamterene
253.2626
C12H11N7
NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
DB00384
5546
9671
http://www.drugs.com/triamterene.html
5345
-2.0
-
-2.0
-
DRUGBANK
148.7
ng.h/ml
148.7
ng.h/ml
Oral single dose; Male, men; fasting;
DRUGBANK
52.0
%
52.0
%
PO, oral;
DRUGBANK
86.84
%
86.84
%
combination drug use;
DRUGBANK
51.0
%
51±18
%
PO, oral;
DRUGBANK
46.4
ng/ml
46.4
ng/ml
Oral single dose; Male, men; fasting;
DRUGBANK
26.4
ng/ml
26.4±17.7
ng/ml
Oral single dose; fasting; young; normal,healthy;
DRUGBANK
779.0
ng/ml
779±310
ng/ml
Oral single dose; Active metabolite; fasting; young; normal,healthy;
DRUGBANK
84.0
ng/ml
84±91
ng/ml
Oral single dose; Elderly;
DRUGBANK
526.0
ng/ml
526±388
ng/ml
Oral single dose; Active metabolite; Elderly;
DRUGBANK
1.1
h
1.1
h
Oral single dose; Male, men; fasting;
DRUGBANK
2.9
h
2.9±1.6
h
PO, oral;
DRUGBANK
4.1
h
4.1±2.0
h
PO, oral; Active metabolite;
DRUGBANK
270.0
L/h
4.5
L/min
Plasma clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
0.22
L/kg
0.22
L/kg
Renal clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
3.78
L/h/kg
63±20
ml/min/kg
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
3.78
L/h/kg
63
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.49
L/kg
1.49
L/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
13.4
L/kg
13.4±4.9
L/kg
DRUGBANK
13.0
L/kg
13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.75
h
1.5-2
h
DRUGBANK
4.25
h
255±42
min
terminal half-life; intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
3.13333333333333
h
188±70
min
terminal half-life; intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
4.2
h
4.2±0.7
h
DRUGBANK
3.1
h
3.1±1.2
h
Metabolite;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
4.3
h
4.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
332.5
mg/kg
285-380
mg/kg
PO, oral; mouse;
DRUGBANK
50.0
%
<50
%
Urinary excretion; PO, oral;
DRUGBANK
20.0
%
~20
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
52.0
%
52±10
%
Urinary excretion; Unchanged drug;
Elderly → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
67.0
%
67
%
DRUGBANK
61.0
%
61±2
%
HL,hyperlipoproteinemia ↑ ;RD, renal impairment, Renal disease，including uremia ↓ ;hypoalbuminemia Alb ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Dyrenium
triamterene
PDR
300.0
mg/day
300
mg/day
PO, oral
Dyrenium
triamterene
PDR
300.0
mg/day
300
mg/day
PO, oral
Dyrenium
triamterene
PDR
300.0
mg/day
300
mg/day
PO, oral
Dyrenium
triamterene
PDR
300.0
mg/day
300
mg/day
PO, oral
Dyrenium
triamterene
PDR
DDPD00385
Valrubicin
723.651
C34H36F3NO13
[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1
DB00385
454216
135876
http://www.drugs.com/cdi/valrubicin.html
399974
-2.0
-
-2.0
-
DRUGBANK
99.0
%
>99
%
DRUGBANK
800.0
mg
800
mg
intravesically
Valstar
valrubicin
PDR
800.0
mg
800
mg
intravesically
Valstar
valrubicin
PDR
DDPD00387
Procyclidine
287.4397
C19H29NO
OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1
DB00387
T3D2773
4919
8448
http://www.drugs.com/cdi/procyclidine.html
4750
-2.0
-
-2.0
-
DRUGBANK
0.0516
L/h/kg
0.86
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.74
L/kg
0.74
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
mg/kg
60.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
60.0
mg/kg
60.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
100.0
%
~100
%
DRUGBANK
DDPD00388
Phenylephrine
167.205
C9H13NO2
CNC[C@H](O)C1=CC(O)=CC=C1
DB00388
6041
8093
http://www.drugs.com/cdi/phenylephrine-solution.html
5818
-2.0
-
-2.0
-
DRUGBANK
38.0
%
38.0
%
PO, oral;
DRUGBANK
126.0
L/h
2100.0
ml/min
Average clearance;
DRUGBANK
340.0
L
340.0
L
DRUGBANK
0.0833333333333333
h
5
min
effective half-life; intravenous injection, IV;
DRUGBANK
2.5
h
2.5
h
elimination half-life; intravenous injection, IV;
DRUGBANK
86.0
%
86
%
Urinary excretion;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
sprays/drops/nostril
3
sprays/drops/nostril
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
4.0
application/day
4
application/day
skin ointment
Vazculep
phenylephrine hydrochloride
PDR
4.0
suppositories/day
4
suppositories/day
Rectal Administration
Vazculep
phenylephrine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
sprays/drops/nostril
3
sprays/drops/nostril
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
4.0
application/day
4
application/day
skin ointment
Vazculep
phenylephrine hydrochloride
PDR
4.0
suppositories/day
4
suppositories/day
Rectal Administration
Vazculep
phenylephrine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
sprays/drops/nostril
3
sprays/drops/nostril
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
4.0
application/day
4
application/day
skin ointment
Vazculep
phenylephrine hydrochloride
PDR
4.0
suppositories/day
4
suppositories/day
Rectal Administration
Vazculep
phenylephrine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
sprays/drops/nostriL
3
sprays/drops/nostriL
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
4.0
appLication/day
4
appLication/day
skin ointment
Vazculep
phenylephrine hydrochloride
PDR
4.0
suppositories/day
4
suppositories/day
Rectal Administration
Vazculep
phenylephrine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
sprays/drops/nostriL
3
sprays/drops/nostriL
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
skin ointment
Vazculep
phenylephrine hydrochloride
PDR
15.0
mg/day
15
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
drop/nostriL
3
drop/nostriL
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
15.0
mg/day
15
mg/day
PO, oral
Vazculep
phenylephrine hydrochloride
PDR
3.0
drop/nostriL
3
drop/nostriL
nasal spray
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
1.0
drop/dose
1
drop/dose
ophthalmic administration
Vazculep
phenylephrine hydrochloride
PDR
DDPD00389
Carbimazole
186.232
C7H10N2O2S
CCOC(=O)N1C=CN(C)C1=S
DB00389
31072
617099
28829
-2.0
-
-2.0
-
DRUGBANK
26.5
%
~25-28
%
Urinary excretion;
DRUGBANK
85.0
%
85
%
DRUGBANK
DDPD00390
Digoxin
780.9385
C41H64O14
[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
DB00390
T3D2670
2724385
4551
http://www.drugs.com/digoxin.html
2006532
-2.0
-
-2.0
-
DRUGBANK
75.0
%
70-80
%
PO, oral;
DRUGBANK
12.5
ng/ml
12.5±2.38
ng/ml
combination drug use;
DRUGBANK
70.0
%
50-90
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
Capsule, PO, Oral;
DRUGBANK
70.0
%
70±13
%
DRUGBANK
1.32
ng/ml
1.32±0.18
ng/ml
combination drug use;
DRUGBANK
1.4
ng/ml
1.4±0.7
ng/ml
PO, oral; heart failure;
DRUGBANK
3.7
ng/ml
3.7±1.0
ng/ml
PO, oral; heart failure;
DRUGBANK
1.0
h
1
h
combination drug use;
DRUGBANK
2.0
h
1-3
h
PO, oral; heart failure;
DRUGBANK
13.0
%
13
%
DRUGBANK
3.05202312138728
L/h/m2
88±44
ml/min/1.73m2
Average clearance; intravenous injection, IV;
DRUGBANK
1.83815028901734
L/h/m2
53.0
ml/min/1.73m2
Average clearance; intravenous injection, IV; Elderly;
DRUGBANK
2.87861271676301
L/h/m2
83.0
ml/min/1.73m2
Average clearance; intravenous injection, IV; young;
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
487.5
L
475-500
L
Apparent volume of distribution;
Age ↓ ;
DRUGBANK
4.1
L/kg
4.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
42.0
h
1.5-2
day
normal,healthy;
DRUGBANK
102.0
h
3.5-5
day
patients;
DRUGBANK
39.0
h
39±13
h
hyperthyroid, HTh ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;congestive heart disease ↑ ;LTh hypothyroid ↑ ;Obesity → ;Age ↑ ;
DRUGBANK
38.0
h
38
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.27
mg/kg
28270.0
ug/kg
PO, oral; Rattus, Rat;
DRUGBANK
7.8
mg/kg
7.8
mg/kg
PO, oral; mouse;
DRUGBANK
0.1
mg/kg
100.0
ug/kg
PO, oral; human, homo sapiens; Female, women;
DRUGBANK
0.075
mg/kg
75.0
ug/kg
PO, oral; human, homo sapiens; Male, men;
DRUGBANK
60.0
%
50-70
%
Urinary excretion; Unchanged drug;
DRUGBANK
60.0
%
60±11
%
Urinary excretion; Unchanged drug;
DRUGBANK
25.0
%
~25
%
DRUGBANK
25.0
%
25±5
%
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
DDPD00391
Sulpiride
341.426
C15H23N3O4S
CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O
DB00391
5355
32168
5162
-2.0
-
-2.0
-
DRUGBANK
30.0
%
25-35
%
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.94
L/kg
0.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
6-8
h
DRUGBANK
6.5
h
6.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00392
Profenamine
312.472
C19H24N2S
CCN(CC)C(C)CN1C2=CC=CC=C2SC2=CC=CC=C12
DB00392
3290
313639
3174
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
DRUGBANK
93.0
%
93
%
DRUGBANK
DDPD00393
Nimodipine
418.4403
C21H26N2O7
COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
DB00393
4497
7575
http://www.drugs.com/cdi/nimodipine.html
4341
-2.0
-
-2.0
-
DRUGBANK
16.5
%
3-30
%
PO, oral;
DRUGBANK
100.0
%
100
%
intravenous injection, IV;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.35
h
1.7-9
h
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
plasma proteins;
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Nimodipine
nimodipine
PDR
48.0
mg/day
48
mg/day
PO, oral
Nimodipine
nimodipine
PDR
60.0
mg/day
60
mg/day
PO, oral
Nimodipine
nimodipine
PDR
360.0
mg/day
360
mg/day
PO, oral
Nimodipine
nimodipine
PDR
30.0
mg/day
30
mg/day
PO, oral
Nimodipine
nimodipine
PDR
48.0
mg/day
48
mg/day
PO, oral
Nimodipine
nimodipine
PDR
60.0
mg/day
60
mg/day
PO, oral
Nimodipine
nimodipine
PDR
360.0
mg/day
360
mg/day
PO, oral
Nimodipine
nimodipine
PDR
DDPD00394
Beclomethasone dipropionate
521.042
C28H37ClO7
[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00394
21700
3002
http://www.drugs.com/cdi/beclomethasone-spray.html
20396
-2.0
-
-2.0
-
DRUGBANK
6.66
ng.h/ml
6660.0
pg.h/ml
PO, oral; different study;
DRUGBANK
6.185
ng.h/ml
6185.0
pg.h/ml
different study; Active metabolite;
DRUGBANK
10.158
ng.h/ml
10158.0
pg.h/ml
PO, oral; different study; Active metabolite;
DRUGBANK
3.66
ng.h/ml
3660.0
pg.h/ml
inhalation, IH; different study; Active metabolite;
DRUGBANK
41.0
%
41.0
%
PO, oral; different study; Active metabolite;
DRUGBANK
44.0
%
44.0
%
inhalation, IH; different study; Active metabolite;
DRUGBANK
0.088
ng/ml
88.0
pg/ml
PO, oral;
DRUGBANK
35.356
ng/ml
35356.0
pg/ml
PO, oral; different study;
DRUGBANK
1.419
ng/ml
1419.0
pg/ml
Active metabolite;
DRUGBANK
2.633
ng/ml
2633.0
pg/ml
different study; Active metabolite;
DRUGBANK
0.703
ng/ml
703.0
pg/ml
PO, oral; different study; Active metabolite;
DRUGBANK
0.31
ng/ml
310.0
pg/ml
inhalation, IH; different study; Active metabolite;
DRUGBANK
0.5
h
0.5
h
PO, oral;
DRUGBANK
0.2
h
0.2
h
PO, oral; different study;
DRUGBANK
0.7
h
0.7
h
Active metabolite;
DRUGBANK
0.2
h
0.2
h
different study; Active metabolite;
DRUGBANK
4.0
h
4
h
PO, oral; different study; Active metabolite;
DRUGBANK
150.0
L/h
150.0
L/h
DRUGBANK
120.0
L/h
120.0
L/h
DRUGBANK
2.16
L/h/kg
36
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L
20.0
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
424.0
L
424.0
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
0.29
L/kg
0.29
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
h
0.5
h
intravenous injection, IV;
DRUGBANK
2.7
h
2.7
h
DRUGBANK
8.8
h
8.8
h
PO, oral;
DRUGBANK
5.7
h
5.7
h
intranasal;
DRUGBANK
0.5
h
0.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3750.0
mg/kg
3750.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
%
<10
%
Urinary excretion;
DRUGBANK
0.64
mg/day
640
mcg/day
inhalation, IH
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.336
mg/day
336
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.32
mg/day
320
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.16
mg/day
160
mcg/day
inhalation, IH
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.336
mg/day
336
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.08
mg/day
80
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.16
mg/day
160
mcg/day
inhalation, IH
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.08
mg/day
80
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.336
mg/day
336
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.32
mg/day
320
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.336
mg/day
336
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.32
mg/day
320
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.336
mg/day
336
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
0.32
mg/day
320
mcg/day
nasal spray
Beconase AQ
beclomethasone dipropionate monohydrate
PDR
DDPD00395
Carisoprodol
260.33
C12H24N2O4
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
DB00395
T3D3491
2576
3419
http://www.drugs.com/carisoprodol.html
2478
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1.5-2
h
high-fat meal;
high-fat meal → ;
DRUGBANK
39.52
L/h
39.52±16.83
L/h
PO, oral;
DRUGBANK
1.115
L/kg
0.93-1.3
L/kg
DRUGBANK
2.0
h
~2
h
terminal half-life;
DRUGBANK
450.0
mg/kg
450.0
mg/kg
intravenous injection, IV; Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
1320.0
mg/kg
1320.0
mg/kg
intragastric;
DRUGBANK
165.0
mg/kg
165.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
2340.0
mg/kg
2340.0
mg/kg
intragastric;
DRUGBANK
124.0
mg/kg
124.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
60.0
%
~60
%
DRUGBANK
1400.0
mg/day
1400
mg/day
PO, oral
Soma
carisoprodol
PDR
1400.0
mg/day
1400
mg/day
PO, oral
Soma
carisoprodol
PDR
1400.0
mg/day
1400
mg/day
PO, oral
Soma
carisoprodol
PDR
DDPD00396
Progesterone
314.4617
C21H30O2
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB00396
5994
17026
http://www.drugs.com/progesterone.html
5773
-2.0
-
-2.0
-
DRUGBANK
7.0
ng/ml
7.0
ng/ml
IM,intramuscular injection;
DRUGBANK
28.0
ng/ml
28.0
ng/ml
IM,intramuscular injection;
DRUGBANK
50.0
ng/ml
50.0
ng/ml
IM,intramuscular injection;
DRUGBANK
3.0
h
3
h
Capsule, PO, Oral;
DRUGBANK
8.0
h
8
h
IM,intramuscular injection;
DRUGBANK
106.0
L/h
106±15
L/h
IM,intramuscular injection;
DRUGBANK
1367.0
L/h
1367±348
L/h
Vaginal Administration;
DRUGBANK
37.5
h
~25-50
h
distribution half-life; gel;
DRUGBANK
0.208333333333333
h
5-20
min
elimination half-life; gel;
DRUGBANK
0.0833333333333333
h
~5
min
elimination half-life; PO, oral;
DRUGBANK
327.0
mg/kg
327.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
97.5
%
96-99
%
DRUGBANK
52.0
%
50-54
%
DRUGBANK
DDPD00397
Phenylpropanolamine
151.209
C9H13NO
[H][C@@](C)(N)[C@]([H])(O)C1=CC=CC=C1
DB00397
26934
80680
http://www.drugs.com/mtm/phenylpropanolamine.html
9875
-2.0
-
-2.0
-
DRUGBANK
2.75
h
2.1-3.4
h
DRUGBANK
1490.0
mg/kg
1490.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00398
Sorafenib
464.825
C21H16ClF3N4O3
CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
DB00398
T3D3533
216239
50924
http://www.drugs.com/cdi/sorafenib.html
187440
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
12.5
%
9-16
%
DRUGBANK
36.5
h
25-48
h
DRUGBANK
77.0
%
77
%
Faeces excretion; PO, oral;
DRUGBANK
19.0
%
19
%
Urinary excretion; PO, oral;
DRUGBANK
99.5
%
99.5
%
plasma proteins;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Nexavar
sorafenib
PDR
800.0
mg/day
800
mg/day
PO, oral
Nexavar
sorafenib
PDR
DDPD00399
Zoledronic acid
272.0896
C5H10N2O7P2
OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
DB00399
T3D2669
68740
46557
61986
-2.0
-
-2.0
-
DRUGBANK
788.0
ng.h/ml
788±181
ng.h/ml
intravenous injection, IV;
DRUGBANK
917.0
ng.h/ml
917±226
ng.h/ml
intravenous injection, IV;
DRUGBANK
370.0
ng/ml
370±78.5
ng/ml
intravenous injection, IV;
DRUGBANK
471.0
ng/ml
471±76.1
ng/ml
intravenous injection, IV;
DRUGBANK
0.317
h
0.317±0.014
h
intravenous injection, IV;
DRUGBANK
0.368
h
0.368±0.005
h
intravenous injection, IV;
DRUGBANK
0.0
%
0
%
DRUGBANK
3.7
L/h
3.7±2.0
L/h
Renal clearance;
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
0.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
146.0
h
146
h
elimination half-life;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39.0
%
39±16
%
Urinary excretion;
DRUGBANK
38.0
%
23-53
%
DRUGBANK
4.0
mg/dose
4
mg/dose
intravenous infusion, iv in drop
Reclast
zoledronic acid
PDR
5.0
mg/dose
5
mg/dose
intravenous infusion, iv in drop
Reclast
zoledronic acid
PDR
4.0
mg/dose
4
mg/dose
intravenous infusion, iv in drop
Reclast
zoledronic acid
PDR
5.0
mg/dose
5
mg/dose
intravenous infusion, iv in drop
Reclast
zoledronic acid
PDR
DDPD00400
Griseofulvin
352.766
C17H17ClO6
COC1=CC(OC)=C(Cl)C2=C1C(=O)[C@]1(O2)[C@H](C)CC(=O)C=C1OC
DB00400
T3D4696
441140
27779
http://www.drugs.com/cdi/griseofulvin-microsize.html
389934
-2.0
-
-2.0
-
DRUGBANK
47.5
%
25-70
%
PO, oral;
DRUGBANK
15.0
h
9-21
h
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
750.0
mg/day
750
mg/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
1000.0
mg/day
1
g/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
750.0
mg/day
750
mg/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
1000.0
mg/day
1
g/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
750.0
mg/day
750
mg/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
1000.0
mg/day
1
g/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
750.0
mg/day
750
mg/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
1000.0
mg/day
1
g/day
PO, oral
Griseofulvin Oral Suspension
griseofulvin
PDR
DDPD00401
Nisoldipine
388.4144
C20H24N2O6
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C
DB00401
4499
76917
http://www.drugs.com/cdi/nisoldipine-extended-release-tablets.html
4343
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5.0
%
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
L/kg
5.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.5
h
7-12
h
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
34.0
mg/day
34
mg/day
PO, oral
Sular
nisoldipine
PDR
34.0
mg/day
34
mg/day
PO, oral
Sular
nisoldipine
PDR
DDPD00402
Eszopiclone
388.808
C17H17ClN6O3
CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1
DB00402
T3D4552
969472
53760
839530
-2.0
-
-2.0
-
DRUGBANK
278.0
ng.h/ml
278.0
ng.h/ml
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
36.0
h
24-48
h
PO, oral;
DRUGBANK
11.04
L/h
184.0
ml/min
Average clearance; normal,healthy; young;
DRUGBANK
89.9
L
89.9
L
DRUGBANK
6.1
h
6.1
h
normal,healthy; patients;
hepatopathy，LD ↑ ;Elderly ↑ ;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
10.0
%
~10
%
Urinary excretion;
DRUGBANK
55.5
%
52-59
%
plasma proteins;
DRUGBANK
3.0
mg/day
3
mg/day
PO, oral
Lunesta
eszopiclone
PDR
2.0
mg/day
2
mg/day
PO, oral
Lunesta
eszopiclone
PDR
DDPD00403
Ceruletide
1352.405
C58H73N13O21S2
[H][C@](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
DB00403
16129675
59219
10481982
-2.0
-
-2.0
-
DRUGBANK
DDPD00404
Alprazolam
308.765
C17H13ClN4
CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
DB00404
T3D2777
2118
2611
http://www.drugs.com/alprazolam.html
2034
-2.0
-
-2.0
-
DRUGBANK
87.5
%
84-91
%
Tablet, PO, oral;
DRUGBANK
88.0
%
88±16
%
PO, oral; adults;
DRUGBANK
17.0
ng/ml
12-22
mcg/L
Oral single dose;
DRUGBANK
21.0
ng/ml
21(15-32)
ng/ml
PO, oral; adults;
DRUGBANK
1.8
h
1.8
h
Tablet, PO, oral;
DRUGBANK
1.5
h
1.5(0.5-3.0)
h
PO, oral; adults;
DRUGBANK
0.054
L/h/kg
0.90±0.21
ml/min/kg
Total clearance; PO, oral;
DRUGBANK
0.1278
L/h/kg
2.13±0.54
ml/min/kg
Total clearance; PO, oral; enzyme-inducers;
DRUGBANK
0.066
L/h/kg
0.70-1.5
ml/min/kg
DRUGBANK
0.0444
L/h/kg
0.74±0.14
ml/min/kg
hydrolysis; Male, men;
Elderly ↓ ;Hepatitis, Hep ↓ ;Obesity ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.0444
L/h/kg
0.74
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.05
L/kg
0.8-1.3
L/kg
PO, oral;
DRUGBANK
0.72
L/kg
0.72±0.12
L/kg
Elderly → ;Obesity → ;Hepatitis, Hep → ;
DRUGBANK
0.8
L/kg
0.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.2
h
11.2
h
normal,healthy; patients;
Asian ↑ ;
DRUGBANK
16.3
h
16.3
h
Elderly;
DRUGBANK
35.55
h
5.8-65.3
h
alcoholic liver disease; patients;
DRUGBANK
25.15
h
9.9-40.4
h
Obesity; patients;
DRUGBANK
12.5
h
9-16
h
different study;
DRUGBANK
12.0
h
12±2
h
Male, men;
Obesity ↑ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ;
DRUGBANK
12.0
h
12±2
h
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1251.0
mg/kg
331-2171
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1020.0
mg/kg
1020.0
mg/kg
PO, oral; mouse;
DRUGBANK
20.0
%
20
%
Urinary excretion; Unchanged drug;
DRUGBANK
80.0
%
~80
%
DRUGBANK
71.0
%
71±3
%
Elderly → ;Hepatic cirrhosis, cirr ↑ ;Obesity → ;
DRUGBANK
0.06
mg/kg/day
0.06
mg/kg/day
PO, oral
Xanax
alprazolam
PDR
10.0
mg/day
10
mg/day
PO, oral
Xanax
alprazolam
PDR
0.06
mg/kg/day
0.06
mg/kg/day
PO, oral
Xanax
alprazolam
PDR
10.0
mg/day
10
mg/day
PO, oral
Xanax
alprazolam
PDR
DDPD00405
Dexbrompheniramine
319.239
C16H19BrN2
CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1
DB00405
16960
59269
16068
-2.0
-
-2.0
-
DRUGBANK
25.0
h
25
h
DRUGBANK
DDPD00406
Gentian violet cation
372.5258
C25H30N3
CN(C)C1=CC=C(C=C1)C(C1=CC=C(C=C1)N(C)C)=C1C=CC(C=C1)=[N+](C)C
DB00406
T3D4821
3468
77181
http://www.drugs.com/cons/gentian-violet-topical.html
3349
-2.0
-
-2.0
-
DRUGBANK
420.0
mg/kg
420.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
420.0
mg/kg
420.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00408
Loxapine
327.808
C18H18ClN3O
CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2
DB00408
T3D2779
3964
50841
http://www.drugs.com/cdi/loxapine.html
3827
-2.0
-
-2.0
-
DRUGBANK
33.0
%
33.0
%
IM,intramuscular injection; Male, men;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
65.0
mg/kg
65.0
mg/kg
PO, oral; mouse;
DRUGBANK
65.0
mg/kg
65.0
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Loxapine
loxapine
PDR
250.0
mg/day
250
mg/day
PO, oral
Loxapine
loxapine
PDR
10.0
mg/day
10
mg/day
inhalation, IH
qd
Loxapine
loxapine
PDR
15.0
mg/day
15
mg/day
PO, oral
Loxapine
loxapine
PDR
100.0
mg/day
100
mg/day
PO, oral
Loxapine
loxapine
PDR
250.0
mg/day
250
mg/day
PO, oral
Loxapine
loxapine
PDR
10.0
mg/day
10
mg/day
inhalation, IH
qd
Loxapine
loxapine
PDR
DDPD00409
Remoxipride
371.269
C16H23BrN2O3
CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC
DB00409
54477
92948
49195
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90.0
%
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.65
L/kg
0.65
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
4-7
h
DRUGBANK
5.5
h
5.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
93.5
%
89-98
%
DRUGBANK
DDPD00410
Mupirocin
500.6222
C26H44O9
C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O
DB00410
446596
7025
http://www.drugs.com/cdi/mupirocin-cream.html
393914
-2.0
-
-2.0
-
DRUGBANK
0.5
h
~20-40
min
elimination half-life; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
0.916666666666667
h
~30-80
min
elimination half-life;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
>95
%
DRUGBANK
5.0
days
5
days
nasal spray
bid
Bactroban Cream
mupirocin calcium
PDR
5.0
days
5
days
nasal spray
bid
Bactroban Cream
mupirocin calcium
PDR
5.0
days
5
days
nasal spray
bid
Bactroban Cream
mupirocin calcium
PDR
5.0
days
5
days
nasal spray
bid
Bactroban Cream
mupirocin calcium
PDR
DDPD00411
Carbamoylcholine
147.1955
C6H15N2O2
C[N+](C)(C)CCOC(N)=O
DB00411
5831
3385
http://www.drugs.com/cdi/carbachol-drops.html
2454
-2.0
-
-2.0
-
DRUGBANK
15.0
mg/kg
15.0
mg/kg
PO, oral; mouse;
DRUGBANK
40.0
mg/kg
40.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.5
ml/dose
0.5
ml/dose
ophthalmic administration
Miostat
carbachol
PDR
6.0
drop/day
6
drop/day
ophthalmic administration
Miostat
carbachol
PDR
0.5
ml/dose
0.5
ml/dose
ophthalmic administration
Miostat
carbachol
PDR
6.0
drop/day
6
drop/day
ophthalmic administration
Miostat
carbachol
PDR
DDPD00412
Rosiglitazone
357.427
C18H19N3O3S
CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1
DB00412
77999
50122
http://www.drugs.com/cdi/rosiglitazone.html
70383
-2.0
-
-2.0
-
DRUGBANK
99.0
%
99.0
%
PO, oral;
DRUGBANK
99.0
%
99.0
%
DRUGBANK
598.0
ng/ml
598±117
ng/ml
Oral single dose;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
2.75
h
2.75
h
PO, oral; food;
food ↑ ;
DRUGBANK
1.0
h
1.0
h
Oral single dose;
DRUGBANK
3.03
L/h
3.03±0.87
L/h
Total clearance; PO, oral; fasting;
DRUGBANK
2.89
L/h
2.89±0.71
L/h
Total clearance; PO, oral; fasting;
DRUGBANK
2.85
L/h
2.85±0.69
L/h
Total clearance; PO, oral; fasting;
DRUGBANK
2.97
L/h
2.97±0.81
L/h
Total clearance; PO, oral; food;
DRUGBANK
3.15
L/h
3.15
L/h
Average clearance; pediatric patients;
DRUGBANK
0.0408
L/h/kg
0.68±0.16
ml/min/kg
apparent clearance; type 2 diabetes; Male, men; Female, women;
DRUGBANK
0.0294
L/h/kg
0.49
ml/min/kg
Average clearance;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.039
L/h/kg
0.65
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.6
L
17.6
L
PO, oral;
DRUGBANK
13.5
L
13.5
L
pediatric patients;
DRUGBANK
0.25
L/kg
0.25±0.08
L/kg
Apparent volume of distribution; type 2 diabetes; Male, men; Female, women;
DRUGBANK
0.21
L/kg
0.21
L/kg
Average volume of distribution;
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
Oral single dose;
dose → ;
DRUGBANK
3.5
h
3-4
h
PO, oral;
chronic liver disease ↑ ;
DRUGBANK
3.9
h
3.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
64.0
%
~64
%
Urinary excretion; PO, oral; intravenous injection, IV;
DRUGBANK
23.0
%
~23
%
Faeces excretion; PO, oral; intravenous injection, IV;
DRUGBANK
0.0
%
~0
%
Urinary excretion; type 2 diabetes; human, homo sapiens; Unchanged drug;
DRUGBANK
99.8
%
99.8
%
plasma proteins;
DRUGBANK
99.8
%
99.8
%
type 2 diabetes; human, homo sapiens;
hepatopathy，LD ↓ ;
DRUGBANK
8.0
mg/day
8
mg/day
PO, oral
Avandia
rosiglitazone maleate
PDR
8.0
mg/day
8
mg/day
PO, oral
Avandia
rosiglitazone maleate
PDR
8.0
mg/day
8
mg/day
PO, oral
Avandia
rosiglitazone maleate
PDR
8.0
mg/day
8
mg/day
PO, oral
Avandia
rosiglitazone maleate
PDR
DDPD00413
Pramipexole
211.327
C10H17N3S
CCCN[C@H]1CCC2=C(C1)SC(N)=N2
DB00413
T3D2783
119570
8356
http://www.drugs.com/cdi/pramipexole.html
106770
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
DRUGBANK
90.0
%
>90
%
PO, oral; normal,healthy;
DRUGBANK
1.6
ng/ml
1.6±0.23
ng/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
2.1
ng/ml
2.1±0.25
ng/ml
PO, oral; Female, women; normal,healthy;
DRUGBANK
1.5
h
1-2
h
PO, oral; normal,healthy;
DRUGBANK
0.0
%
~0
%
DRUGBANK
24.0
L/h
400.0
ml/min
DRUGBANK
0.492
L/h/kg
8.2±1.4
ml/min/kg
apparent clearance; normal,healthy; Male, men; Female, women;
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Parkinson ↓ ;
DRUGBANK
0.432
L/h/kg
7.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
L
~500
L
DRUGBANK
7.3
L/kg
7.3±1.7
L/kg
Apparent volume of distribution; normal,healthy; Male, men; Female, women;
DRUGBANK
7.0
L/kg
7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.25
h
~8.5-12
h
DRUGBANK
11.6
h
11.6±2.57
h
normal,healthy; adults; Male, men; Female, women;
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
12.4
h
12.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
800.0
mg/kg
>800
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
90.0
%
~90
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
15.0
%
~15
%
plasma proteins;
DRUGBANK
15.0
%
15
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
4.5
mg/day
4.5
mg/day
PO, oral
Mirapex
pramipexole dihydrochloride
PDR
4.5
mg/day
4.5
mg/day
PO, oral
Mirapex
pramipexole dihydrochloride
PDR
DDPD00414
Acetohexamide
324.395
C15H20N2O4S
CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
DB00414
1989
28052
http://www.drugs.com/mtm/acetohexamide.html
1912
-2.0
-
-2.0
-
DRUGBANK
1.3
h
1.3
h
elimination half-life;
DRUGBANK
5.5
h
~5-6
h
Active metabolite;
DRUGBANK
5000.0
mg/kg
5.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
2500.0
mg/kg
>2500
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD00415
Ampicillin
349.405
C16H19N3O4S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
DB00415
6249
28971
http://www.drugs.com/cdi/ampicillin.html
6013
-2.0
-
-2.0
-
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
2000.0
mg/day
2
g/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
2000.0
mg/day
2
g/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
2000.0
mg/day
2
g/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
2000.0
mg/day
2
g/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV
Ampicillin Capsules and Oral Suspension
ampicillin trihydrate
PDR
DDPD00416
Metocurine iodide
906.6279
C40H48I2N2O6
[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3
DB00416
24244
6901
22666
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
DRUGBANK
35.0
%
35
%
DRUGBANK
DDPD00417
Phenoxymethylpenicillin
350.39
C16H18N2O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O
DB00417
6869
27446
http://www.drugs.com/penicillin.html
6607
-2.0
-
-2.0
-
DRUGBANK
42.5
%
25-60
%
DRUGBANK
450.0
ng/ml
200-700
ng/ml
PO, oral;
DRUGBANK
4000.0
ng/ml
3-5
ug/ml
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
DRUGBANK
52.5
%
35-70
%
Inactive metabolite; Urinary excretion;
DRUGBANK
0.408
L/h/kg
6.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.4
L
35.4
L
at steady state; intravenous injection, IV;
DRUGBANK
0.41
L/kg
0.41
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
h
~30
min
PO, oral;
DRUGBANK
4.0
h
4
h
RD, renal impairment, Renal disease，including uremia;
DRUGBANK
0.84
h
0.84
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1040.0
mg/kg
>1040
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
25.0
%
25
%
Urinary excretion; Infants; Children;
renal insufficiency → ;
DRUGBANK
65.0
%
~50-80
%
plasma proteins; PO, oral;
DRUGBANK
2000.0
mg/day
2
g/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
2000.0
mg/day
2
g/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
2000.0
mg/day
2
g/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
2000.0
mg/day
2
g/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
2000.0
mg/day
2
g/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Penicillin V Potassium
penicillin V potassium
PDR
DDPD00418
Secobarbital
238.2829
C12H18N2O3
CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
DB00418
T3D2784
5193
9073
http://www.drugs.com/cdi/secobarbital.html
5005
-2.0
-
-2.0
-
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Seconal Sodium
secobarbital sodium
PDR
100.0
mg
100
mg
PO, oral
Seconal Sodium
secobarbital sodium
PDR
300.0
mg/day
300
mg/day
PO, oral
Seconal Sodium
secobarbital sodium
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Seconal Sodium
secobarbital sodium
PDR
100.0
mg
100
mg
PO, oral
Seconal Sodium
secobarbital sodium
PDR
300.0
mg/day
300
mg/day
PO, oral
Seconal Sodium
secobarbital sodium
PDR
DDPD00419
Miglustat
219.278
C10H21NO4
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
DB00419
51634
50381
http://www.drugs.com/cdi/miglustat.html
46764
-2.0
-
-2.0
-
DRUGBANK
97.0
%
97.0
%
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
6.5
h
~6-7
h
effective half-life;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Zavesca
miglustat
PDR
300.0
mg/day
300
mg/day
PO, oral
Zavesca
miglustat
PDR
DDPD00420
Promazine
284.419
C17H20N2S
CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12
DB00420
T3D2565
4926
8459
4757
-2.0
-
-2.0
-
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.1
L/kg
8.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.9
h
7.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
140.0
mg/kg
140.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
94.0
%
94
%
DRUGBANK
DDPD00421
Spironolactone
416.573
C24H32O4S
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
DB00421
T3D4753
5833
9241
http://www.drugs.com/spironolactone.html
5628
-2.0
-
-2.0
-
DRUGBANK
2103.0
ng.h/ml
2103.0
ng.h/ml
PO, oral;
DRUGBANK
4544.0
ng.h/ml
4544.0
ng.h/ml
PO, oral; food;
food ↑ ;
DRUGBANK
95.4
%
95.4
%
PO, oral; food;
food ↑ ;
DRUGBANK
209.0
ng/ml
209.0
ng/ml
PO, oral;
DRUGBANK
301.0
ng/ml
301.0
ng/ml
PO, oral; food;
food ↑ ;
DRUGBANK
185.0
ng/ml
185±51
ng/ml
PO, oral;
DRUGBANK
231.0
ng/ml
231±49
ng/ml
PO, oral; Active metabolite;
DRUGBANK
571.0
ng/ml
571±74
ng/ml
PO, oral; Active metabolite;
DRUGBANK
202.0
ng/ml
202±54
ng/ml
PO, oral; Active metabolite;
DRUGBANK
2.6
h
2.6
h
DRUGBANK
4.3
h
4.3
h
Active metabolite;
DRUGBANK
2.28
h
2.28
h
PO, oral;
DRUGBANK
3.05
h
3.05
h
PO, oral; food;
food ↑ ;
DRUGBANK
1.0
h
1.0
h
PO, oral;
DRUGBANK
2.9
h
2.9±0.6
h
PO, oral; Active metabolite;
DRUGBANK
1.8
h
1.8±0.5
h
PO, oral; Active metabolite;
DRUGBANK
3.1
h
3.1±0.9
h
PO, oral; Active metabolite;
DRUGBANK
5.58
L/h/kg
93.0
ml/min/kg
apparent clearance;
DRUGBANK
10.0
L/kg
10.0
L/kg
Apparent volume of distribution;
DRUGBANK
1.4
h
1.4
h
DRUGBANK
1.3
h
1.3±0.3
h
Oral single dose;
chronic liver disease ↑ ;
DRUGBANK
11.2
h
11.2±2.3
h
Active metabolite; Oral single dose;
chronic liver disease ↑ ;
DRUGBANK
2.8
h
2.8±0.4
h
Active metabolite; Oral single dose;
chronic liver disease ↑ ;
DRUGBANK
10.1
h
10.1±2.3
h
Active metabolite; Oral single dose;
chronic liver disease ↑ ;
DRUGBANK
1000.0
mg/kg
>1
g/kg
PO, oral; mouse; Rattus, Rat; rabbit;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; mouse; Rattus, Rat; rabbit;
DRUGBANK
49.0
%
42-56
%
Urinary excretion;
DRUGBANK
14.4
%
14.2-14.6
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
98.0
%
98
%
DRUGBANK
90.0
%
>90
%
DRUGBANK
4.0
mg/kg/day
4
mg/kg/day
PO, oral
CaroSpir
carospir
PDR
200.0
mg/day
200
mg/day
PO, oral
CaroSpir
carospir
PDR
400.0
mg/day
400
mg/day
PO, oral
CaroSpir
carospir
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
CaroSpir
carospir
PDR
200.0
mg/day
200
mg/day
PO, oral
CaroSpir
carospir
PDR
400.0
mg/day
400
mg/day
PO, oral
CaroSpir
carospir
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
CaroSpir
carospir
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
CaroSpir
carospir
PDR
DDPD00422
Methylphenidate
233.3062
C14H19NO2
COC(=O)C(C1CCCCN1)C1=CC=CC=C1
DB00422
T3D2786
4158
84276
http://www.drugs.com/methylphenidate.html
4015
-2.0
-
-2.0
-
DRUGBANK
85.95
ng.h/ml
50.4-121.5
ng.h/ml
Children; Drug form;
DRUGBANK
30.0
%
30(11-52)
%
Tablet, PO, oral; immediate release formulation; Drug form;
DRUGBANK
22.0
%
22±8
%
PO, oral; Raceme D;
DRUGBANK
5.0
%
5±3
%
PO, oral; Raceme L;
DRUGBANK
10.5
ng/ml
6-15
ng/ml
Children; Drug form;
DRUGBANK
7.8
ng/ml
7.8
ng/ml
PO, oral; Children; Drug form;
DRUGBANK
10.8
ng/ml
10.8
ng/ml
PO, oral; adults; Drug form;
DRUGBANK
18.0
ng/ml
18±4.3
ng/ml
Oral single dose; Raceme D;
DRUGBANK
3.0
ng/ml
3.0±0.9
ng/ml
Oral single dose; Raceme L;
DRUGBANK
8.0
h
6-10
h
PO, oral; Drug form;
DRUGBANK
8.75
h
8.1-9.4
h
Children; Drug form;
DRUGBANK
2.0
h
1-3
h
PO, oral; Drug form;
DRUGBANK
2.4
h
2.4±0.8
h
Oral single dose; Raceme D;
DRUGBANK
2.1
h
2.1±0.6
h
Oral single dose; Raceme L;
DRUGBANK
10.2
L/h/kg
10.2
L/h/kg
Average clearance; PO, oral; Children; adults;
DRUGBANK
0.565
L/h/kg
0.565
L/h/kg
Average clearance; intravenous injection, IV; normal,healthy; adults;
DRUGBANK
0.402
L/h/kg
6.7±2.0
ml/min/kg
normal,healthy; adults; Male, men;
DRUGBANK
0.72
L/h/kg
12±4.7
ml/min/kg
normal,healthy; adults; Male, men;
DRUGBANK
0.5652
L/h/kg
9.42
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L/kg
~20
L/kg
Apparent volume of distribution; Children;
DRUGBANK
2.23
L/kg
2.23
L/kg
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
2.7
L/kg
2.7±1.1
L/kg
normal,healthy; adults; Male, men;
DRUGBANK
1.8
L/kg
1.8±0.9
L/kg
normal,healthy; adults; Male, men;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
~3.5
h
adults;
DRUGBANK
2.4
h
2.4
h
elimination half-life; Children;
DRUGBANK
2.1
h
2.1
h
elimination half-life; adults;
DRUGBANK
2.4
h
2.4
h
elimination half-life; Children; immediate release formulation;
DRUGBANK
2.1
h
2.1
h
elimination half-life; adults; immediate release formulation;
DRUGBANK
6.0
h
6.0±1.7
h
Raceme D;
DRUGBANK
2.2
h
2.2
h
DRUGBANK
3.6
h
3.6±1.1
h
Raceme D/L;
DRUGBANK
4.8
h
4.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
190.0
mg/kg
190.0
mg/kg
PO, oral; mouse;
DRUGBANK
190.0
mg/kg
190.0
mg/kg
PO, oral; mouse;
DRUGBANK
87.5
%
78-97
%
Urinary excretion; PO, oral; immediate release formulation;
DRUGBANK
2.0
%
1-3
%
Faeces excretion; PO, oral; immediate release formulation;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.3
%
1.3±0.5
%
Urinary excretion; Raceme D; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
0.6
%
0.6±0.3
%
Urinary excretion; Raceme D/L; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
15.0
%
15±5
%
plasma proteins;
DRUGBANK
15.5
%
15-16
%
Raceme D; Raceme D/L;
DRUGBANK
85.0
mg/day
85
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
54.0
mg/day
54
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
51.8
mg/day
51.8
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
80.0
mg/day
30
mg/9-hour
Transdermal preparations
Ritalin LA
methylphenidate hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
104.0
mg/day
104
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
72.0
mg/day
72
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
85.0
mg/day
85
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
72.0
mg/day
72
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
51.8
mg/day
51.8
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
0.138888888888889
mg/day
30
mg/9-hour
Transdermal preparations
Ritalin LA
methylphenidate hydrochloride
PDR
104.0
mg/day
104
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Ritalin LA
methylphenidate hydrochloride
PDR
DDPD00423
Methocarbamol
241.2405
C11H15NO5
COC1=C(OCC(O)COC(N)=O)C=CC=C1
DB00423
4107
77498
http://www.drugs.com/methocarbamol.html
3964
-2.0
-
-2.0
-
DRUGBANK
52500.0
ng.h/ml
52.5
mg.h/l
normal,healthy;
DRUGBANK
87100.0
ng.h/ml
87.1
mg.h/l
DRUGBANK
21300.0
ng/ml
21.3
mg/L
normal,healthy;
DRUGBANK
28700.0
ng/ml
28.7
mg/L
DRUGBANK
1.1
h
1.1
h
normal,healthy;
DRUGBANK
1.1
h
1.1
h
DRUGBANK
0.5
h
0.5
h
different study;
DRUGBANK
0.5
L/h/kg
0.2-0.8
L/h/kg
DRUGBANK
0.7285
L/kg
515-942
mL/kg
horse; at steady state;
DRUGBANK
1.14
h
1.14
h
elimination half-life; normal,healthy;
DRUGBANK
1.24
h
1.24
h
elimination half-life; renal insufficiency;
DRUGBANK
1.875
h
1.6-2.15
h
DRUGBANK
3576.2
mg/kg
3576.2
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
88.85
%
88.85
%
Urinary excretion; dog;
DRUGBANK
2.14
%
2.14
%
Faeces excretion; dog;
DRUGBANK
88.5
%
84.5-92.5
%
Urinary excretion; Rattus, Rat;
DRUGBANK
6.65
%
0-13.3
%
Faeces excretion; Rattus, Rat;
DRUGBANK
0.0
%
46-50
%
normal,healthy; patients;
DRUGBANK
48.1
%
47.3-48.9
%
DRUGBANK
DDPD00424
Hyoscyamine
289.3694
C17H23NO3
CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
DB00424
T3D3096
154417
17486
http://www.drugs.com/cdi/hyoscyamine.html
10246417
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
2.75
h
2-3.5
h
DRUGBANK
95.0
mg/kg
95.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
50.0
%
50
%
DRUGBANK
4.0
tablets/day
4
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
1.5
mg/day
1.5
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
2.0
tablets/day
2
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.75
mg/day
0.75
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.005
mg/kg/dose
5
mcg/kg/dose
subcutaneous injection, SC;IM,intramuscular injection;intravenous infusion, iv in drop;
Levsin Tablets
hyoscyamine sulfate
PDR
2.0
tablets/day
2
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.563
mg/day
0.563
mg/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
0.75
mg/day
0.75
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.005
mg/kg/dose
5
mcg/kg/dose
subcutaneous injection, SC;IM,intramuscular injection;intravenous infusion, iv in drop;
Levsin Tablets
hyoscyamine sulfate
PDR
2.0
tablets/day
2
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.375
mg/day
0.375
mg/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
0.75
mg/day
0.75
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.005
mg/kg/dose
5
mcg/kg/dose
subcutaneous injection, SC;IM,intramuscular injection;intravenous infusion, iv in drop;
Levsin Tablets
hyoscyamine sulfate
PDR
2.0
tablets/day
2
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.188
mg/day
0.188
mg/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
0.75
mg/day
0.75
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
0.005
mg/kg/dose
5
mcg/kg/dose
subcutaneous injection, SC;IM,intramuscular injection;intravenous infusion, iv in drop;
Levsin Tablets
hyoscyamine sulfate
PDR
48.0
drop/day
48
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
36.0
drop/day
36
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
30.0
drop/day
30
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
24.0
drop/day
24
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
4.0
tabLets/day
4
tabLets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
1.5
mg/day
1.5
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
4.0
tablets/day
4
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
1.5
mg/day
1.5
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
4.0
tablets/day
4
tablets/day
Tablet,PO，oral
Levsin Tablets
hyoscyamine sulfate
PDR
1.5
mg/day
1.5
mg/day
PO, oral
Levsin Tablets
hyoscyamine sulfate
PDR
48.0
drop/day
48
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
36.0
drop/day
36
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
30.0
drop/day
30
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
24.0
drop/day
24
drop/day
Liquid
Levsin Tablets
hyoscyamine sulfate
PDR
DDPD00425
Zolpidem
307.3895
C19H21N3O
CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
DB00425
T3D2787
5732
10125
http://www.drugs.com/zolpidem.html
5530
-2.0
-
-2.0
-
DRUGBANK
72.0
%
72±7
%
PO, oral;
DRUGBANK
59.0
ng/ml
59.0
ng/ml
DRUGBANK
121.0
ng/ml
121.0
ng/ml
DRUGBANK
107.5
ng/ml
76-139
ng/ml
Oral single dose; adults; young;
DRUGBANK
1.6
h
1.6
h
DRUGBANK
1.6
h
1.6
h
DRUGBANK
1.8
h
1.0-2.6
h
Oral single dose; adults; young;
DRUGBANK
0.0153
L/h/kg
0.24-0.27
ml/min/kg
Total clearance;
DRUGBANK
0.27
L/h/kg
4.5±0.7
ml/min/kg
hydrolysis;
Children ↑ ;Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.258
L/h/kg
4.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.61
L/kg
0.54-0.68
L/kg
human, homo sapiens;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.68
L/kg
0.68±0.06
L/kg
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.54
L/kg
0.54
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
h
2.6
h
elimination half-life;
DRUGBANK
2.5
h
2.5
h
elimination half-life;
DRUGBANK
1.9
h
1.9±0.2
h
Children ↓ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
695.0
mg/kg
695.0
mg/kg
PO, oral; male rat;
DRUGBANK
695.0
mg/kg
695.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
92.5
%
92.5±0.1
%
DRUGBANK
92.0
%
92
%
RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
10.0
mg/day
10
mg/day
Tablet,PO，oral
Edluar
zolpidem tartrate
PDR
10.0
mg/day
10
mg/day
sublingual spray
Edluar
zolpidem tartrate
PDR
10.0
mg/day
10
mg/day
Tablet,PO，oral
Edluar
zolpidem tartrate
PDR
12.5
mg/day
12.5
mg/day
Tablet,PO，oral
Edluar
zolpidem tartrate
PDR
10.0
mg/day
10
mg/day
sublingual
Edluar
zolpidem tartrate
PDR
1.75
mg /night
1.75
mg /night
sublingual
Edluar
zolpidem tartrate
PDR
3.5
mg /night
3.5
mg /night
sublingual
Edluar
zolpidem tartrate
PDR
5.0
mg/day
5
mg/day
Tablet,PO，oral
Edluar
zolpidem tartrate
PDR
5.0
mg/day
5
mg/day
sublingual spray
Edluar
zolpidem tartrate
PDR
6.25
mg/day
6.25
mg/day
Tablet,PO，oral
Edluar
zolpidem tartrate
PDR
5.0
mg/day
5
mg/day
sublingual
Edluar
zolpidem tartrate
PDR
1.75
mg/day
1.75
mg/night
sublingual
Edluar
zolpidem tartrate
PDR
DDPD00426
Famciclovir
321.3318
C14H19N5O4
CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O
DB00426
3324
4974
http://www.drugs.com/cdi/famciclovir.html
3207
-2.0
-
-2.0
-
DRUGBANK
77.0
%
77.0
%
DRUGBANK
36.6
L/h
36.6±6.3
L/h
DRUGBANK
0.48
L/h/kg
0.48±0.09
L/h/kg
DRUGBANK
1.08
L/kg
1.08±0.17
L/kg
normal,healthy; Male, men;
DRUGBANK
10.0
h
10
h
DRUGBANK
22.5
%
20-25
%
DRUGBANK
2000.0
mg/day
2000
mg/day
PO, oral
Famvir
famciclovir
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Famvir
famciclovir
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Famvir
famciclovir
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Famvir
famciclovir
PDR
DDPD00427
Triprolidine
278.3914
C19H22N2
CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1
DB00427
5282443
84116
http://www.drugs.com/cdi/triprolidine-suspension.html
4445597
-2.0
-
-2.0
-
DRUGBANK
5.0
h
4-6
h
DRUGBANK
DDPD00428
Streptozocin
265.2206
C8H15N3O7
CN(N=O)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O
DB00428
T3D2788
29327
9288
http://www.drugs.com/cdi/streptozocin.html
27273
-2.0
-
-2.0
-
DRUGBANK
21.0
%
17-25
%
PO, oral;
DRUGBANK
0.166666666666667
h
5-15
min
DRUGBANK
1500.0
mg/m2/dose
1500
mg/m2/dose
intravenous injection, IV
Zanosar
streptozocin
PDR
1500.0
mg/m2/dose
1500
mg/m2/dose
intravenous injection, IV
Zanosar
streptozocin
PDR
1500.0
mg/m2/dose
1500
mg/m2/dose
intravenous injection, IV
Zanosar
streptozocin
PDR
1500.0
mg/m2/dose
1500
mg/m2/dose
intravenous injection, IV
Zanosar
streptozocin
PDR
DDPD00429
Carboprost tromethamine
489.6426
C25H47NO8
OCC([NH3+])(CO)CO.CCCCC[C@@](O)(C)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)[O-]
DB00429
45266502
3404
http://www.drugs.com/mtm/carboprost.html
4444531
-2.0
-
-2.0
-
DRUGBANK
12.0
mg
12
mg
IM,intramuscular injection
Hemabate
carboprost tromethamine
PDR
2.0
mg
2
mg
IM,intramuscular injection
Hemabate
carboprost tromethamine
PDR
DDPD00430
Cefpiramide
612.637
C25H24N8O7S2
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O
DB00430
636405
59213
552192
-2.0
-
-2.0
-
DRUGBANK
0.0288
L/h/kg
0.48
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.44
h
4.44
h
DRUGBANK
5.4
h
5.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00431
Lindane
290.83
C6H6Cl6
Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl
DB00431
T3D0032
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
727
32888
http://www.drugs.com/cdi/lindane-lotion.html
10481896
-2.0
-
-2.0
-
DRUGBANK
28.0
ng/ml
28.0
ng/ml
skin/dermal;
DRUGBANK
6.0
h
6
h
skin/dermal;
DRUGBANK
18.0
h
18
h
DRUGBANK
139.0
mg/kg
88-190
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
750.0
mg/kg
500-1000
mg/kg
skin/dermal; Isomers; Rattus, Rat;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
skin/dermal; Isomers; mouse;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
skin/dermal; Isomers; guinea pigs;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
skin/dermal; Isomers; rabbit;
DRUGBANK
139.0
mg/kg
88-190
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
750.0
mg/kg
500-1000
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
skin/dermal; mouse;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
skin/dermal; guinea pigs;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
76.0
mg/kg
76.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
125.0
mg/kg
125.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
0.003
mg/kg/day
0.003
mg/kg/day
PO, oral;
DRUGBANK
1e-05
mg/kg/day
1e-05
mg/kg/day
PO, oral;
DRUGBANK
0.003
mg/kg/day
0.003
mg/kg/day
PO, oral;
DRUGBANK
1e-05
mg/kg/day
1e-05
mg/kg/day
PO, oral;
DRUGBANK
91.0
%
91
%
DRUGBANK
60.0
ml
60
ml
skin/dermal
Lindane Lotion
lindane
PDR
0.0
0
skin/dermal
Lindane Lotion
lindane
PDR
60.0
ml
60
ml
skin/dermal
Lindane Lotion
lindane
PDR
0.0
0
skin/dermal
Lindane Lotion
lindane
PDR
60.0
ml
60
ml
skin/dermal
Lindane Lotion
lindane
PDR
0.0
0
skin/dermal
Lindane Lotion
lindane
PDR
0.0
0
Lindane Lotion
lindane
PDR
DDPD00432
Trifluridine
296.1999
C10H11F3N2O5
OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F
DB00432
6256
75179
http://www.drugs.com/cdi/trifluridine-drops.html
6020
-2.0
-
-2.0
-
DRUGBANK
57.0
%
>57
%
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
10.5
L/h
10.5
L/h
Total clearance; PO, oral; tumor; patients;
DRUGBANK
21.0
L
21.0
L
Apparent volume of distribution; tumor; patients;
DRUGBANK
0.25
h
12-18
min
intravenous infusion, IV in drop;
DRUGBANK
1.4
h
1.4
h
elimination half-life; Oral single dose;
DRUGBANK
2.1
h
2.1
h
elimination half-life;
DRUGBANK
2946.0
mg/kg
2946.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
4379.0
mg/kg
>4379
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
55.0
%
~55
%
Urinary excretion;
DRUGBANK
1.5
%
1.5
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
96.0
%
>96
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
9.0
drop/day
9
drop/day
ophthalmic administration
Viroptic
trifluridine
PDR
9.0
drop/day
9
drop/day
ophthalmic administration
Viroptic
trifluridine
PDR
9.0
drop/day
9
drop/day
ophthalmic administration
Viroptic
trifluridine
PDR
9.0
drop/day
9
drop/day
ophthalmic administration
Viroptic
trifluridine
PDR
DDPD00433
Prochlorperazine
373.943
C20H24ClN3S
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
DB00433
T3D2789
4917
8435
http://www.drugs.com/cdi/prochlorperazine.html
4748
-2.0
-
-2.0
-
DRUGBANK
12.5
%
12.5
%
DRUGBANK
5.0
h
5
h
DRUGBANK
168.0
h
7
day
Oral multiple dose;
DRUGBANK
0.98
L/h/kg
~0.98
L/h/kg
Plasma clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
0.0236
L/h
23.6
ml/h
Renal clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1401.0
L
1401.0
L
Apparent volume of distribution; intravenous injection, IV; normal,healthy;
DRUGBANK
1548.0
L
1548.0
L
Apparent volume of distribution; intravenous injection, IV; normal,healthy;
DRUGBANK
22.0
L/kg
22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
9
h
elimination half-life; intravenous injection, IV;
DRUGBANK
8.0
h
8
h
elimination half-life; Oral single dose;
DRUGBANK
9.0
h
9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
750.0
mg/kg
750.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; mouse;
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral;Rectal Administration;
Prochlorperazine Maleate
prochlorperazine maleate
PDR
25.0
mg/day
25
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
10.0
mg/day
10
mg/day
PO, oral;Rectal Administration;
Prochlorperazine Maleate
prochlorperazine maleate
PDR
25.0
mg/day
25
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
15.0
mg/day
15
mg/day
PO, oral;Rectal Administration;
Prochlorperazine Maleate
prochlorperazine maleate
PDR
20.0
mg/day
20
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
10.0
mg/day
10
mg/day
PO, oral;Rectal Administration;
Prochlorperazine Maleate
prochlorperazine maleate
PDR
20.0
mg/day
20
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
7.5
mg/day
7.5
mg/day
PO, oral;Rectal Administration;
Prochlorperazine Maleate
prochlorperazine maleate
PDR
20.0
mg/day
20
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
50.0
mg/day
50
mg/day
Rectal Administration
Prochlorperazine Maleate
prochlorperazine maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Prochlorperazine Maleate
prochlorperazine maleate
PDR
50.0
mg/day
50
mg/day
Rectal Administration
Prochlorperazine Maleate
prochlorperazine maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Prochlorperazine Maleate
prochlorperazine maleate
PDR
50.0
mg/day
50
mg/day
Rectal Administration
Prochlorperazine Maleate
prochlorperazine maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Prochlorperazine Maleate
prochlorperazine maleate
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Prochlorperazine Maleate
prochlorperazine maleate
PDR
DDPD00434
Cyproheptadine
287.3981
C21H21N
CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12
DB00434
T3D2790
2913
4046
http://www.drugs.com/cdi/cyproheptadine.html
2810
-2.0
-
-2.0
-
DRUGBANK
11.0
%
2-20
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
40.0
%
>40
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
97.5
%
96-99
%
DRUGBANK
16.0
mg/day
16
mg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
12.0
mg/day
12
mg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
0.5
mg/kg/day
0.5
mg/kg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
32.0
mg/day
32
mg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
0.5
mg/kg/day
0.5
mg/kg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
32.0
mg/day
32
mg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
16.0
mg/day
16
mg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
0.5
mg/kg/day
0.5
mg/kg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
32.0
mg/day
32
mg/day
PO, oral
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
0.0
0
Cyproheptadine Hydrochloride Syrup
cyproheptadine hydrochloride
PDR
DDPD00435
Nitric Oxide
30.0061
NO
[N]=O
DB00435
145068
16480
http://www.drugs.com/mtm/nitric-oxide-inhalation-gas.html
127983
-2.0
-
-2.0
-
DRUGBANK
0.00111111111111111
h
2-6
second
DRUGBANK
DDPD00436
Bendroflumethiazide
421.415
C15H14F3N3O4S2
NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F
DB00436
2315
3013
http://www.drugs.com/cdi/bendroflumethiazide.html
2225
-2.0
-
-2.0
-
DRUGBANK
8.5
h
8.5
h
at steady state;
DRUGBANK
96.0
%
96
%
DRUGBANK
DDPD00437
Allopurinol
136.1115
C5H4N4O
OC1=NC=NC2=C1C=NN2
DB00437
T3D3477
2094
40279
http://www.drugs.com/allopurinol.html
2010
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90.0
%
DRUGBANK
53.0
%
53±13
%
DRUGBANK
3000.0
ng/ml
3.0
mcg/ml
PO, oral;
DRUGBANK
1400.0
ng/ml
1.4±0.5
mcg/ml
Oral single dose;
DRUGBANK
6400.0
ng/ml
6.4±0.8
mcg/ml
Oral single dose; Active metabolite;
DRUGBANK
3.0
h
1.5-4.5
h
DRUGBANK
1.7
h
1.7±1.0
h
Oral single dose;
DRUGBANK
4.1
h
4.1±1.4
h
Oral single dose; Active metabolite;
DRUGBANK
0.594
L/h/kg
9.9±2.4
ml/min/kg
normal,healthy; Male, men; Female, women;
Elderly ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.87
L/kg
0.87±0.13
L/kg
normal,healthy; Male, men; Female, women;
DRUGBANK
0.58
L/kg
0.58
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
elimination half-life;
DRUGBANK
1.2
h
1.2±0.3
h
normal,healthy;
DRUGBANK
24.0
h
24±4.5
h
normal,healthy;
DRUGBANK
0.8
h
0.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
78.0
mg/kg
78.0
mg/kg
PO, oral; mouse;
DRUGBANK
214.0
mg/kg
214.0
mg/kg
mouse;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; mouse;
DRUGBANK
80.0
%
~80
%
Urinary excretion; PO, oral;
DRUGBANK
20.0
%
~20
%
Faeces excretion; PO, oral;
DRUGBANK
12.0
%
12
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Zyloprim
allopurinol
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Zyloprim
allopurinol
PDR
300.0
mg/day
300
mg/day
PO, oral
Zyloprim
allopurinol
PDR
150.0
mg/day
150
mg/day
PO, oral
Zyloprim
allopurinol
PDR
800.0
mg/day
800
mg/day
PO, oral
Zyloprim
allopurinol
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Zyloprim
allopurinol
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Zyloprim
allopurinol
PDR
DDPD00438
Ceftazidime
546.576
C22H22N6O7S2
[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1
DB00438
5481173
3508
http://www.drugs.com/cdi/ceftazidime.html
4587145
-2.0
-
-2.0
-
DRUGBANK
91.0
%
91.0
%
IM,intramuscular injection;
DRUGBANK
34000.0
ng/ml
29-39
mcg/ml
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
132500.0
ng/ml
119-146
mcg/ml
intravenous injection, IV; adults; normal,healthy;
DRUGBANK
1.0
h
0.7-1.3
h
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
6.9
L/h
115.0
ml/min
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23±0.02
L/kg
Elderly ↑ ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ;Burn ↑ ;
DRUGBANK
0.31
L/kg
0.31
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
h
~1.9
h
intravenous injection, IV;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
1.6
h
1.6±0.1
h
Prem, premature ↑ ;Neonates ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;Age ↑ ;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.0
%
84±4
%
Urinary excretion; Unchanged drug;
Cystic fibrosis → ;
DRUGBANK
10.0
%
<10
%
DRUGBANK
21.0
%
21±6
%
DRUGBANK
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tazicef
ceftazidime
PDR
DDPD00439
Cerivastatin
459.5503
C26H34FNO5
COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C
DB00439
446156
3558
http://www.drugs.com/mtm/cerivastatin.html
393588
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60(39-101)
%
DRUGBANK
0.174
L/h/kg
2.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.33
L/kg
0.33
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
80.0
%
80
%
DRUGBANK
DDPD00440
Trimethoprim
290.3177
C14H18N4O3
COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
DB00440
5578
45924
http://www.drugs.com/cdi/trimethoprim.html
5376
-2.0
-
-2.0
-
DRUGBANK
30000.0
ng.h/ml
30.0
mg.h/l
Oral single dose;
DRUGBANK
63.0
%
>63
%
PO, oral;
DRUGBANK
1000.0
ng/ml
1.0
ug/ml
Oral single dose;
DRUGBANK
2000.0
ng/ml
2.0
ug/ml
Oral single dose;
DRUGBANK
1200.0
ng/ml
1.2
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
2.5
h
1-4
h
Oral single dose;
DRUGBANK
5.0
h
2-8
h
Oral single dose;
DRUGBANK
2.0
h
2.0
h
Oral single dose; adults; normal,healthy;
DRUGBANK
72.0
h
3.0
day
Oral multiple dose;
DRUGBANK
65.0
%
65
%
DRUGBANK
25.0
%
25
%
DRUGBANK
4.29
L/h
51.7-91.3
ml/min
DRUGBANK
0.114
L/h/kg
1.9±0.3
ml/min/kg
Children ↑ ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis ↑ ;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6±0.2
L/kg
Neonates ↑ ;Children ↓ ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
8-10
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
10.0
h
10±2
h
Children ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↓ ;normal BMI → ;
DRUGBANK
9.6
h
9.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2764.0
mg/kg
2764.0
mg/kg
PO, oral; mouse;
DRUGBANK
5300.0
mg/kg
>5300
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
55.0
%
50-60
%
Urinary excretion; PO, oral;
DRUGBANK
80.0
%
~80
%
Urinary excretion; Unchanged drug;
DRUGBANK
63.0
%
63±10
%
Urinary excretion; Unchanged drug;
Cystic fibrosis → ;
DRUGBANK
44.0
%
44
%
plasma proteins;
DRUGBANK
37.0
%
37±5
%
RD, renal impairment, Renal disease，including uremia → ;hypoalbuminemia Alb → ;Cystic fibrosis → ;
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
400.0
mg/day
400
mg/day
PO, oral
Trimethoprim
trimethoprim
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
200.0
mg/day
200
mg/day
PO, oral
Trimethoprim
trimethoprim
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
400.0
mg/day
400
mg/day
PO, oral
Trimethoprim
trimethoprim
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
200.0
mg/day
200
mg/day
PO, oral
Trimethoprim
trimethoprim
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Trimethoprim
trimethoprim
PDR
DDPD00441
Gemcitabine
263.1981
C9H11F2N3O4
NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
DB00441
60750
175901
http://www.drugs.com/cdi/gemcitabine.html
54753
-2.0
-
-2.0
-
DRUGBANK
7080028.89
ng/ml
26.9±9
mM
intravenous infusion, IV in drop;
DRUGBANK
83.95
L/h/m2
75.7-92.2
L/h/m2
Male, men; adults;
DRUGBANK
47.9
L/h/m2
40.7-55.1
L/h/m2
Male, men; Elderly;
DRUGBANK
63.2
L/h/m2
57-69.4
L/h/m2
Female, women; adults;
DRUGBANK
36.1
L/h/m2
30.7-41.5
L/h/m2
Female, women; Elderly;
DRUGBANK
2.268
L/h/kg
37.8±19.4
ml/min/kg
Elderly ↓ ;
DRUGBANK
1.92
L/h/kg
32
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
L/m2
50.0
L/m2
intravenous infusion, IV in drop;
DRUGBANK
370.0
L/m2
370.0
L/m2
intravenous infusion, IV in drop; Oral multiple dose;
DRUGBANK
1.4
L/kg
1.4±1.3
L/kg
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.13333333333333
h
42-94
min
DRUGBANK
7.35833333333333
h
245-638
min
DRUGBANK
0.63
h
0.63±0.48
h
Age ↑ ;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
95.0
%
92-98
%
DRUGBANK
10.0
%
<10
%
Urinary excretion; leukemia; Unchanged drug;
DRUGBANK
10.0
%
<10
%
plasma proteins;
DRUGBANK
0.0
%
~0
%
leukemia;
DRUGBANK
1250.0
mg/m2
1250
mg/m2
intravenous injection, IV
qw
Gemzar
gemcitabine
PDR
1250.0
mg/m2
1250
mg/m2
intravenous injection, IV
qw
Gemzar
gemcitabine
PDR
DDPD00442
Entecavir
277.2792
C12H15N5O3
NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](CO)C1=C
DB00442
153941
473990
http://www.drugs.com/cdi/entecavir.html
135679
-2.0
-
-2.0
-
DRUGBANK
1.0
h
0.5-1.5
h
PO, oral; normal,healthy;
DRUGBANK
22.992
L/h
383.2±101.8
ml/min
Renal clearance; normal,healthy;
DRUGBANK
11.874
L/h
197.9±78.1
ml/min
Renal clearance; mild renal function;
DRUGBANK
8.136
L/h
135.6±31.6
ml/min
Renal clearance; moderate renal function;
DRUGBANK
2.418
L/h
40.3±10.1
ml/min
Renal clearance; severe renal function;
DRUGBANK
35.286
L/h
588.1±153.7
ml/min
Total clearance; PO, oral; normal,healthy;
DRUGBANK
18.552
L/h
309.2±62.6
ml/min
Total clearance; PO, oral; mild renal function;
DRUGBANK
13.578
L/h
226.3±60.1
ml/min
Total clearance; PO, oral; moderate renal function;
DRUGBANK
6.036
L/h
100.6±29.1
ml/min
Total clearance; PO, oral; severe renal function;
DRUGBANK
3.036
L/h
50.6±16.5
ml/min
Total clearance; PO, oral; severe renal function;
DRUGBANK
2.142
L/h
35.7±19.6
ml/min
Total clearance; PO, oral; severe renal function;
DRUGBANK
2.30833333333333
h
128-149
min
elimination half-life;
DRUGBANK
15.0
h
15
h
Metabolite;
DRUGBANK
13.0
%
~13
%
high protein binding; human, homo sapiens;
DRUGBANK
1.0
mg/day
1
mg/day
PO, oral
Baraclude
entecavir
PDR
0.9
mg/day
0.9
mg/day
Liquid
Baraclude
entecavir
PDR
0.8
mg/day
0.8
mg/day
Liquid
Baraclude
entecavir
PDR
0.7
mg/day
0.7
mg/day
Liquid
Baraclude
entecavir
PDR
0.6
mg/day
0.6
mg/day
Liquid
Baraclude
entecavir
PDR
0.5
mg/day
0.5
mg/day
Liquid
Baraclude
entecavir
PDR
0.4
mg/day
0.4
mg/day
Liquid
Baraclude
entecavir
PDR
0.3
mg/day
0.3
mg/day
Liquid
Baraclude
entecavir
PDR
1.0
mg/day
1
mg/day
PO, oral
Baraclude
entecavir
PDR
1.0
mg/day
1
mg/day
PO, oral
Baraclude
entecavir
PDR
1.0
mg/day
1
mg/day
PO, oral
Baraclude
entecavir
PDR
0.9
mg/day
0.9
mg/day
Liquid
Baraclude
entecavir
PDR
0.8
mg/day
0.8
mg/day
Liquid
Baraclude
entecavir
PDR
1.0
mg/day
1
mg/day
PO, oral
Baraclude
entecavir
PDR
DDPD00443
Betamethasone
392.4611
C22H29FO5
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00443
9782
3077
http://www.drugs.com/cdi/betamethasone.html
9399
-2.0
-
-2.0
-
DRUGBANK
6.466
L/h
6466±805
ml/h
Total clearance; IM,intramuscular injection; Female, women; young;
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.584
L
94584±23539
mL
IM,intramuscular injection; Single dose; Female, women;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.2
h
10.2±2.5
h
Asian; Female, women;
DRUGBANK
5.6
h
5.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00444
Teniposide
656.654
C32H32O13S
[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1
DB00444
T3D4715
452548
http://www.drugs.com/cdi/teniposide.html
398606
-2.0
-
-2.0
-
DRUGBANK
0.618
L/h/m2
10.3
ml/min/m2
DRUGBANK
0.0114
L/h/kg
0.19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.41
L/kg
0.41
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5
h
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
0-10
%
DRUGBANK
250.0
mg/m2/dose
250
mg/m2/dose
intravenous injection, IV
qw
Teniposide
teniposide
PDR
165.0
mg/m2/dose
165
mg/m2/dose
intravenous injection, IV
biw
Teniposide
teniposide
PDR
250.0
mg/m2/dose
250
mg/m2/dose
intravenous injection, IV
qw
Teniposide
teniposide
PDR
165.0
mg/m2/dose
165
mg/m2/dose
intravenous injection, IV
biw
Teniposide
teniposide
PDR
250.0
mg/m2/dose
250
mg/m2/dose
intravenous injection, IV
qw
Teniposide
teniposide
PDR
165.0
mg/m2/dose
165
mg/m2/dose
intravenous injection, IV
biw
Teniposide
teniposide
PDR
250.0
mg/m2/dose
250
mg/m2/dose
intravenous injection, IV
qw
Teniposide
teniposide
PDR
165.0
mg/m2/dose
165
mg/m2/dose
intravenous injection, IV
biw
Teniposide
teniposide
PDR
DDPD00445
Epirubicin
543.5193
C27H29NO11
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
DB00445
T3D2791
41867
47898
http://www.drugs.com/cdi/epirubicin.html
38201
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
DRUGBANK
65.0
L/h
65±8
L/h
intravenous injection, IV; tumor; patients;
DRUGBANK
83.0
L/h
83±14
L/h
intravenous injection, IV; tumor; patients;
DRUGBANK
65.0
L/h
65±13
L/h
intravenous injection, IV; tumor; patients;
DRUGBANK
69.0
L/h
69±13
L/h
intravenous injection, IV; tumor; patients;
DRUGBANK
1.2
L/h/kg
20
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.0
L/kg
21±2
L/kg
DRUGBANK
27.0
L/kg
27±11
L/kg
DRUGBANK
23.0
L/kg
23±7
L/kg
DRUGBANK
21.0
L/kg
21±7
L/kg
DRUGBANK
45.0
L/kg
45
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.05
h
3
min
distribution half-life;
DRUGBANK
2.5
h
2.5
h
elimination half-life;
DRUGBANK
33.0
h
33
h
terminal half-life;
DRUGBANK
36.0
h
36
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
77.0
%
77
%
DRUGBANK
120.0
mg/m2/dose
120
mg/m2/dose
Ellence
epirubicin hydrochloride
PDR
120.0
mg/m2 /dose
120
mg/m2 /dose
Ellence
epirubicin hydrochloride
PDR
DDPD00446
Chloramphenicol
323.129
C11H12Cl2N2O5
OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O
DB00446
T3D3954
5959
17698
http://www.drugs.com/mtm/chloramphenicol-ophthalmic.html
5744
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
80.0
%
80.0
%
PO, oral;
DRUGBANK
70.0
%
70.0
%
IM,intramuscular injection;
DRUGBANK
90.0
%
90
%
Liver metabolism; Inactive metabolite;
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.94
L/kg
0.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
1.5-3.5
h
normal renal function; normal hepatic function; adults;
DRUGBANK
3.5
h
3-4
h
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
8.1
h
4.6-11.6
h
severe hepatic impairment; patients;
DRUGBANK
4.75
h
3-6.5
h
Infants; Children;
DRUGBANK
24.0
h
>=24
h
Neonates;
gaining weight ↑ ;
DRUGBANK
4.6
h
4.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; mouse;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; mouse;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
55.0
%
50-60
%
plasma proteins; adults; human, homo sapiens;
DRUGBANK
32.0
%
32
%
plasma proteins; Prem, premature; human, homo sapiens;
DRUGBANK
DDPD00447
Loracarbef
349.769
C16H16ClN3O4
N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1
DB00447
5284585
47544
http://www.drugs.com/cdi/loracarbef.html
4447635
-2.0
-
-2.0
-
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
1.0
h
1
h
DRUGBANK
5.6
h
~5.6
h
elimination half-life; moderate renal function;
DRUGBANK
25.0
%
25
%
DRUGBANK
DDPD00448
Lansoprazole
369.361
C16H14F3N3O2S
CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
DB00448
3883
6375
http://www.drugs.com/lansoprazole.html
3746
-2.0
-
-2.0
-
DRUGBANK
85.0
%
80-90
%
PO, oral;
DRUGBANK
81.0
%
81±22
%
PO, oral; Male, men; normal,healthy;
DRUGBANK
248.0
ng/ml
248±140
ng/ml
Oral single dose; Male, men; normal,healthy;
DRUGBANK
1.7
h
1.7
h
PO, oral;
DRUGBANK
1.3
h
1.3±0.6
h
Oral single dose; Male, men; normal,healthy;
DRUGBANK
30.0
L/h
400-600
ml/min
DRUGBANK
0.3738
L/h/kg
6.23±1.60
ml/min/kg
Elderly ↓ ;severe hepatic impairment ↓ ;
DRUGBANK
0.264
L/h/kg
4.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.4
L/kg
0.4
L/kg
Apparent volume of distribution;
DRUGBANK
0.35
L/kg
0.35±0.05
L/kg
DRUGBANK
0.28
L/kg
0.28
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
<=2
h
DRUGBANK
0.9
h
0.9±0.44
h
normal,healthy; Male, men;
chronic liver disease ↑ ;Hepatic cirrhosis, cirr → ;Age ↑ ;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.5
%
14-23
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
97
%
plasma proteins;
DRUGBANK
97.0
%
97
%
Male, men; normal,healthy; human, homo sapiens;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Prevacid
lansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Prevacid
lansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Prevacid
lansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Prevacid
lansoprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Prevacid
lansoprazole
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Prevacid
lansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Prevacid
lansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Prevacid
lansoprazole
PDR
90.0
mg/day
90
mg/day
PO, oral
Prevacid
lansoprazole
PDR
120.0
mg/day
120
mg/day
PO, oral
Prevacid
lansoprazole
PDR
180.0
mg/day
180
mg/day
PO, oral
Prevacid
lansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Prevacid
lansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Prevacid
lansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Prevacid
lansoprazole
PDR
90.0
mg/day
90
mg/day
PO, oral
Prevacid
lansoprazole
PDR
120.0
mg/day
120
mg/day
PO, oral
Prevacid
lansoprazole
PDR
180.0
mg/day
180
mg/day
PO, oral
Prevacid
lansoprazole
PDR
2.0
mg/kg/day
2
mg/kg/day
Prevacid
lansoprazole
PDR
1.5
mg/kg/day
1.5
mg/kg/day
Prevacid
lansoprazole
PDR
DDPD00449
Dipivefrin
351.4373
C19H29NO5
CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1
DB00449
3105
4646
http://www.drugs.com/cdi/dipivefrin.html
2994
-2.0
-
-2.0
-
DRUGBANK
183.0
mg/kg
183.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00450
Droperidol
379.4274
C22H22FN3O2
FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12
DB00450
3168
4717
http://www.drugs.com/cdi/droperidol.html
3056
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
IM,intramuscular injection;
DRUGBANK
0.5352
L/h/kg
8.92
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.41
L/kg
1.41
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0233333333333333
h
1.4±0.5
min
rapid distribution half-life;
DRUGBANK
0.238333333333333
h
14.3±6.5
min
rapid distribution half-life;
DRUGBANK
2.23333333333333
h
134±13
min
elimination half-life; adults;
patients ↑ ;
DRUGBANK
1.69166666666667
h
101.5±26.4
min
Children;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
31.5
mg/kg
20-43
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
30.0
mg/kg
30.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
25.0
mg/kg
25.0
mg/kg
intravenous injection, IV; dog;
DRUGBANK
12.0
mg/kg
11-13
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
195.0
mg/kg
195
mg/kg
IM,intramuscular injection; mouse;
DRUGBANK
107.0
mg/kg
104-110
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
97.0
mg/kg
97
mg/kg
IM,intramuscular injection; rabbit;
DRUGBANK
200.0
mg/kg
200
mg/kg
IM,intramuscular injection; guinea pigs;
DRUGBANK
0.1
mg/kg
0.1
mg/kg
intravenous injection, IV;IM,intramuscular injection;
Droperidol
droperidol
PDR
2.5
mg/dose
2.5
mg/dose
intravenous injection, IV;IM,intramuscular injection;
Droperidol
droperidol
PDR
2.5
mg/dose
2.5
mg/dose
intravenous injection, IV;IM,intramuscular injection;
Droperidol
droperidol
PDR
2.5
mg/dose
2.5
mg/dose
intravenous injection, IV;IM,intramuscular injection;
Droperidol
droperidol
PDR
DDPD00451
Levothyroxine
776.87
C15H11I4NO4
N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
DB00451
5819
18332
http://www.drugs.com/levothyroxine.html
5614
-2.0
-
-2.0
-
DRUGBANK
60.0
%
40-80
%
PO, oral;
DRUGBANK
156.0
h
6-7
day
DRUGBANK
36.0
h
1-2
day
DRUGBANK
20.0
mg/kg
20.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
20.0
%
20
%
Faeces excretion;
Age ↓ ;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
0.1
mg/day
100
mcg/day
PO, oral
Thyrolar
liotrix (T3;T4)
PDR
0.025
mg/day
25
mcg/day
PO, oral
Thyrolar
liotrix (T3;T4)
PDR
0.1
mg/day
100
mcg/day
PO, oral
Thyrolar
liotrix (T3;T4)
PDR
0.025
mg/day
25
mcg/day
PO, oral
Thyrolar
liotrix (T3;T4)
PDR
0.1
mg/day
100
mcg/day
PO, oral
Thyrolar
liotrix (T3;T4)
PDR
0.025
mg/day
25
mcg/day
PO, oral
Thyrolar
liotrix (T3;T4)
PDR
0.2
mg/day
200
mcg/day
PO, oral
Tirosint
levothyroxine sodium
PDR
0.3
mg/day
300
mcg/day
PO, oral
Tirosint
levothyroxine sodium
PDR
0.2
mg/day
200
mcg/day
PO, oral
Tirosint
levothyroxine sodium
PDR
0.3
mg/day
300
mcg/day
PO, oral
Tirosint
levothyroxine sodium
PDR
0.2
mg/day
200
mcg/day
PO, oral
Tirosint
levothyroxine sodium
PDR
0.3
mg/day
300
mcg/day
PO, oral
Tirosint
levothyroxine sodium
PDR
120.0
mg/day
120
mg/day
PO, oral
Armour Thyroid
thyroid
PDR
120.0
mg/day
120
mg/day
PO, oral
Armour Thyroid
thyroid
PDR
120.0
mg/day
120
mg/day
PO, oral
Armour Thyroid
thyroid
PDR
DDPD00452
Framycetin
614.6437
C23H46N6O13
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
DB00452
8378
7508
8075
-2.0
-
-2.0
-
DRUGBANK
DDPD00454
Meperidine
247.3327
C15H21NO2
CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1
DB00454
T3D2795
4058
6754
http://www.drugs.com/cdi/meperidine.html
3918
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
PO, oral;
DRUGBANK
85.0
%
80-90
%
PO, oral; Hepatitis, Hep;
Hepatitis, Hep ↑ ;
DRUGBANK
27.5
%
25-30
%
parenteral administration;
DRUGBANK
82.5
%
80-85
%
IM,intramuscular injection; normal,healthy; adults;
DRUGBANK
52.0
%
52±3
%
PO, oral;
DRUGBANK
700.0
ng/ml
~0.7
mcg/ml
PO, oral;
DRUGBANK
670.0
ng/ml
0.67
mcg/ml
intravenous injection, IV;
DRUGBANK
1.0
h
<1
h
PO, oral;
DRUGBANK
1.02
L/h/kg
17±5
ml/min/kg
Neonates ↓ ;Prem, premature ↓ ;Elderly → ;Preg, pregnant → ;acute viral hepatitis AVH ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Somking → ;
DRUGBANK
0.294
L/h/kg
4.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.4
L/kg
4.4±0.9
L/kg
Elderly ↑ ;Preg, pregnant → ;Prem, premature ↑ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2.3
L/kg
2.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.108333333333333
h
2-11
min
distribution half-life;
DRUGBANK
4.0
h
3-5
h
elimination half-life;
DRUGBANK
9.0
h
7-11
h
hepatopathy，LD; patients;
DRUGBANK
3.2
h
3.2±0.8
h
Prem, premature ↑ ;Neonates ↑ ;Preg, pregnant → ;acute viral hepatitis AVH ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
7.9
h
7.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
~5
%
Urinary excretion; Unchanged drug;
DRUGBANK
5.0
%
~5(1-25)
%
Urinary excretion; Unchanged drug;
DRUGBANK
70.0
%
60-80
%
plasma proteins;
DRUGBANK
58.0
%
58±9
%
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr → ;
DRUGBANK
1.8
mg/kg/dose
1.8
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
150.0
mg/dose
150
mg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
2.2
mg/kg/dose
2.2
mg/kg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
100.0
mg/kg/dose
100
mg/kg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
150.0
mg/dose
150
mg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
100.0
mg/dose
100
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
1.8
mg/kg/dose
1.8
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
150.0
mg/dose
150
mg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
2.2
mg/kg/dose
2.2
mg/kg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
100.0
mg/kg/dose
100
mg/kg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
150.0
mg/dose
150
mg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
100.0
mg/dose
100
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Meperidine Hydrochloride Injection Solution
meperidine hydrochloride
PDR
DDPD00455
Loratadine
382.883
C22H23ClN2O2
CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
DB00455
T3D2796
3957
6538
http://www.drugs.com/cdi/loratadine.html
3820
-2.0
-
-2.0
-
DRUGBANK
6.14
ng.h/ml
6.14
ng.h/ml
PO, oral; immediate release formulation;
DRUGBANK
49.1
ng.h/ml
49.1
ng.h/ml
DRUGBANK
49.1
ng.h/ml
49.1
ng.h/ml
immediate release formulation; Derivative;
DRUGBANK
48.4
ng.h/ml
48.4
ng.h/ml
Derivative;
DRUGBANK
2.56
ng/ml
2.56
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
3.72
ng/ml
3.72
ng/ml
DRUGBANK
3.72
ng/ml
3.72
ng/ml
immediate release formulation; Derivative;
DRUGBANK
3.66
ng/ml
3.66
ng/ml
Derivative;
DRUGBANK
3.4
ng/ml
3.4±3.4
ng/ml
PO, oral; adults; normal,healthy;
DRUGBANK
4.1
ng/ml
4.1±2.6
ng/ml
PO, oral; Active metabolite; adults; normal,healthy;
DRUGBANK
4.0
ng/ml
4.0±2.1
ng/ml
PO, oral; Active metabolite; Drug form; adults; normal,healthy;
DRUGBANK
2.0
ng/ml
2.0±0.6
ng/ml
PO, oral; Active metabolite; Drug form; adults; normal,healthy;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
3.5
h
3-4
h
Active metabolite;
DRUGBANK
1.14
h
1.14
h
PO, oral; immediate release formulation;
DRUGBANK
1.97
h
1.97
h
DRUGBANK
1.97
h
1.97
h
immediate release formulation; Derivative;
DRUGBANK
1.97
h
1.97
h
Derivative;
DRUGBANK
2.0
h
2.0±0
h
PO, oral; adults; normal,healthy;
DRUGBANK
2.6
h
2.6±2.9
h
PO, oral; Active metabolite; adults; normal,healthy;
DRUGBANK
3.2
h
3.2±1.8
h
PO, oral; Active metabolite; Drug form; adults; normal,healthy;
DRUGBANK
4.8
h
4.8±1.9
h
PO, oral; Active metabolite; Drug form; adults; normal,healthy;
DRUGBANK
12.0
L/h/kg
12.0
L/h/kg
Oral single dose;
DRUGBANK
9.0
L/h/kg
9.0
L/h/kg
Oral single dose;
DRUGBANK
8.52
L/h/kg
142±57
ml/min/kg
apparent clearance;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.96
L/h/kg
14-18
ml/min/kg
apparent clearance;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
120.0
L/kg
120.0
L/kg
DRUGBANK
120.0
L/kg
120±80
L/kg
Apparent volume of distribution;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
26.0
L/kg
26.0
L/kg
Apparent volume of distribution;
DRUGBANK
10.0
h
~10
h
DRUGBANK
20.0
h
20
h
elimination half-life;
DRUGBANK
8.0
h
8±6
h
RD, renal impairment, Renal disease，including uremia → ;chronic liver disease ↑ ;
DRUGBANK
22.5
h
21-24
h
Active metabolite;
DRUGBANK
40.0
%
40
%
Urinary excretion;
DRUGBANK
42.0
%
42
%
Faeces excretion;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.0
%
97-99
%
plasma proteins;
DRUGBANK
97.0
%
97
%
DRUGBANK
84.5
%
82-87
%
Active metabolite;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Claritin
loratadine
PDR
10.0
mg/day
10
mg/day
PO, oral
Claritin
loratadine
PDR
10.0
mg/day
10
mg/day
PO, oral
Claritin
loratadine
PDR
DDPD00456
Cefalotin
396.438
C16H16N2O6S2
[H][C@@]1(NC(=O)CC2=CC=CS2)C(=O)N2C(C(O)=O)=C(COC(C)=O)CS[C@]12[H]
DB00456
6024
124991
5802
-2.0
-
-2.0
-
DRUGBANK
62.5
%
50-75
%
Urinary excretion;
DRUGBANK
0.5
h
30
min
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
72.5
%
65-80
%
DRUGBANK
DDPD00457
Prazosin
383.4011
C19H21N5O4
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1
DB00457
4893
8364
http://www.drugs.com/cdi/prazosin.html
4724
-2.0
-
-2.0
-
DRUGBANK
68.0
%
68±17
%
PO, oral;
DRUGBANK
36.0
ng/ml
36±17
ng/ml
Oral single dose; hypertension;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
2.2
h
2.2±1.1
h
Oral single dose; hypertension;
DRUGBANK
0.18
L/h/kg
3.0±0.3
ml/min/kg
normal,healthy; adults;
Preg, pregnant ↓ ;congestive heart disease ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.282
L/h/kg
4.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
~0.6
L/kg
DRUGBANK
0.6
L/kg
0.60±0.13
L/kg
normal,healthy; adults;
DRUGBANK
0.73
L/kg
0.73
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
~2-3
h
elimination half-life;
DRUGBANK
2.9
h
2.9±0.8
h
Preg, pregnant ↑ ;congestive heart disease ↑ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1950.0
mg/kg
1950.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
102.0
mg/kg
102.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
0.285
mg/kg
285.0
ug/kg
PO, oral; human, homo sapiens;
DRUGBANK
0.01
mg/kg
10.0
ug/kg
PO, oral; Female, women;
DRUGBANK
4.0
%
<4
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
85.0
%
~80-90
%
DRUGBANK
95.0
%
95±1
%
Hepatic cirrhosis, cirr ↓ ;hypoalbuminemia Alb ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease → ;
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
0.4
mg/kg/day
400
mcg/kg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
9.0
mg/day
9
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
9.0
mg/day
9
mg/day
PO, oral
Minipress
prazosin hydrochloride
PDR
DDPD00458
Imipramine
280.4073
C19H24N2
CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
DB00458
T3D2797
3696
47499
http://www.drugs.com/cdi/imipramine.html
3568
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
PO, oral;
DRUGBANK
53.0
%
29-77
%
DRUGBANK
42.0
%
42±3
%
PO, oral;
DRUGBANK
200.0
ng/ml
200±137
ng/ml
PO, oral;
DRUGBANK
4.0
h
2-6
h
DRUGBANK
4.0
h
2-6
h
PO, oral;
DRUGBANK
100.0
%
~100
%
Liver metabolism;
DRUGBANK
5.0
%
5
%
Urinary excretion; PO, oral;
DRUGBANK
1.0
L/h/kg
1.0
L/h/kg
Average clearance;
DRUGBANK
1.8
L/h/kg
1.8
L/h/kg
Average clearance;
DRUGBANK
0.78
L/h/kg
13±1.7
ml/min/kg
Children → ;Elderly ↓ ;Somking ↑ ;
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
L/kg
10-20.0
L/kg
Apparent volume of distribution;
DRUGBANK
18.0
L/kg
18±2
L/kg
Apparent volume of distribution;
Children → ;Elderly → ;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
DRUGBANK
22.5
h
22.5
h
DRUGBANK
16.0
h
16±1.3
h
Children → ;Age ↑ ;
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
518.5
mg/kg
355-682
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
78.0
%
60-96
%
plasma proteins;
DRUGBANK
90.1
%
90.1±1.4
%
Elderly → ;HL,hyperlipoproteinemia ↑ ;myocardial infarction ↑ ;Burn ↑ ;rheumatoid arthritis → ;
DRUGBANK
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
75.0
mg/day
75
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
75.0
mg/day
75
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Tofranil Tablets
imipramine hydrochloride
PDR
DDPD00459
Acitretin
326.4293
C21H26O3
COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
DB00459
5284513
50173
http://www.drugs.com/cdi/acitretin.html
4447573
-2.0
-
-2.0
-
DRUGBANK
72.0
%
72(47-109)
%
Oral single dose;
DRUGBANK
49.0
h
49(33-96)
h
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
34.5
%
16-53
%
Urinary excretion;
DRUGBANK
44.0
%
34-54
%
Faeces excretion;
DRUGBANK
99.9
%
>99.9
%
plasma proteins;
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Soriatane
acitretin
PDR
50.0
mg/day
50
mg/day
PO, oral
Soriatane
acitretin
PDR
DDPD00460
Verteporfin
718.7942
C41H42N4O8
COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C
DB00460
5362420
http://www.drugs.com/cdi/verteporfin.html
4515032
-2.0
-
-2.0
-
DRUGBANK
5.5
h
~5-6
h
elimination half-life; intravenous infusion, IV in drop;
DRUGBANK
6.6
h
~6-7.2
h
mild hepatic impairment;
DRUGBANK
0.01
%
<0.01
%
Urinary excretion;
DRUGBANK
6.0
mg/m2
6
mg/m2
intravenous injection, IV
Visudyne
verteporfin
PDR
6.0
mg/m2
6
mg/m2
intravenous injection, IV
Visudyne
verteporfin
PDR
DDPD00461
Nabumetone
228.2863
C15H16O2
COC1=CC2=C(C=C1)C=C(CCC(C)=O)C=C2
DB00461
4409
7443
http://www.drugs.com/cdi/nabumetone.html
4256
-2.0
-
-2.0
-
DRUGBANK
7.0
h
3-11
h
PO, oral;
DRUGBANK
10.5
h
9-12
h
PO, oral; different study;
DRUGBANK
1.5
L/h
20-30
ml/min
DRUGBANK
53.0
L
53.0
L
DRUGBANK
24.0
h
24(19-36)
h
DRUGBANK
4290.0
mg/kg
4290.0
mg/kg
PO, oral; mouse;
DRUGBANK
2380.0
mg/kg
2380.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
3880.0
mg/kg
3880.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1520.0
mg/kg
1520.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
10000.0
mg/kg
>10
g/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; monkey;
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
10.0
%
10
%
Faeces excretion;
DRUGBANK
99.0
%
<99
%
plasma proteins;
DRUGBANK
DDPD00462
Methscopolamine bromide
398.291
C18H24BrNO4
[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
DB00462
23724781
61276
10481908
-2.0
-
-2.0
-
DRUGBANK
17.5
%
10-25
%
DRUGBANK
DDPD00464
Sodium tetradecyl sulfate
316.43
C14H29NaO4S
[Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O
DB00464
T3D4742
23665772
75273
http://www.drugs.com/cdi/sodium-tetradecyl-sulfate.html
8440
-2.0
-
-2.0
-
DRUGBANK
1250.0
mg/kg
1250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.0
ml/kg
3.0
ml/kg
skin/dermal; Rattus, Rat;
DRUGBANK
1250.0
mg/kg
1250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.0
ml/kg
3.0
ml/kg
skin/dermal; Rattus, Rat;
DRUGBANK
10.0
ml/dose
10
ml/dose
Sotradecol
sodium tetradecyl sulfate
PDR
10.0
ml/dose
10
ml/dose
Sotradecol
sodium tetradecyl sulfate
PDR
DDPD00465
Ketorolac
255.2686
C15H13NO3
OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
DB00465
3826
76223
http://www.drugs.com/cdi/ketorolac-drops.html
3694
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
80.0
%
80.0
%
PO, oral;
DRUGBANK
100.0
%
100±20
%
PO, oral;
DRUGBANK
2600.0
ng/ml
2.2-3.0
mcg/ml
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
850.0
ng/ml
0.8-0.9
mcg/ml
PO, oral; adults; normal,healthy;
DRUGBANK
0.665
h
0.33-1
h
PO, oral;
DRUGBANK
0.75
h
0.67-0.83
h
IM,intramuscular injection;
DRUGBANK
0.75
h
0.7-0.8
h
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
0.6
h
0.3-0.9
h
PO, oral; adults; normal,healthy;
DRUGBANK
0.029
L/h/kg
0.021-0.037
L/h/kg
DRUGBANK
0.03
L/h/kg
0.50±0.15
ml/min/kg
Elderly ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.021
L/h/kg
0.35
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.25
L/kg
0.25
L/kg
Apparent volume of distribution;
DRUGBANK
0.5
L/kg
0.50±0.15
L/kg
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
~2.5
h
Optical rotation S;
DRUGBANK
5.0
h
~5
h
Optical rotation R;
DRUGBANK
5.3
h
5.3±1.2
h
RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr → ;Age ↑ ;
DRUGBANK
5.1
h
5.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
55.2
%
55.2
%
Urinary excretion; Unchanged drug;
DRUGBANK
7.5
%
5-10
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
99.2
%
99.2±0.1
%
Raceme D/L;
DRUGBANK
30.0
mg
30
mg
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
60.0
mg
60
mg
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
120.0
mg/day
120
mg/day
intravenous injection, IV;IM,intramuscular injection;
Acular
ketorolac tromethamine
PDR
40.0
mg/day
40
mg/day
PO, oral
Acular
ketorolac tromethamine
PDR
15.0
mg
15
mg
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
30.0
mg
30
mg
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
60.0
mg/day
60
mg/day
intravenous injection, IV;IM,intramuscular injection;
Acular
ketorolac tromethamine
PDR
40.0
mg/day
40
mg/day
PO, oral
Acular
ketorolac tromethamine
PDR
0.5
mg/kg/dose
0.5
mg/kg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
15.0
mg/dose
15
mg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
1.0
mg/kg/dose
1
mg/kg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
30.0
mg/dose
30
mg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
1.5
mg/kg/day
0.5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
0.75
mg/kg/day
0.25
mg/kg/dose
PO, oral
qid
Acular
ketorolac tromethamine
PDR
10.0
mg/dose
10
mg/dose
PO, oral
qid
Acular
ketorolac tromethamine
PDR
15.0
mg/dose
15
mg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
30.0
mg/dose
30
mg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
60.0
mg/day
60
mg/day
intravenous injection, IV;IM,intramuscular injection;
Acular
ketorolac tromethamine
PDR
40.0
mg/day
40
mg/day
PO, oral
Acular
ketorolac tromethamine
PDR
63.0
mg/day
63
mg/day
intranasal
Acular
ketorolac tromethamine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
60.0
mg/dose
60
mg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
120.0
mg/day
120
mg/day
intravenous injection, IV;IM,intramuscular injection;
Acular
ketorolac tromethamine
PDR
40.0
mg/day
40
mg/day
PO, oral
Acular
ketorolac tromethamine
PDR
126.0
mg/day
126
mg/day
intranasal
Acular
ketorolac tromethamine
PDR
15.0
mg/dose
15
mg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
30.0
mg/dose
30
mg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
60.0
mg/day
60
mg/day
intravenous injection, IV;IM,intramuscular injection;
Acular
ketorolac tromethamine
PDR
40.0
mg/day
40
mg/day
PO, oral
Acular
ketorolac tromethamine
PDR
63.0
mg/day
63
mg/day
intranasal
Acular
ketorolac tromethamine
PDR
0.5
mg/kg/dose
0.5
mg/kg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
15.0
mg/dose
15
mg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
1.0
mg/kg/dose
1
mg/kg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
30.0
mg/dose
30
mg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
2.0
mg/kg/day
0.5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
120.0
mg/day
30
mg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
1.0
mg/kg/day
0.25
mg/kg/dose
PO, oral
qid
Acular
ketorolac tromethamine
PDR
40.0
mg/day
10
mg/dose
PO, oral
qid
Acular
ketorolac tromethamine
PDR
0.5
mg/kg/dose
0.5
mg/kg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
1.0
mg/kg/dose
1
mg/kg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
2.0
mg/kg/day
0.5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
120.0
mg/day
30
mg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
1.0
mg/kg/day
0.25
mg/kg/dose
PO, oral
qid
Acular
ketorolac tromethamine
PDR
40.0
mg/day
10
mg/dose
PO, oral
qid
Acular
ketorolac tromethamine
PDR
0.5
mg/kg/dose
0.5
mg/kg/dose
intravenous injection, IV
Acular
ketorolac tromethamine
PDR
1.0
mg/kg/dose
1
mg/kg/dose
IM,intramuscular injection
Acular
ketorolac tromethamine
PDR
2.0
mg/kg/day
0.5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qid
Acular
ketorolac tromethamine
PDR
2.0
mg/kg/day
0.5
mg/kg/dose
intravenous injection, IV
qid
Acular
ketorolac tromethamine
PDR
DDPD00467
Enoxacin
320.3189
C15H17FN4O3
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
DB00467
3229
157175
http://www.drugs.com/mtm/enoxacin.html
3116
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90.0
%
PO, oral;
DRUGBANK
0.324
L/h/kg
5.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
L/kg
2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
h
3-6
h
elimination half-life;
DRUGBANK
5.1
h
5.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
%
~40
%
plasma proteins; normal,healthy; human, homo sapiens;
DRUGBANK
14.0
%
~14
%
plasma proteins; renal insufficiency;
DRUGBANK
DDPD00468
Quinine
324.4168
C20H24N2O2
[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
DB00468
T3D2800
3034034
15854
http://www.drugs.com/cdi/quinine.html
84989
-2.0
-
-2.0
-
DRUGBANK
82.0
%
76-88
%
DRUGBANK
76.0
%
76±11
%
PO, oral;
DRUGBANK
11000.0
ng/ml
11±2
mcg/ml
intravenous injection, IV; adults; malaria;
DRUGBANK
8350.0
ng/ml
7.3-9.4
mcg/ml
PO, oral; adults; malaria;
DRUGBANK
9050.0
ng/ml
8.7-9.4
mcg/ml
intravenous injection, IV; Children; malaria;
DRUGBANK
7300.0
ng/ml
7.3±1.1
mcg/ml
PO, oral; Children; malaria;
DRUGBANK
5.95
h
3.5-8.4
h
PO, oral; Children; adults; malaria;
DRUGBANK
80.0
%
80
%
Liver metabolism;
DRUGBANK
0.07
L/h/kg
0.07
L/h/kg
normal,healthy;
DRUGBANK
0.19
L/h/kg
0.19
L/h/kg
malaria; patients;
DRUGBANK
18.4
L/h
18.4
L/h
normal,healthy; adults; increasing doses;
DRUGBANK
11.8
L/h
11.8
L/h
normal,healthy; adults;
DRUGBANK
0.06
L/h/kg
0.06
L/h/kg
Total clearance; PO, oral; Elderly;
DRUGBANK
0.114
L/h/kg
1.9±0.5
ml/min/kg
normal,healthy; adults;
DRUGBANK
0.069
L/h/kg
0.9-1.4
ml/min/kg
malaria; adults;
DRUGBANK
0.054
L/h/kg
0.4-1.4
ml/min/kg
malaria; Children;
Elderly ↓ ;Preg, pregnant → ;RD, renal impairment, Renal disease，including uremia → ;Somking ↑ ;
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.43
L/kg
1.43±0.18
L/kg
normal,healthy; Children;
DRUGBANK
0.87
L/kg
0.87±0.12
L/kg
malaria; pediatric patients;
DRUGBANK
4.8
L/kg
2.5-7.1
L/kg
Oral single dose; normal,healthy;
DRUGBANK
1.8
L/kg
1.8±0.4
L/kg
normal,healthy; adults;
DRUGBANK
1.35
L/kg
1.0-1.7
L/kg
malaria; adults;
DRUGBANK
1.45
L/kg
1.2-1.7
L/kg
malaria; Children;
Preg, pregnant ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
~18
h
DRUGBANK
11.0
h
11±2
h
normal,healthy; adults;
Hepatitis, Hep ↑ ;Somking ↓ ;Age ↑ ;
DRUGBANK
14.5
h
11-18
h
malaria; adults;
Preg, pregnant ↓ ;RD, renal impairment, Renal disease，including uremia → ;Hepatitis, Hep ↑ ;Somking ↓ ;Age ↑ ;
DRUGBANK
14.0
h
12-16
h
malaria; Children;
Hepatitis, Hep ↑ ;Somking ↓ ;Age ↑ ;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
Urinary excretion; Unchanged drug;
DRUGBANK
16.0
%
12-20
%
Urinary excretion; adults; normal,healthy; Unchanged drug;
DRUGBANK
33.0
%
33±18
%
Urinary excretion; adults; malaria; Unchanged drug;
DRUGBANK
70.0
%
~70
%
DRUGBANK
87.5
%
~85-90
%
adults; normal,healthy; human, homo sapiens;
Neonates ↓ ;Preg, pregnant → ;
DRUGBANK
94.0
%
93-95
%
adults; malaria; human, homo sapiens;
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Qualaquin
quinine sulfate
PDR
1944.0
mg/day
1944
mg/day
PO, oral
Qualaquin
quinine sulfate
PDR
1944.0
mg/day
1944
mg/day
PO, oral
Qualaquin
quinine sulfate
PDR
1944.0
mg/day
1944
mg/day
PO, oral
Qualaquin
quinine sulfate
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Qualaquin
quinine sulfate
PDR
1944.0
mg/day
1944
mg/day
PO, oral
Qualaquin
quinine sulfate
PDR
1944.0
mg/day
1944
mg/day
PO, oral
Qualaquin
quinine sulfate
PDR
DDPD00469
Tenoxicam
337.37
C13H11N3O4S2
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=CS2)S1(=O)=O
DB00469
54677971
32192
10442339
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
DRUGBANK
100.0
%
100.0
%
DRUGBANK
0.0018
L/h/kg
0.03
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
72.0
h
72(59-74)
h
DRUGBANK
67.0
h
67
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
DDPD00470
Dronabinol
314.4617
C21H30O2
[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1
DB00470
T3D2801
16078
66964
15266
-2.0
-
-2.0
-
DRUGBANK
92.5
%
90-95
%
Oral single dose;
DRUGBANK
15.0
%
10-20
%
Oral single dose;
DRUGBANK
1.32
ng/ml
1.32
ng/ml
Oral single dose;
DRUGBANK
3.0
h
2-4
h
Oral single dose;
DRUGBANK
1.0
h
1
h
Oral single dose;
DRUGBANK
0.2
L/h/kg
0.2
L/h/kg
Average clearance;
DRUGBANK
10.0
L/kg
10.0
L/kg
Apparent volume of distribution;
DRUGBANK
4.0
h
4
h
elimination half-life;
DRUGBANK
30.5
h
25-36
h
terminal half-life;
DRUGBANK
97.0
%
~97
%
plasma proteins;
DRUGBANK
60.0
mg/m2/day
15
mg/m2/dose
PO, oral
q6h-q4h
Marinol
dronabinol
PDR
50.4
mg/m2/day
12.6
mg/m2/dose
PO, oral
q6h-q4h
Marinol
dronabinol
PDR
10.0
mg
10
mg
PO, oral
bid
Marinol
dronabinol
PDR
16.8
mg/day
16.8
mg/day
PO, oral
Marinol
dronabinol
PDR
15.0
mg/m2/dose
15
mg/m2/dose
Capsule, PO, Oral
q6h-q4h
Marinol
dronabinol
PDR
12.6
mg/m2/dose
12.6
mg/m2/dose
Liquid
q6h-q4h
Marinol
dronabinol
PDR
10.0
mg
10
mg
Capsule, PO, Oral
bid
Marinol
dronabinol
PDR
16.8
mg/day
16.8
mg/day
Liquid
Marinol
dronabinol
PDR
DDPD00471
Montelukast
586.183
C35H36ClNO3S
OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1
DB00471
5281040
50730
http://www.drugs.com/cdi/montelukast.html
4444507
-2.0
-
-2.0
-
DRUGBANK
64.0
%
64.0
%
PO, oral;
DRUGBANK
62.0
%
62.0
%
PO, oral;
DRUGBANK
542.0
ng/ml
542±173
ng/ml
Oral single dose;
DRUGBANK
3.0
h
3.0±1.0
h
Oral single dose;
DRUGBANK
2.7
L/h
45.0
ml/min
Plasma clearance;
DRUGBANK
0.042
L/h/kg
0.70±0.17
ml/min/kg
normal,healthy; adults;
Children → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
0.0408
L/h/kg
0.68
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.5
L
8.0-11
L
Steady state volume of distribution;
DRUGBANK
0.15
L/kg
0.15±0.02
L/kg
normal,healthy; adults;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.1
h
2.7-5.5
h
elimination half-life; normal,healthy; young; adults;
DRUGBANK
4.9
h
4.9±0.6
h
Hepatic cirrhosis, cirr ↑ ;mild hepatic impairment ↑ ;moderate hepatic impairment ↑ ;severe hepatic impairment ↑ ;
DRUGBANK
5.0
h
5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
100.0
%
~100
%
Faeces excretion;
DRUGBANK
0.2
%
<0.2
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
99.0
%
>99
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Singulair
montelukast sodium
PDR
4.0
mg/day
4
mg/day
PO, oral
Singulair
montelukast sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Singulair
montelukast sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Singulair
montelukast sodium
PDR
5.0
mg/day
5
mg/day
PO, oral
Singulair
montelukast sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Singulair
montelukast sodium
PDR
4.0
mg/day
4
mg/day
PO, oral
Singulair
montelukast sodium
PDR
DDPD00472
Fluoxetine
309.3261
C17H18F3NO
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
DB00472
T3D2802
3386
86990
http://www.drugs.com/fluoxetine.html
3269
-2.0
-
-2.0
-
DRUGBANK
90.0
%
<90
%
DRUGBANK
11.754
ng/ml
11.754
ng/ml
DRUGBANK
365.5
ng/ml
200-531
ng/ml
PO, oral;
DRUGBANK
284.0
ng/ml
103-465
ng/ml
PO, oral;
DRUGBANK
7.0
h
6-8
h
PO, oral;
DRUGBANK
0.576
L/h/kg
9.6
ml/min/kg
normal,healthy; patients;
DRUGBANK
0.576
L/h/kg
9.6±6.9
ml/min/kg
apparent clearance; Drug combination; hydrolysis;
Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;increasing doses ↓ ;
DRUGBANK
31.0
L/kg
20-42
L/kg
DRUGBANK
35.0
L/kg
35±21
L/kg
Apparent volume of distribution;
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
48.0
h
1-3
day
elimination half-life;
DRUGBANK
120.0
h
4-6
day
elimination half-life; Oral multiple dose;
DRUGBANK
240.0
h
4-16
day
elimination half-life; Oral multiple dose;
DRUGBANK
53.0
h
53±41
h
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;increasing doses ↑ ;Age → ;
DRUGBANK
284.0
mg/kg
284.0
mg/kg
PO, oral; mouse;
DRUGBANK
2.5
%
<2.5
%
Urinary excretion; Unchanged drug;
DRUGBANK
94.0
%
~94
%
plasma proteins;
DRUGBANK
94.0
%
94
%
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
0.5
mg/kg/day
0.5
mg/kg/day
PO, oral
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
80.0
mg/day
80
mg/day
PO, oral
qd
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
12.8571428571429
mg/day
90
mg/week
PO, oral
qw
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
80.0
mg/day
80
mg/day
PO, oral
qd
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
12.8571428571429
mg/day
90
mg/week
PO, oral
qw
Fluoxetine Tablets
fluoxetine hydrochloride
PDR
DDPD00473
Hexylcaine
261.3593
C16H23NO2
CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1
DB00473
10770
34791
10315
-2.0
-
-2.0
-
DRUGBANK
0.166666666666667
h
<10
min
DRUGBANK
DDPD00474
Methohexital
262.3043
C14H18N2O3
CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
DB00474
T3D2803
9034
102216
http://www.drugs.com/cdi/methohexital.html
8683
-2.0
-
-2.0
-
DRUGBANK
17.0
%
17.0
%
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0933333333333333
h
5.6±2.7
min
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
73.0
%
73
%
DRUGBANK
DDPD00475
Chlordiazepoxide
299.755
C16H14ClN3O
CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=[N+]([O-])C1
DB00475
T3D2804
2712
3611
http://www.drugs.com/cdi/chlordiazepoxide.html
10248513
-2.0
-
-2.0
-
DRUGBANK
0.0222
L/h/kg
0.37
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.25
L/kg
0.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
h
24-48
h
DRUGBANK
8.3
h
8.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
537.0
mg/kg
537.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
537.0
mg/kg
537.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.5
%
1-2
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD00476
Duloxetine
297.415
C18H19NOS
CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1
DB00476
T3D2805
60835
36795
http://www.drugs.com/cdi/duloxetine-delayed-release-capsules.html
54822
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50(30-80)
%
PO, oral;
DRUGBANK
6.0
h
6
h
PO, oral;
DRUGBANK
9.0
h
9
h
food;
food ↑ ;
DRUGBANK
85.5
L/h
57-114
L/h
DRUGBANK
0.5142
L/h/kg
8.57
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1710.0
L
1620-1800
L
Apparent volume of distribution;
DRUGBANK
12.0
h
12(8-17)
h
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
491.0
mg/kg
491.0
mg/kg
PO, oral; male rat;
DRUGBANK
279.0
mg/kg
279.0
mg/kg
PO, oral; female rat;
DRUGBANK
90.0
%
>90
%
plasma proteins;
DRUGBANK
120.0
mg/day
120
mg/day
PO, oral
Cymbalta
duloxetine
PDR
120.0
mg/day
120
mg/day
PO, oral
Cymbalta
duloxetine
PDR
120.0
mg/day
120
mg/day
PO, oral
Cymbalta
duloxetine
PDR
60.0
mg/day
60
mg/day
PO, oral
Cymbalta
duloxetine
PDR
120.0
mg/day
120
mg/day
PO, oral
Cymbalta
duloxetine
PDR
DDPD00477
Chlorpromazine
318.864
C17H19ClN2S
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2
DB00477
T3D2806
2726
3647
http://www.drugs.com/cdi/chlorpromazine.html
2625
-2.0
-
-2.0
-
DRUGBANK
32.0
%
32±19
%
PO, oral;
DRUGBANK
87.5
ng/ml
25-150
ng/ml
PO, oral; adults; patients;
DRUGBANK
2.5
h
1-4
h
PO, oral; adults; patients;
DRUGBANK
20.0
%
20
%
Urinary excretion; Unchanged drug;
DRUGBANK
37.0
%
37
%
Urinary excretion;
DRUGBANK
0.516
L/h/kg
8.6±2.9
ml/min/kg
apparent clearance; IM,intramuscular injection;
Children ↓ ;Hepatitis, Hep → ;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L/kg
20.0
L/kg
DRUGBANK
21.0
L/kg
21±9
L/kg
IM,intramuscular injection;
DRUGBANK
10.0
L/kg
10
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
h
~30
h
DRUGBANK
30.0
h
30±7
h
DRUGBANK
25.0
h
25±15
h
terminal half-life; IM,intramuscular injection;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.0
%
~37
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
>90
%
plasma proteins;
DRUGBANK
96.5
%
95-98
%
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
75.0
mg/day
75
mg/day
IM,intramuscular injection
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
40.0
mg/day
40
mg/day
IM,intramuscular injection
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Chlorpromazine Hydrochloride Injection
chlorpromazine hydrochloride
PDR
DDPD00478
Rimantadine
179.3018
C12H21N
CC(N)C12CC3CC(CC(C3)C1)C2
DB00478
5071
94440
http://www.drugs.com/cdi/rimantadine.html
4893
-2.0
-
-2.0
-
DRUGBANK
25.0
%
<25
%
Urinary excretion; Unchanged drug; PO, oral;
DRUGBANK
27.5
h
25-30
h
young; adults;
DRUGBANK
32.0
h
~32
h
Elderly;
DRUGBANK
32.0
h
~32
h
chronic liver disease; patients;
DRUGBANK
25.5
h
~13-38
h
Children;
DRUGBANK
640.0
mg/kg
640.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
25.0
%
<25
%
Urinary excretion; Unchanged drug;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Flumadine
rimantadine hydrochloride
PDR
DDPD00479
Amikacin
585.6025
C22H43N5O13
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
DB00479
37768
2637
http://www.drugs.com/cdi/amikacin.html
34635
-2.0
-
-2.0
-
DRUGBANK
21000.0
ng/ml
17-25
mcg/ml
normal,healthy; adults;
DRUGBANK
38000.0
ng/ml
38.0
mcg/ml
intravenous injection, IV;
DRUGBANK
26000.0
ng/ml
26±4
mcg/ml
intravenous infusion, IV in drop; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
1.375
h
0.75-2
h
normal,healthy; adults;
DRUGBANK
1.0
h
1
h
intravenous injection, IV;
DRUGBANK
6.0
L/h
100.0
ml/min
Plasma clearance;
DRUGBANK
5.64
L/h
94.0
ml/min
Renal clearance; normal,healthy;
DRUGBANK
0.078
L/h/kg
1.3±0.6
ml/min/kg
Obesity ↓ ;Cystic fibrosis ↑ ;
DRUGBANK
0.066
L/h/kg
1.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
L
24.0
L
normal,healthy; Male, men;
DRUGBANK
0.27
L/kg
0.27±0.06
L/kg
Neonates ↑ ;Children → ;Elderly → ;Obesity ↓ ;Cystic fibrosis → ;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
elimination half-life; adults; normal renal function;
DRUGBANK
58.0
h
30-86
h
elimination half-life; adults; severe renal function;
DRUGBANK
2.3
h
2.3±0.4
h
Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;Burn → ;Cystic fibrosis → ;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6000.0
mg/kg
6000.0
mg/kg
PO, oral; mouse;
DRUGBANK
96.0
%
94-98
%
Urinary excretion; adults; human, homo sapiens;
DRUGBANK
98.0
%
98
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
≤10
%
DRUGBANK
4.0
%
4±8
%
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
1500.0
mg/day
1.5
g/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
22.5
mg/kg/day
22.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
35.0
mg/kg/day
35
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
1500.0
mg/day
1.5
g/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
35.0
mg/kg/day
35
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
590.0
mg/day
590
mg/day
inhalation, IH
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
1500.0
mg/day
1.5
g/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
22.5
mg/kg/day
22.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
35.0
mg/kg/day
35
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
1500.0
mg/day
1.5
g/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
35.0
mg/kg/day
35
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
590.0
mg/day
590
mg/day
inhalation, IH
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
22.5
mg/kg/day
22.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
35.0
mg/kg/day
35
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qd
Arikayce
amikacin liposome
PDR
15.0
mg/kg/day
15
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qd
Arikayce
amikacin liposome
PDR
16.5
mg/kg/dose
16.5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qd
Arikayce
amikacin liposome
PDR
DDPD00480
Lenalidomide
259.2606
C13H13N3O3
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
DB00480
216326
63791
http://www.drugs.com/cdi/lenalidomide.html
187515
-2.0
-
-2.0
-
DRUGBANK
1.0625
h
0.625-1.5
h
PO, oral;
DRUGBANK
3.0
h
3
h
normal,healthy;
DRUGBANK
4.0
h
3-5
h
multiple myeloma;
DRUGBANK
4.0
h
3-5
h
Myelodysplastic syndromes;
DRUGBANK
90.0
%
90
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
4.0
%
4
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
30.0
%
30
%
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
Revlimid
lenalidomide
PDR
25.0
mg/day
25
mg/day
PO, oral
Revlimid
lenalidomide
PDR
DDPD00481
Raloxifene
473.583
C28H27NO4S
OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
DB00481
5035
8772
http://www.drugs.com/cdi/raloxifene.html
4859
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60.0
%
PO, oral;
DRUGBANK
27.2
ng.h/ml
27.2
ng.h/ml
Oral single dose; postmenopausal women;
DRUGBANK
24.2
ng.h/ml
24.2
ng.h/ml
Oral multiple dose; postmenopausal women;
DRUGBANK
27.2
ng.h/ml
27.2
ng.h/ml
Oral single dose; postmenopausal women;
high-fat meal ↑ ;
DRUGBANK
24.2
ng.h/ml
24.2
ng.h/ml
Oral multiple dose; postmenopausal women;
high-fat meal ↑ ;
DRUGBANK
2.0
%
2.0
%
PO, oral;
DRUGBANK
2.0
%
2.0
%
PO, oral;
DRUGBANK
0.5
ng/ml
0.5
ng/ml
Oral single dose; postmenopausal women;
DRUGBANK
1.36
ng/ml
1.36
ng/ml
Oral multiple dose; postmenopausal women;
DRUGBANK
0.64
ng/ml
0.64
ng/ml
Oral single dose; postmenopausal women;
high-fat meal ↑ ;
DRUGBANK
1.7408
ng/ml
1.7408
ng/ml
Oral multiple dose; postmenopausal women;
high-fat meal ↑ ;
DRUGBANK
0.5
ng/ml
0.5±0.3
ng/ml
PO, oral;
DRUGBANK
27.7
h
27.7
h
Oral single dose; postmenopausal women;
DRUGBANK
32.5
h
32.5
h
Oral multiple dose; postmenopausal women;
DRUGBANK
32.132
h
32.132
h
Oral single dose; postmenopausal women;
high-fat meal ↑ ;
DRUGBANK
37.7
h
37.7
h
Oral multiple dose; postmenopausal women;
high-fat meal ↑ ;
DRUGBANK
6.0
h
6.0
h
PO, oral;
DRUGBANK
44.1
L/h/kg
44.1
L/h/kg
Total clearance; PO, oral;
DRUGBANK
50.0
L/h/kg
40-60
L/h/kg
Oral multiple dose;
DRUGBANK
47.4
L/h/kg
47.4
L/h/kg
Average clearance; Oral multiple dose; normal,healthy; postmenopausal women;
hepatopathy，LD ↓ ;
DRUGBANK
44.1
L/h/kg
735±338
ml/min/kg
apparent clearance; PO, oral; postmenopausal women; metabolism of ugt;
Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.648
L/h/kg
10.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2348.0
L/kg
2348.0
L/kg
Oral single dose; postmenopausal women;
DRUGBANK
2853.0
L/kg
2853.0
L/kg
Oral multiple dose; postmenopausal women;
DRUGBANK
2348.0
L/kg
2348±1220
L/kg
Apparent volume of distribution; PO, oral; postmenopausal women; metabolism of ugt;
DRUGBANK
7.5
L/kg
7.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.5
h
27-32
h
elimination half-life;
DRUGBANK
28.0
h
28(11-273)
h
postmenopausal women;
DRUGBANK
12.1
h
12.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.2
%
<0.2
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.2
%
<0.2
%
Urinary excretion; postmenopausal women; Unchanged drug;
DRUGBANK
95.0
%
~95
%
plasma proteins;
DRUGBANK
95.0
%
>95
%
postmenopausal women; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Evista
raloxifene hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Evista
raloxifene hydrochloride
PDR
DDPD00482
Celecoxib
381.372
C17H14F3N3O2S
CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
DB00482
T3D4771
2662
41423
http://www.drugs.com/celecoxib.html
2562
-2.0
-
-2.0
-
DRUGBANK
705.0
ng/ml
705.0
ng/ml
DRUGBANK
705000.0
ng/ml
705±268
mcg/ml
Oral single dose; normal,healthy;
DRUGBANK
3.0
h
3
h
Oral single dose;
DRUGBANK
2.8
h
2.8±1.0
h
Oral single dose; normal,healthy;
DRUGBANK
120.0
h
5.0
day
Oral multiple dose;
DRUGBANK
27.7
L/h
27.7
L/h
Total clearance; Oral single dose; normal,healthy;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.396
L/h/kg
6.60±1.85
ml/min/kg
apparent clearance; CYP2D6 genetic polymorphisms; normal,healthy;
Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
429.0
L
429.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
455.0
L
455±166
L
DRUGBANK
6.12
L/kg
6.12±2.08
L/kg
CYP2D6 genetic polymorphisms; normal,healthy;
DRUGBANK
11.0
h
~11
h
effective half-life; Single dose; normal,healthy;
DRUGBANK
11.2
h
11.2±3.47
h
normal,healthy;
DRUGBANK
5.71
mg/kg
5.71
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
57.0
%
~57
%
Faeces excretion; PO, oral;
DRUGBANK
3.0
%
<3
%
Urinary excretion; Faeces excretion; Unchanged drug;
DRUGBANK
3.0
%
<3
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
97.0
%
~97
%
normal,healthy; human, homo sapiens;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Celebrex
celecoxib
PDR
100.0
mg/day
100
mg/day
PO, oral
Celebrex
celecoxib
PDR
800.0
mg/day
800
mg/day
PO, oral
Celebrex
celecoxib
PDR
200.0
mg/day
200
mg/day
PO, oral
Celebrex
celecoxib
PDR
400.0
mg/day
400
mg/day
PO, oral
Celebrex
celecoxib
PDR
DDPD00483
Gallamine triethiodide
891.5291
C30H60I3N3O3
[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
DB00483
6172
5937
-2.0
-
-2.0
-
DRUGBANK
0.0906
L/h/kg
1.51
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.27
L/kg
0.27
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.52
h
2.52
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00484
Brimonidine
292.135
C11H10BrN5
BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
DB00484
T3D3487
2435
3175
http://www.drugs.com/cdi/brimonidine.html
2341
-2.0
-
-2.0
-
DRUGBANK
0.417
ng.h/ml
417±264
pg.h/ml
skin/dermal;
DRUGBANK
0.046
ng/ml
46±62
pg/ml
skin/dermal;
DRUGBANK
2.5
h
1-4
h
ophthalmic administration;
DRUGBANK
3.0
h
~3
h
elimination half-life; intravenous infusion, IV in drop;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
74.0
%
74
%
Urinary excretion;
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Brimonidine Tartrate
brimonidine tartrate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Brimonidine Tartrate
brimonidine tartrate
PDR
1.0
application/day
1
application/day
skin/dermal
Brimonidine Tartrate
brimonidine tartrate
PDR
DDPD00485
Dicloxacillin
470.326
C19H17Cl2N3O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O
DB00485
18381
4511
http://www.drugs.com/cdi/dicloxacillin.html
17358
-2.0
-
-2.0
-
DRUGBANK
67.5
%
50-85
%
DRUGBANK
69000.0
ng/ml
47-91
mcg/ml
PO, oral; fasting; adults; normal,healthy;
DRUGBANK
1.25
h
1-1.5
h
PO, oral; food;
food ↓ ;
DRUGBANK
1.05
h
0.5-1.6
h
PO, oral; fasting; adults; normal,healthy;
DRUGBANK
0.096
L/h/kg
1.6±0.3
ml/min/kg
Renal clearance;
RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis ↑ ;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.086
L/kg
0.086±0.017
L/kg
RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↑ ;
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
h
~0.7
h
elimination half-life;
DRUGBANK
0.7
h
0.70±0.07
h
RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;
DRUGBANK
0.88
h
0.88
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3579.0
mg/kg
3579.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
60.0
%
60±7
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.8
%
95.8±0.2
%
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;Cystic fibrosis → ;
DRUGBANK
4000.0
mg/day
4
g/day
PO, oral
Dicloxacillin Sodium
dicloxacillin sodium
PDR
4000.0
mg/day
4
g/day
PO, oral
Dicloxacillin Sodium
dicloxacillin sodium
PDR
4000.0
mg/day
4
g/day
PO, oral
Dicloxacillin Sodium
dicloxacillin sodium
PDR
DDPD00486
Nabilone
372.5408
C24H36O3
[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC
DB00486
5284592
http://www.drugs.com/cdi/nabilone.html
4447641
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
2.0
ng/ml
~2
ng/ml
PO, oral;
DRUGBANK
12.5
L/kg
12.5
L/kg
Apparent volume of distribution;
DRUGBANK
2.0
h
2
h
elimination half-life;
DRUGBANK
35.0
h
35
h
elimination half-life;
DRUGBANK
67.0
%
~67
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
22.0
%
~22
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
60.0
%
~60
%
Faeces excretion; PO, oral;
DRUGBANK
24.0
%
~24
%
Urinary excretion; PO, oral;
DRUGBANK
3.0
mg/day
3
mg/day
PO, oral
Cesamet
nabilone
PDR
2.0
mg/day
2
mg/day
PO, oral
Cesamet
nabilone
PDR
1.0
mg/day
1
mg/day
PO, oral
Cesamet
nabilone
PDR
6.0
mg/day
6
mg/day
PO, oral
Cesamet
nabilone
PDR
3.0
mg/day
3
mg/day
PO, oral
Cesamet
nabilone
PDR
6.0
mg/day
6
mg/day
PO, oral
Cesamet
nabilone
PDR
DDPD00487
Pefloxacin
333.3574
C17H20FN3O3
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(C)CC1
DB00487
51081
50199
46291
-2.0
-
-2.0
-
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.6
h
8.6
h
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
%
20-30
%
DRUGBANK
DDPD00488
Altretamine
210.2794
C9H18N6
CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
DB00488
2123
24564
http://www.drugs.com/cdi/altretamine.html
2038
-2.0
-
-2.0
-
DRUGBANK
7.45
h
4.7-10.2
h
DRUGBANK
94.0
%
94
%
DRUGBANK
260.0
mg/m2/day
260
mg/m2/day
PO, oral
Hexalen
altretamine
PDR
DDPD00489
Sotalol
272.364
C12H20N2O3S
CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
DB00489
5253
63622
http://www.drugs.com/cdi/sotalol.html
5063
-2.0
-
-2.0
-
DRUGBANK
18.0
%
<18
%
PO, oral; food;
DRUGBANK
95.0
%
90-100
%
DRUGBANK
6.25
null
6.25±2.19
null
PO, oral; food;
DRUGBANK
0.0
%
0
%
DRUGBANK
6.78
L/h
6.78±2.72
L/h
Plasma clearance; normal,healthy; patients;
DRUGBANK
4.99
L/h
4.99±1.43
L/h
Renal clearance; normal,healthy; patients;
DRUGBANK
2.74
L/h
2.74±0.53
L/h
Plasma clearance; moderate renal function; patients;
DRUGBANK
2.0
L/h
2.00±0.67
L/h
Renal clearance; moderate renal function; patients;
DRUGBANK
1.56
L/h
1.56±0.44
L/h
Plasma clearance; severe renal function; patients;
DRUGBANK
0.65
L/h
0.65±0.31
L/h
Renal clearance; severe renal function; patients;
DRUGBANK
0.65
L/h
0.65±0.20
L/h
Plasma clearance; renal insufficiency; patients;
DRUGBANK
0.27
L/h
0.27±0.13
L/h
Renal clearance; renal insufficiency; patients;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
L/kg
1.2-2.4
L/kg
Apparent volume of distribution;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
h
10-20
h
elimination half-life; normal,healthy; patients;
DRUGBANK
17.5
h
17.5±0.97
h
normal renal function; patients;
DRUGBANK
22.7
h
22.7±6.4
h
mild renal function; moderate renal function; patients;
DRUGBANK
64.0
h
64±27.2
h
severe renal function; patients;
DRUGBANK
97.9
h
97.9±57.3
h
renal insufficiency;
DRUGBANK
6.3
h
6.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3450.0
mg/kg
3450.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
680.0
mg/kg
680.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
PO, oral; mouse;
DRUGBANK
670.0
mg/kg
670.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
85.0
%
80-90
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
0
%
DRUGBANK
180.0
mg/m2/day
180
mg/m2/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
320.0
mg/day
320
mg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Betapace/Betapace AF
sotalol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Betapace/Betapace AF
sotalol hydrochloride
PDR
180.0
mg/m2/day
180
mg/m2/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
320.0
mg/day
320
mg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Betapace/Betapace AF
sotalol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Betapace/Betapace AF
sotalol hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Betapace/Betapace AF
sotalol hydrochloride
PDR
DDPD00490
Buspirone
385.5031
C21H31N5O2
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1
DB00490
T3D2807
2477
3223
http://www.drugs.com/buspirone.html
2383
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5.0
%
PO, oral;
DRUGBANK
3.9
%
3.9±4.3
%
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
3.5
ng/ml
1-6
ng/ml
Oral single dose;
DRUGBANK
1.66
ng/ml
1.66±0.21
ng/ml
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
1.085
h
0.67-1.5
h
Oral single dose;
DRUGBANK
0.71
h
0.71±0.06
h
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
1.7
L/h/kg
1.7
L/h/kg
Total clearance;
DRUGBANK
1.698
L/h/kg
28.3±10.3
ml/min/kg
apparent clearance; hydrolysis; normal,healthy; Male, men; adults;
Hepatitis, Hep ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
5.31
L/kg
5.3
L/kg
DRUGBANK
5.3
L/kg
5.3±2.6
L/kg
hydrolysis; normal,healthy; Male, men; adults;
DRUGBANK
2.5
h
~2-3
h
elimination half-life; Single dose;
DRUGBANK
2.4
h
2.4±1.1
h
normal,healthy; adults; Female, women;
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
196.0
mg/kg
196.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
655.0
mg/kg
655.0
mg/kg
PO, oral; mouse;
DRUGBANK
586.0
mg/kg
586.0
mg/kg
PO, oral; dog;
DRUGBANK
356.0
mg/kg
356.0
mg/kg
PO, oral; monkey;
DRUGBANK
136.0
mg/kg
136.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
146.0
mg/kg
146.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
136.0
mg/kg
136.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
46.0
%
~29-63
%
Urinary excretion;
DRUGBANK
28.0
%
~18-38
%
Faeces excretion;
DRUGBANK
0.1
%
<0.1
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
86.0
%
~86
%
plasma proteins; high protein binding;
DRUGBANK
95.0
%
>95
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Buspirone Hydrochloride Tablets, USP, 7.5 mg
buspirone hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Buspirone Hydrochloride Tablets, USP, 7.5 mg
buspirone hydrochloride
PDR
DDPD00491
Miglitol
207.2243
C8H17NO5
OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
DB00491
441314
6935
http://www.drugs.com/cdi/miglitol.html
390074
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
60.0
%
50-70
%
PO, oral;
DRUGBANK
0.0
%
0
%
human, homo sapiens; animals;
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.18
L/kg
0.18
L/kg
DRUGBANK
0.28
L/kg
0.28
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
elimination half-life;
DRUGBANK
2.3
h
2.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
%
4
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Glyset
miglitol
PDR
300.0
mg/day
300
mg/day
PO, oral
Glyset
miglitol
PDR
DDPD00492
Fosinopril
563.672
C30H46NO7P
CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
DB00492
55891
5163
http://www.drugs.com/cdi/fosinopril.html
23089342
-2.0
-
-2.0
-
DRUGBANK
36.0
%
36.0
%
DRUGBANK
1.98
L/h
26-39
ml/min
normal,healthy;
DRUGBANK
12.0
h
12
h
DRUGBANK
95.0
%
95
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Fosinopril Sodium
fosinopril sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Fosinopril Sodium
fosinopril sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Fosinopril Sodium
fosinopril sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Fosinopril Sodium
fosinopril sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Fosinopril Sodium
fosinopril sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Fosinopril Sodium
fosinopril sodium
PDR
DDPD00493
Cefotaxime
455.465
C16H17N5O7S2
[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
DB00493
5742673
204928
http://www.drugs.com/cdi/cefotaxime.html
4674877
-2.0
-
-2.0
-
DRUGBANK
28.0
%
20-36
%
Renal metabolism; Unchanged drug;
DRUGBANK
20.0
%
15-25
%
Renal metabolism; Active metabolite;
DRUGBANK
0.162
L/h/kg
2.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20000.0
mg/kg
>20000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
7000.0
mg/kg
>7000
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
28.0
%
~20-36
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
12.0
12
Claforan
cefotaxime
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
300.0
mg/kg/day
300
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Claforan
cefotaxime
PDR
DDPD00494
Entacapone
305.286
C14H15N3O5
CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N
DB00494
T3D2808
5281081
4798
http://www.drugs.com/cdi/entacapone.html
4444537
-2.0
-
-2.0
-
DRUGBANK
35.0
%
35.0
%
PO, oral;
DRUGBANK
42.0
%
42±9
%
PO, oral; Male, men; normal,healthy;
DRUGBANK
4300.0
ng/ml
4.3±2.0
mcg/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
0.8
h
0.8±0.2
h
PO, oral; Male, men; normal,healthy;
DRUGBANK
34.8
L/h
850.0
ml/min
DRUGBANK
0.618
L/h/kg
10.3±1.74
ml/min/kg
Bile excretion; normal,healthy; Male, men;
hepatopathy，LD → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L
20.0
L
DRUGBANK
0.4
L/kg
0.40±0.16
L/kg
Bile excretion; normal,healthy; Male, men;
DRUGBANK
0.27
L/kg
0.27
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.55
h
0.4-0.7
h
DRUGBANK
0.28
h
0.28±0.06
h
distribution half-life;
DRUGBANK
2.9
h
2.9±2.0
h
terminal half-life;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
98
%
DRUGBANK
98.0
%
98
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
1600.0
mg/day
1600
mg/day
PO, oral
Comtan
entacapone
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Comtan
entacapone
PDR
DDPD00495
Zidovudine
267.2413
C10H13N5O4
CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
DB00495
T3D4720
35370
10110
http://www.drugs.com/cdi/zidovudine.html
32555
-2.0
-
-2.0
-
DRUGBANK
65.0
%
65(52-75)
%
DRUGBANK
89.0
%
89.0
%
PO, oral; Neonates;
DRUGBANK
65.0
%
65.0
%
PO, oral; Children;
DRUGBANK
63.0
%
63±10
%
PO, oral;
DRUGBANK
2600.0
ng/ml
2.6
mcg/ml
PO, oral;
DRUGBANK
1600.0
ng/ml
1.6
mcg/ml
intravenous injection, IV;
DRUGBANK
0.75
h
0.5-1
h
PO, oral; intravenous injection, IV;
DRUGBANK
0.65
L/h/kg
0.65±0.29
L/h/kg
AIDS,HIV; Neonates;
DRUGBANK
1.14
L/h/kg
1.14±0.24
L/h/kg
AIDS,HIV; Infants;
DRUGBANK
1.85
L/h/kg
1.85±0.47
L/h/kg
AIDS,HIV; Infants;
DRUGBANK
1.56
L/h/kg
26±6
ml/min/kg
Neonates ↓ ;Children → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
1.5
L/h/kg
25
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6±0.6
L/kg
Apparent volume of distribution; intravenous injection, IV; AIDS,HIV; patients;
DRUGBANK
1.4
L/kg
1.4±0.4
L/kg
Children → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
h
1.1(0.5-2.9)
h
elimination half-life; AIDS,HIV; patients; intravenous injection, IV;
DRUGBANK
1.1
h
1.1±0.2
h
Preg, pregnant → ;Neonates ↑ ;RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3084.0
mg/kg
3084.0
mg/kg
PO, oral; mouse;
DRUGBANK
3084.0
mg/kg
3084.0
mg/kg
PO, oral; mouse;
DRUGBANK
29.0
%
~29
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
18.0
%
18±5
%
Urinary excretion; Unchanged drug;
DRUGBANK
34.0
%
30-38
%
DRUGBANK
25.0
%
<25
%
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
18.0
mg/kg/day
18
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
24.0
mg/kg/day
24
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
600.0
mg
600
mg
PO, oral
Zidovudine
zidovudine
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Zidovudine
zidovudine
PDR
600.0
mg/day
600
mg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
18.0
mg/kg/day
18
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
600.0
mg/day
600
mg/day
PO, oral
Zidovudine
zidovudine
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Zidovudine
zidovudine
PDR
18.0
mg/kg/day
18
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
24.0
mg/kg/day
24
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
PO, oral
Zidovudine
zidovudine
PDR
480.0
mg/m2/day
480
mg/m2/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
4.6
mg/kg/day
4.6
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Zidovudine
zidovudine
PDR
4.6
mg/kg/day
4.6
mg/kg/day
intravenous injection, IV
Zidovudine
zidovudine
PDR
DDPD00496
Darifenacin
426.55
C28H30N2O2
NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
DB00496
T3D3499
444031
391960
http://www.drugs.com/cdi/darifenacin-extended-release-tablets.html
392054
-2.0
-
-2.0
-
DRUGBANK
15.0
%
15.0
%
Capsule, PO, Oral;
DRUGBANK
19.0
%
19.0
%
Capsule, PO, Oral;
DRUGBANK
40.0
L/h
40.0
L/h
extensive metabolizers, EM;
DRUGBANK
32.0
L/h
32.0
L/h
poor metabolizers, PM;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
163.0
L
163.0
L
DRUGBANK
2.6
L/kg
2.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
h
~13-19
h
elimination half-life; inhalation, IH;
DRUGBANK
3.6
h
3.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
~98
%
plasma proteins;
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Enablex
darifenacin
PDR
15.0
mg/day
15
mg/day
PO, oral
Enablex
darifenacin
PDR
DDPD00497
Oxycodone
315.3636
C18H21NO4
COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C
DB00497
T3D2809
5284603
7852
http://www.drugs.com/oxycodone.html
4447649
-2.0
-
-2.0
-
DRUGBANK
135.0
ng.h/ml
135.0
ng.h/ml
PO, oral; patients;
DRUGBANK
73.5
%
60-87
%
PO, oral; food;
food → ;
DRUGBANK
73.5
%
60-87
%
PO, oral; extended release formulation;
DRUGBANK
42.0
%
42±7
%
PO, oral; immediate release formulation;
DRUGBANK
11.5
ng/ml
11.5
ng/ml
PO, oral; patients;
DRUGBANK
15.1
ng/ml
15.1±4.7
ng/ml
PO, oral; extended release formulation;
DRUGBANK
15.5
ng/ml
15.5±4.5
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
5.11
h
5.11
h
PO, oral; patients;
DRUGBANK
3.2
h
3.2±2.2
h
PO, oral; extended release formulation;
DRUGBANK
1.6
h
1.6±0.8
h
PO, oral; immediate release formulation;
DRUGBANK
0.084
L/h
1.4
ml/min
Plasma clearance;
DRUGBANK
0.744
L/h/kg
12.4(9.2-15.4)
ml/min/kg
hydrolysis; normal,healthy; Male, men; Female, women;
DRUGBANK
0.366
L/h/kg
6.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
L/kg
2.6
L/kg
DRUGBANK
2.0
L/kg
2.0(1.1-2.9)
L/kg
hydrolysis; normal,healthy; Male, men; Female, women;
DRUGBANK
2.5
L/kg
2.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.2
h
3.2
h
elimination half-life;
DRUGBANK
4.5
h
4.5
h
extended release formulation;
DRUGBANK
5.8
h
5.8
h
DRUGBANK
8.8
h
8.8
h
DRUGBANK
9.0
h
9
h
DRUGBANK
2.6
h
2.6(2.1-3.1)
h
DRUGBANK
5.0
h
~5
h
extended release formulation;
DRUGBANK
5.5
h
5.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
320.0
mg/kg
320.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
426.0
mg/kg
426.0
mg/kg
PO, oral; mouse;
DRUGBANK
0.14
mg/kg
0.14
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
1.53
mg/kg
1.53
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
45.0
%
45
%
DRUGBANK
45.0
%
45
%
normal,healthy; human, homo sapiens;
DRUGBANK
288.0
mg/day
288
mg/day
Capsule, PO, Oral
Roxicodone
oxycodone hydrochloride
PDR
320.0
mg/day
320
mg/day
PO, oral
Roxicodone
oxycodone hydrochloride
PDR
288.0
mg/day
288
mg/day
Capsule, PO, Oral
Roxicodone
oxycodone hydrochloride
PDR
320.0
mg/day
320
mg/day
PO, oral
Roxicodone
oxycodone hydrochloride
PDR
DDPD00498
Phenindione
222.2387
C15H10O2
O=C1C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1
DB00498
T3D3107
4760
8066
4596
-2.0
-
-2.0
-
DRUGBANK
7.5
h
5-10
h
DRUGBANK
175.0
mg/kg
175.0
mg/kg
PO, oral; mouse;
DRUGBANK
163.0
mg/kg
163.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
175.0
mg/kg
175.0
mg/kg
PO, oral; mouse;
DRUGBANK
163.0
mg/kg
163.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
88.0
%
88
%
DRUGBANK
DDPD00499
Flutamide
276.2118
C11H11F3N2O3
CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
DB00499
T3D4768
3397
5132
http://www.drugs.com/cdi/flutamide.html
3280
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
DRUGBANK
110.0
ng/ml
0.11±0.21
mcg/ml
PO, oral; Elderly;
DRUGBANK
1600.0
ng/ml
1.6±0.59
mcg/ml
PO, oral; Active metabolite; Elderly;
DRUGBANK
1.3
h
1.3±0.7
h
PO, oral; Elderly;
DRUGBANK
1.9
h
1.9±0.6
h
PO, oral; Active metabolite; Elderly;
DRUGBANK
16.8
L/h/kg
280.0
ml/min/kg
apparent clearance; PO, oral; Male, men; Elderly;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
6.0
h
~6
h
elimination half-life;
DRUGBANK
7.8
h
7.8
h
terminal half-life; PO, oral;
DRUGBANK
8.1
h
8.1
h
terminal half-life; PO, oral;
DRUGBANK
4.2
%
4.2
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Elderly; Male, men; human, homo sapiens; Unchanged drug;
DRUGBANK
95.0
%
94-96
%
DRUGBANK
95.0
%
94-96
%
Elderly; Male, men; human, homo sapiens;
DRUGBANK
93.0
%
92-94
%
Metabolite; Elderly; Male, men; human, homo sapiens;
DRUGBANK
750.0
mg/day
750
mg/day
PO, oral
Flutamide
flutamide
PDR
750.0
mg/day
750
mg/day
PO, oral
Flutamide
flutamide
PDR
DDPD00500
Tolmetin
257.2845
C15H15NO3
CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
DB00500
5509
71941
http://www.drugs.com/cdi/tolmetin.html
5308
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
1.5
h
1-2
h
elimination half-life;
DRUGBANK
5.0
h
~5
h
terminal half-life;
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
Tablet,PO，oral
Tolmetin 600mg Tablets
tolmetin sodium
PDR
1800.0
mg/day
1800
mg/day
Tablet,PO，oral
Tolmetin 600mg Tablets
tolmetin sodium
PDR
1800.0
mg/day
1800
mg/day
Tablet,PO，oral
Tolmetin 600mg Tablets
tolmetin sodium
PDR
30.0
mg/kg/day
30
mg/kg/day
Tablet,PO，oral
Tolmetin 600mg Tablets
tolmetin sodium
PDR
1800.0
mg/day
1800
mg/day
Tablet,PO，oral
Tolmetin 600mg Tablets
tolmetin sodium
PDR
1800.0
mg/day
1800
mg/day
Tablet,PO，oral
Tolmetin 600mg Tablets
tolmetin sodium
PDR
DDPD00501
Cimetidine
252.339
C10H16N6S
CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
DB00501
T3D2810
2756
3699
http://www.drugs.com/cdi/cimetidine.html
2654
-2.0
-
-2.0
-
DRUGBANK
65.0
%
60-70
%
DRUGBANK
60.0
%
60±23
%
PO, oral; peptic ulcer disease;
DRUGBANK
2500.0
ng/ml
2-3
mcg/ml
Oral single dose; fasting; adults; normal,healthy;
DRUGBANK
1.0
h
0.5-1.5
h
Oral single dose; fasting; adults; normal,healthy;
DRUGBANK
0.498
L/h/kg
8.3±2.0
ml/min/kg
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatitis, Hep → ;Cystic fibrosis ↑ ;Burn ↑ ;Ulcer → ;
DRUGBANK
0.486
L/h/kg
8.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1.0±0.2
L/kg
Hepatitis, Hep → ;RD, renal impairment, Renal disease，including uremia → ;Burn → ;Ulcer → ;Cystic fibrosis ↑ ;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
2.0
h
2.0±0.3
h
RD, renal impairment, Renal disease，including uremia ↑ ;Ulcer → ;Hepatic cirrhosis, cirr → ;Cystic fibrosis → ;Burn ↓ ;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.0
%
62±20
%
Urinary excretion; peptic ulcer disease; human, homo sapiens; Unchanged drug;
Hepatic cirrhosis, cirr → ;Cystic fibrosis → ;
DRUGBANK
17.5
%
15-20
%
DRUGBANK
19.0
%
19(13-25)
%
peptic ulcer disease;
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
PO, oral;intravenous injection, IV;
Cimetidine Tablets
cimetidine
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
1200.0
mg/day
1200
mg/day
PO, oral;intravenous injection, IV;
Cimetidine Tablets
cimetidine
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Cimetidine Tablets
cimetidine
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral;intravenous injection, IV;
Cimetidine Tablets
cimetidine
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Cimetidine Tablets
cimetidine
PDR
DDPD00502
Haloperidol
375.864
C21H23ClFNO2
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
DB00502
T3D2576
3559
5613
http://www.drugs.com/cdi/haloperidol.html
3438
-2.0
-
-2.0
-
DRUGBANK
43730.0
ng.h/ml
43.73（14.89-120.96）
ug.h/ml
PO, oral;
DRUGBANK
57.5
%
40-75
%
PO, oral;
DRUGBANK
60.0
%
60±18
%
PO, oral;
DRUGBANK
22.0
ng/ml
22±18
ng/ml
IM,intramuscular injection;
DRUGBANK
9.2
ng/ml
9.2±4.4
ng/ml
Oral single dose;
DRUGBANK
3.9
h
1.7-6.1
h
PO, oral;
DRUGBANK
0.333333333333333
h
20
min
IM,intramuscular injection;
DRUGBANK
0.563333333333333
h
33.8
min
IM,intramuscular injection; schizophrenia;
DRUGBANK
0.6
h
0.6±0.1
h
IM,intramuscular injection;
DRUGBANK
1.7
h
1.7±3.2
h
Oral single dose;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.549
L/h/kg
0.39-0.708
L/h/kg
Plasma clearance; intravenous injection, IV;
DRUGBANK
141.65
L/h
141.65
L/h
PO, oral;
DRUGBANK
1.2
L/h/kg
0.9-1.5
L/h/kg
extravascular administration;
poor metabolizers, PM ↓ ;
DRUGBANK
0.708
L/h/kg
11.8±2.9
ml/min/kg
Children ↑ ;Elderly ↓ ;Somking ↑ ;
DRUGBANK
0.468
L/h/kg
7.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.6
L/kg
9.5-21.7
L/kg
Apparent volume of distribution;
DRUGBANK
18.0
L/kg
18±7
L/kg
DRUGBANK
17.0
L/kg
17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.6
h
14.5-36.7
h
PO, oral;
DRUGBANK
20.7
h
20.7
h
IM,intramuscular injection;
DRUGBANK
18.0
h
18±5
h
Children ↓ ;
DRUGBANK
67.0
h
67±51
h
DRUGBANK
70.0
h
70
h
terminal half-life;
DRUGBANK
35.0
h
35
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
71.0
mg/kg
71.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
128.0
mg/kg
128.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
71.0
mg/kg
71.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
mg/kg
90.0
mg/kg
PO, oral; dog;
DRUGBANK
165.0
mg/kg
165.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
30.0
%
~30
%
Urinary excretion; Oral single dose;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
92.0
%
92±2
%
Elderly → ;Children → ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
0.15
mg/kg/day
0.15
mg/kg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
6.0
mg/day
6
mg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
15.0
mg/day
15
mg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
100.0
mg/day
100
mg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
20.0
mg/day
20
mg/day
IM,intramuscular injection
Haloperidol Oral Solution
haloperidol
PDR
15.0
mg/day
450
mg/month
IM,intramuscular injection
Haloperidol Oral Solution
haloperidol
PDR
15.0
mg/day
15
mg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
100.0
mg/day
100
mg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
0.15
mg/kg/day
0.15
mg/day/kg
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
6.0
mg/day
6
mg/day
PO, oral
Haloperidol Oral Solution
haloperidol
PDR
100.0
mg/day
100
mg/day
Liquid
Haloperidol Oral Solution
haloperidol
PDR
20.0
mg/day
20
mg/day
IM,intramuscular injection
Haloperidol Oral Solution
haloperidol
PDR
15.0
mg/day
450
mg/month
IM,intramuscular injection
Haloperidol Oral Solution
haloperidol
PDR
DDPD00503
Ritonavir
720.944
C37H48N6O5S2
CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
DB00503
392622
45409
http://www.drugs.com/cdi/ritonavir.html
347980
-2.0
-
-2.0
-
DRUGBANK
11000.0
ng/ml
11±4
mcg/ml
PO, oral;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
8.8
L/h
8.8±3.2
L/h
Total clearance; PO, oral;
DRUGBANK
0.1
L/h
<0.1
L/h
DRUGBANK
0.072
L/h/kg
1.2±0.4
ml/min/kg
apparent clearance; Single dose; hydrolysis;
DRUGBANK
0.126
L/h/kg
2.1±0.8
ml/min/kg
apparent clearance; Multiple dose; hydrolysis;
Children ↑ ;hepatopathy，LD ↓ ;
DRUGBANK
0.41
L/kg
0.41±0.25
L/kg
DRUGBANK
0.41
L/kg
0.41±0.25
L/kg
Apparent volume of distribution; Single dose; hydrolysis;
DRUGBANK
4.0
h
3-5
h
DRUGBANK
4.0
h
3-5
h
PO, oral;
moderate renal function ↑ ;
DRUGBANK
2500.0
mg/kg
>2500
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
11.3
%
~11.3±2.3
%
Urinary excretion; Oral single dose;
DRUGBANK
86.4
%
86.4±2.9
%
Faeces excretion; Oral single dose;
DRUGBANK
3.5
%
3.5±1.8
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.5
%
~98-99
%
DRUGBANK
98.5
%
98-99
%
DRUGBANK
800.0
mg/m2/day
800
mg/m2/day
PO, oral
Norvir Capsules
ritonavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Norvir Capsules
ritonavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Norvir Capsules
ritonavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Norvir Capsules
ritonavir
PDR
800.0
mg/m2/day
800
mg/m2/day
PO, oral
Norvir Capsules
ritonavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Norvir Capsules
ritonavir
PDR
800.0
mg/m2/day
800
mg/m2/day
PO, oral
Norvir Capsules
ritonavir
PDR
DDPD00504
Levallorphan
283.4079
C19H25NO
[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2
DB00504
5359371
6431
10481920
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
DRUGBANK
109.0
mg/kg
109±4
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00507
Nitazoxanide
307.282
C12H9N3O5S
CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
DB00507
41684
94807
http://www.drugs.com/cdi/nitazoxanide.html
38037
-2.0
-
-2.0
-
DRUGBANK
7.3
h
7.3
h
DRUGBANK
10000.0
mg/kg
>10000
mg/kg
PO, oral; dog; rodents;
DRUGBANK
66.7
%
~66.7
%
Faeces excretion; PO, oral;
DRUGBANK
33.3
%
~33.3
%
Urinary excretion; PO, oral;
DRUGBANK
99.0
%
>99
%
DRUGBANK
1000.0
mg/day
1000
mg/day
PO, oral
Alinia
nitazoxanide
PDR
400.0
mg/day
400
mg/day
PO, oral
Alinia
nitazoxanide
PDR
200.0
mg/day
200
mg/day
PO, oral
Alinia
nitazoxanide
PDR
4000.0
mg/dose
4000
mg/dose
Tablet,PO，oral
Alinia
nitazoxanide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Alinia
nitazoxanide
PDR
DDPD00508
Triflupromazine
352.417
C18H19F3N2S
CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
DB00508
T3D2813
5568
9711
5367
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
DRUGBANK
DDPD00509
Dextrothyroxine
776.87
C15H11I4NO4
N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
DB00509
8730
30659
8402
-2.0
-
-2.0
-
DRUGBANK
DDPD00511
Acetyldigitoxin
806.9757
C43H66O14
[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
DB00511
5284512
53773
4447572
-2.0
-
-2.0
-
DRUGBANK
70.0
%
60-80
%
PO, oral;
DRUGBANK
7.8
mg/kg
7.8
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00512
Vancomycin
1449.254
C66H75Cl2N9O24
CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
DB00512
T3D3543
14969
28001
http://www.drugs.com/vancomycin.html
14253
-2.0
-
-2.0
-
DRUGBANK
60.0
%
~60
%
DRUGBANK
48500.0
ng/ml
18.5(15-25)
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
48500.0
ng/ml
18.5(15-25)
mcg/ml
intravenous infusion, IV in drop; staphylococcal infections; streptococcal infections;
DRUGBANK
77.5
%
75-80
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.058
L/h/kg
0.058
L/kg/h
Plasma clearance;
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
L/kg
0.4-1
L/kg
DRUGBANK
0.39
L/kg
0.39±0.06
L/kg
Obesity ↓ ;RD, renal impairment, Renal disease，including uremia → ;CPBS → ;
DRUGBANK
0.54
L/kg
0.54
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
~6(4-11)
h
normal renal function; patients;
DRUGBANK
180.0
h
7.5
day
elimination half-life; anephric; patients;
DRUGBANK
5.6
h
5.6±1.8
h
RD, renal impairment, Renal disease，including uremia ↑ ;Obesity ↓ ;Age ↑ ;
DRUGBANK
6.5
h
6.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; mouse;
DRUGBANK
319.0
mg/kg
319.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; mouse;
DRUGBANK
319.0
mg/kg
319.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
77.5
%
~75-80
%
Urinary excretion;
DRUGBANK
79.0
%
79±11
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
~50
%
DRUGBANK
30.0
%
30±11
%
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral;intravenous injection, IV;
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral;intravenous injection, IV;
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral;intravenous injection, IV;
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Vancomycin Hydrochloride for Injection
vancomycin hydrochloride
PDR
DDPD00513
Aminocaproic acid
131.1729
C6H13NO2
NCCCCCC(O)=O
DB00513
564
57826
http://www.drugs.com/cdi/aminocaproic-acid.html
548
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100.0
%
Oral single dose;
DRUGBANK
65.0
%
65
%
Urinary excretion; Unchanged drug;
DRUGBANK
11.0
%
11
%
DRUGBANK
10.14
L/h
169.0
ml/min
DRUGBANK
23.1
L
23.1±6.6
L
DRUGBANK
2.0
h
~2
h
elimination half-life;
DRUGBANK
3000.0
mg/kg
3.0
g/kg
intravenous injection, IV; mouse;
DRUGBANK
12000.0
mg/kg
12.0
g/kg
PO, oral; mouse;
DRUGBANK
3200.0
mg/kg
3.2
g/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
16400.0
mg/kg
16.4
g/kg
intravenous injection, IV; mouse;
DRUGBANK
30000.0
mg/day
30
g/day
PO, oral;intravenous injection, IV;
Amicar
aminocaproic acid
PDR
36000.0
mg/day
36
g/day
PO, oral;intravenous injection, IV;
Amicar
aminocaproic acid
PDR
30000.0
mg/day
30
g/day
PO, oral;intravenous injection, IV;
Amicar
aminocaproic acid
PDR
36000.0
mg/day
36
g/day
PO, oral;intravenous injection, IV;
Amicar
aminocaproic acid
PDR
DDPD00514
Dextromethorphan
271.404
C18H25NO
[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2
DB00514
T3D2815
5360696
4470
http://www.drugs.com/dextromethorphan.html
13109865
-2.0
-
-2.0
-
DRUGBANK
17.8
ng.h/ml
17.8
ng.h/ml
PO, oral;
DRUGBANK
2.9
ng/ml
2.9
ng/ml
PO, oral;
DRUGBANK
5.2
ng/ml
5.2±1.8
ng/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
33.0
ng/ml
33±8.2
ng/ml
PO, oral; extensive metabolizers, EM;
DRUGBANK
879.0
ng/ml
879±60
ng/ml
PO, oral; Drug form; poor metabolizers, PM;
DRUGBANK
2.86
h
2.86
h
PO, oral;
DRUGBANK
2.25
h
2-2.5
h
DRUGBANK
94.5
L/h/kg
1575±658
ml/min/kg
apparent clearance; PO, oral; extensive metabolizers, EM; normal,healthy;
DRUGBANK
0.234
L/h/kg
~3.9±1.4
ml/min/kg
apparent clearance; PO, oral; poor metabolizers, PM; normal,healthy;
DRUGBANK
4.5
h
3-6
h
DRUGBANK
3.4
h
3.4±0.5
h
extensive metabolizers, EM; PO, oral;
DRUGBANK
29.5
h
29.5±8.4
h
poor metabolizers, PM; PO, oral;
DRUGBANK
165.0
mg/kg
165.0
mg/kg
mouse;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
Rattus, Rat;
DRUGBANK
0.19
%
0.19±0.21
%
Urinary excretion; adults; normal,healthy; extensive metabolizers, EM; human, homo sapiens; Unchanged drug;
DRUGBANK
11.1
%
11.1±3
%
Urinary excretion; adults; normal,healthy; poor metabolizers, PM; human, homo sapiens; Unchanged drug;
DRUGBANK
65.0
%
60-70
%
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
30.0
mg/day
30
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
30.0
mg/day
30
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
120.0
mg/day
120
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
960.0
mg/day
960
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
120.0
mg/day
120
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
120.0
mg/day
120
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
960.0
mg/day
960
mg/day
PO, oral
Children's Robitussin
dextromethorphan hydrobromide
PDR
DDPD00515
Cisplatin
300.05
Cl2H6N2Pt
[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
DB00515
T3D4686
2767
27899
http://www.drugs.com/cdi/cisplatin.html
76401
-2.0
-
-2.0
-
DRUGBANK
3400.0
ng/ml
3.4±1.1
mcg/ml
ovarian cancer;
DRUGBANK
1000.0
ng/ml
1.0±0.4
mcg/ml
ovarian cancer;
DRUGBANK
15.5
L/h/m2
15-16
L/h/m2
Total clearance; intravenous infusion, IV in drop;
DRUGBANK
3.72
L/h/m2
62.0
ml/min/m2
Renal clearance; intravenous infusion, IV in drop;
DRUGBANK
3.0
L/h/m2
50.0
ml/min/m2
Renal clearance; intravenous infusion, IV in drop;
DRUGBANK
0.378
L/h/kg
6.3±1.2
ml/min/kg
ovarian cancer; patients;
DRUGBANK
11.5
L/m2
11-12.0
L/m2
at steady state;
DRUGBANK
0.28
L/kg
0.28±0.07
L/kg
ovarian cancer; patients;
DRUGBANK
0.416666666666667
h
20-30
min
DRUGBANK
0.5
h
30
min
elimination half-life;
DRUGBANK
120.0
h
>=5
day
plasma proteins;
DRUGBANK
0.53
h
0.53±0.10
h
DRUGBANK
2.3
%
2.3±9
%
Urinary excretion; ovarian cancer; Unchanged drug;
DRUGBANK
90.0
%
90
%
plasma proteins; intravenous infusion, IV in drop;
DRUGBANK
40.0
mg/m^2
40
mg/m^2
intravenous injection, IV
Cisplatin
cisplatin
PDR
100.0
mg/m2
100
mg/m2
intravenous injection, IV
Cisplatin
cisplatin
PDR
40.0
mg/m2
40
mg/m^2
intravenous injection, IV
Cisplatin
cisplatin
PDR
100.0
mg/m2
100
mg/m2
intravenous injection, IV
Cisplatin
cisplatin
PDR
DDPD00517
Anisotropine methylbromide
362.345
C17H32BrNO2
[Br-].CCCC(CCC)C(=O)O[C@H]1CC2CCC(C1)[N+]2(C)C
DB00517
21867154
2739
10611962
-2.0
-
-2.0
-
DRUGBANK
17.5
%
10-25
%
DRUGBANK
DDPD00518
Albendazole
265.331
C12H15N3O2S
CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
DB00518
T3D3476
2082
16664
http://www.drugs.com/cdi/albendazole.html
1998
-2.0
-
-2.0
-
DRUGBANK
1150.0
ng/ml
0.50-1.8
mcg/ml
PO, oral;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
1.236
L/h/kg
10.5-30.7
ml/min/kg
apparent clearance; Male, men; Female, women; adults;
DRUGBANK
10.0
h
8-12
h
elimination half-life; Single dose;
DRUGBANK
8.0
h
8(6-15)
h
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; mouse;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; adults; human, homo sapiens; Unchanged drug;
DRUGBANK
70.0
%
70
%
plasma proteins;
DRUGBANK
70.0
%
70
%
PO, oral; adults; human, homo sapiens;
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Albenza
albendazole
PDR
800.0
mg/day
800
mg/day
PO, oral
Albenza
albendazole
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Albenza
albendazole
PDR
800.0
mg/day
800
mg/day
PO, oral
Albenza
albendazole
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Albenza
albendazole
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Albenza
albendazole
PDR
800.0
mg/day
800
mg/day
PO, oral
Albenza
albendazole
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Albenza
albendazole
PDR
800.0
mg/day
800
mg/day
PO, oral
Albenza
albendazole
PDR
DDPD00519
Trandolapril
430.5372
C24H34N2O5
[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
DB00519
5484727
9649
http://www.drugs.com/cdi/trandolapril.html
4588590
-2.0
-
-2.0
-
DRUGBANK
50.0
%
~40-60
%
DRUGBANK
9.0
%
4-14
%
DRUGBANK
52.0
L/h
52.0
L/h
intravenous injection, IV;
DRUGBANK
0.75
L/h/kg
12.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
L
18.0
L
DRUGBANK
0.25
L/kg
0.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
6
h
elimination half-life;
DRUGBANK
10.0
h
10
h
elimination half-life;
DRUGBANK
20.0
h
16-24
h
effective half-life;
DRUGBANK
0.26
h
0.26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4875.0
mg/kg
4875.0
mg/kg
PO, oral; female mouse;
DRUGBANK
3990.0
mg/kg
3990.0
mg/kg
PO, oral; male mouse;
DRUGBANK
66.0
%
~66
%
Faeces excretion; PO, oral;
DRUGBANK
33.0
%
~33
%
Urinary excretion; PO, oral;
DRUGBANK
80.0
%
~80
%
Plasma Concentration → ;
DRUGBANK
8.0
mg/day
8
mg/day
PO, oral
Mavik
trandolapril
PDR
4.0
mg/day
4
mg/day
PO, oral
Mavik
trandolapril
PDR
8.0
mg/day
8
mg/day
PO, oral
Mavik
trandolapril
PDR
4.0
mg/day
4
mg/day
PO, oral
Mavik
trandolapril
PDR
DDPD00520
Caspofungin
1093.3131
C52H88N10O15
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN
DB00520
3035406
474180
http://www.drugs.com/cdi/caspofungin.html
17277006
-2.0
-
-2.0
-
DRUGBANK
8700.0
ng/ml
8.7(7.9-9.6)
mcg/ml
intravenous injection, IV;
DRUGBANK
0.72
L/h
12.0
ml/min
intravenous injection, IV;
DRUGBANK
0.0096
L/h/kg
0.16(0.14-0.18)
ml/min/kg
hepatopathy，LD ↓ ;
DRUGBANK
0.0084
L/h/kg
0.14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.12
L/kg
0.12
L/kg
Total volume of distribution;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
9-11
h
DRUGBANK
9.6
h
9.6±0.8
h
DRUGBANK
25.0
h
>25
h
terminal half-life;
DRUGBANK
27.0
h
27
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
%
35
%
Faeces excretion;
DRUGBANK
41.0
%
41
%
Urinary excretion;
DRUGBANK
2.0
%
~2
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
96.5
%
96.5
%
DRUGBANK
70.0
mg/m2/day
70
mg/m2/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
70.0
mg/day
70
mg/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
70.0
mg/m2/day
70
mg/m2/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
70.0
mg/day
70
mg/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
70.0
mg/m2/day
70
mg/m2/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
25.0
mg/m2/day
25
mg/m2/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
25.0
mg/m2/day
25
mg/m2/day
intravenous injection, IV
Cancidas
caspofungin acetate
PDR
DDPD00521
Carteolol
292.3734
C16H24N2O3
CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2
DB00521
2583
3437
http://www.drugs.com/cdi/carteolol-drops.html
2485
-2.0
-
-2.0
-
DRUGBANK
0.606
L/h/kg
10.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.7
h
4.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Carteolol Hydrochloride
carteolol hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Carteolol Hydrochloride
carteolol hydrochloride
PDR
DDPD00523
Alitretinoin
300.4351
C20H28O2
C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
DB00523
449171
50648
http://www.drugs.com/cdi/alitretinoin.html
395778
-2.0
-
-2.0
-
DRUGBANK
4.0
appLications/Lesion/day
4
appLications/Lesion/day
skin/dermal
Panretin
alitretinoin
PDR
4.0
applications/lesion/day
4
applications/lesion/day
skin/dermal
Panretin
alitretinoin
PDR
DDPD00524
Metolazone
365.835
C16H16ClN3O3S
CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O
DB00524
4170
64354
http://www.drugs.com/cdi/metolazone.html
4026
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
0.0
%
~0
%
DRUGBANK
52.5
%
10-95
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.0
h
~14
h
DRUGBANK
20.0
h
20
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
50-70
%
serum albumin;
DRUGBANK
33.0
%
≤33
%
plasma proteins;
DRUGBANK
0.4
mg/kg/day
0.4
mg/kg/day
PO, oral
Metolazone
metolazone
PDR
5.0
mg/day
5
mg/day
PO, oral
Metolazone
metolazone
PDR
20.0
mg/day
20
mg/day
PO, oral
Metolazone
metolazone
PDR
150.0
mg
150
mg
PO, oral
Metolazone
metolazone
PDR
5.0
mg/day
5
mg/day
PO, oral
Metolazone
metolazone
PDR
20.0
mg/day
20
mg/day
PO, oral
Metolazone
metolazone
PDR
150.0
mg
150
mg
PO, oral
Metolazone
metolazone
PDR
DDPD00525
Tolnaftate
307.409
C19H17NOS
CN(C(=S)OC1=CC2=CC=CC=C2C=C1)C1=CC=CC(C)=C1
DB00525
5510
9620
http://www.drugs.com/cdi/tolnaftate-cream.html
5309
-2.0
-
-2.0
-
DRUGBANK
891.0
mg/kg
891.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00526
Oxaliplatin
397.294
C8H14N2O4Pt
[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
DB00526
T3D2674
6857599
31941
http://www.drugs.com/cdi/oxaliplatin.html
8062727
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
intravenous injection, IV;
DRUGBANK
814.0
ng/ml
0.814
mcg/ml
intravenous injection, IV;
DRUGBANK
0.33
mg Pt/ml
0.33(0.28-0.38)
mg Pt/ml
intravenous infusion, IV in drop;
DRUGBANK
0.008
mg Pt/ml
0.008(0.004-0.014)
mg Pt/ml
intravenous infusion, IV in drop; Derivative;
DRUGBANK
13.5
L/h
10.0-17
L/h
Renal clearance;
DRUGBANK
2.94
L/h/kg
49(41-64)
ml/min/kg
DRUGBANK
0.006
L/h/kg
0.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
440.0
L
440.0
L
intravenous injection, IV; Single dose;
DRUGBANK
1.5
L/kg
1.5(1.1-2.1)
L/kg
DRUGBANK
0.5
L/kg
0.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.43
h
0.43
h
distribution half-life;
DRUGBANK
16.8
h
16.8
h
elimination half-life;
DRUGBANK
391.0
h
391
h
terminal half-life;
DRUGBANK
0.32
h
0.32(0.27-0.46)
h
distribution half-life;
DRUGBANK
17.0
h
17
h
elimination half-life;
DRUGBANK
391.0
h
391
h
terminal half-life;
DRUGBANK
58.92
h
58.92
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
54.0
%
~54
%
Urinary excretion;
DRUGBANK
2.0
%
~2
%
Faeces excretion;
DRUGBANK
90.0
%
>90
%
plasma proteins;
DRUGBANK
90.0
%
90
%
DRUGBANK
130.0
mg/m2
130
mg/m2
intravenous injection, IV
Eloxatin
oxaliplatin
PDR
130.0
mg/m2
130
mg/m2
intravenous injection, IV
Eloxatin
oxaliplatin
PDR
DDPD00527
Cinchocaine
343.4632
C20H29N3O2
CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
DB00527
3025
247956
http://www.drugs.com/cdi/dibucaine-ointment.html
2917
-2.0
-
-2.0
-
DRUGBANK
27.0
mg/kg
27.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
DDPD00528
Lercanidipine
611.7272
C36H41N3O6
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
DB00528
65866
135930
59276
-2.0
-
-2.0
-
DRUGBANK
DDPD00529
Foscarnet
126.0053
CH3O5P
OC(=O)P(O)(O)=O
DB00529
3415
127780
http://www.drugs.com/cdi/foscarnet.html
3297
-2.0
-
-2.0
-
DRUGBANK
17.0
%
12-22
%
PO, oral;
DRUGBANK
9.0
%
9±2
%
PO, oral;
DRUGBANK
10836455.8
ng/ml
86±36
mM
PO, oral; severe renal function; AIDS,HIV;
DRUGBANK
1.4
h
1.4±0.6
h
PO, oral; severe renal function; AIDS,HIV;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.1278
L/h/kg
2.13±0.71
ml/min/kg
normal,healthy; patients;
DRUGBANK
4.08
L/h/kg
68±8
ml/min/kg
mild renal function;
DRUGBANK
2.04
L/h/kg
34±9
ml/min/kg
moderate renal function;
DRUGBANK
1.2
L/h/kg
20±4
ml/min/kg
severe renal function;
DRUGBANK
0.0984
L/h/kg
1.6±0.2
ml/min/kg
moderate renal function ↓ ;severe renal function ↓ ;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.35
L/kg
0.35
L/kg
DRUGBANK
0.5
L/kg
0.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.05
h
3.3-6.8
h
DRUGBANK
5.7
h
5.7±0.2
h
moderate renal function; severe renal function;
DRUGBANK
4.7
h
4.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
95±5
%
Urinary excretion; Unchanged drug;
DRUGBANK
15.5
%
14-17
%
DRUGBANK
15.5
%
14-17
%
DRUGBANK
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV
Foscavir
foscarnet sodium
PDR
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV
Foscavir
foscarnet sodium
PDR
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV
Foscavir
foscarnet sodium
PDR
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV
Foscavir
foscarnet sodium
PDR
180.0
mg/kg/day
180
mg/kg/day
intravenous injection, IV
Foscavir
foscarnet sodium
PDR
DDPD00530
Erlotinib
393.4357
C22H23N3O4
COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
DB00530
176870
114785
http://www.drugs.com/cdi/erlotinib.html
154044
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
100.0
%
100
%
PO, oral; food;
food ↑ ;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
0.1014
L/h/kg
1.69
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
232.0
L
232.0
L
Apparent volume of distribution;
DRUGBANK
0.77
L/kg
0.77
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.2
h
36.2
h
DRUGBANK
6.5
h
6.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
83.0
%
83
%
Faeces excretion; PO, oral;
DRUGBANK
8.0
%
8
%
Urinary excretion; PO, oral;
DRUGBANK
1.0
%
1
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
0.3
%
0.3
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
93.0
%
93
%
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Tarceva
erlotinib
PDR
100.0
mg/day
100
mg/day
PO, oral
Tarceva
erlotinib
PDR
150.0
mg/day
150
mg/day
PO, oral
Tarceva
erlotinib
PDR
100.0
mg/day
100
mg/day
PO, oral
Tarceva
erlotinib
PDR
DDPD00531
Cyclophosphamide
261.086
C7H15Cl2N2O2P
ClCCN(CCCl)P1(=O)NCCCO1
DB00531
T3D4688
2907
4027
http://www.drugs.com/cdi/cyclophosphamide.html
2804
-2.0
-
-2.0
-
DRUGBANK
74.0
%
74±22
%
PO, oral;
DRUGBANK
31591406.0
ng/ml
121±21
mM
intravenous injection, IV; breast cancer;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
63.0
L/kg
63±7.6
L/kg
Total clearance;
DRUGBANK
0.078
L/h/kg
1.3±0.5
ml/min/kg
Children ↑ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.066
L/h/kg
1.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
L
30-50
L
DRUGBANK
0.78
L/kg
0.78±0.57
L/kg
Children → ;
DRUGBANK
0.73
L/kg
0.73
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
h
3-12
h
DRUGBANK
7.5
h
7.5±4.0
h
Children ↓ ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
8.0
h
8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
%
10-20
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
6.5
%
6.5±4.3
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
20
%
dose → ;
DRUGBANK
13.0
%
13
%
DRUGBANK
50.0
mg/kg
50
mg/kg
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Cyclophosphamide Tablets
cyclophosphamide
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
2300.0
mg/m2/day
2.3
g/m2/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
80.0
mg/kg/day
80
mg/kg/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
50.0
mg/m2/day
50
mg/m2/day
PO, oral
q2w
Cyclophosphamide Tablets
cyclophosphamide
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
2.3
g/m2/day
2.3
g/m2/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
80.0
mg/kg/day
80
mg/kg/day
intravenous injection, IV
Cyclophosphamide Tablets
cyclophosphamide
PDR
50.0
mg/m2/day
50
mg/m2/day
PO, oral
q2w
Cyclophosphamide Tablets
cyclophosphamide
PDR
DDPD00532
Mephenytoin
218.2518
C12H14N2O2
CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
DB00532
4060
6757
http://www.drugs.com/mtm/mephenytoin.html
3920
-2.0
-
-2.0
-
DRUGBANK
1.4
L/kg
1.4
L/kg
DRUGBANK
7.0
h
~7
h
DRUGBANK
DDPD00533
Rofecoxib
314.356
C17H14O4S
CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
DB00533
5090
8887
http://www.drugs.com/mtm/rofecoxib.html
4911
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93
%
PO, oral;
DRUGBANK
93.0
%
93
%
PO, oral;
DRUGBANK
93.0
%
93
%
PO, oral;
DRUGBANK
64.8
%
64.8
%
Urinary excretion;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
h
17
h
DRUGBANK
7.5
h
7.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.0
%
87
%
DRUGBANK
DDPD00534
Chlormerodrin
367.2
C5H11ClHgN2O2
COC(CNC(N)=O)C[Hg]Cl
DB00534
25210
59445
2615
-2.0
-
-2.0
-
DRUGBANK
DDPD00535
Cefdinir
395.414
C14H13N5O5S2
[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
DB00535
6915944
3485
http://www.drugs.com/cdi/cefdinir.html
5291705
-2.0
-
-2.0
-
DRUGBANK
7050.0
ng.h/ml
7.05
ug.h/ml
PO, oral;
DRUGBANK
11000.0
ng.h/ml
11.0
ug.h/ml
PO, oral;
DRUGBANK
18.5
%
16-21
%
Capsule, PO, Oral;
DRUGBANK
25.0
%
25
%
Liquid;
DRUGBANK
18.5
%
16-21
%
Capsule, PO, Oral;
DRUGBANK
25.0
%
25.0
%
Liquid;
DRUGBANK
1600.0
ng/ml
1.6
ug/ml
PO, oral;
DRUGBANK
2870.0
ng/ml
2.87
ug/ml
PO, oral;
DRUGBANK
2900.0
ng/ml
2.9±1.0
mcg/ml
Capsule, PO, Oral; adults;
DRUGBANK
3900.0
ng/ml
3.9±0.6
mcg/ml
Capsule, PO, Oral; Children;
DRUGBANK
3.0
h
2-4
h
DRUGBANK
3.0
h
3±0.7
h
Capsule, PO, Oral; adults;
DRUGBANK
2.0
h
2±0.4
h
Capsule, PO, Oral; Children;
DRUGBANK
0.12
L/h/kg
2.0±1.0
ml/min/kg
Renal clearance; normal,healthy; adults;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.78
L/h/kg
11-15
ml/min/kg
apparent clearance;
DRUGBANK
0.35
L/kg
0.35
L/kg
Average volume of distribution; adults;
DRUGBANK
0.67
L/kg
0.67
L/kg
Average volume of distribution; Children;
DRUGBANK
1.825
L/kg
1.56-2.09
L/kg
adults;
DRUGBANK
1.85
L/kg
1.6-2.1
L/kg
Steady state volume of distribution;
DRUGBANK
1.7
h
~1.7
h
elimination half-life; adults;
DRUGBANK
1.35
h
1.2-1.5
h
elimination half-life; Children; normal,healthy; Infants;
DRUGBANK
1.45
h
1.4-1.5
h
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
18.4
%
~18.4
%
Urinary excretion; Unchanged drug;
renal insufficiency → ;
DRUGBANK
18.0
%
13-23
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
65.0
%
~60-70
%
plasma proteins;
DRUGBANK
89.0
%
89
%
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
72.5
%
71-74
%
peritoneal dialysis;
DRUGBANK
14.0
mg/kg/day
14
mg/kg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
600.0
mg/day
600
mg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
600.0
mg/day
600
mg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
600.0
mg/day
600
mg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
600.0
mg/day
600
mg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
14.0
mg/kg/day
14
mg/kg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
14.0
mg/kg/day
14
mg/kg/day
PO, oral
Cefdinir Capsules
cefdinir
PDR
DDPD00536
Guanidine
59.0705
CH5N3
NC(N)=N
DB00536
T3D4172
3520
42820
http://www.drugs.com/mtm/guanidine.html
3400
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
7.5
h
7-8
h
DRUGBANK
475.0
mg/kg
475.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
475.0
mg/kg
475.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
35.0
mg/kg/day
35
mg/kg/day
PO, oral
Guanidine Hydrochloride
guanidine hydrochloride
PDR
35.0
mg/kg/day
35
mg/kg/day
PO, oral
Guanidine Hydrochloride
guanidine hydrochloride
PDR
DDPD00537
Ciprofloxacin
331.3415
C17H18FN3O3
OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
DB00537
T3D3495
2764
100241
http://www.drugs.com/cdi/ciprofloxacin-drops.html
2662
-2.0
-
-2.0
-
DRUGBANK
1013000000.0
ng.h/ml
1.013
kg.h/L
DRUGBANK
75.0
%
70-80
%
PO, oral;
DRUGBANK
70.0
%
70
%
PO, oral; different study;
DRUGBANK
60.0
%
60±12
%
PO, oral;
DRUGBANK
940.0
ng/ml
0.94
mg/L
DRUGBANK
2500.0
ng/ml
2.5±1.1
mcg/ml
PO, oral; chronic bronchitis;
DRUGBANK
0.81
h
0.81
h
DRUGBANK
0.6
h
0.6±0.2
h
PO, oral; chronic bronchitis;
DRUGBANK
5.5
%
3-8
%
DRUGBANK
0.3048
L/h/kg
5.08
ml/min/kg
Renal clearance; PO, oral;
DRUGBANK
0.5772
L/h/kg
9.62
ml/min/kg
Average clearance; intravenous injection, IV;
DRUGBANK
0.2652
L/h/kg
4.42
ml/min/kg
Renal clearance; intravenous injection, IV;
DRUGBANK
0.3126
L/h/kg
5.21
ml/min/kg
Plasma clearance; intravenous injection, IV;
DRUGBANK
0.456
L/h/kg
7.6±0.8
ml/min/kg
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis ↑ ;
DRUGBANK
0.498
L/h/kg
8.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.161
L/kg
0.161
L/kg
DRUGBANK
2.52
L/kg
2.00-3.04
L/kg
Total volume of distribution;
DRUGBANK
2.2
L/kg
2.2±0.4
L/kg
Elderly ↓ ;Cystic fibrosis → ;
DRUGBANK
2.1
L/kg
2.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.71
h
4.71
h
PO, oral;
DRUGBANK
3.65
h
3.65
h
intravenous injection, IV;
DRUGBANK
4.0
h
4
h
DRUGBANK
3.3
h
3.3±0.4
h
RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↓ ;Age → ;
DRUGBANK
3.8
h
3.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
45.0
%
45
%
Urinary excretion;
DRUGBANK
62.0
%
62
%
Faeces excretion;
DRUGBANK
50.0
%
50±5
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
20-40
%
DRUGBANK
40.0
%
40
%
DRUGBANK
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1200.0
mg/day
1.2
g/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1.0
mg/ear/day
1
mg/ear/day
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
12.0
mg/ear
12
mg/ear
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1.0
mg/ear/day
1
mg/ear/day
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
12.0
mg/ear
12
mg/ear
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1000.0
mg/day
1
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1200.0
mg/day
1.2
g/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1.0
mg/ear/day
1
mg/ear/day
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
12.0
mg/ear
12
mg/ear
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1200.0
mg/day
1.2
g/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1.0
mg/day
1
mg/ear/day
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
12.0
mg
12
mg/ear
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1000.0
mg/day
1
g/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1200.0
mg/day
1.2
g/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
1.0
mg/ear/day
1
mg/ear/day
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
12.0
mg/ear
12
mg/ear
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
12.0
mg/ear
12
mg/ear
intraaural administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
120.0
drop/day
120
drop/day
ophthalmic administration
Ciloxan Ointment
ciprofloxacin hydrochloride
PDR
DDPD00538
Gadoversetamide
661.76
C20H34GdN5O10
[Gd+3].COCCNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NCCOC)CC([O-])=O)CC([O-])=O
DB00538
444013
31644
392041
-2.0
-
-2.0
-
DRUGBANK
0.072
L/h/kg
72±16.3
ml/h/kg
normal,healthy;
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.162
L/kg
162±25
ml/kg
normal,healthy;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.221666666666667
h
13.3±6.8
min
distribution half-life;
DRUGBANK
1.72666666666667
h
103.6±19.5
min
elimination half-life;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
93.5
%
~93.5
%
Urinary excretion; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
95.8
%
~95.8
%
Urinary excretion; patients;
DRUGBANK
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Optimark
gadoversetamide
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Optimark
gadoversetamide
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Optimark
gadoversetamide
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Optimark
gadoversetamide
PDR
DDPD00539
Toremifene
405.96
C26H28ClNO
CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
DB00539
3005573
9635
http://www.drugs.com/cdi/toremifene.html
2275722
-2.0
-
-2.0
-
DRUGBANK
1200.0
ng/ml
1.1-1.3
mcg/ml
PO, oral; adults; breast cancer;
DRUGBANK
4250.0
ng/ml
2.7-5.8
mcg/ml
PO, oral; adults; breast cancer;
DRUGBANK
2.25
h
1.5-3
h
PO, oral; adults; breast cancer;
DRUGBANK
4.5
h
3-6
h
PO, oral; adults; breast cancer;
DRUGBANK
2.0
L/h
5.0
L/h
DRUGBANK
2.6
L/h/m2
2.6±1.2
L/h/m2
apparent clearance; PO, oral; Male, men; Female, women; patients; Female, women;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
580.0
L
580.0
L
DRUGBANK
479.0
L/m2
479±154
L/m2
Apparent volume of distribution; PO, oral; Male, men; Female, women; patients; Female, women;
Elderly ↑ ;
DRUGBANK
120.0
h
5
day
DRUGBANK
148.0
h
148±53
h
PO, oral;
chronic liver disease ↑ ;Age ↑ ;
DRUGBANK
504.0
h
504±578
h
PO, oral; Metabolite;
DRUGBANK
0.0
%
~0
%
Urinary excretion; adults; Male, men; Female, women; Female, women; breast cancer; human, homo sapiens; Unchanged drug;
DRUGBANK
92.0
%
92
%
DRUGBANK
2.0
%
2
%
DRUGBANK
99.7
%
99.7
%
adults; normal,healthy; Female, women; breast cancer; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Fareston
toremifene citrate
PDR
60.0
mg/day
60
mg/day
PO, oral
Fareston
toremifene citrate
PDR
DDPD00540
Nortriptyline
263.3767
C19H21N
CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
DB00540
T3D2818
4543
7640
http://www.drugs.com/nortriptyline.html
4384
-2.0
-
-2.0
-
DRUGBANK
65.0
%
45-85
%
PO, oral;
DRUGBANK
51.0
%
51±5
%
PO, oral;
DRUGBANK
36345984.6
ng/ml
138(40-350)
mM
PO, oral; adults; normal,healthy;
DRUGBANK
7.75
h
7-8.5
h
PO, oral;
DRUGBANK
8.5
h
7-10
h
PO, oral;
DRUGBANK
54.0
L/h
54.0
L/h
Plasma clearance; normal,healthy;
DRUGBANK
30.6
L/h
30.6±6.9
L/h
Average clearance;
DRUGBANK
0.432
L/h/kg
7.2±1.8
ml/min/kg
hydrolysis;
RD, renal impairment, Renal disease，including uremia → ;inflammation ↓ ;Somking → ;
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1633.0
L
1633±268
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
18.0
L/kg
18±4
L/kg
Apparent volume of distribution;
DRUGBANK
22.0
L/kg
22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
26.0
h
~26(16-38)
h
elimination half-life; normal,healthy;
DRUGBANK
39.0
h
~39
h
different study;
DRUGBANK
31.0
h
31±13
h
RD, renal impairment, Renal disease，including uremia → ;Age ↑ ;
DRUGBANK
30.0
h
30
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
405.0
mg/kg
405.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
33.0
%
~33
%
Urinary excretion; Oral single dose;
DRUGBANK
2.0
%
2
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
2±1
%
Urinary excretion; Unchanged drug;
DRUGBANK
93.0
%
~93
%
plasma proteins;
DRUGBANK
92.0
%
92±2
%
HL,hyperlipoproteinemia ↑ ;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Nortriptyline Hydrochloride Oral Solution
nortriptyline hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Nortriptyline Hydrochloride Oral Solution
nortriptyline hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Nortriptyline Hydrochloride Oral Solution
nortriptyline hydrochloride
PDR
DDPD00541
Vincristine
824.972
C46H56N4O10
[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC
DB00541
T3D4016
5978
28445
http://www.drugs.com/cdi/vincristine.html
4535015
-2.0
-
-2.0
-
DRUGBANK
278.42805
ng/ml
~250-425
nM
intravenous injection, IV;
DRUGBANK
4.92
L/h/m2
4.92±3.01
L/h/m2
tumor; patients; Male, men; Female, women; Bile excretion; hydrolysis;
Children → ;hepatopathy，LD ↓ ;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
96.6
L/m2
96.6±55.7
L/m2
tumor; patients; Male, men; Female, women; Bile excretion; hydrolysis;
DRUGBANK
2.4
L/kg
2.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0833333333333333
h
5
min
distribution half-life; intravenous injection, IV; tumor; patients;
DRUGBANK
2.3
h
2.3
h
elimination half-life; intravenous injection, IV; tumor; patients;
DRUGBANK
85.0
h
85
h
terminal half-life; intravenous injection, IV; tumor; patients;
DRUGBANK
87.0
h
19-155
h
terminal half-life; human, homo sapiens;
DRUGBANK
22.6
h
22.6±16.7
h
chronic liver disease ↑ ;
DRUGBANK
85.0
h
~85±69
h
DRUGBANK
23.0
h
23
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
5.2
mg/kg
5.2
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
5.2
mg/kg
5.2
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
80.0
%
80
%
Faeces excretion;
DRUGBANK
15.0
%
10-20
%
Urinary excretion;
DRUGBANK
15.0
%
10-20
%
Urinary excretion; adults; tumor; human, homo sapiens; Unchanged drug;
DRUGBANK
75.0
%
~75
%
DRUGBANK
2.25
mg/m2
2.25
mg/m2
intravenous injection, IV
qw
Marqibo
vincristine sulfate liposome
PDR
2.25
mg/m2
2.25
mg/m2
intravenous injection, IV
qw
Marqibo
vincristine sulfate liposome
PDR
2.0
mg/m2
2
mg/m2
intravenous injection, IV
qw
Vincristine Sulfate
vincristine sulfate
PDR
1.4
mg/m2
1.4
mg/m2
intravenous injection, IV
qw
Vincristine Sulfate
vincristine sulfate
PDR
2.0
mg/m2
2
mg/m2
intravenous injection, IV
qw
Vincristine Sulfate
vincristine sulfate
PDR
1.4
mg/m2
1.4
mg/m2
intravenous injection, IV
qw
Vincristine Sulfate
vincristine sulfate
PDR
2.0
mg/m2/week
2
mg/m2/week
intravenous injection, IV
qw
Vincristine Sulfate
vincristine sulfate
PDR
0.00714285714285714
mg/kg/day
0.05
mg/kg/week
intravenous injection, IV
qw
Vincristine Sulfate
vincristine sulfate
PDR
DDPD00542
Benazepril
424.4895
C24H28N2O5
[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
DB00542
5362124
3011
http://www.drugs.com/cdi/benazepril.html
4514935
-2.0
-
-2.0
-
DRUGBANK
3.5
%
3-4
%
PO, oral; horse;
DRUGBANK
37.0
%
37
%
PO, oral;
DRUGBANK
18.0
%
≥18
%
PO, oral;
DRUGBANK
127.34685
ng/ml
~300
nM
Oral single dose; adults; normal,healthy;
DRUGBANK
212.24475
ng/ml
~500
nM
Oral single dose; Active metabolite; adults; normal,healthy;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral; different study;
DRUGBANK
0.75
h
0.5-1.0
h
Oral single dose; adults; normal,healthy;
DRUGBANK
1.25
h
1-1.5
h
Oral single dose; Active metabolite; adults; normal,healthy;
DRUGBANK
129.0
L
129±30.0
L
DRUGBANK
0.021
L/h/kg
0.3-0.4
ml/min/kg
apparent clearance;
DRUGBANK
203.0
L
203±69.9
L
DRUGBANK
0.12
L/kg
0.12
L/kg
Apparent volume of distribution;
DRUGBANK
2.7
h
2.7±8.5
h
DRUGBANK
22.3
h
22.3±9.2
h
Active metabolite;
DRUGBANK
10.5
h
10-11
h
DRUGBANK
0.7
h
0.7
h
Age ↑ ;
DRUGBANK
10.5
h
10-11
h
Active metabolite;
Age ↑ ;
DRUGBANK
22.0
h
~22
h
terminal half-life; Active metabolite;
DRUGBANK
11.5
%
~11-12
%
Bile excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
18.0
%
18
%
Urinary excretion; Unchanged drug;
DRUGBANK
96.7
%
96.7
%
DRUGBANK
97.0
%
97
%
Unchanged drug;
Elderly → ;Hepatitis, Hep → ;
DRUGBANK
95.0
%
95
%
Active metabolite;
DRUGBANK
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
80.0
mg/day
80
mg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
80.0
mg/day
80
mg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Lotensin
benazepril hydrochloride
PDR
DDPD00543
Amoxapine
313.781
C17H16ClN3O
ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
DB00543
T3D2819
2170
2675
http://www.drugs.com/cdi/amoxapine.html
2085
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
Oral single dose;
DRUGBANK
1.2
h
1-2
h
Oral single dose;
DRUGBANK
8.0
h
8
h
DRUGBANK
64.5
%
60-69
%
Urinary excretion; Oral single dose;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
90.0
%
~90
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Amoxapine
amoxapine
PDR
600.0
mg/day
600
mg/day
PO, oral
Amoxapine
amoxapine
PDR
300.0
mg/day
300
mg/day
PO, oral
Amoxapine
amoxapine
PDR
DDPD00544
Fluorouracil
130.0772
C4H3FN2O2
FC1=CNC(=O)NC1=O
DB00544
T3D4776
3385
46345
http://www.drugs.com/cdi/fluorouracil.html
3268
-2.0
-
-2.0
-
DRUGBANK
64.0
%
28-100
%
DRUGBANK
28.0
%
28(0-80)
%
PO, oral;
DRUGBANK
1456864.64
ng/ml
11.2
mM
intravenous infusion, IV in drop; tumor;
DRUGBANK
0.96
L/h/kg
16±7
ml/min/kg
DRUGBANK
1.56
L/h/kg
26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.25
L/kg
0.25±0.12
L/kg
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.25
h
10-20
min
DRUGBANK
0.183333333333333
h
11±4
min
DRUGBANK
20.0
h
~20
h
terminal half-life;
DRUGBANK
0.12
h
0.12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
230.0
mg/kg
230.0
mg/kg
PO, oral; mouse;
DRUGBANK
230.0
mg/kg
230.0
mg/kg
PO, oral; mouse;
DRUGBANK
13.5
%
7-20
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
8-12
%
DRUGBANK
10.0
%
8-12
%
DRUGBANK
800.0
mg/day
800
mg/day
intravenous injection, IV
Fluoroplex
fluorouracil
PDR
22.5
mg/kg
22.5
mg/kg
Fluoroplex
fluorouracil
PDR
800.0
mg/day
800
mg/day
intravenous injection, IV
Fluoroplex
fluorouracil
PDR
22.5
mg/kg
22.5
mg/kg
Fluoroplex
fluorouracil
PDR
DDPD00545
Pyridostigmine
181.2117
C9H13N2O2
CN(C)C(=O)OC1=C[N+](C)=CC=C1
DB00545
T3D2820
4991
8665
http://www.drugs.com/cdi/pyridostigmine.html
4817
-2.0
-
-2.0
-
DRUGBANK
7.6
%
7.6±2.4
%
DRUGBANK
0.576
L/h/kg
9.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
mg/dose
60
mg/dose
PO, oral
Regonol
pyridostigmine bromide
PDR
1.0
mg/kg/dose
1
mg/kg/dose
PO, oral
Regonol
pyridostigmine bromide
PDR
300.0
mg/day
300
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
1080.0
mg/day
1080
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
180.0
mg/day
180
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
0.25
mg/kg/dose
0.25
mg/kg/dose
intravenous injection, IV; on days 1, 3, and 5
Regonol
pyridostigmine bromide
PDR
60.0
mg/dose
60
mg/dose
PO, oral
Regonol
pyridostigmine bromide
PDR
1.0
mg/kg/dose
1
mg/kg/dose
PO, oral
Regonol
pyridostigmine bromide
PDR
300.0
mg/day
300
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
1080.0
mg/day
1080
mg/day
Tablet,PO，oral
Regonol
pyridostigmine bromide
PDR
180.0
mg/day
180
mg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
0.25
mg/kg/dose
0.25
mg/kg/dose
intravenous injection, IV
Regonol
pyridostigmine bromide
PDR
1.0
mg/kg/dose
1
mg/kg/dose
PO, oral
Regonol
pyridostigmine bromide
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
1.0
mg/kg/dose
1
mg/kg/dose
PO, oral
Regonol
pyridostigmine bromide
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Regonol
pyridostigmine bromide
PDR
DDPD00547
Desoximetasone
376.4617
C22H29FO4
[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00547
5311067
691037
http://www.drugs.com/cdi/desoximetasone-cream.html
4470604
-2.0
-
-2.0
-
DRUGBANK
15.0
h
15±2
h
DRUGBANK
17.0
h
17±2
h
DRUGBANK
4.1
%
4.1±2.3
%
Urinary excretion; Male, men;
DRUGBANK
1.1
%
1.1±0.6
%
Faeces excretion; Male, men;
DRUGBANK
DDPD00548
Azelaic acid
188.2209
C9H16O4
OC(=O)CCCCCCCC(O)=O
DB00548
T3D4799
2266
48131
http://www.drugs.com/cdi/azelaic-acid-cream.html
2179
-2.0
-
-2.0
-
DRUGBANK
4.0
%
4
%
DRUGBANK
0.75
h
~45
min
PO, oral; normal,healthy;
DRUGBANK
12.0
h
12
h
skin/dermal; normal,healthy;
DRUGBANK
5000.0
mg/kg
>5
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00549
Zafirlukast
575.675
C31H33N3O6S
COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
DB00549
5717
10100
http://www.drugs.com/cdi/zafirlukast.html
5515
-2.0
-
-2.0
-
DRUGBANK
20.0
L/h
20.0
L/h
Total clearance; PO, oral;
DRUGBANK
10.3
L/h
9.2-11.4
L/h
Children;
DRUGBANK
70.0
L
70.0
L
DRUGBANK
10.0
h
10
h
DRUGBANK
99.0
%
99
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Accolate
zafirlukast
PDR
20.0
mg/day
20
mg/day
PO, oral
Accolate
zafirlukast
PDR
40.0
mg/day
40
mg/day
PO, oral
Accolate
zafirlukast
PDR
40.0
mg/day
40
mg/day
PO, oral
Accolate
zafirlukast
PDR
40.0
mg/day
40
mg/day
PO, oral
Accolate
zafirlukast
PDR
DDPD00550
Propylthiouracil
170.232
C7H10N2OS
CCCC1=CC(=O)NC(=S)N1
DB00550
T3D4712
657298
8502
http://www.drugs.com/cdi/propylthiouracil.html
571424
-2.0
-
-2.0
-
DRUGBANK
0.186
L/h/kg
3.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.34
L/kg
0.34
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1250.0
mg/kg
1250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1250.0
mg/kg
1250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
35.0
%
~35
%
Urinary excretion;
DRUGBANK
82.0
%
82
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
900.0
mg/day
900
mg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
900.0
mg/day
900
mg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
300.0
mg/day
300
mg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
150.0
mg/day
150
mg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Propylthiouracil
propylthiouracil
PDR
DDPD00551
Acetohydroxamic acid
75.0666
C2H5NO2
CC(=O)NO
DB00551
1990
49029
http://www.drugs.com/cdi/acetohydroxamic-acid.html
1913
-2.0
-
-2.0
-
DRUGBANK
50.0
%
35-65
%
Urinary excretion; Unchanged drug;
DRUGBANK
7.5
h
5-10
h
patients; normal renal function;
DRUGBANK
4800.0
mg/kg
4.8
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Lithostat
acetohydroxamic acid
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Lithostat
acetohydroxamic acid
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Lithostat
acetohydroxamic acid
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Lithostat
acetohydroxamic acid
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Lithostat
acetohydroxamic acid
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Lithostat
acetohydroxamic acid
PDR
DDPD00552
Pentostatin
268.2691
C11H16N4O4
OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O
DB00552
T3D2822
439693
http://www.drugs.com/cdi/pentostatin.html
388759
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
4.08
L/h/m2
68.0
ml/min/m2
DRUGBANK
0.0978
L/h/kg
1.63
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.59
L/kg
0.59
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.7
h
5.7(2.6-16
h
DRUGBANK
5.3
h
5.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
128.0
mg/kg
128.0
mg/kg
mouse;
DRUGBANK
128.0
mg/kg
128.0
mg/kg
mouse;
DRUGBANK
90.0
%
~90
%
Urinary excretion; human, homo sapiens;
DRUGBANK
4.0
%
4
%
DRUGBANK
4.0
mg/m2
4
mg/m2
intravenous injection, IV
qow
Nipent
pentostatin
PDR
4.0
mg/m2
4
mg/m2
intravenous injection, IV
qow
Nipent
pentostatin
PDR
DDPD00553
Methoxsalen
216.192
C12H8O4
COC1=C2OC(=O)C=CC2=CC2=C1OC=C2
DB00553
T3D0836
4114
18358
http://www.drugs.com/cdi/methoxsalen-hard-gelatin-capsules.html
3971
-2.0
-
-2.0
-
DRUGBANK
2.0
h
~2
h
DRUGBANK
95.0
%
~95
%
Urinary excretion;
DRUGBANK
0.0
0
Oxsoralen
methoxsalen
PDR
0.6
mg/kg
0.6
mg/kg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
20.0
mg
20
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
30.0
mg
30
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
40.0
mg
40
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
50.0
mg
50
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
60.0
mg
60
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
70.0
mg
70
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
80.0
mg
80
mg
Capsule, PO, Oral
qod
Oxsoralen
methoxsalen
PDR
0.0
0
Oxsoralen
methoxsalen
PDR
0.6
mg/kg
0.6
mg/kg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
20.0
mg
20
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
30.0
mg
30
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
40.0
mg
40
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
50.0
mg
50
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
60.0
mg
60
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
70.0
mg
70
mg
PO, oral
qod
Oxsoralen
methoxsalen
PDR
80.0
mg
80
mg
Capsule, PO, Oral
qod
Oxsoralen
methoxsalen
PDR
DDPD00554
Piroxicam
331.346
C15H13N3O4S
CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O
DB00554
54676228
8249
http://www.drugs.com/cdi/piroxicam.html
10442653
-2.0
-
-2.0
-
DRUGBANK
0.14
L/kg
0.14
L/kg
DRUGBANK
58.0
h
30-86
h
DRUGBANK
5.0
%
~5
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Feldene
piroxicam
PDR
20.0
mg/day
20
mg/day
PO, oral
Feldene
piroxicam
PDR
DDPD00555
Lamotrigine
256.091
C9H7Cl2N5
NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
DB00555
T3D2570
3878
6367
http://www.drugs.com/cdi/lamotrigine.html
3741
-2.0
-
-2.0
-
DRUGBANK
98.0
%
~98
%
DRUGBANK
97.6
%
97.6±4.8
%
PO, oral;
DRUGBANK
2500.0
ng/ml
2.5±0.4
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
3.1
h
1.4-4.8
h
DRUGBANK
2.2
h
2.2±1.2
h
Oral single dose; adults; normal,healthy;
DRUGBANK
10.0
%
10
%
Urinary excretion; Unchanged drug;
DRUGBANK
76.0
%
76
%
DRUGBANK
10.0
%
10
%
DRUGBANK
14.0
%
14
%
DRUGBANK
0.0417
L/h/kg
0.18-1.21
ml/min/kg
Plasma clearance;
DRUGBANK
0.0264
L/h/kg
0.44
ml/min/kg
normal,healthy;
DRUGBANK
0.0297
L/h/kg
0.38-0.61
ml/min/kg
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
1.1
L/kg
0.9-1.3
L/kg
Apparent volume of distribution; PO, oral;
DRUGBANK
1.035
L/kg
0.87-1.2
L/kg
DRUGBANK
36.5
h
14-59
h
elimination half-life;
DRUGBANK
29.5
h
24-35
h
moderate hepatic impairment ↑ ;severe hepatic impairment ↑ ;severe renal function ↑ ;enzyme-inducers ↓ ;
DRUGBANK
205.0
mg/kg
205.0
mg/kg
PO, oral; mouse;
DRUGBANK
245.0
mg/kg
245.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
mouse;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
Rattus, Rat;
DRUGBANK
640.0
mg/kg
>640
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
640.0
mg/kg
>640
mg/kg
PO, oral; mouse;
DRUGBANK
94.0
%
~94
%
Urinary excretion; PO, oral;
DRUGBANK
2.0
%
~2
%
Faeces excretion; PO, oral;
DRUGBANK
10.0
%
10
%
Urinary excretion; adults; normal,healthy; epilepsy; human, homo sapiens; Unchanged drug;
DRUGBANK
55.0
%
55
%
plasma proteins;
DRUGBANK
56.0
%
56
%
adults; normal,healthy; epilepsy; human, homo sapiens;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Lamictal
lamotrigine
PDR
400.0
mg/day
400
mg/day
PO, oral
Lamictal
lamotrigine
PDR
300.0
mg/day
300
mg/day
PO, oral
Lamictal
lamotrigine
PDR
200.0
mg/day
200
mg/day
PO, oral
Lamictal
lamotrigine
PDR
100.0
mg/day
100
mg/day
PO, oral
Lamictal
lamotrigine
PDR
400.0
mg/day
400
mg/day
PO, oral
Lamictal
lamotrigine
PDR
200.0
mg/day
200
mg/day
PO, oral
Lamictal
lamotrigine
PDR
100.0
mg/day
100
mg/day
PO, oral
Lamictal
lamotrigine
PDR
400.0
mg/day
400
mg/day
PO, oral
Lamictal
lamotrigine
PDR
DDPD00556
Perflutren
188.0193
C3F8
FC(F)(F)C(F)(F)C(F)(F)F
DB00556
6432
31980
http://www.drugs.com/cdi/perflutren-lipid-microspheres.html
6192
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
35.4426
L/h/kg
590.71
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0316666666666667
h
1.9
min
DRUGBANK
0.02
h
0.02
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
microL/kg
10
microL/kg
intravenous injection, IV
Definity
perflutren lipid microsphere
PDR
1.3
ml
1.3
ml
intravenous infusion, iv in drop
Definity
perflutren lipid microsphere
PDR
10.0
microL/kg
10
microL/kg
intravenous injection, IV
Definity
perflutren lipid microsphere
PDR
1.3
ml
1.3
ml
intravenous infusion, iv in drop
Definity
perflutren lipid microsphere
PDR
DDPD00557
Hydroxyzine
374.904
C21H27ClN2O2
OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
DB00557
T3D2823
3658
5818
http://www.drugs.com/hydroxyzine.html
3531
-2.0
-
-2.0
-
DRUGBANK
72.0
ng/ml
72±11
ng/ml
PO, oral; Elderly; normal,healthy;
DRUGBANK
47.0
ng/ml
47±17
ng/ml
PO, oral; Children; normal,healthy;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
2.1
h
2.1±0.4
h
PO, oral; Elderly; normal,healthy;
DRUGBANK
2.0
h
2.0±0.9
h
PO, oral; Children; normal,healthy;
DRUGBANK
52.5
%
45-60
%
PO, oral;
DRUGBANK
1.866
L/h/kg
31.1±11.1
ml/min/kg
Children;
DRUGBANK
0.588
L/h/kg
9.8±3.3
ml/min/kg
adults;
DRUGBANK
0.588
L/h/kg
9.8±3.3
ml/min/kg
apparent clearance; PO, oral;
DRUGBANK
1.92
L/h/kg
32±11
ml/min/kg
apparent clearance; PO, oral;
DRUGBANK
16.0
L/kg
16.0±3.0
L/kg
Average volume of distribution;
DRUGBANK
16.0
L/kg
16±3
L/kg
Apparent volume of distribution; PO, oral;
DRUGBANK
19.0
L/kg
19±9
L/kg
Apparent volume of distribution; PO, oral;
DRUGBANK
20.0
h
~20(14-25)
h
adults;
DRUGBANK
7.1
h
~7.1
h
Children;
DRUGBANK
29.0
h
29
h
elimination half-life; Elderly;
hepatopathy，LD ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
20.0
h
20±4
h
adults; PO, oral;
chronic liver disease ↑ ;Age ↑ ;
DRUGBANK
7.1
h
7.1±2.3
h
Children; PO, oral;
chronic liver disease ↑ ;Age ↑ ;
DRUGBANK
840.0
mg/kg
840.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
1.1
mg/kg/dose
1.1
mg/kg/dose
IM,intramuscular injection
Vistaril
hydroxyzine pamoate
PDR
50.0
mg/day
50
mg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
1.1
mg/kg/dose
1.1
mg/kg/dose
IM,intramuscular injection
Vistaril
hydroxyzine pamoate
PDR
400.0
mg/day
400
mg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
600.0
mg/day
600
mg/day
IM,intramuscular injection
Vistaril
hydroxyzine pamoate
PDR
100.0
mg/day
100
mg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
1.1
mg/kg/dose
1.1
mg/kg/dose
IM,intramuscular injection
Vistaril
hydroxyzine pamoate
PDR
400.0
mg/day
400
mg/day
PO, oral
Vistaril
hydroxyzine pamoate
PDR
600.0
mg/day
600
mg/day
IM,intramuscular injection
Vistaril
hydroxyzine pamoate
PDR
DDPD00558
Zanamivir
332.3098
C12H20N4O7
[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO
DB00558
60855
50663
http://www.drugs.com/cdi/zanamivir.html
54842
-2.0
-
-2.0
-
DRUGBANK
2.0
%
2
%
DRUGBANK
10.5
%
4-17
%
inhalation, IH;
DRUGBANK
0.0
%
0
%
DRUGBANK
6.7
L/h
2.5-10.9
L/h
PO, oral;
DRUGBANK
5.3
L/h
5.3
L/h
intravenous injection, IV; normal,healthy;
DRUGBANK
2.7
L/h
2.7
L/h
intravenous injection, IV; mild renal function; moderate renal function; patients;
DRUGBANK
0.8
L/h
0.8
L/h
intravenous injection, IV; severe renal function; patients;
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.8
h
2.5-5.1
h
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
<10
%
DRUGBANK
10.0
mg
10
mg
inhalation, IH
q2d
Relenza
zanamivir
PDR
12.0
mg/kg
12
mg/kg
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
600.0
mg/dose
600
mg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
10.0
mg
10
mg
inhalation, IH; for 5 days
q2d
Relenza
zanamivir
PDR
7.0
mg/kg/day
14
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
7.0
mg/kg/day
14
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
10.0
mg
10
mg
inhalation, IH
q2d
Relenza
zanamivir
PDR
600.0
mg
600
mg
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
10.0
mg
10
mg
inhalation, IH
q2d
Relenza
zanamivir
PDR
12.0
mg/kg/dose
12
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
600.0
mg/dose
600
mg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
10.0
mg
10
mg
inhalation, IH
q2d
Relenza
zanamivir
PDR
600.0
mg
600
mg
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
7.0
mg/kg/day
14
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
6.0
mg/kg/day
12
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
5.0
mg/kg/day
10
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
4.0
mg/kg/day
8
mg/kg/dose
intravenous injection, IV
q2d
Relenza
zanamivir
PDR
DDPD00559
Bosentan
551.614
C27H29N5O6S
COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
DB00559
104865
51450
http://www.drugs.com/cdi/bosentan.html
94651
-2.0
-
-2.0
-
DRUGBANK
50.0
%
~50
%
PO, oral; food;
food → ;
DRUGBANK
4.0
L/h
4.0
L/h
pulmonary arterial hypertension; patients;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
L
18.0
L
DRUGBANK
0.29
L/kg
0.29
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~5
h
elimination half-life; normal,healthy; adults;
DRUGBANK
4.1
h
4.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
>98
%
plasma proteins;
DRUGBANK
128.0
mg/day
128
mg/day
PO, oral
Tracleer
bosentan
PDR
96.0
mg/day
96
mg/day
PO, oral
Tracleer
bosentan
PDR
64.0
mg/day
64
mg/day
PO, oral
Tracleer
bosentan
PDR
32.0
mg/day
32
mg/day
PO, oral
Tracleer
bosentan
PDR
62.5
mg/day
62.5
mg/day
PO, oral
Tracleer
bosentan
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Tracleer
bosentan
PDR
31.25
mg/day
31.25
mg/day
PO, oral
Tracleer
bosentan
PDR
250.0
mg/day
250
mg/day
PO, oral
Tracleer
bosentan
PDR
125.0
mg/day
125
mg/day
PO, oral
Tracleer
bosentan
PDR
250.0
mg/day
250
mg/day
PO, oral
Tracleer
bosentan
PDR
125.0
mg/day
125
mg/day
PO, oral
Tracleer
bosentan
PDR
250.0
mg/day
250
mg/day
PO, oral
Tracleer
bosentan
PDR
125.0
mg/day
125
mg/day
PO, oral
Tracleer
bosentan
PDR
62.5
mg/day
62.5
mg/day
PO, oral
Tracleer
bosentan
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Tracleer
bosentan
PDR
31.25
mg/day
31.25
mg/day
PO, oral
Tracleer
bosentan
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Tracleer
bosentan
PDR
DDPD00560
Tigecycline
585.6487
C29H39N5O8
[H][C@@]12CC3=C(C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
DB00560
54686904
149836
http://www.drugs.com/cdi/tigecycline.html
10482314
-2.0
-
-2.0
-
DRUGBANK
0.228
L/h/kg
3.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
h
27-43
h
DRUGBANK
48.0
h
48
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
71-89
%
DRUGBANK
50.0
mg
50
mg
intravenous injection, IV
bid
Tygacil
tigecycline
PDR
2.4
mg/kg/day
1.2
mg/kg/dose
intravenous injection, IV
bid
Tygacil
tigecycline
PDR
50.0
mg/dose
50
mg/dose
intravenous injection, IV
bid
Tygacil
tigecycline
PDR
100.0
mg/day
100
mg/day
intravenous injection, IV
Tygacil
tigecycline
PDR
50.0
mg
50
mg
intravenous injection, IV
bid
Tygacil
tigecycline
PDR
100.0
mg/day
100
mg/day
intravenous injection, IV
Tygacil
tigecycline
PDR
DDPD00561
Doxapram
378.5072
C24H30N2O2
CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
DB00561
3156
681848
http://www.drugs.com/cdi/doxapram.html
3044
-2.0
-
-2.0
-
DRUGBANK
0.318
L/h/kg
5.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.1
h
4.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
mg/kg
~75
mg/kg
intravenous injection, IV; mouse; Rattus, Rat;
DRUGBANK
60.0
mg/kg
40-80
mg/kg
intravenous injection, IV; dog; cat;
DRUGBANK
DDPD00562
Benzthiazide
431.937
C15H14ClN3O4S3
NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O
DB00562
T3D2825
2343
3047
2253
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30
%
DRUGBANK
DDPD00563
Methotrexate
454.4393
C20H22N8O5
CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
DB00563
T3D2486
126941
44185
http://www.drugs.com/methotrexate.html
112728
-2.0
-
-2.0
-
DRUGBANK
77.0
%
64-90
%
DRUGBANK
70.0
%
70±27
%
PO, oral;
DRUGBANK
20.0
%
20
%
PO, oral;
DRUGBANK
499883.23
ng/ml
1.1±0.2
mM
subcutaneous injection, SC; patients;
DRUGBANK
30901872.4
ng/ml
37-99
mM
intravenous injection, IV;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
0.9
h
0.9±0.2
h
subcutaneous injection, SC; patients;
DRUGBANK
0.126
L/h/kg
2.1±0.8
ml/min/kg
Children ↑ ;Children → ;RD, renal impairment, Renal disease，including uremia ↓ ;rheumatoid arthritis → ;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1.0
L/kg
Steady state volume of distribution;
DRUGBANK
0.55
L/kg
0.55±0.19
L/kg
Children → ;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
3-10
h
adults; increasing doses;
DRUGBANK
11.5
h
8-15
h
adults; increasing doses;
DRUGBANK
3.25
h
0.7-5.8
h
terminal half-life; Acute leukaemia; Children; patients;
DRUGBANK
1.6
h
0.9-2.3
h
juvenile idiopathic arthritis; Children; gastroesophageal reflux disease;
DRUGBANK
7.2
h
7.2±2.1
h
rheumatoid arthritis → ;
DRUGBANK
2.0
h
2
h
distribution half-life;
DRUGBANK
52.0
h
52
h
terminal half-life;
DRUGBANK
3.9
h
3.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
135.0
mg/kg
135.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
146.0
mg/kg
146.0
mg/kg
PO, oral; mouse;
DRUGBANK
43.0
mg/kg
43.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
80.0
%
>80
%
Unchanged drug;
DRUGBANK
81.0
%
81±9
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.25
%
46.5-54
%
plasma proteins;
DRUGBANK
46.0
%
46±11
%
DRUGBANK
4.28571428
mg/day
30
mg/week
PO, oral
Methotrexate Tablets
methotrexate
PDR
2.85714285
mg/day
20
mg/week
PO, oral
Methotrexate Tablets
methotrexate
PDR
15.0
mg
15
mg
Methotrexate Tablets
methotrexate
PDR
30.0
mg/m2
30
mg/m2
Methotrexate Tablets
methotrexate
PDR
490.0
mg/m2
490
mg/m2
intravenous injection, IV
Methotrexate Tablets
methotrexate
PDR
1950.0
mg/m2
1950
mg/m2
intravenous injection, IV
Methotrexate Tablets
methotrexate
PDR
4.28571428571429
mg/day
30
mg/week
PO, oral
Methotrexate Tablets
methotrexate
PDR
2.85714285714286
mg/day
20
mg/week
PO, oral
Methotrexate Tablets
methotrexate
PDR
15.0
mg
15
mg
Methotrexate Tablets
methotrexate
PDR
30.0
mg/m2
30
mg/m2
Methotrexate Tablets
methotrexate
PDR
490.0
mg/m2
490
mg/m2
intravenous injection, IV
Methotrexate Tablets
methotrexate
PDR
1950.0
mg/m2
1950
mg/m2
intravenous injection, IV
Methotrexate Tablets
methotrexate
PDR
DDPD00564
Carbamazepine
236.2686
C15H12N2O
NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
DB00564
T3D2826
2554
3387
http://www.drugs.com/carbamazepine.html
2457
-2.0
-
-2.0
-
DRUGBANK
80.0
%
75-85
%
DRUGBANK
70.0
%
>70
%
PO, oral;
DRUGBANK
1900.0
ng/ml
1.9±0.3
mcg/ml
PO, oral; extended release formulation;
DRUGBANK
11000.0
ng/ml
11.0±2.5
mcg/ml
Oral multiple dose;
DRUGBANK
9300.0
ng/ml
9.3(2-18)
mcg/ml
PO, oral; immediate release formulation; adults; epilepsy;
DRUGBANK
19.0
h
19±7
h
PO, oral; extended release formulation;
DRUGBANK
5.9
h
5.9±1.8
h
Oral multiple dose;
DRUGBANK
6.0
h
4-8
h
PO, oral; immediate release formulation; adults; epilepsy;
DRUGBANK
1.5
L/h
25±5
ml/min
Total clearance; Oral single dose;
DRUGBANK
4.8
L/h
80±30
ml/min
Total clearance; Oral multiple dose;
DRUGBANK
0.9
L/h/kg
13±0.5
ml/min/kg
Children → ;Elderly → ;Preg, pregnant ↑ ;Somking → ;
DRUGBANK
1.05
L/kg
0.7-1.4
L/kg
DRUGBANK
1.4
L/kg
1.4±0.4
L/kg
Neonates → ;Children → ;Elderly → ;
DRUGBANK
37.5
h
35-40
h
Single dose; elimination half-life; extended release formulation;
DRUGBANK
14.5
h
12-17
h
Multiple dose;
DRUGBANK
31.9
h
27-36.8
h
elimination half-life; normal,healthy;
DRUGBANK
15.0
h
15±5
h
Oral multiple dose;
Children → ;Neonates → ;Age → ;
DRUGBANK
1957.0
mg/kg
1957.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
72.0
%
72
%
Urinary excretion; PO, oral;
DRUGBANK
28.0
%
28
%
Faeces excretion; PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
77.5
%
75-80
%
plasma proteins;
DRUGBANK
74.0
%
74±3
%
Preg, pregnant → ;RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Epitol
carbamazepine
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Epitol
carbamazepine
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Epitol
carbamazepine
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Epitol
carbamazepine
PDR
1120.0
mg/day
1120
mg/day
intravenous injection, IV
Epitol
carbamazepine
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Epitol
carbamazepine
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Epitol
carbamazepine
PDR
1120.0
mg/day
1120
mg/day
intravenous injection, IV
Epitol
carbamazepine
PDR
1000.0
mg/day
1000
mg/day
Tablet,PO，oral
Epitol
carbamazepine
PDR
35.0
mg/kg/day
35
mg/kg/day
Tablet,PO，oral
Epitol
carbamazepine
PDR
35.0
mg/kg/day
35
mg/kg/day
Capsule, PO, Oral
Epitol
carbamazepine
PDR
DDPD00565
Cisatracurium
929.16
C53H72N2O12
COC1=CC2=C(C=C1OC)[C@@H](CC1=CC(OC)=C(OC)C=C1)[N@@+](C)(CCC(=O)OCCCCCOC(=O)CC[N@@+]1(C)CCC3=C(C=C(OC)C(OC)=C3)[C@H]1CC1=CC(OC)=C(OC)C=C1)CC2
DB00565
62886
140621
http://www.drugs.com/cdi/cisatracurium.html
56615
-2.0
-
-2.0
-
DRUGBANK
0.324
L/h/kg
5.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.366666666666667
h
22
min
elimination half-life;
DRUGBANK
0.42
h
0.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00566
Succimer
182.21
C4H6O4S2
OC(=O)[C@@H](S)[C@@H](S)C(O)=O
DB00566
2724354
63623
http://www.drugs.com/cdi/succimer.html
2006502
-2.0
-
-2.0
-
DRUGBANK
48.0
h
48
h
DRUGBANK
5011.0
mg/kg
>5011
mg/kg
PO, oral; mouse;
DRUGBANK
500.0
mg/dose
500
mg/dose
PO, oral
Chemet
succimer
PDR
400.0
mg/dose
400
mg/dose
PO, oral
Chemet
succimer
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Chemet
succimer
PDR
200.0
mg/dose
200
mg/dose
PO, oral
Chemet
succimer
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Chemet
succimer
PDR
500.0
mg/dose
500
mg/dose
PO, oral
Chemet
succimer
PDR
500.0
mg/dose
500
mg/dose
PO, oral
Chemet
succimer
PDR
400.0
mg/dose
400
mg/dose
PO, oral
Chemet
succimer
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Chemet
succimer
PDR
200.0
mg/dose
200
mg/dose
PO, oral
Chemet
succimer
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Chemet
succimer
PDR
DDPD00567
Cephalexin
347.389
C16H17N3O4S
[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
DB00567
27447
3534
http://www.drugs.com/cephalexin.html
25541
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
90.0
%
90±9
%
PO, oral;
DRUGBANK
7700.0
ng/ml
7.7
mcg/ml
DRUGBANK
12300.0
ng/ml
12.3
mcg/ml
DRUGBANK
28000.0
ng/ml
28±6.4
mcg/ml
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
1.4
h
1.4±0.8
h
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
0.0
%
0
%
DRUGBANK
22.56
L/h
376.0
ml/min
DRUGBANK
0.258
L/h/kg
4.3±1.1
ml/min/kg
normal,healthy; adults;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.234
L/h/kg
3.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
L
5.2-5.8
L
DRUGBANK
0.26
L/kg
0.26±0.03
L/kg
normal,healthy; adults;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.825
h
49.5
min
fasting;
DRUGBANK
1.275
h
76.5
min
food;
DRUGBANK
0.9
h
0.90±0.18
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.57
h
0.57
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
Urinary excretion;
DRUGBANK
91.0
%
91±18
%
Urinary excretion; Unchanged drug;
DRUGBANK
12.5
%
10-15
%
DRUGBANK
14.0
%
14±3
%
DRUGBANK
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Keflex
cephalexin
PDR
4000.0
mg/day
4
g/day
PO, oral
Keflex
cephalexin
PDR
4000.0
mg/day
4
g/day
PO, oral
Keflex
cephalexin
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Keflex
cephalexin
PDR
4000.0
mg/day
4
g/day
PO, oral
Keflex
cephalexin
PDR
4000.0
mg/day
4
g/day
PO, oral
Keflex
cephalexin
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Keflex
cephalexin
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Keflex
cephalexin
PDR
DDPD00568
Cinnarizine
368.5139
C26H28N2
C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
DB00568
2761
31403
1264793
-2.0
-
-2.0
-
DRUGBANK
DDPD00569
Fondaparinux
1508.263
C31H53N3O49S8
CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
DB00569
49852292
61033
http://www.drugs.com/cdi/fondaparinux.html
4445600
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
subcutaneous injection, SC;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.0042
L/h/kg
0.07
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
L
7.0-11
L
normal,healthy; adults;
DRUGBANK
19.0
h
17-21
h
DRUGBANK
19.3
h
19.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.0
%
94
%
high protein binding;
DRUGBANK
2.5
mg/day
2.5
mg/day
subcutaneous injection, SC
Arixtra
fondaparinux sodium
PDR
10.0
mg/day
10
mg/day
subcutaneous injection, SC
Arixtra
fondaparinux sodium
PDR
2.5
mg/day
2.5
mg/day
subcutaneous injection, SC
Arixtra
fondaparinux sodium
PDR
10.0
mg/day
10
mg/day
subcutaneous injection, SC
Arixtra
fondaparinux sodium
PDR
DDPD00570
Vinblastine
810.9741
C46H58N4O9
[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC
DB00570
T3D4017
13342
http://www.drugs.com/cdi/vinblastine.html
12773
-2.0
-
-2.0
-
DRUGBANK
0.186
L/h/kg
3.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.0
L/kg
28
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.583333333333333
h
35
min
distribution half-life;
DRUGBANK
0.883333333333333
h
53
min
elimination half-life;
DRUGBANK
19.0
h
19
h
terminal half-life;
DRUGBANK
67.0
h
67
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
423.0
mg/kg
423.0
mg/kg
PO, oral; mouse;
DRUGBANK
305.0
mg/kg
305.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
423.0
mg/kg
423.0
mg/kg
PO, oral; mouse;
DRUGBANK
305.0
mg/kg
305.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
98.5
%
98-99
%
DRUGBANK
12.5
mg/m2/day
12.5
mg/m2/day
intravenous injection, IV
qw
Vinblastine Sulfate
vinblastine sulfate
PDR
18.5
mg/m2
18.5
mg/m2
intravenous injection, IV
q2w
Vinblastine Sulfate
vinblastine sulfate
PDR
12.5
mg/m2/day
12.5
mg/m2/day
intravenous injection, IV
qw
Vinblastine Sulfate
vinblastine sulfate
PDR
18.5
mg/m2
18.5
mg/m2
intravenous injection, IV
q2w
Vinblastine Sulfate
vinblastine sulfate
PDR
DDPD00571
Propranolol
259.3434
C16H21NO2
CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
DB00571
4946
8499
http://www.drugs.com/propranolol.html
4777
-2.0
-
-2.0
-
DRUGBANK
26.0
%
26±10
%
PO, oral;
DRUGBANK
18.0
ng/ml
18±15
ng/ml
PO, oral;
DRUGBANK
52.0
ng/ml
52±51
ng/ml
PO, oral;
DRUGBANK
121.0
ng/ml
121±98
ng/ml
PO, oral;
DRUGBANK
245.0
ng/ml
245±110
ng/ml
PO, oral;
DRUGBANK
49.0
ng/ml
49±8
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
37.0
ng/ml
37±9
ng/ml
Oral single dose; Active metabolite; adults; normal,healthy;
DRUGBANK
2.0
h
2(1-4)
h
PO, oral; fasting;
DRUGBANK
1.5
h
1.5
h
Oral single dose; adults; normal,healthy;
DRUGBANK
1.0
h
1.0
h
Oral single dose; Active metabolite; adults; normal,healthy;
DRUGBANK
3.0
L/h/kg
2.7-3.3
L/h/kg
Infants;
normal BMI ↓ ;
DRUGBANK
48.6
L/h
810.0
ml/min
hypertension; adults;
DRUGBANK
0.96
L/h/kg
16±5
ml/min/kg
Female, women ↓ ;Elderly → ;Hepatitis, Hep ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;Obesity ↓ ;hyperthyroid, HTh ↑ ;Somking ↑ ;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
L/kg
4.0
L/kg
DRUGBANK
4.3
L/kg
4.3±0.6
L/kg
Female, women → ;Elderly → ;Preg, pregnant → ;Hepatitis, Hep ↑ ;Hepatic cirrhosis, cirr ↑ ;hyperthyroid, HTh ↑ ;Crohn ↓ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;
DRUGBANK
3.1
L/kg
3.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
~8
h
elimination half-life;
DRUGBANK
4.5
h
3-6
h
elimination half-life;
DRUGBANK
3.9
h
3.9±0.4
h
Female, women ↓ ;Preg, pregnant → ;Hepatitis, Hep ↓ ;Hepatic cirrhosis, cirr ↓ ;Obesity ↓ ;RD, renal impairment, Renal disease，including uremia → ;Age → ;Somking → ;
DRUGBANK
3.4
h
3.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
91.0
%
91
%
Urinary excretion; PO, oral;
DRUGBANK
0.5
%
<0.5
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
~90
%
DRUGBANK
87.0
%
87±6
%
Preg, pregnant ↑ ; Female, women → ;Elderly → ;inflammation ↑ ;Crohn ↑ ;Obesity ↑ ;RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
0.25
mg/kg/dose
0.25
mg/kg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
3.0
mg/dose
3
mg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
120.0
mg/day
120
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
0.25
mg/kg/dose
0.25
mg/kg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
3.0
mg/dose
3
mg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
240.0
mg/day
240
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
320.0
mg/day
320
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
120.0
mg/day
120
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
0.25
mg/kg/dose
0.25
mg/kg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
3.0
mg/dose
3
mg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
120.0
mg/day
120
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
240.0
mg/day
240
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
320.0
mg/day
320
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
640.0
mg/day
640
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
3.4
mg/kg/day
3.4
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
3.5
mg/kg/dose
3.5
mg/kg/dose
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
3.5
mg/kg/dose
3.5
mg/kg/dose
PO, oral
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
0.12
mg/kg/dose
0.12
mg/kg/dose
intravenous injection, IV
Propranolol Hydrochloride Tablets
propranolol hydrochloride
PDR
DDPD00572
Atropine
289.3694
C17H23NO3
CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1
DB00572
174174
78734
http://www.drugs.com/cdi/atropine-drops.html
10194105
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50.0
%
PO, oral;
DRUGBANK
2.6
ng/ml
2.6±0.5
ng/ml
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
0.15
h
0.15±0.04
h
IM,intramuscular injection; adults; normal,healthy;
DRUGBANK
31.5
%
13-50
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.48
L/h/kg
8±4
ml/min/kg
Elderly ↓ ;
DRUGBANK
0.456
L/h/kg
7.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
L/kg
2.0±1.1
L/kg
Children ↑ ;
DRUGBANK
3.3
L/kg
3.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3±0.9
h
Male, men;
DRUGBANK
2.3
h
2.3±0.9
h
Female, women;
DRUGBANK
3.5
h
3.5±1.5
h
Children ↑ ;Age ↑ ;
DRUGBANK
4.1
h
4.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
mg/kg
75.0
mg/kg
PO, oral; mouse;
DRUGBANK
31.5
%
13-50
%
Urinary excretion; Unchanged drug;
DRUGBANK
57.0
%
57±8
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
18.0
%
14-22
%
plasma proteins;
DRUGBANK
18.0
%
14-22
%
Elderly → ;
DRUGBANK
DDPD00573
Fenoprofen
242.2699
C15H14O3
CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1
DB00573
3342
5004
http://www.drugs.com/cdi/fenoprofen.html
3225
-2.0
-
-2.0
-
DRUGBANK
50000.0
ng/ml
50.0
mcg/ml
Oral single dose;
DRUGBANK
2.0
h
2
h
Oral single dose;
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
0.036
L/h/kg
0.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
L/kg
0.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
elimination half-life;
DRUGBANK
2.24
h
2.24
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
3200.0
mg/day
3200
mg/day
PO, oral
Nalfon
fenoprofen calcium
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Nalfon
fenoprofen calcium
PDR
DDPD00574
Fenfluramine
231.2573
C12H16F3N
CCNC(C)CC1=CC=CC(=C1)C(F)(F)F
DB00574
3337
5000
3220
-2.0
-
-2.0
-
DRUGBANK
1390.0
ng.h/ml
1390.0
ng.h/ml
PO, oral; Children;
DRUGBANK
71.0
%
68-74
%
DRUGBANK
68.0
ng/ml
68.0
ng/ml
PO, oral; Children;
DRUGBANK
4.5
h
4-5
h
DRUGBANK
24.8
L/h
24.8
L/h
Average clearance; normal,healthy;
DRUGBANK
11.9
L/kg
11.9
L/kg
Apparent volume of distribution; normal,healthy;
DRUGBANK
20.0
h
20
h
elimination half-life; normal,healthy; rheumatoid arthritis;
DRUGBANK
90.0
%
>90
%
Urinary excretion;
DRUGBANK
5.0
%
<5
%
Faeces excretion;
DRUGBANK
25.0
%
<25
%
Unchanged drug;
DRUGBANK
50.0
%
50
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
DDPD00575
Clonidine
230.094
C9H9Cl2N3
ClC1=CC=CC(Cl)=C1NC1=NCCN1
DB00575
T3D2829
2803
46632
http://www.drugs.com/clonidine.html
2701
-2.0
-
-2.0
-
DRUGBANK
5.60678
ng.h/ml
5606.78
pg.h/ml
Tablet, PO, oral;
DRUGBANK
71.0
%
55-87
%
Tablet, PO, oral;
DRUGBANK
95.0
%
95.0
%
PO, oral;
DRUGBANK
60.0
%
60.0
%
Transdermal preparations;
DRUGBANK
0.40072
ng/ml
400.72
pg/ml
Tablet, PO, oral;
DRUGBANK
0.8
ng/ml
0.8
ng/ml
PO, oral;
DRUGBANK
0.35
ng/ml
0.3-0.4
ng/ml
Transdermal preparations;
DRUGBANK
1.25
h
1-1.5
h
PO, oral; food;
food → ;
DRUGBANK
2.0
h
2.0
h
PO, oral;
DRUGBANK
72.0
h
72.0
h
Transdermal preparations;
DRUGBANK
50.0
%
<50
%
Liver metabolism; Inactive metabolite;
DRUGBANK
0.186
L/h/kg
1.9-4.3
ml/min/kg
DRUGBANK
0.186
L/h/kg
3.1±1.2
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.24
L/h/kg
4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
L/kg
2.1±0.4
L/kg
DRUGBANK
2.1
L/kg
2.1±0.4
L/kg
DRUGBANK
3.3
L/kg
3.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
h
30
min
elimination half-life; IM,intramuscular injection;
DRUGBANK
14.5
h
6-23
h
DRUGBANK
12.0
h
12±7
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
7.6
h
7.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
125.0
mg/kg
125.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
150.0
mg/kg
150.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
30.0
mg/kg
30.0
mg/kg
PO, oral; dog;
DRUGBANK
0.07
mg/kg
70.0
ug/kg
Children;
DRUGBANK
0.126
mg/kg
126.0
ug/kg
Female, women;
DRUGBANK
0.069
mg/kg
69.0
ug/kg
Male, men;
DRUGBANK
20.0
%
20
%
Faeces excretion;
DRUGBANK
50.0
%
~50
%
Urinary excretion; Unchanged drug;
DRUGBANK
62.0
%
62±11
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
20-40
%
DRUGBANK
20.0
%
20
%
DRUGBANK
0.4
mg/day
0.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
0.4
mg/day
0.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
0.9
mg/day
0.9
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
0.9
mg/day
0.9
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
2.0
patches/week
2
patches/week
Transdermal preparations
Catapres
clonidine hydrochloride
PDR
0.6
mg/day
0.6
mg/day
Transdermal preparations
Catapres
clonidine hydrochloride
PDR
0.96
mg/day
40
mcg/h
epidural administration
Catapres
clonidine hydrochloride
PDR
0.4
mg/day
0.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Catapres
clonidine hydrochloride
PDR
2.0
patches/week
2
patches/week
Transdermal preparations
Catapres
clonidine hydrochloride
PDR
0.6
mg/day
0.6
mg/day
Transdermal preparations
Catapres
clonidine hydrochloride
PDR
0.96
mg/day
40
mcg/hour
epidural administration
Catapres
clonidine hydrochloride
PDR
0.004
mg/kg
4
mcg/kg
PO, oral
Catapres
clonidine hydrochloride
PDR
0.012
mg/kg/day
12
mcg/kg/day
PO, oral
Catapres
clonidine hydrochloride
PDR
0.012
mg/kg/day
12
mcg/kg/day
PO, oral
Catapres
clonidine hydrochloride
PDR
DDPD00576
Sulfamethizole
270.331
C9H10N4O2S2
CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1
DB00576
5328
9331
5137
-2.0
-
-2.0
-
DRUGBANK
5.5
h
3-8
h
DRUGBANK
98.5
%
98-99
%
DRUGBANK
DDPD00577
Valaciclovir
324.3357
C13H20N6O4
CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O
DB00577
T3D3542
60773
35854
http://www.drugs.com/valacyclovir.html
54770
-2.0
-
-2.0
-
DRUGBANK
54.5
%
54.5±9.1
%
Oral single dose; food;
food → ;
DRUGBANK
54.5
%
54.5±9.1
%
intravenous injection, IV; food;
food → ;
DRUGBANK
54.0
%
54(42-73)
%
PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
560.0
ng/ml
≤0.56
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
4800.0
ng/ml
4.8±1.5
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
1.5
h
1.5
h
Oral single dose; adults; normal,healthy;
DRUGBANK
1.9
h
1.9±0.6
h
Oral single dose; adults; normal,healthy;
DRUGBANK
15.3
L/h
~255±86
ml/min
normal,healthy;
DRUGBANK
1.34
L/kg
1.34±0.65
L/kg
immunocompromised; pediatric patients;
DRUGBANK
2.9
h
2.5-3.3
h
elimination half-life; normal renal function;
DRUGBANK
2.5
h
2.5±0.3
h
Metabolite;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
903.5
mg/kg
903.5
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
46.0
%
46
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
47.0
%
47
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
44.0
%
44±10
%
Urinary excretion; Unchanged drug;
DRUGBANK
15.7
%
13.5-17.9
%
plasma proteins; human, homo sapiens;
DRUGBANK
15.7
%
13.5-17.9
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
27.5
%
22-33
%
Metabolite; adults; normal,healthy; human, homo sapiens;
DRUGBANK
4000.0
mg/day
4
g/day
PO, oral
Valtrex
valacyclovir hydrochloride
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Valtrex
valacyclovir hydrochloride
PDR
3000.0
mg/day
3
g/day
PO, oral
Valtrex
valacyclovir hydrochloride
PDR
4000.0
mg/day
4
g/day
PO, oral
Valtrex
valacyclovir hydrochloride
PDR
4000.0
mg/day
4
g/day
PO, oral
Valtrex
valacyclovir hydrochloride
PDR
4000.0
mg/day
4
g/day
PO, oral
Valtrex
valacyclovir hydrochloride
PDR
DDPD00578
Carbenicillin
378.4
C17H18N2O6S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O
DB00578
20824
3393
http://www.drugs.com/cdi/carbenicillin-indanyl.html
19599
-2.0
-
-2.0
-
DRUGBANK
35.0
%
30-40
%
PO, oral;
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3600.0
mg/kg
3600.0
mg/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
PO, oral; dog;
DRUGBANK
45.0
%
30-60
%
DRUGBANK
DDPD00579
Mazindol
284.74
C16H13ClN2O
OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
DB00579
T3D2830
4020
6702
http://www.drugs.com/mtm/mazindol.html
3880
-2.0
-
-2.0
-
DRUGBANK
11.5
h
10-13
h
DRUGBANK
DDPD00580
Valdecoxib
314.359
C16H14N2O3S
CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
DB00580
119607
63634
http://www.drugs.com/mtm/valdecoxib.html
106796
-2.0
-
-2.0
-
DRUGBANK
83.0
%
83
%
DRUGBANK
6.0
L/h
6.0
L/h
Total clearance; PO, oral;
DRUGBANK
6.5
L/h
6.0-7
L/h
patients;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.0
L
86.0
L
DRUGBANK
0.75
L/kg
0.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.5
h
8-11
h
DRUGBANK
7.4
h
7.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Faeces excretion; Unchanged drug;
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD00581
Lactulose
342.2965
C12H22O11
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O
DB00581
11333
6359
http://www.drugs.com/cdi/lactulose-crystals.html
10856
-2.0
-
-2.0
-
DRUGBANK
3.0
%
3
%
DRUGBANK
48.8
ml/kg
48.8
mL/kg
PO, oral; mouse;
DRUGBANK
30.0
ml/kg
>30
mL/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00582
Voriconazole
349.3105
C16H14F3N5O
C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
DB00582
71616
10023
http://www.drugs.com/cdi/voriconazole.html
64684
-2.0
-
-2.0
-
DRUGBANK
96.0
%
96
%
DRUGBANK
96.0
%
96.0
%
PO, oral;
DRUGBANK
2356.0
ng/ml
2356.0
ng/ml
PO, oral;
DRUGBANK
3621.0
ng/ml
3621.0
ng/ml
intravenous injection, IV;
DRUGBANK
1.1
h
1.1
h
PO, oral;
DRUGBANK
0.228
L/h/kg
3.8
ml/min/kg
at steady state;
hepatopathy，LD ↓ ;
DRUGBANK
0.498
L/h/kg
8.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.6
L/kg
4.6
L/kg
DRUGBANK
1.6
L/kg
1.6
L/kg
at steady state;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.7
h
6.7
h
DRUGBANK
5.6
h
5.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
58.0
%
58
%
DRUGBANK
58.0
%
58
%
DRUGBANK
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV;PO, oral;
VFEND
voriconazole
PDR
700.0
mg/day
700
mg/day
PO, oral
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV;PO, oral;
VFEND
voriconazole
PDR
700.0
mg/day
700
mg/day
PO, oral
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV;PO, oral;
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
300.0
mg/day
300
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
300.0
mg/day
300
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
PO, oral
VFEND
voriconazole
PDR
700.0
mg/day
700
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
300.0
mg/day
300
mg/day
PO, oral
VFEND
voriconazole
PDR
800.0
mg/day
800
mg/day
PO, oral
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV;PO, oral;
VFEND
voriconazole
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV
VFEND
voriconazole
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
VFEND
voriconazole
PDR
DDPD00583
Levocarnitine
161.1989
C7H15NO3
C[N+](C)(C)C[C@H](O)CC([O-])=O
DB00583
T3D2832
10917
16347
10455
-2.0
-
-2.0
-
DRUGBANK
15.0
%
15
%
Tablet, PO, oral; Capsule, PO, Oral;
DRUGBANK
3.3
h
3.3
h
Tablet, PO, oral; Capsule, PO, Oral;
DRUGBANK
4.0
L/h
4.0
L/h
Total clearance;
DRUGBANK
29.0
L
29.0±7.1
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
17.4
h
17.4
h
elimination half-life;
DRUGBANK
8000.0
mg/kg
8.0
g/kg
PO, oral; mouse;
DRUGBANK
73.1
%
73.1±16
%
Urinary excretion;
DRUGBANK
3000.0
mg/day
3
g/day
PO, oral
Carnitor Oral Solution, Tablets, and SF Sugar-Free Oral Solution
levocarnitine
PDR
6000.0
mg/day
6
g/day
PO, oral
Carnitor Oral Solution, Tablets, and SF Sugar-Free Oral Solution
levocarnitine
PDR
3000.0
mg/day
3
g/day
PO, oral
Carnitor Oral Solution, Tablets, and SF Sugar-Free Oral Solution
levocarnitine
PDR
6000.0
mg/day
6
g/day
PO, oral
Carnitor Oral Solution, Tablets, and SF Sugar-Free Oral Solution
levocarnitine
PDR
DDPD00584
Enalapril
376.4467
C20H28N2O5
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
DB00584
5388962
4784
http://www.drugs.com/enalapril.html
4534998
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
41.0
%
41±15
%
PO, oral;
DRUGBANK
69.0
ng/ml
69±37
ng/ml
PO, oral; young; normal,healthy;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral; Active metabolite;
DRUGBANK
3.0
h
3.0±1.6
h
PO, oral; young; normal,healthy;
DRUGBANK
96.0
h
4
day
PO, oral;
DRUGBANK
60.0
%
60
%
DRUGBANK
9.48
L/h
~158±47
ml/min
Renal clearance; normal,healthy; Male, men;
DRUGBANK
0.294
L/h/kg
4.9±1.5
ml/min/kg
apparent clearance; Oral multiple dose;
Female, women → ;Neonates ↓ ;Children ↑ ;Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease ↓ ;
DRUGBANK
1.7
L/kg
1.7±0.7
L/kg
Apparent volume of distribution; Oral multiple dose;
DRUGBANK
36.5
h
35-38
h
terminal half-life;
DRUGBANK
12.5
h
11-14
h
effective half-life; Multiple dose;
DRUGBANK
11.0
h
11.0
h
at steady state; Multiple dose;
RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
61.0
%
~61
%
Urinary excretion;
DRUGBANK
33.0
%
~33
%
Faeces excretion;
DRUGBANK
88.0
%
88±7
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
Hepatitis, Hep → ;
DRUGBANK
50.0
%
<50
%
plasma proteins; human, homo sapiens;
DRUGBANK
55.0
%
50-60
%
DRUGBANK
DDPD00585
Nizatidine
331.45
C12H21N5O2S2
CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
DB00585
3033637
7601
http://www.drugs.com/cdi/nizatidine.html
4356
-2.0
-
-2.0
-
DRUGBANK
70.0
%
>70
%
DRUGBANK
7.0
%
<7
%
Liver metabolism; PO, oral;
DRUGBANK
50.0
L/h
40-60
L/h
DRUGBANK
10.5
L/h
7.0-14
L/h
renal insufficiency; patients;
DRUGBANK
0.588
L/h/kg
9.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.15
L/kg
0.8-1.5
L/kg
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
301.0
mg/kg
301.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
35.0
%
35
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
300.0
mg/day
300
mg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
300.0
mg/day
300
mg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
300.0
mg/day
300
mg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Nizatidine Capsules
nizatidine
PDR
DDPD00586
Diclofenac
296.149
C14H11Cl2NO2
OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
DB00586
T3D4729
3033
47381
http://www.drugs.com/cdi/diclofenac-drops.html
2925
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
54.0
%
54±2
%
PO, oral;
DRUGBANK
2000.0
ng/ml
2.0(1.4-3.0)
mcg/ml
Tablet, PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
420.0
ng/ml
0.42±0.17
mcg/ml
Tablet, PO, oral; Sustained Release formulation; adults; normal,healthy;
DRUGBANK
0.42
h
0.17-0.67
h
Capsule, PO, Oral;
DRUGBANK
1.75
h
1.5-2
h
Tablet, PO, oral;
DRUGBANK
7.25
h
2.5-12
h
PO, oral; food;
food ↑ ;
DRUGBANK
2.5
h
2.5(1.0-4.5)
h
Tablet, PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
5.3
h
5.3±1.5
h
Tablet, PO, oral; Sustained Release formulation; adults; normal,healthy;
DRUGBANK
16.0
L/h
16.0
L/h
Plasma clearance;
DRUGBANK
0.252
L/h/kg
4.2±0.9
ml/min/kg
Urinary excretion; Bile excretion;
Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;
DRUGBANK
0.21
L/h/kg
3.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.15
L/kg
0.1-0.2
L/kg
Total volume of distribution;
DRUGBANK
0.17
L/kg
0.17±0.11
L/kg
rheumatoid arthritis ↑ ;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
terminal half-life;
DRUGBANK
29.4
h
25.8-33
h
Metabolite;
DRUGBANK
1.1
h
1.1±0.2
h
rheumatoid arthritis → ;
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
390.0
mg/kg
390.0
mg/kg
PO, oral; mouse;
DRUGBANK
65.0
%
60-70
%
Urinary excretion;
DRUGBANK
30.0
%
30
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.7
%
>99.7
%
DRUGBANK
99.5
%
>99.5
%
DRUGBANK
2.0
patches/day
2
patches/day
skin/dermal
Zipsor
diclofenac potassium
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Zipsor
diclofenac potassium
PDR
200.0
mg/day
200
mg/day
PO, oral
Zipsor
diclofenac potassium
PDR
150.0
mg/day
150
mg/day
PO, oral
Zipsor
diclofenac potassium
PDR
125.0
mg/day
125
mg/day
PO, oral
Zipsor
diclofenac potassium
PDR
32000.0
mg/day
32
g/day
gel
Zipsor
diclofenac potassium
PDR
16000.0
mg/day
16
g/day
gel
Zipsor
diclofenac potassium
PDR
8000.0
mg/day
8
g/day
gel
Zipsor
diclofenac potassium
PDR
160.0
drops/knee/day
160
drops/knee/day
skin/dermal
Zipsor
diclofenac potassium
PDR
2.0
patches/day
2
patches/day
skin/dermal
Zipsor
diclofenac potassium
PDR
2.0
patches/day
2
patches/day
skin/dermal
Zipsor
diclofenac potassium
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Zipsor
diclofenac potassium
PDR
200.0
mg/day
200
mg/day
PO, oral
Zipsor
diclofenac potassium
PDR
150.0
mg/day
150
mg/day
PO, oral
Zipsor
diclofenac potassium
PDR
125.0
mg/day
125
mg/day
PO, oral
Zipsor
diclofenac potassium
PDR
32000.0
mg/day
32
g/day
gel
Zipsor
diclofenac potassium
PDR
16000.0
mg/day
16
g/day
gel
Zipsor
diclofenac potassium
PDR
8000.0
mg/day
8
g/day
gel
Zipsor
diclofenac potassium
PDR
160.0
drops/knee/day
160
drops/knee/day
skin/dermal
Zipsor
diclofenac potassium
PDR
2.0
patches/day
2
patches/day
skin/dermal
Zipsor
diclofenac potassium
PDR
DDPD00588
Fluticasone propionate
500.571
C25H31F3O5S
[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB00588
444036
31441
http://www.drugs.com/cdi/fluticasone-furoate-spray.html
392059
-2.0
-
-2.0
-
DRUGBANK
2.0
%
<2
%
inhalation, IH;
DRUGBANK
1.0
%
<1
%
PO, oral;
DRUGBANK
9.0
%
9
%
inhalation, IH; Caucasian; Male, men;
DRUGBANK
62.34
L/h
1093.0
ml/min
DRUGBANK
63.9
L/h
63.9
L/h
intravenous injection, IV; Caucasian; Male, men;
DRUGBANK
1.02
L/h/kg
17
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.2
L/kg
4.2
L/kg
intravenous injection, IV;
DRUGBANK
557.0
L
557.0
L
at steady state; intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
3.6
L/kg
3.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.8
h
7.8
h
intravenous injection, IV;
DRUGBANK
14.0
h
14
h
intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
10.8
h
10.8
h
inhalation, IH; normal,healthy; Caucasian; Male, men;
DRUGBANK
6.0
h
6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
<5
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
DRUGBANK
91.0
%
91
%
nasal spray;
DRUGBANK
2.0
application/day
2
application/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
application/day
1
application/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.11
mg/day
110
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.464
mg/day
464
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
1.76
mg/day
1760
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
2.0
application/day
2
application/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
application/day
1
application/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.11
mg/day
110
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.744
mg/day
744
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.464
mg/day
464
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
1.76
mg/day
1760
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
2.0
application/day
2
application/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
application/day
1
application/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.11
mg/day
110
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.744
mg/day
744
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.464
mg/day
464
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
1.76
mg/day
1760
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
2.0
appLication/day
2
appLication/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.11
mg/day
110
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
2.0
mg/day
2000
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.464
mg/day
464
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
1.76
mg/day
1760
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
2.0
appLication/day
2
appLication/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.055
mg/day
55
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.4
mg/day
400
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.176
mg/day
176
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.352
mg/day
352
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.05
mg/day
50
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
2.0
appLication/day
2
appLication/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.055
mg/day
55
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
400.0
400
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.176
mg/day
176
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
0.352
mg/day
352
mcg/day
inhalation, IH
Cutivate Lotion
fluticasone propionate
PDR
2.0
appLication/day
2
appLication/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
0.055
mg/day
55
mcg/day
nasal spray
Cutivate Lotion
fluticasone propionate
PDR
2.0
appLication/day
2
appLication/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
2.0
application/day
2
application/day
skin ointment
bid
Cutivate Lotion
fluticasone propionate
PDR
1.0
application/day
1
application/day
skin/dermal
Cutivate Lotion
fluticasone propionate
PDR
DDPD00589
Lisuride
338.4466
C20H26N4O
[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC
DB00589
28864
51164
26847
-2.0
-
-2.0
-
DRUGBANK
0.798
L/h/kg
13.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.73
L/kg
1.73
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
%
~15
%
DRUGBANK
DDPD00590
Doxazosin
451.4751
C23H25N5O5
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
DB00590
3157
4708
http://www.drugs.com/doxazosin.html
3045
-2.0
-
-2.0
-
DRUGBANK
65.0
%
60-70
%
DRUGBANK
2.5
h
2-3
h
DRUGBANK
0.09
L/h/kg
~1-2
ml/min/kg
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.45
L/kg
1.0-1.9
L/kg
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.5
h
9-12
h
elimination half-life; different study;
DRUGBANK
22.0
h
22
h
elimination half-life;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; mouse;
DRUGBANK
63.0
%
63
%
Faeces excretion; PO, oral; intravenous injection, IV;
DRUGBANK
9.0
%
~9
%
Urinary excretion; PO, oral; intravenous injection, IV;
DRUGBANK
5.0
%
~5
%
Faeces excretion; Unchanged drug;
DRUGBANK
98.0
%
~98
%
plasma proteins;
DRUGBANK
16.0
mg/day
16
mg/day
PO, oral
Cardura
doxazosin mesylate
PDR
8.0
mg/day
8
mg/day
PO, oral
Cardura
doxazosin mesylate
PDR
16.0
mg/day
16
mg/day
PO, oral
Cardura
doxazosin mesylate
PDR
8.0
mg/day
8
mg/day
PO, oral
Cardura
doxazosin mesylate
PDR
DDPD00591
Fluocinolone acetonide
452.4882
C24H30F2O6
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
DB00591
6215
31623
http://www.drugs.com/cdi/fluocinolone-acetonide-implant.html
5980
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1.3-1.7
h
DRUGBANK
4.0
application/day
4
application/day
Retisert
fluocinolone acetonide
PDR
2.0
application/day
2
application/day
Retisert
fluocinolone acetonide
PDR
4.0
application/day
4
application/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
3.0
application/day
3
application/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
30.0
ml/day
30
ml/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
1.0
implant/30 months
1
implant/30 months
subdermal implant
Retisert
fluocinolone acetonide
PDR
1.0
implant/30 months
1
implant/30 months
subdermal implant
Retisert
fluocinolone acetonide
PDR
4.0
application/day
4
application/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
3.0
application/day
3
application/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
1.0
ounce/day
1
ounce/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
30.0
ml/day
30
ml/day
skin/dermal
Retisert
fluocinolone acetonide
PDR
1.0
implant/30 months
1
implant/30 months
subdermal implant
Retisert
fluocinolone acetonide
PDR
1.0
implant/30 months
1
implant/30 months
subdermal implant
Retisert
fluocinolone acetonide
PDR
4.0
appLication/day
4
appLication/day
Retisert
fluocinolone acetonide
PDR
2.0
appLication/day
2
appLication/day
Retisert
fluocinolone acetonide
PDR
2.0
appLication/day
2
appLication/day
Retisert
fluocinolone acetonide
PDR
DDPD00592
Piperazine
86.1356
C4H10N2
C1CNCCN1
DB00592
4837
28568
http://www.drugs.com/cons/piperazine.html
13835459
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25
%
Liver metabolism;
DRUGBANK
5000.0
mg/kg
5.0
g/kg
PO, oral; human, homo sapiens;
DRUGBANK
65.0
%
60-70
%
DRUGBANK
DDPD00593
Ethosuximide
141.1677
C7H11NO2
CCC1(C)CC(=O)NC1=O
DB00593
T3D2834
3291
4887
http://www.drugs.com/cdi/ethosuximide.html
3175
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93
%
PO, oral;
DRUGBANK
53.0
h
53
h
DRUGBANK
1500.0
mg/day
1.5
g/day
PO, oral
Zarontin Oral Solution
ethosuximide
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Zarontin Oral Solution
ethosuximide
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Zarontin Oral Solution
ethosuximide
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Zarontin Oral Solution
ethosuximide
PDR
DDPD00594
Amiloride
229.627
C6H8ClN7O
NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N
DB00594
16231
2639
http://www.drugs.com/cdi/amiloride.html
15403
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
Liver metabolism;
DRUGBANK
100.0
%
100
%
Urinary excretion;
DRUGBANK
7.5
h
6-9
h
elimination half-life;
DRUGBANK
56.0
mg/kg
56.0
mg/kg
PO, oral; mouse;
DRUGBANK
60.5
mg/kg
36-85
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
40.0
%
~40
%
Faeces excretion;
DRUGBANK
0.625
mg/kg/day
0.625
mg/kg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
0.625
mg/kg/day
0.625
mg/kg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Midamor
amiloride hydrochloride
PDR
DDPD00595
Oxytetracycline
460.434
C22H24N2O9
[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
DB00595
T3D3953
54675779
27701
10482174
-2.0
-
-2.0
-
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00596
Ulobetasol
428.9
C22H27ClF2O4
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB00596
5311167
http://www.drugs.com/cdi/halobetasol-cream.html
4470691
-2.0
-
-2.0
-
DRUGBANK
7142.85714285
mg/day
50
g/week
Bryhali
halobetasol propionate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
Bryhali
halobetasol propionate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
Bryhali
halobetasol propionate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
Bryhali
halobetasol propionate
PDR
DDPD00597
Gadoteridol
558.68
C17H29GdN4O7
[Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1
DB00597
60714
31643
54719
-2.0
-
-2.0
-
DRUGBANK
0.09
L/h/kg
1.50±0.35
ml/min/kg
DRUGBANK
0.0846
L/h/kg
1.41±0.33
ml/min/kg
Renal clearance;
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.204
L/kg
204±58
mL/kg
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
h
12
min
distribution half-life;
DRUGBANK
1.66666666666667
h
100
min
elimination half-life;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.4
%
94.4±4.8
%
Urinary excretion;
DRUGBANK
DDPD00598
Labetalol
328.4055
C19H24N2O3
CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1
DB00598
T3D3517
3869
6343
http://www.drugs.com/cdi/labetalol.html
3734
-2.0
-
-2.0
-
DRUGBANK
48.5
%
11-86
%
PO, oral; Age; food;
Age ↑ ;food ↑ ;
DRUGBANK
0.665
h
0.33-1
h
DRUGBANK
2.0
h
2
h
DRUGBANK
90.0
L/h
~1500
ml/min
Plasma clearance;
DRUGBANK
66.0
L/h
1100.0
ml/min
Total clearance;
DRUGBANK
1.38
L/h/kg
23
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
805.0
L
805.0
L
patients;
DRUGBANK
467.5
L
188-747
L
hypertension; patients;
DRUGBANK
4.8
L/kg
4.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.9
h
1.7-6.1
h
DRUGBANK
4.4
h
4.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
>2
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
55.0
mg/kg
50-60
mg/kg
intravenous injection, IV; mouse; Rattus, Rat;
DRUGBANK
66.0
mg/kg
66.0
mg/kg
intravenous injection, IV; parenteral administration; Rattus, Rat;
DRUGBANK
57.5
%
55-60
%
Urinary excretion;
DRUGBANK
19.5
%
12-27
%
Faeces excretion;
DRUGBANK
50.0
%
~50
%
DRUGBANK
1.0
mg/kg/dose
1
mg/kg/dose
intravenous injection, IV
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
40.0
mg/dose
40
mg/dose
intravenous injection, IV
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
72.0
mg/kg/day
3
mg/kg/hour
intravenous infusion, iv in drop
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
1.0
mg/kg/dose
1
mg/kg/dose
intravenous injection, IV
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
40.0
mg/dose
40
mg/dose
intravenous injection, IV
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
0.125
mg/kg/day
3
mg/kg/hour
intravenous infusion, iv in drop
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
300.0
mg/day
300
mg/day
intravenous injection, IV
Labetalol Hydrochloride Injection
labetalol hydrochloride
PDR
DDPD00599
Thiopental
242.338
C11H18N2O2S
CCCC(C)C1(CC)C(=O)NC(=S)NC1=O
DB00599
T3D2835
3000715
102166
http://www.drugs.com/cdi/thiopental.html
2272258
-2.0
-
-2.0
-
DRUGBANK
0.492
L/h/kg
8.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
3-8
h
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.6
mg/kg
50.6
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
80.0
%
~80
%
plasma proteins;
DRUGBANK
DDPD00600
Monobenzone
200.2332
C13H12O2
OC1=CC=C(OCC2=CC=CC=C2)C=C1
DB00600
7638
34380
http://www.drugs.com/mtm/monobenzone-topical.html
7356
-2.0
-
-2.0
-
DRUGBANK
DDPD00601
Linezolid
337.3461
C16H20FN3O4
CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
DB00601
T3D2675
441401
63607
http://www.drugs.com/cdi/linezolid.html
390139
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
16000.0
ng/ml
16±4
mcg/ml
PO, oral;
DRUGBANK
15000.0
ng/ml
15±3
mcg/ml
intravenous injection, IV; gram-positive infection;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
1.4
h
1.4±0.5
h
PO, oral;
DRUGBANK
0.126
L/h/kg
2.1±0.8
ml/min/kg
Children ↑ ;
DRUGBANK
0.108
L/h/kg
1.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
L
40-50
L
normal,healthy; adults;
DRUGBANK
0.64
L/kg
0.57-0.71
L/kg
DRUGBANK
0.58
L/kg
0.58
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
4.5-5.5
h
DRUGBANK
5.2
h
5.2±1.7
h
Children ↓ ;
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
%
35
%
Urinary excretion; Unchanged drug;
DRUGBANK
31.0
%
31
%
DRUGBANK
31.0
%
31
%
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral;intravenous injection, IV;
Zyvox
linezolid
PDR
10.0
mg/kg
10
mg/kg
PO, oral;intravenous injection, IV;
q8h
Zyvox
linezolid
PDR
600.0
mg
600
mg
PO, oral;intravenous injection, IV;
q8h
Zyvox
linezolid
PDR
1200.0
mg/day
1200
mg/day
PO, oral;intravenous injection, IV;
Zyvox
linezolid
PDR
1200.0
mg/day
1200
mg/day
PO, oral;intravenous injection, IV;
Zyvox
linezolid
PDR
1200.0
mg/day
1200
mg/day
PO, oral;intravenous injection, IV;
Zyvox
linezolid
PDR
10.0
mg/kg
10
mg/kg
PO, oral;intravenous injection, IV;
q8h
Zyvox
linezolid
PDR
10.0
mg/kg
10
mg/kg
PO, oral;intravenous injection, IV;
q8h
Zyvox
linezolid
PDR
DDPD00602
Ivermectin
1736.1589
C95H146O28
CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O
DB00602
T3D4996
46936176
http://www.drugs.com/cdi/ivermectin.html
30776735
-2.0
-
-2.0
-
DRUGBANK
38.2
ng/ml
38.2±5.8
ng/ml
onchocerciasis;
DRUGBANK
4.7
h
4.7±0.5
h
onchocerciasis;
DRUGBANK
99.0
%
99
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
0.1236
L/h/kg
2.06±0.81
ml/min/kg
apparent clearance;
DRUGBANK
3.25
L/kg
3-3.5
L/kg
DRUGBANK
2.06
L/kg
2.06±0.81
L/kg
Apparent volume of distribution;
DRUGBANK
16.0
h
16
h
DRUGBANK
25.0
h
22-28
h
different study;
DRUGBANK
56.5
h
56.5±7.5
h
terminal half-life; Male, men; Female, women; patients; onchocerciasis;
DRUGBANK
29.5
mg/kg
29.5
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
29.5
mg/kg
29.5
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
29.5
mg/kg
29.5
mg/kg
PO, oral; mouse;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
%
~100
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; onchocerciasis; human, homo sapiens; Unchanged drug;
DRUGBANK
93.0
%
93
%
DRUGBANK
93.1
%
93.1±0.2
%
onchocerciasis; human, homo sapiens;
DRUGBANK
4.0
oz/topical application
4
oz/topical application
skin/dermal
Sklice
ivermectin
PDR
4.0
oz/topical application
4
oz/topical application
skin/dermal
Sklice
ivermectin
PDR
0.175
mg/kg
175
mcg/kg
PO, oral
Sklice
ivermectin
PDR
0.4
mg/kg
400
mcg/kg
PO, oral
Sklice
ivermectin
PDR
4.0
oz/topicaL appLication
4
oz/topicaL appLication
skin/dermal
Sklice
ivermectin
PDR
175.0
mcg/kg/dose
175
mcg/kg/dose
PO, oral
Sklice
ivermectin
PDR
4.0
oz/topical application
4
oz/topical application
skin/dermal
Sklice
ivermectin
PDR
0.175
mg/kg/dose
175
mcg/kg/dose
PO, oral
Sklice
ivermectin
PDR
4.0
oz/topical application
4
oz/topical application
skin/dermal
Sklice
ivermectin
PDR
175.0
mcg/kg/dose
175
mcg/kg/dose
PO, oral
Sklice
ivermectin
PDR
4.0
oz/topicaL appLication
4
oz/topicaL appLication
skin/dermal
Sklice
ivermectin
PDR
DDPD00603
Medroxyprogesterone acetate
386.5244
C24H34O4
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C
DB00603
T3D4730
6279
6716
http://www.drugs.com/medroxyprogesterone.html
6043
-2.0
-
-2.0
-
DRUGBANK
487.8904239
ng.h/ml
543.4-1981.1
nmol.h/L
PO, oral;
DRUGBANK
756.783853248
ng.h/ml
81.58±27.64
nmol.day/L
IM,intramuscular injection;
DRUGBANK
670.326075456
ng.h/ml
72.26±38.73
nmol.day/L
subcutaneous injection, SC;
DRUGBANK
88.900612
ng/ml
145-315
nmol/L
PO, oral;
DRUGBANK
40.7783242
ng/ml
33-178
nmol/L
PO, oral;
DRUGBANK
1.812799436
ng/ml
4.69±1.52
nmol/L
IM,intramuscular injection;
DRUGBANK
1.480388452
ng/ml
3.83±1.56
nmol/L
subcutaneous injection, SC;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
2.5
h
1.5-3.5
h
PO, oral;
DRUGBANK
114.0
h
4.75±2.09
day
IM,intramuscular injection;
DRUGBANK
156.48
h
6.52±2.07
day
subcutaneous injection, SC;
DRUGBANK
0.9125
L/h/kg
21.9±4.3
L/kg/day
Average clearance;
DRUGBANK
62.5
L/h
1600-4000
L/day
Average clearance; patients;
DRUGBANK
20.0
L
20±3
L
DRUGBANK
0.375
h
15-30
min
distribution half-life; PO, oral;
DRUGBANK
50.0
h
40-60
h
elimination half-life; PO, oral;
DRUGBANK
20.64
h
0.86±0.30
day
distribution half-life; IM,intramuscular injection;
DRUGBANK
576.72
h
24.03±21.74
day
elimination half-life; IM,intramuscular injection;
DRUGBANK
25.2
h
1.05±0.56
day
distribution half-life; subcutaneous injection, SC;
DRUGBANK
741.6
h
30.90±15.11
day
elimination half-life; subcutaneous injection, SC;
DRUGBANK
6400.0
mg/kg
>6400
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
16000.0
mg/kg
>16
g/kg
PO, oral; mouse;
DRUGBANK
900.0
mg/kg
>900
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
900.0
mg/kg
>900
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
86.0
%
86
%
DRUGBANK
DDPD00604
Cisapride
465.945
C23H29ClFN3O4
CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
DB00604
T3D2836
6917698
3720
http://www.drugs.com/mtm/cisapride.html
5292927
-2.0
-
-2.0
-
DRUGBANK
37.5
%
35-40
%
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
6-12
h
DRUGBANK
11.7
h
11.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
97.5
%
97.5
%
DRUGBANK
DDPD00605
Sulindac
356.411
C20H17FO3S
CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O
DB00605
1548887
9352
http://www.drugs.com/cdi/sulindac.html
1265915
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
4.0872
L/h
68.12±27.56
ml/min
Renal clearance; normal,healthy; adults;
DRUGBANK
7.8
h
7.8
h
DRUGBANK
16.4
h
16.4
h
DRUGBANK
264.0
mg/kg
264.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
93.0
%
~93
%
human, homo sapiens;
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Sulindac
sulindac
PDR
400.0
mg/day
400
mg/day
PO, oral
Sulindac
sulindac
PDR
400.0
mg/day
400
mg/day
PO, oral
Sulindac
sulindac
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Sulindac
sulindac
PDR
400.0
mg/day
400
mg/day
PO, oral
Sulindac
sulindac
PDR
400.0
mg/day
400
mg/day
PO, oral
Sulindac
sulindac
PDR
DDPD00606
Cyclothiazide
389.878
C14H16ClN3O4S2
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2
DB00606
2910
31448
2807
-2.0
-
-2.0
-
DRUGBANK
10000.0
mg/kg
>10000
mg/kg
PO, oral; mouse;
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00607
Nafcillin
414.475
C21H22N2O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O
DB00607
8982
7447
http://www.drugs.com/cdi/nafcillin.html
8634
-2.0
-
-2.0
-
DRUGBANK
30000.0
ng/ml
30.0
ug/ml
intravenous injection, IV;
DRUGBANK
0.0833333333333333
h
5
min
intravenous injection, IV;
DRUGBANK
30.0
%
<30
%
Liver metabolism;
DRUGBANK
0.198
L/h/kg
3.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.783333333333333
h
33-61
min
elimination half-life; intravenous injection, IV;
DRUGBANK
0.7
h
0.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
89.9
%
89.9±1.5
%
DRUGBANK
6000.0
mg/day
6
g/day
IM,intramuscular injection
Nafcillin
nafcillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
50.0
mg/kg/day
50
mg/kg/day
IM,intramuscular injection
Nafcillin
nafcillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
6000.0
mg/day
6
g/day
IM,intramuscular injection
Nafcillin
nafcillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
50.0
mg/kg/day
50
mg/kg/day
IM,intramuscular injection
Nafcillin
nafcillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
50.0
mg/kg/day
50
mg/kg/day
IM,intramuscular injection
Nafcillin
nafcillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
20.0
mg/kg/day
20
mg/kg/day
IM,intramuscular injection
Nafcillin
nafcillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Nafcillin
nafcillin
PDR
DDPD00608
Chloroquine
319.872
C18H26ClN3
CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12
DB00608
T3D2561
2719
3638
http://www.drugs.com/cdi/chloroquine.html
2618
-2.0
-
-2.0
-
DRUGBANK
77.0
%
52-102
%
Capsule, PO, Oral;
DRUGBANK
90.5
%
67-114
%
Tablet, PO, oral;
DRUGBANK
80.0
%
~80
%
PO, oral;
DRUGBANK
975.0
ng/ml
650-1300
ug/L
intravenous injection, IV;
DRUGBANK
96.5
ng/ml
65-128
ug/L
PO, oral;
DRUGBANK
76.0
ng/ml
76±14
ng/ml
PO, oral;
DRUGBANK
268.5
ng/ml
57-480
ng/ml
IM,intramuscular injection;
DRUGBANK
837.0
ng/ml
837±248
ng/ml
adults; normal,healthy;
DRUGBANK
0.5
h
0.5
h
PO, oral;
DRUGBANK
3.6
h
3.6±2
h
PO, oral;
DRUGBANK
0.25
h
0.25
h
IM,intramuscular injection;
DRUGBANK
0.675
L/h/kg
0.35-1
L/h/kg
Plasma clearance;
DRUGBANK
0.501
L/h/kg
3.7-13
ml/min/kg
Average clearance; intravenous injection, IV;
DRUGBANK
0.246
L/h/kg
4.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
L/kg
200-800
L/kg
DRUGBANK
196.5
L/kg
132-261
L/kg
Average volume of distribution; intravenous injection, IV;
DRUGBANK
140.0
L/kg
140
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
960.0
h
20-60
day
DRUGBANK
408.0
h
10-24
day
intravenous injection, IV;
DRUGBANK
984.0
h
41±14
day
DRUGBANK
360.0
h
15±6
day
Active metabolite;
DRUGBANK
570.0
h
570
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
50
%
Urinary excretion; Unchanged drug;
DRUGBANK
55.0
%
52-58
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
60.0
%
46-74
%
plasma proteins;
DRUGBANK
66.6
%
66.6±3.3
%
Optical rotation S;
DRUGBANK
42.7
%
42.7±2.1
%
Optical rotation R;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
16.6
mg/kg
16.6
mg/kg
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
10.0
mg/kg/dose
10
mg base/kg/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
1000.0
mg
1000
mg
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
600.0
mg base
600
mg base
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
41.5
mg/kg
41.5
mg/kg
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
25.0
mg/kg
25
mg/kg base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
2500.0
mg
2.5
g
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1500.0
mg base
1.5
g base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1.18571428
mg/kg/day
8.3
mg/kg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
0.7142857
mg/kg/day
5
mg base/kg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
71.42857142
mg/day
500
mg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
0.14285714
mg/day
300
mg base/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
1000.0
mg/dose
1000
mg/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
600.0
mg base/dose
600
mg base/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
2500.0
mg
2.5
g
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1.5
g base
1.5
g base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
71.4285714285714
mg/day
500
mg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
300.0
mg base/week
300
mg base/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
600.0
mg base/day
600
mg base/day
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
16.6
mg/kg
16.6
mg/kg
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
10.0
mg base/kg/dose
10
mg base/kg/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
1000.0
mg
1000
mg
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
600.0
mg base
600
mg base
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
41.5
mg/kg
41.5
mg/kg
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
25.0
mg/kg base
25
mg/kg base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1250.0
mg/day
2.5
g
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
750.0
mg base/day
1.5
g base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1.18571428571429
mg/kg/day
8.3
mg/kg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
0.714285714285714
mg base/kg/day
5
mg base/kg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
71.4285714285714
mg/day
500
mg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
300.0
mg base/week
300
mg base/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
1000.0
mg/dose
1000
mg/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
600.0
mg base/dose
600
mg base/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
2500.0
mg
2.5
g
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1.5
g base
1.5
g base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
71.4285714285714
mg/day
500
mg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
300.0
mg base/week
300
mg base/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
600.0
mg base/day
600
mg base/day
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
16.6
mg/kg
16.6
mg/kg
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
10.0
mg base/kg/dose
10
mg base/kg/dose
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
41.5
mg/kg
41.5
mg/kg
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
25.0
mg/kg base
25
mg/kg base
PO, oral; in 48 hours
Chloroquine Phosphate
chloroquine phosphate
PDR
1.18571428571429
mg/kg/day
8.3
mg/kg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
5.0
mg base/kg/week
5
mg base/kg/week
PO, oral
Chloroquine Phosphate
chloroquine phosphate
PDR
DDPD00609
Ethionamide
166.243
C8H10N2S
CCC1=NC=CC(=C1)C(N)=S
DB00609
2761171
4885
http://www.drugs.com/cdi/ethionamide.html
2041901
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
93.5
L
93.5
L
normal,healthy;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
30.0
%
~30
%
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Trecator
ethionamide
PDR
1000.0
mg/day
1
g/day
PO, oral
Trecator
ethionamide
PDR
1000.0
mg/day
1
g/day
PO, oral
Trecator
ethionamide
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Trecator
ethionamide
PDR
1000.0
mg/day
1
g/day
PO, oral
Trecator
ethionamide
PDR
1000.0
mg/day
1
g/day
PO, oral
Trecator
ethionamide
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Trecator
ethionamide
PDR
DDPD00610
Metaraminol
167.205
C9H13NO2
C[C@H](N)[C@H](O)C1=CC(O)=CC=C1
DB00610
5906
6794
5695
-2.0
-
-2.0
-
DRUGBANK
240.0
mg/kg
240.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
99.0
mg/kg
99.0
mg/kg
PO, oral; mouse;
DRUGBANK
45.0
%
45
%
DRUGBANK
DDPD00611
Butorphanol
327.4605
C21H29NO2
[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1
DB00611
T3D2837
6916249
3242
http://www.drugs.com/cdi/butorphanol-solution.html
16735714
-2.0
-
-2.0
-
DRUGBANK
65.0
%
60-70
%
IM,intramuscular injection;
DRUGBANK
11.0
%
5-17
%
PO, oral;
DRUGBANK
70.0
%
70±20
%
nasal spray;
DRUGBANK
1.4
ng/ml
1.4±0.6
ng/ml
nasal spray;
DRUGBANK
0.5
h
20-40
min
IM,intramuscular injection;
DRUGBANK
0.38
h
0.38(0.25-1)
h
nasal spray;
DRUGBANK
99.0
L/h
99±23
L/h
intravenous injection, IV; young;
DRUGBANK
82.0
L/h
82±21
L/h
intravenous injection, IV;
DRUGBANK
2.4
L/h/kg
40±10
ml/min/kg
PO, oral; hydrolysis; normal,healthy; Male, men; Female, women; adults;
Elderly → ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
2.46
L/h/kg
41
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
603.0
L
305-901
L
DRUGBANK
12.0
L/kg
12±4
L/kg
PO, oral; hydrolysis; normal,healthy; Male, men; Female, women; adults;
hepatopathy，LD ↑ ;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
~18
h
elimination half-life;
DRUGBANK
36.0
h
~36
h
elimination half-life; moderate renal function; patients;
DRUGBANK
54.0
h
~54
h
elimination half-life; intravenous injection, IV; hepatopathy，LD; patients;
DRUGBANK
4.8
h
4.8±1.6
h
normal,healthy; adults; Male, men; Female, women;
chronic liver disease ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
4.8
h
4.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
%
1.9±1.5
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
80.0
%
~80
%
DRUGBANK
81.5
%
80-83
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD00612
Bisoprolol
325.443
C18H31NO4
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
DB00612
2405
3127
http://www.drugs.com/bisoprolol.html
2312
-2.0
-
-2.0
-
DRUGBANK
642870000000.0
ng.h/ml
642.87
g.h/ml
PO, oral;
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
64.0
ng/ml
64±21
ng/ml
Oral multiple dose;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
120.0
h
5.0
day
PO, oral;
DRUGBANK
50.0
%
50
%
Inactive metabolite;
DRUGBANK
14.2
L/h
14.2
L/h
Total clearance; normal,healthy; patients;
DRUGBANK
7.8
L/h
7.8
L/h
Total clearance; RD, renal impairment, Renal disease，including uremia; patients;
hepatopathy，LD ↓ ;
DRUGBANK
0.222
L/h/kg
3.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
L/kg
3.5
L/kg
DRUGBANK
230.0
L/kg
230.0
L/kg
Average volume of distribution; heart disease; patients;
DRUGBANK
2.4
L/kg
2.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
10-12
h
elimination half-life; normal,healthy;
DRUGBANK
10.0
h
~10
h
elimination half-life; normal,healthy; patients;
DRUGBANK
18.5
h
18.5
h
RD, renal impairment, Renal disease，including uremia;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
730.0
mg/kg
730.0
mg/kg
PO, oral; mouse;
DRUGBANK
2.0
%
<2
%
Faeces excretion;
DRUGBANK
50.0
%
~50
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
30.0
%
~30
%
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Zebeta
bisoprolol fumarate
PDR
10.0
mg/day
10
mg/day
PO, oral
Zebeta
bisoprolol fumarate
PDR
20.0
mg/day
20
mg/day
PO, oral
Zebeta
bisoprolol fumarate
PDR
10.0
mg/day
10
mg/day
PO, oral
Zebeta
bisoprolol fumarate
PDR
DDPD00613
Amodiaquine
355.861
C20H22ClN3O
CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1
DB00613
2165
2674
2080
-2.0
-
-2.0
-
DRUGBANK
13.02
L/h/kg
217
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.4
L/kg
17.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0866666666666667
h
5.2±1.7(0.4-5.5)
min
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
225.0
mg/kg
225.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
550.0
mg/kg
550.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00615
Rifabutin
847.0047
C46H62N4O11
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21
DB00615
T3D2838
6323490
45367
http://www.drugs.com/cdi/rifabutin.html
10482168
-2.0
-
-2.0
-
DRUGBANK
0.69
L/h/kg
0.69±0.32
L/h/kg
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.3
L/kg
9.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
h
45±17
h
DRUGBANK
37.0
h
37
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4800.0
mg/kg
4.8
g/kg
male mouse;
DRUGBANK
4800.0
mg/kg
4.8
g/kg
male mouse;
DRUGBANK
53.0
%
53
%
Urinary excretion; PO, oral; adults; normal,healthy; human, homo sapiens;
DRUGBANK
30.0
%
~30
%
Faeces excretion; PO, oral; adults; normal,healthy; human, homo sapiens;
DRUGBANK
85.0
%
85
%
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Mycobutin
rifabutin
PDR
300.0
mg/day
300
mg/day
PO, oral
Mycobutin
rifabutin
PDR
300.0
mg/day
300
mg/day
PO, oral
Mycobutin
rifabutin
PDR
450.0
mg/day
450
mg/day
PO, oral
Mycobutin
rifabutin
PDR
300.0
mg/day
300
mg/day
PO, oral
Mycobutin
rifabutin
PDR
300.0
mg/day
300
mg/day
PO, oral
Mycobutin
rifabutin
PDR
450.0
mg/day
450
mg/day
PO, oral
Mycobutin
rifabutin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Mycobutin
rifabutin
PDR
DDPD00617
Paramethadione
157.1671
C7H11NO3
CCC1(C)OC(=O)N(C)C1=O
DB00617
T3D2839
8280
7921
http://www.drugs.com/mtm/paramethadione.html
7979
-2.0
-
-2.0
-
DRUGBANK
20.0
%
20
%
PO, oral;
DRUGBANK
18.0
h
12-24
h
DRUGBANK
DDPD00618
Demeclocycline
464.853
C21H21ClN2O8
[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C1=C([C@H]2O)C(Cl)=CC=C1O
DB00618
T3D3951
54680690
4392
http://www.drugs.com/cdi/demeclocycline.html
10482117
-2.0
-
-2.0
-
DRUGBANK
1.21387283236994
L/h/m2
35.0
ml/min/1.73m2
Renal clearance;
DRUGBANK
13.5
h
10-17
h
DRUGBANK
2372.0
mg/kg
2372.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2372.0
mg/kg
2372.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
45.5
%
41-50
%
DRUGBANK
1200.0
mg/day
1.2
g/day
PO, oral
Demeclocycline Hydrochloride
demeclocycline hydrochloride
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Demeclocycline Hydrochloride
demeclocycline hydrochloride
PDR
DDPD00619
Imatinib
493.6027
C29H31N7O
CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
DB00619
5291
45783
http://www.drugs.com/cdi/imatinib.html
5101
-2.0
-
-2.0
-
DRUGBANK
98.0
%
98
%
DRUGBANK
98.0
%
98(87-111)
%
PO, oral;
DRUGBANK
2600.0
ng/ml
2.6±0.8
mcg/ml
PO, oral;
DRUGBANK
3.0
h
2-4
h
DRUGBANK
3.3
h
3.3±1.1
h
PO, oral;
DRUGBANK
11.0
L/h
8.0-14
L/h
Gastrointestinal stromal tumor; Chronic myelogenous leukemia; patients;
gaining weight ↑ ;
DRUGBANK
0.198
L/h/kg
3.3±1.2
ml/min/kg
DRUGBANK
0.198
L/h/kg
3.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.2
L/kg
6.2±2.2
L/kg
DRUGBANK
3.9
L/kg
3.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
18
h
normal,healthy;
DRUGBANK
40.0
h
40
h
normal,healthy;
DRUGBANK
22.0
h
22±4
h
DRUGBANK
22.0
h
22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
68.0
%
68
%
Faeces excretion;
DRUGBANK
13.0
%
13
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
20
%
Faeces excretion; Unchanged drug;
DRUGBANK
50.0
%
5
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
95.0
%
95
%
DRUGBANK
340.0
mg/m2/day
340
mg/m2/day
PO, oral
Imatinib Mesylate
imatinib mesylate
PDR
600.0
mg/day
600
mg/day
PO, oral
Imatinib Mesylate
imatinib mesylate
PDR
800.0
mg/day
800
mg/day
PO, oral
Imatinib Mesylate
imatinib mesylate
PDR
340.0
mg/m2/day
340
mg/m2/day
PO, oral
Imatinib Mesylate
imatinib mesylate
PDR
600.0
mg/day
600
mg/day
PO, oral
Imatinib Mesylate
imatinib mesylate
PDR
800.0
mg/day
800
mg/day
PO, oral
Imatinib Mesylate
imatinib mesylate
PDR
DDPD00620
Triamcinolone
394.4339
C21H27FO6
[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00620
T3D4756
31307
9667
http://www.drugs.com/cdi/triamcinolone-spray.html
29046
-2.0
-
-2.0
-
DRUGBANK
36.0
ng.h/ml
36.0±6.2
ng.h/ml
PO, oral;
DRUGBANK
57.7
ng.h/ml
57.7
ng.h/ml
intravenous injection, IV;
DRUGBANK
5.12
ng.h/ml
5.12
ng.h/ml
inhalation, IH;
DRUGBANK
32.7
ng.h/ml
32.7±9.9
ng.h/ml
PO, oral;
DRUGBANK
25.0
%
25
%
inhalation, IH;
DRUGBANK
5.23
ng/ml
5.23±0.84
ng/ml
PO, oral;
DRUGBANK
0.92
ng/ml
0.92
ng/ml
inhalation, IH;
DRUGBANK
5.33
ng/ml
5.33±1.55
ng/ml
PO, oral;
DRUGBANK
2.24
h
2.24±0.78
h
PO, oral;
DRUGBANK
1.74
h
1.74
h
inhalation, IH;
DRUGBANK
1.86
h
1.86±0.47
h
PO, oral;
DRUGBANK
28.6
L/h
28.6±5.6
L/h
DRUGBANK
0.57
L/h
0.57
L/h
Average clearance;
DRUGBANK
34.4
L/h
34.4±10.6
L/h
Average clearance;
DRUGBANK
115.2
L
115.2±10
L
Apparent volume of distribution;
DRUGBANK
1.96
L/kg
1.96
L/kg
Apparent volume of distribution;
DRUGBANK
119.7
L
119.7±33.14
L
Apparent volume of distribution;
DRUGBANK
2.7
h
2.7
h
DRUGBANK
2.4
h
2.4
h
elimination half-life; inhalation, IH;
DRUGBANK
2.8
h
2.8
h
DRUGBANK
13.1
mg/kg
13100.0
ug/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
132.0
mg/kg
132.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
1451.0
mg/kg
1451.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2168.0
mg/kg
2168.0
mg/kg
PO, oral; mouse;
DRUGBANK
105.0
mg/kg
105.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
500.0
mg/kg
>500
mg/kg
Rattus, Rat;
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
20.0
%
~20
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.0
%
~98
%
plasma proteins;
DRUGBANK
DDPD00621
Oxandrolone
306.4397
C19H30O3
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C
DB00621
5878
7820
http://www.drugs.com/cdi/oxandrolone.html
5667
-2.0
-
-2.0
-
DRUGBANK
0.55
h
0.55
h
distribution half-life;
DRUGBANK
9.0
h
9
h
elimination half-life;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse; dog;
DRUGBANK
DDPD00622
Nicardipine
479.525
C26H29N3O6
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
DB00622
4474
7550
http://www.drugs.com/cdi/nicardipine.html
4319
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
35.0
%
35
%
PO, oral;
DRUGBANK
0.4
L/h/kg
0.4
L/h/kg
intravenous infusion, IV in drop;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.3
L/kg
8.3
L/kg
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.6
h
8.6
h
DRUGBANK
4.1
h
4.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
184.0
mg/kg
184.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
322.0
mg/kg
322.0
mg/kg
PO, oral; mouse;
DRUGBANK
95.0
%
>95
%
DRUGBANK
14.4
mg/kg/day
10
mcg/kg/minute
intravenous injection, IV
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
120.0
mg/day
120
mg/day
Tablet,PO，oral
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
360.0
mg/day
15
mg/h
intravenous injection, IV; up to 15 minutes
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
14.4
mg/kg/day
10
mcg/kg/minute
intravenous injection, IV
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
90.0
mg/day
90
mg/day
Tablet,PO，oral
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
120.0
mg/day
120
mg/day
Tablet,PO，oral
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
360.0
mg/day
15
mg/hour
intravenous injection, IV; up to 15 minutes
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
14.4
mg/kg/day
10
mcg/kg/min
intravenous injection, IV
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
4.32
mg/kg/day
3
mcg/kg/minute
intravenous injection, IV
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
8.64
mg/kg/day
6
mcg/kg/minute
intravenous injection, IV
Nicardipine Hydrochloride Capsules
nicardipine hydrochloride
PDR
DDPD00623
Fluphenazine
437.522
C22H26F3N3OS
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
DB00623
T3D2840
3372
5123
http://www.drugs.com/cdi/fluphenazine.html
3255
-2.0
-
-2.0
-
DRUGBANK
2.7
%
2.7(1.7-4.5)
%
PO, oral; immediate release formulation;
DRUGBANK
3.4
%
3.4(2.5-5.0)
%
IM,intramuscular injection; subcutaneous injection, SC;
DRUGBANK
2.3
ng/ml
2.3±2.1
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
1.3
ng/ml
1.3
ng/ml
IM,intramuscular injection; Drug form;
DRUGBANK
1.1
ng/ml
1.1
ng/ml
IM,intramuscular injection; Drug form;
DRUGBANK
2.8
h
2.8±2.1
h
PO, oral; immediate release formulation;
DRUGBANK
36.0
h
24-48
h
IM,intramuscular injection; Drug form;
DRUGBANK
60.0
h
48-72
h
IM,intramuscular injection; Drug form;
DRUGBANK
0.6
L/h/kg
10±7
ml/min/kg
normal,healthy; adults;
DRUGBANK
0.582
L/h/kg
9.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
L/kg
11±10
L/kg
normal,healthy; adults;
DRUGBANK
2.9
L/kg
2.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12±4
h
DRUGBANK
14.4
h
14.4±7.8
h
PO, oral; immediate release formulation;
DRUGBANK
20.3
h
20.3±7.9
h
PO, oral; extended release formulation;
DRUGBANK
12.3
h
12.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0
%
~0
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Fluphenazine Decanoate
fluphenazine decanoate
PDR
40.0
mg/day
40
mg/day
PO, oral
Fluphenazine Decanoate
fluphenazine decanoate
PDR
100.0
mg/dose
100
mg/dose
subcutaneous injection, SC;IM,intramuscular injection;
Fluphenazine Decanoate
fluphenazine decanoate
PDR
10.0
mg/day
10
mg/day
IM,intramuscular injection
Fluphenazine Decanoate
fluphenazine decanoate
PDR
20.0
mg/day
20
mg/day
PO, oral
Fluphenazine Decanoate
fluphenazine decanoate
PDR
40.0
mg/day
40
mg/day
PO, oral
Fluphenazine Decanoate
fluphenazine decanoate
PDR
100.0
mg/dose
100
mg/dose
subcutaneous injection, SC;IM,intramuscular injection;
Fluphenazine Decanoate
fluphenazine decanoate
PDR
10.0
mg/day
10
mg/day
IM,intramuscular injection
Fluphenazine Decanoate
fluphenazine decanoate
PDR
DDPD00624
Testosterone
288.4244
C19H28O2
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O
DB00624
T3D4283
6013
17347
5791
-2.0
-
-2.0
-
DRUGBANK
104.25
ng.h/ml
10425±5521
ng.h/dl
DRUGBANK
10.0
%
~10
%
DRUGBANK
57300.0
ng/ml
573±284
ng/dl
DRUGBANK
33.8333333333333
L/h
812±64
L/day
Average clearance; adults; Male, men;
DRUGBANK
1.47
L/h/kg
24.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.36
L
80.36±24.51
L
Elderly; Male, men;
DRUGBANK
0.35
L/kg
0.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.916666666666667
h
10-100
min
DRUGBANK
0.17
h
0.17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
6.0
%
6
%
Faeces excretion;
DRUGBANK
DDPD00625
Efavirenz
315.675
C14H9ClF3NO2
FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
DB00625
64139
119486
http://www.drugs.com/cdi/efavirenz.html
57715
-2.0
-
-2.0
-
DRUGBANK
4000.0
ng/ml
4.0±1.7
mcg/ml
PO, oral;
DRUGBANK
4.1
h
4.1±1.7
h
PO, oral;
DRUGBANK
0.186
L/h/kg
3.1±1.2
ml/min/kg
apparent clearance; PO, oral;
Children → ;
DRUGBANK
47.5
h
40-55
h
DRUGBANK
64.0
h
52-76
h
Oral single dose;
DRUGBANK
47.5
h
40-55
h
Oral multiple dose;
DRUGBANK
1.0
%
<1
%
Urinary excretion; AIDS,HIV; human, homo sapiens; Unchanged drug;
DRUGBANK
99.625
%
99.5-99.75
%
DRUGBANK
99.625
%
99.5-99.75
%
AIDS,HIV;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Sustiva
efavirenz
PDR
400.0
mg/day
400
mg/day
PO, oral
Sustiva
efavirenz
PDR
350.0
mg/day
350
mg/day
PO, oral
Sustiva
efavirenz
PDR
300.0
mg/day
300
mg/day
PO, oral
Sustiva
efavirenz
PDR
250.0
mg/day
250
mg/day
PO, oral
Sustiva
efavirenz
PDR
200.0
mg/day
200
mg/day
PO, oral
Sustiva
efavirenz
PDR
150.0
mg/day
150
mg/day
PO, oral
Sustiva
efavirenz
PDR
600.0
mg/day
600
mg/day
PO, oral
Sustiva
efavirenz
PDR
600.0
mg/day
600
mg/day
PO, oral
Sustiva
efavirenz
PDR
400.0
mg/day
400
mg/day
PO, oral
Sustiva
efavirenz
PDR
350.0
mg/day
350
mg/day
PO, oral
Sustiva
efavirenz
PDR
600.0
mg/day
600
mg/day
PO, oral
Sustiva
efavirenz
PDR
200.0
mg/day
200
mg/day
PO, oral
Sustiva
efavirenz
PDR
150.0
mg/day
150
mg/day
PO, oral
Sustiva
efavirenz
PDR
100.0
mg/day
100
mg/day
PO, oral
Sustiva
efavirenz
PDR
DDPD00626
Bacitracin
1422.693
C66H103N17O16S
CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC
DB00626
10909430
35862
http://www.drugs.com/cdi/bacitracin-ointment.html
9084687
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
IM,intramuscular injection;
DRUGBANK
11.64
L/h
105-283
ml/min
Renal clearance;
DRUGBANK
9.54
L/h
159.0
ml/min
Renal clearance;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
87.0
%
87
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
1200.0
units/kg/day
1200
units/kg/day
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
100000.0
units/day
100000
units/day
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
25000.0
units/dose
25000
units/dose
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
1200.0
units/kg/day
1200
units/kg/day
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
0.0
0
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
100000.0
units/day
100000
units/day
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
25000.0
units/dose
25000
units/dose
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
1000.0
units/kg/day
1000
units/kg/day
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
900.0
units/kg/day
900
units/kg/day
IM,intramuscular injection
Bacitracin Injection
bacitracin
PDR
DDPD00627
Niacin
123.1094
C6H5NO2
OC(=O)C1=CN=CC=C1
DB00627
T3D2841
938
15940
http://www.drugs.com/niacin.html
913
-2.0
-
-2.0
-
DRUGBANK
1440.0
ng.h/ml
1.44
ug.h/ml
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
6660.0
ng.h/ml
6.66
ug.h/ml
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
12410.0
ng.h/ml
12.41
ug.h/ml
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
60.0
ng/ml
0.06
ug/ml
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
2420.0
ng/ml
2.42
ug/ml
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
4220.0
ng/ml
4.22
ug/ml
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
600.0
ng/ml
0.6
mcg/ml
PO, oral; extended release formulation;
DRUGBANK
15500.0
ng/ml
15.5
mcg/ml
PO, oral; extended release formulation;
DRUGBANK
3.0
h
3
h
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
3.0
h
3
h
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
4.5
h
4-5
h
PO, oral; extended release formulation;
DRUGBANK
0.876
L/h/kg
14.6±5.0
ml/min/kg
DRUGBANK
0.9
h
0.9
h
DRUGBANK
1.3
h
1.3
h
DRUGBANK
4.3
h
4.3
h
DRUGBANK
0.2
h
~0.15-0.25
h
intravenous infusion, IV in drop;
DRUGBANK
3720.0
mg/kg
3720.0
mg/kg
PO, oral; mouse;
DRUGBANK
4550.0
mg/kg
4550.0
mg/kg
PO, oral; rabbit;
DRUGBANK
7000.0
mg/kg
7000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
7000.0
mg/kg
7000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
730.0
mg/kg
730.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3500.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
12.0
%
12
%
Urinary excretion; Oral multiple dose; Unchanged drug;
DRUGBANK
3000.0
mg/day
3
g/day
PO, oral
Niaspan
niacin
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Niaspan
niacin
PDR
6000.0
mg/day
6
g/day
PO, oral
Niaspan
niacin
PDR
2000.0
mg/day
2
g/day
PO, oral
Niaspan
niacin
PDR
6000.0
mg/day
6
g/day
PO, oral
Niaspan
niacin
PDR
2000.0
mg/day
2
g/day
PO, oral
Niaspan
niacin
PDR
3.0
g/day
3
g/day
PO, oral
Niaspan
niacin
PDR
1.5
g/day
1.5
g/day
PO, oral
Niaspan
niacin
PDR
DDPD00628
Clorazepic acid
314.723
C16H11ClN2O3
OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2
DB00628
T3D2842
2809
3761
http://www.drugs.com/cdi/clorazepate.html
2707
-2.0
-
-2.0
-
DRUGBANK
91.0
%
91
%
PO, oral;
DRUGBANK
91.0
%
91±6
%
PO, oral; Drug form;
DRUGBANK
275.0
ng/ml
275±27
ng/ml
IM,intramuscular injection; Drug form;
DRUGBANK
0.72
h
0.72±0.01
h
IM,intramuscular injection; Drug form;
DRUGBANK
0.0102
L/h/kg
0.17±0.02
ml/min/kg
Elderly → ;Hepatitis, Hep ↓ ;Obesity ↓ ;Somking ↑ ;
DRUGBANK
1.24
L/kg
1.24±0.09
L/kg
Elderly → ;Obesity ↑ ;Hepatitis, Hep → ;
DRUGBANK
48.0
h
~2
day
elimination half-life;
DRUGBANK
45.0
h
~40-50
h
DRUGBANK
93.0
h
93±11
h
intravenous injection, IV;
Preg, pregnant ↑ ;Obesity ↑ ;Hepatic cirrhosis, cirr ↓ ;Hepatitis, Hep ↓ ;Age ↑ ;Somking ↓ ;
DRUGBANK
1320.0
mg/kg
1320.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1600.0
mg/kg
>1600
mg/kg
PO, oral; monkey;
DRUGBANK
1320.0
mg/kg
1320.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1600.0
mg/kg
>1600
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.5
%
97-98
%
plasma proteins;
DRUGBANK
97.5
%
97.5
%
Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;Obesity → ;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Tranxene
clorazepate dipotassium
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Tranxene
clorazepate dipotassium
PDR
90.0
mg/kg
90
mg/kg
PO, oral
Tranxene
clorazepate dipotassium
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Tranxene
clorazepate dipotassium
PDR
90.0
mg/kg
90
mg/kg
PO, oral
Tranxene
clorazepate dipotassium
PDR
60.0
mg/kg
60
mg/kg
PO, oral
Tranxene
clorazepate dipotassium
PDR
90.0
mg/kg
90
mg/kg
PO, oral
Tranxene
clorazepate dipotassium
PDR
DDPD00629
Guanabenz
231.082
C8H8Cl2N4
NC(N)=NN=CC1=C(Cl)C=CC=C1Cl
DB00629
3517
5553
http://www.drugs.com/cdi/guanabenz.html
4642445
-2.0
-
-2.0
-
DRUGBANK
75.0
%
75
%
PO, oral;
DRUGBANK
6.0
h
6
h
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD00630
Alendronic acid
249.096
C4H13NO7P2
NCCCC(O)(P(O)(O)=O)P(O)(O)=O
DB00630
T3D2666
2088
2567
http://www.drugs.com/cdi/alendronate.html
2004
-2.0
-
-2.0
-
DRUGBANK
0.64
%
0.64
%
PO, oral; Female, women;
DRUGBANK
0.59
%
0.59
%
PO, oral; Male, men;
DRUGBANK
0.384
%
0.384
%
PO, oral; Female, women; food;
food ↓ ;
DRUGBANK
0.354
%
0.354
%
PO, oral; Male, men; food;
food ↓ ;
DRUGBANK
0.7
%
<0.7
%
intravenous injection, IV; postmenopausal women;
food ↓ ;
DRUGBANK
275.0
ng/ml
~275
ng/ml
postmenopausal women;
DRUGBANK
6.7
ng/ml
<5-8.4
ng/ml
PO, oral; postmenopausal women;
DRUGBANK
2.0
h
2.0
h
postmenopausal women;
DRUGBANK
4.26
L/h
71.0
ml/min
DRUGBANK
0.0666
L/h/kg
1.11(1.00-1.22)
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
28.0
L
28.0
L
DRUGBANK
0.44
L/kg
0.44(0.34-0.55)
L/kg
DRUGBANK
86400.0
h
>10
year
terminal half-life;
DRUGBANK
1.0
h
~1.0
h
normal,healthy; postmenopausal women;
DRUGBANK
102816.0
h
~11.9
year
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
44.9
%
44.9±9.3
%
Urinary excretion; postmenopausal women; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
78.0
%
78
%
DRUGBANK
78.0
%
78
%
postmenopausal women; normal,healthy; human, homo sapiens;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Binosto
alendronate sodium
PDR
10.0
mg/day
70
mg/week
PO, oral
Binosto
alendronate sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Binosto
alendronate sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Binosto
alendronate sodium
PDR
10.0
mg/day
70
mg/week
PO, oral
Binosto
alendronate sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Binosto
alendronate sodium
PDR
DDPD00631
Clofarabine
303.677
C10H11ClFN5O3
[H][C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2=C(N)N=C(Cl)N=C12
DB00631
119182
681569
http://www.drugs.com/cdi/clofarabine.html
106472
-2.0
-
-2.0
-
DRUGBANK
28.8
L/h/m2
28.8
L/h/m2
Children; Adolescents; Acute leukaemia;
DRUGBANK
0.462
L/h/kg
7.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
172.0
L/m2
172.0
L/m2
DRUGBANK
1.75
L/kg
1.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.2
h
5.2
h
terminal half-life;
DRUGBANK
4.0
h
4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
54.5
%
49-60
%
Urinary excretion; Unchanged drug;
DRUGBANK
47.0
%
47
%
plasma proteins;
DRUGBANK
52.0
mg/m2/day
52
mg/m2/day
intravenous injection, IV
Clolar
clofarabine
PDR
52.0
mg/m2/day
52
mg/m2/day
intravenous injection, IV
Clolar
clofarabine
PDR
DDPD00632
Docosanol
326.6
C22H46O
CCCCCCCCCCCCCCCCCCCCCCO
DB00632
12620
31000
http://www.drugs.com/cdi/docosanol.html
12100
-2.0
-
-2.0
-
DRUGBANK
5.0
application/day
5
application/day
skin/dermal
Abreva
docosanol
PDR
5.0
appLication/day
5
appLication/day
skin/dermal
Abreva
docosanol
PDR
5.0
application/day
5
application/day
skin/dermal
Abreva
docosanol
PDR
5.0
application/day
5
application/day
skin/dermal
Abreva
docosanol
PDR
DDPD00633
Dexmedetomidine
200.2795
C13H16N2
C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1
DB00633
5311068
4466
4470605
-2.0
-
-2.0
-
DRUGBANK
39.0
L/h
39.0
L/h
intravenous infusion, IV in drop; normal,healthy; rheumatoid arthritis;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
118.0
L
118.0
L
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95.0
%
95
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
4.0
%
4
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
94.0
%
94
%
DRUGBANK
0.001
mg/kg
1
mcg/kg
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.06
mg/kg/day
2.5
mcg/kg/hour
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.0204
mg/kg/day
0.85
mcg/kg/hour
intravenous infusion, iv in drop
Precedex
dexmedetomidine hydrochloride
PDR
0.001
mg/day
1
mcg/kg
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.0025
mg/kg/day
2.5
mcg/kg/hour
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.00085
mg/kg/day
0.85
mcg/kg/hour
intravenous infusion, iv in drop
Precedex
dexmedetomidine hydrochloride
PDR
0.001
mg/kg
1
mcg/kg
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.06
mg/kg/day
2.5
mcg/kg/h
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.0204
mg/kg/day
0.85
mcg/kg/h
intravenous infusion, iv in drop
Precedex
dexmedetomidine hydrochloride
PDR
0.0005
mg/kg
0.5
mcg/kg
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.048
mg/kg/day
2
mcg/kg/hour
intravenous infusion, iv in drop
Precedex
dexmedetomidine hydrochloride
PDR
0.0005
mg/kg
0.5
mcg/kg
intravenous injection, IV
Precedex
dexmedetomidine hydrochloride
PDR
0.048
mg/kg/day
2
mcg/kg/hour
intravenous infusion, iv in drop
Precedex
dexmedetomidine hydrochloride
PDR
DDPD00634
Sulfacetamide
214.242
C8H10N2O3S
CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1
DB00634
5320
63845
http://www.drugs.com/cdi/sulfacetamide-drops.html
5129
-2.0
-
-2.0
-
DRUGBANK
9.9
h
7-12.8
h
DRUGBANK
16500.0
mg/kg
16500.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00635
Prednisone
358.4281
C21H26O5
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00635
T3D4710
5865
8382
http://www.drugs.com/prednisone.html
5656
-2.0
-
-2.0
-
DRUGBANK
572.0
mg.min/1.73m2
572.0
mg.min/1.73m2
PO, oral;
DRUGBANK
1034.0
mg.min/1.73m2
1034.0
mg.min/1.73m2
PO, oral;
DRUGBANK
2271.0
mg.min/1.73m2
2271.0
mg.min/1.73m2
DRUGBANK
80.0
%
80±11
%
PO, oral;
DRUGBANK
71.5
ng/ml
62-81
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
218.5
ng/ml
198-239
ng/ml
Oral single dose; Active metabolite; adults; normal,healthy;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
6.25
h
6-6.5
h
PO, oral; extended release formulation;
DRUGBANK
2.6
h
2.1-3.1
h
Oral single dose; adults; normal,healthy;
DRUGBANK
1.9
h
1.2-2.6
h
Oral single dose; Active metabolite; adults; normal,healthy;
DRUGBANK
0.066
L/h/kg
0.066±0.12
L/h/kg
Average clearance; intravenous infusion, IV in drop;
DRUGBANK
0.15
L/h/kg
0.15
L/h/kg
Average clearance; intravenous infusion, IV in drop;
DRUGBANK
0.216
L/h/kg
3.6±0.8
ml/min/kg
Hepatitis, Hep → ;
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.3
L
29.3
L
DRUGBANK
44.2
L
44.2
L
DRUGBANK
0.97
L/kg
0.97±0.11
L/kg
Hepatitis, Hep → ;
DRUGBANK
0.57
L/kg
0.57
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
immediate release formulation; extended release formulation;
DRUGBANK
2.0
h
2
h
immediate release formulation; extended release formulation;
DRUGBANK
3.6
h
3.6±0.4
h
Hepatitis, Hep → ;Somking → ;
DRUGBANK
2.9
h
2.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
%
3±2
%
Urinary excretion; Unchanged drug;
hyperthyroid, HTh → ;
DRUGBANK
50.0
%
<50
%
DRUGBANK
75.0
%
75±2
%
DRUGBANK
DDPD00636
Clofibrate
242.699
C12H15ClO3
CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
DB00636
T3D4784
2796
3750
http://www.drugs.com/mtm/clofibrate.html
2694
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
24.5
h
18-22(14-35)
h
normal,healthy;
DRUGBANK
1220.0
mg/kg
1220.0
mg/kg
PO, oral; mouse;
DRUGBANK
1370.0
mg/kg
1370.0
mg/kg
PO, oral; rabbit;
DRUGBANK
940.0
mg/kg
940.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1220.0
mg/kg
1220.0
mg/kg
PO, oral; mouse;
DRUGBANK
1370.0
mg/kg
1370.0
mg/kg
PO, oral; rabbit;
DRUGBANK
940.0
mg/kg
940.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
96.0
%
95-97
%
DRUGBANK
DDPD00637
Astemizole
458.5703
C28H31FN4O
COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1
DB00637
T3D2844
2247
2896
http://www.drugs.com/mtm/astemizole.html
2160
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
Liver metabolism; Faeces excretion;
DRUGBANK
24.0
h
1
day
DRUGBANK
2052.0
mg/kg
2052.0
mg/kg
mouse;
DRUGBANK
2052.0
mg/kg
2052.0
mg/kg
mouse;
DRUGBANK
96.7
%
96.7
%
DRUGBANK
DDPD00638
Inulin
6179.3581
C228H382O191
OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(OC[C@@]%12(OC[C@@]%13(OC[C@@]%14(OC[C@@]%15(OC[C@@]%16(OC[C@@]%17(OC[C@@]%18(OC[C@@]%19(OC[C@@]%20(OC[C@@]%21(OC[C@@]%22(OC[C@@]%23(OC[C@@]%24(OC[C@@]%25(OC[C@@]%26(OC[C@@]%27(OC[C@@]%28(OC[C@@]%29(OC[C@@]%30(OC[C@@]%31(OC[C@@]%32(OC[C@@]%33(OC[C@@]%34(OC[C@@]%35(OC[C@@]%36(OC[C@@]%37(O[C@H]%38O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O
DB00638
24763
15443
http://www.drugs.com/cons/inulin-intravenous.html
23149
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
DRUGBANK
DDPD00639
Butoconazole
411.776
C19H17Cl3N2S
ClC1=CC=C(CCC(CN2C=CN=C2)SC2=C(Cl)C=CC=C2Cl)C=C1
DB00639
47472
3240
http://www.drugs.com/cdi/butoconazole-cream.html
43192
-2.0
-
-2.0
-
DRUGBANK
1.7
%
1.7(1.3-2.2)
%
Vaginal Administration;
DRUGBANK
1720.0
mg/kg
1720.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00640
Adenosine
267.2413
C10H13N5O4
NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
DB00640
T3D4275
60961
16335
http://www.drugs.com/cdi/adenosine.html
54923
-2.0
-
-2.0
-
DRUGBANK
0.00277777777777778
h
<10
second
DRUGBANK
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
0.3
mg/kg/dose
0.3
mg/kg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
0.3
mg/kg/dose
0.3
mg/kg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
0.3
mg/kg/dose
0.3
mg/kg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
0.3
mg/kg/dose
0.3
mg/kg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
12.0
mg/dose
12
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Adenocard
adenosine
PDR
DDPD00641
Simvastatin
418.5662
C25H38O5
[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
DB00641
T3D4788
54454
9150
http://www.drugs.com/simvastatin.html
49179
-2.0
-
-2.0
-
DRUGBANK
40.32
ng.h/ml
40.32
ug.h/L
DRUGBANK
5.0
%
≤5
%
DRUGBANK
9.83
ng/ml
9.83
ug/L
DRUGBANK
46.0
ngEq/ml
46±20
ngEq/ml
PO, oral; Active metabolite; adults; normal,healthy;
DRUGBANK
56.0
ngEq/ml
56±25
ngEq/ml
PO, oral; Active metabolite; adults; normal,healthy;
DRUGBANK
1.44
h
1.44
h
DRUGBANK
1.4
h
1.4±1.0
h
PO, oral; Active metabolite; adults; normal,healthy;
DRUGBANK
1.4
h
1.4±1.0
h
PO, oral; Active metabolite; adults; normal,healthy;
DRUGBANK
0.456
L/h/kg
7.6
ml/min/kg
DRUGBANK
4.85
h
4.85
h
DRUGBANK
2.5
h
2-3
h
DRUGBANK
13.0
%
13
%
Urinary excretion; PO, oral; Male, men; human, homo sapiens;
DRUGBANK
60.0
%
60
%
Faeces excretion; PO, oral; Male, men; human, homo sapiens;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
~95
%
plasma proteins; human, homo sapiens;
DRUGBANK
94.0
%
94
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Zocor
simvastatin
PDR
20.0
mg/day
20
mg/day
PO, oral
Zocor
simvastatin
PDR
40.0
mg/day
40
mg/day
PO, oral
Zocor
simvastatin
PDR
80.0
mg/day
80
mg/day
PO, oral
Zocor
simvastatin
PDR
40.0
mg/day
40
mg/day
PO, oral
Zocor
simvastatin
PDR
40.0
mg/day
40
mg/day
PO, oral
Zocor
simvastatin
PDR
80.0
mg/day
80
mg/day
PO, oral
Zocor
simvastatin
PDR
DDPD00642
Pemetrexed
427.4106
C20H21N5O6
NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
DB00642
446556
63616
http://www.drugs.com/cdi/pemetrexed.html
393879
-2.0
-
-2.0
-
DRUGBANK
5.508
L/h
91.8
ml/min
intravenous infusion, IV in drop; tumor; patients; normal,healthy;
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.1
L
16.1
L
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3.5
h
DRUGBANK
1.85
h
1.85
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
70-90
%
Urinary excretion; Unchanged drug;
DRUGBANK
81.0
%
81
%
DRUGBANK
500.0
mg/m2
500
mg/m2
intravenous infusion, iv in drop
q3w
Alimta
pemetrexed disodium
PDR
500.0
mg/m2
500
mg/m2
intravenous infusion, iv in drop
q3w
Alimta
pemetrexed disodium
PDR
DDPD00643
Mebendazole
295.2927
C16H13N3O3
COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1
DB00643
4030
6704
http://www.drugs.com/cdi/mebendazole.html
3890
-2.0
-
-2.0
-
DRUGBANK
7.5
%
5-10
%
PO, oral;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.75
null
2.5-5.5(2.5-9)
null
normal hepatic function;
DRUGBANK
35.0
h
~35
h
hepatopathy，LD;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
620.0
mg/kg
620.0
mg/kg
PO, oral; mouse;
DRUGBANK
2.0
%
~2
%
Urinary excretion; Male, men; human, homo sapiens;
DRUGBANK
98.0
%
~98
%
Faeces excretion; Male, men; human, homo sapiens;
DRUGBANK
92.5
%
90-95
%
DRUGBANK
500.0
mg/day
500
mg/day
PO, oral
Emverm
mebendazole
PDR
200.0
mg/day
200
mg/day
PO, oral
Emverm
mebendazole
PDR
40.0
mg/day
40
mg/day
PO, oral
Emverm
mebendazole
PDR
500.0
mg/day
500
mg/day
PO, oral
Emverm
mebendazole
PDR
500.0
mg/day
500
mg/day
PO, oral
Emverm
mebendazole
PDR
200.0
mg/day
200
mg/day
PO, oral; 3-day regimen
Emverm
mebendazole
PDR
40.0
mg/day
40
mg/day
PO, oral
Emverm
mebendazole
PDR
500.0
mg/day
500
mg/day
PO, oral
Emverm
mebendazole
PDR
200.0
mg/day
200
mg/day
PO, oral
Emverm
mebendazole
PDR
40.0
mg/day
40
mg/day
PO, oral
Emverm
mebendazole
PDR
500.0
mg/day
500
mg/day
PO, oral
Emverm
mebendazole
PDR
200.0
mg/day
200
mg/day
PO, oral; 3-day regimen
Emverm
mebendazole
PDR
40.0
mg/day
40
mg/day
PO, oral
Emverm
mebendazole
PDR
DDPD00644
Gonadorelin
1182.2901
C55H75N17O13
CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O
DB00644
36523
http://www.drugs.com/cdi/gonadorelin.html
33562
-2.0
-
-2.0
-
DRUGBANK
0.1
h
2-10
min
distribution half-life;
DRUGBANK
0.416666666666667
h
10-40
min
elimination half-life;
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00645
Dyclonine
289.4125
C18H27NO2
CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
DB00645
3180
4724
http://www.drugs.com/cdi/dyclonine-lozenges.html
3068
-2.0
-
-2.0
-
DRUGBANK
0.75
h
~30-60
min
DRUGBANK
DDPD00646
Nystatin
926.107
C47H75NO17
C[C@H]1O[C@H](OC2CC3O[C@@](O)(CC(O)C3C(O)=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O
DB00646
T3D2847
11953884
473992
http://www.drugs.com/cdi/nystatin.html
10468627
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
10000.0
mg/kg
10.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
2400000.0
units/day
2400000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
2400000.0
units/day
2400000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
100000.0
units/day
100000
units/day
Vaginal Administration
Nystatin Tablets
nystatin
PDR
2400000.0
units/day
2400000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
2400000.0
units/day
2400000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
100000.0
units/day
100000
units/day
Vaginal Administration
Nystatin Tablets
nystatin
PDR
800000.0
units/day
800000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
800000.0
units/day
800000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
400000.0
units/day
400000
units/day
PO, oral
Nystatin Tablets
nystatin
PDR
DDPD00647
Dextropropoxyphene
339.4712
C22H29NO2
CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1
DB00647
T3D2848
10100
51173
http://www.drugs.com/propoxyphene.html
9696
-2.0
-
-2.0
-
DRUGBANK
0.156
L/h
2.6
ml/min
DRUGBANK
16.0
L/kg
16.0
L/kg
DRUGBANK
9.0
h
6-12
h
DRUGBANK
230.0
mg/kg
230.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
230.0
mg/kg
230.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
22.5
%
~20-25
%
Urinary excretion;
DRUGBANK
DDPD00648
Mitotane
320.041
C14H10Cl4
ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
DB00648
T3D0151
4211
6954
http://www.drugs.com/cdi/mitotane.html
4066
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
2124.0
h
18-159
day
DRUGBANK
113.0
mg/kg
113.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
9.0
%
1-17
%
Bile excretion;
DRUGBANK
6.0
%
6
%
DRUGBANK
DDPD00649
Stavudine
224.2133
C10H12N2O4
CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
DB00649
T3D4772
18283
63581
http://www.drugs.com/cdi/stavudine.html
17270
-2.0
-
-2.0
-
DRUGBANK
86.0
%
68-104
%
DRUGBANK
16.32
L/h
272.0
ml/min
PO, oral; normal,healthy; rheumatoid arthritis;
DRUGBANK
35.64
L/h
594±164
ml/min
intravenous infusion, IV in drop; AIDS,HIV; adults; pediatric patients;
DRUGBANK
0.585
L/h
9.75±3.76
ml/min
intravenous infusion, IV in drop; AIDS,HIV; pediatric patients;
DRUGBANK
0.492
L/h/kg
8.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
46.0
L
46±21
L
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.15
h
0.8-1.5
h
adults;
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Zerit
stavudine
PDR
60.0
mg/day
60
mg/day
PO, oral
Zerit
stavudine
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Zerit
stavudine
PDR
80.0
mg/day
80
mg/day
PO, oral
Zerit
stavudine
PDR
60.0
mg/day
60
mg/day
PO, oral
Zerit
stavudine
PDR
80.0
mg/day
80
mg/day
PO, oral
Zerit
stavudine
PDR
60.0
mg/day
60
mg/day
PO, oral
Zerit
stavudine
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Zerit
stavudine
PDR
80.0
mg/day
80
mg/day
PO, oral
Zerit
stavudine
PDR
60.0
mg/day
60
mg/day
PO, oral
Zerit
stavudine
PDR
2.0
mg/kg/day
2
mg/kg/day
Liquid
Zerit
stavudine
PDR
2.0
mg/kg/day
2
mg/kg/day
Liquid
Zerit
stavudine
PDR
1.0
mg/kg/day
1
mg/kg/day
Liquid
Zerit
stavudine
PDR
DDPD00650
Leucovorin
473.446
C20H23N7O7
[H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2
DB00650
T3D2849
6006
15640
http://www.drugs.com/cdi/leucovorin.html
5784
-2.0
-
-2.0
-
DRUGBANK
97.0
%
97
%
DRUGBANK
75.0
%
75
%
DRUGBANK
37.0
%
37
%
DRUGBANK
6.2
h
6.2
h
DRUGBANK
8000.0
mg/kg
>8000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8000.0
mg/kg
>8000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
%
~15
%
DRUGBANK
DDPD00651
Dyphylline
254.2426
C10H14N4O4
CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O
DB00651
3182
4728
http://www.drugs.com/cdi/dyphylline.html
3070
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2(1.8-2.1)
h
DRUGBANK
1954.0
mg/kg
1954.0
mg/kg
PO, oral; mouse;
DRUGBANK
88.0
%
~88
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
84.0
%
84
%
DRUGBANK
DDPD00652
Pentazocine
285.4238
C19H27NO
C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C
DB00652
T3D2850
441278
7982
http://www.drugs.com/cdi/pentazocine.html
390041
-2.0
-
-2.0
-
DRUGBANK
1.38
L/h/kg
23
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.4
L/kg
3.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
mg/kg
0.5
mg/kg
IM,intramuscular injection
Talwin
pentazocine
PDR
30.0
mg
30
mg
IM,intramuscular injection
Talwin
pentazocine
PDR
360.0
mg/day
360
mg/day
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Talwin
pentazocine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Talwin
pentazocine
PDR
60.0
mg/dose
60
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Talwin
pentazocine
PDR
360.0
mg/day
360
mg/day
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Talwin
pentazocine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Talwin
pentazocine
PDR
60.0
mg/dose
60
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Talwin
pentazocine
PDR
0.5
mg/kg
0.5
mg/kg
IM,intramuscular injection
Talwin
pentazocine
PDR
30.0
mg
30
mg
IM,intramuscular injection
Talwin
pentazocine
PDR
360.0
mg/day
360
mg/day
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Talwin
pentazocine
PDR
30.0
mg/dose
30
mg/dose
intravenous injection, IV
Talwin
pentazocine
PDR
60.0
mg/dose
60
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Talwin
pentazocine
PDR
DDPD00653
Magnesium sulfate
120.368
MgO4S
[Mg++].[O-]S([O-])(=O)=O
DB00653
T3D2851
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
24083
32599
http://www.drugs.com/cdi/magnesium-sulfate.html
22515
-2.0
-
-2.0
-
DRUGBANK
43.2
h
43.2
h
Neonates;
DRUGBANK
1200.0
mg/kg
1200.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
1200.0
mg/kg
1200.0
mg/kg
subcutaneous injection, SC; parenteral administration; Rattus, Rat;
DRUGBANK
3.5
mg/L
3.5
mmol/l
DRUGBANK
27.5
%
25-30
%
DRUGBANK
DDPD00654
Latanoprost
432.5928
C26H40O5
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
DB00654
5311221
6384
http://www.drugs.com/cdi/latanoprost-drops.html
4470740
-2.0
-
-2.0
-
DRUGBANK
0.053
ng/ml
53.0
pg/ml
ophthalmic administration;
DRUGBANK
0.0833333333333333
h
5
min
ophthalmic administration;
DRUGBANK
0.42
L/h/kg
7.0
ml/min/kg
Total clearance;
DRUGBANK
0.402
L/h/kg
6.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.16
L/kg
0.16±0.02
L/kg
DRUGBANK
0.283333333333333
h
~17
min
elimination half-life;
DRUGBANK
2.5
h
~2-3
h
elimination half-life;
DRUGBANK
0.28
h
0.28
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
mg/kg
>50
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
88.0
%
~88
%
Urinary excretion;
DRUGBANK
15.0
%
~15
%
Faeces excretion;
DRUGBANK
90.0
%
~90
%
plasma proteins;
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
Xalatan
latanoprost
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Xalatan
latanoprost
PDR
DDPD00655
Estrone
270.3661
C18H22O2
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
DB00655
T3D4746
5870
17263
5660
-2.0
-
-2.0
-
DRUGBANK
43.0
%
43
%
DRUGBANK
19.0
h
19
h
DRUGBANK
95.0
%
>95
%
DRUGBANK
DDPD00656
Trazodone
371.864
C19H22ClN5O
ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
DB00656
T3D2852
5533
9654
http://www.drugs.com/trazodone.html
5332
-2.0
-
-2.0
-
DRUGBANK
18193.0
ng.h/ml
18193.0
ng.h/ml
PO, oral;
DRUGBANK
77.0
%
63-91
%
PO, oral;
DRUGBANK
81.0
%
81±6
%
PO, oral;
DRUGBANK
1470.0
ng/ml
1.47±0.16
mcg/ml
PO, oral; food;
food ↓ ;
DRUGBANK
1880.0
ng/ml
1.88±0.42
mcg/ml
PO, oral; fasting;
DRUGBANK
1500.0
ng/ml
1.5±0.2
mcg/ml
Capsule, PO, Oral; food; adults; normal,healthy;
DRUGBANK
8.0
h
8
h
Oral single dose;
DRUGBANK
2.0
h
2.0±1.5
h
Capsule, PO, Oral; food; adults; normal,healthy;
DRUGBANK
5.1
L/h
5.1
L/h
Total clearance; Elderly; fasting;
DRUGBANK
5.3
L/h
5.3±0.9
L/h
Total clearance; normal,healthy; patients;
DRUGBANK
0.126
L/h/kg
2.1±0.1
ml/min/kg
hydrolysis;
Elderly ↓ ;Obesity ↓ ;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.84
L/kg
0.84±0.16
L/kg
Single dose;
DRUGBANK
0.655
L/kg
0.47-0.84
L/kg
DRUGBANK
1.0
L/kg
1.0±0.1
L/kg
Apparent volume of distribution; hydrolysis;
Elderly ↑ ;Obesity ↑ ;
DRUGBANK
0.52
L/kg
0.52
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
6
h
elimination half-life; young;
DRUGBANK
13.6
h
13.6
h
elimination half-life; Elderly;
DRUGBANK
7.3
h
7.3±0.8
h
elimination half-life; normal,healthy; Single dose;
DRUGBANK
4.5
h
3-6
h
distribution half-life;
DRUGBANK
7.0
h
5-9
h
elimination half-life;
DRUGBANK
5.9
h
5.9±0.4
h
Obesity ↑ ;Age ↑ ;
DRUGBANK
7.3
h
7.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
690.0
mg/kg
690.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
96.0
mg/kg
96.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
65.0
%
~60-70
%
Urinary excretion;
DRUGBANK
19.0
%
9-29
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
92.0
%
89-95
%
plasma proteins;
DRUGBANK
93.0
%
93
%
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
375.0
mg/day
375
mg/day
Tablet,PO，oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
375.0
mg/day
375
mg/day
Tablet,PO，oral
Trazodone Hydrochloride
trazodone hydrochloride
PDR
DDPD00657
Mecamylamine
167.2911
C11H21N
CNC1(C)C2CCC(C2)C1(C)C
DB00657
4032
6706
http://www.drugs.com/cdi/mecamylamine.html
3892
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
40.0
%
40
%
DRUGBANK
DDPD00658
Sevelamer
149.619
C6H12ClNO
NCC=C.ClCC1CO1
DB00658
3085017
http://www.drugs.com/cdi/sevelamer.html
2341997
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
14000.0
mg/day
14
g/day
PO, oral
Renagel
sevelamer hydrochloride
PDR
13000.0
mg/day
13
g/day
PO, oral
Renagel
sevelamer hydrochloride
PDR
14000.0
mg/day
14
g/day
PO, oral
Renagel
sevelamer hydrochloride
PDR
14000.0
mg/day
14
g/day
PO, oral
Renagel
sevelamer hydrochloride
PDR
13000.0
mg/day
13
g/day
PO, oral
Renagel
sevelamer hydrochloride
PDR
14000.0
mg/day
14
g/day
PO, oral
Renagel
sevelamer hydrochloride
PDR
DDPD00659
Acamprosate
181.21
C5H11NO4S
CC(=O)NCCCS(O)(=O)=O
DB00659
T3D2853
71158
51041
http://www.drugs.com/cdi/acamprosate.html
64300
-2.0
-
-2.0
-
DRUGBANK
11.0
%
11
%
PO, oral;
food → ;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.225
L/h/kg
3.75
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.5
L
72-109
L
DRUGBANK
0.3
L/kg
0.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
26.5
h
20-33
h
DRUGBANK
3.2
h
3.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00660
Metaxalone
221.2524
C12H15NO3
CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1
DB00660
15459
6797
http://www.drugs.com/cdi/metaxalone.html
14709
-2.0
-
-2.0
-
DRUGBANK
1700.0
ng/ml
1.7
mcg/ml
Oral single dose; fasting;
DRUGBANK
4900.0
ng/ml
4.9
mcg/ml
Oral single dose; food;
DRUGBANK
3.0
h
3.0±1.2
h
Oral single dose; fasting;
DRUGBANK
4.9
h
4.9±2.3
h
Oral single dose; food;
DRUGBANK
68.0
L/h
68±50
L/h
Tablet, PO, oral; fasting;
DRUGBANK
66.0
L/h
66±51
L/h
Tablet, PO, oral; fasting;
DRUGBANK
0.84
L/h/kg
14±7
ml/min/kg
apparent clearance; Oral single dose;
DRUGBANK
800.0
L
800.0
L
DRUGBANK
9.2
h
9.2±4.8
h
DRUGBANK
9.2
h
9.2±4.8
h
fasting; PO, oral;
DRUGBANK
2.4
h
2.4±1.2
h
food; PO, oral;
DRUGBANK
775.0
mg/kg
775.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1690.0
mg/kg
1690.0
mg/kg
PO, oral; mouse;
DRUGBANK
3200.0
mg/day
3200
mg/day
PO, oral
Skelaxin
metaxalone
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Skelaxin
metaxalone
PDR
DDPD00661
Verapamil
454.6016
C27H38N2O4
COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
DB00661
T3D3544
2520
77733
http://www.drugs.com/verapamil.html
2425
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
1037.0
ng.h/ml
1037.0
ng.h/ml
PO, oral; Optical rotation R;
DRUGBANK
195.0
ng.h/ml
195.0
ng.h/ml
PO, oral; Optical rotation S;
DRUGBANK
25.0
%
20-30
%
PO, oral;
DRUGBANK
22.0
%
22±8
%
PO, oral;
DRUGBANK
35.0
%
35±13
%
sublingual;
DRUGBANK
262.5
ng/ml
125-400
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
77.8
ng/ml
77.8
ng/ml
PO, oral; Optical rotation R;
DRUGBANK
16.8
ng/ml
16.8
ng/ml
PO, oral; Optical rotation S;
DRUGBANK
272.0
ng/ml
272.0
ng/ml
Tablet, PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
141.5
ng/ml
118-165
ng/ml
Tablet, PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
1.5
h
1-2
h
PO, oral; immediate release formulation;
DRUGBANK
8.5
h
6-11
h
PO, oral; extended release formulation;
DRUGBANK
1.1
h
1.1
h
Tablet, PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
6.65
h
5.6-7.7
h
Tablet, PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
80.0
%
80
%
Liver metabolism;
DRUGBANK
20.4
L/h
~340
ml/min
Total clearance; Oral multiple dose;
DRUGBANK
39.84
L/h
~664
ml/min
Total clearance; Oral multiple dose;
DRUGBANK
60.42
L/h
~1007
ml/min
Total clearance; Oral single dose;
DRUGBANK
328.86
L/h
~5481
ml/min
Total clearance; Oral single dose;
DRUGBANK
39.06
L/h
~651
ml/min
Total clearance; Oral multiple dose;
DRUGBANK
171.3
L/h
~2855
ml/min
Total clearance; Oral multiple dose;
DRUGBANK
0.9
L/h/kg
15±6
ml/min/kg
hydrolysis; hydrolysis;
Children → ;Elderly ↑ ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;RD, renal impairment, Renal disease，including uremia → ;Attenuated Total Reflectance ↑ ;Attenuated Total Reflectance → ;
DRUGBANK
1.08
L/h/kg
18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
300.0
L
~300
L
DRUGBANK
500.0
L
500.0
L
DRUGBANK
5.0
L/kg
5.0±2.1
L/kg
Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ;
DRUGBANK
3.7
L/kg
3.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.1
h
2.8-7.4
h
elimination half-life; immediate release formulation; Single dose;
DRUGBANK
8.25
h
4.5-12.0
h
Multiple dose;
DRUGBANK
15.0
h
14-16
h
elimination half-life; hepatic insufficiency;
DRUGBANK
20.0
h
~20
h
Elderly;
DRUGBANK
0.0666666666666667
h
~4
min
rapid distribution half-life; intravenous injection, IV;
DRUGBANK
3.5
h
2-5
h
elimination half-life;
DRUGBANK
4.0
h
4.0±1.5
h
Children → ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;atrial fibrillation ↑ ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ;
DRUGBANK
2.8
h
2.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
150.0
mg/kg
150.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
163.0
mg/kg
163.0
mg/kg
PO, oral; mouse;
DRUGBANK
8.0
mg/kg
8.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
14.4
mg/kg
14.4
mg/kg
PO, oral; Female, women;
DRUGBANK
3.429
mg/kg
3.429
mg/kg
PO, oral; Male, men;
DRUGBANK
3.5
%
~3-4
%
Urinary excretion; Unchanged drug;
DRUGBANK
3.0
%
<3
%
Urinary excretion; Unchanged drug;
DRUGBANK
94.0
%
94
%
Optical rotation R;
DRUGBANK
88.0
%
88
%
Optical rotation S;
DRUGBANK
92.0
%
92
%
Optical rotation R;
DRUGBANK
86.0
%
86
%
Optical rotation S;
DRUGBANK
90.0
%
90±2
%
Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;atrial fibrillation → ;
DRUGBANK
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
480.0
mg/day
480
mg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
400.0
mg/day
400
mg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
540.0
mg/day
540
mg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
480.0
mg/day
480
mg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
400.0
mg/day
400
mg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
540.0
mg/day
540
mg/day
PO, oral
Calan SR
verapamil hydrochloride
PDR
DDPD00662
Trimethobenzamide
388.4574
C21H28N2O5
COC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
DB00662
5577
27796
http://www.drugs.com/cdi/trimethobenzamide.html
5375
-2.0
-
-2.0
-
DRUGBANK
8.0
h
7-9
h
elimination half-life;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; mouse;
DRUGBANK
40.0
%
30-50
%
Urinary excretion; Single dose; human, homo sapiens; Unchanged drug;
DRUGBANK
800.0
mg/day
800
mg/day
Capsule, PO, Oral;Rectal Administration;
Tigan Capsules
trimethobenzamide hydrochloride
PDR
15.0
mg/kg/day
15
mg/kg/day
Capsule, PO, Oral;Rectal Administration;
Tigan Capsules
trimethobenzamide hydrochloride
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Tigan Capsules
trimethobenzamide hydrochloride
PDR
15.0
mg/kg/day
15
mg/kg/day
Rectal Administration
Tigan Capsules
trimethobenzamide hydrochloride
PDR
1200.0
mg/day
1200
mg/day
Capsule, PO, Oral
Tigan Capsules
trimethobenzamide hydrochloride
PDR
800.0
mg/day
800
mg/day
IM,intramuscular injection;Rectal Administration;
Tigan Capsules
trimethobenzamide hydrochloride
PDR
800.0
mg/day
800
mg/day
Capsule, PO, Oral;Rectal Administration;
Tigan Capsules
trimethobenzamide hydrochloride
PDR
1200.0
mg/day
1200
mg/day
Capsule, PO, Oral
Tigan Capsules
trimethobenzamide hydrochloride
PDR
800.0
mg/day
800
mg/day
IM,intramuscular injection;Rectal Administration;
Tigan Capsules
trimethobenzamide hydrochloride
PDR
DDPD00663
Flumethasone
410.458
C22H28F2O5
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB00663
16490
34764
15632
-2.0
-
-2.0
-
DRUGBANK
DDPD00664
Sulfametopyrazine
280.303
C11H12N4O3S
COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1
DB00664
9047
32162
8695
-2.0
-
-2.0
-
DRUGBANK
DDPD00665
Nilutamide
317.2207
C12H10F3N3O4
CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
DB00665
T3D4783
4493
7573
http://www.drugs.com/cdi/nilutamide.html
4337
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
2.0
%
<2
%
Urinary excretion;
DRUGBANK
48.55
h
38.0-59.1
h
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Nilandron
nilutamide
PDR
300.0
mg/day
300
mg/day
PO, oral
Nilandron
nilutamide
PDR
DDPD00666
Nafarelin
1322.496
C66H83N17O13
CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
DB00666
T3D2855
25077405
http://www.drugs.com/cdi/nafarelin.html
10482014
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
2.8
%
2.8(1.2-5.6)
%
inhalation, IH;
DRUGBANK
0.0432
L/h/kg
0.72
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3
h
DRUGBANK
3.5
h
3.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
80
%
DRUGBANK
1.8
mg/day
1800
mcg/day
intranasal
Synarel
nafarelin acetate
PDR
0.4
mg/day
400
mcg/day
subcutaneous injection, SC
Synarel
nafarelin acetate
PDR
0.8
mg/day
800
mcg/day
intranasal
Synarel
nafarelin acetate
PDR
1.8
mg/day
1800
mcg/day
intranasal
Synarel
nafarelin acetate
PDR
DDPD00668
Epinephrine
183.2044
C9H13NO3
CNC[C@H](O)C1=CC(O)=C(O)C=C1
DB00668
5816
28918
http://www.drugs.com/mtm/epinephrine-ophthalmic.html
5611
-2.0
-
-2.0
-
DRUGBANK
0.0416666666666667
h
~2-3
min
elimination half-life;
DRUGBANK
62.0
mg/kg
62.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
0.01
mg/kg/dose
0.01
mg/kg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
EI
Adrenaclick
epinephrine
PDR
2.5
mg/dose
2.5
mg/dose
EI
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.5
ml/dose
0.5
ml/dose
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
8.0
oral inhalations/day
8
oral inhalations/day
inhalation, IH
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
EI
Adrenaclick
epinephrine
PDR
2.5
mg/dose
2.5
mg/dose
EI
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.5
ml/dose
0.5
ml/dose
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
EI
Adrenaclick
epinephrine
PDR
2.5
mg/dose
2.5
mg/dose
EI
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.5
ml/dose
0.5
ml/dose
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
intravenous injection, IV;IO;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV;IO;
Adrenaclick
epinephrine
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
EI
Adrenaclick
epinephrine
PDR
2.5
mg/dose
2.5
mg/dose
EI
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
8.0
oral inhalations/day
8
oral inhalations/day
inhalation, IH
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
intravenous injection, IV;IO;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV;IO;
Adrenaclick
epinephrine
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
EI
Adrenaclick
epinephrine
PDR
2.5
mg/dose
2.5
mg/dose
EI
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
IM,intramuscular injection;subcutaneous injection, SC;
Adrenaclick
epinephrine
PDR
1.0
mg/dose
1
mg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.5
ml/dose
0.5
ml/dose
Adrenaclick
epinephrine
PDR
0.01
mg/kg/dose
0.01
mg/kg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.5
mg/dose
0.5
mg/dose
subcutaneous injection, SC
Adrenaclick
epinephrine
PDR
0.03
mg/kg/dose
0.03
mg/kg/dose
intravenous injection, IV
Adrenaclick
epinephrine
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
ET
Adrenaclick
epinephrine
PDR
DDPD00669
Sumatriptan
295.4
C14H21N3O2S
CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1
DB00669
T3D2856
5358
10650
http://www.drugs.com/cdi/sumatriptan.html
5165
-2.0
-
-2.0
-
DRUGBANK
9.0
ng.h/ml
9(7.5-10.9)
ng.h/ml
subcutaneous injection, SC;
DRUGBANK
8.7
ng.h/ml
8.7(6.1-12.5)
ng.h/ml
PO, oral;
DRUGBANK
7.4
ng.h/ml
7.4(5-10.8)
ng.h/ml
inhalation, IH;
DRUGBANK
14.6
ng.h/ml
14.6(11.3-18.8)
ng.h/ml
Rectal Administration;
DRUGBANK
100.0
%
100
%
subcutaneous injection, SC;
DRUGBANK
14.3
%
14.3(11.4-17.9)
%
PO, oral;
DRUGBANK
15.8
%
15.8(12.6-19.8)
%
inhalation, IH;
DRUGBANK
19.2
%
19.2(15.3-24.1)
%
Rectal Administration;
DRUGBANK
14.0
%
14±5
%
PO, oral;
DRUGBANK
97.0
%
97±16
%
subcutaneous injection, SC;
DRUGBANK
69.5
ng/ml
69.5（62.8-76.9）
ng/ml
subcutaneous injection, SC;
DRUGBANK
16.5
ng/ml
16.5(13.5-20.1)
ng/ml
PO, oral;
DRUGBANK
12.9
ng/ml
12.9(10.5-15.9)
ng/ml
inhalation, IH;
DRUGBANK
22.9
ng/ml
22.9(18.4-28.6)
ng/ml
Rectal Administration;
DRUGBANK
54.0
ng/ml
54(27-137)
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
72.0
ng/ml
72(55-108)
ng/ml
adults; normal,healthy;
DRUGBANK
0.17
h
0.17(0.08-0.33)
h
subcutaneous injection, SC;
DRUGBANK
1.5
h
1.5(0.5-2)
h
PO, oral;
DRUGBANK
1.5
h
1.5(0.25-3)
h
inhalation, IH;
DRUGBANK
1.0
h
1(0.75-3)
h
Rectal Administration;
DRUGBANK
1.5
h
~1.5
h
Oral single dose; adults; normal,healthy;
DRUGBANK
0.2
h
0.2(0.1-0.3)
h
adults; normal,healthy;
DRUGBANK
0.0132
L/h
0.22(0.19-0.25)
ml/min
subcutaneous injection, SC;
DRUGBANK
0.0105
L/h
0.14-0.21
ml/min
PO, oral; Rectal Administration;
DRUGBANK
0.0129
L/h
0.18-0.25
ml/min
IM,intramuscular injection;
DRUGBANK
72.0
L/h
~1200
ml/min
Plasma clearance;
DRUGBANK
1.32
L/h/kg
22±5.4
ml/min/kg
normal,healthy; adults;
DRUGBANK
1.14
L/h/kg
19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
L
50±8
L
subcutaneous injection, SC;
DRUGBANK
2.0
L/kg
2.0±0.34
L/kg
normal,healthy; adults;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
h
1.9
h
subcutaneous injection, SC;
DRUGBANK
1.85
h
1.7-2.0
h
subcutaneous injection, SC; 95%CI;
DRUGBANK
1.7
h
1.7
h
PO, oral;
DRUGBANK
1.65
h
1.4-1.9
h
PO, oral; 95%CI;
DRUGBANK
1.8
h
1.8
h
Rectal Administration;
DRUGBANK
1.9
h
1.6-2.2
h
Rectal Administration; 95%CI;
DRUGBANK
1.8
h
1.8
h
DRUGBANK
1.85
h
1.7-2.0
h
95%CI;
DRUGBANK
1.0
h
1.0±0.3
h
DRUGBANK
2.0
h
~2
h
subcutaneous injection, SC; PO, oral;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
%
~40
%
Faeces excretion;
DRUGBANK
24.0
%
24±4
%
Urinary excretion; Unchanged drug;
DRUGBANK
22.0
%
22±4
%
Urinary excretion; Unchanged drug;
DRUGBANK
17.5
%
14-21
%
DRUGBANK
17.5
%
14-21
%
DRUGBANK
6.0
mg/dose
6
mg/dose
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
3.0
mg/dose
3
mg/dose
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Imitrex Injection
sumatriptan succinate
PDR
200.0
mg/day
200
mg/day
PO, oral
Imitrex Injection
sumatriptan succinate
PDR
40.0
mg/day
40
mg/day
intranasal
Imitrex Injection
sumatriptan succinate
PDR
30.0
mg/day
30
mg/day
intranasal
Imitrex Injection
sumatriptan succinate
PDR
44.0
mg/day
44
mg/day
intranasal
Imitrex Injection
sumatriptan succinate
PDR
6.0
mg/dose
6
mg/dose
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
3.0
mg/dose
3
mg/dose
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Imitrex Injection
sumatriptan succinate
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Imitrex Injection
sumatriptan succinate
PDR
200.0
mg/day
200
mg/day
PO, oral
Imitrex Injection
sumatriptan succinate
PDR
40.0
mg/day
40
mg/day
intranasal
Imitrex Injection
sumatriptan succinate
PDR
30.0
mg/day
30
mg/day
intranasal
Imitrex Injection
sumatriptan succinate
PDR
44.0
mg/day
44
mg/day
intranasal
Imitrex Injection
sumatriptan succinate
PDR
DDPD00670
Pirenzepine
351.4023
C19H21N5O2
CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
DB00670
4848
8247
4682
-2.0
-
-2.0
-
DRUGBANK
0.1662
L/h/kg
2.77
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.71
L/kg
1.71
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.1
h
11.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00671
Cefixime
453.45
C16H15N5O7S2
[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O
DB00671
5362065
472657
http://www.drugs.com/cdi/cefixime.html
4514923
-2.0
-
-2.0
-
DRUGBANK
45.0
%
40-50
%
PO, oral; food;
food → ;
DRUGBANK
47.0
%
47±15
%
PO, oral;
DRUGBANK
2300.0
ng/ml
1.7-2.9
mcg/ml
Capsule, PO, Oral; adults; normal,healthy;
DRUGBANK
3.5
h
3-4
h
Capsule, PO, Oral; adults; normal,healthy;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
0.078
L/h/kg
1.3±0.2
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.06
L/h/kg
1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
L/kg
0.30±0.03
L/kg
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
DRUGBANK
11.5
h
11.5
h
severe renal function;
DRUGBANK
3.0
h
3.0±0.4
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
3.2
h
3.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
41.0
%
41±7
%
Urinary excretion; Unchanged drug;
DRUGBANK
65.0
%
65
%
DRUGBANK
67.0
%
67±1
%
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Suprax
cefixime
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Suprax
cefixime
PDR
400.0
mg/day
400
mg/day
PO, oral
Suprax
cefixime
PDR
400.0
mg/day
400
mg/day
PO, oral
Suprax
cefixime
PDR
400.0
mg/day
400
mg/day
PO, oral
Suprax
cefixime
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Suprax
cefixime
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Suprax
cefixime
PDR
DDPD00672
Chlorpropamide
276.74
C10H13ClN2O3S
CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
DB00672
2727
3650
http://www.drugs.com/cdi/chlorpropamide.html
2626
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
DRUGBANK
80.0
%
80
%
Liver metabolism;
DRUGBANK
0.0027
L/h/kg
0.045
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
h
~36(25-60)
h
DRUGBANK
46.0
h
46
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
580.0
mg/kg
580.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
85.0
%
80-90
%
Urinary excretion; Oral single dose;
DRUGBANK
750.0
mg/day
750
mg/day
PO, oral
Chlorpropamide
chlorpropamide
PDR
DDPD00673
Aprepitant
534.4267
C23H21F7N4O3
C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
DB00673
6918365
499361
http://www.drugs.com/cdi/aprepitant.html
5293568
-2.0
-
-2.0
-
DRUGBANK
62.5
%
60-65
%
DRUGBANK
62.5
%
60-65
%
PO, oral;
DRUGBANK
1600.0
ng/ml
1.6
mcg/ml
Oral single dose;
DRUGBANK
4.0
h
4.0
h
Oral single dose;
DRUGBANK
4.56
L/h
62-90
ml/min
Plasma clearance;
DRUGBANK
0.0654
L/h/kg
0.89-1.29
ml/min/kg
hydrolysis;
DRUGBANK
0.06
L/h/kg
1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.0
L
70.0
L
DRUGBANK
1.0
L/kg
1.0
L/kg
hydrolysis;
DRUGBANK
0.94
L/kg
0.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
9-13
h
DRUGBANK
11.0
h
9-13
h
DRUGBANK
13.0
h
13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
>95
%
DRUGBANK
95.0
%
>95
%
DRUGBANK
DDPD00674
Galantamine
287.3535
C17H21NO3
[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
DB00674
T3D2857
9651
42944
http://www.drugs.com/cdi/galantamine.html
9272
-2.0
-
-2.0
-
DRUGBANK
95.0
%
90-100
%
PO, oral;
DRUGBANK
100.0
%
100(91-110)
%
PO, oral;
DRUGBANK
96.0
ng/ml
96±29
ng/ml
PO, oral; Elderly; normal,healthy;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
2.6
h
2.6±1.0
h
PO, oral; Elderly; normal,healthy;
DRUGBANK
75.0
%
75
%
DRUGBANK
3.9
L/h
~65
ml/min
Renal clearance;
DRUGBANK
18.0
L/h
~300
ml/min
Plasma clearance;
DRUGBANK
0.342
L/h/kg
5.7(5.0-6.3)
ml/min/kg
hydrolysis; hydrolysis; metabolism of ugt;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
175.0
L
175.0
L
Average volume of distribution;
DRUGBANK
2.6
L/kg
2.6(2.4-2.9)
L/kg
DRUGBANK
7.0
h
~7
h
terminal half-life;
DRUGBANK
5.7
h
5.7(5.2-6.3)
h
DRUGBANK
75.0
mg/kg
75.0
mg/kg
PO, oral; Components; Rattus, Rat;
DRUGBANK
75.0
mg/kg
75.0
mg/kg
Rattus, Rat;
DRUGBANK
95.0
%
~95
%
Urinary excretion;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
5.0
%
~5
%
Faeces excretion;
DRUGBANK
30.4
%
30.4
%
Urinary excretion; Unchanged drug;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
20.0
%
20(18-22)
%
Urinary excretion; Unchanged drug;
DRUGBANK
18.0
%
18
%
plasma proteins;
DRUGBANK
18.0
%
18
%
DRUGBANK
24.0
mg/day
24
mg/day
PO, oral
Razadyne
galantamine hydrobromide
PDR
24.0
mg/day
24
mg/day
PO, oral
Razadyne
galantamine hydrobromide
PDR
DDPD00675
Tamoxifen
371.5146
C26H29NO
CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
DB00675
T3D4714
2733526
41774
http://www.drugs.com/tamoxifen.html
2015313
-2.0
-
-2.0
-
DRUGBANK
40.0
ng/ml
40.0
ng/ml
PO, oral;
DRUGBANK
15.0
ng/ml
15.0
ng/ml
PO, oral; Active metabolite;
DRUGBANK
120.0
ng/ml
120(67-183)
ng/ml
PO, oral;
DRUGBANK
5.0
h
5
h
PO, oral;
DRUGBANK
5.0
h
5(3-7)
h
PO, oral;
DRUGBANK
11.34
L/h
189.0
ml/min
postmenopausal women;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
apparent clearance; hydrolysis;
DRUGBANK
55.0
L/kg
~50-60
L/kg
DRUGBANK
55.0
L/kg
50-60
L/kg
Apparent volume of distribution;
DRUGBANK
144.0
h
5-7
day
elimination half-life;
DRUGBANK
336.0
h
~14
day
DRUGBANK
180.0
h
4-11
day
at steady state;
DRUGBANK
26.7
%
26.7
%
Urinary excretion; human, homo sapiens;
DRUGBANK
24.7
%
24.7
%
Faeces excretion; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.0
%
>98
%
plasma proteins;
DRUGBANK
98.0
%
>98
%
DRUGBANK
1.0
mg/kg/day
1
mg/kg/day
PO, oral
qd
Soltamox
tamoxifen citrate
PDR
20.0
mg/day
20
mg/day
PO, oral
qd
Soltamox
tamoxifen citrate
PDR
20.0
mg/day
20
mg/day
PO, oral
bid
Soltamox
tamoxifen citrate
PDR
120.0
mg/day
120
mg/day
PO, oral
Soltamox
tamoxifen citrate
PDR
80.0
mg/m2
80
mg/m2
PO, oral
Soltamox
tamoxifen citrate
PDR
120.0
mg/day
120
mg/day
PO, oral
qd
Soltamox
tamoxifen citrate
PDR
20.0
mg/day
20
mg/day
PO, oral
bid
Soltamox
tamoxifen citrate
PDR
120.0
mg/day
120
mg/day
PO, oral
Soltamox
tamoxifen citrate
PDR
80.0
mg/m2
80
mg/m2
PO, oral
Soltamox
tamoxifen citrate
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
qd
Soltamox
tamoxifen citrate
PDR
DDPD00676
Benzyl benzoate
212.2439
C14H12O2
O=C(OCC1=CC=CC=C1)C1=CC=CC=C1
DB00676
2345
41237
http://www.drugs.com/cons/benzyl-benzoate-topical.html
13856959
-2.0
-
-2.0
-
DRUGBANK
1680.0
mg/kg
1680.0
mg/kg
PO, oral; rabbit;
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD00677
Isoflurophate
184.1457
C6H14FO3P
CC(C)OP(F)(=O)OC(C)C
DB00677
5936
17941
5723
-2.0
-
-2.0
-
DRUGBANK
DDPD00678
Losartan
422.911
C22H23ClN6O
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
DB00678
3961
6541
http://www.drugs.com/cdi/losartan.html
3824
-2.0
-
-2.0
-
DRUGBANK
33.0
%
33
%
PO, oral;
DRUGBANK
35.8
%
35.8±15.5
%
PO, oral;
DRUGBANK
225.0
ng/ml
200-250
ng/ml
PO, oral;
DRUGBANK
296.0
ng/ml
296±217
ng/ml
Male, men; normal,healthy;
DRUGBANK
249.0
ng/ml
249±74
ng/ml
Active metabolite; Male, men; normal,healthy;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral; Active metabolite;
DRUGBANK
1.0
h
1.0±0.5
h
Male, men; normal,healthy;
DRUGBANK
4.1
h
4.1±1.6
h
Active metabolite; Male, men; normal,healthy;
DRUGBANK
36.0
L/h
600.0
ml/min
Plasma clearance;
DRUGBANK
4.5
L/h
75.0
ml/min
Plasma clearance;
DRUGBANK
3.0
L/h
50.0
ml/min
Plasma clearance;
DRUGBANK
1.5
L/h
25.0
ml/min
Renal clearance;
DRUGBANK
0.486
L/h/kg
8.1±1.8
ml/min/kg
hydrolysis; normal,healthy; Male, men;
mild hepatic impairment ↓ ;moderate hepatic impairment ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.492
L/h/kg
8.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
34.4
L
34.4±17.9
L
DRUGBANK
10.3
L
10.3±1.1
L
DRUGBANK
0.45
L/kg
0.45±0.24
L/kg
hydrolysis; normal,healthy; Male, men;
DRUGBANK
0.37
L/kg
0.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
1.5-2.5
h
elimination half-life;
DRUGBANK
7.5
h
6-9
h
Active metabolite;
DRUGBANK
2.5
h
2.5±1.0
h
normal,healthy; Male, men;
DRUGBANK
5.4
h
5.4±2.3
h
normal,healthy; Male, men; Active metabolite; Metabolite;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.714285714285714
mg/kg/day
10.0
mg/kg/2W
human, homo sapiens; Male, men;
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/1D
human, homo sapiens; Female, women;
DRUGBANK
35.0
%
35
%
Urinary excretion; PO, oral;
DRUGBANK
60.0
%
60
%
Faeces excretion; PO, oral;
DRUGBANK
45.0
%
45
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
50.0
%
50
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
4.0
%
4
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
12.0
%
12±2.8
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
98.7
%
98.6-98.8
%
DRUGBANK
98.7
%
98.7
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
99.8
%
99.8
%
Active metabolite; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
1.4
mg/kg/day
1.4
mg/kg/day
PO, oral
Losartan Potassium
losartan potassium
PDR
100.0
mg/day
100
mg/day
PO, oral
Losartan Potassium
losartan potassium
PDR
100.0
mg/day
100
mg/day
PO, oral
Losartan Potassium
losartan potassium
PDR
100.0
mg/day
100
mg/day
PO, oral
Losartan Potassium
losartan potassium
PDR
100.0
mg/day
100
mg/day
PO, oral
Losartan Potassium
losartan potassium
PDR
DDPD00679
Thioridazine
370.575
C21H26N2S2
CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1
DB00679
T3D2858
5452
9566
http://www.drugs.com/cdi/thioridazine.html
5253
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
DRUGBANK
23.0
h
21-25
h
DRUGBANK
995.0
mg/kg
956-1034
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
995.0
mg/kg
956-1034
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
95
%
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Thioridazine Hydrochloride
thioridazine hydrochloride
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Thioridazine Hydrochloride
thioridazine hydrochloride
PDR
800.0
mg/day
800
mg/day
PO, oral
Thioridazine Hydrochloride
thioridazine hydrochloride
PDR
DDPD00680
Moricizine
427.517
C22H25N3O4S
CCOC(=O)NC1=CC2=C(SC3=CC=CC=C3N2C(=O)CCN2CCOCC2)C=C1
DB00680
34633
6997
http://www.drugs.com/cdi/moricizine.html
31872
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
38.0
%
38
%
DRUGBANK
300.0
L
300.0
L
DRUGBANK
2.0
h
2(1.5-3.5)
h
DRUGBANK
56.0
%
~56
%
Faeces excretion;
DRUGBANK
39.0
%
~39
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
95.0
%
~95
%
DRUGBANK
DDPD00681
Amphotericin B
924.079
C47H73NO17
[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2
DB00681
5280965
2682
http://www.drugs.com/cdi/amphotericin-b.html
10237579
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
intravenous injection, IV;
DRUGBANK
5.0
%
<5
%
PO, oral;
DRUGBANK
1200.0
ng/ml
1.2±0.33
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
1700.0
ng/ml
1.7±0.8
ug/ml
intravenous infusion, IV in drop; Drug form;
DRUGBANK
83000.0
ng/ml
83±35
ug/ml
intravenous infusion, IV in drop; Drug form;
DRUGBANK
0.039
L/h/kg
39±22
ml/h/kg
intravenous infusion, IV in drop; febrile neutropenic cancer; bone marrow transplant;
DRUGBANK
0.017
L/h/kg
17±6
ml/h/kg
intravenous infusion, IV in drop; febrile neutropenic cancer; bone marrow transplant;
DRUGBANK
0.051
L/h/kg
51±44
ml/h/kg
intravenous infusion, IV in drop; febrile neutropenic cancer; bone marrow transplant;
DRUGBANK
0.022
L/h/kg
22±15
ml/h/kg
intravenous infusion, IV in drop; febrile neutropenic cancer; bone marrow transplant;
DRUGBANK
0.021
L/h/kg
21±14
ml/h/kg
intravenous infusion, IV in drop; febrile neutropenic cancer; bone marrow transplant;
DRUGBANK
0.011
L/h/kg
11±6
ml/h/kg
intravenous infusion, IV in drop; febrile neutropenic cancer; bone marrow transplant;
DRUGBANK
0.0276
L/h/kg
0.46±0.20
ml/min/kg
Children;
Prem, premature → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.0102
L/h/kg
0.17
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.76
L/kg
0.76±0.52
L/kg
Total volume of distribution;
increasing doses ↑ ;
DRUGBANK
0.62
L/kg
0.62
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
360.0
h
~15
day
elimination half-life;
DRUGBANK
24.0
h
~24
h
elimination half-life;
DRUGBANK
18.0
h
18±7
h
Multiple dose;
DRUGBANK
40.0
h
40
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.5
%
2-5
%
Urinary excretion; Capsule, PO, Oral; Unchanged drug;
DRUGBANK
90.0
%
90
%
plasma proteins;
DRUGBANK
90.0
%
>90
%
Capsule, PO, Oral;
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
AmBisome
amphotericin B liposome
PDR
1.25
mg/kg/day
1.25
mg/kg/day
intravenous injection, IV
Amphotericin B
amphotericin B
PDR
1.25
mg/kg/day
1.25
mg/kg/day
intravenous injection, IV
Amphotericin B
amphotericin B
PDR
1.25
mg/kg/day
1.25
mg/kg/day
intravenous injection, IV
Amphotericin B
amphotericin B
PDR
DDPD00682
Warfarin
308.3279
C19H16O4
CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
DB00682
T3D2567
54678486
87732
http://www.drugs.com/warfarin.html
10442445
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
Tablet, PO, oral;
DRUGBANK
93.0
%
93±8
%
PO, oral;
DRUGBANK
900.0
ng/ml
0.9±0.4
mcg/ml
PO, oral; Optical rotation R; patients;
DRUGBANK
500.0
ng/ml
0.5±0.2
mcg/ml
PO, oral; Optical rotation S; patients;
DRUGBANK
4.0
h
4
h
Tablet, PO, oral;
DRUGBANK
4.0
h
<4
h
PO, oral; patients;
DRUGBANK
0.00255
L/h/kg
0.020-0.065
ml/min/kg
DRUGBANK
0.0027
L/h/kg
0.045±0.024
ml/min/kg
Elderly → ;acute viral hepatitis AVH → ;Cystic fibrosis → ;
DRUGBANK
0.0033
L/h/kg
0.055
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14
L/kg
DRUGBANK
0.14
L/kg
0.14±0.06
L/kg
Elderly → ;acute viral hepatitis AVH → ;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
63.0
h
37-89
h
Optical rotation R;
DRUGBANK
32.0
h
21-43
h
Optical rotation S;
DRUGBANK
37.0
h
37±15
h
acute viral hepatitis AVH → ;Age → ;
DRUGBANK
43.0
h
43±14
h
Optical rotation R;
DRUGBANK
32.0
h
32±12
h
Optical rotation S;
DRUGBANK
29.0
h
29
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
mg/kg
3.0
mg/kg
PO, oral; mouse;
DRUGBANK
165.0
mg/kg
165.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
750.0
mg/kg
750.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
1.6
mg/kg
1.6
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
320.0
mg/kg
320.0
mg/kg
inhalation, IH; Rattus, Rat;
DRUGBANK
1400.0
mg/kg
1400.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
800.0
mg/kg
800.0
mg/kg
PO, oral; rabbit;
DRUGBANK
1.0
mg/kg
1.0
mg/kg
PO, oral; pig;
DRUGBANK
3.0
mg/kg
3.0
mg/kg
PO, oral; dog;
DRUGBANK
6.0
mg/kg
6.0
mg/kg
PO, oral; cat;
DRUGBANK
942.0
mg/kg
942.0
mg/kg
PO, oral; chicken;
DRUGBANK
180.0
mg/kg
180.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
374.0
mg/kg
374.0
mg/kg
PO, oral; mouse;
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
20.0
%
20
%
Faeces excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
99.0
%
99±1
%
Preg, pregnant → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
DDPD00683
Midazolam
325.767
C18H13ClFN3
CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
DB00683
T3D2859
4192
6931
http://www.drugs.com/cdi/midazolam.html
4047
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
IM,intramuscular injection;
DRUGBANK
45.0
%
40-50
%
PO, oral;
DRUGBANK
36.0
%
36
%
pediatric patients;
DRUGBANK
50.0
%
50
%
Rectal Administration;
DRUGBANK
56.0
%
55-57
%
inhalation, IH;
DRUGBANK
44.0
%
44±17
%
PO, oral;
DRUGBANK
90.0
ng/ml
90.0
ng/ml
IM,intramuscular injection;
DRUGBANK
78.0
ng/ml
78±27
ng/ml
Oral single dose;
DRUGBANK
113.0
ng/ml
113±16
ng/ml
DRUGBANK
0.5
h
0.5
h
IM,intramuscular injection;
DRUGBANK
0.5
h
0.5
h
Rectal Administration;
DRUGBANK
0.19
h
10.2-12.6
min
inhalation, IH;
DRUGBANK
0.67
h
0.67±0.45
h
Oral single dose;
DRUGBANK
22.038
L/h/kg
367.3±73.5
ml/min/kg
Total clearance; IM,intramuscular injection;
DRUGBANK
0.395
L/h/kg
0.25-0.54
L/h/kg
Total clearance; intravenous injection, IV;
DRUGBANK
0.396
L/h/kg
6.6±1.8
ml/min/kg
hydrolysis;
Neonates ↓ ;Children → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;Somking → ;
DRUGBANK
0.318
L/h/kg
5.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.72
L/kg
1.24-2.2
L/kg
intravenous injection, IV; pediatric patients;
Female, women ↑ ;Elderly ↑ ;Obesity ↑ ;
DRUGBANK
2.05
L/kg
1-3.1
L/kg
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
2.117
L/kg
2117±845.1
ml/kg
Average volume of distribution; IM,intramuscular injection; Single dose; normal,healthy; adults;
DRUGBANK
1.1
L/kg
1.1±0.6
L/kg
Neonates ↓ ;Hepatic cirrhosis, cirr → ;Obesity ↑ ;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3(1.8-6.4)
h
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
4.2
h
4.2
h
elimination half-life; IM,intramuscular injection;
DRUGBANK
1.9
h
1.9±0.6
h
Obesity ↑ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ;Somking → ;
DRUGBANK
3.1
h
3.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
215.0
mg/kg
215.0
mg/kg
Rattus, Rat;
DRUGBANK
825.0
mg/kg
825.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.5
%
<0.5
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
plasma proteins; adults; human, homo sapiens;
DRUGBANK
98.0
%
98
%
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr → ;Somking → ;
DRUGBANK
1.0
mg/kg
1
mg/kg
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
0.4
mg/kg
0.4
mg/kg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
10.0
mg
10
mg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
10.0
mg/dose
10
mg/dose
nasal spray
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
1.0
mg/kg
1
mg/kg
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
0.4
mg/kg
0.4
mg/kg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
10.0
mg
10
mg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
1.0
mg/kg
1
mg/kg
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
0.6
mg/kg
0.6
mg/kg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
6.0
mg
6
mg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
10.0
mg/dose
10
mg/dose
nasal spray
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
1.0
mg/kg
1
mg/kg
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
5.0
mg
5
mg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
10.0
mg/dose
10
mg/dose
nasal spray
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
10.0
mg/dose
10
mg/dose
nasal spray
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
1.0
mg/kg
1
mg/kg
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
0.6
mg/kg
0.6
mg/kg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
6.0
mg
6
mg
intravenous injection, IV
Midazolam Hydrochloride Syrup
midazolam hydrochloride
PDR
DDPD00684
Tobramycin
467.5145
C18H37N5O9
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
DB00684
36294
28864
http://www.drugs.com/cdi/tobramycin-drops.html
33377
-2.0
-
-2.0
-
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
elimination half-life; intravenous injection, IV;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
441.0
mg/kg
441.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
48.0
drop/day
48
drop/day
ophthalmic administration
Tobrex Ophthalmic Solution
tobramycin
PDR
600.0
mg/day
600
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
224.0
mg/day
224
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
48.0
drop/day
48
drop/day
ophthalmic administration
Tobrex Ophthalmic Solution
tobramycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
48.0
drop/day
48
drop/day
ophthalmic administration
Tobrex Ophthalmic Solution
tobramycin
PDR
600.0
mg/day
600
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
224.0
mg/day
224
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
48.0
drop/day
48
drop/day
ophthalmic administration
Tobrex Ophthalmic Solution
tobramycin
PDR
600.0
mg/day
600
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
224.0
mg/day
224
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
48.0
drop/day
48
drop/day
ophthalmic administration
Tobrex Ophthalmic Solution
tobramycin
PDR
600.0
mg/day
600
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
224.0
mg/day
224
mg/day
inhalation, IH
Tobrex Ophthalmic Solution
tobramycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
48.0
drop/day
48
drop/day
ophthalmic administration
Tobrex Ophthalmic Solution
tobramycin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Tobrex Ophthalmic Solution
tobramycin
PDR
DDPD00685
Trovafloxacin
416.36
C20H15F3N4O3
[H][C@@]12CN(C[C@]1([H])[C@H]2N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=C(F)C=C(F)C=C1)C(O)=O
DB00685
62959
9763
http://www.drugs.com/mtm/trovafloxacin.html
16736478
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88
%
PO, oral; food;
food → ;
DRUGBANK
13.0
%
13
%
Urinary excretion;
DRUGBANK
9.0
%
9
%
Faeces excretion;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.65
h
9.1-12.2
h
PO, oral;
DRUGBANK
11.05
h
9.4-12.7
h
intravenous injection, IV;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
43.0
%
43
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
6.0
%
6
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
76.0
%
~76
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
DDPD00686
Pentosan polysulfate
602.497
C10H18O21S4
O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O
DB00686
37720
34595
-2.0
-
-2.0
-
DRUGBANK
4.8
h
4.8
h
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Elmiron
pentosan polysulfate sodium
PDR
300.0
mg/day
300
mg/day
PO, oral
Elmiron
pentosan polysulfate sodium
PDR
300.0
mg/day
300
mg/day
PO, oral
Elmiron
pentosan polysulfate sodium
PDR
DDPD00687
Fludrocortisone
380.4504
C21H29FO5
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB00687
31378
50885
http://www.drugs.com/cdi/fludrocortisone.html
29111
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
2.145
ng.h/ml
1.22-3.07
ug.h/L
PO, oral;
DRUGBANK
0.1006
ng/ml
0.0012-0.2
ug/L
PO, oral;
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
0.48
L/h
0.48
L/h
Plasma clearance;
DRUGBANK
82.5
L
80-85
L
Apparent volume of distribution;
DRUGBANK
2.25
h
1-3.5
h
elimination half-life;
DRUGBANK
27.0
h
18-36
h
DRUGBANK
1000.0
mg/kg
>1
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
80.0
%
~80
%
Urinary excretion;
DRUGBANK
20.0
%
~20
%
Bile excretion; Faeces excretion;
DRUGBANK
75.0
%
70-80
%
plasma proteins;
DRUGBANK
0.3
mg/day
0.3
mg/day
PO, oral
Fludrocortisone Acetate
fludrocortisone acetate
PDR
0.2
mg/day
0.2
mg/day
PO, oral
Fludrocortisone Acetate
fludrocortisone acetate
PDR
0.2
mg/day
0.2
mg/day
PO, oral
Fludrocortisone Acetate
fludrocortisone acetate
PDR
0.2
mg/day
0.2
mg/day
PO, oral
Fludrocortisone Acetate
fludrocortisone acetate
PDR
0.3
mg/day
0.3
mg/day
PO, oral
Fludrocortisone Acetate
fludrocortisone acetate
PDR
DDPD00688
Mycophenolate mofetil
433.4947
C23H31NO7
COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C
DB00688
5281078
8764
http://www.drugs.com/cdi/mycophenolate-mofetil.html
4444535
-2.0
-
-2.0
-
DRUGBANK
63900.0
ng.h/ml
63.9±16.2
ug.h/ml
Oral single dose;
DRUGBANK
65300.0
ng.h/ml
65.3±35.4
ug.h/ml
PO, oral; renal transplant;
DRUGBANK
94.0
%
94
%
Oral single dose;
DRUGBANK
24500.0
ng/ml
24.5±9.5
ug/ml
Oral single dose;
DRUGBANK
24100.0
ng/ml
24.1±12.1
ug/ml
PO, oral; renal transplant;
DRUGBANK
1.25
h
1-1.5
h
PO, oral; Active metabolite;
DRUGBANK
11.58
L/h
193.0
ml/min
Plasma clearance; PO, oral;
DRUGBANK
10.62
L/h
177±31
ml/min
Plasma clearance; intravenous injection, IV;
DRUGBANK
3.9
L/kg
3.6-4.2
L/kg
DRUGBANK
17.9
h
17.9±6.5
h
PO, oral;
DRUGBANK
16.6
h
16.6±5.8
h
intravenous injection, IV;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
PO, oral; mouse;
DRUGBANK
93.0
%
93
%
Urinary excretion;
DRUGBANK
6.0
%
6
%
Faeces excretion;
DRUGBANK
DDPD00689
Cephaloglycin
405.425
C18H19N3O6S
[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
DB00689
19150
34613
18069
-2.0
-
-2.0
-
DRUGBANK
DDPD00690
Flurazepam
387.878
C21H23ClFN3O
CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
DB00690
T3D2860
3393
5128
http://www.drugs.com/cdi/flurazepam.html
3276
-2.0
-
-2.0
-
DRUGBANK
2.3
h
2.3
h
DRUGBANK
73.5
h
47-100
h
elimination half-life;
DRUGBANK
83.0
%
83
%
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral; hs
Flurazepam Hydrochloride
flurazepam hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral; hs
Flurazepam Hydrochloride
flurazepam hydrochloride
PDR
15.0
mg/day
15
mg/day
PO, oral
hs
Flurazepam Hydrochloride
flurazepam hydrochloride
PDR
DDPD00691
Moexipril
498.5681
C27H34N2O7
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O
DB00691
91270
6960
http://www.drugs.com/cdi/moexipril.html
82418
-2.0
-
-2.0
-
DRUGBANK
13.0
%
13
%
PO, oral;
DRUGBANK
26.46
L/h
441.0
ml/min
DRUGBANK
183.0
L
183.0
L
DRUGBANK
1.0
h
~1
h
elimination half-life;
DRUGBANK
5.5
h
2-9
h
elimination half-life;
DRUGBANK
50.0
%
~50
%
DRUGBANK
DDPD00692
Phentolamine
281.3523
C17H19N3O
CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1
DB00692
5775
8081
http://www.drugs.com/cons/phentolamine-injection.html
5571
-2.0
-
-2.0
-
DRUGBANK
2.52
L/h/kg
42
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.316666666666667
h
19
min
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.5
%
10-13
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD00693
Fluorescein
332.3063
C20H12O5
OC1=CC=C2C(OC3=CC(O)=CC=C3C22OC(=O)C3=C2C=CC=C3)=C1
DB00693
T3D4808
16850
31624
15968
-2.0
-
-2.0
-
DRUGBANK
0.105
L/h/kg
1.75
ml/min/kg
Renal clearance; intravenous injection, IV;
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
Total clearance; intravenous injection, IV;
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
L/kg
0.5
L/kg
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
%
85
%
DRUGBANK
DDPD00694
Daunorubicin
527.5199
C27H29NO10
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
DB00694
T3D2861
30323
41977
http://www.drugs.com/cdi/daunorubicin.html
28163
-2.0
-
-2.0
-
DRUGBANK
2.8542
L/h/kg
47.57
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.05
L/kg
32.05
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.5
h
18.5
h
DRUGBANK
14.24
h
14.24
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
mg/kg
20.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
13.0
mg/kg
13.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
20.0
mg/kg
20.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
13.0
mg/kg
13.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
25.0
%
25
%
Urinary excretion;
DRUGBANK
40.0
%
40
%
Bile excretion;
DRUGBANK
97.0
%
97
%
DRUGBANK
25.0
mg/m2
25
mg/m2
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
300.0
mg/m2
300
mg/m2
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
0.14285714
mg/kg/day
1
mg/kg/week
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
10.0
mg/kg/dose
10
mg/kg/dose
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
45.0
mg/m2
45
mg/m2
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
90.0
mg/m2
90
mg/m2
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
500.0
mg/m2
500
mg/m2
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
400.0
mg/m2
400
mg/m2
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
25.0
mg/m2/day
25
mg/m2/day
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
300.0
mg/m2
300
mg/m2
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
45.0
mg/m2
45
mg/m2
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
90.0
mg/m2
90
mg/m2
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
500.0
mg/m2
500
mg/m2
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
400.0
mg/m2
400
mg/m2
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
0.142857142857143
mg/kg/day
1
mg/kg/week
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
10.0
mg/kg/dose
10
mg/kg/dose
intravenous injection, IV
Daunorubicin Hydrochloride
daunorubicin hydrochloride
PDR
DDPD00695
Furosemide
330.744
C12H11ClN2O5S
NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
DB00695
3440
47426
http://www.drugs.com/furosemide.html
3322
-2.0
-
-2.0
-
DRUGBANK
50.0
%
10-90
%
PO, oral; extended release formulation;
DRUGBANK
64.0
%
64
%
Tablet, PO, oral;
DRUGBANK
60.0
%
60
%
Capsule, PO, Oral;
DRUGBANK
71.0
%
71±35(43-73)
%
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
1700.0
ng/ml
1.7±0.9
mcg/ml
Male, men; adults; normal,healthy;
DRUGBANK
1.4
h
1.4±0.8
h
Male, men; adults; normal,healthy;
DRUGBANK
85.0
%
85
%
Urinary excretion;
DRUGBANK
0.0738
L/h/kg
1.23
ml/min/kg
Plasma clearance; intravenous injection, IV; heart disease; patients;
DRUGBANK
0.1404
L/h/kg
2.34
ml/min/kg
Plasma clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
0.135
L/h/kg
1.5-3.0
ml/min/kg
Neonates ↓ ;Elderly ↓ ;Prem, premature ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis ↑ ;congestive heart disease ↓ ;
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.181
L/kg
0.181
L/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; heart disease; patients;
DRUGBANK
0.13
L/kg
0.09-0.17
L/kg
Neonates ↑ ;Prem, premature ↑ ;Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;congestive heart disease → ;nephritic syndrome ↑ ;Somking → ;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV;
DRUGBANK
2.0
h
~2
h
terminal half-life; parenteral administration;
DRUGBANK
24.0
h
24
h
terminal half-life; severe renal failure;
DRUGBANK
1.3
h
1.3±0.8(0.5-2.0)
h
normal,healthy; Male, men;
Prem, premature ↑ ;Neonates ↑ ;mild renal function ↑ ;congestive heart disease ↑ ;Hepatic cirrhosis, cirr ↑ ;nephritic syndrome → ;Age ↑ ;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
800.0
mg/kg
800.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
4600.0
mg/kg
4600.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
6.25
mg/kg
6250.0
ug/kg
Female, women;
DRUGBANK
43.0
%
~43
%
Urinary excretion;
DRUGBANK
50.0
%
~50
%
Urinary excretion; Unchanged drug;
DRUGBANK
71.0
%
71±10
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
Elderly → ;Cystic fibrosis ↓ ;
DRUGBANK
65.0
%
50-80
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
95.0
%
~91-99
%
normal,healthy;
DRUGBANK
97.5
%
96-99
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
98.6
%
98.6±0.4
%
adults; normal,healthy; human, homo sapiens;
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;nephritic syndrome ↓ ;hypoalbuminemia Alb ↓ ;congestive heart disease → ;Somking → ;
DRUGBANK
6.0
mg/kg/dose
6
mg/kg/dose
PO, oral;intravenous injection, IV;
Furosemide Injection
furosemide
PDR
600.0
mg/day
600
mg/day
PO, oral
Furosemide Injection
furosemide
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Furosemide Injection
furosemide
PDR
4000.0
mg/day
4
g/day
PO, oral
Furosemide Injection
furosemide
PDR
6.0
mg/kg/dose
6
mg/kg/dose
PO, oral;intravenous injection, IV;
Furosemide Injection
furosemide
PDR
600.0
mg/day
600
mg/day
PO, oral
Furosemide Injection
furosemide
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Furosemide Injection
furosemide
PDR
4000.0
mg/day
4
g/day
PO, oral
Furosemide Injection
furosemide
PDR
6.0
mg/kg/dose
6
mg/kg/dose
PO, oral;intravenous injection, IV;
Furosemide Injection
furosemide
PDR
4.0
mg/kg/day
2
mg/kg/dose/day
intravenous injection, IV
bid
Furosemide Injection
furosemide
PDR
1.0
mg/kg/dose/day
1
mg/kg/dose/day
intravenous injection, IV
Furosemide Injection
furosemide
PDR
DDPD00696
Ergotamine
581.6615
C33H35N5O5
[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O
DB00696
T3D2460
8223
64318
http://www.drugs.com/cdi/ergotamine.html
7930
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
Bile excretion;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.6
L/kg
3.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.0
mg/kg
62.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
3.0
mg/day
3
mg/day
sublingual
Ergomar
ergotamine tartrate
PDR
6.0
mg/day
6
mg/day
sublingual
Ergomar
ergotamine tartrate
PDR
1.42857142857143
mg/day
10
mg/week
sublingual
Ergomar
ergotamine tartrate
PDR
3.0
mg/day
3
mg/day
sublingual
Ergomar
ergotamine tartrate
PDR
6.0
mg/day
6
mg/day
sublingual
Ergomar
ergotamine tartrate
PDR
1.42857142857143
mg/day
10
mg/week
sublingual
Ergomar
ergotamine tartrate
PDR
DDPD00697
Tizanidine
253.711
C9H8ClN5S
ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
DB00697
T3D2862
5487
63629
http://www.drugs.com/tizanidine.html
5287
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
95.0
%
95
%
Liver metabolism;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.4
L/kg
2.4
L/kg
Steady state volume of distribution;
DRUGBANK
2.4
L/kg
2.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
~2.5
h
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
414.0
mg/kg
414.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
282.0
mg/kg
282.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
235.0
mg/kg
235.0
mg/kg
PO, oral; mouse;
DRUGBANK
30.0
%
~30
%
plasma proteins;
DRUGBANK
36.0
mg/day
36
mg/day
PO, oral
Tizanidine
tizanidine
PDR
36.0
mg/day
36
mg/day
PO, oral
Tizanidine
tizanidine
PDR
DDPD00698
Nitrofurantoin
238.159
C8H6N4O5
[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
DB00698
T3D2679
6604200
71415
http://www.drugs.com/nitrofurantoin.html
5036498
-2.0
-
-2.0
-
DRUGBANK
2315.0
ng.h/ml
2.21-2.42
mg.h/l
DRUGBANK
41.55
%
38.8-44.3
%
DRUGBANK
87.0
%
87±13
%
PO, oral;
DRUGBANK
919.0
ng/ml
0.875-0.963
mg/L
DRUGBANK
428.0
ng/ml
428±146
ng/ml
fasting; adults; normal,healthy;
food → ;
DRUGBANK
2.3
h
2.3±1.4
h
fasting; adults; normal,healthy;
food → ;
DRUGBANK
1.3
%
0.8-1.8
%
DRUGBANK
18.05
L/h
16.7-19.4
L/h
DRUGBANK
0.594
L/h/kg
9.9±0.9
ml/min/kg
normal,healthy; adults;
Urine alkaline ↑ ;
DRUGBANK
0.582
L/h/kg
9.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.46
L/kg
0.46
L/kg
dog;
DRUGBANK
0.58
L/kg
0.58±0.12
L/kg
normal,healthy; adults;
DRUGBANK
0.57
L/kg
0.57
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
h
0.72-0.78
h
DRUGBANK
1.0
h
1.0±0.2
h
Urine alkaline → ;
DRUGBANK
0.97
h
0.97
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
38.5
%
27-50
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
47.0
%
47±13
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
~90
%
plasma proteins;
DRUGBANK
62.0
%
62±4
%
DRUGBANK
DDPD00699
Nicergoline
484.386
C24H26BrN3O3
[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC
DB00699
34040
31902
31373
-2.0
-
-2.0
-
DRUGBANK
DDPD00700
Eplerenone
414.4914
C24H30O6
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
DB00700
443872
31547
http://www.drugs.com/cdi/eplerenone.html
10203511
-2.0
-
-2.0
-
DRUGBANK
1000.0
ng/ml
1.0±0.3
mcg/ml
PO, oral;
DRUGBANK
1.8
h
1.8±0.7
h
PO, oral;
DRUGBANK
10.0
L/h
10.0
L/h
Plasma clearance;
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
hepatopathy，LD ↓ ;congestive heart disease ↓ ;
DRUGBANK
66.5
L
43-90
L
DRUGBANK
0.95
L/kg
0.6-1.3
L/kg
DRUGBANK
5.0
h
4-6
h
DRUGBANK
5.0
h
4-6
h
DRUGBANK
7.0
%
7
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
50.0
%
50
%
DRUGBANK
46.5
%
33-60
%
normal,healthy; human, homo sapiens;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Inspra
eplerenone
PDR
50.0
mg/day
50
mg/day
PO, oral
Inspra
eplerenone
PDR
100.0
mg/day
100
mg/day
PO, oral
Inspra
eplerenone
PDR
50.0
mg/day
50
mg/day
PO, oral
Inspra
eplerenone
PDR
DDPD00701
Amprenavir
505.627
C25H35N3O6S
CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
DB00701
T3D2863
65016
40050
http://www.drugs.com/cdi/amprenavir.html
58532
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
Oral single dose; AIDS,HIV;
DRUGBANK
8.85
h
7.1-10.6
h
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD00703
Methazolamide
236.26
C5H8N4O3S2
CN1N=C(SC1=NC(C)=O)S(N)(=O)=O
DB00703
4100
6822
http://www.drugs.com/cdi/methazolamide.html
10438315
-2.0
-
-2.0
-
DRUGBANK
20.0
L
17-23
L
DRUGBANK
14.0
h
14
h
DRUGBANK
55.0
%
55
%
DRUGBANK
DDPD00704
Naltrexone
341.4009
C20H23NO4
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O
DB00704
T3D2864
5360515
7465
http://www.drugs.com/cdi/naltrexone.html
4514524
-2.0
-
-2.0
-
DRUGBANK
22.5
%
5-40
%
PO, oral;
DRUGBANK
210.0
L/h
~3.5
L/min
intravenous injection, IV;
DRUGBANK
3.42
L/h/kg
57
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1350.0
L
1350.0
L
intravenous injection, IV;
DRUGBANK
7.6
L/kg
7.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
4
h
DRUGBANK
13.0
h
13
h
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1325.0
mg/kg
1100-1550
mg/kg
PO, oral; mouse;
DRUGBANK
1450.0
mg/kg
1450.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1490.0
mg/kg
1490.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
1325.0
mg/kg
1100-1550
mg/kg
PO, oral; mouse;
DRUGBANK
1450.0
mg/kg
1450.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1490.0
mg/kg
1490.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
66.0
%
53-79
%
Urinary excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
21.0
%
21
%
plasma proteins;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Vivitrol
naltrexone
PDR
380.0
mg/dose
380
mg/dose
IM,intramuscular injection
Vivitrol
naltrexone
PDR
150.0
mg/day
150
mg/day
PO, oral
Vivitrol
naltrexone
PDR
380.0
mg/dose
380
mg/dose
IM,intramuscular injection
Vivitrol
naltrexone
PDR
DDPD00705
Delavirdine
456.561
C22H28N6O3S
CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
DB00705
5625
119573
http://www.drugs.com/cdi/delavirdine.html
5423
-2.0
-
-2.0
-
DRUGBANK
5.8
h
5.8
h
DRUGBANK
98.0
%
98
%
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Rescriptor
delavirdine mesylate
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Rescriptor
delavirdine mesylate
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Rescriptor
delavirdine mesylate
PDR
DDPD00706
Tamsulosin
408.512
C20H28N2O5S
CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
DB00706
129211
9398
http://www.drugs.com/cdi/tamsulosin.html
114457
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral; fasting;
DRUGBANK
175.0
ng.h/ml
151-199
ng.h/ml
PO, oral;
DRUGBANK
498.5
ng.h/ml
440-557
ng.h/ml
PO, oral;
DRUGBANK
100.0
%
100.0
%
PO, oral; Male, men; normal,healthy;
DRUGBANK
4.2
ng/ml
3.1-5.3
ng/ml
PO, oral;
DRUGBANK
3.05
ng/ml
2.5-3.6
ng/ml
PO, oral;
DRUGBANK
16.0
ng/ml
16±5
ng/ml
Oral single dose; extended release formulation; normal,healthy;
DRUGBANK
4.5
h
4-5
h
PO, oral; fasting;
DRUGBANK
6.5
h
6-7
h
PO, oral; food;
DRUGBANK
5.3
h
5.3±0.7
h
Oral single dose; extended release formulation; normal,healthy;
DRUGBANK
2.88
L/h
2.88
L/h
DRUGBANK
0.0372
L/h/kg
0.62±0.31
ml/min/kg
normal,healthy; Female, women; hydrolysis; hydrolysis;
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.0372
L/h/kg
0.62
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
L
16.0
L
intravenous injection, IV;
DRUGBANK
0.2
L/kg
0.20±0.06
L/kg
normal,healthy; Female, women; hydrolysis; hydrolysis;
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.9
h
14.9±3.9
h
fasting;
DRUGBANK
6.0
h
5-7
h
elimination half-life; normal,healthy;
DRUGBANK
11.0
h
9-13
h
normal,healthy;
DRUGBANK
14.5
h
14-15
h
patients;
DRUGBANK
6.8
h
6.8±3.5
h
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
14.5
h
~14-15
h
PO, oral; extended release formulation;
DRUGBANK
6.8
h
6.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
650.0
mg/kg
650.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
76.0
%
76
%
Urinary excretion; PO, oral;
DRUGBANK
21.0
%
21
%
Faeces excretion; PO, oral;
DRUGBANK
12.7
%
12.7±3
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
96.5
%
94-99
%
DRUGBANK
99.0
%
99±1
%
Male, men; normal,healthy; human, homo sapiens;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.8
mg/day
0.8
mg/day
PO, oral
Flomax
tamsulosin hydrochloride
PDR
0.8
mg/day
0.8
mg/day
PO, oral
Flomax
tamsulosin hydrochloride
PDR
DDPD00707
Porfimer sodium
N.A.
N.A.
CCC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C(=C(C(=N5)C=C1N2)C)C(C)O)C)CCC(=O)O)C(=C3C)CCC(=O)O)C.[Na+]
DB00707
137321858
60652
http://www.drugs.com/cdi/porfimer.html
10482043
-2.0
-
-2.0
-
DRUGBANK
11.982
L/h
199.7±56.9
ml/min
Oral single dose; normal,healthy;
DRUGBANK
0.49
L/kg
0.49±0.28
L/kg
tumor; patients; Male, men;
DRUGBANK
231.0
h
10-452
h
DRUGBANK
90.0
%
~90
%
DRUGBANK
2.0
mg/kg
2
mg/kg
intravenous injection, IV
Photofrin
porfimer sodium
PDR
2.0
mg/kg
2
mg/kg
intravenous injection, IV
Photofrin
porfimer sodium
PDR
DDPD00708
Sufentanil
386.551
C22H30N2O2S
CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
DB00708
T3D2865
41693
9316
http://www.drugs.com/cdi/sufentanil.html
38043
-2.0
-
-2.0
-
DRUGBANK
52.0
%
52
%
DRUGBANK
35.0
%
35
%
DRUGBANK
0.075
ng/ml
0.05-0.1
ng/ml
epidural administration;
DRUGBANK
55020.0
L/h
917.0
L/min
Plasma clearance; intravenous injection, IV;
Age ↑ ;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.0
L
14.0
L
Total volume of distribution;
DRUGBANK
350.0
L
~350
L
at steady state;
DRUGBANK
9.4
L/kg
9.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.73333333333333
h
164
min
elimination half-life; intravenous injection, IV; adults;
DRUGBANK
1.61666666666667
h
97±42
min
elimination half-life; Infants; Children;
DRUGBANK
7.23333333333333
h
434±160
min
elimination half-life; Neonates;
DRUGBANK
8.0
h
6-10
h
terminal half-life;
DRUGBANK
18.0
h
18
h
terminal half-life; Multiple dose;
DRUGBANK
14.0
h
14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.7
mg/kg
18.7
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
18.7
mg/kg
18.7
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
80.0
%
~80
%
DRUGBANK
2.0
%
2
%
Unchanged drug;
DRUGBANK
93.0
%
93
%
plasma proteins; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
91.0
%
91
%
plasma proteins; Female, women; human, homo sapiens;
DRUGBANK
79.0
%
79
%
plasma proteins; Neonates; human, homo sapiens;
DRUGBANK
DDPD00709
Lamivudine
229.256
C8H11N3O3S
NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
DB00709
60825
63577
http://www.drugs.com/cdi/lamivudine.html
54812
-2.0
-
-2.0
-
DRUGBANK
86.0
%
86±16
%
Tablet, PO, oral; AIDS,HIV;
DRUGBANK
87.0
%
87±13
%
Capsule, PO, Oral; AIDS,HIV;
DRUGBANK
86.0
%
86±17
%
PO, oral; Male, men; normal,healthy;
DRUGBANK
1500.0
ng/ml
1.5±0.5
mcg/ml
PO, oral; AIDS,HIV;
DRUGBANK
1000.0
ng/ml
1.0(0.86-1.2)
mcg/ml
Male, men; normal,healthy;
DRUGBANK
1.0
h
0.5-1.5
h
Male, men; normal,healthy;
DRUGBANK
11.982
L/h
199.7±56.9
ml/min
Renal clearance; PO, oral; normal,healthy;
DRUGBANK
16.824
L/h
280.4±75.2
ml/min
Renal clearance; intravenous injection, IV; AIDS,HIV; patients;
DRUGBANK
23.91
L/h
398.5±69.1
ml/min
Total clearance; AIDS,HIV; patients;
DRUGBANK
0.297
L/h/kg
4.95±0.75
ml/min/kg
Children ↑ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.288
L/h/kg
4.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
L/kg
1.3±0.4
L/kg
Apparent volume of distribution; intravenous injection, IV;
gaining weight → ;increasing doses → ;
DRUGBANK
1.3
L/kg
1.30±0.36
L/kg
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
5-7
h
normal,healthy; patients;
DRUGBANK
6.0
h
5-7
h
HBV-infected; patients;
DRUGBANK
9.11
h
9.11±5.09
h
Children ↓ ;moderate renal function ↑ ;severe renal function ↑ ;
DRUGBANK
9.1
h
9.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
67.0
%
49-85
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
36.0
%
<36
%
plasma proteins;
DRUGBANK
36.0
%
<36
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
300.0
mg/day
300
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
300.0
mg/day
300
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
100.0
mg/day
100
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
300.0
mg/day
300
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
100.0
mg/day
100
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
300.0
mg/day
300
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
100.0
mg/day
100
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
300.0
mg/day
300
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
100.0
mg/day
100
mg/day
PO, oral
Epivir-HBV
lamivudine
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Epivir-HBV
lamivudine
PDR
DDPD00710
Ibandronate
319.2289
C9H23NO7P2
CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
DB00710
T3D2667
60852
http://www.drugs.com/cdi/ibandronate.html
54839
-2.0
-
-2.0
-
DRUGBANK
316.0
ng.h/ml
316.0
ng.h/ml
intravenous injection, IV;
DRUGBANK
518.0
ng.h/ml
518.0
ng.h/ml
intravenous injection, IV;
DRUGBANK
908.0
ng.h/ml
908.0
ng.h/ml
intravenous injection, IV;
DRUGBANK
0.63
%
0.63
%
PO, oral;
DRUGBANK
4.1
ng/ml
4.1±2.6
ng/ml
PO, oral; normal,healthy; Male, men;
DRUGBANK
1.1
h
1.1±0.6
h
PO, oral; normal,healthy; Male, men;
DRUGBANK
7.32
L/h
84-160
ml/min
DRUGBANK
229.0
L
90-368
L
Apparent volume of distribution; normal,healthy;
DRUGBANK
103.0
L
103.0
L
Apparent volume of distribution; osteopenia; postmenopausal women;
DRUGBANK
97.0
h
37-157
h
postmenopausal women;
DRUGBANK
811.0
mg/kg
811.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
92.6
%
85.7-99.5
%
DRUGBANK
86.0
%
86
%
DRUGBANK
2.5
mg/day
2.5
mg/day
PO, oral
q3m
Boniva Tablets
ibandronate sodium
PDR
5.0
mg/day
150
mg/month
PO, oral
q3m
Boniva Tablets
ibandronate sodium
PDR
3.0
mg
3
mg
intravenous injection, IV
q3m
Boniva Tablets
ibandronate sodium
PDR
50.0
mg/day
50
mg/day
PO, oral
Boniva Tablets
ibandronate sodium
PDR
6.0
mg/dose
6
mg/dose
intravenous infusion, iv in drop
Boniva Tablets
ibandronate sodium
PDR
2.5
mg/day
2.5
mg/day
PO, oral
q3m
Boniva Tablets
ibandronate sodium
PDR
5.0
mg/day
150
mg/month
PO, oral
q3m
Boniva Tablets
ibandronate sodium
PDR
3.0
mg
3
mg
intravenous injection, IV
q3m
Boniva Tablets
ibandronate sodium
PDR
50.0
mg/day
50
mg/day
PO, oral
Boniva Tablets
ibandronate sodium
PDR
6.0
mg/dose
6
mg/dose
intravenous infusion, iv in drop
Boniva Tablets
ibandronate sodium
PDR
DDPD00711
Diethylcarbamazine
199.2932
C10H21N3O
CCN(CC)C(=O)N1CCN(C)CC1
DB00711
3052
4527
2944
-2.0
-
-2.0
-
DRUGBANK
8.0
h
~8
h
DRUGBANK
1400.0
mg/kg
1400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
660.0
mg/kg
660.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00712
Flurbiprofen
244.2609
C15H13FO2
CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
DB00712
T3D2866
3394
5130
http://www.drugs.com/cdi/flurbiprofen-drops.html
3277
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
2.25
h
0.5-4
h
PO, oral;
DRUGBANK
14.0
L
14.0
L
normal,healthy; adults;
DRUGBANK
12.0
L
12.0
L
Arthritis; Geriatric;
DRUGBANK
10.0
L
10.0
L
severe renal function; patients;
DRUGBANK
14.0
L
14.0
L
Hepatitis, Hep; patients;
DRUGBANK
0.12
L/kg
0.12
L/kg
DRUGBANK
4.7
h
4.7
h
Optical rotation R;
DRUGBANK
5.7
h
5.7
h
Optical rotation S;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; dog;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; dog;
DRUGBANK
70.0
%
~70
%
Urinary excretion;
DRUGBANK
3.0
%
<3
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Ocufen
flurbiprofen sodium
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Ocufen
flurbiprofen sodium
PDR
300.0
mg/day
300
mg/day
PO, oral
Ocufen
flurbiprofen sodium
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Ocufen
flurbiprofen sodium
PDR
DDPD00713
Oxacillin
401.436
C19H19N3O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O
DB00713
6196
7809
http://www.drugs.com/cdi/oxacillin.html
5961
-2.0
-
-2.0
-
DRUGBANK
0.378
L/h/kg
6.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.416666666666667
h
20-30
min
DRUGBANK
0.7
h
0.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.2
%
94.2±2.1
%
DRUGBANK
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
25.0
mg/kg/day
25
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
200.0
mg/kg/day
200
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Oxacillin
oxacillin
PDR
DDPD00714
Apomorphine
267.3224
C17H17NO2
[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
DB00714
T3D2867
6005
48538
http://www.drugs.com/cdi/apomorphine.html
5783
-2.0
-
-2.0
-
DRUGBANK
0.25
h
10-20
min
DRUGBANK
1440.0
L/h
1440.0
L/h
sublingual;
DRUGBANK
223.0
L/h
223.0
L/h
intravenous injection, IV;
DRUGBANK
2.4
L/h/kg
40
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
263.5
L
123-404
L
Apparent volume of distribution; subcutaneous injection, SC;
DRUGBANK
3630.0
L
3630.0
L
Apparent volume of distribution; sublingual;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
h
1.7
h
elimination half-life; Intraperitoneal, IP;
DRUGBANK
0.833333333333333
h
50
min
elimination half-life; intravenous injection, IV;
DRUGBANK
0.68
h
0.68
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.145
mg/kg
145.0
ug/kg
Intraperitoneal, IP; mouse;
DRUGBANK
160.39344
mg/kg
0.6
mmole/kg
Intraperitoneal, IP; mouse;
DRUGBANK
99.9
%
99.9
%
human, homo sapiens;
DRUGBANK
0.6
ml/dose
0.6
ml/dose
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
6.0
mg/dose
6
mg/dose
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
2.0
ml/day
2
ml/day
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
20.0
mg/day
20
mg/day
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
30.0
mg/dose
30
mg/dose
sublingual
Apokyn
apomorphine hydrochloride
PDR
5.0
dose/day
5
dose/day
sublingual
Apokyn
apomorphine hydrochloride
PDR
0.6
ml/dose
0.6
ml/dose
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
6.0
mg/dose
6
mg/dose
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
2.0
ml/day
2
ml/day
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
20.0
mg/day
20
mg/day
subcutaneous injection, SC
Apokyn
apomorphine hydrochloride
PDR
30.0
mg/dose
30
mg/dose
sublingual
Apokyn
apomorphine hydrochloride
PDR
5.0
dose/day
5
dose/day
sublingual
Apokyn
apomorphine hydrochloride
PDR
DDPD00715
Paroxetine
329.3654
C19H20FNO3
FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
DB00715
T3D2868
43815
7936
http://www.drugs.com/paroxetine.html
39888
-2.0
-
-2.0
-
DRUGBANK
574.0
ng.h/ml
574.0
ng.h/ml
PO, oral;
DRUGBANK
1053.0
ng.h/ml
1053.0
ng.h/ml
PO, oral; moderate renal function;
DRUGBANK
45.0
%
30-60
%
PO, oral;
DRUGBANK
42.817502
ng/ml
~130
nM
PO, oral; extensive metabolizers, EM;
DRUGBANK
72.460388
ng/ml
~220
nM
PO, oral; poor metabolizers, PM;
DRUGBANK
4.3
h
4.3(2-8)
h
PO, oral;
DRUGBANK
5.2
h
5.2±0.5
h
PO, oral; adults;
DRUGBANK
252.0
h
7-14
day
PO, oral;
DRUGBANK
167.0
L/h
167.0
L/h
Total clearance; PO, oral; Liver metabolism;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.516
L/h/kg
8.6±3.2
ml/min/kg
apparent clearance; hydrolysis;
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
1.08
L/h/kg
18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
L/kg
17±10
L/kg
Apparent volume of distribution;
DRUGBANK
18.0
L/kg
18
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.0
h
~21
h
elimination half-life;
DRUGBANK
17.3
h
17.3
h
elimination half-life; normal,healthy; young;
DRUGBANK
60.0
h
1-4
day
different study;
DRUGBANK
17.0
h
17±3
h
Multiple dose; extensive metabolizers, EM;
Hepatic cirrhosis, cirr ↑ ;Age ↑ ;
DRUGBANK
41.0
h
41±8
h
Multiple dose; poor metabolizers, PM;
Hepatic cirrhosis, cirr ↑ ;Age ↑ ;
DRUGBANK
13.0
h
13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
mouse; Rattus, Rat;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
PO, oral; mouse;
DRUGBANK
64.0
%
~64
%
Urinary excretion; PO, oral;
DRUGBANK
36.0
%
~36
%
Faeces excretion; PO, oral;
DRUGBANK
3.0
%
3
%
Unchanged drug;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
plasma proteins;
DRUGBANK
95.0
%
95
%
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Pexeva
paroxetine mesylate
PDR
60.0
mg/day
60
mg/day
PO, oral
Pexeva
paroxetine mesylate
PDR
75.0
mg/day
75
mg/day
PO, oral
Pexeva
paroxetine mesylate
PDR
50.0
mg/day
50
mg/day
PO, oral
Pexeva
paroxetine mesylate
PDR
40.0
mg/day
40
mg/day
PO, oral
Pexeva
paroxetine mesylate
PDR
50.0
mg/day
50
mg/day
PO, oral
Pexeva
paroxetine mesylate
PDR
DDPD00716
Nedocromil
371.3408
C19H17NO7
CCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=O
DB00716
50294
7492
http://www.drugs.com/cdi/nedocromil-drops.html
45608
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
intravenous injection, IV;
DRUGBANK
0.612
L/h/kg
10.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.3
h
~3.3
h
DRUGBANK
0.9
h
0.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.0
%
70
%
Urinary excretion;
DRUGBANK
30.0
%
3
%
Faeces excretion;
DRUGBANK
70.0
%
70
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
30
%
Faeces excretion; Unchanged drug;
DRUGBANK
89.0
%
~89
%
plasma proteins; human, homo sapiens;
DRUGBANK
8.0
sprays/day
8
sprays/day
inhalation, IH
Alocril
nedocromil sodium
PDR
14.0
mg/day
14
mg/day
inhalation, IH
Alocril
nedocromil sodium
PDR
8.0
sprays/day
8
sprays/day
inhalation, IH
Alocril
nedocromil sodium
PDR
14.0
mg/day
14
mg/day
inhalation, IH
Alocril
nedocromil sodium
PDR
8.0
sprays/day
8
sprays/day
inhalation, IH
Alocril
nedocromil sodium
PDR
14.0
mg/day
14
mg/day
inhalation, IH
Alocril
nedocromil sodium
PDR
8.0
sprays/day
8
sprays/day
inhalation, IH
Alocril
nedocromil sodium
PDR
14.0
mg/day
14
mg/day
inhalation, IH
Alocril
nedocromil sodium
PDR
DDPD00717
Norethisterone
298.4192
C20H26O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
DB00717
T3D4745
6230
7627
http://www.drugs.com/cdi/norethindrone.html
5994
-2.0
-
-2.0
-
DRUGBANK
33.5
ng.h/ml
30-37
ng.h/ml
Oral single dose;
DRUGBANK
64.0
%
64
%
PO, oral;
DRUGBANK
6.375
ng/ml
5.39-7.36
ng/ml
Oral single dose;
DRUGBANK
0.8385
ng/ml
617-1060
pg/ml
skin/dermal;
DRUGBANK
1.5
h
1-2
h
Oral single dose;
DRUGBANK
24.0
h
24
h
skin/dermal;
DRUGBANK
0.4
L/h/kg
0.4
L/h/kg
Plasma clearance;
DRUGBANK
77.0
L/h
~73-81
L/h
Total clearance;
DRUGBANK
4.0
L/kg
~4
L/kg
DRUGBANK
9.0
h
8-10
h
DRUGBANK
6000.0
mg/kg
6.0
g/kg
PO, oral; mouse;
DRUGBANK
42.0
mg/kg
42.0
mg/kg
human, homo sapiens; Female, women;
DRUGBANK
50.0
%
>50
%
Urinary excretion;
DRUGBANK
30.0
%
20-40
%
Faeces excretion;
DRUGBANK
61.0
%
61
%
DRUGBANK
DDPD00718
Adefovir dipivoxil
501.4705
C20H32N5O8P
CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
DB00718
60871
31175
http://www.drugs.com/cdi/adefovir.html
54855
-2.0
-
-2.0
-
DRUGBANK
220.0
ng.h/ml
220±70
ng.h/ml
Oral single dose; Hepatitis, Hep; food;
food → ;
DRUGBANK
59.0
%
59
%
PO, oral;
DRUGBANK
18.4
ng/ml
18.4±6.26
ng/ml
Oral single dose; Hepatitis, Hep; food;
food → ;
DRUGBANK
2.29
h
0.58-4
h
Oral single dose; Hepatitis, Hep; food;
food → ;
DRUGBANK
45.0
%
45
%
Urinary excretion;
DRUGBANK
28.14
L/h
469±99.0
ml/min
normal,healthy; patients;
DRUGBANK
21.36
L/h
356±85.6
ml/min
mild renal function; patients;
DRUGBANK
14.22
L/h
237±118
ml/min
moderate renal function; patients;
DRUGBANK
5.502
L/h
91.7±51.3
ml/min
severe renal function; patients;
DRUGBANK
0.392
L/kg
392±75
mL/kg
at steady state; intravenous injection, IV;
DRUGBANK
0.352
L/kg
352±9
mL/kg
at steady state; intravenous injection, IV;
DRUGBANK
7.48
h
7.48±1.65
h
elimination half-life;
DRUGBANK
4.0
%
4
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Hepsera
adefovir dipivoxil
PDR
0.25
mg/kg/day
0.25
mg/kg/day
PO, oral
Hepsera
adefovir dipivoxil
PDR
10.0
mg/day
10
mg/day
PO, oral
Hepsera
adefovir dipivoxil
PDR
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral
Hepsera
adefovir dipivoxil
PDR
10.0
mg/kg
10
mg/kg
PO, oral
Hepsera
adefovir dipivoxil
PDR
10.0
mg/kg
10
mg/kg
PO, oral
Hepsera
adefovir dipivoxil
PDR
10.0
mg/kg
10
mg/kg
PO, oral
Hepsera
adefovir dipivoxil
PDR
DDPD00719
Azatadine
290.4021
C20H22N2
CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2
DB00719
19861
2946
http://www.drugs.com/mtm/azatadine.html
18709
-2.0
-
-2.0
-
DRUGBANK
1700.0
mg/kg
>1700
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
600.0
mg/kg
>600
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00720
Clodronic acid
244.892
CH4Cl2O6P2
OP(O)(=O)C(Cl)(Cl)P(O)(O)=O
DB00720
T3D2663
25419
110423
23731
-2.0
-
-2.0
-
DRUGBANK
44200.0
ng.h/ml
44.2
mg.h/l
intravenous injection, IV;
DRUGBANK
47500.0
ng.h/ml
47.5
mg.h/l
IM,intramuscular injection;
DRUGBANK
1.5
%
1-2
%
PO, oral;
DRUGBANK
16100.0
ng/ml
16.1
mg/L
intravenous injection, IV;
DRUGBANK
12800.0
ng/ml
12.8
mg/L
IM,intramuscular injection;
DRUGBANK
0.0
%
0
%
human, homo sapiens;
DRUGBANK
5.4
L/h
~90
ml/min
Renal clearance;
DRUGBANK
5.6
h
5.6
h
elimination half-life;
DRUGBANK
36.0
%
36
%
plasma proteins;
DRUGBANK
DDPD00721
Procaine
236.3101
C13H20N2O2
CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
DB00721
T3D2869
4914
8430
http://www.drugs.com/mtm/procaine.html
4745
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25(6-60)
%
PO, oral; food;
food → ;
DRUGBANK
58.0
ng/ml
58.0
ng/ml
PO, oral; food;
food → ;
DRUGBANK
7.0
h
6-8
h
PO, oral; food;
food → ;
DRUGBANK
0.128333333333333
h
7.7
min
DRUGBANK
350.0
mg/kg
350.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00722
Lisinopril
405.4879
C21H31N3O5
NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O
DB00722
5362119
43755
http://www.drugs.com/lisinopril.html
4514933
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25±20
%
PO, oral;
DRUGBANK
100.0
%
100.0
%
PO, oral;
DRUGBANK
50.0
ng/ml
50(6.4-343)
ng/ml
PO, oral; adults; hypertension; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
608231.85
ng/ml
1-2
mM
Oral single dose; immediate release formulation;
DRUGBANK
385213.505
ng/ml
0.7-1.2
mM
extended release formulation;
DRUGBANK
7.0
h
~7
h
PO, oral; adults; hypertension; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
1.75
h
0.5-3
h
Oral single dose; immediate release formulation;
DRUGBANK
4.0
h
2-6
h
extended release formulation;
DRUGBANK
0.0
%
0
%
DRUGBANK
100.0
%
100
%
Unchanged drug;
DRUGBANK
10.0
L/h
10.0
L/h
Children;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
7.26
L/h
121.0
ml/min
Renal clearance; normal,healthy; adults; Male, men;
DRUGBANK
0.252
L/h/kg
4.2±2.2
ml/min/kg
apparent clearance;
Female, women → ;Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease ↓ ;
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
124.0
L
124.0
L
Apparent volume of distribution;
DRUGBANK
2.4
L/kg
2.4±1.4
L/kg
Apparent volume of distribution;
Elderly → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.89
L/kg
0.89
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.6
h
12.6
h
effective half-life;
DRUGBANK
46.7
h
46.7
h
terminal half-life;
DRUGBANK
12.0
h
12.0
h
effective half-life; at steady state; Multiple dose;
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
30.0
h
30.0
h
terminal half-life;
DRUGBANK
42.0
h
42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8500.0
mg/kg
>8500
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
9100.0
mg/kg
>9100
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
%
100
%
Urinary excretion;
DRUGBANK
94.0
%
88-100
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95±15
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.0
%
0
%
DRUGBANK
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
40.0
mg/day
40
mg/day
PO, oral
Qbrelis
lisinopril
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
40.0
mg/day
40
mg/day
PO, oral
Qbrelis
lisinopril
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
0.185
mg/kg/day
0.185
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
0.36
mg/kg/day
0.36
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
80.0
mg/day
80
mg/day
PO, oral
Qbrelis
lisinopril
PDR
40.0
mg/day
40
mg/day
PO, oral
Qbrelis
lisinopril
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
40.0
mg/day
40
mg/day
PO, oral
Qbrelis
lisinopril
PDR
80.0
mg/day
80
mg/day
PO, oral
Qbrelis
lisinopril
PDR
40.0
mg/day
40
mg/day
PO, oral
Qbrelis
lisinopril
PDR
0.36
mg/kg/day
0.36
mg/kg/day
PO, oral
Qbrelis
lisinopril
PDR
DDPD00723
Methoxamine
211.2576
C11H17NO3
COC1=CC(C(O)C(C)N)=C(OC)C=C1
DB00723
6082
6839
5857
-2.0
-
-2.0
-
DRUGBANK
DDPD00724
Imiquimod
240.3036
C14H16N4
CC(C)CN1C=NC2=C1C1=C(C=CC=C1)N=C2N
DB00724
57469
36704
http://www.drugs.com/cdi/imiquimod.html
51809
-2.0
-
-2.0
-
DRUGBANK
20.0
h
20
h
skin/dermal;
DRUGBANK
2.0
h
2
h
subcutaneous injection, SC;
DRUGBANK
2.0
packets/application
2
packets/application
skin ointment
Aldara
imiquimod
PDR
25.0
mg
25
mg
skin ointment
Aldara
imiquimod
PDR
1.0
packets/application
1
packets/application
skin ointment
Aldara
imiquimod
PDR
9.4
mg
9.4
mg
skin ointment
Aldara
imiquimod
PDR
1.0
pump actuation/application
1
pump actuation/application
skin ointment
Aldara
imiquimod
PDR
8.8
mg
8.8
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/appLication
2
packets/appLication
skin ointment
Aldara
imiquimod
PDR
25.0
mg
25
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/appLication
2
packets/appLication
skin ointment
Aldara
imiquimod
PDR
18.8
mg
18.8
mg
skin ointment
Aldara
imiquimod
PDR
2.0
pump actuation/appLication
2
pump actuation/appLication
skin ointment
Aldara
imiquimod
PDR
17.6
mg
17.6
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/appLication
2
packets/appLication
skin ointment
Aldara
imiquimod
PDR
12.5
mg
12.5
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/application
2
packets/application
skin ointment
Aldara
imiquimod
PDR
25.0
mg
25
mg
skin ointment
Aldara
imiquimod
PDR
1.0
packets/application
1
packets/application
skin ointment
Aldara
imiquimod
PDR
9.4
mg
9.4
mg
skin ointment
Aldara
imiquimod
PDR
1.0
pump actuation/application
1
pump actuation/application
skin ointment
Aldara
imiquimod
PDR
8.8
mg
8.8
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/application
2
packets/application
skin ointment
Aldara
imiquimod
PDR
25.0
mg
25
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/application
2
packets/application
skin ointment
Aldara
imiquimod
PDR
18.8
mg
18.8
mg
skin ointment
Aldara
imiquimod
PDR
2.0
pump actuation/application
2
pump actuation/application
skin ointment
Aldara
imiquimod
PDR
17.6
mg
17.6
mg
skin ointment
Aldara
imiquimod
PDR
2.0
packets/application
2
packets/application
skin ointment
Aldara
imiquimod
PDR
12.5
mg
12.5
mg
skin ointment
Aldara
imiquimod
PDR
DDPD00725
Homatropine methylbromide
370.281
C17H24BrNO3
[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1
DB00725
6646
50373
http://www.drugs.com/cdi/homatropine-drops.html
6394
-2.0
-
-2.0
-
DRUGBANK
DDPD00726
Trimipramine
294.4338
C20H26N2
CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12
DB00726
T3D2870
5584
9738
http://www.drugs.com/cdi/trimipramine.html
5382
-2.0
-
-2.0
-
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
L/kg
16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.5
h
11-18
h
DRUGBANK
23.0
h
23
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.5
%
93-96
%
plasma proteins;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Surmontil
trimipramine maleate
PDR
300.0
mg/day
300
mg/day
PO, oral
Surmontil
trimipramine maleate
PDR
100.0
mg/day
100
mg/day
PO, oral
Surmontil
trimipramine maleate
PDR
100.0
mg/day
100
mg/day
PO, oral
Surmontil
trimipramine maleate
PDR
DDPD00727
Nitroglycerin
227.0865
C3H5N3O9
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
DB00727
4510
28787
http://www.drugs.com/cdi/nitroglycerin.html
4354
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
sublingual;
DRUGBANK
1.0
%
<1
%
PO, oral;
DRUGBANK
38.0
%
38±26
%
sublingual;
DRUGBANK
72.0
%
72±20
%
skin/dermal;
DRUGBANK
2.56
ng/ml
2.56
ng/ml
sublingual;
DRUGBANK
2.1
ng/ml
2.1
ng/ml
sublingual;
DRUGBANK
1.9
ng/ml
1.9±1.6
ng/ml
sublingual;
DRUGBANK
3.4
ng/ml
3.4±1.7
ng/ml
intravenous injection, IV;
DRUGBANK
0.0733333333333333
h
4.4
min
sublingual;
DRUGBANK
0.12
h
7.2
min
sublingual;
DRUGBANK
0.09
h
0.09±0.03
h
sublingual;
DRUGBANK
3.5
h
3-4
h
skin/dermal;
DRUGBANK
2.0
h
2.0
h
Transdermal preparations;
DRUGBANK
60.0
L/h/kg
1.0
L/kg/min
intravenous injection, IV;
DRUGBANK
1314.0
L/h
21.9
L/min
sublingual; heart disease;
DRUGBANK
11.7
L/h/kg
195±86
ml/min/kg
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
11.658
L/h/kg
194.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.61
L/kg
3.0
L/kg
DRUGBANK
3.3
L/kg
3.3±1.2
L/kg
Apparent volume of distribution; intravenous injection, IV; normal,healthy; adults;
DRUGBANK
0.0466666666666667
h
2.8±0.9
min
elimination half-life; intravenous injection, IV;
DRUGBANK
0.1
h
~6
min
elimination half-life; Intraperitoneal, IP;
DRUGBANK
0.483333333333333
h
32-26
min
elimination half-life;
DRUGBANK
0.0383333333333333
h
2.3±0.6
min
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
105.0
mg/kg
105.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
23.2
mg/kg
23.2
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
60.0
%
~60
%
DRUGBANK
5.0
mcg/kg/min
5
mcg/kg/min
Nitroglycerin in 5% Dextrose
nitroglycerin
PDR
20.0
mcg/kg/min
20
mcg/kg/min
intravenous injection, IV
Nitroglycerin in 5% Dextrose
nitroglycerin
PDR
DDPD00728
Rocuronium
529.7742
C32H53N2O4
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1
DB00728
441290
8884
http://www.drugs.com/cdi/rocuronium.html
390053
-2.0
-
-2.0
-
DRUGBANK
1100.0
ng/ml
0.8-1.4
mcg/ml
intravenous injection, IV;
DRUGBANK
0.25
L/h/kg
0.25
L/kg/h
adults;
DRUGBANK
0.21
L/h/kg
0.21
L/kg/h
Elderly;
DRUGBANK
0.16
L/h/kg
0.16
L/kg/h
normal,healthy;
DRUGBANK
0.13
L/h/kg
0.13
L/kg/h
organ transplants;
DRUGBANK
0.13
L/h/kg
0.13
L/kg/h
hepatopathy，LD;
DRUGBANK
0.35
L/h/kg
0.35±0.08
L/kg/h
pediatric patients; Infants;
DRUGBANK
0.38
L/h/kg
0.32-0.44
L/kg/h
pediatric patients; Children;
DRUGBANK
0.255
L/h/kg
3.3-5.2
ml/min/kg
Average clearance; Bile excretion;
Children ↑ ;hepatopathy，LD → ;
DRUGBANK
0.222
L/h/kg
3.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
L/kg
0.3
L/kg
Infants;
DRUGBANK
0.235
L/kg
0.21-0.26
L/kg
Children;
DRUGBANK
0.25
L/kg
0.19-0.31
L/kg
Average volume of distribution; Bile excretion;
hepatopathy，LD ↑ ;
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.025
h
1-2
min
rapid distribution half-life;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.266666666666667
h
14-18
min
rapid distribution half-life;
DRUGBANK
0.291666666666667
h
~15-20
min
hepatopathy，LD;
DRUGBANK
1.7
h
1.2-2.2
h
different study;
Children ↓ ;chronic liver disease ↑ ;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
%
12-22
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
~30
%
plasma proteins; human, homo sapiens;
DRUGBANK
25.0
%
25
%
DRUGBANK
DDPD00730
Thiabendazole
201.248
C10H7N3S
N1C2=CC=CC=C2N=C1C1=CSC=N1
DB00730
T3D3931
5430
45979
http://www.drugs.com/cdi/thiabendazole.html
5237
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
100.0
%
~100
%
Liver metabolism;
DRUGBANK
1.2
h
1.2(0.9-2)
h
normal,healthy;
DRUGBANK
1.2
h
1.2(0.9-2)
h
anephric;
DRUGBANK
1.7
h
1.7(1.4-2)
h
normal,healthy;
DRUGBANK
1.7
h
1.7(1.4-2)
h
anephric;
DRUGBANK
3600.0
mg/kg
3.6
g/kg
PO, oral; mouse;
DRUGBANK
3100.0
mg/kg
3.1
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
3800.0
mg/kg
3.8
g/kg
PO, oral; rabbit;
DRUGBANK
3600.0
mg/kg
3.6
g/kg
PO, oral; mouse;
DRUGBANK
3100.0
mg/kg
3.1
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
3800.0
mg/kg
3.8
g/kg
PO, oral; rabbit;
DRUGBANK
DDPD00731
Nateglinide
317.429
C19H27NO3
CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O
DB00731
5311309
31897
http://www.drugs.com/cdi/nateglinide.html
10482084
-2.0
-
-2.0
-
DRUGBANK
73.0
%
73
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
0.108
L/h/kg
1.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
L
10.0
L
normal,healthy;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5
h
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
83.0
%
83
%
Urinary excretion;
DRUGBANK
10.0
%
10
%
Faeces excretion;
DRUGBANK
98.0
%
98
%
DRUGBANK
360.0
mg/day
360
mg/day
PO, oral
Starlix
nateglinide
PDR
360.0
mg/day
360
mg/day
PO, oral
Starlix
nateglinide
PDR
DDPD00732
Atracurium besylate
1243.49
C65H82N2O18S2
[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2
DB00732
47320
2915
43068
-2.0
-
-2.0
-
DRUGBANK
0.333333333333333
h
~20
min
elimination half-life;
DRUGBANK
DDPD00733
Pralidoxime
137.1592
C7H9N2O
C[N+]1=C(\C=N\O)C=CC=C1
DB00733
5353894
8354
http://www.drugs.com/mtm/pralidoxime-injection.html
5193737
-2.0
-
-2.0
-
DRUGBANK
0.54
L/h/kg
9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.8
L/kg
0.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.25833333333333
h
74-77
min
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
mg/kg/dose
50
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Protopam Chloride
pralidoxime chloride
PDR
2000.0
mg/dose
2
g/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Protopam Chloride
pralidoxime chloride
PDR
2000.0
mg/dose
2
g/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Protopam Chloride
pralidoxime chloride
PDR
50.0
mg/kg/dose
50
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Protopam Chloride
pralidoxime chloride
PDR
2000.0
mg/dose
2
g/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Protopam Chloride
pralidoxime chloride
PDR
2.0
g/dose
2
g/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Protopam Chloride
pralidoxime chloride
PDR
DDPD00734
Risperidone
410.4845
C23H27FN4O2
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
DB00734
T3D2871
5073
8871
http://www.drugs.com/risperidone.html
4895
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
PO, oral;
DRUGBANK
66.0
%
66±28
%
PO, oral;
DRUGBANK
103.0
%
103±13
%
IM,intramuscular injection;
DRUGBANK
10.0
ng/ml
10.0
ng/ml
PO, oral; schizophrenia;
DRUGBANK
45.0
ng/ml
45.0
ng/ml
PO, oral; Active metabolite; schizophrenia;
DRUGBANK
1.0
h
~1
h
PO, oral; schizophrenia;
DRUGBANK
2.22
L/h
15-59
ml/min
Renal clearance; Elderly; Renal metabolism;
Age ↓ ;
DRUGBANK
0.324
L/h/kg
5.4±1.4
ml/min/kg
hydrolysis;
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.324
L/h/kg
5.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
~1.0-2.0
L/kg
DRUGBANK
1.1
L/kg
1.1±0.2
L/kg
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3
h
extensive metabolizers, EM;
DRUGBANK
20.0
h
20
h
poor metabolizers, PM;
DRUGBANK
3.2
h
3.2±0.8
h
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
20.0
h
20±3
h
Active metabolite;
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
3.2
h
3.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
57.7
mg/kg
57.7
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
34.0
mg/kg
34.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
82.1
mg/kg
82.1
mg/kg
PO, oral; mouse;
DRUGBANK
3.0
%
3±2
%
Urinary excretion; Unchanged drug;
DRUGBANK
88.0
%
88
%
plasma proteins; human, homo sapiens;
DRUGBANK
89.0
%
89
%
Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
6.0
mg/day
6
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
3.0
mg/day
3
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
0.06
mg/kg/day
0.06
mg/kg/day
PO, oral
Risperdal Consta
risperidone
PDR
3.0
mg/day
3
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
0.06
mg/kg/day
0.06
mg/kg/day
PO, oral
Risperdal Consta
risperidone
PDR
16.0
mg/day
16
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
6.0
mg/day
6
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
3.57142857142857
mg/day
50
mg/dose
IM,intramuscular injection
q2w
Risperdal Consta
risperidone
PDR
4.0
mg/day
120
mg/dose
subcutaneous injection, SC; once monthly
Risperdal Consta
risperidone
PDR
6.0
mg/day
6
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
3.0
mg/day
3
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
0.06
mg/kg/day
0.06
mg/kg/day
PO, oral
Risperdal Consta
risperidone
PDR
16.0
mg/day
16
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
6.0
mg/day
6
mg/day
PO, oral
Risperdal Consta
risperidone
PDR
3.57142857142857
mg/day
50
mg/dose
IM,intramuscular injection
q2w
Risperdal Consta
risperidone
PDR
40.0
mg/day
120
mg/dose
subcutaneous injection, SC; nan
qm
Risperdal Consta
risperidone
PDR
DDPD00735
Naftifine
287.3981
C21H21N
CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12
DB00735
73342
7451
http://www.drugs.com/cdi/naftifine-cream.html
43344
-2.0
-
-2.0
-
DRUGBANK
60.0
h
~2-3
day
skin/dermal;
DRUGBANK
DDPD00736
Esomeprazole
345.416
C17H19N3O3S
COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
DB00736
T3D2873
9568614
50275
http://www.drugs.com/cdi/esomeprazole.html
7843323
-2.0
-
-2.0
-
DRUGBANK
3868.6592
ng.h/ml
11.2
umol.h/L
Oral multiple dose;
DRUGBANK
1492.19712
ng.h/ml
4.32
umol.h/L
Oral single dose;
DRUGBANK
90.0
%
90
%
Oral multiple dose;
DRUGBANK
64.0
%
64
%
Oral single dose;
DRUGBANK
89.0
%
89（81-98）
%
PO, oral; Optical rotation S;
DRUGBANK
53.0
%
53±29
%
PO, oral; Raceme D/L;
DRUGBANK
1554372.0
ng/ml
4.5(3.8-5.7)
mM
PO, oral; normal,healthy;
DRUGBANK
234882.88
ng/ml
0.68±0.43
mM
PO, oral; normal,healthy; extensive metabolizers, EM;
DRUGBANK
1208956.0
ng/ml
3.5±1.4
mM
PO, oral; normal,healthy; poor metabolizers, PM;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
1.5
h
1.5(1.3-1.7)
h
PO, oral; normal,healthy;
DRUGBANK
1.0
h
~1
h
PO, oral; normal,healthy; extensive metabolizers, EM;
DRUGBANK
3.5
h
~3-4
h
PO, oral; normal,healthy; poor metabolizers, PM;
DRUGBANK
0.246
L/h/kg
4.1(3.3-5.0)
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.45
L/h/kg
7.5±2.7
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.231
L/h/kg
3.85
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
L
16.0
L
Apparent volume of distribution; normal,healthy;
DRUGBANK
0.25
L/kg
0.25(0.23-0.27)
L/kg
DRUGBANK
0.34
L/kg
0.34±0.09
L/kg
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.25
h
1-1.5
h
DRUGBANK
0.9
h
0.9(0.7-1.0)
h
DRUGBANK
0.7
h
0.7±0.5
h
sever hepatic insufficiency ↑ ;
DRUGBANK
0.83
h
0.83
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Optical rotation S; Raceme D/L; Unchanged drug;
DRUGBANK
97.0
%
97
%
plasma proteins;
DRUGBANK
96.0
%
95-97
%
Optical rotation S; Raceme D/L;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/dose
80
mg/dose
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
240.0
mg/day
240
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
40.0
mg/day
40
mg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
80.0
mg/dose
80
mg/dose
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
240.0
mg/day
240
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
1.33
mg/kg/day
1.33
mg/kg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
0.5
mg/kg/day
0.5
mg/kg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
10.0
mg/day
10
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
0.5
mg/kg/day
0.5
mg/kg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
5.0
mg/day
5
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
0.5
mg/kg/day
0.5
mg/kg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Nexium I.V.
esomeprazole sodium
PDR
0.5
mg/kg/day
0.5
mg/kg/day
intravenous injection, IV
Nexium I.V.
esomeprazole sodium
PDR
0.5
mg/kg/day
0.5
mg/kg/day
PO, oral;intravenous injection, IV;
Nexium I.V.
esomeprazole sodium
PDR
DDPD00737
Meclizine
390.948
C25H27ClN2
CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1
DB00737
T3D2874
4034
6709
http://www.drugs.com/meclizine.html
3894
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3(1.5-6)
h
PO, oral;
DRUGBANK
5.5
h
~5-6
h
elimination half-life;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; mouse;
DRUGBANK
625.0
mg/kg
625.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral;
DRUGBANK
659.0
mg/kg
659.0
mg/kg
Intraperitoneal, IP;
DRUGBANK
800.0
mg/kg
800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Antivert
meclizine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Antivert
meclizine hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Antivert
meclizine hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Antivert
meclizine hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Antivert
meclizine hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Antivert
meclizine hydrochloride
PDR
DDPD00738
Pentamidine
340.4195
C19H24N4O2
NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
DB00738
T3D3526
4735
45081
http://www.drugs.com/cdi/pentamidine.html
4573
-2.0
-
-2.0
-
DRUGBANK
4.44
L/h/kg
74
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
53.0
L/kg
53
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.15
h
9.1-13.2
h
DRUGBANK
25.0
h
25
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
69.0
%
69
%
DRUGBANK
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
300.0
mg/dose
300
mg/dose
intravenous injection, IV;IM,intramuscular injection;
q4w
NebuPent
pentamidine isethionate
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
300.0
mg/dose
300
mg/dose
intravenous injection, IV;IM,intramuscular injection;
q4w
NebuPent
pentamidine isethionate
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
10.7142857142857
mg/day
300
mg/dose
intravenous injection, IV;IM,intramuscular injection;
q4w
NebuPent
pentamidine isethionate
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
300.0
mg/dose
300
mg/dose
intravenous injection, IV;IM,intramuscular injection;
q4w
NebuPent
pentamidine isethionate
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
300.0
mg/dose
300
mg/dose
intravenous injection, IV;IM,intramuscular injection;
q4w
NebuPent
pentamidine isethionate
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
10.7142857142857
mg/dose
300
mg/dose
intravenous injection, IV;IM,intramuscular injection;
q4w
NebuPent
pentamidine isethionate
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
NebuPent
pentamidine isethionate
PDR
DDPD00739
Hetacillin
389.469
C19H23N3O4S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2N1C(=O)[C@H](NC1(C)C)C1=CC=CC=C1)C(O)=O
DB00739
443387
5683
391616
-2.0
-
-2.0
-
DRUGBANK
DDPD00740
Riluzole
234.198
C8H5F3N2OS
NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2
DB00740
T3D2875
5070
8863
http://www.drugs.com/cdi/riluzole.html
4892
-2.0
-
-2.0
-
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
64.0
%
64(30-100)
%
PO, oral;
DRUGBANK
173.0
ng/ml
173±72
ng/ml
PO, oral;
DRUGBANK
0.8
h
0.8±0.5
h
PO, oral;
DRUGBANK
0.33
L/h/kg
5.5±0.9
ml/min/kg
hydrolysis;
hepatopathy，LD ↓ ;
DRUGBANK
0.678
L/h/kg
11.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.4
L/kg
3.4±0.6
L/kg
hydrolysis;
DRUGBANK
3.5
L/kg
3.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
elimination half-life; skin/dermal;
DRUGBANK
14.0
h
14±6
h
DRUGBANK
85.0
mg/kg
85.0
mg/kg
PO, oral; mouse;
DRUGBANK
34.5
mg/kg
34.5
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
45.0
mg/kg
45.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
21.0
mg/kg
21.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
96.0
%
96
%
plasma proteins;
DRUGBANK
98.0
%
98
%
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Rilutek
riluzole
PDR
200.0
mg/day
200
mg/day
PO, oral
Rilutek
riluzole
PDR
100.0
mg/day
100
mg/day
PO, oral
Rilutek
riluzole
PDR
200.0
mg/day
200
mg/day
PO, oral
Rilutek
riluzole
PDR
DDPD00741
Hydrocortisone
362.4599
C21H30O5
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB00741
5754
17650
http://www.drugs.com/cdi/hydrocortisone.html
5551
-2.0
-
-2.0
-
DRUGBANK
32.849740737
ng.h/ml
90.63
nmol.h/L
PO, oral;
DRUGBANK
72.16576609
ng.h/ml
199.1
nmol.h/L
PO, oral;
DRUGBANK
1163.0
ng.h/ml
1163±277
ng.h/ml
intravenous injection, IV;
DRUGBANK
11.5
%
4-19
%
skin/dermal;
DRUGBANK
50.2
%
50.2
%
Rectal Administration; immediate release formulation;
DRUGBANK
81.0
%
81
%
Rectal Administration; extended release formulation;
DRUGBANK
11.848814131
ng/ml
32.69
nmol/L
PO, oral;
DRUGBANK
25.665785519
ng/ml
70.81
nmol/L
PO, oral;
DRUGBANK
24.0
h
24
h
skin/dermal;
DRUGBANK
12.85
L/h
12.85
L/h
Average clearance; PO, oral;
DRUGBANK
18.2
L/h
18.2±4.2
L/h
intravenous injection, IV;
DRUGBANK
0.342
L/h/kg
5.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39.82
L
39.82
L
Total volume of distribution;
DRUGBANK
474.38
L
474.38
L
Total volume of distribution;
DRUGBANK
0.38
L/kg
0.38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.15
h
2.15
h
PO, oral;
DRUGBANK
1.39
h
1.39
h
DRUGBANK
1.9
h
1.9±0.4
h
terminal half-life; intravenous injection, IV;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.1
%
90.1
%
plasma proteins;
DRUGBANK
56.2
%
56.2
%
DRUGBANK
DDPD00742
Mannitol
182.1718
C6H14O6
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
DB00742
6251
16899
http://www.drugs.com/cdi/mannitol.html
6015
-2.0
-
-2.0
-
DRUGBANK
7.0
%
7
%
Rectal Administration; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.66666666666667
h
100
min
DRUGBANK
4.7
h
4.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1700.0
mg/kg
1700.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00743
Gadobenic acid
667.73
C22H28GdN3O11
[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O
DB00743
131704172
94843
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
0.093
L/h/kg
0.093±0.010
l/h/kg
intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
1.0
h
1
h
DRUGBANK
87.0
%
78-96
%
Urinary excretion;
DRUGBANK
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.2
ml/kg/dose
0.2
mL/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Multihance Injection Vials
gadobenate dimeglumine
PDR
DDPD00744
Zileuton
236.29
C11H12N2O2S
CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
DB00744
60490
10112
http://www.drugs.com/cdi/zileuton.html
54531
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
0.42
L/h/kg
7.0
ml/min/kg
Total clearance; PO, oral;
DRUGBANK
1.2
L/kg
1.2
L/kg
DRUGBANK
2.5
h
2.5
h
DRUGBANK
0.5
%
<0.5
%
Urinary excretion; Unchanged drug;
DRUGBANK
93.0
%
93
%
plasma proteins;
DRUGBANK
2400.0
mg/day
2400
mg/day
PO, oral
Zyflo
zileuton
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Zyflo
zileuton
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Zyflo
zileuton
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Zyflo
zileuton
PDR
DDPD00745
Modafinil
273.35
C15H15NO2S
NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1
DB00745
T3D2876
4236
77585
http://www.drugs.com/cdi/modafinil.html
4088
-2.0
-
-2.0
-
DRUGBANK
0.9
L/kg
0.9
L/kg
DRUGBANK
119.0
h
23-215
h
DRUGBANK
60.0
%
60
%
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Provigil
modafinil
PDR
400.0
mg/day
400
mg/day
PO, oral
Provigil
modafinil
PDR
400.0
mg/day
400
mg/day
PO, oral
Provigil
modafinil
PDR
DDPD00746
Deferoxamine
560.684
C25H48N6O8
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
DB00746
2973
4356
http://www.drugs.com/cdi/deferoxamine.html
2867
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
elimination half-life; normal,healthy;
DRUGBANK
6.0
h
6
h
terminal half-life; normal,healthy;
DRUGBANK
340.0
mg/kg
340.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
520.0
mg/kg
520.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
PO, oral; mouse;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
%
<10
%
high protein binding;
DRUGBANK
DDPD00747
Scopolamine
303.3529
C17H21NO4
CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
DB00747
T3D2877
3000322
16794
http://www.drugs.com/cdi/scopolamine-drops.html
10194106
-2.0
-
-2.0
-
DRUGBANK
30.0
%
10-50
%
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.1
L/kg
3.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
h
4.5
h
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
>10
%
Urinary excretion;
DRUGBANK
0.6
mg/dose
0.6
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
3.0
drop/day
3
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
0.3
mg/dose
0.3
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
3.0
drop/day
3
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
0.15
mg/dose
0.15
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
3.0
drop/day
3
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
2.4
mg/dose
2.4
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
8.0
drop/day
8
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
1.0
patch/dose
1
patch/dose
Transdermal preparations
q3d
Scopolamine
scopolamine
PDR
0.6
mg/dose
0.6
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
3.0
drop/day
3
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
2.4
mg/dose
2.4
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
8.0
drop/day
8
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
1.0
patch/dose
1
patch/dose
Transdermal preparations
q3d
Scopolamine
scopolamine
PDR
0.15
mg/dose
0.15
mg/dose
subcutaneous injection, SC;intravenous injection, IV;IM,intramuscular injection;
Scopolamine
scopolamine
PDR
3.0
drop/day
3
drop/day
Vaginal Administration
Scopolamine
scopolamine
PDR
DDPD00748
Carbinoxamine
290.788
C16H19ClN2O
CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
DB00748
T3D4553
2564
3398
http://www.drugs.com/cdi/carbinoxamine-maleate.html
2466
-2.0
-
-2.0
-
DRUGBANK
15.0
h
10-20
h
DRUGBANK
32.0
mg/day
32
mg/day
Tablet,PO，oral
Carbinoxamine Maleate
carbinoxamine maleate
PDR
32.0
mg/day
32
mg/day
Liquid
Carbinoxamine Maleate
carbinoxamine maleate
PDR
32.0
mg/day
32
mg/day
Tablet,PO，oral
Carbinoxamine Maleate
carbinoxamine maleate
PDR
32.0
mg/day
32
mg/day
Liquid
Carbinoxamine Maleate
carbinoxamine maleate
PDR
24.0
mg/day
24
mg/day
Tablet,PO，oral
Carbinoxamine Maleate
carbinoxamine maleate
PDR
32.0
mg/day
32
mg/day
Tablet,PO，oral
Carbinoxamine Maleate
carbinoxamine maleate
PDR
32.0
mg/day
32
mg/day
Liquid
Carbinoxamine Maleate
carbinoxamine maleate
PDR
24.0
mg/day
24
mg/day
Tablet,PO，oral
Carbinoxamine Maleate
carbinoxamine maleate
PDR
DDPD00749
Etodolac
287.3535
C17H21NO3
CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1
DB00749
3308
4909
http://www.drugs.com/etodolac.html
3192
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
Tablet, PO, oral; Capsule, PO, Oral;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
13.0
%
13
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion;
DRUGBANK
20.0
%
20
%
Urinary excretion;
DRUGBANK
16.0
%
16
%
Faeces excretion;
DRUGBANK
2.946
L/h/kg
49.1
ml/min/kg
Total clearance; PO, oral; normal,healthy; adults;
DRUGBANK
2.964
L/h/kg
49.4
ml/min/kg
normal,healthy; Male, men;
DRUGBANK
2.142
L/h/kg
35.7
ml/min/kg
normal,healthy; Female, women;
DRUGBANK
2.742
L/h/kg
45.7
ml/min/kg
Elderly;
DRUGBANK
3.498
L/h/kg
58.3
ml/min/kg
RD, renal impairment, Renal disease，including uremia;
DRUGBANK
2.52
L/h/kg
42.0
ml/min/kg
hepatopathy，LD;
DRUGBANK
0.39
L/kg
390.0
mL/kg
DRUGBANK
7.3
h
7.3±4
h
terminal half-life;
DRUGBANK
0.71
h
0.71±0.5
h
distribution half-life;
DRUGBANK
16.0
%
16
%
Faeces excretion;
DRUGBANK
72.0
%
72
%
Urinary excretion;
DRUGBANK
1.0
%
~1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
400.0
mg/day
400
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
800.0
mg/day
800
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
1000.0
mg/day
1000
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Etodolac Capsules and Tablets
etodolac
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
800.0
mg/day
800
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
1000.0
mg/day
1000
mg/day
Tablet,PO，oral
Etodolac Capsules and Tablets
etodolac
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Etodolac Capsules and Tablets
etodolac
PDR
DDPD00750
Prilocaine
220.3107
C13H20N2O
CCCNC(C)C(=O)NC1=CC=CC=C1C
DB00750
4906
8404
4737
-2.0
-
-2.0
-
DRUGBANK
1.74
L/h/kg
29
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.7
L/kg
3.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD00751
Epinastine
249.3104
C16H15N3
NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21
DB00751
3241
51032
http://www.drugs.com/cdi/epinastine.html
3128
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
DRUGBANK
10.0
%
<10
%
DRUGBANK
56.0
L/h
56.0
L/h
allergic conjunctivitis; patients; ophthalmic administration;
DRUGBANK
12.0
h
12
h
DRUGBANK
64.0
%
64
%
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Elestat
epinastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Elestat
epinastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Elestat
epinastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Elestat
epinastine hydrochloride
PDR
DDPD00752
Tranylcypromine
133.194
C9H11N
NC1CC1C1=CC=CC=C1
DB00752
T3D2881
5530
131512
http://www.drugs.com/cdi/tranylcypromine.html
5329
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
3.4
L/kg
1.1-5.7
L/kg
DRUGBANK
2.35
h
1.5-3.2
h
normal renal function; normal hepatic function; patients;
DRUGBANK
DDPD00753
Isoflurane
184.492
C3H2ClF5O
FC(F)OC(Cl)C(F)(F)F
DB00753
T3D2882
3763
6015
3631
-2.0
-
-2.0
-
DRUGBANK
DDPD00754
Ethotoin
204.2252
C11H12N2O2
CCN1C(=O)NC(C1=O)C1=CC=CC=C1
DB00754
T3D2883
3292
4888
http://www.drugs.com/cdi/ethotoin.html
3176
-2.0
-
-2.0
-
DRUGBANK
6.0
h
3-9
h
DRUGBANK
DDPD00755
Tretinoin
300.442
C20H28O2
C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O
DB00755
T3D2884
5538
15367
http://www.drugs.com/cdi/tretinoin.html
392618
-2.0
-
-2.0
-
DRUGBANK
16.0
%
1-31
%
skin/dermal;
DRUGBANK
1.25
h
0.5-2
h
DRUGBANK
95.0
%
>95
%
DRUGBANK
45.0
mg/m2/day
45
mg/m2/day
PO, oral
Avita Cream
tretinoin
PDR
45.0
mg/m2/day
45
mg/m2/day
PO, oral
Avita Cream
tretinoin
PDR
45.0
mg/m2/day
45
mg/m2/day
PO, oral
Avita Cream
tretinoin
PDR
45.0
mg/m2/day
45
mg/m2/day
PO, oral
Avita Cream
tretinoin
PDR
DDPD00756
Hexachlorophene
406.904
C13H6Cl6O2
OC1=C(CC2=C(O)C(Cl)=CC(Cl)=C2Cl)C(Cl)=C(Cl)C=C1Cl
DB00756
3598
5693
http://www.drugs.com/cdi/hexachlorophene.html
3472
-2.0
-
-2.0
-
DRUGBANK
92.0
%
92
%
DRUGBANK
DDPD00757
Dolasetron
324.38
C19H20N2O3
[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2
DB00757
3033818
http://www.drugs.com/cdi/dolasetron.html
30845229
-2.0
-
-2.0
-
DRUGBANK
0.564
L/h/kg
9.4
ml/min/kg
Total clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
10.8
L/h/kg
180
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.8
L/kg
5.8
L/kg
adults;
DRUGBANK
2.0
L/kg
2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.1
h
8.1
h
DRUGBANK
0.13
h
0.13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
73.0
%
69-77
%
DRUGBANK
1.8
mg/kg
1.8
mg/kg
PO, oral
Anzemet Injection
dolasetron mesylate
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Anzemet Injection
dolasetron mesylate
PDR
0.35
mg/kg
0.35
mg/kg
intravenous injection, IV
Anzemet Injection
dolasetron mesylate
PDR
12.5
mg/dose
12.5
mg/dose
intravenous injection, IV
Anzemet Injection
dolasetron mesylate
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Anzemet Injection
dolasetron mesylate
PDR
12.5
mg/dose
12.5
mg/dose
intravenous injection, IV
Anzemet Injection
dolasetron mesylate
PDR
1.8
mg/kg
1.8
mg/kg
PO, oral
Anzemet Injection
dolasetron mesylate
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Anzemet Injection
dolasetron mesylate
PDR
0.35
mg/kg
0.35
mg/kg
intravenous injection, IV
Anzemet Injection
dolasetron mesylate
PDR
12.5
mg/dose
12.5
mg/dose
intravenous injection, IV
Anzemet Injection
dolasetron mesylate
PDR
100.0
mg/dose
100
mg/dose
PO, oral
Anzemet Injection
dolasetron mesylate
PDR
12.5
mg/dose
12.5
mg/dose
intravenous injection, IV
Anzemet Injection
dolasetron mesylate
PDR
DDPD00758
Clopidogrel
321.822
C16H16ClNO2S
[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
DB00758
60606
37941
http://www.drugs.com/cdi/clopidogrel.html
54632
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral;
DRUGBANK
45.1
ng.h/ml
45.1±16.2
ng.h/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
104.3
ng.h/ml
104.3±57.3
ng.h/ml
PO, oral; high-fat meal;
DRUGBANK
2.01
ng/ml
2.01±2.0
ng/ml
PO, oral;
DRUGBANK
31.3
ng/ml
31.3±13
ng/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
60.8
ng/ml
60.8±34.3
ng/ml
PO, oral; high-fat meal;
DRUGBANK
0.75
h
0.5-1
h
PO, oral; Active metabolite;
DRUGBANK
1.4
h
1.40±1.07
h
PO, oral;
DRUGBANK
85.0
%
80-90
%
Liver metabolism; PO, oral; Inactive metabolite;
DRUGBANK
18960.0
L/h
18960±15890
L/h
PO, oral;
DRUGBANK
16980.0
L/h
16980±10410
L/h
PO, oral;
DRUGBANK
1.419
L/h/kg
23.65
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39240.0
L
39240±33520
L
Apparent volume of distribution;
DRUGBANK
2.01
L/kg
2.01
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
~6
h
PO, oral;
DRUGBANK
0.5
h
~30
min
Active metabolite;
DRUGBANK
5.06
h
5.06
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
50
%
Urinary excretion; PO, oral;
DRUGBANK
46.0
%
46
%
Faeces excretion; PO, oral;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
78.25
%
71-85.5
%
cow;
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
75.0
mg/day
75
mg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
75.0
mg/day
75
mg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
600.0
mg
600
mg
PO, oral
Plavix
clopidogrel bisulfate
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
75.0
mg/day
75
mg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
75.0
mg/day
75
mg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
600.0
mg
600
mg
PO, oral
Plavix
clopidogrel bisulfate
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Plavix
clopidogrel bisulfate
PDR
DDPD00759
Tetracycline
444.4346
C22H24N2O8
[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
DB00759
T3D3955
54675776
27902
http://www.drugs.com/tetracycline.html
10257122
-2.0
-
-2.0
-
DRUGBANK
40.0
%
<40
%
IM,intramuscular injection; fasting; adults;
DRUGBANK
100.0
%
100
%
intravenous injection, IV; fasting; adults;
DRUGBANK
70.0
%
60-80
%
PO, oral; fasting; adults;
DRUGBANK
77.0
%
77.0
%
PO, oral;
DRUGBANK
2300.0
ng/ml
2.3±0.2
mcg/ml
PO, oral; fasting;
DRUGBANK
16400.0
ng/ml
16.4±1.2
mcg/ml
intravenous injection, IV;
DRUGBANK
4.0
h
4.0
h
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.1002
L/h/kg
1.67±0.24
ml/min/kg
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.5±0.1
L/kg
Apparent volume of distribution;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
6-12
h
DRUGBANK
10.6
h
10.6±1.5
h
DRUGBANK
9.4
h
9.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
808.0
mg/kg
808.0
mg/kg
PO, oral; mouse;
DRUGBANK
808.0
mg/kg
808.0
mg/kg
PO, oral; mouse;
DRUGBANK
58.0
%
58±8
%
Urinary excretion; Unchanged drug;
DRUGBANK
43.5
%
20-67
%
DRUGBANK
65.0
%
65±3
%
DRUGBANK
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
4000.0
mg/day
4
g/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
2000.0
mg/day
2
g/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
4000.0
mg/day
4
g/day
PO, oral
Tetracycline Hydrochloride Capsules
tetracycline hydrochloride
PDR
DDPD00760
Meropenem
383.463
C17H25N3O5S
[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H]
DB00760
441130
43968
http://www.drugs.com/cdi/meropenem.html
389924
-2.0
-
-2.0
-
DRUGBANK
0.234
L/h/kg
3.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
L/kg
0.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
Children; Adolescents; adults;
DRUGBANK
1.5
h
~1.5
h
Infants;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.0
%
~70
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
2.0
%
~2
%
DRUGBANK
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
2000.0
mg
2
g
intravenous injection, IV
q8h
Merrem
meropenem
PDR
1000.0
mg
1
g
intravenous injection, IV
q8h
Merrem
meropenem
PDR
2000.0
mg
2
g
intravenous injection, IV
q8h
Merrem
meropenem
PDR
40.0
mg/kg/dose
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
6000.0
mg
2
g
intravenous injection, IV
q8h
Merrem
meropenem
PDR
1000.0
mg
1
g
intravenous injection, IV
q8h
Merrem
meropenem
PDR
2000.0
mg
2
g
intravenous injection, IV
q8h
Merrem
meropenem
PDR
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
90.0
mg/kg/day
30
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
90.0
mg/kg/day
30
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
60.0
mg/kg/day
20
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
60.0
mg/kg/day
20
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
40.0
mg/kg/day
20
mg/kg/dose
intravenous injection, IV
q12h
Merrem
meropenem
PDR
120.0
mg/kg/day
40
mg/kg/dose
intravenous injection, IV
q8h
Merrem
meropenem
PDR
DDPD00761
Potassium chloride
74.551
ClK
[Cl-].[K+]
DB00761
T3D4731
4873
32588
http://www.drugs.com/potassium_chloride.html
4707
-2.0
-
-2.0
-
DRUGBANK
2.0
tabLets/day
2
tabLets/day
PO, oral
K-Tab
potassium chloride
PDR
2.0
tablets/day
2
tablets/day
PO, oral
K-Tab
potassium chloride
PDR
DDPD00762
Irinotecan
586.678
C33H38N4O6
CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
DB00762
60838
80630
http://www.drugs.com/cdi/irinotecan.html
54825
-2.0
-
-2.0
-
DRUGBANK
10200.0
ng.h/ml
10200.0
ng.h/ml
tumor;
DRUGBANK
20604.0
ng.h/ml
20604.0
ng.h/ml
tumor;
DRUGBANK
1660.0
ng/ml
1660.0
ng/ml
tumor;
DRUGBANK
3392.0
ng/ml
3392.0
ng/ml
tumor;
DRUGBANK
1700.0
ng/ml
1.7±0.8
mcg/ml
intravenous infusion, IV in drop; solid tumors;
DRUGBANK
26.0
ng/ml
26±12
ng/ml
intravenous infusion, IV in drop; Active metabolite; solid tumors;
DRUGBANK
0.5
h
0.5
h
intravenous infusion, IV in drop; solid tumors;
DRUGBANK
1.0
h
≤1
h
intravenous infusion, IV in drop; Active metabolite; solid tumors;
DRUGBANK
13.3
L/h/m2
13.3
L/h/m2
tumor; patients;
DRUGBANK
13.9
L/h/m2
13.9
L/h/m2
tumor; patients;
DRUGBANK
14.8
L/h/m2
14.8±4
L/h/m2
DRUGBANK
0.42
L/h/kg
7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
110.0
L/m2
110.0
L/m2
tumor; patients;
DRUGBANK
234.0
L/m2
234.0
L/m2
tumor; patients;
DRUGBANK
150.0
L/m2
150±49
L/m2
DRUGBANK
3.5
L/kg
3.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
~6-12
h
DRUGBANK
15.0
h
10-20
h
elimination half-life;
DRUGBANK
10.8
h
10.8±0.5
h
DRUGBANK
10.4
h
10.4±3.1
h
Male, men; Female, women; patients; malignant solid tumors;
DRUGBANK
9.0
h
9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.7
%
16.7±1
%
Urinary excretion; malignant solid tumors; Unchanged drug;
DRUGBANK
49.0
%
30-68
%
DRUGBANK
49.0
%
30-68
%
malignant solid tumors; human, homo sapiens;
DRUGBANK
95.0
%
95
%
Active metabolite; malignant solid tumors; human, homo sapiens;
DRUGBANK
16.6666666666667
mg/m2/day
350
mg/m2/3 weeks
intravenous injection, IV
Camptosar
irinotecan hydrochloride
PDR
300.0
mg/m2
300
mg/m2
Camptosar
irinotecan hydrochloride
PDR
17.8571428571429
mg/m2/day
125
mg/m2/week
intravenous injection, IV
Camptosar
irinotecan hydrochloride
PDR
12.8571428571429
mg/m2/day
180
mg/m2/2 weeks
intravenous injection, IV
Camptosar
irinotecan hydrochloride
PDR
17.8571428571429
mg/m2/day
125
mg/m2/week
intravenous injection, IV
Camptosar
irinotecan hydrochloride
PDR
350.0
mg/m2/dose
350
mg/m2/dose
intravenous injection, IV
q3w
Camptosar
irinotecan hydrochloride
PDR
125.0
mg/m2/week
125
mg/m2/week
intravenous injection, IV
Camptosar
irinotecan hydrochloride
PDR
180.0
mg/m2/dose
180
mg/m2/dose
intravenous injection, IV
qw
Camptosar
irinotecan hydrochloride
PDR
125.0
mg/m2/week
125
mg/m2/week
intravenous injection, IV
Camptosar
irinotecan hydrochloride
PDR
70.0
mg/m2
70
mg/m2
intravenous injection, IV
q2w
Onivyde
irinotecan liposome
PDR
70.0
mg/m2
70
mg/m2
intravenous injection, IV
q2w
Onivyde
irinotecan liposome
PDR
DDPD00763
Methimazole
114.169
C4H6N2S
CN1C=CNC1=S
DB00763
1349907
50673
http://www.drugs.com/cdi/methimazole.html
1131173
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93
%
PO, oral;
DRUGBANK
2.125
h
0.25-4
h
PO, oral;
DRUGBANK
5.7
L/h
5.7
L/h
intravenous injection, IV; Single dose;
DRUGBANK
3.49
L/h
3.49
L/h
moderate hepatic impairment; patients;
hepatopathy，LD ↓ ;
DRUGBANK
0.84
L/h
0.84
L/h
severe hepatic impairment; patients;
hepatopathy，LD ↓ ;
DRUGBANK
0.222
L/h/kg
3.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L
~20
L
Apparent volume of distribution;
DRUGBANK
0.86
L/kg
0.86
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
h
0.17
h
distribution half-life;
RD, renal impairment, Renal disease，including uremia → ;hyperthyroid, HTh → ;
DRUGBANK
5.3
h
5.3
h
elimination half-life;
DRUGBANK
16.41
h
~16.41
h
DRUGBANK
7.1
h
7.1
h
mild hepatic impairment;
DRUGBANK
22.1
h
22.1
h
severe hepatic impairment;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2250.0
mg/kg
2250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.0
%
~3
%
Faeces excretion;
DRUGBANK
9.5
%
7-12
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
~0
%
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Tapazole
methimazole
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Tapazole
methimazole
PDR
40.0
mg/day
40
mg/day
PO, oral
Tapazole
methimazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Tapazole
methimazole
PDR
40.0
mg/day
40
mg/day
PO, oral
Tapazole
methimazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Tapazole
methimazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Tapazole
methimazole
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Tapazole
methimazole
PDR
DDPD00765
Metyrosine
195.2151
C10H13NO3
C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O
DB00765
441350
6912
http://www.drugs.com/cdi/metyrosine.html
390103
-2.0
-
-2.0
-
DRUGBANK
1.0
%
<1
%
DRUGBANK
3.55
h
3.4-3.7
h
DRUGBANK
442.0
mg/kg
442.0
mg/kg
mouse;
DRUGBANK
752.0
mg/kg
752.0
mg/kg
Rattus, Rat;
DRUGBANK
4000.0
mg/day
4
g/day
PO, oral
Demser
metyrosine
PDR
4000.0
mg/day
4
g/day
PO, oral
Demser
metyrosine
PDR
4000.0
mg/day
4
g/day
PO, oral
Demser
metyrosine
PDR
DDPD00766
Clavulanic acid
199.1608
C8H9NO5
[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO
DB00766
5280980
48947
4444466
-2.0
-
-2.0
-
DRUGBANK
73.0
%
73
%
PO, oral;
DRUGBANK
64.0
%
64
%
PO, oral;
DRUGBANK
2098.0
ng/ml
2.098±0.441
mcg/ml
PO, oral;
DRUGBANK
1.042
h
1.042±0.8
h
PO, oral;
DRUGBANK
1.335
h
0.67-2
h
PO, oral; different study;
DRUGBANK
15.6
%
15.6
%
DRUGBANK
8.8
%
8.8
%
DRUGBANK
12.6
L/h
0.21
L/min
normal,healthy;
DRUGBANK
0.174285714285714
L/h/kg
12.2
L/h/70kg
Average clearance;
DRUGBANK
0.186
L/h/kg
3.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
L
12.0
L
normal,healthy;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.125
h
45-90
min
DRUGBANK
0.8
h
0.8
h
normal,healthy;
DRUGBANK
0.9
h
0.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; adults; rodents;
DRUGBANK
8.0
%
8
%
Faeces excretion;
DRUGBANK
52.5
%
~40-65
%
Urinary excretion; Unchanged drug;
DRUGBANK
25.0
%
~25
%
plasma proteins;
DRUGBANK
DDPD00768
Olopatadine
337.4122
C21H23NO3
CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
DB00768
T3D2886
5281071
http://www.drugs.com/cdi/olopatadine-spray.html
4444528
-2.0
-
-2.0
-
DRUGBANK
9.7
ng.h/ml
9.7±4.4
ng.h/ml
ophthalmic administration; normal,healthy;
DRUGBANK
66.0
ng.h/ml
66±26.8
ng.h/ml
inhalation, IH; normal,healthy;
DRUGBANK
78.0
ng.h/ml
78.0±13.9
ng.h/ml
inhalation, IH; allergic rhinitis;
DRUGBANK
57.0
%
57
%
inhalation, IH; normal,healthy;
DRUGBANK
1.6
ng/ml
1.6±0.9
ng/ml
ophthalmic administration; normal,healthy;
DRUGBANK
6.0
ng/ml
6.0±8.99
ng/ml
inhalation, IH; normal,healthy;
DRUGBANK
23.3
ng/ml
23.3±6.2
ng/ml
inhalation, IH; allergic rhinitis;
DRUGBANK
2.0
h
2
h
ophthalmic administration; normal,healthy;
DRUGBANK
0.75
h
0.5-1
h
inhalation, IH; normal,healthy;
DRUGBANK
1.125
h
0.25-2
h
inhalation, IH; allergic rhinitis;
DRUGBANK
23.45
L/h
23.45
L/h
Average clearance; PO, oral; normal,healthy;
DRUGBANK
133.83
L
133.83
L
normal,healthy;
DRUGBANK
3.4
h
3.4±1.2
h
elimination half-life; ophthalmic administration;
DRUGBANK
10.0
h
8-12
h
elimination half-life; PO, oral;
DRUGBANK
1150.0
mg/kg
>1150
mg/kg
PO, oral; mouse;
DRUGBANK
3870.0
mg/kg
>3870
mg/kg
Rattus, Rat;
DRUGBANK
20.0
mg/kg
20.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.1
mg/kg
0.1
mg/kg
PO, oral; mouse;
DRUGBANK
70.0
%
~70
%
Urinary excretion; PO, oral;
DRUGBANK
17.0
%
~17
%
Faeces excretion;
DRUGBANK
55.0
%
~55
%
human, homo sapiens;
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
4.0
sprays/day
4
sprays/day
nasal spray
Patanol
olopatadine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
2.0
sprays/day
2
sprays/day
nasal spray
Patanol
olopatadine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
2.0
sprays/day
2
sprays/day
nasal spray
Patanol
olopatadine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
4.0
sprays/day
4
sprays/day
nasal spray
Patanol
olopatadine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
4.0
sprays/day
4
sprays/day
nasal spray
Patanol
olopatadine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Patanol
olopatadine hydrochloride
PDR
4.0
sprays/day
4
sprays/day
nasal spray
Patanol
olopatadine hydrochloride
PDR
DDPD00769
Hydrocortamate
475.6175
C27H41NO6
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB00769
84088
50851
75860
-2.0
-
-2.0
-
DRUGBANK
DDPD00770
Alprostadil
354.487
C20H34O5
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
DB00770
149351
15544
http://www.drugs.com/cdi/alprostadil.html
4444306
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
lung metabolism;
DRUGBANK
2.724
L/h/kg
45.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.4
L/kg
2.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.125
h
5-10
min
Single dose; normal,healthy; adults; Neonates;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
186.0
mg/kg
186.0
mg/kg
PO, oral; mouse;
DRUGBANK
228.0
mg/kg
228.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
81.0
%
81
%
DRUGBANK
0.576
mg/kg/day
0.4
mcg/kg/minute
intravenous injection, IV
Prostin VR Pediatric
alprostadil
PDR
DDPD00771
Clidinium
352.4467
C22H26NO3
C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
DB00771
2784
3743
http://www.drugs.com/mtm/clidinium.html
26330531
-2.0
-
-2.0
-
DRUGBANK
DDPD00772
Malathion
330.358
C10H19O6PS2
CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC
DB00772
T3D3870
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
4004
141474
http://www.drugs.com/cdi/malathion.html
3864
-2.0
-
-2.0
-
DRUGBANK
8.0
%
8
%
skin/dermal; skin disease;
skin disease ↑ ;
DRUGBANK
16.0
h
8-24
h
DRUGBANK
5500.0
mg/kg
1000->10000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
5500.0
mg/kg
1000-10000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
0.0002
mg/L
0.2
mg/m3
inhalation, IH;
DRUGBANK
2e-05
mg/L
0.02
mg/m3
inhalation, IH;
DRUGBANK
0.02
mg/kg/day
0.02
mg/kg/day
PO, oral;
DRUGBANK
0.02
mg/kg/day
0.02
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD00773
Etoposide
588.5566
C29H32O13
[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O
DB00773
T3D4695
36462
4911
http://www.drugs.com/cdi/etoposide.html
33510
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50(25-75)
%
PO, oral;
DRUGBANK
52.0
%
52±17
%
PO, oral;
increasing doses ↓ ;
DRUGBANK
2700.0
ng/ml
2.7
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
4700.0
ng/ml
4.7
mcg/ml
intravenous infusion, IV in drop; hematological toxicity;
DRUGBANK
1.25
h
1-1.5
h
PO, oral;
DRUGBANK
1.3
h
1.3
h
DRUGBANK
40.0
%
40
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.43
L/h
33 - 48
ml/min
Total clearance; intravenous injection, IV; adults;
DRUGBANK
0.51
L/h/m2
7.0-10
ml/min/m2
Renal clearance;
DRUGBANK
0.0408
L/h/kg
0.68±0.23
ml/min/kg
hydrolysis;
Children → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.03
L/h/kg
0.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
23.5
L
18-29
L
at steady state;
DRUGBANK
0.36
L/kg
0.36±0.15
L/kg
Children → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
0.18
L/kg
0.18
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
h
4-11
h
DRUGBANK
8.1
h
8.1±4.3
h
Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr → ;
DRUGBANK
5.7
h
5.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
44.0
%
44
%
Faeces excretion;
DRUGBANK
56.0
%
56
%
Urinary excretion;
DRUGBANK
35.0
%
35±5
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
96.0
%
96±0.4
%
hypoalbuminemia Alb ↓ ;
DRUGBANK
150.0
mg/m2/day
150
mg/m2/day
intravenous injection, IV
Toposar
etoposide
PDR
200.0
mg/m2/day
200
mg/m2/day
intravenous injection, IV
Toposar
etoposide
PDR
100.0
mg/m2/day
100
mg/m2/day
PO, oral
Toposar
etoposide
PDR
200.0
mg/m2/day
200
mg/m2/day
intravenous injection, IV
Toposar
etoposide
PDR
200.0
mg/m2/day
200
mg/m2/day
intravenous injection, IV
Toposar
etoposide
PDR
100.0
mg/m2/day
100
mg/m2/day
PO, oral
Toposar
etoposide
PDR
120.0
mg/m2/day
120
mg/m2/day
intravenous injection, IV
Toposar
etoposide
PDR
DDPD00774
Hydroflumethiazide
331.292
C8H8F3N3O4S2
NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F
DB00774
3647
5784
3521
-2.0
-
-2.0
-
DRUGBANK
0.582
L/h/kg
9.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
distribution half-life;
DRUGBANK
17.0
h
~17
h
elimination half-life;
DRUGBANK
5.2
h
5.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
74.0
%
74
%
DRUGBANK
DDPD00775
Tirofiban
440.597
C22H36N2O5S
CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O
DB00775
60947
9605
http://www.drugs.com/cdi/tirofiban.html
54912
-2.0
-
-2.0
-
DRUGBANK
16.62
L/h
213-314
ml/min
normal,healthy;
DRUGBANK
12.57
L/h
152-267
ml/min
coronary artery disease; patients;
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.0
L
22-42
L
DRUGBANK
0.34
L/kg
0.34
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
65.0
%
~65
%
Urinary excretion;
DRUGBANK
25.0
%
~25
%
Faeces excretion;
DRUGBANK
65.0
%
65
%
DRUGBANK
0.025
mg/kg
25
mcg/kg
intravenous injection, IV
Aggrastat
tirofiban hydrochloride
PDR
0.216
mg/kg/day
0.15
mcg/kg/min
intravenous infusion, iv in drop; up to 18 hours
Aggrastat
tirofiban hydrochloride
PDR
25.0
mcg/kg
25
mcg/kg
intravenous injection, IV
Aggrastat
tirofiban hydrochloride
PDR
0.216
mg/kg/day
0.15
mcg/kg/minute
intravenous infusion, iv in drop; up to 18 hours
Aggrastat
tirofiban hydrochloride
PDR
DDPD00776
Oxcarbazepine
252.268
C15H12N2O2
NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2
DB00776
T3D2887
34312
7824
http://www.drugs.com/cdi/oxcarbazepine.html
31608
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; food;
food → ;
DRUGBANK
34.0
ng/ml
34.0
umol/L
Oral single dose;
DRUGBANK
8500.0
ng/ml
8.5±2.0
mcg/ml
PO, oral;
DRUGBANK
4.5
h
4.5
h
Oral single dose;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
60.0
h
2-3
day
Oral multiple dose;
DRUGBANK
84.9
L/h
~84.9
L/h
Plasma clearance;
DRUGBANK
2.0
L/h
2.0
L/h
Plasma clearance; Renal metabolism;
DRUGBANK
4.044
L/h/kg
67.4
ml/min/kg
apparent clearance; metabolism of ugt;
DRUGBANK
49.0
L
49.0
L
Apparent volume of distribution;
DRUGBANK
23.6
L
23.6
L
Apparent volume of distribution;
DRUGBANK
31.7
L
31.7
L
Apparent volume of distribution;
DRUGBANK
2.0
h
~2
h
elimination half-life;
DRUGBANK
9.0
h
~9
h
elimination half-life;
DRUGBANK
2.0
h
~2
h
normal,healthy; adults; Male, men;
DRUGBANK
11.5
h
8-15
h
Active metabolite;
RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
1240.0
mg/kg
1240.0
mg/kg
PO, oral; mammals;
DRUGBANK
73.0
mg/kg
73.0
mg/kg
PO, oral; Children;
DRUGBANK
95.0
%
>95
%
Urinary excretion; PO, oral;
DRUGBANK
4.0
%
4
%
Faeces excretion; PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; adults; Male, men; normal,healthy; Unchanged drug;
DRUGBANK
27.0
%
27
%
Urinary excretion; adults; Male, men; normal,healthy; Unchanged drug;
DRUGBANK
45.0
%
45
%
Active metabolite; adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Trileptal
oxcarbazepine
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Trileptal
oxcarbazepine
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Trileptal
oxcarbazepine
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Trileptal
oxcarbazepine
PDR
DDPD00777
Propiomazine
340.482
C20H24N2OS
CCC(=O)C1=CC2=C(SC3=CC=CC=C3N2CC(C)N(C)C)C=C1
DB00777
T3D2888
4940
8491
4771
-2.0
-
-2.0
-
DRUGBANK
81.0
%
81
%
DRUGBANK
DDPD00778
Roxithromycin
837.0465
C41H76N2O15
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
DB00778
6915744
48935
5291557
-2.0
-
-2.0
-
DRUGBANK
12.0
h
12
h
DRUGBANK
96.0
%
96
%
DRUGBANK
DDPD00779
Nalidixic acid
232.2353
C12H12N2O3
CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2
DB00779
4421
100147
http://www.drugs.com/cdi/nalidixic-acid.html
4268
-2.0
-
-2.0
-
DRUGBANK
96.0
%
96
%
PO, oral;
DRUGBANK
30.0
%
30
%
Liver metabolism; Active metabolite;
DRUGBANK
1.8
h
1.1-2.5
h
normal,healthy; adults;
DRUGBANK
21.0
h
21
h
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
1160.0
mg/kg
1160.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
572.0
mg/kg
572.0
mg/kg
PO, oral; mouse;
DRUGBANK
4.0
%
~4
%
Faeces excretion;
DRUGBANK
93.0
%
93
%
DRUGBANK
DDPD00780
Phenelzine
136.1943
C8H12N2
NNCCC1=CC=CC=C1
DB00780
T3D2889
3675
8060
http://www.drugs.com/cdi/phenelzine.html
3547
-2.0
-
-2.0
-
DRUGBANK
19.8
ng/ml
19.8
ng/ml
PO, oral;
DRUGBANK
0.716666666666667
h
43
min
PO, oral;
DRUGBANK
11.6
h
11.6
h
human, homo sapiens;
DRUGBANK
90.0
mg/day
90
mg/day
PO, oral
Nardil
phenelzine sulfate
PDR
90.0
mg/day
90
mg/day
PO, oral
Nardil
phenelzine sulfate
PDR
DDPD00781
Polymyxin B
1203.499
C56H98N16O13
[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
DB00781
T3D3529
25045120
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
2.435
L/h
2.37-2.5
L/h
DRUGBANK
40.75
L
34.3-47.2
L
DRUGBANK
10.25
h
9-11.5
h
DRUGBANK
6.0
h
6
h
different study;
DRUGBANK
60.0
h
48-72
h
different study; renal insufficiency;
DRUGBANK
60.0
%
60
%
Urinary excretion;
DRUGBANK
85.5
%
79-92
%
DRUGBANK
25000.0
units/kg/day
25000
units/kg/day
intravenous injection, IV
Polymyxin B
polymyxin B sulfate
PDR
30000.0
units/kg/day
30000
units/kg/day
IM,intramuscular injection
Polymyxin B
polymyxin B sulfate
PDR
100000.0
units/day
100000
units/day
ophthalmic administration
Polymyxin B
polymyxin B sulfate
PDR
50000.0
units/day
50000
units/day
intrathecal administration
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
ophthalmic administration;total systemic;
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
intravenous injection, IV
Polymyxin B
polymyxin B sulfate
PDR
30000.0
units/kg/day
30000
units/kg/day
IM,intramuscular injection
Polymyxin B
polymyxin B sulfate
PDR
100000.0
units/day
100000
units/day
ophthalmic administration
Polymyxin B
polymyxin B sulfate
PDR
20000.0
units/day
20000
units/day
intrathecal administration
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
ophthalmic administration;total systemic;
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
intravenous injection, IV
Polymyxin B
polymyxin B sulfate
PDR
30000.0
units/kg/day
30000
units/kg/day
IM,intramuscular injection
Polymyxin B
polymyxin B sulfate
PDR
100000.0
units/day
100000
units/day
ophthalmic administration
Polymyxin B
polymyxin B sulfate
PDR
50000.0
units/day
50000
units/day
intrathecal administration
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
ophthalmic administration;total systemic;
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
intravenous injection, IV
Polymyxin B
polymyxin B sulfate
PDR
30000.0
units/kg/day
30000
units/kg/day
IM,intramuscular injection
Polymyxin B
polymyxin B sulfate
PDR
100000.0
units/day
100000
units/day
ophthalmic administration
Polymyxin B
polymyxin B sulfate
PDR
50000.0
units/day
50000
units/day
intrathecal administration
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
ophthalmic administration;total systemic;
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
intravenous injection, IV
Polymyxin B
polymyxin B sulfate
PDR
30000.0
units/kg/day
30000
units/kg/day
IM,intramuscular injection
Polymyxin B
polymyxin B sulfate
PDR
100000.0
units/day
100000
units/day
ophthalmic administration
Polymyxin B
polymyxin B sulfate
PDR
50000.0
units/day
50000
units/day
intrathecal administration
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
ophthalmic administration;total systemic;
Polymyxin B
polymyxin B sulfate
PDR
40000.0
units/kg/day
40000
units/kg/day
IM,intramuscular injection;intravenous injection, IV;
Polymyxin B
polymyxin B sulfate
PDR
20000.0
units/day
20000
units/day
intrathecal administration
Polymyxin B
polymyxin B sulfate
PDR
100000.0
units/day
100000
units/day
ophthalmic administration
Polymyxin B
polymyxin B sulfate
PDR
25000.0
units/kg/day
25000
units/kg/day
ophthalmic administration;total systemic;
Polymyxin B
polymyxin B sulfate
PDR
45000.0
units/kg/day
45000
units/kg/day
IM,intramuscular injection
Polymyxin B
polymyxin B sulfate
PDR
DDPD00782
Propantheline
368.4892
C23H30NO3
CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C
DB00782
4934
8481
http://www.drugs.com/cdi/propantheline.html
4765
-2.0
-
-2.0
-
DRUGBANK
70.0
%
~70
%
Urinary excretion;
DRUGBANK
DDPD00783
Estradiol
272.382
C18H24O2
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
DB00783
T3D4668
5757
16469
http://www.drugs.com/estradiol.html
5554
-2.0
-
-2.0
-
DRUGBANK
0.471
ng.h/ml
471.0
pg.h/ml
skin/dermal;
DRUGBANK
0.231
ng.h/ml
231±285
pg.h/ml
Vaginal Administration;
DRUGBANK
6.0
%
2-10
%
Tablet, PO, oral;
DRUGBANK
40.0
%
>40
%
Transdermal preparations;
DRUGBANK
0.174
ng/ml
174.0
pg/ml
Transdermal preparations;
DRUGBANK
0.054
ng/ml
54.0
pg/ml
skin/dermal;
DRUGBANK
0.063
ng/ml
63.0
pg/ml
Vaginal Administration;
DRUGBANK
0.0128
ng/ml
12.8±16.6
pg/ml
Vaginal Administration;
DRUGBANK
20.0
h
20
h
skin/dermal;
DRUGBANK
0.75
h
0.5-1
h
Vaginal Administration;
DRUGBANK
8.5
h
8.5±6.2
h
Vaginal Administration;
DRUGBANK
180.0
h
7-8
day
skin/dermal;
DRUGBANK
1.794
L/h/kg
29.9±15.5
ml/min/kg
PO, oral; postmenopausal women;
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV;
DRUGBANK
1.8
L/h/kg
30
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
1-12
h
PO, oral;
DRUGBANK
6.5
h
1-12
h
intravenous injection, IV;
DRUGBANK
16.9
h
16.9±6.0
h
elimination half-life; postmenopausal women; PO, oral;
DRUGBANK
0.4575
h
27.45±5.65
min
elimination half-life; postmenopausal women; intravenous injection, IV;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
960.0
mg/kg
960.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
mg/kg/day
21.0
mg/kg/21D
Female, women;
DRUGBANK
95.0
%
>95
%
plasma proteins;
DRUGBANK
95.0
%
<95
%
DRUGBANK
DDPD00784
Mefenamic acid
241.2851
C15H15NO2
CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
DB00784
4044
6717
http://www.drugs.com/cdi/mefenamic-acid.html
3904
-2.0
-
-2.0
-
DRUGBANK
21.23
L/h
21.23
L/h
PO, oral; normal,healthy; adults;
DRUGBANK
1.06
L/kg
1.06
L/kg
normal,healthy; adults;
DRUGBANK
2.0
h
2
h
DRUGBANK
740.0
mg/kg
740.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
20.0
%
20
%
DRUGBANK
90.0
%
90
%
DRUGBANK
1250.0
mg/day
1250
mg/day
PO, oral
Ponstel
mefenamic acid
PDR
1250.0
mg/day
1250
mg/day
PO, oral
Ponstel
mefenamic acid
PDR
1250.0
mg/day
1250
mg/day
PO, oral
Ponstel
mefenamic acid
PDR
DDPD00787
Acyclovir
225.2046
C8H11N5O3
NC1=NC(=O)C2=C(N1)N(COCCO)C=N2
DB00787
2022
2453
http://www.drugs.com/acyclovir.html
1945
-2.0
-
-2.0
-
DRUGBANK
4.71
%
<0.02-9.4
%
skin/dermal;
DRUGBANK
3029.55
ng.h/ml
2956.6-3102.5
ng.h/ml
DRUGBANK
15.0
%
10-20
%
PO, oral; increasing doses; food;
increasing doses ↑ ;food → ;
DRUGBANK
22.5
%
15-30
%
PO, oral;
increasing doses ↓ ;
DRUGBANK
625.1
ng/ml
593.7-656.5
ng/ml
DRUGBANK
1002160.47
ng/ml
3.5-5.4
mM
Oral multiple dose;
DRUGBANK
1.1
h
1.1±0.4
h
DRUGBANK
1.75
h
1.5-2
h
Oral multiple dose;
DRUGBANK
15.0
%
<15
%
DRUGBANK
1.0
%
1
%
DRUGBANK
8.60115606936416
L/h/m2
248.0
ml/min/1.73m2
Renal clearance;
DRUGBANK
4.23121387283237
L/h/m2
122.0
ml/min/1.73m2
Total clearance; Neonates;
DRUGBANK
0.282
L/h/kg
4.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
0.6
L/kg
DRUGBANK
0.69
L/kg
0.69±0.19
L/kg
Neonates ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.71
L/kg
0.71
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~5
h
elimination half-life;
DRUGBANK
2.6
h
2.6
h
Children;
DRUGBANK
2.4
h
2.4±0.7
h
Neonates ↑ ;Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
%
<0.1
%
lung excretion;
DRUGBANK
2.0
%
<2
%
Faeces excretion;
DRUGBANK
91.0
%
90-92
%
Unchanged drug;
DRUGBANK
75.0
%
75±10
%
Urinary excretion; Unchanged drug;
DRUGBANK
21.0
%
9-33
%
plasma proteins;
DRUGBANK
15.0
%
15±4
%
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
45.0
mg/kg/day
45
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
4000.0
mg/day
4000
mg/day
Zovirax Ointment
acyclovir
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
45.0
mg/kg/day
45
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
4000.0
mg/day
4000
mg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
50.0
mg/dose
50
mg/dose
buccal tablets
Zovirax Ointment
acyclovir
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
45.0
mg/kg/day
45
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
4000.0
mg/day
4000
mg/day
Zovirax Ointment
acyclovir
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
45.0
mg/kg/day
45
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
4000.0
mg/day
4000
mg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
50.0
mg/dose
50
mg/dose
buccal tablets
Zovirax Ointment
acyclovir
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
80.0
mg/kg/day
80
mg/kg/day
PO, oral
Zovirax Ointment
acyclovir
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Zovirax Ointment
acyclovir
PDR
900.0
mg/m2/day
900
mg/m2/day
PO, oral
Zovirax Ointment
acyclovir
PDR
DDPD00788
Naproxen
230.2592
C14H14O3
COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O
DB00788
156391
7476
http://www.drugs.com/naproxen.html
137720
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; Rectal Administration;
DRUGBANK
1446000.0
ng.h/ml
1446.0
mcg.h/ml
PO, oral; Rectal Administration; immediate release formulation;
DRUGBANK
1448000.0
ng.h/ml
1448.0
mcg.h/ml
PO, oral; Rectal Administration; extended release formulation;
DRUGBANK
845000.0
ng.h/ml
845.0
mcg.h/ml
PO, oral; Derivative;
DRUGBANK
767000.0
ng.h/ml
767.0
mcg.h/ml
PO, oral; Rectal Administration; different study;
DRUGBANK
99.0
%
99.0
%
DRUGBANK
95700.0
ng/ml
94-97.4
mcg/ml
PO, oral; Rectal Administration;
DRUGBANK
37.0
null
37.0
null
Tablet, PO, oral; immediate release formulation; adults;
DRUGBANK
94.0
null
94.0
null
Tablet, PO, oral; extended release formulation; adults;
DRUGBANK
55000.0
ng/ml
55±14
mcg/ml
Liquid; Children; patients;
DRUGBANK
2.0
h
2
h
PO, oral; Rectal Administration;
DRUGBANK
3.0
h
3
h
PO, oral; Rectal Administration;
DRUGBANK
5.0
h
5
h
PO, oral; Rectal Administration;
DRUGBANK
4.0
h
4
h
PO, oral; Derivative;
DRUGBANK
1.9
h
1.9
h
PO, oral; Rectal Administration; different study;
DRUGBANK
5.0
h
5
h
combination drug use;
DRUGBANK
1.0
h
1
h
PO, oral; Derivative;
DRUGBANK
3.0
h
2-4
h
Tablet, PO, oral; immediate release formulation; adults;
DRUGBANK
5.0
h
5.0
h
Tablet, PO, oral; extended release formulation; adults;
DRUGBANK
2.2
h
2.2±2.1
h
Liquid; Children; patients;
DRUGBANK
0.0078
L/h/kg
0.13
ml/min/kg
DRUGBANK
0.0078
L/h/kg
0.13±0.02
ml/min/kg
apparent clearance; hydrolysis; hydrolysis;
Children → ;Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;rheumatoid arthritis ↑ ;
DRUGBANK
0.0042
L/h/kg
0.07
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.16
L/kg
0.16
L/kg
DRUGBANK
0.16
L/kg
0.16±0.02
L/kg
Apparent volume of distribution; hydrolysis; hydrolysis;
Elderly → ;RD, renal impairment, Renal disease，including uremia ↑ ;rheumatoid arthritis ↑ ;
DRUGBANK
0.09
L/kg
0.09
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.5
h
12-17
h
elimination half-life;
DRUGBANK
14.0
h
14±1
h
Children → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;Age ↑ ;
DRUGBANK
16.63
h
16.63
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95.0
%
~95
%
Urinary excretion; PO, oral;
DRUGBANK
5.0
%
<5
%
Faeces excretion; PO, oral;
DRUGBANK
5.5
%
5-6
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
99.7
%
99.7±0.1
%
Elderly ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;rheumatoid arthritis ↓ ;hypoalbuminemia Alb ↓ ;
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
660.0
mg/day
660
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1650.0
mg/day
1650
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
660.0
mg/day
660
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1650.0
mg/day
1650
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
660.0
mg/day
660
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
1650.0
mg/day
1650
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
660.0
mg/day
660
mg/day
PO, oral
Anaprox/EC-Naprosyn/Naprosyn
(naproxen); (naproxen sodium)
PDR
DDPD00789
Gadopentetic acid
547.58
C14H20GdN3O10
[Gd+3].OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O
DB00789
55466
35778
http://www.drugs.com/cdi/gadopentetate-dimeglumine.html
138549
-2.0
-
-2.0
-
DRUGBANK
0.1164
L/h/kg
1.94±0.28
ml/min/kg
normal,healthy;
DRUGBANK
0.266
L/kg
266±43
mL/kg
DRUGBANK
0.2
h
12
min
distribution half-life;
DRUGBANK
1.66666666666667
h
100
min
elimination half-life;
DRUGBANK
83.0
%
83±14
%
DRUGBANK
91.0
%
91±13
%
DRUGBANK
0.2
ml/kg
0.2
ml/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.1
mmol/kg
0.1
mmol/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.2
ml/kg
0.2
ml/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.1
mmoL/kg
0.1
mmoL/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.2
ml/kg
0.2
mL/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.1
mmol/kg
0.1
mmol/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.2
ml/kg
0.2
ml/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
0.1
mmol/kg
0.1
mmol/kg
intravenous injection, IV
Magnevist Injection
gadopentetate dimeglumine
PDR
DDPD00790
Perindopril
368.4678
C19H32N2O5
[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
DB00790
107807
8024
http://www.drugs.com/cdi/perindopril.html
96956
-2.0
-
-2.0
-
DRUGBANK
70.0
%
65-75
%
food;
food ↓ ;
DRUGBANK
20.0
%
20
%
Active metabolite;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
6.5
%
1-12
%
Urinary excretion;
DRUGBANK
17.43
L/h
219-362
ml/min
PO, oral;
DRUGBANK
1.2
h
1.2
h
DRUGBANK
75.0
h
30-120
h
DRUGBANK
8.0
%
4-12
%
Urinary excretion; Unchanged drug;
DRUGBANK
15.0
%
10-20
%
plasma proteins;
DRUGBANK
DDPD00791
Uracil mustard
252.098
C8H11Cl2N3O2
ClCCN(CCCl)C1=CNC(=O)NC1=O
DB00791
T3D4718
6194
9884
5959
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5
%
DRUGBANK
DDPD00792
Tripelennamine
255.358
C16H21N3
CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1
DB00792
5587
9741
http://www.drugs.com/mtm/tripelennamine.html
5385
-2.0
-
-2.0
-
DRUGBANK
DDPD00793
Haloprogin
361.391
C9H4Cl3IO
ClC1=CC(Cl)=C(Cl)C=C1OCC#CI
DB00793
3561
5614
http://www.drugs.com/mtm/haloprogin-topical.html
3440
-2.0
-
-2.0
-
DRUGBANK
DDPD00794
Primidone
218.2518
C12H14N2O2
CCC1(C(=O)NCNC1=O)C1=CC=CC=C1
DB00794
4909
8412
http://www.drugs.com/cdi/primidone.html
4740
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
PO, oral;
DRUGBANK
2700.0
ng/ml
2.7±0.4
ug/ml
Oral single dose;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
3.75
h
0.5-7
h
Oral single dose;
DRUGBANK
1.8
L/h
30.0
ml/min
DRUGBANK
0.65
L/kg
0.5-0.8
L/kg
DRUGBANK
14.5
h
7-22
h
adults;
DRUGBANK
8.0
h
5-11
h
Children;
DRUGBANK
44.0
h
8-80
h
Neonates;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
280.0
mg/kg
280.0
mg/kg
PO, oral; mouse;
DRUGBANK
240.0
mg/kg
240.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
332.0
mg/kg
332.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
76.75
%
72.9-80.6
%
Urinary excretion;
DRUGBANK
12.24
%
10.78-13.7
%
DRUGBANK
2000.0
mg/day
2000
mg/day
PO, oral
Mysoline
primidone
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Mysoline
primidone
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Mysoline
primidone
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Mysoline
primidone
PDR
1000.0
mg/kg/day
1000
mg/kg/day
PO, oral
Mysoline
primidone
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Mysoline
primidone
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Mysoline
primidone
PDR
DDPD00795
Sulfasalazine
398.393
C18H14N4O5S
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
DB00795
T3D2892
5359476
9334
http://www.drugs.com/cdi/sulfasalazine.html
10605946
-2.0
-
-2.0
-
DRUGBANK
1.0
L/h
1.0
L/h
intravenous injection, IV;
DRUGBANK
0.0156
L/h/kg
0.26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
L
7.5±1.6
L
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
h
5-10
h
DRUGBANK
7.6
h
7.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
4000.0
mg/day
4
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
2000.0
mg/day
2
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
4000.0
mg/day
4
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
4000.0
mg/day
4
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
3000.0
mg/day
3
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
4000.0
mg/day
4
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
2000.0
mg/day
2
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
4000.0
mg/day
4
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
3000.0
mg/day
3
g/day
PO, oral
Azulfidine EN-tabs
sulfasalazine
PDR
DDPD00796
Candesartan cilexetil
610.671
C33H34N6O6
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
DB00796
2540
3348
http://www.drugs.com/cdi/candesartan.html
2444
-2.0
-
-2.0
-
DRUGBANK
15.0
%
15
%
PO, oral;
DRUGBANK
0.0222
L/h/kg
0.37
ml/min/kg
DRUGBANK
0.13
L/kg
0.13
L/kg
DRUGBANK
9.0
h
~9
h
DRUGBANK
26.0
%
~26
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
32.0
mg/day
32
mg/day
PO, oral
Atacand
candesartan cilexetil
PDR
16.0
mg/day
16
mg/day
PO, oral
Atacand
candesartan cilexetil
PDR
0.4
mg/kg/day
0.4
mg/kg/day
PO, oral
Atacand
candesartan cilexetil
PDR
32.0
mg/day
32
mg/day
PO, oral
Atacand
candesartan cilexetil
PDR
32.0
mg/day
32
mg/day
PO, oral
Atacand
candesartan cilexetil
PDR
16.0
mg/day
16
mg/day
PO, oral
Atacand
candesartan cilexetil
PDR
32.0
mg/day
32
mg/day
PO, oral
Atacand
candesartan cilexetil
PDR
DDPD00797
Tolazoline
160.2157
C10H12N2
C(C1=NCCN1)C1=CC=CC=C1
DB00797
5504
28502
5303
-2.0
-
-2.0
-
DRUGBANK
0.75
h
0.5-1
h
intravenous injection, IV;
DRUGBANK
DDPD00798
Gentamicin
477.5954
C21H43N5O7
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1
DB00798
3467
17833
http://www.drugs.com/cdi/gentamicin-drops.html
3348
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
5000.0
ng/ml
5.0±0.4
mcg/ml
intravenous injection, IV; adults; normal,healthy;
DRUGBANK
4900.0
ng/ml
4.9±0.5
mcg/ml
intravenous infusion, IV in drop; adults; normal,healthy;
DRUGBANK
0.525
h
0.3-0.75
h
intravenous injection, IV; adults; normal,healthy;
DRUGBANK
1.0
h
1.0
h
intravenous infusion, IV in drop; adults; normal,healthy;
DRUGBANK
0.06
L/h/kg
1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.31
L/kg
0.31±0.10
L/kg
Neonates ↑ ;Children → ;Elderly → ;RD, renal impairment, Renal disease，including uremia → ;Obesity ↓ ;Cystic fibrosis → ;
DRUGBANK
0.33
L/kg
0.33
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.27
h
3-3½
h
Infants;
DRUGBANK
2.24
h
5½
h
Neonates; Prem, premature;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
53.0
h
53±25
h
terminal half-life;
DRUGBANK
4.7
h
4.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
52.0
mg/kg
52.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
96.0
mg/kg
96.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
90.0
%
>90
%
Urinary excretion; Unchanged drug;
DRUGBANK
15.0
%
0-30
%
DRUGBANK
10.0
%
<10
%
DRUGBANK
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qd
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
10.0
mg/kg/day
5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
q2d
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
4.5
mg/kg/day
4.5
mg/kg/dose/day
intravenous injection, IV;IM,intramuscular injection;
qd
Gentamicin Sulfate Ointment
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qd
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
10.0
mg/kg/day
5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
q2d
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
4.5
mg/kg/day
4.5
mg/kg/dose/day
intravenous injection, IV;IM,intramuscular injection;
qd
Gentamicin Injection 40 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
7.0
mg/kg/day
7
mg/kg/day
intravenous injection, IV
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
7.5
mg/kg/day
7.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
5.0
mg/kg/day
5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
qd
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
10.0
mg/kg/day
5
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
q2d
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
4.5
mg/kg/day
4.5
mg/kg/dose/day
intravenous injection, IV;IM,intramuscular injection;
qd
Gentamicin Injection 10 mg/mL
gentamicin sulfate
PDR
DDPD00799
Tazarotene
351.462
C21H21NO2S
CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1
DB00799
5381
32184
http://www.drugs.com/cdi/tazarotene-cream.html
5188
-2.0
-
-2.0
-
DRUGBANK
2.232
L/h/kg
37.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.55
L/kg
3.55
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
~18
h
normal,healthy; patients;
DRUGBANK
18.0
h
~18
h
hyperthyroid; patients;
DRUGBANK
6.22
h
6.22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
1.0
application/day
1
application/day
skin/dermal
qd
Avage
tazarotene
PDR
1.0
application/day
1
application/day
skin/dermal
qd
Avage
tazarotene
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
qd
Avage
tazarotene
PDR
1.0
application/day
1
application/day
skin/dermal
qd
Avage
tazarotene
PDR
1.0
application/day
1
application/day
skin/dermal
qd
Avage
tazarotene
PDR
1.0
application/day
1
application/day
skin/dermal
qd
Avage
tazarotene
PDR
DDPD00800
Fenoldopam
305.756
C16H16ClNO3
OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
DB00800
3341
5002
3224
-2.0
-
-2.0
-
DRUGBANK
2.49
L/h/kg
41.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
L/kg
0.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0833333333333333
h
~5
min
elimination half-life; mild hypertensives; mild hepatic impairment; Metabolite;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
~90
%
Urinary excretion;
DRUGBANK
10.0
%
~10
%
Faeces excretion;
DRUGBANK
4.0
%
4
%
Unchanged drug;
DRUGBANK
0.8
mcg/kg/min
0.8
mcg/kg/min
intravenous infusion, iv in drop
Corlopam
fenoldopam mesylate
PDR
2.304
mg/kg/day
1.6
mcg/kg/min
intravenous infusion, iv in drop
Corlopam
fenoldopam mesylate
PDR
1.152
mg/kg/day
0.8
mcg/kg/min
intravenous infusion, iv in drop
Corlopam
fenoldopam mesylate
PDR
2.304
mg/kg/day
1.6
mcg/kg/min
intravenous infusion, iv in drop
Corlopam
fenoldopam mesylate
PDR
DDPD00801
Halazepam
352.738
C17H12ClF3N2O
FC(F)(F)CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1
DB00801
T3D2893
31640
5603
http://www.drugs.com/mtm/halazepam.html
29343
-2.0
-
-2.0
-
DRUGBANK
DDPD00802
Alfentanil
416.5172
C21H32N6O3
CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O
DB00802
T3D2894
51263
2569
46451
-2.0
-
-2.0
-
DRUGBANK
150.0
ng/ml
100-200
ng/ml
DRUGBANK
325.0
ng/ml
310-340
ng/ml
DRUGBANK
0.3
L/h/kg
5.0
ml/min/kg
DRUGBANK
0.402
L/h/kg
6.7±2.4
ml/min/kg
hydrolysis;
Elderly ↓ ;Hepatitis, Hep ↓ ;CPBS → ;
DRUGBANK
0.234
L/h/kg
3.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.57
L/kg
0.4-1
L/kg
DRUGBANK
0.8
L/kg
0.8±0.3
L/kg
Elderly → ;Hepatitis, Hep ↓ ;CPBS ↑ ;
DRUGBANK
0.45
L/kg
0.45
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.675
h
90-111
min
DRUGBANK
1.6
h
1.6±0.2
h
Hepatic cirrhosis, cirr ↑ ;CPBS ↑ ;Age ↑ ;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
1
%
Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
92.0
%
92
%
DRUGBANK
92.0
%
92±2
%
Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
DDPD00803
Colistin
1155.455
C52H98N16O13
CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
DB00803
131704173
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
Urinary excretion; Unchanged drug;
DRUGBANK
5.0
h
5
h
DRUGBANK
5450.0
mg/kg
5450.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00804
Dicyclomine
309.4867
C19H35NO2
CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
DB00804
3042
4514
http://www.drugs.com/cdi/dicyclomine.html
2934
-2.0
-
-2.0
-
DRUGBANK
1.25
h
1-1.5
h
DRUGBANK
3.65
L/kg
3.65
L/kg
intravenous injection, IV;
DRUGBANK
1.8
h
~1.8
h
elimination half-life;
DRUGBANK
625.0
mg/kg
625.0
mg/kg
PO, oral; mouse;
DRUGBANK
79.5
%
79.5
%
Urinary excretion;
DRUGBANK
8.4
%
8.4
%
Faeces excretion;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Bentyl
dicyclomine hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Bentyl
dicyclomine hydrochloride
PDR
80.0
mg/day
80
mg/day
IM,intramuscular injection
Bentyl
dicyclomine hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Bentyl
dicyclomine hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Bentyl
dicyclomine hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Bentyl
dicyclomine hydrochloride
PDR
DDPD00805
Minaprine
298.3828
C17H22N4O
CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1
DB00805
4199
51038
4054
-2.0
-
-2.0
-
DRUGBANK
DDPD00806
Pentoxifylline
278.307
C13H18N4O3
CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
DB00806
4740
7986
http://www.drugs.com/cdi/pentoxifylline.html
4578
-2.0
-
-2.0
-
DRUGBANK
2.34
L/h/kg
39
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
h
0.4-0.8
h
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1385.0
mg/kg
1385.0
mg/kg
PO, oral; mouse;
DRUGBANK
70.0
%
70
%
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Pentoxifylline
pentoxifylline
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Pentoxifylline
pentoxifylline
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Pentoxifylline
pentoxifylline
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Pentoxifylline
pentoxifylline
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Pentoxifylline
pentoxifylline
PDR
DDPD00807
Proparacaine
294.3892
C16H26N2O3
CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
DB00807
T3D2896
4935
8485
http://www.drugs.com/cdi/proparacaine-drops.html
4766
-2.0
-
-2.0
-
DRUGBANK
DDPD00808
Indapamide
365.835
C16H16ClN3O3S
CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
DB00808
3702
5893
http://www.drugs.com/cdi/indapamide.html
3574
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; food;
food → ;
DRUGBANK
2950.0
ng.h/ml
2.95
ug.h/ml
PO, oral;
DRUGBANK
363.0
ng/ml
363.0
ng/ml
PO, oral;
DRUGBANK
2.3
h
2.3
h
PO, oral;
DRUGBANK
0.1026
L/h
1.71
ml/min
Renal clearance;
DRUGBANK
1.302
L/h
20-23.4
ml/min
Total clearance;
DRUGBANK
42.5
L
25-60
L
Apparent volume of distribution;
DRUGBANK
15.95
h
13.9-18
h
elimination half-life; normal,healthy;
DRUGBANK
65.0
%
60-70
%
Urinary excretion;
DRUGBANK
19.5
%
16-23
%
Faeces excretion;
DRUGBANK
77.5
%
~76-79
%
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Indapamide
indapamide
PDR
5.0
mg/day
5
mg/day
PO, oral
Indapamide
indapamide
PDR
DDPD00809
Tropicamide
284.3529
C17H20N2O2
CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1
DB00809
5593
9757
http://www.drugs.com/cdi/tropicamide.html
5391
-2.0
-
-2.0
-
DRUGBANK
45.0
%
45
%
DRUGBANK
5.0
drop/day
5
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Mydriacyl
tropicamide
PDR
DDPD00810
Biperiden
311.4611
C21H29NO
OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1
DB00810
T3D2897
2381
3112
http://www.drugs.com/cdi/biperiden.html
2289
-2.0
-
-2.0
-
DRUGBANK
87.0
%
87
%
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
24
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
760.0
mg/kg
760.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
760.0
mg/kg
760.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD00811
Ribavirin
244.2047
C8H12N4O5
NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
DB00811
37542
63580
http://www.drugs.com/cdi/ribavirin.html
34439
-2.0
-
-2.0
-
DRUGBANK
64.0
%
64
%
Oral single dose;
DRUGBANK
45.0
%
45±5
%
PO, oral; Male, men; AIDS,HIV;
DRUGBANK
3687490.97
ng/ml
15.1±12.8
mM
PO, oral; adults; HCV-positive;
DRUGBANK
2710672.17
ng/ml
11.1±1.2
mM
Capsule, PO, Oral; adults; AIDS,HIV;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
3.0
h
3±1.8
h
PO, oral; adults; HCV-positive;
DRUGBANK
26.0
L/h
26.0
L/h
Total clearance; Oral single dose;
DRUGBANK
0.3
L/h/kg
5.0±1.0
ml/min/kg
asymptomatic HIV-positive; Male, men;
DRUGBANK
0.312
L/h/kg
5.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.3
L/kg
9.3±1.5
L/kg
asymptomatic HIV-positive; Male, men;
DRUGBANK
14.0
L/kg
14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
145.0
h
~120-170
h
terminal half-life; Oral single dose;
DRUGBANK
28.0
h
28±7
h
Oral multiple dose;
DRUGBANK
150.0
h
150±5
h
terminal half-life;
DRUGBANK
45.0
h
45
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2700.0
mg/kg
2700.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
61.0
%
~61
%
Urinary excretion; PO, oral;
DRUGBANK
12.0
%
~12
%
Faeces excretion; PO, oral;
DRUGBANK
17.0
%
17
%
PO, oral; Unchanged drug;
DRUGBANK
35.0
%
35±8
%
Urinary excretion; Male, men; asymptomatic HIV-positive; human, homo sapiens; Unchanged drug;
DRUGBANK
0.0
%
0
%
Male, men; asymptomatic HIV-positive; human, homo sapiens;
DRUGBANK
DDPD00812
Phenylbutazone
308.3743
C19H20N2O2
CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
DB00812
4781
48574
4617
-2.0
-
-2.0
-
DRUGBANK
238.0
mg/kg
238.0
mg/kg
PO, oral; mouse;
DRUGBANK
781.0
mg/kg
781.0
mg/kg
PO, oral; rabbit;
DRUGBANK
245.0
mg/kg
245.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
375.0
mg/kg
375.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00813
Fentanyl
336.4705
C22H28N2O
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
DB00813
T3D2898
3345
119915
http://www.drugs.com/fentanyl.html
3228
-2.0
-
-2.0
-
DRUGBANK
2.86666666666667
ng.h/ml
172±96
ng.min/ml
Tablet, PO, oral;
DRUGBANK
25.1333333333333
ng.h/ml
1508±1360
ng.min/ml
Tablet, PO, oral;
DRUGBANK
1.25
ng.h/ml
1.25±0.67
ng.h/ml
sublingual;
DRUGBANK
10.38
ng.h/ml
10.38±3.70
ng.h/ml
sublingual; increasing doses;
increasing doses ↓ ;
DRUGBANK
0.42
ng.h/ml
0.42±0.35
ng.h/ml
Transdermal preparations;
DRUGBANK
3.772
ng.h/ml
3772.0
pg.h/ml
nasal spray;
DRUGBANK
3.772
ng.h/ml
3772.0
pg.h/ml
DRUGBANK
54.0
%
54
%
sublingual;
DRUGBANK
50.0
%
50
%
Tablet, PO, oral;
DRUGBANK
65.0
%
65
%
buccal;
DRUGBANK
76.0
%
76
%
sublingual;
DRUGBANK
82.0
%
82
%
nasal spray;
DRUGBANK
50.0
%
~50
%
buccal;
DRUGBANK
0.4
ng/ml
0.4±0.1
ng/ml
Tablet, PO, oral;
DRUGBANK
0.2
ng/ml
0.20±0.06
ng/ml
sublingual;
DRUGBANK
1.61
ng/ml
1.61±0.60
ng/ml
sublingual; increasing doses;
increasing doses ↓ ;
DRUGBANK
0.24
ng/ml
0.24±0.20
ng/ml
Transdermal preparations;
DRUGBANK
0.815
ng/ml
815±301
pg/ml
nasal spray;
DRUGBANK
0.815
ng/ml
815±301
pg/ml
DRUGBANK
0.8
ng/ml
0.8±0.3
ng/ml
buccal;
DRUGBANK
1.4
ng/ml
1.4±0.5
ng/ml
Transdermal preparations;
DRUGBANK
0.5
h
20-40
min
Tablet, PO, oral;
DRUGBANK
0.97
h
0.69-1.25
h
sublingual; increasing doses;
increasing doses ↓ ;
DRUGBANK
3.6
h
3.6±1.3
h
Transdermal preparations;
DRUGBANK
1.0
h
<1
h
nasal spray;
DRUGBANK
1.0
h
<1
h
DRUGBANK
0.4
h
0.4(0.3-6)
h
buccal;
DRUGBANK
35.0
h
35±15
h
Transdermal preparations;
DRUGBANK
0.5
L/h/kg
0.5(0.3-0.7)
L/h/kg
Plasma clearance;
DRUGBANK
51.0
L/h
27-75
L/h
intravenous injection, IV; patients;
DRUGBANK
41.5
L/h
3-80
L/h
hepatopathy，LD;
DRUGBANK
54.0
L/h
30-78
L/h
RD, renal impairment, Renal disease，including uremia;
DRUGBANK
0.78
L/h/kg
13±2
ml/min/kg
hydrolysis;
Neonates ↓ ;Children ↓ ;Elderly ↓ ;Prem, premature ↓ ;
DRUGBANK
0.282
L/h/kg
4.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
L/kg
3.0-8
L/kg
intravenous injection, IV;
DRUGBANK
25.4
L/kg
25.4
L/kg
PO, oral;
DRUGBANK
4.4
L/kg
0.8-8
L/kg
intravenous injection, IV; hepatopathy，LD; patients;
DRUGBANK
4.0
L/kg
4.0±0.4
L/kg
DRUGBANK
0.89
L/kg
0.89
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
7
h
DRUGBANK
8.5
h
5-12
h
sublingual;
DRUGBANK
3.7
h
3.7±0.4
h
Prem, premature ↑ ;Children → ;CPBS ↑ ;Age ↑ ;
DRUGBANK
3.0
h
3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.91
mg/kg
2.91
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
18.0
mg/kg
18.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
368.0
mg/kg
368.0
mg/kg
PO, oral; mouse;
DRUGBANK
3.1
mg/kg
3.1
mg/kg
Rattus, Rat;
DRUGBANK
0.03
mg/kg
0.03
mg/kg
monkey;
DRUGBANK
75.0
%
75
%
Urinary excretion;
DRUGBANK
9.0
%
9
%
Faeces excretion;
DRUGBANK
5.3
%
<5.3
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.09
%
0.09
%
Faeces excretion; Unchanged drug;
DRUGBANK
8.0
%
8
%
Urinary excretion; Unchanged drug;
DRUGBANK
82.5
%
80-85
%
plasma proteins;
DRUGBANK
77.9
%
77.9±1.1
%
human, homo sapiens;
DRUGBANK
12.0
%
12±5.4
%
human, homo sapiens;
DRUGBANK
84.0
%
84±2
%
DRUGBANK
4.0
dose/day
4
dose/day
Transdermal preparations
Abstral
fentanyl
PDR
800.0
mcg/dose
800
mcg/dose
Abstral
fentanyl
PDR
2.0
dose
2
dose
Abstral
fentanyl
PDR
4.0
treated episodes/day
4
treated episodes/day
Abstral
fentanyl
PDR
800.0
mcg/dose
800
mcg/dose
inhalation, IH
Abstral
fentanyl
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Abstral
fentanyl
PDR
40.0
mcg/dose
40
mcg/dose
Abstral
fentanyl
PDR
80.0
dose/day
80
dose/day
Abstral
fentanyl
PDR
4.0
units/day
4
units/day
Transdermal preparations
Abstral
fentanyl
PDR
4.0
dose/day
4
dose/day
Transdermal preparations
Abstral
fentanyl
PDR
800.0
mcg/dose
800
mcg/dose
Abstral
fentanyl
PDR
2.0
dose
2
dose
Abstral
fentanyl
PDR
4.0
treated episodes/day
4
treated episodes/day
Abstral
fentanyl
PDR
800.0
mcg/dose
800
mcg/dose
inhalation, IH
Abstral
fentanyl
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Abstral
fentanyl
PDR
40.0
mcg/dose
40
mcg/dose
Abstral
fentanyl
PDR
80.0
dose/day
80
dose/day
Abstral
fentanyl
PDR
DDPD00814
Meloxicam
351.401
C14H13N3O4S2
CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O
DB00814
T3D2899
54677470
6741
http://www.drugs.com/cdi/meloxicam.html
10442740
-2.0
-
-2.0
-
DRUGBANK
89.0
%
89
%
PO, oral;
DRUGBANK
97.0
%
97.0
%
PO, oral;
DRUGBANK
1900.0
ng/ml
1.9±0.6
mcg/ml
Capsule, PO, Oral;
DRUGBANK
5.5
h
5-6
h
PO, oral;
DRUGBANK
7.0
h
5-9
h
Capsule, PO, Oral;
DRUGBANK
100.0
%
~100
%
DRUGBANK
0.45
L/h
0.42–0.48
L/h
Total clearance; Oral single dose;
DRUGBANK
0.48
L/h
7.0-9
ml/min
Plasma clearance;
DRUGBANK
0.0066
L/h/kg
0.10-0.12
ml/min/kg
hydrolysis; hydrolysis; Male, men; Female, women;
DRUGBANK
0.0072
L/h/kg
0.12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.5
L
10.0-15
L
DRUGBANK
0.155
L/kg
0.15-0.16
L/kg
hydrolysis; hydrolysis; Male, men; Female, women;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
h
~20
h
DRUGBANK
16.5
h
15-18
h
Male, men; Female, women;
DRUGBANK
18.0
h
18
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
mg/kg
98.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
84.0
mg/kg
84.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
470.0
mg/kg
470.0
mg/kg
PO, oral; mouse;
DRUGBANK
320.0
mg/kg
320.0
mg/kg
PO, oral; rabbit;
DRUGBANK
0.25
%
<0.25
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.6
%
~1.6
%
Faeces excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; human, homo sapiens; Unchanged drug;
DRUGBANK
99.4
%
~99.4
%
DRUGBANK
99.4
%
~99.4
%
human, homo sapiens;
DRUGBANK
0.125
mg/kg/day
0.125
mg/kg/day
Tablet,PO，oral;Liquid;
Mobic
meloxicam
PDR
7.5
mg/day
7.5
mg/day
Tablet,PO，oral;Liquid;
Mobic
meloxicam
PDR
15.0
mg/day
15
mg/day
Tablet,PO，oral;Liquid;
Mobic
meloxicam
PDR
10.0
mg/day
10
mg/day
Capsule, PO, Oral
Mobic
meloxicam
PDR
30.0
mg/day
30
mg/day
intravenous injection, IV
Mobic
meloxicam
PDR
0.125
mg/kg/day
0.125
mg/kg/day
Tablet,PO，oral;Liquid;
Mobic
meloxicam
PDR
7.5
mg/day
7.5
mg/day
Tablet,PO，oral;Liquid;
Mobic
meloxicam
PDR
15.0
mg/day
15
mg/day
Tablet,PO，oral;Liquid;
Mobic
meloxicam
PDR
10.0
mg/day
10
mg/day
Capsule, PO, Oral
Mobic
meloxicam
PDR
30.0
mg/day
30
mg/day
intravenous injection, IV
Mobic
meloxicam
PDR
DDPD00816
Orciprenaline
211.2576
C11H17NO3
CC(C)NCC(O)C1=CC(O)=CC(O)=C1
DB00816
4086
83329
3944
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
DRUGBANK
6.0
h
6
h
DRUGBANK
42.0
mg/kg
42.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
80.0
mg/day
80
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
40.0
mg/day
40
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
40.0
mg/day
40
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
80.0
mg/day
80
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
80.0
mg/day
80
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
80.0
mg/day
80
mg/day
PO, oral
Metaproterenol Sulfate Syrup
metaproterenol sulfate
PDR
DDPD00817
Rosoxacin
294.3047
C17H14N2O3
CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
DB00817
287180
131715
253208
-2.0
-
-2.0
-
DRUGBANK
DDPD00818
Propofol
178.2707
C12H18O
CC(C)C1=CC=CC(C(C)C)=C1O
DB00818
T3D2900
4943
44915
http://www.drugs.com/propofol.html
4774
-2.0
-
-2.0
-
DRUGBANK
3500.0
ng/ml
3.5±0.06
mcg/ml
intravenous injection, IV;
DRUGBANK
1100.0
ng/ml
1.1±0.4
mcg/ml
PO, oral; patients;
DRUGBANK
2.19
L/h/kg
23-50
ml/kg/min
DRUGBANK
150.0
L/h
1.6-3.4
L/min
adults;
DRUGBANK
1.62
L/h/kg
27±5
ml/min/kg
surgery; normal,healthy; metabolism of ugt;
Children ↑ ;Elderly ↓ ;hepatopathy，LD → ;
DRUGBANK
2.16
L/h/kg
36
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
L/kg
60.0
L/kg
normal,healthy; adults;
DRUGBANK
1.7
L/kg
1.7±0.7
L/kg
Apparent volume of distribution; surgery; normal,healthy; metabolism of ugt;
Children ↑ ;Elderly ↓ ;
DRUGBANK
4.7
L/kg
4.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0941666666666667
h
1.8-9.5
min
distribution half-life;
DRUGBANK
0.758333333333333
h
21-70
min
elimination half-life;
DRUGBANK
16.25
h
1.5-31
h
elimination half-life;
DRUGBANK
3.5
h
3.5±1.2
h
DRUGBANK
3.2
h
3.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
53.0
mg/kg
53.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
42.0
mg/kg
42.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
1230.0
mg/kg
1230.0
mg/kg
PO, oral; mouse;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
53.0
mg/kg
53.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
42.0
mg/kg
42.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
1230.0
mg/kg
1230.0
mg/kg
PO, oral; mouse;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
97.0
%
95-99
%
DRUGBANK
98.55
%
98.3-98.8
%
DRUGBANK
DDPD00819
Acetazolamide
222.245
C4H6N4O3S2
CC(=O)NC1=NN=C(S1)S(N)(=O)=O
DB00819
1986
27690
http://www.drugs.com/cdi/acetazolamide.html
1909
-2.0
-
-2.0
-
DRUGBANK
0.039
L/h/kg
0.65
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.37
L/kg
0.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
3-9
h
DRUGBANK
13.0
h
13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
98
%
DRUGBANK
1000.0
mg/day
1000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
250.0
mg/day
250
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
750.0
mg/day
750
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
250.0
mg/day
250
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
750.0
mg/day
750
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
4000.0
mg/day
4000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
250.0
mg/day
250
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
750.0
mg/day
750
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
1000.0
mg/day
1000
mg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
4000.0
mg/day
4000
mg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Diamox Sequels
acetazolamide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Diamox Sequels
acetazolamide
PDR
DDPD00820
Tadalafil
389.404
C22H19N3O4
[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1
DB00820
110635
71940
http://www.drugs.com/tadalafil.html
99301
-2.0
-
-2.0
-
DRUGBANK
378.0
ng/ml
378.0
ng/ml
Oral single dose;
DRUGBANK
2.0
h
2(0.5-6)
h
Oral single dose;
DRUGBANK
2.0
h
2.0
h
Oral single dose;
DRUGBANK
2.5
L/h
2.5
L/h
PO, oral;
DRUGBANK
0.0354
L/h/kg
0.59
ml/min/kg
apparent clearance; hydrolysis;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
63.0
L
63.0
L
DRUGBANK
0.89
L/kg
0.89
L/kg
Apparent volume of distribution; hydrolysis;
DRUGBANK
17.5
h
17.5
h
DRUGBANK
17.5
h
17.5
h
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
61.0
%
~61
%
Faeces excretion;
DRUGBANK
36.0
%
~36
%
Urinary excretion;
DRUGBANK
94.0
%
94
%
DRUGBANK
94.0
%
94
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Adcirca
tadalafil
PDR
5.0
mg/day
5
mg/day
PO, oral
qd
Adcirca
tadalafil
PDR
20.0
mg/day
20
mg/day
PO, oral
Adcirca
tadalafil
PDR
5.0
mg/day
5
mg/day
PO, oral
qd
Adcirca
tadalafil
PDR
40.0
mg/day
40
mg/day
PO, oral
Adcirca
tadalafil
PDR
5.0
mg/day
5
mg/day
PO, oral
qd
Adcirca
tadalafil
PDR
20.0
mg/day
20
mg/day
PO, oral
Adcirca
tadalafil
PDR
5.0
mg/day
5
mg/day
PO, oral
qd
Adcirca
tadalafil
PDR
DDPD00821
Carprofen
273.714
C15H12ClNO2
CC(C(O)=O)C1=CC2=C(C=C1)C1=C(N2)C=CC(Cl)=C1
DB00821
2581
364453
2483
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
0.0306
L/h/kg
0.51
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
~8(4.5-9.8)
h
dog;
DRUGBANK
9.9
h
9.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
282.0
mg/kg
282.0
mg/kg
PO, oral; mouse;
DRUGBANK
149.0
mg/kg
149.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
99.0
%
99
%
DRUGBANK
DDPD00822
Disulfiram
296.539
C10H20N2S4
CCN(CC)C(=S)SSC(=S)N(CC)CC
DB00822
T3D2557
3117
4659
http://www.drugs.com/cdi/disulfiram.html
3005
-2.0
-
-2.0
-
DRUGBANK
85.0
%
80-90
%
PO, oral;
DRUGBANK
8600.0
mg/kg
8.6
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
8600.0
mg/kg
8.6
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00823
Ethynodiol diacetate
384.5085
C24H32O4
[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]
DB00823
9270
31580
8913
-2.0
-
-2.0
-
DRUGBANK
67.5
%
50-85
%
DRUGBANK
DDPD00824
Enprofylline
194.1906
C8H10N4O2
CCCN1C2=C(NC=N2)C(=O)NC1=O
DB00824
1676
126237
1613
-2.0
-
-2.0
-
DRUGBANK
0.24
L/h/kg
4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.63
L/kg
0.63
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
h
1.9
h
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
49.0
%
49
%
DRUGBANK
DDPD00825
Levomenthol
156.269
C10H20O
CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
DB00825
T3D3224
16666
15409
http://www.drugs.com/cdi/menthol-cream.html
15803
-2.0
-
-2.0
-
DRUGBANK
2900.0
mg/kg
2900.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3100.0
mg/kg
3100.0
mg/kg
PO, oral; mouse;
DRUGBANK
5001.0
mg/kg
5001.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
2900.0
mg/kg
2900.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3100.0
mg/kg
3100.0
mg/kg
PO, oral; mouse;
DRUGBANK
5001.0
mg/kg
5001.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
10001.0
mg/kg
10001.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00826
Natamycin
665.733
C33H47NO13
[H][C@@]12C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(O)=O)[C@]([H])(C[C@@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O)\C=C\C=C\C=C\C=C\C[C@@H](C)OC(=O)\C=C\[C@@]1([H])O2)O3
DB00826
5284447
http://www.drugs.com/cdi/natamycin.html
10468784
-2.0
-
-2.0
-
DRUGBANK
24.0
drop/day
24
drop/day
ophthalmic administration
Natacyn
natamycin
PDR
24.0
drop/day
24
drop/day
ophthalmic administration
Natacyn
natamycin
PDR
DDPD00827
Cinoxacin
262.2182
C12H10N2O5
CCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12
DB00827
2762
3716
http://www.drugs.com/cons/cinoxacin.html
2660
-2.0
-
-2.0
-
DRUGBANK
35.0
%
30-40
%
Liver metabolism; Inactive metabolite;
DRUGBANK
1.5
h
1.5
h
elimination half-life;
DRUGBANK
10.0
h
>10
h
RD, renal impairment, Renal disease，including uremia;
DRUGBANK
3610.0
mg/kg
3610.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1380.0
mg/kg
1380.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
860.0
mg/kg
860.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
2330.0
mg/kg
2330.0
mg/kg
PO, oral; mouse;
DRUGBANK
900.0
mg/kg
900.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
850.0
mg/kg
850.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
70.0
%
60-80
%
DRUGBANK
DDPD00828
Fosfomycin
138.059
C3H7O4P
C[C@@H]1O[C@@H]1P(O)(O)=O
DB00828
446987
28915
http://www.drugs.com/cdi/fosfomycin.html
394204
-2.0
-
-2.0
-
DRUGBANK
37.0
%
37
%
PO, oral; fasting;
DRUGBANK
30.0
%
30
%
PO, oral; food;
food ↓ ;
DRUGBANK
0.0
%
0
%
DRUGBANK
16.9
L/h
16.9±3.5
L/h
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
136.1
L
136.1±44.1
L
DRUGBANK
0.32
L/kg
0.32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.7
h
5.7±2.8
h
DRUGBANK
40.0
h
40
h
elimination half-life; anuric; patients;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
0.0
%
0
%
DRUGBANK
3000.0
mg/dose
3
g/dose
PO, oral
Monurol
fosfomycin tromethamine
PDR
3.0
g/dose
3
g/dose
PO, oral
Monurol
fosfomycin tromethamine
PDR
DDPD00829
Diazepam
284.74
C16H13ClN2O
CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1
DB00829
T3D2903
3016
49575
http://www.drugs.com/diazepam.html
2908
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
100.0
%
100±14
%
PO, oral;
DRUGBANK
90.0
%
90.0
%
Rectal Administration;
DRUGBANK
317.0
ng/ml
317±27
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
400.0
ng/ml
~400
ng/ml
Rectal Administration; adults; normal,healthy;
DRUGBANK
450.0
ng/ml
400-500
ng/ml
adults; normal,healthy;
DRUGBANK
1.25
h
1-1.5（0.25-2.5）
h
PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral; food;
food ↑ ;
DRUGBANK
1.3
h
1.3±0.2
h
Oral single dose; adults; normal,healthy;
DRUGBANK
1.5
h
1.5
h
Rectal Administration; adults; normal,healthy;
DRUGBANK
1.5
L/h
20-30
ml/min
young; adults;
DRUGBANK
0.0228
L/h/kg
0.38±0.06
ml/min/kg
Elderly → ;Hepatic cirrhosis, cirr ↓ ;hyperthyroid, HTh → ;hypoalbuminemia ↑ ;Somking → ;
DRUGBANK
0.0228
L/h/kg
0.38
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
L/kg
0.8-1
L/kg
at steady state; normal,healthy; young; Male, men;
DRUGBANK
1.1
L/kg
1.1±0.3
L/kg
Elderly ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;hyperthyroid, HTh → ;hypoalbuminemia ↑ ;
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
h
1-2
day
elimination half-life;
Neonates ↑ ;Elderly ↑ ;hepatopathy，LD ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
84.0
h
2-5
day
DRUGBANK
43.0
h
43±13
h
Active metabolite;
Hepatic cirrhosis, cirr ↑ ;hyperthyroid, HTh → ;Age ↑ ;
DRUGBANK
42.0
h
42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1200.0
mg/kg
1200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; dog;
DRUGBANK
700.0
mg/kg
700.0
mg/kg
PO, oral; mouse;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.5
%
98-99
%
DRUGBANK
98.7
%
98.7±0.2
%
Preg, pregnant ↓ ;Neonates ↓ ;Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;nephritic syndrome ↓ ;hypoalbuminemia Alb ↓ ;Burn ↓ ;hyperthyroid, HTh → ;
DRUGBANK
0.6
mg/kg
0.6
mg/kg
intravenous injection, IV
tid
Valium
diazepam
PDR
40.0
mg/day
40
mg/day
PO, oral
Valium
diazepam
PDR
0.6
mg/kg
0.6
mg/kg
intravenous injection, IV
tid
Valium
diazepam
PDR
40.0
mg/day
40
mg/day
PO, oral
Valium
diazepam
PDR
DDPD00830
Phenmetrazine
177.2429
C11H15NO
CC1NCCOC1C1=CC=CC=C1
DB00830
T3D2904
4762
8067
4598
-2.0
-
-2.0
-
DRUGBANK
23.5
h
16-31
h
DRUGBANK
17.5
mg/kg
15-20
mg/kg
adults; monkey;
DRUGBANK
5.0
mg/kg
5.0
mg/kg
young; monkey;
DRUGBANK
17.5
mg/kg
15-20
mg/kg
adults; monkey;
DRUGBANK
5.0
mg/kg
5.0
mg/kg
young; monkey;
DRUGBANK
DDPD00831
Trifluoperazine
407.496
C21H24F3N3S
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
DB00831
T3D2905
5566
45951
http://www.drugs.com/cdi/trifluoperazine.html
5365
-2.0
-
-2.0
-
DRUGBANK
15.0
h
10-20
h
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Trifluoperazine Hydrochloride
trifluoperazine hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Trifluoperazine Hydrochloride
trifluoperazine hydrochloride
PDR
15.0
mg/day
15
mg/day
PO, oral
Trifluoperazine Hydrochloride
trifluoperazine hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Trifluoperazine Hydrochloride
trifluoperazine hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Trifluoperazine Hydrochloride
trifluoperazine hydrochloride
PDR
DDPD00832
Phensuximide
189.2105
C11H11NO2
CN1C(=O)CC(C1=O)C1=CC=CC=C1
DB00832
6839
8079
6578
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
21.0
%
21
%
DRUGBANK
DDPD00833
Cefaclor
367.807
C15H14ClN3O4S
[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
DB00833
51039
3478
http://www.drugs.com/cdi/cefaclor.html
46260
-2.0
-
-2.0
-
DRUGBANK
72.5
%
60-85
%
Urinary excretion;
DRUGBANK
0.75
h
0.6-0.9
h
DRUGBANK
72.5
%
~60-85
%
Urinary excretion;
DRUGBANK
72.5
%
~60-85
%
Urinary excretion; Unchanged drug;
DRUGBANK
23.5
%
23.5
%
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1000.0
mg/day
1
g/day
intravenous injection, IV
Cefaclor Extended-Release Tablets
cefaclor
PDR
1500.0
mg/day
1.5
g/day
Capsule, PO, Oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1500.0
mg/day
1.5
g/day
Liquid
Cefaclor Extended-Release Tablets
cefaclor
PDR
1000.0
mg/day
1
g/day
Tablet,PO，oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1000.0
mg/day
1
g/day
PO, oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1000.0
mg/day
1
g/day
PO, oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1000.0
mg/day
1
g/day
PO, oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1500.0
mg/day
1.5
g/day
Capsule, PO, Oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
1500.0
mg/day
1.5
g/day
Liquid
Cefaclor Extended-Release Tablets
cefaclor
PDR
1000.0
mg/day
1
g/day
Tablet,PO，oral
Cefaclor Extended-Release Tablets
cefaclor
PDR
40.0
mg/kg/day
40
mg/kg/day
Liquid
Cefaclor Extended-Release Tablets
cefaclor
PDR
DDPD00834
Mifepristone
429.5937
C29H35NO2
[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
DB00834
T3D2907
55245
50692
http://www.drugs.com/cdi/mifepristone.html
49889
-2.0
-
-2.0
-
DRUGBANK
69.0
%
69
%
PO, oral;
DRUGBANK
0.03
L/h/kg
0.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.45
L/kg
0.45
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
18
h
DRUGBANK
16.6
h
16.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
83.0
%
83
%
Faeces excretion;
DRUGBANK
9.0
%
9
%
Urinary excretion;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
200.0
mg/dose
200
mg/dose
Korlym
mifepristone
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Korlym
mifepristone
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Korlym
mifepristone
PDR
DDPD00835
Brompheniramine
319.239
C16H19BrN2
CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1
DB00835
T3D4554
6834
3183
http://www.drugs.com/cdi/brompheniramine-12-hour-sustained-release-tablets.html
6573
-2.0
-
-2.0
-
DRUGBANK
318.0
mg/kg
318.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
318.0
mg/kg
318.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00836
Loperamide
477.038
C29H33ClN2O2
CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
DB00836
3955
6532
http://www.drugs.com/cdi/loperamide.html
3818
-2.0
-
-2.0
-
DRUGBANK
10.8
h
10.8(9.1-14.4)
h
DRUGBANK
105.0
mg/kg
105.0
mg/kg
PO, oral; mouse;
DRUGBANK
97.0
%
97
%
DRUGBANK
8.0
mg/day
8
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
16.0
mg/day
16
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
6.0
mg/day
6
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
4.0
mg/day
4
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
3.0
mg/day
3
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
8.0
mg/day
8
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
16.0
mg/day
16
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
8.0
mg/day
8
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
16.0
mg/day
16
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
8.0
mg/day
8
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
16.0
mg/day
16
mg/day
PO, oral
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
0.0
0
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
0.0
0
Loperamide Hydrochloride Capsules
loperamide hydrochloride
PDR
DDPD00838
Clocortolone
410.907
C22H28ClFO4
[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB00838
5311052
59582
http://www.drugs.com/cdi/clocortolone.html
4470589
-2.0
-
-2.0
-
DRUGBANK
3.0
application/day
3
application/day
skin/dermal
Cloderm
clocortolone pivalate
PDR
3.0
application/day
3
application/day
skin/dermal
Cloderm
clocortolone pivalate
PDR
3.0
application/day
3
application/day
skin/dermal
Cloderm
clocortolone pivalate
PDR
DDPD00839
Tolazamide
311.4
C14H21N3O3S
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
DB00839
T3D4765
5503
9613
http://www.drugs.com/cdi/tolazamide.html
5302
-2.0
-
-2.0
-
DRUGBANK
7.0
h
7
h
elimination half-life;
DRUGBANK
1000.0
mg/day
1000
mg/day
PO, oral
Tolazamide
tolazamide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
qd
Tolazamide
tolazamide
PDR
DDPD00840
Hydroxypropyl cellulose
N.A.
N.A.
CC(COCC1C(C(C(C(O1)OC2C(OC(C(C2OCC(C)O)OCC(C)O)OCC(C)O)COCC(C)O)OCC(C)O)OCC(C)O)OCC(C)O)O
DB00840
71306830
http://www.drugs.com/cdi/artificial-tear-insert.html
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
10200.0
mg/kg
10200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00841
Dobutamine
301.3801
C18H23NO3
CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1
DB00841
36811
4670
http://www.drugs.com/cdi/dobutamine.html
33786
-2.0
-
-2.0
-
DRUGBANK
6.9
L/h/kg
115
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0333333333333333
h
2
min
DRUGBANK
28.8
mg/kg/day
20
mcg/kg/minute
intravenous infusion, iv in drop
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
57.6
mg/kg/day
40
mcg/kg/minute
intravenous infusion, iv in drop; rarely
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
28.8
mg/kg/day
20
mcg/kg/min
intravenous infusion, iv in drop
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
57.6
mg/kg/day
40
mcg/kg/min
intravenous infusion, iv in drop; rarely
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
28.8
mg/kg/day
20
mcg/kg/minute
intravenous infusion, iv in drop
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
57.6
mg/kg/day
40
mcg/kg/minute
intravenous infusion, iv in drop; rarely
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
28.8
mg/kg/day
20
mcg/kg/minute
intravenous infusion, iv in drop
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
57.6
mg/kg/day
40
mcg/kg/minute
intravenous infusion, iv in drop; rarely
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
28.8
mg/kg/day
20
mcg/kg/min
intravenous infusion, iv in drop
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
57.6
mg/kg/day
40
mcg/kg/min
intravenous infusion, iv in drop; rarely
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
28.8
mg/kg/day
20
mcg/kg/minute
intravenous infusion, iv in drop
Dobutamine Hydrochloride in 5% Dextrose
dobutamine hydrochloride
PDR
DDPD00842
Oxazepam
286.713
C15H11ClN2O2
OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2
DB00842
T3D2909
4616
7823
http://www.drugs.com/cdi/oxazepam.html
4455
-2.0
-
-2.0
-
DRUGBANK
450000000.0
ng/ml
450.0
mg/ml
PO, oral;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
0.066
L/h/kg
1.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.59
L/kg
0.59
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.2
h
8.2
h
elimination half-life;
DRUGBANK
6.7
h
6.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8000.0
mg/kg
>8000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1540.0
mg/kg
1540.0
mg/kg
PO, oral; mouse;
DRUGBANK
21.0
%
~21
%
Faeces excretion; Unchanged drug;
DRUGBANK
89.0
%
~89
%
plasma proteins;
DRUGBANK
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Oxazepam
oxazepam
PDR
120.0
mg/day
120
mg/day
PO, oral
Oxazepam
oxazepam
PDR
120.0
mg/day
120
mg/day
PO, oral
Oxazepam
oxazepam
PDR
60.0
mg/day
60
mg/day
PO, oral
Oxazepam
oxazepam
PDR
120.0
mg/day
120
mg/day
PO, oral
Oxazepam
oxazepam
PDR
DDPD00843
Donepezil
379.492
C24H29NO3
COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1
DB00843
T3D2910
3152
53289
http://www.drugs.com/cdi/donepezil.html
3040
-2.0
-
-2.0
-
DRUGBANK
223.63
ng.h/ml
221.9-225.36
ng.h/ml
Tablet, PO, oral;
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
8.34
ng/ml
8.34
ng/ml
Tablet, PO, oral;
DRUGBANK
30.8
ng/ml
30.8±4.2
ng/ml
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
4.1
h
4.1±1.5
h
PO, oral; different study;
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
432.0
h
15-21
day
PO, oral;
DRUGBANK
0.16
L/h/kg
0.13-0.19
L/h/kg
Plasma clearance;
DRUGBANK
0.11
L/h/kg
0.110±0.02
L/h/kg
Plasma clearance; normal,healthy; patients;
Hepatitis, Hep ↓ ;
DRUGBANK
0.174
L/h/kg
2.90±0.74
ml/min/kg
apparent clearance; PO, oral; hydrolysis; hydrolysis; metabolism of ugt; young; adults; Male, men; Female, women;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
11.8
L/kg
11.8 ± 1.7
L/kg
DRUGBANK
11.6
L/kg
11.6 ± 1.91
L/kg
DRUGBANK
14.0
L/kg
12-16.0
L/kg
at steady state;
DRUGBANK
14.0
L/kg
14.0±2.42
L/kg
Apparent volume of distribution; PO, oral; hydrolysis; hydrolysis; metabolism of ugt; young; adults; Male, men; Female, women;
Elderly ↑ ;
DRUGBANK
70.0
h
~70
h
elimination half-life;
DRUGBANK
81.5
h
81.5±22
h
DRUGBANK
59.7
h
59.7±16.1
h
young; normal,healthy; Male, men; Female, women; PO, oral;
Age ↑ ;
DRUGBANK
32.6
mg/kg
32.6
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
57.0
%
57
%
Urinary excretion; adults; normal,healthy; human, homo sapiens;
DRUGBANK
5.0
%
5
%
Faeces excretion; adults; normal,healthy; guinea pigs;
DRUGBANK
10.6
%
10.6±2.7
%
Urinary excretion; adults; human, homo sapiens; Unchanged drug;
DRUGBANK
96.0
%
96
%
DRUGBANK
75.0
%
~75
%
DRUGBANK
21.0
%
~21
%
DRUGBANK
92.6
%
92.6±0.9
%
young; normal,healthy; human, homo sapiens;
DRUGBANK
23.0
mg/day
23
mg/day
PO, oral
Aricept
donepezil hydrochloride
PDR
23.0
mg/day
23
mg/day
PO, oral
Aricept
donepezil hydrochloride
PDR
DDPD00844
Nalbuphine
357.4434
C21H27NO4
O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5
DB00844
T3D2911
5311304
7454
http://www.drugs.com/cdi/nalbuphine.html
4470813
-2.0
-
-2.0
-
DRUGBANK
81.0
%
81
%
IM,intramuscular injection;
DRUGBANK
83.0
%
83
%
IM,intramuscular injection;
DRUGBANK
79.0
%
79
%
subcutaneous injection, SC;
DRUGBANK
76.0
%
76
%
subcutaneous injection, SC;
DRUGBANK
1.32
L/h/kg
22
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.6
L/kg
4.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~5
h
elimination half-life;
DRUGBANK
3.7
h
3.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; dog;
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; dog;
DRUGBANK
20.0
mg/dose
20
mg/dose
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Nalbuphine Hydrochloride
nalbuphine hydrochloride
PDR
160.0
mg/day
160
mg/day
intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Nalbuphine Hydrochloride
nalbuphine hydrochloride
PDR
DDPD00845
Clofazimine
473.396
C27H22Cl2N4
CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1
DB00845
2794
3749
http://www.drugs.com/cons/clofazimine.html
2692
-2.0
-
-2.0
-
DRUGBANK
53.5
%
45-62
%
PO, oral; leprosy;
DRUGBANK
410.0
ng/ml
0.41
mg/L
PO, oral; food;
DRUGBANK
8.0
h
8
h
PO, oral; food;
DRUGBANK
12.0
h
12
h
PO, oral; fasting;
fasting ↑ ;
DRUGBANK
600.0
h
~25
day
elimination half-life;
DRUGBANK
8400.0
mg/kg
8400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD00846
Flurandrenolide
436.5136
C24H33FO6
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
DB00846
15209
5127
http://www.drugs.com/cdi/flurandrenolide-cream.html
14475
-2.0
-
-2.0
-
DRUGBANK
3.0
application/day
3
application/day
skin/dermal
Cordran Lotion
flurandrenolide
PDR
3.0
application/day
3
application/day
skin/dermal
Cordran Lotion
flurandrenolide
PDR
3.0
application/day
3
application/day
skin/dermal
Cordran Lotion
flurandrenolide
PDR
DDPD00847
Cysteamine
77.149
C2H7NS
NCCS
DB00847
6058
17141
http://www.drugs.com/cdi/cysteamine.html
5834
-2.0
-
-2.0
-
DRUGBANK
1.4
h
1.4
h
DRUGBANK
72.0
L/h
~1.2
L/min
Plasma clearance;
DRUGBANK
156.0
L
156.0
L
DRUGBANK
52.0
%
52
%
plasma proteins;
DRUGBANK
1950.0
mg/m2/day
1.95
g/m2/day
PO, oral
Cystagon
cysteamine bitartrate
PDR
1.0
drop/eye/hour
1
drop/eye/hour
ophthalmic administration
Cystagon
cysteamine bitartrate
PDR
1950.0
mg/m2/day
1.95
g/m2/day
PO, oral
Cystagon
cysteamine bitartrate
PDR
1.0
drop/eye/h
1
drop/eye/h
ophthalmic administration
Cystagon
cysteamine bitartrate
PDR
1950.0
mg/m2/day
1.95
g/m2/day
PO, oral
Cystagon
cysteamine bitartrate
PDR
1.0
drop/hour
1
drop/eye/hour
ophthalmic administration
Cystagon
cysteamine bitartrate
PDR
1.95
g/m2/day
1.95
g/m2/day
PO, oral
Cystagon
cysteamine bitartrate
PDR
1.0
drop/eye/hour
1
drop/eye/hour
ophthalmic administration
Cystagon
cysteamine bitartrate
PDR
1950.0
mg/m2/day
1.95
g/m2/day
PO, oral
Cystagon
cysteamine bitartrate
PDR
1.0
drop/eye/h
1
drop/eye/h
ophthalmic administration; during waking hours
Cystagon
cysteamine bitartrate
PDR
DDPD00848
Levamisole
204.291
C11H12N2S
C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
DB00848
26879
6432
http://www.drugs.com/mtm/levamisole.html
25037
-2.0
-
-2.0
-
DRUGBANK
5.0
h
4.4-5.6
h
DRUGBANK
40.0
mg/kg
40.0
mg/kg
subcutaneous injection, SC; pig;
DRUGBANK
180.0
mg/kg
180.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
22.5
%
20-25
%
DRUGBANK
DDPD00849
Methylphenobarbital
246.2619
C13H14N2O3
CCC1(C(=O)NC(=O)N(C)C1=O)C1=CC=CC=C1
DB00849
8271
6758
7972
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral;
DRUGBANK
75.0
%
75
%
Liver metabolism;
DRUGBANK
34.0
h
34(11-67)
h
DRUGBANK
73.0
%
70-76
%
DRUGBANK
DDPD00850
Perphenazine
403.969
C21H26ClN3OS
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
DB00850
T3D2913
4748
8028
http://www.drugs.com/cdi/perphenazine.html
4586
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
1.62
L/h/kg
27
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
L/kg
18
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.0
h
8-12(8-20)
h
DRUGBANK
9.4
h
9.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
318.0
mg/kg
318.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
64.0
mg/kg
64.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
318.0
mg/kg
318.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
64.0
mg/kg
64.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
24.0
mg/day
24
mg/day
PO, oral
Perphenazine
perphenazine
PDR
64.0
mg/day
64
mg/day
PO, oral
Perphenazine
perphenazine
PDR
24.0
mg/day
24
mg/day
PO, oral
Perphenazine
perphenazine
PDR
64.0
mg/day
64
mg/day
PO, oral
Perphenazine
perphenazine
PDR
24.0
mg/day
24
mg/day
PO, oral
Perphenazine
perphenazine
PDR
64.0
mg/day
64
mg/day
PO, oral
Perphenazine
perphenazine
PDR
24.0
mg/day
24
mg/day
PO, oral
Perphenazine
perphenazine
PDR
64.0
mg/day
64
mg/day
PO, oral
Perphenazine
perphenazine
PDR
DDPD00851
Dacarbazine
182.187
C6H10N6O
CN(C)\N=N\C1=C(N=CN1)C(N)=O
DB00851
T3D4689
5351166
4305
http://www.drugs.com/cdi/dacarbazine.html
10481959
-2.0
-
-2.0
-
DRUGBANK
0.156
L/h/kg
2.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5
h
DRUGBANK
6.2
h
6.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
PO, oral; mouse;
DRUGBANK
350.0
mg/kg
350.0
mg/kg
PO, oral; mouse;
DRUGBANK
5.0
%
<5
%
DRUGBANK
375.0
mg/m2/dose
375
mg/m2/dose
intravenous injection, IV
Dacarbazine
dacarbazine
PDR
900.0
mg/m2/dose
900
mg/m2/dose
intravenous injection, IV
Dacarbazine
dacarbazine
PDR
1000.0
mg/m2/dose
1000
mg/m2/dose
intravenous injection, IV
Dacarbazine
dacarbazine
PDR
375.0
mg/m2/dose
375
mg/m2/dose
intravenous injection, IV
Dacarbazine
dacarbazine
PDR
900.0
mg/m2/dose
900
mg/m2/dose
intravenous injection, IV
Dacarbazine
dacarbazine
PDR
1000.0
mg/m2/dose
1000
mg/m2/dose
intravenous injection, IV
Dacarbazine
dacarbazine
PDR
DDPD00852
Pseudoephedrine
165.2322
C10H15NO
CN[C@@H](C)[C@@H](O)C1=CC=CC=C1
DB00852
T3D4555
7028
51209
http://www.drugs.com/pseudoephedrine.html
6761
-2.0
-
-2.0
-
DRUGBANK
6862.0
ng.h/ml
6862.0±334.1
ng.h/ml
PO, oral; food;
DRUGBANK
7535.1
ng.h/ml
7535.1±333.0
ng.h/ml
PO, oral; fasting;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
246.3
null
246.3±10.5
null
PO, oral;
DRUGBANK
246.3
ng/ml
246.3±10.5
ng/ml
PO, oral; food;
DRUGBANK
272.5
ng/ml
272.5±13.4
ng/ml
PO, oral; fasting;
DRUGBANK
268.5
ng/ml
177-360
ng/ml
Oral single dose; immediate release formulation;
DRUGBANK
289.5
ng/ml
265-314
ng/ml
Oral single dose; extended release formulation;
DRUGBANK
6.6
h
6.60±1.38
h
PO, oral; food;
DRUGBANK
11.87
h
11.87±0.72
h
PO, oral; fasting;
DRUGBANK
1.7
h
1.4-2
h
Oral single dose; immediate release formulation;
DRUGBANK
4.95
h
3.8-6.1
h
Oral single dose; extended release formulation;
DRUGBANK
1.0
%
<1
%
Inactive metabolite;
DRUGBANK
0.354
L/h/kg
5.9±1.7
ml/min/kg
PO, oral;
DRUGBANK
0.4398
L/h/kg
7.33
ml/min/kg
hydrolysis;
DRUGBANK
2.95
L/kg
2.6-3.3
L/kg
Apparent volume of distribution;
DRUGBANK
3.075
L/kg
2.64-3.51
L/kg
DRUGBANK
6.0
h
6
h
elimination half-life;
DRUGBANK
6.15
h
4.3-8
h
PO, oral;
Urine alkaline ↑ ;
DRUGBANK
2206.0
mg/kg
2206.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
726.0
mg/kg
726.0
mg/kg
PO, oral; mouse;
DRUGBANK
65.0
%
55-75
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
69.5
%
43-96
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
6.6
%
6.6±0.4
%
Raceme L; human, homo sapiens;
DRUGBANK
22.5
%
22.5±3.2
%
Raceme L; human, homo sapiens;
DRUGBANK
6.7
%
6.7±1.2
%
Raceme D; human, homo sapiens;
DRUGBANK
25.4
%
25.4±3.9
%
Raceme D; human, homo sapiens;
DRUGBANK
240.0
mg/day
240
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
120.0
mg/day
120
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
240.0
mg/day
240
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
240.0
mg/day
240
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
240.0
mg/day
240
mg/day
PO, oral
Children's Sudafed Non-Drowsy
pseudoephedrine hydrochloride
PDR
DDPD00853
Temozolomide
194.1508
C6H6N6O2
CN1N=NC2=C(N=CN2C1=O)C(N)=O
DB00853
5394
72564
http://www.drugs.com/cdi/temozolomide.html
5201
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
5.5
L/h/m2
5.5
L/h/m2
DRUGBANK
0.216
L/h/kg
3.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.4
L/kg
0.4
L/kg
DRUGBANK
0.5
L/kg
0.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
~1.8
h
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.7
%
37.7
%
Urinary excretion;
DRUGBANK
0.8
%
0.8
%
Faeces excretion;
DRUGBANK
15.0
%
15
%
DRUGBANK
75.0
mg/m2/day
75
mg/m2/day
PO, oral;intravenous injection, IV;
Temodar
temozolomide
PDR
200.0
mg/m2/day
200
mg/m2/day
PO, oral;intravenous injection, IV;
Temodar
temozolomide
PDR
200.0
mg/m2/day
200
mg/m2/day
PO, oral;intravenous injection, IV;
Temodar
temozolomide
PDR
75.0
mg/m2/day
75
mg/m2/day
PO, oral;intravenous injection, IV;
Temodar
temozolomide
PDR
200.0
mg/m2/day
200
mg/m2/day
PO, oral;intravenous injection, IV;
Temodar
temozolomide
PDR
200.0
mg/m2/day
200
mg/m2/day
PO, oral;intravenous injection, IV;
Temodar
temozolomide
PDR
DDPD00854
Levorphanol
257.3706
C17H23NO
[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2
DB00854
T3D2914
5359272
6444
http://www.drugs.com/cdi/levorphanol.html
16736212
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
3.94
L/h/kg
0.78-7.1
L/kg/h
DRUGBANK
0.942
L/h/kg
15.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.5
L/kg
10.0-13
L/kg
DRUGBANK
11.5
L/kg
11.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.5
h
11-16
h
DRUGBANK
13.5
h
13.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
150.0
mg/kg
150.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
150.0
mg/kg
150.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
40.0
%
40
%
DRUGBANK
DDPD00855
Aminolevulinic acid
131.1299
C5H9NO3
NCC(=O)CCC(O)=O
DB00855
T3D4273
137
17549
http://www.drugs.com/cdi/aminolevulinic-acid-solution.html
134
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
DRUGBANK
0.1128
L/h/kg
1.88
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
h
0.7±0.18
h
PO, oral;
DRUGBANK
0.83
h
0.83±0.05
h
intravenous injection, IV;
DRUGBANK
0.83
h
0.83
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
mg/kg
20
mg/kg
Liquid
Levulan
aminolevulinic acid hydrochloride
PDR
1.0
appLication
1
appLication
skin/dermal; nan
q8w
Levulan
aminolevulinic acid hydrochloride
PDR
20.0
cm2/dose
20
cm2/dose
gel
Levulan
aminolevulinic acid hydrochloride
PDR
2000.0
mg
2
g
gel
Levulan
aminolevulinic acid hydrochloride
PDR
20.0
mg/kg
20
mg/kg
Liquid
Levulan
aminolevulinic acid hydrochloride
PDR
1.0
application
1
application
skin/dermal; nan
q8w
Levulan
aminolevulinic acid hydrochloride
PDR
20.0
cm2/dose
20
cm2/dose
gel
Levulan
aminolevulinic acid hydrochloride
PDR
2000.0
mg
2
g
gel
Levulan
aminolevulinic acid hydrochloride
PDR
DDPD00856
Chlorphenesin
202.635
C9H11ClO3
OCC(O)COC1=CC=C(Cl)C=C1
DB00856
7697
3642
http://www.drugs.com/mtm/chlorphenesin.html
7411
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
3.65
h
2.3-5
h
DRUGBANK
DDPD00857
Terbinafine
291.4299
C21H25N
CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12
DB00857
1549008
9448
http://www.drugs.com/cdi/terbinafine.html
1266005
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
DRUGBANK
4560.0
ng.h/ml
4.56
ug.h/ml
DRUGBANK
11593.0
ng/cm2/h
9694-13492
ng/cm2/h
skin/dermal;
DRUGBANK
40.0
%
40
%
DRUGBANK
1000.0
ng/ml
1.0
ug/ml
DRUGBANK
999.0
ng/cm2
949-1049
ng/cm2
skin/dermal;
DRUGBANK
2.0
h
2
h
DRUGBANK
1.11
L/h/kg
1.11
L/h/kg
Oral single dose;
DRUGBANK
16.6
L/kg
16.6
L/kg
at steady state; PO, oral;
DRUGBANK
36.0
h
~36
h
effective half-life; PO, oral;
DRUGBANK
300.0
h
200-400
h
terminal half-life;
DRUGBANK
2000.0
mg/kg
>2
g/kg
subcutaneous injection, SC; Rattus, Rat; mouse;
DRUGBANK
80.0
%
~80
%
Urinary excretion;
DRUGBANK
20.0
%
~20
%
Faeces excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
250.0
mg/day
250
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
187.5
mg/day
187.5
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
125.0
mg/day
125
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
500.0
mg/day
500
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
187.5
mg/day
187.5
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
125.0
mg/day
125
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
500.0
mg/day
500
mg/day
PO, oral
Lamisil Granules
terbinafine hydrochloride
PDR
DDPD00859
Penicillamine
149.211
C5H11NO2S
[H][C@](N)(C(O)=O)C(C)(C)S
DB00859
5852
7959
http://www.drugs.com/cdi/penicillamine.html
5643
-2.0
-
-2.0
-
DRUGBANK
0.639
L/h/kg
10.65
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.26
L/kg
1.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
DRUGBANK
3.04
h
3.04
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
mg/kg/day
210.0
mg/kg/6W
Female, women;
DRUGBANK
80.0
%
>80
%
plasma proteins;
DRUGBANK
1000.0
mg/day
1
g/day
PO, oral
Depen
penicillamine
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Depen
penicillamine
PDR
4000.0
mg/day
4
g/day
PO, oral
Depen
penicillamine
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Depen
penicillamine
PDR
2000.0
mg/day
2
g/day
PO, oral
Depen
penicillamine
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Depen
penicillamine
PDR
1000.0
mg/day
1
g/day
PO, oral
Depen
penicillamine
PDR
5000.0
mg/day
5
g/day
PO, oral
Depen
penicillamine
PDR
250.0
mg/day
250
mg/day
qd
Depen
penicillamine
PDR
625.0
mg/day
625
mg/day
PO, oral
Depen
penicillamine
PDR
1000.0
mg/day
1
g/day
PO, oral
Depen
penicillamine
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Depen
penicillamine
PDR
4000.0
mg/day
4
g/day
PO, oral
Depen
penicillamine
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Depen
penicillamine
PDR
2000.0
mg/day
2
g/day
PO, oral
Depen
penicillamine
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Depen
penicillamine
PDR
1000.0
mg/day
1
g/day
PO, oral
Depen
penicillamine
PDR
5000.0
mg/day
5
g/day
PO, oral
Depen
penicillamine
PDR
DDPD00860
Prednisolone
360.444
C21H28O5
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00860
5755
8378
http://www.drugs.com/cdi/prednisolone-acetate-drops.html
5552
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
PO, oral;
DRUGBANK
82.0
%
82±13
%
PO, oral;
DRUGBANK
728.0
ng/ml
113-1343
ng/ml
PO, oral;
DRUGBANK
458.0
ng/ml
458±150
ng/ml
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
1.8
h
1-2.6
h
PO, oral;
DRUGBANK
1.5
h
1.5±0.5
h
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
0.09
L/h/kg
0.09
L/h/kg
DRUGBANK
0.12
L/h/kg
0.12
L/h/kg
DRUGBANK
0.06
L/h/kg
1.0±0.16
ml/min/kg
Elderly ↓ ;Hepatitis, Hep → ;Hepatic cirrhosis, cirr ↓ ;hyperthyroid, HTh → ;nephritic syndrome → ;chronic respiratory insufficiency → ;Cushing's Disease → ;Somking → ;
DRUGBANK
0.174
L/h/kg
2.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.3
L
29.3
L
DRUGBANK
44.2
L
44.2
L
DRUGBANK
0.42
L/kg
0.42±0.11
L/kg
Elderly ↓ ;Obesity ↓ ;hyperthyroid, HTh ↓ ;Hepatitis, Hep → ;Cushing's Disease → ;RD, renal impairment, Renal disease，including uremia → ;chronic respiratory insufficiency → ;nephritic syndrome → ;increasing doses ↑ ;
DRUGBANK
0.86
L/kg
0.86
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
h
2.1-3.5
h
elimination half-life;
Children ↓ ;hepatopathy，LD ↑ ;
DRUGBANK
2.2
h
2.2±0.5
h
Hepatitis, Hep → ;Cushing's Disease → ;RD, renal impairment, Renal disease，including uremia → ;chronic respiratory insufficiency → ;nephritic syndrome → ;hyperthyroid, HTh ↓ ;Somking → ;Age ↑ ;
DRUGBANK
3.4
h
3.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
2.0
g/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
65.0
mg/kg
65.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
147.0
mg/kg
147.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
3500.0
mg/kg
>3500
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
1680.0
mg/kg
1680.0
mg/kg
PO, oral; mouse;
DRUGBANK
0.642857142857143
mg/kg/day
9.0
mg/kg/2W
PO, oral; Male, men; human, homo sapiens;
DRUGBANK
1.07692307692308
mg/kg/day
14.0
mg/kg/13D
PO, oral; Female, women; human, homo sapiens;
DRUGBANK
98.0
%
>98
%
Urinary excretion;
DRUGBANK
26.0
%
26±9
%
Urinary excretion; Unchanged drug;
Elderly ↓ ;hyperthyroid, HTh ↓ ;
DRUGBANK
78.0
%
65-91
%
normal,healthy; patients;
DRUGBANK
92.5
%
90-95
%
Elderly ↓ ;hypoalbuminemia Alb ↓ ;nephritic syndrome ↓ ;hyperthyroid, HTh ↓ ;Hepatic cirrhosis, cirr ↓ ;Hepatitis, Hep → ;
DRUGBANK
70.0
%
~70
%
DRUGBANK
DDPD00861
Diflunisal
250.1976
C13H8F2O3
OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
DB00861
T3D2918
3059
39669
http://www.drugs.com/cdi/diflunisal.html
2951
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
85.0
%
80-90
%
PO, oral;
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
90.0
%
90
%
Liver metabolism;
DRUGBANK
0.006
L/h/kg
0.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.097
L/kg
0.097
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
8-12
h
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
392.0
mg/kg
392.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
439.0
mg/kg
439.0
mg/kg
PO, oral; mouse;
DRUGBANK
603.0
mg/kg
603.0
mg/kg
PO, oral; rabbit;
DRUGBANK
392.0
mg/kg
392.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
439.0
mg/kg
439.0
mg/kg
PO, oral; mouse;
DRUGBANK
603.0
mg/kg
603.0
mg/kg
PO, oral; rabbit;
DRUGBANK
90.0
%
~90
%
Urinary excretion;
DRUGBANK
98.5
%
98-99
%
plasma proteins;
DRUGBANK
1500.0
mg/day
1500
mg/day
PO, oral
Diflunisal Tablets
diflunisal
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Diflunisal Tablets
diflunisal
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Diflunisal Tablets
diflunisal
PDR
DDPD00862
Vardenafil
488.603
C23H32N6O4S
CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1
DB00862
110634
46295
http://www.drugs.com/cdi/vardenafil.html
99300
-2.0
-
-2.0
-
DRUGBANK
15.0
%
~15
%
DRUGBANK
56.0
L/h
56.0
L/h
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
208.0
L
208.0
L
DRUGBANK
3.0
L/kg
3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
h
4-5
h
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
93.0
%
~91-95
%
Faeces excretion; PO, oral;
DRUGBANK
4.0
%
~2-6
%
Urinary excretion; PO, oral;
DRUGBANK
95.0
%
95
%
DRUGBANK
20.0
mg/day
20
mg/day
Tablet,PO，oral
Staxyn
vardenafil hydrochloride
PDR
10.0
mg/day
10
mg/day
Tablet,PO，oral
Staxyn
vardenafil hydrochloride
PDR
20.0
mg/day
20
mg/day
Tablet,PO，oral
Staxyn
vardenafil hydrochloride
PDR
10.0
mg/day
10
mg/day
Tablet,PO，oral
Staxyn
vardenafil hydrochloride
PDR
DDPD00863
Ranitidine
314.4
C13H22N4O3S
CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
DB00863
3001055
92246
http://www.drugs.com/ranitidine.html
4863
-2.0
-
-2.0
-
DRUGBANK
2488.6
ng.h/ml
2488.6
ng.h/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
55.0
%
50-60
%
PO, oral;
DRUGBANK
52.0
%
52±11
%
PO, oral;
DRUGBANK
462.0
ng/ml
462±54
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
2.83
h
2.83
h
PO, oral; Male, men; normal,healthy;
DRUGBANK
2.1
h
2.1±0.31
h
Oral single dose; adults; normal,healthy;
DRUGBANK
4.0
%
4
%
Urinary excretion;
DRUGBANK
1.0
%
1
%
Urinary excretion;
DRUGBANK
1.0
%
1
%
Urinary excretion;
DRUGBANK
24.6
L/h
410.0
ml/min
Renal clearance;
DRUGBANK
36.0
L/h
~600
ml/min
Plasma clearance;
DRUGBANK
0.624
L/h/kg
10.4±1.1
ml/min/kg
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.576
L/h/kg
9.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.4
L/kg
~1.4
L/kg
DRUGBANK
1.3
L/kg
1.3±0.4
L/kg
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;Burn ↑ ;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.75
h
~2.5-3
h
elimination half-life;
DRUGBANK
3.5
h
3-4
h
elimination half-life; patients;
DRUGBANK
2.1
h
2.1±0.2
h
RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;Burn → ;Age ↑ ;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
77.0
mg/kg
77.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
83.0
mg/kg
83.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
30.0
%
~30
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
69.0
%
69±6
%
Urinary excretion; Unchanged drug;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
15.0
%
~15
%
plasma proteins;
DRUGBANK
15.0
%
15±3
%
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
6000.0
mg/day
6
g/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
5280.0
mg/day
220
mg/h
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
6000.0
mg/day
6
g/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
9.16666666666667
mg/day
220
mg/hour
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
6000.0
mg/day
6
g/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
5280.0
mg/day
220
mg/hour
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
6.0
mg/kg/day
6
mg/kg/day
intravenous injection, IV
Zantac Injection
ranitidine hydrochloride
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Zantac Injection
ranitidine hydrochloride
PDR
DDPD00864
Tacrolimus
804.0182
C44H69NO12
CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
DB00864
T3D4732
445643
61049
http://www.drugs.com/cdi/tacrolimus.html
393220
-2.0
-
-2.0
-
DRUGBANK
17.0
%
17±10
%
PO, oral; adults; renal transplant;
DRUGBANK
22.0
%
22±6
%
PO, oral; adults; liver transplant;
DRUGBANK
18.0
%
18±5
%
PO, oral; normal,healthy;
DRUGBANK
31.0
%
31±24
%
PO, oral; Children;
DRUGBANK
25.0
%
25±10
%
DRUGBANK
31.2
ng/ml
31.2±10.1
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
1.4
h
1.4±0.5
h
Oral single dose; adults; normal,healthy;
DRUGBANK
0.04
L/h/kg
0.04
L/h/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
0.172
L/h/kg
0.172±0.088
L/h/kg
PO, oral; normal,healthy;
DRUGBANK
0.083
L/h/kg
0.083
L/h/kg
intravenous injection, IV; renal transplant; patients; adults;
DRUGBANK
0.053
L/h/kg
0.053
L/h/kg
intravenous injection, IV; liver transplant; patients; adults;
DRUGBANK
0.051
L/h/kg
0.051
L/h/kg
intravenous injection, IV; heart transplant; patients; adults;
DRUGBANK
0.138
L/h/kg
0.138±0.071
L/h/kg
liver transplant; pediatric patients;
DRUGBANK
0.12
L/h/kg
0.12±0.04
L/h/kg
renal transplant; pediatric patients;
DRUGBANK
0.038
L/h/kg
0.038±0.014
L/h/kg
intravenous injection, IV; RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
0.042
L/h/kg
0.042±0.02
L/h/kg
intravenous injection, IV; mild hepatic impairment;
DRUGBANK
0.034
L/h/kg
0.034±0.019
L/h/kg
PO, oral; mild hepatic impairment;
DRUGBANK
0.017
L/h/kg
0.017±0.013
L/h/kg
intravenous injection, IV; severe hepatic impairment;
DRUGBANK
0.016
L/h/kg
0.016±0.011
L/h/kg
PO, oral; severe hepatic impairment;
DRUGBANK
0.054
L/h/kg
0.90±0.29
ml/min/kg
liver transplant; patients; hydrolysis;
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.042
L/h/kg
0.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
L/kg
2.6±2.1
L/kg
liver transplant; pediatric patients;
DRUGBANK
1.07
L/kg
1.07±0.20
L/kg
intravenous injection, IV; RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
3.1
L/kg
3.1±1.6
L/kg
intravenous injection, IV; mild hepatic impairment; patients;
DRUGBANK
3.7
L/kg
3.7±4.7
L/kg
PO, oral; mild hepatic impairment; patients;
DRUGBANK
3.9
L/kg
3.9±1.0
L/kg
intravenous injection, IV; severe hepatic impairment; patients;
DRUGBANK
3.1
L/kg
3.1±3.4
L/kg
PO, oral; severe hepatic impairment; patients;
DRUGBANK
0.91
L/kg
0.91±0.29
L/kg
liver transplant; patients;
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;renal transplant ↑ ;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
h
35
h
elimination half-life; normal,healthy; adults;
DRUGBANK
19.0
h
19
h
elimination half-life; renal transplant; patients;
DRUGBANK
12.0
h
12
h
elimination half-life; liver transplant; patients;
DRUGBANK
24.0
h
24
h
elimination half-life; heart transplant; patients;
DRUGBANK
11.5
h
11.5±3.8
h
elimination half-life; pediatric patients; liver transplant;
DRUGBANK
10.2
h
10.2±5.0(3.4-25)
h
elimination half-life; pediatric patients; renal transplant;
DRUGBANK
12.0
h
12±5
h
liver transplant; patients;
RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
26.0
h
26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
164.0
mg/kg
134-194
mg/kg
Rattus, Rat;
DRUGBANK
164.0
mg/kg
134-194
mg/kg
Rattus, Rat;
DRUGBANK
92.6
%
92.6±30.7
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
2.3
%
2.3±1.1
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
1.0
%
<1
%
Urinary excretion; human, homo sapiens; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
~99
%
plasma proteins; human, homo sapiens;
DRUGBANK
87.0
%
75-99
%
liver transplant; human, homo sapiens;
DRUGBANK
2.0
application/day
2
application/day
skin/dermal
Prograf
tacrolimus
PDR
2.0
appLication/day
2
appLication/day
skin/dermal
Prograf
tacrolimus
PDR
2.0
application/day
2
application/day
skin/dermal
Prograf
tacrolimus
PDR
2.0
application/day
2
application/day
skin/dermal
Prograf
tacrolimus
PDR
DDPD00865
Benzphetamine
239.3553
C17H21N
C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1
DB00865
T3D2919
5311017
3044
http://www.drugs.com/cdi/benzphetamine.html
4470556
-2.0
-
-2.0
-
DRUGBANK
23.5
h
16-31
h
DRUGBANK
160.0
mg/kg
160.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
160.0
mg/kg
160.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
87.0
%
75-99
%
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Regimex
benzphetamine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Regimex
benzphetamine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Regimex
benzphetamine hydrochloride
PDR
DDPD00867
Ritodrine
287.3535
C17H21NO3
C[C@H](NCCC1=CC=C(O)C=C1)[C@H](O)C1=CC=C(O)C=C1
DB00867
33572
8872
http://www.drugs.com/cons/ritodrine-oral-intravenous.html
30971
-2.0
-
-2.0
-
DRUGBANK
1.86
L/h/kg
31
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.4
L/kg
4.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.15
h
1.7-2.6
h
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
64.0
mg/kg
64.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
540.0
mg/kg
540.0
mg/kg
PO, oral; mouse;
DRUGBANK
84.0
mg/kg
84.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
56.0
%
~56
%
DRUGBANK
DDPD00868
Benzonatate
603.7419
C30H53NO11
CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DB00868
7699
3032
http://www.drugs.com/cdi/benzonatate.html
7413
-2.0
-
-2.0
-
DRUGBANK
1063.0
ng/ml
1063±460
ng/ml
PO, oral;
DRUGBANK
1.01
h
1.01±0.41
h
PO, oral; normal,healthy; Asian;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
51.0
mg/kg
51.0
mg/kg
PO, oral; Male, men;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Tessalon
benzonatate
PDR
600.0
mg/day
600
mg/day
PO, oral
Tessalon
benzonatate
PDR
600.0
mg/day
600
mg/day
PO, oral
Tessalon
benzonatate
PDR
600.0
mg/day
600
mg/day
PO, oral
Tessalon
benzonatate
PDR
DDPD00869
Dorzolamide
324.44
C10H16N2O4S3
CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
DB00869
5284549
4702
http://www.drugs.com/cdi/dorzolamide-drops.html
4447604
-2.0
-
-2.0
-
DRUGBANK
1344.0
h
8
week
PO, oral;
DRUGBANK
1344.0
h
8
week
skin/dermal;
DRUGBANK
2880.0
h
>=120
day
elimination half-life;
DRUGBANK
2880.0
h
~4
month
elimination half-life;
DRUGBANK
1927.0
mg/kg
1927.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1320.0
mg/kg
1320.0
mg/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
>2
g/kg
subcutaneous injection, SC; mouse; Rattus, Rat;
DRUGBANK
33.0
%
~33
%
plasma proteins;
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Trusopt
dorzolamide hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Trusopt
dorzolamide hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Trusopt
dorzolamide hydrochloride
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Trusopt
dorzolamide hydrochloride
PDR
DDPD00870
Suprofen
260.308
C14H12O3S
CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
DB00870
5359
9362
http://www.drugs.com/mtm/suprofen-ophthalmic.html
5166
-2.0
-
-2.0
-
DRUGBANK
0.0456
L/h/kg
0.76
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.04
L/kg
0.04
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
20
%
DRUGBANK
DDPD00871
Terbutaline
225.2842
C12H19NO3
CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
DB00871
5403
9449
http://www.drugs.com/cdi/terbutaline.html
5210
-2.0
-
-2.0
-
DRUGBANK
40.0
%
30-50
%
PO, oral;
DRUGBANK
18.66
L/h
311±112
ml/min
DRUGBANK
0.204
L/h/kg
3.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.7
h
5.5-5.9
h
DRUGBANK
15.0
h
15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8700.0
mg/kg
8.7
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
205.0
mg/kg
205.0
mg/kg
PO, oral; mouse;
DRUGBANK
1500.0
mg/kg
1.5
g/kg
PO, oral; dog;
DRUGBANK
220.0
mg/kg
220.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
130.0
mg/kg
130.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
8000.0
mg/kg
>8
g/kg
PO, oral; rabbit;
DRUGBANK
36.0
mg/kg
36.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
116.0
mg/kg
116.0
mg/kg
intravenous injection, IV; dog;
DRUGBANK
110.0
mg/kg
110.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
90.0
%
~90
%
Urinary excretion; subcutaneous injection, SC;
DRUGBANK
54.0
%
~54
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD00872
Conivaptan
498.5744
C32H26N4O2
CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1
DB00872
151171
681850
http://www.drugs.com/cdi/conivaptan.html
133239
-2.0
-
-2.0
-
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.76
L/kg
0.76
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5
h
DRUGBANK
6.7
h
6.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
20.0
mg/dose
20
mg/dose
intravenous injection, IV
Vaprisol
conivaptan hydrochloride
PDR
40.0
mg/day
40
mg/day
intravenous infusion, iv in drop
Vaprisol
conivaptan hydrochloride
PDR
20.0
mg/dose
20
mg/dose
intravenous injection, IV
Vaprisol
conivaptan hydrochloride
PDR
40.0
mg/day
40
mg/day
intravenous infusion, iv in drop
Vaprisol
conivaptan hydrochloride
PDR
DDPD00874
Guaifenesin
198.2158
C10H14O4
COC1=CC=CC=C1OCC(O)CO
DB00874
T3D4556
3516
5551
http://www.drugs.com/guaifenesin.html
3396
-2.0
-
-2.0
-
DRUGBANK
94.8
L/h
94.8
L/h
Average clearance;
DRUGBANK
1.0
h
~1
h
DRUGBANK
1510.0
mg/kg
1510.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1510.0
mg/kg
1510.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2400.0
mg/day
2400
mg/day
PO, oral
Mucinex
guaifenesin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Mucinex
guaifenesin
PDR
600.0
mg/day
600
mg/day
PO, oral
Mucinex
guaifenesin
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Mucinex
guaifenesin
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Mucinex
guaifenesin
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Mucinex
guaifenesin
PDR
DDPD00875
Flupentixol
434.52
C23H25F3N2OS
[H]\C(CCN1CCN(CCO)CC1)=C1/C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F
DB00875
T3D2920
5281881
10454
http://www.drugs.com/international/flupentixol.html
4445173
-2.0
-
-2.0
-
DRUGBANK
0.2484
L/h/kg
4.14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.0
h
19-39
h
DRUGBANK
34.2
h
34.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
791.0
mg/kg
791.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
87.0
mg/kg
87.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
37.0
mg/kg
37.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
791.0
mg/kg
791.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
87.0
mg/kg
87.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
37.0
mg/kg
37.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
95.0
%
>95
%
plasma proteins;
DRUGBANK
DDPD00876
Eprosartan
424.513
C23H24N2O4S
CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
DB00876
5281037
4814
http://www.drugs.com/cdi/eprosartan.html
4444504
-2.0
-
-2.0
-
DRUGBANK
13.0
%
13
%
Oral single dose;
DRUGBANK
2.0
%
<2
%
Urinary excretion; PO, oral;
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
5-9
h
elimination half-life; PO, oral;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
~98
%
DRUGBANK
900.0
mg/day
900
mg/day
PO, oral
Teveten
eprosartan mesylate
PDR
900.0
mg/day
900
mg/day
PO, oral
Teveten
eprosartan mesylate
PDR
DDPD00877
Sirolimus
914.187
C51H79NO13
[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
DB00877
T3D2921
5284616
9168
http://www.drugs.com/cdi/sirolimus.html
10482078
-2.0
-
-2.0
-
DRUGBANK
15.0
%
~15
%
PO, oral;
DRUGBANK
67.0
ng/ml
67±23
ng/ml
Oral single dose; normal,healthy;
DRUGBANK
152.0
ng/ml
94-210
ng/ml
Oral multiple dose; renal transplant;
DRUGBANK
0.81
h
0.81±0.17
h
Oral single dose; normal,healthy;
DRUGBANK
1.4
h
1.4±1.2
h
Oral multiple dose; renal transplant;
DRUGBANK
0.2082
L/h/kg
3.47±1.58
ml/min/kg
apparent clearance; renal transplant; Male, men; Female, women; patients;
DRUGBANK
12.0
L/kg
12±4.6
L/kg
Apparent volume of distribution; renal transplant; Male, men; Female, women; patients;
DRUGBANK
60.0
h
57-63
h
DRUGBANK
62.3
h
62.3±16.2
h
PO, oral;
DRUGBANK
800.0
mg/kg
>800
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
800.0
mg/kg
>800
mg/kg
PO, oral; mouse;
DRUGBANK
92.0
%
92
%
DRUGBANK
40.0
%
40
%
renal transplant; human, homo sapiens;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Rapamune
sirolimus
PDR
40.0
mg/day
40
mg/day
PO, oral
Rapamune
sirolimus
PDR
40.0
mg/day
40
mg/day
PO, oral
Rapamune
sirolimus
PDR
DDPD00878
Chlorhexidine
505.447
C22H30Cl2N10
ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1
DB00878
9552079
3614
http://www.drugs.com/cdi/chlorhexidine-liquid.html
2612
-2.0
-
-2.0
-
DRUGBANK
0.206
ng/mg
0.206
ug/g
Oral single dose;
DRUGBANK
0.5
h
0.5
h
Oral single dose;
DRUGBANK
5000.0
mg/kg
>5
g/kg
subcutaneous injection, SC; mouse;
DRUGBANK
100.0
%
~100
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
DDPD00879
Emtricitabine
247.247
C8H10FN3O3S
NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1
DB00879
60877
31536
http://www.drugs.com/cdi/emtricitabine.html
54859
-2.0
-
-2.0
-
DRUGBANK
10000.0
ng.h/ml
10±3.1
ug.h/ml
DRUGBANK
93.0
%
93
%
Tablet, PO, oral;
DRUGBANK
75.0
%
75
%
Capsule, PO, Oral;
DRUGBANK
1800.0
ng/ml
1.8±0.7
ug/ml
DRUGBANK
1278.0
ng/ml
1.278±0.497
ug/ml
food;
food ↓ ;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
14.0
%
14
%
DRUGBANK
9.0
%
9
%
DRUGBANK
2.0
%
2
%
DRUGBANK
15.1
L/h
15.1
L/h
DRUGBANK
42.3
L
42.3
L
Total volume of distribution;
DRUGBANK
55.4
L
55.4
L
Total volume of distribution;
DRUGBANK
10.0
h
~10
h
DRUGBANK
86.0
%
86
%
Urinary excretion;
DRUGBANK
14.0
%
14
%
Faeces excretion;
DRUGBANK
4.0
%
<4
%
plasma proteins;
DRUGBANK
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Emtriva
emtricitabine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Emtriva
emtricitabine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
240.0
mg/day
240
mg/day
PO, oral
Emtriva
emtricitabine
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Emtriva
emtricitabine
PDR
DDPD00880
Chlorothiazide
295.723
C7H6ClN3O4S2
NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1
DB00880
2720
3640
http://www.drugs.com/cdi/chlorothiazide.html
2619
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
1.375
h
45-120
min
DRUGBANK
10000.0
mg/kg
>10
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
12.5
%
10-15
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
40.0
%
~40
%
plasma proteins;
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
375.0
mg/day
375
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
2000.0
mg/day
2000
mg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
2000.0
mg/day
2000
mg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
2000.0
mg/day
2000
mg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV
Diuril Oral Suspension
chlorothiazide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Diuril Oral Suspension
chlorothiazide
PDR
DDPD00881
Quinapril
438.5161
C25H30N2O5
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O
DB00881
T3D4733
54892
8713
http://www.drugs.com/cdi/quinapril.html
49565
-2.0
-
-2.0
-
DRUGBANK
2443.0
ng.h/ml
2443.0
ng.h/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
65.0
%
50-80
%
PO, oral;
DRUGBANK
47.5
%
35-60
%
PO, oral; high-fat meal;
high-fat meal ↓ ;
DRUGBANK
52.0
%
52±15
%
PO, oral;
DRUGBANK
1526.0
ng/ml
1526.0
ng/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
923.0
ng/ml
923±277
ng/ml
intravenous injection, IV; Drug form;
DRUGBANK
207.0
ng/ml
207±89
ng/ml
PO, oral;
DRUGBANK
1.0
h
<1
h
PO, oral;
DRUGBANK
2.5
h
2.5
h
DRUGBANK
2.3
h
2.3±0.9
h
intravenous injection, IV; Drug form;
DRUGBANK
1.4
h
1.4±0.8
h
PO, oral;
DRUGBANK
4.08
L/h
68.0
ml/min
DRUGBANK
0.0588
L/h/kg
0.98±0.22
ml/min/kg
intravenous injection, IV;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
13.9
L
13.9
L
Average volume of distribution;
DRUGBANK
0.19
L/kg
0.19±0.04
L/kg
intravenous injection, IV;
DRUGBANK
2.3
h
2.3
h
elimination half-life;
DRUGBANK
0.85
h
0.8-0.9
h
PO, oral;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
2.5
h
2.1-2.9
h
intravenous injection, IV;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
3541.0
mg/kg
3541.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1739.0
mg/kg
1739.0
mg/kg
PO, oral; mouse;
DRUGBANK
1739.0
mg/kg
1739.0
mg/kg
PO, oral; mouse;
DRUGBANK
96.0
%
96
%
Urinary excretion;
DRUGBANK
3.1
%
3.1±1.2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
96.0
%
96
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Accupril
quinapril hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Accupril
quinapril hydrochloride
PDR
80.0
mg/day
80
mg/day
PO, oral
Accupril
quinapril hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Accupril
quinapril hydrochloride
PDR
DDPD00882
Clomifene
405.96
C26H28ClNO
CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1
DB00882
T3D4976
2800
3752
2698
-2.0
-
-2.0
-
DRUGBANK
144.0
h
5-7
day
DRUGBANK
1700.0
mg/kg
1700.0
mg/kg
PO, oral; mouse;
DRUGBANK
5750.0
mg/kg
5750.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1700.0
mg/kg
1700.0
mg/kg
PO, oral; mouse;
DRUGBANK
5750.0
mg/kg
5750.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8.0
%
~8
%
Urinary excretion; PO, oral; human, homo sapiens;
DRUGBANK
42.0
%
~42
%
Faeces excretion; PO, oral; human, homo sapiens;
DRUGBANK
DDPD00883
Isosorbide dinitrate
236.1363
C6H8N2O8
[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O
DB00883
6883
6061
http://www.drugs.com/cdi/isosorbide-dinitrate.html
6619
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
25.0
%
25(10-90)
%
PO, oral;
DRUGBANK
22.0
%
22±14
%
PO, oral;
DRUGBANK
45.0
%
45±16
%
sublingual;
DRUGBANK
33.0
%
33±17
%
skin/dermal;
DRUGBANK
9.9177246
ng/ml
42(59-166)
nM
PO, oral; immediate release formulation;
DRUGBANK
48.8802141
ng/ml
207(197-335)
nM
PO, oral; Active metabolite; immediate release formulation;
DRUGBANK
212.52267
ng/ml
900(790-1080)
nM
PO, oral; Active metabolite; immediate release formulation;
DRUGBANK
0.0
ng/ml
~0
nM
PO, oral; Sustained Release formulation;
DRUGBANK
6.6118164
ng/ml
28(23-33)
nM
PO, oral; Active metabolite; Sustained Release formulation;
DRUGBANK
41.3238525
ng/ml
175(154-267)
nM
PO, oral; Active metabolite; Sustained Release formulation;
DRUGBANK
0.3
h
0.3(0.2-0.5)
h
PO, oral; immediate release formulation;
DRUGBANK
0.6
h
0.6(0.2-1.6)
h
PO, oral; Active metabolite; immediate release formulation;
DRUGBANK
0.7
h
0.7(0.3-1.9)
h
PO, oral; Active metabolite; immediate release formulation;
DRUGBANK
0.0
h
~0
h
PO, oral; Sustained Release formulation;
DRUGBANK
2.8
h
2.8(2.7-3.7)
h
PO, oral; Active metabolite; Sustained Release formulation;
DRUGBANK
5.1
h
5.1(4.2-6.6)
h
PO, oral; Active metabolite; Sustained Release formulation;
DRUGBANK
2.76
L/h/kg
46(38-59)
ml/min/kg
normal,healthy; adults;
Female, women → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;congestive heart disease → ;Somking → ;
DRUGBANK
1.86
L/h/kg
31
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
L/kg
2.0-4
L/kg
DRUGBANK
3.1
L/kg
3.1(2.2-8.6)
L/kg
normal,healthy; adults;
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
DRUGBANK
0.7
h
0.7(0.6-2.0)
h
Female, women → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
28.0
%
28±12
%
DRUGBANK
480.0
mg/day
480
mg/day
PO, oral
Isordil Oral Titradose
isosorbide dinitrate
PDR
160.0
mg/day
160
mg/day
PO, oral
Isordil Oral Titradose
isosorbide dinitrate
PDR
480.0
mg/day
480
mg/day
PO, oral
Isordil Oral Titradose
isosorbide dinitrate
PDR
160.0
mg/day
160
mg/day
PO, oral
Isordil Oral Titradose
isosorbide dinitrate
PDR
DDPD00884
Risedronic acid
283.1123
C7H11NO7P2
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
DB00884
T3D2668
5245
8869
http://www.drugs.com/cdi/risedronate-tablets.html
5055
-2.0
-
-2.0
-
DRUGBANK
0.63
%
0.63
%
PO, oral;
DRUGBANK
1.0
%
<1
%
PO, oral;
DRUGBANK
2.8
ng/ml
2.8±0.3
ng/ml
PO, oral; Male, men; normal,healthy;
DRUGBANK
1.7
h
1.7±1.2
h
PO, oral; Male, men; normal,healthy;
DRUGBANK
3.12
L/h
52.0
ml/min
Renal clearance;
DRUGBANK
4.38
L/h
73.0
ml/min
Average clearance;
DRUGBANK
0.09
L/h/kg
1.5(1.2-1.9)
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
13.8
L/kg
13.8
L/kg
DRUGBANK
6.3
L/kg
6.3±1.5
L/kg
DRUGBANK
1.5
h
~1.5
h
elimination half-life;
DRUGBANK
561.0
h
561
h
terminal half-life;
DRUGBANK
200.0
h
200(183-218)
h
DRUGBANK
0.9
h
0.9
h
distribution half-life;
DRUGBANK
13.0
h
13
h
elimination half-life;
DRUGBANK
87.0
%
87(73-102)
%
Urinary excretion; Unchanged drug;
DRUGBANK
24.0
%
~24
%
DRUGBANK
24.0
%
24
%
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Actonel
risedronate sodium
PDR
5.0
mg/day
35
mg/week
PO, oral
Actonel
risedronate sodium
PDR
5.0
mg/day
150
mg/month
PO, oral
Actonel
risedronate sodium
PDR
30.0
mg/day
30
mg/day
PO, oral
Actonel
risedronate sodium
PDR
5.0
mg/day
5
mg/day
PO, oral
Actonel
risedronate sodium
PDR
5.0
mg/day
35
mg/week
PO, oral
Actonel
risedronate sodium
PDR
5.0
mg/day
150
mg/month
PO, oral
Actonel
risedronate sodium
PDR
30.0
mg/day
30
mg/day
PO, oral
Actonel
risedronate sodium
PDR
DDPD00885
Pemirolast
228.2101
C10H8N6O
CC1=CC=CN2C(=O)C(=CN=C12)C1=NNN=N1
DB00885
57697
134936
http://www.drugs.com/cdi/pemirolast.html
51990
-2.0
-
-2.0
-
DRUGBANK
4.5
h
4.5
h
ophthalmic administration;
DRUGBANK
12.5
%
~10-15
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD00887
Bumetanide
364.416
C17H20N2O5S
CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
DB00887
2471
3213
http://www.drugs.com/cdi/bumetanide.html
2377
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
PO, oral; food;
food → ;
DRUGBANK
80.0
%
~80
%
PO, oral; food;
food → ;
DRUGBANK
45.0
%
45
%
Unchanged drug;
DRUGBANK
0.039
L/h/kg
0.2-1.1
ml/min/kg
Prem, premature; respiratory disorders;
DRUGBANK
0.1302
L/h/kg
2.17
ml/min/kg
overdose; Neonates;
DRUGBANK
0.108
L/h/kg
1.8±0.3
ml/min/kg
Elderly;
DRUGBANK
0.174
L/h/kg
2.9±0.2
ml/min/kg
young;
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.25
h
60-90
min
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
81.0
%
81
%
Urinary excretion; PO, oral; human, homo sapiens;
DRUGBANK
2.0
%
2
%
Bile excretion; PO, oral; human, homo sapiens;
DRUGBANK
36.45
%
36.45
%
Urinary excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
10.0
mg/day
10
mg/day
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;PO, oral;IM,intramuscular injection;
Bumetanide Injection
bumetanide
PDR
0.06
mg/kg/dose
0.06
mg/kg/dose
intravenous injection, IV
Bumetanide Injection
bumetanide
PDR
DDPD00888
Mechlorethamine
156.054
C5H11Cl2N
CN(CCCl)CCCl
DB00888
T3D4204
4033
28925
http://www.drugs.com/cdi/mechlorethamine.html
3893
-2.0
-
-2.0
-
DRUGBANK
0.25
h
15
min
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
6.0
mg/m2/dose
6
mg/m2/dose
intravenous injection, IV
Mustargen
mechlorethamine hydrochloride
PDR
0.4
mg/kg/dose
0.4
mg/kg/dose
intravenous injection, IV
Mustargen
mechlorethamine hydrochloride
PDR
6.0
mg/m2/dose
6
mg/m2/dose
intravenous injection, IV
Mustargen
mechlorethamine hydrochloride
PDR
0.4
mg/kg/dose
0.4
mg/kg/dose
Intracavitary
Mustargen
mechlorethamine hydrochloride
PDR
1.0
appLication/day
1
appLication/day
gel
Mustargen
mechlorethamine hydrochloride
PDR
6.0
mg/m2/dose
6
mg/m2/dose
intravenous injection, IV
Mustargen
mechlorethamine hydrochloride
PDR
0.4
mg/kg/dose
0.4
mg/kg/dose
intravenous injection, IV
Mustargen
mechlorethamine hydrochloride
PDR
6.0
mg/m2/dose
6
mg/m2/dose
intravenous injection, IV
Mustargen
mechlorethamine hydrochloride
PDR
0.4
mg/kg/dose
0.4
mg/kg/dose
Intracavitary
Mustargen
mechlorethamine hydrochloride
PDR
1.0
application/day
1
application/day
gel
Mustargen
mechlorethamine hydrochloride
PDR
DDPD00889
Granisetron
312.417
C18H24N4O
CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
DB00889
5284566
5537
http://www.drugs.com/cdi/granisetron.html
10482033
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
60.0
%
~60
%
PO, oral;
DRUGBANK
6.0
ng/ml
6.0(0.6-31)
ng/ml
Oral single dose; tumor;
DRUGBANK
64.0
ng/ml
64(18-176)
ng/ml
intravenous injection, IV; tumor;
DRUGBANK
0.52
L/h/kg
0.52
L/h/kg
tumor; patients;
DRUGBANK
0.41
L/h/kg
0.41
L/h/kg
Single dose; normal,healthy;
DRUGBANK
0.66
L/h/kg
11±9
ml/min/kg
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.546
L/h/kg
9.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
L/kg
3.0±1.5
L/kg
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
3.7
L/kg
3.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
4-6
h
normal,healthy; patients;
DRUGBANK
10.5
h
9-12
h
tumor; patients;
DRUGBANK
5.3
h
5.3±3.5
h
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ;
DRUGBANK
5.2
h
5.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
48.0
%
48
%
Urinary excretion;
DRUGBANK
38.0
%
38
%
Faeces excretion;
DRUGBANK
16.0
%
16±14
%
Urinary excretion; Unchanged drug;
DRUGBANK
65.0
%
65
%
DRUGBANK
65.0
%
65±9
%
DRUGBANK
0.01
mg/kg
10
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.04
mg/kg
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.04
mg/kg
40
mcg/kg
PO, oral
bid
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.04
mg/kg
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
2.0
mg
2
mg
PO, oral
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
1.0
patch
1
patch
skin/dermal
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
10.0
mg
10
mg
subcutaneous injection, SC
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.01
mg/day
10
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.04
mg/day
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.04
mg/day
40
mcg/kg
PO, oral
bid
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
40.0
mcg/kg
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
2.0
mg
2
mg
PO, oral
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
1.0
patch
1
patch
skin/dermal
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
10.0
mg
10
mg
subcutaneous injection, SC
Granisetron Hydrochloride Tablets
granisetron hydrochloride
PDR
0.01
mg/kg
10
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
0.04
mg/kg
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
0.04
mg/kg
40
mcg/kg
PO, oral
bid
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
0.04
mg/kg
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
2.0
mg
2
mg
PO, oral
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
1.0
patch
1
patch
skin/dermal
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
10.0
mg
10
mg
subcutaneous injection, SC
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
0.01
mg/day
10
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
0.04
mg/day
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
0.04
mg/day
40
mcg/kg
PO, oral
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
40.0
mcg/kg
40
mcg/kg
intravenous injection, IV
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
2.0
mg
2
mg
PO, oral
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
1.0
patch
1
patch
skin/dermal
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
10.0
mg
10
mg
subcutaneous injection, SC
Granisetron Hydrochloride Injection 1 mg/mL and 0.1 mg/mL
granisetron hydrochloride
PDR
DDPD00890
Dienestrol
266.34
C18H18O2
[H]\C(C)=C(/C(=C(\[H])C)/C1=CC=C(O)C=C1)\C1=CC=C(O)C=C1
DB00890
667476
4518
580857
-2.0
-
-2.0
-
DRUGBANK
65.0
%
50-80
%
DRUGBANK
DDPD00891
Sulfapyridine
249.289
C11H11N3O2S
NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
DB00891
5336
132842
5145
-2.0
-
-2.0
-
DRUGBANK
70.0
%
60-80
%
DRUGBANK
10.0
h
6-14
h
DRUGBANK
15800.0
mg/kg
15800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
%
~50
%
plasma proteins;
DRUGBANK
DDPD00892
Oxybuprocaine
308.4158
C17H28N2O3
CCCCOC1=CC(=CC=C1N)C(=O)OCCN(CC)CC
DB00892
4633
309594
4472
-2.0
-
-2.0
-
DRUGBANK
DDPD00893
Iron Dextran
N.A.
N.A.
OS(=O)(=O)O.[Fe]
DB00893
105075
http://www.drugs.com/cdi/iron-dextran.html
-2.0
-
-2.0
-
DRUGBANK
5.0
h
5
h
DRUGBANK
10.0
h
10
h
different study;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
100.0
%
100
%
DRUGBANK
100.0
mg/day
100
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
100.0
mg/day
100
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
100.0
mg/day
100
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
100.0
mg/day
100
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
50.0
mg/day
50
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
50.0
mg/day
50
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
25.0
mg/day
25
mg/day
intravenous injection, IV;IM,intramuscular injection;
Dexferrum
iron dextran
PDR
DDPD00894
Testolactone
300.3921
C19H24O3
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H]
DB00894
13769
9460
http://www.drugs.com/cdi/testolactone.html
13172
-2.0
-
-2.0
-
DRUGBANK
1630.0
mg/kg
1630.0
mg/kg
PO, oral; mouse;
DRUGBANK
759.5
mg/kg
593-926
mg/kg
PO, oral; dog;
DRUGBANK
85.0
%
~85
%
DRUGBANK
DDPD00895
Benzylpenicilloyl polylysine
626.765
C28H46N6O8S
[H]N[C@H](CCCCN)C(O)=O.[H]N[C@H](CCCCNC(=O)C(NC(=O)CC1=CC=CC=C1)[C@]1([H])N[C@@H](C(O)=O)C(C)(C)S1)C(O)=O
DB00895
45266800
59297
26331550
-2.0
-
-2.0
-
DRUGBANK
DDPD00896
Rimexolone
370.533
C24H34O3
[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB00896
5311412
135566
http://www.drugs.com/cdi/rimexolone.html
4470902
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
Faeces excretion;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
80.0
%
>80
%
Faeces excretion; intravenous injection, IV; Rattus, Rat;
DRUGBANK
2.0
drops/eye
2
drops/eye
ophthalmic administration; up to 1 week
Vexol
rimexolone
PDR
2.0
drops/eye
2
drops/eye
ophthalmic administration; up to 1 week
Vexol
rimexolone
PDR
DDPD00897
Triazolam
343.21
C17H12Cl2N4
CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12
DB00897
T3D2564
5556
9674
http://www.drugs.com/cdi/triazolam.html
5355
-2.0
-
-2.0
-
DRUGBANK
44.0
%
44
%
PO, oral;
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.58
L/kg
0.58
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
1.5-5.5
h
DRUGBANK
2.7
h
2.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; mouse;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.5
mg/day
0.5
mg/day
PO, oral
Halcion
triazolam
PDR
0.25
mg/day
0.25
mg/day
PO, oral
Halcion
triazolam
PDR
DDPD00898
Ethanol
46.0684
C2H6O
CCO
DB00898
T3D0770
702
16236
http://www.drugs.com/alcohol.html
682
-2.0
-
-2.0
-
DRUGBANK
53.0
%
53
%
sublingual;
DRUGBANK
5628.0
mg/kg
5628.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5628.0
mg/kg
5628.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.05
mg/kg/day
0.05
mg/kg/day
subcutaneous injection, SC
Gattex
teduglutide (rDNA origin)
PDR
0.05
mg/kg/day
0.05
mg/kg/day
subcutaneous injection, SC
Gattex
teduglutide (rDNA origin)
PDR
0.05
mg/kg/day
0.05
mg/kg/day
subcutaneous injection, SC
Gattex
teduglutide (rDNA origin)
PDR
0.05
mg/kg/day
0.05
mg/kg/day
subcutaneous injection, SC
Gattex
teduglutide (rDNA origin)
PDR
DDPD00899
Remifentanil
376.4467
C20H28N2O5
CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
DB00899
60815
8802
http://www.drugs.com/cdi/remifentanil.html
54803
-2.0
-
-2.0
-
DRUGBANK
20.0
ng/ml
~20
ng/ml
intravenous injection, IV;
DRUGBANK
2.4
L/h/kg
40.0
ml/min/kg
normal,healthy; young;
DRUGBANK
3.0
L/h/kg
40-60
ml/min/kg
normal,healthy; adults; patients;
Elderly ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2.22
L/h/kg
37
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.35
L/kg
350.0
ml/kg
DRUGBANK
0.452
L/kg
452±144
ml/kg
Neonates;
DRUGBANK
0.223
L/kg
223±30.6
ml/kg
Adolescents;
DRUGBANK
0.35
L/kg
0.3-0.4
L/kg
normal,healthy; adults; patients;
Elderly ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.4
L/kg
0.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.175
h
1-20
min
DRUGBANK
0.23
h
0.13-0.33
h
RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
0.8
h
0.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0
%
~0
%
Urinary excretion; adults; Male, men; normal,healthy; surgery; human, homo sapiens; Unchanged drug;
DRUGBANK
70.0
%
70
%
plasma proteins;
DRUGBANK
92.0
%
92
%
adults; Male, men; normal,healthy; surgery; human, homo sapiens;
DRUGBANK
0.001
mg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
1.3
mg/kg/minute
1.3
mg/kg/minute
intravenous infusion, iv in drop
Ultiva
remifentanil hydrochloride
PDR
0.00125
mg/kg/dose
1.25
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
0.001
mg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
2.88
mg/kg/day
2
mcg/kg/minute
intravenous infusion, iv in drop
Ultiva
remifentanil hydrochloride
PDR
1.0
mcg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
2.88
mg/kg/day
2
mcg/kg/minute
intravenous infusion, iv in drop
Ultiva
remifentanil hydrochloride
PDR
0.001
mg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
1.872
mg/kg/day
1.3
mg/kg/min
intravenous infusion, iv in drop
Ultiva
remifentanil hydrochloride
PDR
0.004
mg/kg/dose
4
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
1.0
mcg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
1440.0
mg/kg/day
1
mg/kg/minute
intravenous infusion, iv in drop
Ultiva
remifentanil hydrochloride
PDR
4.0
mcg/kg/dose
4
mcg/kg/dose
intravenous injection, IV
Ultiva
remifentanil hydrochloride
PDR
DDPD00900
Didanosine
236.2273
C10H12N4O3
OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O
DB00900
T3D4786
50599
490877
http://www.drugs.com/cdi/didanosine-chewable-dispersible-buffered-tablets.html
45864
-2.0
-
-2.0
-
DRUGBANK
35.0
%
30-40
%
DRUGBANK
38.0
%
38±15
%
PO, oral;
DRUGBANK
1500.0
ng/ml
1.5±0.7
mcg/ml
Tablet, PO, oral; fasting; extended release formulation; AIDS,HIV;
DRUGBANK
930.0
ng/ml
0.93±0.43
mcg/ml
PO, oral; fasting; extended release formulation; AIDS,HIV;
DRUGBANK
1.0
h
0.5-1.5
h
DRUGBANK
0.67
h
0.67(0.33-1.33)
h
Tablet, PO, oral; fasting; extended release formulation; AIDS,HIV;
DRUGBANK
2.0
h
2.0(1.0-5.0)
h
PO, oral; fasting; extended release formulation; AIDS,HIV;
DRUGBANK
0.96
L/h/kg
16±7
ml/min/kg
Children → ;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1.0±0.2
L/kg
DRUGBANK
0.77
L/kg
0.77
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
h
30
min
DRUGBANK
12.0
h
>12
h
DRUGBANK
1.4
h
1.4±0.3
h
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
%
36±9
%
Urinary excretion; Unchanged drug;
DRUGBANK
5.0
%
<5
%
DRUGBANK
5.0
%
<5
%
DRUGBANK
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
400.0
mg/day
400
mg/day
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
Capsule, PO, Oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
Videx
didanosine
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
400.0
mg/day
400
mg/day
PO, oral
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
PO, oral
Videx
didanosine
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
400.0
mg/day
400
mg/day
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
Capsule, PO, Oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
Videx
didanosine
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
Videx
didanosine
PDR
400.0
mg/day
400
mg/day
PO, oral
Videx
didanosine
PDR
250.0
mg/day
250
mg/day
PO, oral
Videx
didanosine
PDR
240.0
mg/m2/day
240
mg/m2/day
Liquid
Videx
didanosine
PDR
300.0
mg/m2/day
300
mg/m2/day
Videx
didanosine
PDR
200.0
mg/m2/day
200
mg/m2/day
Liquid
Videx
didanosine
PDR
200.0
mg/m2/day
200
mg/m2/day
Liquid
Videx
didanosine
PDR
100.0
mg/m2/day
100
mg/m2/day
Videx
didanosine
PDR
200.0
mg/m2/day
200
mg/m2/day
Liquid
Videx
didanosine
PDR
100.0
mg/m2/day
100
mg/m2/day
Videx
didanosine
PDR
DDPD00902
Methdilazine
296.43
C18H20N2S
CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1
DB00902
T3D2924
14677
6823
14009
-2.0
-
-2.0
-
DRUGBANK
DDPD00903
Etacrynic acid
303.138
C13H12Cl2O4
CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1
DB00903
3278
4876
http://www.drugs.com/cdi/ethacrynate-sodium.html
3163
-2.0
-
-2.0
-
DRUGBANK
98.0
%
>98
%
DRUGBANK
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
1.0
mg/kg/day
1
mg/kg/day
intravenous injection, IV
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
400.0
mg/day
400
mg/day
PO, oral
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
100.0
mg/dose
100
mg/dose
intravenous injection, IV
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
1.0
mg/kg/day
1
mg/kg/day
intravenous injection, IV
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
400.0
mg/day
400
mg/day
PO, oral
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
100.0
mg/dose
100
mg/dose
intravenous injection, IV
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
0.0
0
Edecrin/Sodium Edecrin
(ethacrynate sodium); (ethacrynic acid)
PDR
DDPD00904
Ondansetron
293.363
C18H19N3O
CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2
DB00904
T3D2925
4595
7773
http://www.drugs.com/cdi/ondansetron.html
4434
-2.0
-
-2.0
-
DRUGBANK
58.0
%
56-60
%
Tablet, PO, oral;
DRUGBANK
62.0
%
62±15
%
PO, oral;
DRUGBANK
39.0
ng/ml
39(31-48)
ng/ml
PO, oral; adults; normal,healthy;
DRUGBANK
102.0
ng/ml
102(64-136)
ng/ml
DRUGBANK
1.0
h
1.0(0.8-1.5)
h
PO, oral; adults; normal,healthy;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Unchanged drug; human, homo sapiens;
DRUGBANK
0.38
L/h/kg
0.38
L/h/kg
normal,healthy; adults;
DRUGBANK
0.29
L/h/kg
0.26-0.32
L/h/kg
normal,healthy; Elderly;
DRUGBANK
0.354
L/h/kg
5.9±2.6
ml/min/kg
Female, women ↓ ;Children ↑ ;Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
0.348
L/h/kg
5.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
160.0
L
~160
L
DRUGBANK
1.9
L/kg
1.9±0.05
L/kg
Elderly → ;Hepatic cirrhosis, cirr → ;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
3.5
h
3-4
h
intravenous injection, IV;
DRUGBANK
7.0
h
6-8
h
Elderly;
DRUGBANK
3.5
h
3.5±1.2
h
Children ↓ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ;
DRUGBANK
3.4
h
3.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
5
%
Urinary excretion; Unchanged drug;
DRUGBANK
73.0
%
~73
%
plasma proteins;
DRUGBANK
73.0
%
73±2
%
DRUGBANK
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/dose
16
mg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/dose
16
mg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
12.0
mg/day
12
mg/day
PO, oral
Zuplenz
ondansetron
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/dose
16
mg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/day
16
mg/day
PO, oral
Zuplenz
ondansetron
PDR
24.0
mg/day
24
mg/day
PO, oral
Zuplenz
ondansetron
PDR
0.45
mg/kg/day
0.45
mg/kg/day
intravenous injection, IV
Zuplenz
ondansetron
PDR
48.0
mg/day
16
mg/dose
intravenous injection, IV
tid
Zuplenz
ondansetron
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/dose
16
mg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/day
16
mg/day
PO, oral
Zuplenz
ondansetron
PDR
24.0
mg/day
24
mg/day
PO, oral
Zuplenz
ondansetron
PDR
0.45
mg/kg/day
0.45
mg/kg/day
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/dose
16
mg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
0.1
mg/kg
0.1
mg/kg
intravenous injection, IV
Zuplenz
ondansetron
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
16.0
mg/dose
16
mg/dose
intravenous injection, IV
Zuplenz
ondansetron
PDR
DDPD00905
Bimatoprost
415.5656
C25H37NO4
CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
DB00905
5311027
51230
http://www.drugs.com/cdi/bimatoprost-drops.html
4470565
-2.0
-
-2.0
-
DRUGBANK
0.09
null
0.09
null
ophthalmic administration;
DRUGBANK
0.08
ng/ml
0.08
ng/ml
ophthalmic administration;
DRUGBANK
12.2
ng/ml
12.2
ng/ml
different study;
DRUGBANK
0.166666666666667
h
10
min
different study;
DRUGBANK
168.0
h
7
day
different study;
DRUGBANK
0.15
L/h/kg
0.15
L/h/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
1.5
L/h/kg
25
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.67
L/kg
0.67
L/kg
at steady state;
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
h
~45
min
elimination half-life;
DRUGBANK
0.45
h
0.45
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
67.0
%
67
%
Urinary excretion; normal,healthy; human, homo sapiens;
DRUGBANK
25.0
%
25
%
Faeces excretion; normal,healthy; human, homo sapiens;
DRUGBANK
89.0
%
~88-90
%
plasma proteins;
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Latisse
bimatoprost
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Latisse
bimatoprost
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Latisse
bimatoprost
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Latisse
bimatoprost
PDR
DDPD00906
Tiagabine
375.548
C20H25NO2S2
CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1
DB00906
T3D2926
60648
9586
http://www.drugs.com/cdi/tiagabine.html
54661
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
122.0
ng/ml
122±36
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
69.0
ng/ml
69±22
ng/ml
Oral multiple dose; adults; normal,healthy;
DRUGBANK
0.9
h
0.9±0.5
h
Oral single dose; adults; normal,healthy;
DRUGBANK
1.5
h
1.5±1.0
h
Oral multiple dose; adults; normal,healthy;
DRUGBANK
6.54
L/h
109.0
ml/min
normal,healthy;
DRUGBANK
0.12
L/h/kg
2.0±0.4
ml/min/kg
apparent clearance; PO, oral; normal,healthy; Male, men; patients;
Children ↑ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;epilepsy ↑ ;
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
L/kg
1.3±0.4
L/kg
Apparent volume of distribution; PO, oral; normal,healthy; Male, men; patients;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
7-9
h
DRUGBANK
8.0
h
7-9
h
PO, oral;
chronic liver disease ↑ ;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.5
%
24.5
%
Urinary excretion; PO, oral;
DRUGBANK
61.7
%
61.7
%
Faeces excretion; PO, oral;
DRUGBANK
2.0
%
~2
%
PO, oral; Unchanged drug;
DRUGBANK
1.5
%
1-2
%
Urinary excretion; adults; normal,healthy; epilepsy; human, homo sapiens; Unchanged drug;
DRUGBANK
96.0
%
96
%
DRUGBANK
96.0
%
96
%
adults; normal,healthy; epilepsy; human, homo sapiens;
DRUGBANK
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Gabitril
tiagabine hydrochloride
PDR
56.0
mg/day
56
mg/day
PO, oral
Gabitril
tiagabine hydrochloride
PDR
32.0
mg/day
32
mg/day
PO, oral
Gabitril
tiagabine hydrochloride
PDR
56.0
mg/day
56
mg/day
PO, oral
Gabitril
tiagabine hydrochloride
PDR
DDPD00907
Cocaine
303.3529
C17H21NO4
[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C
DB00907
T3D2927
446220
27958
http://www.drugs.com/cons/cocaine-hydrochloride-topical.html
10194104
-2.0
-
-2.0
-
DRUGBANK
70.0
%
60-80
%
inhalation, IH;
DRUGBANK
1.92
L/h/kg
32
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
L/kg
2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
DRUGBANK
0.76
h
0.76
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
96.0
mg/kg
96.0
mg/kg
PO, oral; mouse;
DRUGBANK
96.0
mg/kg
96.0
mg/kg
PO, oral; mouse;
DRUGBANK
95.1
mg/kg
95.1
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
3.0
mg/kg
3
mg/kg
skin/dermal
Goprelto
cocaine hydrochloride
PDR
200.0
mg
200
mg
skin/dermal
Goprelto
cocaine hydrochloride
PDR
3.0
mg/kg
3
mg/kg
intranasal
Goprelto
cocaine hydrochloride
PDR
160.0
mg
160
mg
intranasal
Goprelto
cocaine hydrochloride
PDR
3.0
mg/kg
3
mg/kg
skin/dermal
Goprelto
cocaine hydrochloride
PDR
200.0
mg
200
mg
skin/dermal
Goprelto
cocaine hydrochloride
PDR
3.0
mg/kg
3
mg/kg
intranasal
Goprelto
cocaine hydrochloride
PDR
160.0
mg
160
mg
intranasal
Goprelto
cocaine hydrochloride
PDR
DDPD00908
Quinidine
324.4168
C20H24N2O2
[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1
DB00908
441074
28593
http://www.drugs.com/cdi/quinidine-gluconate-controlled-release-tablets.html
389880
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80±15
%
PO, oral; Derivative;
DRUGBANK
71.0
%
71±17
%
PO, oral; Derivative;
DRUGBANK
1300.0
ng/ml
~1.3
mcg/ml
PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
530.0
ng/ml
0.53±0.22
mcg/ml
PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
2900.0
ng/ml
2.9±1.0
mcg/ml
intravenous injection, IV; adults; normal,healthy;
DRUGBANK
2.0
h
1-3
h
PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
6.3
h
6.3±3.2
h
PO, oral; extended release formulation; adults; normal,healthy;
DRUGBANK
0.24
L/h/kg
3.0-5
ml/min/kg
adults;
DRUGBANK
0.282
L/h/kg
4.7±1.8
ml/min/kg
hydrolysis;
Elderly ↓ ;Hepatic cirrhosis, cirr → ;congestive heart disease ↓ ;Somking → ;
DRUGBANK
0.24
L/h/kg
4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
L/kg
2.0-3
L/kg
DRUGBANK
0.5
L/kg
0.5
L/kg
heart disease;
DRUGBANK
4.0
L/kg
3.0-5
L/kg
Hepatitis, Hep;
DRUGBANK
2.7
L/kg
2.7±1.2
L/kg
Elderly → ;Hepatic cirrhosis, cirr ↑ ;congestive heart disease ↓ ;
DRUGBANK
2.9
L/kg
2.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
6-8
h
DRUGBANK
6.2
h
6.2±1.8
h
Hepatic cirrhosis, cirr ↑ ;congestive heart disease → ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ;
DRUGBANK
12.0
h
12±3
h
Active metabolite;
DRUGBANK
6.6
h
6.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
Urinary excretion; Uric acid; Unchanged drug;
DRUGBANK
5.0
%
5
%
Urinary excretion; Urine alkaline; Unchanged drug;
DRUGBANK
18.0
%
18±5
%
Urinary excretion; Unchanged drug;
congestive heart disease → ;
DRUGBANK
84.0
%
80-88
%
DRUGBANK
87.0
%
87±3
%
Neonates ↓ ;Preg, pregnant ↓ ;Elderly → ;Hepatitis, Hep ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;chronic respiratory insufficiency → ;HL,hyperlipoproteinemia → ;
DRUGBANK
DDPD00909
Zonisamide
212.226
C8H8N2O3S
NS(=O)(=O)CC1=NOC2=CC=CC=C12
DB00909
T3D2928
5734
10127
http://www.drugs.com/cdi/zonisamide.html
5532
-2.0
-
-2.0
-
DRUGBANK
28000.0
ng/ml
28±4
mcg/ml
PO, oral; adults; normal,healthy;
DRUGBANK
3.35
h
2.8-3.9
h
PO, oral; food;
food → ;
DRUGBANK
1.8
h
1.8±0.4
h
PO, oral; adults; normal,healthy;
DRUGBANK
0.0195
L/h/kg
0.3-0.35
ml/min/kg
patients;
DRUGBANK
0.0255
L/h/kg
0.35-0.5
ml/min/kg
Drug combination;
DRUGBANK
0.0078
L/h/kg
0.13
ml/min/kg
DRUGBANK
1.45
L/kg
1.45
L/kg
DRUGBANK
1.5
L/kg
1.2-1.8
L/kg
DRUGBANK
63.0
h
63
h
DRUGBANK
63.0
h
63±14
h
DRUGBANK
38.5
%
29-48
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
40.0
%
40
%
DRUGBANK
39.0
%
38-40
%
DRUGBANK
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Zonegran
zonisamide
PDR
600.0
mg/day
600
mg/day
PO, oral
Zonegran
zonisamide
PDR
600.0
mg/day
600
mg/day
PO, oral
Zonegran
zonisamide
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Zonegran
zonisamide
PDR
600.0
mg/day
600
mg/day
PO, oral
Zonegran
zonisamide
PDR
DDPD00910
Paricalcitol
416.6365
C27H44O3
[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O
DB00910
5281104
7931
http://www.drugs.com/cdi/paricalcitol.html
4444552
-2.0
-
-2.0
-
DRUGBANK
1.49
L/h
1.49±0.60
L/h
Chronic Kidney Disease;
DRUGBANK
1.54
L/h
1.54±0.95
L/h
Chronic Kidney Disease;
DRUGBANK
0.0534
L/h/kg
0.89
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.8
L
30.8±7.5
L
Chronic Kidney Disease;
DRUGBANK
34.9
L
34.9±9.5
L
Chronic Kidney Disease;
DRUGBANK
23.8
L
23.8
L
normal,healthy;
DRUGBANK
0.41
L/kg
0.41
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
4-6
h
DRUGBANK
5.3
h
5.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.8
%
99.8
%
plasma proteins;
DRUGBANK
0.0096
mg
9.6
mcg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
0.0096
mg
9.6
mcg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
0.00024
mg/kg
0.24
mcg/kg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
0.0168
mg
16.8
mcg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
0.0096
mg
9.6
mcg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
0.24
mcg/kg
0.24
mcg/kg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
0.0168
mg
16.8
mcg
intravenous injection, IV
Zemplar Capsules
paricalcitol
PDR
DDPD00911
Tinidazole
247.272
C8H13N3O4S
CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O
DB00911
5479
63627
http://www.drugs.com/cdi/tinidazole.html
5279
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; fasting;
DRUGBANK
901600.0
ng.h/ml
901.6±126.5
mcg.h/ml
PO, oral; food;
DRUGBANK
0.036
L/h/kg
0.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
L
50.0
L
DRUGBANK
0.59
L/kg
0.59
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.2
h
13.2±1.4
h
elimination half-life;
DRUGBANK
13.0
h
12-14
h
elimination half-life;
DRUGBANK
13.0
h
13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3600.0
mg/kg
>3600
mg/kg
PO, oral; mouse;
DRUGBANK
2300.0
mg/kg
>2300
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
12.0
%
~12
%
Faeces excretion;
DRUGBANK
22.5
%
~20-25
%
Urinary excretion; Unchanged drug;
DRUGBANK
12.0
%
12
%
plasma proteins;
DRUGBANK
50.0
mg/kg/dose
50
mg/kg/dose
PO, oral
Tindamax
tinidazole
PDR
2000.0
mg/dose
2
g/dose
PO, oral
Tindamax
tinidazole
PDR
2000.0
mg/day
2
g/day
PO, oral
Tindamax
tinidazole
PDR
50.0
mg/kg/dose
50
mg/kg/dose
PO, oral
Tindamax
tinidazole
PDR
2000.0
mg/dose
2
g/dose
PO, oral
Tindamax
tinidazole
PDR
2000.0
mg/day
2
g/day
PO, oral
Tindamax
tinidazole
PDR
DDPD00912
Repaglinide
452.5857
C27H36N2O4
CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O
DB00912
65981
8805
http://www.drugs.com/cdi/repaglinide.html
59377
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
18.35
ng.h/ml
18.0-18.7
ng.h/ml
Oral single dose;
DRUGBANK
56.0
%
56
%
PO, oral;
DRUGBANK
56.0
%
56±7
%
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
47.0
ng/ml
47±24
ng/ml
Male, men; adults; normal,healthy;
DRUGBANK
1.0
h
1(0.5-1.4)
h
PO, oral;
DRUGBANK
0.5
h
0.25-0.75
h
Male, men; adults; normal,healthy;
DRUGBANK
35.5
L/h
33-38
L/h
intravenous injection, IV;
DRUGBANK
0.558
L/h/kg
9.3±6.8
ml/min/kg
normal,healthy; adults; Male, men; hydrolysis;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.468
L/h/kg
7.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
31.0
L
31.0
L
intravenous injection, IV; normal,healthy;
DRUGBANK
0.52
L/kg
0.52±0.17
L/kg
normal,healthy; adults; Male, men; hydrolysis;
DRUGBANK
0.35
L/kg
0.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
DRUGBANK
0.8
h
0.8±0.2
h
normal,healthy; adults; Male, men;
chronic liver disease ↑ ;
DRUGBANK
0.87
h
0.87
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
mg/kg
>1
g/kg
Rattus, Rat;
DRUGBANK
90.0
%
90
%
Faeces excretion;
DRUGBANK
80.0
%
8
%
Urinary excretion;
DRUGBANK
1.8
%
<1.8
%
Faeces excretion; Unchanged drug;
DRUGBANK
0.008
%
0.008
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.45
%
0.3-2.6
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
>98
%
DRUGBANK
97.4
%
97.4
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
16.0
mg/day
16
mg/day
PO, oral
Prandin
repaglinide
PDR
16.0
mg/day
16
mg/day
PO, oral
Prandin
repaglinide
PDR
DDPD00913
Anileridine
352.4699
C22H28N2O2
CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1
DB00913
T3D2929
8944
61203
8600
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
DRUGBANK
DDPD00914
Phenformin
205.2596
C10H15N5
NC(=N)NC(=N)NCCC1=CC=CC=C1
DB00914
8249
8064
7953
-2.0
-
-2.0
-
DRUGBANK
DDPD00915
Amantadine
151.2487
C10H17N
NC12CC3CC(CC(C3)C1)C2
DB00915
T3D2560
2130
2618
http://www.drugs.com/cdi/amantadine.html
2045
-2.0
-
-2.0
-
DRUGBANK
0.25
L/h/kg
0.2-0.3
L/h/kg
DRUGBANK
0.1
L/h/kg
0.10±0.04
L/h/kg
normal,healthy; Elderly; Male, men;
DRUGBANK
0.288
L/h/kg
4.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
L/kg
3.0-8
L/kg
normal,healthy;
DRUGBANK
6.6
L/kg
6.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
10-14
h
DRUGBANK
204.0
h
7-10
day
RD, renal impairment, Renal disease，including uremia;
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
800.0
mg/kg
800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
700.0
mg/kg
700.0
mg/kg
PO, oral; mouse;
DRUGBANK
67.0
%
~67
%
plasma proteins;
DRUGBANK
200.0
mg/day
200
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
8.8
mg/kg/day
8.8
mg/kg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
150.0
mg/day
150
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
274.0
mg/day
274
mg/day
Capsule, PO, Oral
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
322.0
mg/day
322
mg/day
Tablet,PO，oral
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
274.0
mg/day
274
mg/day
Capsule, PO, Oral
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
322.0
mg/day
322
mg/day
Tablet,PO，oral
Amantadine Hydrochloride Capsules
amantadine hydrochloride
PDR
DDPD00916
Metronidazole
171.154
C6H9N3O3
CC1=NC=C(N1CCO)[N+]([O-])=O
DB00916
T3D4703
4173
6909
http://www.drugs.com/metronidazole.html
4029
-2.0
-
-2.0
-
DRUGBANK
122000.0
ng.h/ml
122±10.3
mg.h/l
Oral single dose;
DRUGBANK
90.0
%
>90
%
Tablet, PO, oral;
DRUGBANK
99.0
%
99±8
%
PO, oral;
DRUGBANK
74.5
%
67-82
%
Rectal Administration;
DRUGBANK
53.0
%
53±16
%
Vaginal Administration;
DRUGBANK
35000.0
ng/ml
30-40
mg/L
intravenous infusion, IV in drop;
DRUGBANK
26000.0
ng/ml
26.0
mg/L
DRUGBANK
10500.0
ng/ml
8-13
mg/L
Oral single dose;
DRUGBANK
19800.0
ng/ml
19.8
mcg/ml
DRUGBANK
1900.0
ng/ml
1.9±0.2
mcg/ml
Vaginal Administration;
DRUGBANK
27000.0
ng/ml
27(11-41)
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
1.0
h
1
h
intravenous infusion, IV in drop;
DRUGBANK
2.125
h
0.25-4
h
Oral single dose;
DRUGBANK
2.8
h
2.8
h
DRUGBANK
11.0
h
11±2
h
Vaginal Administration;
DRUGBANK
72.0
h
3
day
DRUGBANK
0.346820809248555
L/h/m2
10.0
ml/min/1.73m2
Renal clearance;
DRUGBANK
4.25
L/h/kg
2.1-6.4
L/h/kg
Total clearance;
DRUGBANK
0.078
L/h/kg
1.3±0.3
ml/min/kg
Neonates ↓ ;Elderly → ;Preg, pregnant → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;Crohn → ;
DRUGBANK
0.051
L/h/kg
0.85
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.8
L/kg
0.51-1.1
L/kg
Steady state volume of distribution; adults;
DRUGBANK
0.74
L/kg
0.74±0.10
L/kg
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;Crohn → ;
DRUGBANK
0.4
L/kg
0.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.3
h
7.3±1.0
h
elimination half-life; normal,healthy;
DRUGBANK
8.0
h
6-10
h
elimination half-life; different study;
DRUGBANK
8.5
h
8.5±2.9
h
Neonates ↑ ;Preg, pregnant → ;Children → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Crohn → ;
DRUGBANK
7.1
h
7.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
20.8333333333333
mg/kg/h
500.0
mg/kg/day
PO, oral; Rattus, Rat;
DRUGBANK
70.0
%
60-80
%
Urinary excretion;
DRUGBANK
10.5
%
6-15
%
Faeces excretion;
DRUGBANK
10.0
%
10±2
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
<20
%
plasma proteins;
DRUGBANK
11.0
%
11±3
%
DRUGBANK
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Flagyl Capsules
metronidazole
PDR
2250.0
mg/kg/day
2250
mg/kg/day
PO, oral
Flagyl Capsules
metronidazole
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
4000.0
mg/day
4
g/day
PO, oral;intravenous injection, IV;
Flagyl Capsules
metronidazole
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Flagyl Capsules
metronidazole
PDR
2250.0
mg/kg/day
2250
mg/kg/day
PO, oral
Flagyl Capsules
metronidazole
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
4000.0
mg/day
4
g/day
PO, oral;intravenous injection, IV;
Flagyl Capsules
metronidazole
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Flagyl Capsules
metronidazole
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
30.0
mg/kg/day
30
mg/kg/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
22.5
mg/kg/day
22.5
mg/kg/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Flagyl Capsules
metronidazole
PDR
DDPD00917
Dinoprostone
352.4651
C20H32O5
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O
DB00917
5280360
15551
http://www.drugs.com/cdi/dinoprostone-gel.html
4444059
-2.0
-
-2.0
-
DRUGBANK
0.0833333333333333
h
<5
min
DRUGBANK
750.0
mg/kg
750.0
mg/kg
PO, oral; mouse;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
73.0
%
73
%
DRUGBANK
DDPD00918
Almotriptan
335.464
C17H25N3O2S
CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
DB00918
T3D2931
123606
520985
http://www.drugs.com/cdi/almotriptan.html
110198
-2.0
-
-2.0
-
DRUGBANK
0.534
L/h/kg
8.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
190.0
L
180-200
L
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
DRUGBANK
3.4
h
3.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
%
~75
%
Urinary excretion; PO, oral;
DRUGBANK
13.0
%
~13
%
Faeces excretion; PO, oral;
DRUGBANK
40.0
%
~40
%
Urinary excretion; Unchanged drug;
DRUGBANK
35.0
%
35
%
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
Axert
almotriptan malate
PDR
25.0
mg/day
25
mg/day
PO, oral
Axert
almotriptan malate
PDR
25.0
mg/day
25
mg/day
PO, oral
Axert
almotriptan malate
PDR
25.0
mg/day
25
mg/day
PO, oral
Axert
almotriptan malate
PDR
DDPD00919
Spectinomycin
332.3496
C14H24N2O7
[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]1([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]1([H])O2
DB00919
15541
9215
http://www.drugs.com/mtm/spectinomycin.html
14785
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
IM,intramuscular injection;
DRUGBANK
0.0594
L/h/kg
0.99
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
1-3
h
normal renal function; patients;
DRUGBANK
20.0
h
10-30
h
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00920
Ketotifen
309.425
C19H19NOS
CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=CC=CC=C12
DB00920
3827
92511
http://www.drugs.com/cdi/ketotifen-drops.html
3695
-2.0
-
-2.0
-
DRUGBANK
60.0
%
>60
%
PO, oral;
DRUGBANK
21.0
h
21
h
elimination half-life;
DRUGBANK
75.0
%
75
%
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Zaditor
ketotifen fumarate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Zaditor
ketotifen fumarate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Zaditor
ketotifen fumarate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Zaditor
ketotifen fumarate
PDR
DDPD00921
Buprenorphine
467.6401
C29H41NO4
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
DB00921
T3D2932
644073
3216
http://www.drugs.com/cdi/buprenorphine.html
559124
-2.0
-
-2.0
-
DRUGBANK
7.651
ng.h/ml
7.651
ng.h/ml
DRUGBANK
65.0
%
40->90
%
IM,intramuscular injection;
DRUGBANK
51.0
%
51±30
%
subcutaneous injection, SC;
DRUGBANK
28.0
%
28±9
%
buccal;
DRUGBANK
0.78
ng/ml
0.78
ng/ml
DRUGBANK
3.6
ng/ml
3.6±3.0
ng/ml
IM,intramuscular injection;
DRUGBANK
3.3
ng/ml
3.3±0.8
ng/ml
subcutaneous injection, SC;
DRUGBANK
2.0
ng/ml
2.0±0.6
ng/ml
buccal;
DRUGBANK
15.0
h
15
h
DRUGBANK
0.08
h
0.08
h
IM,intramuscular injection;
DRUGBANK
0.7
h
0.7±0.1
h
subcutaneous injection, SC;
DRUGBANK
0.8
h
0.8±0.2
h
buccal;
DRUGBANK
54.612
L/h
901.2±39.7
ml/min
Plasma clearance; intravenous injection, IV; patients;
DRUGBANK
69.66
L/h
1042-1280
ml/min
Plasma clearance; intravenous injection, IV; normal,healthy;
DRUGBANK
0.798
L/h/kg
13.3±0.59
ml/min/kg
surgery; Male, men; Female, women;
Children ↑ ;
DRUGBANK
1.14
L/h/kg
19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
261.5
L
188-335
L
intravenous injection, IV;
DRUGBANK
1.44
L/kg
1.44±0.11
L/kg
surgery; Male, men; Female, women;
Children ↑ ;
DRUGBANK
4.9
L/kg
4.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.76666666666667
h
~166
min
DRUGBANK
30.75
h
30.75
h
Multiple dose; sublingual;
DRUGBANK
2.33
h
2.33±0.24
h
Male, men; Female, women; surgery;
Children ↓ ;
DRUGBANK
3.2
h
3.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
10-30
%
Urinary excretion;
DRUGBANK
0.0
%
~0
%
Urinary excretion; patients; human, homo sapiens; Unchanged drug;
DRUGBANK
96.0
%
~96
%
DRUGBANK
96.0
%
96
%
patients; human, homo sapiens;
DRUGBANK
0.024
mg/kg/day
6
mcg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
q4h-q8h
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.6
mg/dose
0.6
mg/dose
IM,intramuscular injection
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.3
mg/dose
0.3
mg/dose
intravenous injection, IV
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
480.0
mg/day
20
mg/h
Transdermal preparations
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
1.8
mg/day
1800
mcg/day
skin/dermal
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
24.0
mg/day
24
mg/day
sublingual
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
10.0
mg/day
300
mg/month
subcutaneous injection, SC
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
1.62630136986301
mg/day
593.6
mg/year
subdermal implant
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.6
mg/dose
0.6
mg/dose
IM,intramuscular injection
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.3
mg/dose
0.3
mg/dose
intravenous injection, IV
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
1.62630136986301
mg/day
593.6
mg/year
subdermal implant
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.6
mg/dose
0.6
mg/dose
IM,intramuscular injection
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.3
mg/dose
0.3
mg/dose
intravenous injection, IV
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.6
mg/dose
0.6
mg/dose
IM,intramuscular injection
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.3
mg/dose
0.3
mg/dose
intravenous injection, IV
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
480.0
mg/day
20
mg/hour
Transdermal preparations
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
1.8
mg/day
1800
mcg/day
skin/dermal
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
24.0
mg/day
24
mg/day
sublingual
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
10.0
mg/day
300
mg/month
subcutaneous injection, SC
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
1.62630136986301
mg/day
593.6
mg/year
subdermal implant
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
0.06
mg/kg/day
60
mcg/kg/day
sublingual
Buprenorphine Hydrochloride
buprenorphine hydrochloride
PDR
DDPD00922
Levosimendan
280.2847
C14H12N6O
C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1
DB00922
3033825
50567
2298414
-2.0
-
-2.0
-
DRUGBANK
85.0
%
85±6
%
PO, oral; normal,healthy;
DRUGBANK
84.0
%
84±4
PO, oral; patients;
DRUGBANK
100.0
%
100
%
Active metabolite;
DRUGBANK
0.228
L/h/kg
3.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
elimination half-life;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
~98
%
plasma proteins;
DRUGBANK
DDPD00923
Ceforanide
519.554
C20H21N7O6S2
[H][C@]12SCC(CSC3=NN=NN3CC(O)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1CN)C(O)=O
DB00923
43507
3495
39656
-2.0
-
-2.0
-
DRUGBANK
85.0
%
85
%
Urinary excretion;
DRUGBANK
0.0396
L/h/kg
0.66
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.79
h
2.6-2.98
h
DRUGBANK
3.0
h
3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.6
%
80.6
%
DRUGBANK
DDPD00924
Cyclobenzaprine
275.3874
C20H21N
CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12
DB00924
2895
3996
http://www.drugs.com/cyclobenzaprine.html
2792
-2.0
-
-2.0
-
DRUGBANK
177.0
ng.h/ml
177.0
ng.h/ml
PO, oral;
DRUGBANK
44.0
%
33-55
%
PO, oral;
DRUGBANK
20.0
ng/ml
5-35
ng/ml
PO, oral;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
42.0
L/h
~0.7
L/min
Plasma clearance;
DRUGBANK
146.0
L
~146
L
DRUGBANK
18.0
h
~18
h
effective half-life; normal,healthy; young;
DRUGBANK
33.4
h
33.4
h
Elderly;
DRUGBANK
46.2
h
46.2
h
effective half-life; hepatic insufficiency;
DRUGBANK
338.0
mg/kg
338.0
mg/kg
PO, oral; mouse;
DRUGBANK
425.0
mg/kg
425.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
44.5
%
38-51
%
Urinary excretion;
DRUGBANK
14.5
%
14-15
%
Faeces excretion;
DRUGBANK
1.0
%
~1
%
Urinary excretion; Unchanged drug;
DRUGBANK
93.0
%
~93
%
plasma proteins;
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Amrix
cyclobenzaprine hydrochloride
PDR
30.0
mg/day
30
mg/day
Tablet,PO，oral
Amrix
cyclobenzaprine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Amrix
cyclobenzaprine hydrochloride
PDR
DDPD00925
Phenoxybenzamine
303.826
C18H22ClNO
CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1
DB00925
4768
8077
http://www.drugs.com/cdi/phenoxybenzamine.html
4604
-2.0
-
-2.0
-
DRUGBANK
25.0
%
20-30
%
PO, oral;
DRUGBANK
24.0
h
24
h
DRUGBANK
4.0
mg/kg/day
4
mg/kg/day
PO, oral
Dibenzyline
phenoxybenzamine hydrochloride
PDR
DDPD00927
Famotidine
337.445
C8H15N7O2S3
NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
DB00927
3325
4975
http://www.drugs.com/famotidine.html
3208
-2.0
-
-2.0
-
DRUGBANK
45.0
%
40-50
%
PO, oral;
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
27.5
%
25-30
%
Liver metabolism;
DRUGBANK
21.0
L/h
250-450
ml/min
Renal clearance;
DRUGBANK
0.396
L/h/kg
6.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.15
L/kg
1-1.3
L/kg
Steady state volume of distribution;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~2-4
h
elimination half-life;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
2.8
h
2.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4049.0
mg/kg
4049.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4686.0
mg/kg
4686.0
mg/kg
PO, oral; mouse;
DRUGBANK
800.0
mg/kg
800.0
mg/kg
intravenous injection, IV; mouse; Rattus, Rat;
DRUGBANK
0.571428571428571
mg/kg/day
4.0
mg/kg/7D
PO, oral; Male, men;
DRUGBANK
67.5
%
~65-70
%
Urinary excretion;
DRUGBANK
70.0
%
~70
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
17.5
%
15-20
%
DRUGBANK
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Famotidine Injection
famotidine
PDR
80.0
mg/day
80
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
1.0
mg/kg/day
1
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
PO, oral;intravenous injection, IV;
Famotidine Injection
famotidine
PDR
20.0
mg/day
20
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
80.0
mg/day
80
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
640.0
mg/day
640
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
80.0
mg/day
80
mg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Famotidine Injection
famotidine
PDR
80.0
mg/day
80
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
1.0
mg/kg/day
1
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
PO, oral;intravenous injection, IV;
Famotidine Injection
famotidine
PDR
20.0
mg/day
20
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
80.0
mg/day
80
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
640.0
mg/day
640
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
80.0
mg/day
80
mg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
40.0
mg/day
40
mg/day
PO, oral
Famotidine Injection
famotidine
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Famotidine Injection
famotidine
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Famotidine Injection
famotidine
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Famotidine Injection
famotidine
PDR
0.5
mg/kg/day
0.5
mg/kg/day
intravenous injection, IV
Famotidine Injection
famotidine
PDR
DDPD00928
Azacitidine
244.2047
C8H12N4O5
NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
DB00928
T3D4676
9444
2038
http://www.drugs.com/cdi/azacitidine.html
9072
-2.0
-
-2.0
-
DRUGBANK
89.0
%
89
%
subcutaneous injection, SC;
DRUGBANK
167.0
L/h
167±49
L/h
DRUGBANK
76.0
L
76±26
L
DRUGBANK
4.0
h
~4
h
elimination half-life;
DRUGBANK
85.0
%
85
%
Urinary excretion; intravenous injection, IV; tumor;
DRUGBANK
1.0
%
<1
%
Faeces excretion; intravenous injection, IV; tumor;
DRUGBANK
0.5
%
0.5
%
Urinary excretion; subcutaneous injection, SC;
DRUGBANK
100.0
mg/m2/day
100
mg/m2/day
qd
Vidaza
azacitidine
PDR
100.0
mg/m2/day
100
mg/m2/day
qd
Vidaza
azacitidine
PDR
DDPD00929
Misoprostol
382.5341
C22H38O5
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
DB00929
5282381
63610
http://www.drugs.com/cdi/misoprostol.html
4445541
-2.0
-
-2.0
-
DRUGBANK
2.0192
ng.h/ml
2.0192±0.8032
ng.h/ml
PO, oral;
DRUGBANK
3.2094
ng.h/ml
3.2094±1.0417
ng.h/ml
sublingual;
DRUGBANK
2.0726
ng.h/ml
2.0726±0.3578
ng.h/ml
buccal;
DRUGBANK
2.683
ng/ml
2.6830±1.2161
ng/ml
PO, oral;
DRUGBANK
2.4391
ng/ml
2.4391±1.1567
ng/ml
sublingual;
DRUGBANK
1.3611
ng/ml
1.3611±0.3436
ng/ml
buccal;
DRUGBANK
0.345
h
0.345±0.186
h
PO, oral;
DRUGBANK
0.712
h
0.712±0.415
h
sublingual;
DRUGBANK
1.308
h
1.308±0.624
h
buccal;
DRUGBANK
17.16
L/h/kg
0.286
L/kg/min
Total clearance;
DRUGBANK
13.56
L/h/kg
0.226±0.073
L/kg/min
Total clearance; mild renal function;
DRUGBANK
16.2
L/h/kg
0.270±0.103
L/kg/min
Total clearance; moderate renal function;
DRUGBANK
6.3
L/h/kg
0.105±0.052
L/kg/min
Total clearance; severe renal function;
DRUGBANK
13.6
L/kg
13.6±8.0
L/kg
normal renal function;
DRUGBANK
17.3
L/kg
17.3±23.0
L/kg
mild renal function;
DRUGBANK
14.3
L/kg
14.3±6.8
L/kg
moderate renal function;
DRUGBANK
11.0
L/kg
11.0±9.6
L/kg
severe renal function;
DRUGBANK
1.0401
h
1.0401±0.5090
h
PO, oral;
DRUGBANK
0.8542
h
0.8542±0.1170
h
sublingual;
DRUGBANK
0.8365
h
0.8365±0.1346
h
buccal;
DRUGBANK
81.0
mg/kg
81.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
27.0
mg/kg
27.0
mg/kg
PO, oral; mouse;
DRUGBANK
40.0
mg/kg
40.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
70.0
mg/kg
70.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
73.2
%
73.2±4.6
%
Urinary excretion; PO, oral;
DRUGBANK
90.0
%
<90
%
DRUGBANK
0.8
mg/day
800
mcg/day
PO, oral
Cytotec
misoprostol
PDR
0.8
mg/day
800
mcg/day
PO, oral
Cytotec
misoprostol
PDR
DDPD00930
Colesevelam
N.A.
N.A.
CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-]
DB00930
160051
http://www.drugs.com/cdi/colesevelam.html
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
0.05
%
0.05
%
Urinary excretion; normal,healthy; human, homo sapiens;
DRUGBANK
3750.0
mg/day
3.75
g/day
Liquid
Welchol
colesevelam hydrochloride
PDR
3750.0
mg/day
3.75
g/day
PO, oral
Welchol
colesevelam hydrochloride
PDR
3750.0
mg/day
3.75
g/day
Liquid
Welchol
colesevelam hydrochloride
PDR
3750.0
mg/day
3.75
g/day
PO, oral
Welchol
colesevelam hydrochloride
PDR
DDPD00931
Metacycline
442.424
C22H22N2O8
[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=C(C(O)=CC=C4)C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
DB00931
54675785
6805
10468596
-2.0
-
-2.0
-
DRUGBANK
58.0
%
58
%
DRUGBANK
14.0
h
14
h
DRUGBANK
76.5
%
75-78
%
DRUGBANK
DDPD00932
Tipranavir
602.664
C31H33F3N2O5S
[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O
DB00932
54682461
63628
http://www.drugs.com/cdi/tipranavir.html
10482313
-2.0
-
-2.0
-
DRUGBANK
5.5
h
5-6
h
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
99.9
%
>99.9
%
DRUGBANK
28.0
mg/kg/day
28
mg/kg/day
PO, oral
Aptivus
tipranavir
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Aptivus
tipranavir
PDR
28.0
mg/kg/day
28
mg/kg/day
PO, oral
Aptivus
tipranavir
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Aptivus
tipranavir
PDR
DDPD00933
Mesoridazine
386.574
C21H26N2OS2
CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2
DB00933
T3D2933
4078
6780
http://www.drugs.com/mtm/mesoridazine.html
3936
-2.0
-
-2.0
-
DRUGBANK
36.0
h
24-48
h
DRUGBANK
560.0
mg/kg
560±62.5
mg/kg
PO, oral; mouse;
DRUGBANK
644.0
mg/kg
644±48
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
560.0
mg/kg
560±62.5
mg/kg
PO, oral; mouse;
DRUGBANK
644.0
mg/kg
644±48
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4.0
%
4
%
DRUGBANK
DDPD00934
Maprotiline
277.4033
C20H23N
CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21
DB00934
T3D2934
4011
6690
http://www.drugs.com/cdi/maprotiline.html
3871
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
L/kg
45
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
51.0
h
~51(27-58)
h
DRUGBANK
51.0
h
51
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
900.0
mg/kg
~900
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
mg/kg
90.0
mg/kg
PO, oral; Female, women;
DRUGBANK
900.0
mg/kg
900.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
mg/kg
90.0
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
60.0
%
~60
%
Urinary excretion; Oral single dose;
DRUGBANK
30.0
%
30
%
Faeces excretion; Oral single dose;
DRUGBANK
88.0
%
88
%
DRUGBANK
225.0
mg/day
225
mg/day
PO, oral
Maprotiline Hydrochloride
maprotiline hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Maprotiline Hydrochloride
maprotiline hydrochloride
PDR
DDPD00935
Oxymetazoline
260.3746
C16H24N2O
CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
DB00935
4636
7862
http://www.drugs.com/cdi/oxymetazoline-solution.html
4475
-2.0
-
-2.0
-
DRUGBANK
8.0
drop/day
8
drop/day
ophthalmic administration
Rhofade
oxymetazoline hydrochloride
PDR
6.0
sprays/nostril/day
6
sprays/nostril/day
nasal spray
Rhofade
oxymetazoline hydrochloride
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Rhofade
oxymetazoline hydrochloride
PDR
6.0
sprays/nostriL/day
6
sprays/nostriL/day
nasal spray
Rhofade
oxymetazoline hydrochloride
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Rhofade
oxymetazoline hydrochloride
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Rhofade
oxymetazoline hydrochloride
PDR
6.0
sprays/nostril/day
6
sprays/nostril/day
nasal spray
Rhofade
oxymetazoline hydrochloride
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Rhofade
oxymetazoline hydrochloride
PDR
6.0
sprays/nostril/day
6
sprays/nostril/day
nasal spray
Rhofade
oxymetazoline hydrochloride
PDR
1.0
application/day
1
application/day
skin/dermal
Rhofade
oxymetazoline hydrochloride
PDR
DDPD00936
Salicylic acid
138.122
C7H6O3
OC(=O)C1=CC=CC=C1O
DB00936
T3D4816
338
16914
331
-2.0
-
-2.0
-
DRUGBANK
891.0
mg/kg
891.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
891.0
mg/kg
891.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD00937
Diethylpropion
205.2961
C13H19NO
CCN(CC)C(C)C(=O)C1=CC=CC=C1
DB00937
T3D2935
7029
4530
http://www.drugs.com/cdi/diethylpropion.html
6762
-2.0
-
-2.0
-
DRUGBANK
5.0
h
4-6
h
elimination half-life;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; mouse;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
225.0
mg/kg
225.0
mg/kg
PO, oral; dog;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; mouse;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
225.0
mg/kg
225.0
mg/kg
PO, oral; dog;
DRUGBANK
75.0
mg/day
75
mg/day
PO, oral
Diethylpropion Hydrochloride
diethylpropion hydrochloride
PDR
75.0
mg/day
75
mg/day
PO, oral
Diethylpropion Hydrochloride
diethylpropion hydrochloride
PDR
75.0
mg/day
75
mg/day
PO, oral
Diethylpropion Hydrochloride
diethylpropion hydrochloride
PDR
DDPD00938
Salmeterol
415.5656
C25H37NO4
OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
DB00938
T3D4734
5152
64064
http://www.drugs.com/cdi/salmeterol.html
4968
-2.0
-
-2.0
-
DRUGBANK
0.156041
ng.h/ml
156.041
pg.h/ml
inhalation, IH;
DRUGBANK
0.047897
ng/ml
47.897
pg/ml
inhalation, IH;
DRUGBANK
0.24
h
0.24
h
inhalation, IH;
DRUGBANK
392.0
L/h
392.0
L/h
Average clearance; asthma; patients;
DRUGBANK
177.0
L
177.0
L
Total volume of distribution; asthma; patients;
DRUGBANK
3160.0
L
3160.0
L
Total volume of distribution; asthma; patients;
DRUGBANK
5.5
h
5.5
h
DRUGBANK
57.4
%
57.4
%
Faeces excretion;
DRUGBANK
23.0
%
23
%
Urinary excretion;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
96.0
%
96
%
DRUGBANK
0.1
mg/day
100
mcg/day
inhalation, IH
Serevent Diskus
salmeterol xinafoate
PDR
0.1
mg/day
100
mcg/day
inhalation, IH
Serevent Diskus
salmeterol xinafoate
PDR
0.1
mg/day
100
mcg/day
inhalation, IH
Serevent Diskus
salmeterol xinafoate
PDR
0.1
mg/day
100
mcg/day
inhalation, IH
Serevent Diskus
salmeterol xinafoate
PDR
DDPD00939
Meclofenamic acid
296.149
C14H11Cl2NO2
CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
DB00939
4037
6710
3897
-2.0
-
-2.0
-
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
3.0
h
3
h
PO, oral; food;
food ↑ ;
DRUGBANK
12.36
L/h
206.0
ml/min
PO, oral;
DRUGBANK
26.15
L
9.1-43.2
L
DRUGBANK
3.05
h
0.8-5.3
h
elimination half-life; Oral single dose; normal,healthy;
DRUGBANK
15.0
h
15
h
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Meclofenamate Sodium
meclofenamate sodium
PDR
400.0
mg/day
400
mg/day
PO, oral
Meclofenamate Sodium
meclofenamate sodium
PDR
400.0
mg/day
400
mg/day
PO, oral
Meclofenamate Sodium
meclofenamate sodium
PDR
DDPD00941
Hexafluronium
502.745
C36H42N2
C[N+](C)(CCCCCC[N+](C)(C)C1C2=C(C=CC=C2)C2=C1C=CC=C2)C1C2=C(C=CC=C2)C2=C1C=CC=C2
DB00941
3601
135804
3475
-2.0
-
-2.0
-
DRUGBANK
280.0
mg/kg
280.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00942
Cycrimine
287.4397
C19H29NO
OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1
DB00942
2911
59692
2808
-2.0
-
-2.0
-
DRUGBANK
17.5
%
14-21
%
DRUGBANK
DDPD00943
Zalcitabine
211.2178
C9H13N3O3
NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1
DB00943
T3D4719
24066
10101
http://www.drugs.com/cdi/zalcitabine.html
22498
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
PO, oral;
DRUGBANK
0.0
%
~0
%
Liver metabolism;
DRUGBANK
17.1
L/h
285.0
ml/min
intravenous injection, IV; AIDS,HIV; patients;
DRUGBANK
0.336
L/h/kg
5.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.519
L/kg
0.304-0.734
L/kg
DRUGBANK
0.54
L/kg
0.54
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
~80
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
60.0
%
~60
%
Urinary excretion; PO, oral;
DRUGBANK
4.0
%
<4
%
DRUGBANK
DDPD00944
Demecarium
556.7797
C32H52N4O4
CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
DB00944
5966
59719
http://www.drugs.com/mtm/demecarium-bromide-ophthalmic.html
5751
-2.0
-
-2.0
-
DRUGBANK
2.96
mg/kg
2.96
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD00945
Acetylsalicylic acid
180.1574
C9H8O4
CC(=O)OC1=CC=CC=C1C(O)=O
DB00945
T3D2936
2244
15365
http://www.drugs.com/aspirin.html
2157
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
68.0
%
68±3
%
DRUGBANK
24000.0
ng/ml
24±4
mcg/ml
Oral single dose;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
0.39
h
0.39±0.21
h
Oral single dose;
DRUGBANK
0.558
L/h/kg
9.3±1.1
ml/min/kg
Elderly → ;Hepatitis, Hep → ;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.15
L/kg
0.15±0.03
L/kg
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.266666666666667
h
13-19
min
DRUGBANK
4.0
h
3.5-4.5
h
DRUGBANK
0.25
h
0.25±0.03
h
Hepatitis, Hep → ;
DRUGBANK
0.26
h
0.26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
mg/kg
>1
g/kg
PO, oral; human, homo sapiens; cat; dog;
DRUGBANK
1200.0
mg/kg
0.92-1.48
g/kg
PO, oral; albino; Rattus, Rat;
DRUGBANK
1190.0
mg/kg
1.19
g/kg
PO, oral; guinea pigs;
DRUGBANK
1100.0
mg/kg
1.1
g/kg
PO, oral; mouse;
DRUGBANK
1800.0
mg/kg
1.8
g/kg
PO, oral; dog;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
PO, oral; mouse;
DRUGBANK
1010.0
mg/kg
1010.0
mg/kg
PO, oral; rabbit;
DRUGBANK
200.0
mg/kg
200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.4
%
1.4±1.2
%
Urinary excretion; Unchanged drug; Unchanged drug;
DRUGBANK
70.0
%
50-90
%
plasma proteins;
DRUGBANK
49.0
%
49
%
Unchanged drug;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
DDPD00946
Phenprocoumon
280.3178
C18H16O3
CCC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
DB00946
T3D3105
54680692
50438
10441592
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
0.0012
L/h/kg
0.02
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
132.0
h
5-6
day
DRUGBANK
126.0
h
126
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
DDPD00947
Fulvestrant
606.78
C32H47F5O3S
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
DB00947
T3D4757
17756771
31638
http://www.drugs.com/cdi/fulvestrant.html
94553
-2.0
-
-2.0
-
DRUGBANK
8.2
ng/ml
8.2±5.2
ng/ml
IM,intramuscular injection; postmenopausal women; breast cancer;
DRUGBANK
167.0
h
167.0
h
IM,intramuscular injection; postmenopausal women; breast cancer;
DRUGBANK
0.708
L/h/kg
9.3-14.3
ml/min/kg
DRUGBANK
0.708
L/h/kg
11.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
L/kg
3.0-5
L/kg
DRUGBANK
4.15
L/kg
3.0-5.3
L/kg
DRUGBANK
4.15
L/kg
4.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
960.0
h
40
day
DRUGBANK
16.5
h
14-19
h
elimination half-life; intravenous injection, IV;
DRUGBANK
960.0
h
~40
day
IM,intramuscular injection;
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
~90
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; human, homo sapiens; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
99.0
%
99
%
human, homo sapiens;
DRUGBANK
500.0
mg
500
mg
IM,intramuscular injection
Faslodex
fulvestrant
PDR
500.0
mg
500
mg
IM,intramuscular injection
Faslodex
fulvestrant
PDR
DDPD00948
Mezlocillin
539.582
C21H25N5O8S2
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=O
DB00948
656511
6919
570894
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.09
L/kg
0.09
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.85
h
1.3-4.4
h
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.5
%
16-59
%
DRUGBANK
DDPD00949
Felbamate
238.2399
C11H14N2O4
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
DB00949
T3D2937
3331
4995
http://www.drugs.com/cdi/felbamate.html
3214
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
DRUGBANK
0.026
L/h/kg
26±3
ml/h/kg
Single dose;
DRUGBANK
0.03
L/h/kg
30±8
ml/h/kg
Multiple dose;
DRUGBANK
0.756
L/kg
756±82
mL/kg
DRUGBANK
21.5
h
20-23
h
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
27.5
%
20-36
%
DRUGBANK
DDPD00950
Fexofenadine
501.6564
C32H39NO4
CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
DB00950
T3D2938
3348
5050
http://www.drugs.com/cdi/fexofenadine.html
3231
-2.0
-
-2.0
-
DRUGBANK
1367.0
ng.h/ml
1367.0
ng.h/ml
Oral multiple dose;
DRUGBANK
33.0
%
33
%
DRUGBANK
299.0
ng/ml
299
ng/ml
Oral multiple dose;
DRUGBANK
286.0
ng/ml
286±143
ng/ml
PO, oral;
DRUGBANK
2.0
h
1-3
h
DRUGBANK
1.3
h
1.3±0.6
h
PO, oral;
DRUGBANK
5.0
%
5
%
Liver metabolism;
DRUGBANK
3.6
%
3.6
%
DRUGBANK
1.5
%
1.5
%
DRUGBANK
50.6
L/h
50.6
L/h
PO, oral;
DRUGBANK
4.23
L/h
4.23
L/h
Renal clearance;
DRUGBANK
0.564
L/h/kg
9.4±4.2
ml/min/kg
apparent clearance; PO, oral;
DRUGBANK
5.6
L/kg
~5.4-5.8
L/kg
DRUGBANK
13.0
h
~11-15
h
elimination half-life;
DRUGBANK
14.0
h
14±6
h
PO, oral;
mild renal function ↑ ;chronic liver disease → ;
DRUGBANK
80.0
%
~80
%
Faeces excretion;
DRUGBANK
11.0
%
11
%
Urinary excretion;
DRUGBANK
12.0
%
12
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
65.0
%
60-70
%
plasma proteins;
DRUGBANK
62.0
%
56-68
%
plasma proteins; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
65.5
%
56-75
%
plasma proteins; hepatopathy，LD;
DRUGBANK
65.0
%
60-70
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
180.0
mg/day
180
mg/day
PO, oral
qd
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
120.0
mg/day
120
mg/day
PO, oral
bid
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
60.0
mg/day
60
mg/day
PO, oral
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
180.0
mg/day
180
mg/day
Tablet,PO，oral
qd
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
120.0
mg/day
120
mg/day
Tablet,PO，oral
bid
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
180.0
mg/day
180
mg/day
Tablet,PO，oral
qd
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
120.0
mg/day
120
mg/day
Tablet,PO，oral
bid
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
180.0
mg/day
180
mg/day
Tablet,PO，oral
qd
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
120.0
mg/day
120
mg/day
Tablet,PO，oral
bid
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Allegra Allergy Tablets
fexofenadine hydrochloride
PDR
DDPD00951
Isoniazid
137.1393
C6H7N3O
NNC(=O)C1=CC=NC=C1
DB00951
T3D4777
3767
6030
http://www.drugs.com/cdi/isoniazid.html
3635
-2.0
-
-2.0
-
DRUGBANK
5400.0
ng/ml
5.4±2.0
mcg/ml
PO, oral; Drug form; normal,healthy;
DRUGBANK
7100.0
ng/ml
7.1±1.9
mcg/ml
PO, oral; Drug form; normal,healthy;
DRUGBANK
1.1
h
1.1±0.5
h
PO, oral; Drug form; normal,healthy;
DRUGBANK
1.1
h
1.1±0.6
h
PO, oral; Drug form; normal,healthy;
DRUGBANK
0.444
L/h/kg
7.4±2.0
ml/min/kg
extensive metabolizers, EM;
Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.222
L/h/kg
3.7±1.1
ml/min/kg
poor metabolizers, PM;
Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.67
L/kg
0.67±0.15
L/kg
extensive metabolizers, EM;
Elderly → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
1.05
h
0.5-1.6
h
fast acetylators;
DRUGBANK
3.5
h
2-5
h
Slow acetylators;
DRUGBANK
1.1
h
1.1±0.1
h
fast acetylators;
Neonates ↑ ;Children → ;acute viral hepatitis AVH ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;hyperthyroid, HTh → ;Age → ;
DRUGBANK
3.1
h
3.1±1.1
h
Slow acetylators;
Neonates ↑ ;Children → ;acute viral hepatitis AVH ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;hyperthyroid, HTh → ;Age → ;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; mouse;
DRUGBANK
60.0
%
50-70
%
Urinary excretion;
DRUGBANK
7.0
%
7±2
%
Urinary excretion; fast acetylators; Unchanged drug;
DRUGBANK
29.0
%
29±5
%
Urinary excretion; Slow acetylators; Unchanged drug;
DRUGBANK
5.0
%
0-10
%
DRUGBANK
0.0
%
~0
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral;IM,intramuscular injection;
qd
Isoniazid Solution
isoniazid
PDR
900.0
mg/day
900
mg/day
PO, oral;IM,intramuscular injection;
biw
Isoniazid Solution
isoniazid
PDR
300.0
mg/day
300
mg/day
PO, oral;IM,intramuscular injection;
qd
Isoniazid Solution
isoniazid
PDR
900.0
mg/day
900
mg/day
PO, oral;IM,intramuscular injection;
biw
Isoniazid Solution
isoniazid
PDR
300.0
mg/day
300
mg/day
PO, oral;IM,intramuscular injection;
qd
Isoniazid Solution
isoniazid
PDR
900.0
mg/day
900
mg/day
PO, oral;IM,intramuscular injection;
biw
Isoniazid Solution
isoniazid
PDR
300.0
mg/day
300
mg/day
PO, oral;IM,intramuscular injection;
qd
Isoniazid Solution
isoniazid
PDR
900.0
mg/day
900
mg/day
PO, oral;IM,intramuscular injection;
biw
Isoniazid Solution
isoniazid
PDR
300.0
mg/day
300
mg/day
PO, oral;IM,intramuscular injection;
qd
Isoniazid Solution
isoniazid
PDR
900.0
mg/day
900
mg/day
PO, oral;IM,intramuscular injection;
biw
Isoniazid Solution
isoniazid
PDR
DDPD00952
Naratriptan
335.464
C17H25N3O2S
CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1
DB00952
T3D2939
4440
7478
http://www.drugs.com/cdi/naratriptan.html
4287
-2.0
-
-2.0
-
DRUGBANK
74.0
%
74
%
PO, oral;
DRUGBANK
3.5
h
2-5
h
PO, oral;
DRUGBANK
0.396
L/h/kg
6.6
ml/min/kg
DRUGBANK
0.396
L/h/kg
6.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
170.0
L
170.0
L
DRUGBANK
2.4
L/kg
2.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
5-8
h
DRUGBANK
6.6
h
6.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.5
%
28-31
%
DRUGBANK
DDPD00953
Rizatriptan
269.3449
C15H19N5
CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
DB00953
T3D2940
5078
48273
http://www.drugs.com/cdi/rizatriptan.html
4900
-2.0
-
-2.0
-
DRUGBANK
45.0
%
45
%
PO, oral;
DRUGBANK
47.0
%
47.0
%
PO, oral;
DRUGBANK
20.0
ng/ml
20±4.9
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
37.0
ng/ml
37±13
ng/ml
Oral multiple dose; adults; normal,healthy;
DRUGBANK
0.9
h
0.9±0.4
h
Oral single dose; adults; normal,healthy;
DRUGBANK
4.8
h
4.8±0.7
h
Oral multiple dose; adults; normal,healthy;
DRUGBANK
0.738
L/h/kg
12.3±1.4
ml/min/kg
normal,healthy; adults; Male, men;
DRUGBANK
1.134
L/h/kg
18.9±2.8
ml/min/kg
normal,healthy; adults; Male, men;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
140.0
L
140.0
L
Male, men;
DRUGBANK
110.0
L
110.0
L
Female, women;
DRUGBANK
1.5
L/kg
1.5±0.2
L/kg
normal,healthy; adults; Male, men;
DRUGBANK
2.2
L/kg
2.2±0.4
L/kg
normal,healthy; adults; Male, men;
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
2.2
h
2.2
h
normal,healthy; adults; Male, men;
DRUGBANK
2.4
h
2.4
h
normal,healthy; adults; Female, women;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.0
%
~14
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
28.0
%
28±9
%
Urinary excretion; adults; Female, women; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
29.0
%
29
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
14.0
%
14
%
DRUGBANK
14.0
%
14
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
10.0
mg
10
mg
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
5.0
mg
5
mg
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
5.0
mg
5
mg
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
30.0
mg/day
30
mg/day
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
15.0
mg/day
15
mg/day
PO, oral
Maxalt
rizatriptan benzoate
PDR
10.0
mg
10
mg
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
5.0
mg
5
mg
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
5.0
mg
5
mg
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
30.0
mg/day
30
mg/day
PO, oral
qd
Maxalt
rizatriptan benzoate
PDR
15.0
mg/day
15
mg/day
PO, oral
Maxalt
rizatriptan benzoate
PDR
DDPD00955
Netilmicin
475.587
C21H41N5O7
CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
DB00955
441306
7528
20152952
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
IM,intramuscular injection;
DRUGBANK
0.75
h
0.5-1
h
IM,intramuscular injection;
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
0.033
L/h/kg
0.55
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.073
L/kg
0.073
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
DRUGBANK
3.2
h
3.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00956
Hydrocodone
299.3642
C18H21NO3
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
DB00956
T3D2941
5284569
5779
4447623
-2.0
-
-2.0
-
DRUGBANK
6250000.0
ng
2.5-10
mg
Liquid;
DRUGBANK
70000000.0
ng
20-120
mg
Tablet, PO, oral; extended release formulation;
DRUGBANK
7937500.0
ng
3.175-12.7
mg
Liquid; food;
food ↑ ;
DRUGBANK
88900000.0
ng
25.4-152.4
mg
Tablet, PO, oral; extended release formulation; food;
food ↑ ;
DRUGBANK
30.0
ng/ml
30±9.4
ng/ml
PO, oral; extensive metabolizers, EM;
DRUGBANK
27.0
ng/ml
27±5.9
ng/ml
PO, oral; poor metabolizers, PM;
DRUGBANK
1.08
h
0.83-1.33
h
Liquid;
DRUGBANK
15.0
h
14-16
h
Tablet, PO, oral; extended release formulation;
DRUGBANK
0.72
h
0.72±0.46
h
PO, oral; extensive metabolizers, EM;
DRUGBANK
0.93
h
0.93±0.59
h
PO, oral; poor metabolizers, PM;
DRUGBANK
83.0
L/h
83.0
L/h
apparent clearance;
DRUGBANK
41.65
L/h
24.5-58.8
L/h
DRUGBANK
0.666
L/h/kg
11.1±3.57
ml/min/kg
apparent clearance; PO, oral; extensive metabolizers, EM;
DRUGBANK
0.3924
L/h/kg
6.54±1.25
ml/min/kg
apparent clearance; PO, oral; poor metabolizers, PM;
DRUGBANK
402.0
L
402.0
L
Apparent volume of distribution;
DRUGBANK
8.0
h
7-9
h
elimination half-life;
DRUGBANK
4.24
h
4.24±0.99
h
extensive metabolizers, EM; PO, oral;
DRUGBANK
6.16
h
6.16±1.97
h
poor metabolizers, PM; PO, oral;
DRUGBANK
85.7
mg/kg
85.7
mg/kg
subcutaneous injection, SC; parenteral administration; mouse;
DRUGBANK
10.2
%
10.2±1.8
%
Urinary excretion; normal,healthy; extensive metabolizers, EM; human, homo sapiens; Unchanged drug;
DRUGBANK
18.1
%
18.1±4.5
%
Urinary excretion; normal,healthy; poor metabolizers, PM; human, homo sapiens; Unchanged drug;
DRUGBANK
36.0
%
36
%
plasma proteins;
DRUGBANK
DDPD00957
Norgestimate
369.4971
C23H31NO3
[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O
DB00957
6540478
50815
5022837
-2.0
-
-2.0
-
DRUGBANK
16.1
ng.h/ml
16.1
ng.h/ml
PO, oral; Active metabolite;
DRUGBANK
49.9
ng.h/ml
49.9
ng.h/ml
PO, oral; Active metabolite;
DRUGBANK
1.82
ng/ml
1.82
ng/ml
PO, oral; Active metabolite;
DRUGBANK
2.79
ng/ml
2.79
ng/ml
PO, oral; Active metabolite;
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral; Active metabolite;
DRUGBANK
1.7
h
1.7
h
PO, oral; Active metabolite;
DRUGBANK
21.0
h
12-30
h
DRUGBANK
36.4
h
36.4±10.2
h
DRUGBANK
47.0
%
45-49
%
Urinary excretion;
DRUGBANK
32.5
%
16-49
%
Faeces excretion;
DRUGBANK
97.0
%
>97
%
DRUGBANK
DDPD00958
Carboplatin
371.254
C6H12N2O4Pt
[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
DB00958
38904
31355
http://www.drugs.com/cdi/carboplatin.html
8514637
-2.0
-
-2.0
-
DRUGBANK
39000.0
ng/ml
39±17
mcg/ml
adults; ovarian cancer;
DRUGBANK
0.5
h
0.5
h
adults; ovarian cancer;
DRUGBANK
4.4
L/h
4.4
L/h
Total clearance; intravenous injection, IV;
DRUGBANK
0.09
L/h/kg
1.5±0.3
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
L
16.0
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
0.24
L/kg
0.24±0.03
L/kg
DRUGBANK
0.26
L/kg
0.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.55
h
1.1-2
h
distribution half-life;
DRUGBANK
4.25
h
2.6-5.9
h
elimination half-life;
DRUGBANK
2.0
h
2±0.2
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
343.0
mg/kg
343.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
72.0
mg/kg
72.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
118.0
mg/kg
118.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
77.0
%
77±5
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
0
%
DRUGBANK
125.0
ml/min
125
ml/min
Carboplatin
carboplatin
PDR
180000.0
ml/day
125
ml/min
Carboplatin
carboplatin
PDR
125.0
ml/min
125
ml/min
Carboplatin
carboplatin
PDR
125.0
ml/min
125
ml/min
Carboplatin
carboplatin
PDR
180000.0
ml/day
125
ml/min
Carboplatin
carboplatin
PDR
DDPD00959
Methylprednisolone
374.4706
C22H30O5
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
DB00959
6741
6888
http://www.drugs.com/methylprednisolone.html
6485
-2.0
-
-2.0
-
DRUGBANK
89.9
%
89.9
%
PO, oral;
DRUGBANK
14.2
%
14.2
%
Rectal Administration;
DRUGBANK
82.0
%
82±13
%
PO, oral;
increasing doses ↑ ;
DRUGBANK
178.0
ng/ml
178±44
ng/ml
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
225.0
ng/ml
225±44
ng/ml
intravenous injection, IV; Male, men; adults; normal,healthy;
DRUGBANK
1.64
h
1.64±0.64
h
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
0.336
L/h/kg
336.0
ml/h/kg
Plasma clearance;
DRUGBANK
0.372
L/h/kg
6.2±0.9
ml/min/kg
Female, women ↑ ;Hepatic cirrhosis, cirr → ;rheumatoid arthritis → ;Obesity ↑ ;chronic respiratory insufficiency → ;nephritic syndrome → ;
DRUGBANK
0.366
L/h/kg
6.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.38
L/kg
1.38
L/kg
Average volume of distribution;
DRUGBANK
1.2
L/kg
1.2±0.2
L/kg
Female, women → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;Obesity ↓ ;chronic respiratory insufficiency → ;nephritic syndrome → ;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.3
h
2.3
h
DRUGBANK
2.3
h
2.3±0.5
h
Female, women ↓ ;nephritic syndrome → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;chronic respiratory insufficiency → ;Hepatic cirrhosis, cirr → ;Obesity ↑ ;
DRUGBANK
2.3
h
2.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4000.0
mg/kg
>4
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
2292.0
mg/kg
2292.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
28.0
%
25-31
%
Urinary excretion; dog;
DRUGBANK
48.0
%
44-52
%
Faeces excretion; Infants;
DRUGBANK
4.9
%
4.9±2.3
%
Urinary excretion; Unchanged drug;
Hepatitis, Hep → ;
DRUGBANK
76.8
%
76.8
%
DRUGBANK
78.0
%
78±3
%
Female, women → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
DDPD00960
Pindolol
248.3208
C14H20N2O2
CC(C)NCC(O)COC1=CC=CC2=C1C=CN2
DB00960
4828
8214
http://www.drugs.com/cdi/pindolol.html
4662
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
DRUGBANK
62.5
%
60-65
%
DRUGBANK
37.5
%
35-40
%
Urinary excretion;
DRUGBANK
10.5
L/h
50-300
ml/min
Hepatitis, Hep;
DRUGBANK
0.462
L/h/kg
7.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
L/kg
2.0
L/kg
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
263.0
mg/kg
263.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
7.5
%
~6-9
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
37.5
%
35-40
%
Urinary excretion; human, homo sapiens; Unchanged drug;
DRUGBANK
40.0
%
40
%
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Pindolol
pindolol
PDR
40.0
mg/day
40
mg/day
PO, oral
Pindolol
pindolol
PDR
60.0
mg/day
60
mg/day
PO, oral
Pindolol
pindolol
PDR
40.0
mg/day
40
mg/day
PO, oral
Pindolol
pindolol
PDR
DDPD00961
Mepivacaine
246.348
C15H22N2O
CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
DB00961
T3D2942
4062
6759
http://www.drugs.com/cdi/mepivacaine.html
3922
-2.0
-
-2.0
-
DRUGBANK
50.0
%
>50
%
Bile excretion;
DRUGBANK
7.5
%
5-10
%
Urinary excretion;
DRUGBANK
0.408
L/h/kg
6.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.95
L/kg
0.95
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.55
h
1.9-3.2
h
adults;
DRUGBANK
8.85
h
8.7-9
h
Neonates;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.0
mg/kg
23-35
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
280.0
mg/kg
280.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
29.0
mg/kg
23-35
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
280.0
mg/kg
280.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
50.0
%
>50
%
Bile excretion;
DRUGBANK
7.5
%
5-10
%
Urinary excretion; Unchanged drug;
DRUGBANK
75.0
%
~75
%
plasma proteins;
DRUGBANK
DDPD00962
Zaleplon
305.3339
C17H15N5O
CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N
DB00962
T3D2673
5719
10102
http://www.drugs.com/cdi/zaleplon.html
5517
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
31.0
%
31±10
%
Oral single dose; normal,healthy;
DRUGBANK
26.0
ng/ml
26±4.4
ng/ml
Oral single dose; normal,healthy;
DRUGBANK
1.1
h
1.1±0.2
h
Oral single dose; normal,healthy;
DRUGBANK
1.0
L/h/kg
1.0
l/h/kg
DRUGBANK
0.942
L/h/kg
15.7±3.3
ml/min/kg
normal,healthy; Male, men; Female, women;
Elderly → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.4
L/kg
1.4
L/kg
DRUGBANK
1.3
L/kg
1.3±0.2
L/kg
normal,healthy; Male, men; Female, women;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
DRUGBANK
1.0
h
1.0±0.1
h
normal,healthy; adults; Male, men; Female, women;
Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
60.0
%
~60
%
plasma proteins; high protein binding;
DRUGBANK
60.0
%
60±15
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral; hs
Sonata
zaleplon
PDR
10.0
mg/day
10
mg/day
PO, oral
Sonata
zaleplon
PDR
10.0
mg/day
10
mg/day
PO, oral; hs
Sonata
zaleplon
PDR
DDPD00963
Bromfenac
334.165
C15H12BrNO3
NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1
DB00963
60726
240107
http://www.drugs.com/cdi/bromfenac.html
54730
-2.0
-
-2.0
-
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
Prolensa
bromfenac sodium
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Prolensa
bromfenac sodium
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Prolensa
bromfenac sodium
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Prolensa
bromfenac sodium
PDR
DDPD00964
Apraclonidine
245.109
C9H10Cl2N4
NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1
DB00964
2216
2788
http://www.drugs.com/cdi/apraclonidine-drops.html
2130
-2.0
-
-2.0
-
DRUGBANK
0.9
ng/ml
0.9
ng/ml
ophthalmic administration;
DRUGBANK
8.0
h
8
h
DRUGBANK
98.7
%
98.7
%
DRUGBANK
6.0
drop/day
6
drop/day
ophthalmic administration
Iopidine 0.5% Ophthalmic Solution
apraclonidine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Iopidine 0.5% Ophthalmic Solution
apraclonidine hydrochloride
PDR
6.0
drop/day
6
drop/day
ophthalmic administration
Iopidine 0.5% Ophthalmic Solution
apraclonidine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Iopidine 0.5% Ophthalmic Solution
apraclonidine hydrochloride
PDR
DDPD00966
Telmisartan
514.6169
C33H30N4O2
CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
DB00966
65999
9434
http://www.drugs.com/cdi/telmisartan.html
59391
-2.0
-
-2.0
-
DRUGBANK
48.0
L/h
>800
ml/min
DRUGBANK
0.504
L/h/kg
8.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
L
500.0
L
DRUGBANK
5.3
L/kg
5.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
~24
h
elimination half-life;
DRUGBANK
20.0
h
20
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
175.0
mg/kg
150-200
mg/kg
intravenous injection, IV; Male, men; Rattus, Rat;
DRUGBANK
225.0
mg/kg
200-250
mg/kg
intravenous injection, IV; Female, women; Rattus, Rat;
DRUGBANK
97.0
%
>97
%
Faeces excretion; PO, oral;
DRUGBANK
97.0
%
>97
%
Faeces excretion; PO, oral; intravenous injection, IV; Unchanged drug;
DRUGBANK
99.5
%
99.5
%
plasma proteins;
dose → ;
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Micardis
telmisartan
PDR
80.0
mg/day
80
mg/day
PO, oral
Micardis
telmisartan
PDR
DDPD00967
Desloratadine
310.821
C19H19ClN2
ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1
DB00967
T3D4557
124087
291342
http://www.drugs.com/cdi/desloratadine.html
110575
-2.0
-
-2.0
-
DRUGBANK
50.0
h
50
h
DRUGBANK
87.0
%
~87
%
DRUGBANK
84.5
%
82-87
%
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Clarinex
desloratadine
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Clarinex
desloratadine
PDR
1.25
mg/day
1.25
mg/day
PO, oral
Clarinex
desloratadine
PDR
5.0
mg/day
5
mg/day
PO, oral
Clarinex
desloratadine
PDR
5.0
mg/day
5
mg/day
PO, oral
Clarinex
desloratadine
PDR
5.0
mg/day
5
mg/day
PO, oral
Clarinex
desloratadine
PDR
1.0
mg/day
1
mg/day
PO, oral
Clarinex
desloratadine
PDR
DDPD00968
Methyldopa
211.2145
C10H13NO4
C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
DB00968
T3D3577
38853
61058
http://www.drugs.com/cdi/methyldopa.html
35562
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
DRUGBANK
7.8
L/h
130.0
ml/min
Renal clearance; normal,healthy;
DRUGBANK
0.21
L/h/kg
3.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.69
L/kg
0.69
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
105.0
h
105
h
elimination half-life;
DRUGBANK
5.9
h
5.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1500.0
mg/kg
>1.5
g/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
1500.0
mg/kg
>1.5
g/kg
PO, oral; mouse;
DRUGBANK
1500.0
mg/kg
>1.5
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
20.0
%
<20
%
DRUGBANK
65.0
mg/kg/day
65
mg/kg/day
PO, oral;intravenous injection, IV;
Methyldopa
methyldopa
PDR
3000.0
mg/day
3
g/day
PO, oral;intravenous injection, IV;
Methyldopa
methyldopa
PDR
3000.0
mg/day
3
g/day
PO, oral
Methyldopa
methyldopa
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV
Methyldopa
methyldopa
PDR
65.0
mg/kg/day
65
mg/kg/day
PO, oral;intravenous injection, IV;
Methyldopa
methyldopa
PDR
3000.0
mg/day
3
g/day
PO, oral;intravenous injection, IV;
Methyldopa
methyldopa
PDR
1000.0
mg/day
1
g/day
PO, oral;intravenous injection, IV;
Methyldopa
methyldopa
PDR
DDPD00969
Alosetron
294.351
C17H18N4O
CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2
DB00969
2099
253342
http://www.drugs.com/cdi/alosetron.html
2015
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
DRUGBANK
36.0
L/h
600.0
ml/min
DRUGBANK
0.522
L/h/kg
8.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
L
65-95
L
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5
h
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
%
~6
%
Urinary excretion; Unchanged drug;
DRUGBANK
82.0
%
82
%
DRUGBANK
DDPD00970
Dactinomycin
1255.417
C62H86N12O16
[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C
DB00970
457193
27666
http://www.drugs.com/cdi/dactinomycin.html
10482167
-2.0
-
-2.0
-
DRUGBANK
36.0
h
36
h
DRUGBANK
5.0
%
5
%
DRUGBANK
0.015
mg/kg/day
15
mcg/kg/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.045
mg/kg/dose
45
mcg/kg/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
1250.0
mcg/m2/dose
1250
mcg/m2/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.5
mg/m2/day
500
mcg/m2/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.015
mg/kg/day
15
mcg/kg/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.045
mg/kg/dose
45
mcg/kg/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
1.25
mg/m2/dose
1250
mcg/m2/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.5
mg/m2/day
500
mcg/m2/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.015
mg/kg/day
15
mcg/kg/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
45.0
mcg/kg/dose
45
mcg/kg/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
1250.0
mcg/m2/dose
1250
mcg/m2/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
500.0
mcg/m2/day
500
mcg/m2/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.015
mg/kg/day
15
mcg/kg/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.045
mg/kg/dose
45
mcg/kg/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
1250.0
mcg/m2/dose
1250
mcg/m2/dose
intravenous injection, IV
Cosmegen
dactinomycin
PDR
0.5
mg/m2/day
500
mcg/m2/day
intravenous injection, IV
Cosmegen
dactinomycin
PDR
DDPD00971
Selenium Sulfide
143.09
S2Se
S=[Se]=S
DB00971
T3D1820
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
24087
135934
http://www.drugs.com/cdi/selenium-foam.html
22519
-2.0
-
-2.0
-
DRUGBANK
138.0
mg/kg
138.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.005
mg/kg/day
0.005
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD00972
Azelastine
381.898
C22H24ClN3O
CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O
DB00972
T3D4558
2267
2950
http://www.drugs.com/cdi/azelastine-spray.html
2180
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
inhalation, IH;
DRUGBANK
2.5
h
2-3
h
inhalation, IH;
DRUGBANK
0.5
L/h/kg
0.5
l/h/kg
Plasma clearance; PO, oral; intravenous injection, IV;
DRUGBANK
0.54
L/h/kg
9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.5
L/kg
14.5
L/kg
Steady state volume of distribution; PO, oral; intravenous injection, IV;
DRUGBANK
15.0
L/kg
15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
22
h
elimination half-life; PO, oral;
DRUGBANK
54.0
h
54
h
elimination half-life;
DRUGBANK
22.0
h
22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
580.0
mg/kg
580.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
75.0
%
~75
%
Faeces excretion; PO, oral;
DRUGBANK
10.0
%
<10
%
PO, oral; Unchanged drug;
DRUGBANK
88.0
%
~88
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
0.822
mg/day
822
mcg/day
nasal spray
q6h
Optivar
azelastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Optivar
azelastine hydrochloride
PDR
0.274
mg/day
274
mcg/day
nasal spray
bid
Optivar
azelastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Optivar
azelastine hydrochloride
PDR
0.274
mg/day
274
mcg/day
nasal spray
bid
Optivar
azelastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Optivar
azelastine hydrochloride
PDR
0.274
mg/day
274
mcg/day
nasal spray
bid
Optivar
azelastine hydrochloride
PDR
4.0
sprays/day/nostriL
4
sprays/day/nostriL
nasal spray
q6h
Optivar
azelastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Optivar
azelastine hydrochloride
PDR
4.0
sprays/day/nostril
4
sprays/day/nostril
nasal spray
q6h
Optivar
azelastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Optivar
azelastine hydrochloride
PDR
4.0
sprays/day/nostril
4
sprays/day/nostril
nasal spray
q6h
Optivar
azelastine hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Optivar
azelastine hydrochloride
PDR
0.274
mg/day
274
mcg/day
nasal spray
bid
Optivar
azelastine hydrochloride
PDR
DDPD00973
Ezetimibe
409.4252
C24H21F2NO3
[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1
DB00973
150311
49040
http://www.drugs.com/ezetimibe.html
132493
-2.0
-
-2.0
-
DRUGBANK
4.45
ng/ml
3.4-5.5
ng/ml
Oral single dose; adults; fasting;
DRUGBANK
58.0
ng/ml
45-71
ng/ml
PO, oral; Active metabolite;
DRUGBANK
122.0
ng/ml
122.0
ng/ml
PO, oral;
DRUGBANK
8.0
h
4-12
h
Oral single dose; adults; fasting;
DRUGBANK
1.5
h
1-2
h
PO, oral; Active metabolite;
DRUGBANK
1.0
h
1.0
h
PO, oral;
DRUGBANK
0.396
L/h/kg
6.6
ml/min/kg
apparent clearance;
Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
107.5
L
107.5
L
Total volume of distribution;
DRUGBANK
1.56
L/kg
1.5
L/kg
Apparent volume of distribution;
DRUGBANK
22.0
h
22
h
DRUGBANK
22.0
h
22
h
DRUGBANK
29.0
h
28-30
h
effective half-life;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse;
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
PO, oral; dog;
DRUGBANK
78.0
%
~78
%
Faeces excretion; PO, oral;
DRUGBANK
11.0
%
~11
%
Urinary excretion; PO, oral;
DRUGBANK
69.0
%
~69
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
2.0
%
~2
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
>90
%
plasma proteins; human, homo sapiens;
DRUGBANK
99.65
%
99.5-99.8
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Zetia
ezetimibe
PDR
10.0
mg/day
10
mg/day
PO, oral
Zetia
ezetimibe
PDR
10.0
mg/day
10
mg/day
PO, oral
Zetia
ezetimibe
PDR
10.0
mg/day
10
mg/day
PO, oral
Zetia
ezetimibe
PDR
DDPD00974
Edetic acid
292.2426
C10H16N2O8
OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
DB00974
T3D4977
6049
42191
5826
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
0.666666666666667
h
20-60
min
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
95.0
%
>95
%
Urinary excretion;
DRUGBANK
DDPD00975
Dipyridamole
504.6256
C24H40N8O4
OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1
DB00975
3108
4653
http://www.drugs.com/cdi/dipyridamole.html
2997
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
DRUGBANK
0.174
L/h/kg
2.3-3.5
ml/min/kg
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.75
L/kg
1-2.5
L/kg
DRUGBANK
0.82
L/kg
0.82
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.666666666666667
h
40
min
DRUGBANK
13.0
h
13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6000.0
mg/kg
>6000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
400.0
mg/kg
~400
mg/kg
PO, oral; dog;
DRUGBANK
8400.0
mg/kg
8.4
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
99.0
%
99
%
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Dipyridamole
dipyridamole
PDR
400.0
mg/day
400
mg/day
PO, oral
Dipyridamole
dipyridamole
PDR
400.0
mg/day
400
mg/day
PO, oral
Dipyridamole
dipyridamole
PDR
DDPD00976
Telithromycin
812.018
C43H65N5O10
[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
DB00976
T3D3536
3002190
29688
http://www.drugs.com/cdi/telithromycin.html
2273373
-2.0
-
-2.0
-
DRUGBANK
57.0
%
~57
%
PO, oral;
DRUGBANK
57.0
%
57(41-112)
%
PO, oral;
DRUGBANK
2230.0
ng/ml
2.23
mcg/ml
PO, oral;
DRUGBANK
2.25
h
0.5-4
h
PO, oral;
DRUGBANK
1.0
h
1.0（0.5-3.0）
h
PO, oral;
DRUGBANK
50.0
%
50
%
Liver metabolism;
DRUGBANK
0.84
L/h/kg
14（12-16）
ml/min/kg
hydrolysis;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.9
L/kg
2.9
L/kg
DRUGBANK
3.0
L/kg
3.0（2.1-4.5）
L/kg
hydrolysis;
DRUGBANK
3.0
L/kg
3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.5
h
12-13
h
elimination half-life;
DRUGBANK
12.0
h
12(7-23)
h
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
37.0
%
37
%
lung excretion;
DRUGBANK
7.0
%
7
%
Faeces excretion; Unchanged drug;
DRUGBANK
13.0
%
13
%
Urinary excretion; Unchanged drug;
DRUGBANK
23.0
%
23(19-27)
%
Urinary excretion; Unchanged drug;
DRUGBANK
65.0
%
60-70
%
DRUGBANK
70.0
%
70
%
DRUGBANK
0.0
0
Ketek
telithromycin
PDR
800.0
mg/day
800
mg/day
PO, oral
Ketek
telithromycin
PDR
0.0
0
Ketek
telithromycin
PDR
800.0
mg/day
800
mg/day
PO, oral
Ketek
telithromycin
PDR
DDPD00977
Ethinylestradiol
296.4034
C20H24O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
DB00977
T3D4743
5991
4903
5770
-2.0
-
-2.0
-
DRUGBANK
0.4874
ng.h/ml
487.4±166.6
pg.h/ml
PO, oral;
DRUGBANK
3.895
ng.h/ml
3895±1423
pg.h/ml
Transdermal preparations;
DRUGBANK
0.0741
ng/ml
74.1±35.6
pg/ml
PO, oral;
DRUGBANK
0.0288
ng/ml
28.8±10.3
pg/ml
Transdermal preparations;
DRUGBANK
1.5
h
1.5±0.5
h
PO, oral;
DRUGBANK
86.0
h
86±31
h
Transdermal preparations;
DRUGBANK
16.47
L/h
16.47
L/h
intravenous injection, IV;
DRUGBANK
2.1
L/h
~2.1
L/h
Renal clearance;
DRUGBANK
58.0
L/h
58.0±19.8
L/h
PO, oral;
DRUGBANK
303.5
L/h
303.5±100.5
L/h
skin/dermal;
DRUGBANK
0.42
L/h/kg
7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
625.3
L
625.3±228.7
L
Apparent volume of distribution; PO, oral;
DRUGBANK
11745.3
L
11745.3±15934.8
L
Apparent volume of distribution; skin/dermal;
DRUGBANK
4.3
L/kg
4.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.4
h
8.4±4.8
h
PO, oral;
DRUGBANK
27.7
h
27.7±34.2
h
skin/dermal;
DRUGBANK
9.7
h
9.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1737.0
mg/kg
1737.0
mg/kg
PO, oral; mouse;
DRUGBANK
59.2
%
59.2
%
Urinary excretion; Bile excretion;
DRUGBANK
2.5
%
2-3
%
Faeces excretion;
DRUGBANK
98.4
%
98.3-98.5
%
DRUGBANK
DDPD00978
Lomefloxacin
351.3479
C17H19F2N3O3
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12
DB00978
3948
116278
http://www.drugs.com/cdi/lomefloxacin.html
3811
-2.0
-
-2.0
-
DRUGBANK
96.5
%
95-98
%
Oral single dose;
DRUGBANK
65.0
%
65
%
Urinary excretion; Unchanged drug;
DRUGBANK
9.0
%
9
%
Urinary excretion;
DRUGBANK
9.39884393063584
L/h/m2
271.0
ml/min/1.73m2
normal,healthy;
DRUGBANK
1.07514450867052
L/h/m2
31.0
ml/min/1.73m2
renal insufficiency;
DRUGBANK
0.2388
L/h/kg
3.98
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.04
L/kg
2.04
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8
h
DRUGBANK
8.1
h
8.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
10
%
DRUGBANK
DDPD00979
Cyclopentolate
291.3853
C17H25NO3
CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
DB00979
2905
4024
http://www.drugs.com/cdi/cyclopentolate.html
2802
-2.0
-
-2.0
-
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
960.0
mg/kg
960.0
mg/kg
PO, oral; mouse;
DRUGBANK
4.0
drop/day
4
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Cyclogyl
cyclopentolate hydrochloride
PDR
DDPD00980
Ramelteon
259.3434
C16H21NO2
CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2
DB00980
208902
109549
http://www.drugs.com/cdi/ramelteon.html
181000
-2.0
-
-2.0
-
DRUGBANK
84.0
%
>84
%
DRUGBANK
0.786
L/h/kg
13.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
73.6
L
73.6
L
DRUGBANK
1.05
L/kg
1.05
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
~1-2.6
h
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.0
%
84
%
Urinary excretion; PO, oral;
DRUGBANK
4.0
%
~4
%
Faeces excretion; PO, oral;
DRUGBANK
82.0
%
~82
%
human, homo sapiens;
DRUGBANK
DDPD00981
Physostigmine
275.3461
C15H21N3O2
[H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC)=C1)N2C
DB00981
5983
27953
http://www.drugs.com/mtm/physostigmine-ophthalmic.html
5763
-2.0
-
-2.0
-
DRUGBANK
4.32
L/h/kg
72
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.9
L/kg
3.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD00982
Isotretinoin
300.4351
C20H28O2
C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O
DB00982
5282379
6067
http://www.drugs.com/cdi/isotretinoin.html
4445539
-2.0
-
-2.0
-
DRUGBANK
4055.0
ng.h/ml
4055.0
ng.h/ml
PO, oral; fasting;
DRUGBANK
6095.0
ng.h/ml
6095.0
ng.h/ml
PO, oral; high-fat meal;
DRUGBANK
40.0
%
40.0
%
PO, oral;
DRUGBANK
292.5
ng/ml
74-511
ng/ml
PO, oral;
DRUGBANK
314.0
ng/ml
314
ng/ml
PO, oral; fasting;
DRUGBANK
395.0
ng/ml
395
ng/ml
PO, oral; high-fat meal;
DRUGBANK
208.0
ng/ml
208±92
ng/ml
PO, oral;
DRUGBANK
473.0
ng/ml
473±171
ng/ml
PO, oral; Active metabolite;
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
2.9
h
2.9
h
PO, oral; fasting;
DRUGBANK
6.4
h
6.4
h
PO, oral; high-fat meal;
DRUGBANK
4.5
h
4.5±3.4
h
PO, oral;
DRUGBANK
6.8
h
6.8±6.5
h
PO, oral; Active metabolite;
DRUGBANK
15.9
L/h
15.9
L/h
neuroblastoma; pediatric patients;
DRUGBANK
1.278
L/h/kg
21.3
ml/min/kg
guinea pigs;
DRUGBANK
0.432
L/h/kg
7.2
ml/min/kg
Rattus, Rat; Obesity;
DRUGBANK
0.33
L/h/kg
5.5(0.9-11.1)
ml/min/kg
apparent clearance;
DRUGBANK
85.0
L
85.0
L
neuroblastoma; pediatric patients;
DRUGBANK
2.423
L/kg
2423.0
ml/kg
guinea pigs;
DRUGBANK
1.716
L/kg
1716.0
ml/kg
Rattus, Rat; Obesity;
DRUGBANK
5.0
L/kg
5(1-32)
L/kg
Apparent volume of distribution;
DRUGBANK
23.0
h
7-39
h
DRUGBANK
20.0
h
20
h
elimination half-life;
DRUGBANK
33.5
h
17-50
h
DRUGBANK
25.0
h
25
h
elimination half-life;
DRUGBANK
17.0
h
17(5-167)
h
DRUGBANK
29.0
h
29±6
h
DRUGBANK
63.5
%
53-74
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.9
%
>99.9
%
DRUGBANK
99.0
%
>99
%
DRUGBANK
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
1.6
mg/kg/day
1.6
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
1.6
mg/kg/day
1.6
mg/kg/day
PO, oral
Claravis
isotretinoin
PDR
DDPD00983
Formoterol
344.4049
C19H24N2O4
COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
DB00983
3410
63082
http://www.drugs.com/cdi/formoterol.html
3292
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
inhalation, IH; adults; normal,healthy;
DRUGBANK
0.0278967969
ng.h/ml
81.0
pmol.h/L
inhalation, IH; adults; normal,healthy;
DRUGBANK
0.0430506125
ng.h/ml
125.0
pmol.h/L
adults; asthma;
DRUGBANK
0.0778355074
ng.h/ml
226.0
pmol.h/L
adults; asthma;
DRUGBANK
2.2e-05
ng/ml
22
pmol/L
inhalation, IH; adults; normal,healthy;
DRUGBANK
2.2e-05
ng/ml
22
pmol/L
adults; asthma;
DRUGBANK
4.1e-05
ng/ml
41
pmol/L
adults; asthma;
DRUGBANK
0.3335
h
0.167-0.5
h
inhalation, IH; adults; normal,healthy;
DRUGBANK
1.275
h
0.58-1.97
h
adults; asthma;
DRUGBANK
9.42
L/h
157.0
ml/min
Renal clearance;
DRUGBANK
8.5
h
7-10
h
elimination half-life; inhalation, IH;
DRUGBANK
3.5
h
3-4
h
elimination half-life; PO, oral;
DRUGBANK
2.0
h
1.7-2.3
h
elimination half-life; inhalation, IH;
DRUGBANK
3130.0
mg/kg
3130.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
60.5
%
~59-62
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
33.0
%
~32-34
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
10.0
%
~10
%
Urinary excretion; asthma; Unchanged drug;
DRUGBANK
34.5
%
31-38
%
DRUGBANK
0.04
mg/day
40
mcg/day
skin/dermal
Perforomist
formoterol fumarate
PDR
0.04
mg/day
40
mcg/day
skin/dermal
Perforomist
formoterol fumarate
PDR
DDPD00984
Nandrolone phenpropionate
406.5571
C27H34O3
[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
DB00984
229455
7468
http://www.drugs.com/cdi/nandrolone.html
199761
-2.0
-
-2.0
-
DRUGBANK
58.0
%
58
%
DRUGBANK
DDPD00985
Dimenhydrinate
469.97
C24H28ClN5O3
CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
DB00985
441281
94848
http://www.drugs.com/cdi/dimenhydrinate.html
10210
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
DRUGBANK
98.5
%
98-99
%
DRUGBANK
DDPD00986
Glycopyrronium
318.4305
C19H28NO3
C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1
DB00986
9933193
94449
http://www.drugs.com/cdi/glycopyrrolate.html
3374
-2.0
-
-2.0
-
DRUGBANK
0.9
h
0.6-1.2
h
DRUGBANK
709.0
mg/kg
709.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
6.0
mg/day
6
mg/day
Tablet,PO，oral
Robinul Injection
glycopyrrolate
PDR
0.3
mg/kg/day
0.1
mg/kg/dose
PO, oral
tid
Robinul Injection
glycopyrrolate
PDR
3.0
mg/dose
3
mg/dose
Liquid
Robinul Injection
glycopyrrolate
PDR
0.3
mg/kg/day
0.1
mg/kg/dose
PO, oral
tid
Robinul Injection
glycopyrrolate
PDR
3.0
mg/day
3
mg/day
Liquid
Robinul Injection
glycopyrrolate
PDR
0.004
mg/kg
0.004
mg/kg
IM,intramuscular injection
Robinul Injection
glycopyrrolate
PDR
0.2
mg/dose
0.2
mg/dose
intravenous injection, IV
Robinul Injection
glycopyrrolate
PDR
6.0
mg/day
6
mg/day
PO, oral
Robinul Injection
glycopyrrolate
PDR
2.0
capsuLe/day
2
capsuLe/day
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
0.0312
mg
31.2
mcg
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
2.0
viaLs/day
2
viaLs/day
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
0.05
mg
50
mcg
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
6.0
mg/day
6
mg/day
PO, oral
Robinul Injection
glycopyrrolate
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
PO, oral
tid
Robinul Injection
glycopyrrolate
PDR
3.0
mg/dose
3
mg/dose
Liquid
Robinul Injection
glycopyrrolate
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
PO, oral
tid
Robinul Injection
glycopyrrolate
PDR
3.0
mg/day
3
mg/day
Liquid
Robinul Injection
glycopyrrolate
PDR
0.004
mg/kg
0.004
mg/kg
IM,intramuscular injection
Robinul Injection
glycopyrrolate
PDR
0.2
mg/dose
0.2
mg/dose
intravenous injection, IV
Robinul Injection
glycopyrrolate
PDR
6.0
mg/day
6
mg/day
PO, oral
Robinul Injection
glycopyrrolate
PDR
2.0
capsule/day
2
capsule/day
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
0.0312
mg
31.2
mcg
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
2.0
vials/day
2
vials/day
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
0.05
mg
50
mcg
inhalation, IH
Robinul Injection
glycopyrrolate
PDR
DDPD00987
Cytarabine
243.2166
C9H13N3O5
NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
DB00987
T3D4978
6253
28680
http://www.drugs.com/cdi/cytarabine.html
6017
-2.0
-
-2.0
-
DRUGBANK
20.0
%
<20
%
PO, oral;
DRUGBANK
20.0
%
<20
%
PO, oral;
DRUGBANK
5000.0
ng/ml
~5
mcg/ml
intravenous injection, IV; leukemia; malignant solid tumors;
DRUGBANK
75.0
ng/ml
0.05-0.1
mcg/ml
intravenous infusion, IV in drop; leukemia; malignant solid tumors;
DRUGBANK
0.78
L/h/kg
13±4
ml/min/kg
DRUGBANK
2.5002
L/h/kg
41.67
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
L/kg
3.0±11.9
L/kg
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.166666666666667
h
10
min
DRUGBANK
2.6
h
2.6±0.6
h
DRUGBANK
0.17
h
0.17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
%
11±8
%
Urinary excretion; Unchanged drug;
DRUGBANK
13.0
%
13
%
DRUGBANK
13.0
%
13
%
DRUGBANK
50.0
mg/dose
50
mg/dose
intrathecal administration
DepoCyt
cytarabine liposome
PDR
50.0
mg/dose
50
mg/dose
intrathecal administration
DepoCyt
cytarabine liposome
PDR
DDPD00988
Dopamine
153.1784
C8H11NO2
NCCC1=CC(O)=C(O)C=C1
DB00988
T3D4300
681
18243
http://www.drugs.com/cdi/dopamine.html
661
-2.0
-
-2.0
-
DRUGBANK
3.954
L/h/kg
65.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.74
L/kg
0.74
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0333333333333333
h
2
min
DRUGBANK
0.42
h
0.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1460.0
mg/kg
1460.0
mg/kg
PO, oral; mouse;
DRUGBANK
1780.0
mg/kg
1780.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1460.0
mg/kg
1460.0
mg/kg
PO, oral; mouse;
DRUGBANK
1780.0
mg/kg
1780.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
80.0
%
~80
%
Urinary excretion;
DRUGBANK
DDPD00989
Rivastigmine
250.3367
C14H22N2O2
CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
DB00989
77991
8874
http://www.drugs.com/cdi/rivastigmine.html
70377
-2.0
-
-2.0
-
DRUGBANK
72.0
%
72(22-119)
%
DRUGBANK
26.0
ng/ml
26±10
ng/ml
Capsule, PO, Oral;
DRUGBANK
1.2
h
1.2±1.0
h
Capsule, PO, Oral;
DRUGBANK
2.45
L/h
2.1-2.8
L/h
Renal clearance;
DRUGBANK
0.78
L/h/kg
13±4
ml/min/kg
intravenous injection, IV;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.25
L/kg
1.8-2.7
L/kg
DRUGBANK
0.15
L/kg
1.5±0.6
L/kg
intravenous injection, IV;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5
h
DRUGBANK
1.4
h
1.4±0.4
h
intravenous injection, IV;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
10.0
h
~10
h
DRUGBANK
1.4
h
1.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Faeces excretion;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
40.0
%
40
%
DRUGBANK
40.0
%
40
%
DRUGBANK
12.0
mg/day
12
mg/day
Capsule, PO, Oral
Exelon Capsules and Oral Solution
rivastigmine tartrate
PDR
13.3
mg/day
13.3
mg/day
Transdermal preparations
Exelon Capsules and Oral Solution
rivastigmine tartrate
PDR
12.0
mg/day
12
mg/day
Capsule, PO, Oral
Exelon Capsules and Oral Solution
rivastigmine tartrate
PDR
13.3
mg/day
13.3
mg/day
Transdermal preparations
Exelon Capsules and Oral Solution
rivastigmine tartrate
PDR
DDPD00990
Exemestane
296.4034
C20H24O2
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C
DB00990
60198
4953
http://www.drugs.com/cdi/exemestane.html
54278
-2.0
-
-2.0
-
DRUGBANK
42.0
%
42
%
DRUGBANK
24.0
h
24
h
DRUGBANK
90.0
%
90
%
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
Aromasin
exemestane
PDR
50.0
mg/day
50
mg/day
PO, oral
Aromasin
exemestane
PDR
25.0
mg/day
25
mg/day
PO, oral
Aromasin
exemestane
PDR
50.0
mg/day
50
mg/day
PO, oral
Aromasin
exemestane
PDR
DDPD00991
Oxaprozin
293.3166
C18H15NO3
OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
DB00991
4614
7822
http://www.drugs.com/cdi/oxaprozin.html
4453
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
PO, oral; antacids;
antacids → ;
DRUGBANK
0.2
L/kg
11.0-17
L/70kg
DRUGBANK
54.9
h
54.9
h
DRUGBANK
1210.0
mg/kg
1210.0
mg/kg
PO, oral; mouse;
DRUGBANK
172.0
mg/kg
172.0
mg/kg
PO, oral; rabbit;
DRUGBANK
4470.0
mg/kg
4470.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
70.0
%
~70
%
Urinary excretion;
DRUGBANK
5.0
%
~5
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.5
%
>99.5
%
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Daypro
oxaprozin
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Daypro
oxaprozin
PDR
26.0
mg/kg/day
26
mg/kg/day
PO, oral
Daypro
oxaprozin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Daypro
oxaprozin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Daypro
oxaprozin
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Daypro
oxaprozin
PDR
26.0
mg/kg/day
26
mg/kg/day
PO, oral
Daypro
oxaprozin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Daypro
oxaprozin
PDR
DDPD00992
Methyl aminolevulinate
145.1564
C6H11NO3
COC(=O)CCC(=O)CN
DB00992
157922
724125
http://www.drugs.com/mtm/methyl-aminolevulinate-topical.html
138950
-2.0
-
-2.0
-
DRUGBANK
0.26
%
0.26
%
skin/dermal;
DRUGBANK
DDPD00993
Azathioprine
277.263
C9H7N7O2S
CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
DB00993
T3D4677
2265
2948
http://www.drugs.com/cdi/azathioprine.html
2178
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60±31
%
PO, oral;
DRUGBANK
55.0
ng/ml
20-90
ng/ml
PO, oral; Active metabolite; renal transplant;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral; Active metabolite; renal transplant;
DRUGBANK
3.42
L/h/kg
57±31
ml/min/kg
renal transplant; intravenous injection, IV;
DRUGBANK
0.81
L/kg
0.81±0.65
L/kg
renal transplant; intravenous injection, IV;
DRUGBANK
5.0
h
~5
h
DRUGBANK
0.16
h
0.16±0.07
h
renal transplant; patients;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; mouse;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
Oral single dose; mouse;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
Oral single dose; Rattus, Rat;
DRUGBANK
2.0
%
<2
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
30.0
%
30
%
DRUGBANK
1.5
mg/kg/day
1.5
mg/kg/day
PO, oral
Azasan
azathioprine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Azasan
azathioprine
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral;intravenous injection, IV;
Azasan
azathioprine
PDR
1.5
mg/kg/day
1.5
mg/kg/day
PO, oral
Azasan
azathioprine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Azasan
azathioprine
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral;intravenous injection, IV;
Azasan
azathioprine
PDR
DDPD00994
Neomycin
N.A.
N.A.
C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N
DB00994
T3D2951
8378
7507
http://www.drugs.com/cdi/neomycin.html
-2.0
-
-2.0
-
DRUGBANK
8000.0
mg/kg
>8
g/kg
PO, oral; mouse;
DRUGBANK
200.0
mg/kg
200.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
190.0
mg/kg
190.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
305.0
mg/kg
305.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
200.0
mg/kg
200.0
mg/kg
Rattus, Rat;
DRUGBANK
1800.0
mg/kg/day
12600.0
mg/kg/7D
PO, oral; Female, women;
DRUGBANK
30.0
%
0-30
%
DRUGBANK
12000.0
mg/day
12
g/day
PO, oral
Neomycin Sulfate
neomycin sulfate
PDR
12000.0
mg/day
12
g/day
PO, oral
Neomycin Sulfate
neomycin sulfate
PDR
DDPD00995
Auranofin
678.48
C20H34AuO9PS
CC[P+](CC)(CC)[Au-]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
DB00995
70788951
2922
http://www.drugs.com/cdi/auranofin.html
5293650
-2.0
-
-2.0
-
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
%
15
%
Urinary excretion;
DRUGBANK
9.0
mg/day
9
mg/day
PO, oral
Ridaura
auranofin
PDR
9.0
mg/day
9
mg/day
PO, oral
Ridaura
auranofin
PDR
DDPD00996
Gabapentin
171.2368
C9H17NO2
NCC1(CC(O)=O)CCCCC1
DB00996
T3D2952
3446
42797
http://www.drugs.com/gabapentin.html
3328
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
27.0
%
27
%
PO, oral;
DRUGBANK
60.0
%
60.0
%
increasing doses ↑ ;
DRUGBANK
4000.0
ng/ml
4.0
mcg/ml
PO, oral; adults; normal,healthy;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
2.5
h
2-3
h
PO, oral; adults; normal,healthy;
DRUGBANK
1.0
%
1
%
DRUGBANK
99.0
%
~99
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.096
L/h/kg
1.6±0.3
ml/min/kg
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.102
L/h/kg
1.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
58.0
L
58±6
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
0.8
L/kg
0.80±0.09
L/kg
DRUGBANK
0.71
L/kg
0.71
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
5-7
h
elimination half-life; normal renal function; patients;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
52.0
h
52
h
Renal clearance;
DRUGBANK
6.5
h
6.5±1.0
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
5.3
h
5.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8000.0
mg/kg
>8000
mg/kg
DRUGBANK
8000.0
mg/kg
>8000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8053.0
mg/kg
8053.0
mg/kg
PO, oral; mouse;
DRUGBANK
2.86
mg/kg
2.86
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
66.0
%
64-68
%
Urinary excretion; Unchanged drug;
DRUGBANK
3.0
%
<3
%
plasma proteins; PO, oral;
DRUGBANK
3.0
%
<3
%
DRUGBANK
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Gralise
gabapentin
PDR
3600.0
mg/day
3600
mg/day
PO, oral
Gralise
gabapentin
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Gralise
gabapentin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Gralise
gabapentin
PDR
3600.0
mg/day
3600
mg/day
PO, oral
Gralise
gabapentin
PDR
3600.0
mg/day
3600
mg/day
PO, oral
Gralise
gabapentin
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Gralise
gabapentin
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Gralise
gabapentin
PDR
DDPD00997
Doxorubicin
543.5193
C27H29NO11
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
DB00997
T3D2953
31703
28748
http://www.drugs.com/cdi/doxorubicin.html
29400
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5.0
%
PO, oral;
DRUGBANK
950.0
ng/ml
~950
ng/ml
intravenous infusion, IV in drop; depression;
DRUGBANK
519.0
ng/ml
30-1008
ng/ml
intravenous infusion, IV in drop; Active metabolite; depression;
DRUGBANK
6.0
ng/ml
6.0±3.2
ng/ml
intravenous infusion, IV in drop; Advanced tumors;
DRUGBANK
5.0
ng/ml
5.0±3.5
ng/ml
intravenous infusion, IV in drop; Active metabolite; Advanced tumors;
DRUGBANK
33.99
L/h/m2
324-809
ml/min/m2
Bile metabolism;
DRUGBANK
65.28
L/h/m2
1088.0
ml/min/m2
Male, men;
DRUGBANK
25.98
L/h/m2
433.0
ml/min/m2
Female, women;
DRUGBANK
92.4
L/h/m2
1540.0
ml/min/m2
Children;
DRUGBANK
48.78
L/h/m2
813.0
ml/min/m2
Infants;
DRUGBANK
39.96
L/h/m2
666±339
ml/min/m2
Children ↑ ;Hepatic cirrhosis, cirr ↓ ;Obesity ↓ ;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1011.5
L/m2
809-1214
L/m2
Steady state volume of distribution;
DRUGBANK
682.0
L/m2
682±433
L/m2
Hepatic cirrhosis, cirr → ;
DRUGBANK
22.0
L/kg
22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
34.0
h
20-48
h
DRUGBANK
26.0
h
26±17
h
RD, renal impairment, Renal disease，including uremia → ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
29.0
h
29±16
h
Active metabolite;
DRUGBANK
32.0
h
32
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21800.0
mg/kg
21800.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
21.8
mg/kg
21 800
ug/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
40.0
%
40
%
Bile excretion;
DRUGBANK
8.5
%
5-12
%
Urinary excretion;
DRUGBANK
7.0
%
<7
%
Urinary excretion; Unchanged drug;
DRUGBANK
75.0
%
74-76
%
plasma proteins;
DRUGBANK
76.0
%
76
%
DRUGBANK
550.0
mg/m2/lifetime
550
mg/m2/lifetime
intravenous injection, IV
Adriamycin
doxorubicin hydrochloride
PDR
450.0
mg/m2/lifetime
450
mg/m2/lifetime
intravenous injection, IV
Adriamycin
doxorubicin hydrochloride
PDR
550.0
mg/m2/lifetime
550
mg/m2/lifetime
intravenous injection, IV
Adriamycin
doxorubicin hydrochloride
PDR
450.0
mg/m2/lifetime
450
mg/m2/lifetime
intravenous injection, IV
Adriamycin
doxorubicin hydrochloride
PDR
550.0
mg/m2/lifetime
550
mg/m2/lifetime
intravenous injection, IV
Adriamycin
doxorubicin hydrochloride
PDR
450.0
mg/m2/lifetime
450
mg/m2/lifetime
intravenous injection, IV
Adriamycin
doxorubicin hydrochloride
PDR
50.0
mg/m2/dose
50
mg/m2/dose
intravenous injection, IV
q4w
Doxorubicin Hydrochloride Liposome
doxorubicin hydrochloride liposome
PDR
20.0
mg/m2/dose
20
mg/m2/dose
intravenous injection, IV
q3w
Doxorubicin Hydrochloride Liposome
doxorubicin hydrochloride liposome
PDR
30.0
mg/m2/dose
30
mg/m2/dose
intravenous injection, IV
q3w
Doxorubicin Hydrochloride Liposome
doxorubicin hydrochloride liposome
PDR
50.0
mg/m2/dose
50
mg/m2/dose
intravenous injection, IV
q4w
Doxorubicin Hydrochloride Liposome
doxorubicin hydrochloride liposome
PDR
20.0
mg/m2/dose
20
mg/m2/dose
intravenous injection, IV
q3w
Doxorubicin Hydrochloride Liposome
doxorubicin hydrochloride liposome
PDR
30.0
mg/m2/dose
30
mg/m2/dose
intravenous injection, IV
q3w
Doxorubicin Hydrochloride Liposome
doxorubicin hydrochloride liposome
PDR
DDPD00998
Frovatriptan
243.3043
C14H17N3O
CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
DB00998
T3D2954
77992
134991
http://www.drugs.com/cdi/frovatriptan.html
70378
-2.0
-
-2.0
-
DRUGBANK
13.2
L/h
220.0
ml/min
intravenous injection, IV; Male, men;
DRUGBANK
7.8
L/h
130.0
ml/min
intravenous injection, IV; Female, women;
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.2
L/kg
4.2
L/kg
Male, men;
DRUGBANK
3.0
L/kg
3.0
L/kg
Female, women;
DRUGBANK
3.6
L/kg
3.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
26.0
h
26
h
DRUGBANK
24.0
h
24
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
<10
%
Urinary excretion;
DRUGBANK
7.5
mg/day
7.5
mg/day
PO, oral
Frova
frovatriptan succinate
PDR
7.5
mg/day
7.5
mg/day
PO, oral
Frova
frovatriptan succinate
PDR
DDPD00999
Hydrochlorothiazide
297.739
C7H8ClN3O4S2
NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
DB00999
T3D4781
3639
5778
http://www.drugs.com/hctz.html
3513
-2.0
-
-2.0
-
DRUGBANK
70.0
%
65-75
%
PO, oral;
DRUGBANK
60.0
%
55-65
%
PO, oral; food;
DRUGBANK
71.0
%
71±15
%
PO, oral;
DRUGBANK
280.0
ng/ml
70-490
ng/ml
PO, oral;
DRUGBANK
224.0
ng/ml
56-392
ng/ml
PO, oral; food;
DRUGBANK
75.0
ng/ml
75±17
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
91.0
ng/ml
91±0.2
ng/ml
Oral multiple dose; adults; normal,healthy;
DRUGBANK
1.6
h
1.6(1-5)
h
PO, oral;
DRUGBANK
2.9
h
2.9
h
PO, oral; food;
DRUGBANK
1.9
h
1.9±0.5
h
Oral single dose; adults; normal,healthy;
DRUGBANK
2.0
h
2.0
h
Oral multiple dose; adults; normal,healthy;
DRUGBANK
0.0
%
0
%
DRUGBANK
17.1
L/h
285.0
ml/min
Renal clearance; normal renal function; patients;
DRUGBANK
4.5
L/h
75.0
ml/min
Renal clearance; mild renal function; moderate renal function;
DRUGBANK
1.02
L/h
17.0
ml/min
Renal clearance; severe renal function;
DRUGBANK
0.294
L/h/kg
4.9±1.1
ml/min/kg
Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease ↓ ;
DRUGBANK
2.51
L/kg
0.83-4.19
L/kg
DRUGBANK
0.83
L/kg
0.83±0.31
L/kg
Elderly ↓ ;
DRUGBANK
10.2
h
5.6-14.8
h
elimination half-life;
DRUGBANK
2.5
h
2.5±0.2
h
DRUGBANK
8.0
h
8±2.8
h
terminal half-life;
RD, renal impairment, Renal disease，including uremia ↑ ;congestive heart disease ↑ ;Age ↑ ;
DRUGBANK
10000.0
mg/kg
>10
g/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
10000.0
mg/kg
>10
g/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
95.0
%
>95
%
Urinary excretion; Unchanged drug;
DRUGBANK
54.0
%
40-68
%
plasma proteins;
DRUGBANK
58.0
%
58±17
%
DRUGBANK
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
37.5
mg/day
37.5
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
100.0
mg/day
100
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
50.0
mg/day
50
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
100.0
mg/day
100
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
50.0
mg/day
50
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
100.0
mg/day
100
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
50.0
mg/day
50
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
100.0
mg/day
100
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
37.5
mg/day
37.5
mg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
3.3
mg/kg/day
3.3
mg/kg/day
PO, oral
Hydrochlorothiazide Tablets
hydrochlorothiazide
PDR
DDPD01000
Cyclacillin
341.426
C15H23N3O4S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1(N)CCCCC1)C(O)=O
DB01000
19003
31444
17941
-2.0
-
-2.0
-
DRUGBANK
DDPD01001
Salbutamol
239.3107
C13H21NO3
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
DB01001
T3D4735
2083
2549
1999
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30±7
%
PO, oral; Optical rotation R;
DRUGBANK
71.0
%
71±9
%
PO, oral; Optical rotation S;
DRUGBANK
25.0
%
25.0
%
inhalation, IH; Optical rotation R;
DRUGBANK
47.0
%
47.0
%
inhalation, IH; Optical rotation S;
DRUGBANK
3.0
ng/ml
3
ng/ml
PO, oral; Active metabolite;
DRUGBANK
3.6
ng/ml
3.6(1.9-5.9)
ng/ml
Oral single dose; Optical rotation R;
DRUGBANK
11.4
ng/ml
11.4(7.1-16.2)
ng/ml
Oral single dose; Optical rotation S;
DRUGBANK
0.17
h
0.17
h
PO, oral; Active metabolite;
DRUGBANK
0.42
h
0.42
h
PO, oral; Active metabolite;
DRUGBANK
1.5
h
1.5
h
Oral single dose; Optical rotation R;
DRUGBANK
2.0
h
2.0
h
Oral single dose; Optical rotation S;
DRUGBANK
0.0
%
0
%
lung metabolism;
DRUGBANK
16.32
L/h
272±38
ml/min
Renal clearance; PO, oral;
DRUGBANK
17.46
L/h
291±70
ml/min
Renal clearance; intravenous injection, IV;
DRUGBANK
5.91
L/h
98.5±23.5
ml/min
Renal clearance; PO, oral;
DRUGBANK
0.618
L/h/kg
10.3±3.0
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.39
L/h/kg
6.5±2.0
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
156.0
L
156±38
L
intravenous injection, IV;
DRUGBANK
2.0
L/kg
2.00±0.70
L/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
1.77
L/kg
1.77±0.69
L/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
3.85
h
2.7-5
h
elimination half-life; PO, oral;
DRUGBANK
3.85
h
2.7-5
h
elimination half-life; inhalation, IH;
DRUGBANK
4.6
h
~4.6
h
terminal half-life;
DRUGBANK
2.0
h
2.00±0.49
h
normal,healthy; Optical rotation R;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
2.85
h
2.85±0.85
h
normal,healthy; Optical rotation S;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; mouse;
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; mouse;
DRUGBANK
68.0
%
58-78
%
Urinary excretion; PO, oral;
DRUGBANK
46.0
%
46±8
%
Urinary excretion; Optical rotation R; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
55.0
%
55±11
%
Urinary excretion; Optical rotation S; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
7.0
%
7±1
%
Optical rotation R/S; normal,healthy; human, homo sapiens;
DRUGBANK
24.0
mg/day
24
mg/day
Tablet,PO，oral;Liquid;
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
0.6
mg/kg/day
0.6
mg/kg/day
Liquid
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
mg/day
12
mg/day
Liquid
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
0.6
mg/kg/day
0.6
mg/kg/day
Liquid
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
mg/day
12
mg/day
Liquid
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
32.0
mg/day
32
mg/day
Tablet,PO，oral;Liquid;
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
32.0
mg/day
32
mg/day
Tablet,PO，oral;Liquid;
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
24.0
mg/day
24
mg/day
Liquid
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
32.0
mg/day
32
mg/day
Tablet,PO，oral
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
32.0
mg/day
32
mg/day
Tablet,PO，oral;Liquid;
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
12.0
puffs/day
12
puffs/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
4.0
dose/day
4
dose/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
10.0
mg/day
10
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
2.5
mg/day
2.5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
5.0
mg/day
5
mg/day
inhalation, IH
Albuterol Sulfate Inhalation Solution 0.5%
albuterol sulfate
PDR
DDPD01002
Levobupivacaine
288.4277
C18H28N2O
CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C
DB01002
T3D2955
92253
6149
83289
-2.0
-
-2.0
-
DRUGBANK
1200.0
ng/ml
1.2
ug/ml
epidural administration;
DRUGBANK
0.5
h
0.5
h
epidural administration;
DRUGBANK
0.0
%
0
%
Urinary excretion; Faeces excretion;
DRUGBANK
39.06
L/h
39.06±13.29
L/h
intravenous injection, IV; normal,healthy;
DRUGBANK
0.522
L/h/kg
8.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
66.91
L
66.91±18.23
L
intravenous injection, IV; normal,healthy;
DRUGBANK
0.49
L/kg
0.49
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.3
h
3.3
h
DRUGBANK
0.79
h
0.79
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.1
mg/kg
5.1
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
18.0
mg/kg
18.0
mg/kg
PO, oral; rabbit;
DRUGBANK
207.0
mg/kg
207.0
mg/kg
parenteral administration; rabbit;
DRUGBANK
63.0
mg/kg
63.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
5.1
mg/kg
5.1
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
18.0
mg/kg
18.0
mg/kg
PO, oral; rabbit;
DRUGBANK
207.0
mg/kg
207.0
mg/kg
parenteral administration; rabbit;
DRUGBANK
63.0
mg/kg
63.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
71.0
%
~71
%
Urinary excretion; human, homo sapiens;
DRUGBANK
24.0
%
~24
%
Faeces excretion; human, homo sapiens;
DRUGBANK
97.0
%
>97
%
DRUGBANK
DDPD01003
Cromoglicic acid
468.3665
C23H16O11
OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O
DB01003
2882
59773
2779
-2.0
-
-2.0
-
DRUGBANK
1.0
%
1
%
DRUGBANK
1.3
h
1.3
h
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Gastrocrom
cromolyn sodium
PDR
DDPD01004
Ganciclovir
255.2306
C9H13N5O4
NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
DB01004
3454
465284
http://www.drugs.com/cdi/ganciclovir-implant.html
3336
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5
%
PO, oral; fasting;
DRUGBANK
7.5
%
6-9
%
DRUGBANK
30.0
%
30
%
DRUGBANK
4.0
%
3-5
%
PO, oral;
DRUGBANK
1200.0
ng/ml
1.2±0.4
mcg/ml
intravenous infusion, IV in drop; food;
DRUGBANK
6600.0
ng/ml
6.6±1.8
mcg/ml
DRUGBANK
3.0
h
3.0±0.6
h
intravenous infusion, IV in drop; food;
DRUGBANK
90.0
%
~90
%
Urinary excretion;
DRUGBANK
7.68
L/h
128±63
ml/min
mild renal function; patients;
DRUGBANK
3.42
L/h
57±8
ml/min
moderate renal function; patients;
DRUGBANK
1.8
L/h
30±13
ml/min
severe renal function; patients;
DRUGBANK
0.282
L/h
4.7±2.2
ml/min
pediatric patients;
DRUGBANK
0.204
L/h/kg
3.4±0.5
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.276
L/h/kg
4.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.74
L/kg
0.74±0.15
L/kg
DRUGBANK
1.1
L/kg
1.1±0.2
L/kg
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.9
h
2.9(2.5-3.6)
h
intravenous injection, IV; adults;
DRUGBANK
4.3
h
3.1-5.5
h
PO, oral; adults;
DRUGBANK
19.5
h
9-30
h
intravenous injection, IV; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
16.95
h
15.7-18.2
h
PO, oral; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
3.7
h
3.7±0.6
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
3.7
h
3.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2
g/kg
PO, oral; mouse;
DRUGBANK
150.0
mg/kg
>150
mg/kg
intravenous injection, IV; dog;
DRUGBANK
91.0
%
91±5
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.5
%
1-2
%
DRUGBANK
1.5
%
1-2
%
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Cytovene
ganciclovir sodium
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Cytovene
ganciclovir sodium
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Cytovene
ganciclovir sodium
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
5.0
drop/day
5
drop/day
ophthalmic administration
Cytovene
ganciclovir sodium
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
12.0
mg/kg/day
12
mg/kg/day
intravenous injection, IV
Cytovene
ganciclovir sodium
PDR
DDPD01005
Hydroxyurea
76.0547
CH4N2O2
NC(=O)NO
DB01005
T3D4767
3657
44423
http://www.drugs.com/cdi/hydroxyurea.html
3530
-2.0
-
-2.0
-
DRUGBANK
108.0
%
108±18
%
PO, oral; solid tumors;
DRUGBANK
93.5
%
79-108
%
PO, oral; solid tumors;
DRUGBANK
76587082.9
ng/ml
1007±371
mM
intravenous injection, IV; solid tumors;
DRUGBANK
60387431.8
ng/ml
794±241
mM
PO, oral; solid tumors;
DRUGBANK
0.5
h
0.5
h
intravenous injection, IV; solid tumors;
DRUGBANK
1.2
h
1.2±1.2
h
PO, oral; solid tumors;
DRUGBANK
3.255
L/h/m2
36.2-72.3
ml/min/m2
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
19.7
L/m2
19.7±4.6
L/m2
DRUGBANK
0.52
L/kg
0.52
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
DRUGBANK
3.4
h
3.4±0.7(2.8-4.5)
h
Male, men; Female, women; solid tumors; patients;
DRUGBANK
3.4
h
3.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7330.0
mg/kg
7330.0
mg/kg
PO, oral; mouse;
DRUGBANK
5760.0
mg/kg
5760.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
7330.0
mg/kg
7330.0
mg/kg
PO, oral; mouse;
DRUGBANK
5760.0
mg/kg
5760.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
35.8
%
35.8±14.2
%
Urinary excretion; solid tumors; human, homo sapiens; Unchanged drug;
DRUGBANK
0.0
%
~0
%
solid tumors; human, homo sapiens;
DRUGBANK
35.0
mg/kg/day
35
mg/kg/day
PO, oral
Hydrea
hydroxyurea
PDR
3000.0
mg/m2
3000
mg/m2
PO, oral
Hydrea
hydroxyurea
PDR
3000.0
mg/m2
3000
mg/m2
PO, oral
Hydrea
hydroxyurea
PDR
80.0
mg/day
80
mg/day
PO, oral
Hydrea
hydroxyurea
PDR
35.0
mg/kg/day
35
mg/kg/day
PO, oral
Hydrea
hydroxyurea
PDR
3000.0
mg/m2
3000
mg/m2
PO, oral
Hydrea
hydroxyurea
PDR
80.0
mg/kg
80
mg/kg
PO, oral
Hydrea
hydroxyurea
PDR
DDPD01006
Letrozole
285.3027
C17H11N5
N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
DB01006
T3D4803
3902
6413
http://www.drugs.com/cdi/letrozole.html
3765
-2.0
-
-2.0
-
DRUGBANK
2.1075310449
ng.h/ml
7387.0
nmol.h/L
PO, oral;
DRUGBANK
99.0
%
99
%
DRUGBANK
99.9
%
99.9±16.3
%
PO, oral; postmenopausal women; normal,healthy;
DRUGBANK
29.6714808
ng/ml
104
nmol/L
PO, oral;
DRUGBANK
32.8098105
ng/ml
115.0
nM
postmenopausal women; normal,healthy;
DRUGBANK
8.1
h
8.1
h
PO, oral;
DRUGBANK
1.0
h
1.0
h
postmenopausal women; normal,healthy;
DRUGBANK
1.52
L/h
1.52
L/h
Total clearance; Single dose;
DRUGBANK
1.2
L/h
1.2
L/h
Total clearance; at steady state;
DRUGBANK
0.0348
L/h/kg
0.58±0.21
ml/min/kg
severe hepatic impairment ↓ ;
DRUGBANK
0.0342
L/h/kg
0.57
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.87
L/kg
1.87
L/kg
DRUGBANK
1.87
L/kg
1.87±0.46
L/kg
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
42.0
h
~42
h
elimination half-life; normal,healthy;
breast cancer ↑ ;
DRUGBANK
45.0
h
45±16
h
normal,healthy; postmenopausal women;
DRUGBANK
45.0
h
45
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
6.0
%
6
%
Urinary excretion; Unchanged drug;
DRUGBANK
3.9
%
3.9±1.4
%
Urinary excretion; postmenopausal women; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
60.0
%
60
%
DRUGBANK
55.0
%
55
%
DRUGBANK
60.0
%
60
%
postmenopausal women; normal,healthy; human, homo sapiens;
DRUGBANK
2.5
mg/day
2.5
mg/day
PO, oral
Femara
letrozole
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Femara
letrozole
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Femara
letrozole
PDR
7.5
mg/day
7.5
mg/day
PO, oral
Femara
letrozole
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Femara
letrozole
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Femara
letrozole
PDR
DDPD01007
Tioconazole
387.711
C16H13Cl3N2OS
ClC1=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=CS1
DB01007
T3D2956
5482
77898
http://www.drugs.com/cdi/tioconazole.html
5282
-2.0
-
-2.0
-
DRUGBANK
DDPD01008
Busulfan
246.302
C6H14O6S2
CS(=O)(=O)OCCCCOS(C)(=O)=O
DB01008
T3D4750
2478
28901
http://www.drugs.com/cdi/busulfan.html
2384
-2.0
-
-2.0
-
DRUGBANK
130.0
ng.h/ml
130.0
ng.h/ml
Oral single dose; patients;
DRUGBANK
80.0
%
80±20
%
adults;
DRUGBANK
68.0
%
68±31
%
Children;
DRUGBANK
70.0
%
70(44-94)
%
PO, oral;
DRUGBANK
30.0
ng/ml
30
ng/ml
Oral single dose; patients;
DRUGBANK
65.0
ng/ml
65±27
ng/ml
Oral single dose; Chronic myelogenous leukemia;
DRUGBANK
949.0
ng/ml
949±278
ng/ml
Oral single dose; bone marrow transplant;
DRUGBANK
0.9
h
0.9
h
Oral single dose; patients;
DRUGBANK
2.6
h
2.6±1.5
h
PO, oral;
DRUGBANK
0.312
L/h/kg
5.2
ml/min/kg
intravenous infusion, IV in drop;
DRUGBANK
0.27
L/h/kg
4.5±0.9
ml/min/kg
apparent clearance;
DRUGBANK
0.99
L/kg
0.99±0.23
L/kg
Steady state volume of distribution;
DRUGBANK
2.6
h
2.6
h
DRUGBANK
2.6
h
2.6±0.5
h
DRUGBANK
30.0
%
~30
%
Urinary excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
32.0
%
32
%
plasma proteins;
DRUGBANK
47.0
%
47
%
serum albumin;
DRUGBANK
8.35
%
2.7-14
%
DRUGBANK
0.06
mg/kg/day
60
mcg/kg/day
PO, oral
Myleran
busulfan
PDR
1.8
mg/m2/day
1.8
mg/m2/day
PO, oral
Myleran
busulfan
PDR
8.0
mg/day
8
mg/day
PO, oral
Myleran
busulfan
PDR
1.0
mg/kg
1
mg/kg
PO, oral
qid
Myleran
busulfan
PDR
0.8
mg/kg
0.8
mg/kg
intravenous injection, IV
qid
Myleran
busulfan
PDR
1.0
mg/kg
1
mg/kg
intravenous injection, IV
qid
Myleran
busulfan
PDR
0.06
mg/kg/day
60
mcg/kg/day
PO, oral
Myleran
busulfan
PDR
1.8
mg/m2/day
1.8
mg/m2/day
PO, oral
Myleran
busulfan
PDR
8.0
mg/day
8
mg/day
PO, oral
Myleran
busulfan
PDR
1.0
mg/kg
1
mg/kg
PO, oral
qid
Myleran
busulfan
PDR
0.8
mg/kg
0.8
mg/kg
intravenous injection, IV
qid
Myleran
busulfan
PDR
1.0
mg/kg
1
mg/kg
intravenous injection, IV
qid
Myleran
busulfan
PDR
0.06
mg/kg/day
60
mcg/kg/day
PO, oral
Myleran
busulfan
PDR
1.8
mg/m2/day
1.8
mg/m2/day
PO, oral
Myleran
busulfan
PDR
0.06
mg/kg/day
60
mcg/kg/day
PO, oral
Myleran
busulfan
PDR
1.8
mg/m2/day
1.8
mg/m2/day
PO, oral
Myleran
busulfan
PDR
DDPD01009
Ketoprofen
254.2806
C16H14O3
CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
DB01009
3825
6128
http://www.drugs.com/cdi/ketoprofen.html
3693
-2.0
-
-2.0
-
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
6.9
L/h
6.9±0.8
L/h
Capsule, PO, Oral;
DRUGBANK
6.8
L/h
6.8±1.8
L/h
Capsule, PO, Oral;
DRUGBANK
0.08
L/h/kg
0.08
L/kg/h
DRUGBANK
0.7
L/h/kg
0.7
L/kg/h
alcoholic liver disease; Hepatitis, Hep;
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.55
h
1.1-4
h
Capsule, PO, Oral;
DRUGBANK
5.4
h
5.4
h
extended release formulation; Capsule, PO, Oral;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.4
mg/kg
62.4
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
80.0
%
~80
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
200.0
mg/day
200
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
75.0
mg/day
75
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
75.0
mg/day
75
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
300.0
mg/day
300
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
200.0
mg/day
200
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
75.0
mg/day
75
mg/day
PO, oral
Ketoprofen
ketoprofen
PDR
DDPD01010
Edrophonium
166.2401
C10H16NO
CC[N+](C)(C)C1=CC(O)=CC=C1
DB01010
3202
251408
http://www.drugs.com/mtm/edrophonium.html
3090
-2.0
-
-2.0
-
DRUGBANK
0.408
L/h/kg
6.8±2
ml/kg/min
adults;
DRUGBANK
0.384
L/h/kg
6.4±3.9
ml/kg/min
Children;
DRUGBANK
0.174
L/h/kg
2.9±1.9
ml/kg/min
Elderly;
DRUGBANK
0.576
L/h/kg
9.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6±0.4
L/kg
adults;
DRUGBANK
2.2
L/kg
2.2±1.5
L/kg
Children;
DRUGBANK
1.8
L/kg
1.8±1.2
L/kg
Elderly;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.158333333333333
h
7-12
min
distribution half-life;
DRUGBANK
1.19166666666667
h
33-110
min
elimination half-life;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
67.0
%
67
%
Urinary excretion;
DRUGBANK
10.0
mg
10
mg
intravenous injection, IV
Enlon
edrophonium chloride
PDR
5.0
mg
5
mg
intravenous injection, IV
Enlon
edrophonium chloride
PDR
10.0
mg/dose
10
mg/dose
intravenous injection, IV
Enlon
edrophonium chloride
PDR
10.0
mg
10
mg
intravenous injection, IV
Enlon
edrophonium chloride
PDR
10.0
mg/dose
10
mg/dose
intravenous injection, IV
Enlon
edrophonium chloride
PDR
0.5
mg
0.5
mg
intravenous injection, IV
Enlon
edrophonium chloride
PDR
DDPD01011
Metyrapone
226.2738
C14H14N2O
CC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1
DB01011
4174
44241
http://www.drugs.com/cdi/metyrapone.html
4030
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
1.9
h
1.9±0.7
h
DRUGBANK
521.0
mg/kg
521.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.3
%
5.3
%
Urinary excretion;
DRUGBANK
15.0
mg/kg
15
mg/kg
PO, oral
Metopirone
metyrapone
PDR
3000.0
mg
3
g
PO, oral
Metopirone
metyrapone
PDR
15.0
mg/kg/dose/day
15
mg/kg/dose/day
PO, oral
Metopirone
metyrapone
PDR
4500.0
mg/day
4.5
g/day
PO, oral
Metopirone
metyrapone
PDR
3000.0
mg/day
3
g/day
PO, oral
Metopirone
metyrapone
PDR
4500.0
mg/day
4.5
g/day
PO, oral
Metopirone
metyrapone
PDR
3000.0
mg/day
3
g/day
PO, oral
Metopirone
metyrapone
PDR
4500.0
mg/day
4.5
g/day
PO, oral
Metopirone
metyrapone
PDR
3000.0
mg/day
3
g/day
PO, oral
Metopirone
metyrapone
PDR
4500.0
mg/day
4.5
g/day
PO, oral
Metopirone
metyrapone
PDR
DDPD01012
Cinacalcet
357.412
C22H22F3N
C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12
DB01012
156419
48390
http://www.drugs.com/cdi/cinacalcet.html
137743
-2.0
-
-2.0
-
DRUGBANK
20.0
%
~20
%
PO, oral;
DRUGBANK
10.6
ng/ml
10.6±2.8
ng/ml
Oral single dose;
DRUGBANK
4.0
h
2-6
h
DRUGBANK
1.08
L/h/kg
~18
ml/min/kg
hydrolysis; hydrolysis; hydrolysis;
hepatopathy，LD ↓ ;
DRUGBANK
1000.0
L
1000.0
L
DRUGBANK
17.6
L/kg
~17.6
L/kg
hydrolysis; hydrolysis; hydrolysis;
DRUGBANK
35.0
h
30-40
h
terminal half-life;
DRUGBANK
46.65
h
40-53.3
h
moderate hepatic impairment;
DRUGBANK
59.5
h
51-68
h
severe hepatic impairment;
DRUGBANK
34.0
h
34±9
h
chronic liver disease ↑ ;
DRUGBANK
95.0
%
93-97
%
plasma proteins;
DRUGBANK
95.0
%
93-97
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Sensipar
cinacalcet
PDR
360.0
mg/day
360
mg/day
PO, oral
Sensipar
cinacalcet
PDR
300.0
mg/day
300
mg/day
PO, oral
Sensipar
cinacalcet
PDR
360.0
mg/day
360
mg/day
PO, oral
Sensipar
cinacalcet
PDR
DDPD01013
Clobetasol propionate
466.97
C25H32ClFO5
[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB01013
32798
31414
http://www.drugs.com/cdi/clobetasol-cream.html
30399
-2.0
-
-2.0
-
DRUGBANK
0.059
ng/ml
59±36
pg/ml
skin/dermal;
DRUGBANK
0.0563
ng/ml
56.3±104.7
pg/ml
ointment;
DRUGBANK
5.0
h
5
h
skin/dermal;
DRUGBANK
7142.85714285
mg/day
50
g/week
Olux
clobetasol propionate
PDR
7.14285714285714
ml/day
50
ml/week
skin/dermal
Olux
clobetasol propionate
PDR
8.42857142857143
ml/day
59
ml/week
skin/dermal
Olux
clobetasol propionate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
Olux
clobetasol propionate
PDR
7142.85714285714
mg/day
50
g/week
Olux
clobetasol propionate
PDR
50.0
ml/week
50
ml/week
skin/dermal
Olux
clobetasol propionate
PDR
59.0
ml/week
59
ml/week
skin/dermal
Olux
clobetasol propionate
PDR
7142.85714285714
mg/day
50
g/week
skin/dermal
Olux
clobetasol propionate
PDR
DDPD01014
Balsalazide
357.3175
C17H15N3O6
OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
DB01014
T3D2957
6335412
267413
http://www.drugs.com/cdi/balsalazide.html
10662422
-2.0
-
-2.0
-
DRUGBANK
99.0
%
99
%
DRUGBANK
6750.0
mg/day
6.75
g/day
PO, oral
Colazal
balsalazide disodium
PDR
6750.0
mg/day
6.75
g/day
PO, oral
Colazal
balsalazide disodium
PDR
6750.0
mg/day
6.75
g/day
PO, oral
Colazal
balsalazide disodium
PDR
6750.0
mg/day
6.75
g/day
PO, oral
Colazal
balsalazide disodium
PDR
DDPD01015
Sulfamethoxazole
253.278
C10H11N3O3S
CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
DB01015
5329
9332
5138
-2.0
-
-2.0
-
DRUGBANK
88.0
%
86-90
%
PO, oral;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
62700.0
ng/ml
57.4-68
ug/ml
PO, oral;
DRUGBANK
37100.0
ng/ml
37.1
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
4.0
h
4.0
h
Oral single dose; adults; normal,healthy;
DRUGBANK
0.0186
L/h/kg
0.31±0.07
ml/min/kg
normal,healthy; adults;
RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis ↑ ;
DRUGBANK
0.0216
L/h/kg
0.36
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.0
L
13.0
L
PO, oral;
DRUGBANK
0.26
L/kg
0.26±0.04
L/kg
normal,healthy; adults;
Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;
DRUGBANK
0.3
L/kg
0.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
10
h
elimination half-life;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
10.1
h
10.1±2.6
h
Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↓ ;normal BMI → ;
DRUGBANK
9.8
h
9.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2300.0
mg/kg
2300.0
mg/kg
PO, oral; mouse;
DRUGBANK
6200.0
mg/kg
6200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
84.5
%
~84.5
%
Urinary excretion; Oral single dose;
DRUGBANK
14.0
%
14±2
%
Urinary excretion; Unchanged drug;
DRUGBANK
70.0
%
~70
%
plasma proteins;
DRUGBANK
53.0
%
53±5
%
Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;hypoalbuminemia Alb ↓ ;Cystic fibrosis → ;
DRUGBANK
DDPD01016
Glyburide
494.004
C23H28ClN3O5S
COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
DB01016
3488
5441
3368
-2.0
-
-2.0
-
DRUGBANK
348.0
ng.h/ml
348.0
ng.h/ml
PO, oral; patients;
DRUGBANK
95.0
%
90-100
%
Tablet, PO, oral; Drug form;
DRUGBANK
77.0
%
64-90
%
Tablet, PO, oral; Drug form;
DRUGBANK
263.0
ng/ml
211-315
ng/ml
PO, oral; Geriatric;
DRUGBANK
223.0
ng/ml
144-302
ng/ml
PO, oral; adults; patients;
DRUGBANK
106.0
ng/ml
106.0
ng/ml
Tablet, PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
104.0
ng/ml
104.0
ng/ml
Tablet, PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
0.95
h
0.9-1
h
PO, oral; Geriatric;
DRUGBANK
2.15
h
1.3-3
h
PO, oral; adults; patients;
DRUGBANK
1.5
h
~1.5
h
Tablet, PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
3.0
h
2-4
h
Tablet, PO, oral; Drug form; adults; normal,healthy;
DRUGBANK
3.125
L/h
2.70-3.55
L/h
Geriatric;
DRUGBANK
3.29
L/h
2.47-4.11
L/h
young; patients;
DRUGBANK
0.078
L/h/kg
1.3±0.5
ml/min/kg
Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
0.0492
L/h/kg
0.82
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.95
L
19.3-52.6
L
Geriatric;
DRUGBANK
35.4
L
21.5-49.3
L
young; patients;
DRUGBANK
0.2
L/kg
0.20±0.11
L/kg
DRUGBANK
0.08
L/kg
0.08
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.7
h
4.0-13.4
h
elimination half-life; Geriatric;
DRUGBANK
8.95
h
4.0-13.9
h
elimination half-life; young; patients;
DRUGBANK
4.0
h
4±1
h
Hepatic cirrhosis, cirr ↑ ;non-insulin-dependent diabetes mellitus NIDDM
↑ ;
DRUGBANK
8.0
h
6-10
h
nonmicronized formulation;
DRUGBANK
15.0
h
15
h
terminal half-life;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3200.0
mg/kg
>3200
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
PO, oral; mouse;
DRUGBANK
10000.0
mg/kg
>10000
mg/kg
PO, oral; rabbit;
DRUGBANK
1500.0
mg/kg
>1500
mg/kg
PO, oral; guinea pigs;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
50.0
%
50
%
Faeces excretion;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.9
%
99.9
%
plasma proteins;
DRUGBANK
98.0
%
>98
%
DRUGBANK
99.8
%
99.8
%
Elderly ↓ ;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
DiaBeta
glyburide
PDR
20.0
mg/day
20
mg/day
PO, oral
DiaBeta
glyburide
PDR
12.0
mg/day
12
mg/day
PO, oral
DiaBeta
glyburide
PDR
10.0
mg/day
10
mg/day
PO, oral
DiaBeta
glyburide
PDR
20.0
mg/day
20
mg/day
PO, oral
DiaBeta
glyburide
PDR
12.0
mg/day
12
mg/day
PO, oral
DiaBeta
glyburide
PDR
DDPD01017
Minocycline
457.4764
C23H27N3O7
[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
DB01017
54675783
50694
http://www.drugs.com/minocycline.html
16735907
-2.0
-
-2.0
-
DRUGBANK
31600.0
ng.h/ml
31.6
mg.h/l
PO, oral;
DRUGBANK
48300.0
ng.h/ml
48.3
mg.h/l
PO, oral;
DRUGBANK
1600.0
ng/ml
1.6±0.9
mg/L
PO, oral;
DRUGBANK
3100.0
ng/ml
3.1
mg/L
PO, oral;
DRUGBANK
1.9
h
1.9
h
PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral;
DRUGBANK
4.53
L/h
3.36-5.7
L/h
intravenous injection, IV;
DRUGBANK
3.91
L/h
3.42-4.4
L/h
PO, oral;
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
91.25
L
67.5-115
L
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.6
h
11.1-22.1
h
Capsule, PO, Oral;
DRUGBANK
19.0
h
15-23
h
intravenous injection, IV;
DRUGBANK
17.0
h
17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2380.0
mg/kg
2380.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3600.0
mg/kg
3600.0
mg/kg
PO, oral; mouse;
DRUGBANK
331.0
mg/kg
331.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
299.0
mg/kg
299.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
1700.0
mg/kg
1700.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
2290.0
mg/kg
2290.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
6.75
%
4.5-9
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
14.75
%
10-19.5
%
Urinary excretion; PO, oral;
DRUGBANK
27.0
%
20-34
%
Faeces excretion; PO, oral;
DRUGBANK
76.0
%
76
%
DRUGBANK
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
135.0
mg/day
135
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
application/day
1
application/day
skin,foam
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
application/day
1
application/day
skin,foam
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
400.0
mg/day
400
mg/day
intravenous injection, IV
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
135.0
mg/day
135
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
122.0
unit-dose cartridges
122
unit-dose cartridges
Arestin
minocycline hydrochloride
PDR
1.0
appLication/day
1
appLication/day
skin,foam
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
intravenous injection, IV; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
intravenous injection, IV
Arestin
minocycline hydrochloride
PDR
4.0
mg/kg/day
4
mg/kg/day
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
135.0
mg/day
135
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
application/day
1
application/day
skin,foam
Arestin
minocycline hydrochloride
PDR
400.0
mg/day
400
mg/day
intravenous injection, IV
Arestin
minocycline hydrochloride
PDR
300.0
mg
300
mg
PO, oral; day1
Arestin
minocycline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
1.0
mg/kg/day
1
mg/kg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
135.0
mg/day
135
mg/day
PO, oral
Arestin
minocycline hydrochloride
PDR
122.0
unit-dose cartridges
122
unit-dose cartridges
Arestin
minocycline hydrochloride
PDR
1.0
application/day
1
application/day
skin,foam
Arestin
minocycline hydrochloride
PDR
DDPD01018
Guanfacine
246.093
C9H9Cl2N3O
NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl
DB01018
3519
5558
http://www.drugs.com/cdi/guanfacine.html
3399
-2.0
-
-2.0
-
DRUGBANK
56.0
ng.h/ml
56±15
ng.h/ml
PO, oral; immediate release formulation;
DRUGBANK
32.0
ng.h/ml
32±9
ng.h/ml
PO, oral; extended release formulation;
DRUGBANK
80.0
%
80
%
PO, oral;
DRUGBANK
2.5
ng/ml
2.5±0.6
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
1.0
ng/ml
1.0±0.3
ng/ml
PO, oral; extended release formulation;
DRUGBANK
3.58
ng/ml
3.58±1.39
ng/ml
PO, oral; adults; extended release formulation;
DRUGBANK
2.6
ng/ml
2.6±1.03
ng/ml
PO, oral; Children; extended release formulation;
DRUGBANK
1.7
ng/ml
1.7±0.43
ng/ml
PO, oral; Adolescents; extended release formulation;
DRUGBANK
3.0
h
3
h
PO, oral; immediate release formulation;
DRUGBANK
6.0
h
6
h
PO, oral; extended release formulation;
DRUGBANK
5.5
h
5.5
h
PO, oral; adults; extended release formulation;
DRUGBANK
4.98
h
4.98
h
PO, oral; Children; extended release formulation;
DRUGBANK
4.96
h
4.96
h
PO, oral; Adolescents; extended release formulation;
DRUGBANK
21.6
L/h
360±262
ml/min
Total clearance; normal renal function; patients;
DRUGBANK
13.98
L/h
233±245
ml/min
Renal clearance; normal renal function; patients;
DRUGBANK
18.48
L/h
308±274
ml/min
Total clearance; Chronic Kidney Disease;
DRUGBANK
2.04
L/h
34±22
ml/min
Renal clearance; Chronic Kidney Disease;
DRUGBANK
15.42
L/h
257±187
ml/min
Total clearance; renal insufficiency;
DRUGBANK
1.08
L/h
18±15
ml/min
Renal clearance; renal insufficiency;
DRUGBANK
0.27
L/h/kg
4.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.3
L/kg
6.3
L/kg
DRUGBANK
5.6
L/kg
5.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
h
17(10-30)
h
renal insufficiency → ;
DRUGBANK
15.0
h
15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
142.0
mg/kg
142.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.3
mg/kg
15.3
mg/kg
PO, oral; mouse;
DRUGBANK
114.0
mg/kg
114.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
46.0
mg/kg
46.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
57.0
%
57±32
%
Urinary excretion; normal renal function; patients;
DRUGBANK
70.0
%
~70
%
DRUGBANK
4.0
mg/day
4
mg/day
Tablet,PO，oral
Tenex
guanfacine hydrochloride
PDR
4.0
mg/day
4
mg/day
PO, oral
Tenex
guanfacine hydrochloride
PDR
3.5
mg/day
3.5
mg/day
PO, oral
Tenex
guanfacine hydrochloride
PDR
7.0
mg/day
7
mg/day
Tablet,PO，oral
Tenex
guanfacine hydrochloride
PDR
3.5
mg/day
3.5
mg/day
PO, oral
Tenex
guanfacine hydrochloride
PDR
3.5
mg/day
3.5
mg/day
PO, oral
Tenex
guanfacine hydrochloride
PDR
DDPD01019
Bethanechol
161.2221
C7H17N2O2
CC(C[N+](C)(C)C)OC(N)=O
DB01019
T3D2958
2370
3084
http://www.drugs.com/cdi/bethanechol.html
2280
-2.0
-
-2.0
-
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Urecholine
bethanechol chloride
PDR
40.0
mg/day
40
mg/day
subcutaneous injection, SC
Urecholine
bethanechol chloride
PDR
50.0
mg/dose
50
mg/dose
PO, oral
Urecholine
bethanechol chloride
PDR
10.0
mg/dose
10
mg/dose
subcutaneous injection, SC
Urecholine
bethanechol chloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Urecholine
bethanechol chloride
PDR
40.0
mg/day
40
mg/day
subcutaneous injection, SC
Urecholine
bethanechol chloride
PDR
50.0
mg/dose
50
mg/dose
PO, oral
Urecholine
bethanechol chloride
PDR
10.0
mg/dose
10
mg/dose
subcutaneous injection, SC
Urecholine
bethanechol chloride
PDR
DDPD01020
Isosorbide mononitrate
191.1388
C6H9NO6
[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
DB01020
27661
6062
http://www.drugs.com/isosorbide_mononitrate.html
25736
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
93.0
%
93±13
%
PO, oral;
DRUGBANK
230.0355458
ng/ml
314-2093
nM
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
1.25
h
1-1.5
h
PO, oral;
DRUGBANK
7.05
L/h
115-120
ml/min
Total clearance;
DRUGBANK
0.108
L/h/kg
1.80±0.24
ml/min/kg
Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;coronary artery disease → ;
DRUGBANK
0.6
L/kg
~0.6
L/kg
DRUGBANK
0.73
L/kg
0.73±0.09
L/kg
Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;coronary artery disease → ;myocardial infarction → ;
DRUGBANK
5.0
h
~5
h
elimination half-life;
DRUGBANK
6.0
h
6
h
elimination half-life;
DRUGBANK
8.0
h
8
h
elimination half-life;
DRUGBANK
4.9
h
4.9±0.8
h
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;myocardial infarction → ;coronary artery disease → ;Age → ;
DRUGBANK
2010.0
mg/kg
2010.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1771.0
mg/kg
1771.0
mg/kg
PO, oral; mouse;
DRUGBANK
48.0
%
~48
%
Urinary excretion;
DRUGBANK
2.0
%
2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
5.0
%
~5
%
DRUGBANK
0.0
%
0
%
DRUGBANK
DDPD01021
Trichlormethiazide
380.656
C8H8Cl3N3O4S2
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl
DB01021
5560
9683
5359
-2.0
-
-2.0
-
DRUGBANK
5600.0
mg/kg
5600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD01022
Phylloquinone
450.6957
C31H46O2
CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O
DB01022
T3D2959
5284607
18067
http://www.drugs.com/cdi/phytonadione.html
4447652
-2.0
-
-2.0
-
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.32
L/kg
0.32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.3
h
7.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
41.5
ml/kg
41.5
mL/kg
intravenous injection, IV; mouse;
DRUGBANK
52.0
ml/kg
52.0
mL/kg
intravenous injection, IV; mouse;
DRUGBANK
41.5
ml/kg
41.5
mL/kg
intravenous injection, IV; mouse;
DRUGBANK
52.0
ml/kg
52.0
mL/kg
intravenous injection, IV; mouse;
DRUGBANK
10.0
mg/day/dose
10
mg/day/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Mephyton
phytonadione
PDR
10.0
mg/dose/day
10
mg/day/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Mephyton
phytonadione
PDR
10.0
mg/day/dose
10
mg/day/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Mephyton
phytonadione
PDR
10.0
mg/day/dose
10
mg/day/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Mephyton
phytonadione
PDR
10.0
mg/day/dose
10
mg/day/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;subcutaneous injection, SC;
Mephyton
phytonadione
PDR
DDPD01023
Felodipine
384.254
C18H19Cl2NO4
CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
DB01023
3333
585948
http://www.drugs.com/cdi/felodipine.html
3216
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; food;
food → ;
DRUGBANK
15.0
%
15
%
PO, oral; food;
food → ;
DRUGBANK
15.0
%
15±8
%
DRUGBANK
13.064636
ng/ml
34±26
nM
PO, oral; immediate release formulation; normal,healthy;
DRUGBANK
3.4967114
ng/ml
9.1±7.3
nM
PO, oral; extended release formulation; normal,healthy;
DRUGBANK
0.9
h
0.9±0.4
h
PO, oral; immediate release formulation; normal,healthy;
DRUGBANK
3.7
h
3.7±0.9
h
PO, oral; extended release formulation; normal,healthy;
DRUGBANK
48.0
L/h
0.8
L/min
normal,healthy; young;
DRUGBANK
0.72
L/h/kg
12±5
ml/min/kg
hydrolysis;
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;congestive heart disease ↓ ;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
L/kg
10.0
L/kg
DRUGBANK
10.0
L/kg
10±3
L/kg
Elderly → ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
4.4
L/kg
4.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.5
h
17.5-31.5
h
hypertension; patients;
DRUGBANK
27.5
h
19.1-35.9
h
Elderly; hypertension; patients;
DRUGBANK
14.1
h
8.5-19.7
h
normal,healthy;
DRUGBANK
14.0
h
14±4
h
congestive heart disease ↑ ;Hepatic cirrhosis, cirr → ;Age ↑ ;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1050.0
mg/kg
1050.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
99.6
%
99.6±0.2
%
Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Felodipine
felodipine
PDR
20.0
mg/day
20
mg/day
PO, oral
Felodipine
felodipine
PDR
10.0
mg/day
10
mg/day
PO, oral
Felodipine
felodipine
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Felodipine
felodipine
PDR
20.0
mg/day
20
mg/day
PO, oral
Felodipine
felodipine
PDR
10.0
mg/day
10
mg/day
PO, oral
Felodipine
felodipine
PDR
DDPD01024
Mycophenolic acid
320.3371
C17H20O6
COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
DB01024
T3D2960
446541
168396
http://www.drugs.com/cdi/mycophenolic-acid-delayed-release-tablets.html
393865
-2.0
-
-2.0
-
DRUGBANK
82.5
%
70-95
%
Oral single dose; extended release formulation;
DRUGBANK
0.0
%
~0
%
PO, oral; organ transplants;
DRUGBANK
94.0
%
94.0
%
PO, oral; Active metabolite; organ transplants;
DRUGBANK
13500.0
ng/ml
8-19
mcg/ml
PO, oral; Active metabolite; organ transplants;
DRUGBANK
1.65
h
1.1-2.2
h
PO, oral; Active metabolite; organ transplants;
DRUGBANK
8.4
L/h
140±30
ml/min
renal transplant; patients;
DRUGBANK
8.49
L/h/kg
120-163
ml/min/kg
DRUGBANK
0.15
L/h/kg
2.5±0.4
ml/min/kg
apparent clearance;
hepatopathy，LD → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.1398
L/h/kg
2.33
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
54.0
L
54±25
L
DRUGBANK
3.8
L/kg
3.6-4
L/kg
Apparent volume of distribution;
DRUGBANK
0.77
L/kg
0.77
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
8-16
h
elimination half-life;
DRUGBANK
15.0
h
13-17
h
elimination half-life;
DRUGBANK
0.033
h
<0.033
h
intravenous injection, IV; PO, oral;
DRUGBANK
16.6
h
16.6±5.8
h
DRUGBANK
9.7
h
9.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
352.0
mg/kg
352.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; mouse;
DRUGBANK
6000.0
mg/kg
>6000
mg/kg
PO, oral; rabbit;
DRUGBANK
352.0
mg/kg
352.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; mouse;
DRUGBANK
6000.0
mg/kg
>6000
mg/kg
PO, oral; rabbit;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Active metabolite; adults; normal,healthy; organ transplants; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
>98
%
DRUGBANK
97.5
%
97.5
%
Active metabolite; adults; normal,healthy; organ transplants; human, homo sapiens;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
1200.0
mg/m2/day
1200
mg/m2/day
Liquid
Myfortic
mycophenolic acid
PDR
2.0
mg/day
2
mg/day
Liquid
Myfortic
mycophenolic acid
PDR
1500.0
mg/day
1500
mg/day
Capsule, PO, Oral
Myfortic
mycophenolic acid
PDR
2000.0
mg/day
2
g/day
Tablet,PO，oral;Capsule, PO, Oral;
Myfortic
mycophenolic acid
PDR
800.0
mg/m2/day
800
mg/m2/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
1400.0
mg/day
1400
mg/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
3000.0
mg/day
3
g/day
Tablet,PO，oral;Capsule, PO, Oral;intravenous infusion, iv in drop;
Myfortic
mycophenolic acid
PDR
1440.0
mg/day
1440
mg/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
1200.0
mg/m2/day
1200
mg/m2/day
Liquid
Myfortic
mycophenolic acid
PDR
2.0
mg/day
2
mg/day
Liquid
Myfortic
mycophenolic acid
PDR
1500.0
mg/day
1500
mg/day
Capsule, PO, Oral
Myfortic
mycophenolic acid
PDR
2000.0
mg/day
2
g/day
Tablet,PO，oral;Capsule, PO, Oral;
Myfortic
mycophenolic acid
PDR
800.0
mg/m2/day
800
mg/m2/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
1400.0
mg/day
1400
mg/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
3000.0
mg/day
3
g/day
Tablet,PO，oral;Capsule, PO, Oral;intravenous infusion, iv in drop;
Myfortic
mycophenolic acid
PDR
1440.0
mg/day
1440
mg/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
1200.0
mg/m2/day
1200
mg/m2/day
Liquid
Myfortic
mycophenolic acid
PDR
2.0
mg/day
2
mg/day
Liquid
Myfortic
mycophenolic acid
PDR
1500.0
mg/day
1500
mg/day
Capsule, PO, Oral
Myfortic
mycophenolic acid
PDR
2.0
g/day
2
g/day
Tablet,PO，oral;Capsule, PO, Oral;
Myfortic
mycophenolic acid
PDR
800.0
mg/m2/day
800
mg/m2/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
1400.0
mg/day
1400
mg/day
Tablet,PO，oral
Myfortic
mycophenolic acid
PDR
DDPD01025
Amlexanox
298.2934
C16H14N2O4
CC(C)C1=CC2=C(OC3=NC(N)=C(C=C3C2=O)C(O)=O)C=C1
DB01025
2161
31205
http://www.drugs.com/cdi/amlexanox.html
2076
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3.5±1.1
h
elimination half-life;
DRUGBANK
DDPD01026
Ketoconazole
531.431
C26H28Cl2N4O4
CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
DB01026
T3D2961
3823
48339
http://www.drugs.com/cdi/ketoconazole.html
3691
-2.0
-
-2.0
-
DRUGBANK
76.0
%
76
%
DRUGBANK
3050.0
ng/ml
2.5-3.6
mcg/ml
Oral single dose;
DRUGBANK
1700579.2
ng/ml
3.2(1.4-4.5)
mM
PO, oral; superficial mycotic infection;
DRUGBANK
2.5
h
1-4
h
Oral single dose;
DRUGBANK
2.0
h
1-3
h
PO, oral; superficial mycotic infection;
DRUGBANK
8.66
L/h
8.66
L/h
DRUGBANK
0.504
L/h/kg
8.4±4.1
ml/min/kg
apparent clearance;
DRUGBANK
0.36
L/kg
0.36
L/kg
DRUGBANK
8.4
L/kg
8.4±4.1
L/kg
Apparent volume of distribution;
DRUGBANK
2.0
h
2
h
elimination half-life;
DRUGBANK
8.0
h
8
h
terminal half-life;
DRUGBANK
3.3
h
3.3±1.0
h
increasing doses ↑ ;
DRUGBANK
8.0
h
~8
h
Single dose;
DRUGBANK
86.0
mg/kg
86.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
44.0
mg/kg
44.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
702.0
mg/kg
702.0
mg/kg
PO, oral; mouse;
DRUGBANK
95.0
%
>95
%
lung excretion;
DRUGBANK
3.0
%
2-4
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
84.0
%
~84
%
plasma proteins;
DRUGBANK
99.0
%
99±0.1
%
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
4.95
mg/kg/day
4.95
mg/kg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
400.0
mg/day
400
mg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
400.0
mg/day
400
mg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
4.95
mg/kg/day
4.95
mg/kg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
400.0
mg/day
400
mg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Nizoral 2%
ketoconazole
PDR
DDPD01028
Methoxyflurane
164.966
C3H4Cl2F2O
COC(F)(F)C(Cl)Cl
DB01028
T3D2962
4116
6843
3973
-2.0
-
-2.0
-
DRUGBANK
3600.0
mg/kg
3600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3600.0
mg/kg
3600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01029
Irbesartan
428.5294
C25H28N6O
CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
DB01029
3749
5959
http://www.drugs.com/cdi/irbesartan.html
3618
-2.0
-
-2.0
-
DRUGBANK
9700.0
ng.h/ml
9.7±3.0
ug.h/ml
Oral single dose;
DRUGBANK
20000.0
ng.h/ml
20.0±5.2
ug.h/ml
Oral single dose;
DRUGBANK
32600.0
ng.h/ml
32.6±11.9
ug.h/ml
Oral single dose;
DRUGBANK
44800.0
ng.h/ml
44.8±20.0
ug.h/ml
Oral single dose;
DRUGBANK
9300.0
ng.h/ml
9.3±3.0
ug.h/ml
Oral multiple dose;
DRUGBANK
19800.0
ng.h/ml
19.8±5.8
ug.h/ml
Oral multiple dose;
DRUGBANK
31900.0
ng.h/ml
31.9±9.7
ug.h/ml
Oral multiple dose;
DRUGBANK
34200.0
ng.h/ml
34.2±9.3
ug.h/ml
Oral multiple dose;
DRUGBANK
70.0
%
60-80
%
PO, oral; food;
food → ;
DRUGBANK
70.0
%
60-80
%
PO, oral;
DRUGBANK
1900.0
ng/ml
1.9±0.4
ug/ml
Oral single dose;
DRUGBANK
2900.0
ng/ml
2.9±0.9
ug/ml
Oral single dose;
DRUGBANK
4900.0
ng/ml
4.9±1.2
ug/ml
Oral single dose;
DRUGBANK
5300.0
ng/ml
5.3±1.9
ug/ml
Oral single dose;
DRUGBANK
2040.0
ng/ml
2.04±0.4
ug/ml
Oral multiple dose;
DRUGBANK
3300.0
ng/ml
3.3±0.8
ug/ml
Oral multiple dose;
DRUGBANK
4400.0
ng/ml
4.4±0.7
ug/ml
Oral multiple dose;
DRUGBANK
5600.0
ng/ml
5.6±2.1
ug/ml
Oral multiple dose;
DRUGBANK
1300.0
ng/ml
1.3±0.4
mcg/ml
Male, men; normal,healthy;
DRUGBANK
1.75
h
1.5-2
h
PO, oral; food;
food → ;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
1.5
h
1.5
h
Oral multiple dose;
DRUGBANK
2.0
h
2.0
h
Oral multiple dose;
DRUGBANK
1.5
h
1.5
h
Oral multiple dose;
DRUGBANK
1.8
h
1.8
h
Oral multiple dose;
DRUGBANK
1.2
h
1.2(0.7-2)
h
Male, men; normal,healthy;
DRUGBANK
9.99
L/h
157-176
ml/min
Plasma clearance;
DRUGBANK
0.195
L/h
3.0-3.5
ml/min
Renal clearance;
DRUGBANK
0.1272
L/h/kg
2.12±0.54
ml/min/kg
Elderly ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.138
L/h/kg
2.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
73.0
L
53-93
L
DRUGBANK
0.72
L/kg
0.72±0.20
L/kg
DRUGBANK
0.94
L/kg
0.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.0
h
11-15
h
elimination half-life;
DRUGBANK
13.0
h
13±6.2
h
normal,healthy; Male, men;
DRUGBANK
14.0
h
14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.714285714285714
mg/kg/day
30.0
mg/kg/6W
PO, oral; human, homo sapiens;
DRUGBANK
20.0
%
20
%
Urinary excretion; PO, oral;
DRUGBANK
80.0
%
80
%
Faeces excretion; PO, oral;
DRUGBANK
2.0
%
<2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
2.2
%
2.2±0.9
%
Urinary excretion; Male, men; normal,healthy; Unchanged drug;
DRUGBANK
90.0
%
90
%
plasma proteins;
DRUGBANK
90.0
%
90
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
0.58
mg/kg/day
0.58
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.94
mg/kg/day
0.94
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.01
mg/kg/dose
10
mcg/kg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
1.25
mg/dose
1.25
mg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Vasotec
enalapril maleate
PDR
20.0
mg/day
20
mg/day
intravenous injection, IV
Vasotec
enalapril maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.01
mg/kg/dose
10
mcg/kg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
1.25
mg/dose
1.25
mg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
0.58
mg/kg/day
0.58
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.94
mg/kg/day
0.94
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.01
mg/kg/dose
10
mcg/kg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
1.25
mg/dose
1.25
mg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
40.0
mg/day
40
mg/day
PO, oral
Vasotec
enalapril maleate
PDR
20.0
mg/day
20
mg/day
intravenous injection, IV
Vasotec
enalapril maleate
PDR
0.58
mg/kg/day
0.58
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.94
mg/kg/day
0.94
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
0.01
mg/kg/dose
10
mcg/kg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
0.27
mg/kg/day
0.27
mg/kg/day
PO, oral
Vasotec
enalapril maleate
PDR
10.0
mcg/kg/dose
10
mcg/kg/dose
intravenous injection, IV
Vasotec
enalapril maleate
PDR
DDPD01030
Topotecan
421.4458
C23H23N3O5
CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
DB01030
60700
63632
http://www.drugs.com/cdi/topotecan.html
54705
-2.0
-
-2.0
-
DRUGBANK
32.0
%
32±12
%
PO, oral; adults; solid tumors;
DRUGBANK
5.9
ng/ml
5.9±0.8
ng/ml
Oral single dose; Derivative; adults; solid tumors;
DRUGBANK
7.5
ng/ml
7.5±2.6
ng/ml
Oral single dose; Derivative; adults; solid tumors;
DRUGBANK
38.0
ng/ml
38±8
ng/ml
Derivative; adults; solid tumors;
DRUGBANK
19.0
ng/ml
19±2
ng/ml
Derivative; adults; solid tumors;
DRUGBANK
0.92
h
0.92±0.61
h
Oral single dose; Derivative; adults; solid tumors;
DRUGBANK
1.75
h
1.5-2
h
Oral single dose; Derivative; adults; solid tumors;
DRUGBANK
28.6
L/h/m2
28.6±4.1
L/h/m2
tumor; patients; adults; Male, men; Female, women;
Children → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
74.0
L/m2
74±21
L/m2
tumor; patients; adults; Male, men; Female, women;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2-3
h
DRUGBANK
2.4
h
2.4±0.4
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
5.65
h
2.9-8.4
h
intravenous injection, IV;
DRUGBANK
2.3
h
2.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
73.4
%
73.4±2.3
%
Urinary excretion; Faeces excretion; intravenous injection, IV; tumor;
DRUGBANK
40.0
%
40
%
Urinary excretion; adults; solid tumors; human, homo sapiens; Unchanged drug;
DRUGBANK
35.0
%
35
%
DRUGBANK
21.3
%
21.3
%
adults; solid tumors; human, homo sapiens;
DRUGBANK
6.6
%
6.6
%
adults; solid tumors; human, homo sapiens;
DRUGBANK
4.0
mg
4
mg
intravenous injection, IV
Hycamtin Capsules
topotecan
PDR
2.3
mg/m2/day
2.3
mg/m2/day
PO, oral
Hycamtin Capsules
topotecan
PDR
4.0
mg
4
mg
intravenous injection, IV
Hycamtin Capsules
topotecan
PDR
2.3
mg/m2/day
2.3
mg/m2/day
PO, oral
Hycamtin Capsules
topotecan
PDR
DDPD01031
Ethinamate
167.205
C9H13NO2
NC(=O)OC1(CCCCC1)C#C
DB01031
T3D2963
3284
4884
3169
-2.0
-
-2.0
-
DRUGBANK
2.5
h
2.5
h
DRUGBANK
DDPD01032
Probenecid
285.359
C13H19NO4S
CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
DB01032
4911
8426
http://www.drugs.com/cdi/probenecid.html
4742
-2.0
-
-2.0
-
DRUGBANK
0.015
L/h/kg
0.25
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
6-12
h
DRUGBANK
5.9
h
5.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
%
75-95
%
DRUGBANK
2.0
mg/day
2
g/day
PO, oral
Probenecid
probenecid
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Probenecid
probenecid
PDR
1.2
g/m2
1.2
g/m2
PO, oral
Probenecid
probenecid
PDR
2000.0
mg/day
2
g/day
PO, oral
Probenecid
probenecid
PDR
0.0
0
Probenecid
probenecid
PDR
2000.0
mg/day
2
g/day
PO, oral
Probenecid
probenecid
PDR
2000.0
mg/day
2
g/day
PO, oral
Probenecid
probenecid
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Probenecid
probenecid
PDR
1200.0
mg/m2/dose
1.2
g/m2/dose
PO, oral
Probenecid
probenecid
PDR
2000.0
mg/day
2
g/day
PO, oral
Probenecid
probenecid
PDR
2000.0
mg/day
2
g/day
PO, oral
Probenecid
probenecid
PDR
0.0
0
Probenecid
probenecid
PDR
0.0
0
Probenecid
probenecid
PDR
DDPD01033
Mercaptopurine
152.177
C5H4N4S
S=C1N=CNC2=C1NC=N2
DB01033
667490
94796
http://www.drugs.com/cdi/mercaptopurine.html
580869
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral;
DRUGBANK
12.0
%
12±7
%
PO, oral;
DRUGBANK
60.0
%
60
%
combination drug use;
DRUGBANK
112610.98
ng/ml
0.74±0.28
mM
combination drug use; Children; tumor;
DRUGBANK
563054.9
ng/ml
3.7±0.6
mM
combination drug use; Children; tumor;
DRUGBANK
1050021.3
ng/ml
6.9
mM
Children; tumor;
DRUGBANK
2.4
h
2.4±0.4
h
combination drug use; Children; tumor;
DRUGBANK
2.8
h
2.8±0.4
h
combination drug use; Children; tumor;
DRUGBANK
0.66
L/h/kg
11±4
ml/min/kg
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.56
L/kg
0.56±0.38
L/kg
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
h
45
min
distribution half-life;
DRUGBANK
2.5
h
2.5
h
elimination half-life;
DRUGBANK
9.0
h
6-12
h
terminal half-life;
DRUGBANK
0.9
h
0.9±0.37
h
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
480.0
mg/kg
480.0
mg/kg
PO, oral; mouse;
DRUGBANK
425.0
mg/kg
425.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
22.0
%
22±12
%
Urinary excretion; Unchanged drug;
DRUGBANK
19.0
%
19
%
plasma proteins;
DRUGBANK
19.0
%
19
%
DRUGBANK
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Purixan
mercaptopurine
PDR
75.0
mg/m2/day
75
mg/m2/day
PO, oral
Purixan
mercaptopurine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Purixan
mercaptopurine
PDR
75.0
mg/m2/day
75
mg/m2/day
PO, oral
Purixan
mercaptopurine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Purixan
mercaptopurine
PDR
75.0
mg/m2/day
75
mg/m2/day
PO, oral
Purixan
mercaptopurine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Purixan
mercaptopurine
PDR
75.0
mg/m2/day
75
mg/m2/day
PO, oral
Purixan
mercaptopurine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Purixan
mercaptopurine
PDR
75.0
mg/m2/day
75
mg/m2/day
PO, oral
Purixan
mercaptopurine
PDR
DDPD01035
Procainamide
235.3253
C13H21N3O
CCN(CC)CCNC(=O)C1=CC=C(N)C=C1
DB01035
4913
8428
http://www.drugs.com/cdi/procainamide.html
4744
-2.0
-
-2.0
-
DRUGBANK
85.0
%
75-95
%
DRUGBANK
83.0
%
83±16
%
PO, oral;
DRUGBANK
2200.0
ng/ml
2.2
mcg/ml
PO, oral; Male, men; adults;
DRUGBANK
2900.0
ng/ml
2.9
mcg/ml
PO, oral; Female, women; adults;
DRUGBANK
3.6
h
3.6
h
PO, oral; Male, men; adults;
DRUGBANK
3.8
h
3.8
h
PO, oral; Female, women; adults;
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
L/kg
2.0
L/kg
DRUGBANK
1.9
L/kg
1.9±0.3
L/kg
Children → ;Obesity ↓ ;RD, renal impairment, Renal disease，including uremia → ;ventricular tachycardia → ;congestive heart disease → ;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
~2.5-4.5
h
DRUGBANK
3.0
h
3.0±0.6
h
Children ↓ ;Neonates ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;myocardial infarction ↑ ;Obesity → ;ventricular tachycardia → ;congestive heart disease → ;
DRUGBANK
3.1
h
3.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95.0
mg/kg
95.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
312.0
mg/kg
312.0
mg/kg
PO, oral; mouse;
DRUGBANK
103.0
mg/kg
103.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
45.0
%
30-60
%
Urinary excretion; Unchanged drug;
DRUGBANK
67.0
%
67±8
%
Urinary excretion; Unchanged drug;
congestive heart disease ↓ ;COPD, Chronic obstructive pulmonary disease ↓ ;CP,cor pulmonale ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
17.5
%
15-20
%
DRUGBANK
16.0
%
16±5
%
DRUGBANK
DDPD01036
Tolterodine
325.4876
C22H31NO
CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
DB01036
443879
9622
http://www.drugs.com/cdi/tolterodine.html
391967
-2.0
-
-2.0
-
DRUGBANK
26.0
%
26±18
%
PO, oral; Male, men; adults; normal,healthy; extensive metabolizers, EM;
DRUGBANK
91.0
%
91±40
%
PO, oral; Male, men; adults; normal,healthy; poor metabolizers, PM;
DRUGBANK
5.2
ng/ml
5.2±5.7
ng/ml
PO, oral; Male, men; adults; normal,healthy; extensive metabolizers, EM;
DRUGBANK
38.0
ng/ml
38±15
ng/ml
PO, oral; Male, men; adults; normal,healthy; poor metabolizers, PM;
DRUGBANK
1.2
h
1.2±0.5
h
PO, oral; Male, men; adults; normal,healthy; extensive metabolizers, EM;
DRUGBANK
1.9
h
1.9±1.0
h
PO, oral; Male, men; adults; normal,healthy; poor metabolizers, PM;
DRUGBANK
0.576
L/h/kg
9.6±2.8
ml/min/kg
extensive metabolizers, EM; normal,healthy; adults; Male, men;
DRUGBANK
0.12
L/h/kg
2.0±0.3
ml/min/kg
poor metabolizers, PM; normal,healthy; adults; Male, men;
hepatopathy，LD ↓ ;
DRUGBANK
0.504
L/h/kg
8.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
113.0
L
113 ± 26.7
L
DRUGBANK
1.7
L/kg
1.7±0.4
L/kg
extensive metabolizers, EM; normal,healthy; adults; Male, men;
DRUGBANK
1.5
L/kg
1.5±0.4
L/kg
poor metabolizers, PM; normal,healthy; adults; Male, men;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
h
1.9-3.7
h
DRUGBANK
2.3
h
2.3±0.3
h
extensive metabolizers, EM; normal,healthy; adults; Male, men;
chronic liver disease ↑ ;
DRUGBANK
9.2
h
9.2±1.2
h
poor metabolizers, PM; normal,healthy; adults; Male, men;
chronic liver disease ↑ ;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
77.0
%
77
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
17.0
%
17
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
0.0
%
~0
%
Urinary excretion; adults; Male, men; normal,healthy; extensive metabolizers, EM; human, homo sapiens; Unchanged drug;
DRUGBANK
2.5
%
<2.5
%
Urinary excretion; adults; Male, men; normal,healthy; poor metabolizers, PM; human, homo sapiens; Unchanged drug;
DRUGBANK
96.3
%
~96.3
%
DRUGBANK
96.3
%
96.3
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
64.0
%
64
%
Active metabolite; adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
4.0
mg/day
4
mg/day
PO, oral
Detrol
tolterodine tartrate
PDR
4.0
mg/day
4
mg/day
PO, oral
Detrol
tolterodine tartrate
PDR
DDPD01037
Selegiline
187.286
C13H17N
C[C@H](CC1=CC=CC=C1)N(C)CC#C
DB01037
T3D2965
26757
9086
http://www.drugs.com/cdi/selegiline.html
24930
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
1.1
ng/ml
1.1±0.4
ng/ml
PO, oral; adults;
DRUGBANK
15.0
ng/ml
~15
ng/ml
PO, oral; Active metabolite; adults;
DRUGBANK
0.7
h
0.7±0.4
h
PO, oral; adults;
DRUGBANK
1.0
h
~1
h
PO, oral; Active metabolite; adults;
DRUGBANK
90.0
L/h/kg
~1500
ml/min/kg
apparent clearance; metabolism of ugt;
DRUGBANK
9.6
L/h/kg
160.0
ml/min/kg
apparent clearance; normal,healthy;
DRUGBANK
1.2
L/h/kg
20
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
L/kg
1.9
L/kg
normal,healthy; adults;
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
h
1.2-2
h
DRUGBANK
1.9
h
1.9±1.0
h
DRUGBANK
21.0
h
21
h
DRUGBANK
18.0
h
18
h
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
63.0
mg/kg
63.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
63.0
mg/kg
63.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.5
%
>99.5
%
DRUGBANK
94.0
%
94
%
DRUGBANK
0.0
0
Transdermal preparations
Emsam
selegiline
PDR
10.0
mg/day
10
mg/day
PO, oral
Emsam
selegiline
PDR
2.5
mg/day
2.5
mg/day
Tablet,PO，oral
Emsam
selegiline
PDR
12.0
mg/day
12
mg/day
Transdermal preparations
Emsam
selegiline
PDR
10.0
mg/day
10
mg/day
PO, oral
Emsam
selegiline
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Emsam
selegiline
PDR
12.0
mg/day
12
mg/day
Transdermal preparations
Emsam
selegiline
PDR
DDPD01039
Fenofibrate
360.831
C20H21ClO4
CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
DB01039
T3D4775
3339
5001
http://www.drugs.com/fenofibrate.html
3222
-2.0
-
-2.0
-
DRUGBANK
7750.0
ng/ml
6-9.5
mg/L
PO, oral; normal,healthy; fasting;
DRUGBANK
8600.0
ng/ml
8.6±0.9
mcg/ml
Tablet, PO, oral; immediate release formulation;
DRUGBANK
10800.0
ng/ml
10.8±0.6
mcg/ml
Capsule, PO, Oral; Drug form;
DRUGBANK
5.0
h
4-6
h
PO, oral; normal,healthy; fasting;
DRUGBANK
7.0
h
6-8
h
Tablet, PO, oral; immediate release formulation;
DRUGBANK
5.0
h
4-6
h
Capsule, PO, Oral; Drug form;
DRUGBANK
1.1
L/h
1.1
L/h
PO, oral; young; adults;
DRUGBANK
1.2
L/h
1.2
L/h
PO, oral; Elderly;
DRUGBANK
0.027
L/h/kg
0.45
ml/min/kg
apparent clearance;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.89
L/kg
0.89
L/kg
DRUGBANK
0.89
L/kg
0.89
L/kg
Apparent volume of distribution;
DRUGBANK
23.0
h
23
h
DRUGBANK
23.0
h
19-27
h
normal,healthy;
DRUGBANK
143.0
h
143
h
patients;
DRUGBANK
23.5
h
20-27
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
2000.0
mg/kg
>2
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; mouse;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; mouse;
DRUGBANK
9.0
mg/kg
9.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
%
5-25
%
Faeces excretion;
DRUGBANK
74.0
%
60-88
%
Urinary excretion;
DRUGBANK
5.05
%
0.1-10
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
99.0
%
>99
%
Active metabolite;
DRUGBANK
145.0
mg/day
145
mg/day
Tablet,PO，oral
Triglide
fenofibrate
PDR
160.0
mg/day
160
mg/day
Tablet,PO，oral
Triglide
fenofibrate
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Triglide
fenofibrate
PDR
90.0
mg/day
90
mg/day
Capsule, PO, Oral
Triglide
fenofibrate
PDR
150.0
mg/day
150
mg/day
Capsule, PO, Oral
Triglide
fenofibrate
PDR
145.0
mg/day
145
mg/day
Tablet,PO，oral
Triglide
fenofibrate
PDR
160.0
mg/day
160
mg/day
Tablet,PO，oral
Triglide
fenofibrate
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Triglide
fenofibrate
PDR
90.0
mg/day
90
mg/day
Capsule, PO, Oral
Triglide
fenofibrate
PDR
150.0
mg/day
150
mg/day
Capsule, PO, Oral
Triglide
fenofibrate
PDR
DDPD01041
Thalidomide
258.2295
C13H10N2O4
O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
DB01041
T3D3539
5426
74947
http://www.drugs.com/cdi/thalidomide.html
5233
-2.0
-
-2.0
-
DRUGBANK
2000.0
ng/ml
2.0±0.6
mcg/ml
Oral single dose; Male, men; normal,healthy;
DRUGBANK
4.3
h
2.9-5.7
h
PO, oral; normal,healthy; leprosy;
DRUGBANK
3.2
h
3.2±1.4
h
Oral single dose; Male, men; normal,healthy;
DRUGBANK
0.132
L/h/kg
2.2±0.4
ml/min/kg
PO, oral; normal,healthy; Male, men;
DRUGBANK
0.204
L/h/kg
3.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1±0.3
L/kg
PO, oral; normal,healthy; Male, men;
DRUGBANK
0.95
L/kg
0.95
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
~5-7
h
elimination half-life; Single dose;
DRUGBANK
6.2
h
6.2±2.6
h
PO, oral;
DRUGBANK
4.7
h
4.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
550.0
mg/kg
0.4-0.7
g/kg
Optical rotation R;
DRUGBANK
1000.0
mg/kg
0.5-1.5
g/kg
Optical rotation S;
DRUGBANK
550.0
mg/kg
0.4-0.7
g/kg
Optical rotation R;
DRUGBANK
1000.0
mg/kg
0.5-1.5
g/kg
Optical rotation S;
DRUGBANK
0.7
%
<0.7
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
55.0
%
55
%
Optical rotation R;
DRUGBANK
66.0
%
66
%
Optical rotation S;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Thalomid
thalidomide
PDR
400.0
mg/day
400
mg/day
PO, oral
Thalomid
thalidomide
PDR
200.0
mg/day
200
mg/day
PO, oral
Thalomid
thalidomide
PDR
400.0
mg/day
400
mg/day
PO, oral
Thalomid
thalidomide
PDR
400.0
mg/day
400
mg/day
PO, oral
Thalomid
thalidomide
PDR
200.0
mg/day
200
mg/day
PO, oral
Thalomid
thalidomide
PDR
DDPD01042
Melphalan
305.2
C13H18Cl2N2O2
N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
DB01042
T3D4702
460612
28876
http://www.drugs.com/cdi/melphalan.html
405297
-2.0
-
-2.0
-
DRUGBANK
57.0
%
25-89
%
DRUGBANK
71.0
%
71±23
%
PO, oral;
DRUGBANK
310.0
ng/ml
0.31±0.15
mcg/ml
PO, oral; tumor;
DRUGBANK
1300.0
ng/ml
1.3±0.95
mcg/ml
intravenous injection, IV; tumor;
DRUGBANK
0.75
h
0.75±0.24
h
PO, oral; tumor;
DRUGBANK
0.312
L/h/kg
5.2±2.9
ml/min/kg
Children → ;
DRUGBANK
0.42
L/h/kg
7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
L/kg
0.5
L/kg
DRUGBANK
0.45
L/kg
0.45±0.15
L/kg
Children → ;
DRUGBANK
0.48
L/kg
0.48
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5±0.83
h
DRUGBANK
1.4
h
1.4±0.2
h
Children → ;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.2
mg/kg
11.2
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
11.2
mg/kg
11.2
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
%
10±4.5
%
Urinary excretion; patients;
DRUGBANK
12.0
%
12±7
%
Urinary excretion; Unchanged drug;
DRUGBANK
75.0
%
60-90
%
DRUGBANK
90.0
%
90±5
%
DRUGBANK
100.0
mg/m2
100
mg/m2
intravenous injection, IV
Alkeran for Injection
melphalan hydrochloride
PDR
200.0
mg/m2
200
mg/m2
intravenous injection, IV
Alkeran for Injection
melphalan hydrochloride
PDR
16.0
mg/m2
16
mg/m2
intravenous injection, IV; nan
q2w-q4w
Alkeran for Injection
melphalan hydrochloride
PDR
100.0
mg/m2
100
mg/m2
intravenous injection, IV
Alkeran for Injection
melphalan hydrochloride
PDR
200.0
mg/m2
200
mg/m2
intravenous injection, IV
Alkeran for Injection
melphalan hydrochloride
PDR
16.0
mg/m2
16
mg/m2
intravenous injection, IV
q2w-q4w
Alkeran for Injection
melphalan hydrochloride
PDR
DDPD01043
Memantine
179.3018
C12H21N
CC12CC3CC(C)(C1)CC(N)(C3)C2
DB01043
T3D2967
4054
64312
http://www.drugs.com/cdi/memantine.html
3914
-2.0
-
-2.0
-
DRUGBANK
5.0
h
3-7
h
PO, oral; food;
food → ;
DRUGBANK
10.0
L/kg
9.0-11
L/kg
Average volume of distribution;
DRUGBANK
80.0
h
60-100
h
DRUGBANK
467.5
mg/kg
437-498
mg/kg
PO, oral; mouse;
DRUGBANK
349.0
mg/kg
328-370
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
48.0
%
~48
%
Urinary excretion; Unchanged drug;
DRUGBANK
45.0
%
45
%
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Namenda
memantine hydrochloride
PDR
28.0
mg/day
28
mg/day
PO, oral
Namenda
memantine hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Namenda
memantine hydrochloride
PDR
28.0
mg/day
28
mg/day
PO, oral
Namenda
memantine hydrochloride
PDR
DDPD01044
Gatifloxacin
375.3941
C19H22FN3O4
COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
DB01044
T3D2968
5379
5280
http://www.drugs.com/cdi/gatifloxacin-drops.html
5186
-2.0
-
-2.0
-
DRUGBANK
96.0
%
96
%
PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.5
h
7-14
h
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
20
%
DRUGBANK
8.0
drop/day
8
drop/day
ophthalmic administration
Zymaxid
gatifloxacin
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Zymaxid
gatifloxacin
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Zymaxid
gatifloxacin
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Zymaxid
gatifloxacin
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Zymaxid
gatifloxacin
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Zymaxid
gatifloxacin
PDR
DDPD01045
Rifampicin
822.9402
C43H58N4O12
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
DB01045
T3D2969
5381226
71365
http://www.drugs.com/cdi/rifampin.html
10468813
-2.0
-
-2.0
-
DRUGBANK
6500.0
ng/ml
6.5±3.5
mcg/ml
PO, oral; tuberculosis;
DRUGBANK
2.0
h
1-3
h
PO, oral; tuberculosis;
DRUGBANK
0.19
L/h/kg
0.19±0.06
l/h/kg
intravenous injection, IV;
DRUGBANK
0.14
L/h/kg
0.14±0.03
l/h/kg
intravenous injection, IV;
DRUGBANK
0.21
L/h/kg
3.5±1.6
ml/min/kg
Neonates ↑ ;Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.97
L/kg
0.97±0.36
L/kg
Neonates ↑ ;Elderly → ;
DRUGBANK
3.35
h
3.35±0.66
h
DRUGBANK
3.5
h
3.5±0.8
h
Children → ;Hepatitis, Hep ↑ ;Hepatic cirrhosis, cirr ↑ ;acute viral hepatitis AVH ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Age → ;
DRUGBANK
1570.0
mg/kg
1570.0
mg/kg
Rattus, Rat;
DRUGBANK
1570.0
mg/kg
1570.0
mg/kg
Rattus, Rat;
DRUGBANK
30.0
%
<30
%
Urinary excretion;
DRUGBANK
7.0
%
7±3
%
Urinary excretion; Unchanged drug;
Neonates ↑ ;
DRUGBANK
89.0
%
89
%
DRUGBANK
75.0
%
60-90
%
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;PO, oral;
Rifadin
rifampin
PDR
DDPD01046
Lubiprostone
390.468
C20H32F2O5
[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC
DB01046
157920
http://www.drugs.com/cdi/lubiprostone.html
138948
-2.0
-
-2.0
-
DRUGBANK
1.15
h
0.9-1.4
h
DRUGBANK
94.0
%
94
%
DRUGBANK
DDPD01047
Fluocinonide
494.5249
C26H32F2O7
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O
DB01047
9642
5109
http://www.drugs.com/cdi/fluocinonide-cream.html
9265
-2.0
-
-2.0
-
DRUGBANK
6020.0
ng.h/ml
6.02±1.73
mcg.h/ml
Tablet, PO, oral;
DRUGBANK
83.0
%
83
%
Tablet, PO, oral;
DRUGBANK
3000.0
ng/ml
3.0±0.89
mcg/ml
Tablet, PO, oral;
DRUGBANK
4.0
application/day
4
application/day
skin/dermal
Vanos
fluocinonide
PDR
2.0
application/day
2
application/day
skin/dermal
Vanos
fluocinonide
PDR
8571.42857142
mg/day
60
g/week
up to 2 weeks
Vanos
fluocinonide
PDR
4.0
application/day
4
application/day
skin/dermal
Vanos
fluocinonide
PDR
2.0
application/day
2
application/day
skin/dermal
Vanos
fluocinonide
PDR
8571.42857142857
mg/day
60
g/week
up to 2 weeks
Vanos
fluocinonide
PDR
4.0
application/day
4
application/day
skin/dermal
Vanos
fluocinonide
PDR
2.0
application/day
2
application/day
skin/dermal
Vanos
fluocinonide
PDR
8571.42857142857
mg/day
60
g/week
up to 2 weeks
Vanos
fluocinonide
PDR
DDPD01048
Abacavir
286.3323
C14H18N6O
NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1
DB01048
441300
421707
http://www.drugs.com/cdi/abacavir.html
390063
-2.0
-
-2.0
-
DRUGBANK
0.8
L/h/kg
0.80±0.24
l/h/kg
intravenous injection, IV; Single dose; AIDS,HIV; adults;
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.86
L/kg
0.86±0.15
L/kg
intravenous injection, IV;
DRUGBANK
0.84
L/kg
0.84
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.54
h
1.54±0.63
h
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
Urinary excretion;
DRUGBANK
16.0
%
16
%
Faeces excretion;
DRUGBANK
50.0
%
~50
%
DRUGBANK
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Ziagen
abacavir
PDR
600.0
mg/day
600
mg/day
PO, oral
Ziagen
abacavir
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
qd
Ziagen
abacavir
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Ziagen
abacavir
PDR
600.0
mg/day
600
mg/day
PO, oral
Ziagen
abacavir
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Ziagen
abacavir
PDR
600.0
mg/day
600
mg/day
PO, oral
Ziagen
abacavir
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
qd
Ziagen
abacavir
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Ziagen
abacavir
PDR
600.0
mg/day
600
mg/day
PO, oral
Ziagen
abacavir
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral
Ziagen
abacavir
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
qd
Ziagen
abacavir
PDR
DDPD01050
Ibuprofen
206.2808
C13H18O2
CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
DB01050
T3D2970
3672
5855
http://www.drugs.com/ibuprofen.html
3544
-2.0
-
-2.0
-
DRUGBANK
70000.0
ng.h/ml
70.0
mcg.h/ml
PO, oral;
DRUGBANK
80.0
%
>80
%
PO, oral;
DRUGBANK
20000.0
ng
20
mcg
PO, oral;
DRUGBANK
61100.0
ng/ml
61.1±5.5
mcg/ml
Oral single dose; Raceme D/L;
DRUGBANK
1.5
h
1-2
h
intranasal;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
1.6
h
1.6±0.3
h
Oral single dose; Raceme D/L;
DRUGBANK
8.0
L/h
3.0-13
L/h
DRUGBANK
0.045
L/h/kg
0.75±0.20
ml/min/kg
apparent clearance;
Children → ;rheumatoid arthritis → ;Cystic fibrosis ↑ ;
DRUGBANK
0.0492
L/h/kg
0.82
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
L/kg
0.1
L/kg
Apparent volume of distribution;
DRUGBANK
0.15
L/kg
0.15±0.02
L/kg
Apparent volume of distribution;
Cystic fibrosis ↑ ;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
h
1.2-2
h
elimination half-life;
DRUGBANK
3.25
h
3.1-3.4
h
hepatopathy，LD;
DRUGBANK
2.0
h
2±0.5
h
Children → ;rheumatoid arthritis → ;Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
636.0
mg/kg
636.0
mg/kg
Rattus, Rat;
DRUGBANK
740.0
mg/kg
740.0
mg/kg
mouse;
DRUGBANK
495.0
mg/kg
495.0
mg/kg
guinea pigs;
DRUGBANK
1255.0
mg/kg
1255.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
>90
%
Urinary excretion; RD, renal impairment, Renal disease，including uremia; Elderly;
DRUGBANK
1.0
%
<1
%
Bile excretion; RD, renal impairment, Renal disease，including uremia; Elderly; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
99.0
%
>99
%
rheumatoid arthritis → ;hypoalbuminemia Alb → ;
DRUGBANK
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Caldolor
ibuprofen
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
2400.0
mg/day
2400
mg/day
intravenous injection, IV
Caldolor
ibuprofen
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Caldolor
ibuprofen
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Caldolor
ibuprofen
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV
Caldolor
ibuprofen
PDR
2400.0
mg/day
2400
mg/day
intravenous injection, IV
Caldolor
ibuprofen
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Caldolor
ibuprofen
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
3200.0
mg/day
3200
mg/day
PO, oral;intravenous injection, IV;
Caldolor
ibuprofen
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
3200.0
mg/day
3200
mg/day
PO, oral;intravenous injection, IV;
Caldolor
ibuprofen
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Caldolor
ibuprofen
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
2400.0
mg/day
2400
mg/day
intravenous injection, IV
Caldolor
ibuprofen
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
3200.0
mg/day
3200
mg/day
PO, oral;intravenous injection, IV;
Caldolor
ibuprofen
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Caldolor
ibuprofen
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral;intravenous injection, IV;
Caldolor
ibuprofen
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
NeoProfen
ibuprofen lysine
PDR
180.0
mg/day
180
mg/day
PO, oral
Zohydro ER
hydrocodone bitartrate
PDR
180.0
mg/day
180
mg/day
PO, oral
Zohydro ER
hydrocodone bitartrate
PDR
DDPD01051
Novobiocin
612.6243
C31H36N2O11
CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C(O)=C(NC(=O)C2=CC=C(O)C(CC=C(C)C)=C2)C(=O)O3)OC1(C)C
DB01051
54675769
28368
10226117
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
6.0
h
6
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD01053
Benzylpenicillin
334.39
C16H18N2O4S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O
DB01053
5904
18208
5693
-2.0
-
-2.0
-
DRUGBANK
22.5
%
15-30
%
PO, oral; normal,healthy; fasting;
DRUGBANK
30.0
%
30.0
%
PO, oral;
DRUGBANK
740.0
ng/ml
0.28-1.2
mcg/ml
Liquid;
DRUGBANK
12000.0
ng/ml
12.0
mcg/ml
IM,intramuscular injection; Derivative;
DRUGBANK
940.0
ng/ml
0.94
mcg/ml
IM,intramuscular injection; Derivative;
DRUGBANK
160.0
ng/ml
0.16
mcg/ml
IM,intramuscular injection; Derivative;
DRUGBANK
0.75
h
0.5-1
h
Liquid;
DRUGBANK
0.5
h
0.5
h
IM,intramuscular injection; Derivative;
DRUGBANK
2.0
h
1-3
h
IM,intramuscular injection; Derivative;
DRUGBANK
18.0
h
12-24
h
IM,intramuscular injection; Derivative;
DRUGBANK
16.0
%
16
%
Inactive metabolite;
DRUGBANK
33.6
L/h
560.0
ml/min
normal,healthy; human, homo sapiens;
DRUGBANK
0.42
L/h/kg
5-9
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.6
L/kg
0.53–0.67
L/kg
normal renal function; adults;
DRUGBANK
0.33
L/kg
0.33
L/kg
DRUGBANK
0.65
h
0.4-0.9
h
adults; normal renal function;
DRUGBANK
0.5
h
0.5±0.1
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
3.0
h
~3
h
terminal half-life;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
8900.0
mg/kg
8900.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
79.0
%
79
%
Urinary excretion; adults; Adolescents; human, homo sapiens; Unchanged drug;
DRUGBANK
56.5
%
45-68
%
DRUGBANK
60.0
%
60(48-68)
%
adults; Adolescents; human, homo sapiens;
DRUGBANK
300000.0
units/kg/day
300000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
24000000.0
units/kg/day
24000000
units/kg/day
Penicillin G Potassium
penicillin G potassium
PDR
400000.0
units/kg/day
400000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
80000000.0
units/day
80000000
units/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
300000.0
units/kg/day
300000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
24000000.0
units/kg/day
24000000
units/kg/day
Penicillin G Potassium
penicillin G potassium
PDR
400000.0
units/kg/day
400000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
80000000.0
units/day
80000000
units/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
300000.0
units/kg/day
300000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
400000.0
units/kg/day
400000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
100000.0
units/kg/day
100000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
450000.0
units/kg/day
450000
units/kg/day
IM,intramuscular injection;intravenous injection, IV;
Penicillin G Potassium
penicillin G potassium
PDR
150000.0
units/kg/day
150000
units/kg/day
intravenous injection, IV;IM,intramuscular injection;
Penicillin G Potassium
penicillin G potassium
PDR
500000.0
units/kg/day
500000
units/kg/day
IM,intramuscular injection;intravenous injection, IV;
Penicillin G Potassium
penicillin G potassium
PDR
50000.0
units/kg/day
50000
units/kg/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
2400000.0
units/day
2400000
units/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
2400000.0
units/day
2400000
units/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
50000.0
units/kg/day
50000
units/kg/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
2400000.0
units/day
2400000
units/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
2400000.0
units/day
2400000
units/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
50000.0
units/kg/day
50000
units/kg/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
6000000.0
units/kg/day
6000000
units/kg/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
50000.0
units/kg/day
50000
units/kg/day
IM,intramuscular injection
Bicillin L-A
penicillin G benzathine
PDR
DDPD01054
Nitrendipine
360.3612
C18H20N2O6
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
DB01054
4507
7582
4351
-2.0
-
-2.0
-
DRUGBANK
1.5
L/h/kg
25
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.1
L/kg
6.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.2
h
8.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD01056
Tocainide
192.2575
C11H16N2O
CC(N)C(=O)NC1=C(C)C=CC=C1C
DB01056
38945
9611
http://www.drugs.com/mtm/tocainide.html
35632
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; food;
food → ;
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
h
~15
h
elimination half-life; patients;
DRUGBANK
35.0
h
35
h
severe renal function;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
800.0
mg/kg
~800
mg/kg
PO, oral; mouse;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
230.0
mg/kg
230.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
DDPD01057
Echothiophate
256.323
C9H23NO3PS
CCOP(=O)(OCC)SCC[N+](C)(C)C
DB01057
10548
4753
http://www.drugs.com/cdi/echothiophate-eye-drops.html
10108
-2.0
-
-2.0
-
DRUGBANK
0.174
mg/kg
174.0
mcg/kg
Rattus, Rat;
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
Phospholine Iodide
echothiophate iodide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Phospholine Iodide
echothiophate iodide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Phospholine Iodide
echothiophate iodide
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Phospholine Iodide
echothiophate iodide
PDR
DDPD01058
Praziquantel
312.4061
C19H24N2O2
O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
DB01058
4891
91583
http://www.drugs.com/cdi/praziquantel.html
4722
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
DRUGBANK
3550.0
ng/ml
0.8-6.3
mcg/ml
Oral single dose;
DRUGBANK
1.65
h
1.5-1.8
h
Oral single dose;
DRUGBANK
28.02
L/h/kg
467.0
ml/min/kg
apparent clearance;
DRUGBANK
8.37
L/h/kg
57-222
ml/min/kg
apparent clearance;
hepatopathy，LD ↓ ;
DRUGBANK
9.55
L/kg
9.55±2.86
L/kg
DRUGBANK
1.15
h
0.8-1.5
h
DRUGBANK
1.15
h
0.8-1.5
h
Male, men; Female, women; schistosomiasis;
DRUGBANK
2.35
h
1.7-3.0
h
Male, men; Female, women; schistosomiasis;
chronic liver disease ↑ ;
DRUGBANK
0.0
%
~0
%
Urinary excretion; schistosomiasis; human, homo sapiens; Unchanged drug;
DRUGBANK
82.5
%
80-85
%
DRUGBANK
82.5
%
80-85
%
schistosomiasis; human, homo sapiens;
DRUGBANK
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Biltricide
praziquantel
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Biltricide
praziquantel
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Biltricide
praziquantel
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Biltricide
praziquantel
PDR
DDPD01059
Norfloxacin
319.3308
C16H18FN3O3
CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
DB01059
4539
100246
http://www.drugs.com/mtm/norfloxacin-ophthalmic.html
4380
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
DRUGBANK
12.5
%
10-15
%
DRUGBANK
DDPD01060
Amoxicillin
365.404
C16H19N3O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
DB01060
33613
2676
http://www.drugs.com/amoxicillin.html
31006
-2.0
-
-2.0
-
DRUGBANK
27290.0
ng.h/ml
27.29±4.72
mg.h/l
PO, oral;
DRUGBANK
55040.0
ng.h/ml
55.04±12.68
mg.h/l
PO, oral;
DRUGBANK
60.0
%
~60
%
DRUGBANK
93.0
%
93±10
%
PO, oral;
DRUGBANK
50.0
%
50
%
PO, oral;
DRUGBANK
3930.0
ng/ml
3.93±1.13
mg/L
PO, oral;
DRUGBANK
11210.0
ng/ml
11.21±3.42
mg/L
PO, oral;
DRUGBANK
46000.0
ng/ml
46±12
mcg/ml
intravenous injection, IV; Elderly; normal,healthy;
DRUGBANK
5000.0
ng/ml
5.0
mcg/ml
Oral single dose; adults;
DRUGBANK
1.31
h
1.31±0.33
h
PO, oral;
DRUGBANK
1.52
h
1.52±0.40
h
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
21.3
L/h
21.3
L/h
Average clearance;
DRUGBANK
0.156
L/h/kg
2.6±0.4
ml/min/kg
Children → ;Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;normal renal function → ;
DRUGBANK
0.198
L/h/kg
3.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.7
L
22.7
L
Total volume of distribution;
DRUGBANK
0.21
L/kg
0.21±0.03
L/kg
Elderly → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.25
L/kg
0.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.02166666666667
h
61.3
min
DRUGBANK
1.7
h
1.7±0.3
h
Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
74.0
%
70-78
%
Urinary excretion;
DRUGBANK
86.0
%
86±8
%
Urinary excretion; Unchanged drug;
DRUGBANK
17.0
%
~17
%
DRUGBANK
18.0
%
18
%
DRUGBANK
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
4000.0
mg/day
4
g/day
PO, oral
Moxatag
amoxicillin
PDR
1750.0
mg/day
1750
mg/day
PO, oral
Moxatag
amoxicillin
PDR
3000.0
mg/day
3
g/day
PO, oral
Moxatag
amoxicillin
PDR
1750.0
mg/day
1750
mg/day
PO, oral
Moxatag
amoxicillin
PDR
4000.0
mg/day
4
g/day
PO, oral
Moxatag
amoxicillin
PDR
1750.0
mg/day
1750
mg/day
PO, oral
Moxatag
amoxicillin
PDR
3000.0
mg/day
3
g/day
PO, oral
Moxatag
amoxicillin
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
90.0
mg/kg/day
90
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
75.0
mg/kg/day
75
mg/kg/day
PO, oral
Moxatag
amoxicillin
PDR
DDPD01061
Azlocillin
461.492
C20H23N5O6S
[H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1
DB01061
6479523
2956
4980416
-2.0
-
-2.0
-
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.26
L/kg
0.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.4
h
1.3-1.5
h
elimination half-life;
DRUGBANK
4.0
h
2-6
h
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
33.0
%
20-46
%
plasma proteins;
DRUGBANK
DDPD01062
Oxybutynin
357.4864
C22H31NO3
CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1
DB01062
4634
7856
http://www.drugs.com/oxybutynin.html
4473
-2.0
-
-2.0
-
DRUGBANK
16.0
ng.h/ml
16.0
ng.h/ml
PO, oral;
DRUGBANK
6.0
%
6
%
PO, oral;
DRUGBANK
6.25
%
1.6-10.9
%
PO, oral;
DRUGBANK
8.2
ng/ml
8.2
ng/ml
PO, oral;
DRUGBANK
69.7
ng/ml
41-98.4
ng/ml
PO, oral; Active metabolite;
DRUGBANK
12.4
ng/ml
12.4±4.1
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
4.2
ng/ml
4.2±1.6
ng/ml
PO, oral; extended release formulation;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
5.0
h
5.0±4.2
h
PO, oral; immediate release formulation;
DRUGBANK
5.2
h
5.2±3.7
h
PO, oral; extended release formulation;
DRUGBANK
0.486
L/h/kg
8.1±2.3
ml/min/kg
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
0.306
L/h/kg
5.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
193.0
L
193.0
L
DRUGBANK
1.3
L/kg
1.3±0.4
L/kg
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
0.85
L/kg
0.85
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
elimination half-life;
DRUGBANK
5.0
h
5
h
elimination half-life; Elderly;
DRUGBANK
1.9
h
1.9±0.35
h
intravenous injection, IV; normal,healthy; Female, women;
DRUGBANK
5.3
h
5.3
h
intravenous injection, IV;
DRUGBANK
9.0
h
9±2
h
PO, oral; immediate release formulation;
DRUGBANK
14.0
h
14±3
h
PO, oral; extended release formulation;
DRUGBANK
4.0
h
4.0±1.4
h
immediate release formulation;
DRUGBANK
8.3
h
8.3±2.5
h
extended release formulation;
DRUGBANK
7.2
h
7.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
460.0
mg/kg
460.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.1
%
<0.1
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Female, women; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
>97
%
plasma proteins;
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
15.0
mg/day
15
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
17.5
mg/day
17.5
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Ditropan XL
oxybutynin chloride
PDR
DDPD01063
Acetophenazine
411.56
C23H29N3O2S
CC(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN3CCN(CCO)CC3)C2=C1
DB01063
17676
2401
16708
-2.0
-
-2.0
-
DRUGBANK
DDPD01064
Isoprenaline
211.2576
C11H17NO3
CC(C)NCC(O)C1=CC(O)=C(O)C=C1
DB01064
T3D4979
3779
64317
http://www.drugs.com/cdi/isoproterenol.html
3647
-2.0
-
-2.0
-
DRUGBANK
DDPD01065
Melatonin
232.2783
C13H16N2O2
COC1=CC=C2NC=C(CCNC(C)=O)C2=C1
DB01065
T3D2972
896
16796
http://www.drugs.com/melatonin.html
872
-2.0
-
-2.0
-
DRUGBANK
0.99
L/h/kg
16.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.708333333333333
h
35-50
min
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3200.0
mg/kg
>3200
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01066
Cefditoren
506.578
C19H18N6O5S3
[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
DB01066
9870843
59343
http://www.drugs.com/cdi/cefditoren-pivoxil.html
8046534
-2.0
-
-2.0
-
DRUGBANK
14.0
%
14
%
PO, oral; fasting; Active metabolite;
DRUGBANK
16.0
%
16±3
%
PO, oral; low fat meal; Active metabolite;
DRUGBANK
4.5
L/h
4.0-5
L/h
Renal clearance; PO, oral;
DRUGBANK
9.3
L
9.3±1.6
L
DRUGBANK
1.6
h
1.6±0.4
h
elimination half-life; young; normal,healthy; adults;
DRUGBANK
99.0
%
>99
%
Urinary excretion;
DRUGBANK
88.0
%
88
%
plasma proteins; high protein binding;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Spectracef
cefditoren pivoxil
PDR
800.0
mg/day
800
mg/day
PO, oral
Spectracef
cefditoren pivoxil
PDR
800.0
mg/day
800
mg/day
PO, oral
Spectracef
cefditoren pivoxil
PDR
800.0
mg/day
800
mg/day
PO, oral
Spectracef
cefditoren pivoxil
PDR
DDPD01067
Glipizide
445.535
C21H27N5O4S
CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
DB01067
T3D2483
3478
5384
http://www.drugs.com/glipizide.html
3359
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
100
%
Oral single dose; diabetes;
DRUGBANK
95.0
%
95.0
%
PO, oral;
DRUGBANK
465.0
ng/ml
465±139
ng/ml
PO, oral; immediate release formulation; young; normal,healthy;
DRUGBANK
9.0
h
6-12
h
PO, oral;
DRUGBANK
2.1
h
2.1±0.9
h
PO, oral; immediate release formulation; young; normal,healthy;
DRUGBANK
3.0
L/h
~3
L/h
Average clearance; intravenous injection, IV; Single dose; diabetes; patients;
DRUGBANK
0.0312
L/h/kg
0.52±0.18
ml/min/kg
apparent clearance;
Elderly → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.0336
L/h/kg
0.56
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
L
10.0
L
Average volume of distribution; diabetes; patients;
DRUGBANK
0.17
L/kg
0.17±0.02
L/kg
Apparent volume of distribution;
Elderly → ;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
2-5
h
elimination half-life; Single dose; type 2 diabetes;
DRUGBANK
3.5
h
2-5
h
elimination half-life; Multiple dose; type 2 diabetes;
DRUGBANK
3.4
h
3.4±0.7
h
RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
3.3
h
3.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1200.0
mg/kg
1200.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
0.379
mg/kg
379.0
ug/kg
PO, oral; Children;
DRUGBANK
10.0
%
10
%
Urinary excretion; Faeces excretion; Unchanged drug;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.5
%
98-99
%
DRUGBANK
98.4
%
98.4
%
DRUGBANK
20.0
mg/day
20
mg/day
Tablet,PO，oral
Glucotrol
glipizide
PDR
40.0
mg/day
40
mg/day
Tablet,PO，oral
Glucotrol
glipizide
PDR
20.0
mg/day
20
mg/day
Tablet,PO，oral
Glucotrol
glipizide
PDR
40.0
mg/day
40
mg/day
Tablet,PO，oral
Glucotrol
glipizide
PDR
DDPD01068
Clonazepam
315.711
C15H10ClN3O3
[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
DB01068
T3D2973
2802
3756
http://www.drugs.com/clonazepam.html
2700
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
Tablet, PO, oral;
DRUGBANK
90.0
%
~90
%
Tablet, PO, oral;
DRUGBANK
98.0
%
98±31
%
PO, oral;
DRUGBANK
17.0
ng/ml
17±5.4
ng/ml
Tablet, PO, oral; adults; normal,healthy;
DRUGBANK
16.0
ng/ml
3-29
ng/ml
intravenous injection, IV; adults; normal,healthy;
DRUGBANK
2.5
h
1-4
h
Tablet, PO, oral;
DRUGBANK
2.5
h
2.5±1.3
h
Tablet, PO, oral; adults; normal,healthy;
DRUGBANK
3.3
L/h
~55
ml/min
gaining weight ↓ ;
DRUGBANK
0.093
L/h/kg
1.55±0.28
ml/min/kg
apparent clearance; hydrolysis;
DRUGBANK
0.0528
L/h/kg
0.88
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
L/kg
~3
L/kg
Apparent volume of distribution;
DRUGBANK
3.2
L/kg
3.2±1.1
L/kg
DRUGBANK
2.9
L/kg
2.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
h
~30-40
h
elimination half-life;
dose → ;
DRUGBANK
23.0
h
23±5
h
DRUGBANK
38.0
h
38
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
PO, oral; mouse;
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
PO, oral; adults; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; rabbit;
DRUGBANK
15000.0
mg/kg
>15000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
60.0
%
~50-70
%
Urinary excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
84.0
%
82-86
%
plasma proteins;
DRUGBANK
86.0
%
86±0.5
%
Neonates ↓ ;
DRUGBANK
0.15
mg/kg/day
0.15
mg/kg/day
PO, oral
Klonopin
clonazepam
PDR
20.0
mg/day
20
mg/day
PO, oral
Klonopin
clonazepam
PDR
20.0
mg/day
20
mg/day
PO, oral
Klonopin
clonazepam
PDR
0.15
mg/kg/day
0.15
mg/kg/day
PO, oral
Klonopin
clonazepam
PDR
20.0
mg/day
20
mg/day
PO, oral
Klonopin
clonazepam
PDR
0.15
mg/kg/day
0.15
mg/kg/day
PO, oral
Klonopin
clonazepam
PDR
DDPD01069
Promethazine
284.419
C17H20N2S
CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C
DB01069
T3D4560
4927
8461
http://www.drugs.com/promethazine.html
4758
-2.0
-
-2.0
-
DRUGBANK
14466.0
ng.h/ml
14466.0
ng.h/ml
intravenous injection, IV;
DRUGBANK
11511.0
ng.h/ml
11511.0
ng.h/ml
PO, oral;
DRUGBANK
25.0
%
25
%
PO, oral;
DRUGBANK
22.0
ng/ml
22
ng/ml
IM,intramuscular injection;
DRUGBANK
10.0
ng/ml
10
ng/ml
intravenous injection, IV;
DRUGBANK
10.2
ng/ml
2.4-18.0
ng/ml
PO, oral;
DRUGBANK
7.0
h
4-10
h
intravenous injection, IV;
DRUGBANK
2.25
h
1.5-3
h
PO, oral;
DRUGBANK
68.4
L/h
~1.14
L/min
intravenous injection, IV;
DRUGBANK
0.354
L/h
5.9
ml/min
Renal clearance;
DRUGBANK
5.424
L/h
90.4
ml/min
Renal clearance;
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
L/kg
~30
L/kg
DRUGBANK
14.0
L/kg
14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.5
h
~12-15
h
elimination half-life;
DRUGBANK
14.0
h
14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
170.0
mg/kg
170.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
160.0
mg/kg
160.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
240.0
mg/kg
240.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
255.0
mg/kg
255.0
mg/kg
PO, oral; mouse;
DRUGBANK
55.0
mg/kg
55.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
0.64
%
0.64
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
93.0
%
93
%
DRUGBANK
1.1
mg/kg/dose
1.1
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;Rectal Administration;
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
25.0
mg/dose
25
mg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;Rectal Administration;
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
0.0
0
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
50.0
mg/dose
50
mg/dose
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
100.0
mg/day
100
mg/day
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
1.1
mg/kg/dose
1.1
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;Rectal Administration;
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
25.0
mg/dose
25
mg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;Rectal Administration;
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
50.0
mg/dose
50
mg/dose
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
100.0
mg/day
100
mg/day
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
0.0
0
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
0.0
0
Promethazine Hydrochloride Syrup
promethazine hydrochloride
PDR
DDPD01070
Dihydrotachysterol
398.6642
C28H46O
CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C
DB01070
T3D2974
5311071
4591
http://www.drugs.com/mtm/dihydrotachysterol.html
4470607
-2.0
-
-2.0
-
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD01072
Atazanavir
704.8555
C38H52N6O7
COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
DB01072
148192
37924
http://www.drugs.com/cdi/atazanavir.html
130642
-2.0
-
-2.0
-
DRUGBANK
64.0
%
60-68
%
PO, oral;
DRUGBANK
5400.0
ng/ml
5.4±1.4
mcg/ml
PO, oral; food;
DRUGBANK
2.5
h
~2.5
h
DRUGBANK
2.5
h
2.5
h
PO, oral; food;
DRUGBANK
0.204
L/h/kg
3.4±1.0
ml/min/kg
apparent clearance; hydrolysis; normal,healthy; adults;
hepatopathy，LD ↓ ;
DRUGBANK
2.15
L/kg
1.6-2.7
L/kg
Apparent volume of distribution; hydrolysis; normal,healthy; adults;
DRUGBANK
7.0
h
~7
h
elimination half-life; normal,healthy; adults;
DRUGBANK
7.0
h
~7
h
elimination half-life; AIDS,HIV; adults;
DRUGBANK
12.1
h
12.1
h
elimination half-life; hepatopathy，LD; Single dose;
DRUGBANK
7.9
h
7.9±2.9
h
chronic liver disease ↑ ;
DRUGBANK
7.0
%
7
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
86.0
%
86
%
human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
86.0
%
86
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
300.0
mg/day
300
mg/day
Capsule, PO, Oral
Reyataz
atazanavir
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
250.0
mg/day
250
mg/day
PO, oral
Reyataz
atazanavir
PDR
200.0
mg/day
200
mg/day
PO, oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
Capsule, PO, Oral;PO, oral;
Reyataz
atazanavir
PDR
200.0
mg/day
200
mg/day
Capsule, PO, Oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Reyataz
atazanavir
PDR
300.0
mg/day
300
mg/day
PO, oral
Reyataz
atazanavir
PDR
200.0
mg/day
200
mg/day
PO, oral
Reyataz
atazanavir
PDR
DDPD01073
Fludarabine
285.235
C10H12FN5O4
NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
DB01073
T3D4736
657237
94701
http://www.drugs.com/cdi/fludarabine.html
571392
-2.0
-
-2.0
-
DRUGBANK
55.0
%
55
%
PO, oral;
DRUGBANK
570.0
ng/ml
0.57
mcg/ml
adults; tumor;
DRUGBANK
7.86
L/h
117-145
ml/min
intravenous injection, IV; Single dose; Chronic lymphocytic leukemia; patients;
DRUGBANK
0.222
L/h/kg
3.7±1.5
ml/min/kg
intravenous injection, IV; tumor; patients; Male, men; Female, women;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.192
L/h/kg
3.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.4
L/kg
2.4±0.6
L/kg
intravenous injection, IV; tumor; patients; Male, men; Female, women;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
h
20
h
DRUGBANK
20.0
h
10-30
h
Male, men; Female, women; adults; tumor; patients; intravenous injection, IV;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
%
24±3
%
Urinary excretion; intravenous injection, IV; adults; tumor; human, homo sapiens; Unchanged drug;
DRUGBANK
24.0
%
19-29
%
DRUGBANK
25.0
mg/m2
25
mg/m2
intravenous injection, IV
Fludarabine Phosphate for Injection
fludarabine phosphate
PDR
30.0
mg/m2
30
mg/m2
intravenous injection, IV
Fludarabine Phosphate for Injection
fludarabine phosphate
PDR
25.0
mg/m2
25
mg/m2
intravenous injection, IV
Fludarabine Phosphate for Injection
fludarabine phosphate
PDR
30.0
mg/m3
30
mg/m3
intravenous injection, IV
Fludarabine Phosphate for Injection
fludarabine phosphate
PDR
DDPD01074
Perhexiline
277.4879
C19H35N
C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1
DB01074
T3D2975
4746
35553
4584
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
PO, oral;
DRUGBANK
96.0
h
2-6
day
DRUGBANK
720.0
h
30
day
different study;
DRUGBANK
2150.0
mg/kg
2150.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2641.0
mg/kg
2641.0
mg/kg
PO, oral; mouse;
DRUGBANK
2150.0
mg/kg
2150.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2641.0
mg/kg
2641.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
>90
%
DRUGBANK
DDPD01075
Diphenhydramine
255.3547
C17H21NO
CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
DB01075
T3D2976
3100
4636
http://www.drugs.com/cdi/diphenhydramine.html
2989
-2.0
-
-2.0
-
DRUGBANK
50.0
%
40-60
%
PO, oral;
DRUGBANK
72.0
%
72±26
%
PO, oral;
DRUGBANK
66.0
ng/ml
66±22
ng/ml
Oral single dose; fasting; adults; normal,healthy;
DRUGBANK
230.0
ng/ml
~230
ng/ml
fasting; adults; normal,healthy;
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
2.3
h
2.3±0.64
h
Oral single dose; fasting; adults; normal,healthy;
DRUGBANK
57.0
L/h
600-1300
ml/min
Plasma clearance; PO, oral;
DRUGBANK
0.372
L/h/kg
6.2±1.7
ml/min/kg
Children ↑ ;Elderly ↓ ;Asian ↑ ;Hepatic cirrhosis, cirr → ;
DRUGBANK
0.588
L/h/kg
9.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.05
L/kg
3.3-6.8
L/kg
PO, oral;
DRUGBANK
4.5
L/kg
4.5±2.8
L/kg
Apparent volume of distribution;
Asian ↓ ;Hepatic cirrhosis, cirr → ;
DRUGBANK
6.5
L/kg
6.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.85
h
2.4-9.3
h
elimination half-life; normal,healthy; adults;
Hepatitis, Hep ↑ ;
DRUGBANK
8.5
h
8.5±3.2
h
Asian → ;Children ↓ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ;
DRUGBANK
9.3
h
9.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
~1
%
Urinary excretion; Single dose; Unchanged drug;
DRUGBANK
1.9
%
1.9±0.8
%
Urinary excretion; Unchanged drug;
Hepatic cirrhosis, cirr → ;
DRUGBANK
78.0
%
~78
%
DRUGBANK
82.5
%
80-85
%
plasma proteins;
DRUGBANK
78.0
%
78±3
%
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
400.0
mg/day
400
mg/day
intravenous injection, IV;IM,intramuscular injection;
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
400.0
mg/day
400
mg/day
intravenous injection, IV;IM,intramuscular injection;
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
400.0
mg/day
400
mg/day
intravenous injection, IV;IM,intramuscular injection;
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral;intravenous injection, IV;IM,intramuscular injection;
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral;intravenous injection, IV;IM,intramuscular injection;
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Diphenhydramine Hydrochloride
diphenhydramine hydrochloride
PDR
25.0
mg/day
25
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
60.0
mg/day
60
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
30.0
mg/day
30
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
15.0
mg/day
15
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
25.0
mg/day
25
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
60.0
mg/day
60
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
25.0
mg/day
25
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
60.0
mg/day
60
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
25.0
mg/day
25
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
60.0
mg/day
60
mg/day
PO, oral
Unisom
doxylamine succinate
PDR
DDPD01076
Atorvastatin
558.6398
C33H35FN2O5
CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
DB01076
T3D4980
60823
39548
http://www.drugs.com/atorvastatin.html
54810
-2.0
-
-2.0
-
DRUGBANK
200.0
ng.h/ml
200.0
ng.h/ml
PO, oral;
DRUGBANK
14.0
%
14
%
PO, oral;
DRUGBANK
12.0
%
12.0
%
PO, oral; normal,healthy;
DRUGBANK
28.0
ng/ml
28
ng/ml
PO, oral;
DRUGBANK
14.9
ngEq/ml
14.9±1.8
ngEq/ml
PO, oral; normal,healthy;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
2.3
h
2.3±0.96
h
PO, oral; normal,healthy;
DRUGBANK
37.5
L/h
625.0
ml/min
Plasma clearance;
DRUGBANK
1.74
L/h/kg
29.0
ml/min/kg
apparent clearance; at steady state; hydrolysis; PO, oral; normal,healthy; Male, men; Female, women; adults;
Elderly ↓ ;Hepatitis, Hep ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
380.0
L
380.0
L
DRUGBANK
5.4
L/kg
~5.4
L/kg
at steady state; hydrolysis; PO, oral; normal,healthy; Male, men; Female, women; adults;
DRUGBANK
14.0
h
14
h
DRUGBANK
30.0
h
30
h
Metabolite;
DRUGBANK
19.5
h
19.5±9.6
h
normal,healthy; adults; Male, men; Female, women;
Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
2.0
%
<2
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
>98
%
plasma proteins;
DRUGBANK
98.0
%
≥98
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Lipitor
atorvastatin calcium
PDR
10.0
mg/day
10
mg/day
PO, oral
Lipitor
atorvastatin calcium
PDR
80.0
mg/day
80
mg/day
PO, oral
Lipitor
atorvastatin calcium
PDR
20.0
mg/day
20
mg/day
PO, oral
Lipitor
atorvastatin calcium
PDR
80.0
mg/day
80
mg/day
PO, oral
Lipitor
atorvastatin calcium
PDR
DDPD01077
Etidronic acid
206.027
C2H8O7P2
CC(O)(P(O)(O)=O)P(O)(O)=O
DB01077
T3D3483
3305
4907
3189
-2.0
-
-2.0
-
DRUGBANK
5.5
%
1-10
%
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.09
L/h/kg
0.09
L/kg/h
Renal clearance;
DRUGBANK
0.8
L/kg
0.3-1.3
L/kg
DRUGBANK
3.5
h
~1-6
h
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Etidronate Disodium
etidronate disodium
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Etidronate Disodium
etidronate disodium
PDR
DDPD01078
Deslanoside
943.0791
C47H74O19
C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1
DB01078
28620
31468
26618
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
36.0
h
36
h
DRUGBANK
20.0
%
20
%
DRUGBANK
DDPD01079
Tegaserod
301.394
C16H23N5O
CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2
DB01079
5362436
51043
http://www.drugs.com/cdi/tegaserod.html
10609889
-2.0
-
-2.0
-
DRUGBANK
10.0
%
10
%
fasting;
DRUGBANK
11.0
%
11±2
%
PO, oral;
DRUGBANK
2.7
ng/ml
2.7±1.2
ng/ml
PO, oral;
DRUGBANK
1.35
h
0.7-2
h
fasting;
DRUGBANK
0.7
h
0.7
h
PO, oral; high-fat meal;
DRUGBANK
0.8
h
0.8
h
PO, oral;
DRUGBANK
77.0
L/h
77 ± 15
L/h
Plasma clearance; intravenous injection, IV;
DRUGBANK
1.08
L/h/kg
18±4
ml/min/kg
normal,healthy; Male, men; Female, women;
DRUGBANK
1.08
L/h/kg
18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
368.0
L
368±223
L
Average volume of distribution; at steady state; intravenous injection, IV;
DRUGBANK
5.2
L/kg
5.2±3.2
L/kg
normal,healthy; Male, men; Female, women;
DRUGBANK
5.3
L/kg
5.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.35
h
4.6-8.1
h
elimination half-life; PO, oral;
DRUGBANK
11.0
h
11±5
h
normal,healthy; Male, men; Female, women;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
66.7
%
~66.7
%
Faeces excretion; PO, oral;
DRUGBANK
33.3
%
~33.3
%
Urinary excretion; PO, oral;
DRUGBANK
0.0
%
~0
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
~98
%
DRUGBANK
98.0
%
98
%
human, homo sapiens;
DRUGBANK
DDPD01080
Vigabatrin
129.157
C6H11NO2
NC(CCC(O)=O)C=C
DB01080
T3D2977
5665
63638
http://www.drugs.com/cdi/vigabatrin.html
5463
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral; Infants;
Infants ↑ ;
DRUGBANK
0.0
%
0
%
DRUGBANK
2.4
L/h
2.4
L/h
PO, oral; Infants;
DRUGBANK
5.1
L/h
5.1
L/h
PO, oral; Children;
DRUGBANK
5.8
L/h
5.8
L/h
PO, oral; Adolescents;
DRUGBANK
7.0
L/h
7.0
L/h
PO, oral; adults;
DRUGBANK
1.1
L/kg
1.1
L/kg
Steady state volume of distribution;
DRUGBANK
5.7
h
~5.7
h
terminal half-life; Infants;
DRUGBANK
7.0
h
6-8
h
terminal half-life; Children;
DRUGBANK
9.5
h
9.5
h
terminal half-life; Adolescents;
DRUGBANK
10.5
h
10.5
h
terminal half-life; adults;
DRUGBANK
2830.0
mg/kg
2830.0
mg/kg
PO, oral; mouse;
DRUGBANK
3100.0
mg/kg
3100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3000.0
mg/kg
3000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
~95
%
Urinary excretion;
DRUGBANK
76.0
%
~76
%
Urinary excretion; Unchanged drug;
DRUGBANK
3000.0
mg/day
3000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Sabril for Oral Solution
vigabatrin
PDR
DDPD01081
Diphenoxylate
452.5873
C30H32N2O2
CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
DB01081
T3D2978
13505
4639
12919
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
DRUGBANK
13.0
h
12-14
h
DRUGBANK
84.5
%
74-95
%
DRUGBANK
DDPD01082
Streptomycin
581.5741
C21H39N7O12
CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O
DB01082
19649
17076
http://www.drugs.com/cdi/streptomycin.html
18508
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
IM,intramuscular injection;
DRUGBANK
0.0468
L/h/kg
0.78
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.34
L/kg
0.34
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
5-6
h
adults; normal renal function;
DRUGBANK
4.3
h
4.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
430.0
mg/kg
430.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
2000.0
mg/day
2
g/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
2000.0
mg/day
2
g/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
2000.0
mg/day
2
g/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
2000.0
mg/day
2
g/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Streptomycin
streptomycin
PDR
DDPD01083
Orlistat
495.7348
C29H53NO5
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
DB01083
3034010
94686
http://www.drugs.com/orlistat.html
2298564
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
360.0
mg/day
360
mg/day
PO, oral
Xenical
orlistat
PDR
360.0
mg/day
360
mg/day
PO, oral
Xenical
orlistat
PDR
180.0
mg/day
180
mg/day
PO, oral
Xenical
orlistat
PDR
360.0
mg/day
360
mg/day
PO, oral
Xenical
orlistat
PDR
360.0
mg/day
360
mg/day
PO, oral
Xenical
orlistat
PDR
180.0
mg/day
180
mg/day
PO, oral
Xenical
orlistat
PDR
DDPD01084
Emedastine
302.4145
C17H26N4O
CCOCCN1C(=NC2=CC=CC=C12)N1CCCN(C)CC1
DB01084
3219
4779
http://www.drugs.com/mtm/emedastine-ophthalmic.html
3106
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
elimination half-life; PO, oral;
DRUGBANK
44.0
%
~44
%
Urinary excretion; PO, oral;
DRUGBANK
3.6
%
3.6
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
4.0
drop/day
4
drop/day
ophthalmic administration
Emadine
emedastine difumarate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration; ophthalmic solution
Emadine
emedastine difumarate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Emadine
emedastine difumarate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Emadine
emedastine difumarate
PDR
DDPD01085
Pilocarpine
208.2569
C11H16N2O2
CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O
DB01085
T3D2979
5910
8207
http://www.drugs.com/cdi/pilocarpine-drops.html
5699
-2.0
-
-2.0
-
DRUGBANK
0.76
h
0.76
h
DRUGBANK
10.0
mg/dose
10
mg/dose
PO, oral
Salagen
pilocarpine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Salagen
pilocarpine hydrochloride
PDR
10.0
mg/dose
10
mg/dose
PO, oral
Salagen
pilocarpine hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Salagen
pilocarpine hydrochloride
PDR
DDPD01086
Benzocaine
165.1891
C9H11NO2
CCOC(=O)C1=CC=C(N)C=C1
DB01086
T3D2980
2337
116735
http://www.drugs.com/cdi/benzocaine-drops.html
13854242
-2.0
-
-2.0
-
DRUGBANK
3040.0
mg/kg
3040.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3040.0
mg/kg
3040.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01087
Primaquine
259.3467
C15H21N3O
COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1
DB01087
4908
8405
http://www.drugs.com/cdi/primaquine.html
4739
-2.0
-
-2.0
-
DRUGBANK
0.348
L/h/kg
5.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
L/kg
4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.55
h
3.7-7.4
h
DRUGBANK
7.1
h
7.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
30.0
mg/day
30
mg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
15.0
mg/day
15
mg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
30.0
mg/day
30
mg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
30.0
mg/day
30
mg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
15.0
mg/day
15
mg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
30.0
mg/day
30
mg/day
PO, oral
Primaquine Phosphate
primaquine phosphate
PDR
DDPD01088
Iloprost
360.494
C22H32O4
[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O
DB01088
5311181
63916
http://www.drugs.com/cdi/iloprost.html
4470703
-2.0
-
-2.0
-
DRUGBANK
63.0
%
63
%
DRUGBANK
1.2
L/h/kg
20.0
ml/min/kg
normal,healthy;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
L/kg
0.7-0.8
L/kg
DRUGBANK
0.37
L/kg
0.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.416666666666667
h
20-30
min
DRUGBANK
0.57
h
0.57
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
60
%
DRUGBANK
0.07
mg/day
70
mcg/day
Ventavis
iloprost
PDR
0.07
mg/day
70
mcg/day
Ventavis
iloprost
PDR
DDPD01089
Deserpidine
578.6527
C32H38N2O8
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2
DB01089
8550
27478
8232
-2.0
-
-2.0
-
DRUGBANK
DDPD01090
Pentolinium
240.428
C15H32N2
C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1
DB01090
5850
347401
5641
-2.0
-
-2.0
-
DRUGBANK
512.0
mg/kg
512.0
mg/kg
PO, oral; mouse;
DRUGBANK
890.0
mg/kg
890.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01091
Butenafine
317.4672
C23H27N
CN(CC1=CC=C(C=C1)C(C)(C)C)CC1=CC=CC2=CC=CC=C12
DB01091
2484
3238
http://www.drugs.com/cdi/butenafine-cream.html
2390
-2.0
-
-2.0
-
DRUGBANK
35.0
h
35
h
distribution half-life; skin/dermal;
DRUGBANK
150.0
h
150
h
elimination half-life; skin/dermal;
DRUGBANK
DDPD01092
Ouabain
584.6525
C29H44O12
[H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O
DB01092
T3D4018
439501
472805
388599
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD01093
Dimethyl sulfoxide
78.133
C2H6OS
CS(C)=O
DB01093
T3D2982
679
28262
http://www.drugs.com/cdi/dimethyl-sulfoxide.html
659
-2.0
-
-2.0
-
DRUGBANK
10000.0
mg/kg
>10
g/kg
PO, oral; dog;
DRUGBANK
10000.0
mg/kg
>10
g/kg
PO, oral; dog;
DRUGBANK
50.0
ml
50
ml
intravesically
q2w
Rimso-50
dimethyl sulfoxide
PDR
50.0
ml
50
ml
intravesically
q2w
Rimso-50
dimethyl sulfoxide
PDR
DDPD01095
Fluvastatin
411.4659
C24H26FNO4
CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12
DB01095
1548972
5136
http://www.drugs.com/cdi/fluvastatin.html
1265982
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
DRUGBANK
24.0
%
24(9-50)
%
PO, oral;
DRUGBANK
36.0
%
36
%
PO, oral; extended release formulation; high-fat meal;
extended release formulation ↑ ;high-fat meal ↑ ;
DRUGBANK
1.0
h
<1
h
PO, oral;
DRUGBANK
6.0
h
6
h
PO, oral; extended release formulation; high-fat meal;
extended release formulation ↑ ;high-fat meal ↑ ;
DRUGBANK
75.0
%
75
%
Liver metabolism; Faeces excretion; Bile excretion;
DRUGBANK
20.0
%
~20
%
Liver metabolism;
DRUGBANK
5.0
%
~5
%
Liver metabolism;
DRUGBANK
0.8
L/h/kg
0.8
L/h/kg
DRUGBANK
107.0
L/h
107±38.1
L/h
hypercholesterolemia; Single dose;
DRUGBANK
87.8
L/h
87.8±45
L/h
hypercholesterolemia; Multiple dose;
DRUGBANK
108.0
L/h
108±44.7
L/h
hypercholesterolemia; Single dose;
DRUGBANK
64.2
L/h
64.2±21.1
L/h
hypercholesterolemia; Multiple dose;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.35
L/kg
0.35
L/kg
DRUGBANK
0.42
L/kg
0.42
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3
h
DRUGBANK
0.7
h
0.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
~90
%
Faeces excretion; PO, oral;
DRUGBANK
5.0
%
~5
%
Urinary excretion; PO, oral;
DRUGBANK
1.8
%
<1.8
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Lescol/Lescol XL
fluvastatin sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Lescol/Lescol XL
fluvastatin sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Lescol/Lescol XL
fluvastatin sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Lescol/Lescol XL
fluvastatin sodium
PDR
DDPD01096
Oxamniquine
279.3348
C14H21N3O3
CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O
DB01096
4612
78416
http://www.drugs.com/mtm/oxamniquine.html
4451
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1-2.5
h
DRUGBANK
DDPD01097
Leflunomide
270.2073
C12H9F3N2O2
CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
DB01097
3899
6402
http://www.drugs.com/cdi/leflunomide.html
3762
-2.0
-
-2.0
-
DRUGBANK
35000.0
ng/ml
35.0
ug/ml
PO, oral; rheumatoid arthritis;
DRUGBANK
9.0
h
6-12
h
DRUGBANK
9.0
h
6-12
h
PO, oral; rheumatoid arthritis;
DRUGBANK
0.00072
L/h/kg
0.012
ml/min/kg
apparent clearance; normal,healthy;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.13
L/kg
0.13
L/kg
DRUGBANK
0.18
L/kg
0.18(0.09-0.44)
L/kg
Apparent volume of distribution; normal,healthy;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
336.0
h
2
week
DRUGBANK
377.0
h
377(336-432)
h
rheumatoid arthritis; patients;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
175.0
mg/kg
100-250
mg/kg
PO, oral;
DRUGBANK
43.0
%
~43
%
Urinary excretion; Single dose;
DRUGBANK
48.0
%
~48
%
Faeces excretion; Single dose;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Active metabolite; Unchanged drug;
DRUGBANK
99.3
%
>99.3
%
DRUGBANK
99.4
%
99.4
%
Active metabolite;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Arava
leflunomide
PDR
20.0
mg/day
20
mg/day
PO, oral
Arava
leflunomide
PDR
DDPD01098
Rosuvastatin
481.538
C22H28FN3O6S
CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
DB01098
T3D2680
446157
38545
http://www.drugs.com/cdi/rosuvastatin.html
393589
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral; Male, men; Caucasian;
DRUGBANK
20.0
%
20
%
PO, oral; Male, men; Caucasian;
DRUGBANK
20.0
%
20(17-23)
%
PO, oral;
DRUGBANK
6.06
ng/ml
6.06
ng/ml
PO, oral; normal,healthy;
DRUGBANK
4.6
ng/ml
4.6±2.1
ng/ml
PO, oral;
DRUGBANK
5.0
h
5
h
PO, oral; normal,healthy;
DRUGBANK
3.0
h
3(1-6)
h
PO, oral;
DRUGBANK
0.63
L/h/kg
10.5±4.7
ml/min/kg
normal,healthy; Male, men;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
134.0
L
134.0
L
Average volume of distribution; at steady state;
DRUGBANK
1.7
L/kg
1.7±0.5
L/kg
normal,healthy; Male, men;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
19.0
h
~19
h
elimination half-life;
dose → ;
DRUGBANK
20.0
h
20±6
h
normal,healthy; Male, men;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
90
%
Faeces excretion; PO, oral;
DRUGBANK
90.0
%
~90
%
Faeces excretion; adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
10.0
%
10
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
30.0
%
30±7
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
88.0
%
88
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
88.0
%
88
%
DRUGBANK
20.0
mg/day
20
mg/day
Tablet,PO，oral
Crestor
rosuvastatin calcium
PDR
40.0
mg/day
40
mg/day
PO, oral
Crestor
rosuvastatin calcium
PDR
20.0
mg/day
20
mg/day
Tablet,PO，oral
Crestor
rosuvastatin calcium
PDR
40.0
mg/day
40
mg/day
PO, oral
Crestor
rosuvastatin calcium
PDR
DDPD01099
Flucytosine
129.0925
C4H4FN3O
NC1=NC(=O)NC=C1F
DB01099
T3D2983
3366
5100
http://www.drugs.com/cdi/flucytosine.html
3249
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
83.5
%
78-89
%
PO, oral;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.68
L/kg
0.68
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.6
h
2.4-4.8
h
DRUGBANK
4.2
h
4.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15000.0
mg/kg
15.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
15000.0
mg/kg
15.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
29.5
%
28-31
%
DRUGBANK
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
150.0
mg/kg/day
150
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
200.0
mg/kg/day
200
mg/kg/day
PO, oral
Ancobon
flucytosine
PDR
DDPD01100
Pimozide
461.5462
C28H29F2N3O
FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
DB01100
T3D2984
16362
8212
http://www.drugs.com/cdi/pimozide.html
15520
-2.0
-
-2.0
-
DRUGBANK
50.0
%
>50
%
PO, oral;
DRUGBANK
7.0
h
6-8
h
PO, oral;
DRUGBANK
29.0
h
29±10
h
Single dose; normal,healthy;
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
228.0
mg/kg
228.0
mg/kg
PO, oral; mouse;
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
228.0
mg/kg
228.0
mg/kg
PO, oral; mouse;
DRUGBANK
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Orap
pimozide
PDR
10.0
mg/day
10
mg/day
PO, oral
Orap
pimozide
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Orap
pimozide
PDR
6.0
mg/day
6
mg/day
PO, oral
Orap
pimozide
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Orap
pimozide
PDR
10.0
mg/day
10
mg/day
PO, oral
Orap
pimozide
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Orap
pimozide
PDR
10.0
mg/day
10
mg/day
PO, oral
Orap
pimozide
PDR
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral
Orap
pimozide
PDR
10.0
mg/day
10
mg/day
PO, oral
Orap
pimozide
PDR
DDPD01101
Capecitabine
359.3501
C15H22FN3O6
CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
DB01101
T3D3507
60953
31348
http://www.drugs.com/cdi/capecitabine.html
54916
-2.0
-
-2.0
-
DRUGBANK
70.0
%
~70
%
PO, oral;
DRUGBANK
6600.0
ng/ml
6.6±6.0
mcg/ml
PO, oral;
DRUGBANK
470.0
ng/ml
0.47±0.47
mcg/ml
PO, oral; Components;
DRUGBANK
0.5
h
0.5(0.5-1)
h
PO, oral;
DRUGBANK
0.5
h
0.5(0.5-2.1)
h
PO, oral; Components;
DRUGBANK
145.0
h/m2
145.0
h/m2
apparent clearance; tumor; Male, men; Female, women;
hepatopathy，LD ↓ ;
DRUGBANK
270.0
L/m2
270.0
L/m2
Steady state volume of distribution; tumor; Male, men; Female, women;
DRUGBANK
0.875
h
45-60
min
DRUGBANK
0.875
h
45-60
min
Metabolite;
DRUGBANK
1.3
h
1.3
h
Male, men; Female, women; tumor; patients;
DRUGBANK
0.72
h
0.72
h
Male, men; Female, women; tumor; patients;
DRUGBANK
95.5
%
95.5
%
Urinary excretion;
DRUGBANK
2.6
%
2.6
%
Faeces excretion;
DRUGBANK
3.0
%
~3
%
Urinary excretion; Unchanged drug;
DRUGBANK
3.0
%
3
%
Urinary excretion; tumor; human, homo sapiens; Unchanged drug;
DRUGBANK
60.0
%
<60
%
DRUGBANK
60.0
%
<60
%
tumor; human, homo sapiens;
DRUGBANK
2500.0
mg/m2/day
2500
mg/m2/day
PO, oral; on days 1 to 14
Xeloda
capecitabine
PDR
1250.0
mg/m2
1250
mg/m2
PO, oral; on days 1 to 14
bid
Xeloda
capecitabine
PDR
2500.0
mg/m2/day
2500
mg/m2/day
PO, oral; on days 1 to 14
Xeloda
capecitabine
PDR
1250.0
mg/m2
1250
mg/m2
PO, oral; on days 1 to 14
bid
Xeloda
capecitabine
PDR
DDPD01102
Arbutamine
317.3795
C18H23NO4
O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1
DB01102
60789
50580
54785
-2.0
-
-2.0
-
DRUGBANK
0.133333333333333
h
~8
min
elimination half-life;
DRUGBANK
58.0
%
58
%
DRUGBANK
DDPD01104
Sertraline
306.23
C17H17Cl2N
CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
DB01104
T3D2985
68617
9123
http://www.drugs.com/sertraline.html
61881
-2.0
-
-2.0
-
DRUGBANK
456000.0
ng.h/ml
456.0
ug.h/ml
PO, oral; different study;
DRUGBANK
44.0
%
>44
%
PO, oral;
DRUGBANK
37.5
ng/ml
20-55
ug/L
PO, oral;
DRUGBANK
118.0
ng/ml
118±22
ng/ml
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
166.0
ng/ml
166±65
ng/ml
PO, oral; Female, women; adults; normal,healthy;
DRUGBANK
6.45
h
4.5-8.4
h
PO, oral;
DRUGBANK
6.9
h
6.9±1.0
h
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
6.7
h
6.7±1.8
h
PO, oral; Female, women; adults; normal,healthy;
DRUGBANK
168.0
h
1
week
PO, oral;
DRUGBANK
1.09
L/h/kg
1.09±0.38
L/h/kg
young;
DRUGBANK
1.35
L/h/kg
1.35±0.67
L/h/kg
Elderly;
DRUGBANK
2.28
L/h/kg
38±14
ml/min/kg
apparent clearance;
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
20.0
L/kg
>20
L/kg
DRUGBANK
26.0
h
~26
h
elimination half-life;
DRUGBANK
29.0
h
22-36
h
elimination half-life; different study;
DRUGBANK
23.0
h
23.0
h
Hepatic cirrhosis, cirr ↑ ;Age ↑ ;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
Rattus, Rat;
DRUGBANK
483.5
mg/kg
419-548
mg/kg
PO, oral; mouse;
DRUGBANK
1459.0
mg/kg
1327-1591
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
13.0
%
12-14
%
Faeces excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.5
%
~98-99
%
DRUGBANK
98.5
%
98-99
%
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Zoloft
sertraline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Zoloft
sertraline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Zoloft
sertraline hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Zoloft
sertraline hydrochloride
PDR
DDPD01105
Sibutramine
279.848
C17H26ClN
CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
DB01105
T3D2986
5210
9137
http://www.drugs.com/cdi/sibutramine.html
5021
-2.0
-
-2.0
-
DRUGBANK
77.0
%
>77
%
Oral single dose;
DRUGBANK
1750.0
L/h
1750.0
L/h
PO, oral;
DRUGBANK
1.1
h
1.1
h
DRUGBANK
77.0
%
77
%
Urinary excretion; Oral single dose;
DRUGBANK
8.0
%
~8
%
Faeces excretion; Oral single dose;
DRUGBANK
97.0
%
97
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD01106
Levocabastine
420.528
C26H29FN2O2
C[C@@H]1CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@H]1CC[C@](CC1)(C#N)C1=CC=C(F)C=C1
DB01106
54385
135679
http://www.drugs.com/mtm/levocabastine-ophthalmic.html
16736421
-2.0
-
-2.0
-
DRUGBANK
15.0
%
10-20
%
DRUGBANK
0.0258
L/h/kg
0.43
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.17
L/kg
1.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
h
36
h
PO, oral;
DRUGBANK
33.0
h
33
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01107
Methyprylon
183.2475
C10H17NO2
CCC1(CC)C(=O)NCC(C)C1=O
DB01107
T3D2987
4162
31837
4018
-2.0
-
-2.0
-
DRUGBANK
11.0
h
6-16
h
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD01108
Trilostane
329.4333
C20H27NO3
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
DB01108
656583
32260
570949
-2.0
-
-2.0
-
DRUGBANK
8.0
h
8
h
DRUGBANK
DDPD01109
Heparin
N.A.
N.A.
CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
DB01109
T3D2566
772
28304
http://www.drugs.com/heparin.html
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
70.0
ng/ml
70±39
ng/ml
DRUGBANK
3.0
h
3.0
h
DRUGBANK
0.0258
L/h/kg
0.43
ml/kg/min
adults;
DRUGBANK
0.0894
L/h/kg
1.49
ml/kg/min
Preg, pregnant;
DRUGBANK
3.3
L/h
40-70
mL/min
DRUGBANK
0.058
L/kg
0.058±0.11
L/kg
Apparent volume of distribution;
DRUGBANK
1.5
h
1.5
h
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
mouse;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.4
units/ml
0.4
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.7
units/ml
0.7
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.4
units/ml
0.4
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.7
units/ml
0.7
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.4
units/ml
0.4
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.7
units/ml
0.7
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.4
units/ml
0.4
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.7
units/ml
0.7
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.4
units/ml
0.4
units/ml
Heparin Sodium Injection
heparin sodium
PDR
0.7
units/ml
0.7
units/ml
Heparin Sodium Injection
heparin sodium
PDR
DDPD01110
Miconazole
416.129
C18H14Cl4N2O
ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
DB01110
T3D2988
4189
82892
http://www.drugs.com/cdi/miconazole-cream.html
4044
-2.0
-
-2.0
-
DRUGBANK
55200.0
ng.h/ml
55.2±35.1
mcg.h/ml
Tablet, PO, oral; normal,healthy;
DRUGBANK
477.3
ng.h/ml
477.3
ng.h/ml
Vaginal Administration;
DRUGBANK
15100.0
ng/ml
15.1±16.2
mcg/ml
Tablet, PO, oral; normal,healthy;
DRUGBANK
10.71
ng/ml
10.71
ng/ml
Vaginal Administration;
DRUGBANK
7.0
h
7(2-24.1)
h
Tablet, PO, oral; normal,healthy;
DRUGBANK
18.4
h
18.4
h
Vaginal Administration;
DRUGBANK
0.5688
L/h/kg
9.48
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95546.0
L
95546.0
L
Apparent volume of distribution; Vaginal Administration;
DRUGBANK
10911.0
L
10911.0
L
Apparent volume of distribution; Vaginal Administration;
DRUGBANK
7.14
L/kg
7.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
24
h
terminal half-life;
DRUGBANK
19.75
h
19.75
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3800.0
mg/kg
3800.0
mg/kg
PO, oral; mouse;
DRUGBANK
3000.0
mg/kg
3.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD01111
Colistimethate
1634.87
C58H105N16O28S5
CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O
DB01111
70789202
59662
http://www.drugs.com/cdi/colistimethate.html
26329515
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
0.0
%
0
%
Bile excretion;
DRUGBANK
2.5
h
2-3
h
intravenous injection, IV; adults; Children; Prem, premature;
DRUGBANK
2.5
h
2-3
h
intravenous infusion, IV in drop; adults; Children; Prem, premature;
DRUGBANK
5450.0
mg/kg
5450.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Coly-Mycin M
colistimethate sodium
PDR
150.0
mg/day
150
mg/day
inhalation, IH
Coly-Mycin M
colistimethate sodium
PDR
5.0
mg/day
5
mg/day
Coly-Mycin M
colistimethate sodium
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Coly-Mycin M
colistimethate sodium
PDR
300.0
mg/day
300
mg/day
inhalation, IH
Coly-Mycin M
colistimethate sodium
PDR
40.0
mg/day
40
mg/day
Coly-Mycin M
colistimethate sodium
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Coly-Mycin M
colistimethate sodium
PDR
300.0
mg/day
300
mg/day
inhalation, IH
Coly-Mycin M
colistimethate sodium
PDR
40.0
mg/day
40
mg/day
Coly-Mycin M
colistimethate sodium
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Coly-Mycin M
colistimethate sodium
PDR
150.0
mg/day
150
mg/day
inhalation, IH
Coly-Mycin M
colistimethate sodium
PDR
5.0
mg/day
5
mg/day
Coly-Mycin M
colistimethate sodium
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Coly-Mycin M
colistimethate sodium
PDR
DDPD01112
Cefuroxime
424.385
C16H16N4O8S
[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O
DB01112
5479529
3515
http://www.drugs.com/cdi/cefuroxime.html
4586393
-2.0
-
-2.0
-
DRUGBANK
37.0
%
37
%
PO, oral;
DRUGBANK
52.0
%
52
%
PO, oral; food;
food ↑ ;
DRUGBANK
32.0
%
32(21-44)
%
PO, oral;
DRUGBANK
8500.0
ng/ml
7-10
mcg/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
2.5
h
2-3
h
Oral single dose; adults; normal,healthy;
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2
L/kg
0.20±0.04
L/kg
Elderly → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.33333333333333
h
~80
min
intravenous infusion, IV in drop;
DRUGBANK
1.33333333333333
h
~80
min
intravenous injection, IV;
DRUGBANK
1.7
h
1.7±0.6
h
Neonates → ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
96.0
%
96±10
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
50
%
DRUGBANK
33.0
%
33±6
%
DRUGBANK
240.0
mg/kg/day
240
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
9000.0
mg/day
9
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
9000.0
mg/day
9
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
240.0
mg/kg/day
240
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
9000.0
mg/day
9
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
9000.0
mg/day
9
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
240.0
mg/kg/day
240
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Ceftin
cefuroxime axetil
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftin
cefuroxime axetil
PDR
DDPD01113
Papaverine
339.385
C20H21NO4
COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1
DB01113
4680
28241
http://www.drugs.com/cdi/papaverine.html
4518
-2.0
-
-2.0
-
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.25
h
0.5-2
h
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
~90
%
DRUGBANK
600.0
mg/day
600
mg/day
Capsule, PO, Oral
Papaverine Hydrochloride
papaverine hydrochloride
PDR
600.0
mg/day
600
mg/day
Capsule, PO, Oral
Papaverine Hydrochloride
papaverine hydrochloride
PDR
DDPD01114
Chlorpheniramine
274.788
C16H19ClN2
CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
DB01114
T3D2989
2725
52010
http://www.drugs.com/cdi/chlorpheniramine.html
2624
-2.0
-
-2.0
-
DRUGBANK
41.0
%
41±16
%
PO, oral;
DRUGBANK
43.5
ng/ml
16-71
ng/ml
PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
46.5
ng/ml
17-76
ng/ml
PO, oral; Sustained Release formulation; adults; normal,healthy;
DRUGBANK
2.5
h
2-3
h
PO, oral; immediate release formulation; adults; normal,healthy;
DRUGBANK
6.9
h
5.7-8.1
h
PO, oral; Sustained Release formulation; adults; normal,healthy;
DRUGBANK
0.102
L/h/kg
1.7±0.1
ml/min/kg
Children ↑ ;
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.2
L/kg
3.2±0.3
L/kg
Children → ;
DRUGBANK
3.3
L/kg
3.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
21-27
h
DRUGBANK
20.0
h
20±5
h
Children ↓ ;
DRUGBANK
22.0
h
22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
306.0
mg/kg
306.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
130.0
mg/kg
130.0
mg/kg
PO, oral; mouse;
DRUGBANK
198.0
mg/kg
198.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
306.0
mg/kg
306.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
130.0
mg/kg
130.0
mg/kg
PO, oral; mouse;
DRUGBANK
198.0
mg/kg
198.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
306.0
mg/kg
306.0
mg/kg
human, homo sapiens;
DRUGBANK
13.15
%
0.3-26
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
72.0
%
72
%
DRUGBANK
70.0
%
70±3
%
Raceme D/L;
DRUGBANK
DDPD01115
Nifedipine
346.3346
C17H18N2O6
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
DB01115
4485
7565
http://www.drugs.com/nifedipine.html
4330
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
25.0
ng.h/ml
25.0
ng.h/ml
sublingual;
DRUGBANK
152.0
ng.h/ml
152.0
ng.h/ml
PO, oral;
DRUGBANK
56.5
%
45-68
%
PO, oral;
DRUGBANK
50.0
%
50±13
%
DRUGBANK
10.0
ng/ml
10
ng/ml
sublingual;
DRUGBANK
82.0
ng/ml
82
ng/ml
PO, oral;
DRUGBANK
79.0
ng/ml
79±44
ng/ml
Capsule, PO, Oral; immediate release formulation; Male, men; adults; normal,healthy;
DRUGBANK
42.0
ng/ml
35-49
ng/ml
PO, oral; extended release formulation; Male, men; adults; normal,healthy;
DRUGBANK
0.833333333333333
h
50
min
sublingual;
DRUGBANK
0.466666666666667
h
28
min
PO, oral;
DRUGBANK
0.5
h
0.5±0.2
h
Capsule, PO, Oral; immediate release formulation; Male, men; adults; normal,healthy;
DRUGBANK
6.0
h
~6
h
PO, oral; extended release formulation; Male, men; adults; normal,healthy;
DRUGBANK
34.5
L/h
450-700
ml/min
Total clearance;
DRUGBANK
0.42
L/h/kg
7.0±1.8
ml/min/kg
hydrolysis;
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;Somking → ;
DRUGBANK
0.438
L/h/kg
7.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.695
L/kg
0.62-0.77
L/kg
Apparent volume of distribution;
DRUGBANK
0.27
L/kg
0.25-0.29
L/kg
Total volume of distribution;
DRUGBANK
0.78
L/kg
0.78±0.22
L/kg
Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Somking → ;
DRUGBANK
0.79
L/kg
0.79
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
elimination half-life;
DRUGBANK
1.8
h
1.8±0.4
h
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ;Somking → ;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1022.0
mg/kg
1022.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
202.0
mg/kg
202.0
mg/kg
PO, oral; mouse;
DRUGBANK
70.0
%
60-80
%
Urinary excretion;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
92-98
%
DRUGBANK
96.0
%
96±1
%
RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;
DRUGBANK
3.0
mg/kg/day
3
mg/kg/day
Tablet,PO，oral
Nifedipine
nifedipine
PDR
180.0
mg/day
180
mg/day
Tablet,PO，oral
Nifedipine
nifedipine
PDR
0.5
mg/kg/dose
0.5
mg/kg/dose
Nifedipine
nifedipine
PDR
10.0
mg/dose
10
mg/dose
Nifedipine
nifedipine
PDR
90.0
mg/day
90
mg/day
PO, oral
Nifedipine
nifedipine
PDR
180.0
mg/day
180
mg/day
Capsule, PO, Oral
Nifedipine
nifedipine
PDR
90.0
mg/day
90
mg/day
Tablet,PO，oral
Nifedipine
nifedipine
PDR
120.0
mg/day
120
mg/day
PO, oral
Nifedipine
nifedipine
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Nifedipine
nifedipine
PDR
180.0
mg/day
180
mg/day
PO, oral
Nifedipine
nifedipine
PDR
0.5
mg/kg/dose
0.5
mg/kg/dose
Nifedipine
nifedipine
PDR
10.0
mg/dose
10
mg/dose
Nifedipine
nifedipine
PDR
90.0
mg/day
90
mg/day
PO, oral
Nifedipine
nifedipine
PDR
180.0
mg/day
180
mg/day
Capsule, PO, Oral
Nifedipine
nifedipine
PDR
90.0
mg/day
90
mg/day
Tablet,PO，oral
Nifedipine
nifedipine
PDR
120.0
mg/day
120
mg/day
PO, oral
Nifedipine
nifedipine
PDR
DDPD01116
Trimethaphan
365.512
C22H25N2OS
O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1
DB01116
23576
9728
22044
-2.0
-
-2.0
-
DRUGBANK
1850.0
mg/kg
>1850
mg/kg
mouse; Rattus, Rat;
DRUGBANK
30.0
%
20-40
%
Faeces excretion;
DRUGBANK
DDPD01117
Atovaquone
366.837
C22H19ClO3
OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O
DB01117
74989
575568
http://www.drugs.com/cdi/atovaquone.html
10482034
-2.0
-
-2.0
-
DRUGBANK
23.0
%
23
%
PO, oral;
DRUGBANK
47.0
%
47
%
PO, oral; food;
food ↑ ;
DRUGBANK
0.624
L/h
10.4±5.5
ml/min
intravenous injection, IV; AIDS,HIV; patients;
DRUGBANK
0.009
L/h/kg
0.15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
0.60±0.17
L/kg
DRUGBANK
0.6
L/kg
0.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
64.8
h
2.2-3.2
day
DRUGBANK
63.0
h
63
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
%
<0.6
%
Urinary excretion;
DRUGBANK
99.9
%
99.9
%
plasma proteins;
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Mepron
atovaquone
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Mepron
atovaquone
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Mepron
atovaquone
PDR
3000.0
mg/day
3
g/day
PO, oral
Mepron
atovaquone
PDR
3000.0
mg/day
3
g/day
PO, oral
Mepron
atovaquone
PDR
3000.0
mg/day
3
g/day
PO, oral
Mepron
atovaquone
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Mepron
atovaquone
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Mepron
atovaquone
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Mepron
atovaquone
PDR
DDPD01118
Amiodarone
645.3116
C25H29I2NO3
CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
DB01118
T3D4737
2157
2663
http://www.drugs.com/amiodarone.html
2072
-2.0
-
-2.0
-
DRUGBANK
50.0
%
35-65
%
DRUGBANK
46.0
%
46±22
%
PO, oral; adults; patients;
DRUGBANK
1950.0
ng/ml
1.5-2.4
mcg/ml
PO, oral; adults; patients;
DRUGBANK
5.0
h
3-7
h
DRUGBANK
6.0
h
2-10
h
PO, oral; adults; patients;
DRUGBANK
0.33
L/h/kg
220-440
ml/h/kg
intravenous injection, IV; ventricular fibrillation; ventricular tachycardia;
DRUGBANK
26.1
L/h
0.1-0.77
L/min
Total clearance;
hepatopathy，LD ↓ ;
DRUGBANK
0.114
L/h/kg
1.9±0.4
ml/min/kg
hydrolysis;
Female, women → ;Elderly → ;RD, renal impairment, Renal disease，including uremia → ;congestive heart disease → ;
DRUGBANK
13.215
L/kg
9.26-17.17
L/kg
normal,healthy;
DRUGBANK
13.965
L/kg
6.88-21.05
L/kg
ventricular tachycardia; patients;
DRUGBANK
60.0
L/kg
60.0
L/kg
Average volume of distribution;
DRUGBANK
66.0
L/kg
66±44
L/kg
DRUGBANK
1308.0
h
9-100
day
terminal half-life;
DRUGBANK
1392.0
h
58(15-142)
day
elimination half-life;
DRUGBANK
1068.0
h
14-75
day
terminal half-life;
DRUGBANK
41.45
h
3.2-79.7
h
elimination half-life; Single dose;
DRUGBANK
600.0
h
25±12
day
PO, oral; at steady state; adults; patients;
Female, women → ;RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
178.0
mg/kg
178.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
0.0
%
0
%
Urinary excretion; Unchanged drug;
DRUGBANK
96.0
%
~96
%
DRUGBANK
99.98
%
99.98±0.01
%
DRUGBANK
DDPD01119
Diazoxide
230.671
C8H7ClN2O2S
CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2
DB01119
3019
4495
http://www.drugs.com/cdi/diazoxide-suspension.html
2911
-2.0
-
-2.0
-
DRUGBANK
0.0036
L/h/kg
0.06
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.0
h
28±8.3
h
normal,healthy; adults;
DRUGBANK
48.0
h
48
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
444.0
mg/kg
444.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
>90
%
DRUGBANK
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Proglycem
diazoxide
PDR
150.0
mg
150
mg
intravenous injection, IV
Proglycem
diazoxide
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Proglycem
diazoxide
PDR
150.0
mg
150
mg
intravenous injection, IV
Proglycem
diazoxide
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Proglycem
diazoxide
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Proglycem
diazoxide
PDR
DDPD01120
Gliclazide
323.411
C15H21N3O3S
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1
DB01120
3475
31654
580820
-2.0
-
-2.0
-
DRUGBANK
5.0
h
4-6
h
PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug; PO, oral;
DRUGBANK
0.0246
L/h/kg
0.41
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.4
null
10.4
null
DRUGBANK
16.4
h
16.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3000.0
mg/kg
3000.0
mg/kg
PO, oral; mouse;
DRUGBANK
65.0
%
60-70
%
Urinary excretion;
DRUGBANK
15.0
%
10-20
%
Faeces excretion;
DRUGBANK
94.0
%
94
%
DRUGBANK
DDPD01121
Phenacemide
178.1879
C9H10N2O2
NC(=O)NC(=O)CC1=CC=CC=C1
DB01121
T3D2990
4753
8049
4589
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
23.5
h
22-25
h
DRUGBANK
987.0
mg/kg
987.0
mg/kg
PO, oral; mouse;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; rabbit;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
987.0
mg/kg
987.0
mg/kg
PO, oral; mouse;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; rabbit;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01122
Ambenonium
537.565
C28H42Cl2N4O2
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1Cl
DB01122
T3D2991
2131
2627
http://www.drugs.com/cdi/ambenonium.html
2046
-2.0
-
-2.0
-
DRUGBANK
150.0
mg/kg
150±44
mg/kg
PO, oral; mouse;
DRUGBANK
150.0
mg/kg
150±44
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD01123
Proflavine
209.2465
C13H11N3
NC1=CC2=NC3=C(C=CC(N)=C3)C=C2C=C1
DB01123
7099
8452
6832
-2.0
-
-2.0
-
DRUGBANK
DDPD01124
Tolbutamide
270.348
C12H18N2O3S
CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
DB01124
5505
27999
http://www.drugs.com/cdi/tolbutamide.html
5304
-2.0
-
-2.0
-
DRUGBANK
85.0
%
80-90
%
PO, oral;
DRUGBANK
53000.0
ng/ml
53±12
mcg/ml
Oral single dose;
DRUGBANK
4.0
h
3-5
h
Oral single dose;
DRUGBANK
3.1
h
3.1±1.5
h
Oral single dose;
DRUGBANK
0.0132
L/h/kg
0.22±0.06
ml/min/kg
apparent clearance; PO, oral; hydrolysis;
acute viral hepatitis AVH ↑ ;
DRUGBANK
0.0126
L/h/kg
0.21
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.12
L/kg
0.12±0.02
L/kg
Apparent volume of distribution; PO, oral;
acute viral hepatitis AVH → ;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
~7(4-25)
h
DRUGBANK
5.9
h
5.9±1.4
h
PO, oral;
acute viral hepatitis AVH ↓ ;chronic respiratory insufficiency ↓ ;RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
7.0
h
7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
PO, oral; mouse;
DRUGBANK
80.0
%
~75-85
%
Urinary excretion; Oral single dose;
DRUGBANK
0.1
%
~0.1
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
~95
%
plasma proteins;
DRUGBANK
93.5
%
91-96
%
Elderly ↓ ;acute viral hepatitis AVH ↓ ;
DRUGBANK
3000.0
mg/day
3000
mg/day
PO, oral
Tolbutamide
tolbutamide
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Tolbutamide
tolbutamide
PDR
DDPD01125
Anisindione
252.2647
C16H12O3
COC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O
DB01125
2197
133809
http://www.drugs.com/pdr/anisindione.html
2112
-2.0
-
-2.0
-
DRUGBANK
DDPD01126
Dutasteride
528.5297
C27H30F6N2O2
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F
DB01126
6918296
521033
http://www.drugs.com/cdi/dutasteride.html
5293502
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60(40-94)
%
PO, oral; normal,healthy;
DRUGBANK
4320.0
h
6
month
Oral multiple dose;
DRUGBANK
0.58
L/h
0.58
L/h
PO, oral; Single dose; normal,healthy;
DRUGBANK
400.0
L
300-500
L
DRUGBANK
840.0
h
~5
week
elimination half-life; at steady state;
DRUGBANK
3600.0
h
4-6
month
terminal half-life;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
skin/dermal; rabbit;
DRUGBANK
8.0
%
~1-15
%
Faeces excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
~99
%
DRUGBANK
96.6
%
96.6
%
DRUGBANK
DDPD01127
Econazole
381.684
C18H15Cl3N2O
ClC1=CC=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
DB01127
T3D2992
3198
82873
http://www.drugs.com/cdi/econazole-cream.html
3086
-2.0
-
-2.0
-
DRUGBANK
462.0
mg/kg
462.0
mg/kg
PO, oral; mouse;
DRUGBANK
668.0
mg/kg
668.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
272.0
mg/kg
272.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
160.0
mg/kg
>160
mg/kg
PO, oral; dog;
DRUGBANK
462.0
mg/kg
462.0
mg/kg
PO, oral; mouse;
DRUGBANK
462.0
mg/kg
462.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
668.0
mg/kg
668.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
160.0
mg/kg
>160
mg/kg
PO, oral; dog;
DRUGBANK
DDPD01128
Bicalutamide
430.373
C18H14F4N2O4S
CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
DB01128
T3D4818
2375
144093
http://www.drugs.com/cdi/bicalutamide.html
2284
-2.0
-
-2.0
-
DRUGBANK
734.0
ng/ml
734.0
ng/ml
Oral single dose; Optical rotation R; Male, men; normal,healthy;
DRUGBANK
84.0
ng/ml
84.0
ng/ml
Oral single dose; Optical rotation S; Male, men; normal,healthy;
DRUGBANK
8900.0
ng/ml
8.9±3.5
mcg/ml
Oral multiple dose; Optical rotation R/S; Male, men; normal,healthy;
DRUGBANK
23.4
h
23.4
h
PO, oral; Optical rotation R; Male, men; normal,healthy;
DRUGBANK
20.7
h
20.7
h
PO, oral; Optical rotation S; Male, men; normal,healthy;
DRUGBANK
0.32
L/h
0.32
L/h
apparent clearance; PO, oral; normal,healthy; Male, men;
DRUGBANK
0.00258
L/h/kg
0.043±0.013
ml/min/kg
apparent clearance; PO, oral;
Elderly → ;hepatopathy，LD → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.438
L/h/kg
7.3±4.0
ml/min/kg
apparent clearance; PO, oral;
Elderly → ;hepatopathy，LD → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
141.6
h
5.9
day
DRUGBANK
139.0
h
139±32
h
Optical rotation R;
severe hepatic impairment ↑ ;
DRUGBANK
29.0
h
29±8.6
h
Optical rotation S;
chronic liver disease ↑ ;
DRUGBANK
1.7
%
1.7±0.3
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
96.0
%
96
%
DRUGBANK
96.0
%
96
%
Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Casodex
bicalutamide
PDR
50.0
mg/day
50
mg/day
PO, oral
Casodex
bicalutamide
PDR
DDPD01129
Rabeprazole
359.443
C18H21N3O3S
COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1
DB01129
5029
8768
http://www.drugs.com/cdi/rabeprazole.html
4853
-2.0
-
-2.0
-
DRUGBANK
52.0
%
52
%
DRUGBANK
0.24
L/h/kg
4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
~90
%
Urinary excretion; Oral single dose;
DRUGBANK
96.3
%
96.3
%
plasma proteins; human, homo sapiens;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
10.0
mg/day
10
mg/day
Capsule, PO, Oral
Aciphex
rabeprazole sodium
PDR
2.5
mg/kg/day
2.5
mg/kg/day
Capsule, PO, Oral
Aciphex
rabeprazole sodium
PDR
40.0
mg/day
40
mg/day
Capsule, PO, Oral
Aciphex
rabeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
120.0
mg/day
120
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
20.0
mg/day
20
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
40.0
mg/day
40
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
80.0
mg/day
80
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
120.0
mg/day
120
mg/day
PO, oral
Aciphex
rabeprazole sodium
PDR
DDPD01130
Prednicarbate
488.577
C27H36O8
[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB01130
6714002
135791
http://www.drugs.com/cdi/prednicarbate-cream.html
5145991
-2.0
-
-2.0
-
DRUGBANK
DDPD01131
Proguanil
253.731
C11H16ClN5
CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1
DB01131
4923
8455
http://www.drugs.com/cons/proguanil.html
4754
-2.0
-
-2.0
-
DRUGBANK
20.0
h
~20
h
DRUGBANK
75.0
%
~75
%
DRUGBANK
DDPD01132
Pioglitazone
356.439
C19H20N2O3S
CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
DB01132
T3D4981
4829
8228
http://www.drugs.com/cdi/pioglitazone.html
4663
-2.0
-
-2.0
-
DRUGBANK
1600.0
ng/ml
1.6±0.2
mcg/ml
PO, oral;
DRUGBANK
400.0
ng/ml
0.4±0.2
mcg/ml
PO, oral; Active metabolite;
DRUGBANK
1400.0
ng/ml
1.4±0.5
mcg/ml
PO, oral; Active metabolite;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral; food;
food ↑ ;
DRUGBANK
3.5
h
3.5(1-4)
h
PO, oral;
DRUGBANK
11.0
h
11(2-48)
h
PO, oral; Active metabolite;
DRUGBANK
11.0
h
11(4-16)
h
PO, oral; Active metabolite;
DRUGBANK
168.0
h
7
day
PO, oral; Active metabolite;
DRUGBANK
6.0
L/h
5.0-7
L/h
apparent clearance; PO, oral;
DRUGBANK
0.072
L/h/kg
1.2±1.7
ml/min/kg
apparent clearance; PO, oral; normal,healthy; Male, men; patients;
DRUGBANK
0.63
L/kg
0.63±0.41
L/kg
Apparent volume of distribution;
DRUGBANK
0.63
L/kg
0.63±0.41
L/kg
Apparent volume of distribution; PO, oral; normal,healthy; Male, men; patients;
DRUGBANK
5.0
h
3-7
h
elimination half-life;
DRUGBANK
20.0
h
16-24
h
elimination half-life;
DRUGBANK
11.0
h
11±6
h
DRUGBANK
29.0
h
29
h
at steady state; Metabolite;
DRUGBANK
27.0
h
27
h
at steady state; Metabolite;
DRUGBANK
24.0
mg/kg
24.0
mg/kg
PO, oral; mouse;
DRUGBANK
3.0
mg/kg
3.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
22.5
%
~15-30
%
Urinary excretion; PO, oral;
DRUGBANK
0.0
%
~0
%
Urinary excretion; normal,healthy; type 2 diabetes; human, homo sapiens; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
99.0
%
>99
%
normal,healthy; type 2 diabetes; human, homo sapiens;
DRUGBANK
45.0
mg/day
45
mg/day
PO, oral
Actos
pioglitazone
PDR
45.0
mg/day
45
mg/day
PO, oral
Actos
pioglitazone
PDR
DDPD01133
Tiludronic acid
318.608
C7H9ClO6P2S
OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O
DB01133
60937
9598
http://www.drugs.com/cdi/tiludronate.html
54905
-2.0
-
-2.0
-
DRUGBANK
27200.0
ng.h/ml
27.2±9.0
mg.h/l
PO, oral;
DRUGBANK
6.0
%
6（2-11）
%
PO, oral;
DRUGBANK
3350.0
ng/ml
3.35±1.07
mg/L
PO, oral;
DRUGBANK
1.3
h
0.9-1.7
h
PO, oral;
DRUGBANK
0.68
L/h
0.68
L/h
Renal clearance; normal,healthy;
DRUGBANK
0.47
L/h
0.47
L/h
Renal clearance; Paget's disease;
DRUGBANK
45.0
L
30-60
L
DRUGBANK
150.0
h
150
h
elimination half-life;
DRUGBANK
40.0
h
~40
h
terminal half-life;
DRUGBANK
60.0
%
60
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
~90
%
DRUGBANK
DDPD01135
Doxacurium
1035.2223
C56H78N2O16
COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
DB01135
5284551
59819
54249
-2.0
-
-2.0
-
DRUGBANK
0.1596
L/h/kg
2.66
ml/min/kg
normal,healthy; young; patients;
DRUGBANK
0.0738
L/h/kg
1.23
ml/min/kg
renal transplant; patients;
DRUGBANK
0.138
L/h/kg
2.3
ml/min/kg
liver transplant; patients;
DRUGBANK
0.105
L/h/kg
1.75±0.16
ml/min/kg
Geriatric;
DRUGBANK
0.1524
L/h/kg
2.54±0.24
ml/min/kg
patients; young;
DRUGBANK
0.162
L/h/kg
2.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.27
L/kg
0.11-0.43
L/kg
normal,healthy; patients; young;
DRUGBANK
0.36
L/kg
0.17-0.55
L/kg
renal transplant; patients;
DRUGBANK
0.26
L/kg
0.17-0.35
L/kg
liver transplant; patients;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.65
h
99
min
normal,healthy; adults;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
%
~30
%
DRUGBANK
DDPD01136
Carvedilol
406.4742
C24H26N2O4
COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2
DB01136
2585
3441
http://www.drugs.com/cdi/carvedilol.html
2487
-2.0
-
-2.0
-
DRUGBANK
1158.5
ng.h/ml
717-1600
ug.h/L
PO, oral;
DRUGBANK
609.5
ng.h/ml
272-947
ug.h/L
PO, oral;
DRUGBANK
216.5
ng.h/ml
208-225
ug.h/L
DRUGBANK
30.0
%
25-35
%
PO, oral;
DRUGBANK
25.0
%
25.0
%
PO, oral;
DRUGBANK
15.0
%
15.0
%
PO, oral; Optical rotation S;
DRUGBANK
31.0
%
31.0
%
PO, oral; Optical rotation R;
DRUGBANK
192.0
ng/ml
122-262
ug/L
PO, oral;
DRUGBANK
87.5
ng/ml
24-151
ug/L
PO, oral;
DRUGBANK
63.5
ng/ml
58-69
ug/L
DRUGBANK
105.0
ng/ml
105±12
ng/ml
PO, oral; adults; normal,healthy;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
1.3
h
1.3±0.3
h
PO, oral; adults; normal,healthy;
DRUGBANK
0.52
L/kg
0.52
L/kg
Plasma clearance;
DRUGBANK
0.522
L/h/kg
8.7±1.7
ml/min/kg
Elderly → ;Hepatitis, Hep ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.468
L/h/kg
7.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.75
L/kg
1.5-2
L/kg
DRUGBANK
1.5
L/kg
1.5±0.3
L/kg
Hepatitis, Hep ↑ ;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.5
h
7-10
h
DRUGBANK
2.2
h
2.2±0.3
h
Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
6.0
h
6
h
low concentration;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
%
16
%
Urinary excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
95.0
%
95
%
DRUGBANK
95.0
%
95
%
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Coreg
carvedilol
PDR
0.9
mg/kg/day
0.9
mg/kg/day
PO, oral
Coreg
carvedilol
PDR
50.0
mg/day
50
mg/day
PO, oral
Coreg
carvedilol
PDR
100.0
mg/day
100
mg/day
PO, oral
Coreg
carvedilol
PDR
80.0
mg/day
80
mg/day
Capsule, PO, Oral
Coreg
carvedilol
PDR
50.0
mg/day
50
mg/day
PO, oral
Coreg
carvedilol
PDR
0.9
mg/kg/day
0.9
mg/kg/day
PO, oral
Coreg
carvedilol
PDR
50.0
mg/day
50
mg/day
PO, oral
Coreg
carvedilol
PDR
100.0
mg/day
100
mg/day
PO, oral
Coreg
carvedilol
PDR
80.0
mg/day
80
mg/day
Capsule, PO, Oral
Coreg
carvedilol
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral
Coreg
carvedilol
PDR
0.9
mg/kg/day
0.9
mg/kg/day
PO, oral
Coreg
carvedilol
PDR
DDPD01137
Levofloxacin
361.3675
C18H20FN3O4
C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
DB01137
T3D2478
149096
63598
http://www.drugs.com/cdi/levofloxacin-drops.html
131410
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; intravenous injection, IV;
DRUGBANK
50.0
%
~50
%
inhalation, IH;
DRUGBANK
99.0
%
~99
%
PO, oral; intravenous injection, IV;
DRUGBANK
99.0
%
99±10
%
PO, oral; Male, men; adults; normal,healthy;
DRUGBANK
6200.0
ng/ml
6.2±1.0
ug/ml
PO, oral; intravenous injection, IV;
DRUGBANK
11.5
ng/ml
11.5±4.0
ug/L
PO, oral; intravenous injection, IV;
DRUGBANK
4500.0
ng/ml
4.5±0.9
mcg/ml
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
1.5
h
1-2
h
PO, oral; intravenous injection, IV;
DRUGBANK
1.0
h
1
h
PO, oral; intravenous injection, IV;
DRUGBANK
1.5
h
1.5
h
PO, oral; intravenous injection, IV;
DRUGBANK
2.5
h
2-3
h
PO, oral; food;
food ↑ ;
DRUGBANK
1.6
h
1.6±0.8
h
Oral single dose; Male, men; adults; normal,healthy;
DRUGBANK
5.0
%
5
%
Urinary excretion;
DRUGBANK
11.1
L/h
8.64-13.56
L/h
apparent clearance;
DRUGBANK
7.14
L/h
5.76-8.52
L/h
Renal clearance;
DRUGBANK
0.1512
L/h/kg
2.52±0.45
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.175
L/kg
1.09-1.26
L/kg
Average volume of distribution; PO, oral;
DRUGBANK
1.36
L/kg
1.36±0.21
L/kg
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
6-8
h
elimination half-life;
DRUGBANK
7.0
h
7±1
h
mild renal function ↑ ;moderate renal function ↑ ;severe renal function ↑ ;
DRUGBANK
8.8
h
8.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1803.0
mg/kg
1803.0
mg/kg
PO, oral; mouse;
DRUGBANK
1478.0
mg/kg
1478.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
640.0
mg/kg
640.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
87.0
%
~87
%
Urinary excretion; Oral single dose;
DRUGBANK
4.0
%
<4
%
Faeces excretion; Oral single dose;
DRUGBANK
74.0
%
61-87
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
31.0
%
24-38
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
31.0
%
24-38
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
500.0
mg/day
500
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
750.0
mg/day
750
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
500.0
mg/day
500
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
250.0
mg/dose
250
mg/dose
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
750.0
mg/day
750
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
750.0
mg/day
750
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
500.0
mg/day
500
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
750.0
mg/day
750
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
500.0
mg/day
500
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
250.0
mg/dose
250
mg/dose
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
750.0
mg/day
750
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
750.0
mg/day
750
mg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
16.0
mg/kg/day
16
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral;intravenous injection, IV;
Levofloxacin Ophthalmic Solution
levofloxacin
PDR
DDPD01138
Sulfinpyrazone
404.482
C23H20N2O3S
O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1
DB01138
5342
9342
http://www.drugs.com/mtm/sulfinpyrazone.html
5149
-2.0
-
-2.0
-
DRUGBANK
0.0204
L/h/kg
0.34
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~4-6
h
DRUGBANK
6.2
h
6.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.5
%
98-99
%
DRUGBANK
DDPD01139
Cefapirin
423.463
C17H17N3O6S2
[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC1=CC=NC=C1)C(O)=O
DB01139
30699
554446
28486
-2.0
-
-2.0
-
DRUGBANK
14000.0
mg/kg
14000.0
mg/kg
PO, oral;
DRUGBANK
DDPD01140
Cefadroxil
363.388
C16H17N3O5S
[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
DB01140
47965
3479
http://www.drugs.com/cdi/cefadroxil.html
43630
-2.0
-
-2.0
-
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5
h
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
Urinary excretion; Unchanged drug;
DRUGBANK
28.1
%
28.1
%
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
2000.0
mg/day
2
g/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
50.0
mg/kg
50
mg/kg
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
2000.0
mg
2
g
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
2000.0
mg/day
2
g/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
2000.0
mg/day
2
g/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
2000.0
mg/day
2
g/day
PO, oral
Cefadroxil For Oral Suspension
cefadroxil
PDR
DDPD01141
Micafungin
1270.274
C56H71N9O23S
CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O
DB01141
477468
600520
http://www.drugs.com/cdi/micafungin.html
419105
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
0.02154
L/h/kg
0.359±0.179
ml/min/kg
Drug combination; patients; adults;
DRUGBANK
0.01926
L/h/kg
0.321±0.098
ml/min/kg
Drug combination; AIDS,HIV; patients;
DRUGBANK
0.01962
L/h/kg
0.327±0.093
ml/min/kg
Drug combination; AIDS,HIV; patients;
DRUGBANK
0.0204
L/h/kg
0.340±0.092
ml/min/kg
Drug combination; AIDS,HIV; patients;
DRUGBANK
0.01284
L/h/kg
0.214±0.031
ml/min/kg
hematopoietic stem cell transplant; patients;
DRUGBANK
0.01224
L/h/kg
0.204±0.036
ml/min/kg
hematopoietic stem cell transplant; patients;
DRUGBANK
0.01344
L/h/kg
0.224±0.064
ml/min/kg
hematopoietic stem cell transplant; patients;
DRUGBANK
0.01338
L/h/kg
0.223±0.081
ml/min/kg
hematopoietic stem cell transplant; patients;
DRUGBANK
0.0102
L/h/kg
0.17
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.39
L/kg
0.39±0.11
L/kg
esophageal candidiasis; patients; adults;
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.5
h
14-17
h
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
125.0
mg/kg
125.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
200.0
mg/kg
>200
mg/kg
intravenous injection, IV; dog;
DRUGBANK
71.0
%
71
%
Faeces excretion;
DRUGBANK
99.0
%
>99
%
high protein binding;
DRUGBANK
2.5
mg/kg/day
2.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.5
mg/kg/day
4.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
225.0
mg/day
225
mg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.5
mg/kg/day
4.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
2.5
mg/kg/day
2.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.5
mg/kg/day
4.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
225.0
mg/day
225
mg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.5
mg/kg/day
4.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.5
mg/kg/day
4.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.5
mg/kg/day
4.5
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
15.0
mg/kg/day
15
mg/kg/day
intravenous injection, IV
Mycamine
micafungin sodium
PDR
DDPD01142
Doxepin
279.3761
C19H21NO
[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12
DB01142
T3D2993
667468
4710
http://www.drugs.com/cdi/doxepin-capsules.html
3046
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30
%
PO, oral;
DRUGBANK
30.0
%
30±10
%
PO, oral;
DRUGBANK
27.3
ng/ml
8.8-45.8
ng/ml
PO, oral;
DRUGBANK
28.0
ng/ml
28±11
ng/ml
PO, oral; Derivative; depression;
DRUGBANK
39.0
ng/ml
39±19
ng/ml
PO, oral; Derivative; depression;
DRUGBANK
4.0
h
3.5
h
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral; Derivative; depression;
DRUGBANK
8.0
h
4-12
h
PO, oral; Derivative; depression;
DRUGBANK
0.93
L/h/kg
0.93
l/h/kg
Plasma clearance; Oral single dose; normal,healthy;
DRUGBANK
0.84
L/h/kg
14±3
ml/min/kg
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L/kg
20.0
L/kg
Apparent volume of distribution;
DRUGBANK
24.0
L/kg
24±7
L/kg
Apparent volume of distribution;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
h
15
h
elimination half-life;
DRUGBANK
18.0
h
18±5
h
DRUGBANK
37.0
h
37±15
h
Active metabolite;
DRUGBANK
15.0
h
15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
180.0
mg/kg
180.0
mg/kg
PO, oral; mouse;
DRUGBANK
147.0
mg/kg
147.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
26.0
mg/kg
26.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
16.0
mg/kg
16.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
75.5
%
75.5
%
DRUGBANK
82.0
%
82(75-89)
%
DRUGBANK
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
300.0
mg/day
300
mg/day
Capsule, PO, Oral;Liquid;
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
6.0
mg/day
6
mg/day
Tablet,PO，oral
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
300.0
mg/day
300
mg/day
Capsule, PO, Oral;Liquid;
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
6.0
mg/day
6
mg/day
Tablet,PO，oral
Doxepin Hydrochloride Capsules (10 mg, 25 mg, 50 mg, 75 mg, 100 mg)
doxepin hydrochloride
PDR
DDPD01143
Amifostine
214.223
C5H15N2O3PS
NCCCNCCSP(O)(O)=O
DB01143
2141
2636
http://www.drugs.com/cdi/amifostine.html
2056
-2.0
-
-2.0
-
DRUGBANK
1.839
L/h/kg
30.65
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.09
L/kg
0.09
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.133333333333333
h
8
min
DRUGBANK
0.15
h
0.15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
826.0
mg/kg
826.0
mg/kg
Rattus, Rat;
DRUGBANK
910.0
mg/m2
910
mg/m2
intravenous injection, IV
Ethyol
amifostine
PDR
910.0
mg/m2
910
mg/m2
intravenous injection, IV
Ethyol
amifostine
PDR
DDPD01144
Diclofenamide
305.159
C6H6Cl2N2O4S2
NS(=O)(=O)C1=CC(=C(Cl)C(Cl)=C1)S(N)(=O)=O
DB01144
3038
101085
http://www.drugs.com/mtm/dichlorphenamide.html
2930
-2.0
-
-2.0
-
DRUGBANK
55.0
%
55
%
DRUGBANK
DDPD01145
Sulfoxone
404.482
C14H16N2O6S3
OS(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1
DB01145
5351
135651
5158
-2.0
-
-2.0
-
DRUGBANK
5.5
h
3-8
h
DRUGBANK
7000.0
mg/kg
7000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
69.0
%
69
%
DRUGBANK
DDPD01146
Diphenylpyraline
281.392
C19H23NO
CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
DB01146
3103
59788
2992
-2.0
-
-2.0
-
DRUGBANK
99.0
%
>99
%
human, homo sapiens;
DRUGBANK
DDPD01147
Cloxacillin
435.881
C19H18ClN3O5S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl)C(O)=O
DB01147
6098
49566
http://www.drugs.com/mtm/cloxacillin.html
5873
-2.0
-
-2.0
-
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
1660.0
mg/kg
1660.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD01148
Flavoxate
391.4596
C24H25NO4
CC1=C(OC2=C(C=CC=C2C(=O)OCCN2CCCCC2)C1=O)C1=CC=CC=C1
DB01148
3354
5088
http://www.drugs.com/cdi/flavoxate.html
3237
-2.0
-
-2.0
-
DRUGBANK
4273.0
mg/kg
4273.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1837.0
mg/kg
1837.0
mg/kg
PO, oral; mouse;
DRUGBANK
57.0
%
57
%
Urinary excretion;
DRUGBANK
DDPD01149
Nefazodone
470.007
C25H32ClN5O2
CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
DB01149
T3D2995
4449
7494
http://www.drugs.com/cdi/nefazodone.html
4294
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
20.0
%
20
%
DRUGBANK
0.45
L/h/kg
7.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.545
L/kg
0.22-0.87
L/kg
DRUGBANK
0.51
L/kg
0.51
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
2-4
h
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Nefazodone
nefazodone hydrochloride
PDR
600.0
mg/day
600
mg/day
PO, oral
Nefazodone
nefazodone hydrochloride
PDR
600.0
mg/day
600
mg/day
PO, oral
Nefazodone
nefazodone hydrochloride
PDR
600.0
mg/day
600
mg/day
PO, oral
Nefazodone
nefazodone hydrochloride
PDR
DDPD01150
Cefprozil
389.426
C18H19N3O5S
[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O
DB01150
5281006
3506
http://www.drugs.com/cdi/cefprozil.html
4444481
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
DRUGBANK
0.18
L/h/kg
3.0
ml/min/kg
fasting;
DRUGBANK
0.174
L/h/kg
2.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23
L/kg
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
h
1.3
h
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
%
36
%
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Cefprozil
cefprozil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Cefprozil
cefprozil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Cefprozil
cefprozil
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Cefprozil
cefprozil
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Cefprozil
cefprozil
PDR
DDPD01151
Desipramine
266.3807
C18H22N2
CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12
DB01151
T3D2996
2995
47781
http://www.drugs.com/cdi/desipramine.html
2888
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
5.0
h
4-6
h
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
L/kg
15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
33.5
h
7-60
h
elimination half-life;
DRUGBANK
22.0
h
22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
290.0
mg/kg
290.0
mg/kg
Male, men; mouse;
DRUGBANK
320.0
mg/kg
320.0
mg/kg
Female, women; Rattus, Rat;
DRUGBANK
290.0
mg/kg
290.0
mg/kg
mouse;
DRUGBANK
320.0
mg/kg
320.0
mg/kg
Rattus, Rat;
DRUGBANK
70.0
%
70
%
Urinary excretion;
DRUGBANK
82.5
%
73-92
%
plasma proteins;
DRUGBANK
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Norpramin
desipramine hydrochloride
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Norpramin
desipramine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Norpramin
desipramine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Norpramin
desipramine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Norpramin
desipramine hydrochloride
PDR
150.0
mg/day
150
mg/day
PO, oral
Norpramin
desipramine hydrochloride
PDR
DDPD01152
Candicidin
1109.317
C59H84N2O18
CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(OC2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1
DB01152
3349
8255412
-2.0
-
-2.0
-
DRUGBANK
DDPD01153
Sertaconazole
437.77
C20H15Cl3N2OS
ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=CSC2=C1C=CC=C2Cl
DB01153
T3D2997
65863
83682
http://www.drugs.com/cdi/sertaconazole.html
59273
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
DDPD01154
Thiamylal
254.349
C12H18N2O2S
CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O
DB01154
3032285
9536
2297298
-2.0
-
-2.0
-
DRUGBANK
14.3
h
14.3
h
cat;
DRUGBANK
51.0
mg/kg
51.0
mg/kg
intravenous injection, IV;
DRUGBANK
DDPD01155
Gemifloxacin
389.3809
C18H20FN5O4
CO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
DB01155
9571107
101853
http://www.drugs.com/cdi/gemifloxacin.html
7845573
-2.0
-
-2.0
-
DRUGBANK
71.0
%
71
%
PO, oral;
DRUGBANK
10.0
%
10
%
Liver metabolism;
DRUGBANK
11.6
L/h
11.6±3.9
L/h
Renal clearance; Oral multiple dose; normal,healthy;
DRUGBANK
6.89
L/kg
1.66-12.12
L/kg
DRUGBANK
7.0
h
7±2
h
DRUGBANK
61.0
%
61±9.5
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
36.0
%
36±9.3
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
65.0
%
60-70
%
DRUGBANK
DDPD01156
Bupropion
239.741
C13H18ClNO
CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
DB01156
T3D2999
444
3219
http://www.drugs.com/bupropion.html
431
-2.0
-
-2.0
-
DRUGBANK
141.0
ng/ml
141±19
ng/ml
Oral single dose; immediate release formulation; Male, men; adults; normal,healthy;
DRUGBANK
142.0
ng/ml
142±28
ng/ml
Oral single dose; Sustained Release formulation; Male, men; adults; normal,healthy;
DRUGBANK
2.0
h
2
h
Tablet, PO, oral; immediate release formulation;
DRUGBANK
3.0
h
3
h
Tablet, PO, oral; Sustained Release formulation;
DRUGBANK
5.0
h
5
h
Tablet, PO, oral; extended release formulation;
DRUGBANK
1.6
h
1.6±0.1
h
Oral single dose; immediate release formulation; Male, men; adults; normal,healthy;
DRUGBANK
3.1
h
3.1±0.3
h
Oral single dose; Sustained Release formulation; Male, men; adults; normal,healthy;
DRUGBANK
2.16
L/h/kg
36.0±2.2
ml/min/kg
apparent clearance; hydrolysis; normal,healthy; Male, men; adults;
Elderly ↓ ;Hepatitis, Hep ↓ ;Alcohol → ;
DRUGBANK
18.6
L/kg
18.6±1.2
L/kg
Steady state volume of distribution; at steady state; hydrolysis; normal,healthy; Male, men; adults;
Alcohol → ;
DRUGBANK
24.0
h
24
h
DRUGBANK
11.0
h
11±1(7.9-18.4)
h
normal,healthy; PO, oral; terminal half-life; adults; Female, women;
alcoholic liver disease ↑ ;Age ↑ ;
DRUGBANK
87.0
%
87
%
Urinary excretion; PO, oral; human, homo sapiens;
DRUGBANK
10.0
%
10
%
Faeces excretion; PO, oral; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
84.0
%
84
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
80.0
%
>80
%
adults; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
300.0
mg/day
300
mg/day
Tablet,PO，oral
Wellbutrin XL
bupropion hydrochloride
PDR
450.0
mg/day
450
mg/day
Tablet,PO，oral
Wellbutrin XL
bupropion hydrochloride
PDR
150.0
mg/dose
150
mg/dose
Tablet,PO，oral
Wellbutrin XL
bupropion hydrochloride
PDR
400.0
mg/day
400
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
200.0
mg/dose
200
mg/dose
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
150.0
mg/dose
150
mg/dose
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
450.0
mg/day
450
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
522.0
mg/day
522
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
522.0
mg/dose
522
mg/dose
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
450.0
mg/day
450
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
300.0
mg/day
300
mg/day
Tablet,PO，oral
Wellbutrin XL
bupropion hydrochloride
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
450.0
mg/day
450
mg/day
Tablet,PO，oral
Wellbutrin XL
bupropion hydrochloride
PDR
150.0
mg/dose
150
mg/dose
Tablet,PO，oral
Wellbutrin XL
bupropion hydrochloride
PDR
400.0
mg/day
400
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
200.0
mg/dose
200
mg/dose
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
150.0
mg/dose
150
mg/dose
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
450.0
mg/day
450
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
522.0
mg/day
522
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
522.0
mg/dose
522
mg/dose
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
450.0
mg/day
450
mg/day
PO, oral
Wellbutrin XL
bupropion hydrochloride
PDR
DDPD01157
Trimetrexate
369.4176
C19H23N5O3
COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC
DB01157
T3D3000
5583
9737
http://www.drugs.com/cdi/trimetrexate.html
5381
-2.0
-
-2.0
-
DRUGBANK
2.28
L/h/m2
38±15
ml/min/m2
intravenous injection, IV; Drug combination; AIDS,HIV; Pneumonia, Pneu;
DRUGBANK
3.18
L/h/m2
53±41
ml/min/m2
tumor; patients;
DRUGBANK
1.8
L/h/m2
30±8
ml/min/m2
tumor; patients;
DRUGBANK
0.0462
L/h/kg
0.77
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L/m2
20±8
L/m2
DRUGBANK
36.9
L/m2
36.9±6
L/m2
tumor; patients;
DRUGBANK
0.77
L/kg
0.77
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.5
h
11-20
h
DRUGBANK
17.0
h
17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.0
mg/kg
62.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
62.0
mg/kg
62.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
20.0
%
10-30
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD01158
Bretylium
243.163
C11H17BrN
CC[N+](C)(C)CC1=CC=CC=C1Br
DB01158
2431
3172
2337
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
human, homo sapiens; animals;
DRUGBANK
7.8
h
7.8±0.6(6.9-8.1)
h
terminal half-life; normal,healthy;
DRUGBANK
13.0
h
13
h
DRUGBANK
400.0
mg/kg
400.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD01159
Halothane
197.382
C2HBrClF3
[H]C(Cl)(Br)C(F)(F)F
DB01159
T3D3001
3562
5615
3441
-2.0
-
-2.0
-
DRUGBANK
DDPD01160
Dinoprost tromethamine
475.616
C24H45NO8
NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
DB01160
5282415
31502
4445570
-2.0
-
-2.0
-
DRUGBANK
4.5
h
3-6
h
DRUGBANK
0.0166666666666667
h
<1
min
elimination half-life; intravenous injection, IV;
DRUGBANK
DDPD01161
Chloroprocaine
270.755
C13H19ClN2O2
CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1
DB01161
T3D3003
8612
3636
8293
-2.0
-
-2.0
-
DRUGBANK
0.00583333333333333
h
21±2
second
DRUGBANK
97.0
mg/kg
97.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
950.0
mg/kg
950.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
97.0
mg/kg
97.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
950.0
mg/kg
950.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
11.0
mg/kg
11
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
11.0
mg/kg
11
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
50.0
mg/dose
50
mg/dose
intrathecal administration
Nesacaine
chloroprocaine hydrochloride
PDR
11.0
mg/kg
11
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
800.0
mg/dose
800
mg/dose
Nesacaine
chloroprocaine hydrochloride
PDR
14.0
mg/kg
14
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
1000.0
mg
1000
mg
Nesacaine
chloroprocaine hydrochloride
PDR
50.0
mg/dose
50
mg/dose
Nesacaine
chloroprocaine hydrochloride
PDR
11.0
mg/kg
11
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
800.0
mg/dose
800
mg/dose
Nesacaine
chloroprocaine hydrochloride
PDR
14.0
mg/kg
14
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
1000.0
mg
1000
mg
Nesacaine
chloroprocaine hydrochloride
PDR
11.0
mg/kg
11
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
11.0
mg/kg
11
mg/kg
Nesacaine
chloroprocaine hydrochloride
PDR
DDPD01162
Terazosin
387.4329
C19H25N5O4
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1
DB01162
T3D3537
5401
9445
http://www.drugs.com/terazosin.html
5208
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
DRUGBANK
82.0
%
82.0
%
PO, oral;
DRUGBANK
16.0
ng/ml
16.0
ng/ml
Tablet, PO, oral; normal,healthy;
DRUGBANK
1.7
h
1.7
h
Tablet, PO, oral; normal,healthy;
DRUGBANK
4.8
L/h
80.0
ml/min
Plasma clearance;
DRUGBANK
0.6
L/h
10.0
ml/min
Renal clearance;
DRUGBANK
0.069
L/h/kg
1.1-1.2
ml/min/kg
DRUGBANK
0.066
L/h/kg
1.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
27.5
L
25-30
L
DRUGBANK
1.1
L/kg
1.1
L/kg
Plasma clearance; hypertension; patients;
DRUGBANK
0.98
L/kg
0.98
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
DRUGBANK
14.0
h
14
h
Geriatric;
DRUGBANK
11.4
h
11.4
h
adults;
DRUGBANK
10.5
h
9-12
h
DRUGBANK
9.0
h
9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5500.0
mg/kg
5500.0
mg/kg
PO, oral; mouse;
DRUGBANK
259.3
mg/kg
259.3
mg/kg
intravenous injection, IV; parenteral administration; mouse;
DRUGBANK
40.0
%
40
%
Urinary excretion; PO, oral;
DRUGBANK
60.0
%
60
%
Faeces excretion; PO, oral;
DRUGBANK
10.0
%
~10
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
12.5
%
11-14
%
Urinary excretion; Unchanged drug;
DRUGBANK
92.0
%
90-94
%
DRUGBANK
92.0
%
90-94
%
DRUGBANK
DDPD01164
Calcium chloride
110.984
CaCl2
[Cl-].[Cl-].[Ca++]
DB01164
5284359
3312
23237
-2.0
-
-2.0
-
DRUGBANK
DDPD01165
Ofloxacin
361.3675
C18H20FN3O4
CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
DB01165
4583
7731
http://www.drugs.com/cdi/ofloxacin-drops.html
4422
-2.0
-
-2.0
-
DRUGBANK
98.0
%
98
%
DRUGBANK
0.15
L/h/kg
2.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.0
h
9
h
DRUGBANK
8.9
h
8.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5450.0
mg/kg
5450.0
mg/kg
PO, oral; mouse;
DRUGBANK
6.0
%
~4-8
%
Faeces excretion;
DRUGBANK
72.5
%
65-80
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
32.0
%
32
%
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral;intravenous injection, IV;
Ocuflox
ofloxacin
PDR
800.0
mg/day
800
mg/day
PO, oral;intravenous injection, IV;
Ocuflox
ofloxacin
PDR
DDPD01166
Cilostazol
369.4607
C20H27N5O2
O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2
DB01166
2754
31401
http://www.drugs.com/cdi/cilostazol.html
2652
-2.0
-
-2.0
-
DRUGBANK
12.0
h
11-13
h
DRUGBANK
5000.0
mg/kg
>5.0
g/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
>2.0
g/kg
PO, oral; dog;
DRUGBANK
74.0
%
74
%
Urinary excretion;
DRUGBANK
20.0
%
20
%
Faeces excretion;
DRUGBANK
96.5
%
95-98
%
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Pletal
cilostazol
PDR
200.0
mg/day
200
mg/day
PO, oral
Pletal
cilostazol
PDR
DDPD01167
Itraconazole
705.633
C35H38Cl2N8O4
CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
DB01167
T3D3516
55283
6076
http://www.drugs.com/cdi/itraconazole.html
49927
-2.0
-
-2.0
-
DRUGBANK
55.0
%
55
%
DRUGBANK
55.0
%
55.0
%
PO, oral;
DRUGBANK
649.0
ng/ml
649±289
ng/ml
PO, oral; adults;
DRUGBANK
4.0
h
3-5
h
PO, oral; adults;
DRUGBANK
22.86
L/h
381±95
ml/min
intravenous injection, IV;
DRUGBANK
1.38
L/h/kg
23±10
ml/min/kg
apparent clearance;
DRUGBANK
0.306
L/h/kg
5.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
796.0
L
796±185
L
DRUGBANK
14.0
L/kg
14±5
L/kg
Apparent volume of distribution;
DRUGBANK
7.4
L/kg
7.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.0
h
21
h
DRUGBANK
21.0
h
21±6
h
non-saturable concentration;
DRUGBANK
64.0
h
64
h
at steady state;
DRUGBANK
25.0
h
25
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.8
%
99.8
%
DRUGBANK
99.8
%
99.8
%
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
400.0
mg/day
400
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral;Liquid;
Sporanox Oral Solution
itraconazole
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Sporanox Oral Solution
itraconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
260.0
mg/day
260
mg/day
Capsule, PO, Oral
Sporanox Oral Solution
itraconazole
PDR
390.0
mg/day
390
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
400.0
mg/day
400
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral;Liquid;
Sporanox Oral Solution
itraconazole
PDR
400.0
mg/day
400
mg/day
Capsule, PO, Oral
Sporanox Oral Solution
itraconazole
PDR
600.0
mg/day
600
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
260.0
mg/day
260
mg/day
Capsule, PO, Oral
Sporanox Oral Solution
itraconazole
PDR
390.0
mg/day
390
mg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Sporanox Oral Solution
itraconazole
PDR
DDPD01168
Procarbazine
221.2988
C12H19N3O
CNNCC1=CC=C(C=C1)C(=O)NC(C)C
DB01168
T3D4711
4915
71417
http://www.drugs.com/cdi/procarbazine.html
4746
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
0.166666666666667
h
10
min
DRUGBANK
785.0
mg/kg
785.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
785.0
mg/kg
785.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Matulane
procarbazine hydrochloride
PDR
100.0
mg/m2/day
100
mg/m2/day
PO, oral
Matulane
procarbazine hydrochloride
PDR
DDPD01169
Arsenic trioxide
197.84
As2O3
O=[As]O[As]=O
DB01169
T3D0224
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
261004
http://www.drugs.com/cdi/arsenic.html
229103
-2.0
-
-2.0
-
DRUGBANK
871.0
mg/kg
871.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
31.5
mg/kg
31 500
ug/kg
PO, oral; mouse;
DRUGBANK
9.8
mg/kg
9800.0
ug/kg
subcutaneous injection, SC; mouse;
DRUGBANK
10.7
mg/kg
10 700
ug/kg
intravenous injection, IV; mouse;
DRUGBANK
0.005
mg/kg/day
0.005
mg/kg/day
PO, oral;
DRUGBANK
0.0003
mg/kg/day
0.0003
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
1e-05
mg/L
0.01
mg/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
75.0
%
75
%
DRUGBANK
0.15
mg/kg/day
0.15
mg/kg/day
intravenous injection, IV
qd
Trisenox
arsenic trioxide
PDR
0.15
mg/kg/day
0.15
mg/kg/day
intravenous injection, IV
qd
Trisenox
arsenic trioxide
PDR
0.15
mg/kg/day
0.15
mg/kg/day
intravenous injection, IV
qd
Trisenox
arsenic trioxide
PDR
0.15
mg/kg/day
0.15
mg/kg/day
intravenous injection, IV
qd
Trisenox
arsenic trioxide
PDR
DDPD01170
Guanethidine
198.3085
C10H22N4
NC(N)=NCCN1CCCCCCC1
DB01170
3518
5557
http://www.drugs.com/mtm/guanethidine.html
3398
-2.0
-
-2.0
-
DRUGBANK
16.5
%
3-30
%
PO, oral;
DRUGBANK
3.36
L/h
56.0
ml/min
Renal clearance;
DRUGBANK
36.0
h
1.5
day
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD01171
Moclobemide
268.739
C13H17ClN2O2
[H]C1COCCN1CCNC(=O)C1=CC=C(Cl)C=C1
DB01171
T3D3004
4235
83531
4087
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
PO, oral;
DRUGBANK
56.0
%
56
%
PO, oral;
DRUGBANK
90.0
%
90
%
PO, oral; increasing doses;
DRUGBANK
0.65
h
0.3-1
h
PO, oral;
DRUGBANK
100.0
%
~100
%
Liver metabolism;
DRUGBANK
54.0
L/h
30-78
L/h
Urinary excretion;
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.25
L/kg
1-1.5
L/kg
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
4.0
h
4
h
Hepatitis, Hep;
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
730.0
mg/kg
730.0
mg/kg
mouse;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
Rattus, Rat;
DRUGBANK
730.0
mg/kg
730.0
mg/kg
mouse;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
Rattus, Rat;
DRUGBANK
100.0
%
~100
%
Urinary excretion;
DRUGBANK
50.0
%
~50
%
DRUGBANK
DDPD01172
Kanamycin
484.4986
C18H36N4O11
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
DB01172
6032
17630
http://www.drugs.com/cdi/kanamycin.html
5810
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
IM,intramuscular injection;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.26
L/kg
0.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17500.0
mg/kg
17500.0
mg/kg
PO, oral; mouse;
DRUGBANK
4000.0
mg/kg
>4
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
3000.0
mg/kg
>3
g/kg
PO, oral; rabbit;
DRUGBANK
DDPD01173
Orphenadrine
269.3813
C18H23NO
CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C
DB01173
T3D3005
4601
7789
http://www.drugs.com/cdi/orphenadrine.html
4440
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
16.5
h
13-20
h
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; mouse;
DRUGBANK
255.0
mg/kg
255.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; mouse;
DRUGBANK
255.0
mg/kg
255.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
95.0
%
95
%
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Orphenadrine Citrate Extended-Release Tablets
orphenadrine citrate
PDR
120.0
mg/day
120
mg/day
intravenous injection, IV;IM,intramuscular injection;
Orphenadrine Citrate Extended-Release Tablets
orphenadrine citrate
PDR
200.0
mg/day
200
mg/day
PO, oral
Orphenadrine Citrate Extended-Release Tablets
orphenadrine citrate
PDR
120.0
mg/day
120
mg/day
intravenous injection, IV;IM,intramuscular injection;
Orphenadrine Citrate Extended-Release Tablets
orphenadrine citrate
PDR
DDPD01174
Phenobarbital
232.2353
C12H12N2O3
CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
DB01174
T3D3006
4763
8069
http://www.drugs.com/cdi/phenobarbital.html
4599
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100±11
%
PO, oral;
DRUGBANK
13100.0
ng/ml
13.1±4.5
mcg/ml
PO, oral; epilepsy;
DRUGBANK
3.0
h
2-4
h
PO, oral; epilepsy;
DRUGBANK
0.00372
L/h/kg
0.062±0.013
ml/min/kg
Neonates ↑ ;Children ↑ ;Preg, pregnant ↑ ;Somking → ;
DRUGBANK
0.00378
L/h/kg
0.063
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.54
L/kg
0.54±0.03
L/kg
Neonates ↑ ;
DRUGBANK
0.54
L/kg
0.54
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
79.0
h
79(53-118)
h
DRUGBANK
99.0
h
99±18
h
Children ↓ ;Neonates → ;Hepatic cirrhosis, cirr ↑ ;epilepsy → ;Age ↑ ;
DRUGBANK
99.0
h
99
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
%
24±5
%
Urinary excretion; Unchanged drug;
Hepatitis, Hep → ;acute viral hepatitis AVH → ;
DRUGBANK
32.5
%
20-45
%
DRUGBANK
51.0
%
51±3
%
Neonates ↓ ;Preg, pregnant → ;Elderly → ;
DRUGBANK
20.0
mg/kg/dose
20
mg/kg/dose
intravenous injection, IV
Phenobarbital Elixir
phenobarbital
PDR
1000.0
mg/dose
1000
mg/dose
intravenous injection, IV
Phenobarbital Elixir
phenobarbital
PDR
1.0
mg/kg/day
8
mg/kg/day
Phenobarbital Elixir
phenobarbital
PDR
1.0
mg/kg/day
10
mg/kg/day
Phenobarbital Elixir
phenobarbital
PDR
200.0
mg/day
200
mg/day
PO, oral
Phenobarbital Elixir
phenobarbital
PDR
20.0
mg/kg/dose
20
mg/kg/dose
intravenous injection, IV
Phenobarbital Elixir
phenobarbital
PDR
1000.0
mg/dose
1000
mg/dose
intravenous injection, IV
Phenobarbital Elixir
phenobarbital
PDR
6.0
mg/kg/day
6
mg/kg/day
Phenobarbital Elixir
phenobarbital
PDR
200.0
mg/day
200
mg/day
PO, oral
Phenobarbital Elixir
phenobarbital
PDR
20.0
mg/kg/dose
20
mg/kg/dose
intravenous injection, IV
Phenobarbital Elixir
phenobarbital
PDR
10.0
mg/kg/day
10
mg/kg/day
Phenobarbital Elixir
phenobarbital
PDR
20.0
mg/kg/dose
20
mg/kg/dose
intravenous injection, IV
Phenobarbital Elixir
phenobarbital
PDR
5.0
mg/kg/day
5
mg/kg/day
Phenobarbital Elixir
phenobarbital
PDR
DDPD01175
Escitalopram
324.3919
C20H21FN2O
CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
DB01175
T3D3007
146570
36791
http://www.drugs.com/cdi/escitalopram.html
129277
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
360.0
ng.h/ml
360.0
ng.h/ml
PO, oral; patients;
DRUGBANK
1080.0
ng.h/ml
1080.0
ng.h/ml
PO, oral; patients;
DRUGBANK
80.0
%
~80
%
PO, oral;
DRUGBANK
21.0
ng/ml
21
ng/ml
PO, oral; patients;
DRUGBANK
63.0
ng/ml
63
ng/ml
PO, oral; patients;
DRUGBANK
4.5
h
4-5
h
PO, oral;
DRUGBANK
36.0
L/h
600.0
ml/min
Plasma clearance; PO, oral;
DRUGBANK
19.0
L/kg
~12-26
L/kg
Apparent volume of distribution;
DRUGBANK
29.5
h
27-32
h
elimination half-life;
DRUGBANK
44.25
h
40.5-48
h
adults;
DRUGBANK
59.0
h
54-64
h
hepatopathy，LD;
DRUGBANK
54.0
h
~54
h
elimination half-life; at steady state;
DRUGBANK
8.0
%
~8
%
Urinary excretion; PO, oral;
DRUGBANK
8.0
%
~8
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
55.5
%
~55-56
%
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Lexapro
escitalopram oxalate
PDR
20.0
mg/day
20
mg/day
PO, oral
Lexapro
escitalopram oxalate
PDR
20.0
mg/day
20
mg/day
PO, oral
Lexapro
escitalopram oxalate
PDR
20.0
mg/day
20
mg/day
PO, oral
Lexapro
escitalopram oxalate
PDR
10.0
mg/day
10
mg/day
PO, oral
Lexapro
escitalopram oxalate
PDR
DDPD01176
Cyclizine
266.3807
C18H22N2
CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
DB01176
6726
3994
http://www.drugs.com/cdi/cyclizine.html
6470
-2.0
-
-2.0
-
DRUGBANK
0.87
L/h/kg
14.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.5
L/kg
16.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
h
20
h
DRUGBANK
13.53
h
13.53
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01177
Idarubicin
497.4939
C26H27NO9
C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O
DB01177
42890
42068
http://www.drugs.com/cdi/idarubicin.html
39117
-2.0
-
-2.0
-
DRUGBANK
28.0
%
28±4
%
PO, oral; tumor;
DRUGBANK
6.9
ng/ml
6.9±0.1
ng/ml
Oral single dose; tumor;
DRUGBANK
22.0
ng/ml
22±4
ng/ml
Oral single dose; Active metabolite; tumor;
DRUGBANK
5.4
h
5.4±2.4
h
Oral single dose; tumor;
DRUGBANK
7.9
h
7.9±2.3
h
Oral single dose; Active metabolite; tumor;
DRUGBANK
1.74
L/h/kg
29±10
ml/min/kg
mild renal function ↓ ;moderate renal function ↓ ;
DRUGBANK
1.44
L/h/kg
24
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.7
L/kg
24.7±5.9
L/kg
DRUGBANK
38.0
L/kg
38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
22
h
DRUGBANK
15.2
h
15.2±3.7
h
DRUGBANK
41.0
h
41±10
h
mild renal function ↑ ;moderate renal function ↑ ;
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
<5
%
Urinary excretion; tumor; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
97.0
%
97
%
tumor; human, homo sapiens;
DRUGBANK
94.0
%
94
%
Active metabolite; tumor; human, homo sapiens;
DRUGBANK
12.0
mg/m2
12
mg/m2
intravenous injection, IV
Idamycin PFS
idarubicin hydrochloride
PDR
12.0
mg/m2
12
mg/m2
intravenous injection, IV
Idamycin PFS
idarubicin hydrochloride
PDR
12.0
mg/m2
12
mg/m2
intravenous injection, IV
Idamycin PFS
idarubicin hydrochloride
PDR
12.0
mg/m2
12
mg/m2
intravenous injection, IV
Idamycin PFS
idarubicin hydrochloride
PDR
DDPD01178
Chlormezanone
273.736
C11H12ClNO3S
CN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O
DB01178
T3D3009
2717
3619
2616
-2.0
-
-2.0
-
DRUGBANK
DDPD01179
Podofilox
414.4053
C22H22O8
[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O
DB01179
T3D4617
10607
50305
http://www.drugs.com/cdi/podofilox-gel.html
10162
-2.0
-
-2.0
-
DRUGBANK
9.0
ng/ml
1-17
ng/ml
skin/dermal;
DRUGBANK
1.5
h
1-2
h
skin/dermal;
DRUGBANK
2.75
h
1.0-4.5
h
DRUGBANK
500.0
mg/day
0.5
g/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
0.5
ml/day
0.5
ml/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
500.0
mg/day
0.5
g/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
0.5
ml/day
0.5
ml/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
500.0
mg/day
0.5
g/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
0.5
ml/day
0.5
ml/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
500.0
mg/day
0.5
g/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
0.5
ml/day
0.5
ml/day
skin/dermal
Condylox Topical Solution
podofilox
PDR
DDPD01180
Rescinnamine
634.716
C35H42N2O9
[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2
DB01180
32681
28572
4444446
-2.0
-
-2.0
-
DRUGBANK
DDPD01181
Ifosfamide
261.086
C7H15Cl2N2O2P
ClCCNP1(=O)OCCCN1CCCl
DB01181
T3D3513
3690
5864
http://www.drugs.com/cdi/ifosfamide-solution.html
3562
-2.0
-
-2.0
-
DRUGBANK
92.0
%
92.0
%
PO, oral;
DRUGBANK
52217200.0
ng/ml
200（163-245）
mM
PO, oral; Advanced tumors;
DRUGBANK
53000458.0
ng/ml
203(168-232)
mM
intravenous injection, IV; Advanced tumors;
DRUGBANK
0.75
h
0.5-1.0
h
PO, oral; Advanced tumors;
DRUGBANK
2.4
L/h/m2
2.4±0.33
L/h/m2
pediatric patients;
DRUGBANK
3.78
L/h/m2
63.0
ml/min/m2
Elderly → ;
DRUGBANK
0.372
L/h/m2
6.2±1.9
ml/min/m2
Elderly → ;
DRUGBANK
0.066
L/h/kg
1.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.64
L/kg
0.64
L/kg
Average volume of distribution; intravenous injection, IV; tumor;
DRUGBANK
0.72
L/kg
0.72
L/kg
Average volume of distribution; intravenous injection, IV; tumor;
DRUGBANK
21.0
L/m2
21±1.6
L/m2
Average volume of distribution; pediatric patients;
DRUGBANK
12.5
L/m2
12.5±3.6
L/m2
DRUGBANK
0.62
L/kg
0.62
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
7-15
h
Age ↑ ;
DRUGBANK
5.6
h
5.6
h
Male, men; Female, women; patients; Advanced tumors; intravenous injection, IV;
Age ↑ ;
DRUGBANK
15.2
h
15.2±3.6
h
Male, men; Female, women; patients; Advanced tumors; intravenous injection, IV;
Age ↑ ;
DRUGBANK
6.6
h
6.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
697.5
mg/kg
390-1005
mg/kg
mouse;
DRUGBANK
170.0
mg/kg
150-190
mg/kg
Rattus, Rat;
DRUGBANK
697.5
mg/kg
390-1005
mg/kg
mouse;
DRUGBANK
170.0
mg/kg
150-190
mg/kg
Rattus, Rat;
DRUGBANK
78.0
%
70-86
%
Urinary excretion;
DRUGBANK
61.0
%
~61
%
Urinary excretion; Unchanged drug;
DRUGBANK
15.0
%
12-18
%
Urinary excretion; intravenous injection, IV; Advanced tumors; Unchanged drug;
DRUGBANK
53.1
%
53.1±9.6
%
Urinary excretion; intravenous injection, IV; Advanced tumors; Unchanged drug;
DRUGBANK
0.0
%
~0
%
Advanced tumors; human, homo sapiens;
DRUGBANK
3000.0
mg/m2
3000
mg/m2
intravenous injection, IV
Ifex
ifosfamide
PDR
1200.0
mg/m2
1200
mg/m2
intravenous injection, IV; 5d/per 21d
Ifex
ifosfamide
PDR
5000.0
mg/m2
5000
mg/m2
intravenous injection, IV
Ifex
ifosfamide
PDR
1200.0
mg/m2
1200
mg/m2
intravenous injection, IV
Ifex
ifosfamide
PDR
5000.0
mg/m2
5000
mg/m2
intravenous injection, IV
Ifex
ifosfamide
PDR
3000.0
mg/m2
3000
mg/m2
intravenous injection, IV
Ifex
ifosfamide
PDR
DDPD01182
Propafenone
341.444
C21H27NO3
CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
DB01182
4932
63619
http://www.drugs.com/cdi/propafenone.html
4763
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
DRUGBANK
27.5
%
5-50
%
DRUGBANK
3.4
%
3.4
%
Tablet, PO, oral;
DRUGBANK
10.6
%
10.6
%
Tablet, PO, oral;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
252.0
L
252.0
L
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
2-10
h
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
97.0
%
97
%
DRUGBANK
600.0
mg/m2/day
600
mg/m2/day
Tablet,PO，oral
Rythmol
propafenone hydrochloride
PDR
900.0
mg/day
900
mg/day
Tablet,PO，oral
Rythmol
propafenone hydrochloride
PDR
850.0
mg/day
850
mg/day
Capsule, PO, Oral
Rythmol
propafenone hydrochloride
PDR
600.0
mg/m2/day
600
mg/m2/day
Tablet,PO，oral
Rythmol
propafenone hydrochloride
PDR
900.0
mg/day
900
mg/day
Tablet,PO，oral
Rythmol
propafenone hydrochloride
PDR
850.0
mg/day
850
mg/day
Capsule, PO, Oral
Rythmol
propafenone hydrochloride
PDR
DDPD01183
Naloxone
327.3743
C19H21NO4
OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
DB01183
5284596
7459
http://www.drugs.com/cdi/naloxone.html
4447644
-2.0
-
-2.0
-
DRUGBANK
2.0
%
~2
%
PO, oral;
DRUGBANK
0.88
ng/ml
0.88
ng/ml
IM,intramuscular injection;
DRUGBANK
2.91
ng/ml
2.91
ng/ml
nasal spray;
DRUGBANK
4.83
ng/ml
4.83
ng/ml
nasal spray;
DRUGBANK
10.0
ng/ml
10±1
ng/ml
adults; normal,healthy;
DRUGBANK
0.38
h
0.38
h
IM,intramuscular injection;
DRUGBANK
0.33
h
0.33
h
nasal spray;
DRUGBANK
0.5
h
0.5
h
nasal spray;
DRUGBANK
1.32
L/h/kg
22.0
ml/min/kg
Neonates ↑ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
1.38
L/h/kg
23
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
L/kg
2.1
L/kg
Neonates ↑ ;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.24
h
1.24
h
IM,intramuscular injection;
DRUGBANK
1.85
h
1.85
h
nasal spray;
DRUGBANK
2.08
h
2.08
h
nasal spray;
DRUGBANK
1.1
h
1.1±0.6
h
Neonates → ;
DRUGBANK
0.08
h
4.8(2-10)
min
distribution half-life;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
150.0
mg/kg
150±5
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
109.0
mg/kg
109±4
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
0.0
%
~0
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/day
0.1
mg/kg/day
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intraosseous;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/day
0.1
mg/kg/day
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (1 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/day
0.1
mg/kg/day
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
2.0
mg/dose
2
mg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/day
0.1
mg/kg/day
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;intratracheally;subcutaneous injection, SC;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
1.0
spray/dose
1
spray/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
4.0
mg/dose
4
mg/dose
nasal spray
Naloxone Hydrochloride Injection (0.4 mg/mL)
naloxone hydrochloride
PDR
DDPD01184
Domperidone
425.911
C22H24ClN5O2
ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2
DB01184
3151
31515
3039
-2.0
-
-2.0
-
DRUGBANK
0.57
L/h/kg
9.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.4
L/kg
3.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
7
h
DRUGBANK
7.5
h
7.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
92.0
%
91-93
%
DRUGBANK
DDPD01185
Fluoxymesterone
336.4409
C20H29FO3
[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB01185
T3D3010
6446
5120
http://www.drugs.com/cdi/fluoxymesterone.html
6205
-2.0
-
-2.0
-
DRUGBANK
44.0
%
<44
%
PO, oral;
DRUGBANK
9.2
h
9.2
h
DRUGBANK
99.0
%
99
%
DRUGBANK
19.0
%
19
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Androxy
fluoxymesterone
PDR
20.0
mg/day
20
mg/day
PO, oral
Androxy
fluoxymesterone
PDR
40.0
mg/day
40
mg/day
PO, oral
Androxy
fluoxymesterone
PDR
DDPD01186
Pergolide
314.488
C19H26N2S
[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC
DB01186
T3D3011
47811
63617
http://www.drugs.com/cdi/pergolide-mesylate.html
43503
-2.0
-
-2.0
-
DRUGBANK
27.0
h
27
h
DRUGBANK
15.0
mg/kg
15.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
mg/kg
15.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD01187
Iophendylate
416.3368
C19H29IO2
CCOC(=O)CCCCCCCCC(C)C1=CC=CC=C1I
DB01187
3037234
2301035
-2.0
-
-2.0
-
DRUGBANK
DDPD01188
Ciclopirox
207.2689
C12H17NO2
CC1=CC(=O)N(O)C(=C1)C1CCCCC1
DB01188
T3D3012
2749
453011
http://www.drugs.com/cdi/ciclopirox-cream.html
2647
-2.0
-
-2.0
-
DRUGBANK
1.7
h
1.7
h
skin/dermal;
DRUGBANK
10.0
ml/kg
>10
ml/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
ml/kg
>10
ml/kg
PO, oral; Rattus, Rat;
DRUGBANK
96.0
%
~96
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
95.5
%
94-97
%
skin/dermal;
DRUGBANK
DDPD01189
Desflurane
168.0378
C3H2F6O
FC(F)OC(F)C(F)(F)F
DB01189
T3D3013
42113
4445
http://www.drugs.com/cons/desflurane-inhalation-oral-nebulization.html
38403
-2.0
-
-2.0
-
DRUGBANK
0.02
%
0.02
%
Liver metabolism;
DRUGBANK
312.0
mg/kg
312.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
DDPD01190
Clindamycin
424.983
C18H33ClN2O5S
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
DB01190
T3D3497
446598
3745
http://www.drugs.com/clindamycin.html
393915
-2.0
-
-2.0
-
DRUGBANK
11000.0
ng.h/ml
11.0
ug.h/ml
Oral single dose;
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
87.0
%
~87
%
PO, oral;
DRUGBANK
2500.0
ng/ml
2.5
ug/ml
PO, oral;
DRUGBANK
17200.0
ng/ml
17.2±3.5
mcg/ml
intravenous injection, IV; Male, men; adults; normal,healthy;
DRUGBANK
2500.0
ng/ml
2.5
mcg/ml
PO, oral; adults;
DRUGBANK
0.75
h
0.75
h
PO, oral;
DRUGBANK
14.85
L/h
12.3-17.4
L/h
Plasma clearance;
Hepatitis, Hep ↓ ;
DRUGBANK
0.282
L/h/kg
4.7±1.3
ml/min/kg
Children → ;
DRUGBANK
0.27
L/h/kg
4.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
58.5
L
43-74
L
DRUGBANK
1.1
L/kg
1.1±0.3
L/kg
Children → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.79
L/kg
0.79
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
adults;
DRUGBANK
2.5
h
2.5
h
Children;
DRUGBANK
4.0
h
~4
h
Elderly;
DRUGBANK
2.9
h
2.9±0.7
h
Children → ;Preg, pregnant → ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2540.0
mg/kg
2540.0
mg/kg
PO, oral; mouse;
DRUGBANK
2190.0
mg/kg
2190.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
13.0
%
13
%
Urinary excretion; Unchanged drug;
DRUGBANK
77.0
%
60-94
%
DRUGBANK
93.6
%
93.6±0.2
%
DRUGBANK
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cleocin T
clindamycin phosphate
PDR
2700.0
mg/day
2700
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
2400.0
mg/day
2400
mg/day
IM,intramuscular injection
Cleocin T
clindamycin phosphate
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
2.0
application/day
2
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cleocin T
clindamycin phosphate
PDR
2700.0
mg/day
2700
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
2400.0
mg/day
2400
mg/day
IM,intramuscular injection
Cleocin T
clindamycin phosphate
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
2700.0
mg/day
2700
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
4800.0
mg/day
4800
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
2400.0
mg/day
2400
mg/day
IM,intramuscular injection
Cleocin T
clindamycin phosphate
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
2.0
appLication/day
2
appLication/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
appLication/day
1
appLication/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
appLicatorfuL/day
1
appLicatorfuL/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
appLicatorfuL/day
1
appLicatorfuL/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
ovuLe/day
1
ovuLe/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
2700.0
mg/day
2700
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
2400.0
mg/day
2400
mg/day
IM,intramuscular injection
Cleocin T
clindamycin phosphate
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
2.0
application/day
2
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
applicatorful/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
applicatorful/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
ovule/day
1
ovule/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cleocin T
clindamycin phosphate
PDR
2700.0
mg/day
2700
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
2400.0
mg/day
2400
mg/day
IM,intramuscular injection
Cleocin T
clindamycin phosphate
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
2.0
application/day
2
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
applicatorful/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
applicatorful/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
ovule/day
1
ovule/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
2700.0
mg/day
2700
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
4800.0
mg/day
4800
mg/day
intravenous injection, IV
Cleocin T
clindamycin phosphate
PDR
2400.0
mg/day
2400
mg/day
IM,intramuscular injection
Cleocin T
clindamycin phosphate
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
2.0
application/day
2
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
application/day
1
application/day
skin/dermal
Cleocin T
clindamycin phosphate
PDR
1.0
applicatorful/day
1
applicatorful/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
applicatorful/day
1
applicatorful/day
Vaginal Administration; once
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
5000.0
mg/day
5
g/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
1.0
ovule/day
1
ovule/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
100.0
mg/day
100
mg/day
Vaginal Administration
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cleocin T
clindamycin phosphate
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cleocin T
clindamycin phosphate
PDR
25.0
mg/kg/day
25
mg/kg/day
PO, oral
Cleocin T
clindamycin phosphate
PDR
27.0
mg/kg/day
9
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;
tid
Cleocin T
clindamycin phosphate
PDR
21.0
mg/kg/day
7
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;
tid
Cleocin T
clindamycin phosphate
PDR
15.0
mg/kg/day
5
mg/kg/dose
PO, oral;intravenous injection, IV;IM,intramuscular injection;
tid
Cleocin T
clindamycin phosphate
PDR
DDPD01191
Dexfenfluramine
231.2573
C12H16F3N
CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F
DB01191
T3D3014
66265
439329
59646
-2.0
-
-2.0
-
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
L/kg
11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.5
h
17-20
h
DRUGBANK
14.0
h
14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
%
36
%
DRUGBANK
DDPD01192
Oxymorphone
301.3371
C17H19NO4
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
DB01192
T3D3015
5284604
7865
http://www.drugs.com/cdi/oxymorphone.html
4447650
-2.0
-
-2.0
-
DRUGBANK
49.0
%
49
%
Urinary excretion;
DRUGBANK
1.9
%
1.9
%
Faeces excretion;
DRUGBANK
44.1
%
44.1
%
Bile excretion;
DRUGBANK
0.3
%
0.3
%
lung excretion;
DRUGBANK
2.6
%
2.6
%
Urinary excretion;
DRUGBANK
0.1
%
0.1
%
lung excretion;
DRUGBANK
1.3
h
1.3±0.7
h
DRUGBANK
172.0
mg/kg
172.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
172.0
mg/kg
172.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD01193
Acebutolol
336.4259
C18H28N2O4
CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O
DB01193
1978
2379
http://www.drugs.com/cdi/acebutolol.html
1901
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
~3-4
h
elimination half-life;
DRUGBANK
10.5
h
8-13
h
DRUGBANK
3.5
h
3.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
%
~30-40
%
Urinary excretion;
DRUGBANK
26.0
%
26
%
DRUGBANK
DDPD01194
Brinzolamide
383.507
C12H21N3O5S3
CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
DB01194
68844
3176
http://www.drugs.com/cdi/brinzolamide-drops.html
62077
-2.0
-
-2.0
-
DRUGBANK
2664.0
h
111
day
DRUGBANK
60.0
%
~60
%
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Azopt
brinzolamide
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Azopt
brinzolamide
PDR
DDPD01195
Flecainide
414.3427
C17H20F6N2O3
FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
DB01195
T3D2556
3356
75984
http://www.drugs.com/cdi/flecainide.html
3239
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
70.0
%
70±11
%
PO, oral;
DRUGBANK
458.0
ng/ml
458±100
ng/ml
PO, oral; adults; normal,healthy;
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
3.0
h
~3(1-6)
h
PO, oral; adults; normal,healthy;
DRUGBANK
0.501
L/h/kg
4.6-12.1
ml/min/kg
Average clearance; intravenous injection, IV; Male, men;
DRUGBANK
0.72
L/h/kg
4.0-20
ml/min/kg
Average clearance; PO, oral;
DRUGBANK
0.336
L/h/kg
5.6±1.3
ml/min/kg
hydrolysis;
Children ↑ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease ↓ ;
DRUGBANK
0.294
L/h/kg
4.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.2
L/kg
5-13.4
L/kg
Average volume of distribution; Male, men;
DRUGBANK
4.9
L/kg
4.9±0.4
L/kg
Apparent volume of distribution;
Hepatic cirrhosis, cirr ↑ ;
DRUGBANK
6.1
L/kg
6.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.0
h
13
h
normal,healthy;
DRUGBANK
16.0
h
16
h
Oral multiple dose; normal,healthy;
DRUGBANK
20.0
h
20
h
ventricular premature complex; patients;
DRUGBANK
12.6
h
12.6
h
DRUGBANK
11.0
h
11±3
h
hydrolysis;
Children ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;congestive heart disease ↑ ;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1346.0
mg/kg
1346.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
170.0
mg/kg
170.0
mg/kg
PO, oral; mouse;
DRUGBANK
215.0
mg/kg
215.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
188.0
mg/kg
188.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
274.0
mg/kg
50-498
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
20.0
mg/kg
20.0
mg/kg
PO, oral; Female, women;
DRUGBANK
40.0
mg/kg
40.0
mg/kg
PO, oral; Male, men;
DRUGBANK
86.0
%
~86
%
Urinary excretion; Oral single dose;
DRUGBANK
5.0
%
5
%
Faeces excretion; Oral single dose;
DRUGBANK
36.12
%
36.12
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
43.0
%
43±3
%
Urinary excretion; Unchanged drug;
DRUGBANK
40.0
%
40
%
DRUGBANK
61.0
%
61±10
%
myocardial infarction ↓ ;
DRUGBANK
200.0
mg/m2/day
200
mg/m2/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
300.0
mg/day
300
mg/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
400.0
mg/day
400
mg/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
300.0
mg/day
300
mg/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
400.0
mg/day
400
mg/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
200.0
mg/m2/day
200
mg/m2/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
300.0
mg/day
300
mg/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
400.0
mg/day
400
mg/day
PO, oral
Flecainide Acetate
flecainide acetate
PDR
DDPD01196
Estramustine
440.403
C23H31Cl2NO3
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]
DB01196
259331
4868
http://www.drugs.com/cdi/estramustine.html
227635
-2.0
-
-2.0
-
DRUGBANK
20.0
h
20
h
DRUGBANK
16.0
mg/kg/day
16
mg/kg/day
qd
Emcyt
estramustine phosphate sodium
PDR
16.0
mg/kg/day
16
mg/kg/day
qd
Emcyt
estramustine phosphate sodium
PDR
DDPD01197
Captopril
217.285
C9H15NO3S
C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O
DB01197
44093
3380
http://www.drugs.com/captopril.html
40130
-2.0
-
-2.0
-
DRUGBANK
67.5
%
60-75
%
PO, oral;
DRUGBANK
46.0
%
36-56
%
PO, oral; food;
food ↓ ;
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
L/kg
0.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
27.5
%
25-30
%
plasma proteins;
DRUGBANK
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Captopril
captopril
PDR
450.0
mg/day
450
mg/day
PO, oral
Captopril
captopril
PDR
450.0
mg/day
450
mg/day
PO, oral
Captopril
captopril
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Captopril
captopril
PDR
450.0
mg/day
450
mg/day
PO, oral
Captopril
captopril
PDR
450.0
mg/day
450
mg/day
PO, oral
Captopril
captopril
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Captopril
captopril
PDR
1.5
mg/kg/day
1.5
mg/kg/day
PO, oral
Captopril
captopril
PDR
6.0
mg/kg/day
6
mg/kg/day
PO, oral
Captopril
captopril
PDR
1.5
mg/kg/day
1.5
mg/kg/day
PO, oral
Captopril
captopril
PDR
DDPD01198
Zopiclone
388.808
C17H17ClN6O3
CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1
DB01198
T3D3016
5735
32315
http://www.drugs.com/cdi/eszopiclone.html
5533
-2.0
-
-2.0
-
DRUGBANK
12.0
%
12
%
Liver metabolism; Active metabolite;
DRUGBANK
16.0
%
16
%
Liver metabolism; Inactive metabolite;
DRUGBANK
0.198
L/h/kg
3.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~5(3.8-6.5)
h
elimination half-life;
DRUGBANK
11.9
h
11.9
h
hepatic insufficiency; patients;
DRUGBANK
5.2
h
5.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
%
~45
%
DRUGBANK
DDPD01199
Tubocurarine
609.7312
C37H41N2O6
[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3
DB01199
T3D3097
6000
9774
5778
-2.0
-
-2.0
-
DRUGBANK
0.204
L/h/kg
3.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.45
L/kg
0.45
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01200
Bromocriptine
654.595
C32H40BrN5O5
[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
DB01200
T3D3017
31101
3181
http://www.drugs.com/cdi/bromocriptine.html
28858
-2.0
-
-2.0
-
DRUGBANK
28.0
%
28
%
PO, oral;
DRUGBANK
6.0
%
6
%
PO, oral;
DRUGBANK
1.25
h
1-1.5
h
PO, oral;
DRUGBANK
100.0
%
100
%
Liver metabolism;
DRUGBANK
5.0
h
2-8
h
DRUGBANK
6.0
%
6
%
Urinary excretion;
DRUGBANK
93.0
%
90-96
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
5.0
mg/day
5
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
4.8
mg/day
4.8
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
30.0
mg/day
30
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
100.0
mg/day
100
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
15.0
mg/day
15
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
20.0
mg/day
20
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
10.0
mg/day
10
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
20.0
mg/day
20
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
4.8
mg/day
4.8
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
30.0
mg/day
30
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
100.0
mg/day
100
mg/day
PO, oral
Cycloset
bromocriptine mesylate
PDR
DDPD01201
Rifapentine
877.0307
C47H64N4O12
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O
DB01201
T3D3018
6323497
45304
http://www.drugs.com/cdi/rifapentine.html
10482075
-2.0
-
-2.0
-
DRUGBANK
2.51
L/h
2.51±0.14
L/h
apparent clearance; PO, oral; Drug combination; tuberculosis; patients; Male, men;
DRUGBANK
1.69
L/h
1.69±0.41
L/h
apparent clearance; PO, oral; Drug combination; tuberculosis; patients; Female, women;
DRUGBANK
70.2
L
70.2±9.1
L
DRUGBANK
17.0
%
17
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
70.0
%
70
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
97.7
%
97.7
%
plasma proteins;
DRUGBANK
900.0
mg/dose
900
mg/dose
PO, oral
Priftin
rifapentine
PDR
750.0
mg/dose
750
mg/dose
PO, oral
Priftin
rifapentine
PDR
600.0
mg/dose
600
mg/dose
PO, oral
Priftin
rifapentine
PDR
450.0
mg/dose
450
mg/dose
PO, oral
Priftin
rifapentine
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Priftin
rifapentine
PDR
900.0
mg/dose
900
mg/dose
PO, oral
Priftin
rifapentine
PDR
900.0
mg/dose
900
mg/dose
PO, oral
Priftin
rifapentine
PDR
750.0
mg/dose
750
mg/dose
PO, oral
Priftin
rifapentine
PDR
600.0
mg/dose
600
mg/dose
PO, oral
Priftin
rifapentine
PDR
900.0
mg/dose
900
mg/dose
PO, oral
Priftin
rifapentine
PDR
DDPD01202
Levetiracetam
170.212
C8H14N2O2
CC[C@H](N1CCCC1=O)C(N)=O
DB01202
T3D3019
5284583
6437
http://www.drugs.com/cdi/levetiracetam.html
4447633
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
100.0
%
~100
%
PO, oral; adults; epilepsy; normal,healthy;
DRUGBANK
31000.0
ng/ml
31
ug/ml
Oral single dose;
DRUGBANK
43000.0
ng/ml
43
ug/ml
Oral multiple dose;
DRUGBANK
24800.0
ng/ml
24.8
ug/ml
Oral single dose; food;
food ↓ ;
DRUGBANK
10000.0
ng/ml
~10
mcg/ml
PO, oral; adults; normal,healthy;
DRUGBANK
1.3
h
1.3
h
Oral single dose;
DRUGBANK
2.8
h
2.8
h
Oral single dose; food;
food ↑ ;
DRUGBANK
0.75
h
0.5-1.0
h
PO, oral; adults; normal,healthy;
DRUGBANK
24.0
%
24
%
Inactive metabolite;
DRUGBANK
0.0576
L/h/kg
0.96
ml/min/kg
Plasma clearance;
DRUGBANK
0.0366
L/h/kg
0.6
ml/min/kg
Renal clearance;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.24
L/h/kg
4.0
ml/min/kg
Renal clearance;
DRUGBANK
0.0576
L/h/kg
0.96
ml/min/kg
Children ↑ ;Elderly ↓ ;severe hepatic impairment ↓ ;severe renal function ↓ ;
DRUGBANK
0.054
L/h/kg
0.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
~0.5-0.7
L/kg
DRUGBANK
0.6
L/kg
0.5-0.7
L/kg
DRUGBANK
0.6
L/kg
0.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
6-8
h
elimination half-life;
dose → ;
DRUGBANK
7.0
h
7±1
h
normal,healthy; adults; patients; epilepsy;
mild renal function ↑ ;Age ↑ ;
DRUGBANK
8.23
h
8.23
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
mg/kg
10.0
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
0.3
%
0.3
%
Faeces excretion;
DRUGBANK
66.0
%
~66
%
Urinary excretion; Unchanged drug;
DRUGBANK
60.0
%
66
%
Urinary excretion; adults; normal,healthy; epilepsy; human, homo sapiens; Unchanged drug;
DRUGBANK
10.0
%
<10
%
plasma proteins;
DRUGBANK
10.0
%
<10
%
adults; normal,healthy; epilepsy; human, homo sapiens;
DRUGBANK
60.0
mg/kg/day
60
mg/kg/day
Liquid;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
3000.0
mg/day
3000
mg/day
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
3000.0
mg/day
3000
mg/day
Tablet,PO，oral
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg
60
mg/kg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
4500.0
mg
4500
mg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg/day
60
mg/kg/day
Liquid;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
1500.0
mg/day
1500
mg/day
Tablet,PO，oral
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg
60
mg/kg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
50.0
mg/kg/day
50
mg/kg/day
Liquid;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg
60
mg/kg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
3000.0
mg/day
3000
mg/day
PO, oral;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
3000.0
mg/day
3000
mg/day
PO, oral;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg
60
mg/kg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
4500.0
mg
4500
mg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
3000.0
mg/day
3000
mg/day
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg
60
mg/kg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
4500.0
mg
4500
mg
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
3000.0
mg/day
3000
mg/day
PO, oral;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
42.0
mg/kg/day
42
mg/kg/day
PO, oral;intravenous injection, IV;
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Keppra Oral Solution and Tablets
levetiracetam
PDR
80.0
mg/kg/day
80
mg/kg/day
intravenous injection, IV
Keppra Oral Solution and Tablets
levetiracetam
PDR
DDPD01203
Nadolol
309.4006
C17H27NO4
CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2
DB01203
39147
7444
http://www.drugs.com/cdi/nadolol.html
35815
-2.0
-
-2.0
-
DRUGBANK
30.0
%
~30
%
PO, oral;
DRUGBANK
1021.0
ng.h/ml
1021.0
ng.h/ml
Oral single dose;
DRUGBANK
1913.0
ng.h/ml
1913±382
ng.h/ml
DRUGBANK
69.0
ng/ml
69±15
ng/ml
Oral single dose;
DRUGBANK
132.0
ng/ml
132±27
ng/ml
DRUGBANK
2.7
h
2.7
h
Oral single dose;
DRUGBANK
0.0
%
0
%
Liver metabolism;
DRUGBANK
14.07
L/h
219-250
ml/min
Total clearance; normal,healthy;
DRUGBANK
8.43
L/h
131-150
ml/min
Renal clearance; normal,healthy;
DRUGBANK
0.174
L/h/kg
2.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
152.0
L
147-157
L
normal,healthy;
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
20-24
h
DRUGBANK
9.2
h
9.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4500.0
mg/kg
4500.0
mg/kg
PO, oral; mouse;
DRUGBANK
60.0
%
60
%
Urinary excretion; intravenous injection, IV; normal,healthy; human, homo sapiens;
DRUGBANK
15.0
%
15
%
Faeces excretion; intravenous injection, IV; normal,healthy; human, homo sapiens;
DRUGBANK
30.0
%
~30
%
plasma proteins;
DRUGBANK
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Corgard
nadolol
PDR
320.0
mg/day
320
mg/day
PO, oral
Corgard
nadolol
PDR
240.0
mg/day
240
mg/day
PO, oral
Corgard
nadolol
PDR
320.0
mg/day
320
mg/day
PO, oral
Corgard
nadolol
PDR
240.0
mg/day
240
mg/day
PO, oral
Corgard
nadolol
PDR
DDPD01204
Mitoxantrone
444.4809
C22H28N4O6
OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
DB01204
T3D3020
4212
50729
http://www.drugs.com/cdi/mitoxantrone.html
4067
-2.0
-
-2.0
-
DRUGBANK
308.0
ng/ml
308±133
ng/ml
DRUGBANK
21.3
L/h/m2
21.3
L/h/m2
intravenous injection, IV; Geriatric; breast cancer;
DRUGBANK
28.3
L/h/m2
28.3
L/h/m2
intravenous injection, IV; pediatric patients; nasopharyngeal carcinoma;
DRUGBANK
16.2
L/h/m2
16.2
L/h/m2
intravenous injection, IV; pediatric patients; malignant lymphoma;
DRUGBANK
0.78
L/h/kg
13±8
ml/min/kg
tumor; patients;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.474
L/h/kg
7.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1000.0
L/m2
1000.0
L/m2
DRUGBANK
90.0
L/kg
90±42
L/kg
tumor; patients;
DRUGBANK
12.0
L/kg
12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
h
75
h
DRUGBANK
1.1
h
1.1±1.1
h
tumor; patients; intravenous infusion, IV in drop; at steady state;
chronic liver disease ↑ ;
DRUGBANK
72.0
h
72±40
h
tumor; patients; intravenous infusion, IV in drop; at steady state;
chronic liver disease ↑ ;
DRUGBANK
53.0
h
53
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
%
~2
%
Urinary excretion; tumor; human, homo sapiens; Unchanged drug;
DRUGBANK
78.0
%
78
%
DRUGBANK
97.0
%
97
%
tumor; human, homo sapiens;
DRUGBANK
140.0
mg/m2
140
mg/m2
intravenous injection, IV
Mitoxantrone
mitoxantrone
PDR
DDPD01205
Flumazenil
303.2884
C15H14FN3O3
CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1
DB01205
3373
5103
http://www.drugs.com/cdi/flumazenil.html
3256
-2.0
-
-2.0
-
DRUGBANK
16.0
%
16.0
%
PO, oral;
DRUGBANK
15.0
ng/ml
10-20
ng/ml
intravenous injection, IV;
DRUGBANK
99.0
%
99
%
Liver metabolism;
DRUGBANK
1.0
L/h/kg
1.0
l/h/kg
intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
0.594
L/h/kg
9.9±3.1
ml/min/kg
moderate hepatic impairment ↓ ;severe hepatic impairment ↓ ;
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
0.9-1.1
L/kg
DRUGBANK
0.63
L/kg
0.63±0.18
L/kg
DRUGBANK
0.8
L/kg
0.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.125
h
4-11
min
distribution half-life;
DRUGBANK
1.0
h
40-80
min
terminal half-life;
DRUGBANK
1.3
h
1.3
h
moderate hepatic impairment;
DRUGBANK
2.4
h
2.4
h
severe hepatic impairment;
DRUGBANK
0.666666666666667
h
40(20-75)
min
pediatric patients;
DRUGBANK
0.9
h
0.9±0.2
h
moderate hepatic impairment ↑ ;severe hepatic impairment ↑ ;
DRUGBANK
0.78
h
0.78
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
92.5
%
90-95
%
Urinary excretion;
DRUGBANK
7.5
%
5-10
%
Faeces excretion;
DRUGBANK
0.2
%
<0.2
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
~50
%
Hepatitis, Hep ↓ ;
DRUGBANK
33.0
%
33
%
DRUGBANK
40.0
%
40(36-46)
%
DRUGBANK
0.01
mg/kg
10
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.2
mg/dose
200
mcg/dose
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.05
mg/kg
50
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
1.0
mg
1
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.24
mg/kg/day
10
mcg/kg/hour
intravenous infusion, iv in drop
Flumazenil
flumazenil
PDR
5.0
mg
5
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
1.0
mg
1
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.01
mg/day
10
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.2
mg/dose
200
mcg/dose
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.05
mg/day
50
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
1.0
mg
1
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.01
mg/kg/day
10
mcg/kg/hour
intravenous infusion, iv in drop
Flumazenil
flumazenil
PDR
5.0
mg
5
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
1.0
mg
1
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.03
mg/kg
30
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.2
mg/dose
200
mcg/dose
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.05
mg/kg
50
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
1.0
mg
1
mg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.24
mg/kg/day
10
mcg/kg/h
intravenous infusion, iv in drop
Flumazenil
flumazenil
PDR
0.02
mg/kg
20
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.05
mg/kg
50
mcg/kg
intravenous injection, IV
Flumazenil
flumazenil
PDR
0.48
mg/kg/day
20
mcg/kg/hour
intravenous infusion, iv in drop
Flumazenil
flumazenil
PDR
DDPD01206
Lomustine
233.695
C9H16ClN3O2
ClCCN(N=O)C(=O)NC1CCCCC1
DB01206
T3D4700
3950
6520
http://www.drugs.com/cdi/lomustine-ccnu.html
3813
-2.0
-
-2.0
-
DRUGBANK
1.56666666666667
h
~94
min
DRUGBANK
32.0
h
16-48
h
elimination half-life; Metabolite;
DRUGBANK
70.0
mg/kg
70.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
70.0
mg/kg
70.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
%
~50
%
Urinary excretion; PO, oral;
DRUGBANK
50.0
%
50
%
DRUGBANK
130.0
mg/m2
130
mg/m2
PO, oral; nan
q6w
Gleostine
lomustine
PDR
130.0
mg/m2
130
mg/m2
PO, oral
q6wk
Gleostine
lomustine
PDR
200.0
mg/m2
200
mg/m2
PO, oral
Gleostine
lomustine
PDR
130.0
mg/m2
130
mg/m2
PO, oral; nan
q6w
Gleostine
lomustine
PDR
130.0
mg/m2
130
mg/m2
PO, oral; nan
q6w
Gleostine
lomustine
PDR
200.0
mg/m2
200
mg/m2
PO, oral
Gleostine
lomustine
PDR
130.0
mg/m2
130
mg/m2
PO, oral; nan
q6w
Gleostine
lomustine
PDR
DDPD01208
Sparfloxacin
392.3998
C19H22F2N4O3
C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O
DB01208
60464
9212
http://www.drugs.com/mtm/sparfloxacin.html
54517
-2.0
-
-2.0
-
DRUGBANK
92.0
%
92
%
PO, oral;
DRUGBANK
46.0
%
46
%
PO, oral; antacids;
antacids ↓ ;
DRUGBANK
0.162
L/h/kg
2.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.9
L/kg
3.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
h
20(16-30)
h
elimination half-life;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
20.0
h
20
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
%
~45
%
plasma proteins;
DRUGBANK
DDPD01209
Dezocine
245.3599
C16H23NO
[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N
DB01209
3033053
4474
2297867
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
IM,intramuscular injection;
DRUGBANK
1.65
L/h/kg
27.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.6
L/kg
5.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.2
h
2.2
h
elimination half-life; IM,intramuscular injection;
DRUGBANK
2.5
h
1.7-2.6(0.6-4.4)
h
elimination half-life; intravenous injection, IV;
DRUGBANK
4.3
h
2.4-2.6(1.2-7.4)
h
elimination half-life; intravenous injection, IV;
DRUGBANK
3.08
h
2.86-3.3
h
Hepatitis, Hep;
DRUGBANK
3.9
h
3.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01210
Levobunolol
291.3853
C17H25NO3
CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O
DB01210
39468
6438
http://www.drugs.com/cdi/levobunolol-drops.html
36089
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
DRUGBANK
20.0
h
20
h
DRUGBANK
700.0
mg/kg
700.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4.0
drop/day
4
drop/day
ophthalmic administration
Betagan
levobunolol hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Betagan
levobunolol hydrochloride
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Betagan
levobunolol hydrochloride
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Betagan
levobunolol hydrochloride
PDR
DDPD01211
Clarithromycin
747.9534
C38H69NO13
[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
DB01211
84029
3732
http://www.drugs.com/clarithromycin.html
10342604
-2.0
-
-2.0
-
DRUGBANK
55.0
%
55±8
%
PO, oral;
DRUGBANK
2400.0
ng/ml
2.4
mcg/ml
PO, oral; adults; normal,healthy;
DRUGBANK
700.0
ng/ml
0.7
mcg/ml
PO, oral; Derivative; adults; normal,healthy;
DRUGBANK
2.8
h
2.8
h
PO, oral; adults; normal,healthy;
DRUGBANK
3.0
h
3.0
h
PO, oral; Derivative; adults; normal,healthy;
DRUGBANK
0.438
L/h/kg
7.3±1.9
ml/min/kg
PO, oral;
Elderly ↓ ;Hepatitis, Hep → ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.438
L/h/kg
7.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
L/kg
2.6±0.5
L/kg
Elderly → ;Hepatitis, Hep ↑ ;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
DRUGBANK
3.3
h
3.3±0.5
h
PO, oral;
RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;increasing doses ↑ ;Age ↑ ;
DRUGBANK
2.8
h
2.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
36.0
%
36±7
%
Urinary excretion; Oral single dose; Unchanged drug;
Elderly → ;
DRUGBANK
70.0
%
~70
%
DRUGBANK
46.0
%
42-50
%
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Biaxin
clarithromycin
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Biaxin
clarithromycin
PDR
1000.0
mg/day
1
g/day
PO, oral
Biaxin
clarithromycin
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Biaxin
clarithromycin
PDR
1000.0
mg/day
1
g/day
PO, oral
Biaxin
clarithromycin
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Biaxin
clarithromycin
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Biaxin
clarithromycin
PDR
1000.0
mg/day
1
g/day
PO, oral
Biaxin
clarithromycin
PDR
1500.0
mg/day
1.5
g/day
PO, oral
Biaxin
clarithromycin
PDR
1000.0
mg/day
1
g/day
PO, oral
Biaxin
clarithromycin
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Biaxin
clarithromycin
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Biaxin
clarithromycin
PDR
DDPD01212
Ceftriaxone
554.58
C18H18N8O7S3
[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
DB01212
T3D2568
5479530
29007
http://www.drugs.com/cdi/ceftriaxone.html
4586394
-2.0
-
-2.0
-
DRUGBANK
1.015
L/h
0.58-1.45
L/h
normal,healthy; adults;
DRUGBANK
0.0132
L/h/kg
0.22
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.64
L
5.78-13.5
L
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.25
h
5.8-8.7
h
DRUGBANK
7.6
h
7.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10000.0
mg/kg
>10 000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
50.0
%
33-67
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
4000.0
mg/day
4
g/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV
Ceftriaxone
ceftriaxone
PDR
50.0
mg/kg/day
50
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Ceftriaxone
ceftriaxone
PDR
DDPD01213
Fomepizole
82.1038
C4H6N2
CC1=CNN=C1
DB01213
3406
5141
http://www.drugs.com/mtm/fomepizole.html
3289
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
82.5
%
80-85
%
Liver metabolism;
DRUGBANK
0.0438
L/h/kg
0.73
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.81
L/kg
0.6-1.02
L/kg
DRUGBANK
0.35
L/kg
0.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.42
h
4.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.25
%
1-3.5
%
Urinary excretion; PO, oral; intravenous injection, IV; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
DDPD01214
Metipranolol
309.4006
C17H27NO4
CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1
DB01214
31477
6897
http://www.drugs.com/cdi/metipranolol-drops.html
29193
-2.0
-
-2.0
-
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Metipranolol
metipranolol
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Metipranolol
metipranolol
PDR
DDPD01215
Estazolam
294.738
C16H11ClN4
ClC1=CC2=C(C=C1)N1C=NN=C1CN=C2C1=CC=CC=C1
DB01215
T3D3023
3261
4858
http://www.drugs.com/cdi/estazolam.html
3146
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2(0.5-6)
h
PO, oral;
DRUGBANK
17.0
h
10-24
h
elimination half-life;
DRUGBANK
740.0
mg/kg
740.0
mg/kg
PO, oral; male mouse;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; rabbit;
DRUGBANK
87.0
%
87
%
Urinary excretion; human, homo sapiens;
DRUGBANK
4.0
%
<4
%
Urinary excretion; Unchanged drug;
DRUGBANK
93.0
%
93
%
Plasma Concentration → ;
DRUGBANK
2.0
mg/day
2
mg/day
PO, oral
Estazolam
estazolam
PDR
2.0
mg/day
2
mg/day
PO, oral
Estazolam
estazolam
PDR
DDPD01216
Finasteride
372.5441
C23H36N2O2
[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
DB01216
T3D4820
57363
5062
http://www.drugs.com/cdi/finasteride.html
51714
-2.0
-
-2.0
-
DRUGBANK
53.0
ng.h/ml
53(20-154)
ng.h/ml
PO, oral;
DRUGBANK
65.0
%
65(26-170)
%
PO, oral; normal,healthy; Male, men;
DRUGBANK
63.0
%
63(34-108)
%
PO, oral; normal,healthy; Male, men;
DRUGBANK
63.0
%
63±21
%
PO, oral;
DRUGBANK
37.0
ng/ml
37(27-49)
ng/ml
PO, oral;
DRUGBANK
37.0
ng/ml
37(27-49)
ng/ml
Oral single dose; adults; normal,healthy;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
1.5
h
1-2
h
Oral single dose; adults; normal,healthy;
DRUGBANK
9.9
L/h
165.0
ml/min
Plasma clearance; normal,healthy; young;
DRUGBANK
0.138
L/h/kg
2.3±0.8
ml/min/kg
normal,healthy; adults;
Elderly → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
76.0
L
76.0
L
at steady state;
DRUGBANK
1.1
L/kg
1.1±0.2
L/kg
normal,healthy; adults;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5(3-16)
h
elimination half-life; normal,healthy; young;
DRUGBANK
8.0
h
8
h
Elderly;
DRUGBANK
7.9
h
7.9±2.5
h
RD, renal impairment, Renal disease，including uremia → ;Age → ;
DRUGBANK
6.0
h
6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
418.0
mg/kg
~418
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
~90
%
plasma proteins;
DRUGBANK
90.0
%
90
%
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Propecia
finasteride
PDR
80.0
mg/day
80
mg/day
PO, oral
Propecia
finasteride
PDR
1.0
mg/day
1
mg/day
PO, oral
Propecia
finasteride
PDR
5.0
mg/day
5
mg/day
PO, oral
Propecia
finasteride
PDR
80.0
mg/day
80
mg/day
PO, oral
Propecia
finasteride
PDR
1.0
mg/day
1
mg/day
PO, oral
Propecia
finasteride
PDR
DDPD01217
Anastrozole
293.3663
C17H19N5
CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
DB01217
T3D4796
2187
2704
http://www.drugs.com/cdi/anastrozole.html
2102
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80.0
%
PO, oral; postmenopausal women; Female, women;
DRUGBANK
46.0
ng/ml
46.0
ng/ml
Oral single dose; postmenopausal women; Female, women;
DRUGBANK
2.0
h
2
h
PO, oral; fasting;
DRUGBANK
2.0
h
≤2
h
Oral single dose; postmenopausal women; Female, women;
DRUGBANK
3.19
L
3.19
mL/g
mouse;
DRUGBANK
50.0
h
~50
h
elimination half-life;
DRUGBANK
50.0
h
50.0
h
normal,healthy; postmenopausal women; Asian;
DRUGBANK
1.68
mg/kg
1.68
mg/kg
PO, oral; human, homo sapiens; Female, women;
DRUGBANK
85.0
%
85
%
lung excretion;
DRUGBANK
10.0
%
~10
%
Urinary excretion; Unchanged drug;
DRUGBANK
10.0
%
<10
%
Urinary excretion; postmenopausal women; Female, women; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
40.0
%
40
%
Plasma Concentration → ;
DRUGBANK
40.0
%
~40
%
postmenopausal women; Female, women; normal,healthy; human, homo sapiens;
DRUGBANK
1.0
mg
1
mg
PO, oral
qd
Arimidex
anastrozole
PDR
1.0
mg
1
mg
PO, oral
qd
Arimidex
anastrozole
PDR
DDPD01218
Halofantrine
500.424
C26H30Cl2F3NO
CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F
DB01218
37393
94392
http://www.drugs.com/cdi/halofantrine.html
34303
-2.0
-
-2.0
-
DRUGBANK
192.0
h
6-10
day
DRUGBANK
65.0
%
60-70
%
DRUGBANK
DDPD01219
Dantrolene
314.257
C14H10N4O5
[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O
DB01219
6914273
4317
http://www.drugs.com/cdi/dantrolene.html
5290202
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
DRUGBANK
0.0258
L/h/kg
0.43
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.37
L/kg
0.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
4-8
h
elimination half-life; intravenous injection, IV;
DRUGBANK
8.7
h
8.7
h
PO, oral;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7400.0
mg/kg
7400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01220
Rifaximin
785.8785
C43H51N3O11
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C(N=C5C=C(C)C=CN15)C4=C3C2=O
DB01220
6436173
75246
http://www.drugs.com/cdi/rifaximin.html
10482302
-2.0
-
-2.0
-
DRUGBANK
6.0
h
~6
h
DRUGBANK
2000.0
mg/kg
>2
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
96.62
%
96.62
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
0.32
%
0.32
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Xifaxan
rifaximin
PDR
600.0
mg/day
600
mg/day
PO, oral
Xifaxan
rifaximin
PDR
1100.0
mg/day
1100
mg/day
PO, oral
Xifaxan
rifaximin
PDR
1650.0
mg/day
1650
mg/day
Xifaxan
rifaximin
PDR
600.0
mg/day
600
mg/day
PO, oral
Xifaxan
rifaximin
PDR
600.0
mg/day
600
mg/day
PO, oral
Xifaxan
rifaximin
PDR
1100.0
mg/day
1100
mg/day
PO, oral
Xifaxan
rifaximin
PDR
1650.0
mg/day
1650
mg/day
Xifaxan
rifaximin
PDR
DDPD01221
Ketamine
237.725
C13H16ClNO
CNC1(CCCCC1=O)C1=CC=CC=C1Cl
DB01221
T3D3025
3821
6121
http://www.drugs.com/cdi/ketamine.html
3689
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93
%
DRUGBANK
750.0
ng/ml
0.75
mcg/ml
DRUGBANK
1.35714285714286
L/h/kg
95.0
L/h/70kg
DRUGBANK
1.14
L/h/kg
19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3713
L/kg
371.3
ml/kg
Total volume of distribution;
DRUGBANK
4.0603
L/kg
4060.3
ml/kg
at steady state;
DRUGBANK
2.9
L/kg
2.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.1
h
186
min
DRUGBANK
2.8
h
2.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
91.0
%
91
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
3.0
%
3
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
53.5
%
53.5
%
plasma proteins;
DRUGBANK
DDPD01222
Budesonide
430.5339
C25H34O6
[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB01222
5281004
3207
http://www.drugs.com/cdi/budesonide-spray.html
4444479
-2.0
-
-2.0
-
DRUGBANK
7.33
ng.h/ml
7.33
ng.h/ml
PO, oral;
DRUGBANK
16.43
ng.h/ml
16.43±10.52
ng.h/ml
Tablet, PO, oral; extended release formulation; different study;
DRUGBANK
4.31
ng.h/ml
4.31
ng.h/ml
Rectal Administration;
DRUGBANK
15.0
%
9-21
%
Capsule, PO, Oral; extended release formulation;
DRUGBANK
39.0
%
39
%
inhalation, IH;
DRUGBANK
6.0
%
6
%
inhalation, IH;
DRUGBANK
1.5
ng/ml
1.50±0.79
ng/ml
PO, oral;
DRUGBANK
0.47358729
ng/ml
0.6-1.6
nmol/L
inhalation, IH;
DRUGBANK
1.11938814
ng/ml
2.6
nmol/L
inhalation, IH;
DRUGBANK
1.35
ng/ml
1.35±0.96
ng/ml
Tablet, PO, oral; extended release formulation; different study;
DRUGBANK
5.0
h
2-8
h
PO, oral;
DRUGBANK
7.3
h
4.3-10.3
h
Tablet, PO, oral; high-fat meal;
DRUGBANK
0.166666666666667
h
10
min
inhalation, IH;
DRUGBANK
0.333333333333333
h
20
min
inhalation, IH;
DRUGBANK
13.3
h
13.3±5.9
h
Tablet, PO, oral; extended release formulation; different study;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
108.0
L/h
1.8
L/min
Plasma clearance;
DRUGBANK
84.0
L/h
1.4
L/min
DRUGBANK
60.0
L/h
1.0
L/min
DRUGBANK
30.0
L/h
0.5
L/min
asthma; Children;
DRUGBANK
1.2
L/h/kg
20
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.05
L/kg
2.2-3.9
L/kg
DRUGBANK
3.9
L/kg
3.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
h
2-3.6
h
elimination half-life;
DRUGBANK
2.3
h
2.3
h
elimination half-life; asthma; Children;
DRUGBANK
2.8
h
2.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
~60
%
Urinary excretion;
DRUGBANK
87.5
%
85-90
%
plasma proteins;
DRUGBANK
0.256
mg/day
256
mcg/day
intranasal
Entocort EC
budesonide
PDR
0.72
mg/day
720
mcg/day
inhalation, IH
Entocort EC
budesonide
PDR
4.0
mg/day
4
mg/day
Liquid
Entocort EC
budesonide
PDR
12.0
mg/day
12
mg/day
Capsule, PO, Oral
Entocort EC
budesonide
PDR
0.128
mg/day
128
mcg/day
intranasal
Entocort EC
budesonide
PDR
0.72
mg/day
720
mcg/day
inhalation, IH
Entocort EC
budesonide
PDR
1.0
mg/day
1
mg/day
Liquid
Entocort EC
budesonide
PDR
4.0
mg/day
4
mg/day
Liquid
Entocort EC
budesonide
PDR
12.0
mg/day
12
mg/day
Capsule, PO, Oral
Entocort EC
budesonide
PDR
1.0
mg/day
1
mg/day
Liquid
Entocort EC
budesonide
PDR
4.0
mg/day
4
mg/day
Liquid
Entocort EC
budesonide
PDR
8.0
mg/day
8
mg/day
Liquid
Entocort EC
budesonide
PDR
0.256
mg/day
256
mcg/day
intranasal
Entocort EC
budesonide
PDR
0.72
mg/day
720
mcg/day
inhalation, IH
Entocort EC
budesonide
PDR
4.0
mg/day
4
mg/day
Liquid
Entocort EC
budesonide
PDR
12.0
mg/day
12
mg/day
Capsule, PO, Oral
Entocort EC
budesonide
PDR
8.0
mg/day
8
mg/day
Liquid
Entocort EC
budesonide
PDR
1.0
mg/day
1
mg/day
Liquid
Entocort EC
budesonide
PDR
DDPD01223
Aminophylline
420.4264
C16H24N10O4
NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O
DB01223
9433
2659
http://www.drugs.com/cdi/aminophylline.html
9062
-2.0
-
-2.0
-
DRUGBANK
0.0279
L/h/kg
0.29-0.64
ml/kg/min
postnatal;
DRUGBANK
0.099
L/h/kg
1.6-1.7
ml/kg/min
Children;
DRUGBANK
0.069
L/h/kg
0.9-1.4
ml/kg/min
Adolescents;
DRUGBANK
0.039
L/h/kg
0.65
ml/kg/min
adults; asthma;
DRUGBANK
0.0246
L/h/kg
0.41
ml/kg/min
Elderly;
DRUGBANK
0.0198
L/h/kg
0.33
ml/kg/min
Acute pulmonary edema;
DRUGBANK
0.0324
L/h/kg
0.54
ml/kg/min
COPD, Chronic obstructive pulmonary disease;
DRUGBANK
0.0288
L/h/kg
0.48
ml/kg/min
COPD, Chronic obstructive pulmonary disease; CP,cor pulmonale;
DRUGBANK
0.075
L/h/kg
1.25
ml/kg/min
Cystic fibrosis;
DRUGBANK
0.0186
L/h/kg
0.31
ml/kg/min
cholestasis;
DRUGBANK
0.03
L/h/kg
0.35-0.65
ml/kg/min
Hepatitis, Hep;
DRUGBANK
0.0282
L/h/kg
0.47
ml/kg/min
Sepsis; multi-organ failure;
DRUGBANK
0.0228
L/h/kg
0.38
ml/kg/min
LTh hypothyroid;
DRUGBANK
0.048
L/h/kg
0.8
ml/kg/min
hyperthyroid, HTh;
DRUGBANK
0.5
L/kg
0.3-0.7
L/kg
DRUGBANK
8.0
h
7-9
h
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD01224
Quetiapine
383.507
C21H25N3O2S
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
DB01224
T3D2555
5002
8707
http://www.drugs.com/cdi/quetiapine.html
4827
-2.0
-
-2.0
-
DRUGBANK
5094.0
ng.h/ml
5094.0
ng.h/ml
PO, oral; extended release formulation;
DRUGBANK
100.0
%
100
%
Tablet, PO, oral;
DRUGBANK
9.0
%
9.0
%
PO, oral;
DRUGBANK
467.0
ng/ml
467
ng/ml
PO, oral; extended release formulation;
DRUGBANK
278.0
ng/ml
278.0
ng/ml
PO, oral; schizophrenia;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
1.4
h
1-1.8
h
DRUGBANK
48.0
h
48
h
PO, oral;
DRUGBANK
101.04
L/h
101.04±39.11
L/h
normal,healthy; fasting;
Geriatric ↓ ;
DRUGBANK
1.14
L/h/kg
19.0
ml/min/kg
Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
10.0
L/kg
10±4
L/kg
Apparent volume of distribution;
DRUGBANK
10.0
L/kg
10±4
L/kg
DRUGBANK
6.5
h
~6-7
h
terminal half-life;
DRUGBANK
6.0
h
6.0
h
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
73.0
%
~73
%
Urinary excretion;
DRUGBANK
20.0
%
~20
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
83.0
%
83
%
DRUGBANK
83.0
%
83
%
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Seroquel
quetiapine fumarate
PDR
800.0
mg/day
800
mg/day
PO, oral
Seroquel
quetiapine fumarate
PDR
800.0
mg/day
800
mg/day
PO, oral
Seroquel
quetiapine fumarate
PDR
500.0
mg/day
500
mg/day
PO, oral
Seroquel
quetiapine fumarate
PDR
DDPD01226
Mivacurium
1029.2608
C58H80N2O14
COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC
DB01226
5281042
6958
4444509
-2.0
-
-2.0
-
DRUGBANK
0.0358333333333333
h
1.7-2.6
min
elimination half-life; normal,healthy; young;
DRUGBANK
0.0733333333333333
h
4.4
min
elimination half-life; hepatopathy，LD; liver transplant;
DRUGBANK
DDPD01227
Levacetylmethadol
353.4977
C23H31NO2
CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
DB01227
T3D3027
15130
6441
http://www.drugs.com/cons/levomethadyl.html
14401
-2.0
-
-2.0
-
DRUGBANK
62.4
h
2.6
day
DRUGBANK
80.0
%
~80
%
DRUGBANK
DDPD01228
Encainide
352.4699
C22H28N2O2
COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
DB01228
T3D4738
48041
4788
43697
-2.0
-
-2.0
-
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01229
Paclitaxel
853.9061
C47H51NO14
[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
DB01229
T3D4019
36314
45863
http://www.drugs.com/cdi/paclitaxel.html
10368587
-2.0
-
-2.0
-
DRUGBANK
6300.0
ng.h/ml
6300.0
ng.h/ml
intravenous infusion, IV in drop;
DRUGBANK
195.0
ng/ml
195
ng/ml
intravenous infusion, IV in drop;
DRUGBANK
725820.185
ng/ml
0.85±0.21
mM
intravenous infusion, IV in drop; adults; tumor;
DRUGBANK
21.7
L/h/m2
21.7
L/h/m2
intravenous infusion, IV in drop;
DRUGBANK
23.8
L/h/m2
23.8
L/h/m2
intravenous infusion, IV in drop;
DRUGBANK
7.0
L/h/m2
7.0
L/h/m2
intravenous infusion, IV in drop;
DRUGBANK
12.2
L/h/m2
12.2
L/h/m2
intravenous infusion, IV in drop;
DRUGBANK
0.33
L/h/kg
5.5±3.5
ml/min/kg
hydrolysis; hydrolysis;
Children → ;
DRUGBANK
0.384
L/h/kg
6.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
457.5
L/m2
227-688
L/m2
at steady state; intravenous infusion, IV in drop;
DRUGBANK
2.0
L/kg
2.0±1.2
L/kg
Children → ;
DRUGBANK
3.0
L/kg
3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
52.7
h
52.7
h
ovarian cancer;
DRUGBANK
3.0
h
3±1
h
DRUGBANK
30.0
h
30
h
terminal half-life;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.53
mg/kg
32530.0
ug/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
32.53
mg/kg
32530.0
ug/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
71.0
%
71
%
Faeces excretion; patients; human, homo sapiens;
DRUGBANK
14.0
%
14
%
Urinary excretion; patients; human, homo sapiens;
DRUGBANK
5.0
%
5±2
%
Urinary excretion; Unchanged drug;
DRUGBANK
93.5
%
89-98
%
plasma proteins;
DRUGBANK
93.0
%
88-98
%
DRUGBANK
260.0
mg/m2
260
mg/m2
intravenous injection, IV
Abraxane
paclitaxel protein-bound
PDR
260.0
mg/m2
260
mg/m2
intravenous injection, IV
Abraxane
paclitaxel protein-bound
PDR
DDPD01230
Pemoline
176.172
C9H8N2O2
NC1=NC(=O)C(O1)C1=CC=CC=C1
DB01230
4723
7953
http://www.drugs.com/mtm/pemoline.html
4561
-2.0
-
-2.0
-
DRUGBANK
12.0
h
~12
h
elimination half-life;
DRUGBANK
50.0
%
~50
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
~50
%
plasma proteins;
DRUGBANK
DDPD01231
Diphenidol
309.4452
C21H27NO
OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1
DB01231
3055
4638
http://www.drugs.com/cons/diphenidol.html
2947
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
DRUGBANK
DDPD01232
Saquinavir
670.8408
C38H50N6O5
[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
DB01232
441243
63621
http://www.drugs.com/cdi/saquinavir.html
390016
-2.0
-
-2.0
-
DRUGBANK
39026.0
ng.h/ml
39026.0
ng.h/ml
combination drug use;
DRUGBANK
4.0
%
~4
%
PO, oral;
DRUGBANK
90.0
%
>90
%
Liver metabolism;
DRUGBANK
1.14
L/h/kg
1.14
L/h/kg
Total clearance; intravenous injection, IV;
DRUGBANK
0.78
L/h/kg
13
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
700.0
L
700.0
L
Steady state volume of distribution;
DRUGBANK
3.6
L/kg
3.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.0
h
13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5
g/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
84.5
%
~81-88
%
Faeces excretion; PO, oral; intravenous injection, IV;
DRUGBANK
2.0
%
1-3
%
Urinary excretion; PO, oral; intravenous injection, IV;
DRUGBANK
98.0
%
~98
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
2000.0
mg/day
2000
mg/day
PO, oral
Invirase
saquinavir mesylate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Invirase
saquinavir mesylate
PDR
1500.0
mg/m2/day
1500
mg/m2/day
Invirase
saquinavir mesylate
PDR
1600.0
mg
1600
mg
Invirase
saquinavir mesylate
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Invirase
saquinavir mesylate
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Invirase
saquinavir mesylate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Invirase
saquinavir mesylate
PDR
1500.0
mg/m2/day
1500
mg/m2/day
Invirase
saquinavir mesylate
PDR
1600.0
mg
1600
mg
Invirase
saquinavir mesylate
PDR
100.0
mg/kg/day
100
mg/kg/day
PO, oral
Invirase
saquinavir mesylate
PDR
DDPD01233
Metoclopramide
299.796
C14H22ClN3O2
CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
DB01233
4168
107736
http://www.drugs.com/metoclopramide.html
4024
-2.0
-
-2.0
-
DRUGBANK
84.0
%
84
%
PO, oral;
DRUGBANK
367.0
ng.h/ml
367.0
ng.h/ml
inhalation, IH;
DRUGBANK
40.7
%
40.7(30-100)
%
PO, oral;
DRUGBANK
47.0
%
47
%
inhalation, IH;
DRUGBANK
76.0
%
76±38
%
PO, oral;
DRUGBANK
41.0
ng/ml
41.0
ng/ml
inhalation, IH;
DRUGBANK
80.0
ng/ml
80.0
ng/ml
Oral single dose; Elderly;
DRUGBANK
18.0
ng/ml
18±6.2
ng/ml
Oral single dose; Infants;
DRUGBANK
1.25
h
1.25
h
inhalation, IH;
DRUGBANK
1.0
h
≤1
h
Oral single dose; Elderly;
DRUGBANK
2.5
h
2.5±0.7
h
Oral single dose; Infants;
DRUGBANK
0.16
L/h/kg
0.16
L/h/kg
Renal clearance;
DRUGBANK
0.7
L/h/kg
0.7
L/h/kg
Total clearance;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.5
L/h/kg
0.31-0.69
L/h/kg
Total clearance; intravenous injection, IV;
DRUGBANK
0.372
L/h/kg
6.2±1.3
ml/min/kg
Neonates ↑ ;Elderly → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.342
L/h/kg
5.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
L/kg
3.5
L/kg
DRUGBANK
3.4
L/kg
3.4±1.3
L/kg
Neonates ↑ ;Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
3.2
L/kg
3.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
5-6
h
elimination half-life; normal renal function;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
5.0
h
5.0±1.4
h
RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;Age → ;
DRUGBANK
7.2
h
7.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
750.0
mg/kg
750.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
85.0
%
85
%
Urinary excretion; PO, oral;
DRUGBANK
20.0
%
20±9
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
30
%
plasma proteins;
DRUGBANK
40.0
%
40±4
%
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.2
mg/kg/dose
0.2
mg/kg/dose
intravenous injection, IV
Metoclopramide Oral Solution
metoclopramide
PDR
0.2
mg/kg/dose
0.2
mg/kg/dose
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
2.0
mg/kg/dose
2
mg/kg/dose
intravenous infusion, iv in drop
Metoclopramide Oral Solution
metoclopramide
PDR
10.0
mg/dose
10
mg/dose
intravenous injection, IV
Metoclopramide Oral Solution
metoclopramide
PDR
10.0
mg/dose
10
mg/dose
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
60.0
mg/day
60
mg/day
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
20.0
mg/dose
20
mg/dose
Metoclopramide Oral Solution
metoclopramide
PDR
0.2
mg/kg/dose
0.2
mg/kg/dose
intravenous injection, IV
Metoclopramide Oral Solution
metoclopramide
PDR
0.2
mg/kg/dose
0.2
mg/kg/dose
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
2.0
mg/kg/dose
2
mg/kg/dose
intravenous infusion, iv in drop
Metoclopramide Oral Solution
metoclopramide
PDR
10.0
mg/dose
10
mg/dose
intravenous injection, IV
Metoclopramide Oral Solution
metoclopramide
PDR
10.0
mg/dose
10
mg/dose
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
60.0
mg/day
60
mg/day
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
20.0
mg/dose
20
mg/dose
Metoclopramide Oral Solution
metoclopramide
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV
Metoclopramide Oral Solution
metoclopramide
PDR
0.2
mg/kg/dose
0.2
mg/kg/dose
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
0.8
mg/kg/day
0.8
mg/kg/day
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
0.1
mg/kg/dose
0.1
mg/kg/dose
intravenous injection, IV
Metoclopramide Oral Solution
metoclopramide
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
0.6
mg/kg/day
0.6
mg/kg/day
PO, oral
Metoclopramide Oral Solution
metoclopramide
PDR
DDPD01234
Dexamethasone
392.4611
C22H29FO5
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB01234
T3D4982
5743
41879
http://www.drugs.com/cdi/dexamethasone-drops.html
5541
-2.0
-
-2.0
-
DRUGBANK
113.0
ng.h/ml
113±38
ng.h/ml
IM,intramuscular injection;
DRUGBANK
331.0
ng.h/ml
331±50
ng.h/ml
PO, oral;
DRUGBANK
74.0
%
70-78
%
PO, oral;
DRUGBANK
34.6
ng/ml
34.6±6.0
ng/ml
IM,intramuscular injection;
DRUGBANK
13.9
ng/ml
13.9±6.8
ng/ml
PO, oral;
DRUGBANK
2.0
h
2.0±1.2
h
IM,intramuscular injection;
DRUGBANK
2.0
h
2.0±0.5
h
PO, oral;
DRUGBANK
15.7
L/h
15.7
L/h
Tablet, PO, oral;
DRUGBANK
15.6
L/h
15.6±4.9
L/h
PO, oral;
DRUGBANK
9.9
L/h
9.9±1.4
L/h
IM,intramuscular injection;
DRUGBANK
0.198
L/h/kg
3.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
51.0
L
51.0
L
PO, oral;
DRUGBANK
96.0
L
96.0
L
IM,intramuscular injection;
DRUGBANK
0.94
L/kg
0.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
4
h
terminal half-life; Tablet, PO, oral;
DRUGBANK
6.6
h
6.6±4.3
h
PO, oral;
DRUGBANK
4.2
h
4.2±1.2
h
IM,intramuscular injection;
DRUGBANK
3.7
h
3.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6500.0
mg/kg
6.5
g/kg
PO, oral; female mouse;
DRUGBANK
794.0
mg/kg
794.0
mg/kg
intravenous injection, IV; female mouse;
DRUGBANK
3000.0
mg/kg
>3
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
77.0
%
~77
%
plasma proteins;
DRUGBANK
DDPD01235
Levodopa
197.1879
C9H11NO4
N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
DB01235
T3D3028
6047
15765
http://www.drugs.com/mtm/levodopa.html
5824
-2.0
-
-2.0
-
DRUGBANK
41.0
%
41±16
%
PO, oral;
DRUGBANK
86.0
%
86±19
%
combination drug use;
DRUGBANK
1700.0
ng/ml
1.7±0.8
mcg/ml
combination drug use; young;
DRUGBANK
1900.0
ng/ml
1.9±0.6
mcg/ml
combination drug use; Elderly;
DRUGBANK
0.5
h
0.5
h
inhalation, IH;
DRUGBANK
1.4
h
1.4±0.7
h
combination drug use; young;
DRUGBANK
1.4
h
1.4±0.7
h
combination drug use; Elderly;
DRUGBANK
0.852
L/h/kg
14.2
ml/min/kg
intravenous injection, IV; Geriatric;
DRUGBANK
1.404
L/h/kg
23.4
ml/min/kg
intravenous injection, IV; young;
DRUGBANK
0.348
L/h/kg
5.8
ml/min/kg
Drug combination; Geriatric;
DRUGBANK
0.558
L/h/kg
9.3
ml/min/kg
Drug combination; young;
DRUGBANK
1.38
L/h/kg
23±4
ml/min/kg
Elderly ↓ ;
DRUGBANK
0.54
L/h/kg
9±1
ml/min/kg
Drug combination;
Elderly ↓ ;
DRUGBANK
1.38
L/h/kg
23
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
168.0
L
168.0
L
PO, oral;
DRUGBANK
1.7
L/kg
1.7±0.4
L/kg
Elderly ↓ ;
DRUGBANK
0.9
L/kg
0.9±0.2
L/kg
Drug combination;
Elderly ↓ ;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.3
h
2.3
h
inhalation, IH;
DRUGBANK
0.833333333333333
h
50
min
PO, oral;
DRUGBANK
1.5
h
1.5
h
Drug combination;
DRUGBANK
1.4
h
1.4±0.4
h
Age → ;
DRUGBANK
1.5
h
1.5±0.3
h
Drug combination;
Age → ;
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2363.0
mg/kg
2363.0
mg/kg
PO, oral; mouse;
DRUGBANK
609.0
mg/kg
609.0
mg/kg
PO, oral; rabbit;
DRUGBANK
1780.0
mg/kg
1780.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
17.0
%
17
%
Faeces excretion; PO, oral;
DRUGBANK
0.28
%
0.28
%
lung excretion; PO, oral;
DRUGBANK
78.4
%
78.4
%
Urinary excretion; PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
~0
%
plasma proteins;
DRUGBANK
8000.0
mg/day
8
g/day
PO, oral
Inbrija
levodopa
PDR
420.0
mg/day
420
mg/day
inhalation, IH
Inbrija
levodopa
PDR
8000.0
mg/day
8
g/day
PO, oral
Inbrija
levodopa
PDR
420.0
mg/day
420
mg/day
inhalation, IH
Inbrija
levodopa
PDR
DDPD01236
Sevoflurane
200.0548
C4H3F7O
FCOC(C(F)(F)F)C(F)(F)F
DB01236
T3D3029
5206
9130
http://www.drugs.com/cdi/sevoflurane.html
5017
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5
%
DRUGBANK
19.0
h
15-23
h
DRUGBANK
10800.0
mg/kg
10.8
g/kg
Rattus, Rat;
DRUGBANK
10800.0
mg/kg
10.8
g/kg
Rattus, Rat;
DRUGBANK
DDPD01237
Bromodiphenhydramine
334.251
C17H20BrNO
CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1
DB01237
T3D3030
2444
59177
2350
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
DRUGBANK
96.0
%
96
%
DRUGBANK
DDPD01238
Aripiprazole
448.385
C23H27Cl2N3O2
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
DB01238
T3D2677
60795
31236
http://www.drugs.com/cdi/aripiprazole.html
54790
-2.0
-
-2.0
-
DRUGBANK
87.0
%
87
%
Tablet, PO, oral;
DRUGBANK
87.0
%
87.0
%
PO, oral;
DRUGBANK
242.0
ng/ml
242±36
ng/ml
PO, oral;
DRUGBANK
4.0
h
3-5
h
Tablet, PO, oral;
DRUGBANK
3.0
h
3.0±0.6
h
PO, oral;
DRUGBANK
0.048
L/h/kg
0.8
ml/min/kg
DRUGBANK
3.279
L/h
3297±1042
ml/h
DRUGBANK
0.0498
L/h/kg
0.83±0.17
ml/min/kg
apparent clearance; at steady state; hydrolysis; hydrolysis;
DRUGBANK
0.0498
L/h/kg
0.83
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
404.0
L
404.0
L
DRUGBANK
4.9
L/kg
4.9
L/kg
Apparent volume of distribution; at steady state; hydrolysis; hydrolysis;
DRUGBANK
4.9
L/kg
4.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
h
75
h
DRUGBANK
94.0
h
94
h
Active metabolite;
DRUGBANK
146.0
h
146
h
poor CYP2D6 metabolize;
DRUGBANK
61.03
h
61.03±19.59
h
different study;
DRUGBANK
279.0
h
279±299
h
different study; Active metabolite;
DRUGBANK
47.0
h
47±10
h
DRUGBANK
94.0
h
94.0
h
Metabolite;
DRUGBANK
75.0
h
75
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
%
25
%
Urinary excretion;
DRUGBANK
55.0
%
55
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
99.0
%
>99
%
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Abilify
aripiprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Abilify
aripiprazole
PDR
20.0
mg/day
20
mg/day
PO, oral
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Abilify
aripiprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Abilify
aripiprazole
PDR
10.0
mg/day
10
mg/day
PO, oral
Abilify
aripiprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Abilify
aripiprazole
PDR
20.0
mg/day
20
mg/day
PO, oral
Abilify
aripiprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Abilify
aripiprazole
PDR
10.0
mg/day
10
mg/day
PO, oral
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
Tablet,PO，oral
Abilify
aripiprazole
PDR
25.0
mg/day
25
mg/day
Liquid
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
IM,intramuscular injection
Abilify
aripiprazole
PDR
13.3333333333333
mg/day
400
mg/month
IM,intramuscular injection
Abilify
aripiprazole
PDR
29.4
mg/day
882
mg/month
IM,intramuscular injection
Abilify
aripiprazole
PDR
675.0
mg/dose
675
mg/dose
IM,intramuscular injection
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Abilify
aripiprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Abilify
aripiprazole
PDR
20.0
mg/day
20
mg/day
PO, oral
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Abilify
aripiprazole
PDR
15.0
mg/day
15
mg/day
PO, oral
Abilify
aripiprazole
PDR
10.0
mg/day
10
mg/day
PO, oral
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
Tablet,PO，oral
Abilify
aripiprazole
PDR
25.0
mg/day
25
mg/day
Liquid
Abilify
aripiprazole
PDR
30.0
mg/day
30
mg/day
IM,intramuscular injection
Abilify
aripiprazole
PDR
13.3333333333333
mg/day
400
mg/month
IM,intramuscular injection
Abilify
aripiprazole
PDR
29.4
mg/day
882
mg/month
IM,intramuscular injection
Abilify
aripiprazole
PDR
675.0
mg/dose
675
mg/dose
IM,intramuscular injection
Abilify
aripiprazole
PDR
DDPD01239
Chlorprothixene
315.86
C18H18ClNS
CN(C)CC\C=C1\C2=CC=CC=C2SC2=CC=C(Cl)C=C12
DB01239
T3D3031
667466
50931
580849
-2.0
-
-2.0
-
DRUGBANK
0.69
L/h/kg
11.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.7
L/kg
13.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
h
8-12
h
DRUGBANK
25.8
h
25.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01240
Epoprostenol
352.4651
C20H32O5
[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
DB01240
5280427
15552
http://www.drugs.com/cdi/epoprostenol.html
4445566
-2.0
-
-2.0
-
DRUGBANK
0.357
L/kg
357.0
ml/kg
DRUGBANK
0.1
h
~6
min
high protein binding;
DRUGBANK
0.1
h
<6
min
in vivo;
DRUGBANK
DDPD01241
Gemfibrozil
250.3334
C15H22O3
CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1
DB01241
T3D4809
3463
5296
http://www.drugs.com/gemfibrozil.html
3345
-2.0
-
-2.0
-
DRUGBANK
98.0
%
98±1
%
PO, oral;
DRUGBANK
46000.0
ng/ml
46±16
ug/ml
PO, oral; normal,healthy;
DRUGBANK
13800.0
ng/ml
13.8±11.1
ug/ml
PO, oral;
DRUGBANK
23000.0
ng/ml
23.0±10.3
ug/ml
PO, oral; hepatopathy，LD;
DRUGBANK
20000.0
ng/ml
15-25
mcg/ml
PO, oral;
DRUGBANK
2.2
h
2.2±1.1
h
PO, oral; normal,healthy;
DRUGBANK
2.3
h
2.3±1.0
h
PO, oral;
DRUGBANK
2.6
h
2.6±1.7
h
PO, oral; hepatopathy，LD;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
6.0
L/h
6.0
L/h
DRUGBANK
0.102
L/h/kg
1.7±0.4
ml/min/kg
Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.8
L/kg
0.8
L/kg
DRUGBANK
0.14
L/kg
0.14±0.03
L/kg
DRUGBANK
1.5
h
1.5
h
elimination half-life;
DRUGBANK
2.4
h
2.4
h
patients;
DRUGBANK
2.1
h
2.1
h
RD, renal impairment, Renal disease，including uremia; patients;
DRUGBANK
1.1
h
1.1±0.2
h
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2218.0
mg/kg
2218.0
mg/kg
PO, oral; mouse;
DRUGBANK
1414.0
mg/kg
1414.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
445.0
mg/kg
445.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
3162.0
mg/kg
3162.0
mg/kg
PO, oral; mouse;
DRUGBANK
70.0
%
~70
%
Urinary excretion;
DRUGBANK
6.0
%
~6
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
98.6
%
98.6
%
DRUGBANK
0.0
%
~0
%
DRUGBANK
0.8
%
0.8
%
serum albumin;
DRUGBANK
97.0
%
97
%
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Lopid
gemfibrozil
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Lopid
gemfibrozil
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Lopid
gemfibrozil
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Lopid
gemfibrozil
PDR
DDPD01242
Clomipramine
314.852
C19H23ClN2
CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
DB01242
T3D3032
2801
47780
http://www.drugs.com/cdi/clomipramine.html
2699
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral; food;
food → ;
DRUGBANK
92000000.0
ng/ml
92(56-154)
mg/ml
Oral single dose;
DRUGBANK
4.0
h
2-6
h
Oral single dose;
DRUGBANK
252.0
h
1-2
week
Oral multiple dose;
DRUGBANK
0.492
L/h/kg
8.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
L/kg
~17(9-25)
L/kg
DRUGBANK
13.0
L/kg
13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.0
h
32(19-37)
h
elimination half-life; Oral single dose;
DRUGBANK
69.0
h
69(54-77)
h
DRUGBANK
26.0
h
26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
55.5
%
51-60
%
Urinary excretion;
DRUGBANK
28.0
%
24-32
%
Faeces excretion;
DRUGBANK
97.5
%
~97-98
%
plasma proteins;
DRUGBANK
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Anafranil
clomipramine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Anafranil
clomipramine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Anafranil
clomipramine hydrochloride
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral
Anafranil
clomipramine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Anafranil
clomipramine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Anafranil
clomipramine hydrochloride
PDR
DDPD01243
Chloroxine
214.048
C9H5Cl2NO
OC1=C(Cl)C=C(Cl)C2=C1N=CC=C2
DB01243
2722
59477
http://www.drugs.com/cons/chloroxine-topical.html
2621
-2.0
-
-2.0
-
DRUGBANK
DDPD01244
Bepridil
366.5396
C24H34N2O
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
DB01244
2351
3061
http://www.drugs.com/mtm/bepridil.html
2261
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
0.522
L/h/kg
8.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.1
L/kg
10.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.0
h
24-50
h
DRUGBANK
14.9
h
14.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
DRUGBANK
DDPD01245
Decamethonium
258.4863
C16H38N2
C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
DB01245
2968
41934
2862
-2.0
-
-2.0
-
DRUGBANK
190.0
mg/kg
190.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD01246
Alimemazine
298.446
C18H22N2S
CC(CN(C)C)CN1C2=CC=CC=C2SC2=CC=CC=C12
DB01246
5574
9725
5373
-2.0
-
-2.0
-
DRUGBANK
DDPD01247
Isocarboxazid
231.2505
C12H13N3O2
CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1
DB01247
T3D3033
3759
93635
http://www.drugs.com/cdi/isocarboxazid.html
3628
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
2.75
h
1.5-4
h
DRUGBANK
42.5
%
42.5
%
Urinary excretion;
DRUGBANK
22.0
%
22
%
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Marplan
isocarboxazid
PDR
60.0
mg/day
60
mg/day
PO, oral
Marplan
isocarboxazid
PDR
60.0
mg/day
60
mg/day
PO, oral
Marplan
isocarboxazid
PDR
DDPD01248
Docetaxel
807.8792
C43H53NO14
[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
DB01248
T3D3501
148124
4672
http://www.drugs.com/cdi/docetaxel.html
130581
-2.0
-
-2.0
-
DRUGBANK
2400.0
ng/ml
2.4±0.9
mcg/ml
intravenous infusion, IV in drop; tumor;
DRUGBANK
21.0
L/h/m2
21.0
L/h/m2
Total clearance; intravenous injection, IV; tumor; patients;
DRUGBANK
22.6
L/h/m2
22.6±7.7
L/h/m2
mild hepatic impairment ↓ ;moderate hepatic impairment ↓ ;
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
113.0
L
113.0
L
DRUGBANK
72.0
L/m2
72±24
L/m2
DRUGBANK
2.1
L/kg
2.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0666666666666667
h
4
min
distribution half-life;
DRUGBANK
0.6
h
36
min
elimination half-life;
DRUGBANK
11.1
h
11.1
h
terminal half-life;
DRUGBANK
13.6
h
13.6±6.1
h
Male, men; Female, women; tumor;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
6.0
%
6
%
Urinary excretion;
DRUGBANK
75.0
%
75
%
Faeces excretion;
DRUGBANK
2.1
%
2.1±0.2
%
Urinary excretion; tumor; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
97
%
plasma proteins; tumor;
DRUGBANK
94.0
%
94
%
tumor; human, homo sapiens;
DRUGBANK
65.0
mg/m2
65
mg/m2
intravenous injection, IV
q3w
Docefrez
docetaxel
PDR
125.0
mg/m2
125
mg/m2
intravenous injection, IV
Docefrez
docetaxel
PDR
100.0
mg/m2
100
mg/m2
intravenous injection, IV; over 1 hour every 3 weeks
Docefrez
docetaxel
PDR
40.0
mg/m2
40
mg/m2
qw
Docefrez
docetaxel
PDR
100.0
mg/m2
100
mg/m2
Intraperitoneal, IP
q3w
Docefrez
docetaxel
PDR
100.0
mg/m2
100
mg/m2
intravenous injection, IV; over 1 hour every 3 weeks
Docefrez
docetaxel
PDR
40.0
mg/m2
40
mg/m2
qw
Docefrez
docetaxel
PDR
100.0
mg/m2
100
mg/m2
Intraperitoneal, IP
q3w
Docefrez
docetaxel
PDR
DDPD01249
Iodixanol
1550.1819
C35H44I6N6O15
CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
DB01249
3724
31705
http://www.drugs.com/mtm/iodixanol.html
3593
-2.0
-
-2.0
-
DRUGBANK
0.0864
L/h/kg
1.44
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.26
L/kg
0.26
L/kg
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
h
2.1
h
DRUGBANK
23.0
h
23
h
severe renal function;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
97.0
%
~97
%
Urinary excretion; adults; Unchanged drug;
DRUGBANK
DDPD01250
Olsalazine
302.239
C14H10N2O6
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O
DB01250
6003770
http://www.drugs.com/cdi/olsalazine.html
10642377
-2.0
-
-2.0
-
DRUGBANK
98.5
%
98-99
%
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.07
L/kg
0.07
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
h
0.9
h
elimination half-life;
DRUGBANK
168.0
h
7
day
Raceme L;
DRUGBANK
0.9
h
0.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
1000.0
mg/day
1
g/day
PO, oral
Dipentum
olsalazine sodium
PDR
1000.0
mg/day
1
g/day
PO, oral
Dipentum
olsalazine sodium
PDR
DDPD01251
Gliquidone
527.632
C27H33N3O6S
COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O
DB01251
91610
93416
82719
-2.0
-
-2.0
-
DRUGBANK
8.0
h
~8(5.7-9.4)
h
terminal half-life;
DRUGBANK
DDPD01253
Ergometrine
325.4048
C19H23N3O2
[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](C)CO
DB01253
T3D3685
443884
4822
http://www.drugs.com/cdi/ergonovine.html
391970
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; IM,intramuscular injection;
DRUGBANK
0.166666666666667
h
10
min
distribution half-life;
DRUGBANK
2.0
h
2
h
elimination half-life;
DRUGBANK
DDPD01254
Dasatinib
488.006
C22H26ClN7O2S
CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
DB01254
3062316
49375
http://www.drugs.com/cdi/dasatinib.html
2323020
-2.0
-
-2.0
-
DRUGBANK
2505.0
L
2505.0
L
DRUGBANK
4.0
h
3-5
h
terminal half-life;
DRUGBANK
96.0
%
96
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Sprycel
dasatinib
PDR
50.0
mg/day
50
mg/day
PO, oral
Sprycel
dasatinib
PDR
60.0
mg/day
60
mg/day
PO, oral
Sprycel
dasatinib
PDR
70.0
mg/day
70
mg/day
PO, oral
Sprycel
dasatinib
PDR
70.0
mg/day
70
mg/day
PO, oral
Sprycel
dasatinib
PDR
90.0
mg/day
90
mg/day
PO, oral
Sprycel
dasatinib
PDR
100.0
mg/day
100
mg/day
PO, oral
Sprycel
dasatinib
PDR
120.0
mg/day
120
mg/day
PO, oral
Sprycel
dasatinib
PDR
140.0
mg/day
140
mg/day
PO, oral
Sprycel
dasatinib
PDR
180.0
mg/day
180
mg/day
PO, oral
Sprycel
dasatinib
PDR
70.0
mg/day
70
mg/day
PO, oral
Sprycel
dasatinib
PDR
90.0
mg/day
90
mg/day
PO, oral
Sprycel
dasatinib
PDR
100.0
mg/day
100
mg/day
PO, oral
Sprycel
dasatinib
PDR
120.0
mg/day
120
mg/day
PO, oral
Sprycel
dasatinib
PDR
140.0
mg/day
140
mg/day
PO, oral
Sprycel
dasatinib
PDR
180.0
mg/day
180
mg/day
PO, oral
Sprycel
dasatinib
PDR
DDPD01255
Lisdexamfetamine
263.3785
C15H25N3O
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
DB01255
11597698
135925
http://www.drugs.com/cdi/lisdexamfetamine.html
9772458
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
Tablet, PO, oral; normal,healthy; fasting;
DRUGBANK
4.4
h
4.4
h
Tablet, PO, oral; normal,healthy; fasting; Active metabolite;
DRUGBANK
1.0
h
1
h
Capsule, PO, Oral; Children; fasting; Attention deficit hyperactivity disorder;
DRUGBANK
3.5
h
3.5
h
Capsule, PO, Oral; Children; fasting; Attention deficit hyperactivity disorder; Active metabolite;
DRUGBANK
0.625
L/h/kg
0.55-0.7
l/h/kg
Elderly;
DRUGBANK
1.02
L/h/kg
17
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
0.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
~12
h
elimination half-life; PO, oral;
DRUGBANK
1.0
h
<1
h
elimination half-life; Single dose;
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7060.0
mg/kg
7060.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3450.0
mg/kg
3450.0
mg/kg
PO, oral; mouse;
DRUGBANK
96.0
%
96
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
0.3
%
0.3
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
70.0
mg/day
70
mg/day
PO, oral
Vyvanse
lisdexamfetamine dimesylate
PDR
70.0
mg/day
70
mg/day
PO, oral
Vyvanse
lisdexamfetamine dimesylate
PDR
70.0
mg/day
70
mg/day
PO, oral
Vyvanse
lisdexamfetamine dimesylate
PDR
70.0
mg/day
70
mg/day
PO, oral
Vyvanse
lisdexamfetamine dimesylate
PDR
DDPD01256
Retapamulin
517.763
C30H47NO4S
[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C
DB01256
6918462
http://www.drugs.com/cdi/retapamulin-ointment.html
25064484
-2.0
-
-2.0
-
DRUGBANK
94.0
%
~94
%
plasma proteins; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
2.0
% body surface area
2
% body surface area
Altabax
retapamulin
PDR
100.0
cm2
100
cm2
Altabax
retapamulin
PDR
2.0
m2
2
%body surface area
Altabax
retapamulin
PDR
100.0
cm2
100
cm2
Altabax
retapamulin
PDR
2.0
% body surface area
2
% body surface area
Altabax
retapamulin
PDR
DDPD01259
Lapatinib
581.058
C29H26ClFN4O4S
CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
DB01259
208908
49603
http://www.drugs.com/cdi/lapatinib.html
181006
-2.0
-
-2.0
-
DRUGBANK
14.2
h
14.2
h
terminal half-life; Single dose;
DRUGBANK
24.0
h
24
h
effective half-life; Multiple dose;
DRUGBANK
99.0
%
99
%
DRUGBANK
1500.0
mg/day
1500
mg/day
PO, oral
qd
Tykerb
lapatinib
PDR
1500.0
mg/day
1500
mg/day
PO, oral
qd
Tykerb
lapatinib
PDR
DDPD01260
Desonide
416.5073
C24H32O6
[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB01260
5311066
204734
http://www.drugs.com/cdi/desonide-cream.html
4470603
-2.0
-
-2.0
-
DRUGBANK
4.0
application/day
4
application/day
skin/dermal;skin ointment;
Desonide Ointment, 0.05%
desonide
PDR
3.0
application/day
3
application/day
skin/dermal
Desonide Ointment, 0.05%
desonide
PDR
2.0
application/day
2
application/day
skin/dermal;gel;skin,foam;
Desonide Ointment, 0.05%
desonide
PDR
4.0
application/day
4
application/day
skin/dermal;skin ointment;
Desonide Ointment, 0.05%
desonide
PDR
3.0
application/day
3
application/day
skin/dermal
Desonide Ointment, 0.05%
desonide
PDR
2.0
application/day
2
application/day
skin/dermal;gel;skin,foam;
Desonide Ointment, 0.05%
desonide
PDR
2.0
appLication/day
2
appLication/day
skin/dermal;gel;skin,foam;
Desonide Ointment, 0.05%
desonide
PDR
4.0
application/day
4
application/day
skin/dermal;skin ointment;
Desonide Ointment, 0.05%
desonide
PDR
3.0
application/day
3
application/day
skin/dermal
Desonide Ointment, 0.05%
desonide
PDR
2.0
application/day
2
application/day
skin/dermal;gel;skin,foam;
Desonide Ointment, 0.05%
desonide
PDR
DDPD01261
Sitagliptin
407.3136
C16H15F6N5O
N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
DB01261
4369359
40237
http://www.drugs.com/cdi/sitagliptin.html
3571948
-2.0
-
-2.0
-
DRUGBANK
87.0
%
87
%
PO, oral; food;
food → ;
DRUGBANK
2.0
h
2
h
PO, oral; food;
food → ;
DRUGBANK
79.0
%
79
%
DRUGBANK
21.0
L/h
350.0
ml/min
DRUGBANK
0.36
L/h/kg
6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
198.0
L
198.0
L
DRUGBANK
2.8
L/kg
2.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.4
h
~12.4
h
DRUGBANK
11.0
h
~11
h
different study;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.0
%
87
%
Urinary excretion;
DRUGBANK
13.0
%
13
%
Faeces excretion;
DRUGBANK
79.0
%
~79
%
Urinary excretion; Unchanged drug;
DRUGBANK
38.0
%
38
%
DRUGBANK
DDPD01262
Decitabine
228.2053
C8H12N4O4
NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
DB01262
451668
50131
http://www.drugs.com/cdi/decitabine.html
397844
-2.0
-
-2.0
-
DRUGBANK
125.0
L/h/m2
125.0
L/h/m2
intravenous infusion, IV in drop; patients;
DRUGBANK
210.0
L/h/m2
210.0
L/h/m2
intravenous infusion, IV in drop;
DRUGBANK
7.8
L/h/kg
130
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.6
L/kg
4.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.51
h
0.51±0.31
h
elimination half-life;
DRUGBANK
0.58
h
0.58
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
plasma proteins;
DRUGBANK
15.0
mg/m2/day
15
mg/m2/day
intravenous injection, IV
Dacogen
decitabine
PDR
135.0
mg/m2/cycLe
135
mg/m2/cycLe
intravenous injection, IV
Dacogen
decitabine
PDR
20.0
mg/m2/day
20
mg/m2/day
intravenous injection, IV
Dacogen
decitabine
PDR
15.0
mg/m2/day
15
mg/m2/day
intravenous injection, IV
Dacogen
decitabine
PDR
135.0
mg/m2/cycle
135
mg/m2/cycle
intravenous injection, IV
Dacogen
decitabine
PDR
50.0
mg/m2/day
50
mg/m2/day
intravenous injection, IV
Dacogen
decitabine
PDR
DDPD01263
Posaconazole
700.7774
C37H42F2N8O4
[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1
DB01263
T3D3035
468595
64355
http://www.drugs.com/cdi/posaconazole-suspension.html
411709
-2.0
-
-2.0
-
DRUGBANK
4.0
h
3-5
h
DRUGBANK
17.0
%
17
%
Urinary excretion; Faeces excretion;
DRUGBANK
32.0
L/h
32.0
L/h
DRUGBANK
51.0
L/h
51.0
L/h
fasting;
DRUGBANK
21.0
L/h
21.0
L/h
low fat meal;
DRUGBANK
14.0
L/h
14.0
L/h
high-fat meal;
DRUGBANK
91.0
L/h
91.0
L/h
fasting;
DRUGBANK
43.0
L/h
43.0
L/h
liquid nutritional supplement;
DRUGBANK
0.258
L/h/kg
4.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1774.0
L
1774.0
L
DRUGBANK
3.8
L/kg
3.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
h
35(20-66)
h
DRUGBANK
10.6
h
10.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
%
17
%
Urinary excretion; Faeces excretion;
DRUGBANK
98.0
%
>98
%
DRUGBANK
24.0
mg/kg/day
24
mg/kg/day
Liquid
Noxafil
posaconazole
PDR
800.0
mg/day
800
mg/day
Liquid
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Noxafil
posaconazole
PDR
24.0
mg/kg/day
24
mg/kg/day
intravenous injection, IV
Noxafil
posaconazole
PDR
800.0
mg/day
800
mg/day
Liquid
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Noxafil
posaconazole
PDR
800.0
mg/day
800
mg/day
Liquid
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Noxafil
posaconazole
PDR
800.0
mg/day
800
mg/day
Liquid
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
Tablet,PO，oral
Noxafil
posaconazole
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Noxafil
posaconazole
PDR
24.0
mg/kg/day
24
mg/kg/day
Liquid
Noxafil
posaconazole
PDR
24.0
mg/kg/day
24
mg/kg/day
Liquid
Noxafil
posaconazole
PDR
DDPD01264
Darunavir
547.664
C27H37N3O7S
[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
DB01264
213039
367163
http://www.drugs.com/cdi/darunavir.html
184733
-2.0
-
-2.0
-
DRUGBANK
37.0
%
37
%
Oral single dose;
DRUGBANK
82.0
%
82
%
combination drug use;
DRUGBANK
3.2
h
2.4-4
h
PO, oral;
DRUGBANK
32.8
L/h
32.8
L/h
intravenous injection, IV;
DRUGBANK
0.4686
L/h/kg
7.81
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
206.5
L
206.5
L
Drug combination;
DRUGBANK
220.0
L
220.0
L
DRUGBANK
15.0
h
~15
h
elimination half-life; Drug combination;
DRUGBANK
15.0
h
15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
79.5
%
~79.5
%
Faeces excretion; Single dose; Drug combination; normal,healthy; human, homo sapiens;
DRUGBANK
13.9
%
~13.9
%
Urinary excretion; Single dose; Drug combination; Ritonavir; normal,healthy; human, homo sapiens;
DRUGBANK
95.0
%
~95
%
plasma proteins;
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Prezista
darunavir
PDR
900.0
mg/day
900
mg/day
PO, oral
Prezista
darunavir
PDR
750.0
mg/day
750
mg/day
PO, oral
Prezista
darunavir
PDR
560.0
mg/day
560
mg/day
PO, oral
Prezista
darunavir
PDR
520.0
mg/day
520
mg/day
PO, oral
Prezista
darunavir
PDR
480.0
mg/day
480
mg/day
PO, oral
Prezista
darunavir
PDR
440.0
mg/day
440
mg/day
PO, oral
Prezista
darunavir
PDR
400.0
mg/day
400
mg/day
PO, oral
Prezista
darunavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Prezista
darunavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Prezista
darunavir
PDR
900.0
mg/day
900
mg/day
PO, oral
Prezista
darunavir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Prezista
darunavir
PDR
DDPD01265
Telbivudine
242.2286
C10H14N2O5
CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O
DB01265
159269
63624
http://www.drugs.com/cdi/telbivudine.html
140081
-2.0
-
-2.0
-
DRUGBANK
7.6
L/h
7.6±2.9
L/h
normal renal function;
DRUGBANK
5.0
L/h
5.0±1.2
L/h
mild renal function;
DRUGBANK
2.6
L/h
2.6±1.2
L/h
moderate renal function;
DRUGBANK
0.7
L/h
0.7±0.4
L/h
severe renal function;
DRUGBANK
15.0
h
~15
h
DRUGBANK
3.3
%
3.3
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
qd
Tyzeka
telbivudine
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Tyzeka
telbivudine
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Tyzeka
telbivudine
PDR
DDPD01267
Paliperidone
426.4839
C23H27FN4O3
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
DB01267
115237
83804
http://www.drugs.com/cdi/paliperidone.html
103109
-2.0
-
-2.0
-
DRUGBANK
28.0
%
28
%
PO, oral;
DRUGBANK
0.0708
L/h/kg
1.18
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
487.0
L
487.0
L
DRUGBANK
23.0
h
~23
h
elimination half-life;
DRUGBANK
24.6
h
24.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
59.0
%
59(51-67)
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
74.0
%
74
%
plasma proteins;
DRUGBANK
12.0
mg/day
12
mg/day
PO, oral
Invega
paliperidone
PDR
6.0
mg/day
6
mg/day
PO, oral
Invega
paliperidone
PDR
12.0
mg/day
12
mg/day
Tablet,PO，oral
Invega
paliperidone
PDR
7.8
mg/day
234
mg/month
IM,intramuscular injection
Invega
paliperidone
PDR
9.1
mg/day
819
mg/3 months
IM,intramuscular injection
Invega
paliperidone
PDR
12.0
mg/day
12
mg/day
PO, oral
Invega
paliperidone
PDR
6.0
mg/day
6
mg/day
PO, oral
Invega
paliperidone
PDR
12.0
mg/day
12
mg/day
Tablet,PO，oral
Invega
paliperidone
PDR
7.8
mg/day
234
mg/month
IM,intramuscular injection
Invega
paliperidone
PDR
9.1
mg/day
819
mg/3 months
IM,intramuscular injection
Invega
paliperidone
PDR
DDPD01268
Sunitinib
398.4738
C22H27FN4O2
CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
DB01268
5329102
38940
http://www.drugs.com/cdi/sunitinib.html
4486264
-2.0
-
-2.0
-
DRUGBANK
9.0
h
6-12
h
PO, oral;
DRUGBANK
48.0
L/h
34-62
L/h
Total clearance; PO, oral;
DRUGBANK
2230.0
L
2230.0
L
Apparent volume of distribution;
DRUGBANK
50.0
h
40-60
h
terminal half-life; Oral single dose; normal,healthy;
DRUGBANK
95.0
h
80-110
h
terminal half-life; Active metabolite; Oral single dose; normal,healthy;
DRUGBANK
61.0
%
61
%
Faeces excretion;
DRUGBANK
16.0
%
16
%
Urinary excretion;
DRUGBANK
95.0
%
95
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
87.5
mg/day
87.5
mg/day
PO, oral
Sutent
sunitinib malate
PDR
62.5
mg/day
62.5
mg/day
PO, oral
Sutent
sunitinib malate
PDR
87.5
mg/day
87.5
mg/day
PO, oral
Sutent
sunitinib malate
PDR
62.5
mg/day
62.5
mg/day
PO, oral
Sutent
sunitinib malate
PDR
DDPD01273
Varenicline
211.268
C13H13N3
C1C2CNCC1C1=C2C=C2N=CC=NC2=C1
DB01273
T3D2577
5310966
84500
http://www.drugs.com/cdi/varenicline.html
148958
-2.0
-
-2.0
-
DRUGBANK
10.0
%
<10
%
DRUGBANK
81.0
%
81
%
Urinary excretion;
DRUGBANK
24.0
h
~24
h
elimination half-life;
DRUGBANK
92.0
%
92
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
<20
%
DRUGBANK
1.0
mg
1
mg
PO, oral
bid
Chantix
varenicline
PDR
1.0
mg
1
mg
PO, oral
bid
Chantix
varenicline
PDR
DDPD01274
Arformoterol
344.4049
C19H24N2O4
COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1
DB01274
3083544
408174
http://www.drugs.com/cdi/arformoterol.html
2340731
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
8.9
L/h
8.9
L/h
Renal clearance; normal,healthy; Male, men;
DRUGBANK
26.0
h
26
h
COPD, Chronic obstructive pulmonary disease;
DRUGBANK
63.0
%
63
%
Urinary excretion; PO, oral; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
11.0
%
11
%
Faeces excretion; PO, oral; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
58.5
%
52-65
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
0.03
mg/day
30
mcg/day
inhalation, IH
Brovana
arformoterol tartrate
PDR
0.03
mg/day
30
mcg/day
inhalation, IH
Brovana
arformoterol tartrate
PDR
DDPD01275
Hydralazine
160.1759
C8H8N4
NNC1=NN=CC2=CC=CC=C12
DB01275
3637
5775
http://www.drugs.com/cdi/hydralazine.html
3511
-2.0
-
-2.0
-
DRUGBANK
93903.121375
ng.h
17.5-29.4
uM.min
PO, oral;
DRUGBANK
45917.0913333333
ng.h
4.0-30.4
uM.min
PO, oral;
DRUGBANK
114.5257685
mg/ml
0.12-1.31
uM
PO, oral; patients;
DRUGBANK
1.77
L/h/kg
1.77±0.48
L/kg/h
Average clearance; heart disease;
DRUGBANK
2.562
L/h/kg
42.7±8.9
ml/min/kg
Average clearance; hypertension;
DRUGBANK
5.1
L/h/kg
85
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.34
L/kg
1.34±0.79
L/kg
heart disease; patients;
DRUGBANK
1.98
L/kg
1.98±0.22
L/kg
hypertension; patients;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
2.2-7.8
h
fast acetylators;
DRUGBANK
3.9
h
2.0-5.8
h
Slow acetylators;
DRUGBANK
1.75
h
105(57-241)
min
heart failure; patients;
DRUGBANK
3.33333333333333
h
200
min
hypertension; fast acetylators;
DRUGBANK
4.95
h
297
min
hypertension; Slow acetylators;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
180.0
mg/kg
173-187
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10.0
%
<10
%
Faeces excretion;
DRUGBANK
77.5
%
65-90
%
Urinary excretion;
DRUGBANK
87.0
%
87
%
human, homo sapiens;
DRUGBANK
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
3.5
mg/kg/day
3.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
3.5
mg/kg/day
3.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
300.0
mg/day
300
mg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
250.0
mg/day
250
mg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
3.5
mg/kg/day
3.5
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
0.6
mg/kg/dose
0.6
mg/kg/dose
intravenous injection, IV
Hydralazine Hydrochloride Tablets
hydralazine hydrochloride
PDR
DDPD01278
Pramlintide
3949.44
C171H267N51O53S2
[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](C)NC(=O)[C@@]([H])(NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O
DB01278
135922
http://www.drugs.com/cdi/pramlintide.html
44241191
-2.0
-
-2.0
-
DRUGBANK
35.0
%
30-40
%
Oral single dose;
DRUGBANK
0.918
L/h/kg
15.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.41
L/kg
0.41
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.8
h
~48
min
DRUGBANK
0.6
h
0.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
120.0
mcg/dose
120
mcg/dose
subcutaneous injection, SC
Symlin
pramlintide acetate
PDR
120.0
mcg/dose
120
mcg/dose
subcutaneous injection, SC
Symlin
pramlintide acetate
PDR
DDPD01280
Nelarabine
297.2673
C11H15N5O5
COC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
DB01280
3011155
63612
http://www.drugs.com/cdi/nelarabine.html
2280207
-2.0
-
-2.0
-
DRUGBANK
197.0
L/h/m2
197±189
L/h/m2
refractory leukemia; adults; patients;
DRUGBANK
259.0
L/h/m2
259±409
L/h/m2
refractory leukemia; pediatric patients;
DRUGBANK
4.86
L/h/kg
81
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.9
L/kg
4.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
h
30
min
DRUGBANK
3.0
h
3
h
DRUGBANK
0.5
h
0.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
%
<25
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
650.0
mg/m2/day
650
mg/m2/day
intravenous injection, IV
Arranon
nelarabine
PDR
1500.0
mg/m2
1500
mg/m2
intravenous injection, IV
on days 1, 3, and 5
Arranon
nelarabine
PDR
650.0
mg/m2/day
650
mg/m2/day
intravenous injection, IV
Arranon
nelarabine
PDR
1500.0
mg/m2
1500
mg/m2
intravenous injection, IV; on days 1, 3, and 5
Arranon
nelarabine
PDR
DDPD01282
Carbetocin
988.161
C45H69N11O12S
[H][C@]1(NC(=O)[C@H](CC2=CC=C(OC)C=C2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC
DB01282
16681432
59204
16736854
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
IM,intramuscular injection;
DRUGBANK
0.666666666666667
h
40
min
DRUGBANK
DDPD01283
Lumiracoxib
293.721
C15H13ClFNO2
CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1
DB01283
151166
73044
133236
-2.0
-
-2.0
-
DRUGBANK
74.0
%
74
%
PO, oral;
DRUGBANK
4.0
h
~4
h
terminal half-life;
DRUGBANK
98.0
%
≥98
%
plasma proteins;
DRUGBANK
DDPD01284
Tetracosactide
2933.49
C136H210N40O31S
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O
DB01284
16133751
3901
http://www.drugs.com/cdi/cosyntropin.html
10481947
-2.0
-
-2.0
-
DRUGBANK
0.25
h
~15
min
intravenous injection, IV;
DRUGBANK
0.25
mg/dose
0.25
mg/dose
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
0.125
mg/dose
0.125
mg/dose
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
0.25
mg/test
0.25
mg/test
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
0.75
mg
0.75
mg
intravenous injection, IV
Cortrosyn
cosyntropin
PDR
0.25
mg/test
0.25
mg/test
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
0.25
mg/test
0.25
mg/test
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
0.75
mg
0.75
mg
intravenous injection, IV
Cortrosyn
cosyntropin
PDR
0.125
mg
0.125
mg
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
0.015
mg/kg/dose
0.015
mg/kg/dose
intravenous injection, IV;IM,intramuscular injection;
Cortrosyn
cosyntropin
PDR
3.5
mcg/kg/dose
3.5
mcg/kg/dose
intravenous injection, IV
Cortrosyn
cosyntropin
PDR
DDPD01288
Fenoterol
303.3529
C17H21NO4
CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1
DB01288
3343
149226
3226
-2.0
-
-2.0
-
DRUGBANK
1.74
L/h/kg
29
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.87
h
0.87
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01291
Pirbuterol
240.2988
C12H20N2O3
CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1
DB01291
4845
8245
http://www.drugs.com/cdi/pirbuterol.html
4679
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
DRUGBANK
DDPD01294
Bismuth subsalicylate
362.0926
C7H5BiO4
O[Bi]1OC(=O)C2=CC=CC=C2O1
DB01294
16682734
261649
http://www.drugs.com/cdi/bismuth-subsalicylate.html
17215772
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
DDPD01296
Glucosamine
179.1711
C6H13NO5
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
DB01296
439213
47977
http://www.drugs.com/cdi/glucosamine.html
388352
-2.0
-
-2.0
-
DRUGBANK
DDPD01297
Practolol
266.3361
C14H22N2O3
CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1
DB01297
4883
258351
4715
-2.0
-
-2.0
-
DRUGBANK
0.1368
L/h/kg
2.28
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.2
h
12.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01298
Sulfacytine
294.33
C12H14N4O3S
CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O
DB01298
5322
135230
5131
-2.0
-
-2.0
-
DRUGBANK
DDPD01299
Sulfadoxine
310.329
C12H14N4O4S
COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC
DB01299
17134
9329
16218
-2.0
-
-2.0
-
DRUGBANK
DDPD01301
Rolitetracycline
527.5662
C27H33N3O8
[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCN1CCCC1)=C(O)[C@H]2N(C)C
DB01301
54682938
63334
21111754
-2.0
-
-2.0
-
DRUGBANK
0.0582
L/h/kg
0.97
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.54
L/kg
0.54
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.8
h
8.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
262.0
mg/kg
262.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
DDPD01303
Oxtriphylline
283.3268
C12H21N5O3
C[N+](C)(C)CCO.CN1C2=C([N-]C=N2)C(=O)N(C)C1=O
DB01303
656652
http://www.drugs.com/mtm/oxtriphylline.html
25044543
-2.0
-
-2.0
-
DRUGBANK
0.087
L/h/kg
1.45
ml/kg/min
Average clearance; Children;
DRUGBANK
0.00065
L/h/kg
0.65
ml/kg/h
Average clearance; normal,healthy; adults;
DRUGBANK
0.5
L/kg
0.3–0.7
L/kg
Apparent volume of distribution; Children; adults;
DRUGBANK
7.9
h
3-12.8
h
elimination half-life; normal,healthy;
DRUGBANK
5.5
h
1.5-9.5
h
elimination half-life; Children;
DRUGBANK
36.5
h
15-58
h
elimination half-life; Prem, premature;
DRUGBANK
56.0
%
~56
%
plasma proteins; adults; Children; human, homo sapiens;
DRUGBANK
36.0
%
~36
%
plasma proteins; Prem, premature; human, homo sapiens;
DRUGBANK
DDPD01319
Fosamprenavir
585.607
C25H36N3O9PS
CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
DB01319
131536
82941
http://www.drugs.com/cdi/fosamprenavir.html
116245
-2.0
-
-2.0
-
DRUGBANK
7.7
h
~7.7
h
elimination half-life; Active metabolite;
DRUGBANK
90.0
%
~90
%
DRUGBANK
36.0
mg/kg/day
36
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
1400.0
mg/day
1400
mg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
1400.0
mg/day
1400
mg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
46.0
mg/kg/day
46
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
90.0
mg/kg/day
90
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
46.0
mg/kg/day
46
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
90.0
mg/kg/day
90
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
2800.0
mg/day
2800
mg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
36.0
mg/kg/day
36
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
1400.0
mg/day
1400
mg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
2800.0
mg/kg/day
2800
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
2800.0
mg/day
2800
mg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
46.0
mg/kg/day
46
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
60.0
mg/kg/day
60
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
90.0
mg/kg/day
90
mg/kg/day
PO, oral
Lexiva
fosamprenavir calcium
PDR
DDPD01320
Fosphenytoin
362.2739
C16H15N2O6P
OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
DB01320
T3D3036
56339
5165
http://www.drugs.com/cdi/fosphenytoin.html
50839
-2.0
-
-2.0
-
DRUGBANK
0.21
L/h/kg
3.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.55
L
4.3-10.8
L
DRUGBANK
0.06
L/kg
0.06
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.25
h
~15
min
DRUGBANK
0.16
h
0.16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
156.0
mg/kg
156.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
250.0
mg/kg
~250
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
156.0
mg/kg
156.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
97.0
%
95-99
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD01322
Kava
232.275
C14H16O3
COC1=CC(=O)OC(C1)\C=C\C1=CCCC=C1
DB01322
5281052
http://www.drugs.com/cdi/kava.html
4444512
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
DDPD01324
Polythiazide
439.882
C11H13ClF3N3O4S3
CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
DB01324
4870
8327
http://www.drugs.com/cons/polythiazide.html
4704
-2.0
-
-2.0
-
DRUGBANK
DDPD01325
Quinethazone
289.739
C10H12ClN3O3S
CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O
DB01325
6307
8717
6068
-2.0
-
-2.0
-
DRUGBANK
DDPD01326
Cefamandole
462.503
C18H18N6O5S2
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O
DB01326
456255
3480
401748
-2.0
-
-2.0
-
DRUGBANK
0.216
L/h/kg
3.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.533333333333333
h
32
min
intravenous injection, IV;
DRUGBANK
1.0
h
60
min
IM,intramuscular injection;
DRUGBANK
0.75
h
0.75
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
%
75
%
DRUGBANK
DDPD01327
Cefazolin
454.507
C14H14N8O4S3
[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O
DB01327
33255
474053
http://www.drugs.com/cdi/cefazolin.html
30723
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
42000.0
ng/ml
42±9.5
mcg/ml
DRUGBANK
237000.0
ng/ml
237±285
mcg/ml
DRUGBANK
1.5
h
1-2
h
IM,intramuscular injection;
DRUGBANK
1.7
h
1.7±0.7
h
DRUGBANK
0.0
%
0
%
DRUGBANK
0.057
L/h/kg
0.95±0.17
ml/min/kg
Neonates → ;Children → ;Preg, pregnant ↑ ;Hepatitis, Hep → ;RD, renal impairment, Renal disease，including uremia ↓ ;Obesity → ;CPBS ↓ ;
DRUGBANK
0.0534
L/h/kg
0.89
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19±0.06
L/kg
Neonates ↑ ;Children → ;Preg, pregnant → ;Hepatitis, Hep → ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
~1.8
h
elimination half-life; intravenous injection, IV;
DRUGBANK
2.0
h
~2
h
elimination half-life; IM,intramuscular injection;
DRUGBANK
2.2
h
2.2±0.02
h
Neonates ↑ ;Preg, pregnant ↓ ;Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;CPBS ↑ ;Hepatic cirrhosis, cirr ↓ ;Obesity → ;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
~60
%
Urinary excretion;
DRUGBANK
75.0
%
70-80
%
Urinary excretion;
DRUGBANK
80.0
%
80±16
%
Urinary excretion; Unchanged drug;
DRUGBANK
80.0
%
74-86
%
DRUGBANK
89.0
%
89±2
%
Neonates ↓ ;Children ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr ↓ ;CPBS ↓ ;
DRUGBANK
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Cefazolin Sodium
cefazolin sodium
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Cefazolin Sodium
cefazolin sodium
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Cefazolin Sodium
cefazolin sodium
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV
Cefazolin Sodium
cefazolin sodium
PDR
12000.0
mg/day
12
g/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Cefazolin Sodium
cefazolin sodium
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefazolin Sodium
cefazolin sodium
PDR
DDPD01328
Cefonicid
542.566
C18H18N6O8S3
[H][C@]12SCC(CSC3=NN=NN3CS(O)(=O)=O)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O
DB01328
43594
3491
39734
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
0.0228
L/h/kg
0.38
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
h
4.5
h
DRUGBANK
5.1
h
5.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
DDPD01329
Cefoperazone
645.67
C25H27N9O8S2
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O
DB01329
44185
3493
40206
-2.0
-
-2.0
-
DRUGBANK
0.078
L/h/kg
1.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
elimination half-life;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01330
Cefotetan
575.619
C17H17N7O8S4
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O
DB01330
53025
3499
http://www.drugs.com/cdi/cefotetan.html
47904
-2.0
-
-2.0
-
DRUGBANK
91000.0
ng/ml
91.0
mcg/ml
adults; normal,healthy;
DRUGBANK
413500.0
ng/ml
336-491
mcg/ml
adults; normal,healthy;
DRUGBANK
38000.0
ng/ml
38.0
mcg/ml
adults; normal,healthy;
DRUGBANK
2.25
h
1.5-3
h
adults; normal,healthy;
DRUGBANK
1.8
L/h
1.8±0.1
L/h
Geriatric; normal renal function;
DRUGBANK
1.8
L/h
1.8±0.3
L/h
normal,healthy; young;
DRUGBANK
0.0252
L/h/kg
0.42
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.4
L
10.4
L
normal renal function; Geriatric;
DRUGBANK
10.3
L
10.3
L
normal,healthy; adults;
DRUGBANK
0.14
L/kg
0.14±0.03
L/kg
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.6
h
3.6±1.0
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
67.0
%
67±11
%
Urinary excretion; Unchanged drug;
DRUGBANK
88.0
%
88
%
plasma proteins;
DRUGBANK
85.0
%
85±4
%
DRUGBANK
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefotetan
cefotetan disodium
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Cefotetan
cefotetan disodium
PDR
4000.0
mg/day
4
g/day
IM,intramuscular injection
Cefotetan
cefotetan disodium
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Cefotetan
cefotetan disodium
PDR
4000.0
mg/day
4
g/day
IM,intramuscular injection
Cefotetan
cefotetan disodium
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefotetan
cefotetan disodium
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Cefotetan
cefotetan disodium
PDR
4000.0
mg/day
4
g/day
IM,intramuscular injection
Cefotetan
cefotetan disodium
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Cefotetan
cefotetan disodium
PDR
4000.0
mg/day
4
g/day
IM,intramuscular injection
Cefotetan
cefotetan disodium
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Cefotetan
cefotetan disodium
PDR
DDPD01331
Cefoxitin
427.452
C16H17N3O7S2
[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O
DB01331
441199
209807
http://www.drugs.com/cdi/cefoxitin.html
389981
-2.0
-
-2.0
-
DRUGBANK
85.0
%
85
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.216
L/h/kg
3.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.833333333333333
h
41-59
min
intravenous injection, IV;
DRUGBANK
0.81
h
0.81
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8000.0
mg/kg
~8
g/kg
intravenous injection, IV; adults; female mouse;
DRUGBANK
1000.0
mg/kg
>1
g/kg
intravenous injection, IV; adults; rabbit;
DRUGBANK
10000.0
mg/kg
>10
g/kg
Intraperitoneal, IP; adults; Rattus, Rat;
DRUGBANK
85.0
%
~85
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD01332
Ceftizoxime
383.403
C13H13N5O5S2
[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
DB01332
6533629
553473
http://www.drugs.com/cdi/ceftizoxime.html
5018818
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
0.0
%
~0
%
Urinary excretion;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.5
L
15-28
L
Apparent volume of distribution;
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
%
30
%
DRUGBANK
DDPD01333
Cefradine
349.405
C16H19N3O4S
[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CCC=CC1)C(O)=O
DB01333
38103
3547
34933
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD01336
Metocurine
652.8189
C40H48N2O6
[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3
DB01336
21233
6900
19961
-2.0
-
-2.0
-
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.4
L/kg
0.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.1
h
5.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01337
Pancuronium
572.8619
C35H60N2O4
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1
DB01337
441289
7907
390052
-2.0
-
-2.0
-
DRUGBANK
670.0
ng/ml
0.67
mcg/ml
intravenous injection, IV; surgery;
DRUGBANK
0.09
L/h/kg
1.1–1.9
ml/min/kg
Plasma clearance;
DRUGBANK
0.108
L/h/kg
1.8±0.4
ml/min/kg
Elderly ↓ ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ;CPBS → ;
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.2605
L/kg
241-280
ml/kg
DRUGBANK
0.26
L/kg
0.26±0.07
L/kg
Elderly → ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;CPBS → ;
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
h
1.5-2.7
h
DRUGBANK
2.3
h
2.3±0.4
h
RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia ↓ ;CPBS → ;Age ↑ ;Age ↓ ;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
67.0
%
67±18
%
Urinary excretion; Unchanged drug;
CPBS → ;
DRUGBANK
84.0
%
77-91
%
DRUGBANK
7.0
%
7±2
%
Neonates → ; Female, women → ;Preg, pregnant → ;RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
DDPD01338
Pipecuronium
602.8912
C35H62N4O4
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
DB01338
50192
8230
45517
-2.0
-
-2.0
-
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.35
L/kg
0.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.103666666666667
h
6.22(1.34-10.66)
min
distribution half-life; normal renal function;
DRUGBANK
0.0721666666666667
h
4.33(1.69-6.17)
min
distribution half-life; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
1.7
h
1.7(0.9-2.7)
h
elimination half-life; normal renal function;
DRUGBANK
4.0
h
4(2-8.2)
h
elimination half-life; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01339
Vecuronium
557.8274
C34H57N2O4
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
DB01339
39765
9939
http://www.drugs.com/cdi/vecuronium.html
36358
-2.0
-
-2.0
-
DRUGBANK
130.0
ng/ml
130±20
ng/ml
DRUGBANK
100.0
%
100
%
DRUGBANK
0.282
L/h/kg
3.0-6.4
ml/min/kg
Average clearance;
hepatopathy，LD ↓ ;
DRUGBANK
0.35
L/kg
0.19-0.51
L/kg
Average volume of distribution;
DRUGBANK
1.09166666666667
h
51-80
min
DRUGBANK
1.7
h
0.6-2.8
h
different study;
chronic liver disease ↑ ;
DRUGBANK
57.5
%
40-75
%
Faeces excretion;
DRUGBANK
30.0
%
30
%
Urinary excretion;
DRUGBANK
30.0
%
<30
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
20
%
Urinary excretion; Unchanged drug;
DRUGBANK
69.0
%
69
%
DRUGBANK
DDPD01340
Cilazapril
417.4986
C22H31N3O5
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O
DB01340
56330
3698
http://www.drugs.com/international/cilazapril.html
50831
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
Active metabolite;
DRUGBANK
14.85
L/h
12.3-17.4
L/h
Total clearance;
DRUGBANK
10.8
L/h
10.8
L/h
Renal clearance;
DRUGBANK
1.9
h
1.9
h
distribution half-life; intravenous injection, IV;
DRUGBANK
46.2
h
46.2
h
elimination half-life; intravenous injection, IV;
DRUGBANK
91.0
%
91
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD01345
Potassium cation
39.0983
K
[K+]
DB01345
T3D4344
5462222
29103
791
-2.0
-
-2.0
-
DRUGBANK
DDPD01348
Spirapril
466.614
C22H30N2O5S2
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2
DB01348
5311447
135756
4470933
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral;
DRUGBANK
0.714
L/h/kg
11.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.5
h
30-35
h
DRUGBANK
8.6
h
8.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01351
Amobarbital
226.2722
C11H18N2O3
CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
DB01351
T3D4561
2164
2673
2079
-2.0
-
-2.0
-
DRUGBANK
500.0
mg/day
500
mg/day
IM,intramuscular injection
Amytal Sodium
amobarbital sodium
PDR
500.0
mg/day
500
mg/day
IM,intramuscular injection
Amytal Sodium
amobarbital sodium
PDR
DDPD01353
Butobarbital
212.2456
C10H16N2O3
CCCCC1(CC)C(=O)NC(=O)NC1=O
DB01353
T3D3038
6473
134884
6229
-2.0
-
-2.0
-
DRUGBANK
37.0
h
37
h
DRUGBANK
319.6418736
mg/kg
1.506
mM/kg
Intraperitoneal, IP; mouse;
DRUGBANK
DDPD01357
Mestranol
310.4299
C21H26O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3
DB01357
T3D4791
6291
6784
6054
-2.0
-
-2.0
-
DRUGBANK
DDPD01359
Penbutolol
291.4284
C18H29NO2
CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1
DB01359
37464
7954
http://www.drugs.com/cdi/penbutolol.html
34369
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
DRUGBANK
5.0
h
5
h
DRUGBANK
20.0
h
~20
h
normal,healthy;
DRUGBANK
25.0
h
~25
h
normal,healthy; Elderly;
DRUGBANK
100.0
h
~100
h
DRUGBANK
89.0
%
80-98
%
plasma proteins;
DRUGBANK
DDPD01362
Iohexol
821.1379
C19H26I3N3O9
CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
DB01362
3730
31709
3599
-2.0
-
-2.0
-
DRUGBANK
6.54
L/h
109.0
ml/min
intrathecal administration; adults;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5995
L/kg
350-849
ml/kg
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.4
h
3.4
h
DRUGBANK
2.0
h
~2
h
normal renal function;
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01364
Ephedrine
165.2322
C10H15NO
CN[C@@H](C)[C@H](O)C1=CC=CC=C1
DB01364
T3D3040
9294
15407
http://www.drugs.com/ephedrine.html
8935
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88
%
PO, oral;
DRUGBANK
79.5
ng/ml
79.5
ng/ml
PO, oral;
DRUGBANK
1.81
h
1.81
h
PO, oral;
DRUGBANK
23.3
L/h
23.3
L/h
PO, oral;
DRUGBANK
215.6
L
215.6
L
Average volume of distribution; PO, oral;
DRUGBANK
6.0
h
~6
h
elimination half-life; PO, oral;
DRUGBANK
785.0
mg/kg
785.0
mg/kg
PO, oral; mouse;
DRUGBANK
284.0
mg/kg
284.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
425.0
mg/kg
425.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
4.9
%
4.9±0.3
%
Raceme L; human, homo sapiens;
DRUGBANK
6.9
%
6.9±1.4
%
Raceme D; human, homo sapiens;
DRUGBANK
50.0
mg
50
mg
intravenous injection, IV
Akovaz
ephedrine sulfate
PDR
50.0
mg
50
mg
intravenous injection, IV
Akovaz
ephedrine sulfate
PDR
DDPD01365
Mephentermine
163.2594
C11H17N
CNC(C)(C)CC1=CC=CC=C1
DB01365
3677
6755
3549
-2.0
-
-2.0
-
DRUGBANK
17.5
h
17-18
h
DRUGBANK
DDPD01367
Rasagiline
171.2383
C12H13N
C#CCN[C@@H]1CCC2=CC=CC=C12
DB01367
3052776
63620
http://www.drugs.com/cdi/rasagiline.html
2314553
-2.0
-
-2.0
-
DRUGBANK
36.0
%
36
%
PO, oral;
DRUGBANK
87.0
L
87.0
L
DRUGBANK
3.0
h
3
h
DRUGBANK
62.0
%
62
%
Urinary excretion; PO, oral;
DRUGBANK
7.0
%
7
%
Urinary excretion; PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
91.0
%
88-94
%
plasma proteins;
DRUGBANK
62.0
%
61-63
%
human, homo sapiens;
DRUGBANK
1.0
mg/day
1
mg/day
PO, oral
Azilect
rasagiline mesylate
PDR
1.0
mg/day
1
mg/day
PO, oral
Azilect
rasagiline mesylate
PDR
DDPD01369
Quinupristin
1022.23
C53H67N9O10S
[H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)[C@]([H])(CS[C@@H]3CN4CCC3CC4)CN1C(=O)[C@H](CC1=CC=C(C=C1)N(C)C)N(C)C2=O)C1=CC=CC=C1
DB01369
5388937
4470884
-2.0
-
-2.0
-
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.1
h
3.1
h
DRUGBANK
0.87
h
0.87
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01370
Aluminium
26.9815
Al
[Al]
DB01370
T3D0187
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
5359268
28984
4514248
-2.0
-
-2.0
-
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral;
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral;
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD01378
Magnesium cation
24.305
Mg
[Mg++]
DB01378
888
18420
865
-2.0
-
-2.0
-
DRUGBANK
DDPD01380
Cortisone acetate
402.4807
C23H30O6
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB01380
5745
3897
http://www.drugs.com/cdi/cortisone.html
5543
-2.0
-
-2.0
-
DRUGBANK
DDPD01382
Glymidine
309.341
C13H15N3O4S
COCCOC1=CN=C(NS(=O)(=O)C2=CC=CC=C2)N=C1
DB01382
9565
146188
9190
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
4.0
h
4
h
DRUGBANK
90.0
%
90
%
plasma proteins;
DRUGBANK
DDPD01390
Sodium bicarbonate
84.0066
CHNaO3
[Na+].OC([O-])=O
DB01390
516892
32139
http://www.drugs.com/cdi/sodium-bicarbonate.html
8609
-2.0
-
-2.0
-
DRUGBANK
DDPD01392
Yohimbine
354.4427
C21H26N2O3
[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2
DB01392
8969
10093
http://www.drugs.com/cdi/yohimbine.html
8622
-2.0
-
-2.0
-
DRUGBANK
33.0
%
33(7-87)
%
PO, oral;
DRUGBANK
0.876
L/h/kg
14.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.48
L/kg
0.48
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
h
~36
min
elimination half-life;
DRUGBANK
1.5
h
1.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01393
Bezafibrate
361.819
C19H20ClNO4
CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O
DB01393
39042
47612
35728
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
95.0
%
94-96
%
human, homo sapiens;
DRUGBANK
DDPD01394
Colchicine
399.437
C22H25NO6
COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
DB01394
T3D4020
2833
23359
http://www.drugs.com/cdi/colchicine.html
2731
-2.0
-
-2.0
-
DRUGBANK
45.0
%
45
%
PO, oral;
DRUGBANK
56.0
%
24-88
%
PO, oral; different study;
DRUGBANK
2.5
ng/ml
2.5
ng/ml
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
192.0
h
8
day
Oral multiple dose;
DRUGBANK
0.001839
L/h
0.0292-0.0321
ml/min
Oral single dose;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.726
L/h/kg
0.726±0.110
L/h/kg
apparent clearance; Familial Mediterranean Fever; patients;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
L/kg
5.0-8
L/kg
Apparent volume of distribution; normal,healthy; patients; young;
DRUGBANK
6.1
L/kg
6.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.9
h
26.6-31.2
h
elimination half-life;
DRUGBANK
30.0
h
20-40
h
different study;
DRUGBANK
58.0
h
58
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.87
mg/kg
5.87
mg/kg
PO, oral; mouse;
DRUGBANK
52.5
%
40-65
%
Urinary excretion; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
39.0
%
39±5
%
plasma proteins;
DRUGBANK
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Mitigare
colchicine
PDR
1.2
mg/day
1.2
mg/day
PO, oral; rarely
Mitigare
colchicine
PDR
1.8
mg
1.8
mg
Tablet,PO，oral
Mitigare
colchicine
PDR
1.2
mg/day
1.2
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Mitigare
colchicine
PDR
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Mitigare
colchicine
PDR
1.8
mg
1.8
mg
Tablet,PO，oral
Mitigare
colchicine
PDR
1.2
mg/day
1.2
mg/day
Tablet,PO，oral;Capsule, PO, Oral;Liquid;
Mitigare
colchicine
PDR
2.4
mg/day
2.4
mg/day
Tablet,PO，oral
Mitigare
colchicine
PDR
1.8
mg/day
1.8
mg/day
Tablet,PO，oral
Mitigare
colchicine
PDR
DDPD01395
Drospirenone
366.4932
C24H30O3
[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21
DB01395
68873
50838
http://www.drugs.com/yaz.html
62105
-2.0
-
-2.0
-
DRUGBANK
76.0
%
76
%
DRUGBANK
80.5
%
76-85
%
combination drug use;
DRUGBANK
73.5
ng/ml
60-87
ng/ml
DRUGBANK
21.9
ng/ml
21.9
ng/ml
combination drug use;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
1.0
h
1
h
combination drug use;
DRUGBANK
0.081
L/h/kg
1.2-1.5
ml/min/kg
Plasma clearance;
DRUGBANK
4.0
L/kg
4.0
L/kg
DRUGBANK
3.95
L/kg
3.7-4.2
L/kg
Drug combination;
DRUGBANK
30.0
h
30
h
elimination half-life;
DRUGBANK
40.0
h
~40
h
Metabolite;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
96.0
%
95-97
%
DRUGBANK
4.0
mg/day
4
mg/day
PO, oral
Slynd
drospirenone
PDR
4.0
mg/day
4
mg/day
PO, oral
Slynd
drospirenone
PDR
DDPD01396
Digitoxin
764.9391
C41H64O13
[H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1
DB01396
T3D4021
441207
28544
389987
-2.0
-
-2.0
-
DRUGBANK
0.00258
L/h/kg
0.043
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.44
L/kg
0.44
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
180.0
h
180
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01399
Salsalate
258.2262
C14H10O5
OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
DB01399
5161
9014
http://www.drugs.com/cdi/salsalate.html
4977
-2.0
-
-2.0
-
DRUGBANK
1.0
h
~1
h
elimination half-life;
DRUGBANK
3.5
h
3.5
h
Active metabolite;
DRUGBANK
92.5
%
90-95
%
plasma proteins;
DRUGBANK
77.5
%
70-85
%
plasma proteins;
DRUGBANK
42.5
%
25-60
%
plasma proteins;
DRUGBANK
DDPD01400
Neostigmine
223.2915
C12H19N2O2
CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
DB01400
4456
7514
http://www.drugs.com/cdi/neostigmine.html
4301
-2.0
-
-2.0
-
DRUGBANK
275.0
ng/ml
200-350
ng/ml
patients;
DRUGBANK
1.002
L/h/kg
16.7±5.4
ml/min/kg
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.552
L/h/kg
9.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.4
L/kg
1.4±0.5
L/kg
DRUGBANK
0.74
L/kg
0.74
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.866666666666667
h
52(42-60)
min
DRUGBANK
1.3
h
1.3±0.8
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
mg/kg
0.3±0.02
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
0.54
mg/kg
0.54±0.03
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
0.395
mg/kg
0.395±0.025
mg/kg
IM,intramuscular injection; mouse;
DRUGBANK
0.315
mg/kg
0.315±0.019
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
0.445
mg/kg
0.445±0.032
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
0.423
mg/kg
0.423±0.032
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
67.0
%
67
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
15-25
%
human, homo sapiens;
DRUGBANK
0.07
mg/kg
0.07
mg/kg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
5.0
mg
5
mg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
375.0
mg/day
375
mg/day
PO, oral
Bloxiverz
neostigmine methylsulfate
PDR
0.5
mg
0.5
mg
IM,intramuscular injection;subcutaneous injection, SC;
Bloxiverz
neostigmine methylsulfate
PDR
0.07
mg/kg
0.07
mg/kg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
5.0
mg
5
mg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
0.07
mg/kg
0.07
mg/kg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
5.0
mg
5
mg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
375.0
mg/day
375
mg/day
PO, oral
Bloxiverz
neostigmine methylsulfate
PDR
0.5
mg
0.5
mg
IM,intramuscular injection;subcutaneous injection, SC;
Bloxiverz
neostigmine methylsulfate
PDR
0.07
mg/kg
0.07
mg/kg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
5.0
mg
5
mg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
0.07
mg/kg
0.07
mg/kg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
0.07
mg/kg
0.07
mg/kg
intravenous injection, IV
Bloxiverz
neostigmine methylsulfate
PDR
DDPD01403
Methotrimeprazine
328.472
C19H24N2OS
COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1
DB01403
T3D3041
72287
6838
65239
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
PO, oral;
DRUGBANK
20.0
h
~20
h
DRUGBANK
DDPD01406
Danazol
337.4553
C22H27NO2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3
DB01406
28417
4315
http://www.drugs.com/cdi/danazol.html
26436
-2.0
-
-2.0
-
DRUGBANK
0.9426
L/h/kg
15.71
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.18
L/kg
5.18
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
~24
h
DRUGBANK
2.31
h
2.31
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Danazol
danazol
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Danazol
danazol
PDR
DDPD01407
Clenbuterol
277.19
C12H18Cl2N2O
CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1
DB01407
2783
174690
2681
-2.0
-
-2.0
-
DRUGBANK
93.5
%
89-98
%
PO, oral;
DRUGBANK
37.5
h
36-39
h
DRUGBANK
DDPD01409
Tiotropium
392.512
C19H22NO4S2
[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
DB01409
5487427
90960
http://www.drugs.com/cdi/tiotropium.html
19618474
-2.0
-
-2.0
-
DRUGBANK
33.0
%
33
%
inhalation, IH;
DRUGBANK
2.5
%
2-3
%
Liquid;
DRUGBANK
19.5
%
19.5
%
inhalation, IH;
DRUGBANK
0.1
h
5-7
min
nasal spray;
DRUGBANK
74.0
%
74
%
Urinary excretion; Unchanged drug; intravenous injection, IV;
DRUGBANK
52.8
L/h
880.0
ml/min
Total clearance; normal,healthy;
DRUGBANK
40.14
L/h
669.0
ml/min
Renal clearance;
DRUGBANK
21.9
L/h
365.0
ml/min
adults;
DRUGBANK
16.26
L/h
271.0
ml/min
Elderly;
DRUGBANK
0.756
L/h/kg
12.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
32.0
L/kg
32.0
L/kg
DRUGBANK
32.0
L/kg
32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
24
h
terminal half-life; COPD, Chronic obstructive pulmonary disease; patients;
DRUGBANK
44.0
h
44
h
terminal half-life; asthma; patients;
DRUGBANK
14.0
%
14
%
Urinary excretion; inhalation, IH; Unchanged drug;
DRUGBANK
72.0
%
72
%
plasma proteins;
DRUGBANK
0.0025
mg/day
2.5
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.0025
mg/day
2.5
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.005
mg/day
5
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.018
mg/day
18
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.0025
mg/day
2.5
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.0025
mg/day
2.5
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.005
mg/day
5
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
0.018
mg/day
18
mcg/day
inhalation, IH
Spiriva
tiotropium bromide
PDR
DDPD01410
Ciclesonide
540.697
C32H44O7
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C
DB01410
6918155
31397
http://www.drugs.com/cdi/ciclesonide-spray.html
5293368
-2.0
-
-2.0
-
DRUGBANK
1.0
%
<1
%
PO, oral;
DRUGBANK
152.0
L/h
152.0
L/h
intravenous injection, IV;
DRUGBANK
1.998
L/h/kg
33.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.9
L/kg
2.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.04
h
1.04
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
plasma proteins; human, homo sapiens;
DRUGBANK
0.2
mg/day
200
mcg/day
intranasal
qd
Omnaris
ciclesonide
PDR
0.074
mg/day
74
mcg/day
intranasal
qd
Omnaris
ciclesonide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Omnaris
ciclesonide
PDR
0.2
mg/day
200
mcg/day
intranasal
Omnaris
ciclesonide
PDR
0.16
mg/day
160
mcg/day
inhalation, IH
Omnaris
ciclesonide
PDR
0.16
mg/day
160
mcg/day
inhalation, IH
Omnaris
ciclesonide
PDR
0.2
mg/day
200
mcg/day
intranasal
Omnaris
ciclesonide
PDR
0.074
mg/day
74
mcg/day
intranasal
Omnaris
ciclesonide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Omnaris
ciclesonide
PDR
0.2
mg/day
200
mcg/day
intranasal
qd
Omnaris
ciclesonide
PDR
0.074
mg/day
74
mcg/day
intranasal
qd
Omnaris
ciclesonide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Omnaris
ciclesonide
PDR
0.2
mg/day
200
mcg/day
intranasal
Omnaris
ciclesonide
PDR
0.074
mg/day
74
mcg/day
intranasal
Omnaris
ciclesonide
PDR
0.64
mg/day
640
mcg/day
inhalation, IH
Omnaris
ciclesonide
PDR
DDPD01413
Cefepime
480.561
C19H24N6O5S2
CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1
DB01413
5479537
478164
http://www.drugs.com/cdi/cefepime.html
4586395
-2.0
-
-2.0
-
DRUGBANK
82.3
%
82.3±15
%
IM,intramuscular injection; patients;
DRUGBANK
65000.0
ng/ml
65±7
mcg/ml
intravenous injection, IV;
DRUGBANK
7.2
L/h
120.0
ml/min
intravenous infusion, IV in drop; Single dose; normal,healthy; adults; Male, men;
DRUGBANK
0.198
L/h/kg
3.3±1.0
ml/min/kg
intravenous injection, IV; Single dose; pediatric patients;
DRUGBANK
0.108
L/h/kg
1.8(1.7-1.5)
ml/min/kg
apparent clearance; normal,healthy; patients; adults;
RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
L
18.0±2.0
L
DRUGBANK
0.3
L/kg
0.3±0.1
L/kg
pediatric patients;
DRUGBANK
0.26
L/kg
0.26(0.24-0.31)
L/kg
Apparent volume of distribution; Oral single dose; normal,healthy; patients; adults;
DRUGBANK
0.28
L/kg
0.28
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2.0±0.3
h
normal,healthy; patients;
DRUGBANK
1.35
h
1.35±2.7
h
patients;
DRUGBANK
19.0
h
19±2
h
patients;
DRUGBANK
2.1
h
2.1(1.3-2.4)
h
Single dose;
mild renal function ↑ ;
DRUGBANK
1.9
h
1.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
80
%
Urinary excretion; adults; normal,healthy; patients; human, homo sapiens; Unchanged drug;
DRUGBANK
20.0
%
~20
%
DRUGBANK
17.5
%
16-19
%
adults; normal,healthy; patients; human, homo sapiens;
DRUGBANK
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
100.0
mg/kg/day
100
mg/kg/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
2000.0
mg/day
2
g/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
2000.0
mg/day
2
g/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
100.0
mg/kg/day
100
mg/kg/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
2000.0
mg/day
2
g/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
6000.0
mg/day
6
g/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
2000.0
mg/day
2
g/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
100.0
mg/kg/day
100
mg/kg/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
150.0
mg/kg/day
150
mg/kg/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
100.0
mg/kg/day
100
mg/kg/day
IM,intramuscular injection
Maxipime
cefepime hydrochloride
PDR
100.0
mg/kg/day
100
mg/kg/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
60.0
mg/kg/day
60
mg/kg/day
intravenous injection, IV
Maxipime
cefepime hydrochloride
PDR
DDPD01415
Ceftibuten
410.425
C15H14N4O6S2
[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
DB01415
T3D3492
5282242
3510
http://www.drugs.com/cdi/ceftibuten.html
4445419
-2.0
-
-2.0
-
DRUGBANK
0.21
L/kg
0.21
L/kg
adults;
DRUGBANK
0.5
L/kg
0.5
L/kg
fasting; pediatric patients;
DRUGBANK
95.0
%
95
%
Urinary excretion; Faeces excretion;
DRUGBANK
65.0
%
65
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Cedax
ceftibuten
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Cedax
ceftibuten
PDR
400.0
mg/day
400
mg/day
PO, oral
Cedax
ceftibuten
PDR
400.0
mg/day
400
mg/day
PO, oral
Cedax
ceftibuten
PDR
9.0
mg/kg/day
9
mg/kg/day
PO, oral
Cedax
ceftibuten
PDR
400.0
mg/day
400
mg/day
PO, oral
Cedax
ceftibuten
PDR
DDPD01416
Cefpodoxime
427.455
C15H17N5O6S2
[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
DB01416
6335986
3504
http://www.drugs.com/cdi/cefpodoxime.html
4891496
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral; fasting;
DRUGBANK
2.465
h
2.09-2.84
h
DRUGBANK
31.0
%
~29-33
%
Urinary excretion; Unchanged drug;
DRUGBANK
27.5
%
22-33
%
DRUGBANK
25.0
%
21-29
%
plasma proteins;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
400.0
mg/day
400
mg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
200.0
mg/day
200
mg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
800.0
mg/day
800
mg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
800.0
mg/day
800
mg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
10.0
mg/kg/day
10
mg/kg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
800.0
mg/day
800
mg/day
PO, oral
Cefpodoxime Proxetil Oral Suspension
cefpodoxime proxetil
PDR
DDPD01418
Acenocoumarol
353.3255
C19H15NO6
CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O
DB01418
T3D3106
54676537
53766
10443441
-2.0
-
-2.0
-
DRUGBANK
60.0
%
>60
%
PO, oral;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
0.0768
L/h/kg
1.28
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.078
L/kg
78.0
ml/kg
at steady state;
DRUGBANK
0.088
L/kg
88.0
ml/kg
at steady state;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.5
h
8-11
h
DRUGBANK
7.22
h
7.22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1470.0
mg/kg
1470.0
mg/kg
PO, oral; mouse;
DRUGBANK
115.0
mg/kg
115.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
98.7
%
98.7
%
DRUGBANK
DDPD01419
Antrafenine
588.5435
C30H26F6N4O2
FC(F)(F)C1=CC(=CC=C1)N1CCN(CCOC(=O)C2=CC=CC=C2NC2=C3C=CC(=CC3=NC=C2)C(F)(F)F)CC1
DB01419
68723
135841
61973
-2.0
-
-2.0
-
DRUGBANK
DDPD01420
Testosterone propionate
344.4877
C22H32O3
[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB01420
T3D4754
5995
9466
http://www.drugs.com/testosterone.html
5774
-2.0
-
-2.0
-
DRUGBANK
195.0
ng.h/ml
180-210
ng.h/ml
IM,intramuscular injection;
DRUGBANK
120.0
L/h
~2000
ml/min
DRUGBANK
97.5
L/kg
75-120
L/kg
DRUGBANK
108.0
h
4.5
day
DRUGBANK
90.0
%
~90
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
6.0
%
~6
%
Faeces excretion; IM,intramuscular injection;
DRUGBANK
DDPD01421
Paromomycin
615.6285
C23H45N5O14
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
DB01421
165580
7934
http://www.drugs.com/cdi/paromomycin.html
145115
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
35.0
mg/kg/day
35
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
35.0
mg/kg/day
35
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
45.0
mg/kg/day
45
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
35.0
mg/kg/day
35
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
45.0
mg/kg/day
45
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
35.0
mg/kg/day
35
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
45.0
mg/kg/day
45
mg/kg/day
Paromomycin Sulfate
paromomycin sulfate
PDR
DDPD01424
Aminophenazone
231.2936
C13H17N3O
CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
DB01424
6009
160246
5787
-2.0
-
-2.0
-
DRUGBANK
DDPD01426
Ajmaline
326.4326
C20H26N2O2
CC[C@H]1[C@@H]2C[C@H]3[C@@H]4N(C)C5=CC=CC=C5[C@]44C[C@@H](C2[C@H]4O)N3[C@@H]1O
DB01426
441080
28462
10145712
-2.0
-
-2.0
-
DRUGBANK
0.588
L/h/kg
9.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
L/kg
4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.3
h
7.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01427
Amrinone
187.198
C10H9N3O
NC1=CC(=CNC1=O)C1=CC=NC=C1
DB01427
3698
2686
3570
-2.0
-
-2.0
-
DRUGBANK
0.534
L/h/kg
8.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
1.2
L/kg
normal,healthy;
DRUGBANK
1.3
L/kg
1.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
5-8
h
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
29.5
%
10-49
%
DRUGBANK
DDPD01428
Oxybenzone
228.2433
C14H12O3
COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1
DB01428
T3D4807
4632
34283
4471
-2.0
-
-2.0
-
DRUGBANK
DDPD01430
Almitrine
477.5522
C26H29F2N7
FC1=CC=C(C=C1)C(N1CCN(CC1)C1=NC(NCC=C)=NC(NCC=C)=N1)C1=CC=C(F)C=C1
DB01430
33887
53778
31235
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
0.0582
L/h/kg
0.97
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.37
L/kg
35.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1344.0
h
1344
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01432
Cholestyramine
N.A.
N.A.
CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C
DB01432
70695641
http://www.drugs.com/cdi/cholestyramine-powder.html
-2.0
-
-2.0
-
DRUGBANK
0.1
h
6
min
DRUGBANK
8000.0
mg/day
8
g/day
PO, oral
Prevalite
cholestyramine
PDR
24000.0
mg/day
24
g/day
PO, oral
Prevalite
cholestyramine
PDR
16000.0
mg/day
16
g/day
PO, oral
Prevalite
cholestyramine
PDR
8000.0
mg/day
8
g/day
PO, oral
Prevalite
cholestyramine
PDR
24000.0
mg/day
24
g/day
PO, oral
Prevalite
cholestyramine
PDR
16000.0
mg/day
16
g/day
PO, oral
Prevalite
cholestyramine
PDR
DDPD01435
Antipyrine
188.2258
C11H12N2O
CN1N(C(=O)C=C1C)C1=CC=CC=C1
DB01435
2206
31225
2121
-2.0
-
-2.0
-
DRUGBANK
0.0384
L/h/kg
0.64
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.77
L/kg
0.77
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01436
Alfacalcidol
400.6371
C27H44O2
CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
DB01436
5282181
31186
4445376
-2.0
-
-2.0
-
DRUGBANK
0.0492
L/h/kg
0.82
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
48.6
h
48.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01437
Glutethimide
217.2637
C13H15NO2
CCC1(CCC(=O)NC1=O)C1=CC=CC=C1
DB01437
3487
5439
3367
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
Liver metabolism;
DRUGBANK
11.0
h
10-12
h
DRUGBANK
DDPD01438
Phenazopyridine
213.2385
C11H11N5
NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
DB01438
4756
71416
http://www.drugs.com/cdi/phenazopyridine.html
4592
-2.0
-
-2.0
-
DRUGBANK
431.77
ng.h/ml
431.77±87.82
ng.h/ml
DRUGBANK
65.0
ng/ml
65.00±29.23
ng/ml
DRUGBANK
2.48
h
2.48±0.50
h
DRUGBANK
41.0
%
41
%
Urinary excretion; Unchanged drug;
DRUGBANK
7.35
h
7.35
h
elimination half-life; normal renal function; Rattus, Rat;
DRUGBANK
472.0
mg/kg
472.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
90
%
PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
80.07
%
80.07±4.54
%
Urinary excretion;
DRUGBANK
40.7
%
40.7
%
Bile excretion; Rattus, Rat;
DRUGBANK
65.0
%
65
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Pyridium
phenazopyridine hydrochloride
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Pyridium
phenazopyridine hydrochloride
PDR
600.0
mg/day
600
mg/day
PO, oral
Pyridium
phenazopyridine hydrochloride
PDR
600.0
mg/day
600
mg/day
PO, oral
Pyridium
phenazopyridine hydrochloride
PDR
600.0
mg/day
600
mg/day
PO, oral
Pyridium
phenazopyridine hydrochloride
PDR
DDPD01440
gamma-Hydroxybutyric acid
104.1045
C4H8O3
OCCCC(O)=O
DB01440
T3D4269
3037032
30830
9984
-2.0
-
-2.0
-
DRUGBANK
0.576
L/h/kg
9.6
ml/min/kg
apparent clearance; Oral single dose; normal,healthy; adults;
DRUGBANK
0.258
L/h/kg
4.1-4.5
ml/min/kg
Oral single dose; Hepatitis, Hep;
DRUGBANK
0.287
L/kg
190-384
ml/kg
DRUGBANK
0.75
h
30-60
min
DRUGBANK
5.0
%
5
%
Urinary excretion;
DRUGBANK
DDPD01452
Diamorphine
369.411
C21H23NO5
[H][C@@]12C=C[C@H](OC(C)=O)[C@@H]3OC4=C(OC(C)=O)C=CC5=C4[C@]13CCN(C)[C@@H]2C5
DB01452
T3D4562
5462328
27808
http://www.drugs.com/heroin.html
4575379
-2.0
-
-2.0
-
DRUGBANK
35.0
%
<35
%
PO, oral;
DRUGBANK
22.9
%
22.9(16.4-29.4)
%
PO, oral; different study;
DRUGBANK
0.125
h
5-10
min
subcutaneous injection, SC;
DRUGBANK
0.0666666666666667
h
3-5
min
IM,intramuscular injection;
DRUGBANK
0.0666666666666667
h
3-5
min
intranasal;
DRUGBANK
0.0166666666666667
h
<1
min
intravenous injection, IV;
DRUGBANK
522.0
L/h
8.7±2.6
L/min
Total clearance;
DRUGBANK
3.5
L/kg
1.0-6
L/kg
DRUGBANK
0.0416666666666667
h
2-3
min
human, homo sapiens;
DRUGBANK
8.5
%
7-10
%
Faeces excretion;
DRUGBANK
DDPD01495
Dichloralphenazone
519.032
C15H18Cl6N2O5
OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1N(C(=O)C=C1C)C1=CC=CC=C1
DB01495
10188
9776
-2.0
-
-2.0
-
DRUGBANK
DDPD01501
Difenoxin
424.5341
C28H28N2O2
OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1
DB01501
34328
4534
http://www.drugs.com/cdi/motofen.html
31620
-2.0
-
-2.0
-
DRUGBANK
0.833333333333333
h
40-60
min
DRUGBANK
7.24
h
7.24
h
elimination half-life;
DRUGBANK
0.82
h
0.82
h
DRUGBANK
DDPD01544
Flunitrazepam
313.2832
C16H12FN3O3
CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F
DB01544
T3D3047
3380
31622
3263
-2.0
-
-2.0
-
DRUGBANK
70.5
%
64-77
%
PO, oral;
DRUGBANK
50.0
%
50
%
Rectal Administration;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
18-26
h
DRUGBANK
25.0
h
25
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01551
Dihydrocodeine
301.3801
C18H23NO3
[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC
DB01551
5284543
135276
http://www.drugs.com/international/dihydrocodeine.html
4447600
-2.0
-
-2.0
-
DRUGBANK
3203.0
ng.h/ml
3203.0
ug.h/L
PO, oral;
DRUGBANK
3401.0
ng.h/ml
3401.0
ug.h/L
intravenous injection, IV;
DRUGBANK
20.0
%
20
%
PO, oral;
DRUGBANK
71.8
ng/ml
71.8
ug/L
intravenous injection, IV;
DRUGBANK
146.0
ng/ml
146
ug/L
PO, oral;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV;
DRUGBANK
1.8
h
1.8
h
PO, oral;
DRUGBANK
18.0
L/h
~300
ml/min
Plasma clearance;
DRUGBANK
0.2526
L/h/kg
4.21
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.07
L/kg
1.07
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
4
h
DRUGBANK
3.42
h
3.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01558
Bromazepam
316.153
C14H10BrN3O
BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1
DB01558
T3D3048
2441
31302
http://www.drugs.com/international/bromazepam.html
2347
-2.0
-
-2.0
-
DRUGBANK
84.0
%
84
%
PO, oral;
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
0.0492
L/h/kg
0.82
ml/min/kg
DRUGBANK
0.0306
L/h/kg
0.51
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.56
L/kg
1.56
L/kg
DRUGBANK
0.85
L/kg
0.85
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
h
10-20
h
DRUGBANK
21.0
h
21
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.0
%
70
%
DRUGBANK
DDPD01559
Clotiazepam
318.821
C16H15ClN2OS
CCC1=CC2=C(S1)N(C)C(=O)CN=C2C1=CC=CC=C1Cl
DB01559
T3D3049
2811
31425
2709
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD01563
Chloral hydrate
165.403
C2H3Cl3O2
OC(O)C(Cl)(Cl)Cl
DB01563
2707
28142
http://www.drugs.com/cdi/chloral-hydrate.html
2606
-2.0
-
-2.0
-
DRUGBANK
DDPD01576
Dextroamphetamine
135.2062
C9H13N
C[C@H](N)CC1=CC=CC=C1
DB01576
T3D3051
5826
4469
http://www.drugs.com/cdi/dextroamphetamine.html
5621
-2.0
-
-2.0
-
DRUGBANK
61.0
ng/ml
61±20
ng/ml
PO, oral; Raceme D; extended release formulation;
DRUGBANK
3.1
h
3.1±1.1
h
PO, oral; Raceme D; extended release formulation;
DRUGBANK
17.0
L/h
17.0
L/h
DRUGBANK
0.333
L/h/kg
3.4-7.7
ml/min/kg
apparent clearance; PO, oral; adults;
DRUGBANK
0.0582
L/h/kg
0.23-1.71
ml/min/kg
apparent clearance; PO, oral; adults;
DRUGBANK
195.0
L
195.0
L
DRUGBANK
6.11
L/kg
6.11±0.22
L/kg
DRUGBANK
11.75
h
11.75
h
DRUGBANK
16.0
h
16
h
post-stroke; Female, women;
DRUGBANK
12.4
h
12.4
h
post-stroke; Male, men;
DRUGBANK
7.9
h
7.9
h
normal,healthy;
DRUGBANK
3.85
h
3.5-4.2
h
Raceme D/L; PO, oral; adults; Urine alkaline;
DRUGBANK
18.0
h
14-22
h
Raceme D/L; PO, oral; adults; Uric acid;
DRUGBANK
6.8
h
6.8±0.5
h
Raceme D; Isomers; Children;
DRUGBANK
96.8
mg/kg
96.8
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
33.3
%
33.3
%
Urinary excretion;
DRUGBANK
14.5
%
14.5
%
Urinary excretion; Raceme D/L; Unchanged drug;
DRUGBANK
24.5
%
23-26
%
Raceme D/L;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
ProCentra
dextroamphetamine sulfate
PDR
40.0
mg/day
40
mg/day
PO, oral
ProCentra
dextroamphetamine sulfate
PDR
60.0
mg/day
60
mg/day
PO, oral
ProCentra
dextroamphetamine sulfate
PDR
60.0
mg/day
60
mg/day
PO, oral
ProCentra
dextroamphetamine sulfate
PDR
60.0
mg/day
60
mg/day
PO, oral
ProCentra
dextroamphetamine sulfate
PDR
DDPD01577
Metamfetamine
149.2328
C10H15N
CN[C@@H](C)CC1=CC=CC=C1
DB01577
T3D3052
10836
6809
http://www.drugs.com/methamphetamine.html
10379
-2.0
-
-2.0
-
DRUGBANK
4.715
h
3.13-6.3
h
PO, oral;
DRUGBANK
4.5
h
4-5
h
elimination half-life;
DRUGBANK
45.0
%
45
%
intravenous injection, IV; Unchanged drug;
DRUGBANK
22.5
mg/day
22.5
mg/day
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
5.0
mg
5
mg
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
22.5
mg/day
22.5
mg/day
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
5.0
mg
5
mg
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
22.5
mg/day
22.5
mg/day
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
5.0
mg
5
mg
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
22.5
mg/day
22.5
mg/day
PO, oral
Desoxyn
methamphetamine hydrochloride
PDR
DDPD01579
Phendimetrazine
191.274
C12H17NO
C[C@H]1[C@@H](OCCN1C)C1=CC=CC=C1
DB01579
30487
8059
http://www.drugs.com/phendimetrazine.html
28295
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1-3
h
DRUGBANK
30.0
%
30
%
DRUGBANK
21.5
h
19-24
h
DRUGBANK
210.0
mg/day
210
mg/day
PO, oral
Bontril PDM
phendimetrazine tartrate
PDR
105.0
mg/day
105
mg/day
PO, oral
Bontril PDM
phendimetrazine tartrate
PDR
105.0
mg/day
105
mg/day
PO, oral
Bontril PDM
phendimetrazine tartrate
PDR
210.0
mg/day
210
mg/day
PO, oral
Bontril PDM
phendimetrazine tartrate
PDR
105.0
mg/day
105
mg/day
PO, oral
Bontril PDM
phendimetrazine tartrate
PDR
DDPD01580
Oxprenolol
265.348
C15H23NO3
CC(C)NCC(O)COC1=CC=CC=C1OCC=C
DB01580
4631
91704
4470
-2.0
-
-2.0
-
DRUGBANK
45.0
%
20-70
%
DRUGBANK
0.462
L/h/kg
7.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.72
L/kg
0.72
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
1.09
h
1.09
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01581
Sulfamerazine
264.304
C11H12N4O2S
CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1
DB01581
5325
102130
5134
-2.0
-
-2.0
-
DRUGBANK
DDPD01582
Sulfamethazine
278.33
C12H14N4O2S
CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1
DB01582
5327
102265
5136
-2.0
-
-2.0
-
DRUGBANK
DDPD01586
Ursodeoxycholic acid
392.572
C24H40O4
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O
DB01586
31401
9907
29131
-2.0
-
-2.0
-
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
Rattus, Rat;
DRUGBANK
7500.0
mg/kg
>7500
mg/kg
mouse;
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Actigall
ursodiol
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Actigall
ursodiol
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Actigall
ursodiol
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Actigall
ursodiol
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Actigall
ursodiol
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Actigall
ursodiol
PDR
DDPD01587
Ketazolam
368.814
C20H17ClN2O3
CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1
DB01587
T3D4571
33746
135556
31110
-2.0
-
-2.0
-
DRUGBANK
113.0
h
26-200
h
DRUGBANK
DDPD01588
Prazepam
324.804
C19H17ClN2O
ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1
DB01588
T3D3054
4890
8362
4721
-2.0
-
-2.0
-
DRUGBANK
118.0
h
36-200
h
DRUGBANK
DDPD01589
Quazepam
386.794
C17H11ClF4N2S
FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2
DB01589
T3D3055
4999
8694
http://www.drugs.com/cdi/quazepam.html
4825
-2.0
-
-2.0
-
DRUGBANK
32.0
%
29-35
%
DRUGBANK
39.0
h
39
h
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Doral
quazepam
PDR
15.0
mg/day
15
mg/day
PO, oral
Doral
quazepam
PDR
DDPD01590
Everolimus
958.24
C53H83NO14
[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
DB01590
6442177
68478
http://www.drugs.com/cdi/everolimus.html
21106307
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
PO, oral; tumor;
DRUGBANK
336.0
h
2
week
PO, oral;
DRUGBANK
30.0
h
~30
h
DRUGBANK
80.0
%
80
%
Faeces excretion; Single dose; patients; human, homo sapiens;
DRUGBANK
5.0
%
5
%
Urinary excretion; Single dose; patients; human, homo sapiens;
DRUGBANK
74.0
%
~74
%
normal,healthy; moderate hepatic impairment;
DRUGBANK
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
10.0
mg/day
10
mg/day
Afinitor
everolimus
PDR
5.5
ng/ml
5.5
ng/ml
Afinitor
everolimus
PDR
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
10.0
ng/mL
10
ng/mL
Afinitor
everolimus
PDR
10.0
ng/mL
10
ng/mL
Afinitor
everolimus
PDR
10.0
mg/day
10
mg/day
Afinitor
everolimus
PDR
5.5
ng/ml
5.5
ng/ml
Afinitor
everolimus
PDR
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
10.0
ng/ml
10
ng/ml
Afinitor
everolimus
PDR
DDPD01591
Solifenacin
362.473
C23H26N2O2
O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1
DB01591
154059
135530
http://www.drugs.com/cdi/solifenacin.html
135771
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88
%
DRUGBANK
32.3
ng/ml
32.3
ng/ml
PO, oral;
DRUGBANK
62.9
ng/ml
62.9
ng/ml
PO, oral;
DRUGBANK
5.5
h
3-8
h
PO, oral;
DRUGBANK
10.5
L/h
7.0-14
L/h
DRUGBANK
1.09
L/h
0.67-1.51
L/h
Renal clearance;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
600.0
L
600.0
L
DRUGBANK
8.2
L/kg
8.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
59.0
h
33-85
h
elimination half-life;
DRUGBANK
52.0
h
52
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3000.0
mg/kg
3.0
g/kg
PO, oral;
DRUGBANK
16.8541666666667
mg/kg/h
186-623
mg/kg/day
mouse; Rattus, Rat;
DRUGBANK
69.2
%
69.2±7.8
%
Urinary excretion;
DRUGBANK
22.5
%
22.5±3.3
%
Faeces excretion;
DRUGBANK
0.4
%
0.4±7.8
%
lung excretion;
DRUGBANK
94.5
%
93-96
%
plasma proteins;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
8.0
mg/day
8
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
6.0
mg/day
6
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
5.0
mg/day
5
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
4.0
mg/day
4
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
10.0
mg/day
10
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
10.0
mg/day
10
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
8.0
mg/day
8
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
6.0
mg/day
6
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
5.0
mg/day
5
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
4.0
mg/day
4
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
10.0
mg/day
10
mg/day
PO, oral
VESIcare
solifenacin succinate
PDR
DDPD01592
Iron
55.845
Fe
[Fe]
DB01592
T3D4697
23925
18248
http://www.drugs.com/mtm/ferrous-gluconate.html
22368
-2.0
-
-2.0
-
DRUGBANK
22.5
%
10-35
%
DRUGBANK
95.0
%
95
%
iron deficient;
iron deficient ↑ ;
DRUGBANK
DDPD01593
Zinc
65.409
Zn
[Zn]
DB01593
T3D0074
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
23994
30185
http://www.drugs.com/cdi/zinc-oxide-cream.html
22430
-2.0
-
-2.0
-
DRUGBANK
65.0
%
60-70
%
Liquid;
DRUGBANK
33.0
%
33
%
different study;
DRUGBANK
0.0378
mg/h
0.63±0.39
ug/min
normal,healthy;
DRUGBANK
6720.0
h
~280
day
human, homo sapiens;
DRUGBANK
630.0
mg/kg
630.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
65.0
%
~60-70
%
DRUGBANK
DDPD01595
Nitrazepam
281.2661
C15H11N3O3
[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1
DB01595
T3D3057
4506
7581
4350
-2.0
-
-2.0
-
DRUGBANK
73.5
%
53-94
%
PO, oral;
DRUGBANK
0.0516
L/h/kg
0.86
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
26.0
h
26(15-38)
h
elimination half-life;
DRUGBANK
26.0
h
26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01597
Cilastatin
358.453
C16H26N2O5S
CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O
DB01597
6435415
3697
4940183
-2.0
-
-2.0
-
DRUGBANK
10100.0
ng/ml
8.2-12
mcg/ml
IM,intramuscular injection;
DRUGBANK
65000.0
ng/ml
60-70
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
1.5
h
1-2
h
IM,intramuscular injection;
DRUGBANK
0.21
L/h/kg
0.2
l/h/kg
Total clearance;
DRUGBANK
0.13
L/h/kg
0.1-0.16
l/h/kg
Renal clearance;
DRUGBANK
0.174
L/h/kg
2.9
ml/min/kg
Neonates → ;Children ↑ ;Elderly → ;Prem, premature → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis → ;inflammation → ;Burn → ;
DRUGBANK
0.18
L/h/kg
3.0±0.3
ml/min/kg
Neonates ↓ ;Children ↑ ;Prem, premature ↓ ;Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis → ;
DRUGBANK
0.138
L/h/kg
2.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.35
L
14.6-20.1
L
DRUGBANK
0.23
L/kg
0.23±0.05
L/kg
Neonates ↑ ;Children ↑ ;Prem, premature ↑ ;Elderly → ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ;
DRUGBANK
0.2
L/kg
0.20±0.03
L/kg
Neonates → ;Elderly → ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
DRUGBANK
0.9
h
0.9±0.1
h
Neonates ↑ ;Prem, premature ↑ ;Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;Age → ;
DRUGBANK
0.8
h
0.8±0.1
h
Neonates ↑ ;Prem, premature ↑ ;Cystic fibrosis → ;Age → ;
DRUGBANK
0.86
h
0.86
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.0
%
70
%
Urinary excretion;
DRUGBANK
98.0
%
98
%
Urinary excretion;
DRUGBANK
69.0
%
69±15
%
Urinary excretion; Drug combination; Unchanged drug;
Neonates ↓ ;Children → ;inflammation ↓ ;Cystic fibrosis → ;
DRUGBANK
70.0
%
70±3
%
Urinary excretion; Drug combination; Unchanged drug;
Neonates ↓ ;Cystic fibrosis → ;
DRUGBANK
37.5
%
35-40
%
plasma proteins;
DRUGBANK
20.0
%
<20
%
Drug combination;
DRUGBANK
35.0
%
~35
%
Drug combination;
DRUGBANK
DDPD01598
Imipenem
299.346
C12H17N3O4S
[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
DB01598
T3D4739
104838
471744
94631
-2.0
-
-2.0
-
DRUGBANK
89.0
%
89
%
IM,intramuscular injection;
DRUGBANK
10100.0
ng/ml
8.2-12
mcg/ml
IM,intramuscular injection;
DRUGBANK
65000.0
ng/ml
60-70
mcg/ml
intravenous infusion, IV in drop;
DRUGBANK
1.5
h
1-2
h
IM,intramuscular injection;
DRUGBANK
0.21
L/h/kg
0.2
l/h/kg
Total clearance;
DRUGBANK
0.05
L/h/kg
0.05
l/h/kg
Renal clearance; Single dose;
DRUGBANK
0.15
L/h/kg
0.15
l/h/kg
Renal clearance; Drug combination;
DRUGBANK
0.174
L/h/kg
2.9
ml/min/kg
Neonates → ;Children ↑ ;Elderly → ;Prem, premature → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis → ;inflammation → ;Burn → ;
DRUGBANK
0.18
L/h/kg
3.0±0.3
ml/min/kg
Neonates ↓ ;Children ↑ ;Prem, premature ↓ ;Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis → ;
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.27
L/kg
0.23-0.31
L/kg
DRUGBANK
0.23
L/kg
0.23±0.05
L/kg
Neonates ↑ ;Children ↑ ;Prem, premature ↑ ;Elderly → ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ;
DRUGBANK
0.2
L/kg
0.20±0.03
L/kg
Neonates → ;Elderly → ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
intravenous injection, IV;
DRUGBANK
3.2
h
1.3-5.1
h
IM,intramuscular injection;
DRUGBANK
0.9
h
0.9±0.1
h
Neonates ↑ ;Prem, premature ↑ ;Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;Age → ;
DRUGBANK
0.8
h
0.8±0.1
h
Neonates ↑ ;Prem, premature ↑ ;Cystic fibrosis → ;Age → ;
DRUGBANK
0.95
h
0.95
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
69.0
%
69±15
%
Urinary excretion; Drug combination; Unchanged drug;
Neonates ↓ ;Children → ;inflammation ↓ ;Cystic fibrosis → ;
DRUGBANK
70.0
%
70±3
%
Urinary excretion; Drug combination; Unchanged drug;
Neonates ↓ ;Cystic fibrosis → ;
DRUGBANK
20.0
%
20
%
plasma proteins;
DRUGBANK
20.0
%
<20
%
Drug combination;
DRUGBANK
35.0
%
~35
%
Drug combination;
DRUGBANK
DDPD01599
Probucol
516.842
C31H48O2S2
CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C
DB01599
4912
8427
http://www.drugs.com/cons/probucol.html
4743
-2.0
-
-2.0
-
DRUGBANK
7.0
%
7
%
PO, oral;
DRUGBANK
256.0
h
12-500
h
DRUGBANK
DDPD01600
Tiaprofenic acid
260.308
C14H12O3S
CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1
DB01600
5468
32221
5269
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
10.0
%
10
%
Liver metabolism;
DRUGBANK
0.0372
L/h/kg
0.62
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.08
L/kg
0.08
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
1.5-2.5
h
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01601
Lopinavir
628.8008
C37H48N4O5
CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
DB01601
92727
31781
83706
-2.0
-
-2.0
-
DRUGBANK
123350.0
ng.h/ml
92.6±36.7-154.1±61.4
ug.h/ml
combination drug use;
DRUGBANK
25.0
%
~25
%
PO, oral;
DRUGBANK
10800.0
ng/ml
9.8±3.7-11.8±3.7
ug/ml
combination drug use;
DRUGBANK
9800.0
ng/ml
9.8±3.7
mcg/ml
combination drug use;
DRUGBANK
4.4
h
4.4
h
combination drug use;
DRUGBANK
4.4
h
4.4±2.4
h
combination drug use;
DRUGBANK
6.5
L/h
6.0-7
L/h
apparent clearance; PO, oral;
DRUGBANK
0.072
L/h/kg
1.2
ml/min/kg
apparent clearance; AIDS,HIV; Male, men; Female, women;
DRUGBANK
16.9
L
~16.9
L
DRUGBANK
0.6
L/kg
0.6
L/kg
Apparent volume of distribution; AIDS,HIV; Male, men; Female, women;
DRUGBANK
6.9
h
6.9±2.2
h
elimination half-life;
DRUGBANK
5.3
h
5.3±2.5
h
DRUGBANK
10.4
%
10.4±2.3
%
Urinary excretion; PO, oral;
DRUGBANK
82.6
%
82.6±2.5
%
Faeces excretion; PO, oral;
DRUGBANK
2.2
%
2.2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
19.8
%
19.8
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
3.0
%
<3
%
Urinary excretion; AIDS,HIV; human, homo sapiens; Unchanged drug;
DRUGBANK
98.0
%
>98
%
plasma proteins;
DRUGBANK
98.5
%
98-99
%
AIDS,HIV; human, homo sapiens;
DRUGBANK
DDPD01602
Bacampicillin
465.52
C21H27N3O7S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OC(C)OC(=O)OCC
DB01602
441397
2968
http://www.drugs.com/mtm/bacampicillin.html
390135
-2.0
-
-2.0
-
DRUGBANK
DDPD01603
Meticillin
380.415
C17H20N2O6S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OC)C=CC=C1OC)C(O)=O
DB01603
6087
6827
5862
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
30.0
%
20-40
%
Liver metabolism;
DRUGBANK
0.708333333333333
h
25-60
min
DRUGBANK
DDPD01604
Pivampicillin
463.547
C22H29N3O6S
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(=O)OCOC(=O)C(C)(C)C
DB01604
33478
8255
30899
-2.0
-
-2.0
-
DRUGBANK
1.0
h
~1
h
DRUGBANK
DDPD01605
Pivmecillinam
439.569
C21H33N3O5S
[H]C(=N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@]12[H])N1CCCCCC1
DB01605
115163
51210
16735658
-2.0
-
-2.0
-
DRUGBANK
DDPD01606
Tazobactam
300.291
C10H12N4O5S
[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O
DB01606
123630
9421
110216
-2.0
-
-2.0
-
DRUGBANK
24700.0
ng.h/ml
24.4-25
mcg.h/ml
combination drug use;
DRUGBANK
18200.0
ng/ml
18-18.4
mcg/ml
combination drug use;
DRUGBANK
24.0
h
1
day
combination drug use;
DRUGBANK
3.957
L/h
48.3-83.6
ml/min
Average clearance; intravenous injection, IV; Drug combination; renal transplant; patients;
DRUGBANK
0.2886
L/h/kg
4.81
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.2
L
18.2
L
Drug combination;
DRUGBANK
15.85
L
13.5-18.2
L
Drug combination;
DRUGBANK
0.26
L/kg
0.26
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.95
h
0.7-1.2
h
elimination half-life; normal,healthy; Single dose; Drug combination;
DRUGBANK
0.97
h
0.91-1.03
h
DRUGBANK
0.97
h
0.97
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
~80
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
~30
%
plasma proteins;
DRUGBANK
DDPD01607
Ticarcillin
384.427
C15H16N2O6S2
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C1=CSC=C1)C(O)=O
DB01607
36921
9587
http://www.drugs.com/cdi/ticarcillin.html
33876
-2.0
-
-2.0
-
DRUGBANK
0.108
L/h/kg
1.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
h
1.1
h
DRUGBANK
1.0
h
1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
%
45
%
DRUGBANK
DDPD01608
Periciazine
365.492
C21H23N3OS
OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1
DB01608
4747
31981
4585
-2.0
-
-2.0
-
DRUGBANK
DDPD01609
Deferasirox
373.3615
C21H15N3O4
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
DB01609
5493381
49005
http://www.drugs.com/cdi/deferasirox.html
10770206
-2.0
-
-2.0
-
DRUGBANK
8.0
%
8
%
Liver metabolism; Bile excretion;
DRUGBANK
0.0504
L/h/kg
0.84
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.37
L
14.37±2.69
L
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
8-16
h
elimination half-life; PO, oral;
DRUGBANK
4.05
h
4.05
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.0
%
84
%
Faeces excretion;
DRUGBANK
8.0
%
8
%
Urinary excretion;
DRUGBANK
99.0
%
~99
%
DRUGBANK
28.0
mg/kg/day
28
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
28.0
mg/kg/day
28
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
28.0
mg/kg/day
28
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
28.0
mg/kg/day
28
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
40.0
mg/kg/day
40
mg/kg/day
PO, oral
Jadenu
deferasirox
PDR
DDPD01610
Valganciclovir
354.3617
C14H22N6O5
CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O
DB01610
64147
63635
http://www.drugs.com/cdi/valganciclovir.html
57721
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
Tablet, PO, oral; food;
DRUGBANK
61.0
%
61±9
%
PO, oral;
DRUGBANK
200.0
ng/ml
0.20±0.7
mcg/ml
PO, oral; food;
DRUGBANK
5600.0
ng/ml
5.6±1.5
mcg/ml
PO, oral; Drug form; food;
DRUGBANK
0.5
h
0.5±0.3
h
PO, oral; food;
DRUGBANK
2.0
h
1-3
h
PO, oral; Drug form; food;
DRUGBANK
0.1842
L/h/kg
3.07±0.64
ml/min/kg
intravenous injection, IV;
DRUGBANK
5.3
L/h
5.3±0.9
L/h
mild renal function; patients;
DRUGBANK
0.703
L/kg
0.703±0.134
L/kg
DRUGBANK
4.08
h
~4.08
h
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.5
h
0.5±0.2
h
PO, oral; Male, men; Female, women; viral infections;
DRUGBANK
3.7
h
3.7±0.6
h
Metabolite; PO, oral; Male, men; Female, women; viral infections;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
0.5
h
0.5
h
elimination half-life;
DRUGBANK
1.5
%
1-2
%
plasma proteins;
DRUGBANK
900.0
mg/day
900
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
900.0
mg/day
900
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
900.0
mg/day
900
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
900.0
mg/day
900
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
900.0
mg/day
900
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
32.0
mg/kg/day
32
mg/kg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
32.0
mg/kg/day
32
mg/kg/day
PO, oral
Valcyte
valganciclovir hydrochloride
PDR
DDPD01611
Hydroxychloroquine
335.872
C18H26ClN3O
CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
DB01611
T3D3512
3652
5801
http://www.drugs.com/cdi/hydroxychloroquine.html
3526
-2.0
-
-2.0
-
DRUGBANK
70.5
%
67-74
%
Optical rotation R/S;
DRUGBANK
50.3
ng/ml
50.3
ng/ml
PO, oral;
DRUGBANK
1918.0
ng/ml
1918(1161-2436)
ng/ml
intravenous injection, IV;
DRUGBANK
1918.0
ng/ml
1918(1161-2436)
ng/ml
intravenous injection, IV;
DRUGBANK
3.74
h
3.74
h
PO, oral;
DRUGBANK
5.76
L/h
96.0
ml/min
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5522.0
L
5522.0
L
Total volume of distribution;
DRUGBANK
44257.0
L
44257.0
L
Total volume of distribution;
DRUGBANK
700.0
L/kg
700
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3-4
h
distribution half-life; PO, oral;
DRUGBANK
537.6
h
22.4
day
PO, oral;
DRUGBANK
2964.0
h
123.5
day
PO, oral;
DRUGBANK
960.0
h
40
day
intravenous injection, IV;
DRUGBANK
850.0
h
850
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
%
40-50
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
slough off in skin;
DRUGBANK
24.5
%
24-25
%
Faeces excretion;
DRUGBANK
18.5
%
16-21
%
Urinary excretion; Single dose; Unchanged drug;
DRUGBANK
32.0
%
32
%
plasma proteins; Optical rotation S;
DRUGBANK
16.0
%
16
%
Optical rotation S;
DRUGBANK
9.28
%
9.28
%
Optical rotation S;
DRUGBANK
18.5
%
18.5
%
plasma proteins; Optical rotation R;
DRUGBANK
5.37
%
5.37
%
Optical rotation R;
DRUGBANK
7.58
%
7.58
%
Optical rotation R;
DRUGBANK
50.0
%
50
%
plasma proteins;
DRUGBANK
13.0
mg/kg/dose
13
mg/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
10.0
mg/kg/dose
10
mg base/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
800.0
mg
800
mg
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
620.0
mg base
620
mg base
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
16.25
mg/kg/day
16.25
mg/kg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
12.5
mg/kg/day
12.5
mg base/kg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
1.0
mg/day
1
mg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
775.0
mg/day
0.775
g base/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.92857142
mg/kg/day
6.5
mg/kg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
5.0
mg/kg/dose
5
mg base/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
2800.0
mg/day
400
mg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.14285714
mg/day
310
mg base/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
800.0
mg/dose
800
mg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
620.0
mg base/dose
620
mg base/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
1.0
mg/day
1
mg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.775
g base/day
0.775
g base/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
57.1428571428571
mg/day
400
mg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
310.0
mg base/week
310
mg base/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
85.7142857142857
mg/day
600
mg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
465.0
mg base/week
465
mg base/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
13.0
mg/kg/dose
13
mg/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
10.0
mg base/kg/dose
10
mg base/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
800.0
mg
800
mg
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
620.0
mg base
620
mg base
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
16.25
mg/kg/day
16.25
mg/kg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
12.5
mg base/kg/day
12.5
mg base/kg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
1.0
mg/day
1
mg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.775
g base/day
0.775
g base/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.928571428571428
mg/kg/day
6.5
mg/kg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
5.0
mg base/kg/dose
5
mg base/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
57.1428571428571
mg/day
400
mg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
310.0
mg base/week
310
mg base/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
800.0
mg/dose
800
mg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
620.0
mg base/dose
620
mg base/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
1.0
mg/day
1
mg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.775
g base/day
0.775
g base/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
57.1428571428571
mg/day
400
mg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
310.0
mg base/week
310
mg base/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
85.7142857142857
mg/day
600
mg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
465.0
mg base/week
465
mg base/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
13.0
mg/kg/dose
13
mg/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
10.0
mg base/kg/dose
10
mg base/kg/dose
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
16.25
mg/kg/day
16.25
mg/kg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
12.5
mg base/kg/day
12.5
mg base/kg/day
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
0.928571428571429
mg/kg/day
6.5
mg/kg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
5.0
mg base/kg/week
5
mg base/kg/week
PO, oral
Plaquenil
hydroxychloroquine sulfate
PDR
DDPD01612
Amyl Nitrite
117.1463
C5H11NO2
CCCCCON=O
DB01612
10026
55344
http://www.drugs.com/cons/amyl-nitrite-inhalation-oral-nebulization.html
9632
-2.0
-
-2.0
-
DRUGBANK
33.3
%
33.3
%
Urinary excretion; inhalation, IH;
DRUGBANK
DDPD01613
Erythrityl tetranitrate
302.11
C4H6N4O12
[O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
DB01613
5284553
60072
4447608
-2.0
-
-2.0
-
DRUGBANK
DDPD01616
Alverine
281.4351
C20H27N
CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1
DB01616
3678
518413
3550
-2.0
-
-2.0
-
DRUGBANK
0.8
h
0.8
h
elimination half-life;
DRUGBANK
5.7
h
5.7
h
Active metabolite;
DRUGBANK
DDPD01618
Molindone
276.374
C16H24N2O2
CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2
DB01618
23897
6965
http://www.drugs.com/cdi/molindone.html
22342
-2.0
-
-2.0
-
DRUGBANK
225.0
mg/day
225
mg/day
PO, oral
Molindone Hydrochloride
molindone hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Molindone Hydrochloride
molindone hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Molindone Hydrochloride
molindone hydrochloride
PDR
225.0
mg/day
225
mg/day
PO, oral
Molindone Hydrochloride
molindone hydrochloride
PDR
DDPD01619
Phenindamine
261.3609
C19H19N
CN1CCC2=C(C1)C(C1=CC=CC=C21)C1=CC=CC=C1
DB01619
T3D3060
11291
8065
http://www.drugs.com/mtm/phenindamine.html
10817
-2.0
-
-2.0
-
DRUGBANK
DDPD01620
Pheniramine
240.3434
C16H20N2
CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1
DB01620
4761
91591
4597
-2.0
-
-2.0
-
DRUGBANK
0.2335
ng/ml
173-294
ng/L
DRUGBANK
1.75
h
1-2.5
h
DRUGBANK
12.5
h
8-17
h
terminal half-life; intravenous injection, IV;
DRUGBANK
DDPD01623
Thiothixene
443.625
C23H29N3O2S2
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1
DB01623
941651
9571
http://www.drugs.com/cdi/thiothixene.html
819430
-2.0
-
-2.0
-
DRUGBANK
15.0
h
10-20
h
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Thiothixene
thiothixene
PDR
60.0
mg/day
60
mg/day
PO, oral
Thiothixene
thiothixene
PDR
60.0
mg/day
60
mg/day
PO, oral
Thiothixene
thiothixene
PDR
60.0
mg/day
60
mg/day
PO, oral
Thiothixene
thiothixene
PDR
DDPD01624
Zuclopenthixol
400.965
C22H25ClN2OS
OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
DB01624
5311507
51364
http://www.drugs.com/international/zuclopenthixol.html
4470984
-2.0
-
-2.0
-
DRUGBANK
54.0
L/h
~0.9
L/min
DRUGBANK
20.0
L/kg
20.0
L/kg
DRUGBANK
20.0
h
20(12-28)
h
Tablet, PO, oral;
DRUGBANK
456.0
h
19
day
extended release formulation;
DRUGBANK
10.0
%
10
%
Urinary excretion;
DRUGBANK
98.5
%
98-99
%
DRUGBANK
DDPD01625
Isopropamide
353.5209
C23H33N2O
CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C
DB01625
3775
6043
3643
-2.0
-
-2.0
-
DRUGBANK
DDPD01627
Lincomycin
406.54
C18H34N2O6S
[H][C@]1(C[C@@H](CCC)CN1C)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
DB01627
3000540
6472
http://www.drugs.com/cdi/lincomycin.html
2272112
-2.0
-
-2.0
-
DRUGBANK
25.0
%
20-30
%
PO, oral; fasting;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.4
h
5.4±1.0
h
elimination half-life; intravenous injection, IV;
severe renal function ↑ ;
DRUGBANK
5.4
h
5.4±1.0
h
elimination half-life; IM,intramuscular injection;
DRUGBANK
10.8
h
10.8±2.0
h
hepatopathy，LD; patients;
DRUGBANK
5.6
h
5.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.3
%
1.8-24.8
%
Urinary excretion;
DRUGBANK
57.0
%
28-86
%
plasma proteins;
DRUGBANK
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Lincocin
lincomycin hydrochloride
PDR
8000.0
mg/day
8
g/day
intravenous injection, IV
Lincocin
lincomycin hydrochloride
PDR
1200.0
mg/day
1.2
g/day
IM,intramuscular injection
Lincocin
lincomycin hydrochloride
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Lincocin
lincomycin hydrochloride
PDR
8000.0
mg/day
8
g/day
intravenous injection, IV
Lincocin
lincomycin hydrochloride
PDR
1200.0
mg/day
1.2
g/day
IM,intramuscular injection
Lincocin
lincomycin hydrochloride
PDR
20.0
mg/kg/day
20
mg/kg/day
intravenous injection, IV;IM,intramuscular injection;
Lincocin
lincomycin hydrochloride
PDR
DDPD01628
Etoricoxib
358.842
C18H15ClN2O2S
CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O
DB01628
123619
6339
110209
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
0.0474
L/h/kg
0.79
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
L/kg
1.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
22
h
DRUGBANK
26.0
h
26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
92.0
%
92
%
DRUGBANK
DDPD01638
Sorbitol
182.1718
C6H14O6
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
DB01638
5780
17924
5576
-2.0
-
-2.0
-
DRUGBANK
15900.0
mg/kg
15900.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01656
Roflumilast
403.207
C17H14Cl2F2N2O3
FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl
DB01656
449193
47657
http://www.drugs.com/mtm/roflumilast.html
395793
-2.0
-
-2.0
-
DRUGBANK
80.0
%
~80
%
PO, oral;
DRUGBANK
1.25
h
0.5-2
h
PO, oral; fasting;
DRUGBANK
2.25
h
1.5-3
h
PO, oral; food;
food ↑ ;
DRUGBANK
9.6
L/h
~9.6
L/h
DRUGBANK
0.132
L/h/kg
2.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.9
L/kg
2.9
L/kg
DRUGBANK
1.92
L/kg
1.92
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
h
17
h
elimination half-life; PO, oral;
DRUGBANK
30.0
h
30
h
Metabolite;
DRUGBANK
15.1
h
15.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
0.5
mg/day
500
mcg/day
PO, oral
Daliresp
roflumilast
PDR
0.5
mg/day
500
mcg/day
PO, oral
Daliresp
roflumilast
PDR
DDPD01698
Rutin
610.5175
C27H30O16
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=CC(O)=CC(O)=C4C3=O)C3=CC(O)=C(O)C=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
DB01698
5280805
28527
4444362
-2.0
-
-2.0
-
DRUGBANK
DDPD01708
Prasterone
288.4244
C19H28O2
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@]([H])(O)CC[C@]12C
DB01708
5881
28689
5670
-2.0
-
-2.0
-
DRUGBANK
3.1
%
3.1±0.4
%
PO, oral; monkey;
DRUGBANK
12.0
h
12
h
DRUGBANK
10000.0
mg/kg
>10000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.714285714285714
mg/kg/day
10.0
mg/kg/2W
DRUGBANK
6.5
mg
6.5
mg
Vaginal Administration
qd
Intrarosa
prasterone insert
PDR
6.5
mg
6.5
mg
Vaginal Administration
qd
Intrarosa
prasterone insert
PDR
DDPD01718
Cetrimonium
284.5435
C19H42N
CCCCCCCCCCCCCCCC[N+](C)(C)C
DB01718
T3D4814
2681
39561
2580
-2.0
-
-2.0
-
DRUGBANK
DDPD01744
Camphor
152.2334
C10H16O
[H][C@@]12CC[C@@](C)(C(=O)C1)C2(C)C
DB01744
159055
15396
http://www.drugs.com/cdi/camphor-liquid.html
139902
-2.0
-
-2.0
-
DRUGBANK
DDPD01764
Dalfopristin
690.85
C34H50N4O9S
CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC(=CO1)C2=O
DB01764
6323289
16736919
-2.0
-
-2.0
-
DRUGBANK
0.96
L/h/kg
16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.39
L/kg
0.39
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.7
h
~0.7
h
elimination half-life;
DRUGBANK
0.74
h
0.74
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD01783
Pantothenic acid
219.235
C9H17NO5
CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O
DB01783
988
46905
6361
-2.0
-
-2.0
-
DRUGBANK
DDPD01839
Propylene glycol
76.0944
C3H8O2
CC(O)CO
DB01839
T3D4778
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
1030
16997
13835224
-2.0
-
-2.0
-
DRUGBANK
0.009
mg/kg
0.009
ppm
inhalation, IH;
DRUGBANK
DDPD01914
D-glucose
180.1559
C6H12O6
[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C=O
DB01914
107526
42758
96749
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
intravenous injection, IV;
DRUGBANK
0.666666666666667
h
40
min
PO, oral;
DRUGBANK
0.1362
L/h/kg
2.27±0.37
ml/min/kg
Average clearance; normal,healthy;
DRUGBANK
0.0906
L/h/kg
1.51±0.21
ml/min/kg
Average clearance; hypertension;
DRUGBANK
0.1146
L/h/kg
1.91±0.31
ml/min/kg
Average clearance; normal,healthy;
DRUGBANK
10.6
L
10.6
L
intravenous infusion, IV in drop;
DRUGBANK
0.238333333333333
h
14.3
min
intravenous injection, IV;
normal BMI ↓ ;
DRUGBANK
1.31666666666667
h
79±2
min
Female, women;
DRUGBANK
1.08333333333333
h
65±3
min
Male, men;
DRUGBANK
25800.0
mg/kg
25800.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD01956
Taurine
125.147
C2H7NO3S
NCCS(O)(=O)=O
DB01956
1123
507393
1091
-2.0
-
-2.0
-
DRUGBANK
29.5083333333333
ng.h/ml
89-3452
mcg.min/L
PO, oral;
DRUGBANK
200250.0
ng.h/ml
116-284.5
mg.h/l
normal,healthy;
DRUGBANK
8850.0
ng/ml
2-15.7
mcg.min/ml
PO, oral;
DRUGBANK
85800.0
ng/ml
59-112.6
mg/L
normal,healthy;
DRUGBANK
0.25
h
15
min
PO, oral;
DRUGBANK
1.75
h
1-2.5
h
normal,healthy;
DRUGBANK
0.702
L/h/kg
11.7
ml/min/kg
PO, oral;
DRUGBANK
1.122
L/h/kg
18.7
ml/min/kg
PO, oral;
DRUGBANK
0.564
L/h/kg
9.4
ml/min/kg
PO, oral;
DRUGBANK
24.2
L/h
14-34.4
L/h
normal,healthy;
DRUGBANK
0.326
L/kg
299-353
ml/kg
DRUGBANK
6.491
L/kg
4608-8374
ml/kg
mouse;
DRUGBANK
30.25
L
19.8-40.7
L
normal,healthy; human, homo sapiens;
DRUGBANK
1.05
h
0.7-1.4
h
elimination half-life; PO, oral; normal,healthy;
DRUGBANK
DDPD02266
Flufenamic acid
281.2299
C14H10F3NO2
OC(=O)C1=CC=CC=C1NC1=CC(=CC=C1)C(F)(F)F
DB02266
3371
42638
3254
-2.0
-
-2.0
-
DRUGBANK
DDPD02300
Calcipotriol
412.6047
C27H40O3
O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1
DB02300
T3D3062
5288783
50749
4450880
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5
%
skin/dermal; hyperthyroid;
DRUGBANK
6.0
%
6
%
skin/dermal;
DRUGBANK
14285.7142857143
mg/day
100
g/week
skin/dermal
Calcipotriene Ointment
calcipotriene
PDR
14285.7142857143
mg/day
100
g/week
skin/dermal
Calcipotriene Ointment
calcipotriene
PDR
DDPD02325
Isopropyl alcohol
60.095
C3H8O
CC(C)O
DB02325
T3D4699
3776
17824
3644
-2.0
-
-2.0
-
DRUGBANK
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qw
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
10.0
mg
10
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qw
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
20.0
mg
20
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
40.0
mg
40
mg
subcutaneous injection, SC
qow
Humira
adalimumab
PDR
1.66666666666667
mg/day
150
mg/dose
subcutaneous injection, SC
q3m
Skyrizi
risankizumab-rzaa
PDR
1.66666666666667
mg/day
150
mg/dose
subcutaneous injection, SC
q3m
Skyrizi
risankizumab-rzaa
PDR
DDPD02362
Aminobenzoic acid
137.136
C7H7NO2
NC1=CC=C(C=C1)C(O)=O
DB02362
978
30753
953
-2.0
-
-2.0
-
DRUGBANK
1000.0
mg/day
1
g/day
PO, oral
Potaba
aminobenzoate potassium
PDR
20000.0
mg/day
20
g/day
PO, oral
Potaba
aminobenzoate potassium
PDR
20000.0
mg/day
20
g/day
PO, oral
Potaba
aminobenzoate potassium
PDR
20000.0
mg/day
20
g/day
PO, oral
Potaba
aminobenzoate potassium
PDR
DDPD02513
Thymol
150.221
C10H14O
CC(C)C1=C(O)C=C(C)C=C1
DB02513
6989
27607
21105998
-2.0
-
-2.0
-
DRUGBANK
DDPD02546
Vorinostat
264.3202
C14H20N2O3
ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
DB02546
5311
45716
http://www.drugs.com/cdi/vorinostat.html
5120
-2.0
-
-2.0
-
DRUGBANK
1.68
L/h/kg
28
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
L/kg
0.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.76
h
0.76
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
71.0
%
71
%
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Zolinza
vorinostat
PDR
400.0
mg/day
400
mg/day
PO, oral
Zolinza
vorinostat
PDR
DDPD02638
Terlipressin
1227.372
C52H74N16O15S2
NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
DB02638
72081
135905
65067
-2.0
-
-2.0
-
DRUGBANK
0.492
L/h/kg
8.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.9
h
0.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
%
~30
%
DRUGBANK
DDPD02659
Cholic Acid
408.5714
C24H40O5
[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])C[C@]([H])(O)[C@]12C
DB02659
T3D4343
221493
16359
http://www.drugs.com/mtm/cholic-acid.html
192176
-2.0
-
-2.0
-
DRUGBANK
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
17.0
mg/kg/day
17
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
17.0
mg/kg/day
17
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
17.0
mg/kg/day
17
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
17.0
mg/kg/day
17
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
17.0
mg/kg/day
17
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
15.0
mg/kg/day
15
mg/kg/day
PO, oral
Cholbam
cholic acid
PDR
DDPD02701
Nicotinamide
122.1246
C6H6N2O
NC(=O)C1=CN=CC=C1
DB02701
T3D4168
936
17154
http://www.drugs.com/cdi/niacinamide-gel.html
911
-2.0
-
-2.0
-
DRUGBANK
DDPD02703
Fusidic acid
516.7092
C31H48O6
[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O
DB02703
3000226
29013
2271900
-2.0
-
-2.0
-
DRUGBANK
91.0
%
91
%
Tablet, PO, oral;
DRUGBANK
22.5
%
22.5
%
Liquid; Children; patients;
DRUGBANK
5.5
h
~5-6
h
adults;
DRUGBANK
98.0
%
97-99
%
DRUGBANK
DDPD02772
Sucrose
342.2965
C12H22O11
OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
DB02772
5988
17992
5768
-2.0
-
-2.0
-
DRUGBANK
DDPD02893
D-Methionine
149.211
C5H11NO2S
CSCC[C@@H](N)C(O)=O
DB02893
84815
57932
76512
-2.0
-
-2.0
-
DRUGBANK
DDPD02925
Piretanide
362.4
C17H18N2O5S
NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O
DB02925
4849
32015
4683
-2.0
-
-2.0
-
DRUGBANK
0.186
L/h/kg
3.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD02959
Oxitriptan
220.2246
C11H12N2O3
N[C@@H](CC1=CNC2=C1C=C(O)C=C2)C(O)=O
DB02959
T3D4298
439280
58266
388413
-2.0
-
-2.0
-
DRUGBANK
DDPD03017
Lauric acid
200.3178
C12H24O2
CCCCCCCCCCCC(O)=O
DB03017
T3D4596
3893
30805
3756
-2.0
-
-2.0
-
DRUGBANK
DDPD03085
Glycolic acid
76.0514
C2H4O3
OCC(O)=O
DB03085
T3D3660
757
17497
737
-2.0
-
-2.0
-
DRUGBANK
1950.0
mg/kg
1950.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
intravenous injection, IV; cat;
DRUGBANK
DDPD03088
Pidolic acid
129.114
C5H7NO3
OC(=O)[C@@H]1CCC(=O)N1
DB03088
T3D4270
7405
18183
7127
-2.0
-
-2.0
-
DRUGBANK
6.78
%
6.78
%
skin/dermal;
DRUGBANK
6480.0
h
~9
month
DRUGBANK
30.0
%
30
%
Urinary excretion; PO, oral; dog; Unchanged drug;
DRUGBANK
DDPD03147
Flavin adenine dinucleotide
785.5497
C27H33N9O15P2
CC1=CC2=C(C=C1C)N(C[C@H](O)[C@H](O)[C@H](O)CO[P@](O)(=O)O[P@@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC3=C1N=CN=C3N)C1=NC(=O)NC(=O)C1=N2
DB03147
643975
16238
559059
-2.0
-
-2.0
-
DRUGBANK
700.0
mg/kg
>700
mg/kg
PO, oral; mouse;
DRUGBANK
589.0
mg/kg
589.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
DDPD03166
Acetic acid
60.052
C2H4O2
CC(O)=O
DB03166
T3D3268
176
15366
http://www.drugs.com/cdi/acetic-acid-solution.html
171
-2.0
-
-2.0
-
DRUGBANK
3530.0
mg/kg
3.53
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
525.0
mg/kg
525.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
1060.0
mg/kg
1060.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD03175
Propyl alcohol
60.095
C3H8O
CCCO
DB03175
1031
28831
1004
-2.0
-
-2.0
-
DRUGBANK
DDPD03193
Stearic acid
284.4772
C18H36O2
CCCCCCCCCCCCCCCCCC(O)=O
DB03193
T3D4755
5281
28842
5091
-2.0
-
-2.0
-
DRUGBANK
4640.0
mg/kg
4640.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
skin/dermal; rabbit;
DRUGBANK
4640.0
mg/kg
4640.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD03209
Oteracil
157.0843
C4H3N3O4
OC(=O)C1=NC(=O)NC(=O)N1
DB03209
4604
30863
4443
-2.0
-
-2.0
-
DRUGBANK
0.5
h
0.5
h
PO, oral; Components;
DRUGBANK
1.0
h
1
h
PO, oral; Components;
DRUGBANK
2.0
h
2
h
PO, oral; Components;
DRUGBANK
16.0
L/m2
16.0
L/m2
Apparent volume of distribution; Drug combination;
DRUGBANK
17.0
L/m2
17.0
L/m2
Apparent volume of distribution; Drug combination;
DRUGBANK
23.0
L/m2
23.0
L/m2
Apparent volume of distribution; Drug combination;
DRUGBANK
9.0
h
6.7-11.3
h
Single dose;
DRUGBANK
3.6
h
3.1-4.1
h
Single dose;
DRUGBANK
5.65
h
1.8-9.5
h
Single dose;
DRUGBANK
8.4
%
8.4
%
DRUGBANK
DDPD03255
Phenol
94.1112
C6H6O
OC1=CC=CC=C1
DB03255
T3D0182
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
996
15882
http://www.drugs.com/cdi/phenol-spray.html
971
-2.0
-
-2.0
-
DRUGBANK
325.0
mg/kg
0.3-0.35
g/kg
subcutaneous injection, SC; mouse;
DRUGBANK
450.0
mg/kg
0.45
g/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
530.0
mg/kg
0.53
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
650.0
mg/kg
0.65
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
670.0
mg/kg
0.67
g/kg
skin/dermal; Rattus, Rat;
DRUGBANK
16.6666666666667
mg/kg/h
400.0
mg/kg/day
PO, oral; Rattus, Rat;
DRUGBANK
27.875
mg/m2/h
669.0
mg/m2/day
skin/dermal; Rattus, Rat;
DRUGBANK
58.3333333333333
mg/m2/h
1400.0
mg/m2/day
skin/dermal; rabbit;
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral;
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral; Rattus, Rat;
DRUGBANK
DDPD03585
Oxyphenbutazone
324.3737
C19H20N2O3
CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
DB03585
4641
76258
4480
-2.0
-
-2.0
-
DRUGBANK
DDPD03614
Mecobalamin
1344.3823
C63H91CoN13O14P
C1(CC[C@@]2([C@@H](CC(N)=O)[C@@]3([C@@]4([N+]5=C([C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C(C)=C4[N+]6=C(C=C7[N+]8=C([C@H](C7(C)C)CCC(N)=O)C(C)=C2N3[Co-3]568([N+]2=CN([C@H]3O[C@@H]([C@@H](OP(O[C@@H](CN1)C)([O-])=O)[C@H]3O)CO)C1=CC(C)=C(C=C21)C)C)[C@H]([C@@]4(CC(N)=O)C)CCC(N)=O)C)[H])C)=O
DB03614
T3D0679
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
71306319
28115
28534328
-2.0
-
-2.0
-
DRUGBANK
1e-07
mg/L
0.0001
mg/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
DDPD03615
Ribostamycin
454.4727
C17H34N4O10
[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@@H](O)[C@H]1O
DB03615
33042
45257
30581
-2.0
-
-2.0
-
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.25
L/kg
0.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD03619
Deoxycholic acid
392.572
C24H40O4
[H][C@@]12CC[C@H]([C@H](C)CCC(O)=O)[C@@]1(C)[C@@H](O)C[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@H](O)CC[C@]12C
DB03619
T3D4961
222528
28834
http://www.drugs.com/mtm/deoxycholic-acid.html
193196
-2.0
-
-2.0
-
DRUGBANK
DDPD03756
Doconexent
328.4883
C22H32O2
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O
DB03756
445580
28125
393183
-2.0
-
-2.0
-
DRUGBANK
20.0
h
~20
h
DRUGBANK
7060.0
mg/kg
7060.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3450.0
mg/kg
3450.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD03766
Propanoic acid
74.0785
C3H6O2
[H]CCC(O)=O
DB03766
T3D4444
1032
30768
1005
-2.0
-
-2.0
-
DRUGBANK
0.115
h
6.9±0.4
min
sheep; intravenous injection, IV;
DRUGBANK
77.0
%
77
%
lung excretion; Oral single dose;
DRUGBANK
7.0
%
7
%
Urinary excretion; Faeces excretion;
DRUGBANK
DDPD03793
Benzoic acid
122.123
C7H6O2
OC(=O)C1=CC=CC=C1
DB03793
T3D4785
243
30746
238
-2.0
-
-2.0
-
DRUGBANK
DDPD03796
Palmitic Acid
256.4241
C16H32O2
CCCCCCCCCCCCCCCC(O)=O
DB03796
T3D4797
985
15756
960
-2.0
-
-2.0
-
DRUGBANK
10000.0
mg/kg
>10000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD03843
Formaldehyde
30.026
CH2O
[H]C([H])=O
DB03843
T3D0244
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
712
16842
http://www.drugs.com/cdi/formaldehyde-solution.html
692
-2.0
-
-2.0
-
DRUGBANK
42.0
mg/kg
42.0
mg/kg
PO, oral; mouse;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
42.0
mg/kg
42.0
mg/kg
PO, oral; mouse;
DRUGBANK
87.0
mg/kg
87.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
16.0
mg/kg
16.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
0.04
mg/kg
0.04
ppm
inhalation, IH;
DRUGBANK
0.03
mg/kg
0.03
ppm
inhalation, IH;
DRUGBANK
0.008
mg/kg
0.008
ppm
inhalation, IH; Oral multiple dose;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral;
DRUGBANK
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
0.04
mg/kg
0.04
ppm
inhalation, IH;
DRUGBANK
0.03
mg/kg
0.03
ppm
inhalation, IH;
DRUGBANK
0.008
mg/kg
0.008
ppm
inhalation, IH; Oral multiple dose;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral;
DRUGBANK
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD03904
Urea
60.0553
CH4N2O
NC(N)=O
DB03904
1176
16199
http://www.drugs.com/cons/urea-intravenous.html
1143
-2.0
-
-2.0
-
DRUGBANK
2.0
application/day
2
application/day
skin/dermal
Hydro 35
urea
PDR
2000.0
mg/kg/day
2
g/kg/day
PO, oral
Hydro 35
urea
PDR
2.0
appLication/day
2
appLication/day
skin/dermal
Hydro 35
urea
PDR
180000.0
mg/day
180
g/day
PO, oral
Hydro 35
urea
PDR
2.0
application/day
2
application/day
skin/dermal
Hydro 35
urea
PDR
2000.0
mg/kg/day
2
g/kg/day
PO, oral
Hydro 35
urea
PDR
2.0
application/day
2
application/day
skin/dermal
Hydro 35
urea
PDR
180000.0
mg/day
180
g/day
PO, oral
Hydro 35
urea
PDR
2000.0
mg/kg/day
2
g/kg/day
PO, oral
Hydro 35
urea
PDR
DDPD03929
D-Serine
105.0926
C3H7NO3
N[C@H](CO)C(O)=O
DB03929
71077
16523
64231
-2.0
-
-2.0
-
DRUGBANK
DDPD04038
Ergosterol
396.659
C28H44O
CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
DB04038
444679
16933
392539
-2.0
-
-2.0
-
DRUGBANK
DDPD04115
Berberine
336.3612
C20H18NO4
COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC
DB04115
2353
16118
2263
-2.0
-
-2.0
-
DRUGBANK
DDPD04160
Pyrophosphoric acid
177.9751
H4O7P2
OP(O)(=O)OP(O)(O)=O
DB04160
1023
29888
996
-2.0
-
-2.0
-
DRUGBANK
DDPD04173
Fructose
180.1559
C6H12O6
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O
DB04173
T3D4345
439553
43703
388644
-2.0
-
-2.0
-
DRUGBANK
15000.0
mg/kg
15000.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
DDPD04209
Dequalinium
456.6654
C30H40N4
CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2
DB04209
2993
41872
https://www.drugs.com/international/dequalinium-chloride.html
2886
-2.0
-
-2.0
-
DRUGBANK
0.1
%
<0.1
%
PO, oral;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
18.3
mg/kg
18.3
mg/kg
rodents;
DRUGBANK
DDPD04224
Oleic Acid
282.4614
C18H34O2
CCCCCCCC\C=C\CCCCCCCC(O)=O
DB04224
T3D4802
637517
27997
553123
-2.0
-
-2.0
-
DRUGBANK
15.6
h
15.6
h
PO, oral; Rattus, Rat;
DRUGBANK
74000.0
mg/kg
74.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
2.4
mg/kg
2.4
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
skin/dermal; guinea pigs;
DRUGBANK
10.0
%
<10
%
Faeces excretion; PO, oral;
DRUGBANK
DDPD04272
Citric acid
192.1235
C6H8O7
OC(=O)CC(O)(CC(O)=O)C(O)=O
DB04272
311
30769
305
-2.0
-
-2.0
-
DRUGBANK
5040.0
mg/kg
5040.0
mg/kg
PO, oral; mouse;
DRUGBANK
3000.0
mg/kg
3000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD04348
Taurocholic acid
515.703
C26H45NO7S
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCCS(O)(=O)=O
DB04348
6675
28865
6423
-2.0
-
-2.0
-
DRUGBANK
DDPD04398
Lactic acid
90.0779
C3H6O3
CC(O)C(O)=O
DB04398
612
78320
http://www.drugs.com/cdi/lactic-acid-cream.html
592
-2.0
-
-2.0
-
DRUGBANK
DDPD04465
Lactose
342.2965
C12H22O11
OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O
DB04465
440995
17716
389820
-2.0
-
-2.0
-
DRUGBANK
DDPD04540
Cholesterol
386.6535
C27H46O
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C
DB04540
T3D4314
5997
16113
5775
-2.0
-
-2.0
-
DRUGBANK
DDPD04564
Gluconolactone
178.14
C6H10O6
OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O
DB04564
7027
16217
6760
-2.0
-
-2.0
-
DRUGBANK
DDPD04570
Latamoxef
520.473
C20H20N6O9S
[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C(C(O)=O)C1=CC=C(O)C=C1)OC)C(O)=O
DB04570
47499
599928
43215
-2.0
-
-2.0
-
DRUGBANK
8.51
L
8.51
L
DRUGBANK
1.6
h
1.6
h
DRUGBANK
75.0
%
75
%
Urinary excretion;
DRUGBANK
40.0
%
40
%
DRUGBANK
DDPD04571
Trioxsalen
228.2433
C14H12O3
CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
DB04571
5585
28329
http://www.drugs.com/cons/trioxsalen.html
5383
-2.0
-
-2.0
-
DRUGBANK
DDPD04572
Thiotepa
189.218
C6H12N3PS
S=P(N1CC1)(N1CC1)N1CC1
DB04572
T3D4716
5453
9570
http://www.drugs.com/cdi/thiotepa.html
5254
-2.0
-
-2.0
-
DRUGBANK
26.76
L/h
446±63
ml/min
intravenous infusion, IV in drop; ovarian cancer; patients; Female, women;
DRUGBANK
0.402
L/h/kg
6.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
h
1.5-4.1
h
DRUGBANK
2.7
h
2.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
63.0
%
63
%
Urinary excretion; intravenous injection, IV; patients;
DRUGBANK
5.0
mg/kg
5
mg/kg
intravenous injection, IV
bid
Tepadina
thiotepa
PDR
0.8
mg/kg
0.8
mg/kg
Intraperitoneal, IP
Tepadina
thiotepa
PDR
60.0
mg
60
mg
intravesically
Tepadina
thiotepa
PDR
0.4
mg/kg
0.4
mg/kg
intravenous injection, IV
Tepadina
thiotepa
PDR
5.0
mg/kg
5
mg/kg
intravenous injection, IV
bid
Tepadina
thiotepa
PDR
0.8
mg/kg
0.8
mg/kg
Intraperitoneal, IP
Tepadina
thiotepa
PDR
60.0
mg
60
mg
intravesically
Tepadina
thiotepa
PDR
0.4
mg/kg
0.4
mg/kg
intravenous injection, IV
Tepadina
thiotepa
PDR
5.0
mg/kg
5
mg/kg
intravenous injection, IV
bid
Tepadina
thiotepa
PDR
DDPD04573
Estriol
288.3814
C18H24O3
[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
DB04573
T3D4790
5756
27974
5553
-2.0
-
-2.0
-
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD04574
Estrone sulfate
350.429
C18H22O5S
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OS(O)(=O)=O)C=C3
DB04574
3001028
17474
2272513
-2.0
-
-2.0
-
DRUGBANK
9.0
mg/day
9
mg/day
PO, oral
Estropipate
estropipate
PDR
9.0
mg/day
9
mg/day
PO, oral
Estropipate
estropipate
PDR
6.0
mg/day
6
mg/day
PO, oral
Estropipate
estropipate
PDR
DDPD04575
Quinestrol
364.5204
C25H32O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3
DB04575
T3D3063
9046
8716
8694
-2.0
-
-2.0
-
DRUGBANK
DDPD04657
Carboxin
235.302
C12H13NO2S
CC1=C(SCCO1)C(=O)NC1=CC=CC=C1
DB04657
T3D4483
21307
3405
20027
-2.0
-
-2.0
-
DRUGBANK
DDPD04711
Iodipamide
1139.7618
C20H14I6N2O6
OC(=O)C1=C(I)C(NC(=O)CCCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I
DB04711
3739
31176
3608
-2.0
-
-2.0
-
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
3195.0
mg/kg
3195.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
1200.0
mg/kg
1200.0
mg/kg
intravenous injection, IV; dog;
DRUGBANK
DDPD04743
Nimesulide
308.31
C13H12N2O5S
CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
DB04743
4495
44445
http://www.drugs.com/international/nimesulide.html
4339
-2.0
-
-2.0
-
DRUGBANK
3.25
h
1.8-4.7
h
DRUGBANK
200.0
mg/kg
200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
392.0
mg/kg
392.0
mg/kg
PO, oral; mouse;
DRUGBANK
1.429
mg/kg
1.429
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
2.0
mg/kg
2.0
mg/kg
PO, oral; Female, women;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
29.0
%
29
%
Faeces excretion;
DRUGBANK
97.5
%
>97.5
%
DRUGBANK
DDPD04794
Bifonazole
310.3917
C22H18N2
C1=CN(C=N1)C(C1=CC=CC=C1)C1=CC=C(C=C1)C1=CC=CC=C1
DB04794
2378
78692
2287
-2.0
-
-2.0
-
DRUGBANK
0.6
%
0.6
%
skin/dermal;
DRUGBANK
3.1
%
3.1
%
skin/dermal; skin disease;
skin disease ↑ ;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
DDPD04812
Benoxaprofen
301.724
C16H12ClNO3
CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1
DB04812
39941
76114
36518
-2.0
-
-2.0
-
DRUGBANK
DDPD04813
Bithionol
356.052
C12H6Cl4O2S
OC1=C(SC2=C(O)C(Cl)=CC(Cl)=C2)C=C(Cl)C=C1Cl
DB04813
2406
3131
2313
-2.0
-
-2.0
-
DRUGBANK
DDPD04815
Clioquinol
305.5
C9H5ClINO
OC1=C(I)C=C(Cl)C2=C1N=CC=C2
DB04815
2788
74460
http://www.drugs.com/mtm/clioquinol-topical.html
2686
-2.0
-
-2.0
-
DRUGBANK
DDPD04816
Dantron
240.2109
C14H8O4
OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O
DB04816
2950
3682
2845
-2.0
-
-2.0
-
DRUGBANK
DDPD04820
Nialamide
298.3397
C16H18N4O2
O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1
DB04820
4472
94510
4317
-2.0
-
-2.0
-
DRUGBANK
DDPD04821
Nomifensine
238.3275
C16H18N2
CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2
DB04821
4528
116225
4371
-2.0
-
-2.0
-
DRUGBANK
1.32
L/h/kg
22
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
L/kg
6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.5
h
6.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD04822
Oxeladin
335.4809
C20H33NO3
CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1
DB04822
4619
135424
4458
-2.0
-
-2.0
-
DRUGBANK
DDPD04824
Phenolphthalein
318.3228
C20H14O4
OC1=CC=C(C=C1)C1(OC(=O)C2=CC=CC=C12)C1=CC=C(O)C=C1
DB04824
T3D4708
4764
34914
4600
-2.0
-
-2.0
-
DRUGBANK
DDPD04825
Prenylamine
329.4779
C24H27N
CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
DB04825
9801
8397
9418
-2.0
-
-2.0
-
DRUGBANK
DDPD04826
Thenalidine
286.435
C17H22N2S
CN1CCC(CC1)N(CC1=CC=CS1)C1=CC=CC=C1
DB04826
27901
135187
25957
-2.0
-
-2.0
-
DRUGBANK
DDPD04827
Urethane
89.0932
C3H7NO2
CCOC(N)=O
DB04827
T3D4583
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
5641
17967
5439
-2.0
-
-2.0
-
DRUGBANK
2000.0
mg/kg
2.0
g/kg
rodents;
DRUGBANK
0.3
mg/kg/day
>0.3
mg/kg/day
depression;
DRUGBANK
DDPD04832
Zimelidine
317.23
C16H17BrN2
CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1
DB04832
41987
135357
4517305
-2.0
-
-2.0
-
DRUGBANK
0.828
L/h/kg
13.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.8
L/kg
6.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.4
h
8.4±2.0
h
DRUGBANK
19.4
h
19.4±3.6
h
DRUGBANK
6.26
h
6.26
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD04834
Rapacuronium
597.904
C37H61N2O4
[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1
DB04834
5311399
135845
4470890
-2.0
-
-2.0
-
DRUGBANK
2.35
h
141
min
DRUGBANK
69.0
%
50-88
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
DDPD04835
Maraviroc
513.6655
C29H41F2N5O
CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
DB04835
3002977
63608
http://www.drugs.com/cdi/maraviroc.html
20078004
-2.0
-
-2.0
-
DRUGBANK
23.0
%
23
%
PO, oral;
DRUGBANK
33.0
%
33
%
PO, oral;
DRUGBANK
0.564
L/h/kg
9.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
194.0
L
194.0
L
DRUGBANK
2.3
L/kg
2.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
h
14-18
h
DRUGBANK
12.8
h
12.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
76.0
%
~76
%
plasma proteins; human, homo sapiens;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Selzentry
maraviroc
PDR
300.0
mg/day
300
mg/day
PO, oral
Selzentry
maraviroc
PDR
600.0
mg/day
600
mg/day
PO, oral
Selzentry
maraviroc
PDR
200.0
mg/day
200
mg/day
PO, oral
Selzentry
maraviroc
PDR
150.0
mg/day
150
mg/day
PO, oral
Selzentry
maraviroc
PDR
160.0
mg/day
160
mg/day
PO, oral
Selzentry
maraviroc
PDR
100.0
mg/day
100
mg/day
PO, oral
Selzentry
maraviroc
PDR
600.0
mg/day
600
mg/day
PO, oral
Selzentry
maraviroc
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Selzentry
maraviroc
PDR
300.0
mg/day
300
mg/day
PO, oral
Selzentry
maraviroc
PDR
600.0
mg/day
600
mg/day
PO, oral
Selzentry
maraviroc
PDR
300.0
mg/day
300
mg/day
PO, oral
Selzentry
maraviroc
PDR
600.0
mg/day
600
mg/day
PO, oral
Selzentry
maraviroc
PDR
200.0
mg/day
200
mg/day
PO, oral
Selzentry
maraviroc
PDR
600.0
mg/day
600
mg/day
PO, oral
Selzentry
maraviroc
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Selzentry
maraviroc
PDR
300.0
mg/day
300
mg/day
PO, oral
Selzentry
maraviroc
PDR
DDPD04837
Clofedanol
289.8
C17H20ClNO
CN(C)CCC(O)(C1=CC=CC=C1)C1=CC=CC=C1Cl
DB04837
T3D3064
2795
135207
http://www.drugs.com/cons/chlophedianol.html
2693
-2.0
-
-2.0
-
DRUGBANK
DDPD04838
Cyclandelate
276.3707
C17H24O3
CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1
DB04838
2893
3988
http://www.drugs.com/mtm/cyclandelate.html
2790
-2.0
-
-2.0
-
DRUGBANK
3950.0
mg/kg
3950.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
DDPD04839
Cyproterone acetate
416.938
C24H29ClO4
[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]
DB04839
T3D4747
9880
50743
9496
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
38.0
h
38
h
elimination half-life; PO, oral;
DRUGBANK
96.0
h
96
h
elimination half-life; IM,intramuscular injection;
DRUGBANK
60.0
%
~60
%
Bile excretion;
DRUGBANK
33.0
%
33
%
Urinary excretion;
DRUGBANK
DDPD04840
Debrisoquine
175.2303
C10H13N3
NC(=N)N1CCC2=CC=CC=C2C1
DB04840
2966
34665
2860
-2.0
-
-2.0
-
DRUGBANK
DDPD04841
Flunarizine
404.4948
C26H26F2N2
FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1
DB04841
941361
135652
http://www.drugs.com/international/flunarizine.html
819216
-2.0
-
-2.0
-
DRUGBANK
85.0
%
85
%
DRUGBANK
432.0
h
18
day
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD04842
Fluspirilene
475.5727
C29H31F2N3O
FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1
DB04842
3396
93369
3279
-2.0
-
-2.0
-
DRUGBANK
DDPD04843
Mepenzolate
340.436
C21H26NO3
C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
DB04843
4057
94411
http://www.drugs.com/cdi/mepenzolate.html
3917
-2.0
-
-2.0
-
DRUGBANK
750.0
mg/kg
>750
mg/kg
PO, oral; mouse;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
12.5
%
3-22
%
Urinary excretion; PO, oral;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Cantil
mepenzolate bromide
PDR
200.0
mg/day
200
mg/day
PO, oral
Cantil
mepenzolate bromide
PDR
DDPD04844
Tetrabenazine
317.4226
C19H27NO3
COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1
DB04844
6018
64028
http://www.drugs.com/cdi/tetrabenazine.html
5796
-2.0
-
-2.0
-
DRUGBANK
75.0
%
>75
%
PO, oral;
DRUGBANK
4.8
ng/ml
4.8
ng/ml
PO, oral; Huntington's disease; tardive dyskinesia;
DRUGBANK
1.15
h
69
min
PO, oral; Huntington's disease; tardive dyskinesia;
DRUGBANK
100.2
L/h
1.67
L/min
intravenous injection, IV;
DRUGBANK
385.0
L
385.0
L
intravenous injection, IV; at steady state;
DRUGBANK
7.0
h
7
h
distribution half-life;
DRUGBANK
5.0
h
5
h
elimination half-life;
DRUGBANK
12.0
h
12
h
elimination half-life;
DRUGBANK
550.0
mg/kg
550.0
mg/kg
PO, oral; mouse;
DRUGBANK
75.0
%
75
%
Urinary excretion; PO, oral;
DRUGBANK
85.0
%
82-88
%
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Xenazine
tetrabenazine
PDR
50.0
mg/day
50
mg/day
PO, oral
Xenazine
tetrabenazine
PDR
100.0
mg/day
100
mg/day
PO, oral
Xenazine
tetrabenazine
PDR
50.0
mg/day
50
mg/day
PO, oral
Xenazine
tetrabenazine
PDR
DDPD04845
Ixabepilone
506.7
C27H42N2O5S
[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
DB04845
6445540
63605
20145579
-2.0
-
-2.0
-
DRUGBANK
0.6
L/h/kg
10
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
L/kg
11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
52.0
h
52
h
DRUGBANK
17.0
h
17
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
72.0
%
67-77
%
DRUGBANK
40.0
mg/m2
40
mg/m2
intravenous injection, IV
q3w
Ixempra
ixabepilone
PDR
20.0
mg/m2
20
mg/m2
intravenous injection, IV
q3w
Ixempra
ixabepilone
PDR
40.0
mg/m2
40
mg/m2
intravenous injection, IV
q3w
Ixempra
ixabepilone
PDR
20.0
mg/m2
20
mg/m2
intravenous injection, IV
q3w
Ixempra
ixabepilone
PDR
DDPD04846
Celiprolol
379.501
C20H33N3O4
CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O
DB04846
2663
94461
http://www.drugs.com/international/celiprolol.html
2563
-2.0
-
-2.0
-
DRUGBANK
55.0
%
55
%
DRUGBANK
74.0
%
74
%
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
2.0
%
1-3
%
Liver metabolism;
DRUGBANK
4.5
L/kg
4.5
L/kg
DRUGBANK
5.0
h
5
h
DRUGBANK
27.5
%
25-30
%
DRUGBANK
DDPD04854
Febuxostat
316.375
C16H16N2O3S
CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N
DB04854
134018
31596
http://www.drugs.com/international/Febuxostat.html
118173
-2.0
-
-2.0
-
DRUGBANK
49.0
%
>49
%
DRUGBANK
35.0
%
35
%
DRUGBANK
10.0
%
10
%
DRUGBANK
11.0
%
11
%
DRUGBANK
14.0
%
14
%
DRUGBANK
50.0
L
50.0
L
Steady state volume of distribution;
DRUGBANK
6.5
h
~5-8
h
DRUGBANK
99.2
%
99.2
%
DRUGBANK
120.0
mg/day
120
mg/day
PO, oral
Febuxostat
febuxostat
PDR
120.0
mg/day
120
mg/day
PO, oral
Febuxostat
febuxostat
PDR
DDPD04855
Dronedarone
556.756
C31H44N2O5S
CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2
DB04855
208898
50659
http://www.drugs.com/ppa/dronedarone.html
180996
-2.0
-
-2.0
-
DRUGBANK
70.0
%
>70
%
PO, oral;
DRUGBANK
4.0
%
4
%
PO, oral;
DRUGBANK
15.0
%
15
%
PO, oral; high-fat meal;
DRUGBANK
4.5
h
3-6
h
PO, oral; Active metabolite;
DRUGBANK
144.0
h
4-8
day
Oral multiple dose;
DRUGBANK
140.0
L/h
130-150
L/h
intravenous injection, IV;
DRUGBANK
1.9998
L/h/kg
33.33
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1300.0
L
1200-1400
L
at steady state; intravenous injection, IV;
DRUGBANK
20.0
L/kg
20
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
h
13-19
h
elimination half-life;
DRUGBANK
16.0
h
16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
84.0
%
~84
%
Faeces excretion; PO, oral;
DRUGBANK
6.0
%
6
%
Urinary excretion; PO, oral;
DRUGBANK
99.7
%
99.7
%
plasma proteins; high protein binding;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Multaq
dronedarone
PDR
800.0
mg/day
800
mg/day
PO, oral
Multaq
dronedarone
PDR
DDPD04861
Nebivolol
405.435
C22H25F2NO4
OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2
DB04861
71301
64019
http://www.drugs.com/cdi/nebivolol.html
64421
-2.0
-
-2.0
-
DRUGBANK
13.78
ng.h/ml
13.78±15.27
ng.h/ml
Raceme D;
DRUGBANK
27.72
ng.h/ml
27.72±15.32
ng.h/ml
Raceme L;
DRUGBANK
41.5
ng.h/ml
41.50±29.76
ng.h/ml
Raceme D/L;
DRUGBANK
396.78
ng.h/ml
396.78±297.94
ng.h/ml
Derivative;
DRUGBANK
54.0
%
12-96
%
PO, oral; poor metabolizers, PM; extensive metabolizers, EM;
DRUGBANK
2.75
ng/ml
2.75±1.55
ng/ml
Raceme D;
DRUGBANK
5.29
ng/ml
5.29±2.06
ng/ml
Raceme L;
DRUGBANK
8.02
ng/ml
8.02±3.47
ng/ml
Raceme D/L;
DRUGBANK
68.34
ng/ml
68.34±44.68
ng/ml
Derivative;
DRUGBANK
2.75
h
1.5-4
h
PO, oral; poor metabolizers, PM; extensive metabolizers, EM;
DRUGBANK
1241.63
L/h
1241.63±749.77
L/h
DRUGBANK
435.53
L/h
435.53±180.93
L/h
DRUGBANK
635.31
L/h
635.31±300.25
L/h
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10290.81
L
10290.81±3911.72
L
Apparent volume of distribution;
DRUGBANK
8066.66
L
8066.66±4055.50
L
Apparent volume of distribution;
DRUGBANK
10423.42
L
10423.42±6796.50
L
Apparent volume of distribution;
DRUGBANK
11.0
L/kg
11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
Raceme D; extensive metabolizers, EM;
DRUGBANK
19.0
h
19
h
Raceme D; poor metabolizers, PM;
DRUGBANK
10.0
h
10
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
38.0
%
38
%
Urinary excretion; extensive metabolizers, EM;
DRUGBANK
44.0
%
44
%
Faeces excretion; extensive metabolizers, EM;
DRUGBANK
67.0
%
67
%
Urinary excretion; poor metabolizers, PM;
DRUGBANK
13.0
%
13
%
Faeces excretion; poor metabolizers, PM;
DRUGBANK
98.0
%
98
%
plasma proteins;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Bystolic
nebivolol
PDR
40.0
mg/day
40
mg/day
PO, oral
Bystolic
nebivolol
PDR
DDPD04864
Huperzine A
242.3162
C15H18N2O
[H][C@@]12CC3=C(C=CC(=O)N3)[C@@](N)(CC(C)=C1)\C2=C\C
DB04864
854026
78330
16736021
-2.0
-
-2.0
-
DRUGBANK
DDPD04865
Omacetaxine mepesuccinate
545.6213
C29H39NO9
[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]
DB04865
285033
71019
http://www.drugs.com/cdi/omacetaxine-injection.html
251215
-2.0
-
-2.0
-
DRUGBANK
0.5
h
30
min
DRUGBANK
0.0
%
0
%
Liver metabolism;
DRUGBANK
141.0
L
141±93.4
L
Steady state volume of distribution;
DRUGBANK
6.0
h
~6
h
subcutaneous injection, SC;
DRUGBANK
15.0
%
<15
%
Urinary excretion;
DRUGBANK
50.0
%
≤50
%
plasma proteins;
DRUGBANK
2.5
mg/m2/day
2.5
mg/m2/day
subcutaneous injection, SC
Synribo
omacetaxine mepesuccinate
PDR
2.5
mg/m2/day
2.5
mg/m2/day
subcutaneous injection, SC
Synribo
omacetaxine mepesuccinate
PDR
DDPD04868
Nilotinib
529.5158
C28H22F3N7O
CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F
DB04868
644241
52172
559260
-2.0
-
-2.0
-
DRUGBANK
15.0
h
15
h
DRUGBANK
230.0
mg/m2
230
mg/m2
bid
Tasigna
nilotinib
PDR
400.0
mg/dose
400
mg/dose
Tasigna
nilotinib
PDR
800.0
mg/day
800
mg/day
PO, oral
Tasigna
nilotinib
PDR
230.0
mg/m2/day
230
mg/m2/day
bid
Tasigna
nilotinib
PDR
400.0
mg/dose
400
mg/dose
Tasigna
nilotinib
PDR
800.0
mg/day
800
mg/day
PO, oral
Tasigna
nilotinib
PDR
DDPD04871
Lorcaserin
195.69
C11H14ClN
C[C@H]1CNCCC2=CC=C(Cl)C=C12
DB04871
11658860
65353
http://www.drugs.com/mtm/lorcaserin.html
9833595
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1.5-2
h
DRUGBANK
11.0
h
~11
h
elimination half-life;
DRUGBANK
92.3
%
92.3
%
Urinary excretion;
DRUGBANK
2.2
%
2.2
%
Faeces excretion;
DRUGBANK
70.0
%
~70
%
plasma proteins;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Belviq XR
lorcaserin hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Belviq XR
lorcaserin hydrochloride
PDR
DDPD04876
Vildagliptin
303.3993
C17H25N3O2
OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N
DB04876
6918537
135285
5293734
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
0.594
L/h/kg
9.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.03
L/kg
1.03
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.5
h
~90
min
elimination half-life;
DRUGBANK
1.67
h
1.67
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.3
%
9.3
%
DRUGBANK
DDPD04880
Enoximone
248.301
C12H12N2O2S
CSC1=CC=C(C=C1)C(=O)C1=C(C)NC(=O)N1
DB04880
53708
135010
48492
-2.0
-
-2.0
-
DRUGBANK
50.0
%
50
%
PO, oral;
DRUGBANK
1.146
L/h/kg
19.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.48
L/kg
1.48
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.116666666666667
h
4-10
min
DRUGBANK
1.94
h
1.94
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
%
85
%
DRUGBANK
DDPD04890
Bepotastine
388.888
C21H25ClN2O3
OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1
DB04890
T3D3066
2350
71204
http://www.drugs.com/cdi/bepotastine-eye-drops.html
2260
-2.0
-
-2.0
-
DRUGBANK
7.3
ng/ml
7.3±1.9
ng/ml
DRUGBANK
1.2
h
1.2
h
DRUGBANK
2.5
h
2.5
h
elimination half-life;
DRUGBANK
82.5
%
75-90
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
55.4
%
55.4
%
plasma proteins; PO, oral;
Plasma Concentration → ;
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Bepreve
bepotastine besilate
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Bepreve
bepotastine besilate
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Bepreve
bepotastine besilate
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Bepreve
bepotastine besilate
PDR
DDPD04896
Milnacipran
246.354
C15H22N2O
CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
DB04896
65833
135005
http://www.drugs.com/cdi/milnacipran.html
9797657
-2.0
-
-2.0
-
DRUGBANK
5196.0
ng.h/ml
5196.0
ng.h/ml
PO, oral; Raceme L;
DRUGBANK
87.5
%
85-90
%
PO, oral;
DRUGBANK
92.0
%
92
%
PO, oral; Raceme L;
DRUGBANK
341.0
ng/ml
341
ng/ml
PO, oral; Raceme L;
DRUGBANK
3.0
h
2-4
h
PO, oral; Raceme D/L;
DRUGBANK
7.0
h
6-8
h
PO, oral; Raceme L;
DRUGBANK
42.0
h
36-48
h
PO, oral; Raceme D/L;
DRUGBANK
40.0
L/h
~40
L/h
Plasma clearance;
DRUGBANK
0.4902
L/h/kg
8.17
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
430.0
L
387-473
L
Apparent volume of distribution;
DRUGBANK
400.0
L
400.0
L
Average volume of distribution; intravenous injection, IV; Single dose; normal,healthy;
DRUGBANK
4.51
L/kg
4.51
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
~6-8
h
elimination half-life; Raceme D/L;
DRUGBANK
9.0
h
8-10
h
elimination half-life; Raceme D;
DRUGBANK
5.0
h
4-6
h
elimination half-life;
DRUGBANK
12.0
h
~12
h
elimination half-life;
DRUGBANK
6.48
h
6.48
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
213.0
mg/kg
213.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
58.0
%
~58
%
Urinary excretion; Liquid; Unchanged drug;
DRUGBANK
13.0
%
13
%
Raceme D/L;
DRUGBANK
22.0
%
22
%
plasma proteins; Raceme L;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Savella
milnacipran hydrochloride
PDR
100.0
mg/day
100
mg/day
PO, oral
Savella
milnacipran hydrochloride
PDR
200.0
mg/day
200
mg/day
PO, oral
Savella
milnacipran hydrochloride
PDR
DDPD04898
Ximelagatran
473.5652
C24H35N5O5
CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1
DB04898
9574101
65172
7848559
-2.0
-
-2.0
-
DRUGBANK
20.0
%
20
%
PO, oral;
DRUGBANK
4.0
h
3-5
h
DRUGBANK
DDPD04908
Flibanserin
390.4021
C20H21F3N4O
FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
DB04908
6918248
90865
http://www.drugs.com/addyi.html
5293454
-2.0
-
-2.0
-
DRUGBANK
33.0
%
33
%
PO, oral;
DRUGBANK
11.0
h
~11
h
DRUGBANK
51.0
%
51
%
Faeces excretion; Oral single dose;
DRUGBANK
44.0
%
44
%
Urinary excretion; PO, oral;
DRUGBANK
98.0
%
~98
%
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Addyi
flibanserin
PDR
DDPD04911
Oritavancin
1793.101
C86H97Cl3N10O26
CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2
DB04911
16136912
82699
17286443
-2.0
-
-2.0
-
DRUGBANK
2800000.0
ng.h/ml
2800.0
ug.h/ml
DRUGBANK
11111000.0
ng.h/ml
11111.0
ug.h/ml
normal,healthy;
DRUGBANK
138000.0
ng/ml
138
ug/ml
DRUGBANK
6150.0
ng/ml
4.7-7.6
mcg/ml
different study;
DRUGBANK
24.0
h
24
h
different study;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.445
L/h
0.445
L/h
DRUGBANK
0.02742
L/h
0.457
ml/min
Renal clearance;
DRUGBANK
0.0042
L/h/kg
0.07
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.6
L
87.6
L
DRUGBANK
0.3
L/kg
0.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
245.0
h
~245
h
terminal half-life;
DRUGBANK
96.2
h
96.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
mg/kg
>500
mg/kg
Rattus, Rat;
DRUGBANK
85.0
%
~85
%
plasma proteins;
DRUGBANK
1200.0
mg
1200
mg
intravenous injection, IV
Orbactiv
oritavancin
PDR
1200.0
mg
1200
mg
intravenous injection, IV
Orbactiv
oritavancin
PDR
DDPD04918
Ceftobiprole
534.57
C20H22N8O6S2
[H][C@@]1(NC(=O)C(=N/O)\C2=NSC(N)=N2)C(=O)N2C(C(O)=O)=C(CS[C@]12[H])\C=C1/CCN(C1=O)[C@]1([H])CCNC1
DB04918
12993649
140407
23350302
-2.0
-
-2.0
-
DRUGBANK
0.09
L/h/kg
1.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.27
L/kg
0.27
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.3
h
3.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD04920
Clevidipine
456.316
C21H23Cl2NO6
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
DB04920
153994
135738
135722
-2.0
-
-2.0
-
DRUGBANK
8.52
L/h/kg
142
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.58
L/kg
0.58
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0166666666666667
h
1
min
DRUGBANK
0.3
h
0.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
68.5
%
63-74
%
Urinary excretion;
DRUGBANK
14.5
%
7-22
%
Faeces excretion;
DRUGBANK
99.5
%
>99.5
%
DRUGBANK
768.0
mg/day
32
mg/h
intravenous injection, IV
Cleviprex
clevidipine
PDR
1000.0
mg/day
1000
mg/day
intravenous injection, IV
Cleviprex
clevidipine
PDR
504.0
mg/day
21
mg/h
intravenous injection, IV
Cleviprex
clevidipine
PDR
32.0
mg/hr
32
mg/hr
intravenous injection, IV
Cleviprex
clevidipine
PDR
1000.0
mg/day
1000
mg/day
intravenous injection, IV
Cleviprex
clevidipine
PDR
21.0
mg/hr
21
mg/hr
intravenous injection, IV
Cleviprex
clevidipine
PDR
DDPD04930
Permethrin
391.288
C21H20Cl2O3
CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC(OC2=CC=CC=C2)=CC=C1
DB04930
T3D1850
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
40326
34911
http://www.drugs.com/cdi/permethrin-cream.html
36845
-2.0
-
-2.0
-
DRUGBANK
2215.0
mg/kg
430-4000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
2215.0
mg/kg
430-4000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
3801.0
mg/kg
3801.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral;
DRUGBANK
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral;
DRUGBANK
0.2
mg/kg/day
0.2
mg/kg/day
PO, oral; Rattus, Rat;
DRUGBANK
DDPD04931
Afamelanotide
1646.8452
C78H111N21O19
CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O
DB04931
16197727
17310725
-2.0
-
-2.0
-
DRUGBANK
138.9
ng.h/ml
138.9±42.6
ng.h/ml
DRUGBANK
3.7
ng/ml
3.7±1.3
ng/ml
DRUGBANK
36.0
h
36
h
DRUGBANK
0.54
L/kg
~0.54
L/kg
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
0.5
h
~30
min
DRUGBANK
15.0
h
15
h
extended release formulation; subdermal implant;
DRUGBANK
DDPD04938
Ospemifene
378.891
C24H23ClO2
OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1
DB04938
3036505
73275
http://www.drugs.com/osphena.html
2300501
-2.0
-
-2.0
-
DRUGBANK
4165.0
ng.h/ml
4165.0
ng.h/ml
Oral single dose; postmenopausal women; fasting;
DRUGBANK
7521.0
ng.h/ml
7521.0
ng.h/ml
Oral single dose; postmenopausal women; food;
food ↑ ;
DRUGBANK
533.0
ng/ml
533
ng/ml
Oral single dose; postmenopausal women; fasting;
DRUGBANK
1198.0
ng/ml
1198
ng/ml
Oral single dose; postmenopausal women; food;
food ↑ ;
DRUGBANK
2.0
h
2(1-8)
h
Oral single dose; postmenopausal women; fasting;
DRUGBANK
2.5
h
2.5(1-6)
h
Oral single dose; postmenopausal women; food;
food ↑ ;
DRUGBANK
216.0
h
9
day
Oral multiple dose;
DRUGBANK
9.16
L/h
9.16
L/h
Plasma clearance;
DRUGBANK
448.0
L
448.0
L
DRUGBANK
26.0
h
26
h
terminal half-life;
DRUGBANK
75.0
%
~75
%
Faeces excretion; PO, oral;
DRUGBANK
7.0
%
~7
%
Urinary excretion; PO, oral;
DRUGBANK
0.2
%
<0.2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD04946
Iloperidone
426.4806
C24H27FN2O4
COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O
DB04946
71360
65173
http://www.drugs.com/fanapt.html
64459
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
DRUGBANK
84.0
h
3-4
day
DRUGBANK
74.5
L/h
47-102
L/h
apparent clearance;
DRUGBANK
2070.0
L
1340-2800
L
Apparent volume of distribution;
DRUGBANK
18.0
h
18
h
elimination half-life; extensive metabolizers, EM;
DRUGBANK
26.0
h
26
h
elimination half-life; extensive metabolizers, EM;
DRUGBANK
23.0
h
23
h
elimination half-life; extensive metabolizers, EM;
DRUGBANK
33.0
h
33
h
elimination half-life; poor metabolizers, PM;
DRUGBANK
37.0
h
37
h
elimination half-life; poor metabolizers, PM;
DRUGBANK
31.0
h
31
h
elimination half-life; poor metabolizers, PM;
DRUGBANK
1.0
%
<1
%
Unchanged drug;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD04948
Lofexidine
259.132
C11H12Cl2N2O
CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1
DB04948
30668
51368
28460
-2.0
-
-2.0
-
DRUGBANK
72.0
%
>72
%
PO, oral;
DRUGBANK
1.26
ng/ml
1.26
ng/ml
PO, oral;
DRUGBANK
3.5
h
2-5
h
PO, oral;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
17.6
L/h
17.6
L/h
Total clearance; intravenous injection, IV;
DRUGBANK
300.0
L
300.0
L
DRUGBANK
11.0
h
11
h
elimination half-life;
DRUGBANK
94.0
%
94
%
Urinary excretion;
DRUGBANK
0.93
%
0.93
%
Faeces excretion;
DRUGBANK
55.0
%
~55
%
DRUGBANK
DDPD04951
Pirfenidone
185.2218
C12H11NO
CC1=CN(C(=O)C=C1)C1=CC=CC=C1
DB04951
40632
32016
37115
-2.0
-
-2.0
-
DRUGBANK
2.25
h
2-2.5
h
DRUGBANK
2403.0
mg/day
2403
mg/day
PO, oral
Esbriet
pirfenidone
PDR
2403.0
mg/day
2403
mg/day
PO, oral
Esbriet
pirfenidone
PDR
DDPD04953
Ezogabine
303.3314
C16H18FN3O2
CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
DB04953
121892
68584
http://www.drugs.com/mtm/ezogabine.html
108740
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
1.25
h
0.5-2
h
Oral single dose;
DRUGBANK
72.0
h
3
day
Oral multiple dose;
DRUGBANK
0.67
L/h/kg
0.58 - 0.76
L/h/kg
DRUGBANK
0.498
L/h/kg
8.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.7
L/kg
8.7
L/kg
DRUGBANK
2.5
L/kg
2.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
h
7.5
h
terminal half-life;
DRUGBANK
9.0
h
9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
%
85
%
Urinary excretion;
DRUGBANK
14.0
%
14
%
Faeces excretion;
DRUGBANK
36.0
%
36
%
Urinary excretion; Unchanged drug;
DRUGBANK
3.0
%
3
%
Faeces excretion; Unchanged drug;
DRUGBANK
80.0
%
~80
%
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Potiga
ezogabine
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Potiga
ezogabine
PDR
750.0
mg/day
750
mg/day
PO, oral
Potiga
ezogabine
PDR
DDPD05013
Ingenol mebutate
430.541
C25H34O6
[H][C@@]12C[C@@H](C)[C@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(CO)=C[C@@]([H])(C4=O)[C@]1([H])C2(C)C
DB05013
6918670
66913
http://www.drugs.com/ppa/ingenol-mebutate.html
28533061
-2.0
-
-2.0
-
DRUGBANK
1.0
tube/dose
1
tube/dose
skin/dermal
Picato
ingenol mebutate
PDR
1.0
tube/dose
1
tube/dose
skin/dermal
Picato
ingenol mebutate
PDR
DDPD05015
Belinostat
318.35
C15H14N2O4S
ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1
DB05015
6918638
61076
5293831
-2.0
-
-2.0
-
DRUGBANK
74.4
L/h
1240.0
ml/min
DRUGBANK
1.416
L/h/kg
23.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
409.0
L
409±76.7
L
DRUGBANK
0.8
L/kg
0.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
h
1.1
h
elimination half-life;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
%
<2
%
Unchanged drug;
DRUGBANK
92.9
%
92.9
%
DRUGBANK
95.8
%
95.8
%
DRUGBANK
1000.0
mg/m2/day
1000
mg/m2/day
intravenous injection, IV
Beleodaq
belinostat
PDR
1000.0
mg/m2/day
1000
mg/m2/day
intravenous injection, IV
Beleodaq
belinostat
PDR
DDPD05016
Ataluren
284.242
C15H9FN2O3
OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F
DB05016
11219835
94805
9394889
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1.5
h
PO, oral; food;
DRUGBANK
4.0
h
2-6
h
elimination half-life;
dose → ;
DRUGBANK
50.0
%
~50
%
Faeces excretion; Oral single dose;
DRUGBANK
50.0
%
~50
%
Urinary excretion; Oral single dose;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.6
%
99.6
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD05018
Migalastat
163.1717
C6H13NO4
OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
DB05018
176077
135923
153388
-2.0
-
-2.0
-
DRUGBANK
75.0
%
75
%
Oral single dose;
DRUGBANK
75.0
%
75
%
DRUGBANK
3.0
h
3
h
Liquid;
DRUGBANK
12.5
L/h
11.0-14
L/h
DRUGBANK
105.0
L
77-133
L
Oral single dose; normal,healthy; increasing doses;
DRUGBANK
4.0
h
~3-5
h
elimination half-life;
DRUGBANK
77.0
%
~77
%
Urinary excretion; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
Faeces excretion; Male, men; normal,healthy; human, homo sapiens;
DRUGBANK
123.0
mg
123
mg
PO, oral
q2d
Galafold
migalastat
PDR
123.0
mg
123
mg
PO, oral
q2d
Galafold
migalastat
PDR
DDPD05039
Indacaterol
392.4907
C24H28N2O3
CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
DB05039
6918554
68575
http://www.drugs.com/international/indacaterol.html
5293751
-2.0
-
-2.0
-
DRUGBANK
44.0
%
43-45
%
inhalation, IH;
DRUGBANK
0.25
h
15
min
inhalation, IH;
DRUGBANK
0.83
L/h
0.46-1.2
L/h
Renal clearance;
DRUGBANK
21.05
L/h
18.8-23.3
L/h
Plasma clearance;
DRUGBANK
0.2688
L/h/kg
4.48
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2459.0
L
2361-2557
L
intravenous infusion, IV in drop;
DRUGBANK
19.4
L/kg
19.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.75
h
45.5-126
h
DRUGBANK
48.0
h
40-56
h
effective half-life; Multiple dose;
DRUGBANK
324.0
h
12-15
day
at steady state;
DRUGBANK
92.5
h
92.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
54.0
%
54
%
Faeces excretion; PO, oral; human, homo sapiens; Unchanged drug;
DRUGBANK
94.7
%
94.1-95.3
%
high protein binding; human, homo sapiens;
DRUGBANK
95.65
%
95.1-96.2
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
0.075
mg/day
75
mcg/day
inhalation, IH
Arcapta Neohaler
indacaterol
PDR
0.075
mg/day
75
mcg/day
inhalation, IH
Arcapta Neohaler
indacaterol
PDR
DDPD05109
Trabectedin
761.837
C39H43N3O11S
[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31
DB05109
108150
84050
97236
-2.0
-
-2.0
-
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
L/kg
25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
41.5
h
33-50
h
DRUGBANK
44.0
h
44
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
96.0
%
94-98
%
DRUGBANK
1.5
mg/m2
1.5
mg/m2
intravenous injection, IV
q3w
Yondelis
trabectedin
PDR
1.5
mg/m2
1.5
mg/m2
intravenous injection, IV
q3w
Yondelis
trabectedin
PDR
DDPD05154
Pretomanid
359.2574
C14H12F3N3O5
[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1
DB05154
456199
401693
-2.0
-
-2.0
-
DRUGBANK
28100.0
ng.h/ml
28.1
ug.h/ml
PO, oral; fasting;
DRUGBANK
51600.0
ng.h/ml
51.6
ug.h/ml
PO, oral; food;
DRUGBANK
1700.0
ng/ml
1.7
ug/ml
Oral single dose;
DRUGBANK
1100.0
ng/ml
1.1
ug/ml
Oral single dose; different study;
DRUGBANK
4.5
h
4-5
h
PO, oral; food; fasting;
DRUGBANK
20.0
%
20
%
DRUGBANK
4.8
L/h
4.8±0.2
L/h
DRUGBANK
7.6
L/h
7.6
L/h
Oral single dose; fasting;
DRUGBANK
3.9
L/h
3.9
L/h
Oral single dose; food;
DRUGBANK
130.0
L
130±5
L
DRUGBANK
180.0
L
180±51.3
L
normal,healthy; fasting;
DRUGBANK
97.0
L
97.0±17.2
L
normal,healthy; food;
DRUGBANK
17.15
h
16.9-17.4
h
elimination half-life; normal,healthy;
DRUGBANK
18.0
h
18
h
DRUGBANK
53.0
%
~53
%
Urinary excretion; PO, oral; Male, men; adults; normal,healthy; human, homo sapiens;
DRUGBANK
1.0
%
~1
%
Urinary excretion; PO, oral; Male, men; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
86.4
%
86.4
%
plasma proteins;
DRUGBANK
DDPD05219
Crisaborole
251.05
C14H10BNO3
OB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2
DB05219
44591583
134677
https://www.drugs.com/monograph/crisaborole.html
24701949
-2.0
-
-2.0
-
DRUGBANK
500.0
mg/kg
>500
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
97.0
%
97
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
DDPD05239
Cobimetinib
531.318
C21H21F3IN3O2
OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1
DB05239
16222096
90851
http://www.drugs.com/cotellic.html
17349374
-2.0
-
-2.0
-
DRUGBANK
46.0
%
46
%
DRUGBANK
13.9
L/h
13.9
L/h
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
806.0
L
806.0
L
tumor; patients;
DRUGBANK
15.4
L/kg
15.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
44.0
h
44
h
DRUGBANK
68.8
h
68.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
76.0
%
76
%
Faeces excretion;
DRUGBANK
17.8
%
17.8
%
Urinary excretion;
DRUGBANK
6.6
%
6.6
%
Faeces excretion; Unchanged drug;
DRUGBANK
1.6
%
1.6
%
Urinary excretion; Unchanged drug;
DRUGBANK
95.0
%
95
%
plasma proteins; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
q4w
Cotellic
cobimetinib
PDR
60.0
mg/day
60
mg/day
PO, oral
q4w
Cotellic
cobimetinib
PDR
DDPD05245
Silver sulfadiazine
357.137
C10H9AgN4O2S
[Ag+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C1=NC=CC=N1
DB05245
T3D3068
441244
9142
http://www.drugs.com/cdi/silver-sulfadiazine.html
390017
-2.0
-
-2.0
-
DRUGBANK
10001.0
mg/kg
10001.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10001.0
mg/kg
10001.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2.0
application/day
2
application/day
SSD
silver sulfadiazine
PDR
2.0
appLication/day
2
appLication/day
SSD
silver sulfadiazine
PDR
2.0
application/day
2
application/day
SSD
silver sulfadiazine
PDR
2.0
appLication/day
2
appLication/day
SSD
silver sulfadiazine
PDR
2.0
application/day
2
application/day
SSD
silver sulfadiazine
PDR
DDPD05246
Methsuximide
203.2371
C12H13NO2
CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
DB05246
T3D3069
6476
6846
http://www.drugs.com/cdi/methsuximide.html
6231
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1.4-2.6
h
DRUGBANK
33.0
h
28-38
h
Active metabolite;
DRUGBANK
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Celontin
methsuximide
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Celontin
methsuximide
PDR
30.0
mg/kg/day
30
mg/kg/day
PO, oral
Celontin
methsuximide
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Celontin
methsuximide
PDR
1200.0
mg/day
1.2
g/day
PO, oral
Celontin
methsuximide
PDR
DDPD05260
Gallium nitrate
255.738
GaN3O9
[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O
DB05260
61635
http://www.drugs.com/cdi/gallium.html
55543
-2.0
-
-2.0
-
DRUGBANK
0.15
L/h/kg
0.15
l/h/kg
intravenous infusion, IV in drop; tumor; patients;
DRUGBANK
1.0
h
1
h
distribution half-life;
DRUGBANK
24.0
h
24
h
elimination half-life;
DRUGBANK
93.5
h
72-115
h
intravenous infusion, IV in drop;
DRUGBANK
DDPD05271
Rotigotine
315.48
C19H25NOS
CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
DB05271
59227
135351
http://www.drugs.com/cons/rotigotine-transdermal.html
53406
-2.0
-
-2.0
-
DRUGBANK
16.5
h
15-18
h
DRUGBANK
60.0
h
2-3
day
DRUGBANK
2.22
L/h/kg
37
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.0
L/kg
84.0
L/kg
Steady state volume of distribution; Multiple dose;
DRUGBANK
5.7
L/kg
5.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.0
h
5-7
h
terminal half-life;
DRUGBANK
3.0
h
3
h
distribution half-life;
DRUGBANK
4.0
h
4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
71.0
%
71
%
Urinary excretion;
DRUGBANK
23.0
%
23
%
Faeces excretion;
DRUGBANK
7.1
%
<7.1
%
Urinary excretion; Unchanged drug;
DRUGBANK
92.0
%
92
%
high protein binding;
DRUGBANK
89.5
%
89.5
%
in vivo;
DRUGBANK
8.0
mg/day
8
mg/day
Transdermal preparations
Neupro
rotigotine
PDR
3.0
mg/day
3
mg/day
Transdermal preparations
Neupro
rotigotine
PDR
8.0
mg/day
8
mg/day
Transdermal preparations
Neupro
rotigotine
PDR
3.0
mg/day
3
mg/day
Transdermal preparations
Neupro
rotigotine
PDR
DDPD05294
Vandetanib
475.354
C22H24BrFN4O2
COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
DB05294
3081361
49960
2338979
-2.0
-
-2.0
-
DRUGBANK
6.0
h
6
h
DRUGBANK
2160.0
h
3
month
DRUGBANK
7450.0
L
7450.0
L
DRUGBANK
456.0
h
19
day
DRUGBANK
44.0
%
44
%
Faeces excretion; Single dose;
DRUGBANK
25.0
%
25
%
Urinary excretion; Single dose;
DRUGBANK
90.0
%
~90
%
DRUGBANK
DDPD05316
Pimavanserin
427.564
C25H34FN3O2
CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1
DB05316
10071196
133017
8246736
-2.0
-
-2.0
-
DRUGBANK
34.0
mg/day
34
mg/day
PO, oral
Nuplazid
pimavanserin
PDR
34.0
mg/day
34
mg/day
PO, oral
Nuplazid
pimavanserin
PDR
DDPD05351
Dexlansoprazole
369.36
C16H14F3N3O2S
CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1
DB05351
9578005
135931
7852369
-2.0
-
-2.0
-
DRUGBANK
3275.0
ng.h/ml
3275.0
ng.h/ml
PO, oral;
DRUGBANK
688.0
ng/ml
688
ng/ml
PO, oral;
DRUGBANK
4.0
h
4(1-6)
h
PO, oral;
DRUGBANK
11.5
L/h
11.4-11.6
L/h
apparent clearance; normal,healthy;
DRUGBANK
40.3
L
40.3
L
Steady state volume of distribution; Multiple dose; gastroesophageal reflux disease; patients;
DRUGBANK
1.5
h
~1-2
h
normal,healthy;
DRUGBANK
1.5
h
~1-2
h
gastroesophageal reflux disease; patients;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse; Rattus, Rat; dog;
DRUGBANK
50.7
%
50.7
%
Faeces excretion; PO, oral;
DRUGBANK
47.6
%
47.6
%
Urinary excretion; PO, oral;
DRUGBANK
97.5
%
96-99
%
plasma proteins; normal,healthy; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
60.0
mg/day
60
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
30.0
mg/day
30
mg/day
PO, oral
Dexilant
dexlansoprazole
PDR
DDPD05381
Histamine
111.1451
C5H9N3
NCCC1=CNC=N1
DB05381
774
18295
http://www.drugs.com/cons/histamine-phosphate-intradermal.html
753
-2.0
-
-2.0
-
DRUGBANK
2.5
%
2-3
%
DRUGBANK
6.0
%
4-8
%
DRUGBANK
44.5
%
42-47
%
DRUGBANK
10.0
%
9-11
%
DRUGBANK
19.5
%
16-23
%
DRUGBANK
807.0
mg/kg
807.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD05382
Iodine
253.8089
I2
II
DB05382
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
807
17606
785
-2.0
-
-2.0
-
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD05521
Telaprevir
679.8493
C36H53N7O6
[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1
DB05521
3010818
68595
http://www.drugs.com/cdi/telaprevir.html
2279948
-2.0
-
-2.0
-
DRUGBANK
4.5
h
4-5
h
PO, oral;
DRUGBANK
32.4
L/h
32.4
L/h
Total clearance;
DRUGBANK
252.0
L
252.0
L
DRUGBANK
4.35
h
4.0-4.7
h
Single dose;
DRUGBANK
10.0
h
9-11
h
effective half-life; at steady state;
DRUGBANK
82.0
%
82
%
Faeces excretion;
DRUGBANK
9.0
%
9
%
lung excretion;
DRUGBANK
1.0
%
1
%
Urinary excretion;
DRUGBANK
67.5
%
59-76
%
plasma proteins; Single dose; human, homo sapiens;
DRUGBANK
2250.0
mg/day
2250
mg/day
PO, oral
Incivek
telaprevir
PDR
2250.0
mg/day
2250
mg/day
PO, oral
Incivek
telaprevir
PDR
DDPD05528
Mipomersen
7177.11
C230H324N67O122P19S19
COCCO[C@@H]1[C@H](O)[C@@H](COP(S)(=O)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]5[C@@H](COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@H]6C[C@@H](O[C@@H]6COP(S)(=O)O[C@@H]6[C@@H](COP(S)(=O)O[C@@H]7[C@@H](COP(S)(=O)O[C@@H]8[C@@H](COP(S)(=O)O[C@@H]9[C@@H](COP(S)(=O)O[C@@H]%10[C@@H](CO)O[C@H]([C@@H]%10OCCOC)N%10C=NC%11=C%10N=C(N)NC%11=O)O[C@H]([C@@H]9OCCOC)N9C=C(C)C(N)=NC9=O)O[C@H]([C@@H]8OCCOC)N8C=C(C)C(N)=NC8=O)O[C@H]([C@@H]7OCCOC)N7C=C(C)C(=O)NC7=O)O[C@H]([C@@H]6OCCOC)N6C=C(C)C(N)=NC6=O)N6C=NC7=C6N=CN=C7N)N6C=NC7=C6N=C(N)NC7=O)N6C=C(C)C(=O)NC6=O)N6C=C(C)C(N)=NC6=O)N6C=C(C)C(=O)NC6=O)N6C=NC7=C6N=C(N)NC7=O)N6C=C(C)C(N)=NC6=O)N6C=C(C)C(=O)NC6=O)N6C=C(C)C(=O)NC6=O)N6C=C(C)C(N)=NC6=O)O[C@H]([C@@H]5OCCOC)N5C=NC6=C5N=C(N)NC6=O)O[C@H]([C@@H]4OCCOC)N4C=C(C)C(N)=NC4=O)O[C@H]([C@@H]3OCCOC)N3C=NC4=C3N=CN=C4N)O[C@H]([C@@H]2OCCOC)N2C=C(C)C(N)=NC2=O)O[C@H]1N1C=C(C)C(N)=NC1=O
DB05528
131704297
http://www.drugs.com/mtm/mipomersen.html
34983392
-2.0
-
-2.0
-
DRUGBANK
66.0
%
54-78
%
subcutaneous injection, SC;
DRUGBANK
3.5
h
3-4
h
subcutaneous injection, SC;
DRUGBANK
0.0402
L/h/kg
0.67
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
L/kg
0.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1080.0
h
1-2
month
DRUGBANK
17.6
h
17.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
≥90
%
plasma proteins;
DRUGBANK
28.5714285714286
mg/day
200
mg/week
subcutaneous injection, SC
qw
Kynamro
mipomersen sodium
PDR
28.5714285714286
mg/day
200
mg/week
subcutaneous injection, SC
qw
Kynamro
mipomersen sodium
PDR
DDPD05541
Brivaracetam
212.2887
C11H20N2O2
CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
DB05541
9837243
133013
8012964
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
0.0531
L/h/kg
0.7-1.07
ml/min/kg
DRUGBANK
0.045
L/h/kg
0.75
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.5
L/kg
0.5
L/kg
DRUGBANK
0.56
L/kg
0.56
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
h
7-8
h
DRUGBANK
8.98
h
8.98
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95.0
%
>95
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Faeces excretion;
DRUGBANK
20.0
%
<20
%
plasma proteins;
DRUGBANK
DDPD05676
Apremilast
460.5
C22H24N2O7S
CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O
DB05676
11561674
78540
http://www.drugs.com/cdi/apremilast.html
9736448
-2.0
-
-2.0
-
DRUGBANK
73.0
%
73
%
PO, oral;
DRUGBANK
584.0
ng/ml
584
ng/ml
PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral;
DRUGBANK
10.0
L/h
10.0
L/h
Plasma clearance; normal,healthy; patients;
DRUGBANK
0.1428
L/h/kg
2.38
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.0
L
87.0
L
Average volume of distribution;
DRUGBANK
7.5
h
6-9
h
elimination half-life;
DRUGBANK
6.03
h
6.03
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; Male, men; Rattus, Rat;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; Female, women; Rattus, Rat;
DRUGBANK
3.0
%
3
%
Urinary excretion; Unchanged drug;
DRUGBANK
7.0
%
7
%
Faeces excretion; Unchanged drug;
DRUGBANK
68.0
%
~68
%
plasma proteins;
DRUGBANK
DDPD05812
Abiraterone
349.509
C24H31NO
[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
DB05812
132971
68642
http://www.drugs.com/mtm/abiraterone.html
117349
-2.0
-
-2.0
-
DRUGBANK
2.75
h
1.5-4
h
PO, oral;
DRUGBANK
19669.0
L
19669±13358
L
Steady state volume of distribution;
DRUGBANK
9.5
h
5-14
h
elimination half-life;
DRUGBANK
88.0
%
~88
%
Faeces excretion;
DRUGBANK
5.0
%
~5
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
1000.0
mg/day
1000
mg/day
PO, oral
Zytiga
abiraterone acetate
PDR
500.0
mg/day
500
mg/day
PO, oral
Zytiga
abiraterone acetate
PDR
1000.0
mg/day
1000
mg/day
PO, oral
Zytiga
abiraterone acetate
PDR
500.0
mg/day
500
mg/day
PO, oral
Zytiga
abiraterone acetate
PDR
DDPD05990
Obeticholic acid
420.6252
C26H44O4
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O
DB05990
447715
43602
394730
-2.0
-
-2.0
-
DRUGBANK
402.35
ng.h/ml
236.6-568.1
ng.h/ml
PO, oral;
DRUGBANK
41.25
ng/ml
28.8-53.7
ng/ml
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
10.0
h
10
h
PO, oral; Derivative;
DRUGBANK
4.5
h
4.5
h
PO, oral; different study;
DRUGBANK
4.5
h
4.5
h
PO, oral; different study;
DRUGBANK
618.0
L
618.0
L
DRUGBANK
24.0
h
24
h
elimination half-life;
DRUGBANK
87.0
%
~87
%
Faeces excretion; PO, oral;
DRUGBANK
3.0
%
<3
%
Urinary excretion; PO, oral;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
qd
Ocaliva
obeticholic acid
PDR
10.0
mg/day
10
mg/day
PO, oral
qd
Ocaliva
obeticholic acid
PDR
DDPD06016
Cariprazine
427.41
C21H32Cl2N4O
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
DB06016
11154555
90933
http://www.drugs.com/mtm/cariprazine.html
25999972
-2.0
-
-2.0
-
DRUGBANK
13.8
%
13.8
%
Liver metabolism;
DRUGBANK
12.3
%
12.3
%
Liver metabolism;
DRUGBANK
168.0
h
~1
week
Drug combination;
DRUGBANK
21.0
%
21
%
Urinary excretion;
DRUGBANK
94.0
%
91-97
%
DRUGBANK
6.0
mg/day
6
mg/day
PO, oral
Vraylar
cariprazine
PDR
3.0
mg/day
3
mg/day
PO, oral
Vraylar
cariprazine
PDR
6.0
mg/day
6
mg/day
PO, oral
Vraylar
cariprazine
PDR
3.0
mg/day
3
mg/day
PO, oral
Vraylar
cariprazine
PDR
DDPD06077
Lumateperone
393.506
C24H28FN3O
[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C
DB06077
21302490
19328801
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
27.9
L/h
27.9
L/h
DRUGBANK
4.1
L/kg
4.1
L/kg
intravenous injection, IV;
DRUGBANK
15.5
h
13-18
h
DRUGBANK
20.0
h
20
h
Metabolite;
DRUGBANK
21.0
h
21
h
Metabolite;
DRUGBANK
58.0
%
~58
%
Urinary excretion;
DRUGBANK
29.0
%
~29
%
Faeces excretion;
DRUGBANK
97.4
%
~97.4
%
plasma proteins;
DRUGBANK
DDPD06119
Cenobamate
267.67
C10H10ClN5O2
NC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1
DB06119
10136642
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88
%
PO, oral; high-fat meal;
high-fat meal → ;
DRUGBANK
2.5
h
1-4
h
PO, oral; high-fat meal;
high-fat meal → ;
DRUGBANK
0.54
L/h
0.45-0.63
L/h
apparent clearance; PO, oral;
DRUGBANK
45.0
L
40-50
L
Apparent volume of distribution;
DRUGBANK
55.0
h
50-60
h
terminal half-life;
DRUGBANK
87.8
%
87.8
%
Urinary excretion;
DRUGBANK
5.2
%
5.2
%
Faeces excretion;
DRUGBANK
60.0
%
60
%
plasma proteins;
DRUGBANK
DDPD06144
Sertindole
440.941
C24H26ClFN4O
FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2
DB06144
60149
9122
54229
-2.0
-
-2.0
-
DRUGBANK
72.0
h
3
day
DRUGBANK
DDPD06145
Spiramycin
843.065
C43H74N2O14
CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C
DB06145
6440717
85260
4944970
-2.0
-
-2.0
-
DRUGBANK
34.5
%
30-39
%
DRUGBANK
0.768
L/h/kg
12.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
300.0
L
>300
L
DRUGBANK
5.4
L/kg
5.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.35
h
~4.5-6.2
h
young; intravenous injection, IV;
DRUGBANK
11.65
h
~9.8-13.5
h
Elderly; intravenous injection, IV;
DRUGBANK
6.75
h
5.5-8
h
PO, oral;
DRUGBANK
8.0
h
8
h
Children; Rectal Administration;
DRUGBANK
5.2
h
5.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.5
%
10-25
%
DRUGBANK
DDPD06147
Sulfathiazole
255.317
C9H9N3O2S2
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1
DB06147
5340
9337
5148
-2.0
-
-2.0
-
DRUGBANK
4500.0
mg/kg
4500.0
mg/kg
PO, oral; nasal spray; mouse;
DRUGBANK
DDPD06148
Mianserin
264.3648
C18H20N2
CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
DB06148
4184
51137
4040
-2.0
-
-2.0
-
DRUGBANK
1.314
L/h/kg
21.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.75
L/kg
13.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.5
h
10-17
h
DRUGBANK
9.6
h
9.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
780.0
mg/kg
780.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD06149
Teicoplanin
N.A.
N.A.
CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O
DB06149
133065662
29687
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
IM,intramuscular injection;
DRUGBANK
85.0
h
70-100
h
DRUGBANK
92.5
%
90-95
%
DRUGBANK
DDPD06150
Sulfadimethoxine
310.329
C12H14N4O4S
COC1=NC(OC)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1
DB06150
5323
32161
5132
-2.0
-
-2.0
-
DRUGBANK
DDPD06151
Acetylcysteine
163.195
C5H9NO3S
CC(=O)N[C@@H](CS)C(O)=O
DB06151
12035
28939
http://www.drugs.com/cdi/acetylcysteine-solution.html
11540
-2.0
-
-2.0
-
DRUGBANK
8.0
%
6-10
%
PO, oral;
DRUGBANK
3.0
%
<3
%
skin/dermal;
DRUGBANK
0.186
L/h/kg
3.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.55
L/kg
0.55
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.6
h
5.6
h
adults;
DRUGBANK
11.0
h
11
h
Neonates;
DRUGBANK
5.5
h
5.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
83.0
%
83
%
DRUGBANK
150.0
mg/kg
150
mg/kg
intravenous injection, IV
Acetadote
acetylcysteine
PDR
1500.0
mg
1500
mg
intravenous injection, IV
Acetadote
acetylcysteine
PDR
50.0
mg/kg
50
mg/kg
intravenous injection, IV
Acetadote
acetylcysteine
PDR
5000.0
mg
5000
mg
intravenous injection, IV
Acetadote
acetylcysteine
PDR
100.0
mg/kg
100
mg/kg
intravenous injection, IV
Acetadote
acetylcysteine
PDR
10000.0
mg
10000
mg
intravenous injection, IV
Acetadote
acetylcysteine
PDR
DDPD06152
Nylidrin
299.414
C19H25NO2
CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1
DB06152
4567
91656
4407
-2.0
-
-2.0
-
DRUGBANK
DDPD06153
Pizotifen
295.44
C19H21NS
CN1CCC(CC1)=C1C2=C(CCC3=CC=CC=C13)SC=C2
DB06153
27400
50212
25497
-2.0
-
-2.0
-
DRUGBANK
80.0
%
~80
%
PO, oral; Male, men; adults;
DRUGBANK
78.0
%
78
%
PO, oral; Male, men; adults;
DRUGBANK
5.0
h
5
h
PO, oral; Male, men; adults;
DRUGBANK
65.0
%
60-70
%
Urinary excretion;
DRUGBANK
833.0
null
833.0
null
adults; Male, men;
DRUGBANK
70.0
null
70.0
null
adults; Male, men;
DRUGBANK
23.0
h
~23
h
DRUGBANK
23.0
h
~23
h
DRUGBANK
955.0
mg/kg
410-1500
mg/kg
PO, oral; mouse;
DRUGBANK
880.0
mg/kg
880.0
mg/kg
PO, oral; rabbit;
DRUGBANK
700.0
mg/kg
700.0
mg/kg
PO, oral; rabbit;
DRUGBANK
17.0
mg/kg
17.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
12.86
mg/kg
12.86
mg/kg
PO, oral; Male, men;
DRUGBANK
33.3
%
~33.3
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
90.0
%
>90
%
plasma proteins;
DRUGBANK
DDPD06154
Pentaerythritol tetranitrate
316.1366
C5H8N4O12
[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O
DB06154
6518
25879
6271
-2.0
-
-2.0
-
DRUGBANK
36.6
L/h/kg
0.61±0.16
L/min/kg
DRUGBANK
4.2
L/kg
4.2±1.1
L/kg
Steady state volume of distribution; Rattus, Rat;
DRUGBANK
4.5
h
4-5
h
elimination half-life; PO, oral; Male, men;
DRUGBANK
25000.0
mg/kg
25000.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD06155
Rimonabant
463.787
C22H21Cl3N4O
CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1
DB06155
104850
34967
http://www.drugs.com/acomplia.html
94641
-2.0
-
-2.0
-
DRUGBANK
180.0
h
6-9
day
DRUGBANK
384.0
h
16
day
BMI over;
DRUGBANK
100.0
%
~100
%
DRUGBANK
DDPD06174
Noscapine
413.4205
C22H23NO7
[H][C@@]1(OC(=O)C2=C1C=CC(OC)=C2OC)[C@]1([H])N(C)CCC2=CC3=C(OCO3)C(OC)=C12
DB06174
73237
242139
-2.0
-
-2.0
-
DRUGBANK
1.0128
L/h/kg
16.88
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.3
L/kg
2.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.13
h
2.13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD06176
Romidepsin
540.69
C24H36N4O6S2
C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
DB06176
57515973
61080
http://www.drugs.com/mtm/romidepsin.html
10122002
-2.0
-
-2.0
-
DRUGBANK
8.4
L/h
8.4
L/h
DRUGBANK
0.444
L/h/kg
7.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
44.5
L
44.5
L
DRUGBANK
1.2
L/kg
1.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
93.0
%
92-94
%
plasma proteins;
DRUGBANK
14.0
mg/m2
14
mg/m2
intravenous injection, IV
Istodax
romidepsin
PDR
14.0
mg/m2
14
mg/m2
intravenous injection, IV
Istodax
romidepsin
PDR
DDPD06193
Pixantrone
325.372
C17H19N5O2
NCCNC1=CC=C(NCCN)C2=C1C(=O)C1=C(C=NC=C1)C2=O
DB06193
134019
135945
http://www.drugs.com/history/pixuvri.html
118174
-2.0
-
-2.0
-
DRUGBANK
1.03
L/h/kg
0.75 - 1.31
l/h/kg
Plasma clearance;
DRUGBANK
1.062
L/h/kg
17.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
19.7
L/kg
9.7-29.7
L/kg
DRUGBANK
10.1
L/kg
10.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
DRUGBANK
13.4
h
13.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD06196
Icatibant
1304.54
C59H89N19O13S
[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
DB06196
71364
68556
http://www.drugs.com/cdi/icatibant.html
5293384
-2.0
-
-2.0
-
DRUGBANK
2165.0
ng.h/ml
2165±568
ng.h/ml
subcutaneous injection, SC;
DRUGBANK
97.0
%
~97
%
subcutaneous injection, SC;
DRUGBANK
974.0
ng/ml
974±280
ng/ml
subcutaneous injection, SC;
DRUGBANK
14.7
L/h
245±58
ml/min
Plasma clearance; subcutaneous injection, SC;
DRUGBANK
29.0
L
29.0 ± 8.7
L
subcutaneous injection, SC;
DRUGBANK
1.4
h
1.4±0.4
h
elimination half-life; subcutaneous injection, SC;
DRUGBANK
10.0
%
<10
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
mg/dose
30
mg/dose
subcutaneous injection, SC
Firazyr
icatibant
PDR
90.0
mg/day
90
mg/day
subcutaneous injection, SC
qid
Firazyr
icatibant
PDR
30.0
mg/dose
30
mg/dose
subcutaneous injection, SC
Firazyr
icatibant
PDR
90.0
mg/day
90
mg/day
subcutaneous injection, SC
qid
Firazyr
icatibant
PDR
DDPD06201
Rufinamide
238.1935
C10H8F2N4O
NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
DB06201
129228
134966
http://www.drugs.com/cdi/rufinamide.html
114471
-2.0
-
-2.0
-
DRUGBANK
85.0
%
>85
%
Oral single dose; food;
DRUGBANK
37800.0
ng.h/ml
37.8±47
ug.h/ml
PO, oral;
DRUGBANK
89300.0
ng.h/ml
89.3±59
ug.h/ml
PO, oral;
DRUGBANK
77.5
%
70-85
%
PO, oral; increasing doses;
increasing doses ↓ ;
DRUGBANK
4010.0
ng/ml
4.01
ug/ml
PO, oral;
DRUGBANK
8680.0
ng/ml
8.68
ug/ml
PO, oral;
DRUGBANK
5.0
h
4-6
h
PO, oral; food; fasting;
DRUGBANK
50.0
L
50.0
L
Apparent volume of distribution;
DRUGBANK
8.0
h
6-10
h
elimination half-life; normal,healthy;
DRUGBANK
8.0
h
6-10
h
elimination half-life; epilepsy; patients;
DRUGBANK
91.0
%
91
%
Urinary excretion;
DRUGBANK
9.0
%
9
%
Faeces excretion;
DRUGBANK
30.55
%
26.3-34.8
%
DRUGBANK
27.0
%
27
%
DRUGBANK
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Banzel
rufinamide
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Banzel
rufinamide
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Banzel
rufinamide
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Banzel
rufinamide
PDR
45.0
mg/kg/day
45
mg/kg/day
PO, oral
Banzel
rufinamide
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Banzel
rufinamide
PDR
3200.0
mg/day
3200
mg/day
PO, oral
Banzel
rufinamide
PDR
DDPD06202
Lasofoxifene
413.5512
C28H31NO2
[H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1
DB06202
216416
https://www.drugs.com/international/lasofoxifene.html
187585
-2.0
-
-2.0
-
DRUGBANK
62.0
%
62
%
Rattus, Rat;
DRUGBANK
6.65
h
6-7.3
h
DRUGBANK
6.6
L/h
~6.6
L/h
apparent clearance; PO, oral; Female, women;
DRUGBANK
1350.0
L
1350.0
L
Apparent volume of distribution;
DRUGBANK
144.0
h
~6
day
elimination half-life;
DRUGBANK
2.0
%
<2
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
DDPD06203
Alogliptin
339.3916
C18H21N5O2
CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
DB06203
11450633
72323
http://www.drugs.com/mtm/alogliptin.html
9625485
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; food;
food → ;
DRUGBANK
1.5
h
1-2
h
PO, oral; normal,healthy; diabetes;
DRUGBANK
15.0
%
10-20
%
Liver metabolism;
DRUGBANK
9.6
L/h
9.6
L/h
Plasma clearance;
DRUGBANK
14.0
L/h
14.0
L/h
Total clearance;
DRUGBANK
417.0
L
417.0
L
intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
21.0
h
21
h
terminal half-life;
DRUGBANK
76.0
%
76
%
Urinary excretion;
DRUGBANK
13.0
%
13
%
Faeces excretion;
DRUGBANK
65.5
%
60-71
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
20
%
plasma proteins;
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
Nesina
alogliptin
PDR
25.0
mg/day
25
mg/day
PO, oral
Nesina
alogliptin
PDR
DDPD06204
Tapentadol
221.3385
C14H23NO
CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
DB06204
9838022
135935
http://www.drugs.com/monograph/tapentadol-hydrochloride.html
8013742
-2.0
-
-2.0
-
DRUGBANK
32.0
%
32
%
PO, oral; immediate release formulation;
DRUGBANK
32.0
%
32
%
PO, oral; extended release formulation;
DRUGBANK
64.2
ng/ml
64.2
ng/ml
PO, oral; immediate release formulation;
DRUGBANK
22.5
ng/ml
22.5
ng/ml
PO, oral; extended release formulation;
DRUGBANK
1.5
h
1.5
h
PO, oral; immediate release formulation;
DRUGBANK
5.0
h
5.0
h
PO, oral; extended release formulation;
DRUGBANK
97.0
%
97
%
Inactive metabolite;
DRUGBANK
91.8
L/h
1530 ± 177
ml/min
Total clearance;
DRUGBANK
1.2798
L/h/kg
21.33
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
540.0
L
540±98
L
intravenous injection, IV;
DRUGBANK
4.64
L/kg
4.64
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
h
4
h
elimination half-life; intravenous injection, IV;
DRUGBANK
2.39
h
2.39
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
99.0
%
99
%
Urinary excretion;
DRUGBANK
3.0
%
3
%
Urinary excretion; Unchanged drug;
DRUGBANK
20.0
%
~20
%
DRUGBANK
500.0
mg/day
500
mg/day
PO, oral
Nucynta
tapentadol
PDR
700.0
mg/day
700
mg/day
PO, oral
Nucynta
tapentadol
PDR
500.0
mg/day
500
mg/day
PO, oral
Nucynta
tapentadol
PDR
700.0
mg/day
700
mg/day
PO, oral
Nucynta
tapentadol
PDR
DDPD06206
Sugammadex
2002.12
C72H112O48S8
O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(O)=O)[C@@H](O[C@H]4O[C@H](CSCCC(O)=O)[C@@H](O[C@H]5O[C@H](CSCCC(O)=O)[C@@H](O[C@H]6O[C@H](CSCCC(O)=O)[C@@H](O[C@H]7O[C@H](CSCCC(O)=O)[C@@H](O[C@H]8O[C@H](CSCCC(O)=O)[C@@H](O[C@H]9O[C@H](CSCCC(O)=O)[C@@H](O[C@H]1O[C@@H]2CSCCC(O)=O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
DB06206
6918585
90953
32689915
-2.0
-
-2.0
-
DRUGBANK
5280.0
L/h
88.0
L/min
DRUGBANK
0.0768
L/h/kg
1.28
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.5
L
11.0-14
L
at steady state; normal renal function; patients; adults;
DRUGBANK
0.18
L/kg
0.18
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
~2
h
DRUGBANK
2.53
h
2.53
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
DRUGBANK
0.02
%
0.02
%
Faeces excretion;
DRUGBANK
0.0
%
0
%
plasma proteins;
DRUGBANK
16.0
mg/kg
16
mg/kg
intravenous injection, IV
Bridion
sugammadex
PDR
16.0
mg/kg
16
mg/kg
intravenous injection, IV
Bridion
sugammadex
PDR
DDPD06207
Silodosin
495.5345
C25H32F3N3O4
C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F
DB06207
5312125
135929
http://www.drugs.com/cdi/silodosin.html
4471557
-2.0
-
-2.0
-
DRUGBANK
373.0
ng.h/ml
373.0
ng.h/ml
PO, oral; food;
DRUGBANK
1870.0
ng.h/ml
1870.0
ng.h/ml
PO, oral; food; Active metabolite;
DRUGBANK
32.0
%
32
%
PO, oral;
DRUGBANK
61.6
ng/ml
61.6±27.54
ng/ml
PO, oral; food;
DRUGBANK
2.6
h
2.6±0.90
h
PO, oral; food;
DRUGBANK
10.0
L/h
10.0
L/h
Plasma clearance;
DRUGBANK
0.168
L/h/kg
2.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
49.5
L
49.5
L
DRUGBANK
13.3
h
13.3±8.07
h
DRUGBANK
24.0
h
24
h
Active metabolite;
DRUGBANK
3.6
h
3.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
54.9
%
54.9
%
Faeces excretion;
DRUGBANK
33.5
%
33.5
%
Urinary excretion;
DRUGBANK
97.0
%
97
%
DRUGBANK
DDPD06209
Prasugrel
373.441
C20H20FNO3S
CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
DB06209
6918456
87723
http://www.drugs.com/cdi/prasugrel.html
5293653
-2.0
-
-2.0
-
DRUGBANK
79.0
%
>79
%
PO, oral;
DRUGBANK
0.5
h
0.5
h
PO, oral;
DRUGBANK
1.0
h
0.5-1.5
h
PO, oral; high-fat meal;
DRUGBANK
139.0
L/h
112-166
L/h
apparent clearance;
DRUGBANK
56.0
L
44-68
L
DRUGBANK
7.4
h
~7.4(2-15)
h
elimination half-life; Active metabolite;
DRUGBANK
1500.0
mg/kg
1000-2000
mg/kg
Rattus, Rat;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
rabbit;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Effient
prasugrel
PDR
60.0
mg/dose
60
mg/dose
PO, oral
Effient
prasugrel
PDR
10.0
mg/day
10
mg/day
PO, oral
Effient
prasugrel
PDR
60.0
mg/dose
60
mg/dose
PO, oral
Effient
prasugrel
PDR
60.0
mg/dose
60
mg/dose
PO, oral
Effient
prasugrel
PDR
10.0
mg/day
10
mg/day
PO, oral
Effient
prasugrel
PDR
DDPD06210
Eltrombopag
442.4666
C25H22N4O4
CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1
DB06210
9846180
85010
http://www.drugs.com/ppa/eltrombopag.html
19879943
-2.0
-
-2.0
-
DRUGBANK
52.0
%
>52
%
PO, oral;
DRUGBANK
26.5
h
~21-32
h
normal,healthy; patients;
DRUGBANK
30.5
h
~26-35
h
idiopathic thrombocytopenic purpura; patients;
DRUGBANK
59.0
%
59
%
Faeces excretion;
DRUGBANK
31.0
%
31
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
150.0
mg/day
150
mg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
100.0
mg/day
100
mg/day
PO, oral
Promacta
eltrombopag
PDR
150.0
mg/day
150
mg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
150.0
mg/day
150
mg/day
PO, oral
Promacta
eltrombopag
PDR
75.0
mg/day
75
mg/day
PO, oral
Promacta
eltrombopag
PDR
100.0
mg/day
100
mg/day
PO, oral
Promacta
eltrombopag
PDR
150.0
mg/day
150
mg/day
PO, oral
Promacta
eltrombopag
PDR
DDPD06211
Doripenem
420.504
C15H24N4O6S2
[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
DB06211
73303
135928
http://www.drugs.com/cdi/doripenem.html
66040
-2.0
-
-2.0
-
DRUGBANK
10.3
L/h
10.3
L/h
DRUGBANK
0.1956
L/h/kg
3.26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.8
L
16.8(8.09-55.5）
L
Average volume of distribution; at steady state; normal,healthy;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
1
h
normal,healthy;
DRUGBANK
1.2
h
1.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Faeces excretion; Single dose; adults; normal,healthy; human, homo sapiens;
DRUGBANK
71.0
%
71
%
Urinary excretion; adults; normal,healthy; Unchanged drug;
DRUGBANK
8.1
%
8.1
%
DRUGBANK
500.0
mg
500
mg
intravenous injection, IV
q8h
Doribax
doripenem
PDR
500.0
mg
500
mg
intravenous injection, IV
q8h
Doribax
doripenem
PDR
DDPD06212
Tolvaptan
448.941
C26H25ClN2O3
CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2
DB06212
443894
http://www.drugs.com/monograph/tolvaptan.html
391976
-2.0
-
-2.0
-
DRUGBANK
4550.0
ng.h/ml
4.55
ug.h/ml
DRUGBANK
374.0
ng/ml
374
ng/ml
DRUGBANK
418.0
ng/ml
418
ng/ml
DRUGBANK
460.0
ng/ml
460
ng/ml
heart failure;
DRUGBANK
723.0
ng/ml
723
ng/ml
heart failure;
DRUGBANK
3.0
h
2-4
h
DRUGBANK
0.24
L/h/kg
4.0
ml/min/kg
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
L/kg
3.0
L/kg
normal,healthy;
DRUGBANK
0.5
L/kg
0.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
12
h
terminal half-life; PO, oral;
DRUGBANK
2.9
h
2.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat; dog;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral; up to 30 days
Jynarque
tolvaptan
PDR
120.0
mg/day
120
mg/day
PO, oral
Jynarque
tolvaptan
PDR
60.0
mg/day
60
mg/day
PO, oral; up to 30 days
Jynarque
tolvaptan
PDR
120.0
mg/day
120
mg/day
PO, oral
Jynarque
tolvaptan
PDR
DDPD06213
Regadenoson
390.354
C15H18N8O5
CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1
DB06213
219024
135613
http://www.drugs.com/ppa/regadenoson.html
189859
-2.0
-
-2.0
-
DRUGBANK
12.3
ng/ml
12.3
ng/ml
intravenous injection, IV;
DRUGBANK
0.0333333333333333
h
1-3
min
intravenous injection, IV;
DRUGBANK
27.0
L/h
450.0
ml/min
Plasma clearance; Renal clearance;
DRUGBANK
0.438
L/h/kg
7.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.5
L
11.5
L
Total volume of distribution;
DRUGBANK
78.7
L
78.7
L
Steady state volume of distribution;
DRUGBANK
0.94
L/kg
0.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.05
h
2-4
min
distribution half-life;
DRUGBANK
0.5
h
30
min
elimination half-life;
DRUGBANK
2.0
h
2
h
terminal half-life;
DRUGBANK
2.0
h
2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
58.0
%
58
%
Urinary excretion;
DRUGBANK
0.4
mg/dose
0.4
mg/dose
intravenous injection, IV
Lexiscan
regadenoson
PDR
0.4
mg/dose
0.4
mg/dose
intravenous injection, IV
Lexiscan
regadenoson
PDR
DDPD06215
Ferumoxytol
231.531
Fe3O4
[O--].[O--].[O--].[O--].[Fe++].[Fe+3].[Fe+3]
DB06215
16211978
50821
4937312
-2.0
-
-2.0
-
DRUGBANK
0.0221
L/h
0.0221
L/h
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
2.71
L
2.71
L
Total volume of distribution;
DRUGBANK
15.0
h
~15
h
human, homo sapiens;
DRUGBANK
510.0
mg/dose
510
mg/dose
intravenous injection, IV
Feraheme
ferumoxytol
PDR
510.0
mg/dose
510
mg/dose
intravenous injection, IV
Feraheme
ferumoxytol
PDR
DDPD06216
Asenapine
401.84
C21H20ClNO5
OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1
DB06216
11954293
71253
http://www.drugs.com/mtm/asenapine.html
10128588
-2.0
-
-2.0
-
DRUGBANK
35.0
%
35
%
sublingual;
DRUGBANK
2.0
%
<2%
%
PO, oral;
DRUGBANK
4.0
ng/ml
4
ng/ml
DRUGBANK
1.0
h
<1
h
DRUGBANK
1.0
h
0.5-1.5
h
DRUGBANK
72.0
h
3
day
DRUGBANK
0.744
L/h/kg
12.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.5
L/kg
20-25
L/kg
DRUGBANK
23.0
L/kg
23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
24.0
h
24(13.4-39.2)
h
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
50.0
%
50
%
Faeces excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
20.0
mg/day
20
mg/day
sublingual
Saphris
asenapine
PDR
20.0
mg/day
20
mg/day
sublingual
Saphris
asenapine
PDR
7.6
mg/day
7.6
mg/day
skin/dermal
Saphris
asenapine
PDR
20.0
mg/day
20
mg/day
sublingual
Saphris
asenapine
PDR
20.0
mg/day
20
mg/day
sublingual
Saphris
asenapine
PDR
7.6
mg/day
7.6
mg/day
skin/dermal
Saphris
asenapine
PDR
DDPD06217
Vernakalant
349.471
C20H31NO4
COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1
DB06217
9930049
135956
8105680
-2.0
-
-2.0
-
DRUGBANK
3900.0
ng/ml
3.9
ug/ml
patients;
DRUGBANK
4300.0
ng/ml
4.3
ug/ml
patients;
DRUGBANK
0.41
L/h/kg
0.41
l/h/kg
Total clearance;
DRUGBANK
0.4974
L/h/kg
8.29
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
L/kg
~2
L/kg
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
3
h
elimination half-life; extensive metabolizers, EM;
DRUGBANK
5.5
h
5.5
h
elimination half-life; poor metabolizers, PM;
DRUGBANK
3.13
h
3.13
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD06218
Lacosamide
250.2936
C13H18N2O3
COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
DB06218
219078
135939
189902
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; food;
food → ;
DRUGBANK
2.5
h
1-4
h
PO, oral; food;
food → ;
DRUGBANK
0.0342
L/h/kg
0.57
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.6
L/kg
~0.6
L/kg
DRUGBANK
0.58
L/kg
0.58
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.0
h
13
h
DRUGBANK
12.3
h
12.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
%
<15
%
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Vimpat
lacosamide
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Vimpat
lacosamide
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Vimpat
lacosamide
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Vimpat
lacosamide
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Vimpat
lacosamide
PDR
400.0
mg/day
400
mg/day
PO, oral
Vimpat
lacosamide
PDR
8.0
mg/kg/day
8
mg/kg/day
PO, oral
Vimpat
lacosamide
PDR
12.0
mg/kg/day
12
mg/kg/day
PO, oral
Vimpat
lacosamide
PDR
400.0
mg/day
400
mg/day
PO, oral;intravenous injection, IV;
Vimpat
lacosamide
PDR
DDPD06219
Dalbavancin
N.A.
N.A.
CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
DB06219
16134627
82721
http://www.drugs.com/dalvance.html
30791917
-2.0
-
-2.0
-
DRUGBANK
0.0513
L/h
0.0513
L/h
DRUGBANK
0.0006
L/h/kg
0.01
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
346.0
h
346
h
terminal half-life;
DRUGBANK
170.0
h
170
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
Faeces excretion; normal,healthy; human, homo sapiens;
DRUGBANK
42.0
%
42
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
93.0
%
93
%
plasma proteins;
DRUGBANK
1500.0
mg
1500
mg
intravenous injection, IV
Dalvance
dalbavancin
PDR
1500.0
mg
1500
mg
intravenous injection, IV
Dalvance
dalbavancin
PDR
DDPD06228
Rivaroxaban
435.881
C19H18ClN3O5S
[H][C@]1(CNC(=O)C2=CC=C(Cl)S2)CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
DB06228
9875401
68579
http://www.drugs.com/cdi/rivaroxaban.html
8051086
-2.0
-
-2.0
-
DRUGBANK
80.0
%
>80
%
PO, oral;
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
10.0
L/h
10.0
L/h
Total clearance;
DRUGBANK
3.5
L/h
~3.0-4
L/h
Renal clearance;
DRUGBANK
0.144
L/h/kg
2.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
L
50.0
L
Steady state volume of distribution;
DRUGBANK
0.7
L/kg
0.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.0
h
5-9
h
terminal half-life; adults;
DRUGBANK
12.0
h
11-13
h
terminal half-life; Elderly;
DRUGBANK
7.0
h
7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
66.7
%
~66.7
%
Urinary excretion;
DRUGBANK
33.3
%
~33.3
%
Faeces excretion;
DRUGBANK
23.76
%
23.76
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.3
%
2.3
%
Faeces excretion; Unchanged drug;
DRUGBANK
93.5
%
92-95
%
plasma proteins;
DRUGBANK
30.0
mg/day
30
mg/day
PO, oral
Xarelto
rivaroxaban
PDR
30.0
mg/day
30
mg/day
PO, oral
Xarelto
rivaroxaban
PDR
DDPD06230
Nalmefene
339.435
C21H25NO3
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C
DB06230
7457
4447642
-2.0
-
-2.0
-
DRUGBANK
131.0
ng.h/ml
131.0
ng.h/ml
Oral single dose;
DRUGBANK
183.4
ng.h/ml
170.3-196.5
ng.h/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
41.0
%
41
%
PO, oral;
DRUGBANK
40.0
%
40.0
%
PO, oral; normal,healthy;
DRUGBANK
16.5
ng/ml
16.5
ng/ml
Oral single dose;
DRUGBANK
23.1
ng/ml
21.45-24.75
ng/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
24.0
ng/ml
24±11
ng/ml
Oral single dose; Male, men; normal,healthy;
DRUGBANK
17.0
ng/ml
17±6.3
ng/ml
Male, men; normal,healthy;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
2.0
h
2
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
1.9
h
1.5-2.3
h
IM,intramuscular injection;
DRUGBANK
1.9
h
1.5-2.3
h
subcutaneous injection, SC;
DRUGBANK
2.5
h
2.5±0.58
h
Oral single dose; Male, men; normal,healthy;
DRUGBANK
16.0
L/h
16.0
L/h
PO, oral;
DRUGBANK
0.8
L/h/kg
0.8±0.2
L/h/kg
Total clearance; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
0.08
L/h/kg
0.08±0.04
L/h/kg
Renal clearance; intravenous injection, IV; normal,healthy; Male, men;
DRUGBANK
0.9
L/h/kg
15±4.5
ml/min/kg
normal,healthy; adults; Male, men; Female, women; metabolism of ugt;
hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;
DRUGBANK
0.9
L/h/kg
15
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3200.0
L
~3200
L
PO, oral;
DRUGBANK
3.9
L/kg
3.9±1.1
L/kg
Total volume of distribution;
DRUGBANK
8.6
L/kg
8.6±1.7
L/kg
Steady state volume of distribution;
DRUGBANK
8.0
L/kg
8.0±1.8
L/kg
normal,healthy; adults; Male, men; Female, women; metabolism of ugt;
RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
8.2
L/kg
8.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.5
h
12.5
h
PO, oral;
DRUGBANK
10.8
h
10.8±5.2
h
terminal half-life; adults; Male, men; intravenous injection, IV;
DRUGBANK
8.0
h
8.0±2.2
h
normal,healthy; adults; Male, men; Female, women;
moderate hepatic impairment ↑ ;severe hepatic impairment ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;
DRUGBANK
8.8
h
8.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.0
%
~17
%
Faeces excretion;
DRUGBANK
9.6
%
9.6±4.9
%
Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
37.5
%
30-45
%
plasma proteins;
DRUGBANK
34.4
%
34.4±13.6
%
adults; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD06237
Avanafil
483.951
C23H26ClN7O3
COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1
DB06237
9869929
66876
http://www.drugs.com/mtm/avanafil.html
8045620
-2.0
-
-2.0
-
DRUGBANK
0.625
h
30-45
min
DRUGBANK
8.01
h
5.36-10.66
h
elimination half-life;
DRUGBANK
62.0
%
~62
%
Faeces excretion; PO, oral;
DRUGBANK
21.0
%
~21
%
Urinary excretion; PO, oral;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Stendra
avanafil
PDR
50.0
mg/day
50
mg/day
PO, oral
Stendra
avanafil
PDR
200.0
mg/day
200
mg/day
PO, oral
Stendra
avanafil
PDR
50.0
mg/day
50
mg/day
PO, oral
Stendra
avanafil
PDR
DDPD06243
Eflornithine
182.171
C6H12F2N2O2
NCCCC(N)(C(F)F)C(O)=O
DB06243
3009
41948
http://www.drugs.com/monograph/eflornithine.html
2902
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
8.0
h
8
h
DRUGBANK
500.0
mg/kg/day
500
mg/kg/day
intravenous injection, IV
Vaniqa
eflornithine hydrochloride
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV
Vaniqa
eflornithine hydrochloride
PDR
500.0
mg/kg/day
500
mg/kg/day
intravenous injection, IV
Vaniqa
eflornithine hydrochloride
PDR
400.0
mg/kg/day
400
mg/kg/day
intravenous injection, IV
Vaniqa
eflornithine hydrochloride
PDR
DDPD06261
Hexaminolevulinate
215.293
C11H21NO3
[H]N([H])CC(=O)CCC(=O)OCCCCCC
DB06261
6433083
134892
http://www.drugs.com/international/hexaminolevulinate-hydrochloride.html
4938272
-2.0
-
-2.0
-
DRUGBANK
7.0
%
7(5-10)
%
DRUGBANK
0.65
h
39
min
elimination half-life;
DRUGBANK
76.0
h
~76
h
terminal half-life;
DRUGBANK
100.0
mg
100
mg
intravesically
Cysview
hexaminolevulinate hydrochloride
PDR
50.0
ml
50
ml
intravesically
Cysview
hexaminolevulinate hydrochloride
PDR
100.0
mg
100
mg
intravesically
Cysview
hexaminolevulinate hydrochloride
PDR
50.0
ml
50
ml
intravesically
Cysview
hexaminolevulinate hydrochloride
PDR
DDPD06262
Droxidopa
213.189
C9H11NO5
N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O
DB06262
92974
31524
83927
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
DRUGBANK
2.5
h
2-3
h
DRUGBANK
5000.0
mg/kg
5.0
g/kg
PO, oral; mouse; Rattus, Rat; dog; monkey;
DRUGBANK
1800.0
mg/day
1800
mg/day
PO, oral
Northera
droxidopa
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Northera
droxidopa
PDR
DDPD06268
Sitaxentan
454.905
C18H15ClN2O6S2
CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl
DB06268
216235
135736
187436
-2.0
-
-2.0
-
DRUGBANK
85.0
%
70-100
%
DRUGBANK
10.0
h
10
h
DRUGBANK
55.0
%
50-60
%
Urinary excretion;
DRUGBANK
45.0
%
40-50
%
Faeces excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD06274
Alvimopan
424.5326
C25H32N2O4
C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
DB06274
5488548
135686
http://www.drugs.com/cdi/alvimopan.html
4589864
-2.0
-
-2.0
-
DRUGBANK
7.0
%
<7
%
PO, oral;
DRUGBANK
24.12
L/h
402±89
ml/min
DRUGBANK
0.3504
L/h/kg
5.84
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
L
30±10
L
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.5
h
10-17
h
DRUGBANK
14.0
h
10-18
h
Bile metabolism;
DRUGBANK
5.3
h
5.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
%
35
%
Urinary excretion; Faeces excretion;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
24.0
mg/day
24
mg/day
PO, oral
Entereg
alvimopan
PDR
12.0
mg
12
mg
PO, oral
bid
Entereg
alvimopan
PDR
24.0
mg/day
24
mg/day
PO, oral
Entereg
alvimopan
PDR
12.0
mg
12
mg
PO, oral
bid
Entereg
alvimopan
PDR
DDPD06282
Levocetirizine
388.89
C21H25ClN2O3
OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
DB06282
1549000
94559
http://www.drugs.com/monograph/levocetirizine-dihydrochloride.html
1266001
-2.0
-
-2.0
-
DRUGBANK
2310.0
ng.h/ml
2.31±0.50
ug.h/ml
PO, oral;
DRUGBANK
27000.0
ng/ml
27±0.04
ug/ml
PO, oral;
DRUGBANK
0.75
h
0.75±0.50
h
PO, oral;
DRUGBANK
2.0
h
2±0.50
h
PO, oral; food;
food ↑ ;
DRUGBANK
85.8
%
85.8
%
Urinary excretion; Faeces excretion; Unchanged drug;
DRUGBANK
0.0342
L/h/kg
0.57±0.18
ml/min/kg
Average clearance;
DRUGBANK
0.33
L/kg
0.33±0.02
L/kg
DRUGBANK
7.05
h
7.05±1.54
h
DRUGBANK
80.8
%
80.8
%
Urinary excretion;
DRUGBANK
9.5
%
9.5
%
Faeces excretion;
DRUGBANK
62.2
%
62.2
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.86
%
0.86
%
Faeces excretion; Unchanged drug;
DRUGBANK
96.1
%
96.1
%
DRUGBANK
91.9
%
91.9
%
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
2.5
mg/day
2.5
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
1.25
mg/day
1.25
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
1.25
mg/day
1.25
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
0.125
mg/dose
0.125
mg/dose
PO, oral
bid
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
5.0
mg/day
5
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
5.0
mg/day
5
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
5.0
mg/day
5
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
1.25
mg/day
1.25
mg/day
PO, oral
Children's Xyzal Allergy
(levocetirizine dihydrochloride)
PDR
DDPD06283
Ziconotide
N.A.
N.A.
CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
DB06283
16135415
-2.0
-
-2.0
-
DRUGBANK
345.8
ng.h/ml
83.6-608
ng.h/ml
intrathecal administration;
DRUGBANK
74.2
ng/ml
16.4-132
ng/ml
intrathecal administration;
DRUGBANK
0.0228
L/h
0.38 ± 0.56
ml/min
DRUGBANK
16.2
L/h
270 ± 44
ml/min
Plasma clearance;
DRUGBANK
0.243
L/h/kg
4.05
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.155
L
155 ± 263
mL
Apparent volume of distribution; patients;
DRUGBANK
30.46
L
30460±6366
mL
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
0.43
L/kg
0.43
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.6
h
4.6±0.9
h
elimination half-life; intrathecal administration; patients;
DRUGBANK
1.3
h
1.3±0.3
h
elimination half-life; intravenous injection, IV;
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
50.0
%
~50
%
plasma proteins; human, homo sapiens;
DRUGBANK
0.0192
mg/day
19.2
mcg/day
intrathecal administration
Prialt
ziconotide
PDR
0.0192
mg/day
0.8
mcg/h
intrathecal administration
Prialt
ziconotide
PDR
0.0192
mg/day
19.2
mcg/day
intrathecal administration
Prialt
ziconotide
PDR
0.0192
mg/day
0.8
mcg/hour
intrathecal administration
Prialt
ziconotide
PDR
DDPD06287
Temsirolimus
1030.2871
C56H87NO16
OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
DB06287
23724530
79699
http://www.drugs.com/cdi/temsirolimus.html
21468899
-2.0
-
-2.0
-
DRUGBANK
0.75
h
0.5-1
h
intravenous infusion, IV in drop;
DRUGBANK
16.2
L/h
16.2
L/h
DRUGBANK
0.462
L/h/kg
7.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
172.0
L
172.0
L
tumor; patients;
DRUGBANK
3.0
L/kg
3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.3
h
17.3
h
DRUGBANK
54.6
h
54.6
h
DRUGBANK
18.0
h
18
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
76.0
%
76
%
Faeces excretion;
DRUGBANK
4.6
%
4.6
%
Urinary excretion;
DRUGBANK
87.0
%
87
%
plasma proteins;
DRUGBANK
3.57142857142857
mg/day
25
mg/week
intravenous injection, IV
qw
Torisel
temsirolimus
PDR
3.57142857142857
mg/day
25
mg/week
intravenous injection, IV
qw
Torisel
temsirolimus
PDR
DDPD06288
Amisulpride
369.479
C17H27N3O4S
CCN1CCCC1CNC(=O)C1=CC(=C(N)C=C1OC)S(=O)(=O)CC
DB06288
2159
64045
2074
-2.0
-
-2.0
-
DRUGBANK
48.0
%
48
%
PO, oral;
DRUGBANK
12.0
h
~12
h
DRUGBANK
17.0
%
17
%
DRUGBANK
DDPD06290
Simeprevir
749.939
C38H47N5O7S2
[H][C@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C1C=CC(OC)=C2C)C1=NC(=CS1)C(C)C)C(=O)NS(=O)(=O)C1CC1
DB06290
24873435
134743
http://www.drugs.com/olysio.html
23331536
-2.0
-
-2.0
-
DRUGBANK
62.0
%
62
%
DRUGBANK
5.0
h
4-6
h
PO, oral;
DRUGBANK
41.0
h
~41
h
elimination half-life; HCV-positive;
DRUGBANK
11.5
h
10-13
h
elimination half-life; normal,healthy;
DRUGBANK
91.0
%
91
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
31.0
%
31
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.9
%
99.9
%
plasma proteins;
DRUGBANK
DDPD06292
Dapagliflozin
408.873
C21H25ClO6
CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1
DB06292
9887712
85078
http://www.drugs.com/farxiga.html
8063384
-2.0
-
-2.0
-
DRUGBANK
78.0
%
78
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral; patients; fasting;
DRUGBANK
2.0
h
2
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
0.294
L/h/kg
4.9
ml/min/kg
Plasma clearance; PO, oral;
DRUGBANK
0.336
L/h
5.6
ml/min
Renal clearance; PO, oral;
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
118.0
L
118.0
L
DRUGBANK
1.7
L/kg
1.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.8
h
13.8
h
DRUGBANK
12.2
h
12.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.2
%
75.2
%
Urinary excretion;
DRUGBANK
21.0
%
21
%
Faeces excretion;
DRUGBANK
91.0
%
91
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Farxiga
dapagliflozin
PDR
10.0
mg/day
10
mg/day
PO, oral
Farxiga
dapagliflozin
PDR
DDPD06335
Saxagliptin
315.41
C18H25N3O2
[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
DB06335
11243969
71272
http://www.drugs.com/international/saxagliptin.html
9419005
-2.0
-
-2.0
-
DRUGBANK
78.0
ng.h/ml
78.0
ng.h/ml
Oral single dose; normal,healthy;
DRUGBANK
214.0
ng.h/ml
214.0
ng.h/ml
Oral single dose; Active metabolite; normal,healthy;
DRUGBANK
67.0
%
67
%
DRUGBANK
24.0
ng/ml
24
ng/ml
Oral single dose; normal,healthy;
DRUGBANK
47.0
ng/ml
47
ng/ml
Oral single dose; Active metabolite; normal,healthy;
DRUGBANK
2.0
h
2
h
Oral single dose; normal,healthy;
DRUGBANK
4.0
h
4
h
Oral single dose; Active metabolite; normal,healthy;
DRUGBANK
50.0
%
50
%
Liver metabolism;
DRUGBANK
14.0
L/h
14.0
L/h
Renal clearance;
DRUGBANK
0.426
L/h/kg
7.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
151.0
L
151.0
L
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
DRUGBANK
3.1
h
3.1
h
DRUGBANK
7.5
h
7.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
%
22
%
Faeces excretion; Single dose;
DRUGBANK
DDPD06401
Bazedoxifene
470.613
C30H34N2O3
CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1
DB06401
154257
135947
http://www.drugs.com/international/bazedoxifene.html
135921
-2.0
-
-2.0
-
DRUGBANK
6.0
%
~6
%
DRUGBANK
2.0
h
2
h
DRUGBANK
4.5
L/h/kg
~4.0-5
l/h/kg
apparent clearance; PO, oral;
DRUGBANK
0.402
L/h/kg
6.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.7
L/kg
14.7 ± 3.9
L/kg
intravenous injection, IV;
DRUGBANK
15.4
L/kg
15.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
h
~30
h
DRUGBANK
30.0
h
30
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
98.5
%
98-99
%
DRUGBANK
DDPD06402
Telavancin
1755.65
C80H106Cl2N11O27P
CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O
DB06402
3081362
71229
http://www.drugs.com/cdi/telavancin.html
2338980
-2.0
-
-2.0
-
DRUGBANK
747000.0
ng.h/ml
747±129
ug.h/ml
intravenous injection, IV;
DRUGBANK
93600.0
ng/ml
93.6±14.2
ug/ml
intravenous injection, IV;
DRUGBANK
72.0
h
3
day
intravenous injection, IV;
DRUGBANK
0.0139
L/h/kg
13.9±2.9
ml/h/kg
normal,healthy;
DRUGBANK
0.012
L/h/kg
0.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.14
L/kg
0.14
L/kg
Steady state volume of distribution; normal,healthy;
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8±1.5
h
elimination half-life; normal renal function;
DRUGBANK
6.7
h
6.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
DRUGBANK
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Vibativ
telavancin
PDR
10.0
mg/kg/day
10
mg/kg/day
intravenous injection, IV
Vibativ
telavancin
PDR
DDPD06403
Ambrisentan
378.428
C22H22N2O4
COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
DB06403
6918493
135949
http://www.drugs.com/cdi/ambrisentan.html
5293690
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
2.28
L/h
38.0
ml/min
Average clearance; PO, oral; normal,healthy;
DRUGBANK
1.14
L/h
19.0
ml/min
Average clearance; PO, oral; pulmonary arterial hypertension; patients;
DRUGBANK
15.0
h
15
h
DRUGBANK
3160.0
mg/kg
>=3160
mg/kg
Rattus, Rat;
DRUGBANK
22.0
%
~22
%
Urinary excretion; PO, oral;
DRUGBANK
0.72
%
~0.72
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
96.5
%
96.5
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Letairis
ambrisentan
PDR
10.0
mg/day
10
mg/day
PO, oral
Letairis
ambrisentan
PDR
DDPD06410
Doxercalciferol
412.6478
C28H44O2
[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C
DB06410
46705423
4712
http://www.drugs.com/international/doxercalciferol.html
4444554
-2.0
-
-2.0
-
DRUGBANK
34.5
h
32-37
h
DRUGBANK
20.0
mcg/dose
20
mcg/dose
PO, oral
tiw
Hectorol Capsules
doxercalciferol
PDR
6.0
mcg/dose
6
mcg/dose
intravenous injection, IV
tiw
Hectorol Capsules
doxercalciferol
PDR
0.00857142857142857
mg/day
60
mcg/week
PO, oral
Hectorol Capsules
doxercalciferol
PDR
0.00257142857142857
mg/day
18
mcg/week
intravenous injection, IV
Hectorol Capsules
doxercalciferol
PDR
8.0
mcg/dose
8
mcg/dose
intravenous injection, IV
Hectorol Capsules
doxercalciferol
PDR
0.00342857142857143
mg/day
24
mcg/week
intravenous injection, IV
Hectorol Capsules
doxercalciferol
PDR
0.0035
mg/day
3.5
mcg/day
Capsule, PO, Oral
Hectorol Capsules
doxercalciferol
PDR
20.0
mcg/dose
20
mcg/dose
PO, oral
tiw
Hectorol Capsules
doxercalciferol
PDR
6.0
mcg/dose
6
mcg/dose
intravenous injection, IV
tiw
Hectorol Capsules
doxercalciferol
PDR
0.00857142857142857
mg/day
60
mcg/week
PO, oral
Hectorol Capsules
doxercalciferol
PDR
0.00257142857142857
mg/day
18
mcg/week
intravenous injection, IV
Hectorol Capsules
doxercalciferol
PDR
8.0
mcg/dose
8
mcg/dose
intravenous injection, IV
Hectorol Capsules
doxercalciferol
PDR
0.00342857142857143
mg/day
24
mcg/week
intravenous injection, IV
Hectorol Capsules
doxercalciferol
PDR
0.0035
mg/day
3.5
mcg/day
Capsule, PO, Oral
Hectorol Capsules
doxercalciferol
PDR
DDPD06412
Oxymetholone
332.484
C21H32O3
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O
DB06412
5281034
7864
http://www.drugs.com/international/Oxymetholone.html
4444502
-2.0
-
-2.0
-
DRUGBANK
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Anadrol-50
oxymetholone
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Anadrol-50
oxymetholone
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Anadrol-50
oxymetholone
PDR
5.0
mg/kg/day
5
mg/kg/day
PO, oral
Anadrol-50
oxymetholone
PDR
DDPD06413
Armodafinil
273.35
C15H15NO2S
NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
DB06413
9690109
77590
http://www.drugs.com/international/armodafinil.html
7962943
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
PO, oral; fasting;
DRUGBANK
3.0
h
2-4
h
PO, oral; food;
DRUGBANK
1.98
L/h
~33
ml/min
PO, oral;
DRUGBANK
42.0
L
42.0
L
Apparent volume of distribution;
DRUGBANK
15.0
h
~15
h
terminal half-life;
DRUGBANK
60.0
%
~60
%
DRUGBANK
250.0
mg/day
250
mg/day
PO, oral
Nuvigil
armodafinil
PDR
150.0
mg/day
150
mg/day
PO, oral
Nuvigil
armodafinil
PDR
250.0
mg/day
250
mg/day
PO, oral
Nuvigil
armodafinil
PDR
150.0
mg/day
150
mg/day
PO, oral
Nuvigil
armodafinil
PDR
250.0
mg/day
250
mg/day
PO, oral
Nuvigil
armodafinil
PDR
150.0
mg/day
150
mg/day
PO, oral
Nuvigil
armodafinil
PDR
DDPD06414
Etravirine
435.277
C20H15BrN6O
CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N
DB06414
193962
63589
http://www.drugs.com/cdi/etravirine.html
168313
-2.0
-
-2.0
-
DRUGBANK
25.025
h
9.05-41
h
DRUGBANK
93.7
%
93.7
%
Faeces excretion;
DRUGBANK
1.2
%
1.2
%
Urinary excretion;
DRUGBANK
99.9
%
99.9
%
plasma proteins; high protein binding;
DRUGBANK
99.6
%
99.6
%
high protein binding;
DRUGBANK
98.34
%
97.66-99.02
%
high protein binding;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Intelence
etravirine
PDR
300.0
mg/day
300
mg/day
PO, oral
Intelence
etravirine
PDR
250.0
mg/day
250
mg/day
PO, oral
Intelence
etravirine
PDR
200.0
mg/day
200
mg/day
PO, oral
Intelence
etravirine
PDR
400.0
mg/day
400
mg/day
PO, oral
Intelence
etravirine
PDR
400.0
mg/day
400
mg/day
PO, oral
Intelence
etravirine
PDR
300.0
mg/day
300
mg/day
PO, oral
Intelence
etravirine
PDR
400.0
mg/day
400
mg/day
PO, oral
Intelence
etravirine
PDR
DDPD06439
Tyloxapol
N.A.
N.A.
CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1
DB06439
71388
http://www.drugs.com/ingredient/tyloxapol.html
26330335
-2.0
-
-2.0
-
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; mouse;
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD06441
Cangrelor
776.35
C17H25Cl2F3N5O12P3S2
CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1
DB06441
9854012
90841
http://www.drugs.com/cons/cangrelor-intravenous.html
8029718
-2.0
-
-2.0
-
DRUGBANK
43.2
L/h
43.2
L/h
Average clearance;
DRUGBANK
0.5436
L/h/kg
9.06
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.9
L
3.9
L
normal,healthy;
DRUGBANK
0.035
L/kg
0.035
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.075
h
~3-6
min
elimination half-life;
DRUGBANK
0.14
h
0.14
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
58.0
%
58
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
35.0
%
35
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
97.5
%
~97-98
%
DRUGBANK
0.03
mg/day
30
mcg/day
intravenous injection, IV
Kengreal
cangrelor
PDR
5.76
mg/kg/day
4
mcg/kg/min
intravenous infusion, iv in drop
Kengreal
cangrelor
PDR
0.03
mg/day
30
mcg/day
intravenous injection, IV
Kengreal
cangrelor
PDR
5.76
mg/kg/day
4
mcg/kg/minute
intravenous infusion, iv in drop
Kengreal
cangrelor
PDR
DDPD06480
Prucalopride
367.87
C18H26ClN3O3
COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1
DB06480
3052762
135552
2314539
-2.0
-
-2.0
-
DRUGBANK
96.5
mn.h/ml
96.5
mn.h/ml
DRUGBANK
90.0
%
>90
%
PO, oral; food;
food → ;
DRUGBANK
3.79
ng/ml
3.79
ng/ml
DRUGBANK
2.77
h
2.77
h
DRUGBANK
6.0
%
6
%
DRUGBANK
17.0
L/h
17.0
L/h
Renal clearance;
DRUGBANK
0.273
L/h/kg
4.55
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
623.0
L
623.0
L
Average volume of distribution;
DRUGBANK
8.73
L/kg
8.73
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
19.0
h
~18-20
h
DRUGBANK
22.5
h
22.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.0
%
84
%
Urinary excretion;
DRUGBANK
13.0
%
13
%
Faeces excretion;
DRUGBANK
30.0
%
30
%
plasma proteins;
DRUGBANK
DDPD06589
Pazopanib
437.518
C21H23N7O2S
CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
DB06589
10113978
71219
http://www.drugs.com/cdi/pazopanib.html
8289501
-2.0
-
-2.0
-
DRUGBANK
1037000.0
ng.h/ml
1037.0
ug.h/ml
PO, oral;
DRUGBANK
21.0
%
21
%
PO, oral; tumor;
DRUGBANK
58100.0
ng/ml
58.1
ug/ml
PO, oral;
DRUGBANK
0.24
L/h
4.0
ml/min
intravenous injection, IV; tumor; patients;
DRUGBANK
0.0036
L/h/kg
0.06
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.1
L
11.1
L
Steady state volume of distribution; intravenous injection, IV; tumor; patients;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
35.0
h
35
h
DRUGBANK
82.2
%
82.2
%
Faeces excretion; tumor;
DRUGBANK
4.0
%
<4
%
Urinary excretion; tumor;
DRUGBANK
99.0
%
>99
%
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Votrient
pazopanib
PDR
800.0
mg/day
800
mg/day
PO, oral
Votrient
pazopanib
PDR
DDPD06590
Ceftaroline fosamil
684.67
C22H21N8O8PS4
[H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O
DB06590
9852981
70718
http://www.drugs.com/teflaro.html
8028692
-2.0
-
-2.0
-
DRUGBANK
5.016
L/h/kg
83.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.3
L
20.3
L
Average volume of distribution;
DRUGBANK
0.53
L/kg
0.53
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
h
1.60
h
DRUGBANK
0.09
h
0.09
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
6.0
%
6
%
Faeces excretion;
DRUGBANK
20.0
%
~20
%
DRUGBANK
1200.0
mg/day
1200
mg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
36.0
mg/kg/day
36
mg/kg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
24.0
mg/kg/day
24
mg/kg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
36.0
mg/kg/day
36
mg/kg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
1200.0
mg/day
1200
mg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
24.0
mg/kg/day
24
mg/kg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
18.0
mg/kg/day
18
mg/kg/day
intravenous injection, IV
Teflaro
ceftaroline fosamil
PDR
DDPD06594
Agomelatine
243.301
C15H17NO2
COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
DB06594
82148
134990
74141
-2.0
-
-2.0
-
DRUGBANK
5.0
%
<5
%
DRUGBANK
90.0
%
90
%
Liver metabolism;
DRUGBANK
10.0
%
10
%
Liver metabolism;
DRUGBANK
2.0
h
<2
h
DRUGBANK
95.0
%
>95
%
DRUGBANK
DDPD06595
Midostaurin
570.649
C35H30N4O4
CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1
DB06595
9829523
63452
https://www.drugs.com/history/rydapt.html
8005258
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1-3
h
PO, oral; patients; fasting;
DRUGBANK
1.47
L/h
1.47
L/h
DRUGBANK
0.501
L/h
0.501
L/h
DRUGBANK
95.2
L
95.2
L
DRUGBANK
21.0
h
~21
h
elimination half-life;
DRUGBANK
32.0
h
32
h
elimination half-life;
DRUGBANK
482.0
h
482
h
elimination half-life;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
95.0
%
95
%
Faeces excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion;
DRUGBANK
3.8
%
3.8
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.8
%
>99.8
%
plasma proteins; high protein binding;
DRUGBANK
100.0
mg
100
mg
PO, oral
bid
Rydapt
midostaurin
PDR
100.0
mg
100
mg
PO, oral
bid
Rydapt
midostaurin
PDR
DDPD06603
Panobinostat
349.434
C21H23N3O2
CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1
DB06603
6918837
85990
http://www.drugs.com/mtm/panobinostat.html
5294028
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
DRUGBANK
2.0
%
2
%
Urinary excretion;
DRUGBANK
3.0
%
3
%
Faeces excretion;
DRUGBANK
0.612
L/h/kg
10.2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
h
30
h
DRUGBANK
13.1
h
13.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
mg/dose
20
mg/dose
PO, oral
Farydak
panobinostat
PDR
10.0
mg/dose
10
mg/dose
PO, oral
Farydak
panobinostat
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Farydak
panobinostat
PDR
10.0
mg/dose
10
mg/dose
PO, oral
Farydak
panobinostat
PDR
DDPD06605
Apixaban
459.4971
C25H25N5O4
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
DB06605
10182969
72296
http://www.drugs.com/eliquis.html
8358471
-2.0
-
-2.0
-
DRUGBANK
50.0
%
~50
%
DRUGBANK
44.5
%
43-46
%
different study;
DRUGBANK
50.0
%
50
%
Urinary excretion; Faeces excretion; Unchanged drug;
DRUGBANK
3.3
L/h
3.3
L/h
DRUGBANK
0.048
L/h/kg
0.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.0
L
~21
L
DRUGBANK
0.3
L/kg
0.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.7
h
12.7±8.55
h
DRUGBANK
12.0
h
12
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
56.0
%
56
%
Faeces excretion; PO, oral;
DRUGBANK
26.65
%
24.5-28.8
%
Urinary excretion; PO, oral;
DRUGBANK
93.0
%
92-94
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Eliquis
apixaban
PDR
20.0
mg/day
20
mg/day
PO, oral
Eliquis
apixaban
PDR
10.0
mg/day
10
mg/day
PO, oral
Eliquis
apixaban
PDR
20.0
mg/day
20
mg/day
PO, oral
Eliquis
apixaban
PDR
DDPD06608
Tafenoquine
463.501
C24H28F3N3O3
COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1
DB06608
141487
103196
-2.0
-
-2.0
-
DRUGBANK
13.8
h
13.8
h
DRUGBANK
6.0
L/h
~6
L/h
DRUGBANK
2560.0
L
~2560
L
DRUGBANK
336.0
h
~14
day
DRUGBANK
99.5
%
~99.5
%
plasma proteins; human, homo sapiens;
DRUGBANK
300.0
mg/dose
300
mg/dose
PO, oral
Krintafel
tafenoquine
PDR
200.0
mg/day
200
mg/day
PO, oral
Krintafel
tafenoquine
PDR
28.5714285714286
mg/day
200
mg/week
PO, oral
Krintafel
tafenoquine
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Krintafel
tafenoquine
PDR
300.0
mg/dose
300
mg/dose
PO, oral
Krintafel
tafenoquine
PDR
200.0
mg/day
200
mg/day
PO, oral
Krintafel
tafenoquine
PDR
28.5714285714286
mg/day
200
mg/week
PO, oral
Krintafel
tafenoquine
PDR
DDPD06614
Peramivir
328.4072
C15H28N4O4
[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O
DB06614
154234
85202
135903
-2.0
-
-2.0
-
DRUGBANK
12.0
mg/kg/dose
12
mg/kg/dose
intravenous injection, IV
Rapivab
peramivir
PDR
600.0
mg/dose
600
mg/dose
intravenous injection, IV
Rapivab
peramivir
PDR
12.0
mg/kg/dose/day
12
mg/kg/dose/day
intravenous injection, IV
qd
Rapivab
peramivir
PDR
600.0
mg/dose
600
mg/dose
intravenous injection, IV
Rapivab
peramivir
PDR
600.0
mg/dose
600
mg/dose
intravenous injection, IV
Rapivab
peramivir
PDR
600.0
mg/dose
600
mg/dose
intravenous injection, IV
Rapivab
peramivir
PDR
12.0
mg/kg/dose/day
12
mg/kg/dose/day
intravenous injection, IV
Rapivab
peramivir
PDR
10.0
mg/kg/dose/day
10
mg/kg/dose/day
intravenous injection, IV
Rapivab
peramivir
PDR
8.0
mg/kg/dose/day
8
mg/kg/dose/day
intravenous injection, IV
Rapivab
peramivir
PDR
6.0
mg/kg/dose/day
6
mg/kg/dose/day
intravenous injection, IV
Rapivab
peramivir
PDR
DDPD06616
Bosutinib
530.446
C26H29Cl2N5O3
COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl
DB06616
5328940
39112
http://www.drugs.com/cdi/bosutinib.html
4486102
-2.0
-
-2.0
-
DRUGBANK
3650.0
ng.h/ml
3650.0
ng.h/ml
PO, oral; Chronic myelogenous leukemia; food;
DRUGBANK
200.0
ng/ml
200
ng/ml
PO, oral; Chronic myelogenous leukemia; food;
DRUGBANK
5.0
h
4-6
h
Oral single dose; tumor; food;
DRUGBANK
189.0
L/h
189.0
L/h
Average clearance; Oral single dose; food;
DRUGBANK
6080.0
L
6080 ± 1230
L
Apparent volume of distribution;
DRUGBANK
22.5
h
22.5
h
elimination half-life; Oral single dose;
DRUGBANK
91.3
%
91.3
%
Faeces excretion; Oral single dose;
DRUGBANK
3.0
%
3
%
Urinary excretion; Oral single dose;
DRUGBANK
94.0
%
94
%
plasma proteins; high protein binding;
Plasma Concentration → ;
DRUGBANK
96.0
%
96
%
plasma proteins; in vivo; normal,healthy; human, homo sapiens;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Bosulif
bosutinib
PDR
600.0
mg/day
600
mg/day
PO, oral
Bosulif
bosutinib
PDR
DDPD06626
Axitinib
386.47
C22H18N4OS
CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
DB06626
6450551
66910
http://www.drugs.com/mtm/axitinib.html
4953153
-2.0
-
-2.0
-
DRUGBANK
3.3
h
2.5-4.1
h
DRUGBANK
38.0
L/h
38.0
L/h
Average clearance;
DRUGBANK
0.3
L/h/kg
5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
160.0
L
160.0
L
DRUGBANK
4.3
h
2.5-6.1
h
DRUGBANK
4.3
h
4.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
23.0
%
23
%
Urinary excretion;
DRUGBANK
12.0
%
12
%
Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
DDPD06636
Isavuconazonium
717.77
C35H35F2N8O5S
[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1
DB06636
6918606
85978
5293801
-2.0
-
-2.0
-
DRUGBANK
98.0
%
98
%
PO, oral;
DRUGBANK
450.0
L
450.0
L
DRUGBANK
105.0
h
80-130
h
DRUGBANK
45.0
%
45
%
Faeces excretion; Bile excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
1116.0
mg/day
1116
mg/day
PO, oral;intravenous injection, IV;
Cresemba
isavuconazonium sulfate
PDR
600.0
mg/day
600
mg/day
PO, oral;intravenous injection, IV;
Cresemba
isavuconazonium sulfate
PDR
1116.0
mg/day
1116
mg/day
PO, oral;intravenous injection, IV;
Cresemba
isavuconazonium sulfate
PDR
600.0
mg/day
600
mg/day
PO, oral;intravenous injection, IV;
Cresemba
isavuconazonium sulfate
PDR
DDPD06637
Dalfampridine
94.1145
C5H6N2
NC1=CC=NC=C1
DB06637
T3D2553
1727
34385
http://www.drugs.com/ampyra.html
1664
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
19.45
ng/ml
17.3-21.6
ng/ml
PO, oral; extended release formulation;
DRUGBANK
1.0
h
1
h
PO, oral; immediate release formulation;
DRUGBANK
3.5
h
3.5
h
PO, oral; extended release formulation;
DRUGBANK
0.558
L/h/kg
9.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.6
L/kg
2.6
L/kg
DRUGBANK
2.6
L/kg
2.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3.5
h
distribution half-life;
DRUGBANK
5.47
h
5.47
h
elimination half-life;
DRUGBANK
3.6
h
3.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
19.0
mg/kg
19.0
mg/kg
PO, oral; mouse;
DRUGBANK
21.0
mg/kg
21.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
19.0
mg/kg
19.0
mg/kg
PO, oral; mouse;
DRUGBANK
21.0
mg/kg
21.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
24.5
mg/kg
20-29
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3.7
mg/kg
3.7
mg/kg
PO, oral; dog;
DRUGBANK
326.0
mg/kg
326.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
96.0
%
96
%
Urinary excretion;
DRUGBANK
0.5
%
0.5
%
Faeces excretion;
DRUGBANK
90.0
%
90
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
1-3
%
extended release formulation;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
bid
Ampyra
dalfampridine
PDR
10.0
mg/day
10
mg/day
PO, oral
bid
Ampyra
dalfampridine
PDR
DDPD06654
Safinamide
302.349
C17H19FN2O2
C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O
DB06654
131682
134718
116349
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
DRUGBANK
3.0
h
2-4
h
DRUGBANK
0.01753
L/h/kg
17.53±2.71
ml/h/kg
Plasma clearance; PO, oral;
DRUGBANK
0.0702
L/h/kg
1.17
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
L/kg
1.8
L/kg
DRUGBANK
2.19
L/kg
2.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
22
h
DRUGBANK
21.67
h
21.67
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
76.0
%
76
%
Urinary excretion;
DRUGBANK
1.5
%
1.5
%
Faeces excretion;
DRUGBANK
89.0
%
88-90
%
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Xadago
safinamide
PDR
100.0
mg/day
100
mg/day
PO, oral
Xadago
safinamide
PDR
DDPD06663
Pasireotide
1047.2062
C58H66N10O9
NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1
DB06663
9941444
72312
http://www.drugs.com/signifor.html
8117062
-2.0
-
-2.0
-
DRUGBANK
0.375
h
0.25-0.5
h
DRUGBANK
7.6
L/h
~7.6
L/h
normal,healthy; patients;
DRUGBANK
3.8
L/h
~3.8
L/h
Cushing's Disease; patients;
DRUGBANK
100.0
L
>100
L
DRUGBANK
12.0
h
12
h
DRUGBANK
48.0
%
~48
%
Bile excretion;
DRUGBANK
7.63
%
~7.63
%
Urinary excretion;
DRUGBANK
88.0
%
88
%
plasma proteins;
DRUGBANK
1.8
mg/day
1.8
mg/day
subcutaneous injection, SC
Signifor
pasireotide
PDR
40.0
mg
40
mg
IM,intramuscular injection
q4w
Signifor
pasireotide
PDR
60.0
mg
60
mg
IM,intramuscular injection
q4w
Signifor
pasireotide
PDR
1.8
mg/day
1.8
mg/day
subcutaneous injection, SC
Signifor
pasireotide
PDR
40.0
mg
40
mg
IM,intramuscular injection
q4w
Signifor
pasireotide
PDR
60.0
mg
60
mg
IM,intramuscular injection
q4w
Signifor
pasireotide
PDR
DDPD06684
Vilazodone
441.5249
C26H27N5O2
NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
DB06684
6918314
70707
http://www.drugs.com/cdi/vilazodone.html
5293518
-2.0
-
-2.0
-
DRUGBANK
72.0
%
72
%
PO, oral; food;
DRUGBANK
22.5
L/h
19.9-25.1
L/h
mild renal function; moderate renal function;
DRUGBANK
26.65
L/h
26.4-26.9
L/h
normal,healthy;
DRUGBANK
0.2256
L/h/kg
3.76
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.85
L/kg
4.85
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
h
25
h
DRUGBANK
24.0
h
24±5.2
h
Single dose;
DRUGBANK
28.9
h
28.9±3.2
h
Multiple dose;
DRUGBANK
15.66
h
15.66
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
1
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
%
2
%
Faeces excretion; Unchanged drug;
DRUGBANK
97.5
%
96-99
%
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Viibryd
vilazodone hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Viibryd
vilazodone hydrochloride
PDR
DDPD06689
Ethanolamine oleate
343.5444
C20H41NO3
NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O
DB06689
5282489
http://www.drugs.com/mtm/ethanolamine-oleate.html
4445632
-2.0
-
-2.0
-
DRUGBANK
156.0
mg/kg
156.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
175.0
mg/kg
175.0
mg/kg
intravenous injection, IV; dog;
DRUGBANK
DDPD06690
Nitrous oxide
44.0128
N2O
[N-]=[N+]=O
DB06690
948
17045
923
-2.0
-
-2.0
-
DRUGBANK
DDPD06691
Mepyramine
285.384
C17H23N3O
COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1
DB06691
4992
6762
4818
-2.0
-
-2.0
-
DRUGBANK
DDPD06694
Xylometazoline
244.3752
C16H24N2
CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
DB06694
5709
10082
5507
-2.0
-
-2.0
-
DRUGBANK
DDPD06695
Dabigatran etexilate
627.7332
C34H41N7O5
CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
DB06695
6445226
70746
http://www.drugs.com/cdi/dabigatran.html
4948999
-2.0
-
-2.0
-
DRUGBANK
5.0
%
3-7
%
PO, oral; fasting;
DRUGBANK
1.0
h
1
h
PO, oral; fasting;
DRUGBANK
2.0
h
2
h
PO, oral; high-fat meal;
DRUGBANK
60.0
L
50-70
L
DRUGBANK
14.5
h
12-17
h
DRUGBANK
7.0
%
7
%
Urinary excretion;
DRUGBANK
86.0
%
86
%
Faeces excretion;
DRUGBANK
35.0
%
~35
%
plasma proteins;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Pradaxa
dabigatran etexilate mesylate
PDR
300.0
mg/day
300
mg/day
PO, oral
Pradaxa
dabigatran etexilate mesylate
PDR
DDPD06697
Artemether
298.3746
C16H26O5
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](OC)[C@@H]2C)O4
DB06697
68911
195280
http://www.drugs.com/pro/coartem.html
62138
-2.0
-
-2.0
-
DRUGBANK
1.6
h
1.6±0.7
h
distribution half-life;
DRUGBANK
2.2
h
2.2±1.9
h
elimination half-life;
DRUGBANK
1.6
h
1.6±0.6
h
distribution half-life;
DRUGBANK
2.2
h
2.2±1.5
h
elimination half-life;
DRUGBANK
895.0
mg/kg
895.0
mg/kg
mouse;
DRUGBANK
296.0
mg/kg
296.0
mg/kg
mouse;
DRUGBANK
597.0
mg/kg
597.0
mg/kg
Rattus, Rat;
DRUGBANK
95.4
%
95.4
%
human, homo sapiens;
DRUGBANK
DDPD06698
Betahistine
136.1943
C8H12N2
CNCCC1=CC=CC=N1
DB06698
2366
35677
2276
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
DRUGBANK
DDPD06699
Degarelix
1632.29
C82H103ClN18O16
CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
DB06699
16136245
135961
http://www.drugs.com/degarelix.html
17292756
-2.0
-
-2.0
-
DRUGBANK
330.0
ng/ml
330
ng/ml
subcutaneous injection, SC;
DRUGBANK
6.0
h
6
h
subcutaneous injection, SC;
DRUGBANK
9.0
L/h
~9
L/h
subcutaneous injection, SC; metastatic prostate cancer;
DRUGBANK
0.0408
L/h/kg
0.68
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.14
L
8.88-11.4
L
Total volume of distribution;
DRUGBANK
40.9
L
40.9
L
Total volume of distribution;
DRUGBANK
0.74
L/kg
0.74
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1340.4
h
41.5-70.2
day
terminal half-life;
DRUGBANK
32.9
h
32.9
h
distribution half-life;
DRUGBANK
28.08
h
1.17
day
DRUGBANK
18.6
h
18.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.0
%
70-80
%
Faeces excretion;
DRUGBANK
25.0
%
20-30
%
Urinary excretion; Unchanged drug;
DRUGBANK
90.0
%
90
%
plasma proteins;
DRUGBANK
240.0
mg
240
mg
subcutaneous injection, SC
Firmagon
degarelix
PDR
240.0
mg
240
mg
subcutaneous injection, SC
Firmagon
degarelix
PDR
DDPD06700
Desvenlafaxine
263.3752
C16H25NO2
CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
DB06700
125017
83527
http://www.drugs.com/ppa/desvenlafaxine-succinate.html
111300
-2.0
-
-2.0
-
DRUGBANK
80.0
%
80
%
PO, oral; food;
food → ;
DRUGBANK
7.5
h
7.5
h
PO, oral;
DRUGBANK
0.294
L/h/kg
4.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.4
L/kg
3.4
L/kg
DRUGBANK
3.5
L/kg
3.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.1
h
11.1
h
terminal half-life;
moderate hepatic impairment ↑ ;severe hepatic impairment ↑ ;moderate renal function ↑ ;severe renal function ↑ ;
DRUGBANK
8.4
h
8.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
45.0
%
45
%
Urinary excretion; Unchanged drug;
DRUGBANK
30.0
%
30
%
Plasma Concentration → ;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Khedezla
desvenlafaxine
PDR
400.0
mg/day
400
mg/day
PO, oral
Khedezla
desvenlafaxine
PDR
DDPD06701
Dexmethylphenidate
233.3062
C14H19NO2
[H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1
DB06701
T3D4563
154101
51860
135807
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
23.0
%
23
%
PO, oral;
DRUGBANK
5.0
%
5
%
PO, oral; Raceme L;
DRUGBANK
1.25
h
1-1.5
h
PO, oral; Raceme L;
DRUGBANK
0.4
L/h/kg
0.4
l/h/kg
intravenous injection, IV;
DRUGBANK
0.005
L/h/kg
0.005
l/h/kg
Renal clearance;
DRUGBANK
0.4002
L/h/kg
6.67
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.65
L/kg
2.65
L/kg
intravenous injection, IV;
DRUGBANK
2.65
L/kg
2.65
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.2
h
~2.2
h
terminal half-life;
DRUGBANK
3.85
h
3.8-3.9
h
different study;
DRUGBANK
5.96
h
5.96
h
intravenous injection, IV;
DRUGBANK
5.69
h
5.69
h
PO, oral;
DRUGBANK
8.0
h
8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
190.0
mg/kg
190.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
3.3
%
3.3
%
Faeces excretion;
DRUGBANK
13.5
%
12-15
%
DRUGBANK
15.2
%
15.2±5.2
%
Children;
DRUGBANK
16.2
%
16.2±1.1
%
adults;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
30.0
mg/day
30
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
50.0
mg/day
50
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
20.0
mg/day
20
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
40.0
mg/day
40
mg/day
PO, oral
Focalin XR
dexmethylphenidate hydrochloride
PDR
DDPD06702
Fesoterodine
411.5769
C26H37NO3
CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
DB06702
6918558
135920
http://www.drugs.com/cdi/fesoterodine.html
5293755
-2.0
-
-2.0
-
DRUGBANK
49.5
ng.h/ml
49.5
ng.h/ml
DRUGBANK
52.0
%
52
%
DRUGBANK
5.0
h
5
h
DRUGBANK
14.4
L/h
14.4
L/h
normal,healthy;
DRUGBANK
169.0
L
169.0
L
intravenous injection, IV;
DRUGBANK
7.5
h
7-8
h
Active metabolite;
DRUGBANK
681.0
mg/kg
~681
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
316.0
mg/kg
~316
mg/kg
PO, oral; mouse;
DRUGBANK
7.0
%
7
%
Faeces excretion;
DRUGBANK
50.0
%
50
%
DRUGBANK
8.0
mg/day
8
mg/day
PO, oral
Toviaz
fesoterodine fumarate
PDR
8.0
mg/day
8
mg/day
PO, oral
Toviaz
fesoterodine fumarate
PDR
DDPD06703
Gadobutrol
604.72
C18H31GdN4O9
OC[C@H](O)[C@H](CO)[N+]12CC[N+]3(CC([O-])=O)CC[N+]4(CC([O-])=O)CC[N+](CC([O-])=O)(CC1)[Gd-]234
DB06703
70678987
68841
http://www.drugs.com/international/gadavist.html
28533281
-2.0
-
-2.0
-
DRUGBANK
665192.0
ng.h/ml
1.1±0.1
mmol.h/L
normal renal function;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.084
L/h/kg
1.1-1.7
ml/min/kg
Renal clearance; normal,healthy;
DRUGBANK
0.115
L/h/kg
0.1-0.13
L/h/kg
Average clearance; Children;
DRUGBANK
0.09
L/h/kg
0.09
L/h/kg
Average clearance; Adolescents;
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.81
h
1.81(1.33-2.13)
h
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
ml/kg/dose
0.1
mL/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Gadavist
gadobutrol
PDR
DDPD06704
Iobenguane
275.0896
C8H10IN3
NC(N)=NCC1=CC(I)=CC=C1
DB06704
60860
92769
http://www.drugs.com/mtm/iobenguane-i-123.html
54847
-2.0
-
-2.0
-
DRUGBANK
10.0
%
<10
%
DRUGBANK
13.2
h
13.2
h
physical half-life;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
<1
%
Faeces excretion;
DRUGBANK
296.0
MBq/kg
296
MBq/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
8.0
mCi/kg
8
mCi/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
18500.0
MBq
18500
MBq
intravenous injection, IV
Azedra
iobenguane I 131
PDR
500.0
mCi
500
mCi
intravenous injection, IV
Azedra
iobenguane I 131
PDR
296.0
MBq/kg
296
MBq/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
8.0
mCi/kg
8
mCi/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
18500.0
MBq
18500
MBq
intravenous injection, IV
Azedra
iobenguane I 131
PDR
500.0
mCi
500
mCi
intravenous injection, IV
Azedra
iobenguane I 131
PDR
296.0
MBq/kg
296
MBq/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
8.0
mCi/kg
8
mCi/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
18500.0
MBq
18500
MBq
intravenous injection, IV
Azedra
iobenguane I 131
PDR
500.0
mCi
500
mCi
intravenous injection, IV
Azedra
iobenguane I 131
PDR
296.0
MBq/kg
296
MBq/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
8.0
mCi/kg
8
mCi/kg
intravenous injection, IV
Azedra
iobenguane I 131
PDR
DDPD06705
Gadofosveset trisodium
957.87
C33H38GdN3Na3O14P
[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC(COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O
DB06705
73049652
http://www.drugs.com/mtm/gadofosveset-trisodium.html
58829621
-2.0
-
-2.0
-
DRUGBANK
0.00657
L/h/kg
6.57 ± 0.97
ml/h/kg
DRUGBANK
0.048
L/kg
48±16
ml/kg
DRUGBANK
18.5
h
18.5
h
DRUGBANK
83.5
%
~83.5
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
94.0
%
94
%
Urinary excretion;
DRUGBANK
4.7
%
~4.7
%
Faeces excretion;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
DDPD06707
Levonordefrin
183.2044
C9H13NO3
C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1
DB06707
164739
10304
144416
-2.0
-
-2.0
-
DRUGBANK
1000.0
mg/day
1000
mg/day
Polocaine
mepivacaine hydrochloride
PDR
7.0
mg/kg
7
mg/kg
Polocaine
mepivacaine hydrochloride
PDR
550.0
mg
550
mg
Polocaine
mepivacaine hydrochloride
PDR
DDPD06708
Lumefantrine
528.94
C30H32Cl3NO
CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1
DB06708
6437380
156095
http://www.drugs.com/pro/coartem.html
4941944
-2.0
-
-2.0
-
DRUGBANK
108.0
h
~4.5
day
DRUGBANK
99.7
%
99.7
%
DRUGBANK
DDPD06709
Methacholine
160.234
C8H18NO2
CC(C[N+](C)(C)C)OC(C)=O
DB06709
1993
6804
1916
-2.0
-
-2.0
-
DRUGBANK
0.38
mg/dose
380
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
0.758516
mg/dose
758.516
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
380.0
mcg/dose
380
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
758.516
mcg/dose
758.516
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
0.38
mg/dose
380
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
0.758516
mg/dose
758.516
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
380.0
mcg/dose
380
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
758.516
mcg/dose
758.516
mcg/dose
inhalation, IH
Provocholine
methacholine chloride
PDR
DDPD06710
Methyltestosterone
302.451
C20H30O2
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB06710
T3D4748
6010
27436
5788
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
10.0
%
10
%
Faeces excretion;
DRUGBANK
DDPD06711
Naphazoline
210.2744
C14H14N2
C(C1=NCCN1)C1=CC=CC2=CC=CC=C12
DB06711
4436
93363
4283
-2.0
-
-2.0
-
DRUGBANK
7.0
h
2-12
h
DRUGBANK
16.0
drop/day
16
drop/day
ophthalmic administration
Naphazoline
naphazoline hydrochloride
PDR
16.0
drop/day
16
drop/day
ophthalmic administration
Naphazoline
naphazoline hydrochloride
PDR
DDPD06716
Fospropofol
288.2766
C13H21O5P
CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
DB06716
3038498
135193
http://www.drugs.com/ppa/fospropofol.html
2302062
-2.0
-
-2.0
-
DRUGBANK
19000.0
ng.h/ml
19.0
ug.h/ml
intravenous injection, IV; normal,healthy;
DRUGBANK
78700.0
ng/ml
78.7
ug/ml
intravenous injection, IV; normal,healthy;
DRUGBANK
0.0666666666666667
h
4
min
intravenous injection, IV; normal,healthy;
DRUGBANK
0.28
L/h/kg
0.28
L/h/kg
Total clearance; normal,healthy;
DRUGBANK
0.31
L/h/kg
0.31
L/h/kg
Total clearance; patients;
DRUGBANK
0.33
L/kg
0.33±0.069
L/kg
DRUGBANK
5.8
L/kg
5.8
L/kg
DRUGBANK
0.81
h
0.81
h
DRUGBANK
1.13
h
1.13
h
Metabolite;
DRUGBANK
98.0
%
~98
%
DRUGBANK
DDPD06717
Fosaprepitant
614.4066
C23H22F7N4O6P
C[C@@H](O[C@H]1OCCN(CC2=NC(=O)N(N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
DB06717
219090
64321
189912
-2.0
-
-2.0
-
DRUGBANK
1.116
L/h/kg
18.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.07
L/kg
0.07
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
9-13
h
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
95.0
%
>95
%
DRUGBANK
125.0
mg/day
125
mg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
80.0
mg/day
80
mg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
115.0
mg/day
115
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
125.0
mg/day
125
mg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
80.0
mg/day
80
mg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
4.0
mg/kg/day
4
mg/kg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
115.0
mg/day
115
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
125.0
mg/day
125
mg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
80.0
mg/day
80
mg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
115.0
mg/day
115
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
125.0
mg/day
125
mg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
80.0
mg/day
80
mg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
130.0
mg/day
130
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
125.0
mg/day
125
mg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
80.0
mg/day
80
mg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
115.0
mg/day
115
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
125.0
mg/day
125
mg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
80.0
mg/day
80
mg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
150.0
mg/day
150
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
130.0
mg/day
130
mg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
3.0
mg/kg/day
3
mg/kg/day
PO, oral; day1
Fosaprepitant
fosaprepitant
PDR
2.0
mg/kg/day
2
mg/kg/day
PO, oral; day2 and day3
Fosaprepitant
fosaprepitant
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
3.0
mg/kg/day
3
mg/kg/day
intravenous injection, IV; day1
Fosaprepitant
fosaprepitant
PDR
DDPD06718
Stanozolol
328.4916
C21H32N2O
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C
DB06718
25249
9249
23582
-2.0
-
-2.0
-
DRUGBANK
24.0
h
24
h
DRUGBANK
DDPD06723
Aluminum hydroxide
78.0036
AlH3O3
[OH-].[OH-].[OH-].[Al+3]
DB06723
10176082
33130
8351587
-2.0
-
-2.0
-
DRUGBANK
23.5
%
17-30
%
DRUGBANK
0.0
%
0
%
DRUGBANK
DDPD06724
Calcium carbonate
100.087
CCaO3
[Ca++].[O-]C([O-])=O
DB06724
10112
3311
9708
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
DDPD06725
Lornoxicam
371.81
C13H10ClN3O4S2
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=C(C=C(Cl)S2)S1(=O)=O
DB06725
54690031
31783
10442760
-2.0
-
-2.0
-
DRUGBANK
95.0
%
90-100
%
DRUGBANK
66.7
%
66.7
%
Liver metabolism;
DRUGBANK
33.3
%
33.3
%
Renal metabolism;
DRUGBANK
4.0
h
3-5
h
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD06729
Sulfaphenazole
314.362
C15H14N4O2S
NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1
DB06729
5335
77780
http://www.drugs.com/international/sulfabid.html
5144
-2.0
-
-2.0
-
DRUGBANK
DDPD06736
Aceclofenac
354.18
C16H13Cl2NO4
OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
DB06736
71771
31159
64809
-2.0
-
-2.0
-
DRUGBANK
2.125
h
1.25-3
h
PO, oral;
DRUGBANK
5.0
L/h
~5
L/h
Average clearance;
DRUGBANK
25.0
L
~25
L
DRUGBANK
4.0
h
~4
h
DRUGBANK
75.0
%
70-80
%
Urinary excretion;
DRUGBANK
20.0
%
~20
%
Faeces excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD06742
Ambroxol
378.108
C13H18Br2N2O
NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1
DB06742
2132
135590
10276826
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
9.5
h
7-12
h
DRUGBANK
90.0
%
~90
%
DRUGBANK
DDPD06751
Drotaverine
397.5072
C24H31NO4
CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1
DB06751
1712095
135630
1361582
-2.0
-
-2.0
-
DRUGBANK
0.21
L/h/kg
3.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.9
L/kg
1.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.5
h
7-12
h
DRUGBANK
9.3
h
9.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.5
%
80-95
%
DRUGBANK
DDPD06755
Beta carotene
536.888
C40H56
C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C
DB06755
5280489
17579
4444129
-2.0
-
-2.0
-
DRUGBANK
26.3
ng.h/ml
26.3
mcg.h/L
Oral single dose;
DRUGBANK
0.58
ng/ml
0.58
mcg/L
Oral single dose;
DRUGBANK
6.0
h
6
h
Oral single dose;
DRUGBANK
0.00036508384
mg/L/h
0.68
nmol/L/h
PO, oral;
DRUGBANK
180.0
h
4-11
day
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
DRUGBANK
DDPD06756
Glycine betaine
117.1463
C5H11NO2
C[N+](C)(C)CC([O-])=O
DB06756
247
17750
http://www.drugs.com/pro/cystadane.html
242
-2.0
-
-2.0
-
DRUGBANK
105431.67
ng/ml
0.9±0.2
mM
Oral single dose;
DRUGBANK
0.9
h
0.9±0.3
h
Oral single dose;
DRUGBANK
0.084
L/h/kg
84.0
ml/h/kg
DRUGBANK
1.38
L/kg
1.3
L/kg
DRUGBANK
14.0
h
14
h
DRUGBANK
DDPD06757
Manganese
54.938
Mn
[Mn++]
DB06757
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
27854
29035
http://www.drugs.com/pro/manganese.html
25916
-2.0
-
-2.0
-
DRUGBANK
3e-07
mg/L
0.3
ug/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
DDPD06762
Pinacidil
245.33
C13H19N5
CC(N\C(NC#N)=N\C1=CC=NC=C1)C(C)(C)C
DB06762
91706
4660
-2.0
-
-2.0
-
DRUGBANK
0.3408
L/h/kg
5.68
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD06764
Tetryzoline
200.285
C13H16N2
C1CN=C(N1)C1CCCC2=CC=CC=C12
DB06764
5419
28674
http://www.drugs.com/international/tetryzoline.html
5226
-2.0
-
-2.0
-
DRUGBANK
DDPD06766
Alcaftadine
307.3895
C19H21N3O
CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12
DB06766
19371515
71023
http://www.drugs.com/pro/lastacaft.html
14201635
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
elimination half-life; skin/dermal;
DRUGBANK
39.2
%
39.2
%
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Lastacaft
alcaftadine
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Lastacaft
alcaftadine
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Lastacaft
alcaftadine
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Lastacaft
alcaftadine
PDR
DDPD06767
Ammonium chloride
53.49
ClH4N
[NH4+].[Cl-]
DB06767
25517
31206
23807
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
DRUGBANK
1650.0
mg/kg
1650.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD06768
Ammonium lactate
107.1085
C3H9NO3
[NH4+].CC(O)C([O-])=O
DB06768
62358
56149
-2.0
-
-2.0
-
DRUGBANK
12.0
%
12
%
skin/dermal; human cadaver;
DRUGBANK
15.0
ml/kg
>15
mL/kg
DRUGBANK
DDPD06769
Bendamustine
358.263
C16H21Cl2N3O2
CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
DB06769
65628
135515
59069
-2.0
-
-2.0
-
DRUGBANK
42.0
L/h
700.0
ml/min
DRUGBANK
0.2694
L/h/kg
4.49
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.5
L
~20-25
L
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.666666666666667
h
40
min
DRUGBANK
0.41
h
0.41
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
%
~50
%
Urinary excretion; intravenous infusion, IV in drop; tumor;
DRUGBANK
25.0
%
~25
%
Faeces excretion; intravenous infusion, IV in drop; tumor;
DRUGBANK
95.0
%
94-96
%
plasma proteins; high protein binding;
DRUGBANK
100.0
mg/m2
100
mg/m2
Treanda
bendamustine hydrochloride
PDR
120.0
mg/m2
120
mg/m2
Treanda
bendamustine hydrochloride
PDR
100.0
mg/m2
100
mg/m2
Treanda
bendamustine hydrochloride
PDR
120.0
mg/m2
120
mg/m2
Treanda
bendamustine hydrochloride
PDR
DDPD06770
Benzyl alcohol
108.1378
C7H8O
OCC1=CC=CC=C1
DB06770
244
17987
13860335
-2.0
-
-2.0
-
DRUGBANK
1250.0
mg/kg
1250.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
400.0
mg/kg
400.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
53.0
mg/kg
53.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
1.0
application/week
1
application/week
Ulesfia
benzyl alcohol
PDR
1.0
appLication/week
1
appLication/week
Ulesfia
benzyl alcohol
PDR
0.142857142857143
application/day
1
application/week
Ulesfia
benzyl alcohol
PDR
1.0
appLication/week
1
appLication/week
Ulesfia
benzyl alcohol
PDR
DDPD06771
Besifloxacin
393.84
C19H21ClFN3O3
N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O
DB06771
10178705
135622
http://www.drugs.com/besivance.html
8354210
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
7.0
h
7
h
elimination half-life; Multiple dose;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
Rattus, Rat;
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Besivance
besifloxacin
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Besivance
besifloxacin
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Besivance
besifloxacin
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Besivance
besifloxacin
PDR
DDPD06772
Cabazitaxel
835.9324
C45H57NO14
[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C
DB06772
9854073
63584
http://www.drugs.com/pro/jevtana.html
8029779
-2.0
-
-2.0
-
DRUGBANK
991.0
ng.h/ml
991.0
ng.h/ml
intravenous injection, IV; metastatic prostate cancer;
DRUGBANK
226.0
ng/ml
226
ng/ml
intravenous injection, IV; metastatic prostate cancer;
DRUGBANK
1.0
h
1
h
intravenous injection, IV; metastatic prostate cancer;
DRUGBANK
95.0
%
>95
%
Liver metabolism;
DRUGBANK
48.5
L/h
48.5
L/h
Plasma clearance; metastatic prostate cancer;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4864.0
L
4864.0
L
at steady state;
DRUGBANK
48.0
L/kg
48
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.0666666666666667
h
4
min
distribution half-life; intravenous infusion, IV in drop;
DRUGBANK
2.0
h
2
h
elimination half-life; intravenous infusion, IV in drop;
DRUGBANK
95.0
h
95
h
terminal half-life; intravenous infusion, IV in drop;
DRUGBANK
74.5
h
74.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
Rattus, Rat;
DRUGBANK
80.0
%
~80
%
intravenous infusion, IV in drop;
DRUGBANK
82.0
%
82
%
human, homo sapiens;
DRUGBANK
25.0
mg/m2
25
mg/m2
intravenous injection, IV
q3w
Jevtana
cabazitaxel
PDR
25.0
mg/m2
25
mg/m2
intravenous injection, IV
q3w
Jevtana
cabazitaxel
PDR
DDPD06774
Capsaicin
305.4119
C18H27NO3
COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
DB06774
1548943
3374
http://www.drugs.com/ppa/capsaicin.html
1265957
-2.0
-
-2.0
-
DRUGBANK
70.0
%
50-90
%
PO, oral;
DRUGBANK
2.47
ng/ml
2.47±0.13
ng/ml
PO, oral;
DRUGBANK
1.86
ng/ml
1.86
ng/ml
skin/dermal;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
0.785
h
47.1±2.0
min
PO, oral;
DRUGBANK
0.415
h
~24.9±5.0
min
PO, oral;
DRUGBANK
24.0
h
~24
h
skin/dermal;
DRUGBANK
1.64
h
1.64
h
elimination half-life; Transdermal preparations;
DRUGBANK
47.2
mg/kg
47.2
mg/kg
PO, oral; mouse;
DRUGBANK
512.0
mg/kg
>512
mg/kg
skin/dermal; mouse;
DRUGBANK
10.0
%
<10
%
Faeces excretion; animals;
DRUGBANK
4.0
application/day
4
application/day
skin/dermal
Qutenza
capsaicin
PDR
4.0
application/day
4
application/day
skin/dermal
Qutenza
capsaicin
PDR
4.0
application/day
4
application/day
skin/dermal
Qutenza
capsaicin
PDR
4.0
patches/treatment
4
patches/treatment
Transdermal preparations
Qutenza
capsaicin
PDR
4.0
appLication/day
4
appLication/day
skin ointment;skin/dermal;
Qutenza
capsaicin
PDR
5.0
times/day
5
times/day
skin/dermal
Qutenza
capsaicin
PDR
4.0
application/day
4
application/day
skin/dermal
Qutenza
capsaicin
PDR
4.0
patches/treatment
4
patches/treatment
Transdermal preparations
Qutenza
capsaicin
PDR
4.0
application/day
4
application/day
skin ointment;skin/dermal;
Qutenza
capsaicin
PDR
5.0
times/day
5
times/day
skin/dermal
Qutenza
capsaicin
PDR
DDPD06775
Carglumic acid
190.154
C6H10N2O5
NC(=O)N[C@@H](CCC(O)=O)C(O)=O
DB06775
121396
71028
http://www.drugs.com/carbaglu.html
108351
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30
%
DRUGBANK
2600.0
ng/ml
2.6(1.9-4.8)
ug/ml
DRUGBANK
342.0
L/h
5.7(3.0-9.7)
L/min
apparent clearance;
DRUGBANK
17.4
L/h
290.0
ml/min
Renal clearance;
DRUGBANK
2657.0
L
2657.0
L
Apparent volume of distribution;
DRUGBANK
5.6
h
5.6(4.3-9.5)
h
terminal half-life; intravenous infusion, IV in drop;
DRUGBANK
1000.0
mg/kg
>1000
mg/kg
PO, oral; mouse;
DRUGBANK
9.0
%
9
%
Urinary excretion; Single dose; Unchanged drug;
DRUGBANK
60.0
%
60
%
Faeces excretion; Single dose; Unchanged drug;
DRUGBANK
DDPD06777
Chenodeoxycholic acid
392.572
C24H40O4
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O
DB06777
10133
16755
http://www.drugs.com/cdi/chenodiol.html
9728
-2.0
-
-2.0
-
DRUGBANK
0.342
L/h/kg
5.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.42
h
1.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD06778
Cupric sulfate
159.609
CuO4S
[Cu++].[O-]S([O-])(=O)=O
DB06778
24462
23414
22870
-2.0
-
-2.0
-
DRUGBANK
40.0
%
20-60
%
PO, oral;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
552.0
h
13-33
day
elimination half-life;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD06781
Difluprednate
508.5515
C27H34F2O7
[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB06781
443936
31485
http://www.drugs.com/durezol.html
391990
-2.0
-
-2.0
-
DRUGBANK
78.5
%
78.5
%
Single dose; rabbit;
DRUGBANK
99.5
%
99.5
%
Single dose; rabbit;
DRUGBANK
4.0
drop/day
4
drop/day
ophthalmic administration
Durezol
difluprednate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Durezol
difluprednate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Durezol
difluprednate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Durezol
difluprednate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Durezol
difluprednate
PDR
DDPD06782
Dimercaprol
124.225
C3H8OS2
OCC(S)CS
DB06782
3080
64198
2971
-2.0
-
-2.0
-
DRUGBANK
105.0
mg/kg
~105
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
140.0
mg/kg
140.0
mg/kg
Intraperitoneal, IP;
DRUGBANK
DDPD06783
Prussian blue
859.239
C18Fe7N18
[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N.N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N
DB06783
2724251
30069
20074656
-2.0
-
-2.0
-
DRUGBANK
2.0
%
2
%
PO, oral;
DRUGBANK
0.0
%
0
%
Liver metabolism;
DRUGBANK
DDPD06784
Gallium citrate Ga-67
256.0279
C6H5GaO7
[67Ga+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
DB06784
65430
31645
http://www.drugs.com/pro/gallium-citrate-ga-67.html
58893
-2.0
-
-2.0
-
DRUGBANK
78.26
h
78.26
h
DRUGBANK
DDPD06785
Ganirelix
1570.35
C80H113ClN18O13
CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
DB06785
16130957
135910
http://www.drugs.com/mtm/ganirelix.html
17287671
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
subcutaneous injection, SC;
DRUGBANK
17.75
%
17.1-18.4
%
Urinary excretion;
DRUGBANK
2.4
L/h
2.4
L/h
Single dose;
DRUGBANK
3.3
L/h
3.3
L/h
Multiple dose;
DRUGBANK
0.0378
L/h/kg
0.63
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
43.7
L
43.7
L
Average volume of distribution; intravenous injection, IV; normal,healthy;
DRUGBANK
0.21
L/kg
0.21
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.2
h
16.2
h
DRUGBANK
9.09
h
9.09
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
75.1
%
75.1
%
Faeces excretion;
DRUGBANK
22.1
%
22.1
%
Urinary excretion;
DRUGBANK
81.9
%
81.9
%
DRUGBANK
0.25
mg/day
250
mcg/day
subcutaneous injection, SC
Ganirelix Acetate
ganirelix acetate
PDR
DDPD06786
Halcinonide
454.96
C24H32ClFO5
[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB06786
443943
31663
http://www.drugs.com/mtm/halog.html
391997
-2.0
-
-2.0
-
DRUGBANK
DDPD06787
Hexocyclium
317.496
C20H33N2O
C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
DB06787
24199
5707
22621
-2.0
-
-2.0
-
DRUGBANK
DDPD06788
Histrelin
1443.632
C70H94N18O16
CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
DB06788
56927879
63530
http://www.drugs.com/mtm/histrelin-implant.html
26606349
-2.0
-
-2.0
-
DRUGBANK
1.1
ng/ml
1.10±0.375
ng/ml
subdermal implant;
DRUGBANK
12.0
h
12
h
subdermal implant;
DRUGBANK
10.44
L/h
174.0
ml/min
Average clearance; metastatic prostate cancer; patients;
DRUGBANK
58.4
L
58.4±7.86
L
Apparent volume of distribution; subcutaneous injection, SC; normal,healthy;
DRUGBANK
1.0
1
subdermal implant
Supprelin LA
histrelin acetate
PDR
1.0
1
subdermal implant
Supprelin LA
histrelin acetate
PDR
1.0
1
subdermal implant
Supprelin LA
histrelin acetate
PDR
1.0
1
subdermal implant
Supprelin LA
histrelin acetate
PDR
DDPD06789
Hydroxyprogesterone caproate
428.6041
C27H40O4
[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB06789
169870
5812
http://www.drugs.com/makena.html
148552
-2.0
-
-2.0
-
DRUGBANK
384.0
h
16±6
day
DRUGBANK
50.0
%
~50
%
Faeces excretion; IM,intramuscular injection;
DRUGBANK
30.0
%
~30
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
35.7142857142857
mg/day
250
mg/week
IM,intramuscular injection
qw
Makena
hydroxyprogesterone caproate
PDR
39.2857142857143
mg/day
275
mg/week
subcutaneous injection, SC
qw
Makena
hydroxyprogesterone caproate
PDR
375.0
mg/dose
375
mg/dose
IM,intramuscular injection
Makena
hydroxyprogesterone caproate
PDR
1000.0
mg/dose
1000
mg/dose
IM,intramuscular injection
Makena
hydroxyprogesterone caproate
PDR
5.10204081632653
mg/day
250
mg/week
IM,intramuscular injection
qw
Makena
hydroxyprogesterone caproate
PDR
5.61224489795918
mg/day
275
mg/week
subcutaneous injection, SC
qw
Makena
hydroxyprogesterone caproate
PDR
375.0
mg/dose
375
mg/dose
IM,intramuscular injection
Makena
hydroxyprogesterone caproate
PDR
375.0
mg/dose
375
mg/dose
IM,intramuscular injection
Makena
hydroxyprogesterone caproate
PDR
375.0
mg/dose
375
mg/dose
IM,intramuscular injection
Makena
hydroxyprogesterone caproate
PDR
1000.0
mg/dose
1000
mg/dose
IM,intramuscular injection
Makena
hydroxyprogesterone caproate
PDR
DDPD06791
Lanreotide
1096.33
C54H69N11O10S2
[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]
DB06791
71349
http://www.drugs.com/mtm/lanreotide.html
64450
-2.0
-
-2.0
-
DRUGBANK
23.1
L/h
23.1
L/h
DRUGBANK
0.342
L/h/kg
5.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.1
L
15.1
L
DRUGBANK
0.2
L/kg
0.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
528.0
h
~22
day
DRUGBANK
1.03
h
1.03
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
%
<5
%
Urinary excretion;
DRUGBANK
0.5
%
<0.5
%
Faeces excretion; Unchanged drug;
DRUGBANK
4.28571428571429
mg/day
120
mg/dose
subcutaneous injection, SC
q4w
Somatuline Depot
lanreotide
PDR
4.28571428571429
mg/day
120
mg/dose
subcutaneous injection, SC
q4w
Somatuline Depot
lanreotide
PDR
DDPD06792
Lanthanum carbonate
457.835
C3La2O9
[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O
DB06792
168924
http://www.drugs.com/mtm/lanthanum-carbonate.html
147758
-2.0
-
-2.0
-
DRUGBANK
0.002
%
<0.002
%
Oral single dose;
DRUGBANK
0.002
%
<0.002
%
Oral multiple dose;
DRUGBANK
0.0
%
0
%
DRUGBANK
53.0
h
53
h
elimination half-life;
DRUGBANK
99.0
%
~99
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
94.0
%
~94
%
Faeces excretion; PO, oral; dog;
DRUGBANK
99.0
%
>99
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
4500.0
mg/day
4500
mg/day
PO, oral
Fosrenol
lanthanum carbonate
PDR
4500.0
mg/day
4500
mg/day
PO, oral
Fosrenol
lanthanum carbonate
PDR
DDPD06794
Lodoxamide
311.63
C11H6ClN3O6
OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N
DB06794
44564
135333
http://www.drugs.com/pro/alomide.html
40543
-2.0
-
-2.0
-
DRUGBANK
8.5
h
8.5
h
elimination half-life;
DRUGBANK
8.0
drop/day
8
drop/day
ophthalmic administration
Alomide
lodoxamide tromethamine
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Alomide
lodoxamide tromethamine
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Alomide
lodoxamide tromethamine
PDR
8.0
drop/day
8
drop/day
ophthalmic administration
Alomide
lodoxamide tromethamine
PDR
DDPD06795
Mafenide
186.232
C7H10N2O2S
NCC1=CC=C(C=C1)S(N)(=O)=O
DB06795
3998
6633
http://www.drugs.com/international/Mafenide.html
3858
-2.0
-
-2.0
-
DRUGBANK
0.0
0
Sulfamylon Cream
mafenide acetate
PDR
DDPD06796
Mangafodipir
691.382
C22H30MnN4O14P2
[Mn++].CC1=C(O)C(CN(CCN(CC([O-])=O)CC2=CC(COP(O)(O)=O)=NC(C)=C2O)CC([O-])=O)=CC(COP(O)(O)=O)=N1
DB06796
131704299
32700460
-2.0
-
-2.0
-
DRUGBANK
0.186
L/h/kg
~3.1
ml/min/kg
Total clearance; dog;
DRUGBANK
1.0
L/kg
0.5-1.5
L/kg
DRUGBANK
0.333333333333333
h
~20
min
distribution half-life;
DRUGBANK
0.833333333333333
h
50
min
DRUGBANK
3456.91
mg/kg
5.0
mmol/kg
mouse;
DRUGBANK
17.5
%
~15-20
%
Urinary excretion;
DRUGBANK
27.0
%
~27
%
DRUGBANK
DDPD06797
Mebutamate
232.2768
C10H20N2O4
CCC(C)C(C)(COC(N)=O)COC(N)=O
DB06797
31804
5919
-2.0
-
-2.0
-
DRUGBANK
DDPD06799
Methenamine
140.1863
C6H12N4
C1N2CN3CN1CN(C2)C3
DB06799
4101
6824
https://www.drugs.com/mtm/methenamine.html
3959
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
elimination half-life; normal renal function;
DRUGBANK
2000.0
mg/day
2
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
2000.0
mg/day
2
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
73.6
mg/kg/day
73.6
mg/kg/day
PO, oral
Hiprex
methenamine hippurate
PDR
4000.0
mg/day
4
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
2000.0
mg/day
2
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
4000.0
mg/day
4
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
2000.0
mg/day
2
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
4000.0
mg/kg/day
4
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
2000.0
mg/day
2
g/day
PO, oral
Hiprex
methenamine hippurate
PDR
DDPD06800
Methylnaltrexone
356.441
C21H26NO4
C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
DB06800
16089915
http://www.drugs.com/cdi/methylnaltrexone.html
17248532
-2.0
-
-2.0
-
DRUGBANK
175.0
ng.h/ml
175.0
ng.h/ml
DRUGBANK
117.0
ng/ml
117
ng/ml
DRUGBANK
0.5
h
0.5
h
increasing doses;
increasing doses → ;
DRUGBANK
60.0
%
60
%
DRUGBANK
5.0
%
5
%
DRUGBANK
1.3
%
1.3
%
DRUGBANK
0.63
L/h/kg
10.5±1.5
ml/min/kg
intravenous injection, IV;
DRUGBANK
1.32
L/h/kg
22
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.1
L/kg
1.1
L/kg
Steady state volume of distribution;
DRUGBANK
2.6
L/kg
2.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.89
h
8.89±2.59
h
intravenous injection, IV;
DRUGBANK
7.485
h
6.14-8.83
h
subcutaneous injection, SC;
DRUGBANK
2.5
h
2.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
primate;
DRUGBANK
50.0
%
~50
%
Urinary excretion;
DRUGBANK
50.0
%
<50
%
Faeces excretion;
DRUGBANK
85.0
%
85
%
Unchanged drug;
DRUGBANK
13.0
%
11-15
%
plasma proteins; human, homo sapiens;
DRUGBANK
0.15
mg/kg/day
0.15
mg/kg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
8.0
mg/day
8
mg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
0.15
mg/kg/day
0.15
mg/kg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
450.0
mg/day
450
mg/day
PO, oral
Relistor
methylnaltrexone bromide
PDR
0.15
mg/kg/day
0.15
mg/kg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
8.0
mg/day
8
mg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
0.15
mg/kg/day
0.15
mg/kg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
12.0
mg/day
12
mg/day
subcutaneous injection, SC
Relistor
methylnaltrexone bromide
PDR
450.0
mg/day
450
mg/day
PO, oral
Relistor
methylnaltrexone bromide
PDR
DDPD06802
Nepafenac
254.2839
C15H14N2O2
NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N
DB06802
151075
75922
http://www.drugs.com/ppa/nepafenac.html
133160
-2.0
-
-2.0
-
DRUGBANK
85.0
%
~85
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
6.0
%
~6
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
95.4
%
95.4
%
high protein binding; human, homo sapiens;
DRUGBANK
99.1
%
99.1
%
high protein binding; human, homo sapiens;
DRUGBANK
3.0
drop/day
3
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Ilevro
nepafenac
PDR
DDPD06803
Niclosamide
327.12
C13H8Cl2N2O4
OC1=C(C=C(Cl)C=C1)C(=O)NC1=C(Cl)C=C(C=C1)[N+]([O-])=O
DB06803
T3D3891
4477
7553
http://www.drugs.com/cons/niclosamide.html
4322
-2.0
-
-2.0
-
DRUGBANK
DDPD06809
Plerixafor
502.782
C28H54N8
C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
DB06809
65015
125354
http://www.drugs.com/ppa/plerixafor.html
58531
-2.0
-
-2.0
-
DRUGBANK
0.24
ng/mg
0.24
mg/kg
subcutaneous injection, SC;
DRUGBANK
0.75
h
0.5-1
h
subcutaneous injection, SC;
DRUGBANK
4.38
L/h
4.38
L/h
Plasma clearance;
DRUGBANK
3.15
L/h
3.15
L/h
Renal clearance;
DRUGBANK
0.3
L/kg
0.3
L/kg
DRUGBANK
4.4
h
4.4
h
elimination half-life; Non-Hodgkin lymphoma; patients;
DRUGBANK
5.6
h
5.6
h
elimination half-life; multiple myeloma; patients;
DRUGBANK
3.5
h
3.5
h
elimination half-life; Hodgkin's lymphoma;
DRUGBANK
0.3
h
0.3
h
distribution half-life;
DRUGBANK
16.3
mg/kg
16.3
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
50.0
mg/kg
>50
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
5.2
mg/kg
5.2
mg/kg
intravenous injection, IV; mouse; Rattus, Rat;
DRUGBANK
58.0
%
58
%
DRUGBANK
0.24
mg/kg
0.24
mg/kg
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
80.0
mg/day
20
mg/dose
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
0.24
mg/kg
0.24
mg/kg
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
160.0
mg/day
40
mg/dose
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
0.24
mg/kg
0.24
mg/kg
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
80.0
20
mg/dose
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
0.24
mg/kg
0.24
mg/kg
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
160.0
40
mg/dose
subcutaneous injection, SC
qid
Mozobil
plerixafor
PDR
DDPD06810
Plicamycin
1085.1454
C52H76O24
CO[C@@H]([C@@H]1CC2=CC3=CC(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)=C(C)C(O)=C3C(O)=C2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O
DB06810
163659
31856
http://www.drugs.com/mtm/plicamycin.html
143544
-2.0
-
-2.0
-
DRUGBANK
67.0
%
67
%
mouse;
DRUGBANK
75.0
%
75
%
mouse;
DRUGBANK
90.0
%
90
%
mouse;
DRUGBANK
DDPD06811
Polidocanol
582.8073
C30H62O10
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
DB06811
656641
46859
http://www.drugs.com/international/asclera.html
570993
-2.0
-
-2.0
-
DRUGBANK
0.25
h
15
min
DRUGBANK
18.0
L/h
0.2-0.4
L/min
Total clearance;
DRUGBANK
58.5
L
35-82
L
intravenous injection, IV;
DRUGBANK
1.5
h
~1.5
h
DRUGBANK
5.0
ml/dose
5
ml/dose
Varithena
polidocanol
PDR
15.0
ml/session
15
ml/session
Varithena
polidocanol
PDR
0.3
ml/dose
0.3
ml/dose
Varithena
polidocanol
PDR
10.0
ml/session
10
ml/session
Varithena
polidocanol
PDR
5.0
ml/dose
5
ml/dose
Varithena
polidocanol
PDR
15.0
ml/session
15
ml/session
Varithena
polidocanol
PDR
0.3
ml/dose
0.3
ml/dose
Varithena
polidocanol
PDR
10.0
ml/session
10
ml/session
Varithena
polidocanol
PDR
DDPD06812
Povidone-iodine
N.A.
N.A.
C=CN1CCCC1=O.II
DB06812
410087
8347
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
8000.0
mg/kg
8000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8100.0
mg/kg
8100.0
mg/kg
PO, oral; mouse;
DRUGBANK
1.0
appLication
1
appLication
ophthalmic administration
Betadine 5%
povidone iodine
PDR
3.0
appLication/day
3
appLication/day
skin/dermal; up to 7 days
Betadine 5%
povidone iodine
PDR
1.0
application
1
application
ophthalmic administration
Betadine 5%
povidone iodine
PDR
3.0
application/day
3
application/day
skin/dermal; up to 7 days
Betadine 5%
povidone iodine
PDR
DDPD06813
Pralatrexate
477.4726
C23H23N7O5
NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1
DB06813
148121
71223
http://www.drugs.com/cdi/pralatrexate.html
130578
-2.0
-
-2.0
-
DRUGBANK
16.5
%
13-20
%
DRUGBANK
11.46
L/h
191.0
ml/min
DRUGBANK
25.02
L/h
417.0
ml/min
DRUGBANK
13.2
L/h
220.0
ml/min
Average clearance;
DRUGBANK
37.0
L
37.0
L
DRUGBANK
105.0
L
105.0
L
DRUGBANK
15.0
h
12-18
h
DRUGBANK
35.0
%
35
%
Urinary excretion; Unchanged drug;
DRUGBANK
76.5
%
67-86
%
plasma proteins;
DRUGBANK
30.0
mg/m2
30
mg/m2
intravenous injection, IV
qw
Folotyn
pralatrexate
PDR
30.0
mg/m2
30
mg/m2
intravenous injection, IV
qw
Folotyn
pralatrexate
PDR
DDPD06815
Pyrithione
127.16
C5H5NOS
[O-][N+]1=C(S)C=CC=C1
DB06815
26041
36584
10446934
-2.0
-
-2.0
-
DRUGBANK
85.0
%
80-90
%
skin/dermal; rabbit; monkey;
DRUGBANK
1.0
%
<1
%
skin/dermal;
DRUGBANK
177.0
mg/kg
177.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
160.0
mg/kg
160.0
mg/kg
PO, oral; mouse;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
3.0
%
3
%
Urinary excretion; animals;
DRUGBANK
DDPD06816
Pyrvinium
382.53
C26H28N3
CN(C)C1=CC2=C(C=C1)[N+](C)=C(\C=C\C1=C(C)N(C(C)=C1)C1=CC=CC=C1)C=C2
DB06816
5281035
8687
21125
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
DDPD06817
Raltegravir
444.4163
C20H21FN6O5
CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
DB06817
54671008
http://www.drugs.com/monograph/isentress.html
16445111
-2.0
-
-2.0
-
DRUGBANK
9.0
h
9
h
DRUGBANK
83.0
%
83
%
DRUGBANK
600.0
mg/day
600
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
1200.0
mg/day
1200
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
400.0
mg/day
400
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
300.0
mg/day
300
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
300.0
mg/day
300
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
200.0
mg/day
200
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
160.0
mg/day
160
mg/day
Liquid
Isentress
raltegravir
PDR
150.0
mg/day
150
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
120.0
mg/day
120
mg/day
Liquid
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
PO, oral
Isentress
raltegravir
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Isentress
raltegravir
PDR
1200.0
mg/day
1200
mg/day
Isentress
raltegravir
PDR
600.0
mg/day
600
mg/day
PO, oral
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
PO, oral
Isentress
raltegravir
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Isentress
raltegravir
PDR
400.0
mg/day
400
mg/day
PO, oral
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
PO, oral
Isentress
raltegravir
PDR
800.0
mg/day
800
mg/day
PO, oral
Isentress
raltegravir
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Isentress
raltegravir
PDR
1200.0
mg/day
1200
mg/day
Isentress
raltegravir
PDR
160.0
mg/day
160
mg/day
Liquid
Isentress
raltegravir
PDR
150.0
mg/day
150
mg/day
Tablet,PO，oral
Isentress
raltegravir
PDR
120.0
mg/day
120
mg/day
Liquid
Isentress
raltegravir
PDR
80.0
mg/day
80
mg/day
Liquid
Isentress
raltegravir
PDR
60.0
mg/day
60
mg/day
Liquid
Isentress
raltegravir
PDR
50.0
mg/day
50
mg/day
Liquid
Isentress
raltegravir
PDR
30.0
mg/day
30
mg/day
Liquid
Isentress
raltegravir
PDR
20.0
mg/day
20
mg/day
Liquid
Isentress
raltegravir
PDR
16.0
mg/day
16
mg/day
Liquid
Isentress
raltegravir
PDR
7.0
mg/day
7
mg/day
Liquid
Isentress
raltegravir
PDR
5.0
mg/day
5
mg/day
Liquid
Isentress
raltegravir
PDR
4.0
mg/day
4
mg/day
Liquid
Isentress
raltegravir
PDR
DDPD06819
Phenylbutyric acid
164.2011
C10H12O2
OC(=O)CCCC1=CC=CC=C1
DB06819
4775
41500
https://www.drugs.com/cdi/sodium-phenylbutyrate.html
4611
-2.0
-
-2.0
-
DRUGBANK
218000.0
ng/ml
218
mcg/ml
Tablet, PO, oral; fasting;
DRUGBANK
195000.0
ng/ml
195
mcg/ml
PO, oral; fasting;
DRUGBANK
0.21
L/kg
0.21
L/kg
DRUGBANK
0.77
h
0.77
h
DRUGBANK
1.15
h
1.15
h
DRUGBANK
20000.0
mg/day
20
g/day
Buphenyl
sodium phenylbutyrate
PDR
20000.0
mg/day
20
g/day
Buphenyl
sodium phenylbutyrate
PDR
20000.0
mg/day
20
g/day
Buphenyl
sodium phenylbutyrate
PDR
20000.0
mg/day
20
g/day
Buphenyl
sodium phenylbutyrate
PDR
20.0
g/day
20
g/day
Buphenyl
sodium phenylbutyrate
PDR
20000.0
mg/day
20
g/day
Buphenyl
sodium phenylbutyrate
PDR
DDPD06820
Sulconazole
397.74
C18H15Cl3N2S
ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
DB06820
5318
77776
http://www.drugs.com/mtm/sulconazole-topical.html
5127
-2.0
-
-2.0
-
DRUGBANK
8.71
%
8.71
%
skin/dermal;
DRUGBANK
6.7
%
~6.7
%
Urinary excretion;
DRUGBANK
2.01
%
~2.01
%
Faeces excretion;
DRUGBANK
2.0
appLication/day
2
appLication/day
Exelderm Cream
sulconazole nitrate
PDR
2.0
application/day
2
application/day
Exelderm Cream
sulconazole nitrate
PDR
DDPD06823
Tiopronin
163.19
C5H9NO3S
CC(S)C(=O)NCC(O)=O
DB06823
5483
32229
http://www.drugs.com/cdi/tiopronin.html
5283
-2.0
-
-2.0
-
DRUGBANK
63.0
%
63
%
PO, oral; normal,healthy;
DRUGBANK
4.5
h
3-6
h
PO, oral; normal,healthy;
DRUGBANK
12.5
%
10-15
%
hydrolysis;
DRUGBANK
3.3
L/h
3.3
L/h
Renal clearance;
DRUGBANK
13.3
L/h
13.3
L/h
Renal clearance;
DRUGBANK
0.0888
L/h/kg
1.48
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
455.0
L
455.0
L
DRUGBANK
1.39
L/kg
1.39
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
53.0
h
53
h
terminal half-life; normal,healthy;
DRUGBANK
1.8
h
1.8
h
DRUGBANK
55.0
h
55
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
100.0
%
100
%
Urinary excretion;
DRUGBANK
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Thiola EC
tiopronin
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Thiola EC
tiopronin
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Thiola EC
tiopronin
PDR
50.0
mg/kg/day
50
mg/kg/day
PO, oral
Thiola EC
tiopronin
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Thiola EC
tiopronin
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Thiola EC
tiopronin
PDR
DDPD06824
Triethylenetetramine
146.2339
C6H18N4
NCCNCCNCCN
DB06824
5565
39501
21106175
-2.0
-
-2.0
-
DRUGBANK
19.0
%
8-30
%
PO, oral;
DRUGBANK
2.4
h
0.8-4
h
PO, oral;
DRUGBANK
393.0
L
393.0
L
Total volume of distribution;
DRUGBANK
252.0
L
252.0
L
Total volume of distribution;
DRUGBANK
2.65
h
1.3-4
h
elimination half-life; normal,healthy;
DRUGBANK
2.65
h
1.3-4
h
elimination half-life; Wilson's disease; patients;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1600.0
mg/kg
1600.0
mg/kg
PO, oral; mouse;
DRUGBANK
5500.0
mg/kg
5500.0
mg/kg
PO, oral; rabbit;
DRUGBANK
1500.0
mg/day
1500
mg/day
PO, oral
Syprine
trientine hydrochloride
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Syprine
trientine hydrochloride
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Syprine
trientine hydrochloride
PDR
2000.0
mg/day
2000
mg/day
PO, oral
Syprine
trientine hydrochloride
PDR
DDPD06825
Triptorelin
1311.473
C64H82N18O13
CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
DB06825
25074470
63633
http://www.drugs.com/search.php?searchterm=triptorelin
17290424
-2.0
-
-2.0
-
DRUGBANK
12.714
L/h
211.9
ml/min
Total clearance; normal,healthy; Male, men;
DRUGBANK
0.1602
L/h/kg
2.67
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
31.5
L
30-33
L
intravenous injection, IV; Single dose; normal,healthy; Male, men;
DRUGBANK
0.4
L/kg
0.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
h
6
min
distribution half-life;
DRUGBANK
0.75
h
45
min
elimination half-life;
DRUGBANK
3.0
h
3
h
terminal half-life;
DRUGBANK
2.81
h
2.81
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.5
mg/dose
22.5
mg/dose
IM,intramuscular injection; nan
q24w
Triptodur
triptorelin
PDR
0.133928571428571
mg/day
3.75
mg/dose
IM,intramuscular injection; nan
q4w
Triptodur
triptorelin
PDR
11.25
mg/dose
11.25
mg/dose
IM,intramuscular injection; nan
q12w
Triptodur
triptorelin
PDR
22.5
mg/dose
22.5
mg/dose
IM,intramuscular injection; nan
q24w
Triptodur
triptorelin
PDR
22.5
mg/dose
22.5
mg/dose
IM,intramuscular injection; nan
q24w
Triptodur
triptorelin
PDR
0.133928571428571
mg/dose
3.75
mg/dose
IM,intramuscular injection
q4w
Triptodur
triptorelin
PDR
11.25
mg/dose
11.25
mg/dose
IM,intramuscular injection; nan
q12w
Triptodur
triptorelin
PDR
22.5
mg/dose
22.5
mg/dose
IM,intramuscular injection; nan
q24w
Triptodur
triptorelin
PDR
DDPD06826
Unoprostone
382.541
C22H38O5
CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O
DB06826
5311236
39455
http://www.drugs.com/cdi/unoprostone-drops.html
4470755
-2.0
-
-2.0
-
DRUGBANK
1.5
ng/ml
<1.5
ng/ml
ophthalmic administration;
DRUGBANK
0.233333333333333
h
14
min
DRUGBANK
1000.0
mg/kg
1.0
g/kg
subcutaneous injection, SC;
DRUGBANK
93.5
mg/kg
93500.0
ug/kg
intravenous injection, IV;
DRUGBANK
DDPD07565
Chloramphenicol succinate
423.202
C15H16Cl2N2O8
O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O
DB07565
656580
3606
570947
-2.0
-
-2.0
-
DRUGBANK
11210.0
ng/ml
11.21±3.42
ug/ml
DRUGBANK
1.65
h
0.3-3
h
DRUGBANK
1.0
h
1
h
DRUGBANK
32.1
L/h
530-540
ml/min
Total clearance; normal renal function; normal hepatic function; patients;
DRUGBANK
21.24
L/h
354.0
ml/min
Total clearance; RD, renal impairment, Renal disease，including uremia; hepatopathy，LD; patients;
DRUGBANK
14.46
L/h
222-260
ml/min
Renal clearance; normal renal function; normal hepatic function; patients;
DRUGBANK
3.96
L/h
66.0
ml/min
Renal clearance; RD, renal impairment, Renal disease，including uremia; hepatopathy，LD; patients;
DRUGBANK
1.65
L/kg
0.2-3.1
L/kg
DRUGBANK
1.65
h
0.6-2.7
h
normal renal function; normal hepatic function; patients;
DRUGBANK
30.0
%
30(6-80)
%
Urinary excretion; Unchanged drug;
DRUGBANK
74.5
%
57-92
%
plasma proteins;
DRUGBANK
DDPD08439
Parecoxib
370.422
C19H18N2O4S
CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1
DB08439
119828
73038
106990
-2.0
-
-2.0
-
DRUGBANK
0.366666666666667
h
22
min
DRUGBANK
8.0
h
8
h
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD08604
Triclosan
289.542
C12H7Cl3O2
OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
DB08604
T3D3939
5564
164200
5363
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
21.0
h
21
h
terminal half-life;
DRUGBANK
3700.0
mg/kg
3700.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
9300.0
mg/kg
9300.0
mg/kg
skin/dermal;
DRUGBANK
3700.0
mg/kg
3700.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
9300.0
mg/kg
9300.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
12.0
%
12
%
Faeces excretion; mouse;
DRUGBANK
DDPD08797
Salicylamide
137.136
C7H7NO2
NC(=O)C1=CC=CC=C1O
DB08797
5147
32114
4963
-2.0
-
-2.0
-
DRUGBANK
1890.0
mg/kg
1890.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD08799
Antazoline
265.3529
C17H19N3
C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1
DB08799
2200
84115
2115
-2.0
-
-2.0
-
DRUGBANK
1.1802
L/h/kg
19.67
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.9
L/kg
3.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.29
h
2.29
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08801
Dimetindene
292.418
C20H24N2
CC(C1=C(CCN(C)C)CC2=CC=CC=C12)C1=CC=CC=N1
DB08801
21855
135222
20541
-2.0
-
-2.0
-
DRUGBANK
0.2898
L/h/kg
4.83
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.16
L/kg
2.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.6
h
4.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08804
Nandrolone decanoate
428.6472
C28H44O3
[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
DB08804
9677
7467
http://www.drugs.com/cdi/nandrolone.html
9296
-2.0
-
-2.0
-
DRUGBANK
58.0
%
58
%
DRUGBANK
DDPD08809
Dichloroacetic acid
128.942
C2H2Cl2O2
OC(=O)C(Cl)Cl
DB08809
T3D4690
6597
36386
10771217
-2.0
-
-2.0
-
DRUGBANK
0.318
L/h/kg
5.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.65
h
0.65
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2820.0
mg/kg
2820.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
510.0
mg/kg
510.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
2820.0
mg/kg
2820.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
510.0
mg/kg
510.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD08814
Triflusal
248.157
C10H7F3O4
CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O
DB08814
9458
94721
9086
-2.0
-
-2.0
-
DRUGBANK
91.5
%
83-100
%
DRUGBANK
11600.0
ng/ml
11.6
mcg/ml
DRUGBANK
92700.0
ng/ml
92.7
mcg/ml
DRUGBANK
0.88
h
0.88
h
DRUGBANK
4.96
h
4.96
h
DRUGBANK
0.8
L/h
0.8±0.2
L/h
Renal clearance;
DRUGBANK
0.18
L/h
0.18±1 0.04
L/h
Renal clearance; Drug combination;
DRUGBANK
34.0
L
34.0
L
DRUGBANK
0.5
h
0.5±0.1
h
DRUGBANK
34.3
h
34.3±5.3
h
Metabolite;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD08815
Lurasidone
492.676
C28H36N4O2S
[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O
DB08815
213046
70735
http://www.drugs.com/cdi/lurasidone.html
184739
-2.0
-
-2.0
-
DRUGBANK
14.0
%
9-19
%
DRUGBANK
2.5
h
1-4
h
DRUGBANK
3.5
h
1.5-5.5
h
PO, oral; food;
DRUGBANK
234.12
L/h
3902.0
ml/min
DRUGBANK
6173.0
L
6173.0
L
DRUGBANK
18.0
h
18
h
DRUGBANK
33.0
h
29-37
h
DRUGBANK
9.0
%
~9
%
Urinary excretion;
DRUGBANK
80.0
%
~80
%
Faeces excretion;
DRUGBANK
99.0
%
~99
%
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Latuda
lurasidone hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Latuda
lurasidone hydrochloride
PDR
80.0
mg/day
80
mg/day
PO, oral
Latuda
lurasidone hydrochloride
PDR
160.0
mg/day
160
mg/day
PO, oral
Latuda
lurasidone hydrochloride
PDR
DDPD08816
Ticagrelor
522.568
C23H28F2N6O4S
CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1
DB08816
9871419
68558
http://www.drugs.com/cdi/ticagrelor.html
8047109
-2.0
-
-2.0
-
DRUGBANK
6675.0
ng.h/ml
6675.0
ng.h/ml
Oral single dose;
DRUGBANK
2538.0
ng.h/ml
2538.0
ng.h/ml
Oral single dose; Active metabolite;
DRUGBANK
36.0
%
36
%
PO, oral;
DRUGBANK
923.0
ng/ml
923
ng/ml
Oral single dose;
DRUGBANK
264.0
ng/ml
264
ng/ml
Oral single dose; Active metabolite;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
3.0
h
3.0
h
Oral single dose; Active metabolite;
DRUGBANK
0.00584
L/h
0.00584
L/h
Renal clearance;
DRUGBANK
0.2028
L/h/kg
3.38
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
88.0
L
88.0
L
Steady state volume of distribution;
DRUGBANK
1.25
L/kg
1.25
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
~8
h
elimination half-life;
DRUGBANK
12.0
h
~12
h
elimination half-life; Active metabolite;
DRUGBANK
6.8
h
6.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
57.8
%
57.8
%
Faeces excretion;
DRUGBANK
26.5
%
26.5
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
180.0
mg/day
180
mg/day
PO, oral
Brilinta
ticagrelor
PDR
180.0
mg/day
180
mg/day
PO, oral
Brilinta
ticagrelor
PDR
DDPD08818
Hyaluronic acid
776.6486
C28H44N2O23
CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O
DB08818
24759
23145
-2.0
-
-2.0
-
DRUGBANK
2400.0
mg/kg
>2400
mg/kg
PO, oral; mouse;
DRUGBANK
4000.0
mg/kg
>4000
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
DDPD08819
Tafluprost
452.5313
C25H34F2O5
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1
DB08819
9868491
66899
http://www.drugs.com/zioptan.html
8044182
-2.0
-
-2.0
-
DRUGBANK
0.0688333333333333
ng.h/ml
394-432
pg.min/ml
ophthalmic administration; Active metabolite;
DRUGBANK
0.026
ng/ml
26
pg/ml
ophthalmic administration; Active metabolite;
DRUGBANK
0.166666666666667
h
10
min
ophthalmic administration; Active metabolite;
DRUGBANK
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Zioptan
tafluprost
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
qd
Zioptan
tafluprost
PDR
DDPD08820
Ivacaftor
392.4907
C24H28N2O3
CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C
DB08820
16220172
66901
http://www.drugs.com/kalydeco.html
17347474
-2.0
-
-2.0
-
DRUGBANK
10600.0
ng.h/ml
10600.0
ng.h/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
768.0
ng/ml
768
ng/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
4.0
h
4
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
17.3
L/h
17.3
L/h
normal,healthy;
DRUGBANK
353.0
L
353(122)
L
Apparent volume of distribution; PO, oral; normal,healthy; food;
DRUGBANK
12.0
h
~12
h
terminal half-life; Single dose;
DRUGBANK
13.0
h
12-14
h
different study;
DRUGBANK
87.8
%
87.8
%
Faeces excretion; PO, oral;
DRUGBANK
99.0
%
~99
%
plasma proteins;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
150.0
mg/day
150
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
100.0
mg/day
100
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
50.0
mg/day
50
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
300.0
mg/day
300
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
300.0
mg/day
300
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
300.0
mg/day
300
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
150.0
mg/day
150
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
100.0
mg/day
100
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
50.0
mg/day
50
mg/day
PO, oral
Kalydeco
ivacaftor
PDR
DDPD08822
Azilsartan medoxomil
568.5336
C30H24N4O8
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1
DB08822
11238823
68845
http://www.drugs.com/ingredient/azilsartan-medoxomil.html
9413866
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
PO, oral; food;
food → ;
DRUGBANK
2.25
h
1.5-3
h
PO, oral; food;
food → ;
DRUGBANK
16.0
L
16.0
L
DRUGBANK
11.0
h
11
h
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD08823
Spinosad
1477.963
C83H132N2O20
[H][C@]1(C[C@@]2([H])C=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC.[H][C@]1(C[C@@]2([H])C(C)=C[C@@]3([H])[C@]4([H])CC(=O)O[C@@]([H])(CC)CCC[C@]([H])(O[C@@]5([H])CC[C@]([H])(N(C)C)[C@@]([H])(C)O5)[C@@]([H])(C)C(=O)C4=C[C@@]3([H])[C@]2([H])C1)O[C@]1([H])O[C@@]([H])(C)[C@]([H])(OC)[C@@]([H])(OC)[C@@]1([H])OC
DB08823
17754356
39211
http://www.drugs.com/mtm/spinosad-topical.html
16736513
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
skin/dermal;
DRUGBANK
120.0
ml/application
120
ml/application
Natroba
spinosad
PDR
120.0
ml/appLication
120
ml/appLication
Natroba
spinosad
PDR
120.0
ml/application
120
ml/application
Natroba
spinosad
PDR
120.0
ml/appLication
120
ml/appLication
Natroba
spinosad
PDR
DDPD08824
Ioflupane I-123
427.291
C18H23FINO2
[H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF
DB08824
3086674
68855
http://www.drugs.com/mtm/ioflupane-i-123.html
2343241
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
intravenous injection, IV;
DRUGBANK
13.2
h
13.2
h
DRUGBANK
60.0
%
~60
%
Urinary excretion;
DRUGBANK
14.0
%
~14
%
Faeces excretion;
DRUGBANK
DDPD08826
Deferiprone
139.1519
C7H9NO2
CN1C=CC(=O)C(O)=C1C
DB08826
2972
68554
http://www.drugs.com/mtm/deferiprone.html
2866
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral; fasting;
DRUGBANK
2.0
h
2
h
PO, oral; food;
DRUGBANK
1.0
L/kg
1.0
L/kg
normal,healthy; patients;
DRUGBANK
1.6
L/kg
1.6
L/kg
thalassemia; patients;
DRUGBANK
1.9
h
1.9
h
DRUGBANK
10.0
%
<10
%
plasma proteins;
DRUGBANK
99.0
mg/kg/day
99
mg/kg/day
PO, oral
Ferriprox Tablets
deferiprone
PDR
99.0
mg/kg/day
99
mg/kg/day
PO, oral
Ferriprox Tablets
deferiprone
PDR
0.0
0
Ferriprox Tablets
deferiprone
PDR
0.0
0
Ferriprox Tablets
deferiprone
PDR
DDPD08827
Lomitapide
693.7204
C39H37F6N3O2
FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12
DB08827
9853053
72297
http://www.drugs.com/juxtapid.html
8028764
-2.0
-
-2.0
-
DRUGBANK
7.0
%
7
%
Oral single dose;
DRUGBANK
6.0
h
6
h
Oral single dose;
DRUGBANK
0.522
L/h/kg
8.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1138.5
L
985-1292
L
Steady state volume of distribution;
DRUGBANK
16.3
L/kg
16.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39.7
h
~39.7
h
DRUGBANK
39.7
h
39.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
56.2
%
~52.9-59.5
%
Urinary excretion;
DRUGBANK
34.25
%
~33.4-35.1
%
Faeces excretion;
DRUGBANK
99.8
%
~99.8
%
plasma proteins;
DRUGBANK
60.0
mg/day
60
mg/day
PO, oral
Juxtapid
lomitapide
PDR
60.0
mg/day
60
mg/day
PO, oral
Juxtapid
lomitapide
PDR
DDPD08828
Vismodegib
421.297
C19H14Cl2N2O3S
CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1
DB08828
24776445
66903
http://www.drugs.com/mtm/vismodegib.html
23337846
-2.0
-
-2.0
-
DRUGBANK
31.8
%
31.8
%
PO, oral; food;
food → ;
DRUGBANK
0.0006
L/h/kg
0.01
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.5
L
16.4-26.6
L
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
288.0
h
12
day
Single dose;
DRUGBANK
96.0
h
4
day
Multiple dose;
DRUGBANK
245.0
h
245
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
82.0
%
82
%
Faeces excretion;
DRUGBANK
4.4
%
4.4
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Erivedge
vismodegib
PDR
150.0
mg/day
150
mg/day
PO, oral
Erivedge
vismodegib
PDR
DDPD08842
Acetylcarnitine
203.238
C9H17NO4
CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C
DB08842
7045767
57589
5406074
-2.0
-
-2.0
-
DRUGBANK
DDPD08860
Pitavastatin
421.4608
C25H24FNO4
O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC(O)=O
DB08860
5282452
32020
http://www.drugs.com/ppa/pitavastatin.html
4445604
-2.0
-
-2.0
-
DRUGBANK
51.0
%
51
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
43.4
L/h
43.4
L/h
apparent clearance; Oral single dose;
DRUGBANK
0.351
L/h/kg
5.85
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
148.0
L
148.0
L
DRUGBANK
0.9
L/kg
0.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
~12
h
elimination half-life;
DRUGBANK
4.6
h
4.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.0
%
15
%
Urinary excretion; Oral single dose;
DRUGBANK
79.0
%
79
%
Faeces excretion; Oral single dose;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
4.0
mg/day
4
mg/day
PO, oral
Livalo
pitavastatin
PDR
4.0
mg/day
4
mg/day
PO, oral
Livalo
pitavastatin
PDR
4.0
mg/day
4
mg/day
PO, oral
Livalo
pitavastatin
PDR
4.0
mg/day
4
mg/day
PO, oral
Livalo
pitavastatin
PDR
DDPD08862
Cholecystokinin
N.A.
N.A.
CCC(C)C(C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(C1=CC=C(C=C1)OS(=O)(=O)O)C(=O)NC(CCSC)C(=O)NCC(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC4=CC=CC=C4)C(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC5=CNC=N5)NC(=O)C(CO)NC(=O)C6CCCN6C(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CO)NC(=O)C7CCCN7C(=O)C(C)NC(=O)C(CCCCN)N
DB08862
16129670
-2.0
-
-2.0
-
DRUGBANK
0.0416666666666667
h
2.5
min
DRUGBANK
2730.0
mg/kg
2730.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD08864
Rilpivirine
366.4185
C22H18N6
CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
DB08864
6451164
68606
http://www.drugs.com/cdi/rilpivirine.html
4953643
-2.0
-
-2.0
-
DRUGBANK
2235.0
ng.h/ml
2235.0
ng.h/ml
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
11.15
L/h
10.5-11.8
L/h
apparent clearance; PO, oral;
DRUGBANK
162.5
L
152-173
L
Apparent volume of distribution; AIDS,HIV; patients;
DRUGBANK
44.5
h
34-55
h
PO, oral;
DRUGBANK
85.0
%
85
%
Faeces excretion;
DRUGBANK
6.0
%
6
%
Urinary excretion;
DRUGBANK
25.0
%
25
%
Faeces excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
Edurant
rilpivirine
PDR
50.0
mg/day
50
mg/day
PO, oral
Edurant
rilpivirine
PDR
25.0
mg/day
25
mg/day
PO, oral
Edurant
rilpivirine
PDR
50.0
mg/day
50
mg/day
PO, oral
Edurant
rilpivirine
PDR
25.0
mg/day
25
mg/day
PO, oral
Edurant
rilpivirine
PDR
50.0
mg/day
50
mg/day
PO, oral
Edurant
rilpivirine
PDR
25.0
mg/day
25
mg/day
PO, oral
Edurant
rilpivirine
PDR
50.0
mg/day
50
mg/day
PO, oral
Edurant
rilpivirine
PDR
DDPD08865
Crizotinib
450.337
C21H22Cl2FN5O
[H][C@](C)(OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
DB08865
11626560
64310
http://www.drugs.com/cdi/crizotinib.html
9801307
-2.0
-
-2.0
-
DRUGBANK
43.0
%
43
%
Oral single dose;
DRUGBANK
5.0
h
4-6
h
Oral single dose;
DRUGBANK
360.0
h
15
day
PO, oral;
DRUGBANK
0.585
L/h/kg
9.75
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1772.0
L
1772.0
L
Average volume of distribution; intravenous injection, IV;
DRUGBANK
22.15
L/kg
22.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
42.0
h
42
h
terminal half-life; patients;
DRUGBANK
38.9
h
38.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
63.0
%
63
%
Faeces excretion; Single dose; normal,healthy; human, homo sapiens;
DRUGBANK
22.0
%
22
%
Urinary excretion; Single dose; normal,healthy; human, homo sapiens;
DRUGBANK
53.0
%
53
%
Faeces excretion; Unchanged drug;
DRUGBANK
2.3
%
2.3
%
Urinary excretion; Unchanged drug;
DRUGBANK
91.0
%
91
%
plasma proteins;
DRUGBANK
500.0
mg/day
500
mg/day
PO, oral
Xalkori
crizotinib
PDR
500.0
mg/day
500
mg/day
PO, oral
Xalkori
crizotinib
PDR
DDPD08867
Ulipristal
433.592
C28H35NO3
CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12
DB08867
13559281
71025
http://www.drugs.com/cdi/ulipristal.html
19349271
-2.0
-
-2.0
-
DRUGBANK
556.0
ng.h/ml
556±260
ng.h/ml
Oral single dose; normal,healthy;
DRUGBANK
176.0
ng/ml
176±89
ng/ml
Oral single dose; normal,healthy;
DRUGBANK
1.5
h
1-2
h
Oral single dose; normal,healthy;
DRUGBANK
76.8
L/h
76.8±64.0
L/h
Average clearance; Oral single dose; normal,healthy;
DRUGBANK
32.4
h
32.4±6.3
h
elimination half-life; Oral single dose; normal,healthy;
DRUGBANK
94.0
%
>94
%
plasma proteins;
DRUGBANK
30.0
mg/dose
30
mg/dose
PO, oral
Ella
ulipristal acetate
PDR
30.0
mg/dose
30
mg/dose
PO, oral
Ella
ulipristal acetate
PDR
DDPD08868
Fingolimod
307.4708
C19H33NO2
CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
DB08868
107970
63115
http://www.drugs.com/cdi/fingolimod.html
97087
-2.0
-
-2.0
-
DRUGBANK
91.5
%
90-93
%
PO, oral;
DRUGBANK
14.0
h
12-16
h
PO, oral;
DRUGBANK
1080.0
h
1-2
month
PO, oral;
DRUGBANK
6.3
L/h
6.3±2.3
L/h
DRUGBANK
0.0918
L/h/kg
1.53
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1200.0
L
1200±260
L
DRUGBANK
17.3
L/kg
17.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
180.0
h
6-9
day
DRUGBANK
180.0
h
6-9
day
Active metabolite;
DRUGBANK
144.0
h
144
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
450.0
mg/kg
300-600
mg/kg
Rattus, Rat;
DRUGBANK
99.7
%
>99.7
%
DRUGBANK
0.5
mg/day
0.5
mg/day
PO, oral
Gilenya
fingolimod
PDR
0.25
mg/day
0.25
mg/day
PO, oral
Gilenya
fingolimod
PDR
0.5
mg/day
0.5
mg/day
PO, oral
Gilenya
fingolimod
PDR
0.5
mg/day
0.5
mg/day
PO, oral
Gilenya
fingolimod
PDR
0.25
mg/day
0.25
mg/day
PO, oral
Gilenya
fingolimod
PDR
0.5
mg/day
0.5
mg/day
PO, oral
Gilenya
fingolimod
PDR
DDPD08869
Tesamorelin
5005.76
C216H360N72O63S
CC\C=C\CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O
DB08869
56928011
63626
http://www.drugs.com/egrifta.html
34999256
-2.0
-
-2.0
-
DRUGBANK
4.0
%
<4
%
subcutaneous injection, SC; normal,healthy;
DRUGBANK
9.4
L/kg
9.4±3.1
L/kg
normal,healthy; patients;
DRUGBANK
10.5
L/kg
10.5±6.1
L/kg
AIDS,HIV; patients;
DRUGBANK
0.433333333333333
h
26
min
normal,healthy;
DRUGBANK
0.633333333333333
h
38
min
AIDS,HIV; patients;
DRUGBANK
1.4
mg/day
1.4
mg/day
subcutaneous injection, SC
Egrifta
tesamorelin
PDR
2.0
mg/day
2
mg/day
subcutaneous injection, SC
Egrifta
tesamorelin
PDR
1.4
mg/day
1.4
mg/day
subcutaneous injection, SC
Egrifta
tesamorelin
PDR
2.0
mg/day
2
mg/day
subcutaneous injection, SC
Egrifta
tesamorelin
PDR
DDPD08871
Eribulin
729.908
C40H59NO11
[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@H]7O[C@@]8(C[C@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2
DB08871
73425383
63587
http://www.drugs.com/halaven.html
24721813
-2.0
-
-2.0
-
DRUGBANK
1.79
L/h/m2
1.16-2.42
L/h/m2
DRUGBANK
0.045
L/h/kg
0.75
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
78.5
L/m2
43-114
L/m2
DRUGBANK
1.46
L/kg
1.46
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
h
~40
h
DRUGBANK
37.8
h
37.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
57.0
%
49-65
%
DRUGBANK
1.4
mg/m2
1.4
mg/m2
intravenous injection, IV
Halaven
eribulin mesylate
PDR
1.4
mg/m2
1.4
mg/m2
intravenous injection, IV
Halaven
eribulin mesylate
PDR
DDPD08872
Gabapentin enacarbil
329.393
C16H27NO6
CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
DB08872
9883933
68840
http://www.drugs.com/sfx/gabapentin-enacarbil-side-effects.html
8059607
-2.0
-
-2.0
-
DRUGBANK
6.0
L/h
5.0-7
L/h
Renal clearance;
DRUGBANK
76.0
L
76.0
L
DRUGBANK
5.55
h
5.1-6.0
h
elimination half-life;
DRUGBANK
94.0
%
94
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
Faeces excretion;
DRUGBANK
3.0
%
<3
%
plasma proteins;
DRUGBANK
DDPD08873
Boceprevir
519.6767
C27H45N5O5
[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C
DB08873
10324367
68621
http://www.drugs.com/cdi/boceprevir.html
8499830
-2.0
-
-2.0
-
DRUGBANK
2.0
h
2
h
DRUGBANK
161.0
L/h
161.0
L/h
Average clearance;
DRUGBANK
772.0
L
772.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
3.4
h
3.4
h
DRUGBANK
79.0
%
79
%
Faeces excretion;
DRUGBANK
9.0
%
9
%
Urinary excretion;
DRUGBANK
75.0
%
~75
%
plasma proteins; Single dose; human, homo sapiens;
DRUGBANK
2400.0
mg/day
2400
mg/day
PO, oral
Victrelis
boceprevir
PDR
2400.0
mg/day
2400
mg/day
PO, oral
Victrelis
boceprevir
PDR
DDPD08874
Fidaxomicin
1058.05
C52H74Cl2O18
[H][C@@]1(O[C@@H]2[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\C(=O)O[C@@H](C\C=C(/C)\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O
DB08874
70678896
68590
http://www.drugs.com/ppa/fidaxomicin.html
8209640
-2.0
-
-2.0
-
DRUGBANK
5.2
ng/ml
5.20±2.81
ng/ml
PO, oral; normal,healthy; adults;
DRUGBANK
12.0
ng/ml
12.0±6.06
ng/ml
PO, oral; normal,healthy; adults; Active metabolite;
DRUGBANK
2.0
h
2
h
DRUGBANK
11.7
h
11.7±4.80
h
normal,healthy; adults; Oral single dose;
DRUGBANK
200.0
mg/kg
~200
mg/kg
Rattus, Rat;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Dificid
fidaxomicin
PDR
400.0
mg/day
400
mg/day
PO, oral
Dificid
fidaxomicin
PDR
DDPD08875
Cabozantinib
501.514
C28H24FN3O5
COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
DB08875
25102847
72317
http://www.drugs.com/mtm/cabozantinib.html
25948202
-2.0
-
-2.0
-
DRUGBANK
3.5
h
2-5
h
PO, oral;
DRUGBANK
4.4
L/h
4.4
L/h
at steady state;
DRUGBANK
349.0
L
349.0
L
DRUGBANK
55.0
h
55
h
DRUGBANK
54.0
%
54
%
Faeces excretion;
DRUGBANK
27.0
%
27
%
Urinary excretion;
DRUGBANK
99.7
%
>99.7
%
plasma proteins;
DRUGBANK
140.0
mg/day
140
mg/day
PO, oral
Cometriq
cabozantinib
PDR
180.0
mg/day
180
mg/day
PO, oral
Cometriq
cabozantinib
PDR
100.0
mg/day
100
mg/day
PO, oral
Cometriq
cabozantinib
PDR
60.0
mg/day
60
mg/day
PO, oral
Cometriq
cabozantinib
PDR
80.0
mg/day
80
mg/day
PO, oral
Cometriq
cabozantinib
PDR
40.0
mg/day
40
mg/day
PO, oral
Cometriq
cabozantinib
PDR
140.0
mg/day
140
mg/day
PO, oral
Cometriq
cabozantinib
PDR
180.0
mg/day
180
mg/day
PO, oral
Cometriq
cabozantinib
PDR
100.0
mg/day
100
mg/day
PO, oral
Cometriq
cabozantinib
PDR
60.0
mg/day
60
mg/day
PO, oral
Cometriq
cabozantinib
PDR
80.0
mg/day
80
mg/day
PO, oral
Cometriq
cabozantinib
PDR
40.0
mg/day
40
mg/day
PO, oral
Cometriq
cabozantinib
PDR
DDPD08877
Ruxolitinib
306.365
C17H18N6
N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
DB08877
25126798
66919
http://www.drugs.com/mtm/ruxolitinib.html
25027389
-2.0
-
-2.0
-
DRUGBANK
198.830885
ng/ml
649
nmol/L
PO, oral; normal,healthy;
DRUGBANK
1.5
h
1.5
h
PO, oral; normal,healthy;
DRUGBANK
18.7
L/h
18.7
L/h
normal,healthy;
DRUGBANK
76.6
L
76.6
L
normal,healthy;
DRUGBANK
2.8
h
2.8
h
elimination half-life; normal,healthy;
DRUGBANK
74.0
%
74
%
Urinary excretion;
DRUGBANK
22.0
%
22
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Faeces excretion; Unchanged drug;
DRUGBANK
97.0
%
97
%
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
bid
Jakafi
ruxolitinib
PDR
25.0
mg/day
25
mg/day
PO, oral
bid
Jakafi
ruxolitinib
PDR
10.0
mg/day
10
mg/day
PO, oral
bid
Jakafi
ruxolitinib
PDR
10.0
mg/day
10
mg/day
PO, oral
bid
Jakafi
ruxolitinib
PDR
25.0
mg/day
25
mg/day
PO, oral
bid
Jakafi
ruxolitinib
PDR
10.0
mg/day
10
mg/day
PO, oral
bid
Jakafi
ruxolitinib
PDR
DDPD08880
Teriflunomide
270.2073
C12H9F3N2O2
C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
DB08880
54684141
68540
http://www.drugs.com/mtm/teriflunomide.html
16737143
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
0.0305
L/h
30.5
ml/h
Total clearance; intravenous injection, IV;
DRUGBANK
0.00042
L/h/kg
0.007
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
L
11.0
L
intravenous injection, IV; Single dose;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
444.0
h
18-19
day
DRUGBANK
350.0
h
350
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
37.5
%
37.5
%
Faeces excretion;
DRUGBANK
22.6
%
22.6
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
14.0
mg/day
14
mg/day
PO, oral
Aubagio
teriflunomide
PDR
14.0
mg/day
14
mg/day
PO, oral
Aubagio
teriflunomide
PDR
DDPD08881
Vemurafenib
489.922
C23H18ClF2N3O3S
CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
DB08881
42611257
63637
http://www.drugs.com/mtm/vemurafenib.html
24747352
-2.0
-
-2.0
-
DRUGBANK
601000.0
ng.h/ml
601.0
mcg.h/ml
PO, oral; patients;
DRUGBANK
62000.0
ng/ml
62
mcg/ml
PO, oral; patients;
DRUGBANK
3.0
h
3
h
PO, oral; patients;
DRUGBANK
5.0
%
5
%
DRUGBANK
95.0
%
95
%
Unchanged drug;
DRUGBANK
1.29166666666667
L/h
31.0
L/day
Total clearance;
DRUGBANK
106.0
L
106.0
L
DRUGBANK
57.0
h
57(30-120)
h
elimination half-life;
DRUGBANK
94.0
%
94
%
Faeces excretion;
DRUGBANK
1.0
%
1
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
1920.0
mg/day
1920
mg/day
PO, oral
Zelboraf
vemurafenib
PDR
1920.0
mg/day
1920
mg/day
PO, oral
Zelboraf
vemurafenib
PDR
DDPD08882
Linagliptin
472.5422
C25H28N8O2
CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=C(C=CC=C3)C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
DB08882
10096344
68610
http://www.drugs.com/cdi/linagliptin.html
8271879
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30
%
PO, oral;
DRUGBANK
90.0
%
90
%
Urinary excretion; Faeces excretion;
DRUGBANK
22.44
L/h
374.0
ml/min
Total clearance;
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1110.0
L
1110.0
L
intravenous injection, IV; Single dose;
DRUGBANK
960.0
L
380-1540
L
intravenous infusion, IV in drop; Single dose;
DRUGBANK
16.0
L/kg
16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
155.0
h
155
h
terminal half-life;
DRUGBANK
129.0
h
129
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.7
%
84.7
%
Faeces excretion;
DRUGBANK
5.4
%
5.4
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
DRUGBANK
82.0
%
75-89
%
DRUGBANK
5.0
mg/day
5
mg/day
PO, oral
Tradjenta
linagliptin
PDR
5.0
mg/day
5
mg/day
PO, oral
Tradjenta
linagliptin
PDR
DDPD08883
Perampanel
349.393
C23H15N3O
O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1
DB08883
9924495
71013
http://www.drugs.com/mtm/perampanel.html
8100130
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
0.72
L/h
12.0
ml/min
normal,healthy; patients;
DRUGBANK
0.006
L/h/kg
0.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.36
L/kg
1.36
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
105.0
h
~105
h
elimination half-life;
DRUGBANK
183.0
h
183
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
48.0
%
48
%
Faeces excretion;
DRUGBANK
22.0
%
22
%
Urinary excretion;
DRUGBANK
95.5
%
95-96
%
plasma proteins;
DRUGBANK
12.0
mg/day
12
mg/day
PO, oral
Fycompa
perampanel
PDR
12.0
mg/day
12
mg/day
PO, oral
Fycompa
perampanel
PDR
12.0
mg/day
12
mg/day
PO, oral
Fycompa
perampanel
PDR
12.0
mg/day
12
mg/day
PO, oral
Fycompa
perampanel
PDR
DDPD08884
Gadoxetic acid
681.75
C23H30GdN3O11
[Gd+3].[H][C@@](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)(CC1=CC=C(OCC)C=C1)N(CC(O)=O)CC(O)=O
DB08884
131704314
http://www.drugs.com/mtm/gadoxetate.html
189907
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
15.0
L/h
250.0
ml/min
Plasma clearance;
DRUGBANK
7.2
L/h
120.0
ml/min
Renal clearance;
DRUGBANK
0.21
L/kg
0.21
L/kg
Total volume of distribution; at steady state;
DRUGBANK
0.93
h
0.91-0.95
h
elimination half-life; normal,healthy; adults;
DRUGBANK
18100.0
mg/kg
18100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
14500.0
mg/kg
14500.0
mg/kg
PO, oral; mouse;
DRUGBANK
5450.0
mg/kg
3600-7300
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
8150.0
mg/kg
5400-10900
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
2200.0
mg/kg
>2200
mg/kg
intravenous injection, IV; dog;
DRUGBANK
10.0
%
<10
%
DRUGBANK
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.025
mmol/kg/dose
0.025
mmol/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.025
mmoL/kg/dose
0.025
mmoL/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.1
ml/kg/dose
0.1
mL/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.025
mmol/kg/dose
0.025
mmol/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.025
mmol/kg/dose
0.025
mmol/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.1
ml/kg/dose
0.1
ml/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
0.025
mmoL/kg/dose
0.025
mmoL/kg/dose
intravenous injection, IV
Eovist
gadoxetate disodium
PDR
DDPD08887
Icosapent ethyl
330.5042
C22H34O2
CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
DB08887
9831415
84883
http://www.drugs.com/cdi/icosapent-ethyl.html
8007147
-2.0
-
-2.0
-
DRUGBANK
5.0
h
5
h
PO, oral;
DRUGBANK
0.684
L/h
684.0
ml/h
Plasma clearance;
DRUGBANK
88.0
L
88.0
L
Steady state volume of distribution;
DRUGBANK
89.0
h
89
h
DRUGBANK
4000.0
mg/day
4
g/day
PO, oral
Vascepa
icosapent ethyl
PDR
4000.0
mg/day
4
g/day
PO, oral
Vascepa
icosapent ethyl
PDR
DDPD08889
Carfilzomib
719.9099
C40H57N5O7
CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
DB08889
11556711
65347
http://www.drugs.com/kyprolis.html
9731489
-2.0
-
-2.0
-
DRUGBANK
379.0
ng.h/ml
379.0
ng.h/ml
DRUGBANK
4232.0
ng/ml
4232
ng/ml
DRUGBANK
207.0
L/h
151 - 263
L/h
Total clearance;
DRUGBANK
2.37
L/h/kg
39.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.0
L
28.0
L
at steady state;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
<=1
h
intravenous injection, IV;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
97.0
%
97
%
DRUGBANK
70.0
mg/m2/dose
70
mg/m2/dose
intravenous injection, IV
Kyprolis
carfilzomib
PDR
2.2
m2
2.2
m2
skin/dermal
Kyprolis
carfilzomib
PDR
154.0
mg
154
mg
intravenous injection, IV
Kyprolis
carfilzomib
PDR
70.0
mg/m2/dose
70
mg/m2/dose
intravenous injection, IV
Kyprolis
carfilzomib
PDR
2.2
m2
2.2
m2
skin/dermal
Kyprolis
carfilzomib
PDR
154.0
mg
154
mg
intravenous injection, IV
Kyprolis
carfilzomib
PDR
DDPD08890
Linaclotide
1526.736
C59H79N15O21S6
[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
DB08890
16158208
68551
http://www.drugs.com/cdi/linaclotide.html
17314504
-2.0
-
-2.0
-
DRUGBANK
0.0
0
Linzess
linaclotide
PDR
0.29
mg/day
290
mcg/day
PO, oral
Linzess
linaclotide
PDR
0.29
mg/day
290
mcg/day
PO, oral
Linzess
linaclotide
PDR
0.0
0
Linzess
linaclotide
PDR
0.0
0
Linzess
linaclotide
PDR
DDPD08893
Mirabegron
396.506
C21H24N4O2S
NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1
DB08893
9865528
65349
http://www.drugs.com/cdi/mirabegron.html
8041219
-2.0
-
-2.0
-
DRUGBANK
29.0
%
29
%
PO, oral;
DRUGBANK
35.0
%
35
%
PO, oral;
DRUGBANK
3.5
h
3.5
h
PO, oral; normal,healthy;
DRUGBANK
168.0
h
7
day
PO, oral;
DRUGBANK
57.0
L/h
57.0
L/h
Total clearance; intravenous injection, IV;
DRUGBANK
13.0
L/h
13.0
L/h
Renal clearance;
DRUGBANK
0.816
L/h/kg
13.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1670.0
L
1670.0
L
at steady state; intravenous injection, IV;
DRUGBANK
23.8
L/kg
23.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
50.0
h
50
h
elimination half-life;
DRUGBANK
50.0
h
50
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
55.0
%
55
%
Urinary excretion;
DRUGBANK
34.0
%
34
%
Faeces excretion;
DRUGBANK
25.0
%
~25
%
Urinary excretion; Unchanged drug;
DRUGBANK
0.0
%
0
%
Faeces excretion; Unchanged drug;
DRUGBANK
71.0
%
71
%
plasma proteins;
DRUGBANK
50.0
mg/day
50
mg/day
PO, oral
Myrbetriq
mirabegron
PDR
50.0
mg/day
50
mg/day
PO, oral
Myrbetriq
mirabegron
PDR
DDPD08895
Tofacitinib
312.3696
C16H20N6O
[H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
DB08895
9926791
71200
http://www.drugs.com/pro/xeljanz.html
8102425
-2.0
-
-2.0
-
DRUGBANK
74.0
%
74
%
PO, oral;
DRUGBANK
74.0
%
74
%
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
0.3528
L/h/kg
5.88
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
87.0
L
87.0
L
intravenous injection, IV;
DRUGBANK
1.24
L/kg
1.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.0
h
~3
h
DRUGBANK
30.0
%
30
%
Unchanged drug;
DRUGBANK
40.0
%
40
%
DRUGBANK
DDPD08896
Regorafenib
482.815
C21H15ClF4N4O3
CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
DB08896
11167602
68647
http://www.drugs.com/cdi/regorafenib.html
9342697
-2.0
-
-2.0
-
DRUGBANK
70400.0
ng.h/ml
70.4
ug.h/ml
DRUGBANK
2500.0
ng/ml
2.5
ug/ml
DRUGBANK
4.0
h
4
h
DRUGBANK
28.0
h
28(14-58)
h
DRUGBANK
71.0
%
~71
%
Faeces excretion; PO, oral;
DRUGBANK
19.0
%
19
%
Urinary excretion; PO, oral;
DRUGBANK
99.5
%
99.5
%
plasma proteins; human, homo sapiens;
DRUGBANK
160.0
mg/day
160
mg/day
PO, oral; on days 1 to 21
Stivarga
regorafenib
PDR
160.0
mg/day
160
mg/day
PO, oral; on days 1 to 21
Stivarga
regorafenib
PDR
DDPD08897
Aclidinium
484.651
C26H30NO4S2
OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
DB08897
11434515
65346
http://www.drugs.com/tudorza.html
9609381
-2.0
-
-2.0
-
DRUGBANK
6.0
%
6
%
normal,healthy;
DRUGBANK
0.166666666666667
h
10
min
normal,healthy;
DRUGBANK
48.0
h
2
day
normal,healthy;
DRUGBANK
170.0
L/h
170.0
L/h
Total clearance; intravenous injection, IV; normal,healthy; young;
DRUGBANK
300.0
L
300.0
L
intravenous injection, IV;
DRUGBANK
0.04
h
2.4
min
elimination half-life;
DRUGBANK
6.5
h
5-8
h
effective half-life;
DRUGBANK
59.5
%
~54-65
%
Urinary excretion; intravenous injection, IV; normal,healthy; human, homo sapiens;
DRUGBANK
26.5
%
~20-33
%
Faeces excretion; intravenous injection, IV; normal,healthy; human, homo sapiens;
DRUGBANK
0.8
mg/day
800
mcg/day
PO, oral
Tudorza Pressair
aclidinium bromide
PDR
2.0
actuations/day
2
actuations/day
PO, oral
Tudorza Pressair
aclidinium bromide
PDR
0.8
mg/day
800
mcg/day
PO, oral
Tudorza Pressair
aclidinium bromide
PDR
2.0
actuations/day
2
actuations/day
PO, oral
Tudorza Pressair
aclidinium bromide
PDR
DDPD08899
Enzalutamide
464.436
C21H16F4N4O2S
CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
DB08899
15951529
68534
http://www.drugs.com/cdi/enzalutamide.html
13093347
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
DRUGBANK
672.0
h
28
day
Active metabolite;
DRUGBANK
0.56
L/h
0.56
L/h
apparent clearance; Oral single dose;
DRUGBANK
110.0
L
110.0
L
Apparent volume of distribution; Oral single dose;
DRUGBANK
139.2
h
5.8(2.8-10.2)
day
terminal half-life; patients; Oral single dose;
DRUGBANK
196.8
h
7.8-8.6
day
terminal half-life; normal,healthy; Oral single dose;
DRUGBANK
71.0
%
71
%
Urinary excretion;
DRUGBANK
14.0
%
14
%
Faeces excretion;
DRUGBANK
0.056
%
0.056
%
Faeces excretion; Unchanged drug;
DRUGBANK
97.5
%
97-98
%
plasma proteins;
DRUGBANK
160.0
mg/day
160
mg/day
PO, oral
Xtandi
enzalutamide
PDR
160.0
mg/day
160
mg/day
PO, oral
Xtandi
enzalutamide
PDR
DDPD08901
Ponatinib
532.5595
C29H27F3N6O
CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
DB08901
24826799
78543
http://www.drugs.com/mtm/ponatinib.html
24747381
-2.0
-
-2.0
-
DRUGBANK
1253.0
ng.h/ml
1253.0
ng.h/ml
DRUGBANK
73.0
ng/ml
73
ng/ml
DRUGBANK
6.0
h
6
h
PO, oral;
DRUGBANK
64.0
%
64
%
DRUGBANK
1223.0
L
1223.0
L
Steady state volume of distribution; PO, oral; tumor; patients;
DRUGBANK
24.0
h
24(12-66)
h
elimination half-life; tumor; patients; Oral multiple dose;
DRUGBANK
87.0
%
~87
%
Faeces excretion; Oral single dose;
DRUGBANK
5.0
%
~5
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
45.0
mg/day
45
mg/day
PO, oral
Iclusig
ponatinib
PDR
30.0
mg/day
30
mg/day
PO, oral
Iclusig
ponatinib
PDR
45.0
mg/day
45
mg/day
PO, oral
Iclusig
ponatinib
PDR
30.0
mg/day
30
mg/day
PO, oral
Iclusig
ponatinib
PDR
DDPD08903
Bedaquiline
555.505
C32H31BrN2O2
COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2
DB08903
5388906
72292
4534966
-2.0
-
-2.0
-
DRUGBANK
64750.0
ng.h/ml
64.75
ug.h/ml
PO, oral;
DRUGBANK
5500.0
ng/ml
5.5
ug/ml
PO, oral;
DRUGBANK
5.0
h
5
h
PO, oral;
DRUGBANK
164.0
L
164.0
L
Total volume of distribution;
DRUGBANK
3960.0
h
5.5
month
elimination half-life;
DRUGBANK
3960.0
h
5.5
month
elimination half-life;
DRUGBANK
99.9
%
>99.9
%
plasma proteins;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Sirturo
bedaquiline
PDR
200.0
mg/day
200
mg/day
PO, oral
Sirturo
bedaquiline
PDR
400.0
mg/day
400
mg/day
PO, oral
Sirturo
bedaquiline
PDR
400.0
mg/day
400
mg/day
PO, oral
Sirturo
bedaquiline
PDR
200.0
mg/day
200
mg/day
PO, oral
Sirturo
bedaquiline
PDR
400.0
mg/day
400
mg/day
PO, oral
Sirturo
bedaquiline
PDR
DDPD08905
Formestane
302.4079
C19H26O3
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C
DB08905
11273
75172
http://www.drugs.com/international/formestane.html
10799
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
IM,intramuscular injection;
DRUGBANK
14.5155792
ng/ml
48±20.9
nmol/L
IM,intramuscular injection;
DRUGBANK
36.0
h
24-48
h
IM,intramuscular injection;
DRUGBANK
4.2
L/h
4.2
L/h
Plasma clearance; intravenous injection, IV;
DRUGBANK
1.8
L/kg
1.8
L/kg
DRUGBANK
0.3
h
18
min
elimination half-life; intravenous injection, IV;
DRUGBANK
95.0
%
>95
%
Urinary excretion;
DRUGBANK
5.0
%
<5
%
Faeces excretion;
DRUGBANK
DDPD08906
Fluticasone furoate
538.576
C27H29F3O6S
[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB08906
9854489
74899
http://www.drugs.com/cdi/fluticasone-furoate-spray.html
8030195
-2.0
-
-2.0
-
DRUGBANK
0.5
%
0.50
%
intranasal;
DRUGBANK
1.26
%
1.26
%
PO, oral;
DRUGBANK
13.9
%
13.9
%
inhalation, IH;
DRUGBANK
12.35
%
6.3-18.4
%
inhalation, IH; normal,healthy; postmenopausal women;
DRUGBANK
57.8
L/h
57.8
L/h
DRUGBANK
71.8
L/h
71.8
L/h
intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
0.804
L/h/kg
13.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
608.0
L
608.0
L
at steady state; intravenous injection, IV;
DRUGBANK
661.0
L
661.0
L
Average volume of distribution; at steady state;
DRUGBANK
704.0
L
704.0
L
at steady state; intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
4.95
L/kg
4.95
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
15.1
h
15.1
h
intranasal;
DRUGBANK
24.0
h
24
h
inhalation, IH;
DRUGBANK
13.6
h
13.6
h
intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
20.6
h
17.3-23.9
h
inhalation, IH; normal,healthy; Caucasian; Male, men;
DRUGBANK
10.6
h
10.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
≥90
%
Faeces excretion;
DRUGBANK
1.5
%
1-2
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD08907
Canagliflozin
444.516
C24H25FO5S
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
DB08907
24812758
73274
http://www.drugs.com/invokana.html
26333259
-2.0
-
-2.0
-
DRUGBANK
65.0
%
65
%
PO, oral;
DRUGBANK
4.5
h
4-5
h
PO, oral;
DRUGBANK
11.52
L/h
192.0
ml/min
intravenous injection, IV; normal,healthy;
DRUGBANK
0.0855
L/h
1.3-1.55
ml/min
Renal clearance;
DRUGBANK
0.1644
L/h/kg
2.74
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
83.5
L
83.5
L
at steady state; intravenous injection, IV; Single dose; normal,healthy; patients;
DRUGBANK
1.19
L/kg
1.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.6
h
10.6
h
terminal half-life;
DRUGBANK
13.1
h
13.1
h
terminal half-life;
DRUGBANK
10.3
h
10.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
51.7
%
51.7
%
Faeces excretion;
DRUGBANK
33.0
%
~33
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Invokana
canagliflozin
PDR
300.0
mg/day
300
mg/day
PO, oral
Invokana
canagliflozin
PDR
DDPD08908
Dimethyl fumarate
144.1253
C6H8O4
[H]\C(=C(\[H])C(=O)OC)C(=O)OC
DB08908
637568
76004
http://www.drugs.com/cdi/dimethyl-fumarate.html
553171
-2.0
-
-2.0
-
DRUGBANK
1870.0
ng/ml
1.87
mg/L
Active metabolite;
DRUGBANK
2.5
h
2.5
h
Active metabolite;
DRUGBANK
63.0
L
53-73
L
normal,healthy;
DRUGBANK
1.0
h
~1
h
DRUGBANK
60.0
%
60
%
lung excretion;
DRUGBANK
16.0
%
16
%
Urinary excretion;
DRUGBANK
1.0
%
1
%
Faeces excretion;
DRUGBANK
480.0
mg/day
480
mg/day
PO, oral
Tecfidera
dimethyl fumarate
PDR
480.0
mg/day
480
mg/day
PO, oral
Tecfidera
dimethyl fumarate
PDR
DDPD08909
Glycerol phenylbutyrate
530.6512
C33H38O6
O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1
DB08909
10482134
134745
http://www.drugs.com/cdi/glycerol-phenylbutyrate.html
8657541
-2.0
-
-2.0
-
DRUGBANK
37000.0
ng/ml
37.0
ug/ml
Oral single dose; fasting; Active metabolite;
DRUGBANK
14900.0
ng/ml
14.9
ug/ml
Oral single dose; fasting; Active metabolite;
DRUGBANK
30200.0
ng/ml
30.2
ug/ml
Oral single dose; fasting; Active metabolite;
DRUGBANK
2.0
h
2
h
Oral single dose; fasting; Active metabolite;
DRUGBANK
4.0
h
4
h
Oral single dose; fasting; Active metabolite;
DRUGBANK
4.0
h
4
h
Oral single dose; fasting; Active metabolite;
DRUGBANK
8.0
h
8
h
PO, oral; adults; Urea Cycle Disorder;
DRUGBANK
10.0
h
10
h
PO, oral; adults; Urea Cycle Disorder;
DRUGBANK
12.0
h
12
h
PO, oral; adults; Urea Cycle Disorder;
DRUGBANK
68.9
%
68.9
%
Urinary excretion; adults; human, homo sapiens;
DRUGBANK
66.5
%
66.5
%
Urinary excretion; Children; usual childhood diseases; human, homo sapiens;
DRUGBANK
36.0
%
27-45
%
plasma proteins;
DRUGBANK
17.5
ml/day
17.5
ml/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
19000.0
mg/day
19
g/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
17.5
ml/day
17.5
ml/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
19000.0
mg/day
19
g/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
17.5
ml/day
17.5
ml/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
19000.0
mg/day
19
g/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
17.5
ml/day
17.5
ml/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
19000.0
mg/day
19
g/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
17.5
ml/day
17.5
ml/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
19.0
g/day
19
g/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
17.5
ml/day
17.5
ml/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
19000.0
mg/day
19
g/day
PO, oral
Ravicti
glycerol phenylbutyrate
PDR
DDPD08910
Pomalidomide
273.2441
C13H11N3O4
NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
DB08910
134780
72690
http://www.drugs.com/cdi/pomalidomide.html
118785
-2.0
-
-2.0
-
DRUGBANK
400.0
ng.h/ml
400.0
ng.h/ml
PO, oral; multiple myeloma;
DRUGBANK
75.0
ng/ml
75
ng/ml
PO, oral; multiple myeloma;
DRUGBANK
2.5
h
2-3
h
Oral single dose;
DRUGBANK
8.5
L/h
7.0-10
L/h
Total clearance;
DRUGBANK
100.0
L
62-138
L
Apparent volume of distribution; at steady state;
DRUGBANK
9.4
h
9.4
h
normal,healthy;
DRUGBANK
7.5
h
7.5
h
multiple myeloma; patients;
DRUGBANK
73.0
%
73
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
15.0
%
15
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
2.0
%
2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
8.0
%
8
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
28.0
%
12-44
%
Plasma Concentration → ;
DRUGBANK
4.0
mg/day
4
mg/day
PO, oral
Pomalyst
pomalidomide
PDR
4.0
mg/day
4
mg/day
PO, oral
Pomalyst
pomalidomide
PDR
DDPD08911
Trametinib
615.3948
C26H23FIN5O4
CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
DB08911
11707110
75998
http://www.drugs.com/mekinist.html
9881833
-2.0
-
-2.0
-
DRUGBANK
72.0
%
72
%
Oral single dose;
DRUGBANK
22.2
ng/ml
22.2
ng/ml
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral; BRAF V600 mutation-positive melanoma;
DRUGBANK
4.9
L/h
4.9
L/h
apparent clearance;
DRUGBANK
0.048
L/h/kg
0.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
214.0
L
214.0
L
Apparent volume of distribution;
DRUGBANK
13.94
L/kg
13.94
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
104.4
h
3.9-4.8
day
elimination half-life;
DRUGBANK
229.0
h
229
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
80
%
Faeces excretion;
DRUGBANK
0.1
%
<0.1
%
Urinary excretion;
DRUGBANK
97.4
%
97.4
%
plasma proteins; human, homo sapiens;
DRUGBANK
2.0
mg/day
2
mg/day
PO, oral
Mekinist
trametinib
PDR
2.0
mg/day
2
mg/day
PO, oral
Mekinist
trametinib
PDR
DDPD08912
Dabrafenib
519.562
C23H20F3N5O2S2
CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
DB08912
44462760
75045
http://www.drugs.com/tafinlar.html
25948204
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
17.0
L/h
17.0
L/h
Single dose;
DRUGBANK
34.4
L/h
34.4
L/h
Multiple dose;
DRUGBANK
0.1716
L/h/kg
2.86
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.3
L
70.3
L
Apparent volume of distribution;
DRUGBANK
0.65
L/kg
0.65
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8
h
terminal half-life; PO, oral;
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
Rattus, Rat;
DRUGBANK
99.7
%
99.7
%
plasma proteins; human, homo sapiens;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Tafinlar
dabrafenib
PDR
300.0
mg/day
300
mg/day
PO, oral
Tafinlar
dabrafenib
PDR
DDPD08913
Radium Ra 223 dichloride
293.924
Cl2Ra
[Cl-].[Cl-].[223Ra++]
DB08913
74895
http://www.drugs.com/xofigo.html
28528370
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
intravenous injection, IV;
DRUGBANK
273.6
h
11.4
day
DRUGBANK
13.0
%
13
%
Faeces excretion;
DRUGBANK
2.0
%
2
%
Urinary excretion;
DRUGBANK
0.0
%
~0
%
plasma proteins;
DRUGBANK
1.49
microcurie/kg
1.49
microcurie/kg
Xofigo
radium Ra 223 dichloride
PDR
55.0
kBq/kg
55
kBq/kg
Xofigo
radium Ra 223 dichloride
PDR
0.00149
mg/kg
1.49
microcurie/kg
Xofigo
radium Ra 223 dichloride
PDR
55.0
kBq/kg
55
kBq/kg
Xofigo
radium Ra 223 dichloride
PDR
DDPD08916
Afatinib
485.938
C24H25ClFN5O3
CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1
DB08916
10184653
61390
http://www.drugs.com/gilotrif.html
8360155
-2.0
-
-2.0
-
DRUGBANK
3.5
h
2-5
h
PO, oral;
DRUGBANK
91.8
L/h
1530.0
ml/min
apparent clearance; normal,healthy; Male, men;
DRUGBANK
4500.0
L
4500.0
L
normal,healthy; Male, men;
DRUGBANK
37.0
h
37
h
effective half-life;
DRUGBANK
344.0
h
344
h
terminal half-life; Multiple dose; patients;
DRUGBANK
85.9
%
85.9
%
Faeces excretion; PO, oral; human, homo sapiens;
DRUGBANK
4.3
%
4.3
%
Urinary excretion; PO, oral; human, homo sapiens;
DRUGBANK
95.0
%
~95
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
40.0
mg/day
40
mg/day
PO, oral
Gilotrif
afatinib
PDR
50.0
mg/day
50
mg/day
PO, oral
Gilotrif
afatinib
PDR
40.0
mg/day
40
mg/day
PO, oral
Gilotrif
afatinib
PDR
50.0
mg/day
50
mg/day
PO, oral
Gilotrif
afatinib
PDR
DDPD08917
Ferric carboxymaltose
N.A.
N.A.
C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3]
DB08917
86278165
http://www.drugs.com/international/ferric-carboxymaltose.html
-2.0
-
-2.0
-
DRUGBANK
185000.0
ng/ml
37-333
ug/ml
PO, oral; iron deficient;
DRUGBANK
0.73
h
0.25-1.21
h
PO, oral; iron deficient;
DRUGBANK
3.0
L
3.0
L
DRUGBANK
9.5
h
7-12
h
DRUGBANK
1500.0
mg/course
1500
mg/course
intravenous injection, IV
Injectafer
ferric carboxymaltose
PDR
1500.0
mg/course
1500
mg/course
intravenous injection, IV
Injectafer
ferric carboxymaltose
PDR
DDPD08918
Levomilnacipran
246.348
C15H22N2O
CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
DB08918
6917779
136040
5293005
-2.0
-
-2.0
-
DRUGBANK
5196.0
ng.h/ml
5196.0
ng.h/ml
Capsule, PO, Oral; extended release formulation;
DRUGBANK
341.0
ng/ml
341
ng/ml
Capsule, PO, Oral; extended release formulation;
DRUGBANK
7.0
h
6-8
h
PO, oral;
DRUGBANK
25.0
L/h
21-29
L/h
apparent clearance;
DRUGBANK
430.0
L
387-473
L
Apparent volume of distribution;
DRUGBANK
12.0
h
12
h
DRUGBANK
58.0
%
58
%
Urinary excretion; Unchanged drug;
DRUGBANK
22.0
%
22
%
plasma proteins; human, homo sapiens;
DRUGBANK
120.0
mg/day
120
mg/day
PO, oral
Fetzima
levomilnacipran
PDR
120.0
mg/day
120
mg/day
PO, oral
Fetzima
levomilnacipran
PDR
DDPD08930
Dolutegravir
419.3788
C20H19F2N3O5
[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2
DB08930
54726191
76010
http://www.drugs.com/cdi/dolutegravir.html
25051637
-2.0
-
-2.0
-
DRUGBANK
53600.0
ng.h/ml
53.6
mcg.h/ml
PO, oral; AIDS,HIV;
DRUGBANK
46000.0
ng.h/ml
46.0
mcg.h/ml
PO, oral; Caucasian; AIDS,HIV;
DRUGBANK
3670.0
ng/ml
3.67
mcg/ml
PO, oral; AIDS,HIV;
DRUGBANK
3490.0
ng/ml
3.49
mcg/ml
PO, oral; Caucasian; AIDS,HIV;
DRUGBANK
2.5
h
2-3
h
PO, oral; AIDS,HIV;
DRUGBANK
120.0
h
5
day
PO, oral; AIDS,HIV;
DRUGBANK
1.0
L/h
1.0
L/h
apparent clearance;
DRUGBANK
17.4
L
17.4
L
Apparent volume of distribution;
DRUGBANK
14.0
h
14
h
DRUGBANK
31.0
%
31
%
Urinary excretion;
DRUGBANK
98.9
%
98.9
%
plasma proteins; human, homo sapiens;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Tivicay
dolutegravir
PDR
70.0
mg/day
70
mg/day
PO, oral
Tivicay
dolutegravir
PDR
100.0
mg/day
100
mg/day
PO, oral
Tivicay
dolutegravir
PDR
100.0
mg/day
100
mg/day
PO, oral
Tivicay
dolutegravir
PDR
70.0
mg/day
70
mg/day
PO, oral
Tivicay
dolutegravir
PDR
100.0
mg/day
100
mg/day
PO, oral
Tivicay
dolutegravir
PDR
DDPD08931
Riociguat
422.4157
C20H19FN8O2
COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2
DB08931
11304743
76018
http://www.drugs.com/international/riociguat.html
9479719
-2.0
-
-2.0
-
DRUGBANK
94.0
%
94
%
PO, oral; food;
food → ;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
0.0444
L/h/kg
0.74
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
30.0
L
30.0
L
at steady state;
DRUGBANK
0.44
L/kg
0.44
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
~12
h
patients;
DRUGBANK
7.0
h
7
h
normal,healthy;
DRUGBANK
9.1
h
9.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
%
40
%
Urinary excretion;
DRUGBANK
53.0
%
53
%
Faeces excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
7.5
mg/day
2.5
mg/dose
PO, oral
tid
Adempas
riociguat
PDR
7.5
mg/day
2.5
mg/dose
PO, oral
tid
Adempas
riociguat
PDR
DDPD08932
Macitentan
588.273
C19H20Br2N6O4S
CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1
DB08932
16004692
76607
http://www.drugs.com/cons/macitentan.html
13134960
-2.0
-
-2.0
-
DRUGBANK
8.0
h
8
h
PO, oral;
DRUGBANK
50.0
L
50.0
L
DRUGBANK
16.0
h
16
h
DRUGBANK
48.0
h
48
h
Active metabolite;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
24.0
%
24
%
Faeces excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
10.0
mg/day
10
mg/day
PO, oral
Opsumit
macitentan
PDR
10.0
mg/day
10
mg/day
PO, oral
Opsumit
macitentan
PDR
DDPD08933
Luliconazole
354.27
C14H9Cl2N3S2
ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1
DB08933
3003141
34825
http://www.drugs.com/ingredient/luliconazole.html
2273807
-2.0
-
-2.0
-
DRUGBANK
0.4
ng/ml
0.40±0.76
ng/ml
PO, oral; tinea pedis;
DRUGBANK
16.9
h
16.9±9.39
h
PO, oral; tinea pedis;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
DDPD08934
Sofosbuvir
529.458
C22H29FN3O9P
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
DB08934
45375808
85083
http://www.drugs.com/sovaldi.html
26286922
-2.0
-
-2.0
-
DRUGBANK
567.0
ng/ml
567
ng/ml
PO, oral;
DRUGBANK
1.25
h
0.5-2
h
PO, oral;
DRUGBANK
0.4
h
0.4
h
terminal half-life;
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
14.0
%
14
%
Faeces excretion;
DRUGBANK
2.5
%
2.5
%
lung excretion;
DRUGBANK
63.0
%
~61-65
%
plasma proteins; human, homo sapiens;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
200.0
mg/day
200
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
150.0
mg/day
150
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
400.0
mg/day
400
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
400.0
mg/day
400
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
200.0
mg/day
200
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
400.0
mg/day
400
mg/day
PO, oral
Sovaldi
sofosbuvir
PDR
DDPD08936
Chlorcyclizine
300.826
C18H21ClN2
CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
DB08936
2710
94402
http://www.drugs.com/international/chlorcyclizine.html
2609
-2.0
-
-2.0
-
DRUGBANK
12.0
h
~12
h
DRUGBANK
87.5
%
~85-90
%
DRUGBANK
DDPD08942
Isoxicam
335.335
C14H13N3O5S
CN1C(C(=O)NC2=NOC(C)=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O
DB08942
54677972
76163
10442695
-2.0
-
-2.0
-
DRUGBANK
0.0042
L/h/kg
0.07
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.19
L/kg
0.19
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
33.0
h
33
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08943
Isoconazole
416.129
C18H14Cl4N2O
ClC1=CC(Cl)=C(C=C1)C(CN1C=CN=C1)OCC1=C(Cl)C=CC=C1Cl
DB08943
3760
83667
3629
-2.0
-
-2.0
-
DRUGBANK
DDPD08947
Iopamidol
777.0853
C17H22I3N3O8
C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I
DB08947
65492
31711
http://www.drugs.com/international/Iopamidol.html
58940
-2.0
-
-2.0
-
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.28
L/kg
0.28
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08949
Inositol nicotinate
810.732
C42H30N6O12
O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1
DB08949
3720
31699
http://www.drugs.com/international/inositol-nicotinate.html
16736141
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
PO, oral;
DRUGBANK
8.0
h
6-10
h
PO, oral;
DRUGBANK
3.924
L/h/kg
65.4±19
ml/min/kg
Average clearance; intravenous injection, IV;
DRUGBANK
1.051
L/kg
1051±250
mL/kg
Average volume of distribution; intravenous injection, IV;
DRUGBANK
1.0
h
~1
h
elimination half-life; normal,healthy; human, homo sapiens; adults;
DRUGBANK
DDPD08950
Indoramin
347.4534
C22H25N3O
O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C1=CC=CC=C1
DB08950
33625
135470
http://www.drugs.com/international/indoramin.html
31014
-2.0
-
-2.0
-
DRUGBANK
1.2
L/h/kg
20
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.9
L/kg
4.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.3
h
4.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08954
Ifenprodil
325.4446
C21H27NO2
CC(C(O)C1=CC=C(O)C=C1)N1CCC(CC2=CC=CC=C2)CC1
DB08954
3689
93829
http://www.drugs.com/international/ifenprodil.html
3561
-2.0
-
-2.0
-
DRUGBANK
3.8742
L/h/kg
64.57
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.99
L/kg
18.99
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.32
h
4.32
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08964
Gemeprost
394.552
C23H38O5
CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(=O)OC
DB08964
5282237
135626
4445416
-2.0
-
-2.0
-
DRUGBANK
20.0
%
12-28
%
DRUGBANK
2.5
h
2-3
h
Vaginal Administration;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
DDPD08966
Fursultiamine
398.543
C17H26N4O3S2
C\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\CCO)SSCC1CCCO1
DB08966
3002119
135636
2273321
-2.0
-
-2.0
-
DRUGBANK
DDPD08971
Fluocortolone
376.4617
C22H29FO4
[H][C@@]1(C)C[C@@]2([H])[C@]3([H])C[C@]([H])(F)C4=CC(=O)C=C[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]2(C)[C@@]1([H])C(=O)CO
DB08971
9053
135581
8701
-2.0
-
-2.0
-
DRUGBANK
0.42
L/h/kg
7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.68
L/kg
0.68
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
h
1.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08976
Floctafenine
406.3552
C20H17F3N2O4
OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C=CC=C12)C(F)(F)F
DB08976
76958517
31612
3243
-2.0
-
-2.0
-
DRUGBANK
DDPD08981
Fenbufen
254.2806
C16H14O3
OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
DB08981
3335
31599
3218
-2.0
-
-2.0
-
DRUGBANK
DDPD08985
Etilefrine
181.2316
C10H15NO2
CCNCC(O)C1=CC(O)=CC=C1
DB08985
3306
91518
3190
-2.0
-
-2.0
-
DRUGBANK
0.84
L/h/kg
14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
L/kg
2.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD08987
Etidocaine
276.417
C17H28N2O
CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
DB08987
37497
4904
34400
-2.0
-
-2.0
-
DRUGBANK
DDPD08988
Ethoheptazine
261.3593
C16H23NO2
CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1
DB08988
6469
135074
http://www.drugs.com/international/ethoheptazine.html
6225
-2.0
-
-2.0
-
DRUGBANK
DDPD09009
Articaine
284.374
C13H20N2O3S
CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC
DB09009
32170
91834
http://www.drugs.com/monograph/articaine-hydrochloride.html
29837
-2.0
-
-2.0
-
DRUGBANK
7.602
L/h/kg
126.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.7
L/kg
7.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.98
h
0.98
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD09015
Canrenoic acid
358.478
C22H30O4
[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C
DB09015
656615
50156
http://www.drugs.com/international/potassium-canrenoate.html
570976
-2.0
-
-2.0
-
DRUGBANK
DDPD09019
Bromhexine
376.13
C14H20Br2N2
CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1
DB09019
2442
77032
http://www.drugs.com/international/bromhexine.html
2348
-2.0
-
-2.0
-
DRUGBANK
DDPD09020
Bisacodyl
361.3906
C22H19NO4
CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1
DB09020
2391
3125
http://www.drugs.com/monograph/bisacodyl.html
2299
-2.0
-
-2.0
-
DRUGBANK
15.0
%
15
%
DRUGBANK
16.0
h
16
h
DRUGBANK
10.0
mg/day
10
mg/day
Rectal Administration
Fleet Bisacodyl Enema
bisacodyl
PDR
15.0
mg/day
15
mg/day
PO, oral
Fleet Bisacodyl Enema
bisacodyl
PDR
5.0
mg/day
5
mg/day
PO, oral;Rectal Administration;
Fleet Bisacodyl Enema
bisacodyl
PDR
15.0
mg/day
15
mg/day
PO, oral
Fleet Bisacodyl Enema
bisacodyl
PDR
10.0
mg/day
10
mg/day
Rectal Administration
Fleet Bisacodyl Enema
bisacodyl
PDR
15.0
mg/day
15
mg/day
PO, oral
Fleet Bisacodyl Enema
bisacodyl
PDR
10.0
mg/day
10
mg/day
Rectal Administration
Fleet Bisacodyl Enema
bisacodyl
PDR
15.0
mg/day
15
mg/day
PO, oral
Fleet Bisacodyl Enema
bisacodyl
PDR
10.0
mg/day
10
mg/day
Rectal Administration
Fleet Bisacodyl Enema
bisacodyl
PDR
DDPD09026
Aliskiren
551.7583
C30H53N3O6
COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
DB09026
5493444
601027
http://www.drugs.com/cdi/aliskiren.html
4591452
-2.0
-
-2.0
-
DRUGBANK
2.25
%
2-2.5
%
PO, oral;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
180.0
h
7-8
day
PO, oral;
DRUGBANK
80.0
%
80
%
Unchanged drug; PO, oral;
DRUGBANK
2.0
%
1-3
%
DRUGBANK
1.28
L/h
1280±500
ml/h
Renal clearance; normal,healthy;
DRUGBANK
35.0
h
30-40
h
elimination half-life;
DRUGBANK
24.0
h
~24
h
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.6
%
0.6
%
Urinary excretion;
DRUGBANK
80.0
%
>80
%
Faeces excretion;
DRUGBANK
25.0
%
~25
%
Urinary excretion; Unchanged drug;
DRUGBANK
49.0
%
47-51
%
plasma proteins;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Aliskiren
aliskiren
PDR
150.0
mg/day
150
mg/day
PO, oral
Aliskiren
aliskiren
PDR
0.0
0
Aliskiren
aliskiren
PDR
300.0
mg/day
300
mg/day
PO, oral
Aliskiren
aliskiren
PDR
300.0
mg/day
300
mg/day
PO, oral
Aliskiren
aliskiren
PDR
150.0
mg/day
150
mg/day
PO, oral
Aliskiren
aliskiren
PDR
300.0
mg/day
300
mg/day
PO, oral
Aliskiren
aliskiren
PDR
0.0
0
Aliskiren
aliskiren
PDR
0.0
0
Aliskiren
aliskiren
PDR
DDPD09027
Ledipasvir
888.9999
C49H54F2N8O6
COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC=C2NC(=NC2=C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C
DB09027
67505836
85089
http://www.drugs.com/cdi/ledipasvir-and-sofosbuvir.html
29271894
-2.0
-
-2.0
-
DRUGBANK
323.0
ng/ml
323
ng/ml
PO, oral;
DRUGBANK
4.25
h
4-4.5
h
PO, oral;
DRUGBANK
47.0
h
47
h
DRUGBANK
86.0
%
~86
%
Faeces excretion; Oral single dose;
DRUGBANK
1.0
%
~1
%
Urinary excretion; Oral single dose;
DRUGBANK
99.8
%
>99.8
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09030
Vorapaxar
492.5817
C29H33FN2O4
[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC
DB09030
10077130
82702
http://www.drugs.com/zontivity.html
8252668
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral; food;
food → ;
DRUGBANK
1.0
h
1
h
PO, oral; fasting;
DRUGBANK
0.0204
L/h/kg
0.34
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
424.0
L
424.0
L
DRUGBANK
3.74
L/kg
3.74
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
84.0
h
3-4
day
effective half-life;
DRUGBANK
192.0
h
8
day
terminal half-life;
DRUGBANK
149.0
h
149
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
2.08
mg/day
2.08
mg/day
PO, oral
Zontivity
vorapaxar
PDR
2.08
mg/day
2.08
mg/day
PO, oral
Zontivity
vorapaxar
PDR
DDPD09031
Miltefosine
407.576
C21H46NO4P
CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
DB09031
3599
75283
http://www.drugs.com/international/miltefosine.html
3473
-2.0
-
-2.0
-
DRUGBANK
82.0
%
82
%
PO, oral; Rattus, Rat;
DRUGBANK
94.0
%
94
%
PO, oral; dog;
DRUGBANK
169.2
h
7.05(5.45-9.10)
day
elimination half-life;
DRUGBANK
741.6
h
30.9(30.8-31.2)
day
terminal half-life;
DRUGBANK
97.0
%
96-98
%
plasma proteins;
DRUGBANK
97.0
%
97
%
DRUGBANK
3.0
%
3
%
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Impavido
miltefosine
PDR
100.0
mg/day
100
mg/day
PO, oral
Impavido
miltefosine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Impavido
miltefosine
PDR
2.5
mg/kg/day
2.5
mg/kg/day
PO, oral
Impavido
miltefosine
PDR
150.0
mg/day
150
mg/day
PO, oral
Impavido
miltefosine
PDR
100.0
mg/day
100
mg/day
PO, oral
Impavido
miltefosine
PDR
150.0
mg/day
150
mg/day
PO, oral
Impavido
miltefosine
PDR
100.0
mg/day
100
mg/day
PO, oral
Impavido
miltefosine
PDR
150.0
mg/day
150
mg/day
PO, oral
Impavido
miltefosine
PDR
100.0
mg/day
100
mg/day
PO, oral
Impavido
miltefosine
PDR
DDPD09034
Suvorexant
450.93
C23H23ClN6O2
[H][C@@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2
DB09034
24965990
82698
http://www.drugs.com/belsomra.html
24662178
-2.0
-
-2.0
-
DRUGBANK
82.0
%
82
%
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral; fasting;
DRUGBANK
3.5
h
3.5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
0.0504
L/h/kg
0.84
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
49.0
L
~49
L
Average volume of distribution;
DRUGBANK
0.69
L/kg
0.69
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
~12
h
DRUGBANK
10.37
h
10.37
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
66.0
%
~66
%
Faeces excretion;
DRUGBANK
23.0
%
23
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09038
Empagliflozin
450.91
C23H27ClO7
OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1
DB09038
11949646
82720
http://www.drugs.com/jardiance.html
10123957
-2.0
-
-2.0
-
DRUGBANK
843.2017
ng.h/ml
1870.0
nmol.h/L
PO, oral;
DRUGBANK
2137.3134
ng.h/ml
4740.0
nmol.h/L
PO, oral;
DRUGBANK
116.78569
ng/ml
259
nmol/L
PO, oral;
DRUGBANK
309.77517
ng/ml
687
nmol/L
PO, oral;
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
10.6
L/h
10.6
L/h
apparent clearance; PO, oral;
DRUGBANK
73.8
L
73.8
L
Steady state volume of distribution;
DRUGBANK
12.4
h
12.4
h
elimination half-life;
DRUGBANK
41.2
%
~41.2
%
Faeces excretion; PO, oral;
DRUGBANK
54.4
%
~54.4
%
Urinary excretion; PO, oral;
DRUGBANK
27.2
%
~27.2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
86.2
%
~86.2
%
plasma proteins;
DRUGBANK
DDPD09039
Eliglustat
404.551
C23H36N2O4
CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1
DB09039
23652731
82752
28475348
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1.5-2
h
Oral multiple dose; CYP2D6 genetic polymorphisms; extensive metabolizers, EM;
DRUGBANK
88.0
L/h
88.0
L/h
CYP2D6 genetic polymorphisms;
DRUGBANK
1.257
L/h/kg
20.95
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
835.0
L
835.0
L
CYP2D6 genetic polymorphisms;
DRUGBANK
6.5
h
6.5
h
extensive metabolizers, EM;
DRUGBANK
8.9
h
8.9
h
poor metabolizers, PM;
DRUGBANK
7.7
h
7.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
41.8
%
41.8
%
Urinary excretion; PO, oral;
DRUGBANK
51.4
%
51.4
%
Faeces excretion; PO, oral;
DRUGBANK
79.5
%
76-83
%
DRUGBANK
84.0
mg/dose
84
mg/dose
PO, oral
bid
Cerdelga
eliglustat
PDR
84.0
mg/dose
84
mg/dose
PO, oral
bid
Cerdelga
eliglustat
PDR
84.0
mg/dose/day
84
mg/dose/day
PO, oral
qd
Cerdelga
eliglustat
PDR
168.0
mg/dose
84
mg/dose
PO, oral
bid
Cerdelga
eliglustat
PDR
168.0
mg/dose
84
mg/dose
PO, oral
bid
Cerdelga
eliglustat
PDR
84.0
mg/dose/day
84
mg/dose/day
PO, oral
qd
Cerdelga
eliglustat
PDR
DDPD09040
Efinaconazole
348.398
C18H22F2N4O
C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
DB09040
489181
82718
http://www.drugs.com/mtm/efinaconazole-topical.html
428538
-2.0
-
-2.0
-
DRUGBANK
29.9
h
29.9
h
normal,healthy; patients;
DRUGBANK
DDPD09041
Tavaborole
151.93
C7H6BFO2
OB1OCC2=CC(F)=CC=C12
DB09041
11499245
77942
http://www.drugs.com/cdi/tavaborole.html
9674047
-2.0
-
-2.0
-
DRUGBANK
7.5
%
7.5
%
DRUGBANK
28.5
h
28.5
h
DRUGBANK
DDPD09042
Tedizolid phosphate
450.323
C17H16FN6O6P
CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O
DB09042
11476460
83326
http://www.drugs.com/sivextro.html
9651289
-2.0
-
-2.0
-
DRUGBANK
25600.0
ng.h/ml
25.6±8.4
mcg.h/ml
PO, oral;
DRUGBANK
29200.0
ng.h/ml
29.2±6.2
mcg.h/ml
intravenous injection, IV;
DRUGBANK
23800.0
ng.h/ml
23.8±6.8
mcg.h/ml
Oral single dose;
DRUGBANK
26600.0
ng.h/ml
26.6±5.2
mcg.h/ml
DRUGBANK
91.0
%
91
%
PO, oral;
DRUGBANK
2000.0
ng/ml
2.0±0.7
mcg/ml
Oral single dose;
DRUGBANK
2300.0
ng/ml
2.3±0.6
mcg/ml
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
1.0
h
1
h
intravenous injection, IV;
DRUGBANK
3.5
h
3.5(1.0-6.0)
h
PO, oral;
DRUGBANK
1.2
h
1.2(0.9-1.5)
h
intravenous injection, IV;
DRUGBANK
2.5
h
2.5(1.0-8.0)
h
Oral single dose;
DRUGBANK
1.1
h
1.1(0.9-1.5)
h
DRUGBANK
72.0
h
3
day
PO, oral;
DRUGBANK
72.0
h
3
day
intravenous injection, IV;
DRUGBANK
6.9
L/h
6.9±1.7
L/h
apparent clearance; Oral single dose;
DRUGBANK
8.4
L/h
8.4±2.1
L/h
apparent clearance; at steady state;
DRUGBANK
6.4
L/h
6.4±1.2
L/h
Total clearance; Single dose;
DRUGBANK
5.9
L/h
5.9±1.4
L/h
Total clearance; at steady state;
DRUGBANK
73.5
L
67-80
L
intravenous injection, IV; Single dose;
DRUGBANK
108.0
L
108 ± 21
L
PO, oral;
DRUGBANK
113.3
L
113.3 ± 19.3
L
Apparent volume of distribution; Oral single dose;
DRUGBANK
12.0
h
~12
h
DRUGBANK
82.0
%
~82
%
Faeces excretion; Oral single dose;
DRUGBANK
18.0
%
~18
%
Urinary excretion; Oral single dose;
DRUGBANK
3.0
%
3
%
Oral single dose; Unchanged drug;
DRUGBANK
80.0
%
~70-90
%
plasma proteins; human, homo sapiens;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral;intravenous injection, IV;
qd
Sivextro
tedizolid phosphate
PDR
200.0
mg/day
200
mg/day
PO, oral;intravenous injection, IV;
qd
Sivextro
tedizolid phosphate
PDR
DDPD09047
Finafloxacin
398.394
C20H19FN4O4
[H][C@]12CN(C[C@]1([H])OCCN2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1C#N)C(O)=O
DB09047
11567473
85176
9742243
-2.0
-
-2.0
-
DRUGBANK
0.345
L/h/kg
5.75
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.42
L/kg
1.42
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.42
h
13.42
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD09048
Netupitant
578.603
C30H32F6N4O
CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1
DB09048
6451149
85155
4953629
-2.0
-
-2.0
-
DRUGBANK
5.0
h
5
h
Oral single dose;
DRUGBANK
20.3
L/h
20.3±9.2
L/h
Total clearance;
DRUGBANK
0.1698
L/h/kg
2.83
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1982.0
L
1982±906
L
Average volume of distribution; tumor; patients;
DRUGBANK
5.54
L/kg
5.54
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
96.0
h
96
h
DRUGBANK
34.28
h
34.28
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
99.5
%
>99.5
%
DRUGBANK
DDPD09049
Naloxegol
651.794
C34H53NO11
COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
DB09049
56959087
82975
http://www.drugs.com/mtm/naloxegol.html
28651656
-2.0
-
-2.0
-
DRUGBANK
2.0
h
<2
h
PO, oral;
DRUGBANK
1554.0
L
968-2140
L
DRUGBANK
8.5
h
6-11
h
DRUGBANK
68.0
%
68
%
Faeces excretion; PO, oral;
DRUGBANK
16.0
%
16
%
Urinary excretion; PO, oral;
DRUGBANK
4.2
%
~4.2
%
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
qd
Movantik
naloxegol
PDR
25.0
mg/day
25
mg/day
PO, oral
qd
Movantik
naloxegol
PDR
DDPD09050
Ceftolozane
666.69
C23H30N12O8S2
CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O
DB09050
53234134
134719
25999973
-2.0
-
-2.0
-
DRUGBANK
172000.0
ng.h/ml
172.0
mcg.h/ml
intravenous injection, IV;
DRUGBANK
69100.0
ng/ml
69.1
mcg/ml
intravenous injection, IV;
DRUGBANK
0.0
%
0
%
DRUGBANK
5.05
L/h
3.41 – 6.69
L/h
Renal clearance; Single dose;
DRUGBANK
0.0696
L/h/kg
1.16
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.5
L
13.5
L
DRUGBANK
0.17
L/kg
0.17
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.77
h
2.77
h
DRUGBANK
3.12
h
3.12
h
Multiple dose;
DRUGBANK
2.58
h
2.58
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.5
%
16-21
%
plasma proteins;
DRUGBANK
DDPD09053
Ibrutinib
440.507
C25H24N6O2
NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
DB09053
24821094
76612
http://www.drugs.com/imbruvica.html
26637187
-2.0
-
-2.0
-
DRUGBANK
953000000.0
ng.h/ml
953.0
mg.h/ml
PO, oral;
DRUGBANK
35.0
ng/ml
35
ng/ml
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
8.13
L/h
112-159
ml/min
normal renal function; patients;
DRUGBANK
0.984
L/h/kg
16.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10000.0
L
10000.0
L
at steady state;
DRUGBANK
9.75
L/kg
9.75
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~4-6
h
elimination half-life;
DRUGBANK
5.0
h
5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.8
%
~7.8
%
Urinary excretion;
DRUGBANK
80.0
%
80
%
Faeces excretion;
DRUGBANK
97.3
%
97.3
%
plasma proteins;
DRUGBANK
560.0
mg/day
560
mg/day
PO, oral
Imbruvica
ibrutinib
PDR
560.0
mg/day
560
mg/day
PO, oral
Imbruvica
ibrutinib
PDR
DDPD09054
Idelalisib
415.432
C22H18FN7O
[H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
DB09054
11625818
82701
http://www.drugs.com/cdi/idelalisib.html
9800565
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
14.9
L/h
14.9
L/h
DRUGBANK
23.0
L
23.0
L
DRUGBANK
8.2
h
8.2
h
elimination half-life;
DRUGBANK
78.0
%
78
%
Faeces excretion; Single dose;
DRUGBANK
14.0
%
14
%
Urinary excretion; Single dose;
DRUGBANK
84.0
%
>84
%
plasma proteins; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
300.0
mg/day
150
mg/dose
PO, oral
bid
Zydelig
idelalisib
PDR
300.0
mg/day
150
mg/dose
PO, oral
bid
Zydelig
idelalisib
PDR
DDPD09059
Atosiban
994.19
C43H67N11O12S2
[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O
DB09059
135899
http://www.drugs.com/international/atosiban.html
4470550
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
intravenous infusion, IV in drop; Female, women;
DRUGBANK
41.8
L/h
41.8
L/h
Average clearance;
DRUGBANK
41.8
L
41.8
L
Average volume of distribution;
DRUGBANK
0.21
h
0.21
h
distribution half-life;
DRUGBANK
1.7
h
1.7
h
terminal half-life;
DRUGBANK
47.0
%
46-48
%
plasma proteins; Preg, pregnant;
DRUGBANK
DDPD09060
Avibactam
265.24
C7H11N3O6S
NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O
DB09060
9835049
85984
http://www.drugs.com/mtm/avibactam-and-ceftazidime.html
8010770
-2.0
-
-2.0
-
DRUGBANK
85.0
%
80-90
%
Urinary excretion; Unchanged drug;
DRUGBANK
12.0
L/h
~12
L/h
DRUGBANK
0.1656
L/h/kg
2.76
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.2
L
22.2
L
Steady state volume of distribution;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.85
h
~2.7-3.0
h
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.95
%
5.7-8.2
%
plasma proteins;
DRUGBANK
DDPD09061
Cannabidiol
314.469
C21H30O2
CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1
DB09061
644019
69478
559095
-2.0
-
-2.0
-
DRUGBANK
2.5
ng/ml
2.50
ng/ml
sublingual; Derivative;
DRUGBANK
3.02
ng/ml
3.02
ng/ml
buccal; Derivative;
DRUGBANK
3.0
h
2-4
h
buccal;
DRUGBANK
1.63
h
1.63
h
sublingual; Derivative;
DRUGBANK
2.8
h
2.8
h
buccal; Derivative;
DRUGBANK
0.813
L/h/kg
13.55
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
6.69
L/kg
6.69
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.44
h
1.44
h
Components;
DRUGBANK
1.81
h
1.81
h
Components;
DRUGBANK
23.82
h
23.82
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD09063
Ceritinib
558.14
C28H36ClN5O3S
CC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC1
DB09063
57379345
78432
http://www.drugs.com/mtm/ceritinib.html
29315053
-2.0
-
-2.0
-
DRUGBANK
5.0
h
4-6
h
PO, oral;
DRUGBANK
33.2
L/h
33.2
L/h
apparent clearance;
DRUGBANK
88.5
L/h
88.5
L/h
apparent clearance; Single dose;
DRUGBANK
4230.0
L
4230.0
L
Apparent volume of distribution; Single dose;
DRUGBANK
41.0
h
41
h
terminal half-life;
DRUGBANK
92.3
%
92.3
%
Faeces excretion; Oral single dose;
DRUGBANK
1.3
%
1.3
%
Urinary excretion; Oral single dose;
DRUGBANK
62.8
%
~62.8
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
97.0
%
97
%
plasma proteins; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
450.0
mg/day
450
mg/day
PO, oral
Zykadia
ceritinib
PDR
450.0
mg/day
450
mg/day
PO, oral
Zykadia
ceritinib
PDR
DDPD09065
Cobicistat
776.03
C40H53N7O5S2
CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
DB09065
25151504
72291
http://www.drugs.com/cdi/cobicistat.html
25084912
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3.5
h
DRUGBANK
3.5
h
~3-4
h
terminal half-life;
DRUGBANK
86.2
%
86.2
%
Faeces excretion; Drug combination;
DRUGBANK
8.2
%
8.2
%
Urinary excretion; Drug combination;
DRUGBANK
97.5
%
97-98
%
plasma proteins; human, homo sapiens;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral
Tybost
cobicistat
PDR
150.0
mg/day
150
mg/day
PO, oral
Tybost
cobicistat
PDR
150.0
mg/day
150
mg/day
PO, oral
Tybost
cobicistat
PDR
150.0
mg/day
150
mg/day
PO, oral
Tybost
cobicistat
PDR
DDPD09067
Corticorelin ovine triflutate
4670.38
C205H339N59O63S
CC[C@H](C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C)C(N)=O
DB09067
16132344
65307
http://www.drugs.com/mtm/corticorelin-ovine-triflutate.html
17289003
-2.0
-
-2.0
-
DRUGBANK
0.208333333333333
h
10-15
min
intravenous injection, IV; normal,healthy; Active metabolite;
DRUGBANK
0.75
h
0.5-1
h
intravenous injection, IV; normal,healthy;
DRUGBANK
3.95833333333333
L/h/m2
95±11
L/m2/day
DRUGBANK
6.2
L
6.2±0.5
L
Average volume of distribution;
DRUGBANK
0.193333333333333
h
11.6±1.5
min
elimination half-life;
DRUGBANK
1.21666666666667
h
73±8
min
elimination half-life;
DRUGBANK
1.0
mcg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Acthrel
corticorelin ovine triflutate
PDR
100.0
mcg/dose
100
mcg/dose
intravenous injection, IV
Acthrel
corticorelin ovine triflutate
PDR
0.001
mg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Acthrel
corticorelin ovine triflutate
PDR
0.1
mg/dose
100
mcg/dose
intravenous injection, IV
Acthrel
corticorelin ovine triflutate
PDR
1.0
mcg/kg/dose
1
mcg/kg/dose
intravenous injection, IV
Acthrel
corticorelin ovine triflutate
PDR
100.0
mcg/dose
100
mcg/dose
intravenous injection, IV
Acthrel
corticorelin ovine triflutate
PDR
DDPD09068
Vortioxetine
298.45
C18H22N2S
CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
DB09068
71768094
76016
http://www.drugs.com/cdi/vortioxetine.html
8141643
-2.0
-
-2.0
-
DRUGBANK
9.0
h
7-11
h
DRUGBANK
0.348
L/h/kg
5.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2600.0
L
~2600
L
Apparent volume of distribution;
DRUGBANK
35.3
L/kg
35.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
66.0
h
~66
h
terminal half-life;
DRUGBANK
72.0
h
72
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
98
%
plasma proteins; human, homo sapiens;
DRUGBANK
20.0
mg/day
20
mg/day
PO, oral
Trintellix
vortioxetine
PDR
20.0
mg/day
20
mg/day
PO, oral
Trintellix
vortioxetine
PDR
DDPD09069
Trimetazidine
266.341
C14H22N2O3
COC1=C(OC)C(OC)=C(CN2CCNCC2)C=C1
DB09069
21109
94789
http://www.drugs.com/international/trimetazidine.html
19853
-2.0
-
-2.0
-
DRUGBANK
75.0
%
75
%
DRUGBANK
8.0
h
~8
h
extended release formulation; young;
DRUGBANK
12.0
h
~12
h
extended release formulation; Elderly;
DRUGBANK
DDPD09070
Tibolone
312.453
C21H28O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC(=O)CC3)C[C@@]([H])(C)[C@@]21[H]
DB09070
444008
32223
392038
-2.0
-
-2.0
-
DRUGBANK
1.25
h
1-1.5
h
PO, oral; Active metabolite;
DRUGBANK
45.0
h
~45
h
elimination half-life;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
DRUGBANK
DDPD09071
Tasimelteon
245.322
C15H19NO2
CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2
DB09071
10220503
79042
http://www.drugs.com/cdi/tasimelteon.html
8395995
-2.0
-
-2.0
-
DRUGBANK
0.5424
L/h/kg
9.04
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
91.0
L
56-126
L
Apparent volume of distribution; at steady state; PO, oral; normal,healthy; young;
DRUGBANK
0.33
L/kg
0.33
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.3
h
1.3±0.4
h
elimination half-life;
DRUGBANK
0.75
h
0.75
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
80.0
%
80
%
Urinary excretion; PO, oral;
DRUGBANK
4.0
%
~4
%
Faeces excretion; PO, oral;
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD09072
Sodium oxybate
126.087
C4H7NaO3
[Na+].OCCCC([O-])=O
DB09072
23663870
9983
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88
%
DRUGBANK
0.688333333333333
h
30.7-51.9
min
DRUGBANK
67.68
L/h
895-1361
ml/min
Total clearance;
DRUGBANK
52.7
L
37.7-67.7
L
DRUGBANK
0.75
h
0.5-1
h
DRUGBANK
9690.0
mg/kg
9690.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
1.0
%
<1
%
DRUGBANK
9000.0
mg/day
9
g/day
PO, oral
Xyrem
sodium oxybate
PDR
7500.0
mg/day
7.5
g/day
PO, oral
Xyrem
sodium oxybate
PDR
6000.0
mg/day
6
g/day
PO, oral
Xyrem
sodium oxybate
PDR
6000.0
mg/day
6
g/day
PO, oral
Xyrem
sodium oxybate
PDR
9.0
g/night
9
g/night
PO, oral
Xyrem
sodium oxybate
PDR
9000.0
mg/day
9
g/day
PO, oral
Xyrem
sodium oxybate
PDR
7500.0
mg/day
7.5
g/day
PO, oral
Xyrem
sodium oxybate
PDR
6000.0
mg/day
6
g/day
PO, oral
Xyrem
sodium oxybate
PDR
9.0
g/night
9
g/night
PO, oral
Xyrem
sodium oxybate
PDR
DDPD09073
Palbociclib
447.5328
C24H29N7O2
CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
DB09073
5330286
85993
http://www.drugs.com/cdi/palbociclib.html
4487437
-2.0
-
-2.0
-
DRUGBANK
46.0
%
46
%
PO, oral;
DRUGBANK
9.0
h
6-12
h
PO, oral;
DRUGBANK
192.0
h
8
day
PO, oral;
DRUGBANK
63.1
L/h
63.1
L/h
apparent clearance; PO, oral;
DRUGBANK
2583.0
L
2583.0
L
Apparent volume of distribution;
DRUGBANK
29.0
h
29
h
elimination half-life;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral;
DRUGBANK
17.5
%
17.5
%
Urinary excretion;
DRUGBANK
85.0
%
85
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
125.0
mg/day
125
mg/day
PO, oral
Ibrance
palbociclib
PDR
125.0
mg/day
125
mg/day
PO, oral
Ibrance
palbociclib
PDR
DDPD09074
Olaparib
434.4628
C24H23FN4O3
FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
DB09074
83766
http://www.drugs.com/cdi/olaparib.html
23343272
-2.0
-
-2.0
-
DRUGBANK
25.8
ng.h/ml
25.8
mcg.h/L
PO, oral;
DRUGBANK
6900.0
ng/ml
4.7-9.1
mcg/ml
PO, oral;
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
8.35
L/h
4.6-12.1
L/h
Total clearance;
DRUGBANK
40.3
L
40.3
L
DRUGBANK
8.0
h
5-11
h
elimination half-life;
DRUGBANK
44.0
%
44
%
Urinary excretion;
DRUGBANK
42.0
%
42
%
Faeces excretion;
DRUGBANK
82.0
%
82
%
plasma proteins; high protein binding;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
bid
Lynparza
olaparib
PDR
300.0
mg/day
300
mg/day
PO, oral
bid
Lynparza
olaparib
PDR
DDPD09075
Edoxaban
548.06
C24H30ClN7O4S
CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
DB09075
10280735
85973
http://www.drugs.com/international/edoxaban.html
8456212
-2.0
-
-2.0
-
DRUGBANK
62.0
%
62
%
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
22.0
L/h
22.0
L/h
DRUGBANK
0.3114
L/h/kg
5.19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
107.0
L
107.0
L
Steady state volume of distribution;
DRUGBANK
1.53
L/kg
1.53
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
10-14
h
elimination half-life; PO, oral;
DRUGBANK
6.7
h
6.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
55.0
%
~55
%
plasma proteins; high protein binding;
DRUGBANK
DDPD09076
Umeclidinium
428.595
C29H34NO2
OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
DB09076
11519070
79041
http://www.drugs.com/cons/umeclidinium-inhalation.html
9693858
-2.0
-
-2.0
-
DRUGBANK
0.166666666666667
h
5-15
min
DRUGBANK
336.0
h
14
day
DRUGBANK
2.157
L/h/kg
35.95
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.0
L
86.0
L
Average volume of distribution;
DRUGBANK
1.23
L/kg
1.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
11
h
effective half-life; Multiple dose;
DRUGBANK
19.0
h
19
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
58.0
%
58
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
22.0
%
22
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
89.0
%
89
%
DRUGBANK
0.0625
mg/day
62.5
mcg/day
inhalation, IH
Incruse Ellipta
umeclidinium
PDR
0.0625
mg/day
62.5
mcg/day
inhalation, IH
Incruse Ellipta
umeclidinium
PDR
DDPD09078
Lenvatinib
426.86
C21H19ClN4O4
COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O
DB09078
9823820
85994
http://www.drugs.com/cdi/lenvatinib.html
7999567
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
DRUGBANK
28.0
h
~28
h
elimination half-life;
DRUGBANK
64.0
%
~64
%
Faeces excretion;
DRUGBANK
25.0
%
~25
%
Urinary excretion;
DRUGBANK
98.5
%
98-99
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
24.0
mg/day
24
mg/day
PO, oral
Lenvima
lenvatinib
PDR
18.0
mg/day
18
mg/day
PO, oral
Lenvima
lenvatinib
PDR
12.0
mg/day
12
mg/day
PO, oral
Lenvima
lenvatinib
PDR
24.0
mg/day
24
mg/day
PO, oral
Lenvima
lenvatinib
PDR
18.0
mg/day
18
mg/day
PO, oral
Lenvima
lenvatinib
PDR
12.0
mg/day
12
mg/day
PO, oral
Lenvima
lenvatinib
PDR
DDPD09079
Nintedanib
539.6248
C31H33N5O4
COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1
DB09079
9809715
85164
http://www.drugs.com/cdi/nintedanib.html
7985471
-2.0
-
-2.0
-
DRUGBANK
4.7
%
4.7
%
PO, oral; patients; fasting;
DRUGBANK
2.0
h
2
h
PO, oral; patients; fasting;
DRUGBANK
4.0
h
4
h
PO, oral; 421AA genotype; food;
DRUGBANK
5.0
%
5
%
DRUGBANK
0.03
%
0.03
%
Urinary excretion;
DRUGBANK
0.01
%
0.01
%
Urinary excretion;
DRUGBANK
83.4
L/h
1390.0
ml/min
Plasma clearance;
DRUGBANK
1.2
L/h
20.0
ml/min
Renal clearance;
DRUGBANK
1.194
L/h/kg
19.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1050.0
L
1050.0
L
intravenous injection, IV;
DRUGBANK
15.0
L/kg
15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.5
h
~10-15
h
elimination half-life;
DRUGBANK
9.5
h
~9.5
h
effective half-life; idiopathic pulmonary fibrosis;
DRUGBANK
9.5
h
9.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
93.4
%
93.4
%
Faeces excretion;
DRUGBANK
0.05
%
0.05
%
PO, oral; Unchanged drug;
DRUGBANK
1.4
%
1.4
%
intravenous injection, IV; Unchanged drug;
DRUGBANK
97.8
%
97.8
%
plasma proteins;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
Ofev
nintedanib
PDR
300.0
mg/day
300
mg/day
PO, oral
Ofev
nintedanib
PDR
DDPD09080
Olodaterol
386.448
C21H26N2O5
COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
DB09080
11504295
82700
http://www.drugs.com/cdi/olodaterol.html
9679097
-2.0
-
-2.0
-
DRUGBANK
30.0
%
~30
%
inhalation, IH; normal,healthy;
DRUGBANK
1.0
%
<1
%
Liquid;
DRUGBANK
0.25
h
10-20
min
inhalation, IH;
DRUGBANK
52.32
L/h
872.0
ml/min
Total clearance; normal,healthy;
DRUGBANK
10.38
L/h
173.0
ml/min
Renal clearance; normal,healthy;
DRUGBANK
0.747
L/h/kg
12.45
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1110.0
L
1110.0
L
DRUGBANK
15.85
L/kg
15.85
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
22.0
h
22
h
terminal half-life; intravenous injection, IV;
DRUGBANK
45.0
h
~45
h
terminal half-life; inhalation, IH;
DRUGBANK
22.1
h
22.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
38.0
%
38
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
53.0
%
53
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
9.0
%
9
%
Urinary excretion; PO, oral;
DRUGBANK
84.0
%
84
%
Faeces excretion; PO, oral;
DRUGBANK
19.0
%
19
%
Urinary excretion; intravenous injection, IV; Unchanged drug;
DRUGBANK
9.0
%
<9
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
60.0
%
~60
%
plasma proteins; high protein binding; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
0.005
mg/day
5
mcg/day
inhalation, IH
Striverdi Respimat
olodaterol
PDR
0.005
mg/day
5
mcg/day
inhalation, IH
Striverdi Respimat
olodaterol
PDR
DDPD09081
Idebenone
366.498
C21H34O5
COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O
DB09081
12881464
31687
https://www.drugs.com/international/idebenone.html
14944546
-2.0
-
-2.0
-
DRUGBANK
0.67
h
0.67(0.33-2)
h
PO, oral;
DRUGBANK
DDPD09082
Vilanterol
486.43
C24H33Cl2NO5
OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
DB09082
10184665
75037
http://www.drugs.com/breo-ellipta.html
8360167
-2.0
-
-2.0
-
DRUGBANK
27.3
%
27.3
%
inhalation, IH;
DRUGBANK
2.0
%
<2
%
PO, oral;
DRUGBANK
0.166666666666667
h
10
min
inhalation, IH;
DRUGBANK
78.0
%
78
%
DRUGBANK
5.0
%
5
%
DRUGBANK
1.542
L/h/kg
25.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
661.0
L
661.0
L
Average volume of distribution; intravenous injection, IV; normal,healthy;
DRUGBANK
2.38
L/kg
2.38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
21.3
h
21.3
h
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
70.0
%
70
%
Urinary excretion; PO, oral;
DRUGBANK
30.0
%
30
%
Faeces excretion; PO, oral;
DRUGBANK
93.9
%
93.9
%
plasma proteins;
DRUGBANK
DDPD09083
Ivabradine
468.594
C27H36N2O5
COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
DB09083
132999
85966
http://www.drugs.com/international/ivabradine-hydrochloride.html
117373
-2.0
-
-2.0
-
DRUGBANK
40.0
%
~40
%
PO, oral;
DRUGBANK
24.0
L/h
400.0
ml/min
Total clearance;
DRUGBANK
4.2
L/h
70.0
ml/min
Renal clearance;
DRUGBANK
0.6162
L/h/kg
10.27
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
100.0
L
100.0
L
DRUGBANK
1.66
L/kg
1.66
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
h
2
h
DRUGBANK
70.0
%
70
%
plasma proteins;
DRUGBANK
7.5
mg
7.5
mg
PO, oral
bid
Corlanor
ivabradine
PDR
0.6
mg/kg/day
0.3
mg/kg/dose
PO, oral
bid
Corlanor
ivabradine
PDR
7.5
mg/dose
7.5
mg/dose
PO, oral
Corlanor
ivabradine
PDR
7.5
mg
7.5
mg
PO, oral
bid
Corlanor
ivabradine
PDR
7.5
mg
7.5
mg
PO, oral
bid
Corlanor
ivabradine
PDR
0.3
mg/kg/dose
0.3
mg/kg/dose
PO, oral
bid
Corlanor
ivabradine
PDR
7.5
mg/dose
7.5
mg/dose
PO, oral
Corlanor
ivabradine
PDR
7.5
mg
7.5
mg
PO, oral
bid
Corlanor
ivabradine
PDR
0.4
mg/kg/day
0.2
mg/kg/dose
PO, oral
bid
Corlanor
ivabradine
PDR
DDPD09084
Benzydamine
309.413
C19H23N3O
CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12
DB09084
12555
94563
12036
-2.0
-
-2.0
-
DRUGBANK
10.2
L/h
170.0
ml/min
Total clearance;
DRUGBANK
0.1368
L/h/kg
2.28
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.0
L
10.0
L
DRUGBANK
1.53
L/kg
1.53
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.0
h
~13
h
PO, oral;
DRUGBANK
7.7
h
~7.7
h
terminal half-life;
DRUGBANK
8.1
h
8.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
<20
%
plasma proteins; PO, oral;
DRUGBANK
DDPD09087
Potassium alum
258.205
AlKO8S2
[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
DB09087
24856
86463
23239
-2.0
-
-2.0
-
DRUGBANK
4.5
h
4.5
h
intravenous injection, IV;
DRUGBANK
0.2
%
0.1-0.3
%
Urinary excretion;
DRUGBANK
80.0
%
70-90
%
plasma proteins;
DRUGBANK
DDPD09089
Trimebutine
387.476
C22H29NO5
CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1
DB09089
5573
94458
5372
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral; Derivative;
DRUGBANK
0.8
h
0.8
h
Oral single dose;
DRUGBANK
1.0
h
~1
h
elimination half-life; Oral single dose;
DRUGBANK
2.77
h
2.77
h
Oral single dose;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; rabbit;
DRUGBANK
8.5
%
5-12
%
Faeces excretion;
DRUGBANK
94.0
%
~94
%
Urinary excretion;
DRUGBANK
2.4
%
<2.4
%
Urinary excretion; Unchanged drug;
DRUGBANK
5.0
%
5
%
DRUGBANK
DDPD09090
Pinaverium
511.52
C26H41BrNO4
COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1
DB09090
40704
135811
37182
-2.0
-
-2.0
-
DRUGBANK
7.5
%
5-10
%
PO, oral;
DRUGBANK
1.0
%
<1
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
1.5
h
~1.5
h
elimination half-life;
DRUGBANK
1531.0
mg/kg
1531.0
mg/kg
PO, oral; mouse;
DRUGBANK
1145.0
mg/kg
1145.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
154.0
mg/kg
154.0
mg/kg
PO, oral; rabbit;
DRUGBANK
97.0
%
97
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09091
Tixocortol
378.53
C21H30O4S
[H][C@@]12CC[C@](O)(C(=O)CS)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB09091
162955
63560
143053
-2.0
-
-2.0
-
DRUGBANK
15.0
%
10-20
%
PO, oral;
DRUGBANK
21.7
L/kg
21.7
L/kg
PO, oral; intravenous injection, IV;
DRUGBANK
DDPD09092
Xanthinol
311.342
C13H21N5O4
CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C
DB09092
9913
94314
9526
-2.0
-
-2.0
-
DRUGBANK
0.63
L/h/kg
0.63
l/h/kg
Total clearance;
DRUGBANK
0.93
L/kg
0.93
L/kg
DRUGBANK
1.67
h
1.67
h
elimination half-life;
DRUGBANK
95.45
%
90.9-100
%
DRUGBANK
DDPD09093
Chlortetracycline
478.88
C22H23ClN2O8
[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC(Cl)=C1[C@@]3(C)O
DB09093
54708735
27644
10469370
-2.0
-
-2.0
-
DRUGBANK
22.5
%
15-30
%
DRUGBANK
3.0
h
3
h
DRUGBANK
0.12
L/h/kg
2
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
100.0
L
100.0
L
DRUGBANK
0.9
L/kg
0.9
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.6
h
5.6
h
DRUGBANK
7.0
h
7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2314.0
mg/kg
2314.0
mg/kg
PO, oral; mouse;
DRUGBANK
52.5
%
50-55
%
plasma proteins;
DRUGBANK
DDPD09094
Podophyllin
1693.67
C88H92O34
COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C2C(COC2=O)C(O)C2=CC3=C(OCO3)C=C12.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O.COC1=CC(=CC(OC)=C1OC)C1C(C(CO)C(O)C2=CC3=C(OCO3)C=C12)C(O)=O
DB09094
11979494
10152781
-2.0
-
-2.0
-
DRUGBANK
8.7
mg/kg
8.7
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
15.0
mg/kg
15.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
8.0
mg/kg
8.0
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
3.0
mg/kg
3.0
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
30.0
mg/kg
30.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
24.6
mg/kg
24.6
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
DDPD09095
Difluocortolone
394.459
C22H28F2O4
[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB09095
11954369
135624
10128664
-2.0
-
-2.0
-
DRUGBANK
10.8
ng.h/ml
10.8
ng.h/ml
Rectal Administration;
DRUGBANK
0.75
ng/ml
0.75
ng/ml
Rectal Administration;
DRUGBANK
4.75
h
4.75±2.09
h
Rectal Administration;
DRUGBANK
4.5
h
~4-5
h
DRUGBANK
9.0
h
~9
h
DRUGBANK
75.0
%
75
%
Urinary excretion;
DRUGBANK
25.0
%
25
%
Faeces excretion;
DRUGBANK
DDPD09096
Benzoyl peroxide
242.2268
C14H10O4
O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
DB09096
7187
82405
http://www.drugs.com/cons/benzoyl-peroxide-topical.html
6919
-2.0
-
-2.0
-
DRUGBANK
DDPD09097
Quinagolide
395.56
C20H33N3O3S
[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CC
DB09097
3086401
135627
2343034
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
PO, oral;
DRUGBANK
4.0
%
4
%
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
100.0
L
~100
L
DRUGBANK
11.5
h
11.5
h
terminal half-life; Single dose;
DRUGBANK
17.0
h
17
h
at steady state;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
90.0
%
~90
%
plasma proteins;
DRUGBANK
DDPD09099
Somatostatin
1637.9
C76H104N18O19S2
C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
DB09099
16129681
64628
17286507
-2.0
-
-2.0
-
DRUGBANK
3.0
L/h
50.0
ml/min
Total clearance;
DRUGBANK
180.0
L/h
3000.0
ml/min
Total clearance; Male, men;
DRUGBANK
0.0333333333333333
h
1-3
min
DRUGBANK
DDPD09101
Elvitegravir
447.884
C23H23ClFNO5
[H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2
DB09101
5277135
72289
4441060
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
PO, oral; AIDS,HIV;
DRUGBANK
8.7
h
~8.7
h
terminal half-life; Drug combination;
DRUGBANK
94.8
%
94.8
%
Faeces excretion; PO, oral;
DRUGBANK
98.5
%
98-99
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09102
Daclatasvir
738.89
C40H50N8O6
COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
DB09102
25154714
82977
http://www.drugs.com/mtm/daclatasvir.html
24609522
-2.0
-
-2.0
-
DRUGBANK
67.0
%
67
%
Tablet, PO, oral;
DRUGBANK
2.0
h
<2
h
Oral multiple dose;
DRUGBANK
96.0
h
4
day
PO, oral;
DRUGBANK
4.2
L/h
4.2
L/h
Total clearance; PO, oral;
DRUGBANK
0.06
L/h/kg
1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
47.0
L
47.0
L
Tablet, PO, oral; intravenous injection, IV;
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
13.5
h
~12-15
h
elimination half-life; Multiple dose; HCV-positive;
DRUGBANK
13.5
h
13.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
88.0
%
~88
%
Faeces excretion; Bile excretion;
DRUGBANK
6.6
%
6.6
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
99
%
DRUGBANK
90.0
mg/day
90
mg/day
PO, oral
qd
Daklinza
daclatasvir
PDR
90.0
mg/day
90
mg/day
PO, oral
qd
Daklinza
daclatasvir
PDR
DDPD09104
Magnesium hydroxide
58.32
H2MgO2
[OH-].[OH-].[Mg++]
DB09104
73981
6637
14107
-2.0
-
-2.0
-
DRUGBANK
32.5
%
15-50
%
DRUGBANK
0.0
%
0
%
DRUGBANK
100.0
%
100
%
Urinary excretion;
DRUGBANK
8500.0
mg/kg
8500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09106
Hydroxyethyl Starch
N.A.
N.A.
C(COCC1C(C(C(C(O1)OCCO)OCCO)OCCO)OCCO)O.C(C1C(C(C(C(O1)O)O)O)O)O
DB09106
16213095
-2.0
-
-2.0
-
DRUGBANK
4340000.0
ng/ml
4.34
mg/ml
DRUGBANK
0.204
L/h
3.4
ml/min
DRUGBANK
5.9
L
5.9
L
DRUGBANK
16.1
h
16.1
h
terminal half-life;
DRUGBANK
12.0
h
12
h
elimination half-life;
DRUGBANK
8460.0
mg/kg
8460.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
62.0
%
~62
%
Urinary excretion;
DRUGBANK
DDPD09110
Coenzyme M
142.197
C2H6O3S2
OS(=O)(=O)CCS
DB09110
598
17905
https://www.drugs.com/mtm/mesna-oral-injection.html
578
-2.0
-
-2.0
-
DRUGBANK
58.0
%
58
%
PO, oral; Derivative;
DRUGBANK
89.0
%
89
%
PO, oral; Derivative;
DRUGBANK
2.75
h
1.5-4
h
PO, oral; Derivative;
DRUGBANK
5.0
h
3-7
h
PO, oral; Derivative;
DRUGBANK
1.23
L/h/kg
1.23
l/h/kg
Plasma clearance;
DRUGBANK
0.652
L/kg
0.652±0.242
L/kg
intravenous injection, IV;
DRUGBANK
0.36
h
0.36
h
Derivative;
DRUGBANK
1.17
h
1.17
h
Metabolite;
DRUGBANK
28.0
%
28
%
plasma proteins;
DRUGBANK
DDPD09112
Nitrous acid
47.0134
HNO2
ON=O
DB09112
23668193
25567
22936
-2.0
-
-2.0
-
DRUGBANK
0.59
h
0.4-0.78
h
DRUGBANK
157.9
mg/kg
157.9
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
175.0
mg/kg
175.0
mg/kg
PO, oral; mouse;
DRUGBANK
35.0
mg/kg
35.0
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
DDPD09114
Colfosceril palmitate
734.0389
C40H80NO8P
[H][C@@](COC(=O)CCCCCCCCCCCCCCC)(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC
DB09114
452110
72999
398235
-2.0
-
-2.0
-
DRUGBANK
28.0
h
20-36
h
DRUGBANK
4.0
%
4
%
Urinary excretion;
DRUGBANK
2.0
%
2
%
Faeces excretion;
DRUGBANK
DDPD09116
Calcium carbimide
80.103
CCaN2
[Ca++].[N-]=C=[N-]
DB09116
56955933
64301
21106503
-2.0
-
-2.0
-
DRUGBANK
1297.66666666667
ng.h/mg
77.86
mcg.min/mg
DRUGBANK
65.5
%
50-81
%
increasing doses;
increasing doses ↑ ;
DRUGBANK
1650.0
ng/ml
1.65
mcg/ml
DRUGBANK
1.0
h
1
h
DRUGBANK
0.2
h
12
min
DRUGBANK
0.939
L/h/kg
0.0123-0.0190
L/kg/min
Plasma clearance; intravenous injection, IV;
DRUGBANK
0.64
L/kg
0.64
L/kg
Apparent volume of distribution; Drug combination;
DRUGBANK
1.54
h
92.4
min
DRUGBANK
DDPD09117
Paraldehyde
132.1577
C6H12O3
CC1OC(C)OC(C)O1
DB09117
31264
27909
21106173
-2.0
-
-2.0
-
DRUGBANK
93.0
%
93
%
PO, oral;
DRUGBANK
7.5
h
7.5(3.5-9.5)
h
DRUGBANK
4150.0
mg/kg
3.3-5
g/kg
PO, oral; rabbit;
DRUGBANK
1575.0
mg/kg
1.5-1.65
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
1375.0
mg/kg
1.3-1.45
g/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3-4
g/kg
PO, oral; dog;
DRUGBANK
2750.0
mg/kg
2.75
g/kg
PO, oral; mouse;
DRUGBANK
3300.0
mg/kg
3.3
g/kg
PO, oral; cat;
DRUGBANK
75.0
%
70-80
%
lung excretion;
DRUGBANK
DDPD09118
Stiripentol
234.295
C14H18O3
CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1
DB09118
5311454
4470940
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1.5
h
PO, oral;
DRUGBANK
1.66666666666667
L/h/kg
40.0
L/kg/day
Plasma clearance;
DRUGBANK
0.333333333333333
L/h/kg
8.0
L/kg/day
Plasma clearance;
DRUGBANK
1.03
L/kg
1.03
L/kg
Average volume of distribution;
DRUGBANK
8.75
h
4.5-13
h
elimination half-life;
DRUGBANK
73.0
%
~73
%
Urinary excretion;
DRUGBANK
18.5
%
13-24
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
~99
%
plasma proteins;
DRUGBANK
DDPD09119
Eslicarbazepine acetate
296.326
C17H16N2O3
CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12
DB09119
179344
87016
http://www.drugs.com/mtm/eslicarbazepine.html
156110
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
DRUGBANK
1.2
L/h
20.0
ml/min
Renal clearance; normal renal function;
DRUGBANK
61.3
L
61.3
L
Apparent volume of distribution;
DRUGBANK
15.0
h
10-20
h
elimination half-life; normal,healthy; rheumatoid arthritis;
DRUGBANK
16.5
h
13-20
h
elimination half-life; epilepsy;
DRUGBANK
40.0
%
<40
%
plasma proteins;
DRUGBANK
1200.0
mg/day
1200
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
900.0
mg/day
900
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
800.0
mg/day
800
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
600.0
mg/day
600
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
900.0
mg/day
900
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
800.0
mg/day
800
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
1600.0
mg/day
1600
mg/day
PO, oral
Aptiom
eslicarbazepine acetate
PDR
DDPD09120
Zucapsaicin
305.4119
C18H27NO3
COC1=C(O)C=CC(CNC(=O)CCCC\C=C/C(C)C)=C1
DB09120
1548942
135952
1265956
-2.0
-
-2.0
-
DRUGBANK
0.075
%
0.075
%
animals;
DRUGBANK
9.0
h
~7-11
h
elimination half-life; Rattus, Rat;
DRUGBANK
9.0
h
~7-11
h
elimination half-life; Rattus, Rat; Metabolite;
DRUGBANK
87500.0
mg/kg
>87.5
g/kg
PO, oral; Male, men; mouse;
DRUGBANK
60.0
mg/kg
<60
mg/kg
PO, oral; Female, women; mouse;
DRUGBANK
90.0
mg/kg
>90
mg/kg
PO, oral; Male, men; Rattus, Rat;
DRUGBANK
60.0
mg/kg
>60
mg/kg
PO, oral; Female, women; Rattus, Rat;
DRUGBANK
66.7
%
<66.7
%
Urinary excretion; Faeces excretion; Rattus, Rat;
DRUGBANK
DDPD09121
Aurothioglucose
392.18
C6H11AuO5S
OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O
DB09121
6104
2930
5879
-2.0
-
-2.0
-
DRUGBANK
3425000000.0
ng/ml
342.5
g/dl
DRUGBANK
5.0
h
4-6
h
IM,intramuscular injection;
DRUGBANK
360.0
h
~3-27
day
elimination half-life; Single dose;
dose ↑ ;
DRUGBANK
648.0
h
14-40
day
DRUGBANK
4032.0
h
168
day
DRUGBANK
3.357
mg/kg
~3.357
mg/kg
IM,intramuscular injection; Male, men;
DRUGBANK
5.5
mg/kg
~5.5
mg/kg
IM,intramuscular injection; Male, men;
DRUGBANK
2.65
mg/kg
2.6-2.7
mg/kg
IM,intramuscular injection; Female, women; cholestatic jaundice;
DRUGBANK
14.402
mg/kg
~14.402
mg/kg
IM,intramuscular injection; Female, women; acute renal failure; acute tubular necrosis;
DRUGBANK
70.0
%
~70
%
Urinary excretion; IM,intramuscular injection; patients; human, homo sapiens;
DRUGBANK
30.0
%
~30
%
Faeces excretion; IM,intramuscular injection; patients; human, homo sapiens;
DRUGBANK
97.0
%
95-99
%
DRUGBANK
DDPD09123
Dienogest
311.425
C20H25NO2
[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]
DB09123
68861
70708
62093
-2.0
-
-2.0
-
DRUGBANK
91.0
%
91
%
PO, oral;
DRUGBANK
47.0
ng/ml
47
ng/ml
Oral single dose;
DRUGBANK
1.5
h
1.5
h
Oral single dose;
DRUGBANK
48.0
h
2
day
PO, oral;
DRUGBANK
3.84
L/h
64.0
ml/min
Total clearance;
DRUGBANK
0.0774
L/h/kg
1.29
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
40.0
L
40.0
L
Apparent volume of distribution;
DRUGBANK
0.6
L/kg
0.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.5
h
~9-10
h
elimination half-life;
DRUGBANK
14.0
h
14
h
Urinary excretion;
DRUGBANK
11.0
h
11
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.0
mg/kg
4.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
90
%
DRUGBANK
DDPD09124
Medrogestone
340.507
C23H32O2
[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C
DB09124
9949848
135446
8125459
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
12.5
ng/ml
10-15
ng/ml
PO, oral;
DRUGBANK
4.0
h
4
h
DRUGBANK
DDPD09125
Potassium citrate
306.394
C6H5K3O7
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
DB09125
13344
64733
12775
-2.0
-
-2.0
-
DRUGBANK
176.0
mg/kg
176.0
mg/kg
intravenous injection, IV; dog;
DRUGBANK
5.0
%
<5
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.0
mEq/kg/day
2
mEq/kg/day
PO, oral
Urocit-K
potassium citrate
PDR
100.0
mEq/day
100
mEq/day
PO, oral
Urocit-K
potassium citrate
PDR
100.0
mEq/day
100
mEq/day
PO, oral
Urocit-K
potassium citrate
PDR
100.0
mEq/kg/day
100
mEq/kg/day
PO, oral
Urocit-K
potassium citrate
PDR
DDPD09128
Brexpiprazole
433.57
C25H27N3O2S
O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
DB09128
11978813
134716
http://www.drugs.com/mtm/brexpiprazole.html
10152155
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
PO, oral; food;
food → ;
DRUGBANK
4.0
h
4
h
DRUGBANK
264.0
h
10-12
day
DRUGBANK
0.0198
L/h/kg
19.8
ml/h/kg
DRUGBANK
0.0204
L/h/kg
0.34
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.56
L/kg
1.56
L/kg
intravenous injection, IV;
DRUGBANK
1.46
L/kg
1.46
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
91.0
h
91
h
DRUGBANK
96.0
h
96
h
Metabolite;
DRUGBANK
54.37
h
54.37
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
25.0
%
~25
%
Urinary excretion;
DRUGBANK
46.0
%
~46
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
14.0
%
~14
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
4.0
mg/day
4
mg/day
PO, oral
Rexulti
brexpiprazole
PDR
4.0
mg/day
4
mg/day
PO, oral
Rexulti
brexpiprazole
PDR
DDPD09129
Chromic chloride
158.35
Cl3Cr
[Cl-].[Cl-].[Cl-].[Cr+3]
DB09129
6452300
53351
23193
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
lung metabolism;
DRUGBANK
4.0
%
4
%
Renal metabolism; Liver metabolism; plasma metabolism; spleen metabolism;
DRUGBANK
6.0
%
6
%
Urinary excretion;
DRUGBANK
36.0
h
31-41
h
DRUGBANK
14.0
mg/kg
10-18
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
DDPD09130
Copper
63.546
Cu
[Cu]
DB09130
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
23978
28694
22414
-2.0
-
-2.0
-
DRUGBANK
38.5
%
12-65
%
increasing doses;
increasing doses ↓ ;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
18.0
%
18
%
DRUGBANK
DDPD09131
Cupric Chloride
134.452
Cl2Cu
Cl[Cu]Cl
DB09131
24014
49553
22447
-2.0
-
-2.0
-
DRUGBANK
57.0
%
57（40-70）
%
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
DDPD09132
Gadoteric acid
558.65
C16H25GdN4O8
[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1
DB09132
158536
73732
http://www.drugs.com/international/gadoteric-acid.html
139460
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
0.0762
L/h/kg
1.27
ml/min/kg
Renal clearance; normal,healthy; Female, women;
DRUGBANK
0.1044
L/h/kg
1.74
ml/min/kg
Total clearance; normal,healthy; Female, women;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
Renal clearance; normal,healthy; Male, men;
DRUGBANK
0.0984
L/h/kg
1.64
ml/min/kg
Total clearance; normal,healthy; Male, men;
DRUGBANK
0.179
L/kg
179.0
ml/kg
at steady state; normal,healthy; Female, women;
DRUGBANK
0.211
L/kg
211.0
ml/kg
at steady state; normal,healthy; Male, men;
DRUGBANK
1.4
h
1.4
h
elimination half-life; Female, women;
DRUGBANK
2.0
h
2.0
h
elimination half-life; Male, men;
DRUGBANK
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.2
ml/kg/dose
0.2
mL/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.1
mmoL/kg/dose
0.1
mmoL/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.2
ml/kg/dose
0.2
ml/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
0.1
mmol/kg/dose
0.1
mmol/kg/dose
intravenous injection, IV
Dotarem Injection
gadoterate meglumine
PDR
DDPD09133
Iothalamic acid
613.916
C11H9I3N2O4
CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
DB09133
3737
31713
https://www.drugs.com/international/iotalamic-acid.html
3606
-2.0
-
-2.0
-
DRUGBANK
0.166666666666667
h
~10
min
distribution half-life; normal renal function;
DRUGBANK
1.5
h
~90
min
elimination half-life; normal renal function;
DRUGBANK
DDPD09134
Ioversol
807.115
C18H24I3N3O9
OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
DB09134
3741
31717
https://www.drugs.com/mtm/ioversol.html
3610
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
1.5
h
1.5
h
DRUGBANK
95.0
%
>95
%
DRUGBANK
DDPD09135
Ioxilan
791.116
C18H24I3N3O8
CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I
DB09135
3743
135884
https://www.drugs.com/international/ioxilan.html
3612
-2.0
-
-2.0
-
DRUGBANK
5.724
L/h
95.4±11.1
ml/min
Total clearance; Female, women;
DRUGBANK
6.06
L/h
101.0±14.7
ml/min
Total clearance; Male, men;
DRUGBANK
5.364
L/h
89.4±13.3
ml/min
Renal clearance; Female, women;
DRUGBANK
5.694
L/h
94.9±16.6
ml/min
Renal clearance; Male, men;
DRUGBANK
7.2
L
7.2±1.0
L
Apparent volume of distribution; Female, women;
DRUGBANK
10.0
L
10.0±2.4
L
Apparent volume of distribution; Male, men;
DRUGBANK
0.218333333333333
h
13.1±4.2
min
distribution half-life; Female, women;
DRUGBANK
0.391666666666667
h
23.5±15.3
min
distribution half-life; Male, men;
DRUGBANK
1.7
h
102.0±16.9
min
elimination half-life; Female, women;
DRUGBANK
2.28333333333333
h
137±35.4
min
elimination half-life; Male, men;
DRUGBANK
93.7
%
93.7
%
Urinary excretion; intravenous injection, IV; young; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD09136
Isosulfan blue
545.69
C27H33N2O6S2
CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=CC(=CC=C1S(O)(=O)=O)S(O)(=O)=O
DB09136
50108
4533
-2.0
-
-2.0
-
DRUGBANK
150.0
mg/kg
>150
mg/kg
Rattus, Rat;
DRUGBANK
1.0
%
1
%
DRUGBANK
DDPD09137
Technetium Tc-99m mebrofenin
486.136
C15H19BrN2O5Tc
[99Tc].[H]OC(=O)C([H])([H])N(C([H])([H])C(=O)O[H])C([H])([H])C(=O)N([H])C1=C(C(Br)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H]
DB09137
11431716
https://www.drugs.com/pro/technetium-tc-99m-mebrofenin.html
28476619
-2.0
-
-2.0
-
DRUGBANK
6.02
h
6.02
h
physical half-life;
DRUGBANK
1.0
%
1
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD09138
Technetium Tc-99m medronate
305.906
CH6O8P2Tc
O.O.[98Tc+4].[O-]P([O-])(=O)CP([O-])([O-])=O
DB09138
131704315
32186
https://www.drugs.com/cons/technetium-tc-99m-medronate-intravenous.html
34995234
-2.0
-
-2.0
-
DRUGBANK
6.02
h
6.02
h
physical half-life;
DRUGBANK
DDPD09139
Technetium Tc-99m oxidronate
290.906
CH6O7P2Tc
[99Tc].OC(P(O)(O)=O)P(O)(O)=O
DB09139
123801
-2.0
-
-2.0
-
DRUGBANK
0.0583333333333333
h
3.5
min
distribution half-life;
DRUGBANK
0.45
h
27
min
elimination half-life;
DRUGBANK
2.4
h
144
min
terminal half-life;
DRUGBANK
25.0
%
20-30
%
intravenous injection, IV;
DRUGBANK
DDPD09140
Oxygen
31.9988
O2
O=O
DB09140
977
27140
https://www.drugs.com/pro/oxygen.html
952
-2.0
-
-2.0
-
DRUGBANK
0.0339555555555556
h
~122.24
second
DRUGBANK
DDPD09143
Sonidegib
485.507
C26H26F3N3O3
[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1
DB09143
24775005
90863
http://www.drugs.com/mtm/sonidegib.html
25027390
-2.0
-
-2.0
-
DRUGBANK
6.5
%
6-7
%
PO, oral; fasting;
DRUGBANK
3.0
h
2-4
h
PO, oral; fasting;
DRUGBANK
9166.0
L
9166.0
L
DRUGBANK
672.0
h
~28
day
DRUGBANK
70.0
%
~70
%
Faeces excretion;
DRUGBANK
30.0
%
~30
%
Urinary excretion;
DRUGBANK
97.0
%
>97
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
Odomzo
sonidegib
PDR
200.0
mg/day
200
mg/day
PO, oral
Odomzo
sonidegib
PDR
DDPD09144
Uridine triacetate
370.314
C15H18N2O9
CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N1C=CC(=O)NC1=O
DB09144
20058
90914
https://www.drugs.com/mtm/uridine-triacetate.html
18897
-2.0
-
-2.0
-
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
2.25
h
2-2.5
h
DRUGBANK
120.0
mg/kg/day
120
mg/kg/day
PO, oral
Xuriden
uridine triacetate
PDR
8000.0
mg/day
8
g/day
PO, oral
Xuriden
uridine triacetate
PDR
6.2
g/m2/dose
6.2
g/m2/dose
PO, oral
Xuriden
uridine triacetate
PDR
10000.0
mg/dose
10
g/dose
PO, oral
Xuriden
uridine triacetate
PDR
24800.0
mg/m2/day
24.8
g/m2/day
PO, oral
Xuriden
uridine triacetate
PDR
40000.0
mg/day
40
g/day
PO, oral
Xuriden
uridine triacetate
PDR
8000.0
mg/day
8
g/day
PO, oral
Xuriden
uridine triacetate
PDR
40000.0
mg/day
40
g/day
PO, oral
Xuriden
uridine triacetate
PDR
120.0
mg/kg/day
120
mg/kg/day
PO, oral
Xuriden
uridine triacetate
PDR
8000.0
mg/day
8
g/day
PO, oral
Xuriden
uridine triacetate
PDR
6200.0
mg/m2/dose
6.2
g/m2/dose
PO, oral
Xuriden
uridine triacetate
PDR
10000.0
mg/dose
10
g/dose
PO, oral
Xuriden
uridine triacetate
PDR
24800.0
mg/m2/day
24.8
g/m2/day
PO, oral
Xuriden
uridine triacetate
PDR
40000.0
mg/day
40
g/day
PO, oral
Xuriden
uridine triacetate
PDR
8000.0
mg/day
8
g/day
PO, oral
Xuriden
uridine triacetate
PDR
40000.0
mg/day
40
g/day
PO, oral
Xuriden
uridine triacetate
PDR
120.0
mg/kg/day
120
mg/kg/day
PO, oral
Xuriden
uridine triacetate
PDR
DDPD09145
Water
18.0153
H2O
O
DB09145
962
15377
http://www.drugs.com/pro/sterile-water-for-injection.html
937
-2.0
-
-2.0
-
DRUGBANK
0.5
ml/dose
0.5
ml/dose
IM,intramuscular injection
Hiberix
haemophilus b conjugate vaccine (tetanus toxoid conjugate)
PDR
0.5
ml/dose
0.5
ml/dose
IM,intramuscular injection
Hiberix
haemophilus b conjugate vaccine (tetanus toxoid conjugate)
PDR
0.5
ml/dose
0.5
mL/dose
IM,intramuscular injection
Hiberix
haemophilus b conjugate vaccine (tetanus toxoid conjugate)
PDR
0.5
ml/dose
0.5
ml/dose
IM,intramuscular injection
Hiberix
haemophilus b conjugate vaccine (tetanus toxoid conjugate)
PDR
0.0
0
Hiberix
haemophilus b conjugate vaccine (tetanus toxoid conjugate)
PDR
0.5
ml
0.5
ml
IM,intramuscular injection
Hiberix
haemophilus b conjugate vaccine (tetanus toxoid conjugate)
PDR
5.6
mg/kg/day
0.8
mg/kg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
7.14285714
mg/day
50
mg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
7.14285714285714
mg/day
50
mg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
14.2857142857143
mg/day
100
mg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
50.0
mg/dose
50
mg/dose
subcutaneous injection, SC
Enbrel
etanercept
PDR
0.114285714285714
mg/kg/day
0.8
mg/kg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
7.14285714285714
mg/day
50
mg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
7.14285714285714
mg/day
50
mg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
14.2857142857143
mg/day
100
mg/week
subcutaneous injection, SC
Enbrel
etanercept
PDR
50.0
mg/dose
50
mg/dose
subcutaneous injection, SC
Enbrel
etanercept
PDR
DDPD09146
Iron sucrose
866.546
C12H29Fe5Na2O23
O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
DB09146
91663255
32699616
-2.0
-
-2.0
-
DRUGBANK
30000.0
ng/ml
30
mg/L
intravenous injection, IV;
DRUGBANK
0.166666666666667
h
10
min
intravenous injection, IV;
DRUGBANK
1.23
L/h
20.5
ml/min
Total clearance;
DRUGBANK
7.3
L
7.3
L
DRUGBANK
6.0
h
6
h
DRUGBANK
0.5
mg/kg
0.5
mg/kg
intravenous injection, IV
Velphoro
sucroferric oxyhydroxide
PDR
100.0
mg/dose
100
mg/dose
intravenous injection, IV
Velphoro
sucroferric oxyhydroxide
PDR
500.0
mg/dose
500
mg/dose
intravenous injection, IV
Velphoro
sucroferric oxyhydroxide
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Velphoro
sucroferric oxyhydroxide
PDR
0.5
mg/kg
0.5
mg/kg
intravenous injection, IV
Velphoro
sucroferric oxyhydroxide
PDR
100.0
mg/dose
100
mg/dose
intravenous injection, IV
Velphoro
sucroferric oxyhydroxide
PDR
500.0
mg/dose
500
mg/dose
intravenous injection, IV
Velphoro
sucroferric oxyhydroxide
PDR
3000.0
mg/day
3000
mg/day
PO, oral
Velphoro
sucroferric oxyhydroxide
PDR
DDPD09148
Florbetaben (18F)
358.444
C21H26FNO3
CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1
DB09148
11501341
79033
9676143
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
DRUGBANK
30.0
%
~30
%
Urinary excretion;
DRUGBANK
98.5
%
98.5
%
plasma proteins;
DRUGBANK
DDPD09151
Flutemetamol (18F)
273.32
C14H11FN2OS
CNC1=C([18F])C=C(C=C1)C1=NC2=CC=C(O)C=C2S1
DB09151
15950376
76611
https://www.drugs.com/vizamyl.html
13092196
-2.0
-
-2.0
-
DRUGBANK
37.0
%
~37
%
Urinary excretion;
DRUGBANK
DDPD09153
Sodium chloride
58.443
ClNa
[Na+].[Cl-]
DB09153
5234
26710
5044
-2.0
-
-2.0
-
DRUGBANK
0.64
L/kg
0.64
L/kg
DRUGBANK
0.283333333333333
h
17
min
DRUGBANK
0.044
mg
44
mcg
subcutaneous injection, SC
q2d
Rebif
interferon beta-1a
PDR
0.03
mg
30
mcg
IM,intramuscular injection
qw
Rebif
interferon beta-1a
PDR
0.044
mg
44
mcg
subcutaneous injection, SC
q2d
Rebif
interferon beta-1a
PDR
0.03
mg
30
mcg
IM,intramuscular injection
qw
Rebif
interferon beta-1a
PDR
20.0
ml/kg/bolus
20
ml/kg/bolus
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1000.0
ml/bolus
1000
ml/bolus
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1.0
mEq/kg/hour
1
mEq/kg/hour
intravenous infusion, iv in drop
Sodium Chloride
sodium chloride
PDR
10.0
ml/kg/dose
10
ml/kg/dose
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1000.0
ml/boLus
1000
ml/boLus
Sodium Chloride
sodium chloride
PDR
20.0
ml/kg/bolus
20
mL/kg/bolus
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1000.0
ml/bolus
1000
mL/bolus
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1.0
mEq/kg/hour
1
mEq/kg/hour
intravenous infusion, iv in drop
Sodium Chloride
sodium chloride
PDR
10.0
ml/kg/dose
10
mL/kg/dose
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1000.0
ml/bolus
1000
ml/bolus
Sodium Chloride
sodium chloride
PDR
20.0
ml/kg/boLus
20
ml/kg/boLus
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
1.0
mEq/kg/h
1
mEq/kg/h
intravenous infusion, iv in drop
Sodium Chloride
sodium chloride
PDR
10.0
ml/kg/dose
10
ml/kg/dose
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
10.0
ml/kg/dose
10
ml/kg/dose
intravenous injection, IV
Sodium Chloride
sodium chloride
PDR
DDPD09154
Sodium citrate
258.068
C6H5Na3O7
[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
DB09154
6224
53258
5989
-2.0
-
-2.0
-
DRUGBANK
1.9
h
98-130
min
DRUGBANK
42.6
L/h
313-1107
ml/min
Total clearance;
DRUGBANK
29.0
L
19-39
L
DRUGBANK
0.6
h
18-54
min
DRUGBANK
DDPD09155
Helium
4.0026
He
[He]
DB09155
23987
33681
https://www.drugs.com/pro/helium.html
22423
-2.0
-
-2.0
-
DRUGBANK
0.000222222222222222
h
0.8
second
DRUGBANK
DDPD09156
Iopromide
791.1119
C18H24I3N3O8
COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
DB09156
3736
63578
https://www.drugs.com/cons/iopromide-injection.html
3605
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
6.42
L/h
107.0
ml/min
Average clearance;
DRUGBANK
6.24
L/h
104.0
ml/min
Renal clearance;
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
L
16.0
L
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.24
h
0.24
h
distribution half-life; normal,healthy; young;
DRUGBANK
2.0
h
2
h
elimination half-life; normal,healthy; young;
DRUGBANK
6.2
h
6.2
h
elimination half-life; normal,healthy; young;
DRUGBANK
2.6
h
2.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
%
1
%
plasma proteins;
DRUGBANK
1480.0
ml/kg
1480
ml/kg
intra-arterial infusion
Ultravist Injection
iopromide
PDR
900.0
ml/kg
900
ml/kg
intravenous injection, IV
Ultravist Injection
iopromide
PDR
86000.0
mg
86
g
total systemic
Ultravist Injection
iopromide
PDR
1480.0
ml/kg
1480
ml/kg
intra-arterial infusion
Ultravist Injection
iopromide
PDR
900.0
ml/kg
900
ml/kg
intravenous injection, IV
Ultravist Injection
iopromide
PDR
86000.0
mg
86
g
total systemic
Ultravist Injection
iopromide
PDR
DDPD09157
Carbon dioxide
44.0095
CO2
O=C=O
DB09157
280
16526
274
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
DDPD09158
Trypan blue free acid
872.87
C34H28N6O14S4
CC1=CC(=CC=C1\N=N\C1=C(C=C2C=C(C=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C=C(C=C2C=C1S(O)(=O)=O)S(O)(=O)=O
DB09158
9562061
78900
14833963
-2.0
-
-2.0
-
DRUGBANK
6200.0
mg/kg
6200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09160
Technetium Tc-99m tetrofosmin
898.86
C36H84O10P4Tc
O.O.[98Tc].CCOCCP(CCOCC)CCP(CCOCC)CCOCC.CCOCCP(CCOCC)CCP(CCOCC)CCOCC
DB09160
131704316
-2.0
-
-2.0
-
DRUGBANK
6.03
h
6.03
h
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
50.0
%
50
%
Faeces excretion;
DRUGBANK
DDPD09161
Technetium Tc-99m sestamibi
775.96
C36H66N6O6Tc
[Tc+].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-]
DB09161
22617237
9423
https://www.drugs.com/pro/technetium-tc-99m-sestamibi.html
58829659
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
6.02
h
6.02
h
physical half-life;
DRUGBANK
0.0716666666666667
h
4.3
min
rest; Components;
DRUGBANK
0.0266666666666667
h
1.6
min
exercise; Components;
DRUGBANK
6.0
h
~6
h
elimination half-life; rest; exercise;
DRUGBANK
0.5
h
~30
min
elimination half-life; rest; exercise;
DRUGBANK
27.0
%
27
%
Urinary excretion;
DRUGBANK
48.0
%
~48
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
plasma proteins;
DRUGBANK
DDPD09163
Technetium Tc-99m exametazime
N.A.
N.A.
CC(C(=NO)C)NCC(C)(C)CNC(C)C(=NO)C.[Tc]
DB09163
139032814
-2.0
-
-2.0
-
DRUGBANK
40.0
%
~40
%
Urinary excretion;
DRUGBANK
DDPD09164
Technetium Tc-99m disofenin
449.321
C18H26N2O5Tc
[99Tc].CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O
DB09164
11430828
-2.0
-
-2.0
-
DRUGBANK
6.02
h
6.02
h
physical half-life;
DRUGBANK
0.316666666666667
h
19
min
elimination half-life; terminal half-life;
DRUGBANK
7.8
mg/kg
7.8
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
9.0
%
~9
%
Urinary excretion;
DRUGBANK
DDPD09165
Technetium Tc-99m pyrophosphate
272.847
O7P2Tc
[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O
DB09165
6452753
-2.0
-
-2.0
-
DRUGBANK
40.0
%
~40
%
Urinary excretion;
DRUGBANK
DDPD09167
Dosulepin
295.44
C19H21NS
CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12
DB09167
5284550
36803
4447605
-2.0
-
-2.0
-
DRUGBANK
37.6
ng/ml
37.6
ng/ml
PO, oral;
DRUGBANK
2.18
h
2.18
h
PO, oral;
DRUGBANK
1.36
L/h/kg
1.36
l/h/kg
Oral single dose;
DRUGBANK
45.0
L/kg
45.0
L/kg
Apparent volume of distribution; PO, oral;
DRUGBANK
20.4
h
~20.4
h
elimination half-life; PO, oral;
DRUGBANK
31.0
mg/kg
31.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
90.0
mg/kg
90.0
mg/kg
PO, oral; Infants;
DRUGBANK
4.5
mg/kg
4.5
mg/kg
PO, oral; adults; Female, women;
DRUGBANK
55.0
%
50-60
%
Urinary excretion;
DRUGBANK
27.5
%
15-40
%
Faeces excretion; Bile excretion;
DRUGBANK
DDPD09183
Dasabuvir
493.58
C26H27N3O5S
COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C
DB09183
56640146
85182
http://www.drugs.com/mtm/dasabuvir-ombitasvir-paritaprevir-and-ritonavir.html
29776744
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
DRUGBANK
4.0
h
4
h
DRUGBANK
149.0
L
149.0
L
DRUGBANK
2.13
L/kg
2.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.75
h
5.5-6
h
elimination half-life;
DRUGBANK
5.7
h
5.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
94.4
%
94.4
%
Faeces excretion;
DRUGBANK
2.0
%
2
%
Urinary excretion;
DRUGBANK
99.5
%
>99.5
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09185
Viloxazine
237.299
C13H19NO3
CCOC1=CC=CC=C1OCC1CNCCO1
DB09185
5666
94405
5464
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
1070.0
ng/ml
540-1600
ng/ml
PO, oral;
DRUGBANK
1.43333333333333
h
86
min
PO, oral;
DRUGBANK
0.126
L/h/kg
2.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.73
L/kg
0.73
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
~3-4
h
DRUGBANK
4.1
h
4.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.0
%
~2
%
Faeces excretion;
DRUGBANK
13.5
%
~12-15
%
Unchanged drug;
DRUGBANK
DDPD09195
Lorpiprazole
405.469
C21H26F3N5
[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2
DB09195
20055414
16736802
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
17.0
h
11-23
h
DRUGBANK
DDPD09205
Moxisylyte
279.38
C16H25NO3
CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1
DB09205
4260
94754
4110
-2.0
-
-2.0
-
DRUGBANK
152600.0
ng.h/ml
152.6
mg.h/l
intravenous injection, IV;
DRUGBANK
10.0
%
10
%
DRUGBANK
352.8
ng/ml
352.8
ng/ml
intravenous injection, IV;
DRUGBANK
0.4302
L/h/kg
7.17
ml/kg/min
Plasma clearance; dog;
DRUGBANK
0.905
L/kg
0.83-0.98
L/kg
dog;
DRUGBANK
1.5
h
1-2
h
DRUGBANK
69.0
%
69
%
Urinary excretion; PO, oral;
DRUGBANK
14.0
%
14
%
Faeces excretion;
DRUGBANK
DDPD09209
Pholcodine
398.4953
C23H30N2O4
[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
DB09209
5311356
53579
4470854
-2.0
-
-2.0
-
DRUGBANK
88.0
%
88
%
PO, oral;
DRUGBANK
1670.0
ng.h/ml
1.67
mg.h/l
PO, oral;
DRUGBANK
26.3
ng/ml
26.3
ng/ml
PO, oral;
DRUGBANK
1.3
h
1.3
h
PO, oral;
DRUGBANK
1.0
%
1
%
DRUGBANK
7.56
L/h
126.0
ml/min
PO, oral;
DRUGBANK
265.0
L
265.0
L
one-compartment;
DRUGBANK
3207.0
L
3207.0
L
two-compartment;
DRUGBANK
45.0
h
45
h
PO, oral;
DRUGBANK
55.0
h
55
h
PO, oral;
DRUGBANK
45.0
h
45
h
PO, oral;
DRUGBANK
22.0
%
21-23
%
DRUGBANK
DDPD09210
Piracetam
142.1558
C6H10N2O2
NC(=O)CN1CCCC1=O
DB09210
32010
4677
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
DRUGBANK
84000.0
ng/ml
84
ug/ml
Oral single dose;
DRUGBANK
1.0
h
1
h
PO, oral; fasting;
DRUGBANK
1.5
h
1.5
h
PO, oral; food;
food ↑ ;
DRUGBANK
72.0
h
3
day
DRUGBANK
5.1
L/h
80-90
ml/min
Total clearance;
DRUGBANK
0.6
L/kg
~0.6
L/kg
DRUGBANK
5.0
h
~5
h
PO, oral;
DRUGBANK
5.0
h
~5
h
intravenous injection, IV;
DRUGBANK
8.5
h
8.5
h
DRUGBANK
90.0
%
~80-100
%
Urinary excretion;
DRUGBANK
90.0
%
~90
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD09212
Loxoprofen
246.3016
C15H18O3
CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1
DB09212
3965
76172
3828
-2.0
-
-2.0
-
DRUGBANK
95.0
%
95
%
PO, oral;
DRUGBANK
0.16
L/kg
0.16
L/kg
DRUGBANK
15.0
h
~15
h
elimination half-life;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
25.0
%
20-30
%
Faeces excretion;
DRUGBANK
99.0
%
99
%
DRUGBANK
DDPD09213
Dexibuprofen
206.2808
C13H18O2
CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O
DB09213
39912
43415
https://www.drugs.com/international/dexibuprofen.html
36498
-2.0
-
-2.0
-
DRUGBANK
3.625
h
2.25-5
h
Tablet, PO, oral;
DRUGBANK
3.45
h
2.2-4.7
h
Tablet, PO, oral;
DRUGBANK
636.0
mg/kg
636.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09214
Dexketoprofen
254.2806
C16H14O3
[H][C@@](C)(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
DB09214
667550
76128
580922
-2.0
-
-2.0
-
DRUGBANK
0.5
h
0.5
h
PO, oral;
DRUGBANK
0.25
L/kg
<0.25
L/kg
DRUGBANK
1.65
h
1.65
h
DRUGBANK
75.0
%
~70-80
%
Urinary excretion;
DRUGBANK
DDPD09216
Tolfenamic acid
261.704
C14H12ClNO2
CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O
DB09216
610479
32243
530683
-2.0
-
-2.0
-
DRUGBANK
31500.0
ng.h/ml
13-50
mcg.h/ml
increasing doses ↑ ;
DRUGBANK
75.0
%
75
%
DRUGBANK
11100.0
ng/ml
11.1
mcg/ml
PO, oral;
DRUGBANK
1.49
h
0.94-2.04
h
DRUGBANK
20.0
%
20
%
Liver metabolism; Urinary excretion;
DRUGBANK
0.1585
L/h/kg
0.142-0.175
L/h/kg
DRUGBANK
4.344
L/h/kg
72.4
ml/min/kg
intravenous injection, IV;
DRUGBANK
0.1422
L/h/kg
2.37
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.495
L/kg
1.79-3.2
L/kg
intravenous injection, IV;
DRUGBANK
0.33
L/kg
0.33
L/kg
Steady state volume of distribution;
DRUGBANK
0.16
L/kg
0.16
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
10.755
h
8.01-13.50
h
DRUGBANK
6.1
h
6.1
h
intravenous injection, IV;
DRUGBANK
2.15
h
2.15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
600.0
mg/kg
200-1000
mg/kg
DRUGBANK
8.8
%
<8.8
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.7
%
99.7
%
DRUGBANK
DDPD09219
Bisoxatin
333.343
C20H15NO4
OC1=CC=C(C=C1)C1(OC2=CC=CC=C2NC1=O)C1=CC=C(O)C=C1
DB09219
28689
135955
http://www.drugs.com/international/bisoxatin.html
26684
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
DRUGBANK
DDPD09220
Nicorandil
211.177
C8H9N3O4
[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1
DB09220
47528
31905
43240
-2.0
-
-2.0
-
DRUGBANK
75.0
%
75
%
PO, oral;
DRUGBANK
300.0
ng/ml
300
ng/ml
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
108.0
h
96-120
h
DRUGBANK
108.0
h
96-120
h
DRUGBANK
69.0
L/h
1.15
L/min
Total clearance;
DRUGBANK
0.534
L/h/kg
8.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.2
L/kg
~1-1.4
L/kg
Apparent volume of distribution; PO, oral;
DRUGBANK
1.4
L/kg
1.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
elimination half-life;
DRUGBANK
3.6
h
3.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
626.0
mg/kg
626.0
mg/kg
PO, oral; mouse;
DRUGBANK
1220.0
mg/kg
1220.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
62.5
mg/kg
62.5
mg/kg
PO, oral; dog;
DRUGBANK
60.0
%
>60
%
Urinary excretion;
DRUGBANK
1.0
%
~1
%
Urinary excretion; Unchanged drug;
DRUGBANK
25.0
%
~25
%
plasma proteins;
DRUGBANK
DDPD09225
Zotepine
331.86
C18H18ClNOS
CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12
DB09225
5736
32316
5534
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
13.25
ng/ml
6.9-19.6
ng/ml
increasing doses;
increasing doses ↑ ;
DRUGBANK
3.0
h
2-4
h
increasing doses;
increasing doses ↑ ;
DRUGBANK
4.6
mg/h/kg
4.6
mg/h/kg
apparent clearance; PO, oral;
DRUGBANK
109.0
L/kg
109.0
L/kg
Apparent volume of distribution;
DRUGBANK
21.0
h
21
h
DRUGBANK
97.0
%
97
%
plasma proteins;
DRUGBANK
DDPD09236
Lacidipine
455.551
C26H33NO6
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC
DB09236
5311217
135737
4470736
-2.0
-
-2.0
-
DRUGBANK
10.0
%
<10
%
DRUGBANK
3.65
ng/ml
1.6-5.7
ug/L
Oral single dose; normal,healthy; adults;
DRUGBANK
1.5
h
0.5-2.5
h
PO, oral;
DRUGBANK
16.0
h
13-19
h
terminal half-life; at steady state;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
70.0
%
~70
%
Faeces excretion;
DRUGBANK
30.0
%
~30
%
Urinary excretion;
DRUGBANK
95.0
%
>95
%
DRUGBANK
DDPD09237
Levamlodipine
408.88
C20H25ClN2O5
CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
DB09237
9822750
53796
7998499
-2.0
-
-2.0
-
DRUGBANK
351.0
ng.h/ml
351±72
ng.h/ml
PO, oral; Derivative;
DRUGBANK
330.0
ng.h/ml
330±88
ng.h/ml
PO, oral; Derivative;
DRUGBANK
77.0
%
64-90
%
PO, oral;
DRUGBANK
6.13
ng/ml
6.13±1.29
ng/ml
PO, oral; Derivative;
DRUGBANK
5.07
ng/ml
5.07±1.09
ng/ml
PO, oral; Derivative;
DRUGBANK
9.0
h
6-12
h
PO, oral;
DRUGBANK
8.4
h
8.4±3.6
h
PO, oral; Derivative;
DRUGBANK
10.7
h
10.7±3.4
h
PO, oral; Derivative;
DRUGBANK
90.0
%
90
%
Liver metabolism; Inactive metabolite;
DRUGBANK
0.414
L/h/kg
6.9±1.6
ml/min/kg
PO, oral;
DRUGBANK
0.438
L/h/kg
7.3±2.1
ml/min/kg
PO, oral;
DRUGBANK
21.0
L/kg
21.0
L/kg
DRUGBANK
40.0
h
30-50
h
DRUGBANK
60.0
%
60
%
Urinary excretion;
DRUGBANK
93.0
%
93
%
plasma proteins;
DRUGBANK
DDPD09238
Manidipine
610.711
C35H38N4O6
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
DB09238
4008
135849
3868
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1.5
h
DRUGBANK
5.5
%
4-7
%
Urinary excretion;
DRUGBANK
23.0
%
22-24
%
Urinary excretion;
DRUGBANK
3.94
h
3.94
h
DRUGBANK
5.02
h
5.02
h
DRUGBANK
7.95
h
7.95
h
DRUGBANK
63.0
%
63
%
Faeces excretion;
DRUGBANK
3.31
%
3.31
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09241
Methylene blue
319.85
C16H18ClN3S
[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1
DB09241
6099
6872
5874
-2.0
-
-2.0
-
DRUGBANK
180.0
L/h
3.0±0.7
L/min
DRUGBANK
0.7
mg/kg
10.0
mg/kg
DRUGBANK
5.75
h
5-6.5
h
intravenous injection, IV;
DRUGBANK
1180.0
mg/kg
1180.0
mg/kg
Rattus, Rat;
DRUGBANK
75.0
%
~75
%
Urinary excretion; PO, oral;
DRUGBANK
74.0
%
71-77
%
plasma proteins; rabbit;
DRUGBANK
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Methylene Blue 1%
methylene blue
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Methylene Blue 1%
methylene blue
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Methylene Blue 1%
methylene blue
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Methylene Blue 1%
methylene blue
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Methylene Blue 1%
methylene blue
PDR
2.0
mg/kg/day
2
mg/kg/day
intravenous injection, IV
Methylene Blue 1%
methylene blue
PDR
DDPD09242
Moxonidine
241.677
C9H12ClN5O
COC1=NC(C)=NC(Cl)=C1NC1=NCCN1
DB09242
4810
7009
4645
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
DRUGBANK
88.0
%
88
%
DRUGBANK
15.0
%
10-20
%
Active metabolite;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
L/kg
1.8±0.4
L/kg
DRUGBANK
1.8
L/kg
1.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.25
h
2.2-2.3
h
elimination half-life;
DRUGBANK
2.7
h
2.6-2.8
h
elimination half-life;
DRUGBANK
2.2
h
2.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
Urinary excretion;
DRUGBANK
10.0
%
~10
%
plasma proteins;
DRUGBANK
DDPD09255
Dextran
N.A.
N.A.
C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(C=O)O)O)O)O)O)O)O)O)O)O)O
DB09255
4125253
-2.0
-
-2.0
-
DRUGBANK
0.12
L
~120
mL
DRUGBANK
1.9
h
1.9
h
DRUGBANK
42.0
h
42
h
DRUGBANK
10700.0
mg/kg
10700.0
mg/kg
Rattus, Rat;
DRUGBANK
DDPD09256
Tegafur
200.169
C8H9FN2O3
FC1=CN(C2CCCO2)C(=O)NC1=O
DB09256
5386
32188
5193
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
DRUGBANK
0.057
L/h/kg
0.95
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.0
L/m2
16.0
L/m2
DRUGBANK
0.62
L/kg
0.62
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
~11
h
elimination half-life;
DRUGBANK
8.69
h
8.69
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
930.0
mg/kg
930.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
775.0
mg/kg
775.0
mg/kg
PO, oral; mouse;
DRUGBANK
340.0
mg/kg
340.0
mg/kg
PO, oral; dog;
DRUGBANK
20.0
%
<20
%
Urinary excretion; Unchanged drug;
DRUGBANK
52.3
%
52.3
%
DRUGBANK
DDPD09257
Gimeracil
145.54
C5H4ClNO2
OC1=CC(=O)NC=C1Cl
DB09257
54679224
31652
3353
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
combination drug use;
DRUGBANK
0.5
h
0.5
h
PO, oral; Components;
DRUGBANK
1.0
h
1
h
PO, oral; Components;
DRUGBANK
2.0
h
2
h
PO, oral; Components;
DRUGBANK
17.0
L/m2
17.0
L/m2
DRUGBANK
9.0
h
6.7-11.3
h
DRUGBANK
3.6
h
3.1-4.1
h
DRUGBANK
5.65
h
1.8-9.5
h
DRUGBANK
32.2
%
32.2
%
DRUGBANK
DDPD09265
Lixisenatide
4858.56
C215H347N61O65S
CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O
DB09265
131704317
85662
17295846
-2.0
-
-2.0
-
DRUGBANK
2.25
h
1-3.5
h
subcutaneous injection, SC;
DRUGBANK
35.0
L/h
35.0
L/h
DRUGBANK
100.0
L
100.0
L
DRUGBANK
3.0
h
3
h
DRUGBANK
55.0
%
55
%
plasma proteins;
DRUGBANK
0.02
mg/day
20
mcg/day
subcutaneous injection, SC
Adlyxin
lixisenatide
PDR
0.02
mg/day
20
mcg/day
subcutaneous injection, SC
Adlyxin
lixisenatide
PDR
DDPD09267
Strontium ranelate
513.49
C12H6N2O8SSr2
[Sr++].[Sr++].[O-]C(=O)CN(CC([O-])=O)C1=C(C#N)C(CC([O-])=O)=C(S1)C([O-])=O
DB09267
6918182
5293393
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25（19-27）
%
PO, oral;
DRUGBANK
4.0
h
3-5
h
PO, oral;
DRUGBANK
336.0
h
2
week
DRUGBANK
0.0
%
0
%
DRUGBANK
0.72
L/h
12.0
ml/min
Plasma clearance;
DRUGBANK
0.42
L/h
7.0
ml/min
Renal clearance;
DRUGBANK
1.0
L/kg
1.0
L/kg
DRUGBANK
60.0
h
~60
h
effective half-life;
DRUGBANK
25.0
%
25
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09268
Picosulfuric acid
437.44
C18H15NO8S2
OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1
DB09268
5243
5053
-2.0
-
-2.0
-
DRUGBANK
0.05
ng/ml
0.05
ng/ml
Active metabolite;
DRUGBANK
7.0
h
7
h
DRUGBANK
7.4
h
7.4
h
terminal half-life;
DRUGBANK
0.19
%
0.19
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD09269
Phenylacetic acid
136.1479
C8H8O2
OC(=O)CC1=CC=CC=C1
DB09269
999
30745
10181341
-2.0
-
-2.0
-
DRUGBANK
19.2
L
19.2±3.3
L
DRUGBANK
2250.0
mg/kg
2250.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD09270
Ubidecarenone
863.3435
C59H90O4
COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O
DB09270
5281915
46245
4445197
-2.0
-
-2.0
-
DRUGBANK
11510.0
ng.h/ml
11.51
mcg.h/ml
PO, oral;
DRUGBANK
320.0
ng/ml
0.32
mcg/ml
PO, oral;
DRUGBANK
7.9
h
7.9
h
PO, oral;
DRUGBANK
504.0
h
3
week
PO, oral;
DRUGBANK
0.00118
L/h/kg
1.18
ml/h/kg
Total clearance;
DRUGBANK
20.4
L/kg
20.4
L/kg
DRUGBANK
21.7
h
21.7
h
DRUGBANK
60.0
%
>60
%
Faeces excretion; PO, oral;
DRUGBANK
8.3
%
8.3
%
Urinary excretion; PO, oral;
DRUGBANK
60.0
%
>60
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
DDPD09272
Eluxadoline
569.662
C32H35N5O5
COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O
DB09272
11250029
85980
http://www.drugs.com/cons/eluxadoline.html
9425062
-2.0
-
-2.0
-
DRUGBANK
1.02
%
1.02
%
PO, oral;
DRUGBANK
4.85
h
3.7-6
h
elimination half-life;
DRUGBANK
82.0
%
82
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
81.0
%
81
%
DRUGBANK
DDPD09274
Artesunate
384.425
C19H28O8
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4
DB09274
6917864
63918
5293084
-2.0
-
-2.0
-
DRUGBANK
700.0
ng.h/ml
0.7
ug.h/ml
DRUGBANK
3500.0
ng.h/ml
3.5
ug.h/ml
Active metabolite;
DRUGBANK
3300.0
ng/ml
3.3
ug/ml
DRUGBANK
3100.0
ng/ml
3.1
ug/ml
Active metabolite;
DRUGBANK
0.129166666666667
h
0.5-15
min
intravenous injection, IV; patients; adults;
DRUGBANK
0.708333333333333
h
21-64
min
intravenous injection, IV; patients; Children;
DRUGBANK
0.166666666666667
h
8-12
min
IM,intramuscular injection;
DRUGBANK
180.0
L/h
180.0
L/h
DRUGBANK
64.2
L/h/kg
1070
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
68.5
L
68.5
L
DRUGBANK
15.0
L/kg
15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.3
h
0.3(0.1-1.8)
h
elimination half-life;
DRUGBANK
1.3
h
1.3(0.9-2.9)
h
elimination half-life;
DRUGBANK
0.8
h
48
min
IM,intramuscular injection;
DRUGBANK
0.683333333333333
h
41
min
IM,intramuscular injection;
DRUGBANK
0.22
h
0.22
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
56.1
%
56.1
%
Urinary excretion; Rattus, Rat;
DRUGBANK
38.5
%
38.5
%
Faeces excretion; Rattus, Rat;
DRUGBANK
93.0
%
~93
%
plasma proteins;
DRUGBANK
DDPD09275
Bismuth subcitrate potassium
780.654
C12H8BiK5O14
[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O
DB09275
118987133
34989447
-2.0
-
-2.0
-
DRUGBANK
50000.0
ng/ml
>50
mg/L
DRUGBANK
0.5
h
30
min
DRUGBANK
120.0
h
~5
day
elimination half-life;
DRUGBANK
90.0
%
>90
%
DRUGBANK
DDPD09276
Sodium aurothiomalate
390.07
C4H3AuNa2O4S
[Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O
DB09276
16760302
35864
20946
-2.0
-
-2.0
-
DRUGBANK
4.5
h
3-6
h
IM,intramuscular injection;
DRUGBANK
0.000291666666666667
L/h/kg
7.0
ml/kg/day
DRUGBANK
0.26
L/kg
0.26±0.051
L/kg
Apparent volume of distribution;
DRUGBANK
300.0
h
12.5
day
DRUGBANK
35.0
%
35
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
9.4
%
9.4
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
87.5
%
~85-90
%
DRUGBANK
DDPD09277
Choline C 11
138.62
C5H14ClNO
[Cl-].C[N+](C)([11CH3])CCO
DB09277
14989482
72321
28514887
-2.0
-
-2.0
-
DRUGBANK
0.00084
L/h
0.014
ml/min
DRUGBANK
0.34
h
20.4
min
DRUGBANK
2.0
%
2
%
Urinary excretion;
DRUGBANK
DDPD09278
Activated charcoal
12.011
C
[C]
DB09278
297
27594
4575370
-2.0
-
-2.0
-
DRUGBANK
15400.0
mg/kg
15400.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09280
Lumacaftor
452.414
C24H18F2N2O5
CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O
DB09280
16678941
90951
http://www.drugs.com/mtm/ivacaftor-and-lumacaftor.html
17611836
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
PO, oral; high-fat meal;
DRUGBANK
2.38
L/h
2.38
L/h
apparent clearance;
DRUGBANK
86.0
L
86.0 (69.8)
L
Apparent volume of distribution; PO, oral; Cystic fibrosis; patients;
DRUGBANK
26.0
h
~26
h
DRUGBANK
51.0
%
51
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD09281
Magnesium trisilicate
260.857
Mg2O8Si3
[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
DB09281
5311266
4470779
-2.0
-
-2.0
-
DRUGBANK
18.0
h
16-20
h
DRUGBANK
33.0
%
33
%
DRUGBANK
DDPD09282
Molsidomine
242.235
C9H14N4O4
CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1
DB09282
5353788
92623
4090
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
DRUGBANK
56.0
%
56
%
Liver metabolism;
DRUGBANK
95.0
%
95
%
Urinary excretion;
DRUGBANK
0.66
L/h/kg
11
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
L
98.0
L
DRUGBANK
1.4
L/kg
1.4
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
h
1.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD09291
Rolapitant
500.485
C25H26F6N2O2
C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
DB09291
10311306
90908
http://www.drugs.com/varubi.html
8486772
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
DRUGBANK
0.96
L/h
0.96
L/h
DRUGBANK
0.0228
L/h/kg
0.38
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
460.0
L
460.0
L
DRUGBANK
176.0
h
169-183
h
terminal half-life;
DRUGBANK
148.5
h
148.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.2
%
14.2
%
Urinary excretion;
DRUGBANK
73.0
%
73
%
Faeces excretion;
DRUGBANK
99.8
%
99.8
%
plasma proteins; human, homo sapiens;
DRUGBANK
180.0
mg/dose
180
mg/dose
PO, oral; on day 1 of the chemotherapy regimen
Varubi
rolapitant
PDR
166.5
mg/dose
166.5
mg/dose
intravenous injection, IV; on day 1 of the chemotherapy regimen
Varubi
rolapitant
PDR
180.0
mg/dose
180
mg/dose
PO, oral; on day 1 of the chemotherapy regimen
Varubi
rolapitant
PDR
166.5
mg/dose
166.5
mg/dose
intravenous injection, IV; on day 1 of the chemotherapy regimen
Varubi
rolapitant
PDR
DDPD09292
Sacubitril
411.498
C24H29NO5
CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O
DB09292
9811834
134714
http://www.drugs.com/mtm/sacubitril-and-valsartan.html
7987587
-2.0
-
-2.0
-
DRUGBANK
60.0
%
>60
%
DRUGBANK
0.5
h
0.5
h
DRUGBANK
2.0
h
2
h
Active metabolite;
DRUGBANK
103.0
L
103.0
L
DRUGBANK
2.35
h
1.1-3.6
h
DRUGBANK
10.5
h
9.9-11.1
h
Metabolite;
DRUGBANK
60.0
%
52-68
%
Urinary excretion;
DRUGBANK
42.5
%
37-48
%
Faeces excretion;
DRUGBANK
95.5
%
94-97
%
plasma proteins;
DRUGBANK
DDPD09293
Iodide I-131
130.9067
I
[131I-]
DB09293
167195
https://www.drugs.com/pro/sodium-iodide-i-131.html
146281
-2.0
-
-2.0
-
DRUGBANK
90.0
%
>90
%
PO, oral;
DRUGBANK
192.96
h
8.04
day
physical half-life;
DRUGBANK
56.0
%
37-75
%
Urinary excretion;
DRUGBANK
DDPD09296
Ombitasvir
894.127
C50H67N7O8
COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1
DB09296
54767916
85183
http://www.drugs.com/mtm/ombitasvir-paritaprevir-and-ritonavir.html
31136214
-2.0
-
-2.0
-
DRUGBANK
48.0
%
48
%
DRUGBANK
5.0
h
5
h
DRUGBANK
0.1008
L/h/kg
1.68
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
173.0
L
173.0
L
at steady state;
DRUGBANK
2.32
L/kg
2.32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
23.0
h
21-25
h
elimination half-life;
DRUGBANK
28.49
h
28.49
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.2
%
90.2
%
Faeces excretion;
DRUGBANK
1.91
%
1.91
%
Urinary excretion;
DRUGBANK
99.9
%
99.9
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09297
Paritaprevir
765.89
C40H43N7O7S
[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1
DB09297
68498031
85188
https://www.drugs.com/cons/ombitasvir-paritaprevir-ritonavir-and-dasabuvir.html
32700634
-2.0
-
-2.0
-
DRUGBANK
194.0
ng/ml
194
ng/ml
DRUGBANK
4.5
h
4-5
h
DRUGBANK
0.3444
L/h/kg
5.74
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
103.0
L
~103
L
at steady state;
DRUGBANK
1.37
L/kg
1.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.5
h
5.5
h
DRUGBANK
8.71
h
8.71
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
88.0
%
~88
%
Faeces excretion;
DRUGBANK
8.8
%
8.8
%
Urinary excretion;
DRUGBANK
0.97
%
0.97
%
Faeces excretion; Unchanged drug;
DRUGBANK
97.8
%
97-98.6
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09299
Tenofovir alafenamide
476.474
C21H29N6O5P
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1
DB09299
9574768
90926
http://www.drugs.com/history/genvoya.html
7849225
-2.0
-
-2.0
-
DRUGBANK
73.0
%
73
%
Oral single dose;
DRUGBANK
270.0
ng.h/ml
270.0
ng.h/ml
Oral single dose;
DRUGBANK
16.0
ng/ml
16
ng/ml
Oral single dose;
DRUGBANK
2.0
h
2
h
Oral single dose;
DRUGBANK
117.0
L/h
117.0
L/h
DRUGBANK
61.7
L/h
61.7
L/h
severe renal function; patients;
DRUGBANK
100.0
L
>100
L
DRUGBANK
0.51
h
0.51
h
DRUGBANK
47.0
%
47
%
Bile excretion;
DRUGBANK
36.0
%
36
%
Urinary excretion;
DRUGBANK
80.0
%
~80
%
plasma proteins; in vivo;
DRUGBANK
25.0
mg/day
25
mg/day
PO, oral
Vemlidy
tenofovir alafenamide
PDR
25.0
mg/day
25
mg/day
PO, oral
Vemlidy
tenofovir alafenamide
PDR
DDPD09300
Butylscopolamine
360.473
C21H30NO4
CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1
DB09300
6852391
145701
21782131
-2.0
-
-2.0
-
DRUGBANK
0.535
%
0.25-0.82
%
DRUGBANK
1.125
h
0.25-2
h
DRUGBANK
72.0
L/h
1.2
L/min
Total clearance;
DRUGBANK
128.0
L
128.0
L
DRUGBANK
3.0
h
1-5
h
elimination half-life;
DRUGBANK
69.7
%
69.7
%
Faeces excretion;
DRUGBANK
4.4
%
4.4
%
Urinary excretion;
DRUGBANK
2.8
%
2.8
%
Bile excretion;
DRUGBANK
DDPD09301
Chondroitin sulfate
N.A.
N.A.
CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O
DB09301
24766
-2.0
-
-2.0
-
DRUGBANK
15.0
%
10-20
%
PO, oral;
DRUGBANK
4600.0
ng/ml
4.6
mcg/ml
PO, oral;
DRUGBANK
3800.0
ng/ml
3.8
mcg/ml
IM,intramuscular injection;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
1.5
h
1.5
h
IM,intramuscular injection;
DRUGBANK
84.0
h
3-4
day
PO, oral;
DRUGBANK
0.4
L
0.4
ml/g
Apparent volume of distribution; IM,intramuscular injection;
DRUGBANK
0.44
L
0.44
ml/g
Apparent volume of distribution; PO, oral;
DRUGBANK
15.0
h
15
h
DRUGBANK
15.0
h
15
h
Derivative;
DRUGBANK
4.58333333333333
h
275
min
elimination half-life; human, homo sapiens; IM,intramuscular injection;
DRUGBANK
5.16666666666667
h
310
min
elimination half-life; human, homo sapiens; PO, oral;
DRUGBANK
37.0
%
~37
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
0.23
%
0.23
%
DRUGBANK
DDPD09313
Ioxaglic acid
1268.886
C24H21I6N5O8
CNC(=O)C1=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C(I)C(N(C)C(C)=O)=C1I
DB09313
3742
31718
3611
-2.0
-
-2.0
-
DRUGBANK
2100000.0
ng/ml
2.1(1.8-2.8)
mg/ml
intravenous injection, IV; normal,healthy;
DRUGBANK
0.0333333333333333
h
2(1-3)
min
intravenous injection, IV; normal,healthy;
DRUGBANK
100.0
%
100
%
Unchanged drug;
DRUGBANK
0.245
L/kg
245.0
ml/kg
DRUGBANK
1.5
h
~90
min
DRUGBANK
DDPD09315
Xenon-133
132.9059
Xe
[133Xe]
DB09315
66376
59751
-2.0
-
-2.0
-
DRUGBANK
125.88
h
5.245
day
DRUGBANK
DDPD09316
Thallous Chloride
239.83
ClTl
Cl[Tl]
DB09316
24642
37117
23044
-2.0
-
-2.0
-
DRUGBANK
0.166666666666667
h
10
min
intravenous injection, IV;
DRUGBANK
6.5
L/kg
3.0-10
L/kg
DRUGBANK
0.0833333333333333
h
5
min
91%blood radioactivity;
DRUGBANK
40.0
h
40
h
9%blood radioactivity;
DRUGBANK
24.0
mg/kg
24.0
mg/kg
mouse;
DRUGBANK
DDPD09320
Procaine benzylpenicillin
570.71
C29H38N4O6S
CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O
DB09320
5903
52154
5692
-2.0
-
-2.0
-
DRUGBANK
0.5
h
30.0
min
elimination half-life; IM,intramuscular injection;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; mouse; Rattus, Rat;
DRUGBANK
75.0
%
~60-90
%
Urinary excretion;
DRUGBANK
60.0
%
~60
%
DRUGBANK
DDPD09321
Zinc oxide
81.408
OZn
O=[Zn]
DB09321
14806
36560
14122
-2.0
-
-2.0
-
DRUGBANK
7950.0
mg/kg
7950.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD09322
Zinc sulfate
161.472
O4SZn
[Zn++].[O-]S([O-])(=O)=O
DB09322
24424
35176
22833
-2.0
-
-2.0
-
DRUGBANK
25.0
%
20-30
%
PO, oral;
DRUGBANK
3.0
h
3
h
DRUGBANK
245.0
mg/kg
245.0
mg/kg
PO, oral; mouse;
DRUGBANK
781.0
mg/kg
781.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
6.42857142857143
mg/kg/day
45.0
mg/kg/7D
PO, oral; human, homo sapiens;
DRUGBANK
106.0
mg/kg
106.0
mg/kg
human, homo sapiens;
DRUGBANK
90.0
%
~90
%
Faeces excretion;
DRUGBANK
60.0
%
60
%
DRUGBANK
DDPD09324
Sulbactam
233.242
C8H11NO5S
[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O
DB09324
130313
9321
http://www.drugs.com/cdi/ampicillin-sulbactam.html
115306
-2.0
-
-2.0
-
DRUGBANK
68000.0
ng/ml
48-88
mcg/ml
DRUGBANK
15000.0
ng/ml
6-24
mcg/ml
DRUGBANK
0.25
h
15
min
intravenous injection, IV;
DRUGBANK
0.306
L/h/kg
5.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.32
L/kg
0.32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
h
~1
h
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
38.0
%
~38
%
human, homo sapiens;
DRUGBANK
DDPD09325
Sodium fluoride
41.9882
FNa
[F-].[Na+]
DB09325
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
5235
28741
5045
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
1140.0
ng.h/ml
1.14±0.12
ug.h/ml
PO, oral; different study;
DRUGBANK
100.0
%
~100
%
PO, oral; fasting;
DRUGBANK
848.0
ng/ml
848±116
ng/ml
Liquid;
DRUGBANK
0.665
h
0.33-1
h
PO, oral;
DRUGBANK
0.46
h
0.46±0.17
h
Liquid;
DRUGBANK
4.644
L/h
77.4±11.2
ml/min
Renal clearance; Tablet, PO, oral; normal,healthy; young; adults;
DRUGBANK
4.734
L/h
78.4 ± 6.9
ml/min
Renal clearance; Tablet, PO, oral; normal,healthy; young; adults;
DRUGBANK
2.4
L/h
35-45
ml/min
Renal clearance;
DRUGBANK
6.5
h
3-10
h
elimination half-life;
DRUGBANK
172800.0
h
20
year
DRUGBANK
44.0
mg/kg
44.0
mg/kg
PO, oral; mouse;
DRUGBANK
31.0
mg/kg
31.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
200.0
mg/kg
200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
0.05
mg/kg/day
0.05
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
10.0
%
~10
%
Faeces excretion;
DRUGBANK
DDPD09326
Ammonia N-13
16.03
H3N
[13NH3]
DB09326
119432
135980
106665
-2.0
-
-2.0
-
DRUGBANK
0.8
L
0.8
mL/g
DRUGBANK
0.0466666666666667
h
2.8
min
DRUGBANK
DDPD09327
Tegafur-uracil
312.257
C12H13FN4O5
O=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=O
DB09327
104747
94558
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
DRUGBANK
0.75
h
0.5-1
h
Derivative;
DRUGBANK
6.66
L/h
47-175
ml/min
DRUGBANK
59.0
L
59.0
L
DRUGBANK
474.0
L
474.0
L
DRUGBANK
11.0
h
11
h
DRUGBANK
0.5
h
20-40
min
elimination half-life;
DRUGBANK
52.0
%
52
%
DRUGBANK
DDPD09330
Osimertinib
499.619
C28H33N7O2
COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
DB09330
71496458
90943
http://www.drugs.com/tagrisso.html
31042598
-2.0
-
-2.0
-
DRUGBANK
6.0
h
6
h
DRUGBANK
14.2
L/h
14.2
L/h
PO, oral;
DRUGBANK
986.0
L
986.0
L
Average volume of distribution; at steady state;
DRUGBANK
48.0
h
48
h
DRUGBANK
68.0
%
68
%
Faeces excretion;
DRUGBANK
14.0
%
14
%
Urinary excretion;
DRUGBANK
2.0
%
2
%
Unchanged drug;
DRUGBANK
DDPD09332
Kappadione
422.084
C11H8Na4O8P2
[Na+].[Na+].[Na+].[Na+].CC1=C(OP([O-])([O-])=O)C2=CC=CC=C2C(OP([O-])([O-])=O)=C1
DB09332
8555
8237
-2.0
-
-2.0
-
DRUGBANK
49.32
L/h
0.822±0.254
L/min
Plasma clearance;
DRUGBANK
30.833
L
30.833±12.835
L
rabbit; Apparent volume of distribution;
DRUGBANK
0.452833333333333
h
27.17
min
elimination half-life; Active metabolite; rabbit;
DRUGBANK
DDPD09333
Iopodic acid
597.961
C12H13I3N2O2
CN(C)C=NC1=C(I)C=C(I)C(CCC(O)=O)=C1I
DB09333
5241
20473670
-2.0
-
-2.0
-
DRUGBANK
65.0
%
65
%
Faeces excretion;
DRUGBANK
35.0
%
35
%
Urinary excretion;
DRUGBANK
DDPD09340
Tyropanoic acid
641.026
C15H18I3NO3
CCCC(=O)NC1=C(I)C=C(I)C(CC(CC)C(O)=O)=C1I
DB09340
5611
135862
5409
-2.0
-
-2.0
-
DRUGBANK
720.0
mg/kg
720.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
5.0
%
<5
%
DRUGBANK
DDPD09342
Propoxycaine
294.395
C16H26N2O3
CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC
DB09342
6843
8496
6582
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
intravenous infusion, IV in drop;
DRUGBANK
0.666666666666667
h
40
min
PO, oral;
DRUGBANK
DDPD09343
Tipiracil
242.662
C9H11ClN4O2
ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
DB09343
6323266
90879
13243748
-2.0
-
-2.0
-
DRUGBANK
301.0
ng.h/ml
301.0
ng.h/ml
Oral single dose;
DRUGBANK
69.0
ng/ml
69
ng/ml
Oral single dose;
DRUGBANK
3.0
h
3
h
Oral single dose;
DRUGBANK
109.0
L/h
109.0
L/h
tumor; patients;
DRUGBANK
333.0
L
333.0
L
Drug combination; tumor; patients;
DRUGBANK
2.1
h
2.1
h
elimination half-life;
DRUGBANK
49.7
%
49.7
%
Faeces excretion;
DRUGBANK
27.0
%
27
%
Urinary excretion;
DRUGBANK
21.357
%
21.357
%
Urinary excretion; Unchanged drug;
DRUGBANK
23.96
%
23.96
%
Faeces excretion; Unchanged drug;
DRUGBANK
8.0
%
<8
%
plasma proteins;
DRUGBANK
DDPD09345
Pramocaine
293.407
C17H27NO3
CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1
DB09345
4886
8357
4717
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
750.0
mg/kg
750.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
DDPD09348
Propiolactone
72.063
C3H4O2
O=C1CCO1
DB09348
2365
49073
2275
-2.0
-
-2.0
-
DRUGBANK
3.75
h
225
min
DRUGBANK
DDPD09350
Piperonyl butoxide
338.4385
C19H30O5
CCCCOCCOCCOCC1=CC2=C(OCO2)C=C1CCC
DB09350
5794
32687
http://www.drugs.com/mtm/piperonyl-butoxide-and-pyrethrins-topical.html
5590
-2.0
-
-2.0
-
DRUGBANK
2.0
%
2
%
skin/dermal;
DRUGBANK
32.0
h
32
h
DRUGBANK
8685.0
mg/kg
4570-12800
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4000.0
mg/kg
2700-5300
mg/kg
PO, oral; rabbit;
DRUGBANK
DDPD09351
Levobetaxolol
307.434
C18H29NO3
CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1
DB09351
60657
59254
54669
-2.0
-
-2.0
-
DRUGBANK
20.0
h
20
h
DRUGBANK
DDPD09353
Octasulfur
256.52
S8
S1SSSSSSS1
DB09353
66348
29385
59726
-2.0
-
-2.0
-
DRUGBANK
0.0
null
0
null
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8437.0
mg/kg
>8437
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09357
Dexpanthenol
205.2515
C9H19NO4
CC(C)(CO)[C@@H](O)C(=O)NCCCO
DB09357
131204
https://www.drugs.com/pro/dexpanthenol.html
115991
-2.0
-
-2.0
-
DRUGBANK
9000.0
mg/kg
9.0
g/kg
Intraperitoneal, IP; mouse;
DRUGBANK
7000.0
mg/kg
7.0
g/kg
intravenous injection, IV; mouse;
DRUGBANK
15000.0
mg/kg
15.0
g/kg
PO, oral; mouse;
DRUGBANK
4000.0
mg/kg
4.0
g/kg
PO, oral; rabbit;
DRUGBANK
DDPD09372
Tannic acid
1701.206
C76H52O46
OC1=CC(=CC(O)=C1O)C(=O)OC1=C(O)C(O)=CC(=C1)C(=O)OC[C@H]1OC(OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H](OC(=O)C2=CC(OC(=O)C3=CC(O)=C(O)C(O)=C3)=C(O)C(O)=C2)[C@@H]1OC(=O)C1=CC(OC(=O)C2=CC(O)=C(O)C(O)=C2)=C(O)C(O)=C1
DB09372
75211
17288010
-2.0
-
-2.0
-
DRUGBANK
2260.0
mg/kg
2.26
g/kg
Rattus, Rat;
DRUGBANK
DDPD09374
Indocyanine green acid form
753.99
C43H49N2O6S2
CC1(C)\C(=C\C=C\C=C\C=C\C2=[N+](CCCCS(O)(=O)=O)C3=C(C4=CC=CC=C4C=C3)C2(C)C)N(CCCCS(O)(=O)=O)C2=C1C1=CC=CC=C1C=C2
DB09374
11967809
31696
https://www.drugs.com/pro/indocyanine-green.html
18109
-2.0
-
-2.0
-
DRUGBANK
0.0458333333333333
h
150-180
second
DRUGBANK
60.0
mg/kg
60.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
87.0
mg/kg
87.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
98.0
%
98
%
DRUGBANK
DDPD09376
Lapyrium
363.521
C21H35N2O3
CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1
DB09376
22660
135534
21241
-2.0
-
-2.0
-
DRUGBANK
18.0
mg/kg
18.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
8200.0
mg/kg
8.2
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09394
Phosphoric acid
97.9952
H3O4P
OP(O)(O)=O
DB09394
1004
26078
979
-2.0
-
-2.0
-
DRUGBANK
8.0
h
5-11
h
elimination half-life; normal renal function; Infants; Oral single dose;
DRUGBANK
8.0
h
5-11
h
elimination half-life; normal renal function; Infants; Oral single dose; Rectal Administration; overdose;
DRUGBANK
2740.0
mg/kg
2740.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
1530.0
mg/kg
1530.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
66.7
%
~66.7
%
Urinary excretion; adults; human, homo sapiens;
DRUGBANK
DDPD09395
Sodium acetate
82.0338
C2H3NaO2
[Na+].CC([O-])=O
DB09395
517045
32954
29105
-2.0
-
-2.0
-
DRUGBANK
25956.0
mg/kg
25956.0
mg/kg
Rattus, Rat;
DRUGBANK
DDPD09397
Technetium Tc-99m sulfur colloid
355.39
S8Tc
[99Tc].S1SSSSSSS1
DB09397
76957057
-2.0
-
-2.0
-
DRUGBANK
7.5
%
5-10
%
spleen metabolism;
DRUGBANK
6.02
h
6.02
h
physical half-life;
DRUGBANK
0.0416666666666667
h
2.5
min
elimination half-life; intravenous injection, IV;
DRUGBANK
DDPD09398
Fluoride ion F-18
18.0015
F
[18F-]
DB09398
23690531
8373100
-2.0
-
-2.0
-
DRUGBANK
5.85
L/h
48-147
ml/min
Renal clearance;
DRUGBANK
0.6
L/kg
0.5-0.7
L/kg
DRUGBANK
1.83333333333333
h
110
min
DRUGBANK
20.0
%
>20
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD09407
Magnesium chloride
95.211
Cl2Mg
[Mg++].[Cl-].[Cl-]
DB09407
5360315
6636
22987
-2.0
-
-2.0
-
DRUGBANK
50.0
%
40-60
%
PO, oral;
DRUGBANK
25.5
%
15-36
%
PO, oral; increasing doses;
increasing doses ↓ ;
DRUGBANK
27.7
h
27.7
h
elimination half-life; adults; overdose;
DRUGBANK
775.0
mg/kg
775.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
7600.0
mg/kg
7600.0
mg/kg
PO, oral; mouse;
DRUGBANK
8100.0
mg/kg
8100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
176.0
mg/kg
176.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
30.0
%
30
%
DRUGBANK
DDPD09409
Magnesium acetate tetrahydrate
214.453
C4H14MgO8
O.O.O.O.[Mg++].CC([O-])=O.CC([O-])=O
DB09409
134717
118734
-2.0
-
-2.0
-
DRUGBANK
0.3
L/kg
0.2-0.4
L/kg
DRUGBANK
27.7
h
27.7
h
elimination half-life; adults; overdose;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral;
DRUGBANK
97.0
%
97
%
Urinary excretion; hypermagnesemia;
DRUGBANK
30.0
%
30
%
DRUGBANK
DDPD09413
Monopotassium phosphate
136.0855
H2KO4P
[K+].OP(O)([O-])=O
DB09413
516951
63036
22914
-2.0
-
-2.0
-
DRUGBANK
7.7
h
4.8-10.6
h
normal,healthy; Children; overdose;
DRUGBANK
17.0
h
17
h
renal insufficiency; Children;
DRUGBANK
4640.0
mg/kg
>4640
mg/kg
skin/dermal; rabbit;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
10.0
%
10
%
Faeces excretion;
DRUGBANK
1.0
mmol/kg/dose
1
mmol/kg/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
8.0
tabLets/day
8
tabLets/day
PO, oral
K-Phos Original
potassium acid phosphate
PDR
1.0
mmoL/kg/dose
1
mmoL/kg/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
50.0
mmoL/dose
50
mmoL/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
1.0
mmol/kg/dose
1
mmol/kg/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
8.0
tablets/day
8
tablets/day
PO, oral
K-Phos Original
potassium acid phosphate
PDR
1.0
mmol/kg/dose
1
mmol/kg/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
50.0
mmol/dose
50
mmol/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
1.0
mmoL/kg/dose
1
mmoL/kg/dose
intravenous injection, IV
K-Phos Original
potassium acid phosphate
PDR
DDPD09414
Dipotassium phosphate
174.1759
HK2O4P
[K+].[K+].OP([O-])([O-])=O
DB09414
24450
131527
22858
-2.0
-
-2.0
-
DRUGBANK
7.7
h
4.8-10.6
h
normal,healthy; Children; overdose;
DRUGBANK
17.0
h
17
h
renal insufficiency; Children;
DRUGBANK
DDPD09418
Potassium perchlorate
138.549
ClKO4
[K+].[O-][Cl](=O)(=O)=O
DB09418
516900
22913
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
7.0
h
~6-8
h
human, homo sapiens;
DRUGBANK
3621.0
mg/kg
3621.0
mg/kg
PO, oral; mouse;
DRUGBANK
95.0
%
~95
%
Urinary excretion;
DRUGBANK
DDPD09419
Xylose
150.1299
C5H10O5
OC[C@@H](O)[C@H](O)[C@@H](O)C=O
DB09419
644160
15936
559198
-2.0
-
-2.0
-
DRUGBANK
69.4
%
~69.4
%
PO, oral;
DRUGBANK
69.0
%
69
%
DRUGBANK
530.0
ng/ml
0.53
mg/L
DRUGBANK
1.2
h
72
min
DRUGBANK
5.34
L/h
89.0
ml/min
Renal clearance; normal,healthy;
DRUGBANK
10.8
L/h
180.0
ml/min
Plasma clearance;
DRUGBANK
5.46
L/h
91.0
ml/min
Plasma clearance;
DRUGBANK
0.22
L/kg
0.22
L/kg
normal,healthy;
DRUGBANK
1.25
h
75
min
elimination half-life; normal,healthy;
DRUGBANK
23000.0
mg/kg
23000.0
mg/kg
PO, oral; mouse;
DRUGBANK
50.0
%
~50
%
Urinary excretion; normal renal function;
DRUGBANK
DDPD09420
Iodide I-123
122.9061
I
[123I-]
DB09420
135300
https://www.drugs.com/pro/sodium-iodide-i-123.html
119193
-2.0
-
-2.0
-
DRUGBANK
13.2
h
13.2
h
physical half-life;
DRUGBANK
DDPD09425
Indium In-111 pentetate
501.23
C14H20InN3O10
[111In+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)CC(O)=O
DB09425
131704319
https://www.drugs.com/pro/indium-dtpa.html
25048228
-2.0
-
-2.0
-
DRUGBANK
67.9
h
67.9
h
DRUGBANK
65.0
%
~65
%
Urinary excretion;
DRUGBANK
85.0
%
85
%
Urinary excretion;
DRUGBANK
DDPD09449
Sodium phosphate, monobasic
119.977
H2NaO4P
[Na+].OP(O)([O-])=O
DB09449
23672064
37585
22626
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1-3
h
Liquid;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
8290.0
mg/kg
8290.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09460
Sodium carbonate
105.9884
CNa2O3
[Na+].[Na+].[O-]C([O-])=O
DB09460
10340
29377
9916
-2.0
-
-2.0
-
DRUGBANK
714.0
mg/kg
714.0
mg/kg
PO, oral; Male, men;
DRUGBANK
6600.0
mg/kg
6600.0
mg/kg
PO, oral; mouse;
DRUGBANK
2210.0
mg/kg
2210.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
4090.0
mg/kg
4090.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09462
Glycerin
92.0938
C3H8O3
OCC(O)CO
DB09462
753
17754
733
-2.0
-
-2.0
-
DRUGBANK
0.625
h
30-45
min
DRUGBANK
12600.0
mg/kg
12600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
4090.0
mg/kg
4090.0
mg/kg
PO, oral; mouse;
DRUGBANK
1428.0
mg/kg
1428.0
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
10.5
%
~7-14
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD09472
Sodium sulfate
142.042
Na2O4S
[Na+].[Na+].[O-]S([O-])(=O)=O
DB09472
24436
32149
22844
-2.0
-
-2.0
-
DRUGBANK
100.0
%
~100
%
PO, oral; Rattus, Rat;
DRUGBANK
8.5
h
8.5
h
DRUGBANK
5989.0
mg/kg
5989.0
mg/kg
PO, oral; mouse;
DRUGBANK
1220.0
mg/kg
1220.0
mg/kg
intravenous injection, IV; rabbit;
DRUGBANK
DDPD09473
Indium In-111 oxyquinoline
543.364
C27H18InN3O3
[111In+3].[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2.[O-]C1=CC=CC2=C1N=CC=C2
DB09473
119117
https://www.drugs.com/pro/indium-oxyquinoline.html
106429
-2.0
-
-2.0
-
DRUGBANK
67.2
h
67.2
h
DRUGBANK
4.15
h
2.8-5.5
h
elimination half-life;
DRUGBANK
90.0
h
64-116
h
elimination half-life;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Faeces excretion;
DRUGBANK
DDPD09477
Enalaprilat
348.3936
C18H24N2O5
[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O
DB09477
5462501
4786
4575429
-2.0
-
-2.0
-
DRUGBANK
9.48
L/h
158±47
ml/min
Renal clearance;
DRUGBANK
0.096
L/h/kg
1.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.38
L/kg
0.38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
11
h
DRUGBANK
39.0
h
39
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
90.0
%
>90
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
~50
%
plasma proteins;
DRUGBANK
DDPD09479
Rubidium Rb-82
81.9177
Rb
[82Rb+]
DB09479
71357
8351588
-2.0
-
-2.0
-
DRUGBANK
0.0211666666666667
h
1.27
min
DRUGBANK
DDPD09481
Magnesium carbonate
84.314
CMgO3
[Mg++].[O-]C([O-])=O
DB09481
11029
31793
10563
-2.0
-
-2.0
-
DRUGBANK
50.0
%
40-60
%
PO, oral; increasing doses;
increasing doses ↓ ;
DRUGBANK
0.0
%
0
%
DRUGBANK
0.3
L/kg
0.2-0.4
L/kg
DRUGBANK
27.7
h
27.7
h
overdose; adults;
DRUGBANK
30.0
%
30
%
DRUGBANK
DDPD09484
Sodium fluorophosphate
143.949
FNa2O3P
[Na+].[Na+].[O-]P([O-])(F)=O
DB09484
86431
22686
-2.0
-
-2.0
-
DRUGBANK
570.0
mg/kg
502-638
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09487
Iotrolan
1626.242
C37H48I6N6O18
CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I
DB09487
31715
3607
-2.0
-
-2.0
-
DRUGBANK
0.0894
L/h/kg
1.49
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.03
h
2.03
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD09488
Acrivastine
348.4382
C22H24N2O2
[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O
DB09488
5284514
83168
https://www.drugs.com/ppa/acrivastine-and-pseudoephedrine.html
4447574
-2.0
-
-2.0
-
DRUGBANK
1.14
h
1.14±0.23
h
Capsule, PO, Oral;
DRUGBANK
0.174
L/h/kg
2.9±0.7
ml/min/kg
DRUGBANK
0.46
L/kg
0.46±0.05
L/kg
DRUGBANK
1.9
h
1.9±0.3
h
terminal half-life; Oral single dose;
DRUGBANK
3.5
h
3.5±1.9
h
terminal half-life; at steady state;
DRUGBANK
3.8
h
3.8±1.4
h
Metabolite;
DRUGBANK
84.0
%
~84
%
Urinary excretion; normal,healthy; human, homo sapiens;
DRUGBANK
13.0
%
~13
%
Faeces excretion; normal,healthy; human, homo sapiens;
DRUGBANK
50.0
%
50±2
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09490
Indium In-111 chloride
217.26
Cl3In
Cl[111In](Cl)Cl
DB09490
49800058
4954694
-2.0
-
-2.0
-
DRUGBANK
67.2
h
2.8
day
DRUGBANK
DDPD09494
Cetyl alcohol
242.4406
C16H34O
CCCCCCCCCCCCCCCCO
DB09494
2682
16125
2581
-2.0
-
-2.0
-
DRUGBANK
26.0
%
26
%
PO, oral; poultry;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; mouse;
DRUGBANK
2600.0
mg/kg
>2600
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD09496
Octinoxate
290.3972
C18H26O3
[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
DB09496
5355130
88667
4511170
-2.0
-
-2.0
-
DRUGBANK
7.0
ng/ml
7
ng/ml
skin/dermal; Male, men;
DRUGBANK
16.0
ng/ml
16
ng/ml
skin/dermal; Female, women;
DRUGBANK
DDPD09498
Strontium chloride Sr-89
159.81
Cl2Sr
[Cl-].[Cl-].[89Sr++]
DB09498
5362485
36383
64523
-2.0
-
-2.0
-
DRUGBANK
53.5
L
40-67
L
DRUGBANK
1212.0
h
50.5
day
DRUGBANK
35.0
%
30-40
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD09499
Thiosulfuric acid
114.144
H2O3S2
OS(O)(=O)=S
DB09499
24478
29279
22886
-2.0
-
-2.0
-
DRUGBANK
0.1116
L/h/kg
1.86±0.45
ml/min/kg
DRUGBANK
0.15
L/kg
150.0
ml/kg
DRUGBANK
0.291666666666667
h
15-20
min
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD09502
Fludeoxyglucose (18F)
181.15
C6H11FO5
[H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)CO
DB09502
68614
49136
61878
-2.0
-
-2.0
-
DRUGBANK
0.191666666666667
h
10-13
min
DRUGBANK
DDPD09512
Simethicone
238.461
C6H18O4Si3
O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C
DB09512
4938661
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
100.0
%
100
%
Faeces excretion;
DRUGBANK
4070.0
mg/kg
4070.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
480.0
mg/day
480
mg/day
PO, oral
Gas-X
simethicone
PDR
240.0
mg/day
240
mg/day
PO, oral
Gas-X
simethicone
PDR
500.0
mg/day
500
mg/day
PO, oral
Gas-X
simethicone
PDR
480.0
mg/day
480
mg/day
PO, oral
Gas-X
simethicone
PDR
500.0
mg/day
500
mg/day
PO, oral
Gas-X
simethicone
PDR
240.0
mg/day
240
mg/day
PO, oral
Gas-X
simethicone
PDR
DDPD09513
Urea C-14
62.048
CH4N2O
N[14C](N)=O
DB09513
11457650
134711
https://www.drugs.com/pro/pytest.html
9632491
-2.0
-
-2.0
-
DRUGBANK
12.0
h
~12
h
Urinary excretion;
DRUGBANK
960.0
h
40
day
elimination half-life;
DRUGBANK
DDPD09516
Mequinol
124.1372
C7H8O2
COC1=CC=C(O)C=C1
DB09516
9015
69441
8665
-2.0
-
-2.0
-
DRUGBANK
1.0
h
30-90
min
elimination half-life; intravenous infusion, IV in drop; melanoma; patients;
DRUGBANK
DDPD09517
Sodium ferric gluconate complex
2089.309
C66H121Fe2NaO65
[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
DB09517
76968835
34989638
-2.0
-
-2.0
-
DRUGBANK
9.92
ng/ml
9.92(4.22-23.62)
ng/ml
skin/dermal; normal,healthy;
DRUGBANK
2.0
h
2(1-2)
h
skin/dermal; normal,healthy;
DRUGBANK
4.185
L/h
3.02-5.35
L/h
Total clearance; adults; patients;
DRUGBANK
6.3
L
6.0
L
DRUGBANK
1.0
h
~1
h
elimination half-life; drug bound iron;
normal BMI → ;
DRUGBANK
0.825
h
>=0.825
h
elimination half-life; adults;
DRUGBANK
1.45
h
<=1.45
h
elimination half-life; adults;
DRUGBANK
2.0
h
2
h
pediatric patients;
DRUGBANK
2.5
h
2.5
h
pediatric patients;
DRUGBANK
DDPD09526
Hydroquinone
110.1106
C6H6O2
OC1=CC=C(O)C=C1
DB09526
785
17594
http://www.drugs.com/mtm/hydroquinone-topical.html
764
-2.0
-
-2.0
-
DRUGBANK
DDPD09534
Ecamsule
562.69
C28H34O8S2
CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC1=CC=C(C=C2C3CCC(CS(O)(=O)=O)(C2=O)C3(C)C)C=C1
DB09534
9915879
135830
28534218
-2.0
-
-2.0
-
DRUGBANK
0.1
%
<0.1
%
DRUGBANK
0.0
%
0
%
DRUGBANK
DDPD09536
Titanium dioxide
79.865
O2Ti
O=[Ti]=O
DB09536
26042
32234
24256
-2.0
-
-2.0
-
DRUGBANK
3360.0
h
140
day
Rattus, Rat;
DRUGBANK
336.0
h
14
day
distribution half-life;
DRUGBANK
2112.0
h
88
day
elimination half-life;
DRUGBANK
0.1
mg/kg
>100
ug/kg
Intratracheal; Rattus, Rat;
DRUGBANK
DDPD09543
Methyl salicylate
152.1473
C8H8O3
COC(=O)C1=CC=CC=C1O
DB09543
4133
31832
https://www.drugs.com/international/methyl-salicylate.html
13848808
-2.0
-
-2.0
-
DRUGBANK
16.0
%
12-20
%
skin/dermal;
DRUGBANK
21.25
%
11.8-30.7
%
skin/dermal;
DRUGBANK
2.5
h
2-3
h
elimination half-life; increasing doses;
DRUGBANK
12.0
h
~12
h
elimination half-life;
DRUGBANK
22.5
h
15-30
h
DRUGBANK
1100.0
mg/kg
1100.0
mg/kg
PO, oral; mouse;
DRUGBANK
887.0
mg/kg
887.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1300.0
mg/kg
1300.0
mg/kg
PO, oral; rabbit;
DRUGBANK
228.0
mg/kg
228.0
mg/kg
PO, oral; Children; human, homo sapiens;
DRUGBANK
506.0
mg/kg
506.0
mg/kg
PO, oral; adults; human, homo sapiens;
DRUGBANK
DDPD09546
Iobenguane sulfate I-123
640.26
C16H22I2N6O4S
OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1
DB09546
56840904
32701571
-2.0
-
-2.0
-
DRUGBANK
1.0
%
<1
%
Faeces excretion;
DRUGBANK
DDPD09552
Thonzonium
511.818
C32H55N4O
CCCCCCCCCCCCCCCC[N+](C)(C)CCN(CC1=CC=C(OC)C=C1)C1=NC=CC=N1
DB09552
5456
94514
5257
-2.0
-
-2.0
-
DRUGBANK
DDPD09555
Dexchlorpheniramine maleate
390.86
C20H23ClN2O4
OC(=O)\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1
DB09555
5281070
4465
4444527
-2.0
-
-2.0
-
DRUGBANK
40.5
%
40.5
%
PO, oral;
DRUGBANK
9.8
L/h
9.8
L/h
DRUGBANK
321.0
L
321.0
L
DRUGBANK
25.0
h
20-30
h
DRUGBANK
38.0
%
38
%
plasma proteins;
DRUGBANK
20.0
%
20
%
DRUGBANK
23.0
%
23
%
DRUGBANK
DDPD09561
Sodium glycerophosphate
216.036
C3H7Na2O6P
[Na+].[Na+].OCC(O)COP([O-])([O-])=O
DB09561
22251426
14071
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
DRUGBANK
2.06
h
2.06
h
elimination half-life;
DRUGBANK
DDPD09563
Choline C-11
103.173
C5H14NO
C[N+](C)([11CH3])CCO
DB09563
449688
72322
396147
-2.0
-
-2.0
-
DRUGBANK
2.0
%
<2
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD09570
Ixazomib
361.03
C14H19BCl2N2O4
CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B(O)O
DB09570
25183872
90942
http://www.drugs.com/ninlaro.html
25027391
-2.0
-
-2.0
-
DRUGBANK
58.0
%
58
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
42.0
%
42
%
DRUGBANK
26.0
%
26
%
DRUGBANK
16.0
%
16
%
DRUGBANK
6.0
%
6
%
DRUGBANK
5.0
%
5
%
DRUGBANK
5.0
%
5
%
DRUGBANK
1.0
%
<1
%
DRUGBANK
0.03
L/h/kg
0.5
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
543.0
L
543.0
L
Steady state volume of distribution;
DRUGBANK
3.61
L/kg
3.61
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
228.0
h
9.5
day
terminal half-life;
DRUGBANK
97.0
h
97
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
62.0
%
62
%
Urinary excretion;
DRUGBANK
22.0
%
22
%
Faeces excretion;
DRUGBANK
99.0
%
99
%
DRUGBANK
4.0
mg/dose
4
mg/dose
PO, oral
Ninlaro
ixazomib
PDR
4.0
mg/dose
4
mg/dose
PO, oral
Ninlaro
ixazomib
PDR
DDPD09571
Levmetamfetamine
149.237
C10H15N
CN[C@H](C)CC1=CC=CC=C1
DB09571
36604
136013
33634
-2.0
-
-2.0
-
DRUGBANK
14.15
h
13.3-15
h
elimination half-life;
DRUGBANK
DDPD11056
Stannous chloride
189.62
Cl2Sn
[Cl-].[Cl-].[Sn++]
DB11056
78067
22887
-2.0
-
-2.0
-
DRUGBANK
DDPD11060
Polyvinyl alcohol
N.A.
N.A.
C=CO
DB11060
11199
-2.0
-
-2.0
-
DRUGBANK
1.5
h
90
min
intravenous injection, IV;
DRUGBANK
0.12
h
7.2
min
ophthalmic administration; ophthalmic administration;
DRUGBANK
20000.0
mg/kg
20.0
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
14700.0
mg/kg
14.7
g/kg
PO, oral; mouse;
DRUGBANK
DDPD11062
Octisalate
250.3334
C15H22O3
CCCCC(CC)COC(=O)C1=C(O)C=CC=C1
DB11062
88639
8061
-2.0
-
-2.0
-
DRUGBANK
0.0
null
0
null
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD11064
Homosalate
262.349
C16H22O3
CC1CC(CC(C)(C)C1)OC(=O)C1=C(O)C=CC=C1
DB11064
91642
8059
-2.0
-
-2.0
-
DRUGBANK
0.0
null
0
null
DRUGBANK
DDPD11068
Selenic acid
144.97
H2O4Se
O[Se](O)(=O)=O
DB11068
1089
18170
1058
-2.0
-
-2.0
-
DRUGBANK
1665.0
ng/ml
0.79-2.54
mg/L
PO, oral; sheep;
DRUGBANK
9.5
h
7-12
h
PO, oral; sheep;
DRUGBANK
313.0
h
313
h
elimination half-life; Oral single dose; sheep;
DRUGBANK
142.0
h
142
h
elimination half-life; Oral single dose; sheep;
DRUGBANK
0.5
mg/kg
0.5
mg/kg
IM,intramuscular injection; sheep;
DRUGBANK
DDPD11071
Phenyl salicylate
214.2167
C13H10O3
OC1=CC=CC=C1C(=O)OC1=CC=CC=C1
DB11071
8361
34918
8058
-2.0
-
-2.0
-
DRUGBANK
1.1
h
1.1
h
DRUGBANK
3000.0
mg/kg
3000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11072
Hydrogen fluoride
20.0063
FH
F
DB11072
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
14917
29228
14214
-2.0
-
-2.0
-
DRUGBANK
0.02
mg/kg
0.02
ppm
inhalation, IH;
DRUGBANK
DDPD11079
Trolamine salicylate
287.312
C13H21NO6
OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
DB11079
25213
23549
-2.0
-
-2.0
-
DRUGBANK
0.024
L
24.0
mL
Rattus, Rat; Total volume of distribution;
DRUGBANK
1.4
%
1.4
%
Urinary excretion; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD11081
Aluminum chloride
133.341
AlCl3
Cl[Al](Cl)Cl
DB11081
24012
30114
22445
-2.0
-
-2.0
-
DRUGBANK
23.5
%
17-30
%
PO, oral;
DRUGBANK
0.57
%
0.57
%
PO, oral; rabbit;
DRUGBANK
0.00887
L/h/kg
8.87±1.76
ml/h/kg
PO, oral;
DRUGBANK
0.0384
L/kg
38.4±6.4
ml/kg
Steady state volume of distribution; PO, oral;
DRUGBANK
5.29
h
5.29±0.47
h
PO, oral;
DRUGBANK
3470.0
mg/kg
3470.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2
g/kg
skin/dermal; rabbit;
DRUGBANK
98.0
%
~98
%
plasma proteins; PO, oral;
DRUGBANK
DDPD11085
Resorcinol
110.1106
C6H6O2
OC1=CC(O)=CC=C1
DB11085
5054
27810
4878
-2.0
-
-2.0
-
DRUGBANK
14.0
h
~14
h
elimination half-life; adults; Male, men; skin/dermal;
DRUGBANK
DDPD11089
Docusate
422.577
C20H38O7S
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O
DB11089
534
https://www.drugs.com/mtm/colace-oral-rectal.html
10862
-2.0
-
-2.0
-
DRUGBANK
1900.0
mg/kg
1900.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
240.0
mg/day
240
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
360.0
mg/day
360
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
240.0
mg/day
240
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
360.0
mg/day
360
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
240.0
mg/day
240
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
360.0
mg/day
360
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
240.0
mg/day
240
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
360.0
mg/day
360
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
849.0
mg/day
849
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
150.0
mg/day
150
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
283.0
mg/day
283
mg/day
Rectal Administration
Colace Capsules
docusate sodium
PDR
40.0
mg/day
40
mg/day
Capsule, PO, Oral
Colace Capsules
docusate sodium
PDR
DDPD11090
Potassium nitrate
101.1032
KNO3
[K+].[O-][N+]([O-])=O
DB11090
24434
63043
22843
-2.0
-
-2.0
-
DRUGBANK
1901.0
mg/kg
1901.0
mg/kg
PO, oral; rabbit;
DRUGBANK
3750.0
mg/kg
3750.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11091
Hydrogen peroxide
34.0147
H2O2
OO
DB11091
784
16240
763
-2.0
-
-2.0
-
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
PO, oral; mouse;
DRUGBANK
4060.0
mg/kg
4060.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; pig;
DRUGBANK
DDPD11092
Stannous fluoride
156.71
F2Sn
F[Sn]F
DB11092
24550
135933
https://www.drugs.com/pro/stannous-fluoride-oral-rinse.html
22956
-2.0
-
-2.0
-
DRUGBANK
0.216666666666667
h
13
min
DRUGBANK
360.0
mg/kg
360.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
skin/dermal;
DRUGBANK
DDPD11093
Calcium citrate
498.432
C12H10Ca3O14
[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
DB11093
13136
12584
-2.0
-
-2.0
-
DRUGBANK
4.25
h
3.5-5
h
PO, oral;
DRUGBANK
46.4
%
~46.4
%
plasma proteins;
DRUGBANK
DDPD11096
Meradimate
275.392
C17H25NO2
CC(C)C1CCC(C)CC1OC(=O)C1=CC=CC=C1N
DB11096
135974
8312
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
skin/dermal;
DRUGBANK
0.0
null
0
null
DRUGBANK
DDPD11098
Potassium bicarbonate
100.1151
CHKO3
[K+].OC([O-])=O
DB11098
516893
81862
55053
-2.0
-
-2.0
-
DRUGBANK
7.0
h
<7
h
DRUGBANK
90.0
%
~90
%
Urinary excretion;
DRUGBANK
10.0
%
~10
%
Faeces excretion;
DRUGBANK
100.0
mEq/day
100
mEq/day
PO, oral
Klor-Con/EF
potassium bicarbonate effervescent
PDR
200.0
mEq/day
200
mEq/day
PO, oral
Klor-Con/EF
potassium bicarbonate effervescent
PDR
100.0
mEq/day
100
mEq/day
PO, oral
Klor-Con/EF
potassium bicarbonate effervescent
PDR
200.0
mEq/day
200
mEq/day
PO, oral
Klor-Con/EF
potassium bicarbonate effervescent
PDR
DDPD11100
Allantoin
158.1154
C4H6N4O3
NC(=O)NC1NC(=O)NC1=O
DB11100
15676
199
-2.0
-
-2.0
-
DRUGBANK
7.38
L/h
123.0
ml/min
Renal clearance; normal,healthy;
DRUGBANK
1.5
null
1-2
null
DRUGBANK
DDPD11102
N-acetyltyrosine
223.2252
C11H13NO4
CC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
DB11102
68310
21563
61606
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1-2.5
h
horse; sheep; cattle;
DRUGBANK
DDPD11104
Sulfur hexafluoride
146.05
F6S
FS(F)(F)(F)(F)F
DB11104
17358
30496
16425
-2.0
-
-2.0
-
DRUGBANK
0.025
h
1-2
min
intravenous injection, IV;
DRUGBANK
0.025
h
1-2
min
intravenous injection, IV;
DRUGBANK
88.0
%
88
%
lung excretion;
DRUGBANK
341.0
L
341.0
L
Steady state volume of distribution; Drug combination; normal,healthy;
DRUGBANK
710.0
L
710.0
L
Steady state volume of distribution; Drug combination; normal,healthy;
DRUGBANK
0.166666666666667
h
~10
min
terminal half-life;
DRUGBANK
DDPD11110
Magnesium citrate
451.113
C12H10Mg3O14
[Mg++].[Mg++].[Mg++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
DB11110
6099959
131391
2925651
-2.0
-
-2.0
-
DRUGBANK
DDPD11115
Ensulizole
274.29
C13H10N2O3S
OS(=O)(=O)C1=CC2=C(C=C1)N=C(N2)C1=CC=CC=C1
DB11115
33919
135132
31267
-2.0
-
-2.0
-
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
16000.0
mg/kg
>16000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11117
Undecylenic acid
184.2753
C11H20O2
OC(=O)CCCCCCCCC=C
DB11117
35045
10771160
-2.0
-
-2.0
-
DRUGBANK
2500.0
mg/kg
2500.0
mg/kg
PO, oral; nasal spray; Rattus, Rat;
DRUGBANK
8150.0
mg/kg
8150.0
mg/kg
PO, oral; nasal spray; mouse;
DRUGBANK
50.0
mg/kg
50.0
mg/kg
skin/dermal; nasal spray; guinea pigs;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; nasal spray; Rattus, Rat;
DRUGBANK
DDPD11118
Ammonia
N.A.
N.A.
N
DB11118
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
222
-2.0
-
-2.0
-
DRUGBANK
0.000833333333333333
h
<3
second
normal,healthy; Rattus, Rat;
DRUGBANK
1.7
mg/kg
1.7
ppm
inhalation, IH;
DRUGBANK
0.1
mg/kg
0.1
ppm
inhalation, IH;
DRUGBANK
DDPD11119
Sodium iodide
149.8942
INa
[Na+].[I-]
DB11119
5238
33167
5048
-2.0
-
-2.0
-
DRUGBANK
4340.0
mg/kg
4340.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD11121
Chloroxylenol
156.61
C8H9ClO
CC1=CC(O)=CC(C)=C1Cl
DB11121
2723
34393
21106017
-2.0
-
-2.0
-
DRUGBANK
13.76
L/h
13.76
L/h
Average clearance; intravenous injection, IV; Single dose; normal,healthy; dog;
DRUGBANK
22.45
L
22.45
L
dog; Steady state volume of distribution; intravenous injection, IV; Single dose; normal,healthy;
DRUGBANK
1.7
h
1.7
h
terminal half-life; normal,healthy; dog;
DRUGBANK
10.0
h
~10
h
Urinary excretion;
DRUGBANK
85.2
%
85.2±2.32
%
DRUGBANK
89.8
%
89.8±2.99
%
human, homo sapiens;
DRUGBANK
DDPD11123
Hypochlorite
51.452
ClO
[O-]Cl
DB11123
61739
29222
55632
-2.0
-
-2.0
-
DRUGBANK
0.0
null
0
null
DRUGBANK
5800.0
mg/kg
5800.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD11125
Benzethonium
412.637
C27H42NO2
CC(C)(C)CC(C)(C)C1=CC=C(OCCOCC[N+](C)(C)CC2=CC=CC=C2)C=C1
DB11125
2335
94725
2245
-2.0
-
-2.0
-
DRUGBANK
295.0
mg/kg
295.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11126
Calcium gluconate
430.372
C12H22CaO14
[Ca++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O
DB11126
9290
3309
8932
-2.0
-
-2.0
-
DRUGBANK
950.0
mg/kg
950.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
143.0
mg/kg
143.0
mg/kg
IM,intramuscular injection; Infants;
DRUGBANK
20.0
%
20
%
Urinary excretion;
DRUGBANK
80.0
%
80
%
Faeces excretion;
DRUGBANK
45.0
%
~45
%
plasma proteins;
DRUGBANK
DDPD11127
Selenious acid
128.97
H2O3Se
O[Se](O)=O
DB11127
1091
26642
1060
-2.0
-
-2.0
-
DRUGBANK
55.0
%
40-70
%
PO, oral;
DRUGBANK
720.0
h
30
day
dog;
DRUGBANK
DDPD11129
Carbamide peroxide
94.07
CH6N2O3
OO.NC(N)=O
DB11129
31294
75178
29034
-2.0
-
-2.0
-
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11132
Silicon dioxide
60.0843
O2Si
O=[Si]=O
DB11132
22644374
30563
22683
-2.0
-
-2.0
-
DRUGBANK
DDPD11134
Cupric oxide
79.545
CuO
[O--].[Cu++]
DB11134
164827
75955
144499
-2.0
-
-2.0
-
DRUGBANK
DDPD11135
Selenium
78.96
Se
[Se]
DB11135
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
6326970
27568
4885617
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral; Raceme L;
DRUGBANK
9.17
h
9.17
h
PO, oral; Raceme L;
DRUGBANK
40.8
h
1.7
day
DRUGBANK
72.0
h
3
day
DRUGBANK
266.4
h
11.1
day
DRUGBANK
6700.0
mg/kg
6700.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.005
mg/kg/day
0.005
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD11136
Chromium
51.9961
Cr
[Cr]
DB11136
23976
28073
22412
-2.0
-
-2.0
-
DRUGBANK
5.25
%
0.5-10
%
PO, oral; Drug form;
DRUGBANK
28.0
h
15-41
h
elimination half-life;
DRUGBANK
155.0
mg/kg
135-175
mg/kg
PO, oral; mouse;
DRUGBANK
79.5
mg/kg
46-113
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3.5
g/kg
Rattus, Rat;
DRUGBANK
11300.0
mg/kg
11.3
g/kg
Rattus, Rat;
DRUGBANK
3300.0
mg/kg
3.3
g/kg
Rattus, Rat;
DRUGBANK
1500.0
mg/kg
1.5
g/kg
Rattus, Rat;
DRUGBANK
80.0
%
80
%
Urinary excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD11137
Molybdenum
95.94
Mo
[Mo]
DB11137
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
23932
28685
22374
-2.0
-
-2.0
-
DRUGBANK
2e-06
mg/L
2.0
ug/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
0.06
mg/kg/day
0.06
mg/kg/day
PO, oral;
DRUGBANK
DDPD11145
Oxyquinoline
145.158
C9H7NO
OC1=CC=CC2=C1N=CC=C2
DB11145
1923
48981
1847
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
Urinary excretion;
DRUGBANK
23.0
%
23
%
Urinary excretion;
DRUGBANK
9.0
%
9
%
Bile excretion;
DRUGBANK
DDPD11148
Butamben
193.246
C11H15NO2
CCCCOC(=O)C1=CC=C(N)C=C1
DB11148
2482
3231
2388
-2.0
-
-2.0
-
DRUGBANK
1.5
h
90
min
effective half-life;
DRUGBANK
400.0
h
400
h
Capsule, PO, Oral;
DRUGBANK
67.0
mg/kg
67.0
mg/kg
DRUGBANK
DDPD11150
Barium sulfate
233.39
BaO4S
[Ba++].[O-]S([O-])(=O)=O
DB11150
24414
133326
22823
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
0.0
%
0
%
Rectal Administration;
DRUGBANK
DDPD11151
Sodium hydroxide
39.9971
HNaO
[OH-].[Na+]
DB11151
14798
32145
14114
-2.0
-
-2.0
-
DRUGBANK
DDPD11153
Potassium hydroxide
56.1056
HKO
[OH-].[K+]
DB11153
14797
32035
14113
-2.0
-
-2.0
-
DRUGBANK
0.7515
KOH/kg body weight/day
0.273-1.230
KOH/kg body weight/day
Rattus, Rat;
DRUGBANK
DDPD11155
Triclocarban
315.58
C13H9Cl3N2O
ClC1=CC=C(NC(=O)NC2=CC(Cl)=C(Cl)C=C2)C=C1
DB11155
7547
48347
7266
-2.0
-
-2.0
-
DRUGBANK
0.6
%
0.6
%
DRUGBANK
27.0
%
27
%
Urinary excretion;
DRUGBANK
70.0
%
70
%
Faeces excretion;
DRUGBANK
10.0
h
10
h
DRUGBANK
2100.0
mg/kg
2100.0
mg/kg
mouse;
DRUGBANK
27.0
%
27
%
Urinary excretion; PO, oral;
DRUGBANK
70.0
%
70
%
Faeces excretion; PO, oral;
DRUGBANK
DDPD11156
Pyrantel
206.31
C11H14N2S
[H]\C(=C(\[H])C1=NCCCN1C)C1=CC=CS1
DB11156
708857
8654
618121
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
PO, oral;
DRUGBANK
2.0
h
1-3
h
DRUGBANK
1.75
h
1.75±0.19
h
intravenous injection, IV; pig;
DRUGBANK
535.0
mg/kg
535.0
mg/kg
Rattus, Rat;
DRUGBANK
7.0
%
<7
%
Urinary excretion; Unchanged drug;
DRUGBANK
11.0
mg/kg/dose
11
mg/kg/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
11.0
mg/kg/dose
11
mg/kg/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
1000.0
mg/dose
1
g/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
11.0
mg/kg/dose
11
mg/kg/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
1000.0
mg/dose
1
g/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
11.0
mg/kg/dose
11
mg/kg/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
1000.0
mg/dose
1
g/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
11.0
mg/kg/dose
11
mg/kg/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
1.0
g/dose
1
g/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
11.0
mg/kg/dose
11
mg/kg/dose
PO, oral
Reese's Pinworm Medicine
(pyrantel pamoate)
PDR
DDPD11157
Anthralin
226.231
C14H10O3
OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2
DB11157
2202
37510
2117
-2.0
-
-2.0
-
DRUGBANK
1.0
application/day
1
application/day
up to 4 days/week
Zithranol-RR
anthralin
PDR
1.0
appLication/day
1
appLication/day
Zithranol-RR
anthralin
PDR
1.0
appLication/day
1
appLication/day
up to 4 days/week
Zithranol-RR
anthralin
PDR
1.0
application/day
1
application/day
Zithranol-RR
anthralin
PDR
1.0
application/day
1
application/day
up to 4 days/week
Zithranol-RR
anthralin
PDR
1.0
application/day
1
application/day
skin/dermal
Zithranol-RR
anthralin
PDR
1.0
application/day
1
application/day
up to 4 days/week
Zithranol-RR
anthralin
PDR
DDPD11158
Pectin
N.A.
N.A.
C1(C(C(OC(C1O)O)C(=O)O)O)O
DB11158
441476
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
0.0
null
0
null
DRUGBANK
DDPD11164
Bicisate
324.45
C12H24N2O4S2
CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC
DB11164
72048
65035
-2.0
-
-2.0
-
DRUGBANK
3.5
%/h
3.5
%/h
DRUGBANK
0.74
L
0.74
L
intravenous injection, IV;
DRUGBANK
6.02
h
6.02
h
DRUGBANK
0.0119444444444444
h
43
second
distribution half-life;
DRUGBANK
0.825
h
49.5
min
elimination half-life;
DRUGBANK
8.88333333333333
h
533
min
terminal half-life;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
74.0
%
74
%
Urinary excretion;
DRUGBANK
12.5
%
12.5
%
Faeces excretion;
DRUGBANK
DDPD11168
Calcium threonate
310.268
C8H14CaO10
[Ca++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O
DB11168
13388558
9337769
-2.0
-
-2.0
-
DRUGBANK
32300.0
ng/ml
32.3
mg/L
Oral single dose; normal,healthy; Asian;
DRUGBANK
2.0
h
2
h
Oral single dose; normal,healthy; Asian;
DRUGBANK
14.5
L/h
~14.5
L/h
Total clearance; PO, oral; normal,healthy; Asian; adults;
DRUGBANK
53.6
L
53.6
L
Average volume of distribution; Oral single dose; normal,healthy; Asian;
DRUGBANK
2.7
h
~2.7
h
elimination half-life; Oral single dose; Asian; normal,healthy; adults;
DRUGBANK
30.0
%
~30
%
Urinary excretion; PO, oral; Rattus, Rat;
DRUGBANK
40.0
%
~40
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
DDPD11171
Ferric sulfate
489.93
Fe2H10O17S3
O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
DB11171
23443659
11640309
-2.0
-
-2.0
-
DRUGBANK
DDPD11180
Tetrofosmin
382.462
C18H40O4P2
CCOCCP(CCOCC)CCP(CCOCC)CCOCC
DB11180
4274
135598
4124
-2.0
-
-2.0
-
DRUGBANK
6.03
h
6.03
h
DRUGBANK
DDPD11181
Homatropine
275.348
C16H21NO3
[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C
DB11181
5747
16498795
-2.0
-
-2.0
-
DRUGBANK
1200.0
mg/kg
1200.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1400.0
mg/kg
1400.0
mg/kg
PO, oral; mouse;
DRUGBANK
1000.0
mg/kg
1000.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
DDPD11182
Rose bengal
973.673
C20H4Cl4I4O5
OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C12
DB11182
87202
23774
-2.0
-
-2.0
-
DRUGBANK
0.0333333333333333
h
2
min
distribution half-life; Rattus, Rat;
DRUGBANK
1.66666666666667
h
100
min
terminal half-life; Rattus, Rat;
DRUGBANK
0.5
h
30
min
effective half-life; Rattus, Rat;
DRUGBANK
0.5
h
30
min
effective half-life; rabbit;
DRUGBANK
DDPD11186
Pentoxyverine
333.472
C20H31NO3
CCN(CC)CCOCCOC(=O)C1(CCCC1)C1=CC=CC=C1
DB11186
2562
94484
2464
-2.0
-
-2.0
-
DRUGBANK
1.2
h
1.2
h
PO, oral;
DRUGBANK
2.3
h
2.3
h
PO, oral;
DRUGBANK
810.0
mg/kg
810.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
230.0
mg/kg
230.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD11191
Cobamamide
1579.5818
C72H100CoN18O17P
[C@H]1(C[Co-3]2345[N+]6=C7C(C)=C8N2[C@]([H])([C@H](CC(=O)N)[C@]8(CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@@H]2[C@@H](CO)O[C@H](N8C=[N+]3C3=CC(C)=C(C)C=C83)[C@@H]2O)C)[C@@]2(C)[C@@](CC(=O)N)([C@H](CCC(=O)N)C(C(C)=C3[N+]4=C(C=C6C([C@@H]7CCC(=O)N)(C)C)[C@@H](CCC(=O)N)[C@@]3(CC(=O)N)C)=[N+]52)C)O[C@@H](N2C3=C(N=C2)C(=NC=N3)N)[C@H](O)[C@@H]1O
DB11191
18408
21864853
-2.0
-
-2.0
-
DRUGBANK
5000.0
mg/kg
5000.0
mg/kg
PO, oral; guinea pigs;
DRUGBANK
DDPD11200
Aluminum zirconium octachlorohydrex gly
263.74
C2H8AlClNO4Zr
O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
DB11200
32698594
-2.0
-
-2.0
-
DRUGBANK
0.012
%
0.012
%
skin/dermal;
DRUGBANK
456.0
mg/kg
162-750
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
572.0
mg/kg
164-980
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD11201
Menthyl salicylate
276.376
C17H24O3
CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1O
DB11201
135976
16736426
-2.0
-
-2.0
-
DRUGBANK
DDPD11206
Bemotrizinol
627.826
C38H49N3O5
CCCCC(CC)COC1=CC(O)=C(C=C1)C1=NC(=NC(=N1)C1=CC=C(OC)C=C1)C1=C(O)C=C(OCC(CC)CCCC)C=C1
DB11206
135857
10645286
-2.0
-
-2.0
-
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD11207
Amiloxate
248.322
C15H20O3
COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1
DB11207
1266578
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
skin/dermal;
DRUGBANK
9600.0
mg/kg
9600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11217
Arbutin
272.2512
C12H16O7
OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O
DB11217
440936
18305
389765
-2.0
-
-2.0
-
DRUGBANK
9804.0
mg/kg
9804.0
mg/kg
PO, oral; mouse;
DRUGBANK
8715.0
mg/kg
8715.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
928.0
mg/kg
>928
mg/kg
skin/dermal; mouse; Rattus, Rat;
DRUGBANK
DDPD11219
Enzacamene
254.373
C18H22O
CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1
DB11219
7019255
135937
4939160
-2.0
-
-2.0
-
DRUGBANK
16.0
ng/ml
16
ng/ml
skin/dermal; normal,healthy; Female, women;
DRUGBANK
10.0
h
10
h
PO, oral; Active metabolite;
DRUGBANK
15.0
h
~15
h
PO, oral; Rattus, Rat;
DRUGBANK
15.0
h
~15
h
Rattus, Rat;
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
PO, oral; skin/dermal; Rattus, Rat;
DRUGBANK
7.0
mg/kg
7.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
238.0
mg/kg/day
476.0
mg/kg/2D
Rattus, Rat;
DRUGBANK
2.0
mg/kg/day
4.0
mg/kg/2D
Rattus, Rat;
DRUGBANK
DDPD11221
Dioxybenzone
244.246
C14H12O4
COC1=CC(O)=C(C=C1)C(=O)C1=CC=CC=C1O
DB11221
34208
8251
-2.0
-
-2.0
-
DRUGBANK
DDPD11226
Ethylhexyl methoxycrylene
391.511
C25H29NO3
CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C1=CC=C(OC)C=C1
DB11226
52085894
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
skin/dermal;
DRUGBANK
DDPD11228
Methylcellulose
N.A.
N.A.
COCC1C(C(C(C(O1)OC2C(OC(C(C2OC)OC)OC3C(OC(C(C3OC)OC)OC)COC)COC)OC)OC)OC
DB11228
44263857
53448
23107149
-2.0
-
-2.0
-
DRUGBANK
0.07
h
4.2
min
DRUGBANK
275000.0
mg/kg
275000.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
DDPD11235
Thonzylamine
286.379
C16H22N4O
COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1
DB11235
5457
104017
5258
-2.0
-
-2.0
-
DRUGBANK
DDPD11239
Aluminum sulfate
342.151
Al2O12S3
[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
DB11239
24850
74768
23233
-2.0
-
-2.0
-
DRUGBANK
0.0
null
0
null
DRUGBANK
9000.0
mg/kg
>9000
mg/kg
PO, oral; mouse;
DRUGBANK
9000.0
mg/kg
>9000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2.0
%
~2
%
Bile excretion;
DRUGBANK
DDPD11248
Zinc gluconate
455.67
C12H22O14Zn
[Zn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O
DB11248
443445
29708
391659
-2.0
-
-2.0
-
DRUGBANK
6720.0
h
280
day
DRUGBANK
1290.0
mg/kg
1290.0
mg/kg
nasal spray; mouse;
DRUGBANK
DDPD11254
Hexylresorcinol
194.2701
C12H18O2
CCCCCCC1=C(O)C=C(O)C=C1
DB11254
3610
93749
21106121
-2.0
-
-2.0
-
DRUGBANK
2750.0
mg/kg
500-5000
mg/kg
PO, oral; human, homo sapiens;
DRUGBANK
18.0
%
18
%
Urinary excretion;
DRUGBANK
DDPD11256
Levomefolic acid
459.4558
C20H25N7O6
CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2
DB11256
444412
15641
https://www.drugs.com/international/levomefolic-acid.html
392351
-2.0
-
-2.0
-
DRUGBANK
18.10255852
ng/ml
39.4
nmol/L
Oral single dose; Female, women;
DRUGBANK
3.0
h
~3
h
elimination half-life; PO, oral;
DRUGBANK
56.0
%
~56
%
plasma proteins;
DRUGBANK
DDPD11262
Bisoctrizole
658.891
C41H50N6O2
CC(C)(C)CC(C)(C)C1=CC(CC2=C(O)C(=CC(=C2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)=C(O)C(=C1)N1N=C2C=CC=CC2=N1
DB11262
135865
2808671
-2.0
-
-2.0
-
DRUGBANK
0.01
%
0.01
%
skin/dermal;
DRUGBANK
0.06
%
0.06
%
skin/dermal; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; skin/dermal; Rattus, Rat;
DRUGBANK
DDPD11264
Calcium glycerophosphate
210.135
C3H7CaO6P
[Ca++].OCC(CO)OP([O-])([O-])=O
DB11264
31336
56554
-2.0
-
-2.0
-
DRUGBANK
DDPD11269
Diethylamino hydroxybenzoyl hexyl benzoate
397.515
C24H31NO4
CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(C=C1O)N(CC)CC
DB11269
136006
8286957
-2.0
-
-2.0
-
DRUGBANK
0.04
%
0.04±0.05
%
skin/dermal; Rattus, Rat;
DRUGBANK
0.04
%
0.04±0.05
%
skin/dermal; pig;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11273
Dihydroergocornine
563.699
C31H41N5O5
[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
DB11273
59909
147720
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25
%
PO, oral;
DRUGBANK
0.57
ngEq/ml
0.57
ngEq/ml
PO, oral;
DRUGBANK
1.4
h
1.4
h
PO, oral;
DRUGBANK
3.5
h
3.5
h
elimination half-life;
DRUGBANK
13.0
h
13
h
terminal half-life;
DRUGBANK
100.0
%
~100
%
Faeces excretion; PO, oral;
DRUGBANK
2.5
%
2.5
%
Urinary excretion; PO, oral;
DRUGBANK
10.0
%
10
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD11274
Dihydro-alpha-ergocryptine
577.726
C32H43N5O5
[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
DB11274
59919
102887
-2.0
-
-2.0
-
DRUGBANK
5.0
%
<5
%
DRUGBANK
2.157
ng/ml
2157
pg/ml
Oral multiple dose;
DRUGBANK
1.25
h
0.5-2
h
DRUGBANK
1.0
h
1
h
Oral multiple dose;
DRUGBANK
1.129
L/h
1.129
L/h
intravenous injection, IV;
DRUGBANK
25.98
L/h
25.98
L/h
PO, oral;
DRUGBANK
11.054
L
11.054
L
intravenous injection, IV;
DRUGBANK
218.63
L
218.63
L
PO, oral;
DRUGBANK
14.0
h
12-16
h
Parkinson;
DRUGBANK
DDPD11275
Epicriptine
577.726
C32H43N5O5
[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
DB11275
135927
59102
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3.5
h
elimination half-life;
DRUGBANK
13.0
h
13
h
terminal half-life;
DRUGBANK
14.0
h
12-16
h
Parkinson;
DRUGBANK
DDPD11278
DL-Methylephedrine
179.263
C11H17NO
C[C@@H]([C@H](O)C1=CC=CC=C1)N(C)C
DB11278
113556
58315
-2.0
-
-2.0
-
DRUGBANK
2.5
h
2-3
h
PO, oral;
DRUGBANK
2.75
L/kg
2.5-3.0
L/kg
DRUGBANK
4.5
h
3-6
h
DRUGBANK
185.0
mg/kg
185.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
70.0
%
~70
%
Urinary excretion; Urine alkaline;
Urine alkaline ↓ ;
DRUGBANK
DDPD11282
Diethyltoluamide
191.2695
C12H17NO
CCN(CC)C(=O)C1=CC(C)=CC=C1
DB11282
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
7071
4133
-2.0
-
-2.0
-
DRUGBANK
32.5
%
9-56
%
skin/dermal;
DRUGBANK
1.0
h
1
h
skin/dermal;
DRUGBANK
12.0
%
10-14
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.5
h
~2.5
h
DRUGBANK
1.0
mg/kg/day
1.0
mg/kg/day
PO, oral;
DRUGBANK
DDPD11283
DL-dimyristoylphosphatidylcholine
677.945
C36H72NO8P
CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC
DB11283
241349
24408
-2.0
-
-2.0
-
DRUGBANK
DDPD11284
DL-dimyristoylphosphatidylglycerol
666.874
C34H67O10P
CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC
DB11284
96926
-2.0
-
-2.0
-
DRUGBANK
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV
Abelcet
amphotericin B lipid complex
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV
Abelcet
amphotericin B lipid complex
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV
Abelcet
amphotericin B lipid complex
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV
Abelcet
amphotericin B lipid complex
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV
Abelcet
amphotericin B lipid complex
PDR
5.0
mg/kg/day
5
mg/kg/day
intravenous injection, IV
Abelcet
amphotericin B lipid complex
PDR
6.5
mg/kg/day
6.5
mg/kg/day
rarely
Abelcet
amphotericin B lipid complex
PDR
DDPD11304
Phenoxyethanol
138.166
C8H10O2
OCCOC1=CC=CC=C1
DB11304
31236
64275
13848467
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
Urinary excretion;
DRUGBANK
2250.0
mg/kg
2250.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
90.0
%
>90
%
Urinary excretion; Male, men; Rattus, Rat;
DRUGBANK
90.0
%
~90
%
Urinary excretion; Female, women; Rattus, Rat;
DRUGBANK
2.0
%
~2
%
lung excretion; Female, women; Rattus, Rat;
DRUGBANK
1.3
%
~1.3
%
lung excretion; Male, men; Rattus, Rat;
DRUGBANK
DDPD11323
Glycol salicylate
182.175
C9H10O4
OCCOC(=O)C1=CC=CC=C1O
DB11323
6880
86541
6616
-2.0
-
-2.0
-
DRUGBANK
0.266666666666667
h
13-19
min
elimination half-life;
DRUGBANK
4.0
h
3.5-4.5
h
elimination half-life;
DRUGBANK
0.333333333333333
h
20
min
DRUGBANK
DDPD11326
Boric acid
61.833
BH3O3
OB(O)O
DB11326
7628
33118
7346
-2.0
-
-2.0
-
DRUGBANK
1.0
h
0.5-1.5
h
Intraperitoneal, IP;
DRUGBANK
0.99
L/h
0.99
L/h
Total clearance; PO, oral; acute boric acid poisoning;
DRUGBANK
0.335
L/kg
0.17-0.5
L/kg
human, homo sapiens;
DRUGBANK
18.5
h
13-24
h
elimination half-life;
DRUGBANK
2660.0
mg/kg
2660.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.0
%
1
%
Urinary excretion; ointment;
DRUGBANK
90.0
%
>90
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD11327
Dipyrithione
252.31
C10H8N2O2S2
[O-][N+]1=CC=CC=C1SSC1=CC=CC=[N+]1[O-]
DB11327
136010
2998
-2.0
-
-2.0
-
DRUGBANK
DDPD11328
Tetradecyl hydrogen sulfate (ester)
294.45
C14H30O4S
CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O
DB11328
75275
8441
-2.0
-
-2.0
-
DRUGBANK
90.0
mg/kg
90±5
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
72.0
mg/kg
72.0
mg/kg
intravenous injection, IV; Other correlations; Rattus, Rat;
DRUGBANK
108.0
mg/kg
108.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
70.0
%
70
%
Urinary excretion; intravenous injection, IV; Rattus, Rat;
DRUGBANK
73.5
%
73.5
%
Urinary excretion; intravenous injection, IV; Rattus, Rat;
DRUGBANK
18.2
%
18.2
%
Faeces excretion; intravenous injection, IV; Rattus, Rat;
DRUGBANK
DDPD11348
Calcium Phosphate
310.177
Ca3O8P2
[Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O
DB11348
24456
9679
22864
-2.0
-
-2.0
-
DRUGBANK
DDPD11359
Guaiacol
124.139
C7H8O2
COC1=C(O)C=CC=C1
DB11359
460
28591
447
-2.0
-
-2.0
-
DRUGBANK
0.166666666666667
h
10
min
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11362
Selexipag
496.63
C26H32N4O4S
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
DB11362
9913767
90844
http://www.drugs.com/uptravi.html
8089417
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1-3
h
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral; Active metabolite;
DRUGBANK
35.7
L/h
35.7±19.6
L/h
Average clearance;
DRUGBANK
1.65
h
0.8-2.5
h
terminal half-life;
DRUGBANK
9.85
h
6.2-13.5
h
terminal half-life; Active metabolite;
DRUGBANK
93.0
%
93
%
Faeces excretion;
DRUGBANK
12.0
%
12
%
Urinary excretion;
DRUGBANK
99.0
%
~99
%
DRUGBANK
3.2
mg/day
3200
mcg/day
PO, oral
Uptravi
selexipag
PDR
3.2
mg/day
3200
mcg/day
PO, oral
Uptravi
selexipag
PDR
DDPD11363
Alectinib
482.6166
C30H34N4O2
CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
DB11363
49806720
90936
26326738
-2.0
-
-2.0
-
DRUGBANK
37.0
%
37
%
DRUGBANK
4.0
h
4
h
DRUGBANK
81.9
L/h
81.9
L/h
apparent clearance;
DRUGBANK
217.0
L/h
217.0
L/h
apparent clearance;
DRUGBANK
0.4614
L/h/kg
7.69
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4016.0
L
4016.0
L
DRUGBANK
6.35
L/kg
6.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
33.0
h
33
h
elimination half-life;
DRUGBANK
31.0
h
31
h
elimination half-life;
DRUGBANK
11.7
h
11.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
98.0
%
98
%
Faeces excretion;
DRUGBANK
0.5
%
<0.5
%
Urinary excretion;
DRUGBANK
82.32
%
82.32
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
1200.0
mg/day
600
mg/dose
PO, oral
bid
Alecensa
alectinib
PDR
600.0
mg/day
600
mg/day
PO, oral
bid
Alecensa
alectinib
PDR
1200.0
mg/dose
600
mg/dose
PO, oral
bid
Alecensa
alectinib
PDR
600.0
mg/day
600
mg/day
PO, oral
bid
Alecensa
alectinib
PDR
DDPD11386
Chlorobutanol
177.45
C4H7Cl3O
CC(C)(O)C(Cl)(Cl)Cl
DB11386
5977
134813
13842993
-2.0
-
-2.0
-
DRUGBANK
0.696
L/h
11.6±1.0
ml/min
PO, oral; normal,healthy;
DRUGBANK
233.0
L
233±141
L
PO, oral; normal,healthy;
DRUGBANK
247.2
h
10.3±1.3
day
elimination half-life; normal,healthy; PO, oral;
DRUGBANK
510.0
mg/kg
510.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
9.6
%
9.6
%
Urinary excretion; PO, oral;
DRUGBANK
57.0
%
57±3
%
plasma proteins;
DRUGBANK
DDPD11387
Chloroform
119.378
CHCl3
ClC(Cl)Cl
DB11387
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
35255
5977
-2.0
-
-2.0
-
DRUGBANK
0.1
mg/kg
0.1
ppm
inhalation, IH;
DRUGBANK
0.05
mg/kg
0.05
ppm
inhalation, IH;
DRUGBANK
0.02
mg/kg
0.02
ppm
inhalation, IH; Oral multiple dose;
DRUGBANK
0.3
mg/kg/day
0.3
mg/kg/day
PO, oral;
DRUGBANK
0.1
mg/kg/day
0.1
mg/kg/day
PO, oral;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD11431
Moxidectin
639.83
C37H53NO8
[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O
DB11431
22901017
-2.0
-
-2.0
-
DRUGBANK
8726400.0
ng.h/ml
363.6
mcg.day/ml
DRUGBANK
70.4
ng/mg
70.4
mg/kg
DRUGBANK
8.88
h
0.37
day
DRUGBANK
3.5
L/h
3.5
L/h
apparent clearance;
DRUGBANK
1.2
L/kg
1.2
L/kg
DRUGBANK
484.8
h
20.2
day
terminal half-life;
DRUGBANK
100.5
mg/kg
70-131
mg/kg
mouse;
DRUGBANK
2.0
%
2
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
DDPD11560
Lesinurad
404.28
C17H14BrN3O2S
OC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2
DB11560
53465279
90929
https://www.drugs.com/mtm/lesinurad.html
28527877
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
PO, oral; food; fasting;
DRUGBANK
0.0858
L/h/kg
1.43
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
L
20.0
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
0.29
L/kg
0.29
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
63.0
%
63
%
Urinary excretion; Oral single dose;
DRUGBANK
32.0
%
32
%
Faeces excretion; Oral single dose;
DRUGBANK
30.0
%
~30
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
98.0
%
>98
%
plasma proteins;
DRUGBANK
DDPD11570
Padimate O
277.408
C17H27NO2
CCCCC(CC)COC(=O)C1=CC=C(C=C1)N(C)C
DB11570
30541
135932
28343
-2.0
-
-2.0
-
DRUGBANK
DDPD11573
Aluminum chlorohydrate
192.46
Al2ClH7O6
O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
DB11573
71586946
32699791
-2.0
-
-2.0
-
DRUGBANK
0.035
%
0.01-0.06
%
skin/dermal;
DRUGBANK
0.012
%
0.012
%
skin/dermal;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD11574
Elbasvir
882.035
C49H55N9O7
[H][C@]1(CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C)C1=NC=C(N1)C1=CC2=C(C=C1)N1[C@@H](OC3=C(C=CC(=C3)C3=CN=C(N3)[C@]3([H])CCCN3C(=O)[C@@H](NC(=O)OC)C(C)C)C1=C2)C1=CC=CC=C1
DB11574
71661251
132967
30843797
-2.0
-
-2.0
-
DRUGBANK
32.0
%
32
%
DRUGBANK
4.5
h
3-6
h
DRUGBANK
680.0
L
680.0
L
Apparent volume of distribution;
DRUGBANK
24.0
h
24
h
terminal half-life; HCV-positive;
DRUGBANK
90.0
%
90
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
99.9
%
>99.9
%
plasma proteins;
DRUGBANK
DDPD11575
Grazoprevir
766.903
C38H50N6O9S
COC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)O3)C(C)(C)C)N=C2C=C1
DB11575
44603531
132975
https://www.drugs.com/mtm/elbasvir-and-grazoprevir.html
28506694
-2.0
-
-2.0
-
DRUGBANK
27.0
%
27
%
DRUGBANK
2.0
h
0.5-3.5
h
DRUGBANK
1250.0
L
1250.0
L
Apparent volume of distribution;
DRUGBANK
31.0
h
31
h
terminal half-life; HCV-positive;
DRUGBANK
90.0
%
90
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
98.8
%
>98.8
%
plasma proteins;
DRUGBANK
DDPD11577
Indigotindisulfonic acid
422.389
C16H10N2O8S2
OS(=O)(=O)C1=CC2=C(N\C(C2=O)=C2\NC3=C(C=C(C=C3)S(O)(=O)=O)C2=O)C=C1
DB11577
5282430
90117
4445584
-2.0
-
-2.0
-
DRUGBANK
0.075
h
4-5
min
DRUGBANK
DDPD11581
Venetoclax
868.45
C45H50ClN7O7S
CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1
DB11581
49846579
133021
https://www.drugs.com/venclexta.html
29315017
-2.0
-
-2.0
-
DRUGBANK
32800.0
ng.h/ml
32.8±16.9
ug.h/ml
PO, oral; low fat meal;
DRUGBANK
2100.0
ng/ml
2.1±1.1
ug/ml
PO, oral; low fat meal;
DRUGBANK
6.5
h
5-8
h
PO, oral; food;
DRUGBANK
288.5
L
256-321
L
Apparent volume of distribution;
DRUGBANK
22.5
h
19-26
h
Single dose;
DRUGBANK
2001.0
mg/kg
>2001
mg/kg
PO, oral; mouse;
DRUGBANK
99.9
%
>99.9
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
0.01
%
<0.01
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
20.8
%
20.8
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Venclexta
venetoclax
PDR
400.0
mg/day
400
mg/day
PO, oral
Venclexta
venetoclax
PDR
600.0
mg/day
600
mg/day
PO, oral
Venclexta
venetoclax
PDR
400.0
mg/day
400
mg/day
PO, oral
Venclexta
venetoclax
PDR
400.0
mg/day
400
mg/day
PO, oral
Venclexta
venetoclax
PDR
600.0
mg/day
600
mg/day
PO, oral
Venclexta
venetoclax
PDR
DDPD11583
Cetalkonium
360.649
C25H46N
CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1
DB11583
31203
135523
28944
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
skin/dermal;
DRUGBANK
0.0
%
~0
%
PO, oral;
DRUGBANK
0.0
%
~0
%
parenteral administration;
DRUGBANK
230.0
mg/kg
60-400
mg/kg
DRUGBANK
DDPD11584
Pipradrol
267.372
C18H21NO
[H]N1CCCCC1C(O)(C1=CC=CC=C1)C1=CC=CC=C1
DB11584
135101
9681
-2.0
-
-2.0
-
DRUGBANK
180.0
mg/kg
180.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
120.0
mg/kg
120.0
mg/kg
PO, oral; mouse;
DRUGBANK
180.0
mg/kg
180.0
mg/kg
PO, oral; rabbit;
DRUGBANK
3.5
%
3.5
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
Faeces excretion;
DRUGBANK
DDPD11585
Drometrizole trisiloxane
501.849
C24H39N3O3Si3
CC(CC1=C(O)C(=CC(C)=C1)N1N=C2C=CC=CC2=N1)C[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C
DB11585
8024601
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
DDPD11586
Asunaprevir
748.286
C35H46ClN5O9S
COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2
DB11586
16076883
134723
17235944
-2.0
-
-2.0
-
DRUGBANK
1887.0
ng.h/ml
1887.0
ng.h/ml
DRUGBANK
9.3
%
9.3
%
DRUGBANK
572.0
ng/ml
572
ng/ml
DRUGBANK
3.0
h
2-4
h
DRUGBANK
396.5
L/h
302-491
L/h
Average clearance; PO, oral;
DRUGBANK
0.7068
L/h/kg
11.78
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
194.0
L
194.0
L
at steady state;
DRUGBANK
2.77
L/kg
2.77
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.5
h
15-20
h
terminal half-life;
DRUGBANK
20.0
h
20
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.5
%
7.5
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD11587
Etafedrine
193.29
C12H19NO
CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1
DB11587
85308
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
100.0
ng/ml
0.10
mg/L
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
3.0
L/kg
3.0
L/kg
DRUGBANK
4.5
h
3-6
h
elimination half-life;
DRUGBANK
DDPD11588
Carbon monoxide
28.01
CO
[C-]#[O+]
DB11588
281
17245
275
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
DRUGBANK
1.0
h
30-90
min
DRUGBANK
0.316666666666667
h
15-23
min
DRUGBANK
1807.0
mg/kg
1807.0
ppm
Rattus, Rat;
DRUGBANK
DDPD11589
Neon
20.1797
Ne
[Ne]
DB11589
23935
33310
22377
-2.0
-
-2.0
-
DRUGBANK
DDPD11590
Thimerosal
404.81
C9H9HgNaO2S
[Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O
DB11590
16684434
9546
5697
-2.0
-
-2.0
-
DRUGBANK
0.01
%
<0.01
%
Rattus, Rat;
DRUGBANK
266.0
L
266.0
L
DRUGBANK
211.2
h
8.8
day
DRUGBANK
256.8
h
10.7
day
DRUGBANK
187.2
h
7.8
day
DRUGBANK
184.8
h
7.7
day
DRUGBANK
1084.8
h
45.2
day
DRUGBANK
1200.0
h
~50
day
human, homo sapiens;
DRUGBANK
75.0
mg/kg
75.0
mg/kg
PO, oral; mouse;
DRUGBANK
91.0
mg/kg
91.0
mg/kg
PO, oral; mouse;
DRUGBANK
97.0
%
95-99
%
DRUGBANK
DDPD11591
Bilastine
463.622
C28H37N3O3
CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1
DB11591
185460
135954
161234
-2.0
-
-2.0
-
DRUGBANK
61.0
%
61
%
DRUGBANK
1.13
h
1.13
h
DRUGBANK
9.2
L/h
9.2
L/h
Total clearance;
DRUGBANK
8.7
L/h
8.7
L/h
Renal clearance;
DRUGBANK
0.1722
L/h/kg
2.87
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.61
L/kg
0.61
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.5
h
14.5
h
elimination half-life;
DRUGBANK
5.16
h
5.16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
66.5
%
66.5
%
Faeces excretion;
DRUGBANK
28.3
%
28.3
%
Urinary excretion;
DRUGBANK
87.0
%
84-90
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD11596
Levoleucovorin
473.4393
C20H23N7O7
NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
DB11596
149436
63606
https://www.drugs.com/levoleucovorin.html
131714
-2.0
-
-2.0
-
DRUGBANK
1722.0
ng/ml
1722
ng/ml
intravenous injection, IV; Derivative;
DRUGBANK
275.0
ng/ml
275
ng/ml
intravenous injection, IV; Derivative;
DRUGBANK
0.9
h
0.9
h
intravenous injection, IV; Derivative;
DRUGBANK
0.246
L/h/kg
4.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.27
L/kg
0.27
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.1
h
5.1
h
terminal half-life;
DRUGBANK
6.8
h
6.8
h
terminal half-life;
DRUGBANK
1.1
h
1.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
575.0
mg/kg
575.0
mg/kg
adults; mouse;
DRUGBANK
378.0
mg/kg
378.0
mg/kg
adults; Rattus, Rat;
DRUGBANK
DDPD11602
Hydroxyethyl cellulose
806.937
C36H70O19
CC(O)COCC1OC(OC2C(COCC(C)O)OC(OCC(C)O)C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C(OCC(C)O)C1OCC(C)O
DB11602
4327536
85249
3532118
-2.0
-
-2.0
-
DRUGBANK
DDPD11610
Oxilofrine
181.235
C10H15NO2
[H][C@@](C)(NC)[C@]([H])(O)C1=CC=C(O)C=C1
DB11610
688009
134822
599505
-2.0
-
-2.0
-
DRUGBANK
DDPD11611
Lifitegrast
615.48
C29H24Cl2N2O7S
CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1
DB11611
11965427
133023
https://www.drugs.com/xiidra.html
10139520
-2.0
-
-2.0
-
DRUGBANK
1.7
ng/ml
1.70
ng/ml
DRUGBANK
2.145
ng/ml
0.55-3.74
ng/ml
different study;
DRUGBANK
0.25
h
15
min
DRUGBANK
99.0
%
~99
%
plasma proteins; human, homo sapiens;
DRUGBANK
96.5
%
95-98
%
human, homo sapiens;
DRUGBANK
41.35
%
31.6-51.1
%
human, homo sapiens;
DRUGBANK
2.0
drop/day
2
drop/day
ophthalmic administration
Xiidra
lifitegrast
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Xiidra
lifitegrast
PDR
2.0
drop/day
2
drop/day
ophthalmic administration
Xiidra
lifitegrast
PDR
DDPD11613
Velpatasvir
883.019
C49H54N8O8
COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC=C(N1)C1=CC=C2C(COC3=CC4=C(C=CC5=C4NC(=N5)[C@@H]4CC[C@H](C)N4C(=O)[C@@H](NC(=O)OC)C(C)C)C=C23)=C1
DB11613
67683363
133009
https://www.drugs.com/history/epclusa.html
34501056
-2.0
-
-2.0
-
DRUGBANK
27.5
%
25-30
%
DRUGBANK
0.12
L/h/kg
0.12
L/h/kg
DRUGBANK
1.5
L/kg
1.4-1.6
L/kg
DRUGBANK
15.0
h
15
h
DRUGBANK
94.0
%
94
%
Faeces excretion;
DRUGBANK
0.4
%
0.4
%
Urinary excretion;
DRUGBANK
99.5
%
>99.5
%
plasma proteins;
DRUGBANK
DDPD11614
Rupatadine
415.97
C26H26ClN3
CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1
DB11614
133017
135673
117388
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
DRUGBANK
2.0
h
2
h
high-fat meal;
high-fat meal ↑ ;
DRUGBANK
1556.2
L/h
1556.2
L/h
Total clearance; young; adults;
DRUGBANK
798.2
L/h
798.2
L/h
Total clearance; Geriatric;
DRUGBANK
9799.0
L
9799.0
L
Apparent volume of distribution;
DRUGBANK
15.9
h
15.9
h
Children;
DRUGBANK
12.3
h
12.3
h
Children;
DRUGBANK
5.9
h
5.9
h
adults;
DRUGBANK
8.7
h
8.7
h
Geriatric;
DRUGBANK
98.75
%
98.5-99.0
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD11619
Gestrinone
308.4141
C21H24O2
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]
DB11619
27812
89642
25877
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30±30
%
PO, oral;
DRUGBANK
67.0
L
67.0
L
DRUGBANK
24.0
h
24
h
elimination half-life;
DRUGBANK
42.5
%
~40-45
%
Urinary excretion;
DRUGBANK
32.5
%
~30-35
%
Faeces excretion;
DRUGBANK
DDPD11622
Dehydrocholic acid
402.531
C24H34O5
[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O
DB11622
6674
31459
6422
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
DRUGBANK
20.0
%
20
%
DRUGBANK
10.0
%
10
%
DRUGBANK
4000.0
mg/kg
4000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
750.0
mg/kg
750.0
mg/kg
intravenous injection, IV; Rattus, Rat;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
3100.0
mg/kg
3100.0
mg/kg
PO, oral; mouse;
DRUGBANK
1620.0
mg/kg
1620.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
1492.0
mg/kg
1492.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
DDPD11629
Laropiprant
435.89
C21H19ClFNO4S
CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1
DB11629
135942
8043333
-2.0
-
-2.0
-
DRUGBANK
0.0726
L/h/kg
1.21
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.0
L/kg
1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.8
h
11.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD11630
Temoporfin
680.764
C44H32N4O4
OC1=CC=CC(=C1)C-1=C2\CCC(=N2)\C(=C2/N\C(\C=C2)=C(/C2=N/C(/C=C2)=C(\C2=CC=C\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1
DB11630
9437
54754
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
intravenous injection, IV;
DRUGBANK
0.004
L/h/kg
3.9-4.1
ml/h/kg
DRUGBANK
0.0036
L/h/kg
0.06
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.4
L/kg
0.34-0.46
L/kg
DRUGBANK
65.0
h
65
h
terminal half-life;
DRUGBANK
30.0
h
30
h
distribution half-life;
DRUGBANK
68.0
h
68
h
terminal half-life;
DRUGBANK
91.5
h
91.5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.5
%
85-88
%
plasma proteins;
DRUGBANK
DDPD11632
Opicapone
413.17
C15H10Cl2N4O6
CC1=C(C2=NOC(=N2)C2=CC(=C(O)C(O)=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl
DB11632
134699
24667564
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1.0-2.5
h
DRUGBANK
22.0
L/h
22.0
L/h
Total clearance; PO, oral;
DRUGBANK
30.0
L
~30
L
DRUGBANK
3.04
h
1.58-4.50
h
DRUGBANK
99.7
%
>99.7
%
DRUGBANK
DDPD11633
Isavuconazole
437.47
C22H17F2N5OS
C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1
DB11633
85979
5293682
-2.0
-
-2.0
-
DRUGBANK
189462.8
ng.h/ml
189462.8
ng.h/ml
PO, oral;
DRUGBANK
193906.8
ng.h/ml
193906.8
ng.h/ml
intravenous injection, IV;
DRUGBANK
98.0
%
98
%
Oral single dose;
DRUGBANK
7499.0
ng/ml
7499
ng/ml
PO, oral;
DRUGBANK
20028.0
ng/ml
20028
ng/ml
PO, oral;
DRUGBANK
2.5
h
2-3
h
Oral single dose;
DRUGBANK
2.5
h
2-3
h
Oral multiple dose;
DRUGBANK
2.5
L/h
2.5±1.6
L/h
PO, oral; intravenous injection, IV;
DRUGBANK
0.051
L/h/kg
0.85
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
450.0
L
450.0
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
5.37
L/kg
5.37
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
130.0
h
130
h
elimination half-life; normal,healthy;
DRUGBANK
130.0
h
130
h
elimination half-life; patients;
DRUGBANK
110.0
h
110
h
PO, oral;
DRUGBANK
115.0
h
115
h
intravenous injection, IV;
DRUGBANK
86.9
h
86.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
46.1
%
46.1
%
Faeces excretion; PO, oral;
DRUGBANK
45.5
%
~45.5
%
Urinary excretion; PO, oral;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD11637
Delamanid
534.492
C25H25F3N4O6
C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O
DB11637
134742
4981055
-2.0
-
-2.0
-
DRUGBANK
47.5
%
35-60
%
PO, oral; mouse; Rattus, Rat; dog;
DRUGBANK
36.0
%
25-47
%
PO, oral; human, homo sapiens;
DRUGBANK
135.0
ng/ml
135
ng/ml
Oral single dose;
DRUGBANK
288.0
h
10-14
day
PO, oral;
DRUGBANK
2100.0
L
2100.0
L
Apparent volume of distribution;
DRUGBANK
34.0
h
30-38
h
DRUGBANK
5.0
%
<5
%
Urinary excretion;
DRUGBANK
99.5
%
>99.5
%
plasma proteins;
DRUGBANK
DDPD11640
Amifampridine
109.132
C5H7N3
NC1=CC=NC=C1N
DB11640
135948
5705
-2.0
-
-2.0
-
DRUGBANK
96.5
%
93-100
%
DRUGBANK
76.5
ng/ml
16-137
ng/ml
Oral single dose; fasting;
DRUGBANK
0.95
h
0.6-1.3
h
PO, oral;
DRUGBANK
2.5
h
~2.5
h
elimination half-life;
DRUGBANK
4.0
h
4
h
elimination half-life;
DRUGBANK
25.0
mg/kg
~>25
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
mg/kg
~100
mg/kg
PO, oral; mouse;
DRUGBANK
25.0
mg/kg
~25
mg/kg
intravenous injection, IV; mouse; Rattus, Rat;
DRUGBANK
20.0
mg/kg
20.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
35.0
mg/kg
35.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
24.0
%
>24
%
Urinary excretion; PO, oral;
DRUGBANK
30.0
mg/dose
30
mg/dose
PO, oral
Ruzurgi
amifampridine
PDR
100.0
mg/day
100
mg/day
PO, oral
Ruzurgi
amifampridine
PDR
50.0
mg/day
50
mg/day
PO, oral
Ruzurgi
amifampridine
PDR
15.0
mg/dose
15
mg/dose
PO, oral
Ruzurgi
amifampridine
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Ruzurgi
amifampridine
PDR
80.0
mg/day
80
mg/day
PO, oral
Ruzurgi
amifampridine
PDR
30.0
mg/dose
30
mg/dose
PO, oral
Ruzurgi
amifampridine
PDR
100.0
mg/day
100
mg/day
PO, oral
Ruzurgi
amifampridine
PDR
50.0
mg/day
50
mg/day
PO, oral
Ruzurgi
amifampridine
PDR
15.0
mg/dose
15
mg/dose
PO, oral
Ruzurgi
amifampridine
PDR
20.0
mg/dose
20
mg/dose
PO, oral
Ruzurgi
amifampridine
PDR
80.0
mg/day
80
mg/day
PO, oral
Ruzurgi
amifampridine
PDR
DDPD11641
Vinflunine
816.944
C45H54F2N4O8
CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC
DB11641
90241
8804619
-2.0
-
-2.0
-
DRUGBANK
40.0
L/h
40.0
L/h
Total clearance;
DRUGBANK
2422.0
L
2422±676
L
DRUGBANK
40.0
h
~40
h
terminal half-life;
DRUGBANK
120.0
h
~120
h
Metabolite;
DRUGBANK
66.7
%
~66.7
%
Faeces excretion;
DRUGBANK
33.3
%
~33.3
%
Urinary excretion;
DRUGBANK
67.2
%
67.2±1.1
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD11642
Pitolisant
295.85
C17H26ClNO
ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1
DB11642
134709
8123714
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90
%
PO, oral;
DRUGBANK
812.0
ng.h/ml
812.0
ng.h/ml
Oral multiple dose;
DRUGBANK
30.0
ng/ml
~30
ng/ml
PO, oral;
DRUGBANK
73.0
ng/ml
73
ng/ml
Oral multiple dose;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
132.0
h
5-6
day
PO, oral;
DRUGBANK
43.9
L/h
43.9
L/h
apparent clearance; Oral single dose;
DRUGBANK
1912.5
L
1000-2825
L
Apparent volume of distribution; PO, oral; adults;
DRUGBANK
11.0
h
10-12
h
elimination half-life;
DRUGBANK
20.0
h
~20
h
Single dose;
DRUGBANK
25.0
%
~25
%
lung excretion;
DRUGBANK
3.0
%
<3
%
Faeces excretion;
DRUGBANK
93.5
%
~91-96
%
DRUGBANK
DDPD11644
Tafamidis
308.116
C14H7Cl2NO3
OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1
DB11644
11001318
78538
9176510
-2.0
-
-2.0
-
DRUGBANK
47864.31
ng.h/ml
47864.31
ng.h/ml
PO, oral; fasting;
DRUGBANK
1430.93
ng/ml
1430.93
ng/ml
PO, oral; fasting;
DRUGBANK
1.75
h
1.75
h
PO, oral; fasting;
DRUGBANK
1.0
h
4
h
PO, oral; food;
DRUGBANK
90.0
%
90
%
Unchanged drug;
DRUGBANK
0.263
L/h
0.263
L/h
PO, oral;
DRUGBANK
0.44
L/h
0.44
L/h
apparent clearance;
DRUGBANK
18.5
L
18.5
L
Apparent volume of distribution; at steady state;
DRUGBANK
49.0
h
49
h
DRUGBANK
59.0
%
~59
%
Faeces excretion; PO, oral;
DRUGBANK
22.0
%
~22
%
Urinary excretion; PO, oral;
DRUGBANK
99.9
%
99.9
%
plasma proteins;
DRUGBANK
80.0
mg/day
80
mg/day
Vyndaqel, Vyndamax
(tafamidis); (tafamidis meglumine)
PDR
61.0
mg/day
61
mg/day
Vyndaqel, Vyndamax
(tafamidis); (tafamidis meglumine)
PDR
80.0
mg/day
80
mg/day
Vyndaqel, Vyndamax
(tafamidis); (tafamidis meglumine)
PDR
61.0
mg/day
61
mg/day
Vyndaqel, Vyndamax
(tafamidis); (tafamidis meglumine)
PDR
DDPD11652
Tucatinib
480.532
C26H24N8O2
CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1
DB11652
51039094
34995558
-2.0
-
-2.0
-
DRUGBANK
7120.0
ng.h/ml
7120.0
ng.h/ml
different study;
DRUGBANK
1120.0
ng/ml
1120
ng/ml
different study;
DRUGBANK
2.5
h
1-4
h
DRUGBANK
2.0
h
1-3
h
different study;
DRUGBANK
148.0
L/h
148.0
L/h
apparent clearance;
DRUGBANK
1670.0
L
1670.0
L
DRUGBANK
5.38
h
~5.38
h
DRUGBANK
8.21
h
~8.21
h
elimination half-life;
DRUGBANK
86.0
%
~86
%
Faeces excretion;
DRUGBANK
4.1
%
~4.1
%
Urinary excretion;
DRUGBANK
13.76
%
13.76
%
Faeces excretion; Unchanged drug;
DRUGBANK
97.0
%
~97
%
plasma proteins;
DRUGBANK
DDPD11653
Bremelanotide
1025.182
C50H68N14O10
CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
DB11653
9941379
8116997
-2.0
-
-2.0
-
DRUGBANK
276.0
ng.h/ml
276.0
ng.h/ml
DRUGBANK
100.0
%
100
%
DRUGBANK
72.8
ng/ml
72.8
ng/ml
DRUGBANK
1.0
h
1(0.5-1)
h
DRUGBANK
6.5
L/h
6.5±1.0
L/h
Average clearance;
DRUGBANK
25.0
L
25.0±5.8
L
Average volume of distribution;
DRUGBANK
2.7
h
2.7(1.9-4.0)
h
DRUGBANK
64.8
%
64.8
%
Urinary excretion;
DRUGBANK
22.8
%
22.8
%
Faeces excretion;
DRUGBANK
21.0
%
21
%
DRUGBANK
DDPD11660
Latanoprostene bunod
507.624
C27H41NO8
O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1
DB11660
11156438
9331546
-2.0
-
-2.0
-
DRUGBANK
0.0591
ng/ml
59.1
pg/ml
normal,healthy; Derivative;
DRUGBANK
0.0833333333333333
h
5
min
normal,healthy; Derivative;
DRUGBANK
1.8
h
1.8
h
rabbit;
DRUGBANK
2.1
h
2.1
h
rabbit;
DRUGBANK
4.6
h
4.6
h
rabbit;
DRUGBANK
0.0
0
Vyzulta
latanoprostene bunod
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Vyzulta
latanoprostene bunod
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Vyzulta
latanoprostene bunod
PDR
0.0
0
Vyzulta
latanoprostene bunod
PDR
1.0
drop/day
1
drop/day
ophthalmic administration
Vyzulta
latanoprostene bunod
PDR
0.0
0
Vyzulta
latanoprostene bunod
PDR
0.0
0
Vyzulta
latanoprostene bunod
PDR
DDPD11672
Curcumin
368.3799
C21H20O6
COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O
DB11672
969516
3962
839564
-2.0
-
-2.0
-
DRUGBANK
5000.0
ng/ml
<5
ug/ml
Oral single dose;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; mouse;
DRUGBANK
75.0
%
~75
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
40.0
%
~40
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
73.0
%
73
%
Faeces excretion; Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
11.0
%
11
%
Bile excretion; Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
40.0
%
40
%
Faeces excretion; PO, oral; Rattus, Rat; Unchanged drug;
DRUGBANK
DDPD11678
Treosulfan
278.29
C6H14O8S2
CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
DB11678
9882105
82557
8057780
-2.0
-
-2.0
-
DRUGBANK
0.294
L/h/kg
4.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.59
L/kg
0.59
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.83
h
1.83
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD11689
Selumetinib
457.68
C17H15BrClFN4O3
CN1C=NC2=C(F)C(NC3=C(Cl)C=C(Br)C=C3)=C(C=C12)C(=O)NOCCO
DB11689
10127622
90227
8303141
-2.0
-
-2.0
-
DRUGBANK
62.0
%
62
%
PO, oral; adults;
DRUGBANK
1.25
h
1-1.5
h
DRUGBANK
8.8
L/h
8.8
L/h
pediatric patients;
DRUGBANK
15.7
L/h
15.7
L/h
normal,healthy; adults; Male, men;
DRUGBANK
12.55
L/h
9.2-15.9
L/h
Asian;
DRUGBANK
124.5
L
78-171
L
Apparent volume of distribution; at steady state; pediatric patients;
DRUGBANK
146.0
L
146.0
L
Apparent volume of distribution; normal,healthy; Male, men; adults;
DRUGBANK
110.65
L
73.2-148.1
L
Apparent volume of distribution; at steady state; dose; patients; Asian;
DRUGBANK
6.2
h
6.2
h
elimination half-life; Children; patients;
DRUGBANK
9.9
h
9.2-10.6
h
Asian; patients;
DRUGBANK
13.0
h
~13
h
different study;
DRUGBANK
59.0
%
~59
%
Faeces excretion;
DRUGBANK
33.0
%
~33
%
Urinary excretion;
DRUGBANK
96.0
%
96
%
DRUGBANK
35.0
%
<35
%
DRUGBANK
98.4
%
~98.4
%
plasma proteins;
DRUGBANK
DDPD11691
Naldemedine
570.646
C32H34N4O6
[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]5(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O)=CC=C3O
DB11691
54732242
28530803
-2.0
-
-2.0
-
DRUGBANK
0.75
h
0.75
h
DRUGBANK
2.5
h
2.5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
155.0
L
155.0
L
Apparent volume of distribution;
DRUGBANK
11.0
h
11
h
elimination half-life;
DRUGBANK
57.0
%
57
%
Urinary excretion;
DRUGBANK
35.0
%
35
%
Faeces excretion;
DRUGBANK
93.5
%
93-94
%
plasma proteins; human, homo sapiens;
DRUGBANK
0.2
mg/day
0.2
mg/day
PO, oral
qd
Symproic
naldemedine
PDR
0.2
mg/day
0.2
mg/day
PO, oral
qd
Symproic
naldemedine
PDR
DDPD11699
Tropisetron
284.3529
C17H20N2O2
[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C1=CNC3=CC=CC=C13)N2C
DB11699
656665
32269
16736476
-2.0
-
-2.0
-
DRUGBANK
95.0
%
>95
%
PO, oral;
DRUGBANK
60.0
%
60
%
PO, oral;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
83.33
%
83.33
%
Urinary excretion;
DRUGBANK
16.67
%
16.67
%
Faeces excretion;
DRUGBANK
108.0
L/h
1800.0
ml/min
DRUGBANK
1.56
L/h/kg
26
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
500.0
L
400-600
L
DRUGBANK
9.7
L/kg
9.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.7
h
5.7
h
DRUGBANK
5.6
h
5.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
265.0
mg/kg
265.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
%
15
%
Faeces excretion;
DRUGBANK
8.0
%
~8
%
Urinary excretion; Unchanged drug;
DRUGBANK
71.0
%
71
%
plasma proteins;
DRUGBANK
DDPD11703
Acalabrutinib
465.517
C26H23N7O2
CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1
DB11703
71226662
36764951
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25
%
DRUGBANK
0.75
h
0.75
h
DRUGBANK
159.0
L/h
159.0
L/h
apparent clearance; PO, oral;
DRUGBANK
34.0
L
34.0
L
Steady state volume of distribution;
DRUGBANK
0.9
h
0.9(0.6-2.8)
h
elimination half-life; Oral single dose;
DRUGBANK
84.0
%
84
%
Faeces excretion; Single dose; normal,healthy; human, homo sapiens;
DRUGBANK
12.0
%
12
%
Urinary excretion; Single dose; normal,healthy; human, homo sapiens;
DRUGBANK
97.5
%
~97.5
%
plasma proteins; human, homo sapiens;
DRUGBANK
93.7
%
93.7
%
human, homo sapiens;
DRUGBANK
41.1
%
41.1
%
human, homo sapiens;
DRUGBANK
DDPD11705
Iomeprol
777.089
C17H22I3N3O8
CN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
DB11705
3731
31710
3600
-2.0
-
-2.0
-
DRUGBANK
0.084
L/h/kg
1.4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.3
h
2.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD11712
Tezacaftor
520.505
C26H27F3N2O6
CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO
DB11712
46199646
28637762
-2.0
-
-2.0
-
DRUGBANK
84500.0
ng.h/ml
84.5
mcg.h/ml
combination drug use;
DRUGBANK
5950.0
ng/ml
5.95
mcg/ml
combination drug use;
DRUGBANK
4.0
h
2-6
h
combination drug use;
DRUGBANK
1.31
L/h
1.31
L/h
apparent clearance; food; patients;
DRUGBANK
271.0
L
271.0
L
Apparent volume of distribution; food; patients;
DRUGBANK
57.2
h
~57.2
h
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
72.0
%
<72
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD11718
Encorafenib
540.01
C22H27ClFN7O4S
COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C
DB11718
50922675
28536139
-2.0
-
-2.0
-
DRUGBANK
86.0
%
>86
%
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
83.0
%
83
%
Liver metabolism;
DRUGBANK
16.0
%
16
%
Liver metabolism;
DRUGBANK
1.0
%
1
%
Liver metabolism;
DRUGBANK
14.0
L/h
14.0
L/h
apparent clearance;
DRUGBANK
32.0
L/h
32.0
L/h
apparent clearance; at steady state;
DRUGBANK
164.0
L
164.0
L
Apparent volume of distribution;
DRUGBANK
3.5
h
3.5
h
terminal half-life;
DRUGBANK
47.0
%
47
%
Faeces excretion; Oral single dose;
DRUGBANK
47.0
%
47
%
Urinary excretion; Oral single dose;
DRUGBANK
5.0
%
5
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
2.0
%
2
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
86.0
%
86
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
450.0
mg/day
450
mg/day
PO, oral
Braftovi
encorafenib
PDR
450.0
mg/day
450
mg/day
PO, oral
Braftovi
encorafenib
PDR
DDPD11730
Ribociclib
434.548
C23H30N8O
CN(C)C(=O)C1=CC2=CN=C(NC3=CC=C(C=N3)N3CCNCC3)N=C2N1C1CCCC1
DB11730
44631912
30798107
-2.0
-
-2.0
-
DRUGBANK
3.0
h
1-5
h
DRUGBANK
192.0
h
8
day
DRUGBANK
32.6
h
32.6
h
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
qd
Kisqali
ribociclib
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Kisqali
ribociclib
PDR
DDPD11732
Lasmiditan
377.367
C19H18F3N3O2
CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1
DB11732
11610526
9785281
-2.0
-
-2.0
-
DRUGBANK
1892.0
ng.h/ml
1892±746.0
ng.h/ml
PO, oral;
DRUGBANK
2251.48
ng.h/ml
2251.48
ng.h/ml
PO, oral; high-fat meal;
DRUGBANK
40.0
%
40
%
PO, oral;
DRUGBANK
322.8
ng/ml
322.8±122.0
ng/ml
PO, oral;
DRUGBANK
393.82
ng/ml
393.82
ng/ml
PO, oral; high-fat meal;
DRUGBANK
1.8
h
1.8
h
PO, oral;
DRUGBANK
2.8
h
2.8
h
PO, oral; high-fat meal;
DRUGBANK
5.7
h
5.7
h
elimination half-life;
DRUGBANK
3.0
%
3
%
Urinary excretion; Unchanged drug;
DRUGBANK
57.5
%
~55-60
%
plasma proteins;
DRUGBANK
DDPD11735
Galactose
180.1559
C6H12O6
[H]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO
DB11735
3037556
17118
2301265
-2.0
-
-2.0
-
DRUGBANK
90.0
L/h
1.5±0.1
L/min
Total clearance; normal renal function;
DRUGBANK
DDPD11738
Rilmenidine
180.251
C10H16N2O
C1CC1C(NC1=NCCO1)C1CC1
DB11738
68712
8862
61963
-2.0
-
-2.0
-
DRUGBANK
0.426
L/h/kg
7.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.5
L/kg
4.5
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.3
h
8.3
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD11753
Rifamycin
697.778
C37H47NO12
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O
DB11753
29673
16735998
-2.0
-
-2.0
-
DRUGBANK
11840.0
ng.h/ml
11.84
mg.h/l
PO, oral;
DRUGBANK
0.1
%
<0.1
%
PO, oral; patients;
DRUGBANK
2.0
ng/ml
<2
ng/ml
PO, oral; patients;
DRUGBANK
36000.0
ng/ml
36
mg/L
PO, oral;
DRUGBANK
0.0833333333333333
h
5
min
PO, oral;
DRUGBANK
23.3
L/h
23.3
L/h
DRUGBANK
101.8
L
101.8
L
DRUGBANK
3.0
h
3
h
DRUGBANK
18.0
%
18
%
Faeces excretion;
DRUGBANK
50.0
%
50
%
Faeces excretion;
DRUGBANK
21.0
%
21
%
Faeces excretion;
DRUGBANK
87.5
%
~80-95
%
DRUGBANK
DDPD11757
Istradefylline
384.436
C20H24N4O4
[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC
DB11757
5311037
134726
4470574
-2.0
-
-2.0
-
DRUGBANK
11100.0
ng.h/ml
11100.0
ng.h/ml
DRUGBANK
610.0
ng.h/ml
610.0
ng.h/ml
Active metabolite;
DRUGBANK
181.1
ng/ml
181.1
ng/ml
DRUGBANK
4.34
ng/ml
4.34
ng/ml
Active metabolite;
DRUGBANK
12.6
ng/ml
12.6
ng/ml
Active metabolite;
DRUGBANK
2.0
h
2
h
DRUGBANK
3.5
h
3.5
h
Active metabolite;
DRUGBANK
3.0
h
3
h
Active metabolite;
DRUGBANK
5.05
L/h
4.1-6
L/h
apparent clearance;
DRUGBANK
502.5
L
448-557
L
Apparent volume of distribution;
DRUGBANK
66.5
h
64-69
h
elimination half-life;
DRUGBANK
300.0
mg/kg
>300
mg/kg
PO, oral; mouse;
DRUGBANK
17.6
%
17.6
%
Urinary excretion; PO, oral; Male, men; Rattus, Rat;
DRUGBANK
68.3
%
68.3
%
Faeces excretion; PO, oral; Male, men; Rattus, Rat;
DRUGBANK
1.62
%
1.62
%
Faeces excretion; PO, oral; Male, men; Rattus, Rat; Unchanged drug;
DRUGBANK
98.0
%
~98
%
plasma proteins;
DRUGBANK
DDPD11760
Talazoparib
380.359
C19H14F2N6O
CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1
DB11760
44819241
28637772
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1-2
h
Capsule, PO, Oral;
DRUGBANK
2.5
h
1-4
h
PO, oral; high-fat meal;
DRUGBANK
6.45
L/h
6.45
L/h
apparent clearance; PO, oral;
RD, renal impairment, Renal disease，including uremia → ;
DRUGBANK
420.0
L
420.0
L
Steady state volume of distribution;
DRUGBANK
90.0
h
90±58
h
terminal half-life; Capsule, PO, Oral;
DRUGBANK
64.7
%
64.7
%
Urinary excretion;
DRUGBANK
19.7
%
19.7
%
Faeces excretion;
DRUGBANK
35.32
%
35.32
%
Urinary excretion; Unchanged drug;
DRUGBANK
2.67
%
2.67
%
Faeces excretion; Unchanged drug;
DRUGBANK
74.0
%
74
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
1.0
mg
1
mg
PO, oral
qd
Talzenna
talazopari
PDR
1.0
mg
1
mg
PO, oral
qd
Talzenna
talazopari
PDR
DDPD11761
Tenapanor
1145.04
C50H66Cl4N8O10S2
CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2
DB11761
71587953
32056950
-2.0
-
-2.0
-
DRUGBANK
70.0
%
70
%
Faeces excretion;
DRUGBANK
79.0
%
79
%
Faeces excretion;
DRUGBANK
9.0
%
9
%
Urinary excretion;
DRUGBANK
65.0
%
~65
%
Unchanged drug;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD11791
Capmatinib
412.428
C23H17FN6O
CNC(=O)C1=C(F)C=C(C=C1)C1=NN2C(CC3=CC4=C(C=C3)N=CC=C4)=CN=C2N=C1
DB11791
25145656
25069712
-2.0
-
-2.0
-
DRUGBANK
70.0
%
>70
%
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
24.0
L/h
24.0
L/h
apparent clearance; at steady state;
DRUGBANK
164.0
L
164.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
6.5
h
6.5
h
elimination half-life;
DRUGBANK
78.0
%
~78
%
Faeces excretion; PO, oral;
DRUGBANK
22.0
%
~22
%
Urinary excretion; PO, oral;
DRUGBANK
32.76
%
~32.76
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
96.0
%
~96
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
DDPD11793
Niraparib
320.396
C19H20N4O
NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1
DB11793
24958200
24531930
-2.0
-
-2.0
-
DRUGBANK
73.0
%
73
%
DRUGBANK
804.0
ng/ml
804±403
ng/ml
Oral single dose;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
16.2
L/h
16.2
L/h
apparent clearance; tumor; patients;
DRUGBANK
1220.0
L
1220±1114
L
Steady state volume of distribution;
DRUGBANK
36.0
h
36
h
DRUGBANK
47.5
%
47.5
%
Urinary excretion; Oral single dose;
DRUGBANK
38.8
%
38.8
%
Faeces excretion; Oral single dose;
DRUGBANK
83.0
%
83
%
plasma proteins; human, homo sapiens;
DRUGBANK
300.0
mg/day
300
mg/day
PO, oral
qd
Zejula
niraparib
PDR
300.0
mg/day
300
mg/day
PO, oral
qd
Zejula
niraparib
PDR
DDPD11799
Bictegravir
449.386
C21H18F3N3O5
OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O
DB11799
90311989
44208822
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
DRUGBANK
0.2
L/kg
0.2
L/kg
human, homo sapiens;
DRUGBANK
17.3
h
17.3
h
DRUGBANK
1.0
%
~1
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD11817
Baricitinib
371.42
C16H17N7O2S
CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
DB11817
44205240
95341
26373084
-2.0
-
-2.0
-
DRUGBANK
79.0
%
79
%
PO, oral;
DRUGBANK
1.0
h
1(0.5-3)
h
PO, oral;
DRUGBANK
0.5
h
0.5
h
PO, oral; food;
food ↓ ;
DRUGBANK
10.0
%
<10
%
DRUGBANK
9.42
L/h
~9.42
L/h
apparent clearance; rheumatoid arthritis; patients;
DRUGBANK
76.0
L
76.0
L
Average volume of distribution; intravenous infusion, IV in drop;
DRUGBANK
12.5
h
~12.5
h
rheumatoid arthritis; patients;
DRUGBANK
50.0
%
~50
%
plasma proteins;
DRUGBANK
2.0
mg/day
2
mg/day
PO, oral
Olumiant
baricitinib
PDR
2.0
mg/day
2
mg/day
PO, oral
Olumiant
baricitinib
PDR
DDPD11823
Esketamine
237.73
C13H16ClNO
CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl
DB11823
182137
60799
158414
-2.0
-
-2.0
-
DRUGBANK
48.0
%
48
%
nasal spray;
DRUGBANK
0.5
h
20-40
min
nasal spray;
DRUGBANK
89.0
L/h
89.0
L/h
Average clearance; intravenous injection, IV;
DRUGBANK
709.0
L
709.0
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
9.5
h
7-12
h
terminal half-life;
DRUGBANK
447.0
mg/kg
447.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
78.0
%
≥78
%
Urinary excretion; PO, oral; intravenous injection, IV;
DRUGBANK
2.0
%
≤2
%
Faeces excretion; PO, oral; intravenous injection, IV;
DRUGBANK
1.0
%
<1
%
Unchanged drug;
DRUGBANK
44.0
%
43-45
%
DRUGBANK
84.0
mg
84
mg
intranasal
biw
Spravato
esketamine hydrochloride
PDR
84.0
mg
84
mg
intranasal
biw
Spravato
esketamine hydrochloride
PDR
0.0
0
Spravato
esketamine hydrochloride
PDR
DDPD11827
Ertugliflozin
436.89
C22H25ClO7
CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1
DB11827
44814423
26340533
-2.0
-
-2.0
-
DRUGBANK
1193.0
ng.h/ml
1193.0
ng.h/ml
PO, oral;
DRUGBANK
80.0
%
70-90
%
PO, oral;
DRUGBANK
268.0
ng/ml
268
ng/ml
PO, oral;
DRUGBANK
1.0
h
0.5-1.5
h
PO, oral;
DRUGBANK
10.722
L/h
178.7
ml/min
Plasma clearance; PO, oral;
DRUGBANK
11.232
L/h
187.2
ml/min
Total clearance; intravenous injection, IV;
DRUGBANK
215.3
L
215.3
L
Apparent volume of distribution; PO, oral;
DRUGBANK
85.53
L
85.53
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
14.0
h
11-17
h
elimination half-life;
DRUGBANK
50.0
%
50
%
Urinary excretion;
DRUGBANK
41.0
%
41
%
Faeces excretion;
DRUGBANK
95.0
%
94-96
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Steglatro
ertugliflozin
PDR
15.0
mg/day
15
mg/day
PO, oral
Steglatro
ertugliflozin
PDR
DDPD11828
Neratinib
557.05
C30H29ClN6O3
CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N
DB11828
9915743
61397
8091392
-2.0
-
-2.0
-
DRUGBANK
5.0
h
2-8
h
DRUGBANK
15.0
%
15
%
Active metabolite;
DRUGBANK
33.0
%
33
%
Derivative;
DRUGBANK
22.0
%
22
%
Components;
DRUGBANK
4.0
%
4
%
Drug form;
DRUGBANK
216.0
L/h
216.0
L/h
Total clearance; Multiple dose;
DRUGBANK
281.0
L/h
281.0
L/h
Total clearance; at steady state;
DRUGBANK
6433.0
L
6433.0
L
Apparent volume of distribution;
DRUGBANK
12.0
h
7-17
h
Single dose;
DRUGBANK
14.6
h
14.6
h
elimination half-life; Multiple dose;
DRUGBANK
21.6
h
21.6
h
DRUGBANK
13.8
h
13.8
h
DRUGBANK
10.4
h
10.4
h
DRUGBANK
97.1
%
97.1
%
Faeces excretion;
DRUGBANK
1.13
%
1.13
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
240.0
mg/day
240
mg/day
PO, oral
Nerlynx
neratinib
PDR
240.0
mg/day
240
mg/day
PO, oral
Nerlynx
neratinib
PDR
DDPD11837
Osilodrostat
227.242
C13H10FN3
FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12
DB11837
44139752
29340911
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
DRUGBANK
80.0
%
80
%
DRUGBANK
51.0
%
51
%
DRUGBANK
9.0
%
9
%
DRUGBANK
7.0
%
7
%
DRUGBANK
17.0
%
17
%
Urinary excretion;
DRUGBANK
13.0
%
13
%
Urinary excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion;
DRUGBANK
13.0
%
13
%
Urinary excretion;
DRUGBANK
100.0
L
100.0
L
Apparent volume of distribution;
DRUGBANK
4.0
h
~4
h
elimination half-life;
DRUGBANK
90.6
%
90.6
%
Urinary excretion; PO, oral;
DRUGBANK
1.58
%
1.58
%
Faeces excretion; PO, oral;
DRUGBANK
5.2
%
5.2
%
Urinary excretion; Unchanged drug;
DRUGBANK
40.0
%
<40
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
DDPD11842
Angiotensin II
1046.1786
C50H71N13O12
CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O
DB11842
172198
58506
150504
-2.0
-
-2.0
-
DRUGBANK
0.0166666666666667
h
<1
min
elimination half-life; intravenous injection, IV;
DRUGBANK
0.1152
mg/kg/day
80
ng/kg/minut
intravenous infusion, iv in drop
Giapreza
angiotensin II
PDR
0.0576
mg/kg/day
40
ng/kg/minut
intravenous infusion, iv in drop
Giapreza
angiotensin II
PDR
0.001152
mg/kg/day
80
ng/kg/minut
intravenous infusion, iv in drop
Giapreza
angiotensin II
PDR
0.000576
mg/kg/day
40
ng/kg/minut
intravenous infusion, iv in drop
Giapreza
angiotensin II
PDR
DDPD11855
Revefenacin
597.76
C35H43N5O4
CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1
DB11855
11753673
9928376
-2.0
-
-2.0
-
DRUGBANK
0.195
ng.h/ml
0.03-0.36
ng.h/ml
DRUGBANK
0.085
ng/ml
0.02-0.15
ng/ml
DRUGBANK
0.495
h
0.48-0.51
h
DRUGBANK
168.0
h
7
day
DRUGBANK
218.0
L
218.0
L
intravenous injection, IV;
DRUGBANK
46.15
h
22.3-70
h
terminal half-life;
DRUGBANK
54.0
%
54
%
Faeces excretion; intravenous injection, IV;
DRUGBANK
27.0
%
27
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
71.0
%
71
%
plasma proteins;
DRUGBANK
0.175
mg/day
175
mcg/day
inhalation, IH
Yupelri
revefenacin
PDR
0.175
mg/day
175
mcg/day
inhalation, IH
Yupelri
revefenacin
PDR
DDPD11859
Brexanolone
318.4935
C21H34O2
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O
DB11859
92786
50169
83760
-2.0
-
-2.0
-
DRUGBANK
5.0
%
<5
%
PO, oral; adults;
DRUGBANK
1.0
L/h/kg
~1
l/h/kg
Plasma clearance;
DRUGBANK
3.0
L/kg
~3
L/kg
DRUGBANK
9.0
h
~9
h
terminal half-life;
DRUGBANK
0.42
%
0.42
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins;
Plasma Concentration → ;
DRUGBANK
DDPD11901
Apalutamide
477.44
C21H15F4N5O2S
CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F
DB11901
24872560
28424131
-2.0
-
-2.0
-
DRUGBANK
100000.0
ng.h/ml
100.0
mcg.h/ml
PO, oral;
DRUGBANK
124000.0
ng.h/ml
124.0
mcg.h/ml
Active metabolite;
DRUGBANK
100.0
%
~100
%
PO, oral;
DRUGBANK
6000.0
ng/ml
6.0
mcg/ml
PO, oral;
DRUGBANK
5900.0
ng/ml
5.9
mcg/ml
Active metabolite;
DRUGBANK
2.0
h
2(1-5)
h
PO, oral;
DRUGBANK
672.0
h
4
week
PO, oral;
DRUGBANK
1.3
L/h
1.3
L/h
apparent clearance; Single dose;
extended release formulation ↑ ;
DRUGBANK
2.0
L/h
2.0
L/h
apparent clearance; Multiple dose; at steady state;
DRUGBANK
276.0
L
~276
L
Apparent volume of distribution; at steady state;
DRUGBANK
72.0
h
~3
day
effective half-life; NM-CRPC; patients; at steady state;
DRUGBANK
65.0
%
65
%
Urinary excretion; Oral single dose;
DRUGBANK
24.0
%
24
%
Faeces excretion; Oral single dose;
DRUGBANK
0.78
%
0.78
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
0.36
%
0.36
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
96.0
%
96
%
DRUGBANK
240.0
mg/day
240
mg/day
PO, oral
Erleada
apalutamide
PDR
240.0
mg/day
240
mg/day
PO, oral
Erleada
apalutamide
PDR
DDPD11915
Valbenazine
418.578
C24H38N2O4
COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1
DB11915
24795069
28536134
-2.0
-
-2.0
-
DRUGBANK
49.0
%
49
%
PO, oral;
DRUGBANK
0.75
h
0.5-1
h
PO, oral;
DRUGBANK
7.2
L/h
7.2
L/h
DRUGBANK
0.1026
L/h/kg
1.71
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
92.0
L
92.0
L
DRUGBANK
1.31
L/kg
1.31
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.5
h
15-22
h
DRUGBANK
18.5
h
15-22
h
Active metabolite;
DRUGBANK
18.0
h
18
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
~60
%
Urinary excretion;
DRUGBANK
30.0
%
~30
%
Faeces excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
80.0
mg/day
80
mg/day
PO, oral
Ingrezza
valbenazine
PDR
80.0
mg/day
80
mg/day
PO, oral
Ingrezza
valbenazine
PDR
DDPD11921
Deflazacort
441.524
C25H31NO6
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@]([H])(O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O
DB11921
189821
135720
164861
-2.0
-
-2.0
-
DRUGBANK
280.0
ng.h/ml
280.0
ng.h/ml
PO, oral;
DRUGBANK
1.5
h
1-2
h
PO, oral;
DRUGBANK
114.0
L/h
114±27
L/h
DRUGBANK
204.0
L
204±84
L
DRUGBANK
1.5
h
1.1-1.9
h
DRUGBANK
5200.0
mg/kg
5200.0
mg/kg
PO, oral; mouse;
DRUGBANK
0.12
mg/kg
0.12
mg/kg
PO, oral; Female, women;
DRUGBANK
70.0
%
~70
%
Urinary excretion;
DRUGBANK
30.0
%
~30
%
Faeces excretion;
DRUGBANK
0.9
mg/kg/day
0.9
mg/kg/dose
PO, oral
qd
Emflaza
deflazacort
PDR
0.9
mg/kg/day
0.9
mg/kg/dose
PO, oral
qd
Emflaza
deflazacort
PDR
0.9
mg/kg/dose
0.9
mg/kg/dose
PO, oral
qd
Emflaza
deflazacort
PDR
DDPD11936
Bempedoic acid
344.492
C19H36O5
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
DB11936
10472693
8648104
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3.5
h
PO, oral;
DRUGBANK
0.672
L/h
11.2
ml/min
at steady state;
DRUGBANK
18.0
L
18.0
L
Apparent volume of distribution;
DRUGBANK
19.5
h
15-24
h
DRUGBANK
70.0
%
70
%
Urinary excretion;
DRUGBANK
30.0
%
30
%
Faeces excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion; Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
~99
%
plasma proteins;
DRUGBANK
DDPD11942
Selinexor
443.313
C17H11F6N7O
FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F
DB11942
71481097
32701989
-2.0
-
-2.0
-
DRUGBANK
5386.0
ng.h/ml
5386.0
ng.h/ml
Oral single dose;
DRUGBANK
680.0
ng/ml
680
ng/ml
Oral single dose;
DRUGBANK
4.0
h
4
h
DRUGBANK
3.0
h
2-4
h
different study;
DRUGBANK
17.9
L/h
17.9
L/h
apparent clearance;
DRUGBANK
125.0
L
125.0
L
Apparent volume of distribution;
DRUGBANK
2.4
L/kg
1.9-2.9
L/kg
Apparent volume of distribution; food;
DRUGBANK
7.0
h
6-8
h
elimination half-life;
DRUGBANK
95.0
%
95
%
plasma proteins;
DRUGBANK
DDPD11943
Delafloxacin
440.76
C18H12ClF3N4O4
NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F
DB11943
487101
427049
-2.0
-
-2.0
-
DRUGBANK
58.8
%
58.8
%
PO, oral;
DRUGBANK
0.75
h
0.75(0.5-4)
h
Oral single dose;
DRUGBANK
1.0
h
1(1-1.2)
h
intravenous injection, IV;
DRUGBANK
1.0
h
1(0.5-6)
h
Oral single dose;
DRUGBANK
1.0
h
1
h
intravenous injection, IV;
DRUGBANK
16.3
L/h
16.3
L/h
Average clearance;
DRUGBANK
0.1398
L/h/kg
2.33
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39.0
L
30-48
L
Steady state volume of distribution;
DRUGBANK
0.35
L/kg
0.35
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.7
h
3.7
h
elimination half-life;
DRUGBANK
6.35
h
4.2-8.5
h
elimination half-life; Oral multiple dose;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
28.0
%
28
%
Faeces excretion; Unchanged drug;
DRUGBANK
84.0
%
84
%
plasma proteins; human, homo sapiens;
DRUGBANK
900.0
mg/day
900
mg/day
PO, oral
Baxdela
delafloxacin
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Baxdela
delafloxacin
PDR
900.0
mg/day
900
mg/day
PO, oral
Baxdela
delafloxacin
PDR
600.0
mg/day
600
mg/day
intravenous injection, IV
Baxdela
delafloxacin
PDR
DDPD11951
Lemborexant
410.425
C22H20F2N4O2
CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=NC=C(F)C=C2)C2=CC=CC(F)=C2)C(C)=N1
DB11951
56944144
34500836
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1-3
h
DRUGBANK
4.0
h
3-5
h
PO, oral; high-fat meal;
DRUGBANK
1.0
%
<1
%
Urinary excretion; Unchanged drug;
DRUGBANK
1970.0
L
1970.0
L
DRUGBANK
17.0
h
17
h
DRUGBANK
19.0
h
19
h
DRUGBANK
57.4
%
57.4
%
Faeces excretion; PO, oral;
DRUGBANK
29.1
%
29.1
%
Urinary excretion; PO, oral;
DRUGBANK
2.91
%
<2.91
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
94.0
%
~94
%
high protein binding;
DRUGBANK
DDPD11952
Duvelisib
416.87
C22H17ClN6O
C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
DB11952
50905713
131169
28637766
-2.0
-
-2.0
-
DRUGBANK
10530.0
ng.h/ml
2001-19059
ng.h/ml
DRUGBANK
42.0
%
42
%
DRUGBANK
1882.5
ng/ml
471-3294
ng/ml
DRUGBANK
1.5
h
1-2
h
DRUGBANK
7.4
L/h
3.6-11.2
L/h
DRUGBANK
64.0
L
26-102
L
DRUGBANK
8.05
h
5.2-10.9
h
DRUGBANK
79.0
%
79
%
Faeces excretion;
DRUGBANK
14.0
%
14
%
Urinary excretion;
DRUGBANK
10.0
%
~10
%
Unchanged drug;
DRUGBANK
98.0
%
>98
%
DRUGBANK
DDPD11963
Dacomitinib
469.939
C24H25ClFN5O2
COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
DB11963
11511120
132268
9685914
-2.0
-
-2.0
-
DRUGBANK
2213.0
ng.h/ml
2213.0
ng.h/ml
PO, oral;
DRUGBANK
80.0
%
80
%
PO, oral;
DRUGBANK
104.0
ng/ml
104
ng/ml
PO, oral;
DRUGBANK
6.0
h
6
h
PO, oral;
DRUGBANK
27.6
L/h
27.6
L/h
apparent clearance;
DRUGBANK
2415.0
L
2415.0
L
DRUGBANK
70.0
h
70
h
DRUGBANK
79.0
%
79
%
Faeces excretion;
DRUGBANK
3.0
%
3
%
Urinary excretion;
DRUGBANK
98.0
%
98
%
DRUGBANK
45.0
mg
45
mg
PO, oral
qd
Vizimpro
dacomitinib
PDR
45.0
mg
45
mg
PO, oral
qd
Vizimpro
dacomitinib
PDR
DDPD11967
Binimetinib
441.233
C17H15BrF2N4O3
CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
DB11967
10288191
145371
8463660
-2.0
-
-2.0
-
DRUGBANK
50.0
%
>50
%
PO, oral;
DRUGBANK
1.6
h
1.6
h
PO, oral;
DRUGBANK
20.2
L/h
20.2
L/h
DRUGBANK
92.0
L
92.0
L
Apparent volume of distribution;
DRUGBANK
3.5
h
3.5
h
terminal half-life;
DRUGBANK
62.0
%
62
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
31.0
%
31
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
19.84
%
19.84
%
Faeces excretion; Oral single dose; human, homo sapiens; Unchanged drug;
DRUGBANK
2.01
%
2.01
%
Urinary excretion; Oral single dose; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
97
%
plasma proteins; human, homo sapiens;
DRUGBANK
90.0
mg/day
90
mg/day
PO, oral
Mektovi
binimetinib
PDR
90.0
mg/day
90
mg/day
PO, oral
Mektovi
binimetinib
PDR
DDPD11978
Glasdegib
374.448
C21H22N6O
CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N
DB11978
25166913
145428
28518072
-2.0
-
-2.0
-
DRUGBANK
9587.0
ng.h/ml
9587.0
ng.h/ml
DRUGBANK
9310.0
ng.h/ml
9310.0
ng.h/ml
Oral multiple dose;
DRUGBANK
55.0
%
55
%
PO, oral;
DRUGBANK
321.0
ng/ml
321
ng/ml
DRUGBANK
542.0
ng/ml
542
ng/ml
Oral multiple dose;
DRUGBANK
4.0
h
4
h
DRUGBANK
4.0
h
4
h
Oral multiple dose;
DRUGBANK
5.22
L/h
5.22
L/h
DRUGBANK
225.0
L
225.0
L
DRUGBANK
17.4
h
17.4
h
DRUGBANK
3000.0
mg/kg
3000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
49.0
%
49
%
Urinary excretion;
DRUGBANK
42.0
%
42
%
Faeces excretion;
DRUGBANK
8.3
%
8.3
%
Urinary excretion; Unchanged drug;
DRUGBANK
8.4
%
8.4
%
Faeces excretion; Unchanged drug;
DRUGBANK
91.0
%
91
%
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Daurismo
glasdegib
PDR
100.0
mg/day
100
mg/day
PO, oral
Daurismo
glasdegib
PDR
DDPD11979
Elagolix
631.6
C32H30F5N3O5
COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O
DB11979
11250647
9425680
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
DRUGBANK
123.0
L/h
123.0
L/h
apparent clearance; Oral single dose;
DRUGBANK
144.0
L/h
144.0
L/h
apparent clearance; Oral multiple dose;
DRUGBANK
1674.0
L
1674.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
881.0
L
881.0
L
Apparent volume of distribution; Multiple dose; at steady state;
DRUGBANK
5.0
h
4-6
h
elimination half-life;
DRUGBANK
80.0
%
80
%
plasma proteins; human, homo sapiens;
DRUGBANK
150.0
mg/day
150
mg/day
PO, oral; up to 24months
Orilissa
elagolix
PDR
400.0
mg/day
400
mg/day
PO, oral; up to 6 months
Orilissa
elagolix
PDR
DDPD11986
Entrectinib
560.65
C31H34F2N6O2
CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1
DB11986
25141092
24808589
-2.0
-
-2.0
-
DRUGBANK
4.5
h
4-5
h
Oral single dose;
DRUGBANK
76.0
%
76
%
DRUGBANK
19.6
L/h
19.6
L/h
apparent clearance;
DRUGBANK
52.4
L/h
52.4
L/h
apparent clearance;
DRUGBANK
551.0
L
551.0
L
Apparent volume of distribution;
DRUGBANK
81.1
L
81.1
L
Apparent volume of distribution;
DRUGBANK
20.0
h
20
h
elimination half-life;
DRUGBANK
40.0
h
40
h
Active metabolite;
DRUGBANK
83.0
%
83
%
Faeces excretion; Single dose;
DRUGBANK
3.0
%
3
%
Urinary excretion; Single dose;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
Rozlytrek
entrectinib
PDR
500.0
mg/day
500
mg/day
PO, oral
Rozlytrek
entrectinib
PDR
400.0
mg/day
400
mg/day
PO, oral
Rozlytrek
entrectinib
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Rozlytrek
entrectinib
PDR
600.0
mg/day
600
mg/day
PO, oral
Rozlytrek
entrectinib
PDR
500.0
mg/day
500
mg/day
PO, oral
Rozlytrek
entrectinib
PDR
400.0
mg/day
400
mg/day
PO, oral
Rozlytrek
entrectinib
PDR
600.0
mg/day
600
mg/day
PO, oral
qd
Rozlytrek
entrectinib
PDR
DDPD11989
Benznidazole
260.253
C12H12N4O3
[O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1
DB11989
31593
133833
29299
-2.0
-
-2.0
-
DRUGBANK
91.7
%
91.7
%
DRUGBANK
2.93
h
2.93
h
DRUGBANK
2.04
L/h
2.04
L/h
apparent clearance; PO, oral;
DRUGBANK
39.19
L
39.19
L
Apparent volume of distribution;
DRUGBANK
13.27
h
13.27
h
elimination half-life;
DRUGBANK
8.0
mg/kgday
8
mg/kgday
PO, oral
Benznidazole
benznidazole
PDR
400.0
mg/day
400
mg/day
PO, oral
Benznidazole
benznidazole
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Benznidazole
benznidazole
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Benznidazole
benznidazole
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Benznidazole
benznidazole
PDR
7.0
mg/kg/day
7
mg/kg/day
PO, oral
Benznidazole
benznidazole
PDR
7.5
mg/kg/day
7.5
mg/kg/day
PO, oral
Benznidazole
benznidazole
PDR
DDPD11994
Diacerein
368.297
C19H12O8
CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O
DB11994
26248
94708
24456
-2.0
-
-2.0
-
DRUGBANK
55.0
%
50-60
%
DRUGBANK
1.5
L/h
1.5
L/h
Total clearance;
DRUGBANK
0.1
L/h
0.1
L/h
Renal clearance;
DRUGBANK
37.5
L
15-60
L
DRUGBANK
7.0
h
4-10
h
DRUGBANK
6476.0
mg/kg
>6476
mg/kg
DRUGBANK
37.0
%
37
%
Urinary excretion; Rattus, Rat;
DRUGBANK
53.0
%
53
%
Urinary excretion; Rattus, Rat;
DRUGBANK
99.0
%
99
%
plasma proteins;
DRUGBANK
DDPD11995
Avatrombopag
649.65
C29H34Cl2N6O3S2
OC(=O)C1CCN(CC1)C1=C(Cl)C=C(C=N1)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1
DB11995
9852519
8028230
-2.0
-
-2.0
-
DRUGBANK
4198.0
ng.h/ml
4198.0
ng.h/ml
normal,healthy;
DRUGBANK
166.0
ng/ml
166
ng/ml
normal,healthy;
DRUGBANK
6.5
h
5-8
h
PO, oral; Caucasian; Asian;
DRUGBANK
6.9
L/h
6.9
L/h
Average clearance;
DRUGBANK
180.0
L
180.0
L
Average volume of distribution;
DRUGBANK
19.0
h
~19
h
elimination half-life;
DRUGBANK
88.0
%
88
%
Faeces excretion;
DRUGBANK
6.0
%
6
%
Urinary excretion;
DRUGBANK
29.92
%
29.92
%
Faeces excretion; Unchanged drug;
DRUGBANK
96.0
%
>96
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD12001
Abemaciclib
506.606
C27H32F2N8
CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
DB12001
46220502
29340700
-2.0
-
-2.0
-
DRUGBANK
45.0
%
45
%
DRUGBANK
158.0
ng/ml
158
ng/ml
Oral single dose;
DRUGBANK
6.0
h
6
h
Oral single dose;
DRUGBANK
5.0
h
4-6
h
PO, oral;
DRUGBANK
26.0
L/h
26.0
L/h
Average clearance; patients;
DRUGBANK
690.3
L
690.3
L
Average volume of distribution;
DRUGBANK
18.3
h
18.3
h
elimination half-life; patients;
DRUGBANK
81.0
%
81
%
Faeces excretion; Oral single dose;
DRUGBANK
3.0
%
3
%
Urinary excretion; Oral single dose;
DRUGBANK
96.5
%
95-98
%
animals; high protein binding;
DRUGBANK
200.0
mg/day
200
mg/day
PO, oral
bid
Verzenio
abemaciclib
PDR
150.0
mg/day
150
mg/day
PO, oral
bid
Verzenio
abemaciclib
PDR
200.0
mg/day
200
mg/day
PO, oral
bid
Verzenio
abemaciclib
PDR
150.0
mg/day
150
mg/day
PO, oral
bid
Verzenio
abemaciclib
PDR
DDPD12010
Fostamatinib
580.4595
C23H26FN6O9P
COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
DB12010
11671467
9846198
-2.0
-
-2.0
-
DRUGBANK
55.0
%
55
%
DRUGBANK
1.5
h
1.5
h
DRUGBANK
4.5
h
4.5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
18.0
L/h
~300
ml/min
apparent clearance; PO, oral;
DRUGBANK
400.0
L
400.0
L
Apparent volume of distribution; PO, oral;
DRUGBANK
15.0
h
~15
h
elimination half-life;
DRUGBANK
80.0
%
~80
%
Faeces excretion;
DRUGBANK
98.3
%
98.3
%
plasma proteins;
DRUGBANK
DDPD12015
Alpelisib
441.47
C19H22F3N5O2S
CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F
DB12015
56649450
93752
28424123
-2.0
-
-2.0
-
DRUGBANK
11100.0
ng.h/ml
11,100±3770
ng.h/ml
DRUGBANK
19203.0
ng.h/ml
19203.0
ng.h/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
19647.0
ng.h/ml
19647.0
ng.h/ml
PO, oral; low fat meal;
low fat meal ↑ ;
DRUGBANK
1320.0
ng/ml
1320±912
ng/ml
DRUGBANK
2429.0
ng/ml
2429
ng/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
2831.0
ng/ml
2831
ng/ml
PO, oral; low fat meal;
low fat meal ↑ ;
DRUGBANK
2.0
h
2
h
DRUGBANK
39.0
L/h
39.0
L/h
apparent clearance; PO, oral;
DRUGBANK
9.2
L/h
9.2
L/h
food;
DRUGBANK
114.0
L
114.0
L
Apparent volume of distribution;
DRUGBANK
8.5
h
8-9
h
DRUGBANK
81.0
%
81
%
Faeces excretion; PO, oral;
DRUGBANK
14.0
%
14
%
Urinary excretion; PO, oral;
DRUGBANK
36.0
%
36
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
2.0
%
2
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
89.0
%
89
%
DRUGBANK
DDPD12020
Tecovirimat
376.335
C19H15F3N2O3
FC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O
DB12020
16124688
17281586
-2.0
-
-2.0
-
DRUGBANK
3.5
h
3-4
h
PO, oral;
DRUGBANK
144.0
h
6
day
PO, oral;
DRUGBANK
1356.0
L
1356.0
L
mouse; PO, oral;
DRUGBANK
20.0
h
~20
h
DRUGBANK
23.0
%
~23
%
Faeces excretion; Unchanged drug;
DRUGBANK
80.0
%
~80
%
DRUGBANK
DDPD12026
Voxilaprevir
868.94
C40H52F4N6O9S
CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C
DB12026
89921642
https://www.drugs.com/history/vosevi.html
44209500
-2.0
-
-2.0
-
DRUGBANK
192.0
ng/ml
192
ng/ml
combination drug use;
DRUGBANK
4.0
h
4
h
combination drug use;
DRUGBANK
33.0
h
33
h
DRUGBANK
99.0
%
>99
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD12035
Sarecycline
487.509
C24H29N3O8
[H][C@@]12CC3=C(CN(C)OC)C=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
DB12035
54681908
28540486
-2.0
-
-2.0
-
DRUGBANK
1.75
h
1.5-2
h
DRUGBANK
2.28
h
2.03-2.53
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
15.0
%
<15
%
Liver metabolism;
DRUGBANK
3.0
L/h
3.0
L/h
apparent clearance; PO, oral; at steady state;
DRUGBANK
94.2
L
91.4-97.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
21.5
h
21-22
h
elimination half-life;
DRUGBANK
42.6
%
42.6
%
Faeces excretion; Oral single dose;
DRUGBANK
44.1
%
44.1
%
Urinary excretion; Oral single dose;
DRUGBANK
6.34
%
6.34
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
10.89
%
10.89
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
68.6
%
62.5-74.7
%
high protein binding;
DRUGBANK
DDPD12070
Letermovir
572.561
C29H28F4N4O4
COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=CC(=CC=C1OC)C(F)(F)F
DB12070
26352849
-2.0
-
-2.0
-
DRUGBANK
94.0
%
94
%
DRUGBANK
35.0
%
35
%
hematopoietic stem cell transplant;
DRUGBANK
85.0
%
85
%
Drug combination; hematopoietic stem cell transplant;
DRUGBANK
1.5
h
0.75-2.25
h
DRUGBANK
228.0
h
9-10
day
DRUGBANK
11.25
L/h
11.25
L/h
Average clearance; normal,healthy;
DRUGBANK
45.5
L
45.5
L
Steady state volume of distribution;
DRUGBANK
12.0
h
12
h
terminal half-life; intravenous injection, IV;
DRUGBANK
93.0
%
93
%
Faeces excretion;
DRUGBANK
2.0
%
<2
%
Urinary excretion;
DRUGBANK
99.0
%
99
%
plasma proteins; high protein binding;
DRUGBANK
480.0
mg/day
480
mg/day
PO, oral;intravenous injection, IV;
Prevymis
letermovir
PDR
480.0
mg/day
480
mg/day
PO, oral;intravenous injection, IV;
Prevymis
letermovir
PDR
DDPD12095
Telotristat ethyl
574.99
C27H26ClF3N6O3
CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1
DB12095
25025298
28189674
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
DRUGBANK
8.0
h
4-12
h
DRUGBANK
250.0
mg
250
mg
PO, oral
tid
Xermelo
telotristat ethyl
PDR
250.0
mg
250
mg
PO, oral
tid
Xermelo
telotristat ethyl
PDR
DDPD12107
Vaborbactam
297.13
C12H16BNO5S
OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1
DB12107
56649692
35035409
-2.0
-
-2.0
-
DRUGBANK
588000.0
ng.h/ml
588.0
mg.h/l
normal,healthy; adults;
DRUGBANK
835000.0
ng.h/ml
835.0
mg.h/l
patients; adults;
DRUGBANK
55600.0
ng/ml
55.6
mg/L
normal,healthy; adults;
DRUGBANK
71300.0
ng/ml
71.3
mg/L
patients; adults;
DRUGBANK
8.9
L/h
8.9
L/h
Renal clearance;
DRUGBANK
2.0
L/h
2.0
L/h
Plasma clearance;
DRUGBANK
10.9
L/h
10.9
L/h
intravenous infusion, IV in drop; Multiple dose; normal,healthy;
DRUGBANK
7.95
L/h
7.95
L/h
intravenous infusion, IV in drop; Multiple dose; patients;
DRUGBANK
0.1764
L/h/kg
2.94
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.6
L
18.6
L
Steady state volume of distribution; at steady state;
DRUGBANK
0.29
L/kg
0.29
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.68
h
1.68
h
normal,healthy;
DRUGBANK
2.25
h
2.25
h
DRUGBANK
1.34
h
1.34
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
85.0
%
~75-95
%
Urinary excretion; Unchanged drug;
DRUGBANK
33.0
%
~33
%
DRUGBANK
DDPD12130
Lorlatinib
406.421
C21H19FN6O2
C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
DB12130
71731823
143117
32813339
-2.0
-
-2.0
-
DRUGBANK
81.0
%
81
%
PO, oral;
DRUGBANK
1.2
h
1.2(0.5-4)
h
Oral single dose;
DRUGBANK
2.0
h
2(0.53-23)
h
Oral multiple dose;
DRUGBANK
11.0
L/h
11.0
L/h
Average clearance; Oral single dose;
DRUGBANK
18.0
L/h
18.0
L/h
Average clearance; at steady state;
DRUGBANK
305.0
L
305.0
L
Steady state volume of distribution; intravenous injection, IV; Single dose;
DRUGBANK
24.0
h
24
h
elimination half-life; Oral single dose;
DRUGBANK
48.0
%
48
%
Urinary excretion; Oral single dose;
DRUGBANK
41.0
%
41
%
Faeces excretion; Oral single dose;
DRUGBANK
0.48
%
<0.48
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
3.69
%
~3.69
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
66.0
%
66
%
plasma proteins; high protein binding;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
qd
Lorbrena
lorlatinib
PDR
100.0
mg/day
100
mg/day
PO, oral
qd
Lorbrena
lorlatinib
PDR
DDPD12141
Gilteritinib
552.724
C29H44N8O3
CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O
DB12141
49803313
145372
32055842
-2.0
-
-2.0
-
DRUGBANK
6943.0
ng.h/ml
6943.0
ng.h/ml
PO, oral;
DRUGBANK
374.0
ng/ml
374
ng/ml
PO, oral;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
5.0
h
4-6
h
PO, oral; fasting;
DRUGBANK
7.0
h
6-8
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
360.0
h
15
day
PO, oral;
DRUGBANK
14.85
L/h
14.85
L/h
DRUGBANK
1092.0
L
1092.0
L
Total volume of distribution;
DRUGBANK
1100.0
L
1100.0
L
Total volume of distribution;
DRUGBANK
102.0
h
~45-159
h
DRUGBANK
64.5
%
64.5
%
Faeces excretion;
DRUGBANK
94.0
%
94
%
plasma proteins;
DRUGBANK
120.0
mg/day
120
mg/day
PO, oral
Xospata
gilteritinib
PDR
120.0
mg/day
120
mg/day
PO, oral
Xospata
gilteritinib
PDR
DDPD12147
Erdafitinib
446.555
C25H30N6O2
COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1
DB12147
67462786
35308353
-2.0
-
-2.0
-
DRUGBANK
29268.0
ng.h/ml
29268.0
ng.h/ml
DRUGBANK
1399.0
ng/ml
1399
ng/ml
DRUGBANK
2.5
h
2.5
h
DRUGBANK
336.0
h
2
week
DRUGBANK
0.362
L/h
0.362
L/h
apparent clearance;
DRUGBANK
0.26
L/h
0.26
L/h
PO, oral;
DRUGBANK
27.5
L
26-29
L
Apparent volume of distribution; patients;
DRUGBANK
59.0
h
59
h
effective half-life;
DRUGBANK
55.0
h
50-60
h
effective half-life;
DRUGBANK
69.0
%
69
%
Faeces excretion; Oral single dose;
DRUGBANK
19.0
%
19
%
Urinary excretion; Oral single dose;
DRUGBANK
13.11
%
~13.11
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
2.47
%
2.47
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
99.8
%
~99.8
%
DRUGBANK
9.0
mg/day
9
mg/day
PO, oral
qd
Balversa
erdafitinib
PDR
9.0
mg/day
9
mg/day
PO, oral
qd
Balversa
erdafitinib
PDR
DDPD12161
Deutetrabenazine
323.466
C19H27NO3
[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
DB12161
73442840
32700662
-2.0
-
-2.0
-
DRUGBANK
47.0
L/h
47.0
L/h
Average clearance; Huntington's disease;
DRUGBANK
70.0
L/h
70.0
L/h
Average clearance; Huntington's disease;
DRUGBANK
500.0
L
~500
L
Average volume of distribution;
DRUGBANK
730.0
L
~730
L
Average volume of distribution;
DRUGBANK
9.5
h
9-10
h
DRUGBANK
80.5
%
~75-86
%
Urinary excretion; normal,healthy; human, homo sapiens;
DRUGBANK
9.5
%
8-11
%
Faeces excretion; normal,healthy; human, homo sapiens;
DRUGBANK
48.0
mg/day
48
mg/day
PO, oral
Austedo
deutetrabenazine
PDR
18.0
mg/dose
18
mg/dose
PO, oral
Austedo
deutetrabenazine
PDR
36.0
mg/day
36
mg/day
PO, oral
Austedo
deutetrabenazine
PDR
48.0
mg/day
48
mg/day
PO, oral
Austedo
deutetrabenazine
PDR
18.0
mg/dose
18
mg/dose
PO, oral
Austedo
deutetrabenazine
PDR
36.0
mg/day
36
mg/day
PO, oral
Austedo
deutetrabenazine
PDR
DDPD12243
Edaravone
174.203
C10H10N2O
CC1=NN(C(=O)C1)C1=CC=CC=C1
DB12243
4021
31530
3881
-2.0
-
-2.0
-
DRUGBANK
38.0
%
38
%
PO, oral; mouse;
DRUGBANK
888.0
ng/ml
888
ng/ml
intravenous infusion, IV in drop; normal,healthy; Male, men; adults;
DRUGBANK
6.0
L/h
0.1
L/min
Plasma clearance; intravenous infusion, IV in drop; Single dose;
DRUGBANK
0.0852
L/h/kg
1.42
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.5
L/kg
18.5
L/kg
Average volume of distribution; intravenous infusion, IV in drop;
DRUGBANK
0.23
L/kg
0.23
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.25
h
4.5-6
h
elimination half-life;
DRUGBANK
2.4
h
2-2.8
h
Metabolite;
DRUGBANK
2.36
h
2.36
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1915.0
mg/kg
1915.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
0.8
%
~0.7-0.9
%
Unchanged drug;
DRUGBANK
92.0
%
92
%
high protein binding; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
90.0
%
89-91
%
high protein binding; human, homo sapiens;
DRUGBANK
60.0
mg/day
60
mg/day
intravenous injection, IV
Radicava
edaravone
PDR
60.0
mg/day
60
mg/day
intravenous injection, IV
Radicava
edaravone
PDR
DDPD12245
Triclabendazole
359.65
C14H9Cl3N2OS
CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2
DB12245
50248
94759
45565
-2.0
-
-2.0
-
DRUGBANK
2057.198
ng.h/ml
5.72
umol.h/L
Oral single dose; fascioliasis; food;
DRUGBANK
138824.9
ng.h/ml
386.0
umol.h/L
Oral single dose; fascioliasis; food; Components;
DRUGBANK
10969.325
ng.h/ml
30.5
umol.h/L
Oral single dose; fascioliasis; food; Active metabolite;
DRUGBANK
1.16
ng/ml
1.16
umol/L
Oral single dose; fascioliasis; food;
DRUGBANK
38.6
ng/ml
38.6
umol/L
Oral single dose; fascioliasis; food; Components;
DRUGBANK
2.29
ng/ml
2.29
umol/L
Oral single dose; fascioliasis; food; Active metabolite;
DRUGBANK
3.5
h
3-4
h
Oral single dose; fascioliasis; food;
DRUGBANK
3.5
h
3-4
h
Oral single dose; fascioliasis; food; Components;
DRUGBANK
3.5
h
3-4
h
Oral single dose; fascioliasis; food; Active metabolite;
DRUGBANK
1.0
L/kg
1.0
L/kg
Apparent volume of distribution; food; patients;
DRUGBANK
8.0
h
~8
h
DRUGBANK
14.0
h
~14
h
Metabolite;
DRUGBANK
11.0
h
~11
h
Metabolite;
DRUGBANK
8000.0
mg/kg
>8
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
8000.0
mg/kg
>8
g/kg
PO, oral; mouse;
DRUGBANK
90.0
%
90
%
Faeces excretion; animals;
DRUGBANK
10.0
%
<10
%
Urinary excretion; PO, oral; animals;
DRUGBANK
96.7
%
96.7
%
plasma proteins;
DRUGBANK
DDPD12267
Brigatinib
584.1
C29H39ClN7O2P
COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1
DB12267
68165256
34982928
-2.0
-
-2.0
-
DRUGBANK
8165.0
ng.h/ml
8165.0
ng.h/ml
DRUGBANK
20276.0
ng.h/ml
20276.0
ng.h/ml
DRUGBANK
552.0
ng/ml
552
ng/ml
DRUGBANK
1452.0
ng/ml
1452
ng/ml
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
72.4
%
72.4
%
Liver metabolism;
DRUGBANK
27.6
%
27.6
%
Liver metabolism;
DRUGBANK
12.7
L/h
12.7
L/h
apparent clearance; PO, oral; at steady state;
DRUGBANK
153.0
L
153.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
25.0
h
25
h
at steady state;
DRUGBANK
65.0
%
65
%
Faeces excretion;
DRUGBANK
25.0
%
25
%
Urinary excretion;
DRUGBANK
66.0
%
66
%
plasma proteins;
DRUGBANK
180.0
mg/day
180
mg/day
PO, oral
qd
Alunbrig
brigatinib
PDR
180.0
mg/day
180
mg/day
PO, oral
qd
Alunbrig
brigatinib
PDR
DDPD12278
Propiverine
367.4813
C23H29NO3
CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1
DB12278
4942
8493
4773
-2.0
-
-2.0
-
DRUGBANK
40.5
%
40.5
%
Tablet, PO, oral;
DRUGBANK
2.3
h
2.3
h
PO, oral;
DRUGBANK
22.26
L/h
371(191–870)
ml/min
Average clearance; Single dose;
DRUGBANK
0.1764
L/h/kg
2.94
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2791.0
L
2791(125-4731)
L
intravenous injection, IV; normal,healthy;
DRUGBANK
2.73
L/kg
2.73
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.1
h
14.1
h
elimination half-life; normal,healthy; different study;
DRUGBANK
20.1
h
20.1
h
elimination half-life; normal,healthy; different study;
DRUGBANK
22.1
h
22.1
h
elimination half-life; normal,healthy; different study;
DRUGBANK
15.2
h
15.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
60.0
%
60
%
Urinary excretion;
DRUGBANK
21.0
%
21
%
Faeces excretion;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
DDPD12293
Nefopam
253.345
C17H19NO
CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1
DB12293
4450
88318
4295
-2.0
-
-2.0
-
DRUGBANK
0.72
L/h/kg
12
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.6
L/kg
5.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
5
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD12301
Doravirine
425.749
C17H11ClF3N5O3
CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
DB12301
58460047
28424197
-2.0
-
-2.0
-
DRUGBANK
64.0
%
64
%
DRUGBANK
2.0
h
2
h
DRUGBANK
6.36
L/h
106.0
ml/min
PO, oral;
DRUGBANK
0.558
L/h
9.3
ml/min
Renal clearance;
DRUGBANK
60.5
L
60.5
L
Steady state volume of distribution; intravenous injection, IV;
DRUGBANK
15.0
h
15
h
elimination half-life;
DRUGBANK
6.0
%
6
%
Urinary excretion; Unchanged drug;
DRUGBANK
76.0
%
~76
%
plasma proteins;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Pifeltro
doravirine
PDR
200.0
mg/day
200
mg/day
PO, oral
Pifeltro
doravirine
PDR
100.0
mg/day
100
mg/day
PO, oral
Pifeltro
doravirine
PDR
200.0
mg/day
200
mg/day
PO, oral
Pifeltro
doravirine
PDR
DDPD12329
Eravacycline
558.563
C27H31FN4O8
[H][C@@]12CC3=C(F)C=C(NC(=O)CN4CCCC4)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
DB12329
54726192
28495485
-2.0
-
-2.0
-
DRUGBANK
1069.2
L/h
17.82
L/min
DRUGBANK
0.2226
L/h/kg
3.71
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
321.0
L
321.0
L
at steady state;
DRUGBANK
2.3
L/kg
2.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
h
20
h
elimination half-life;
DRUGBANK
47.0
%
47
%
Faeces excretion;
DRUGBANK
34.0
%
~34
%
Urinary excretion;
DRUGBANK
20.0
%
20
%
Urinary excretion; Unchanged drug;
DRUGBANK
17.0
%
17
%
Urinary excretion; Unchanged drug;
DRUGBANK
84.5
%
79-90
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD12332
Rucaparib
323.371
C19H18FN3O
CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3
DB12332
9931954
134689
8107584
-2.0
-
-2.0
-
DRUGBANK
16900.0
ng.h/ml
16900.0
ng.h/ml
DRUGBANK
1940.0
ng/ml
1940
ng/ml
DRUGBANK
1.9
h
1.9
h
DRUGBANK
47.25
L/h
15.3-79.2
L/h
apparent clearance; Multiple dose;
DRUGBANK
16.15
L/h
13.9-18.4
L/h
intravenous injection, IV; Single dose;
DRUGBANK
0.2586
L/h/kg
4.31
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
187.5
L
113-262
L
Steady state volume of distribution; intravenous injection, IV; Single dose;
DRUGBANK
3.28
L/kg
3.28
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
18.0
h
17-19
h
terminal half-life; Oral single dose;
DRUGBANK
16.6
h
16.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
79.0
%
≥79
%
Faeces excretion;
DRUGBANK
70.0
%
70
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
600.0
mg/day
600
mg/day
PO, oral
bid
Rubraca
rucaparib
PDR
600.0
mg/day
600
mg/day
PO, oral
bid
Rubraca
rucaparib
PDR
DDPD12343
Temocillin
414.45
C16H18N2O7S2
CO[C@]1(NC(=O)C(C(O)=O)C2=CSC=C2)[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O
DB12343
171758
51817
150149
-2.0
-
-2.0
-
DRUGBANK
36.0
%
36(30-45)
%
Tablet, PO, oral; immediate release formulation;
DRUGBANK
0.0204
L/h/kg
0.34
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.11
L/kg
0.11
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.1
h
4.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD12364
Betrixaban
451.91
C23H22ClN5O3
COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1
DB12364
10275777
140421
18981107
-2.0
-
-2.0
-
DRUGBANK
34.0
%
34
%
PO, oral;
DRUGBANK
3.5
h
3-4
h
PO, oral; normal,healthy;
DRUGBANK
1.0
%
<1
%
Liver metabolism;
DRUGBANK
32.0
L/kg
32.0
L/kg
Apparent volume of distribution;
DRUGBANK
23.0
h
19-27
h
DRUGBANK
85.0
%
85
%
Faeces excretion;
DRUGBANK
11.0
%
11
%
Urinary excretion;
DRUGBANK
60.0
%
~60
%
DRUGBANK
160.0
mg
160
mg
PO, oral
Bevyxxa
betrixaban
PDR
160.0
mg
160
mg
PO, oral
Bevyxxa
betrixaban
PDR
DDPD12371
Siponimod
516.605
C29H35F3N2O3
CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
DB12371
44599207
29315058
-2.0
-
-2.0
-
DRUGBANK
70.0
%
>70
%
PO, oral;
DRUGBANK
84.0
%
84
%
PO, oral;
DRUGBANK
4.0
h
4(3-8)
h
PO, oral; immediate release formulation;
DRUGBANK
6.5
h
6-7
h
PO, oral; food;
food ↑ ;
DRUGBANK
144.0
h
6
day
PO, oral;
DRUGBANK
79.3
%
79.3
%
DRUGBANK
18.5
%
18.5
%
DRUGBANK
3.11
L/h
3.11
L/h
multiple sclerosis;
DRUGBANK
124.0
L
124.0
L
Average volume of distribution;
DRUGBANK
30.0
h
~30
h
elimination half-life;
DRUGBANK
99.9
%
>99.9
%
normal,healthy; hepatopathy，LD; renal insufficiency;
DRUGBANK
DDPD12377
Relebactam
348.37
C12H20N4O6S
OS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NC2CCNCC2)C1=O
DB12377
44129647
31137585
-2.0
-
-2.0
-
DRUGBANK
8.4
L/h
130-150
ml/min
Total clearance;
DRUGBANK
19.0
L
19.0
L
Single dose; at steady state;
DRUGBANK
1.2
h
1.2
h
DRUGBANK
1.575
h
1.35-1.8
h
different study;
DRUGBANK
95.0
%
~90-100
%
Urinary excretion;
DRUGBANK
22.0
%
~22
%
plasma proteins;
DRUGBANK
DDPD12404
Remimazolam
439.313
C21H19BrN4O2
COC(=O)CC[C@@H]1N=C(C2=CC=CC=N2)C2=CC(Br)=CC=C2N2C(C)=CN=C12
DB12404
9867812
8043503
-2.0
-
-2.0
-
DRUGBANK
0.9012
L/h/kg
15.02
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.44
L/kg
0.44
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.75
h
0.75
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD12455
Omadacycline
556.66
C29H40N4O7
[H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C
DB12455
54697325
20131003
-2.0
-
-2.0
-
DRUGBANK
34.5
%
34.5
%
PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral;
DRUGBANK
11.24
L/h
11.24
L/h
Average clearance;
DRUGBANK
2.85
L/h
2.4-3.3
L/h
Renal clearance;
DRUGBANK
0.1404
L/h/kg
2.34
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
256.0
L
256.0
L
Average volume of distribution;
DRUGBANK
190.0
L
190.0
L
Steady state volume of distribution;
DRUGBANK
2.7
L/kg
2.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
16.2
h
16.2
h
elimination half-life;
DRUGBANK
15.0
h
15
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
27.0
%
27
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
14.4
%
14.4
%
Urinary excretion; PO, oral;
DRUGBANK
81.1
%
81.1
%
Faeces excretion; PO, oral;
DRUGBANK
20.0
%
20
%
Plasma Concentration → ;
DRUGBANK
DDPD12457
Rimegepant
534.568
C28H28F2N6O3
N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N2C(=O)NC3=NC=CC=C23)C2=C1C=CC=N2)C1=C(F)C(F)=CC=C1
DB12457
51049968
27289072
-2.0
-
-2.0
-
DRUGBANK
64.0
%
64
%
PO, oral;
DRUGBANK
1.5
h
1.5
h
Tablet, PO, oral;
DRUGBANK
2.5
h
2.5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
120.0
L
~120
L
at steady state;
DRUGBANK
11.0
h
~11
h
elimination half-life; normal,healthy;
DRUGBANK
78.0
%
78
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
24.0
%
24
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
32.76
%
32.76
%
Faeces excretion; PO, oral; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
12.24
%
12.24
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
96.0
%
~96
%
plasma proteins;
DRUGBANK
DDPD12466
Favipiravir
157.104
C5H4FN3O2
NC(=O)C1=NC(F)=CN=C1O
DB12466
492405
134722
431002
-2.0
-
-2.0
-
DRUGBANK
91400.0
ng.h/ml
91.4
ug.h/ml
Oral single dose; Asian;
DRUGBANK
44110.0
ng.h/ml
44.11
ug.h/ml
Oral single dose; Caucasian;
DRUGBANK
215050.0
ng.h/ml
215.05
ug.h/ml
Oral multiple dose; Asian;
DRUGBANK
73270.0
ng.h/ml
73.27
ug.h/ml
Oral multiple dose; Caucasian;
DRUGBANK
97.6
%
97.6
%
DRUGBANK
51500.0
ng/ml
51.5
ug/ml
DRUGBANK
36240.0
ng/ml
36.24
ug/ml
Oral single dose; Asian;
DRUGBANK
22010.0
ng/ml
22.01
ug/ml
Oral single dose; Caucasian;
DRUGBANK
36230.0
ng/ml
36.23
ug/ml
Oral multiple dose; Asian;
DRUGBANK
23940.0
ng/ml
23.94
ug/ml
Oral multiple dose; Caucasian;
DRUGBANK
0.5
h
0.5
h
Oral single dose; Asian;
DRUGBANK
0.5
h
0.5
h
Oral single dose; Caucasian;
DRUGBANK
0.5
h
0.5
h
Oral multiple dose; Asian;
DRUGBANK
0.6
h
0.6
h
Oral multiple dose; Caucasian;
DRUGBANK
2.98
L/h
2.98±0.30
L/h
apparent clearance; Single dose;
DRUGBANK
6.27
L/h
6.72±1.68
L/h
apparent clearance;
DRUGBANK
2890.91
L/h
2.890.91
L/h
apparent clearance;
DRUGBANK
17.5
L
15-20
L
Apparent volume of distribution;
DRUGBANK
3.75
h
2-5.5
h
elimination half-life;
DRUGBANK
54.0
%
54
%
plasma proteins;
DRUGBANK
35.1
%
35.1
%
DRUGBANK
3.51
%
3.51
%
DRUGBANK
DDPD12483
Copanlisib
480.529
C23H28N8O4
COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
DB12483
24989044
25069683
-2.0
-
-2.0
-
DRUGBANK
463.0
ng/ml
463(105-1670)
ng/ml
DRUGBANK
90.0
%
90
%
DRUGBANK
10.0
%
<10
%
DRUGBANK
17.9
L/h
17.9
L/h
Average clearance;
DRUGBANK
0.3852
L/h/kg
6.42
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
871.0
L
871.0
L
Average volume of distribution;
DRUGBANK
10.34
L/kg
10.34
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
39.1
h
39.1(14.6-82.4)
h
elimination half-life;
DRUGBANK
25.2
h
25.2
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
Faeces excretion;
DRUGBANK
22.0
%
22
%
Urinary excretion;
DRUGBANK
30.0
%
~30
%
Faeces excretion; Unchanged drug;
DRUGBANK
15.0
%
~15
%
Urinary excretion; Unchanged drug;
DRUGBANK
84.2
%
84.2
%
plasma proteins; high protein binding; human, homo sapiens;
DRUGBANK
60.0
mg
60
mg
intravenous injection, IV
ALIQOPA
copanlisib
PDR
60.0
mg
60
mg
intravenous injection, IV
ALIQOPA
copanlisib
PDR
DDPD12492
Piritramide
430.5851
C27H34N4O
NC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)N1CCCCC1
DB12492
9331
135699
8967
-2.0
-
-2.0
-
DRUGBANK
0.468
L/h/kg
7.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.7
L/kg
4.7
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD12500
Fedratinib
524.678
C27H36N6O3S
CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
DB12500
16722836
91408
17626393
-2.0
-
-2.0
-
DRUGBANK
26870.0
ng.h/ml
26870.0
ng.h/ml
PO, oral;
DRUGBANK
1804.0
ng/ml
1804
ng/ml
PO, oral;
DRUGBANK
2.375
h
1.75-3
h
PO, oral;
DRUGBANK
13.0
L/h
13.0
L/h
DRUGBANK
1770.0
L
1770.0
L
Apparent volume of distribution;
DRUGBANK
41.0
h
41
h
DRUGBANK
114.0
h
114
h
terminal half-life;
DRUGBANK
77.0
%
77
%
Faeces excretion; PO, oral;
DRUGBANK
5.0
%
5
%
Urinary excretion; PO, oral;
DRUGBANK
17.71
%
17.71
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
0.15
%
0.15
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
92.0
%
≥92
%
plasma proteins;
DRUGBANK
400.0
mg/day
400
mg/day
PO, oral
Inrebic
fedratinib
PDR
400.0
mg/day
400
mg/day
PO, oral
Inrebic
fedratinib
PDR
DDPD12523
Mizolastine
432.503
C24H25FN6O
CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1
DB12523
65906
31857
59315
-2.0
-
-2.0
-
DRUGBANK
0.0618
L/h/kg
1.03
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.38
L/kg
0.38
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
9.6
h
9.6
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD12529
Nitrite
46.0055
NO2
[O-]N=O
DB12529
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
946
16301
921
-2.0
-
-2.0
-
DRUGBANK
0.1
mg/kg/day
0.1
mg/kg/day
PO, oral;
DRUGBANK
0.1
mg/kg/day
0.1
mg/kg/day
PO, oral;
DRUGBANK
0.1
mg/kg/day
0.1
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD12532
Oxetacaine
467.654
C28H41N3O3
CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1
DB12532
4621
31947
4460
-2.0
-
-2.0
-
DRUGBANK
33.33
%
<33.33
%
PO, oral;
DRUGBANK
20.0
ng/ml
20
ng/ml
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
1.0
h
~1
h
DRUGBANK
DDPD12612
Ozanimod
404.47
C23H24N4O3
CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N
DB12612
52938427
34979946
-2.0
-
-2.0
-
DRUGBANK
4.46
ng.h/ml
4.46
ng.h/ml
PO, oral;
DRUGBANK
0.244
ng/ml
0.244
ng/ml
PO, oral;
DRUGBANK
7.0
h
6-8
h
PO, oral;
DRUGBANK
102.0
h
102
h
PO, oral;
DRUGBANK
73.0
%
73
%
DRUGBANK
15.0
%
15
%
DRUGBANK
192.0
L/h
192.0
L/h
apparent clearance; PO, oral;
DRUGBANK
233.0
L/h
233.0
L/h
PO, oral;
DRUGBANK
5590.0
L
5590.0
L
Average volume of distribution;
DRUGBANK
87.0
L
73-101
L
DRUGBANK
19.0
h
17-21
h
DRUGBANK
26.0
%
~26
%
Urinary excretion;
DRUGBANK
37.0
%
~37
%
Faeces excretion;
DRUGBANK
98.0
%
>98
%
DRUGBANK
DDPD12615
Plazomicin
592.691
C25H48N6O10
CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O
DB12615
42613186
26390008
-2.0
-
-2.0
-
DRUGBANK
257000.0
ng.h/ml
257±67.0
ug.h/ml
intravenous infusion, IV in drop; normal,healthy; adults;
DRUGBANK
226000.0
ng.h/ml
226±113
ug.h/ml
intravenous infusion, IV in drop; complicated urinary tract infections; adults;
DRUGBANK
73700.0
ng/ml
73.7±19.7
ug/ml
intravenous infusion, IV in drop; normal,healthy; adults;
DRUGBANK
51000.0
ng/ml
51.0±26.7
ug/ml
intravenous infusion, IV in drop; complicated urinary tract infections; adults;
DRUGBANK
4.5
L/h
4.5±0.9
L/h
Average clearance; intravenous infusion, IV in drop; normal,healthy; adults;
DRUGBANK
5.1
L/h
5.1±2.01
L/h
Average clearance; intravenous infusion, IV in drop; complicated urinary tract infections; patients;
DRUGBANK
0.0684
L/h/kg
1.14
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
17.9
L
17.9±4.8
L
Average volume of distribution; normal,healthy; adults;
DRUGBANK
30.8
L
30.8±12.1
L
Average volume of distribution; complicated urinary tract infections; patients;
DRUGBANK
0.22
L/kg
0.22
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.5
h
3.5±0.5
h
normal,healthy; adults; normal renal function; intravenous infusion, IV in drop;
DRUGBANK
3.4
h
3.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
20.0
%
~20
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD12674
Lurbinectedin
784.88
C41H44N4O10S
[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC4=CC=C(OC)C=C54)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@@]2([H])N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31
DB12674
57327016
32701856
-2.0
-
-2.0
-
DRUGBANK
551.0
ng.h/ml
551.0
ug.h/L
intravenous injection, IV;
DRUGBANK
107.0
ng/ml
107
ug/L
intravenous injection, IV;
DRUGBANK
11.0
L/h
~11
L/h
Plasma clearance;
DRUGBANK
0.1656
L/h/kg
2.76
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
504.0
L
504.0
L
Steady state volume of distribution;
DRUGBANK
7.3
L/kg
7.3
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
51.0
h
51
h
terminal half-life;
DRUGBANK
50.68
h
50.68
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
89.0
%
~89
%
Faeces excretion;
DRUGBANK
6.0
%
6
%
Urinary excretion;
DRUGBANK
0.178
%
~0.178
%
Faeces excretion; Unchanged drug;
DRUGBANK
0.06
%
0.06
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
~99
%
DRUGBANK
DDPD12783
Benserazide
257.246
C10H15N3O5
NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1
DB12783
2327
64187
2237
-2.0
-
-2.0
-
DRUGBANK
1.5
h
1.5
h
DRUGBANK
5300.0
mg/kg
5300.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
88.5
%
86-91
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
58.5
%
53-64
%
Urinary excretion; PO, oral;
DRUGBANK
30.0
%
~30
%
Faeces excretion;
DRUGBANK
0.0
%
0
%
DRUGBANK
DDPD12808
Trifarotene
459.586
C29H33NO4
CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=CC(=CC=C1OCCO)C1=CC=C(C=C1)C(O)=O
DB12808
11518241
9693029
-2.0
-
-2.0
-
DRUGBANK
0.0895
ng.h/ml
75-104
pg.h/ml
DRUGBANK
0.005
ng/ml
0-10
pg/ml
DRUGBANK
5.5
h
2-9
h
terminal half-life;
DRUGBANK
99.9
%
99.9
%
plasma proteins;
DRUGBANK
DDPD12825
Lefamulin
507.73
C28H45NO5S
[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O
DB12825
25185057
-2.0
-
-2.0
-
DRUGBANK
49200.0
ng.h/ml
49.2
mcg.h/ml
PO, oral;
DRUGBANK
25.0
%
25
%
Tablet, PO, oral;
DRUGBANK
37100.0
ng/ml
37.1
mcg/ml
PO, oral;
DRUGBANK
1.0
h
1
h
intravenous injection, IV;
DRUGBANK
1.76
h
1.76
h
Tablet, PO, oral;
DRUGBANK
16.45
L/h
2.9-30
L/h
Total clearance;
DRUGBANK
0.2376
L/h/kg
3.96
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
86.1
L
86.1(34.2-153)
L
Average volume of distribution; Pneumonia, Pneu; patients;
DRUGBANK
1.32
L/kg
1.32
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
8.0
h
8
h
elimination half-life; community-acquired bacterial pneumonia; patients;
DRUGBANK
13.2
h
13.2
h
normal,healthy; intravenous infusion, IV in drop;
DRUGBANK
6.4
h
6.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
14.0
%
~14
%
Urinary excretion;
DRUGBANK
77.3
%
77.3
%
Faeces excretion; intravenous injection, IV; adults; normal,healthy; human, homo sapiens;
DRUGBANK
88.5
%
88.5
%
Faeces excretion; PO, oral; adults; normal,healthy; human, homo sapiens;
DRUGBANK
15.5
%
15.5
%
Urinary excretion; intravenous injection, IV; adults; normal,healthy; human, homo sapiens;
DRUGBANK
5.3
%
5.3
%
Urinary excretion; PO, oral; adults; normal,healthy; human, homo sapiens;
DRUGBANK
5.135
%
3.24-7.03
%
Faeces excretion; intravenous injection, IV; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
14.425
%
6.9-21.95
%
Faeces excretion; PO, oral; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
1.835
%
1.49-2.18
%
Urinary excretion; intravenous injection, IV; adults; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
95.95
%
94.8-97.1
%
plasma proteins; adults; normal,healthy; human, homo sapiens;
DRUGBANK
83.5
%
80-87
%
plasma proteins;
DRUGBANK
DDPD12834
Secnidazole
185.183
C7H11N3O3
CC(O)CN1C(C)=NC=C1N(=O)=O
DB12834
71815
94433
64839
-2.0
-
-2.0
-
DRUGBANK
100.0
%
100
%
PO, oral;
DRUGBANK
1331600.0
ng.h/ml
1331.6
mcg.h/ml
PO, oral; normal,healthy; Female, women;
DRUGBANK
45400.0
ng/ml
45.4
mcg/ml
PO, oral; normal,healthy; Female, women;
DRUGBANK
4.0
h
4(3-4)
h
PO, oral; normal,healthy; Female, women;
DRUGBANK
1.0
%
<1
%
Liver metabolism;
DRUGBANK
1.5
L/h
~25
ml/min
Total clearance;
DRUGBANK
0.234
L/h
~3.9
ml/min
Renal clearance;
DRUGBANK
45.5
L
~42-49
L
Apparent volume of distribution;
DRUGBANK
17.0
h
~17
h
elimination half-life;
DRUGBANK
300.0
mg/kg
300.0
mg/kg
PO, oral; mouse;
DRUGBANK
3200.0
mg/kg
3200.0
mg/kg
PO, oral; rabbit;
DRUGBANK
980.0
mg/kg
980.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
15.0
%
~15
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
10.0
%
<5-15
%
plasma proteins;
DRUGBANK
DDPD12839
Pegvaliase
318.414
C15H30N2O5
COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O
DB12839
86278362
58172730
-2.0
-
-2.0
-
DRUGBANK
14000.0
ng/ml
14.0±16.3
mg/L
DRUGBANK
34380.0
ng/ml
0.26-68.5
mg/L
DRUGBANK
16700.0
ng/ml
16.7±19.5
mg/L
DRUGBANK
32020.0
ng/ml
0.24-63.8
mg/L
DRUGBANK
8.0
h
8
h
DRUGBANK
8.0
h
8
h
DRUGBANK
0.39
L/h
0.39±0.87
L/h
apparent clearance; Multiple dose; at steady state;
DRUGBANK
1.25
L/h
1.25±2.46
L/h
apparent clearance; Multiple dose; at steady state;
DRUGBANK
121.4
L
1.8-241
L
Apparent volume of distribution; at steady state;
DRUGBANK
26.3
L
3.1-49.5
L
Apparent volume of distribution; subcutaneous injection, SC;
DRUGBANK
47.0
h
47±42(14-132)
h
subcutaneous injection, SC; at steady state;
DRUGBANK
60.0
h
60±45(14-127)
h
subcutaneous injection, SC; at steady state;
DRUGBANK
DDPD12865
Etelcalcetide
1048.26
C38H73N21O10S2
C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O
DB12865
71511839
134700
32697932
-2.0
-
-2.0
-
DRUGBANK
180.0
h
7-8
day
intravenous injection, IV;
DRUGBANK
7.66
L/h
7.66
L/h
DRUGBANK
796.0
L
796.0
L
DRUGBANK
84.0
h
3-4
day
DRUGBANK
15.0
mg
15
mg
intravenous injection, IV
tiw
Parsabiv
etelcalcetide
PDR
15.0
mg
15
mg
intravenous injection, IV
tiw
Parsabiv
etelcalcetide
PDR
DDPD12867
Benperidol
381.451
C22H24FN3O2
OC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
DB12867
16363
93403
15521
-2.0
-
-2.0
-
DRUGBANK
0.498
L/h/kg
8.3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
3.8
L/kg
3.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.8
h
5.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD12887
Tazemetostat
572.75
C34H44N4O4
CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O
DB12887
66558664
30208713
-2.0
-
-2.0
-
DRUGBANK
3340.0
ng.h/ml
3340.0
ng.h/ml
DRUGBANK
33.0
%
33
%
DRUGBANK
829.0
ng/ml
829
ng/ml
DRUGBANK
1.5
h
1-2
h
DRUGBANK
274.0
L/h
274.0
L/h
Total clearance;
DRUGBANK
1230.0
L
1230.0
L
DRUGBANK
3.1
h
3.1
h
elimination half-life;
DRUGBANK
15.0
%
15
%
Urinary excretion;
DRUGBANK
79.0
%
79
%
Faeces excretion;
DRUGBANK
88.0
%
88
%
plasma proteins;
DRUGBANK
DDPD12911
Nicoboxil
223.272
C12H17NO3
CCCCOCCOC(=O)C1=CN=CC=C1
DB12911
14866
32322
14176
-2.0
-
-2.0
-
DRUGBANK
0.25
h
<15
min
plasma proteins;
DRUGBANK
DDPD12924
Ozenoxacin
363.417
C21H21N3O3
CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O
DB12924
9863827
136050
8039521
-2.0
-
-2.0
-
DRUGBANK
82.5
%
~80-85
%
plasma proteins;
DRUGBANK
DDPD12941
Darolutamide
398.85
C19H19ClN6O2
C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O
DB12941
67171867
38772320
-2.0
-
-2.0
-
DRUGBANK
52.82
ng.h/ml
52.82
ng.h/ml
PO, oral;
DRUGBANK
30.0
%
30
%
PO, oral; fasting;
DRUGBANK
67.5
%
60-75
%
PO, oral; food;
DRUGBANK
4.0
h
3-5
h
PO, oral; fasting;
DRUGBANK
5.5
h
3-8
h
PO, oral; food;
DRUGBANK
4.5
h
3-6
h
PO, oral;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
6.96
L/h
116.0
ml/min
DRUGBANK
119.0
L
119.0
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
20.0
h
~20
h
DRUGBANK
20.0
h
~20
h
Active metabolite;
DRUGBANK
12.5
h
10-15
h
terminal half-life; different study;
DRUGBANK
63.4
%
63.4
%
Urinary excretion; PO, oral;
DRUGBANK
32.4
%
32.4
%
Faeces excretion; PO, oral;
DRUGBANK
4.43
%
4.43
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
9.72
%
9.72
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
92.0
%
92
%
plasma proteins;
DRUGBANK
DDPD12942
Lactitol
344.3124
C12H24O11
OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
DB12942
157355
75323
138481
-2.0
-
-2.0
-
DRUGBANK
6019.0
ng.h/ml
6,019±1,771
ng.h/ml
PO, oral; normal,healthy; food;
DRUGBANK
776.0
ng/ml
776±253
ng/ml
PO, oral; normal,healthy; food;
DRUGBANK
3.6
h
3.6±1.2
h
PO, oral; normal,healthy; food;
DRUGBANK
0.0
%
~0
%
DRUGBANK
2.4
h
2.4
h
PO, oral;
DRUGBANK
23000.0
mg/kg
23.0
g/kg
mouse;
DRUGBANK
30000.0
mg/kg
>30
g/kg
Rattus, Rat;
DRUGBANK
DDPD12965
Silver
107.8682
Ag
[Ag]
DB12965
23954
9141
22394
-2.0
-
-2.0
-
DRUGBANK
5.5
%
1-10
%
PO, oral;
DRUGBANK
1200.0
h
50
day
elimination half-life; human, homo sapiens;
DRUGBANK
636.0
h
1-52
day
elimination half-life; human, homo sapiens;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
0.00516
mg/L
>5.16
mg/m3
inhalation, IH; Rattus, Rat;
DRUGBANK
34.5
%
24-45
%
Bile excretion; Rattus, Rat;
DRUGBANK
99.0
%
99
%
Faeces excretion; animals;
DRUGBANK
DDPD12978
Pexidartinib
417.82
C20H15ClF3N5
FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
DB12978
25151352
145373
35308322
-2.0
-
-2.0
-
DRUGBANK
77465.0
ng.h/ml
77465.0
ng.h/ml
PO, oral;
DRUGBANK
154930.0
ng.h/ml
154930.0
ng.h/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
8625.0
ng/ml
8625
ng/ml
PO, oral;
DRUGBANK
17250.0
ng/ml
17250
ng/ml
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
2.5
h
2.5
h
PO, oral;
DRUGBANK
5.0
h
5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
168.0
h
7
day
PO, oral;
DRUGBANK
5.1
L/h
5.1
L/h
apparent clearance;
DRUGBANK
187.0
L
187.0
L
Apparent volume of distribution;
DRUGBANK
26.6
h
~26.6
h
elimination half-life;
DRUGBANK
65.0
%
65
%
Faeces excretion;
DRUGBANK
27.0
%
27
%
Urinary excretion;
DRUGBANK
28.6
%
~28.6
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.0
%
~99
%
high protein binding; human, homo sapiens;
DRUGBANK
98.9
%
~98.9
%
high protein binding; human, homo sapiens;
DRUGBANK
89.0
%
~89
%
high protein binding; human, homo sapiens;
DRUGBANK
800.0
mg/day
800
mg/day
PO, oral
Turalio
pexidartinib
PDR
800.0
mg/day
800
mg/day
PO, oral
Turalio
pexidartinib
PDR
DDPD12982
Silicon
28.085
Si
[Si]
DB12982
5461123
27573
4574465
-2.0
-
-2.0
-
DRUGBANK
1.0
h
0.5-1.5
h
PO, oral; Adult growth hormone deficiency; fasting;
DRUGBANK
DDPD13074
Macimorelin
474.565
C26H30N6O3
CC(C)(N)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC1=CNC2=CC=CC=C12)NC=O
DB13074
7980698
-2.0
-
-2.0
-
DRUGBANK
2244.66
L/h
37411±4554.6
ml/min
Average clearance; Oral single dose;
DRUGBANK
5733.0
L
5733.4±565.7
L
Average volume of distribution; Oral single dose;
DRUGBANK
4.1
h
4.1
h
terminal half-life; Oral single dose; normal,healthy;
DRUGBANK
DDPD13125
Lusutrombopag
591.54
C29H32Cl2N2O5S
CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1
DB13125
49843517
136051
28529616
-2.0
-
-2.0
-
DRUGBANK
2931.0
ng.h/ml
2931.0
ng.h/ml
PO, oral; normal,healthy;
DRUGBANK
111.0
ng/ml
111
ng/ml
PO, oral; normal,healthy;
DRUGBANK
7.0
h
6-8
h
PO, oral; chronic liver disease;
DRUGBANK
120.0
h
5
day
Oral multiple dose;
DRUGBANK
18.6
L/h
1.1(36.1)
L/h
Average clearance; Hepatitis, Hep; patients;
DRUGBANK
39.5
L
39.5(23.5)
L
Apparent volume of distribution; normal,healthy; adults;
DRUGBANK
27.0
h
~27
h
elimination half-life; normal,healthy; adults;
DRUGBANK
1.0
%
~1
%
Urinary excretion;
DRUGBANK
83.0
%
~83
%
Faeces excretion;
DRUGBANK
13.28
%
13.28
%
Faeces excretion; Unchanged drug;
DRUGBANK
99.9
%
>99.9
%
plasma proteins;
DRUGBANK
DDPD13139
Levosalbutamol
239.3107
C13H21NO3
CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1
DB13139
123600
8746
110192
-2.0
-
-2.0
-
DRUGBANK
3.65
h
3.3-4
h
DRUGBANK
2.0
puffs
2
puffs
q4h
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
1.25
mg/dose
1.25
mg/dose
Liquid
tid
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
5.0
mg/dose
5
mg/dose
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
2.0
puffs
2
puffs
q4h
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
0.63
mg/dose
0.63
mg/dose
Liquid
tid
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
5.0
mg/dose
5
mg/dose
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
2.0
puffs
2
puffs
q4h
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
0.15
mg/kg/dose
0.15
mg/kg/dose
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
5.0
mg/dose
5
mg/dose
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
2.0
puffs
2
puffs
q4h
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
3.75
mg/day
1.25
mg/dose
Liquid
tid
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
2.0
puffs
2
puffs
q4h
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
1.25
mg/dose
1.25
mg/dose
Liquid
tid
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
5.0
mg/dose
5
mg/dose
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
2.0
puffs
2
puffs
q4h
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
3.75
mg/day
1.25
mg/dose
Liquid
tid
Xopenex Inhalation Solution Concentrate
levalbuterol hydrochloride
PDR
DDPD13142
Calcium glubionate anhydrous
592.513
C18H32CaO19
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
DB13142
131704325
58310
-2.0
-
-2.0
-
DRUGBANK
60.0
%
60
%
PO, oral; Infants;
DRUGBANK
28.0
%
28
%
PO, oral; Children;
DRUGBANK
34.0
%
34
%
PO, oral; Adolescents;
DRUGBANK
25.0
%
25
%
PO, oral; adults;
DRUGBANK
75.0
%
75
%
Faeces excretion;
DRUGBANK
22.0
%
22
%
Urinary excretion;
DRUGBANK
40.0
%
~40
%
DRUGBANK
DDPD13145
Nedaplatin
303.181
C2H8N2O3Pt
[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H]
DB13145
9548889
31898
7972206
-2.0
-
-2.0
-
DRUGBANK
4.47
L/h
4.47
L/h
DRUGBANK
0.243
L/h/kg
4.05
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
L
12.0
L
DRUGBANK
0.67
L/kg
0.67
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
59.6
%
59.6
%
Urinary excretion;
DRUGBANK
50.0
%
~50
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD13146
Fluciclovine (18F)
132.125
C5H8FNO2
N[C@]1(C[C@H]([18F])C1)C(O)=O
DB13146
450601
134703
23313216
-2.0
-
-2.0
-
DRUGBANK
1.51
L
0.79-2.23
L
DRUGBANK
1.82833333333333
h
109.7
min
physical half-life;
DRUGBANK
3.0
%
3
%
Urinary excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion;
DRUGBANK
0.0
%
0
%
plasma proteins;
DRUGBANK
DDPD13154
Parachlorophenol
128.556
C6H5ClO
OC1=CC=C(Cl)C=C1
DB13154
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
4684
28078
13875219
-2.0
-
-2.0
-
DRUGBANK
367.0
mg/kg
367.0
mg/kg
PO, oral; mouse;
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
DDPD13155
Esculin
340.284
C15H16O9
OC[C@H]1O[C@@H](OC2=C(O)C=C3OC(=O)C=CC3=C2)[C@H](O)[C@@H](O)[C@@H]1O
DB13155
5281417
4853
4444765
-2.0
-
-2.0
-
DRUGBANK
1.0
h
1
h
distribution half-life;
DRUGBANK
20.0
h
20
h
elimination half-life;
DRUGBANK
1900.0
mg/kg
1900.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
DDPD13156
Inosine pranobex
1115.249
C52H78N10O17
C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O
DB13156
131704326
58829622
-2.0
-
-2.0
-
DRUGBANK
0.833333333333333
h
50
min
DRUGBANK
1570.0
mg/kg
1570.0
mg/kg
intravenous injection, IV; mouse;
DRUGBANK
9410.0
mg/kg
9410.0
mg/kg
PO, oral; mouse;
DRUGBANK
2960.0
mg/kg
2960.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
DDPD13158
Clobetasone
408.89
C22H26ClFO4
[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]2(C)[C@@]1(O)C(=O)CCl
DB13158
71387
64482
-2.0
-
-2.0
-
DRUGBANK
6000.0
mg/kg
>6
g/kg
PO, oral; mouse;
DRUGBANK
3600.0
mg/kg
>3600
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
1510.0
mg/kg
1510.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
6000.0
mg/kg
>6
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
2600.0
mg/kg
>2600
mg/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
DDPD13163
Terpin hydrate
190.283
C10H22O3
O.CC(C)(O)[C@H]1CC[C@@](C)(O)CC1
DB13163
17141
16736914
-2.0
-
-2.0
-
DRUGBANK
DDPD13167
Alclofenac
226.66
C11H11ClO3
OC(=O)CC1=CC(Cl)=C(OCC=C)C=C1
DB13167
30951
31183
28714
-2.0
-
-2.0
-
DRUGBANK
2.5
h
1-4
h
PO, oral;
DRUGBANK
2.5
h
1-4
h
Rectal Administration;
DRUGBANK
2.1
L/h
35.0
ml/min
Renal clearance; PO, oral;
DRUGBANK
3.18
L/h
37-69
ml/min
Total clearance; PO, oral;
DRUGBANK
0.1
L/kg
0.1
L/kg
DRUGBANK
3.5
h
1.5-5.5
h
elimination half-life;
DRUGBANK
94.5
%
90-99
%
plasma proteins;
DRUGBANK
DDPD13170
Plecanatide
1681.89
C65H104N18O26S4
[H][C@@]12CSSC[C@H](NC(=O)CNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O
DB13170
70693500
28530494
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
human, homo sapiens; human, homo sapiens;
DRUGBANK
0.0
0
Trulance
plecanatide
PDR
3.0
mg/day
3
mg/day
PO, oral
qd
Trulance
plecanatide
PDR
0.0
0
Trulance
plecanatide
PDR
3.0
mg/day
3
mg/day
PO, oral
qd
Trulance
plecanatide
PDR
0.0
0
Trulance
plecanatide
PDR
0.0
0
Trulance
plecanatide
PDR
DDPD13178
Inositol
180.1559
C6H12O6
O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O
DB13178
17268
10239179
-2.0
-
-2.0
-
DRUGBANK
40500.0
ng
36-45
mcg
PO, oral;
DRUGBANK
4.0
h
4
h
PO, oral; inositol deficiency;
DRUGBANK
0.0679
L/h/kg
0.0679
L/h/kg
Prem, premature;
DRUGBANK
0.5115
L/kg
0.5115
L/kg
Prem, premature;
DRUGBANK
5.22
h
5.22
h
Prem, premature;
DRUGBANK
DDPD13179
Troleandomycin
813.9684
C41H67NO15
CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
DB13179
202225
45735
http://www.drugs.com/mtm/troleandomycin.html
16707
-2.0
-
-2.0
-
DRUGBANK
DDPD13209
Bismuth subnitrate
1461.98
Bi5H9N4O22
[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O--].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O
DB13209
31293
32699716
-2.0
-
-2.0
-
DRUGBANK
0.26
%
0.26
%
PO, oral;
DRUGBANK
1.0
h
1
h
PO, oral;
DRUGBANK
2.5
h
~1-4
h
distribution half-life;
DRUGBANK
192.0
h
5-11
day
elimination half-life;
DRUGBANK
DDPD13219
Medifoxamine
257.333
C16H19NO2
CN(C)CC(OC1=CC=CC=C1)OC1=CC=CC=C1
DB13219
135061
33212
-2.0
-
-2.0
-
DRUGBANK
0.822
L/h/kg
13.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.8
L/kg
2.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
4.4
h
4.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13231
Calcium lactate
218.218
C6H10CaO6
[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O
DB13231
13144
12592
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25(10-40)
%
PO, oral;
DRUGBANK
25.0
%
20-30
%
Urinary excretion; PO, oral; human, homo sapiens;
DRUGBANK
DDPD13235
Perboric acid
59.82
BHO3
OOB=O
DB13235
30175
102872
-2.0
-
-2.0
-
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
skin/dermal;
DRUGBANK
DDPD13249
Magnesium silicate
100.387
MgO3Si
[O--].[O--].[O--].[Mg++].[Si+4]
DB13249
32698785
-2.0
-
-2.0
-
DRUGBANK
0.0
null
0
null
DRUGBANK
500.0
mg/kg
>500
mg/kg
human, homo sapiens;
DRUGBANK
DDPD13257
Ferrous sulfate anhydrous
151.908
FeO4S
[Fe++].[O-]S([O-])(=O)=O
DB13257
62662
75832
22804
-2.0
-
-2.0
-
DRUGBANK
7.5
%
5-10
%
PO, oral;
DRUGBANK
30.0
%
30
%
PO, oral; iron deficient;
DRUGBANK
60.0
%
60
%
PO, oral; Drug form;
DRUGBANK
797.517
ng.h/ml
-46.93-5.25
umol.h/L
Tablet, PO, oral; Other correlations; normal,healthy; extended release formulation;
DRUGBANK
30.0
%
30
%
Tablet, PO, oral; Other correlations; normal,healthy; extended release formulation;
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
90.0
%
≥90
%
DRUGBANK
DDPD13259
Ethyl chloride
64.514
C2H5Cl
CCCl
DB13259
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
6337
47554
6097
-2.0
-
-2.0
-
DRUGBANK
15.0
mg/kg
15.0
ppm
inhalation, IH;
DRUGBANK
DDPD13268
Acetarsol
275.0903
C8H10AsNO5
CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O
DB13268
135135
1908
-2.0
-
-2.0
-
DRUGBANK
DDPD13269
Dichlorobenzyl alcohol
177.02
C7H6Cl2O
OCC1=C(Cl)C=C(Cl)C=C1
DB13269
48220
14918
-2.0
-
-2.0
-
DRUGBANK
0.0583333333333333
h
3-4
min
DRUGBANK
2700.0
mg/kg
~2.7
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
90.0
%
90
%
Urinary excretion; skin/dermal;
DRUGBANK
DDPD13270
Dibekacin
451.521
C18H37N5O8
NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1
DB13270
37945
413666
-2.0
-
-2.0
-
DRUGBANK
0.048
L/h/kg
0.8
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.13
L/kg
0.13
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13274
Micronomicin
463.576
C20H41N5O7
CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1
DB13274
81283
2301017
-2.0
-
-2.0
-
DRUGBANK
0.066
L/h/kg
1.1
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.15
L/kg
0.15
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.1
h
2.1
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13295
Atracurium
N.A.
N.A.
C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DB13295
47319
-2.0
-
-2.0
-
DRUGBANK
0.342
L/h/kg
5.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.1
L/kg
0.1
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.31
h
0.31
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13306
Chlorquinaldol
228.07
C10H7Cl2NO
CC1=NC2=C(C=C1)C(Cl)=CC(Cl)=C2O
DB13306
74500
6062
-2.0
-
-2.0
-
DRUGBANK
13.85
%
4.2-23.5
%
skin/dermal;
DRUGBANK
67.6
%
67.6
%
PO, oral;
DRUGBANK
98.0
%
98
%
Urinary excretion;
DRUGBANK
600.0
mg/kg
600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD13323
Trichloroethylene
131.388
C2HCl3
ClC=C(Cl)Cl
DB13323
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
16602
13837280
-2.0
-
-2.0
-
DRUGBANK
0.0004
mg/kg
0.0004
ppm
inhalation, IH;
DRUGBANK
0.0004
mg/kg
0.0004
ppm
inhalation, IH; Oral multiple dose;
DRUGBANK
0.0005
mg/kg/day
0.0005
mg/kg/day
PO, oral;
DRUGBANK
0.0005
mg/kg/day
0.0005
mg/kg/day
PO, oral; Oral multiple dose;
DRUGBANK
DDPD13345
Dihydroergocristine
611.743
C35H41N5O5
[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C
DB13345
59912
96884
-2.0
-
-2.0
-
DRUGBANK
25.0
%
25
%
PO, oral;
DRUGBANK
0.39
ng.h/ml
0.39
mcg.h/L
PO, oral;
DRUGBANK
0.28
ng/ml
0.28
mcg/L
PO, oral;
DRUGBANK
0.46
h
0.46±0.17
h
PO, oral;
DRUGBANK
2.65
L/h/kg
2.65
L/h/kg
Total clearance;
DRUGBANK
52.0
L/kg
52.0
L/kg
DRUGBANK
3.5
h
3.5
h
elimination half-life;
DRUGBANK
13.0
h
13
h
terminal half-life;
DRUGBANK
85.0
%
>85
%
Bile excretion;
DRUGBANK
5.0
%
5
%
Urinary excretion;
DRUGBANK
68.0
%
68
%
plasma proteins;
DRUGBANK
3.0
mg/day
3
mg/day
PO, oral
Ergoloid Mesylates
ergoloid mesylates
PDR
9.0
mg/day
9
mg/day
PO, oral
Ergoloid Mesylates
ergoloid mesylates
PDR
3.0
mg/day
3
mg/day
PO, oral
Ergoloid Mesylates
ergoloid mesylates
PDR
9.0
mg/day
9
mg/day
PO, oral
Ergoloid Mesylates
ergoloid mesylates
PDR
DDPD13346
Bufexamac
223.272
C12H17NO3
CCCCOC1=CC=C(CC(=O)NO)C=C1
DB13346
2466
31317
2372
-2.0
-
-2.0
-
DRUGBANK
3370.0
mg/kg
3370.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
805.0
mg/kg
805.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
48.0
%
48
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD13421
Edoxudine
256.258
C11H16N2O5
CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O
DB13421
66377
135051
59752
-2.0
-
-2.0
-
DRUGBANK
49.0
%
49
%
intravenous injection, IV; mouse;
DRUGBANK
2.4
ng/mg
2.4
mcg/g
intravenous injection, IV; mouse;
DRUGBANK
0.518333333333333
h
31.1
min
intravenous injection, IV; mouse;
DRUGBANK
5.1
L/h
85.0
ml/min
Plasma clearance;
DRUGBANK
0.0233333333333333
h
1.4
min
distribution half-life; intravenous injection, IV; mouse;
DRUGBANK
0.401666666666667
h
24.1
min
elimination half-life; intravenous injection, IV; mouse; different study;
DRUGBANK
7.0
%
~7
%
plasma proteins;
DRUGBANK
DDPD13444
Ioxitalamic acid
643.942
C12H11I3N2O5
CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I
DB13444
83517
31782
-2.0
-
-2.0
-
DRUGBANK
0.0
%
0
%
DRUGBANK
7.2
L/h
120.0
ml/min
Total clearance;
DRUGBANK
0.194
L/kg
194.0
ml/kg
DRUGBANK
1.1
h
1.1
h
elimination half-life;
DRUGBANK
13.5
%
0-27
%
plasma proteins;
DRUGBANK
DDPD13501
Bendazac
282.299
C16H14N2O3
OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12
DB13501
31257
2223
-2.0
-
-2.0
-
DRUGBANK
45000.0
ng/ml
35-55
mg/L
PO, oral; normal,healthy; Derivative;
DRUGBANK
0.75
h
0.5-1
h
PO, oral; normal,healthy; Derivative;
DRUGBANK
0.036
L/h/kg
0.018-0.054
L/h/kg
Plasma clearance;
DRUGBANK
0.033
L/h/kg
0.033
L/h/kg
Average clearance;
DRUGBANK
0.26
L/kg
0.26
L/kg
DRUGBANK
3.5
h
3.5(1.7-5.2)
h
elimination half-life;
DRUGBANK
60.0
%
~60
%
Urinary excretion;
DRUGBANK
15.0
%
<15
%
Urinary excretion; Unchanged drug;
DRUGBANK
99.0
%
>99
%
plasma proteins; normal,healthy; human, homo sapiens;
DRUGBANK
DDPD13520
Metergoline
403.526
C25H29N3O2
[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@@]1([H])C[C@@H](CNC(=O)OCC1=CC=CC=C1)CN2C
DB13520
28693
64216
26687
-2.0
-
-2.0
-
DRUGBANK
0.576
L/h/kg
9.6
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.57
L/kg
0.57
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.93
h
0.93
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13583
Mephenesin
182.219
C10H14O3
CC1=CC=CC=C1OCC(O)CO
DB13583
94398
3919
-2.0
-
-2.0
-
DRUGBANK
DDPD13595
Almasilate
280.445
Al2H2MgO9Si2
O.[Mg++].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-]
DB13595
131704329
32700646
-2.0
-
-2.0
-
DRUGBANK
0.505
%
0.01-1
%
PO, oral; antacids;
DRUGBANK
0.346
L/kg
0.250-0.442
L/kg
Preg, pregnant; Female, women;
DRUGBANK
95.0
%
95
%
Urinary excretion;
DRUGBANK
DDPD13615
Mifamurtide
1277.515
C59H110N6NaO20P
O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC
DB13615
32700228
-2.0
-
-2.0
-
DRUGBANK
21717.755
ng.h
17.0±4.86
nM.h
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
20.0569855
ng/ml
15.7±3.72
nMol/L
intravenous injection, IV; normal,healthy; adults;
DRUGBANK
34.02
L/h
565-569
ml/min
Average clearance; intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
2.922
L/h/kg
48.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
126.85
L
225-28.7
L
Average volume of distribution; at steady state; intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
5.8
L/kg
5.8
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.05
h
2.05±0.40
h
normal,healthy; adults; intravenous injection, IV;
DRUGBANK
2.04
h
2.04±0.456
h
psteosarcoma; pediatric patients; adults; patients;
DRUGBANK
2.05
h
2.05
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13620
Potassium gluconate
234.245
C6H11KO7
[K+].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O
DB13620
16760467
32032
8931
-2.0
-
-2.0
-
DRUGBANK
94.0
%
94
%
PO, oral; Components;
DRUGBANK
9100.0
mg/kg
9100.0
mg/kg
PO, oral; mouse;
DRUGBANK
90.0
%
90
%
Urinary excretion;
DRUGBANK
DDPD13682
Cefpirome
514.577
C22H22N6O5S2
[H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C([O-])=O
DB13682
3503
4586396
-2.0
-
-2.0
-
DRUGBANK
0.114
L/h/kg
1.9
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.24
L/kg
0.24
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.7
h
1.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13707
Sodium tartrate
194.05
C4H4Na2O6
[Na+].[Na+].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O
DB13707
162637
63017
142788
-2.0
-
-2.0
-
DRUGBANK
4360.0
mg/kg
4360.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD13720
Diphemanil
278.418
C20H24N
C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1
DB13720
93636
5897
-2.0
-
-2.0
-
DRUGBANK
20.0
%
15-25
%
PO, oral;
DRUGBANK
DDPD13746
Bioallethrin
N.A.
N.A.
CC1=C(C(=O)CC1OC(=O)C2C(C2(C)C)C=C(C)C)CC=C
DB13746
15558638
39118
18923353
-2.0
-
-2.0
-
DRUGBANK
709.0
mg/kg
709.0
mg/kg
PO, oral; Male, men; Rattus, Rat;
DRUGBANK
1040.0
mg/kg
1040.0
mg/kg
PO, oral; Female, women; Rattus, Rat;
DRUGBANK
2.51
mg/L
2.51
mg/L
inhalation, IH; Rattus, Rat;
DRUGBANK
3000.0
mg/kg
>3000
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD13747
Trolamine
149.1882
C6H15NO3
OCCN(CCO)CCO
DB13747
7618
28621
13835630
-2.0
-
-2.0
-
DRUGBANK
23.5
%
19-28
%
Neonates;
DRUGBANK
70.0
%
60-80
%
Female, women;
DRUGBANK
8000.0
mg/kg
8.0
g/kg
PO, oral; guinea pigs;
DRUGBANK
7725.0
mg/kg
4.19-11.26
g/kg
PO, oral; Rattus, Rat;
DRUGBANK
53.0
%
53
%
Urinary excretion; PO, oral; Rattus, Rat;
DRUGBANK
20.0
%
20
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
98.0
%
98
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD13749
Magnesium gluconate
450.629
C12H26MgO16
O.O.[Mg++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O
DB13749
71587201
28295928
-2.0
-
-2.0
-
DRUGBANK
22.5
%
15-30
%
DRUGBANK
9100.0
mg/kg
9100.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
27.5
%
~25-30
%
DRUGBANK
DDPD13751
Glycyrrhizic acid
822.942
C42H62O16
[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O
DB13751
15939
14263
-2.0
-
-2.0
-
DRUGBANK
0.0205
L/h/kg
16-25
ml/h/kg
DRUGBANK
0.0505
L/kg
37-64
ml/kg
Total volume of distribution;
DRUGBANK
0.0785
L/kg
59-98
ml/kg
Apparent volume of distribution; at steady state;
DRUGBANK
3.5
h
3.5
h
elimination half-life; dose;
DRUGBANK
6504.0
mg/kg
308-12700
mg/kg
DRUGBANK
1.8
%
~1.1-2.5
%
Urinary excretion;
DRUGBANK
1.8
%
~1.1-2.5
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD13781
Xamoterol
339.392
C16H25N3O5
OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1
DB13781
155774
10055
137213
-2.0
-
-2.0
-
DRUGBANK
0.18
L/h/kg
3
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.64
L/kg
0.64
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
7.7
h
7.7
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD13783
Acemetacin
415.83
C21H18ClNO6
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O
DB13783
1981
31162
1904
-2.0
-
-2.0
-
DRUGBANK
597.5
ng.h/ml
483-712
ng.h/ml
PO, oral;
DRUGBANK
66.0
%
66
%
Oral multiple dose;
DRUGBANK
276.8
ng/ml
276.8
ng/ml
PO, oral; Elderly;
DRUGBANK
187.0
ng/ml
187
ng/ml
PO, oral; young;
DRUGBANK
2.5
h
2.5
h
PO, oral;
DRUGBANK
0.2754
L/h/kg
4.59
ml/min/kg
intravenous injection, IV; normal,healthy;
DRUGBANK
0.6
L/kg
0.5-0.7
L/kg
Apparent volume of distribution;
DRUGBANK
4.5
h
4.5
h
elimination half-life; at steady state;
DRUGBANK
40.0
%
40
%
Urinary excretion;
DRUGBANK
60.0
%
60
%
Faeces excretion;
DRUGBANK
90.0
%
>90
%
plasma proteins;
DRUGBANK
DDPD13800
Calcium levulinate
270.294
C10H14CaO6
[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O
DB13800
81717
11090
-2.0
-
-2.0
-
DRUGBANK
4.0
%
4
%
DRUGBANK
10.4166666666667
mg/h
250.0
mg/24h
DRUGBANK
DDPD13813
Iodoform
393.732
CHI3
[H]C(I)(I)I
DB13813
6374
37758
6134
-2.0
-
-2.0
-
DRUGBANK
355.0
mg/kg
355.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1184.0
mg/kg
1184.0
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
DDPD13848
Fluorodopa (18F)
214.183
C9H10FNO4
N[C@@H](CC1=CC(O)=C(O)C=C1[18F])C(O)=O
DB13848
49166
50970
-2.0
-
-2.0
-
DRUGBANK
2.0
h
~1-3
h
elimination half-life; intravenous injection, IV;
DRUGBANK
80.0
%
~80
%
Urinary excretion;
DRUGBANK
DDPD13853
Anethole trithione
240.35
C10H8OS3
COC1=CC=C(C=C1)C1=CC(=S)SS1
DB13853
2194
31221
2109
-2.0
-
-2.0
-
DRUGBANK
0.98
ng/ml
0.98±0.49
ng/ml
normal,healthy; Asian;
DRUGBANK
2.2
h
2.2±1.9
h
normal,healthy; Asian;
DRUGBANK
113.2
L/h/kg
113.20±52.37
L/h/kg
Rattus, Rat; PO, oral;
DRUGBANK
3.78
h
~3.78±2.12
h
normal,healthy; Asian;
DRUGBANK
DDPD13854
Gamolenic acid
278.4296
C18H30O2
CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
DB13854
28661
4444436
-2.0
-
-2.0
-
DRUGBANK
168.0
h
7
day
PO, oral; fasting;
DRUGBANK
0.130833333333333
mg/kg/day
3.14
mg/kg/24D
Male, men;
DRUGBANK
DDPD13858
Dimazole
293.43
C15H23N3OS
CCN(CC)CCOC1=CC2=C(C=C1)N=C(S2)N(C)C
DB13858
103934
8384
-2.0
-
-2.0
-
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD13867
Fluticasone
444.51
C22H27F3O4S
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB13867
5134
4470631
-2.0
-
-2.0
-
DRUGBANK
0.05
%
0.05
%
intranasal; Drug form;
DRUGBANK
1.26
%
1.26
%
PO, oral; Drug form;
DRUGBANK
13.9
%
13.9
%
inhalation, IH; Drug form;
DRUGBANK
12.35
%
6.3-18.4
%
inhalation, IH; Drug form; Male, men; Caucasian;
DRUGBANK
2.0
%
<2
%
intranasal; Drug form;
DRUGBANK
1.0
%
<1
%
PO, oral; Drug form;
DRUGBANK
9.0
%
9
%
inhalation, IH; Drug form; Male, men; Caucasian;
DRUGBANK
57.8
L/h
57.8
L/h
DRUGBANK
71.8
L/h
71.8
L/h
intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
65.58
L/h
1093.0
ml/min
DRUGBANK
63.9
L/h
63.9
L/h
intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
608.0
L
608.0
L
at steady state; intravenous injection, IV;
DRUGBANK
661.0
L
661.0
L
Average volume of distribution; at steady state;
DRUGBANK
704.0
L
704.0
L
at steady state; intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
4.2
L/kg
4.2
L/kg
intravenous injection, IV;
DRUGBANK
557.0
L
557.0
L
at steady state; intravenous injection, IV; normal,healthy; Caucasian; Male, men;
DRUGBANK
15.1
h
15.1
h
inhalation, IH;
DRUGBANK
24.0
h
24
h
intranasal;
DRUGBANK
90.0
%
≥90
%
Faeces excretion;
DRUGBANK
1.5
%
1-2
%
Urinary excretion;
DRUGBANK
5.0
%
<5
%
Urinary excretion;
DRUGBANK
DDPD13872
Lormetazepam
335.185
C16H12Cl2N2O2
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1Cl
DB13872
13314
52993
12750
-2.0
-
-2.0
-
DRUGBANK
0.24
L/h/kg
4
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.6
L/kg
1.6
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
11.0
h
11
h
terminal half-life;
DRUGBANK
4.9
h
4.9
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
780.0
mg/kg
780.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
1790.0
mg/kg
1790.0
mg/kg
PO, oral; mouse;
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
subcutaneous injection, SC; mouse;
DRUGBANK
6250.0
mg/kg
6250.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
DDPD13873
Fenofibric acid
318.75
C17H15ClO4
CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O
DB13873
64929
83469
58457
-2.0
-
-2.0
-
DRUGBANK
82.75
%
~82.75
%
Liquid; normal,healthy; food;
DRUGBANK
2.5
h
2.5
h
Liquid; normal,healthy; food;
DRUGBANK
1.2
L/h
1.2
L/h
Oral single dose; Elderly;
DRUGBANK
1.1
L/h
1.1
L/h
Oral single dose; young; adults;
DRUGBANK
70.9
L
70.9±27.5
L
DRUGBANK
20.0
h
~20
h
DRUGBANK
1242.0
mg/kg
1242.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
100.0
mg/kg
100.0
mg/kg
PO, oral; mouse;
DRUGBANK
500.0
mg/kg
500.0
mg/kg
Intraperitoneal, IP; mouse;
DRUGBANK
99.0
%
~99
%
hyperlipoidemia; normal,healthy; human, homo sapiens;
DRUGBANK
135.0
mg/day
135
mg/day
Capsule, PO, Oral
Fibricor
fenofibric acid
PDR
105.0
mg/day
105
mg/day
Tablet,PO，oral
Fibricor
fenofibric acid
PDR
135.0
mg/day
135
mg/day
Capsule, PO, Oral
Fibricor
fenofibric acid
PDR
105.0
mg/day
105
mg/day
Tablet,PO，oral
Fibricor
fenofibric acid
PDR
DDPD13874
Enasidenib
473.383
C19H17F6N7O
CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F
DB13874
89683805
145374
38772329
-2.0
-
-2.0
-
DRUGBANK
57.0
%
57
%
Oral single dose;
DRUGBANK
1300.0
ng/ml
1.3
mcg/ml
Oral single dose;
DRUGBANK
696.0
h
29
day
Oral single dose;
DRUGBANK
11.0
%
11
%
DRUGBANK
0.74
L/h
0.74
L/h
Average clearance;
DRUGBANK
55.8
L
55.8
L
Average volume of distribution;
DRUGBANK
137.0
h
137
h
terminal half-life;
DRUGBANK
89.0
%
89
%
Faeces excretion;
DRUGBANK
11.0
%
11
%
Urinary excretion;
DRUGBANK
34.0
%
34
%
Faeces excretion; Unchanged drug;
DRUGBANK
0.4
%
0.4
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.5
%
98.5
%
plasma proteins; human, homo sapiens;
DRUGBANK
100.0
mg/day
100
mg/day
PO, oral
Idhifa
enasidenib
PDR
100.0
mg/day
100
mg/day
PO, oral
Idhifa
enasidenib
PDR
DDPD13878
Pibrentasvir
1113.201
C57H65F5N10O8
CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F
DB13878
58031952
35013016
-2.0
-
-2.0
-
DRUGBANK
110.0
ng/ml
110
ng/ml
Hepatitis, Hep;
DRUGBANK
5.0
h
5
h
normal,healthy;
DRUGBANK
0.0
%
0
%
DRUGBANK
13.0
h
~13
h
elimination half-life;
DRUGBANK
96.6
%
96.6
%
Faeces excretion;
DRUGBANK
0.0
%
0
%
Urinary excretion;
DRUGBANK
99.9
%
>99.9
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD13879
Glecaprevir
838.87
C38H46F4N6O9S
[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\C=C\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1
DB13879
66828839
35013015
-2.0
-
-2.0
-
DRUGBANK
597.0
ng/ml
597
ng/ml
Hepatitis, Hep;
DRUGBANK
5.0
h
5
h
normal,healthy;
DRUGBANK
6.0
h
~6
h
elimination half-life;
DRUGBANK
92.1
%
92.1
%
Faeces excretion;
DRUGBANK
0.7
%
0.7
%
Urinary excretion;
DRUGBANK
97.5
%
>97.5
%
plasma proteins; human, homo sapiens;
DRUGBANK
DDPD13882
Methyl nicotinate
137.136
C7H7NO2
COC(=O)C1=CN=CC=C1
DB13882
7151
134761
21111785
-2.0
-
-2.0
-
DRUGBANK
85.0
%
80-90
%
skin/dermal;
DRUGBANK
0.108333333333333
h
3-10
min
high protein binding;
DRUGBANK
1680.0
mg/kg
1.68
g/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
5.0
g/kg
subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
15.0
%
~15
%
Urinary excretion; human, homo sapiens;
DRUGBANK
DDPD13908
Amylmetacresol
178.275
C12H18O
CCCCCC1=CC=C(C)C=C1O
DB13908
48213
14076
-2.0
-
-2.0
-
DRUGBANK
1500.0
mg/kg
1500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD13909
Bismuth subgallate
394.091
C7H5BiO6
O[Bi]1OC2=CC(=CC(O)=C2O1)C(O)=O
DB13909
31292
10607905
-2.0
-
-2.0
-
DRUGBANK
0.04
%
0.04
%
PO, oral;
DRUGBANK
4.35
L/h
50-95
ml/min
Average clearance;
DRUGBANK
1116.0
h
21-72
day
terminal half-life;
DRUGBANK
10.0
%
~10
%
Faeces excretion;
DRUGBANK
DDPD13925
Dotatate gallium Ga-68
1500.54
C65H87GaN14O19S2
[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
DB13925
58828606
-2.0
-
-2.0
-
DRUGBANK
0.00045
L/m3
0.25-0.65
ml/cm3
DRUGBANK
1.13333333333333
h
68
min
DRUGBANK
12.0
%
~12
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
DDPD13928
Semaglutide
4113.641
C187H291N45O59
CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O
DB13928
34985066
-2.0
-
-2.0
-
DRUGBANK
12848.5462994
ng.h/ml
3123.4
nmol.h/L
DRUGBANK
89.0
%
89
%
DRUGBANK
44.8386869
ng/ml
10.9
nmol/L
DRUGBANK
56.0
h
56
h
DRUGBANK
108.0
h
4-5
day
Tablet, PO, oral;
DRUGBANK
7.7
%
7.7
%
DRUGBANK
0.039
L/h
0.039
L/h
DRUGBANK
0.05
L/h
0.05
L/h
type 2 diabetes; patients;
DRUGBANK
8.7
L
8-9.4
L
DRUGBANK
168.0
h
168
h
plasma proteins;
DRUGBANK
270.0
mg/kg
270.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
53.0
%
53
%
Urinary excretion;
DRUGBANK
18.6
%
18.6
%
Faeces excretion;
DRUGBANK
3.2
%
3.2
%
lung excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
0.142857142857143
mg/day
1
mg/week
subcutaneous injection, SC
Ozempic
semaglutide
PDR
14.0
mg/day
14
mg/day
PO, oral
Ozempic
semaglutide
PDR
0.142857142857143
mg/day
1
mg/week
subcutaneous injection, SC
Ozempic
semaglutide
PDR
14.0
mg/day
14
mg/day
PO, oral
Ozempic
semaglutide
PDR
DDPD13931
Netarsudil
453.542
C28H27N3O3
CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
DB13931
34980598
-2.0
-
-2.0
-
DRUGBANK
2.91666666666667
h
175
min
high protein binding; human, homo sapiens;
DRUGBANK
60.0
%
≥60
%
DRUGBANK
DDPD13943
Testosterone cypionate
412.614
C27H40O3
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1
DB13943
9463
390140
-2.0
-
-2.0
-
DRUGBANK
112200.0
ng/ml
1122
ng/dl
IM,intramuscular injection;
DRUGBANK
108.0
h
4-5
day
IM,intramuscular injection;
DRUGBANK
1.0
L/kg
1.0
L/kg
intravenous injection, IV;
DRUGBANK
192.0
h
~8
day
DRUGBANK
90.0
%
~90
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
6.0
%
~6
%
Faeces excretion; IM,intramuscular injection;
DRUGBANK
DDPD13944
Testosterone enanthate
400.594
C26H40O3
[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB13944
9464
9045
-2.0
-
-2.0
-
DRUGBANK
120000.0
ng/ml
1200
ng/dl
Multiple dose;
DRUGBANK
1.0
L/kg
1.0
L/kg
intravenous injection, IV;
DRUGBANK
192.0
h
7-9
day
DRUGBANK
90.0
%
~90
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
6.0
%
~6
%
Faeces excretion; IM,intramuscular injection;
DRUGBANK
DDPD13946
Testosterone undecanoate
456.711
C30H48O3
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
DB13946
135741
58664
-2.0
-
-2.0
-
DRUGBANK
813.6
h
33.9
day
IM,intramuscular injection;
DRUGBANK
90.0
%
~90
%
Urinary excretion; IM,intramuscular injection;
DRUGBANK
6.0
%
~6
%
Faeces excretion; IM,intramuscular injection;
DRUGBANK
DDPD13949
Ferric cation
55.845
Fe
[Fe+3]
DB13949
29034
27815
-2.0
-
-2.0
-
DRUGBANK
0.0416666666666667
mg/h
~1
mg/day
DRUGBANK
DDPD13952
Estradiol acetate
314.4186
C20H26O3
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H]
DB13952
9818306
135981
https://www.drugs.com/mtm/estradiol-vaginal.html
7994056
-2.0
-
-2.0
-
DRUGBANK
1.129
ng/ml
1129
pg/ml
DRUGBANK
1.0
h
1(0.25-1.5)
h
DRUGBANK
DDPD13956
Estradiol valerate
356.4984
C23H32O3
[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
DB13956
13791
31561
13194
-2.0
-
-2.0
-
DRUGBANK
1.301
ng.h/ml
1301.0
pg.h/ml
DRUGBANK
0.0733
ng/ml
73.3
pg/ml
DRUGBANK
6.0
h
6(1.5-12)
h
DRUGBANK
DDPD13960
Bronopol
199.988
C3H6BrNO4
OCC(Br)(CO)[N+]([O-])=O
DB13960
31306
2356
-2.0
-
-2.0
-
DRUGBANK
40.0
%
40
%
skin/dermal; Rattus, Rat;
DRUGBANK
2.0
h
2
h
PO, oral; Rattus, Rat;
DRUGBANK
264.0
h
11
day
high protein binding;
DRUGBANK
24.0
h
24
h
water;
DRUGBANK
48.0
h
2
day
natural sunlight;
DRUGBANK
180.0
mg/kg
180.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
112.0
mg/kg
64-160
mg/kg
skin/dermal; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5000
mg/kg
inhalation, IH; Rattus, Rat;
DRUGBANK
81.0
%
~81
%
Urinary excretion; PO, oral; Rattus, Rat;
DRUGBANK
6.0
%
6
%
lung excretion; PO, oral; Rattus, Rat;
DRUGBANK
74.0
%
74
%
Urinary excretion; intravenous injection, IV; Rattus, Rat;
DRUGBANK
9.0
%
9
%
lung excretion; intravenous injection, IV; Rattus, Rat;
DRUGBANK
DDPD13967
Patent Blue
561.69
C27H33N2O7S2
CCN(CC)C1=CC=C(C=C1)C(=C1C=CC(C=C1)=[N+](CC)CC)C1=C(C=C(C(O)=C1)S(O)(=O)=O)S(O)(=O)=O
DB13967
59601
69520
-2.0
-
-2.0
-
DRUGBANK
36.0
h
~24-48
h
elimination half-life;
DRUGBANK
DDPD13971
Vanadium
50.9415
V
[V]
DB13971
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
27698
22426
-2.0
-
-2.0
-
DRUGBANK
8e-07
mg/L
0.0008
mg/m3
inhalation, IH;
DRUGBANK
1e-07
mg/L
0.0001
mg/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
inhalation, IH;
DRUGBANK
DDPD13985
Lutetium Lu 177 dotatate
1609.55
C65H87LuN14O19S2
[177Lu+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
DB13985
32699095
-2.0
-
-2.0
-
DRUGBANK
41.0
ng.h/ml
41.0
ng.h/ml
intravenous injection, IV;
DRUGBANK
10000000.0
ng/ml
10
mg/ml
intravenous injection, IV;
DRUGBANK
0.0
%
0
%
Liver metabolism;
DRUGBANK
4.5
L/h
4.5
L/h
Average clearance;
DRUGBANK
460.0
L
460.0
L
Average volume of distribution;
DRUGBANK
3.5
h
3.5±1.4
h
effective half-life;
DRUGBANK
71.0
h
71±28
h
terminal half-life;
DRUGBANK
44.0
%
44
%
Urinary excretion; intravenous infusion, IV in drop;
DRUGBANK
58.0
%
58
%
Urinary excretion; intravenous infusion, IV in drop;
DRUGBANK
65.0
%
65
%
Urinary excretion; intravenous infusion, IV in drop;
DRUGBANK
43.0
%
43
%
plasma proteins; human, homo sapiens;
DRUGBANK
7.4
GBq
7.4
GBq
intravenous injection, IV
Lutathera
lutetium lu 177 dotatate
PDR
200.0
mCi
200
mCi
intravenous injection, IV
Lutathera
lutetium lu 177 dotatate
PDR
7.4
GBq
7.4
GBq
intravenous injection, IV
Lutathera
lutetium lu 177 dotatate
PDR
200.0
mCi
200
mCi
intravenous injection, IV
Lutathera
lutetium lu 177 dotatate
PDR
DDPD13987
Strontium chloride
158.52
Cl2Sr
[Cl-].[Cl-].[Sr++]
DB13987
55440
-2.0
-
-2.0
-
DRUGBANK
30.0
%
30
%
PO, oral;
DRUGBANK
60.0
%
~60
%
Infants;
DRUGBANK
35.0
%
30-40
%
DRUGBANK
DDPD13995
Ferric pyrophosphate citrate
1321.571
C18H24Fe4O42P6
[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
DB13995
34994433
-2.0
-
-2.0
-
DRUGBANK
12575.0
ng.h/ml
675-1840
mcg.h/dl
increasing doses ↑ ;
DRUGBANK
88.5
%
83-94
%
DRUGBANK
1870.0
ng/ml
113-261
mcg/dl
increasing doses ↑ ;
DRUGBANK
4.5
h
4.5
h
DRUGBANK
0.481
L/h
0.406-0.556
L/h
Average clearance;
DRUGBANK
0.812
L
0.765-0.859
L
Apparent volume of distribution; intravenous injection, IV;
DRUGBANK
1.48
h
1.48
h
DRUGBANK
1.5
mg/kg/dose
1.5
mg/kg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
125.0
mg/dose
125
mg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
125.0
mg/dose
125
mg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
6.75
mcg/kg
6.75
mg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
1.5
mg/kg/dose
1.5
mg/kg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
125.0
mg/dose
125
mg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
125.0
mg/dose
125
mg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
6.75
mg/dose
6.75
mg/dose
intravenous injection, IV
Triferic
ferric pyrophosphate citrate
PDR
DDPD13997
Baloxavir marboxil
571.55
C27H23F2N3O7S
[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12
DB13997
59718643
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
DRUGBANK
10.3
L/h
10.3
L/h
DRUGBANK
1180.0
L
1180.0
L
Apparent volume of distribution;
DRUGBANK
79.1
h
79.1
h
elimination half-life;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
14.7
%
14.7
%
Urinary excretion; Single dose;
DRUGBANK
80.1
%
80.1
%
Faeces excretion; Single dose;
DRUGBANK
93.4
%
92.9-93.9
%
DRUGBANK
80.0
mg
80
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
40.0
mg
40
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
80.0
mg
80
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
40.0
mg
40
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
80.0
mg
80
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
40.0
mg
40
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
80.0
mg
80
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
40.0
mg
40
mg
PO, oral
Xofluza
baloxavir marboxil
PDR
DDPD14001
alpha-Tocopherol succinate
530.79
C33H54O5
[H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@]1(C)CCC2=C(C)C(OC(=O)CCC(O)=O)=C(C)C(C)=C2O1
DB14001
135821
19171
-2.0
-
-2.0
-
DRUGBANK
65.0
%
50-80
%
PO, oral;
DRUGBANK
DDPD14002
D-alpha-Tocopherol acetate
472.7428
C31H52O3
CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(C)C(OC(C)=O)=C(C)C(C)=C2O1
DB14002
32321
77987
-2.0
-
-2.0
-
DRUGBANK
65.0
%
50-80
%
PO, oral;
DRUGBANK
DDPD14003
alpha-Tocopherol acetate
N.A.
N.A.
CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OC(=O)C)C
DB14003
86472
-2.0
-
-2.0
-
DRUGBANK
1828.0
ng/ml
1828±48.24
ng/ml
Oral single dose; normal,healthy; Male, men;
DRUGBANK
1931.0
ng/ml
1931±92.54
ng/ml
Oral single dose; normal,healthy; Male, men;
DRUGBANK
2188.0
ng/ml
2188±147.61
ng/ml
Oral single dose; normal,healthy; Male, men;
DRUGBANK
0.017
L/h
0.017±0.015
L/h
Single dose; normal,healthy; Male, men;
DRUGBANK
0.011
L/h
0.011±0.001
L/h
Single dose; normal,healthy; Male, men;
DRUGBANK
0.019
L/h
0.019±0.001
L/h
Single dose; normal,healthy; Male, men;
DRUGBANK
0.07
L/kg
0.070±0.002
L/kg
Apparent volume of distribution; Single dose; normal,healthy; Male, men;
DRUGBANK
0.127
L/kg
0.127±0.004
L/kg
Apparent volume of distribution; Single dose; normal,healthy; Male, men;
DRUGBANK
0.232
L/kg
0.232±0.010
L/kg
Apparent volume of distribution; Single dose; normal,healthy; Male, men;
DRUGBANK
48.0
h
~48
h
normal,healthy;
DRUGBANK
48.0
h
~48
h
normal,healthy;
DRUGBANK
DDPD14006
Choline salicylate
241.287
C12H19NO4
C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O
DB14006
3668
15385
-2.0
-
-2.0
-
DRUGBANK
0.15
L/kg
0.15
L/kg
DRUGBANK
3.0
h
2-4
h
elimination half-life;
DRUGBANK
2690.0
mg/kg
2690.0
mg/kg
PO, oral; mouse;
DRUGBANK
1000.0
mg/kg
1.0
g/kg
subcutaneous injection, SC; mouse;
DRUGBANK
85.0
%
80-90
%
DRUGBANK
DDPD14007
Pentetic acid
393.349
C14H23N3O10
OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O
DB14007
35739
2945
-2.0
-
-2.0
-
DRUGBANK
20.0
%
20
%
inhalation, IH;
DRUGBANK
6.0
L/h
80-120
ml/min
normal renal function; patients;
DRUGBANK
17.0
L
17.0
L
DRUGBANK
0.419166666666667
h
18.5-31.8
min
intravenous injection, IV;
DRUGBANK
DDPD14018
Bromotheophylline
259.063
C7H7BrN4O2
CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
DB14018
11315
-2.0
-
-2.0
-
DRUGBANK
27000.0
ng.h/ml
27.0
mg.h/l
Oral single dose;
DRUGBANK
2500.0
ng/ml
2.5
mg/L
Oral single dose;
DRUGBANK
0.78
h
0.78
h
Oral single dose;
DRUGBANK
21.35
h
21.35
h
elimination half-life;
DRUGBANK
DDPD14019
Fosnetupitant
688.608
C31H35F6N4O5P
CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1
DB14019
44208829
-2.0
-
-2.0
-
DRUGBANK
73.5
%
42-105
%
PO, oral; Rattus, Rat;
DRUGBANK
58.5
%
34-83
%
PO, oral; dog;
DRUGBANK
49.5
%
37-62
%
PO, oral; monkey;
DRUGBANK
0.5
h
0.5
h
intravenous infusion, IV in drop; patients;
DRUGBANK
0.5
h
0.5
h
intravenous infusion, IV in drop; normal,healthy;
DRUGBANK
0.3
L/h
0.3±9.2
L/h
Average clearance; Oral single dose;
DRUGBANK
124.0
L
124±76
L
Average volume of distribution; normal,healthy;
DRUGBANK
296.0
L
296±535
L
Average volume of distribution; patients;
DRUGBANK
80.0
h
80±29
h
elimination half-life; tumor; patients;
DRUGBANK
3.95
%
3.95
%
Urinary excretion; PO, oral;
DRUGBANK
70.7
%
70.7
%
Faeces excretion; PO, oral;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
DDPD14020
Benzoin
212.2439
C14H12O2
OC(C(=O)C1=CC=CC=C1)C1=CC=CC=C1
DB14020
17682
8093
-2.0
-
-2.0
-
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
8870.0
mg/kg
8870.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD14033
Acetyl sulfisoxazole
309.34
C13H15N3O4S
CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1
DB14033
6662
135975
6410
-2.0
-
-2.0
-
DRUGBANK
0.95
%
0.95±0.04
%
PO, oral;
DRUGBANK
1.122
L/h
18.7±3.9
ml/min
Total clearance;
DRUGBANK
13.92
L/h
232±64
ml/min
Plasma clearance;
DRUGBANK
10.9
L
10.9±2.0
L
Apparent volume of distribution;
DRUGBANK
136.0
L
136±36
L
Total volume of distribution;
DRUGBANK
11.0
h
10-12
h
elimination half-life;
DRUGBANK
6800.0
mg/kg
6800.0
mg/kg
PO, oral; mouse;
DRUGBANK
97.0
%
97
%
Urinary excretion; PO, oral;
DRUGBANK
85.0
%
~85
%
plasma proteins;
DRUGBANK
DDPD14048
Sodium zirconium cyclosilicate
365.452
Na2O9Si3Zr
[Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1
DB14048
-2.0
-
-2.0
-
DRUGBANK
30000.0
mg/day
30
g/day
PO, oral
Lokelma
sodium zirconium cyclosilicate
PDR
30000.0
mg/day
30
g/day
PO, oral
Lokelma
sodium zirconium cyclosilicate
PDR
DDPD14151
Phosphorus
30.9738
P
[P]
DB14151
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
30207
4575369
-2.0
-
-2.0
-
DRUGBANK
2e-05
mg/L
0.02
mg/m3
inhalation, IH;
DRUGBANK
0.0002
mg/kg/day
0.0002
mg/kg/day
PO, oral;
DRUGBANK
DDPD14183
Geraniol
154.253
C10H18O
CC(C)=CCC\C(C)=C\CO
DB14183
17447
13849989
-2.0
-
-2.0
-
DRUGBANK
92.0
%
92.0
%
PO, oral; Rattus, Rat;
DRUGBANK
270000.0
ng/ml
270.0
ug/ml
PO, oral; Rattus, Rat;
DRUGBANK
0.5
h
30
min
PO, oral; Rattus, Rat;
DRUGBANK
0.2
h
~12
min
intravenous injection, IV;
DRUGBANK
DDPD14184
Cinnamaldehyde
132.1592
C9H8O
O=C\C=C\C1=CC=CC=C1
DB14184
16731
553117
-2.0
-
-2.0
-
DRUGBANK
52.0
%
52.0
%
skin/dermal;
DRUGBANK
83.5
%
69-98
%
Urinary excretion; Faeces excretion; PO, oral; Intraperitoneal, IP; mouse; Rattus, Rat;
DRUGBANK
DDPD14185
Aripiprazole lauroxil
660.72
C36H51Cl2N3O4
CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12
DB14185
90930
28651973
-2.0
-
-2.0
-
DRUGBANK
0.32
L/h/kg
0.32±0.11
L/h/kg
Rattus, Rat; intravenous injection, IV;
DRUGBANK
268.0
L
268.0
L
Apparent volume of distribution; IM,intramuscular injection;
DRUGBANK
769.2
h
29.2-34.9
day
elimination half-life;
DRUGBANK
60.0
mg
>60
mg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
750.0
mg/kg
750.0
mg/kg
PO, oral; Female, women; Rattus, Rat;
DRUGBANK
965.0
mg/kg
965.0
mg/kg
PO, oral; Male, men; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; monkey;
DRUGBANK
1.0
%
<1
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
18.0
%
~18
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD14186
Cinnamyl alcohol
134.1751
C9H10O
OC\C=C\C1=CC=CC=C1
DB14186
33227
21105870
-2.0
-
-2.0
-
DRUGBANK
66.0
%
66.0
%
skin/dermal;
DRUGBANK
76.5
%
76-77
%
Urinary excretion; Faeces excretion; PO, oral; Intraperitoneal, IP; mouse; Rattus, Rat;
DRUGBANK
DDPD14187
Hydroxycitronellal
172.2646
C10H20O2
[H]C(=O)CC(C)CCCC(C)(C)O
DB14187
53459
7600
-2.0
-
-2.0
-
DRUGBANK
3.3
h
3.3
h
elimination half-life;
DRUGBANK
DDPD14189
Ethylenediamine
60.0983
C2H8N2
NCCN
DB14189
30347
13835550
-2.0
-
-2.0
-
DRUGBANK
34.0
%
34.0
%
PO, oral;
DRUGBANK
0.133
L/kg
0.133
L/kg
DRUGBANK
0.55
h
~0.55
h
DRUGBANK
DDPD14487
Zinc acetate
183.497
C4H6O4Zn
[Zn++].CC([O-])=O.CC([O-])=O
DB14487
62984
10719
-2.0
-
-2.0
-
DRUGBANK
65.0
%
60-70
%
Liquid; fasting;
DRUGBANK
33.0
%
33.0
%
DRUGBANK
0.0378
mg/h
0.63±0.39
ug/min
normal,healthy; patients;
DRUGBANK
6720.0
h
~280
day
human, homo sapiens;
DRUGBANK
65.0
%
~60-70
%
DRUGBANK
34.0
mg/day
34
mg/day
PO, oral
Galzin
zinc acetate
PDR
40.0
mg/day
40
mg/day
PO, oral
Galzin
zinc acetate
PDR
23.0
mg/day
23
mg/day
PO, oral
Galzin
zinc acetate
PDR
12.0
mg/day
12
mg/day
PO, oral
Galzin
zinc acetate
PDR
7.0
mg/day
7
mg/day
PO, oral
Galzin
zinc acetate
PDR
40.0
mg/day
40
mg/day
PO, oral
Galzin
zinc acetate
PDR
DDPD14488
Ferrous gluconate
446.139
C12H22FeO14
[Fe++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O
DB14488
9291
19953133
-2.0
-
-2.0
-
DRUGBANK
22.5
%
10-35
%
DRUGBANK
95.0
%
≤95
%
PO, oral; iron deficient;
iron deficient ↑ ;
DRUGBANK
DDPD14489
Ferrous succinate
171.917
C4H4FeO4
[Fe++].[O-]C(=O)CCC([O-])=O
DB14489
159252
8640173
-2.0
-
-2.0
-
DRUGBANK
22.5
%
10-35
%
DRUGBANK
95.0
%
≤95
%
PO, oral; iron deficient;
iron deficient ↑ ;
DRUGBANK
DDPD14490
Ferrous ascorbate
406.077
C12H14FeO12
[Fe++].[H][C@](O)(CO)[C@@]1([H])OC(=O)C(O)=C1O.[H][C@](O)(CO)[C@@]1([H])OC(=O)C([O-])=C1[O-]
DB14490
54710214
21169558
-2.0
-
-2.0
-
DRUGBANK
22.5
%
10-35
%
DRUGBANK
95.0
%
≤95
%
PO, oral; iron deficient;
iron deficient ↑ ;
DRUGBANK
DDPD14491
Ferrous fumarate
169.901
C4H2FeO4
[Fe++].[H]\C(=C(\[H])C([O-])=O)C([O-])=O
DB14491
6433164
31607
10607713
-2.0
-
-2.0
-
DRUGBANK
22.5
%
10-35
%
DRUGBANK
95.0
%
≤95
%
PO, oral; iron deficient;
iron deficient ↑ ;
DRUGBANK
DDPD14500
Potassium
39.0983
K
[KH]
DB14500
32589
16787786
-2.0
-
-2.0
-
DRUGBANK
90.0
%
~90
%
PO, oral;
DRUGBANK
94.0
%
94.0
%
PO, oral; Drug form;
DRUGBANK
100.0
%
100
%
DRUGBANK
7.8
h
1.6-14
h
PO, oral;
DRUGBANK
456.0
h
10-28
day
elimination half-life;
DRUGBANK
2600.0
mg/kg
2600.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD14501
Ferrous glycine sulfate
302.041
C4H10FeN2O8S
[Fe++].NCC([O-])=O.NCC([O-])=O.OS(O)(=O)=O
DB14501
167159
146251
-2.0
-
-2.0
-
DRUGBANK
22.5
%
10-35
%
DRUGBANK
95.0
%
≤95
%
PO, oral; iron deficient;
iron deficient ↑ ;
DRUGBANK
DDPD14502
Sodium phosphate, dibasic
141.9588
HNa2O4P
[Na+].[Na+].OP([O-])([O-])=O
DB14502
34683
22625
-2.0
-
-2.0
-
DRUGBANK
2.0
h
1-3
h
Liquid;
DRUGBANK
250.0
mg/kg
250.0
mg/kg
IM,intramuscular injection; Rattus, Rat;
DRUGBANK
8290.0
mg/kg
8290.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
DDPD14505
Sodium borate
201.219
B4Na2O7
[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2
DB14505
8395345
-2.0
-
-2.0
-
DRUGBANK
0.5
h
0.5
h
Intraperitoneal, IP;
DRUGBANK
0.99
L/h
0.99
L/h
Total clearance; PO, oral; acute boric acid poisoning;
DRUGBANK
0.335
L/kg
0.17-0.5
L/kg
human, homo sapiens;
DRUGBANK
18.5
h
13-24
h
elimination half-life;
DRUGBANK
4750.0
mg/kg
4500-5000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
10000.0
mg/kg
10000.0
mg/kg
intradermal; rabbit;
DRUGBANK
1.0
%
1
%
Urinary excretion; ointment;
DRUGBANK
90.0
%
>90
%
Urinary excretion; Unchanged drug;
DRUGBANK
DDPD14509
Lithium carbonate
73.89
CLi2O3
[Li+].[Li+].[O-]C([O-])=O
DB14509
6504
10654
-2.0
-
-2.0
-
DRUGBANK
1.0
%
~100
%
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
1.5
L/h
10-40
ml/min
normal,healthy;
DRUGBANK
0.9
L/h
15.0
ml/min
Geriatric; RD, renal impairment, Renal disease，including uremia;
DRUGBANK
0.85
L/kg
0.7-1
L/kg
Apparent volume of distribution;
DRUGBANK
27.0
h
18-36
h
DRUGBANK
13.5
h
7-20
h
different study;
DRUGBANK
525.0
mg/kg
525.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1.5
mEq/L
1.5
mEq/L
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1200.0
mg/day
1200
mg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1800.0
mg/day
1800
mg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1.5
mEq/L
1.5
mEq/L
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
20.0
mg/kg/day
20
mg/kg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1.5
mEq/L
1.5
mEq/L
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1.5
mEq/L
1.5
mEq/L
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1.5
mEq/L
1.5
mEq/L
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
1500.0
mg/day
1500
mg/day
PO, oral
Lithium Carbonate Capsules and Tablets, Lithium Oral Solution
(lithium); (lithium carbonate)
PDR
DDPD14512
Mometasone furoate
521.429
C27H30Cl2O6
[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB14512
47564
390091
-2.0
-
-2.0
-
DRUGBANK
1.0
%
<1
%
inhalation, IH;
DRUGBANK
11.0
%
11.0
%
different study;
increasing dosing frequency ↑ ;
DRUGBANK
0.7
%
0.7
%
ointment;
DRUGBANK
1.75
h
1.0-2.5
h
inhalation, IH;
DRUGBANK
90.0
L/h
~90
L/h
DRUGBANK
0.762
L/h/kg
12.7
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
152.0
L
152.0
L
Steady state volume of distribution;
DRUGBANK
2.2
L/kg
2.2
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
5.0
h
~5
h
terminal half-life;
DRUGBANK
5.8
h
5.8
h
different study;
DRUGBANK
4.4
h
4.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
74.0
%
~74
%
Faeces excretion;
DRUGBANK
8.0
%
~8
%
Urinary excretion;
DRUGBANK
98.5
%
98-99
%
high protein binding;
DRUGBANK
1.0
application/day
1
application/day
skin ointment
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.88
mg/day
880
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.8
mg/day
800
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.4
mg/day
400
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.88
mg/day
880
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.8
mg/day
800
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.4
mg/day
400
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.88
mg/day
880
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.8
mg/day
800
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
1.0
appLication/day
1
appLication/day
skin ointment
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.2
mg/day
200
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.88
mg/day
880
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.8
mg/day
800
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
1.0
appLication/day
1
appLication/day
skin ointment
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.1
mg/day
100
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.11
mg/day
110
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.2
mg/day
200
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
1.0
appLication/day
1
appLication/day
skin ointment
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.1
mg/day
100
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.11
mg/day
110
mcg/day
inhalation, IH
Mometasone Furoate Topical Solution
mometasone furoate
PDR
1.0
appLication/day
1
appLication/day
skin ointment
Mometasone Furoate Topical Solution
mometasone furoate
PDR
0.1
mg/day
100
mcg/day
nasal spray
Mometasone Furoate Topical Solution
mometasone furoate
PDR
DDPD14513
Magnesium
26.321
H2Mg
[MgH2]
DB14513
16787263
-2.0
-
-2.0
-
DRUGBANK
50.0
%
24-76
%
PO, oral;
DRUGBANK
0.0
%
0
%
DRUGBANK
31.325
L
13.65-49
L
eclampsia; patients;
DRUGBANK
1008.0
h
~42
day
elimination half-life;
DRUGBANK
20.0
%
20
%
human, homo sapiens;
DRUGBANK
13.0
%
12-14
%
human, homo sapiens;
DRUGBANK
DDPD14520
Tetraferric tricitrate decahydrate
967.803
C18H32Fe4O31
O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O
DB14520
34993203
-2.0
-
-2.0
-
DRUGBANK
19.0
%
19.0
%
Drug form;
DRUGBANK
1487.0
mg/kg
1487.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
1520.0
mg/kg
1520.0
mg/kg
PO, oral; mouse;
DRUGBANK
2000.0
mg/kg
2000.0
mg/kg
skin/dermal; rabbit;
DRUGBANK
DDPD14527
Chromic nitrate
238.0108
CrN3O9
[Cr+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O
DB14527
86204
23000
-2.0
-
-2.0
-
DRUGBANK
5.25
%
0.5-10
%
PO, oral;
DRUGBANK
28.0
h
15-41
h
DRUGBANK
155.0
mg/kg
135-175
mg/kg
PO, oral; mouse;
DRUGBANK
79.5
mg/kg
46-113
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3.5
g/kg
DRUGBANK
11300.0
mg/kg
11.3
g/kg
DRUGBANK
3300.0
mg/kg
3.3
g/kg
DRUGBANK
1500.0
mg/kg
1.5
g/kg
DRUGBANK
0.8
%
0.8
%
Urinary excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14528
Chromium gluconate
637.437
C18H33CrO21
[Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O
DB14528
32701256
-2.0
-
-2.0
-
DRUGBANK
5.25
%
0.5-10
%
PO, oral;
DRUGBANK
28.0
h
15-41
h
DRUGBANK
155.0
mg/kg
135-175
mg/kg
PO, oral; mouse;
DRUGBANK
79.5
mg/kg
46-113
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3.5
g/kg
DRUGBANK
11300.0
mg/kg
11.3
g/kg
DRUGBANK
1500.0
mg/kg
1.5
g/kg
DRUGBANK
0.8
%
0.8
%
Urinary excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14529
Chromium nicotinate
418.305
C18H12CrN3O6
[Cr+3].[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1.[O-]C(=O)C1=CN=CC=C1
DB14529
50368
8085563
-2.0
-
-2.0
-
DRUGBANK
5.25
%
0.5-10
%
PO, oral;
DRUGBANK
28.0
h
15-41
h
DRUGBANK
155.0
mg/kg
135-175
mg/kg
PO, oral; mouse;
DRUGBANK
79.5
mg/kg
46-113
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3.5
g/kg
DRUGBANK
11300.0
mg/kg
11.3
g/kg
DRUGBANK
1500.0
mg/kg
1.5
g/kg
DRUGBANK
0.8
%
0.8
%
Urinary excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14530
Chromous sulfate
148.05
CrO4S
[Cr++].[O-]S([O-])(=O)=O
DB14530
55589
-2.0
-
-2.0
-
DRUGBANK
5.25
%
0.5-10
%
PO, oral;
DRUGBANK
28.0
h
15-41
h
DRUGBANK
155.0
mg/kg
135-175
mg/kg
PO, oral; mouse;
DRUGBANK
79.5
mg/kg
46-113
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
2000.0
mg/kg
>2000
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
5000.0
mg/kg
>5
g/kg
Rattus, Rat;
DRUGBANK
3500.0
mg/kg
3.5
g/kg
DRUGBANK
11300.0
mg/kg
11.3
g/kg
DRUGBANK
1500.0
mg/kg
1.5
g/kg
DRUGBANK
0.8
%
0.8
%
Urinary excretion;
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14533
Zinc chloride
136.315
Cl2Zn
[Cl-].[Cl-].[Zn++]
DB14533
49976
5525
-2.0
-
-2.0
-
DRUGBANK
33.0
%
~33
%
PO, oral;
DRUGBANK
0.0378
mg/h
0.63±0.39
ug/min
normal,healthy; patients;
DRUGBANK
366.0
h
4.5-26
day
distribution half-life;
DRUGBANK
10380.0
h
387-478
day
elimination half-life;
DRUGBANK
70.0
%
70
%
plasma proteins;
DRUGBANK
DDPD14539
Hydrocortisone acetate
404.4966
C23H32O6
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB14539
5744
17609
5542
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14540
Hydrocortisone butyrate
432.557
C25H36O6
[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB14540
31674
24344
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14541
Hydrocortisone cypionate
486.649
C29H42O6
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB14541
5783
193884
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14542
Hydrocortisone phosphate
442.445
C21H31O8P
[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB14542
68634
390143
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14543
Hydrocortisone probutate
488.613
C28H40O7
[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB14543
636398
31675
552186
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14544
Hydrocortisone valerate
446.5763
C26H38O6
[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
DB14544
5282494
50865
4445635
-2.0
-
-2.0
-
DRUGBANK
7.0
h
6-8
h
DRUGBANK
95.0
%
95
%
DRUGBANK
DDPD14554
Dotatate
1435.63
C65H90N14O19S2
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
DB14554
9345959
-2.0
-
-2.0
-
DRUGBANK
2.0
MBq/kg/dose
2
MBq/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
0.054
mCi/kg/dose
0.054
mCi/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
200.0
MBq/dose
200
MBq/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
5.4
mCi/dose
5.4
mCi/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
2.0
MBq/kg/dose
2
MBq/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
0.054
mCi/kg/dose
0.054
mCi/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
200.0
MBq/dose
200
MBq/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
5.4
mCi/dose
5.4
mCi/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
2.0
MBq/kg/dose
2
MBq/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
0.054
mCi/kg/dose
0.054
mCi/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
200.0
MBq/dose
200
MBq/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
5.4
mCi/dose
5.4
mCi/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
2.0
MBq/kg/dose
2
MBq/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
0.054
mCi/kg/dose
0.054
mCi/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
200.0
MBq/dose
200
MBq/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
5.4
mCi/dose
5.4
mCi/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
2.0
MBq/kg/dose
2
MBq/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
0.054
mCi/kg/dose
0.054
mCi/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
2.0
MBq/kg/dose
2
MBq/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
0.054
mCi/kg/dose
0.054
mCi/kg/dose
intravenous injection, IV
Netspot
gallium Ga 68 dotatate
PDR
DDPD14568
Ivosidenib
582.97
C28H22ClF3N6O3
[H][C@@](N(C(=O)[C@]1([H])CCC(=O)N1C1=NC=CC(=C1)C#N)C1=CC(F)=CN=C1)(C(=O)NC1CC(F)(F)C1)C1=C(Cl)C=CC=C1
DB14568
145430
38772333
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
336.0
h
14.0
day
Oral multiple dose;
DRUGBANK
8.0
%
<8
%
DRUGBANK
4.3
L/h
4.3
L/h
apparent clearance;
DRUGBANK
234.0
L
234.0
L
Apparent volume of distribution; at steady state;
DRUGBANK
93.0
h
93
h
terminal half-life;
DRUGBANK
0.77
%
0.77
%
Faeces excretion; PO, oral;
DRUGBANK
0.17
%
0.17
%
Urinary excretion; PO, oral;
DRUGBANK
94.0
%
92-96
%
plasma proteins; high protein binding;
DRUGBANK
DDPD14569
Tedizolid
370.344
C17H15FN6O3
CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O
DB14569
82717
9409096
-2.0
-
-2.0
-
DRUGBANK
23800.0
ng.h/ml
23.8±6.8
mcg.h/ml
PO, oral;
DRUGBANK
26600.0
ng.h/ml
26.6±5.2
mcg.h/ml
intravenous injection, IV;
DRUGBANK
91.0
%
~91
%
PO, oral;
DRUGBANK
2000.0
ng/ml
2.0±0.7
mcg/ml
PO, oral;
DRUGBANK
3000.0
ng/ml
3.0±0.7
mcg/ml
intravenous injection, IV;
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
2.5
h
2.5(1.0-8.0)
h
PO, oral;
DRUGBANK
1.2
h
1.2(0.9-1.5)
h
intravenous injection, IV;
DRUGBANK
72.0
h
3.0
day
PO, oral;
DRUGBANK
72.0
h
3.0
day
intravenous injection, IV;
DRUGBANK
3.5
h
3.5(1.0-6.0)
h
PO, oral;
DRUGBANK
1.1
h
1.1(0.9-1.5)
h
intravenous injection, IV;
DRUGBANK
6.9
L/h
6.9±1.7
L/h
apparent clearance; Oral single dose;
DRUGBANK
8.4
L/h
8.4±2.1
L/h
apparent clearance; at steady state;
DRUGBANK
6.4
L/h
6.4±1.2
L/h
Total clearance; Oral single dose;
DRUGBANK
5.9
L/h
5.9±1.4
L/h
Total clearance; at steady state;
DRUGBANK
0.0714
L/h/kg
1.19
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
73.5
L
67-80
L
intravenous injection, IV; Single dose;
DRUGBANK
108.0
L
108 ± 21
L
PO, oral;
DRUGBANK
113.3
L
113.3 ± 19.3
L
Apparent volume of distribution; Oral single dose;
DRUGBANK
0.91
L/kg
0.91
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
12.0
h
~12
h
DRUGBANK
10.16
h
10.16
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
82.0
%
~82
%
Faeces excretion; Oral single dose;
DRUGBANK
18.0
%
~18
%
Urinary excretion; Oral single dose;
DRUGBANK
80.0
%
~70-90
%
plasma proteins;
DRUGBANK
DDPD14574
Cobalt
58.9332
Co
[Co]
DB14574
https://www.atsdr.cdc.gov/mrls/pdfs/ATSDR MRLs - May 2021 - H.pdf
27638
94547
-2.0
-
-2.0
-
DRUGBANK
1e-07
mg/L
0.0001
mg/m3
inhalation, IH; Oral multiple dose;
DRUGBANK
0.01
mg/kg/day
0.01
mg/kg/day
PO, oral;
DRUGBANK
4.0
mSv
4.0
mSv
intradermal;
DRUGBANK
1.0
mSv/yr
1.0
mSv/yr
intradermal; Oral multiple dose;
DRUGBANK
DDPD14583
Segesterone acetate
370.489
C23H30O4
[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
DB14583
135563
97161
-2.0
-
-2.0
-
DRUGBANK
1.147
ng/ml
1147.0
pg/ml
Vaginal Administration; different medication cycle;
DRUGBANK
0.363
ng/ml
363.0
pg/ml
Vaginal Administration; different medication cycle;
DRUGBANK
0.294
ng/ml
294.0
pg/ml
Vaginal Administration; different medication cycle;
DRUGBANK
2.0
h
2
h
Vaginal Administration;
DRUGBANK
96.0
h
96.0
h
Vaginal Administration;
DRUGBANK
19.6
L/kg
19.6
L/kg
DRUGBANK
4.5
h
4.5
h
DRUGBANK
81.4
%
~81.4
%
Faeces excretion; subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
7.62
%
~7.62
%
Urinary excretion; subcutaneous injection, SC; Rattus, Rat;
DRUGBANK
95.0
%
~95
%
DRUGBANK
DDPD14596
Loteprednol etabonate
466.96
C24H31ClO7
[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB14596
9865442
31784
http://www.drugs.com/international/loteprednol.html
392049
-2.0
-
-2.0
-
DRUGBANK
0.00021
L/h/kg
0.21±0.04
ml/h/kg
Renal clearance;
DRUGBANK
0.00241
L/h/kg
2.41±0.13
ml/h/kg
Plasma clearance;
DRUGBANK
3.7
L/kg
3.7
L/kg
dog;
DRUGBANK
2.8
h
2.8
h
terminal half-life; dog; intravenous injection, IV;
DRUGBANK
98.0
%
~98
%
DRUGBANK
24.0
drop/day
24
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
24.0
drop/day
24
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
4.0
drop/day
4
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
3.0
drop/day
3
drop/day
ophthalmic administration
Inveltys
loteprednol etabonate
PDR
DDPD14598
Edetate calcium disodium anhydrous
374.268
C10H12CaN2Na2O8
[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
DB14598
6109
4757
5883
-2.0
-
-2.0
-
DRUGBANK
5.0
%
5.0
%
PO, oral;
DRUGBANK
0.0
%
~0
%
DRUGBANK
1.89364161849711
L/h/m2
54.6
ml/min/1.73m2
Average clearance; Neonates;
DRUGBANK
3.95028901734104
L/h/m2
113.9±24.4
ml/min/1.73m2
Average clearance; Children; Adolescents;
DRUGBANK
0.19
L/kg
0.19±0.10
L/kg
DRUGBANK
0.666666666666667
h
20-60
min
DRUGBANK
95.0
%
95
%
Urinary excretion;
DRUGBANK
88.32
%
88.32
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
10.3
%
10.3
%
Urinary excretion; PO, oral; Rattus, Rat;
DRUGBANK
1500.0
mg/m2/day
1500
mg/m2/day
intravenous injection, IV;IM,intramuscular injection;
Calcium Disodium Versenate
edetate calcium disodium
PDR
1500.0
mg/m2/day
1500
mg/m2/day
intravenous injection, IV;IM,intramuscular injection;
Calcium Disodium Versenate
edetate calcium disodium
PDR
1500.0
mg/m2/day
1500
mg/m2/day
intravenous injection, IV;IM,intramuscular injection;
Calcium Disodium Versenate
edetate calcium disodium
PDR
1500.0
mg/m2/day
1500
mg/m2/day
intravenous injection, IV;IM,intramuscular injection;
Calcium Disodium Versenate
edetate calcium disodium
PDR
1500.0
mg/m2/day
1500
mg/m2/day
intravenous injection, IV;IM,intramuscular injection;
Calcium Disodium Versenate
edetate calcium disodium
PDR
DDPD14600
Edetate disodium anhydrous
336.2063
C10H14N2Na2O8
[Na+].[Na+].OC(=O)CN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O
DB14600
8759
64734
8429
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
95.0
%
95
%
Urinary excretion; intravenous injection, IV;
DRUGBANK
5.3
%
5.3
%
Urinary excretion; PO, oral; Rattus, Rat;
DRUGBANK
88.5
%
88.5
%
Faeces excretion; PO, oral; Rattus, Rat;
DRUGBANK
DDPD14631
Prednisolone phosphate
440.429
C21H29O8P
[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB14631
145705
65064
-2.0
-
-2.0
-
DRUGBANK
2426.1
ng.h/ml
2426.1±360.0
ng.h/ml
Liquid;
DRUGBANK
2408.1
ng.h/ml
2408.1±361.5
ng.h/ml
Tablet, PO, oral;
DRUGBANK
461.33
ng/ml
461.33±77.94
ng/ml
Liquid;
DRUGBANK
420.91
ng/ml
420.91±78.28
ng/ml
Tablet, PO, oral;
DRUGBANK
0.46
L/kg
0.22-0.7
L/kg
DRUGBANK
3.0
h
2-4
h
DRUGBANK
80.0
%
70-90
%
plasma proteins;
DRUGBANK
DDPD14638
Diloxanide furoate
328.147
C14H11Cl2NO4
CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1
DB14638
4601
18400
-2.0
-
-2.0
-
DRUGBANK
90.0
%
90.0
%
Derivative;
DRUGBANK
99.0
%
99
%
DRUGBANK
1.0
%
1
%
DRUGBANK
3.0
h
3
h
DRUGBANK
DDPD14669
Betamethasone phosphate
472.446
C22H30FO8P
[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB14669
68603
96937
-2.0
-
-2.0
-
DRUGBANK
506.95
ng.h/ml
506.95±125.03
ng.h/ml
IM,intramuscular injection;
DRUGBANK
506.95
ng.h/ml
506.95±125.03
ng.h/ml
IM,intramuscular injection; Derivative;
DRUGBANK
33.21
ng/ml
33.21±8.71
ng/ml
IM,intramuscular injection;
DRUGBANK
33.21
ng/ml
33.21±8.71
ng/ml
IM,intramuscular injection; Derivative;
DRUGBANK
1.56
h
1.56±1.32
h
IM,intramuscular injection;
DRUGBANK
1.56
h
1.56±1.32
h
IM,intramuscular injection; Derivative;
DRUGBANK
12.62
L/h
12.62±3.45
L/h
IM,intramuscular injection; Drug combination;
DRUGBANK
226.0
L
226.00±61.64
L
IM,intramuscular injection; Drug combination;
DRUGBANK
12.47
h
12.47±1.91
h
DRUGBANK
DDPD14674
Estramustine phosphate
520.38
C23H32Cl2NO6P
[H][C@@]12CC[C@H](OP(O)(O)=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)N(CCCl)CCCl)C=C3
DB14674
68643
227633
-2.0
-
-2.0
-
DRUGBANK
0.0564
L/h/kg
0.94
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.12
L/kg
0.12
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
2.4
h
2.4
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD14723
Larotrectinib
428.444
C21H22F2N6O2
O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1
DB14723
44210503
-2.0
-
-2.0
-
DRUGBANK
4351.0
ng.h/ml
4351.0
ng.h/ml
Capsule, PO, Oral; adults;
DRUGBANK
34.0
%
34(32-37）
%
Capsule, PO, Oral;
DRUGBANK
788.0
ng/ml
788.0
ng/ml
Capsule, PO, Oral; adults;
DRUGBANK
1.0
h
1
h
Capsule, PO, Oral; adults;
DRUGBANK
72.0
h
3.0
day
Capsule, PO, Oral; adults;
DRUGBANK
98.0
L/h
98.0
L/h
Average clearance;
DRUGBANK
48.0
L
48.0
L
Average volume of distribution; intravenous injection, IV; normal,healthy;
DRUGBANK
2.9
h
2.9
h
DRUGBANK
58.0
%
58
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
39.0
%
39
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
2.9
%
2.9
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
7.8
%
7.8
%
Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
70.0
%
~70
%
plasma proteins; human, homo sapiens;
Plasma Concentration → ;
DRUGBANK
100.0
mg
100
mg
PO, oral
bid
Vitrakvi
larotrectinib
PDR
100.0
mg/m2
100
mg/m2
PO, oral
bid
Vitrakvi
larotrectinib
PDR
100.0
mg
100
mg
PO, oral
bid
Vitrakvi
larotrectinib
PDR
100.0
mg
100
mg
PO, oral
bid
Vitrakvi
larotrectinib
PDR
100.0
mg
100
mg
PO, oral
bid
Vitrakvi
larotrectinib
PDR
100.0
mg/m2
100
mg/m2
PO, oral
q2d
Vitrakvi
larotrectinib
PDR
DDPD14754
Solriamfetol
194.234
C10H14N2O2
N[C@@H](COC(N)=O)CC1=CC=CC=C1
DB14754
8305853
-2.0
-
-2.0
-
DRUGBANK
95.0
%
~95
%
PO, oral;
DRUGBANK
2.0
h
2(1.25-3)
h
PO, oral; fasting;
DRUGBANK
3.0
h
3.0
h
PO, oral; high-fat meal;
DRUGBANK
1.0
%
<1
%
DRUGBANK
18.2
L/h
18.2
L/h
Renal clearance;
DRUGBANK
19.5
L/h
19.5
L/h
Total clearance;
DRUGBANK
18.4
L/h
18.4±4.2
L/h
fasting;
DRUGBANK
18.4
L/h
18.8±4.2
L/h
food;
DRUGBANK
199.0
L
199.0
L
DRUGBANK
158.2
L
158.2±37.3
L
fasting;
DRUGBANK
159.8
L
159.8±38.9
L
food;
DRUGBANK
7.1
h
7.1
h
DRUGBANK
6.1
h
6.1±1.2
h
fasting;
DRUGBANK
5.9
h
5.9±1.2
h
food;
DRUGBANK
16.35
%
13.3-19.4
%
plasma proteins;
DRUGBANK
DDPD14761
Remdesivir
602.585
C27H35N6O8P
CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
DB14761
145994
58827832
-2.0
-
-2.0
-
DRUGBANK
0.39
h
0.39
h
elimination half-life; intravenous injection, IV; non-human primate;
DRUGBANK
14.0
h
14
h
Metabolite; non-human primate;
DRUGBANK
20.0
h
~20
h
Metabolite; human, homo sapiens;
DRUGBANK
74.0
%
74
%
Urinary excretion;
DRUGBANK
18.0
%
18
%
Faeces excretion;
DRUGBANK
DDPD14783
Diroximel fumarate
255.226
C11H13NO6
COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O
DB14783
57423290
-2.0
-
-2.0
-
DRUGBANK
1466.66666666667
ng.h/ml
88.0
mg.min/L
PO, oral; multiple sclerosis; Active metabolite;
DRUGBANK
2110.0
ng/ml
2.11
mg/L
PO, oral;
DRUGBANK
2.75
h
2.5-3
h
PO, oral;
DRUGBANK
1.54
mg/L
1.54
mg/L
Average clearance; PO, oral;
DRUGBANK
77.5
L
72-83
L
Apparent volume of distribution;
DRUGBANK
1.0
h
1
h
terminal half-life; Active metabolite;
DRUGBANK
2240.0
mg/kg
2240.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
924.0
mg/day
924
mg/day
PO, oral
Vumerity
diroximel fumarate
PDR
924.0
mg/day
924
mg/day
PO, oral
Vumerity
diroximel fumarate
PDR
DDPD14840
Ripretinib
510.367
C24H21BrFN5O2
CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1
DB14840
67886378
-2.0
-
-2.0
-
DRUGBANK
4.0
h
4
h
PO, oral;
DRUGBANK
336.0
h
14.0
day
PO, oral;
DRUGBANK
47.25
L/h
15.3-79.2
L/h
apparent clearance;
DRUGBANK
307.0
L
307.0
L
Average volume of distribution;
DRUGBANK
14.8
h
14.8
h
DRUGBANK
34.0
%
34
%
Faeces excretion;
DRUGBANK
0.2
%
0.2
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
DRUGBANK
DDPD14879
Cefiderocol
752.21
C30H34ClN7O10S2
[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O
DB14879
52084902
-2.0
-
-2.0
-
DRUGBANK
386000.0
ng.h/ml
386.0
mg.h/l
normal,healthy;
DRUGBANK
394700.0
ng.h/ml
394.7
mg.h/l
intravenous injection, IV; complicated urinary tract infections;
DRUGBANK
89700.0
ng/ml
89.7
mg/L
normal,healthy;
DRUGBANK
138000.0
ng/ml
138.0
mg/L
intravenous injection, IV; complicated urinary tract infections;
DRUGBANK
5.18
L/h
5.18
L/h
Average clearance;
DRUGBANK
18.0
L
18.0
L
Average volume of distribution;
DRUGBANK
2.5
h
2-3
h
elimination half-life;
DRUGBANK
98.6
%
98.6
%
Urinary excretion;
DRUGBANK
2.8
%
2.8
%
Faeces excretion;
DRUGBANK
89.3
%
89.3
%
Urinary excretion; Unchanged drug;
DRUGBANK
50.0
%
40-60
%
plasma proteins;
DRUGBANK
DDPD14881
Oliceridine
386.55
C22H30N2O2S
COC1=C(CNCC[C@]2(CCOC3(CCCC3)C2)C2=NC=CC=C2)SC=C1
DB14881
30841043
-2.0
-
-2.0
-
DRUGBANK
0.4134
L/h/kg
6.89
ml/min/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.78
L/kg
0.78
L/kg
intravenous injection, IV; human, homo sapiens;
DRUGBANK
1.8
h
1.8
h
intravenous injection, IV; human, homo sapiens;
DRUGBANK
DDPD14914
Flortaucipir F-18
262.278
C16H10FN3
[18F]C1=CC=C(C=N1)C1=CC=C2C(NC3=C2C=NC=C3)=C1
DB14914
32701063
-2.0
-
-2.0
-
DRUGBANK
0.0833333333333333
h
5
min
intravenous injection, IV; human, homo sapiens;
DRUGBANK
0.283333333333333
h
17.0±4.2
min
elimination half-life;
DRUGBANK
0.301666666666667
h
18.1±5.8
min
Metabolite; distribution half-life;
DRUGBANK
0.04
h
2.4±0.5
min
Metabolite; elimination half-life;
DRUGBANK
DDPD14975
Voxelotor
337.379
C19H19N3O3
CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1
DB14975
37999268
-2.0
-
-2.0
-
DRUGBANK
4950000.0
ug.h/ml
4950.0
ug.h/ml
Oral multiple dose;
DRUGBANK
9610000.0
ug.h/ml
9610.0
ug.h/ml
Oral multiple dose;
DRUGBANK
4000000.0
ug.h/ml
4000.0
ug.h/ml
Oral multiple dose;
DRUGBANK
2.0
h
2
h
PO, oral;
DRUGBANK
6.7
L/h
6.7
L/h
apparent clearance; PO, oral;
DRUGBANK
338.0
L
338.0
L
Total volume of distribution;
DRUGBANK
72.2
L
72.2
L
Total volume of distribution;
DRUGBANK
35.5
h
35.5
h
elimination half-life; sickle cell disease; patients;
DRUGBANK
1440.0
h
60
day
DRUGBANK
50.0
h
50
h
elimination half-life; sickle cell disease; patients; different study;
DRUGBANK
73.0
h
61-85
h
elimination half-life; normal,healthy; patients; different study;
DRUGBANK
62.6
%
62.6
%
Faeces excretion; PO, oral;
DRUGBANK
35.5
%
35.5
%
Urinary excretion; PO, oral;
DRUGBANK
20.8
%
~20.8
%
Faeces excretion; PO, oral; Unchanged drug;
DRUGBANK
0.03
%
~0.03
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
99.8
%
99.8
%
high protein binding;
DRUGBANK
DDPD15035
Zanubrutinib
471.561
C27H29N5O3
NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1
DB15035
64835237
-2.0
-
-2.0
-
DRUGBANK
314.0
ng/ml
314.0
ng/ml
Oral multiple dose;
DRUGBANK
543.0
ng/ml
543.0
ng/ml
Oral multiple dose;
DRUGBANK
2.0
h
2
h
Oral multiple dose;
DRUGBANK
182.0
L/h
182.0
L/h
apparent clearance; PO, oral;
DRUGBANK
881.0
L
881.0
L
Steady state volume of distribution;
DRUGBANK
3.0
h
~2-4
h
Oral single dose;
DRUGBANK
87.0
%
~87
%
Faeces excretion; PO, oral;
DRUGBANK
8.0
%
~8
%
Urinary excretion; PO, oral;
DRUGBANK
0.08
%
~0.08
%
Urinary excretion; PO, oral; Unchanged drug;
DRUGBANK
94.0
%
~94
%
plasma proteins;
DRUGBANK
DDPD15091
Upadacitinib
380.375
C17H19F3N6O
CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
DB15091
44210449
-2.0
-
-2.0
-
DRUGBANK
3.0
h
2-4
h
PO, oral;
DRUGBANK
96.0
h
4.0
day
Oral multiple dose;
DRUGBANK
79.0
%
79
%
Unchanged drug;
DRUGBANK
13.0
%
13
%
DRUGBANK
53.7
L/h
53.7
L/h
apparent clearance; PO, oral; normal,healthy;
DRUGBANK
224.0
L
224.0
L
PO, oral; rheumatoid arthritis; patients;
DRUGBANK
294.0
L
294.0
L
Steady state volume of distribution; normal,healthy;
DRUGBANK
11.0
h
8-14
h
elimination half-life; extended release formulation;
DRUGBANK
14500.0
mg/kg
14500.0
mg/kg
PO, oral; Rattus, Rat;
DRUGBANK
53.0
%
~53
%
Faeces excretion; Single dose;
DRUGBANK
43.0
%
~43
%
Urinary excretion; Single dose;
DRUGBANK
20.14
%
~20.14
%
Faeces excretion; Single dose; Unchanged drug;
DRUGBANK
10.32
%
~10.32
%
Urinary excretion; Single dose; Unchanged drug;
DRUGBANK
52.0
%
52
%
plasma proteins; human, homo sapiens;
DRUGBANK
15.0
mg/day
15
mg/day
PO, oral
Rinvoq
upadacitinib
PDR
15.0
mg/day
15
mg/day
PO, oral
Rinvoq
upadacitinib
PDR
DDPD15102
Pemigatinib
487.508
C24H27F2N5O4
CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F
DB15102
68007304
-2.0
-
-2.0
-
DRUGBANK
1277270.96
ng.h
2620.0
nM.h
Oral multiple dose;
DRUGBANK
115.051888
ng/ml
236.0
nM
Oral multiple dose;
DRUGBANK
1.13
h
1.13(0.5-6)
h
Oral single dose;
DRUGBANK
96.0
h
4.0
day
Oral multiple dose;
DRUGBANK
10.6
L/h
10.6
L/h
apparent clearance; Oral single dose;
DRUGBANK
235.0
L
235.0
L
Apparent volume of distribution; Oral single dose;
DRUGBANK
15.4
h
15.4
h
elimination half-life; Oral single dose;
DRUGBANK
82.4
%
82.4
%
Faeces excretion; Oral single dose;
DRUGBANK
12.6
%
~12.6
%
Urinary excretion; Oral single dose;
DRUGBANK
1.15
%
~1.15
%
Faeces excretion; Oral single dose; Unchanged drug;
DRUGBANK
0.126
%
~0.126
%
Urinary excretion; Oral single dose; Unchanged drug;
DRUGBANK
90.6
%
90.6
%
DRUGBANK
DDPD15233
Avapritinib
498.57
C26H27FN10
CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1
DB15233
58828673
-2.0
-
-2.0
-
DRUGBANK
15400.0
ng.h/ml
15400.0
ng.h/ml
PO, oral;
DRUGBANK
813.0
ng/ml
813.0
ng/ml
PO, oral;
DRUGBANK
3.05
h
2.0-4.1
h
PO, oral;
DRUGBANK
49.0
%
49
%
Unchanged drug;
DRUGBANK
35.0
%
35
%
DRUGBANK
14.0
%
14
%
DRUGBANK
19.5
L/h
19.5
L/h
apparent clearance; PO, oral;
DRUGBANK
1200.0
L
1200.0
L
Apparent volume of distribution;
DRUGBANK
44.5
h
32-57
h
DRUGBANK
70.0
%
70
%
Faeces excretion;
DRUGBANK
0.23
%
0.23
%
Urinary excretion;
DRUGBANK
7.7
%
7.7
%
Faeces excretion; Unchanged drug;
DRUGBANK
0.04
%
0.04
%
Urinary excretion; Unchanged drug;
DRUGBANK
98.8
%
98.8
%
DRUGBANK
DDPD15305
Risdiplam
401.474
C22H23N7O
CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CCNC2(CC2)C1
DB15305
67886354
-2.0
-
-2.0
-
DRUGBANK
3.0
h
3
h
PO, oral;
DRUGBANK
DDPD15328
Ubrogepant
549.554
C29H26F3N5O3
C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1
DB15328
28536135
-2.0
-
-2.0
-
DRUGBANK
1.1
h
0.7-1.5
h
PO, oral;
DRUGBANK
3.1
h
2.7-3.5
h
PO, oral; high-fat meal;
high-fat meal ↑ ;
DRUGBANK
87.0
L/h
~87
L/h
apparent clearance; PO, oral;
DRUGBANK
350.0
L
350.0
L
Total volume of distribution; PO, oral;
DRUGBANK
6.0
h
5-7
h
elimination half-life;
DRUGBANK
42.0
%
~42
%
Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens;
DRUGBANK
6.0
%
~6
%
Urinary excretion; PO, oral; normal,healthy; human, homo sapiens;
DRUGBANK
87.0
%
87
%
high protein binding;
DRUGBANK
DDPD15444
Elexacaftor
597.66
C26H34F3N7O4S
C[C@@H]1CN(C2=NC(=CC=C2C(=O)NS(=O)(=O)C2=CN(C)N=C2C)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(C)(C)C1
DB15444
75531299
-2.0
-
-2.0
-
DRUGBANK
162000.0
ng.h/ml
162.0
mcg.h/ml
Oral multiple dose;
DRUGBANK
80.0
%
~80
%
PO, oral;
DRUGBANK
8700.0
ng/ml
8.7
mcg/ml
Oral multiple dose;
DRUGBANK
6.0
h
6
h
Oral multiple dose;
DRUGBANK
1.18
L/h
1.18
L/h
apparent clearance;
DRUGBANK
53.7
L
53.7
L
Apparent volume of distribution;
DRUGBANK
24.7
h
~24.7
h
terminal half-life;
DRUGBANK
87.3
%
~87.3
%
Faeces excretion;
DRUGBANK
0.23
%
0.23
%
Urinary excretion;
DRUGBANK
99.0
%
>99
%
plasma proteins;
DRUGBANK
DDPD15465
Benzhydrocodone
403.478
C25H25NO4
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1
DB15465
34222482
-2.0
-
-2.0
-
DRUGBANK
125.73
ng.h/ml
125.73
ng.h/ml
Oral single dose; Active metabolite;
DRUGBANK
19.18
ng/ml
19.18
ng/ml
Oral single dose; Active metabolite;
DRUGBANK
1.25
h
1.25
h
Oral single dose; Active metabolite;
DRUGBANK
64.4
L/h
64.4
L/h
apparent clearance;
DRUGBANK
714.0
L
714.0
L
Apparent volume of distribution;
DRUGBANK
4.5
h
4.5
h
elimination half-life; Metabolite;
DRUGBANK
DDPD15494
Edotreotide gallium Ga-68
1486.55
C65H89GaN14O18S2
[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
DB15494
52083916
-2.0
-
-2.0
-
DRUGBANK
0.0
%
~0
%
DRUGBANK
1.13333333333333
h
68
min
radioactive half-life;
DRUGBANK
0.0333333333333333
h
2.0±0.3
min
distribution half-life;
DRUGBANK
0.8
h
48±7
min
elimination half-life;
DRUGBANK
16.0
%
16
%
Urinary excretion;
DRUGBANK
80.0
%
>80
%
Urinary excretion; animals;
DRUGBANK
1.0
%
<1
%
Faeces excretion; animals;
DRUGBANK
DDPD15566
Prednisolone acetate
402.4807
C23H30O6
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
DB15566
5834
8380
5629
-2.0
-
-2.0
-
DRUGBANK
1999.4
ng.h/ml
1999.4
ng.h/ml
Liquid;
DRUGBANK
321.1
ng/hr
321.1
ng/hr
Liquid;
DRUGBANK
1.5
h
1-2
h
Liquid;
DRUGBANK
0.46
L/kg
0.22-0.7
L/kg
DRUGBANK
2.5
h
2-3
h
elimination half-life; PO, oral;
DRUGBANK
1680.0
mg/kg
1680.0
mg/kg
PO, oral; mouse;
DRUGBANK
DDPD15594
Brilliant blue G
854.02
C47H48N3NaO7S2
[Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(=C2\C=C/C(/C=C2C)=[N+](/CC)CC2=CC(=CC=C2)S([O-])(=O)=O)\C2=C(C)C=C(C=C2)N(CC)CC2=CC(=CC=C2)S([O-])(=O)=O)C=C1
DB15594
4884338
-2.0
-
-2.0
-
DRUGBANK
100.0
mg/kg
100.0
mg/kg
Intraperitoneal, IP; Rattus, Rat;
DRUGBANK
DDPD15598
Ferric maltol
431.154
C18H15FeO9
[Fe+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1
DB15598
148265
-2.0
-
-2.0
-
DRUGBANK
113.5
ng.h/ml
0.022-0.205
ug.h/ml
DRUGBANK
20365.0
ng.h/ml
9.83-30.9
ug.h/ml
Derivative;
DRUGBANK
14.0
%
~14
%
DRUGBANK
2.25
h
1.5-3
h
PO, oral;
DRUGBANK
0.7
h
0.7
h
DRUGBANK
DDPD15617
Ferric derisomaltose
562.297
C18H34FeO16
[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O
DB15617
-2.0
-
-2.0
-
DRUGBANK
17730000.0
ng.h/ml
17730.0
ug.h/ml
Oral single dose;
DRUGBANK
408000.0
ng/ml
408.0
ug/ml
Oral single dose;
DRUGBANK
168.0
h
7
day
DRUGBANK
3.0
L
3.0
L
intravenous injection, IV; adults;
DRUGBANK
60.0
h
~1-4
day
elimination half-life; intravenous injection, IV;
DRUGBANK
140.0
mg/kg
140.0
mg/kg
intravenous injection, IV; Male, men; Rattus, Rat;
DRUGBANK
DDPD15685
Selpercatinib
525.613
C29H31N7O3
COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1
DB15685
72379991
-2.0
-
-2.0
-
DRUGBANK
51600.0
null
51600.0
null
tumor;
DRUGBANK
73.0
%
73(60-82)
%
tumor;
DRUGBANK
2980.0
null
2980.0
null
tumor;
DRUGBANK
2.0
h
2
h
tumor;
DRUGBANK
168.0
h
7.0
day
tumor;
DRUGBANK
6.0
L/h
6.0
L/h
apparent clearance;
gaining weight ↑ ;
DRUGBANK
191.0
L
191.0
L
Apparent volume of distribution;
gaining weight ↑ ;
DRUGBANK
32.0
h
32
h
normal,healthy;
DRUGBANK
69.0
%
69
%
Faeces excretion; Single dose; normal,healthy; human, homo sapiens;
DRUGBANK
24.0
%
24
%
Urinary excretion; Single dose; normal,healthy; human, homo sapiens;
DRUGBANK
9.6
%
9.6
%
Faeces excretion; Single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
2.88
%
2.88
%
Urinary excretion; Single dose; normal,healthy; human, homo sapiens; Unchanged drug;
DRUGBANK
97.0
%
97
%
high protein binding;
Plasma Concentration → ;
DRUGBANK
DDPD15690
Fluoroestradiol F-18
289.381
C18H23FO2
[H][C@@]12C[C@@H]([18F])[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
DB15690
9045262
-2.0
-
-2.0
-
DRUGBANK
10.0
%
10
%
Unchanged drug;
DRUGBANK
95.0
%
~95
%
plasma proteins; intravenous injection, IV;
DRUGBANK
95.0
%
<95
%
intravenous injection, IV;
DRUGBANK